{
      "name": "Test",
      "interface": {
            "type": "text_entity_relations",
            "description": "",
            "entityLabels": [
                  {
                        "id": 0,
                        "displayName": "year_0"
                  },
                  {
                        "id": 1,
                        "displayName": "year_1"
                  },
                  {
                        "id": 2,
                        "displayName": "year_2"
                  },
                  {
                        "id": 3,
                        "displayName": "year_3"
                  },
                  {
                        "id": 4,
                        "displayName": "year_4"
                  },
                  {
                        "id": 5,
                        "displayName": "year_5"
                  },
                  {
                        "id": 6,
                        "displayName": "year_6"
                  },
                  {
                        "id": 7,
                        "displayName": "year_7"
                  },
                  {
                        "id": 8,
                        "displayName": "year_8"
                  },
                  {
                        "id": 9,
                        "displayName": "year_9"
                  },
                  {
                        "id": 10,
                        "displayName": "year_10"
                  },
                  {
                        "id": 11,
                        "displayName": "year_11"
                  },
                  {
                        "id": 12,
                        "displayName": "year_12"
                  },
                  {
                        "id": 13,
                        "displayName": "year_13"
                  },
                  {
                        "id": 14,
                        "displayName": "year_14"
                  },
                  {
                        "id": 15,
                        "displayName": "year_15"
                  },
                  {
                        "id": 16,
                        "displayName": "year_16"
                  },
                  {
                        "id": 17,
                        "displayName": "year_17"
                  },
                  {
                        "id": 18,
                        "displayName": "year_18"
                  },
                  {
                        "id": 19,
                        "displayName": "year_19"
                  },
                  {
                        "id": 20,
                        "displayName": "year_20"
                  },
                  {
                        "id": 21,
                        "displayName": "year_21"
                  },
                  {
                        "id": 22,
                        "displayName": "year_22"
                  },
                  {
                        "id": 23,
                        "displayName": "year_23"
                  },
                  {
                        "id": 24,
                        "displayName": "year_24"
                  },
                  {
                        "id": 25,
                        "displayName": "year_25"
                  },
                  {
                        "id": 26,
                        "displayName": "year_26"
                  },
                  {
                        "id": 27,
                        "displayName": "year_27"
                  },
                  {
                        "id": 28,
                        "displayName": "year_28"
                  },
                  {
                        "id": 29,
                        "displayName": "year_29"
                  },
                  {
                        "id": 30,
                        "displayName": "year_30"
                  },
                  {
                        "id": 31,
                        "displayName": "year_31"
                  },
                  {
                        "id": 32,
                        "displayName": "year_32"
                  },
                  {
                        "id": 33,
                        "displayName": "year_33"
                  },
                  {
                        "id": 34,
                        "displayName": "year_34"
                  },
                  {
                        "id": 35,
                        "displayName": "year_35"
                  },
                  {
                        "id": 36,
                        "displayName": "year_36"
                  },
                  {
                        "id": 37,
                        "displayName": "year_37"
                  },
                  {
                        "id": 38,
                        "displayName": "year_38"
                  },
                  {
                        "id": 39,
                        "displayName": "year_39"
                  },
                  {
                        "id": 40,
                        "displayName": "year_40"
                  },
                  {
                        "id": 41,
                        "displayName": "year_41"
                  },
                  {
                        "id": 42,
                        "displayName": "year_42"
                  },
                  {
                        "id": 43,
                        "displayName": "year_43"
                  },
                  {
                        "id": 44,
                        "displayName": "year_44"
                  },
                  {
                        "id": 45,
                        "displayName": "year_45"
                  },
                  {
                        "id": 46,
                        "displayName": "year_46"
                  },
                  {
                        "id": 47,
                        "displayName": "year_47"
                  },
                  {
                        "id": 48,
                        "displayName": "year_48"
                  },
                  {
                        "id": 49,
                        "displayName": "year_49"
                  },
                  {
                        "id": 50,
                        "displayName": "year_50"
                  },
                  {
                        "id": 51,
                        "displayName": "year_51"
                  },
                  {
                        "id": 52,
                        "displayName": "year_52"
                  },
                  {
                        "id": 53,
                        "displayName": "year_53"
                  },
                  {
                        "id": 54,
                        "displayName": "year_54"
                  },
                  {
                        "id": 55,
                        "displayName": "year_55"
                  },
                  {
                        "id": 56,
                        "displayName": "year_56"
                  },
                  {
                        "id": 57,
                        "displayName": "year_57"
                  },
                  {
                        "id": 58,
                        "displayName": "year_58"
                  },
                  {
                        "id": 59,
                        "displayName": "year_59"
                  },
                  {
                        "id": 60,
                        "displayName": "year_60"
                  },
                  {
                        "id": 61,
                        "displayName": "year_61"
                  },
                  {
                        "id": 62,
                        "displayName": "year_62"
                  },
                  {
                        "id": 63,
                        "displayName": "year_63"
                  },
                  {
                        "id": 64,
                        "displayName": "year_64"
                  },
                  {
                        "id": 65,
                        "displayName": "year_65"
                  },
                  {
                        "id": 66,
                        "displayName": "year_66"
                  },
                  {
                        "id": 67,
                        "displayName": "year_67"
                  },
                  {
                        "id": 68,
                        "displayName": "year_68"
                  },
                  {
                        "id": 69,
                        "displayName": "year_69"
                  },
                  {
                        "id": 70,
                        "displayName": "year_70"
                  },
                  {
                        "id": 71,
                        "displayName": "year_71"
                  },
                  {
                        "id": 72,
                        "displayName": "year_72"
                  },
                  {
                        "id": 73,
                        "displayName": "year_73"
                  },
                  {
                        "id": 74,
                        "displayName": "year_74"
                  },
                  {
                        "id": 75,
                        "displayName": "year_75"
                  },
                  {
                        "id": 76,
                        "displayName": "year_76"
                  },
                  {
                        "id": 77,
                        "displayName": "year_77"
                  },
                  {
                        "id": 78,
                        "displayName": "year_78"
                  },
                  {
                        "id": 79,
                        "displayName": "year_79"
                  },
                  {
                        "id": 80,
                        "displayName": "year_80"
                  },
                  {
                        "id": 81,
                        "displayName": "year_81"
                  },
                  {
                        "id": 82,
                        "displayName": "year_82"
                  },
                  {
                        "id": 83,
                        "displayName": "year_83"
                  },
                  {
                        "id": 84,
                        "displayName": "year_84"
                  },
                  {
                        "id": 85,
                        "displayName": "year_85"
                  },
                  {
                        "id": 86,
                        "displayName": "year_86"
                  },
                  {
                        "id": 87,
                        "displayName": "year_87"
                  },
                  {
                        "id": 88,
                        "displayName": "year_88"
                  },
                  {
                        "id": 89,
                        "displayName": "year_89"
                  },
                  {
                        "id": 90,
                        "displayName": "year_90"
                  },
                  {
                        "id": 91,
                        "displayName": "year_91"
                  },
                  {
                        "id": 92,
                        "displayName": "year_92"
                  },
                  {
                        "id": 93,
                        "displayName": "year_93"
                  },
                  {
                        "id": 94,
                        "displayName": "year_94"
                  },
                  {
                        "id": 95,
                        "displayName": "year_95"
                  },
                  {
                        "id": 96,
                        "displayName": "year_96"
                  },
                  {
                        "id": 97,
                        "displayName": "year_97"
                  },
                  {
                        "id": 98,
                        "displayName": "year_98"
                  },
                  {
                        "id": 99,
                        "displayName": "year_99"
                  },
                  {
                        "id": 100,
                        "displayName": "year_100"
                  },
                  {
                        "id": 101,
                        "displayName": "year_101"
                  },
                  {
                        "id": 102,
                        "displayName": "year_102"
                  },
                  {
                        "id": 103,
                        "displayName": "year_103"
                  },
                  {
                        "id": 104,
                        "displayName": "year_104"
                  },
                  {
                        "id": 105,
                        "displayName": "year_105"
                  },
                  {
                        "id": 106,
                        "displayName": "year_106"
                  },
                  {
                        "id": 107,
                        "displayName": "year_107"
                  },
                  {
                        "id": 108,
                        "displayName": "year_108"
                  },
                  {
                        "id": 109,
                        "displayName": "year_109"
                  },
                  {
                        "id": 110,
                        "displayName": "year_110"
                  },
                  {
                        "id": 111,
                        "displayName": "year_111"
                  },
                  {
                        "id": 112,
                        "displayName": "year_112"
                  },
                  {
                        "id": 113,
                        "displayName": "year_113"
                  },
                  {
                        "id": 114,
                        "displayName": "year_114"
                  },
                  {
                        "id": 115,
                        "displayName": "year_115"
                  },
                  {
                        "id": 116,
                        "displayName": "year_116"
                  },
                  {
                        "id": 117,
                        "displayName": "year_117"
                  },
                  {
                        "id": 118,
                        "displayName": "year_118"
                  },
                  {
                        "id": 119,
                        "displayName": "year_119"
                  },
                  {
                        "id": 120,
                        "displayName": "year_120"
                  },
                  {
                        "id": 121,
                        "displayName": "year_121"
                  },
                  {
                        "id": 122,
                        "displayName": "year_122"
                  },
                  {
                        "id": 123,
                        "displayName": "year_123"
                  },
                  {
                        "id": 124,
                        "displayName": "year_124"
                  },
                  {
                        "id": 125,
                        "displayName": "year_125"
                  },
                  {
                        "id": 126,
                        "displayName": "year_126"
                  },
                  {
                        "id": 127,
                        "displayName": "year_127"
                  },
                  {
                        "id": 128,
                        "displayName": "year_128"
                  },
                  {
                        "id": 129,
                        "displayName": "year_129"
                  },
                  {
                        "id": 130,
                        "displayName": "year_130"
                  },
                  {
                        "id": 131,
                        "displayName": "year_131"
                  },
                  {
                        "id": 132,
                        "displayName": "year_132"
                  },
                  {
                        "id": 133,
                        "displayName": "year_133"
                  },
                  {
                        "id": 134,
                        "displayName": "year_134"
                  },
                  {
                        "id": 135,
                        "displayName": "year_135"
                  },
                  {
                        "id": 136,
                        "displayName": "year_136"
                  },
                  {
                        "id": 137,
                        "displayName": "year_137"
                  },
                  {
                        "id": 138,
                        "displayName": "year_138"
                  },
                  {
                        "id": 139,
                        "displayName": "year_139"
                  },
                  {
                        "id": 140,
                        "displayName": "year_140"
                  },
                  {
                        "id": 141,
                        "displayName": "year_141"
                  },
                  {
                        "id": 142,
                        "displayName": "year_142"
                  },
                  {
                        "id": 143,
                        "displayName": "year_143"
                  },
                  {
                        "id": 144,
                        "displayName": "year_144"
                  },
                  {
                        "id": 145,
                        "displayName": "year_145"
                  },
                  {
                        "id": 146,
                        "displayName": "year_146"
                  },
                  {
                        "id": 147,
                        "displayName": "year_147"
                  },
                  {
                        "id": 148,
                        "displayName": "year_148"
                  },
                  {
                        "id": 149,
                        "displayName": "year_149"
                  },
                  {
                        "id": 150,
                        "displayName": "year_150"
                  },
                  {
                        "id": 151,
                        "displayName": "year_151"
                  },
                  {
                        "id": 152,
                        "displayName": "year_152"
                  },
                  {
                        "id": 153,
                        "displayName": "year_153"
                  },
                  {
                        "id": 154,
                        "displayName": "year_154"
                  },
                  {
                        "id": 155,
                        "displayName": "year_155"
                  },
                  {
                        "id": 156,
                        "displayName": "year_156"
                  },
                  {
                        "id": 157,
                        "displayName": "year_157"
                  },
                  {
                        "id": 158,
                        "displayName": "year_158"
                  },
                  {
                        "id": 159,
                        "displayName": "year_159"
                  },
                  {
                        "id": 160,
                        "displayName": "year_160"
                  },
                  {
                        "id": 161,
                        "displayName": "year_161"
                  },
                  {
                        "id": 162,
                        "displayName": "year_162"
                  },
                  {
                        "id": 163,
                        "displayName": "year_163"
                  },
                  {
                        "id": 164,
                        "displayName": "year_164"
                  },
                  {
                        "id": 165,
                        "displayName": "year_165"
                  },
                  {
                        "id": 166,
                        "displayName": "year_166"
                  },
                  {
                        "id": 167,
                        "displayName": "year_167"
                  },
                  {
                        "id": 168,
                        "displayName": "year_168"
                  },
                  {
                        "id": 169,
                        "displayName": "year_169"
                  },
                  {
                        "id": 170,
                        "displayName": "year_170"
                  },
                  {
                        "id": 171,
                        "displayName": "year_171"
                  },
                  {
                        "id": 172,
                        "displayName": "year_172"
                  },
                  {
                        "id": 173,
                        "displayName": "year_173"
                  },
                  {
                        "id": 174,
                        "displayName": "year_174"
                  },
                  {
                        "id": 175,
                        "displayName": "year_175"
                  },
                  {
                        "id": 176,
                        "displayName": "year_176"
                  },
                  {
                        "id": 177,
                        "displayName": "year_177"
                  },
                  {
                        "id": 178,
                        "displayName": "year_178"
                  },
                  {
                        "id": 179,
                        "displayName": "year_179"
                  },
                  {
                        "id": 180,
                        "displayName": "year_180"
                  },
                  {
                        "id": 181,
                        "displayName": "year_181"
                  },
                  {
                        "id": 182,
                        "displayName": "year_182"
                  },
                  {
                        "id": 183,
                        "displayName": "year_183"
                  },
                  {
                        "id": 184,
                        "displayName": "year_184"
                  },
                  {
                        "id": 185,
                        "displayName": "year_185"
                  },
                  {
                        "id": 186,
                        "displayName": "year_186"
                  },
                  {
                        "id": 187,
                        "displayName": "year_187"
                  },
                  {
                        "id": 188,
                        "displayName": "year_188"
                  },
                  {
                        "id": 189,
                        "displayName": "year_189"
                  },
                  {
                        "id": 190,
                        "displayName": "year_190"
                  },
                  {
                        "id": 191,
                        "displayName": "year_191"
                  },
                  {
                        "id": 192,
                        "displayName": "year_192"
                  },
                  {
                        "id": 193,
                        "displayName": "year_193"
                  },
                  {
                        "id": 194,
                        "displayName": "year_194"
                  },
                  {
                        "id": 195,
                        "displayName": "year_195"
                  },
                  {
                        "id": 196,
                        "displayName": "year_196"
                  },
                  {
                        "id": 197,
                        "displayName": "year_197"
                  },
                  {
                        "id": 198,
                        "displayName": "year_198"
                  },
                  {
                        "id": 199,
                        "displayName": "year_199"
                  },
                  {
                        "id": 200,
                        "displayName": "year_200"
                  },
                  {
                        "id": 201,
                        "displayName": "year_201"
                  },
                  {
                        "id": 202,
                        "displayName": "year_202"
                  },
                  {
                        "id": 203,
                        "displayName": "year_203"
                  },
                  {
                        "id": 204,
                        "displayName": "year_204"
                  },
                  {
                        "id": 205,
                        "displayName": "year_205"
                  },
                  {
                        "id": 206,
                        "displayName": "year_206"
                  },
                  {
                        "id": 207,
                        "displayName": "year_207"
                  },
                  {
                        "id": 208,
                        "displayName": "year_208"
                  },
                  {
                        "id": 209,
                        "displayName": "year_209"
                  },
                  {
                        "id": 210,
                        "displayName": "year_210"
                  },
                  {
                        "id": 211,
                        "displayName": "year_211"
                  },
                  {
                        "id": 212,
                        "displayName": "year_212"
                  },
                  {
                        "id": 213,
                        "displayName": "year_213"
                  },
                  {
                        "id": 214,
                        "displayName": "year_214"
                  },
                  {
                        "id": 215,
                        "displayName": "year_215"
                  },
                  {
                        "id": 216,
                        "displayName": "year_216"
                  },
                  {
                        "id": 217,
                        "displayName": "year_217"
                  },
                  {
                        "id": 218,
                        "displayName": "year_218"
                  },
                  {
                        "id": 219,
                        "displayName": "year_219"
                  },
                  {
                        "id": 220,
                        "displayName": "year_220"
                  },
                  {
                        "id": 221,
                        "displayName": "year_221"
                  },
                  {
                        "id": 222,
                        "displayName": "year_222"
                  },
                  {
                        "id": 223,
                        "displayName": "year_223"
                  },
                  {
                        "id": 224,
                        "displayName": "year_224"
                  },
                  {
                        "id": 225,
                        "displayName": "year_225"
                  },
                  {
                        "id": 226,
                        "displayName": "year_226"
                  },
                  {
                        "id": 227,
                        "displayName": "year_227"
                  },
                  {
                        "id": 228,
                        "displayName": "year_228"
                  },
                  {
                        "id": 229,
                        "displayName": "year_229"
                  },
                  {
                        "id": 230,
                        "displayName": "year_230"
                  },
                  {
                        "id": 231,
                        "displayName": "year_231"
                  },
                  {
                        "id": 232,
                        "displayName": "year_232"
                  },
                  {
                        "id": 233,
                        "displayName": "year_233"
                  },
                  {
                        "id": 234,
                        "displayName": "year_234"
                  },
                  {
                        "id": 235,
                        "displayName": "year_235"
                  },
                  {
                        "id": 236,
                        "displayName": "year_236"
                  },
                  {
                        "id": 237,
                        "displayName": "year_237"
                  },
                  {
                        "id": 238,
                        "displayName": "year_238"
                  },
                  {
                        "id": 239,
                        "displayName": "year_239"
                  },
                  {
                        "id": 240,
                        "displayName": "year_240"
                  },
                  {
                        "id": 241,
                        "displayName": "year_241"
                  },
                  {
                        "id": 242,
                        "displayName": "year_242"
                  },
                  {
                        "id": 243,
                        "displayName": "year_243"
                  },
                  {
                        "id": 244,
                        "displayName": "year_244"
                  },
                  {
                        "id": 245,
                        "displayName": "year_245"
                  },
                  {
                        "id": 246,
                        "displayName": "year_246"
                  },
                  {
                        "id": 247,
                        "displayName": "year_247"
                  },
                  {
                        "id": 248,
                        "displayName": "year_248"
                  },
                  {
                        "id": 249,
                        "displayName": "year_249"
                  },
                  {
                        "id": 250,
                        "displayName": "year_250"
                  },
                  {
                        "id": 251,
                        "displayName": "year_251"
                  },
                  {
                        "id": 252,
                        "displayName": "year_252"
                  },
                  {
                        "id": 253,
                        "displayName": "year_253"
                  },
                  {
                        "id": 254,
                        "displayName": "year_254"
                  },
                  {
                        "id": 255,
                        "displayName": "year_255"
                  },
                  {
                        "id": 256,
                        "displayName": "year_256"
                  },
                  {
                        "id": 257,
                        "displayName": "year_257"
                  },
                  {
                        "id": 258,
                        "displayName": "year_258"
                  },
                  {
                        "id": 259,
                        "displayName": "year_259"
                  },
                  {
                        "id": 260,
                        "displayName": "year_260"
                  },
                  {
                        "id": 261,
                        "displayName": "year_261"
                  },
                  {
                        "id": 262,
                        "displayName": "year_262"
                  },
                  {
                        "id": 263,
                        "displayName": "year_263"
                  },
                  {
                        "id": 264,
                        "displayName": "year_264"
                  },
                  {
                        "id": 265,
                        "displayName": "year_265"
                  },
                  {
                        "id": 266,
                        "displayName": "year_266"
                  },
                  {
                        "id": 267,
                        "displayName": "year_267"
                  },
                  {
                        "id": 268,
                        "displayName": "year_268"
                  },
                  {
                        "id": 269,
                        "displayName": "year_269"
                  },
                  {
                        "id": 270,
                        "displayName": "year_270"
                  },
                  {
                        "id": 271,
                        "displayName": "year_271"
                  },
                  {
                        "id": 272,
                        "displayName": "year_272"
                  },
                  {
                        "id": 273,
                        "displayName": "year_273"
                  },
                  {
                        "id": 274,
                        "displayName": "year_274"
                  },
                  {
                        "id": 275,
                        "displayName": "year_275"
                  },
                  {
                        "id": 276,
                        "displayName": "year_276"
                  },
                  {
                        "id": 277,
                        "displayName": "year_277"
                  },
                  {
                        "id": 278,
                        "displayName": "year_278"
                  },
                  {
                        "id": 279,
                        "displayName": "year_279"
                  },
                  {
                        "id": 280,
                        "displayName": "year_280"
                  },
                  {
                        "id": 281,
                        "displayName": "year_281"
                  },
                  {
                        "id": 282,
                        "displayName": "year_282"
                  },
                  {
                        "id": 283,
                        "displayName": "year_283"
                  },
                  {
                        "id": 284,
                        "displayName": "year_284"
                  },
                  {
                        "id": 285,
                        "displayName": "year_285"
                  },
                  {
                        "id": 286,
                        "displayName": "year_286"
                  },
                  {
                        "id": 287,
                        "displayName": "year_287"
                  },
                  {
                        "id": 288,
                        "displayName": "year_288"
                  },
                  {
                        "id": 289,
                        "displayName": "year_289"
                  },
                  {
                        "id": 290,
                        "displayName": "year_290"
                  },
                  {
                        "id": 291,
                        "displayName": "year_291"
                  },
                  {
                        "id": 292,
                        "displayName": "year_292"
                  },
                  {
                        "id": 293,
                        "displayName": "year_293"
                  },
                  {
                        "id": 294,
                        "displayName": "year_294"
                  },
                  {
                        "id": 295,
                        "displayName": "year_295"
                  },
                  {
                        "id": 296,
                        "displayName": "year_296"
                  },
                  {
                        "id": 297,
                        "displayName": "year_297"
                  },
                  {
                        "id": 298,
                        "displayName": "year_298"
                  },
                  {
                        "id": 299,
                        "displayName": "year_299"
                  },
                  {
                        "id": 300,
                        "displayName": "year_300"
                  },
                  {
                        "id": 301,
                        "displayName": "year_301"
                  },
                  {
                        "id": 302,
                        "displayName": "year_302"
                  },
                  {
                        "id": 303,
                        "displayName": "year_303"
                  },
                  {
                        "id": 304,
                        "displayName": "year_304"
                  },
                  {
                        "id": 305,
                        "displayName": "year_305"
                  },
                  {
                        "id": 306,
                        "displayName": "year_306"
                  },
                  {
                        "id": 307,
                        "displayName": "year_307"
                  },
                  {
                        "id": 308,
                        "displayName": "year_308"
                  },
                  {
                        "id": 309,
                        "displayName": "year_309"
                  },
                  {
                        "id": 310,
                        "displayName": "year_310"
                  },
                  {
                        "id": 311,
                        "displayName": "year_311"
                  },
                  {
                        "id": 312,
                        "displayName": "year_312"
                  },
                  {
                        "id": 313,
                        "displayName": "year_313"
                  },
                  {
                        "id": 314,
                        "displayName": "year_314"
                  },
                  {
                        "id": 315,
                        "displayName": "year_315"
                  },
                  {
                        "id": 316,
                        "displayName": "year_316"
                  },
                  {
                        "id": 317,
                        "displayName": "year_317"
                  },
                  {
                        "id": 318,
                        "displayName": "year_318"
                  },
                  {
                        "id": 319,
                        "displayName": "year_319"
                  },
                  {
                        "id": 320,
                        "displayName": "year_320"
                  },
                  {
                        "id": 321,
                        "displayName": "year_321"
                  },
                  {
                        "id": 322,
                        "displayName": "year_322"
                  },
                  {
                        "id": 323,
                        "displayName": "year_323"
                  },
                  {
                        "id": 324,
                        "displayName": "year_324"
                  },
                  {
                        "id": 325,
                        "displayName": "year_325"
                  },
                  {
                        "id": 326,
                        "displayName": "year_326"
                  },
                  {
                        "id": 327,
                        "displayName": "year_327"
                  },
                  {
                        "id": 328,
                        "displayName": "year_328"
                  },
                  {
                        "id": 329,
                        "displayName": "year_329"
                  },
                  {
                        "id": 330,
                        "displayName": "year_330"
                  },
                  {
                        "id": 331,
                        "displayName": "year_331"
                  },
                  {
                        "id": 332,
                        "displayName": "year_332"
                  },
                  {
                        "id": 333,
                        "displayName": "year_333"
                  },
                  {
                        "id": 334,
                        "displayName": "year_334"
                  },
                  {
                        "id": 335,
                        "displayName": "year_335"
                  },
                  {
                        "id": 336,
                        "displayName": "year_336"
                  },
                  {
                        "id": 337,
                        "displayName": "year_337"
                  },
                  {
                        "id": 338,
                        "displayName": "year_338"
                  },
                  {
                        "id": 339,
                        "displayName": "year_339"
                  },
                  {
                        "id": 340,
                        "displayName": "year_340"
                  },
                  {
                        "id": 341,
                        "displayName": "year_341"
                  },
                  {
                        "id": 342,
                        "displayName": "year_342"
                  },
                  {
                        "id": 343,
                        "displayName": "year_343"
                  },
                  {
                        "id": 344,
                        "displayName": "year_344"
                  },
                  {
                        "id": 345,
                        "displayName": "year_345"
                  },
                  {
                        "id": 346,
                        "displayName": "year_346"
                  },
                  {
                        "id": 347,
                        "displayName": "year_347"
                  },
                  {
                        "id": 348,
                        "displayName": "year_348"
                  },
                  {
                        "id": 349,
                        "displayName": "year_349"
                  },
                  {
                        "id": 350,
                        "displayName": "year_350"
                  },
                  {
                        "id": 351,
                        "displayName": "year_351"
                  },
                  {
                        "id": 352,
                        "displayName": "year_352"
                  },
                  {
                        "id": 353,
                        "displayName": "year_353"
                  },
                  {
                        "id": 354,
                        "displayName": "year_354"
                  },
                  {
                        "id": 355,
                        "displayName": "year_355"
                  },
                  {
                        "id": 356,
                        "displayName": "year_356"
                  },
                  {
                        "id": 357,
                        "displayName": "year_357"
                  },
                  {
                        "id": 358,
                        "displayName": "year_358"
                  },
                  {
                        "id": 359,
                        "displayName": "year_359"
                  },
                  {
                        "id": 360,
                        "displayName": "year_360"
                  },
                  {
                        "id": 361,
                        "displayName": "year_361"
                  },
                  {
                        "id": 362,
                        "displayName": "year_362"
                  },
                  {
                        "id": 363,
                        "displayName": "year_363"
                  },
                  {
                        "id": 364,
                        "displayName": "year_364"
                  },
                  {
                        "id": 365,
                        "displayName": "year_365"
                  },
                  {
                        "id": 366,
                        "displayName": "year_366"
                  },
                  {
                        "id": 367,
                        "displayName": "year_367"
                  },
                  {
                        "id": 368,
                        "displayName": "year_368"
                  },
                  {
                        "id": 369,
                        "displayName": "year_369"
                  },
                  {
                        "id": 370,
                        "displayName": "year_370"
                  },
                  {
                        "id": 371,
                        "displayName": "year_371"
                  },
                  {
                        "id": 372,
                        "displayName": "year_372"
                  },
                  {
                        "id": 373,
                        "displayName": "year_373"
                  },
                  {
                        "id": 374,
                        "displayName": "year_374"
                  },
                  {
                        "id": 375,
                        "displayName": "year_375"
                  },
                  {
                        "id": 376,
                        "displayName": "year_376"
                  },
                  {
                        "id": 377,
                        "displayName": "year_377"
                  },
                  {
                        "id": 378,
                        "displayName": "year_378"
                  },
                  {
                        "id": 379,
                        "displayName": "year_379"
                  },
                  {
                        "id": 380,
                        "displayName": "year_380"
                  },
                  {
                        "id": 381,
                        "displayName": "year_381"
                  },
                  {
                        "id": 382,
                        "displayName": "year_382"
                  },
                  {
                        "id": 383,
                        "displayName": "year_383"
                  },
                  {
                        "id": 384,
                        "displayName": "year_384"
                  },
                  {
                        "id": 385,
                        "displayName": "year_385"
                  },
                  {
                        "id": 386,
                        "displayName": "year_386"
                  },
                  {
                        "id": 387,
                        "displayName": "year_387"
                  },
                  {
                        "id": 388,
                        "displayName": "year_388"
                  },
                  {
                        "id": 389,
                        "displayName": "year_389"
                  },
                  {
                        "id": 390,
                        "displayName": "year_390"
                  },
                  {
                        "id": 391,
                        "displayName": "year_391"
                  },
                  {
                        "id": 392,
                        "displayName": "year_392"
                  },
                  {
                        "id": 393,
                        "displayName": "year_393"
                  },
                  {
                        "id": 394,
                        "displayName": "year_394"
                  },
                  {
                        "id": 395,
                        "displayName": "year_395"
                  },
                  {
                        "id": 396,
                        "displayName": "year_396"
                  },
                  {
                        "id": 397,
                        "displayName": "year_397"
                  },
                  {
                        "id": 398,
                        "displayName": "year_398"
                  },
                  {
                        "id": 399,
                        "displayName": "year_399"
                  },
                  {
                        "id": 400,
                        "displayName": "year_400"
                  },
                  {
                        "id": 401,
                        "displayName": "year_401"
                  },
                  {
                        "id": 402,
                        "displayName": "year_402"
                  },
                  {
                        "id": 403,
                        "displayName": "year_403"
                  },
                  {
                        "id": 404,
                        "displayName": "year_404"
                  },
                  {
                        "id": 405,
                        "displayName": "year_405"
                  },
                  {
                        "id": 406,
                        "displayName": "year_406"
                  },
                  {
                        "id": 407,
                        "displayName": "year_407"
                  },
                  {
                        "id": 408,
                        "displayName": "year_408"
                  },
                  {
                        "id": 409,
                        "displayName": "year_409"
                  },
                  {
                        "id": 410,
                        "displayName": "year_410"
                  },
                  {
                        "id": 411,
                        "displayName": "year_411"
                  },
                  {
                        "id": 412,
                        "displayName": "year_412"
                  },
                  {
                        "id": 413,
                        "displayName": "year_413"
                  },
                  {
                        "id": 414,
                        "displayName": "year_414"
                  },
                  {
                        "id": 415,
                        "displayName": "year_415"
                  },
                  {
                        "id": 416,
                        "displayName": "year_416"
                  },
                  {
                        "id": 417,
                        "displayName": "year_417"
                  },
                  {
                        "id": 418,
                        "displayName": "year_418"
                  },
                  {
                        "id": 419,
                        "displayName": "year_419"
                  },
                  {
                        "id": 420,
                        "displayName": "year_420"
                  },
                  {
                        "id": 421,
                        "displayName": "year_421"
                  },
                  {
                        "id": 422,
                        "displayName": "year_422"
                  },
                  {
                        "id": 423,
                        "displayName": "year_423"
                  },
                  {
                        "id": 424,
                        "displayName": "year_424"
                  },
                  {
                        "id": 425,
                        "displayName": "year_425"
                  },
                  {
                        "id": 426,
                        "displayName": "year_426"
                  },
                  {
                        "id": 427,
                        "displayName": "year_427"
                  },
                  {
                        "id": 428,
                        "displayName": "year_428"
                  },
                  {
                        "id": 429,
                        "displayName": "year_429"
                  },
                  {
                        "id": 430,
                        "displayName": "year_430"
                  },
                  {
                        "id": 431,
                        "displayName": "year_431"
                  },
                  {
                        "id": 432,
                        "displayName": "year_432"
                  },
                  {
                        "id": 433,
                        "displayName": "year_433"
                  },
                  {
                        "id": 434,
                        "displayName": "year_434"
                  },
                  {
                        "id": 435,
                        "displayName": "year_435"
                  },
                  {
                        "id": 436,
                        "displayName": "year_436"
                  },
                  {
                        "id": 437,
                        "displayName": "year_437"
                  },
                  {
                        "id": 438,
                        "displayName": "year_438"
                  },
                  {
                        "id": 439,
                        "displayName": "year_439"
                  },
                  {
                        "id": 440,
                        "displayName": "year_440"
                  },
                  {
                        "id": 441,
                        "displayName": "year_441"
                  },
                  {
                        "id": 442,
                        "displayName": "year_442"
                  },
                  {
                        "id": 443,
                        "displayName": "year_443"
                  },
                  {
                        "id": 444,
                        "displayName": "year_444"
                  },
                  {
                        "id": 445,
                        "displayName": "year_445"
                  },
                  {
                        "id": 446,
                        "displayName": "year_446"
                  },
                  {
                        "id": 447,
                        "displayName": "year_447"
                  },
                  {
                        "id": 448,
                        "displayName": "year_448"
                  },
                  {
                        "id": 449,
                        "displayName": "year_449"
                  },
                  {
                        "id": 450,
                        "displayName": "year_450"
                  },
                  {
                        "id": 451,
                        "displayName": "year_451"
                  },
                  {
                        "id": 452,
                        "displayName": "year_452"
                  },
                  {
                        "id": 453,
                        "displayName": "year_453"
                  },
                  {
                        "id": 454,
                        "displayName": "year_454"
                  },
                  {
                        "id": 455,
                        "displayName": "year_455"
                  },
                  {
                        "id": 456,
                        "displayName": "year_456"
                  },
                  {
                        "id": 457,
                        "displayName": "year_457"
                  },
                  {
                        "id": 458,
                        "displayName": "year_458"
                  },
                  {
                        "id": 459,
                        "displayName": "year_459"
                  },
                  {
                        "id": 460,
                        "displayName": "year_460"
                  },
                  {
                        "id": 461,
                        "displayName": "year_461"
                  },
                  {
                        "id": 462,
                        "displayName": "year_462"
                  },
                  {
                        "id": 463,
                        "displayName": "year_463"
                  },
                  {
                        "id": 464,
                        "displayName": "year_464"
                  },
                  {
                        "id": 465,
                        "displayName": "year_465"
                  },
                  {
                        "id": 466,
                        "displayName": "year_466"
                  },
                  {
                        "id": 467,
                        "displayName": "year_467"
                  },
                  {
                        "id": 468,
                        "displayName": "year_468"
                  },
                  {
                        "id": 469,
                        "displayName": "year_469"
                  },
                  {
                        "id": 470,
                        "displayName": "year_470"
                  },
                  {
                        "id": 471,
                        "displayName": "year_471"
                  },
                  {
                        "id": 472,
                        "displayName": "year_472"
                  },
                  {
                        "id": 473,
                        "displayName": "year_473"
                  },
                  {
                        "id": 474,
                        "displayName": "year_474"
                  },
                  {
                        "id": 475,
                        "displayName": "year_475"
                  },
                  {
                        "id": 476,
                        "displayName": "year_476"
                  },
                  {
                        "id": 477,
                        "displayName": "year_477"
                  },
                  {
                        "id": 478,
                        "displayName": "year_478"
                  },
                  {
                        "id": 479,
                        "displayName": "year_479"
                  },
                  {
                        "id": 480,
                        "displayName": "year_480"
                  },
                  {
                        "id": 481,
                        "displayName": "year_481"
                  },
                  {
                        "id": 482,
                        "displayName": "year_482"
                  },
                  {
                        "id": 483,
                        "displayName": "year_483"
                  },
                  {
                        "id": 484,
                        "displayName": "year_484"
                  },
                  {
                        "id": 485,
                        "displayName": "year_485"
                  },
                  {
                        "id": 486,
                        "displayName": "year_486"
                  },
                  {
                        "id": 487,
                        "displayName": "year_487"
                  },
                  {
                        "id": 488,
                        "displayName": "year_488"
                  },
                  {
                        "id": 489,
                        "displayName": "year_489"
                  },
                  {
                        "id": 490,
                        "displayName": "year_490"
                  },
                  {
                        "id": 491,
                        "displayName": "year_491"
                  },
                  {
                        "id": 492,
                        "displayName": "year_492"
                  },
                  {
                        "id": 493,
                        "displayName": "year_493"
                  },
                  {
                        "id": 494,
                        "displayName": "year_494"
                  },
                  {
                        "id": 495,
                        "displayName": "year_495"
                  },
                  {
                        "id": 496,
                        "displayName": "year_496"
                  },
                  {
                        "id": 497,
                        "displayName": "year_497"
                  },
                  {
                        "id": 498,
                        "displayName": "year_498"
                  },
                  {
                        "id": 499,
                        "displayName": "year_499"
                  },
                  {
                        "id": 500,
                        "displayName": "year_500"
                  },
                  {
                        "id": 501,
                        "displayName": "year_501"
                  },
                  {
                        "id": 502,
                        "displayName": "year_502"
                  },
                  {
                        "id": 503,
                        "displayName": "year_503"
                  },
                  {
                        "id": 504,
                        "displayName": "year_504"
                  },
                  {
                        "id": 505,
                        "displayName": "year_505"
                  },
                  {
                        "id": 506,
                        "displayName": "year_506"
                  },
                  {
                        "id": 507,
                        "displayName": "year_507"
                  },
                  {
                        "id": 508,
                        "displayName": "year_508"
                  },
                  {
                        "id": 509,
                        "displayName": "year_509"
                  },
                  {
                        "id": 510,
                        "displayName": "year_510"
                  },
                  {
                        "id": 511,
                        "displayName": "year_511"
                  },
                  {
                        "id": 512,
                        "displayName": "year_512"
                  },
                  {
                        "id": 513,
                        "displayName": "year_513"
                  },
                  {
                        "id": 514,
                        "displayName": "year_514"
                  },
                  {
                        "id": 515,
                        "displayName": "year_515"
                  },
                  {
                        "id": 516,
                        "displayName": "year_516"
                  },
                  {
                        "id": 517,
                        "displayName": "year_517"
                  },
                  {
                        "id": 518,
                        "displayName": "year_518"
                  },
                  {
                        "id": 519,
                        "displayName": "year_519"
                  },
                  {
                        "id": 520,
                        "displayName": "year_520"
                  },
                  {
                        "id": 521,
                        "displayName": "year_521"
                  },
                  {
                        "id": 522,
                        "displayName": "year_522"
                  },
                  {
                        "id": 523,
                        "displayName": "year_523"
                  },
                  {
                        "id": 524,
                        "displayName": "year_524"
                  },
                  {
                        "id": 525,
                        "displayName": "year_525"
                  },
                  {
                        "id": 526,
                        "displayName": "year_526"
                  },
                  {
                        "id": 527,
                        "displayName": "year_527"
                  },
                  {
                        "id": 528,
                        "displayName": "year_528"
                  },
                  {
                        "id": 529,
                        "displayName": "year_529"
                  },
                  {
                        "id": 530,
                        "displayName": "year_530"
                  },
                  {
                        "id": 531,
                        "displayName": "year_531"
                  },
                  {
                        "id": 532,
                        "displayName": "year_532"
                  },
                  {
                        "id": 533,
                        "displayName": "year_533"
                  },
                  {
                        "id": 534,
                        "displayName": "year_534"
                  },
                  {
                        "id": 535,
                        "displayName": "year_535"
                  },
                  {
                        "id": 536,
                        "displayName": "year_536"
                  },
                  {
                        "id": 537,
                        "displayName": "year_537"
                  },
                  {
                        "id": 538,
                        "displayName": "year_538"
                  },
                  {
                        "id": 539,
                        "displayName": "year_539"
                  },
                  {
                        "id": 540,
                        "displayName": "year_540"
                  },
                  {
                        "id": 541,
                        "displayName": "year_541"
                  },
                  {
                        "id": 542,
                        "displayName": "year_542"
                  },
                  {
                        "id": 543,
                        "displayName": "year_543"
                  },
                  {
                        "id": 544,
                        "displayName": "year_544"
                  },
                  {
                        "id": 545,
                        "displayName": "year_545"
                  },
                  {
                        "id": 546,
                        "displayName": "year_546"
                  },
                  {
                        "id": 547,
                        "displayName": "year_547"
                  },
                  {
                        "id": 548,
                        "displayName": "year_548"
                  },
                  {
                        "id": 549,
                        "displayName": "year_549"
                  },
                  {
                        "id": 550,
                        "displayName": "year_550"
                  },
                  {
                        "id": 551,
                        "displayName": "year_551"
                  },
                  {
                        "id": 552,
                        "displayName": "year_552"
                  },
                  {
                        "id": 553,
                        "displayName": "year_553"
                  },
                  {
                        "id": 554,
                        "displayName": "year_554"
                  },
                  {
                        "id": 555,
                        "displayName": "year_555"
                  },
                  {
                        "id": 556,
                        "displayName": "year_556"
                  },
                  {
                        "id": 557,
                        "displayName": "year_557"
                  },
                  {
                        "id": 558,
                        "displayName": "year_558"
                  },
                  {
                        "id": 559,
                        "displayName": "year_559"
                  },
                  {
                        "id": 560,
                        "displayName": "year_560"
                  },
                  {
                        "id": 561,
                        "displayName": "year_561"
                  },
                  {
                        "id": 562,
                        "displayName": "year_562"
                  },
                  {
                        "id": 563,
                        "displayName": "year_563"
                  },
                  {
                        "id": 564,
                        "displayName": "year_564"
                  },
                  {
                        "id": 565,
                        "displayName": "year_565"
                  },
                  {
                        "id": 566,
                        "displayName": "year_566"
                  },
                  {
                        "id": 567,
                        "displayName": "year_567"
                  },
                  {
                        "id": 568,
                        "displayName": "year_568"
                  },
                  {
                        "id": 569,
                        "displayName": "year_569"
                  },
                  {
                        "id": 570,
                        "displayName": "year_570"
                  },
                  {
                        "id": 571,
                        "displayName": "year_571"
                  },
                  {
                        "id": 572,
                        "displayName": "year_572"
                  },
                  {
                        "id": 573,
                        "displayName": "year_573"
                  },
                  {
                        "id": 574,
                        "displayName": "year_574"
                  },
                  {
                        "id": 575,
                        "displayName": "year_575"
                  },
                  {
                        "id": 576,
                        "displayName": "year_576"
                  },
                  {
                        "id": 577,
                        "displayName": "year_577"
                  },
                  {
                        "id": 578,
                        "displayName": "year_578"
                  },
                  {
                        "id": 579,
                        "displayName": "year_579"
                  },
                  {
                        "id": 580,
                        "displayName": "year_580"
                  },
                  {
                        "id": 581,
                        "displayName": "year_581"
                  },
                  {
                        "id": 582,
                        "displayName": "year_582"
                  },
                  {
                        "id": 583,
                        "displayName": "year_583"
                  },
                  {
                        "id": 584,
                        "displayName": "year_584"
                  },
                  {
                        "id": 585,
                        "displayName": "year_585"
                  },
                  {
                        "id": 586,
                        "displayName": "year_586"
                  },
                  {
                        "id": 587,
                        "displayName": "year_587"
                  },
                  {
                        "id": 588,
                        "displayName": "year_588"
                  },
                  {
                        "id": 589,
                        "displayName": "year_589"
                  },
                  {
                        "id": 590,
                        "displayName": "year_590"
                  },
                  {
                        "id": 591,
                        "displayName": "year_591"
                  },
                  {
                        "id": 592,
                        "displayName": "year_592"
                  },
                  {
                        "id": 593,
                        "displayName": "year_593"
                  },
                  {
                        "id": 594,
                        "displayName": "year_594"
                  },
                  {
                        "id": 595,
                        "displayName": "year_595"
                  },
                  {
                        "id": 596,
                        "displayName": "year_596"
                  },
                  {
                        "id": 597,
                        "displayName": "year_597"
                  },
                  {
                        "id": 598,
                        "displayName": "year_598"
                  },
                  {
                        "id": 599,
                        "displayName": "year_599"
                  },
                  {
                        "id": 600,
                        "displayName": "year_600"
                  },
                  {
                        "id": 601,
                        "displayName": "year_601"
                  },
                  {
                        "id": 602,
                        "displayName": "year_602"
                  },
                  {
                        "id": 603,
                        "displayName": "year_603"
                  },
                  {
                        "id": 604,
                        "displayName": "year_604"
                  },
                  {
                        "id": 605,
                        "displayName": "year_605"
                  },
                  {
                        "id": 606,
                        "displayName": "year_606"
                  },
                  {
                        "id": 607,
                        "displayName": "year_607"
                  },
                  {
                        "id": 608,
                        "displayName": "year_608"
                  },
                  {
                        "id": 609,
                        "displayName": "year_609"
                  },
                  {
                        "id": 610,
                        "displayName": "year_610"
                  },
                  {
                        "id": 611,
                        "displayName": "year_611"
                  },
                  {
                        "id": 612,
                        "displayName": "year_612"
                  },
                  {
                        "id": 613,
                        "displayName": "year_613"
                  },
                  {
                        "id": 614,
                        "displayName": "year_614"
                  },
                  {
                        "id": 615,
                        "displayName": "year_615"
                  },
                  {
                        "id": 616,
                        "displayName": "year_616"
                  },
                  {
                        "id": 617,
                        "displayName": "year_617"
                  },
                  {
                        "id": 618,
                        "displayName": "year_618"
                  },
                  {
                        "id": 619,
                        "displayName": "year_619"
                  },
                  {
                        "id": 620,
                        "displayName": "year_620"
                  },
                  {
                        "id": 621,
                        "displayName": "year_621"
                  },
                  {
                        "id": 622,
                        "displayName": "year_622"
                  },
                  {
                        "id": 623,
                        "displayName": "year_623"
                  },
                  {
                        "id": 624,
                        "displayName": "year_624"
                  },
                  {
                        "id": 625,
                        "displayName": "year_625"
                  },
                  {
                        "id": 626,
                        "displayName": "year_626"
                  },
                  {
                        "id": 627,
                        "displayName": "year_627"
                  },
                  {
                        "id": 628,
                        "displayName": "year_628"
                  },
                  {
                        "id": 629,
                        "displayName": "year_629"
                  },
                  {
                        "id": 630,
                        "displayName": "year_630"
                  },
                  {
                        "id": 631,
                        "displayName": "year_631"
                  },
                  {
                        "id": 632,
                        "displayName": "year_632"
                  },
                  {
                        "id": 633,
                        "displayName": "year_633"
                  },
                  {
                        "id": 634,
                        "displayName": "year_634"
                  },
                  {
                        "id": 635,
                        "displayName": "year_635"
                  },
                  {
                        "id": 636,
                        "displayName": "year_636"
                  },
                  {
                        "id": 637,
                        "displayName": "year_637"
                  },
                  {
                        "id": 638,
                        "displayName": "year_638"
                  },
                  {
                        "id": 639,
                        "displayName": "year_639"
                  },
                  {
                        "id": 640,
                        "displayName": "year_640"
                  },
                  {
                        "id": 641,
                        "displayName": "year_641"
                  },
                  {
                        "id": 642,
                        "displayName": "year_642"
                  },
                  {
                        "id": 643,
                        "displayName": "year_643"
                  },
                  {
                        "id": 644,
                        "displayName": "year_644"
                  },
                  {
                        "id": 645,
                        "displayName": "year_645"
                  },
                  {
                        "id": 646,
                        "displayName": "year_646"
                  },
                  {
                        "id": 647,
                        "displayName": "year_647"
                  },
                  {
                        "id": 648,
                        "displayName": "year_648"
                  },
                  {
                        "id": 649,
                        "displayName": "year_649"
                  },
                  {
                        "id": 650,
                        "displayName": "year_650"
                  },
                  {
                        "id": 651,
                        "displayName": "year_651"
                  },
                  {
                        "id": 652,
                        "displayName": "year_652"
                  },
                  {
                        "id": 653,
                        "displayName": "year_653"
                  },
                  {
                        "id": 654,
                        "displayName": "year_654"
                  },
                  {
                        "id": 655,
                        "displayName": "year_655"
                  },
                  {
                        "id": 656,
                        "displayName": "year_656"
                  },
                  {
                        "id": 657,
                        "displayName": "year_657"
                  },
                  {
                        "id": 658,
                        "displayName": "year_658"
                  },
                  {
                        "id": 659,
                        "displayName": "year_659"
                  },
                  {
                        "id": 660,
                        "displayName": "year_660"
                  },
                  {
                        "id": 661,
                        "displayName": "year_661"
                  },
                  {
                        "id": 662,
                        "displayName": "year_662"
                  },
                  {
                        "id": 663,
                        "displayName": "year_663"
                  },
                  {
                        "id": 664,
                        "displayName": "year_664"
                  },
                  {
                        "id": 665,
                        "displayName": "year_665"
                  },
                  {
                        "id": 666,
                        "displayName": "year_666"
                  },
                  {
                        "id": 667,
                        "displayName": "year_667"
                  },
                  {
                        "id": 668,
                        "displayName": "year_668"
                  },
                  {
                        "id": 669,
                        "displayName": "year_669"
                  },
                  {
                        "id": 670,
                        "displayName": "year_670"
                  },
                  {
                        "id": 671,
                        "displayName": "year_671"
                  },
                  {
                        "id": 672,
                        "displayName": "year_672"
                  },
                  {
                        "id": 673,
                        "displayName": "year_673"
                  },
                  {
                        "id": 674,
                        "displayName": "year_674"
                  },
                  {
                        "id": 675,
                        "displayName": "year_675"
                  },
                  {
                        "id": 676,
                        "displayName": "year_676"
                  },
                  {
                        "id": 677,
                        "displayName": "year_677"
                  },
                  {
                        "id": 678,
                        "displayName": "year_678"
                  },
                  {
                        "id": 679,
                        "displayName": "year_679"
                  },
                  {
                        "id": 680,
                        "displayName": "year_680"
                  },
                  {
                        "id": 681,
                        "displayName": "year_681"
                  },
                  {
                        "id": 682,
                        "displayName": "year_682"
                  },
                  {
                        "id": 683,
                        "displayName": "year_683"
                  },
                  {
                        "id": 684,
                        "displayName": "year_684"
                  },
                  {
                        "id": 685,
                        "displayName": "year_685"
                  },
                  {
                        "id": 686,
                        "displayName": "year_686"
                  },
                  {
                        "id": 687,
                        "displayName": "year_687"
                  },
                  {
                        "id": 688,
                        "displayName": "year_688"
                  },
                  {
                        "id": 689,
                        "displayName": "year_689"
                  },
                  {
                        "id": 690,
                        "displayName": "year_690"
                  },
                  {
                        "id": 691,
                        "displayName": "year_691"
                  },
                  {
                        "id": 692,
                        "displayName": "year_692"
                  },
                  {
                        "id": 693,
                        "displayName": "year_693"
                  },
                  {
                        "id": 694,
                        "displayName": "year_694"
                  },
                  {
                        "id": 695,
                        "displayName": "year_695"
                  },
                  {
                        "id": 696,
                        "displayName": "year_696"
                  },
                  {
                        "id": 697,
                        "displayName": "year_697"
                  },
                  {
                        "id": 698,
                        "displayName": "year_698"
                  },
                  {
                        "id": 699,
                        "displayName": "year_699"
                  },
                  {
                        "id": 700,
                        "displayName": "year_700"
                  },
                  {
                        "id": 701,
                        "displayName": "year_701"
                  },
                  {
                        "id": 702,
                        "displayName": "year_702"
                  },
                  {
                        "id": 703,
                        "displayName": "year_703"
                  },
                  {
                        "id": 704,
                        "displayName": "year_704"
                  },
                  {
                        "id": 705,
                        "displayName": "year_705"
                  },
                  {
                        "id": 706,
                        "displayName": "year_706"
                  },
                  {
                        "id": 707,
                        "displayName": "year_707"
                  },
                  {
                        "id": 708,
                        "displayName": "year_708"
                  },
                  {
                        "id": 709,
                        "displayName": "year_709"
                  },
                  {
                        "id": 710,
                        "displayName": "year_710"
                  },
                  {
                        "id": 711,
                        "displayName": "year_711"
                  },
                  {
                        "id": 712,
                        "displayName": "year_712"
                  },
                  {
                        "id": 713,
                        "displayName": "year_713"
                  },
                  {
                        "id": 714,
                        "displayName": "year_714"
                  },
                  {
                        "id": 715,
                        "displayName": "year_715"
                  },
                  {
                        "id": 716,
                        "displayName": "year_716"
                  },
                  {
                        "id": 717,
                        "displayName": "year_717"
                  },
                  {
                        "id": 718,
                        "displayName": "year_718"
                  },
                  {
                        "id": 719,
                        "displayName": "year_719"
                  },
                  {
                        "id": 720,
                        "displayName": "year_720"
                  },
                  {
                        "id": 721,
                        "displayName": "year_721"
                  },
                  {
                        "id": 722,
                        "displayName": "year_722"
                  },
                  {
                        "id": 723,
                        "displayName": "year_723"
                  },
                  {
                        "id": 724,
                        "displayName": "year_724"
                  },
                  {
                        "id": 725,
                        "displayName": "year_725"
                  },
                  {
                        "id": 726,
                        "displayName": "year_726"
                  },
                  {
                        "id": 727,
                        "displayName": "year_727"
                  },
                  {
                        "id": 728,
                        "displayName": "year_728"
                  },
                  {
                        "id": 729,
                        "displayName": "year_729"
                  },
                  {
                        "id": 730,
                        "displayName": "year_730"
                  },
                  {
                        "id": 731,
                        "displayName": "year_731"
                  },
                  {
                        "id": 732,
                        "displayName": "year_732"
                  },
                  {
                        "id": 733,
                        "displayName": "year_733"
                  },
                  {
                        "id": 734,
                        "displayName": "year_734"
                  },
                  {
                        "id": 735,
                        "displayName": "year_735"
                  },
                  {
                        "id": 736,
                        "displayName": "year_736"
                  },
                  {
                        "id": 737,
                        "displayName": "year_737"
                  },
                  {
                        "id": 738,
                        "displayName": "year_738"
                  },
                  {
                        "id": 739,
                        "displayName": "year_739"
                  },
                  {
                        "id": 740,
                        "displayName": "year_740"
                  },
                  {
                        "id": 741,
                        "displayName": "year_741"
                  },
                  {
                        "id": 742,
                        "displayName": "year_742"
                  },
                  {
                        "id": 743,
                        "displayName": "year_743"
                  },
                  {
                        "id": 744,
                        "displayName": "year_744"
                  },
                  {
                        "id": 745,
                        "displayName": "year_745"
                  },
                  {
                        "id": 746,
                        "displayName": "year_746"
                  },
                  {
                        "id": 747,
                        "displayName": "year_747"
                  },
                  {
                        "id": 748,
                        "displayName": "year_748"
                  },
                  {
                        "id": 749,
                        "displayName": "year_749"
                  },
                  {
                        "id": 750,
                        "displayName": "year_750"
                  },
                  {
                        "id": 751,
                        "displayName": "year_751"
                  },
                  {
                        "id": 752,
                        "displayName": "year_752"
                  },
                  {
                        "id": 753,
                        "displayName": "year_753"
                  },
                  {
                        "id": 754,
                        "displayName": "year_754"
                  },
                  {
                        "id": 755,
                        "displayName": "year_755"
                  },
                  {
                        "id": 756,
                        "displayName": "year_756"
                  },
                  {
                        "id": 757,
                        "displayName": "year_757"
                  },
                  {
                        "id": 758,
                        "displayName": "year_758"
                  },
                  {
                        "id": 759,
                        "displayName": "year_759"
                  },
                  {
                        "id": 760,
                        "displayName": "year_760"
                  },
                  {
                        "id": 761,
                        "displayName": "year_761"
                  },
                  {
                        "id": 762,
                        "displayName": "year_762"
                  },
                  {
                        "id": 763,
                        "displayName": "year_763"
                  },
                  {
                        "id": 764,
                        "displayName": "year_764"
                  },
                  {
                        "id": 765,
                        "displayName": "year_765"
                  },
                  {
                        "id": 766,
                        "displayName": "year_766"
                  },
                  {
                        "id": 767,
                        "displayName": "year_767"
                  },
                  {
                        "id": 768,
                        "displayName": "year_768"
                  },
                  {
                        "id": 769,
                        "displayName": "year_769"
                  },
                  {
                        "id": 770,
                        "displayName": "year_770"
                  },
                  {
                        "id": 771,
                        "displayName": "year_771"
                  },
                  {
                        "id": 772,
                        "displayName": "year_772"
                  },
                  {
                        "id": 773,
                        "displayName": "year_773"
                  },
                  {
                        "id": 774,
                        "displayName": "year_774"
                  },
                  {
                        "id": 775,
                        "displayName": "year_775"
                  },
                  {
                        "id": 776,
                        "displayName": "year_776"
                  },
                  {
                        "id": 777,
                        "displayName": "year_777"
                  },
                  {
                        "id": 778,
                        "displayName": "year_778"
                  },
                  {
                        "id": 779,
                        "displayName": "year_779"
                  },
                  {
                        "id": 780,
                        "displayName": "year_780"
                  },
                  {
                        "id": 781,
                        "displayName": "year_781"
                  },
                  {
                        "id": 782,
                        "displayName": "year_782"
                  },
                  {
                        "id": 783,
                        "displayName": "year_783"
                  },
                  {
                        "id": 784,
                        "displayName": "year_784"
                  },
                  {
                        "id": 785,
                        "displayName": "year_785"
                  },
                  {
                        "id": 786,
                        "displayName": "year_786"
                  },
                  {
                        "id": 787,
                        "displayName": "year_787"
                  },
                  {
                        "id": 788,
                        "displayName": "year_788"
                  },
                  {
                        "id": 789,
                        "displayName": "year_789"
                  },
                  {
                        "id": 790,
                        "displayName": "year_790"
                  },
                  {
                        "id": 791,
                        "displayName": "year_791"
                  },
                  {
                        "id": 792,
                        "displayName": "year_792"
                  },
                  {
                        "id": 793,
                        "displayName": "year_793"
                  },
                  {
                        "id": 794,
                        "displayName": "year_794"
                  },
                  {
                        "id": 795,
                        "displayName": "year_795"
                  },
                  {
                        "id": 796,
                        "displayName": "year_796"
                  },
                  {
                        "id": 797,
                        "displayName": "year_797"
                  },
                  {
                        "id": 798,
                        "displayName": "year_798"
                  },
                  {
                        "id": 799,
                        "displayName": "year_799"
                  },
                  {
                        "id": 800,
                        "displayName": "year_800"
                  },
                  {
                        "id": 801,
                        "displayName": "year_801"
                  },
                  {
                        "id": 802,
                        "displayName": "year_802"
                  },
                  {
                        "id": 803,
                        "displayName": "year_803"
                  },
                  {
                        "id": 804,
                        "displayName": "year_804"
                  },
                  {
                        "id": 805,
                        "displayName": "year_805"
                  },
                  {
                        "id": 806,
                        "displayName": "year_806"
                  },
                  {
                        "id": 807,
                        "displayName": "year_807"
                  },
                  {
                        "id": 808,
                        "displayName": "year_808"
                  },
                  {
                        "id": 809,
                        "displayName": "year_809"
                  },
                  {
                        "id": 810,
                        "displayName": "year_810"
                  },
                  {
                        "id": 811,
                        "displayName": "year_811"
                  },
                  {
                        "id": 812,
                        "displayName": "year_812"
                  },
                  {
                        "id": 813,
                        "displayName": "year_813"
                  },
                  {
                        "id": 814,
                        "displayName": "year_814"
                  },
                  {
                        "id": 815,
                        "displayName": "year_815"
                  },
                  {
                        "id": 816,
                        "displayName": "year_816"
                  },
                  {
                        "id": 817,
                        "displayName": "year_817"
                  },
                  {
                        "id": 818,
                        "displayName": "year_818"
                  },
                  {
                        "id": 819,
                        "displayName": "year_819"
                  },
                  {
                        "id": 820,
                        "displayName": "year_820"
                  },
                  {
                        "id": 821,
                        "displayName": "year_821"
                  },
                  {
                        "id": 822,
                        "displayName": "year_822"
                  },
                  {
                        "id": 823,
                        "displayName": "year_823"
                  },
                  {
                        "id": 824,
                        "displayName": "year_824"
                  },
                  {
                        "id": 825,
                        "displayName": "year_825"
                  },
                  {
                        "id": 826,
                        "displayName": "year_826"
                  },
                  {
                        "id": 827,
                        "displayName": "year_827"
                  },
                  {
                        "id": 828,
                        "displayName": "year_828"
                  },
                  {
                        "id": 829,
                        "displayName": "year_829"
                  },
                  {
                        "id": 830,
                        "displayName": "year_830"
                  },
                  {
                        "id": 831,
                        "displayName": "year_831"
                  },
                  {
                        "id": 832,
                        "displayName": "year_832"
                  },
                  {
                        "id": 833,
                        "displayName": "year_833"
                  },
                  {
                        "id": 834,
                        "displayName": "year_834"
                  },
                  {
                        "id": 835,
                        "displayName": "year_835"
                  },
                  {
                        "id": 836,
                        "displayName": "year_836"
                  },
                  {
                        "id": 837,
                        "displayName": "year_837"
                  },
                  {
                        "id": 838,
                        "displayName": "year_838"
                  },
                  {
                        "id": 839,
                        "displayName": "year_839"
                  },
                  {
                        "id": 840,
                        "displayName": "year_840"
                  },
                  {
                        "id": 841,
                        "displayName": "year_841"
                  },
                  {
                        "id": 842,
                        "displayName": "year_842"
                  },
                  {
                        "id": 843,
                        "displayName": "year_843"
                  },
                  {
                        "id": 844,
                        "displayName": "year_844"
                  },
                  {
                        "id": 845,
                        "displayName": "year_845"
                  },
                  {
                        "id": 846,
                        "displayName": "year_846"
                  },
                  {
                        "id": 847,
                        "displayName": "year_847"
                  },
                  {
                        "id": 848,
                        "displayName": "year_848"
                  },
                  {
                        "id": 849,
                        "displayName": "year_849"
                  },
                  {
                        "id": 850,
                        "displayName": "year_850"
                  },
                  {
                        "id": 851,
                        "displayName": "year_851"
                  },
                  {
                        "id": 852,
                        "displayName": "year_852"
                  },
                  {
                        "id": 853,
                        "displayName": "year_853"
                  },
                  {
                        "id": 854,
                        "displayName": "year_854"
                  },
                  {
                        "id": 855,
                        "displayName": "year_855"
                  },
                  {
                        "id": 856,
                        "displayName": "year_856"
                  },
                  {
                        "id": 857,
                        "displayName": "year_857"
                  },
                  {
                        "id": 858,
                        "displayName": "year_858"
                  },
                  {
                        "id": 859,
                        "displayName": "year_859"
                  },
                  {
                        "id": 860,
                        "displayName": "year_860"
                  },
                  {
                        "id": 861,
                        "displayName": "year_861"
                  },
                  {
                        "id": 862,
                        "displayName": "year_862"
                  },
                  {
                        "id": 863,
                        "displayName": "year_863"
                  },
                  {
                        "id": 864,
                        "displayName": "year_864"
                  },
                  {
                        "id": 865,
                        "displayName": "year_865"
                  },
                  {
                        "id": 866,
                        "displayName": "year_866"
                  },
                  {
                        "id": 867,
                        "displayName": "year_867"
                  },
                  {
                        "id": 868,
                        "displayName": "year_868"
                  },
                  {
                        "id": 869,
                        "displayName": "year_869"
                  },
                  {
                        "id": 870,
                        "displayName": "year_870"
                  },
                  {
                        "id": 871,
                        "displayName": "year_871"
                  },
                  {
                        "id": 872,
                        "displayName": "year_872"
                  },
                  {
                        "id": 873,
                        "displayName": "year_873"
                  },
                  {
                        "id": 874,
                        "displayName": "year_874"
                  },
                  {
                        "id": 875,
                        "displayName": "year_875"
                  },
                  {
                        "id": 876,
                        "displayName": "year_876"
                  },
                  {
                        "id": 877,
                        "displayName": "year_877"
                  },
                  {
                        "id": 878,
                        "displayName": "year_878"
                  },
                  {
                        "id": 879,
                        "displayName": "year_879"
                  },
                  {
                        "id": 880,
                        "displayName": "year_880"
                  },
                  {
                        "id": 881,
                        "displayName": "year_881"
                  },
                  {
                        "id": 882,
                        "displayName": "year_882"
                  },
                  {
                        "id": 883,
                        "displayName": "year_883"
                  },
                  {
                        "id": 884,
                        "displayName": "year_884"
                  },
                  {
                        "id": 885,
                        "displayName": "year_885"
                  },
                  {
                        "id": 886,
                        "displayName": "year_886"
                  },
                  {
                        "id": 887,
                        "displayName": "year_887"
                  },
                  {
                        "id": 888,
                        "displayName": "year_888"
                  },
                  {
                        "id": 889,
                        "displayName": "year_889"
                  },
                  {
                        "id": 890,
                        "displayName": "year_890"
                  },
                  {
                        "id": 891,
                        "displayName": "year_891"
                  },
                  {
                        "id": 892,
                        "displayName": "year_892"
                  },
                  {
                        "id": 893,
                        "displayName": "year_893"
                  },
                  {
                        "id": 894,
                        "displayName": "year_894"
                  },
                  {
                        "id": 895,
                        "displayName": "year_895"
                  },
                  {
                        "id": 896,
                        "displayName": "year_896"
                  },
                  {
                        "id": 897,
                        "displayName": "year_897"
                  },
                  {
                        "id": 898,
                        "displayName": "year_898"
                  },
                  {
                        "id": 899,
                        "displayName": "year_899"
                  },
                  {
                        "id": 900,
                        "displayName": "year_900"
                  },
                  {
                        "id": 901,
                        "displayName": "year_901"
                  },
                  {
                        "id": 902,
                        "displayName": "year_902"
                  },
                  {
                        "id": 903,
                        "displayName": "year_903"
                  },
                  {
                        "id": 904,
                        "displayName": "year_904"
                  },
                  {
                        "id": 905,
                        "displayName": "year_905"
                  },
                  {
                        "id": 906,
                        "displayName": "year_906"
                  },
                  {
                        "id": 907,
                        "displayName": "year_907"
                  },
                  {
                        "id": 908,
                        "displayName": "year_908"
                  },
                  {
                        "id": 909,
                        "displayName": "year_909"
                  },
                  {
                        "id": 910,
                        "displayName": "year_910"
                  },
                  {
                        "id": 911,
                        "displayName": "year_911"
                  },
                  {
                        "id": 912,
                        "displayName": "year_912"
                  },
                  {
                        "id": 913,
                        "displayName": "year_913"
                  },
                  {
                        "id": 914,
                        "displayName": "year_914"
                  },
                  {
                        "id": 915,
                        "displayName": "year_915"
                  },
                  {
                        "id": 916,
                        "displayName": "year_916"
                  },
                  {
                        "id": 917,
                        "displayName": "year_917"
                  },
                  {
                        "id": 918,
                        "displayName": "year_918"
                  },
                  {
                        "id": 919,
                        "displayName": "year_919"
                  },
                  {
                        "id": 920,
                        "displayName": "year_920"
                  },
                  {
                        "id": 921,
                        "displayName": "year_921"
                  },
                  {
                        "id": 922,
                        "displayName": "year_922"
                  },
                  {
                        "id": 923,
                        "displayName": "year_923"
                  },
                  {
                        "id": 924,
                        "displayName": "year_924"
                  },
                  {
                        "id": 925,
                        "displayName": "year_925"
                  },
                  {
                        "id": 926,
                        "displayName": "year_926"
                  },
                  {
                        "id": 927,
                        "displayName": "year_927"
                  },
                  {
                        "id": 928,
                        "displayName": "year_928"
                  },
                  {
                        "id": 929,
                        "displayName": "year_929"
                  },
                  {
                        "id": 930,
                        "displayName": "year_930"
                  },
                  {
                        "id": 931,
                        "displayName": "year_931"
                  },
                  {
                        "id": 932,
                        "displayName": "year_932"
                  },
                  {
                        "id": 933,
                        "displayName": "year_933"
                  },
                  {
                        "id": 934,
                        "displayName": "year_934"
                  },
                  {
                        "id": 935,
                        "displayName": "year_935"
                  },
                  {
                        "id": 936,
                        "displayName": "year_936"
                  },
                  {
                        "id": 937,
                        "displayName": "year_937"
                  },
                  {
                        "id": 938,
                        "displayName": "year_938"
                  },
                  {
                        "id": 939,
                        "displayName": "year_939"
                  },
                  {
                        "id": 940,
                        "displayName": "year_940"
                  },
                  {
                        "id": 941,
                        "displayName": "year_941"
                  },
                  {
                        "id": 942,
                        "displayName": "year_942"
                  },
                  {
                        "id": 943,
                        "displayName": "year_943"
                  },
                  {
                        "id": 944,
                        "displayName": "year_944"
                  },
                  {
                        "id": 945,
                        "displayName": "year_945"
                  },
                  {
                        "id": 946,
                        "displayName": "year_946"
                  },
                  {
                        "id": 947,
                        "displayName": "year_947"
                  },
                  {
                        "id": 948,
                        "displayName": "year_948"
                  },
                  {
                        "id": 949,
                        "displayName": "year_949"
                  },
                  {
                        "id": 950,
                        "displayName": "year_950"
                  },
                  {
                        "id": 951,
                        "displayName": "year_951"
                  },
                  {
                        "id": 952,
                        "displayName": "year_952"
                  },
                  {
                        "id": 953,
                        "displayName": "year_953"
                  },
                  {
                        "id": 954,
                        "displayName": "year_954"
                  },
                  {
                        "id": 955,
                        "displayName": "year_955"
                  },
                  {
                        "id": 956,
                        "displayName": "year_956"
                  },
                  {
                        "id": 957,
                        "displayName": "year_957"
                  },
                  {
                        "id": 958,
                        "displayName": "year_958"
                  },
                  {
                        "id": 959,
                        "displayName": "year_959"
                  },
                  {
                        "id": 960,
                        "displayName": "year_960"
                  },
                  {
                        "id": 961,
                        "displayName": "year_961"
                  },
                  {
                        "id": 962,
                        "displayName": "year_962"
                  },
                  {
                        "id": 963,
                        "displayName": "year_963"
                  },
                  {
                        "id": 964,
                        "displayName": "year_964"
                  },
                  {
                        "id": 965,
                        "displayName": "year_965"
                  },
                  {
                        "id": 966,
                        "displayName": "year_966"
                  },
                  {
                        "id": 967,
                        "displayName": "year_967"
                  },
                  {
                        "id": 968,
                        "displayName": "year_968"
                  },
                  {
                        "id": 969,
                        "displayName": "year_969"
                  },
                  {
                        "id": 970,
                        "displayName": "year_970"
                  },
                  {
                        "id": 971,
                        "displayName": "year_971"
                  },
                  {
                        "id": 972,
                        "displayName": "year_972"
                  },
                  {
                        "id": 973,
                        "displayName": "year_973"
                  },
                  {
                        "id": 974,
                        "displayName": "year_974"
                  },
                  {
                        "id": 975,
                        "displayName": "year_975"
                  },
                  {
                        "id": 976,
                        "displayName": "year_976"
                  },
                  {
                        "id": 977,
                        "displayName": "year_977"
                  },
                  {
                        "id": 978,
                        "displayName": "year_978"
                  },
                  {
                        "id": 979,
                        "displayName": "year_979"
                  },
                  {
                        "id": 980,
                        "displayName": "year_980"
                  },
                  {
                        "id": 981,
                        "displayName": "year_981"
                  },
                  {
                        "id": 982,
                        "displayName": "year_982"
                  },
                  {
                        "id": 983,
                        "displayName": "year_983"
                  },
                  {
                        "id": 984,
                        "displayName": "year_984"
                  },
                  {
                        "id": 985,
                        "displayName": "year_985"
                  },
                  {
                        "id": 986,
                        "displayName": "year_986"
                  },
                  {
                        "id": 987,
                        "displayName": "year_987"
                  },
                  {
                        "id": 988,
                        "displayName": "year_988"
                  },
                  {
                        "id": 989,
                        "displayName": "year_989"
                  },
                  {
                        "id": 990,
                        "displayName": "year_990"
                  },
                  {
                        "id": 991,
                        "displayName": "year_991"
                  },
                  {
                        "id": 992,
                        "displayName": "year_992"
                  },
                  {
                        "id": 993,
                        "displayName": "year_993"
                  },
                  {
                        "id": 994,
                        "displayName": "year_994"
                  },
                  {
                        "id": 995,
                        "displayName": "year_995"
                  },
                  {
                        "id": 996,
                        "displayName": "year_996"
                  },
                  {
                        "id": 997,
                        "displayName": "year_997"
                  },
                  {
                        "id": 998,
                        "displayName": "year_998"
                  },
                  {
                        "id": 999,
                        "displayName": "year_999"
                  },
                  {
                        "id": 1000,
                        "displayName": "year_1000"
                  },
                  {
                        "id": 1001,
                        "displayName": "year_1001"
                  },
                  {
                        "id": 1002,
                        "displayName": "year_1002"
                  },
                  {
                        "id": 1003,
                        "displayName": "year_1003"
                  },
                  {
                        "id": 1004,
                        "displayName": "year_1004"
                  },
                  {
                        "id": 1005,
                        "displayName": "year_1005"
                  },
                  {
                        "id": 1006,
                        "displayName": "year_1006"
                  },
                  {
                        "id": 1007,
                        "displayName": "year_1007"
                  },
                  {
                        "id": 1008,
                        "displayName": "year_1008"
                  },
                  {
                        "id": 1009,
                        "displayName": "year_1009"
                  },
                  {
                        "id": 1010,
                        "displayName": "year_1010"
                  },
                  {
                        "id": 1011,
                        "displayName": "year_1011"
                  },
                  {
                        "id": 1012,
                        "displayName": "year_1012"
                  },
                  {
                        "id": 1013,
                        "displayName": "year_1013"
                  },
                  {
                        "id": 1014,
                        "displayName": "year_1014"
                  },
                  {
                        "id": 1015,
                        "displayName": "year_1015"
                  },
                  {
                        "id": 1016,
                        "displayName": "year_1016"
                  },
                  {
                        "id": 1017,
                        "displayName": "year_1017"
                  },
                  {
                        "id": 1018,
                        "displayName": "year_1018"
                  },
                  {
                        "id": 1019,
                        "displayName": "year_1019"
                  },
                  {
                        "id": 1020,
                        "displayName": "year_1020"
                  },
                  {
                        "id": 1021,
                        "displayName": "year_1021"
                  },
                  {
                        "id": 1022,
                        "displayName": "year_1022"
                  },
                  {
                        "id": 1023,
                        "displayName": "year_1023"
                  },
                  {
                        "id": 1024,
                        "displayName": "year_1024"
                  },
                  {
                        "id": 1025,
                        "displayName": "year_1025"
                  },
                  {
                        "id": 1026,
                        "displayName": "year_1026"
                  },
                  {
                        "id": 1027,
                        "displayName": "year_1027"
                  },
                  {
                        "id": 1028,
                        "displayName": "year_1028"
                  },
                  {
                        "id": 1029,
                        "displayName": "year_1029"
                  },
                  {
                        "id": 1030,
                        "displayName": "year_1030"
                  },
                  {
                        "id": 1031,
                        "displayName": "year_1031"
                  },
                  {
                        "id": 1032,
                        "displayName": "year_1032"
                  },
                  {
                        "id": 1033,
                        "displayName": "year_1033"
                  },
                  {
                        "id": 1034,
                        "displayName": "year_1034"
                  },
                  {
                        "id": 1035,
                        "displayName": "year_1035"
                  },
                  {
                        "id": 1036,
                        "displayName": "year_1036"
                  },
                  {
                        "id": 1037,
                        "displayName": "year_1037"
                  },
                  {
                        "id": 1038,
                        "displayName": "year_1038"
                  },
                  {
                        "id": 1039,
                        "displayName": "year_1039"
                  },
                  {
                        "id": 1040,
                        "displayName": "year_1040"
                  },
                  {
                        "id": 1041,
                        "displayName": "year_1041"
                  },
                  {
                        "id": 1042,
                        "displayName": "year_1042"
                  },
                  {
                        "id": 1043,
                        "displayName": "year_1043"
                  },
                  {
                        "id": 1044,
                        "displayName": "year_1044"
                  },
                  {
                        "id": 1045,
                        "displayName": "year_1045"
                  },
                  {
                        "id": 1046,
                        "displayName": "year_1046"
                  },
                  {
                        "id": 1047,
                        "displayName": "year_1047"
                  },
                  {
                        "id": 1048,
                        "displayName": "year_1048"
                  },
                  {
                        "id": 1049,
                        "displayName": "year_1049"
                  },
                  {
                        "id": 1050,
                        "displayName": "year_1050"
                  },
                  {
                        "id": 1051,
                        "displayName": "year_1051"
                  },
                  {
                        "id": 1052,
                        "displayName": "year_1052"
                  },
                  {
                        "id": 1053,
                        "displayName": "year_1053"
                  },
                  {
                        "id": 1054,
                        "displayName": "year_1054"
                  },
                  {
                        "id": 1055,
                        "displayName": "year_1055"
                  },
                  {
                        "id": 1056,
                        "displayName": "year_1056"
                  },
                  {
                        "id": 1057,
                        "displayName": "year_1057"
                  },
                  {
                        "id": 1058,
                        "displayName": "year_1058"
                  },
                  {
                        "id": 1059,
                        "displayName": "year_1059"
                  },
                  {
                        "id": 1060,
                        "displayName": "year_1060"
                  },
                  {
                        "id": 1061,
                        "displayName": "year_1061"
                  },
                  {
                        "id": 1062,
                        "displayName": "year_1062"
                  },
                  {
                        "id": 1063,
                        "displayName": "year_1063"
                  },
                  {
                        "id": 1064,
                        "displayName": "year_1064"
                  },
                  {
                        "id": 1065,
                        "displayName": "year_1065"
                  },
                  {
                        "id": 1066,
                        "displayName": "year_1066"
                  },
                  {
                        "id": 1067,
                        "displayName": "year_1067"
                  },
                  {
                        "id": 1068,
                        "displayName": "year_1068"
                  },
                  {
                        "id": 1069,
                        "displayName": "year_1069"
                  },
                  {
                        "id": 1070,
                        "displayName": "year_1070"
                  },
                  {
                        "id": 1071,
                        "displayName": "year_1071"
                  },
                  {
                        "id": 1072,
                        "displayName": "year_1072"
                  },
                  {
                        "id": 1073,
                        "displayName": "year_1073"
                  },
                  {
                        "id": 1074,
                        "displayName": "year_1074"
                  },
                  {
                        "id": 1075,
                        "displayName": "year_1075"
                  },
                  {
                        "id": 1076,
                        "displayName": "year_1076"
                  },
                  {
                        "id": 1077,
                        "displayName": "year_1077"
                  },
                  {
                        "id": 1078,
                        "displayName": "year_1078"
                  },
                  {
                        "id": 1079,
                        "displayName": "year_1079"
                  },
                  {
                        "id": 1080,
                        "displayName": "year_1080"
                  },
                  {
                        "id": 1081,
                        "displayName": "year_1081"
                  },
                  {
                        "id": 1082,
                        "displayName": "year_1082"
                  },
                  {
                        "id": 1083,
                        "displayName": "year_1083"
                  },
                  {
                        "id": 1084,
                        "displayName": "year_1084"
                  },
                  {
                        "id": 1085,
                        "displayName": "year_1085"
                  },
                  {
                        "id": 1086,
                        "displayName": "year_1086"
                  },
                  {
                        "id": 1087,
                        "displayName": "year_1087"
                  },
                  {
                        "id": 1088,
                        "displayName": "year_1088"
                  },
                  {
                        "id": 1089,
                        "displayName": "year_1089"
                  },
                  {
                        "id": 1090,
                        "displayName": "year_1090"
                  },
                  {
                        "id": 1091,
                        "displayName": "year_1091"
                  },
                  {
                        "id": 1092,
                        "displayName": "year_1092"
                  },
                  {
                        "id": 1093,
                        "displayName": "year_1093"
                  },
                  {
                        "id": 1094,
                        "displayName": "year_1094"
                  },
                  {
                        "id": 1095,
                        "displayName": "year_1095"
                  },
                  {
                        "id": 1096,
                        "displayName": "year_1096"
                  },
                  {
                        "id": 1097,
                        "displayName": "year_1097"
                  },
                  {
                        "id": 1098,
                        "displayName": "year_1098"
                  },
                  {
                        "id": 1099,
                        "displayName": "year_1099"
                  },
                  {
                        "id": 1100,
                        "displayName": "year_1100"
                  },
                  {
                        "id": 1101,
                        "displayName": "year_1101"
                  },
                  {
                        "id": 1102,
                        "displayName": "year_1102"
                  },
                  {
                        "id": 1103,
                        "displayName": "year_1103"
                  },
                  {
                        "id": 1104,
                        "displayName": "year_1104"
                  },
                  {
                        "id": 1105,
                        "displayName": "year_1105"
                  },
                  {
                        "id": 1106,
                        "displayName": "year_1106"
                  },
                  {
                        "id": 1107,
                        "displayName": "year_1107"
                  },
                  {
                        "id": 1108,
                        "displayName": "year_1108"
                  },
                  {
                        "id": 1109,
                        "displayName": "year_1109"
                  },
                  {
                        "id": 1110,
                        "displayName": "year_1110"
                  },
                  {
                        "id": 1111,
                        "displayName": "year_1111"
                  },
                  {
                        "id": 1112,
                        "displayName": "year_1112"
                  },
                  {
                        "id": 1113,
                        "displayName": "year_1113"
                  },
                  {
                        "id": 1114,
                        "displayName": "year_1114"
                  },
                  {
                        "id": 1115,
                        "displayName": "year_1115"
                  },
                  {
                        "id": 1116,
                        "displayName": "year_1116"
                  },
                  {
                        "id": 1117,
                        "displayName": "year_1117"
                  },
                  {
                        "id": 1118,
                        "displayName": "year_1118"
                  },
                  {
                        "id": 1119,
                        "displayName": "year_1119"
                  },
                  {
                        "id": 1120,
                        "displayName": "year_1120"
                  },
                  {
                        "id": 1121,
                        "displayName": "year_1121"
                  },
                  {
                        "id": 1122,
                        "displayName": "year_1122"
                  },
                  {
                        "id": 1123,
                        "displayName": "year_1123"
                  },
                  {
                        "id": 1124,
                        "displayName": "year_1124"
                  },
                  {
                        "id": 1125,
                        "displayName": "year_1125"
                  },
                  {
                        "id": 1126,
                        "displayName": "year_1126"
                  },
                  {
                        "id": 1127,
                        "displayName": "year_1127"
                  },
                  {
                        "id": 1128,
                        "displayName": "year_1128"
                  },
                  {
                        "id": 1129,
                        "displayName": "year_1129"
                  },
                  {
                        "id": 1130,
                        "displayName": "year_1130"
                  },
                  {
                        "id": 1131,
                        "displayName": "year_1131"
                  },
                  {
                        "id": 1132,
                        "displayName": "year_1132"
                  },
                  {
                        "id": 1133,
                        "displayName": "year_1133"
                  },
                  {
                        "id": 1134,
                        "displayName": "year_1134"
                  },
                  {
                        "id": 1135,
                        "displayName": "year_1135"
                  },
                  {
                        "id": 1136,
                        "displayName": "year_1136"
                  },
                  {
                        "id": 1137,
                        "displayName": "year_1137"
                  },
                  {
                        "id": 1138,
                        "displayName": "year_1138"
                  },
                  {
                        "id": 1139,
                        "displayName": "year_1139"
                  },
                  {
                        "id": 1140,
                        "displayName": "year_1140"
                  },
                  {
                        "id": 1141,
                        "displayName": "year_1141"
                  },
                  {
                        "id": 1142,
                        "displayName": "year_1142"
                  },
                  {
                        "id": 1143,
                        "displayName": "year_1143"
                  },
                  {
                        "id": 1144,
                        "displayName": "year_1144"
                  },
                  {
                        "id": 1145,
                        "displayName": "year_1145"
                  },
                  {
                        "id": 1146,
                        "displayName": "year_1146"
                  },
                  {
                        "id": 1147,
                        "displayName": "year_1147"
                  },
                  {
                        "id": 1148,
                        "displayName": "year_1148"
                  },
                  {
                        "id": 1149,
                        "displayName": "year_1149"
                  },
                  {
                        "id": 1150,
                        "displayName": "year_1150"
                  },
                  {
                        "id": 1151,
                        "displayName": "year_1151"
                  },
                  {
                        "id": 1152,
                        "displayName": "year_1152"
                  },
                  {
                        "id": 1153,
                        "displayName": "year_1153"
                  },
                  {
                        "id": 1154,
                        "displayName": "year_1154"
                  },
                  {
                        "id": 1155,
                        "displayName": "year_1155"
                  },
                  {
                        "id": 1156,
                        "displayName": "year_1156"
                  },
                  {
                        "id": 1157,
                        "displayName": "year_1157"
                  },
                  {
                        "id": 1158,
                        "displayName": "year_1158"
                  },
                  {
                        "id": 1159,
                        "displayName": "year_1159"
                  },
                  {
                        "id": 1160,
                        "displayName": "year_1160"
                  },
                  {
                        "id": 1161,
                        "displayName": "year_1161"
                  },
                  {
                        "id": 1162,
                        "displayName": "year_1162"
                  },
                  {
                        "id": 1163,
                        "displayName": "year_1163"
                  },
                  {
                        "id": 1164,
                        "displayName": "year_1164"
                  },
                  {
                        "id": 1165,
                        "displayName": "year_1165"
                  },
                  {
                        "id": 1166,
                        "displayName": "year_1166"
                  },
                  {
                        "id": 1167,
                        "displayName": "year_1167"
                  },
                  {
                        "id": 1168,
                        "displayName": "year_1168"
                  },
                  {
                        "id": 1169,
                        "displayName": "year_1169"
                  },
                  {
                        "id": 1170,
                        "displayName": "year_1170"
                  },
                  {
                        "id": 1171,
                        "displayName": "year_1171"
                  },
                  {
                        "id": 1172,
                        "displayName": "year_1172"
                  },
                  {
                        "id": 1173,
                        "displayName": "year_1173"
                  },
                  {
                        "id": 1174,
                        "displayName": "year_1174"
                  },
                  {
                        "id": 1175,
                        "displayName": "year_1175"
                  },
                  {
                        "id": 1176,
                        "displayName": "year_1176"
                  },
                  {
                        "id": 1177,
                        "displayName": "year_1177"
                  },
                  {
                        "id": 1178,
                        "displayName": "year_1178"
                  },
                  {
                        "id": 1179,
                        "displayName": "year_1179"
                  },
                  {
                        "id": 1180,
                        "displayName": "year_1180"
                  },
                  {
                        "id": 1181,
                        "displayName": "year_1181"
                  },
                  {
                        "id": 1182,
                        "displayName": "year_1182"
                  },
                  {
                        "id": 1183,
                        "displayName": "year_1183"
                  },
                  {
                        "id": 1184,
                        "displayName": "year_1184"
                  },
                  {
                        "id": 1185,
                        "displayName": "year_1185"
                  },
                  {
                        "id": 1186,
                        "displayName": "year_1186"
                  },
                  {
                        "id": 1187,
                        "displayName": "year_1187"
                  },
                  {
                        "id": 1188,
                        "displayName": "year_1188"
                  },
                  {
                        "id": 1189,
                        "displayName": "year_1189"
                  },
                  {
                        "id": 1190,
                        "displayName": "year_1190"
                  },
                  {
                        "id": 1191,
                        "displayName": "year_1191"
                  },
                  {
                        "id": 1192,
                        "displayName": "year_1192"
                  },
                  {
                        "id": 1193,
                        "displayName": "year_1193"
                  },
                  {
                        "id": 1194,
                        "displayName": "year_1194"
                  },
                  {
                        "id": 1195,
                        "displayName": "year_1195"
                  },
                  {
                        "id": 1196,
                        "displayName": "year_1196"
                  },
                  {
                        "id": 1197,
                        "displayName": "year_1197"
                  },
                  {
                        "id": 1198,
                        "displayName": "year_1198"
                  },
                  {
                        "id": 1199,
                        "displayName": "year_1199"
                  },
                  {
                        "id": 1200,
                        "displayName": "year_1200"
                  },
                  {
                        "id": 1201,
                        "displayName": "year_1201"
                  },
                  {
                        "id": 1202,
                        "displayName": "year_1202"
                  },
                  {
                        "id": 1203,
                        "displayName": "year_1203"
                  },
                  {
                        "id": 1204,
                        "displayName": "year_1204"
                  },
                  {
                        "id": 1205,
                        "displayName": "year_1205"
                  },
                  {
                        "id": 1206,
                        "displayName": "year_1206"
                  },
                  {
                        "id": 1207,
                        "displayName": "year_1207"
                  },
                  {
                        "id": 1208,
                        "displayName": "year_1208"
                  },
                  {
                        "id": 1209,
                        "displayName": "year_1209"
                  },
                  {
                        "id": 1210,
                        "displayName": "year_1210"
                  },
                  {
                        "id": 1211,
                        "displayName": "year_1211"
                  },
                  {
                        "id": 1212,
                        "displayName": "year_1212"
                  },
                  {
                        "id": 1213,
                        "displayName": "year_1213"
                  },
                  {
                        "id": 1214,
                        "displayName": "year_1214"
                  },
                  {
                        "id": 1215,
                        "displayName": "year_1215"
                  },
                  {
                        "id": 1216,
                        "displayName": "year_1216"
                  },
                  {
                        "id": 1217,
                        "displayName": "year_1217"
                  },
                  {
                        "id": 1218,
                        "displayName": "year_1218"
                  },
                  {
                        "id": 1219,
                        "displayName": "year_1219"
                  },
                  {
                        "id": 1220,
                        "displayName": "year_1220"
                  },
                  {
                        "id": 1221,
                        "displayName": "year_1221"
                  },
                  {
                        "id": 1222,
                        "displayName": "year_1222"
                  },
                  {
                        "id": 1223,
                        "displayName": "year_1223"
                  },
                  {
                        "id": 1224,
                        "displayName": "year_1224"
                  },
                  {
                        "id": 1225,
                        "displayName": "year_1225"
                  },
                  {
                        "id": 1226,
                        "displayName": "year_1226"
                  },
                  {
                        "id": 1227,
                        "displayName": "year_1227"
                  },
                  {
                        "id": 1228,
                        "displayName": "year_1228"
                  },
                  {
                        "id": 1229,
                        "displayName": "year_1229"
                  },
                  {
                        "id": 1230,
                        "displayName": "year_1230"
                  },
                  {
                        "id": 1231,
                        "displayName": "year_1231"
                  },
                  {
                        "id": 1232,
                        "displayName": "year_1232"
                  },
                  {
                        "id": 1233,
                        "displayName": "year_1233"
                  },
                  {
                        "id": 1234,
                        "displayName": "year_1234"
                  },
                  {
                        "id": 1235,
                        "displayName": "year_1235"
                  },
                  {
                        "id": 1236,
                        "displayName": "year_1236"
                  },
                  {
                        "id": 1237,
                        "displayName": "year_1237"
                  },
                  {
                        "id": 1238,
                        "displayName": "year_1238"
                  },
                  {
                        "id": 1239,
                        "displayName": "year_1239"
                  },
                  {
                        "id": 1240,
                        "displayName": "year_1240"
                  },
                  {
                        "id": 1241,
                        "displayName": "year_1241"
                  },
                  {
                        "id": 1242,
                        "displayName": "year_1242"
                  },
                  {
                        "id": 1243,
                        "displayName": "year_1243"
                  },
                  {
                        "id": 1244,
                        "displayName": "year_1244"
                  },
                  {
                        "id": 1245,
                        "displayName": "year_1245"
                  },
                  {
                        "id": 1246,
                        "displayName": "year_1246"
                  },
                  {
                        "id": 1247,
                        "displayName": "year_1247"
                  },
                  {
                        "id": 1248,
                        "displayName": "year_1248"
                  },
                  {
                        "id": 1249,
                        "displayName": "year_1249"
                  },
                  {
                        "id": 1250,
                        "displayName": "year_1250"
                  },
                  {
                        "id": 1251,
                        "displayName": "year_1251"
                  },
                  {
                        "id": 1252,
                        "displayName": "year_1252"
                  },
                  {
                        "id": 1253,
                        "displayName": "year_1253"
                  },
                  {
                        "id": 1254,
                        "displayName": "year_1254"
                  },
                  {
                        "id": 1255,
                        "displayName": "year_1255"
                  },
                  {
                        "id": 1256,
                        "displayName": "year_1256"
                  },
                  {
                        "id": 1257,
                        "displayName": "year_1257"
                  },
                  {
                        "id": 1258,
                        "displayName": "year_1258"
                  },
                  {
                        "id": 1259,
                        "displayName": "year_1259"
                  },
                  {
                        "id": 1260,
                        "displayName": "year_1260"
                  },
                  {
                        "id": 1261,
                        "displayName": "year_1261"
                  },
                  {
                        "id": 1262,
                        "displayName": "year_1262"
                  },
                  {
                        "id": 1263,
                        "displayName": "year_1263"
                  },
                  {
                        "id": 1264,
                        "displayName": "year_1264"
                  },
                  {
                        "id": 1265,
                        "displayName": "year_1265"
                  },
                  {
                        "id": 1266,
                        "displayName": "year_1266"
                  },
                  {
                        "id": 1267,
                        "displayName": "year_1267"
                  },
                  {
                        "id": 1268,
                        "displayName": "year_1268"
                  },
                  {
                        "id": 1269,
                        "displayName": "year_1269"
                  },
                  {
                        "id": 1270,
                        "displayName": "year_1270"
                  },
                  {
                        "id": 1271,
                        "displayName": "year_1271"
                  },
                  {
                        "id": 1272,
                        "displayName": "year_1272"
                  },
                  {
                        "id": 1273,
                        "displayName": "year_1273"
                  },
                  {
                        "id": 1274,
                        "displayName": "year_1274"
                  },
                  {
                        "id": 1275,
                        "displayName": "year_1275"
                  },
                  {
                        "id": 1276,
                        "displayName": "year_1276"
                  },
                  {
                        "id": 1277,
                        "displayName": "year_1277"
                  },
                  {
                        "id": 1278,
                        "displayName": "year_1278"
                  },
                  {
                        "id": 1279,
                        "displayName": "year_1279"
                  },
                  {
                        "id": 1280,
                        "displayName": "year_1280"
                  },
                  {
                        "id": 1281,
                        "displayName": "year_1281"
                  },
                  {
                        "id": 1282,
                        "displayName": "year_1282"
                  },
                  {
                        "id": 1283,
                        "displayName": "year_1283"
                  },
                  {
                        "id": 1284,
                        "displayName": "year_1284"
                  },
                  {
                        "id": 1285,
                        "displayName": "year_1285"
                  },
                  {
                        "id": 1286,
                        "displayName": "year_1286"
                  },
                  {
                        "id": 1287,
                        "displayName": "year_1287"
                  },
                  {
                        "id": 1288,
                        "displayName": "year_1288"
                  },
                  {
                        "id": 1289,
                        "displayName": "year_1289"
                  },
                  {
                        "id": 1290,
                        "displayName": "year_1290"
                  },
                  {
                        "id": 1291,
                        "displayName": "year_1291"
                  },
                  {
                        "id": 1292,
                        "displayName": "year_1292"
                  },
                  {
                        "id": 1293,
                        "displayName": "year_1293"
                  },
                  {
                        "id": 1294,
                        "displayName": "year_1294"
                  },
                  {
                        "id": 1295,
                        "displayName": "year_1295"
                  },
                  {
                        "id": 1296,
                        "displayName": "year_1296"
                  },
                  {
                        "id": 1297,
                        "displayName": "year_1297"
                  },
                  {
                        "id": 1298,
                        "displayName": "year_1298"
                  },
                  {
                        "id": 1299,
                        "displayName": "year_1299"
                  },
                  {
                        "id": 1300,
                        "displayName": "year_1300"
                  },
                  {
                        "id": 1301,
                        "displayName": "year_1301"
                  },
                  {
                        "id": 1302,
                        "displayName": "year_1302"
                  },
                  {
                        "id": 1303,
                        "displayName": "year_1303"
                  },
                  {
                        "id": 1304,
                        "displayName": "year_1304"
                  },
                  {
                        "id": 1305,
                        "displayName": "year_1305"
                  },
                  {
                        "id": 1306,
                        "displayName": "year_1306"
                  },
                  {
                        "id": 1307,
                        "displayName": "year_1307"
                  },
                  {
                        "id": 1308,
                        "displayName": "year_1308"
                  },
                  {
                        "id": 1309,
                        "displayName": "year_1309"
                  },
                  {
                        "id": 1310,
                        "displayName": "year_1310"
                  },
                  {
                        "id": 1311,
                        "displayName": "year_1311"
                  },
                  {
                        "id": 1312,
                        "displayName": "year_1312"
                  },
                  {
                        "id": 1313,
                        "displayName": "year_1313"
                  },
                  {
                        "id": 1314,
                        "displayName": "year_1314"
                  },
                  {
                        "id": 1315,
                        "displayName": "year_1315"
                  },
                  {
                        "id": 1316,
                        "displayName": "year_1316"
                  },
                  {
                        "id": 1317,
                        "displayName": "year_1317"
                  },
                  {
                        "id": 1318,
                        "displayName": "year_1318"
                  },
                  {
                        "id": 1319,
                        "displayName": "year_1319"
                  },
                  {
                        "id": 1320,
                        "displayName": "year_1320"
                  },
                  {
                        "id": 1321,
                        "displayName": "year_1321"
                  },
                  {
                        "id": 1322,
                        "displayName": "year_1322"
                  },
                  {
                        "id": 1323,
                        "displayName": "year_1323"
                  },
                  {
                        "id": 1324,
                        "displayName": "year_1324"
                  },
                  {
                        "id": 1325,
                        "displayName": "year_1325"
                  },
                  {
                        "id": 1326,
                        "displayName": "year_1326"
                  },
                  {
                        "id": 1327,
                        "displayName": "year_1327"
                  },
                  {
                        "id": 1328,
                        "displayName": "year_1328"
                  },
                  {
                        "id": 1329,
                        "displayName": "year_1329"
                  },
                  {
                        "id": 1330,
                        "displayName": "year_1330"
                  },
                  {
                        "id": 1331,
                        "displayName": "year_1331"
                  },
                  {
                        "id": 1332,
                        "displayName": "year_1332"
                  },
                  {
                        "id": 1333,
                        "displayName": "year_1333"
                  },
                  {
                        "id": 1334,
                        "displayName": "year_1334"
                  },
                  {
                        "id": 1335,
                        "displayName": "year_1335"
                  },
                  {
                        "id": 1336,
                        "displayName": "year_1336"
                  },
                  {
                        "id": 1337,
                        "displayName": "year_1337"
                  },
                  {
                        "id": 1338,
                        "displayName": "year_1338"
                  },
                  {
                        "id": 1339,
                        "displayName": "year_1339"
                  },
                  {
                        "id": 1340,
                        "displayName": "year_1340"
                  },
                  {
                        "id": 1341,
                        "displayName": "year_1341"
                  },
                  {
                        "id": 1342,
                        "displayName": "year_1342"
                  },
                  {
                        "id": 1343,
                        "displayName": "year_1343"
                  },
                  {
                        "id": 1344,
                        "displayName": "year_1344"
                  },
                  {
                        "id": 1345,
                        "displayName": "year_1345"
                  },
                  {
                        "id": 1346,
                        "displayName": "year_1346"
                  },
                  {
                        "id": 1347,
                        "displayName": "year_1347"
                  },
                  {
                        "id": 1348,
                        "displayName": "year_1348"
                  },
                  {
                        "id": 1349,
                        "displayName": "year_1349"
                  },
                  {
                        "id": 1350,
                        "displayName": "year_1350"
                  },
                  {
                        "id": 1351,
                        "displayName": "year_1351"
                  },
                  {
                        "id": 1352,
                        "displayName": "year_1352"
                  },
                  {
                        "id": 1353,
                        "displayName": "year_1353"
                  },
                  {
                        "id": 1354,
                        "displayName": "year_1354"
                  },
                  {
                        "id": 1355,
                        "displayName": "year_1355"
                  },
                  {
                        "id": 1356,
                        "displayName": "year_1356"
                  },
                  {
                        "id": 1357,
                        "displayName": "year_1357"
                  },
                  {
                        "id": 1358,
                        "displayName": "year_1358"
                  },
                  {
                        "id": 1359,
                        "displayName": "year_1359"
                  },
                  {
                        "id": 1360,
                        "displayName": "year_1360"
                  },
                  {
                        "id": 1361,
                        "displayName": "year_1361"
                  },
                  {
                        "id": 1362,
                        "displayName": "year_1362"
                  },
                  {
                        "id": 1363,
                        "displayName": "year_1363"
                  },
                  {
                        "id": 1364,
                        "displayName": "year_1364"
                  },
                  {
                        "id": 1365,
                        "displayName": "year_1365"
                  },
                  {
                        "id": 1366,
                        "displayName": "year_1366"
                  },
                  {
                        "id": 1367,
                        "displayName": "year_1367"
                  },
                  {
                        "id": 1368,
                        "displayName": "year_1368"
                  },
                  {
                        "id": 1369,
                        "displayName": "year_1369"
                  },
                  {
                        "id": 1370,
                        "displayName": "year_1370"
                  },
                  {
                        "id": 1371,
                        "displayName": "year_1371"
                  },
                  {
                        "id": 1372,
                        "displayName": "year_1372"
                  },
                  {
                        "id": 1373,
                        "displayName": "year_1373"
                  },
                  {
                        "id": 1374,
                        "displayName": "year_1374"
                  },
                  {
                        "id": 1375,
                        "displayName": "year_1375"
                  },
                  {
                        "id": 1376,
                        "displayName": "year_1376"
                  },
                  {
                        "id": 1377,
                        "displayName": "year_1377"
                  },
                  {
                        "id": 1378,
                        "displayName": "year_1378"
                  },
                  {
                        "id": 1379,
                        "displayName": "year_1379"
                  },
                  {
                        "id": 1380,
                        "displayName": "year_1380"
                  },
                  {
                        "id": 1381,
                        "displayName": "year_1381"
                  },
                  {
                        "id": 1382,
                        "displayName": "year_1382"
                  },
                  {
                        "id": 1383,
                        "displayName": "year_1383"
                  },
                  {
                        "id": 1384,
                        "displayName": "year_1384"
                  },
                  {
                        "id": 1385,
                        "displayName": "year_1385"
                  },
                  {
                        "id": 1386,
                        "displayName": "year_1386"
                  },
                  {
                        "id": 1387,
                        "displayName": "year_1387"
                  },
                  {
                        "id": 1388,
                        "displayName": "year_1388"
                  },
                  {
                        "id": 1389,
                        "displayName": "year_1389"
                  },
                  {
                        "id": 1390,
                        "displayName": "year_1390"
                  },
                  {
                        "id": 1391,
                        "displayName": "year_1391"
                  },
                  {
                        "id": 1392,
                        "displayName": "year_1392"
                  },
                  {
                        "id": 1393,
                        "displayName": "year_1393"
                  },
                  {
                        "id": 1394,
                        "displayName": "year_1394"
                  },
                  {
                        "id": 1395,
                        "displayName": "year_1395"
                  },
                  {
                        "id": 1396,
                        "displayName": "year_1396"
                  },
                  {
                        "id": 1397,
                        "displayName": "year_1397"
                  },
                  {
                        "id": 1398,
                        "displayName": "year_1398"
                  },
                  {
                        "id": 1399,
                        "displayName": "year_1399"
                  },
                  {
                        "id": 1400,
                        "displayName": "year_1400"
                  },
                  {
                        "id": 1401,
                        "displayName": "year_1401"
                  },
                  {
                        "id": 1402,
                        "displayName": "year_1402"
                  },
                  {
                        "id": 1403,
                        "displayName": "year_1403"
                  },
                  {
                        "id": 1404,
                        "displayName": "year_1404"
                  },
                  {
                        "id": 1405,
                        "displayName": "year_1405"
                  },
                  {
                        "id": 1406,
                        "displayName": "year_1406"
                  },
                  {
                        "id": 1407,
                        "displayName": "year_1407"
                  },
                  {
                        "id": 1408,
                        "displayName": "year_1408"
                  },
                  {
                        "id": 1409,
                        "displayName": "year_1409"
                  },
                  {
                        "id": 1410,
                        "displayName": "year_1410"
                  },
                  {
                        "id": 1411,
                        "displayName": "year_1411"
                  },
                  {
                        "id": 1412,
                        "displayName": "year_1412"
                  },
                  {
                        "id": 1413,
                        "displayName": "year_1413"
                  },
                  {
                        "id": 1414,
                        "displayName": "year_1414"
                  },
                  {
                        "id": 1415,
                        "displayName": "year_1415"
                  },
                  {
                        "id": 1416,
                        "displayName": "year_1416"
                  },
                  {
                        "id": 1417,
                        "displayName": "year_1417"
                  },
                  {
                        "id": 1418,
                        "displayName": "year_1418"
                  },
                  {
                        "id": 1419,
                        "displayName": "year_1419"
                  },
                  {
                        "id": 1420,
                        "displayName": "year_1420"
                  },
                  {
                        "id": 1421,
                        "displayName": "year_1421"
                  },
                  {
                        "id": 1422,
                        "displayName": "year_1422"
                  },
                  {
                        "id": 1423,
                        "displayName": "year_1423"
                  },
                  {
                        "id": 1424,
                        "displayName": "year_1424"
                  },
                  {
                        "id": 1425,
                        "displayName": "year_1425"
                  },
                  {
                        "id": 1426,
                        "displayName": "year_1426"
                  },
                  {
                        "id": 1427,
                        "displayName": "year_1427"
                  },
                  {
                        "id": 1428,
                        "displayName": "year_1428"
                  },
                  {
                        "id": 1429,
                        "displayName": "year_1429"
                  },
                  {
                        "id": 1430,
                        "displayName": "year_1430"
                  },
                  {
                        "id": 1431,
                        "displayName": "year_1431"
                  },
                  {
                        "id": 1432,
                        "displayName": "year_1432"
                  },
                  {
                        "id": 1433,
                        "displayName": "year_1433"
                  },
                  {
                        "id": 1434,
                        "displayName": "year_1434"
                  },
                  {
                        "id": 1435,
                        "displayName": "year_1435"
                  },
                  {
                        "id": 1436,
                        "displayName": "year_1436"
                  },
                  {
                        "id": 1437,
                        "displayName": "year_1437"
                  },
                  {
                        "id": 1438,
                        "displayName": "year_1438"
                  },
                  {
                        "id": 1439,
                        "displayName": "year_1439"
                  },
                  {
                        "id": 1440,
                        "displayName": "year_1440"
                  },
                  {
                        "id": 1441,
                        "displayName": "year_1441"
                  },
                  {
                        "id": 1442,
                        "displayName": "year_1442"
                  },
                  {
                        "id": 1443,
                        "displayName": "year_1443"
                  },
                  {
                        "id": 1444,
                        "displayName": "year_1444"
                  },
                  {
                        "id": 1445,
                        "displayName": "year_1445"
                  },
                  {
                        "id": 1446,
                        "displayName": "year_1446"
                  },
                  {
                        "id": 1447,
                        "displayName": "year_1447"
                  },
                  {
                        "id": 1448,
                        "displayName": "year_1448"
                  },
                  {
                        "id": 1449,
                        "displayName": "year_1449"
                  },
                  {
                        "id": 1450,
                        "displayName": "year_1450"
                  },
                  {
                        "id": 1451,
                        "displayName": "year_1451"
                  },
                  {
                        "id": 1452,
                        "displayName": "year_1452"
                  },
                  {
                        "id": 1453,
                        "displayName": "year_1453"
                  },
                  {
                        "id": 1454,
                        "displayName": "year_1454"
                  },
                  {
                        "id": 1455,
                        "displayName": "year_1455"
                  },
                  {
                        "id": 1456,
                        "displayName": "year_1456"
                  },
                  {
                        "id": 1457,
                        "displayName": "year_1457"
                  },
                  {
                        "id": 1458,
                        "displayName": "year_1458"
                  },
                  {
                        "id": 1459,
                        "displayName": "year_1459"
                  },
                  {
                        "id": 1460,
                        "displayName": "year_1460"
                  },
                  {
                        "id": 1461,
                        "displayName": "year_1461"
                  },
                  {
                        "id": 1462,
                        "displayName": "year_1462"
                  },
                  {
                        "id": 1463,
                        "displayName": "year_1463"
                  },
                  {
                        "id": 1464,
                        "displayName": "year_1464"
                  },
                  {
                        "id": 1465,
                        "displayName": "year_1465"
                  },
                  {
                        "id": 1466,
                        "displayName": "year_1466"
                  },
                  {
                        "id": 1467,
                        "displayName": "year_1467"
                  },
                  {
                        "id": 1468,
                        "displayName": "year_1468"
                  },
                  {
                        "id": 1469,
                        "displayName": "year_1469"
                  },
                  {
                        "id": 1470,
                        "displayName": "year_1470"
                  },
                  {
                        "id": 1471,
                        "displayName": "year_1471"
                  },
                  {
                        "id": 1472,
                        "displayName": "year_1472"
                  },
                  {
                        "id": 1473,
                        "displayName": "year_1473"
                  },
                  {
                        "id": 1474,
                        "displayName": "year_1474"
                  },
                  {
                        "id": 1475,
                        "displayName": "year_1475"
                  },
                  {
                        "id": 1476,
                        "displayName": "year_1476"
                  },
                  {
                        "id": 1477,
                        "displayName": "year_1477"
                  },
                  {
                        "id": 1478,
                        "displayName": "year_1478"
                  },
                  {
                        "id": 1479,
                        "displayName": "year_1479"
                  },
                  {
                        "id": 1480,
                        "displayName": "year_1480"
                  },
                  {
                        "id": 1481,
                        "displayName": "year_1481"
                  },
                  {
                        "id": 1482,
                        "displayName": "year_1482"
                  },
                  {
                        "id": 1483,
                        "displayName": "year_1483"
                  },
                  {
                        "id": 1484,
                        "displayName": "year_1484"
                  },
                  {
                        "id": 1485,
                        "displayName": "year_1485"
                  },
                  {
                        "id": 1486,
                        "displayName": "year_1486"
                  },
                  {
                        "id": 1487,
                        "displayName": "year_1487"
                  },
                  {
                        "id": 1488,
                        "displayName": "year_1488"
                  },
                  {
                        "id": 1489,
                        "displayName": "year_1489"
                  },
                  {
                        "id": 1490,
                        "displayName": "year_1490"
                  },
                  {
                        "id": 1491,
                        "displayName": "year_1491"
                  },
                  {
                        "id": 1492,
                        "displayName": "year_1492"
                  },
                  {
                        "id": 1493,
                        "displayName": "year_1493"
                  },
                  {
                        "id": 1494,
                        "displayName": "year_1494"
                  },
                  {
                        "id": 1495,
                        "displayName": "year_1495"
                  },
                  {
                        "id": 1496,
                        "displayName": "year_1496"
                  },
                  {
                        "id": 1497,
                        "displayName": "year_1497"
                  },
                  {
                        "id": 1498,
                        "displayName": "year_1498"
                  },
                  {
                        "id": 1499,
                        "displayName": "year_1499"
                  },
                  {
                        "id": 1500,
                        "displayName": "year_1500"
                  },
                  {
                        "id": 1501,
                        "displayName": "year_1501"
                  },
                  {
                        "id": 1502,
                        "displayName": "year_1502"
                  },
                  {
                        "id": 1503,
                        "displayName": "year_1503"
                  },
                  {
                        "id": 1504,
                        "displayName": "year_1504"
                  },
                  {
                        "id": 1505,
                        "displayName": "year_1505"
                  },
                  {
                        "id": 1506,
                        "displayName": "year_1506"
                  },
                  {
                        "id": 1507,
                        "displayName": "year_1507"
                  },
                  {
                        "id": 1508,
                        "displayName": "year_1508"
                  },
                  {
                        "id": 1509,
                        "displayName": "year_1509"
                  },
                  {
                        "id": 1510,
                        "displayName": "year_1510"
                  },
                  {
                        "id": 1511,
                        "displayName": "year_1511"
                  },
                  {
                        "id": 1512,
                        "displayName": "year_1512"
                  },
                  {
                        "id": 1513,
                        "displayName": "year_1513"
                  },
                  {
                        "id": 1514,
                        "displayName": "year_1514"
                  },
                  {
                        "id": 1515,
                        "displayName": "year_1515"
                  },
                  {
                        "id": 1516,
                        "displayName": "year_1516"
                  },
                  {
                        "id": 1517,
                        "displayName": "year_1517"
                  },
                  {
                        "id": 1518,
                        "displayName": "year_1518"
                  },
                  {
                        "id": 1519,
                        "displayName": "year_1519"
                  },
                  {
                        "id": 1520,
                        "displayName": "year_1520"
                  },
                  {
                        "id": 1521,
                        "displayName": "year_1521"
                  },
                  {
                        "id": 1522,
                        "displayName": "year_1522"
                  },
                  {
                        "id": 1523,
                        "displayName": "year_1523"
                  },
                  {
                        "id": 1524,
                        "displayName": "year_1524"
                  },
                  {
                        "id": 1525,
                        "displayName": "year_1525"
                  },
                  {
                        "id": 1526,
                        "displayName": "year_1526"
                  },
                  {
                        "id": 1527,
                        "displayName": "year_1527"
                  },
                  {
                        "id": 1528,
                        "displayName": "year_1528"
                  },
                  {
                        "id": 1529,
                        "displayName": "year_1529"
                  },
                  {
                        "id": 1530,
                        "displayName": "year_1530"
                  },
                  {
                        "id": 1531,
                        "displayName": "year_1531"
                  },
                  {
                        "id": 1532,
                        "displayName": "year_1532"
                  },
                  {
                        "id": 1533,
                        "displayName": "year_1533"
                  },
                  {
                        "id": 1534,
                        "displayName": "year_1534"
                  },
                  {
                        "id": 1535,
                        "displayName": "year_1535"
                  },
                  {
                        "id": 1536,
                        "displayName": "year_1536"
                  },
                  {
                        "id": 1537,
                        "displayName": "year_1537"
                  },
                  {
                        "id": 1538,
                        "displayName": "year_1538"
                  },
                  {
                        "id": 1539,
                        "displayName": "year_1539"
                  },
                  {
                        "id": 1540,
                        "displayName": "year_1540"
                  },
                  {
                        "id": 1541,
                        "displayName": "year_1541"
                  },
                  {
                        "id": 1542,
                        "displayName": "year_1542"
                  },
                  {
                        "id": 1543,
                        "displayName": "year_1543"
                  },
                  {
                        "id": 1544,
                        "displayName": "year_1544"
                  },
                  {
                        "id": 1545,
                        "displayName": "year_1545"
                  },
                  {
                        "id": 1546,
                        "displayName": "year_1546"
                  },
                  {
                        "id": 1547,
                        "displayName": "year_1547"
                  },
                  {
                        "id": 1548,
                        "displayName": "year_1548"
                  },
                  {
                        "id": 1549,
                        "displayName": "year_1549"
                  },
                  {
                        "id": 1550,
                        "displayName": "year_1550"
                  },
                  {
                        "id": 1551,
                        "displayName": "year_1551"
                  },
                  {
                        "id": 1552,
                        "displayName": "year_1552"
                  },
                  {
                        "id": 1553,
                        "displayName": "year_1553"
                  },
                  {
                        "id": 1554,
                        "displayName": "year_1554"
                  },
                  {
                        "id": 1555,
                        "displayName": "year_1555"
                  },
                  {
                        "id": 1556,
                        "displayName": "year_1556"
                  },
                  {
                        "id": 1557,
                        "displayName": "year_1557"
                  },
                  {
                        "id": 1558,
                        "displayName": "year_1558"
                  },
                  {
                        "id": 1559,
                        "displayName": "year_1559"
                  },
                  {
                        "id": 1560,
                        "displayName": "year_1560"
                  },
                  {
                        "id": 1561,
                        "displayName": "year_1561"
                  },
                  {
                        "id": 1562,
                        "displayName": "year_1562"
                  },
                  {
                        "id": 1563,
                        "displayName": "year_1563"
                  },
                  {
                        "id": 1564,
                        "displayName": "year_1564"
                  },
                  {
                        "id": 1565,
                        "displayName": "year_1565"
                  },
                  {
                        "id": 1566,
                        "displayName": "year_1566"
                  },
                  {
                        "id": 1567,
                        "displayName": "year_1567"
                  },
                  {
                        "id": 1568,
                        "displayName": "year_1568"
                  },
                  {
                        "id": 1569,
                        "displayName": "year_1569"
                  },
                  {
                        "id": 1570,
                        "displayName": "year_1570"
                  },
                  {
                        "id": 1571,
                        "displayName": "year_1571"
                  },
                  {
                        "id": 1572,
                        "displayName": "year_1572"
                  },
                  {
                        "id": 1573,
                        "displayName": "year_1573"
                  },
                  {
                        "id": 1574,
                        "displayName": "year_1574"
                  },
                  {
                        "id": 1575,
                        "displayName": "year_1575"
                  },
                  {
                        "id": 1576,
                        "displayName": "year_1576"
                  },
                  {
                        "id": 1577,
                        "displayName": "year_1577"
                  },
                  {
                        "id": 1578,
                        "displayName": "year_1578"
                  },
                  {
                        "id": 1579,
                        "displayName": "year_1579"
                  },
                  {
                        "id": 1580,
                        "displayName": "year_1580"
                  },
                  {
                        "id": 1581,
                        "displayName": "year_1581"
                  },
                  {
                        "id": 1582,
                        "displayName": "year_1582"
                  },
                  {
                        "id": 1583,
                        "displayName": "year_1583"
                  },
                  {
                        "id": 1584,
                        "displayName": "year_1584"
                  },
                  {
                        "id": 1585,
                        "displayName": "year_1585"
                  },
                  {
                        "id": 1586,
                        "displayName": "year_1586"
                  },
                  {
                        "id": 1587,
                        "displayName": "year_1587"
                  },
                  {
                        "id": 1588,
                        "displayName": "year_1588"
                  },
                  {
                        "id": 1589,
                        "displayName": "year_1589"
                  },
                  {
                        "id": 1590,
                        "displayName": "year_1590"
                  },
                  {
                        "id": 1591,
                        "displayName": "year_1591"
                  },
                  {
                        "id": 1592,
                        "displayName": "year_1592"
                  },
                  {
                        "id": 1593,
                        "displayName": "year_1593"
                  },
                  {
                        "id": 1594,
                        "displayName": "year_1594"
                  },
                  {
                        "id": 1595,
                        "displayName": "year_1595"
                  },
                  {
                        "id": 1596,
                        "displayName": "year_1596"
                  },
                  {
                        "id": 1597,
                        "displayName": "year_1597"
                  },
                  {
                        "id": 1598,
                        "displayName": "year_1598"
                  },
                  {
                        "id": 1599,
                        "displayName": "year_1599"
                  },
                  {
                        "id": 1600,
                        "displayName": "year_1600"
                  },
                  {
                        "id": 1601,
                        "displayName": "year_1601"
                  },
                  {
                        "id": 1602,
                        "displayName": "year_1602"
                  },
                  {
                        "id": 1603,
                        "displayName": "year_1603"
                  },
                  {
                        "id": 1604,
                        "displayName": "year_1604"
                  },
                  {
                        "id": 1605,
                        "displayName": "year_1605"
                  },
                  {
                        "id": 1606,
                        "displayName": "year_1606"
                  },
                  {
                        "id": 1607,
                        "displayName": "year_1607"
                  },
                  {
                        "id": 1608,
                        "displayName": "year_1608"
                  },
                  {
                        "id": 1609,
                        "displayName": "year_1609"
                  },
                  {
                        "id": 1610,
                        "displayName": "year_1610"
                  },
                  {
                        "id": 1611,
                        "displayName": "year_1611"
                  },
                  {
                        "id": 1612,
                        "displayName": "year_1612"
                  },
                  {
                        "id": 1613,
                        "displayName": "year_1613"
                  },
                  {
                        "id": 1614,
                        "displayName": "year_1614"
                  },
                  {
                        "id": 1615,
                        "displayName": "year_1615"
                  },
                  {
                        "id": 1616,
                        "displayName": "year_1616"
                  },
                  {
                        "id": 1617,
                        "displayName": "year_1617"
                  },
                  {
                        "id": 1618,
                        "displayName": "year_1618"
                  },
                  {
                        "id": 1619,
                        "displayName": "year_1619"
                  },
                  {
                        "id": 1620,
                        "displayName": "year_1620"
                  },
                  {
                        "id": 1621,
                        "displayName": "year_1621"
                  },
                  {
                        "id": 1622,
                        "displayName": "year_1622"
                  },
                  {
                        "id": 1623,
                        "displayName": "year_1623"
                  },
                  {
                        "id": 1624,
                        "displayName": "year_1624"
                  },
                  {
                        "id": 1625,
                        "displayName": "year_1625"
                  },
                  {
                        "id": 1626,
                        "displayName": "year_1626"
                  },
                  {
                        "id": 1627,
                        "displayName": "year_1627"
                  },
                  {
                        "id": 1628,
                        "displayName": "year_1628"
                  },
                  {
                        "id": 1629,
                        "displayName": "year_1629"
                  },
                  {
                        "id": 1630,
                        "displayName": "year_1630"
                  },
                  {
                        "id": 1631,
                        "displayName": "year_1631"
                  },
                  {
                        "id": 1632,
                        "displayName": "year_1632"
                  },
                  {
                        "id": 1633,
                        "displayName": "year_1633"
                  },
                  {
                        "id": 1634,
                        "displayName": "year_1634"
                  },
                  {
                        "id": 1635,
                        "displayName": "year_1635"
                  },
                  {
                        "id": 1636,
                        "displayName": "year_1636"
                  },
                  {
                        "id": 1637,
                        "displayName": "year_1637"
                  },
                  {
                        "id": 1638,
                        "displayName": "year_1638"
                  },
                  {
                        "id": 1639,
                        "displayName": "year_1639"
                  },
                  {
                        "id": 1640,
                        "displayName": "year_1640"
                  },
                  {
                        "id": 1641,
                        "displayName": "year_1641"
                  },
                  {
                        "id": 1642,
                        "displayName": "year_1642"
                  },
                  {
                        "id": 1643,
                        "displayName": "year_1643"
                  },
                  {
                        "id": 1644,
                        "displayName": "year_1644"
                  },
                  {
                        "id": 1645,
                        "displayName": "year_1645"
                  },
                  {
                        "id": 1646,
                        "displayName": "year_1646"
                  },
                  {
                        "id": 1647,
                        "displayName": "year_1647"
                  },
                  {
                        "id": 1648,
                        "displayName": "year_1648"
                  },
                  {
                        "id": 1649,
                        "displayName": "year_1649"
                  },
                  {
                        "id": 1650,
                        "displayName": "year_1650"
                  },
                  {
                        "id": 1651,
                        "displayName": "year_1651"
                  },
                  {
                        "id": 1652,
                        "displayName": "year_1652"
                  },
                  {
                        "id": 1653,
                        "displayName": "year_1653"
                  },
                  {
                        "id": 1654,
                        "displayName": "year_1654"
                  },
                  {
                        "id": 1655,
                        "displayName": "year_1655"
                  },
                  {
                        "id": 1656,
                        "displayName": "year_1656"
                  },
                  {
                        "id": 1657,
                        "displayName": "year_1657"
                  },
                  {
                        "id": 1658,
                        "displayName": "year_1658"
                  },
                  {
                        "id": 1659,
                        "displayName": "year_1659"
                  },
                  {
                        "id": 1660,
                        "displayName": "year_1660"
                  },
                  {
                        "id": 1661,
                        "displayName": "year_1661"
                  },
                  {
                        "id": 1662,
                        "displayName": "year_1662"
                  },
                  {
                        "id": 1663,
                        "displayName": "year_1663"
                  },
                  {
                        "id": 1664,
                        "displayName": "year_1664"
                  },
                  {
                        "id": 1665,
                        "displayName": "year_1665"
                  },
                  {
                        "id": 1666,
                        "displayName": "year_1666"
                  },
                  {
                        "id": 1667,
                        "displayName": "year_1667"
                  },
                  {
                        "id": 1668,
                        "displayName": "year_1668"
                  },
                  {
                        "id": 1669,
                        "displayName": "year_1669"
                  },
                  {
                        "id": 1670,
                        "displayName": "year_1670"
                  },
                  {
                        "id": 1671,
                        "displayName": "year_1671"
                  },
                  {
                        "id": 1672,
                        "displayName": "year_1672"
                  },
                  {
                        "id": 1673,
                        "displayName": "year_1673"
                  },
                  {
                        "id": 1674,
                        "displayName": "year_1674"
                  },
                  {
                        "id": 1675,
                        "displayName": "year_1675"
                  },
                  {
                        "id": 1676,
                        "displayName": "year_1676"
                  },
                  {
                        "id": 1677,
                        "displayName": "year_1677"
                  },
                  {
                        "id": 1678,
                        "displayName": "year_1678"
                  },
                  {
                        "id": 1679,
                        "displayName": "year_1679"
                  },
                  {
                        "id": 1680,
                        "displayName": "year_1680"
                  },
                  {
                        "id": 1681,
                        "displayName": "year_1681"
                  },
                  {
                        "id": 1682,
                        "displayName": "year_1682"
                  },
                  {
                        "id": 1683,
                        "displayName": "year_1683"
                  },
                  {
                        "id": 1684,
                        "displayName": "year_1684"
                  },
                  {
                        "id": 1685,
                        "displayName": "year_1685"
                  },
                  {
                        "id": 1686,
                        "displayName": "year_1686"
                  },
                  {
                        "id": 1687,
                        "displayName": "year_1687"
                  },
                  {
                        "id": 1688,
                        "displayName": "year_1688"
                  },
                  {
                        "id": 1689,
                        "displayName": "year_1689"
                  },
                  {
                        "id": 1690,
                        "displayName": "year_1690"
                  },
                  {
                        "id": 1691,
                        "displayName": "year_1691"
                  },
                  {
                        "id": 1692,
                        "displayName": "year_1692"
                  },
                  {
                        "id": 1693,
                        "displayName": "year_1693"
                  },
                  {
                        "id": 1694,
                        "displayName": "year_1694"
                  },
                  {
                        "id": 1695,
                        "displayName": "year_1695"
                  },
                  {
                        "id": 1696,
                        "displayName": "year_1696"
                  },
                  {
                        "id": 1697,
                        "displayName": "year_1697"
                  },
                  {
                        "id": 1698,
                        "displayName": "year_1698"
                  },
                  {
                        "id": 1699,
                        "displayName": "year_1699"
                  },
                  {
                        "id": 1700,
                        "displayName": "year_1700"
                  },
                  {
                        "id": 1701,
                        "displayName": "year_1701"
                  },
                  {
                        "id": 1702,
                        "displayName": "year_1702"
                  },
                  {
                        "id": 1703,
                        "displayName": "year_1703"
                  },
                  {
                        "id": 1704,
                        "displayName": "year_1704"
                  },
                  {
                        "id": 1705,
                        "displayName": "year_1705"
                  },
                  {
                        "id": 1706,
                        "displayName": "year_1706"
                  },
                  {
                        "id": 1707,
                        "displayName": "year_1707"
                  },
                  {
                        "id": 1708,
                        "displayName": "year_1708"
                  },
                  {
                        "id": 1709,
                        "displayName": "year_1709"
                  },
                  {
                        "id": 1710,
                        "displayName": "year_1710"
                  },
                  {
                        "id": 1711,
                        "displayName": "year_1711"
                  },
                  {
                        "id": 1712,
                        "displayName": "year_1712"
                  },
                  {
                        "id": 1713,
                        "displayName": "year_1713"
                  },
                  {
                        "id": 1714,
                        "displayName": "year_1714"
                  },
                  {
                        "id": 1715,
                        "displayName": "year_1715"
                  },
                  {
                        "id": 1716,
                        "displayName": "year_1716"
                  },
                  {
                        "id": 1717,
                        "displayName": "year_1717"
                  },
                  {
                        "id": 1718,
                        "displayName": "year_1718"
                  },
                  {
                        "id": 1719,
                        "displayName": "year_1719"
                  },
                  {
                        "id": 1720,
                        "displayName": "year_1720"
                  },
                  {
                        "id": 1721,
                        "displayName": "year_1721"
                  },
                  {
                        "id": 1722,
                        "displayName": "year_1722"
                  },
                  {
                        "id": 1723,
                        "displayName": "year_1723"
                  },
                  {
                        "id": 1724,
                        "displayName": "year_1724"
                  },
                  {
                        "id": 1725,
                        "displayName": "year_1725"
                  },
                  {
                        "id": 1726,
                        "displayName": "year_1726"
                  },
                  {
                        "id": 1727,
                        "displayName": "year_1727"
                  },
                  {
                        "id": 1728,
                        "displayName": "year_1728"
                  },
                  {
                        "id": 1729,
                        "displayName": "year_1729"
                  },
                  {
                        "id": 1730,
                        "displayName": "year_1730"
                  },
                  {
                        "id": 1731,
                        "displayName": "year_1731"
                  },
                  {
                        "id": 1732,
                        "displayName": "year_1732"
                  },
                  {
                        "id": 1733,
                        "displayName": "year_1733"
                  },
                  {
                        "id": 1734,
                        "displayName": "year_1734"
                  },
                  {
                        "id": 1735,
                        "displayName": "year_1735"
                  },
                  {
                        "id": 1736,
                        "displayName": "year_1736"
                  },
                  {
                        "id": 1737,
                        "displayName": "year_1737"
                  },
                  {
                        "id": 1738,
                        "displayName": "year_1738"
                  },
                  {
                        "id": 1739,
                        "displayName": "year_1739"
                  },
                  {
                        "id": 1740,
                        "displayName": "year_1740"
                  },
                  {
                        "id": 1741,
                        "displayName": "year_1741"
                  },
                  {
                        "id": 1742,
                        "displayName": "year_1742"
                  },
                  {
                        "id": 1743,
                        "displayName": "year_1743"
                  },
                  {
                        "id": 1744,
                        "displayName": "year_1744"
                  },
                  {
                        "id": 1745,
                        "displayName": "year_1745"
                  },
                  {
                        "id": 1746,
                        "displayName": "year_1746"
                  },
                  {
                        "id": 1747,
                        "displayName": "year_1747"
                  },
                  {
                        "id": 1748,
                        "displayName": "year_1748"
                  },
                  {
                        "id": 1749,
                        "displayName": "year_1749"
                  },
                  {
                        "id": 1750,
                        "displayName": "year_1750"
                  },
                  {
                        "id": 1751,
                        "displayName": "year_1751"
                  },
                  {
                        "id": 1752,
                        "displayName": "year_1752"
                  },
                  {
                        "id": 1753,
                        "displayName": "year_1753"
                  },
                  {
                        "id": 1754,
                        "displayName": "year_1754"
                  },
                  {
                        "id": 1755,
                        "displayName": "year_1755"
                  },
                  {
                        "id": 1756,
                        "displayName": "year_1756"
                  },
                  {
                        "id": 1757,
                        "displayName": "year_1757"
                  },
                  {
                        "id": 1758,
                        "displayName": "year_1758"
                  },
                  {
                        "id": 1759,
                        "displayName": "year_1759"
                  },
                  {
                        "id": 1760,
                        "displayName": "year_1760"
                  },
                  {
                        "id": 1761,
                        "displayName": "year_1761"
                  },
                  {
                        "id": 1762,
                        "displayName": "year_1762"
                  },
                  {
                        "id": 1763,
                        "displayName": "year_1763"
                  },
                  {
                        "id": 1764,
                        "displayName": "year_1764"
                  },
                  {
                        "id": 1765,
                        "displayName": "year_1765"
                  },
                  {
                        "id": 1766,
                        "displayName": "year_1766"
                  },
                  {
                        "id": 1767,
                        "displayName": "year_1767"
                  },
                  {
                        "id": 1768,
                        "displayName": "year_1768"
                  },
                  {
                        "id": 1769,
                        "displayName": "year_1769"
                  },
                  {
                        "id": 1770,
                        "displayName": "year_1770"
                  },
                  {
                        "id": 1771,
                        "displayName": "year_1771"
                  },
                  {
                        "id": 1772,
                        "displayName": "year_1772"
                  },
                  {
                        "id": 1773,
                        "displayName": "year_1773"
                  },
                  {
                        "id": 1774,
                        "displayName": "year_1774"
                  },
                  {
                        "id": 1775,
                        "displayName": "year_1775"
                  },
                  {
                        "id": 1776,
                        "displayName": "year_1776"
                  },
                  {
                        "id": 1777,
                        "displayName": "year_1777"
                  },
                  {
                        "id": 1778,
                        "displayName": "year_1778"
                  },
                  {
                        "id": 1779,
                        "displayName": "year_1779"
                  },
                  {
                        "id": 1780,
                        "displayName": "year_1780"
                  },
                  {
                        "id": 1781,
                        "displayName": "year_1781"
                  },
                  {
                        "id": 1782,
                        "displayName": "year_1782"
                  },
                  {
                        "id": 1783,
                        "displayName": "year_1783"
                  },
                  {
                        "id": 1784,
                        "displayName": "year_1784"
                  },
                  {
                        "id": 1785,
                        "displayName": "year_1785"
                  },
                  {
                        "id": 1786,
                        "displayName": "year_1786"
                  },
                  {
                        "id": 1787,
                        "displayName": "year_1787"
                  },
                  {
                        "id": 1788,
                        "displayName": "year_1788"
                  },
                  {
                        "id": 1789,
                        "displayName": "year_1789"
                  },
                  {
                        "id": 1790,
                        "displayName": "year_1790"
                  },
                  {
                        "id": 1791,
                        "displayName": "year_1791"
                  },
                  {
                        "id": 1792,
                        "displayName": "year_1792"
                  },
                  {
                        "id": 1793,
                        "displayName": "year_1793"
                  },
                  {
                        "id": 1794,
                        "displayName": "year_1794"
                  },
                  {
                        "id": 1795,
                        "displayName": "year_1795"
                  },
                  {
                        "id": 1796,
                        "displayName": "year_1796"
                  },
                  {
                        "id": 1797,
                        "displayName": "year_1797"
                  },
                  {
                        "id": 1798,
                        "displayName": "year_1798"
                  },
                  {
                        "id": 1799,
                        "displayName": "year_1799"
                  },
                  {
                        "id": 1800,
                        "displayName": "year_1800"
                  },
                  {
                        "id": 1801,
                        "displayName": "year_1801"
                  },
                  {
                        "id": 1802,
                        "displayName": "year_1802"
                  },
                  {
                        "id": 1803,
                        "displayName": "year_1803"
                  },
                  {
                        "id": 1804,
                        "displayName": "year_1804"
                  },
                  {
                        "id": 1805,
                        "displayName": "year_1805"
                  },
                  {
                        "id": 1806,
                        "displayName": "year_1806"
                  },
                  {
                        "id": 1807,
                        "displayName": "year_1807"
                  },
                  {
                        "id": 1808,
                        "displayName": "year_1808"
                  },
                  {
                        "id": 1809,
                        "displayName": "year_1809"
                  },
                  {
                        "id": 1810,
                        "displayName": "year_1810"
                  },
                  {
                        "id": 1811,
                        "displayName": "year_1811"
                  },
                  {
                        "id": 1812,
                        "displayName": "year_1812"
                  },
                  {
                        "id": 1813,
                        "displayName": "year_1813"
                  },
                  {
                        "id": 1814,
                        "displayName": "year_1814"
                  },
                  {
                        "id": 1815,
                        "displayName": "year_1815"
                  },
                  {
                        "id": 1816,
                        "displayName": "year_1816"
                  },
                  {
                        "id": 1817,
                        "displayName": "year_1817"
                  },
                  {
                        "id": 1818,
                        "displayName": "year_1818"
                  },
                  {
                        "id": 1819,
                        "displayName": "year_1819"
                  },
                  {
                        "id": 1820,
                        "displayName": "year_1820"
                  },
                  {
                        "id": 1821,
                        "displayName": "year_1821"
                  },
                  {
                        "id": 1822,
                        "displayName": "year_1822"
                  },
                  {
                        "id": 1823,
                        "displayName": "year_1823"
                  },
                  {
                        "id": 1824,
                        "displayName": "year_1824"
                  },
                  {
                        "id": 1825,
                        "displayName": "year_1825"
                  },
                  {
                        "id": 1826,
                        "displayName": "year_1826"
                  },
                  {
                        "id": 1827,
                        "displayName": "year_1827"
                  },
                  {
                        "id": 1828,
                        "displayName": "year_1828"
                  },
                  {
                        "id": 1829,
                        "displayName": "year_1829"
                  },
                  {
                        "id": 1830,
                        "displayName": "year_1830"
                  },
                  {
                        "id": 1831,
                        "displayName": "year_1831"
                  },
                  {
                        "id": 1832,
                        "displayName": "year_1832"
                  },
                  {
                        "id": 1833,
                        "displayName": "year_1833"
                  },
                  {
                        "id": 1834,
                        "displayName": "year_1834"
                  },
                  {
                        "id": 1835,
                        "displayName": "year_1835"
                  },
                  {
                        "id": 1836,
                        "displayName": "year_1836"
                  },
                  {
                        "id": 1837,
                        "displayName": "year_1837"
                  },
                  {
                        "id": 1838,
                        "displayName": "year_1838"
                  },
                  {
                        "id": 1839,
                        "displayName": "year_1839"
                  },
                  {
                        "id": 1840,
                        "displayName": "year_1840"
                  },
                  {
                        "id": 1841,
                        "displayName": "year_1841"
                  },
                  {
                        "id": 1842,
                        "displayName": "year_1842"
                  },
                  {
                        "id": 1843,
                        "displayName": "year_1843"
                  },
                  {
                        "id": 1844,
                        "displayName": "year_1844"
                  },
                  {
                        "id": 1845,
                        "displayName": "year_1845"
                  },
                  {
                        "id": 1846,
                        "displayName": "year_1846"
                  },
                  {
                        "id": 1847,
                        "displayName": "year_1847"
                  },
                  {
                        "id": 1848,
                        "displayName": "year_1848"
                  },
                  {
                        "id": 1849,
                        "displayName": "year_1849"
                  },
                  {
                        "id": 1850,
                        "displayName": "year_1850"
                  },
                  {
                        "id": 1851,
                        "displayName": "year_1851"
                  },
                  {
                        "id": 1852,
                        "displayName": "year_1852"
                  },
                  {
                        "id": 1853,
                        "displayName": "year_1853"
                  },
                  {
                        "id": 1854,
                        "displayName": "year_1854"
                  },
                  {
                        "id": 1855,
                        "displayName": "year_1855"
                  },
                  {
                        "id": 1856,
                        "displayName": "year_1856"
                  },
                  {
                        "id": 1857,
                        "displayName": "year_1857"
                  },
                  {
                        "id": 1858,
                        "displayName": "year_1858"
                  },
                  {
                        "id": 1859,
                        "displayName": "year_1859"
                  },
                  {
                        "id": 1860,
                        "displayName": "year_1860"
                  },
                  {
                        "id": 1861,
                        "displayName": "year_1861"
                  },
                  {
                        "id": 1862,
                        "displayName": "year_1862"
                  },
                  {
                        "id": 1863,
                        "displayName": "year_1863"
                  },
                  {
                        "id": 1864,
                        "displayName": "year_1864"
                  },
                  {
                        "id": 1865,
                        "displayName": "year_1865"
                  },
                  {
                        "id": 1866,
                        "displayName": "year_1866"
                  },
                  {
                        "id": 1867,
                        "displayName": "year_1867"
                  },
                  {
                        "id": 1868,
                        "displayName": "year_1868"
                  },
                  {
                        "id": 1869,
                        "displayName": "year_1869"
                  },
                  {
                        "id": 1870,
                        "displayName": "year_1870"
                  },
                  {
                        "id": 1871,
                        "displayName": "year_1871"
                  },
                  {
                        "id": 1872,
                        "displayName": "year_1872"
                  },
                  {
                        "id": 1873,
                        "displayName": "year_1873"
                  },
                  {
                        "id": 1874,
                        "displayName": "year_1874"
                  },
                  {
                        "id": 1875,
                        "displayName": "year_1875"
                  },
                  {
                        "id": 1876,
                        "displayName": "year_1876"
                  },
                  {
                        "id": 1877,
                        "displayName": "year_1877"
                  },
                  {
                        "id": 1878,
                        "displayName": "year_1878"
                  },
                  {
                        "id": 1879,
                        "displayName": "year_1879"
                  },
                  {
                        "id": 1880,
                        "displayName": "year_1880"
                  },
                  {
                        "id": 1881,
                        "displayName": "year_1881"
                  },
                  {
                        "id": 1882,
                        "displayName": "year_1882"
                  },
                  {
                        "id": 1883,
                        "displayName": "year_1883"
                  },
                  {
                        "id": 1884,
                        "displayName": "year_1884"
                  },
                  {
                        "id": 1885,
                        "displayName": "year_1885"
                  },
                  {
                        "id": 1886,
                        "displayName": "year_1886"
                  },
                  {
                        "id": 1887,
                        "displayName": "year_1887"
                  },
                  {
                        "id": 1888,
                        "displayName": "year_1888"
                  },
                  {
                        "id": 1889,
                        "displayName": "year_1889"
                  },
                  {
                        "id": 1890,
                        "displayName": "year_1890"
                  },
                  {
                        "id": 1891,
                        "displayName": "year_1891"
                  },
                  {
                        "id": 1892,
                        "displayName": "year_1892"
                  },
                  {
                        "id": 1893,
                        "displayName": "year_1893"
                  },
                  {
                        "id": 1894,
                        "displayName": "year_1894"
                  },
                  {
                        "id": 1895,
                        "displayName": "year_1895"
                  },
                  {
                        "id": 1896,
                        "displayName": "year_1896"
                  },
                  {
                        "id": 1897,
                        "displayName": "year_1897"
                  },
                  {
                        "id": 1898,
                        "displayName": "year_1898"
                  },
                  {
                        "id": 1899,
                        "displayName": "year_1899"
                  },
                  {
                        "id": 1900,
                        "displayName": "year_1900"
                  },
                  {
                        "id": 1901,
                        "displayName": "year_1901"
                  },
                  {
                        "id": 1902,
                        "displayName": "year_1902"
                  },
                  {
                        "id": 1903,
                        "displayName": "year_1903"
                  },
                  {
                        "id": 1904,
                        "displayName": "year_1904"
                  },
                  {
                        "id": 1905,
                        "displayName": "year_1905"
                  },
                  {
                        "id": 1906,
                        "displayName": "year_1906"
                  },
                  {
                        "id": 1907,
                        "displayName": "year_1907"
                  },
                  {
                        "id": 1908,
                        "displayName": "year_1908"
                  },
                  {
                        "id": 1909,
                        "displayName": "year_1909"
                  },
                  {
                        "id": 1910,
                        "displayName": "year_1910"
                  },
                  {
                        "id": 1911,
                        "displayName": "year_1911"
                  },
                  {
                        "id": 1912,
                        "displayName": "year_1912"
                  },
                  {
                        "id": 1913,
                        "displayName": "year_1913"
                  },
                  {
                        "id": 1914,
                        "displayName": "year_1914"
                  },
                  {
                        "id": 1915,
                        "displayName": "year_1915"
                  },
                  {
                        "id": 1916,
                        "displayName": "year_1916"
                  },
                  {
                        "id": 1917,
                        "displayName": "year_1917"
                  },
                  {
                        "id": 1918,
                        "displayName": "year_1918"
                  },
                  {
                        "id": 1919,
                        "displayName": "year_1919"
                  },
                  {
                        "id": 1920,
                        "displayName": "year_1920"
                  },
                  {
                        "id": 1921,
                        "displayName": "year_1921"
                  },
                  {
                        "id": 1922,
                        "displayName": "year_1922"
                  },
                  {
                        "id": 1923,
                        "displayName": "year_1923"
                  },
                  {
                        "id": 1924,
                        "displayName": "year_1924"
                  },
                  {
                        "id": 1925,
                        "displayName": "year_1925"
                  },
                  {
                        "id": 1926,
                        "displayName": "year_1926"
                  },
                  {
                        "id": 1927,
                        "displayName": "year_1927"
                  },
                  {
                        "id": 1928,
                        "displayName": "year_1928"
                  },
                  {
                        "id": 1929,
                        "displayName": "year_1929"
                  },
                  {
                        "id": 1930,
                        "displayName": "year_1930"
                  },
                  {
                        "id": 1931,
                        "displayName": "year_1931"
                  },
                  {
                        "id": 1932,
                        "displayName": "year_1932"
                  },
                  {
                        "id": 1933,
                        "displayName": "year_1933"
                  },
                  {
                        "id": 1934,
                        "displayName": "year_1934"
                  },
                  {
                        "id": 1935,
                        "displayName": "year_1935"
                  },
                  {
                        "id": 1936,
                        "displayName": "year_1936"
                  },
                  {
                        "id": 1937,
                        "displayName": "year_1937"
                  },
                  {
                        "id": 1938,
                        "displayName": "year_1938"
                  },
                  {
                        "id": 1939,
                        "displayName": "year_1939"
                  },
                  {
                        "id": 1940,
                        "displayName": "year_1940"
                  },
                  {
                        "id": 1941,
                        "displayName": "year_1941"
                  },
                  {
                        "id": 1942,
                        "displayName": "year_1942"
                  },
                  {
                        "id": 1943,
                        "displayName": "year_1943"
                  },
                  {
                        "id": 1944,
                        "displayName": "year_1944"
                  },
                  {
                        "id": 1945,
                        "displayName": "year_1945"
                  },
                  {
                        "id": 1946,
                        "displayName": "year_1946"
                  },
                  {
                        "id": 1947,
                        "displayName": "year_1947"
                  },
                  {
                        "id": 1948,
                        "displayName": "year_1948"
                  },
                  {
                        "id": 1949,
                        "displayName": "year_1949"
                  },
                  {
                        "id": 1950,
                        "displayName": "year_1950"
                  },
                  {
                        "id": 1951,
                        "displayName": "year_1951"
                  },
                  {
                        "id": 1952,
                        "displayName": "year_1952"
                  },
                  {
                        "id": 1953,
                        "displayName": "year_1953"
                  },
                  {
                        "id": 1954,
                        "displayName": "year_1954"
                  },
                  {
                        "id": 1955,
                        "displayName": "year_1955"
                  },
                  {
                        "id": 1956,
                        "displayName": "year_1956"
                  },
                  {
                        "id": 1957,
                        "displayName": "year_1957"
                  },
                  {
                        "id": 1958,
                        "displayName": "year_1958"
                  },
                  {
                        "id": 1959,
                        "displayName": "year_1959"
                  },
                  {
                        "id": 1960,
                        "displayName": "year_1960"
                  },
                  {
                        "id": 1961,
                        "displayName": "year_1961"
                  },
                  {
                        "id": 1962,
                        "displayName": "year_1962"
                  },
                  {
                        "id": 1963,
                        "displayName": "year_1963"
                  },
                  {
                        "id": 1964,
                        "displayName": "year_1964"
                  },
                  {
                        "id": 1965,
                        "displayName": "year_1965"
                  },
                  {
                        "id": 1966,
                        "displayName": "year_1966"
                  },
                  {
                        "id": 1967,
                        "displayName": "year_1967"
                  },
                  {
                        "id": 1968,
                        "displayName": "year_1968"
                  },
                  {
                        "id": 1969,
                        "displayName": "year_1969"
                  },
                  {
                        "id": 1970,
                        "displayName": "year_1970"
                  },
                  {
                        "id": 1971,
                        "displayName": "year_1971"
                  },
                  {
                        "id": 1972,
                        "displayName": "year_1972"
                  },
                  {
                        "id": 1973,
                        "displayName": "year_1973"
                  },
                  {
                        "id": 1974,
                        "displayName": "year_1974"
                  },
                  {
                        "id": 1975,
                        "displayName": "year_1975"
                  },
                  {
                        "id": 1976,
                        "displayName": "year_1976"
                  },
                  {
                        "id": 1977,
                        "displayName": "year_1977"
                  },
                  {
                        "id": 1978,
                        "displayName": "year_1978"
                  },
                  {
                        "id": 1979,
                        "displayName": "year_1979"
                  },
                  {
                        "id": 1980,
                        "displayName": "year_1980"
                  },
                  {
                        "id": 1981,
                        "displayName": "year_1981"
                  },
                  {
                        "id": 1982,
                        "displayName": "year_1982"
                  },
                  {
                        "id": 1983,
                        "displayName": "year_1983"
                  },
                  {
                        "id": 1984,
                        "displayName": "year_1984"
                  },
                  {
                        "id": 1985,
                        "displayName": "year_1985"
                  },
                  {
                        "id": 1986,
                        "displayName": "year_1986"
                  },
                  {
                        "id": 1987,
                        "displayName": "year_1987"
                  },
                  {
                        "id": 1988,
                        "displayName": "year_1988"
                  },
                  {
                        "id": 1989,
                        "displayName": "year_1989"
                  },
                  {
                        "id": 1990,
                        "displayName": "year_1990"
                  },
                  {
                        "id": 1991,
                        "displayName": "year_1991"
                  },
                  {
                        "id": 1992,
                        "displayName": "year_1992"
                  },
                  {
                        "id": 1993,
                        "displayName": "year_1993"
                  },
                  {
                        "id": 1994,
                        "displayName": "year_1994"
                  },
                  {
                        "id": 1995,
                        "displayName": "year_1995"
                  },
                  {
                        "id": 1996,
                        "displayName": "year_1996"
                  },
                  {
                        "id": 1997,
                        "displayName": "year_1997"
                  },
                  {
                        "id": 1998,
                        "displayName": "year_1998"
                  },
                  {
                        "id": 1999,
                        "displayName": "year_1999"
                  },
                  {
                        "id": 2000,
                        "displayName": "year_2000"
                  },
                  {
                        "id": 2001,
                        "displayName": "year_2001"
                  },
                  {
                        "id": 2002,
                        "displayName": "year_2002"
                  },
                  {
                        "id": 2003,
                        "displayName": "year_2003"
                  },
                  {
                        "id": 2004,
                        "displayName": "year_2004"
                  },
                  {
                        "id": 2005,
                        "displayName": "year_2005"
                  },
                  {
                        "id": 2006,
                        "displayName": "year_2006"
                  },
                  {
                        "id": 2007,
                        "displayName": "year_2007"
                  },
                  {
                        "id": 2008,
                        "displayName": "year_2008"
                  },
                  {
                        "id": 2009,
                        "displayName": "year_2009"
                  },
                  {
                        "id": 2010,
                        "displayName": "year_2010"
                  },
                  {
                        "id": 2011,
                        "displayName": "year_2011"
                  },
                  {
                        "id": 2012,
                        "displayName": "year_2012"
                  },
                  {
                        "id": 2013,
                        "displayName": "year_2013"
                  },
                  {
                        "id": 2014,
                        "displayName": "year_2014"
                  },
                  {
                        "id": 2015,
                        "displayName": "year_2015"
                  },
                  {
                        "id": 2016,
                        "displayName": "year_2016"
                  },
                  {
                        "id": 2017,
                        "displayName": "year_2017"
                  },
                  {
                        "id": 2018,
                        "displayName": "year_2018"
                  },
                  {
                        "id": 2019,
                        "displayName": "year_2019"
                  },
                  {
                        "id": 2020,
                        "displayName": "year_2020"
                  },
                  {
                        "id": 2021,
                        "displayName": "year_2021"
                  },
                  {
                        "id": 2022,
                        "displayName": "year_2022"
                  },
                  {
                        "id": 2023,
                        "displayName": "year_2023"
                  },
                  {
                        "id": 2024,
                        "displayName": "year_2024"
                  },
                  {
                        "id": 2025,
                        "displayName": "year_2025"
                  },
                  {
                        "id": 2026,
                        "displayName": "year_2026"
                  },
                  {
                        "id": 2027,
                        "displayName": "year_2027"
                  },
                  {
                        "id": 2028,
                        "displayName": "year_2028"
                  },
                  {
                        "id": 2029,
                        "displayName": "year_2029"
                  },
                  {
                        "id": 2030,
                        "displayName": "year_2030"
                  },
                  {
                        "id": 2031,
                        "displayName": "year_2031"
                  },
                  {
                        "id": 2032,
                        "displayName": "year_2032"
                  },
                  {
                        "id": 2033,
                        "displayName": "year_2033"
                  },
                  {
                        "id": 2034,
                        "displayName": "year_2034"
                  },
                  {
                        "id": 2035,
                        "displayName": "year_2035"
                  },
                  {
                        "id": 2036,
                        "displayName": "year_2036"
                  },
                  {
                        "id": 2037,
                        "displayName": "year_2037"
                  },
                  {
                        "id": 2038,
                        "displayName": "year_2038"
                  },
                  {
                        "id": 2039,
                        "displayName": "year_2039"
                  },
                  {
                        "id": 2040,
                        "displayName": "year_2040"
                  },
                  {
                        "id": 2041,
                        "displayName": "year_2041"
                  },
                  {
                        "id": 2042,
                        "displayName": "year_2042"
                  },
                  {
                        "id": 2043,
                        "displayName": "year_2043"
                  },
                  {
                        "id": 2044,
                        "displayName": "year_2044"
                  },
                  {
                        "id": 2045,
                        "displayName": "year_2045"
                  },
                  {
                        "id": 2046,
                        "displayName": "year_2046"
                  },
                  {
                        "id": 2047,
                        "displayName": "year_2047"
                  },
                  {
                        "id": 2048,
                        "displayName": "year_2048"
                  },
                  {
                        "id": 2049,
                        "displayName": "year_2049"
                  },
                  {
                        "id": 2050,
                        "displayName": "year_2050"
                  },
                  {
                        "id": 2051,
                        "displayName": "year_2051"
                  },
                  {
                        "id": 2052,
                        "displayName": "year_2052"
                  },
                  {
                        "id": 2053,
                        "displayName": "year_2053"
                  },
                  {
                        "id": 2054,
                        "displayName": "year_2054"
                  },
                  {
                        "id": 2055,
                        "displayName": "year_2055"
                  },
                  {
                        "id": 2056,
                        "displayName": "year_2056"
                  },
                  {
                        "id": 2057,
                        "displayName": "year_2057"
                  },
                  {
                        "id": 2058,
                        "displayName": "year_2058"
                  },
                  {
                        "id": 2059,
                        "displayName": "year_2059"
                  },
                  {
                        "id": 2060,
                        "displayName": "year_2060"
                  },
                  {
                        "id": 2061,
                        "displayName": "year_2061"
                  },
                  {
                        "id": 2062,
                        "displayName": "year_2062"
                  },
                  {
                        "id": 2063,
                        "displayName": "year_2063"
                  },
                  {
                        "id": 2064,
                        "displayName": "year_2064"
                  },
                  {
                        "id": 2065,
                        "displayName": "year_2065"
                  },
                  {
                        "id": 2066,
                        "displayName": "year_2066"
                  },
                  {
                        "id": 2067,
                        "displayName": "year_2067"
                  },
                  {
                        "id": 2068,
                        "displayName": "year_2068"
                  },
                  {
                        "id": 2069,
                        "displayName": "year_2069"
                  },
                  {
                        "id": 2070,
                        "displayName": "year_2070"
                  },
                  {
                        "id": 2071,
                        "displayName": "year_2071"
                  },
                  {
                        "id": 2072,
                        "displayName": "year_2072"
                  },
                  {
                        "id": 2073,
                        "displayName": "year_2073"
                  },
                  {
                        "id": 2074,
                        "displayName": "year_2074"
                  },
                  {
                        "id": 2075,
                        "displayName": "year_2075"
                  },
                  {
                        "id": 2076,
                        "displayName": "year_2076"
                  },
                  {
                        "id": 2077,
                        "displayName": "year_2077"
                  },
                  {
                        "id": 2078,
                        "displayName": "year_2078"
                  },
                  {
                        "id": 2079,
                        "displayName": "year_2079"
                  },
                  {
                        "id": 2080,
                        "displayName": "year_2080"
                  },
                  {
                        "id": 2081,
                        "displayName": "year_2081"
                  },
                  {
                        "id": 2082,
                        "displayName": "year_2082"
                  },
                  {
                        "id": 2083,
                        "displayName": "year_2083"
                  },
                  {
                        "id": 2084,
                        "displayName": "year_2084"
                  },
                  {
                        "id": 2085,
                        "displayName": "year_2085"
                  },
                  {
                        "id": 2086,
                        "displayName": "year_2086"
                  },
                  {
                        "id": 2087,
                        "displayName": "year_2087"
                  },
                  {
                        "id": 2088,
                        "displayName": "year_2088"
                  },
                  {
                        "id": 2089,
                        "displayName": "year_2089"
                  },
                  {
                        "id": 2090,
                        "displayName": "year_2090"
                  },
                  {
                        "id": 2091,
                        "displayName": "year_2091"
                  },
                  {
                        "id": 2092,
                        "displayName": "year_2092"
                  },
                  {
                        "id": 2093,
                        "displayName": "year_2093"
                  },
                  {
                        "id": 2094,
                        "displayName": "year_2094"
                  },
                  {
                        "id": 2095,
                        "displayName": "year_2095"
                  },
                  {
                        "id": 2096,
                        "displayName": "year_2096"
                  },
                  {
                        "id": 2097,
                        "displayName": "year_2097"
                  },
                  {
                        "id": 2098,
                        "displayName": "year_2098"
                  },
                  {
                        "id": 2099,
                        "displayName": "year_2099"
                  },
                  {
                        "id": 2100,
                        "displayName": "year_2100"
                  },
                  {
                        "id": 2101,
                        "displayName": "year_2101"
                  },
                  {
                        "id": 2102,
                        "displayName": "year_2102"
                  },
                  {
                        "id": 2103,
                        "displayName": "year_2103"
                  },
                  {
                        "id": 2104,
                        "displayName": "year_2104"
                  },
                  {
                        "id": 2105,
                        "displayName": "year_2105"
                  },
                  {
                        "id": 2106,
                        "displayName": "year_2106"
                  },
                  {
                        "id": 2107,
                        "displayName": "year_2107"
                  },
                  {
                        "id": 2108,
                        "displayName": "year_2108"
                  },
                  {
                        "id": 2109,
                        "displayName": "year_2109"
                  },
                  {
                        "id": 2110,
                        "displayName": "year_2110"
                  },
                  {
                        "id": 2111,
                        "displayName": "year_2111"
                  },
                  {
                        "id": 2112,
                        "displayName": "year_2112"
                  },
                  {
                        "id": 2113,
                        "displayName": "year_2113"
                  },
                  {
                        "id": 2114,
                        "displayName": "year_2114"
                  },
                  {
                        "id": 2115,
                        "displayName": "year_2115"
                  },
                  {
                        "id": 2116,
                        "displayName": "year_2116"
                  },
                  {
                        "id": 2117,
                        "displayName": "year_2117"
                  },
                  {
                        "id": 2118,
                        "displayName": "year_2118"
                  },
                  {
                        "id": 2119,
                        "displayName": "year_2119"
                  },
                  {
                        "id": 2120,
                        "displayName": "year_2120"
                  },
                  {
                        "id": 2121,
                        "displayName": "year_2121"
                  },
                  {
                        "id": 2122,
                        "displayName": "year_2122"
                  },
                  {
                        "id": 2123,
                        "displayName": "year_2123"
                  },
                  {
                        "id": 2124,
                        "displayName": "year_2124"
                  },
                  {
                        "id": 2125,
                        "displayName": "year_2125"
                  },
                  {
                        "id": 2126,
                        "displayName": "year_2126"
                  },
                  {
                        "id": 2127,
                        "displayName": "year_2127"
                  },
                  {
                        "id": 2128,
                        "displayName": "year_2128"
                  },
                  {
                        "id": 2129,
                        "displayName": "year_2129"
                  },
                  {
                        "id": 2130,
                        "displayName": "year_2130"
                  },
                  {
                        "id": 2131,
                        "displayName": "year_2131"
                  },
                  {
                        "id": 2132,
                        "displayName": "year_2132"
                  },
                  {
                        "id": 2133,
                        "displayName": "year_2133"
                  },
                  {
                        "id": 2134,
                        "displayName": "year_2134"
                  },
                  {
                        "id": 2135,
                        "displayName": "year_2135"
                  },
                  {
                        "id": 2136,
                        "displayName": "year_2136"
                  },
                  {
                        "id": 2137,
                        "displayName": "year_2137"
                  },
                  {
                        "id": 2138,
                        "displayName": "year_2138"
                  },
                  {
                        "id": 2139,
                        "displayName": "year_2139"
                  },
                  {
                        "id": 2140,
                        "displayName": "year_2140"
                  },
                  {
                        "id": 2141,
                        "displayName": "year_2141"
                  },
                  {
                        "id": 2142,
                        "displayName": "year_2142"
                  },
                  {
                        "id": 2143,
                        "displayName": "year_2143"
                  },
                  {
                        "id": 2144,
                        "displayName": "year_2144"
                  },
                  {
                        "id": 2145,
                        "displayName": "year_2145"
                  },
                  {
                        "id": 2146,
                        "displayName": "year_2146"
                  },
                  {
                        "id": 2147,
                        "displayName": "year_2147"
                  },
                  {
                        "id": 2148,
                        "displayName": "year_2148"
                  },
                  {
                        "id": 2149,
                        "displayName": "year_2149"
                  },
                  {
                        "id": 2150,
                        "displayName": "year_2150"
                  },
                  {
                        "id": 2151,
                        "displayName": "year_2151"
                  },
                  {
                        "id": 2152,
                        "displayName": "year_2152"
                  },
                  {
                        "id": 2153,
                        "displayName": "year_2153"
                  },
                  {
                        "id": 2154,
                        "displayName": "year_2154"
                  },
                  {
                        "id": 2155,
                        "displayName": "year_2155"
                  },
                  {
                        "id": 2156,
                        "displayName": "year_2156"
                  },
                  {
                        "id": 2157,
                        "displayName": "year_2157"
                  },
                  {
                        "id": 2158,
                        "displayName": "year_2158"
                  },
                  {
                        "id": 2159,
                        "displayName": "year_2159"
                  },
                  {
                        "id": 2160,
                        "displayName": "year_2160"
                  },
                  {
                        "id": 2161,
                        "displayName": "year_2161"
                  },
                  {
                        "id": 2162,
                        "displayName": "year_2162"
                  },
                  {
                        "id": 2163,
                        "displayName": "year_2163"
                  },
                  {
                        "id": 2164,
                        "displayName": "year_2164"
                  },
                  {
                        "id": 2165,
                        "displayName": "year_2165"
                  },
                  {
                        "id": 2166,
                        "displayName": "year_2166"
                  },
                  {
                        "id": 2167,
                        "displayName": "year_2167"
                  },
                  {
                        "id": 2168,
                        "displayName": "year_2168"
                  },
                  {
                        "id": 2169,
                        "displayName": "year_2169"
                  },
                  {
                        "id": 2170,
                        "displayName": "year_2170"
                  },
                  {
                        "id": 2171,
                        "displayName": "year_2171"
                  },
                  {
                        "id": 2172,
                        "displayName": "year_2172"
                  },
                  {
                        "id": 2173,
                        "displayName": "year_2173"
                  },
                  {
                        "id": 2174,
                        "displayName": "year_2174"
                  },
                  {
                        "id": 2175,
                        "displayName": "year_2175"
                  },
                  {
                        "id": 2176,
                        "displayName": "year_2176"
                  },
                  {
                        "id": 2177,
                        "displayName": "year_2177"
                  },
                  {
                        "id": 2178,
                        "displayName": "year_2178"
                  },
                  {
                        "id": 2179,
                        "displayName": "year_2179"
                  },
                  {
                        "id": 2180,
                        "displayName": "year_2180"
                  },
                  {
                        "id": 2181,
                        "displayName": "year_2181"
                  },
                  {
                        "id": 2182,
                        "displayName": "year_2182"
                  },
                  {
                        "id": 2183,
                        "displayName": "year_2183"
                  },
                  {
                        "id": 2184,
                        "displayName": "year_2184"
                  },
                  {
                        "id": 2185,
                        "displayName": "year_2185"
                  },
                  {
                        "id": 2186,
                        "displayName": "year_2186"
                  },
                  {
                        "id": 2187,
                        "displayName": "year_2187"
                  },
                  {
                        "id": 2188,
                        "displayName": "year_2188"
                  },
                  {
                        "id": 2189,
                        "displayName": "year_2189"
                  },
                  {
                        "id": 2190,
                        "displayName": "year_2190"
                  },
                  {
                        "id": 2191,
                        "displayName": "year_2191"
                  },
                  {
                        "id": 2192,
                        "displayName": "year_2192"
                  },
                  {
                        "id": 2193,
                        "displayName": "year_2193"
                  },
                  {
                        "id": 2194,
                        "displayName": "year_2194"
                  },
                  {
                        "id": 2195,
                        "displayName": "year_2195"
                  },
                  {
                        "id": 2196,
                        "displayName": "year_2196"
                  },
                  {
                        "id": 2197,
                        "displayName": "year_2197"
                  },
                  {
                        "id": 2198,
                        "displayName": "year_2198"
                  },
                  {
                        "id": 2199,
                        "displayName": "year_2199"
                  },
                  {
                        "id": 2200,
                        "displayName": "year_2200"
                  },
                  {
                        "id": 2201,
                        "displayName": "year_2201"
                  },
                  {
                        "id": 2202,
                        "displayName": "year_2202"
                  },
                  {
                        "id": 2203,
                        "displayName": "year_2203"
                  },
                  {
                        "id": 2204,
                        "displayName": "year_2204"
                  },
                  {
                        "id": 2205,
                        "displayName": "year_2205"
                  },
                  {
                        "id": 2206,
                        "displayName": "year_2206"
                  },
                  {
                        "id": 2207,
                        "displayName": "year_2207"
                  },
                  {
                        "id": 2208,
                        "displayName": "year_2208"
                  },
                  {
                        "id": 2209,
                        "displayName": "year_2209"
                  },
                  {
                        "id": 2210,
                        "displayName": "year_2210"
                  },
                  {
                        "id": 2211,
                        "displayName": "year_2211"
                  },
                  {
                        "id": 2212,
                        "displayName": "year_2212"
                  },
                  {
                        "id": 2213,
                        "displayName": "year_2213"
                  },
                  {
                        "id": 2214,
                        "displayName": "year_2214"
                  },
                  {
                        "id": 2215,
                        "displayName": "year_2215"
                  },
                  {
                        "id": 2216,
                        "displayName": "year_2216"
                  },
                  {
                        "id": 2217,
                        "displayName": "year_2217"
                  },
                  {
                        "id": 2218,
                        "displayName": "year_2218"
                  },
                  {
                        "id": 2219,
                        "displayName": "year_2219"
                  },
                  {
                        "id": 2220,
                        "displayName": "year_2220"
                  },
                  {
                        "id": 2221,
                        "displayName": "year_2221"
                  },
                  {
                        "id": 2222,
                        "displayName": "year_2222"
                  },
                  {
                        "id": 2223,
                        "displayName": "year_2223"
                  },
                  {
                        "id": 2224,
                        "displayName": "year_2224"
                  },
                  {
                        "id": 2225,
                        "displayName": "year_2225"
                  },
                  {
                        "id": 2226,
                        "displayName": "year_2226"
                  },
                  {
                        "id": 2227,
                        "displayName": "year_2227"
                  },
                  {
                        "id": 2228,
                        "displayName": "year_2228"
                  },
                  {
                        "id": 2229,
                        "displayName": "year_2229"
                  },
                  {
                        "id": 2230,
                        "displayName": "year_2230"
                  },
                  {
                        "id": 2231,
                        "displayName": "year_2231"
                  },
                  {
                        "id": 2232,
                        "displayName": "year_2232"
                  },
                  {
                        "id": 2233,
                        "displayName": "year_2233"
                  },
                  {
                        "id": 2234,
                        "displayName": "year_2234"
                  },
                  {
                        "id": 2235,
                        "displayName": "year_2235"
                  },
                  {
                        "id": 2236,
                        "displayName": "year_2236"
                  },
                  {
                        "id": 2237,
                        "displayName": "year_2237"
                  },
                  {
                        "id": 2238,
                        "displayName": "year_2238"
                  },
                  {
                        "id": 2239,
                        "displayName": "year_2239"
                  },
                  {
                        "id": 2240,
                        "displayName": "year_2240"
                  },
                  {
                        "id": 2241,
                        "displayName": "year_2241"
                  },
                  {
                        "id": 2242,
                        "displayName": "year_2242"
                  },
                  {
                        "id": 2243,
                        "displayName": "year_2243"
                  },
                  {
                        "id": 2244,
                        "displayName": "year_2244"
                  },
                  {
                        "id": 2245,
                        "displayName": "year_2245"
                  },
                  {
                        "id": 2246,
                        "displayName": "year_2246"
                  },
                  {
                        "id": 2247,
                        "displayName": "year_2247"
                  },
                  {
                        "id": 2248,
                        "displayName": "year_2248"
                  },
                  {
                        "id": 2249,
                        "displayName": "year_2249"
                  },
                  {
                        "id": 2250,
                        "displayName": "year_2250"
                  },
                  {
                        "id": 2251,
                        "displayName": "year_2251"
                  },
                  {
                        "id": 2252,
                        "displayName": "year_2252"
                  },
                  {
                        "id": 2253,
                        "displayName": "year_2253"
                  },
                  {
                        "id": 2254,
                        "displayName": "year_2254"
                  },
                  {
                        "id": 2255,
                        "displayName": "year_2255"
                  },
                  {
                        "id": 2256,
                        "displayName": "year_2256"
                  },
                  {
                        "id": 2257,
                        "displayName": "year_2257"
                  },
                  {
                        "id": 2258,
                        "displayName": "year_2258"
                  },
                  {
                        "id": 2259,
                        "displayName": "year_2259"
                  },
                  {
                        "id": 2260,
                        "displayName": "year_2260"
                  },
                  {
                        "id": 2261,
                        "displayName": "year_2261"
                  },
                  {
                        "id": 2262,
                        "displayName": "year_2262"
                  },
                  {
                        "id": 2263,
                        "displayName": "year_2263"
                  },
                  {
                        "id": 2264,
                        "displayName": "year_2264"
                  },
                  {
                        "id": 2265,
                        "displayName": "year_2265"
                  },
                  {
                        "id": 2266,
                        "displayName": "year_2266"
                  },
                  {
                        "id": 2267,
                        "displayName": "year_2267"
                  },
                  {
                        "id": 2268,
                        "displayName": "year_2268"
                  },
                  {
                        "id": 2269,
                        "displayName": "year_2269"
                  },
                  {
                        "id": 2270,
                        "displayName": "year_2270"
                  },
                  {
                        "id": 2271,
                        "displayName": "year_2271"
                  },
                  {
                        "id": 2272,
                        "displayName": "year_2272"
                  },
                  {
                        "id": 2273,
                        "displayName": "year_2273"
                  },
                  {
                        "id": 2274,
                        "displayName": "year_2274"
                  },
                  {
                        "id": 2275,
                        "displayName": "year_2275"
                  },
                  {
                        "id": 2276,
                        "displayName": "year_2276"
                  },
                  {
                        "id": 2277,
                        "displayName": "year_2277"
                  },
                  {
                        "id": 2278,
                        "displayName": "year_2278"
                  },
                  {
                        "id": 2279,
                        "displayName": "year_2279"
                  },
                  {
                        "id": 2280,
                        "displayName": "year_2280"
                  },
                  {
                        "id": 2281,
                        "displayName": "year_2281"
                  },
                  {
                        "id": 2282,
                        "displayName": "year_2282"
                  },
                  {
                        "id": 2283,
                        "displayName": "year_2283"
                  },
                  {
                        "id": 2284,
                        "displayName": "year_2284"
                  },
                  {
                        "id": 2285,
                        "displayName": "year_2285"
                  },
                  {
                        "id": 2286,
                        "displayName": "year_2286"
                  },
                  {
                        "id": 2287,
                        "displayName": "year_2287"
                  },
                  {
                        "id": 2288,
                        "displayName": "year_2288"
                  },
                  {
                        "id": 2289,
                        "displayName": "year_2289"
                  },
                  {
                        "id": 2290,
                        "displayName": "year_2290"
                  },
                  {
                        "id": 2291,
                        "displayName": "year_2291"
                  },
                  {
                        "id": 2292,
                        "displayName": "year_2292"
                  },
                  {
                        "id": 2293,
                        "displayName": "year_2293"
                  },
                  {
                        "id": 2294,
                        "displayName": "year_2294"
                  },
                  {
                        "id": 2295,
                        "displayName": "year_2295"
                  },
                  {
                        "id": 2296,
                        "displayName": "year_2296"
                  },
                  {
                        "id": 2297,
                        "displayName": "year_2297"
                  },
                  {
                        "id": 2298,
                        "displayName": "year_2298"
                  },
                  {
                        "id": 2299,
                        "displayName": "year_2299"
                  },
                  {
                        "id": 2300,
                        "displayName": "year_2300"
                  },
                  {
                        "id": 2301,
                        "displayName": "year_2301"
                  },
                  {
                        "id": 2302,
                        "displayName": "year_2302"
                  },
                  {
                        "id": 2303,
                        "displayName": "year_2303"
                  },
                  {
                        "id": 2304,
                        "displayName": "year_2304"
                  },
                  {
                        "id": 2305,
                        "displayName": "year_2305"
                  },
                  {
                        "id": 2306,
                        "displayName": "year_2306"
                  },
                  {
                        "id": 2307,
                        "displayName": "year_2307"
                  },
                  {
                        "id": 2308,
                        "displayName": "year_2308"
                  },
                  {
                        "id": 2309,
                        "displayName": "year_2309"
                  },
                  {
                        "id": 2310,
                        "displayName": "year_2310"
                  },
                  {
                        "id": 2311,
                        "displayName": "year_2311"
                  },
                  {
                        "id": 2312,
                        "displayName": "year_2312"
                  },
                  {
                        "id": 2313,
                        "displayName": "year_2313"
                  },
                  {
                        "id": 2314,
                        "displayName": "year_2314"
                  },
                  {
                        "id": 2315,
                        "displayName": "year_2315"
                  },
                  {
                        "id": 2316,
                        "displayName": "year_2316"
                  },
                  {
                        "id": 2317,
                        "displayName": "year_2317"
                  },
                  {
                        "id": 2318,
                        "displayName": "year_2318"
                  },
                  {
                        "id": 2319,
                        "displayName": "year_2319"
                  },
                  {
                        "id": 2320,
                        "displayName": "year_2320"
                  },
                  {
                        "id": 2321,
                        "displayName": "year_2321"
                  },
                  {
                        "id": 2322,
                        "displayName": "year_2322"
                  },
                  {
                        "id": 2323,
                        "displayName": "year_2323"
                  },
                  {
                        "id": 2324,
                        "displayName": "year_2324"
                  },
                  {
                        "id": 2325,
                        "displayName": "year_2325"
                  },
                  {
                        "id": 2326,
                        "displayName": "year_2326"
                  },
                  {
                        "id": 2327,
                        "displayName": "year_2327"
                  },
                  {
                        "id": 2328,
                        "displayName": "year_2328"
                  },
                  {
                        "id": 2329,
                        "displayName": "year_2329"
                  },
                  {
                        "id": 2330,
                        "displayName": "year_2330"
                  },
                  {
                        "id": 2331,
                        "displayName": "year_2331"
                  },
                  {
                        "id": 2332,
                        "displayName": "year_2332"
                  },
                  {
                        "id": 2333,
                        "displayName": "year_2333"
                  },
                  {
                        "id": 2334,
                        "displayName": "year_2334"
                  },
                  {
                        "id": 2335,
                        "displayName": "year_2335"
                  },
                  {
                        "id": 2336,
                        "displayName": "year_2336"
                  },
                  {
                        "id": 2337,
                        "displayName": "year_2337"
                  },
                  {
                        "id": 2338,
                        "displayName": "year_2338"
                  },
                  {
                        "id": 2339,
                        "displayName": "year_2339"
                  },
                  {
                        "id": 2340,
                        "displayName": "year_2340"
                  },
                  {
                        "id": 2341,
                        "displayName": "year_2341"
                  },
                  {
                        "id": 2342,
                        "displayName": "year_2342"
                  },
                  {
                        "id": 2343,
                        "displayName": "year_2343"
                  },
                  {
                        "id": 2344,
                        "displayName": "year_2344"
                  },
                  {
                        "id": 2345,
                        "displayName": "year_2345"
                  },
                  {
                        "id": 2346,
                        "displayName": "year_2346"
                  },
                  {
                        "id": 2347,
                        "displayName": "year_2347"
                  },
                  {
                        "id": 2348,
                        "displayName": "year_2348"
                  },
                  {
                        "id": 2349,
                        "displayName": "year_2349"
                  },
                  {
                        "id": 2350,
                        "displayName": "year_2350"
                  },
                  {
                        "id": 2351,
                        "displayName": "year_2351"
                  },
                  {
                        "id": 2352,
                        "displayName": "year_2352"
                  },
                  {
                        "id": 2353,
                        "displayName": "year_2353"
                  },
                  {
                        "id": 2354,
                        "displayName": "year_2354"
                  },
                  {
                        "id": 2355,
                        "displayName": "year_2355"
                  },
                  {
                        "id": 2356,
                        "displayName": "year_2356"
                  },
                  {
                        "id": 2357,
                        "displayName": "year_2357"
                  },
                  {
                        "id": 2358,
                        "displayName": "year_2358"
                  },
                  {
                        "id": 2359,
                        "displayName": "year_2359"
                  },
                  {
                        "id": 2360,
                        "displayName": "year_2360"
                  },
                  {
                        "id": 2361,
                        "displayName": "year_2361"
                  },
                  {
                        "id": 2362,
                        "displayName": "year_2362"
                  },
                  {
                        "id": 2363,
                        "displayName": "year_2363"
                  },
                  {
                        "id": 2364,
                        "displayName": "year_2364"
                  },
                  {
                        "id": 2365,
                        "displayName": "year_2365"
                  },
                  {
                        "id": 2366,
                        "displayName": "year_2366"
                  },
                  {
                        "id": 2367,
                        "displayName": "year_2367"
                  },
                  {
                        "id": 2368,
                        "displayName": "year_2368"
                  },
                  {
                        "id": 2369,
                        "displayName": "year_2369"
                  },
                  {
                        "id": 2370,
                        "displayName": "year_2370"
                  },
                  {
                        "id": 2371,
                        "displayName": "year_2371"
                  },
                  {
                        "id": 2372,
                        "displayName": "year_2372"
                  },
                  {
                        "id": 2373,
                        "displayName": "year_2373"
                  },
                  {
                        "id": 2374,
                        "displayName": "year_2374"
                  },
                  {
                        "id": 2375,
                        "displayName": "year_2375"
                  },
                  {
                        "id": 2376,
                        "displayName": "year_2376"
                  },
                  {
                        "id": 2377,
                        "displayName": "year_2377"
                  },
                  {
                        "id": 2378,
                        "displayName": "year_2378"
                  },
                  {
                        "id": 2379,
                        "displayName": "year_2379"
                  },
                  {
                        "id": 2380,
                        "displayName": "year_2380"
                  },
                  {
                        "id": 2381,
                        "displayName": "year_2381"
                  },
                  {
                        "id": 2382,
                        "displayName": "year_2382"
                  },
                  {
                        "id": 2383,
                        "displayName": "year_2383"
                  },
                  {
                        "id": 2384,
                        "displayName": "year_2384"
                  },
                  {
                        "id": 2385,
                        "displayName": "year_2385"
                  },
                  {
                        "id": 2386,
                        "displayName": "year_2386"
                  },
                  {
                        "id": 2387,
                        "displayName": "year_2387"
                  },
                  {
                        "id": 2388,
                        "displayName": "year_2388"
                  },
                  {
                        "id": 2389,
                        "displayName": "year_2389"
                  },
                  {
                        "id": 2390,
                        "displayName": "year_2390"
                  },
                  {
                        "id": 2391,
                        "displayName": "year_2391"
                  },
                  {
                        "id": 2392,
                        "displayName": "year_2392"
                  },
                  {
                        "id": 2393,
                        "displayName": "year_2393"
                  },
                  {
                        "id": 2394,
                        "displayName": "year_2394"
                  },
                  {
                        "id": 2395,
                        "displayName": "year_2395"
                  },
                  {
                        "id": 2396,
                        "displayName": "year_2396"
                  },
                  {
                        "id": 2397,
                        "displayName": "year_2397"
                  },
                  {
                        "id": 2398,
                        "displayName": "year_2398"
                  },
                  {
                        "id": 2399,
                        "displayName": "year_2399"
                  },
                  {
                        "id": 2400,
                        "displayName": "year_2400"
                  },
                  {
                        "id": 2401,
                        "displayName": "year_2401"
                  },
                  {
                        "id": 2402,
                        "displayName": "year_2402"
                  },
                  {
                        "id": 2403,
                        "displayName": "year_2403"
                  },
                  {
                        "id": 2404,
                        "displayName": "year_2404"
                  },
                  {
                        "id": 2405,
                        "displayName": "year_2405"
                  },
                  {
                        "id": 2406,
                        "displayName": "year_2406"
                  },
                  {
                        "id": 2407,
                        "displayName": "year_2407"
                  },
                  {
                        "id": 2408,
                        "displayName": "year_2408"
                  },
                  {
                        "id": 2409,
                        "displayName": "year_2409"
                  },
                  {
                        "id": 2410,
                        "displayName": "year_2410"
                  },
                  {
                        "id": 2411,
                        "displayName": "year_2411"
                  },
                  {
                        "id": 2412,
                        "displayName": "year_2412"
                  },
                  {
                        "id": 2413,
                        "displayName": "year_2413"
                  },
                  {
                        "id": 2414,
                        "displayName": "year_2414"
                  },
                  {
                        "id": 2415,
                        "displayName": "year_2415"
                  },
                  {
                        "id": 2416,
                        "displayName": "year_2416"
                  },
                  {
                        "id": 2417,
                        "displayName": "year_2417"
                  },
                  {
                        "id": 2418,
                        "displayName": "year_2418"
                  },
                  {
                        "id": 2419,
                        "displayName": "year_2419"
                  },
                  {
                        "id": 2420,
                        "displayName": "year_2420"
                  },
                  {
                        "id": 2421,
                        "displayName": "year_2421"
                  },
                  {
                        "id": 2422,
                        "displayName": "year_2422"
                  },
                  {
                        "id": 2423,
                        "displayName": "year_2423"
                  },
                  {
                        "id": 2424,
                        "displayName": "year_2424"
                  },
                  {
                        "id": 2425,
                        "displayName": "year_2425"
                  },
                  {
                        "id": 2426,
                        "displayName": "year_2426"
                  },
                  {
                        "id": 2427,
                        "displayName": "year_2427"
                  },
                  {
                        "id": 2428,
                        "displayName": "year_2428"
                  },
                  {
                        "id": 2429,
                        "displayName": "year_2429"
                  },
                  {
                        "id": 2430,
                        "displayName": "year_2430"
                  },
                  {
                        "id": 2431,
                        "displayName": "year_2431"
                  },
                  {
                        "id": 2432,
                        "displayName": "year_2432"
                  },
                  {
                        "id": 2433,
                        "displayName": "year_2433"
                  },
                  {
                        "id": 2434,
                        "displayName": "year_2434"
                  },
                  {
                        "id": 2435,
                        "displayName": "year_2435"
                  },
                  {
                        "id": 2436,
                        "displayName": "year_2436"
                  },
                  {
                        "id": 2437,
                        "displayName": "year_2437"
                  },
                  {
                        "id": 2438,
                        "displayName": "year_2438"
                  },
                  {
                        "id": 2439,
                        "displayName": "year_2439"
                  },
                  {
                        "id": 2440,
                        "displayName": "year_2440"
                  },
                  {
                        "id": 2441,
                        "displayName": "year_2441"
                  },
                  {
                        "id": 2442,
                        "displayName": "year_2442"
                  },
                  {
                        "id": 2443,
                        "displayName": "year_2443"
                  },
                  {
                        "id": 2444,
                        "displayName": "year_2444"
                  },
                  {
                        "id": 2445,
                        "displayName": "year_2445"
                  },
                  {
                        "id": 2446,
                        "displayName": "year_2446"
                  },
                  {
                        "id": 2447,
                        "displayName": "year_2447"
                  },
                  {
                        "id": 2448,
                        "displayName": "year_2448"
                  },
                  {
                        "id": 2449,
                        "displayName": "year_2449"
                  },
                  {
                        "id": 2450,
                        "displayName": "year_2450"
                  },
                  {
                        "id": 2451,
                        "displayName": "year_2451"
                  },
                  {
                        "id": 2452,
                        "displayName": "year_2452"
                  },
                  {
                        "id": 2453,
                        "displayName": "year_2453"
                  },
                  {
                        "id": 2454,
                        "displayName": "year_2454"
                  },
                  {
                        "id": 2455,
                        "displayName": "year_2455"
                  },
                  {
                        "id": 2456,
                        "displayName": "year_2456"
                  },
                  {
                        "id": 2457,
                        "displayName": "year_2457"
                  },
                  {
                        "id": 2458,
                        "displayName": "year_2458"
                  },
                  {
                        "id": 2459,
                        "displayName": "year_2459"
                  },
                  {
                        "id": 2460,
                        "displayName": "year_2460"
                  },
                  {
                        "id": 2461,
                        "displayName": "year_2461"
                  },
                  {
                        "id": 2462,
                        "displayName": "year_2462"
                  },
                  {
                        "id": 2463,
                        "displayName": "year_2463"
                  },
                  {
                        "id": 2464,
                        "displayName": "year_2464"
                  },
                  {
                        "id": 2465,
                        "displayName": "year_2465"
                  },
                  {
                        "id": 2466,
                        "displayName": "year_2466"
                  },
                  {
                        "id": 2467,
                        "displayName": "year_2467"
                  },
                  {
                        "id": 2468,
                        "displayName": "year_2468"
                  },
                  {
                        "id": 2469,
                        "displayName": "year_2469"
                  },
                  {
                        "id": 2470,
                        "displayName": "year_2470"
                  },
                  {
                        "id": 2471,
                        "displayName": "year_2471"
                  },
                  {
                        "id": 2472,
                        "displayName": "year_2472"
                  },
                  {
                        "id": 2473,
                        "displayName": "year_2473"
                  },
                  {
                        "id": 2474,
                        "displayName": "year_2474"
                  },
                  {
                        "id": 2475,
                        "displayName": "year_2475"
                  },
                  {
                        "id": 2476,
                        "displayName": "year_2476"
                  },
                  {
                        "id": 2477,
                        "displayName": "year_2477"
                  },
                  {
                        "id": 2478,
                        "displayName": "year_2478"
                  },
                  {
                        "id": 2479,
                        "displayName": "year_2479"
                  },
                  {
                        "id": 2480,
                        "displayName": "year_2480"
                  },
                  {
                        "id": 2481,
                        "displayName": "year_2481"
                  },
                  {
                        "id": 2482,
                        "displayName": "year_2482"
                  },
                  {
                        "id": 2483,
                        "displayName": "year_2483"
                  },
                  {
                        "id": 2484,
                        "displayName": "year_2484"
                  },
                  {
                        "id": 2485,
                        "displayName": "year_2485"
                  },
                  {
                        "id": 2486,
                        "displayName": "year_2486"
                  },
                  {
                        "id": 2487,
                        "displayName": "year_2487"
                  },
                  {
                        "id": 2488,
                        "displayName": "year_2488"
                  },
                  {
                        "id": 2489,
                        "displayName": "year_2489"
                  },
                  {
                        "id": 2490,
                        "displayName": "year_2490"
                  },
                  {
                        "id": 2491,
                        "displayName": "year_2491"
                  },
                  {
                        "id": 2492,
                        "displayName": "year_2492"
                  },
                  {
                        "id": 2493,
                        "displayName": "year_2493"
                  },
                  {
                        "id": 2494,
                        "displayName": "year_2494"
                  },
                  {
                        "id": 2495,
                        "displayName": "year_2495"
                  },
                  {
                        "id": 2496,
                        "displayName": "year_2496"
                  },
                  {
                        "id": 2497,
                        "displayName": "year_2497"
                  },
                  {
                        "id": 2498,
                        "displayName": "year_2498"
                  },
                  {
                        "id": 2499,
                        "displayName": "year_2499"
                  },
                  {
                        "id": 2500,
                        "displayName": "year_2500"
                  },
                  {
                        "id": 2501,
                        "displayName": "year_2501"
                  },
                  {
                        "id": 2502,
                        "displayName": "year_2502"
                  },
                  {
                        "id": 2503,
                        "displayName": "year_2503"
                  },
                  {
                        "id": 2504,
                        "displayName": "year_2504"
                  },
                  {
                        "id": 2505,
                        "displayName": "year_2505"
                  },
                  {
                        "id": 2506,
                        "displayName": "year_2506"
                  },
                  {
                        "id": 2507,
                        "displayName": "year_2507"
                  },
                  {
                        "id": 2508,
                        "displayName": "year_2508"
                  },
                  {
                        "id": 2509,
                        "displayName": "year_2509"
                  },
                  {
                        "id": 2510,
                        "displayName": "year_2510"
                  },
                  {
                        "id": 2511,
                        "displayName": "year_2511"
                  },
                  {
                        "id": 2512,
                        "displayName": "year_2512"
                  },
                  {
                        "id": 2513,
                        "displayName": "year_2513"
                  },
                  {
                        "id": 2514,
                        "displayName": "year_2514"
                  },
                  {
                        "id": 2515,
                        "displayName": "year_2515"
                  },
                  {
                        "id": 2516,
                        "displayName": "year_2516"
                  },
                  {
                        "id": 2517,
                        "displayName": "year_2517"
                  },
                  {
                        "id": 2518,
                        "displayName": "year_2518"
                  },
                  {
                        "id": 2519,
                        "displayName": "year_2519"
                  },
                  {
                        "id": 2520,
                        "displayName": "year_2520"
                  },
                  {
                        "id": 2521,
                        "displayName": "year_2521"
                  },
                  {
                        "id": 2522,
                        "displayName": "year_2522"
                  },
                  {
                        "id": 2523,
                        "displayName": "year_2523"
                  },
                  {
                        "id": 2524,
                        "displayName": "year_2524"
                  },
                  {
                        "id": 2525,
                        "displayName": "year_2525"
                  },
                  {
                        "id": 2526,
                        "displayName": "year_2526"
                  },
                  {
                        "id": 2527,
                        "displayName": "year_2527"
                  },
                  {
                        "id": 2528,
                        "displayName": "year_2528"
                  },
                  {
                        "id": 2529,
                        "displayName": "year_2529"
                  },
                  {
                        "id": 2530,
                        "displayName": "year_2530"
                  },
                  {
                        "id": 2531,
                        "displayName": "year_2531"
                  },
                  {
                        "id": 2532,
                        "displayName": "year_2532"
                  },
                  {
                        "id": 2533,
                        "displayName": "year_2533"
                  },
                  {
                        "id": 2534,
                        "displayName": "year_2534"
                  },
                  {
                        "id": 2535,
                        "displayName": "year_2535"
                  },
                  {
                        "id": 2536,
                        "displayName": "year_2536"
                  },
                  {
                        "id": 2537,
                        "displayName": "year_2537"
                  },
                  {
                        "id": 2538,
                        "displayName": "year_2538"
                  },
                  {
                        "id": 2539,
                        "displayName": "year_2539"
                  },
                  {
                        "id": 2540,
                        "displayName": "year_2540"
                  },
                  {
                        "id": 2541,
                        "displayName": "year_2541"
                  },
                  {
                        "id": 2542,
                        "displayName": "year_2542"
                  },
                  {
                        "id": 2543,
                        "displayName": "year_2543"
                  },
                  {
                        "id": 2544,
                        "displayName": "year_2544"
                  },
                  {
                        "id": 2545,
                        "displayName": "year_2545"
                  },
                  {
                        "id": 2546,
                        "displayName": "year_2546"
                  },
                  {
                        "id": 2547,
                        "displayName": "year_2547"
                  },
                  {
                        "id": 2548,
                        "displayName": "year_2548"
                  },
                  {
                        "id": 2549,
                        "displayName": "year_2549"
                  },
                  {
                        "id": 2550,
                        "displayName": "year_2550"
                  },
                  {
                        "id": 2551,
                        "displayName": "year_2551"
                  },
                  {
                        "id": 2552,
                        "displayName": "year_2552"
                  },
                  {
                        "id": 2553,
                        "displayName": "year_2553"
                  },
                  {
                        "id": 2554,
                        "displayName": "year_2554"
                  },
                  {
                        "id": 2555,
                        "displayName": "year_2555"
                  },
                  {
                        "id": 2556,
                        "displayName": "year_2556"
                  },
                  {
                        "id": 2557,
                        "displayName": "year_2557"
                  },
                  {
                        "id": 2558,
                        "displayName": "year_2558"
                  },
                  {
                        "id": 2559,
                        "displayName": "year_2559"
                  },
                  {
                        "id": 2560,
                        "displayName": "year_2560"
                  },
                  {
                        "id": 2561,
                        "displayName": "year_2561"
                  },
                  {
                        "id": 2562,
                        "displayName": "year_2562"
                  },
                  {
                        "id": 2563,
                        "displayName": "year_2563"
                  },
                  {
                        "id": 2564,
                        "displayName": "year_2564"
                  },
                  {
                        "id": 2565,
                        "displayName": "year_2565"
                  },
                  {
                        "id": 2566,
                        "displayName": "year_2566"
                  },
                  {
                        "id": 2567,
                        "displayName": "year_2567"
                  },
                  {
                        "id": 2568,
                        "displayName": "year_2568"
                  },
                  {
                        "id": 2569,
                        "displayName": "year_2569"
                  },
                  {
                        "id": 2570,
                        "displayName": "year_2570"
                  },
                  {
                        "id": 2571,
                        "displayName": "year_2571"
                  },
                  {
                        "id": 2572,
                        "displayName": "year_2572"
                  },
                  {
                        "id": 2573,
                        "displayName": "year_2573"
                  },
                  {
                        "id": 2574,
                        "displayName": "year_2574"
                  },
                  {
                        "id": 2575,
                        "displayName": "year_2575"
                  },
                  {
                        "id": 2576,
                        "displayName": "year_2576"
                  },
                  {
                        "id": 2577,
                        "displayName": "year_2577"
                  },
                  {
                        "id": 2578,
                        "displayName": "year_2578"
                  },
                  {
                        "id": 2579,
                        "displayName": "year_2579"
                  },
                  {
                        "id": 2580,
                        "displayName": "year_2580"
                  },
                  {
                        "id": 2581,
                        "displayName": "year_2581"
                  },
                  {
                        "id": 2582,
                        "displayName": "year_2582"
                  },
                  {
                        "id": 2583,
                        "displayName": "year_2583"
                  },
                  {
                        "id": 2584,
                        "displayName": "year_2584"
                  },
                  {
                        "id": 2585,
                        "displayName": "year_2585"
                  },
                  {
                        "id": 2586,
                        "displayName": "year_2586"
                  },
                  {
                        "id": 2587,
                        "displayName": "year_2587"
                  },
                  {
                        "id": 2588,
                        "displayName": "year_2588"
                  },
                  {
                        "id": 2589,
                        "displayName": "year_2589"
                  },
                  {
                        "id": 2590,
                        "displayName": "year_2590"
                  },
                  {
                        "id": 2591,
                        "displayName": "year_2591"
                  },
                  {
                        "id": 2592,
                        "displayName": "year_2592"
                  },
                  {
                        "id": 2593,
                        "displayName": "year_2593"
                  },
                  {
                        "id": 2594,
                        "displayName": "year_2594"
                  },
                  {
                        "id": 2595,
                        "displayName": "year_2595"
                  },
                  {
                        "id": 2596,
                        "displayName": "year_2596"
                  },
                  {
                        "id": 2597,
                        "displayName": "year_2597"
                  },
                  {
                        "id": 2598,
                        "displayName": "year_2598"
                  },
                  {
                        "id": 2599,
                        "displayName": "year_2599"
                  },
                  {
                        "id": 2600,
                        "displayName": "year_2600"
                  },
                  {
                        "id": 2601,
                        "displayName": "year_2601"
                  },
                  {
                        "id": 2602,
                        "displayName": "year_2602"
                  },
                  {
                        "id": 2603,
                        "displayName": "year_2603"
                  },
                  {
                        "id": 2604,
                        "displayName": "year_2604"
                  },
                  {
                        "id": 2605,
                        "displayName": "year_2605"
                  },
                  {
                        "id": 2606,
                        "displayName": "year_2606"
                  },
                  {
                        "id": 2607,
                        "displayName": "year_2607"
                  },
                  {
                        "id": 2608,
                        "displayName": "year_2608"
                  },
                  {
                        "id": 2609,
                        "displayName": "year_2609"
                  },
                  {
                        "id": 2610,
                        "displayName": "year_2610"
                  },
                  {
                        "id": 2611,
                        "displayName": "year_2611"
                  },
                  {
                        "id": 2612,
                        "displayName": "year_2612"
                  },
                  {
                        "id": 2613,
                        "displayName": "year_2613"
                  },
                  {
                        "id": 2614,
                        "displayName": "year_2614"
                  },
                  {
                        "id": 2615,
                        "displayName": "year_2615"
                  },
                  {
                        "id": 2616,
                        "displayName": "year_2616"
                  },
                  {
                        "id": 2617,
                        "displayName": "year_2617"
                  },
                  {
                        "id": 2618,
                        "displayName": "year_2618"
                  },
                  {
                        "id": 2619,
                        "displayName": "year_2619"
                  },
                  {
                        "id": 2620,
                        "displayName": "year_2620"
                  },
                  {
                        "id": 2621,
                        "displayName": "year_2621"
                  },
                  {
                        "id": 2622,
                        "displayName": "year_2622"
                  },
                  {
                        "id": 2623,
                        "displayName": "year_2623"
                  },
                  {
                        "id": 2624,
                        "displayName": "year_2624"
                  },
                  {
                        "id": 2625,
                        "displayName": "year_2625"
                  },
                  {
                        "id": 2626,
                        "displayName": "year_2626"
                  },
                  {
                        "id": 2627,
                        "displayName": "year_2627"
                  },
                  {
                        "id": 2628,
                        "displayName": "year_2628"
                  },
                  {
                        "id": 2629,
                        "displayName": "year_2629"
                  },
                  {
                        "id": 2630,
                        "displayName": "year_2630"
                  },
                  {
                        "id": 2631,
                        "displayName": "year_2631"
                  },
                  {
                        "id": 2632,
                        "displayName": "year_2632"
                  },
                  {
                        "id": 2633,
                        "displayName": "year_2633"
                  },
                  {
                        "id": 2634,
                        "displayName": "year_2634"
                  },
                  {
                        "id": 2635,
                        "displayName": "year_2635"
                  },
                  {
                        "id": 2636,
                        "displayName": "year_2636"
                  },
                  {
                        "id": 2637,
                        "displayName": "year_2637"
                  },
                  {
                        "id": 2638,
                        "displayName": "year_2638"
                  },
                  {
                        "id": 2639,
                        "displayName": "year_2639"
                  },
                  {
                        "id": 2640,
                        "displayName": "year_2640"
                  },
                  {
                        "id": 2641,
                        "displayName": "year_2641"
                  },
                  {
                        "id": 2642,
                        "displayName": "year_2642"
                  },
                  {
                        "id": 2643,
                        "displayName": "year_2643"
                  },
                  {
                        "id": 2644,
                        "displayName": "year_2644"
                  },
                  {
                        "id": 2645,
                        "displayName": "year_2645"
                  },
                  {
                        "id": 2646,
                        "displayName": "year_2646"
                  },
                  {
                        "id": 2647,
                        "displayName": "year_2647"
                  },
                  {
                        "id": 2648,
                        "displayName": "year_2648"
                  },
                  {
                        "id": 2649,
                        "displayName": "year_2649"
                  },
                  {
                        "id": 2650,
                        "displayName": "year_2650"
                  },
                  {
                        "id": 2651,
                        "displayName": "year_2651"
                  },
                  {
                        "id": 2652,
                        "displayName": "year_2652"
                  },
                  {
                        "id": 2653,
                        "displayName": "year_2653"
                  },
                  {
                        "id": 2654,
                        "displayName": "year_2654"
                  },
                  {
                        "id": 2655,
                        "displayName": "year_2655"
                  },
                  {
                        "id": 2656,
                        "displayName": "year_2656"
                  },
                  {
                        "id": 2657,
                        "displayName": "year_2657"
                  },
                  {
                        "id": 2658,
                        "displayName": "year_2658"
                  },
                  {
                        "id": 2659,
                        "displayName": "year_2659"
                  },
                  {
                        "id": 2660,
                        "displayName": "year_2660"
                  },
                  {
                        "id": 2661,
                        "displayName": "year_2661"
                  },
                  {
                        "id": 2662,
                        "displayName": "year_2662"
                  },
                  {
                        "id": 2663,
                        "displayName": "year_2663"
                  },
                  {
                        "id": 2664,
                        "displayName": "year_2664"
                  },
                  {
                        "id": 2665,
                        "displayName": "year_2665"
                  },
                  {
                        "id": 2666,
                        "displayName": "year_2666"
                  },
                  {
                        "id": 2667,
                        "displayName": "year_2667"
                  },
                  {
                        "id": 2668,
                        "displayName": "year_2668"
                  },
                  {
                        "id": 2669,
                        "displayName": "year_2669"
                  },
                  {
                        "id": 2670,
                        "displayName": "year_2670"
                  },
                  {
                        "id": 2671,
                        "displayName": "year_2671"
                  },
                  {
                        "id": 2672,
                        "displayName": "year_2672"
                  },
                  {
                        "id": 2673,
                        "displayName": "year_2673"
                  },
                  {
                        "id": 2674,
                        "displayName": "year_2674"
                  },
                  {
                        "id": 2675,
                        "displayName": "year_2675"
                  },
                  {
                        "id": 2676,
                        "displayName": "year_2676"
                  },
                  {
                        "id": 2677,
                        "displayName": "year_2677"
                  },
                  {
                        "id": 2678,
                        "displayName": "year_2678"
                  },
                  {
                        "id": 2679,
                        "displayName": "year_2679"
                  },
                  {
                        "id": 2680,
                        "displayName": "year_2680"
                  },
                  {
                        "id": 2681,
                        "displayName": "year_2681"
                  },
                  {
                        "id": 2682,
                        "displayName": "year_2682"
                  },
                  {
                        "id": 2683,
                        "displayName": "year_2683"
                  },
                  {
                        "id": 2684,
                        "displayName": "year_2684"
                  },
                  {
                        "id": 2685,
                        "displayName": "year_2685"
                  },
                  {
                        "id": 2686,
                        "displayName": "year_2686"
                  },
                  {
                        "id": 2687,
                        "displayName": "year_2687"
                  },
                  {
                        "id": 2688,
                        "displayName": "year_2688"
                  },
                  {
                        "id": 2689,
                        "displayName": "year_2689"
                  },
                  {
                        "id": 2690,
                        "displayName": "year_2690"
                  },
                  {
                        "id": 2691,
                        "displayName": "year_2691"
                  },
                  {
                        "id": 2692,
                        "displayName": "year_2692"
                  },
                  {
                        "id": 2693,
                        "displayName": "year_2693"
                  },
                  {
                        "id": 2694,
                        "displayName": "year_2694"
                  },
                  {
                        "id": 2695,
                        "displayName": "year_2695"
                  },
                  {
                        "id": 2696,
                        "displayName": "year_2696"
                  },
                  {
                        "id": 2697,
                        "displayName": "year_2697"
                  },
                  {
                        "id": 2698,
                        "displayName": "year_2698"
                  },
                  {
                        "id": 2699,
                        "displayName": "year_2699"
                  },
                  {
                        "id": 2700,
                        "displayName": "year_2700"
                  },
                  {
                        "id": 2701,
                        "displayName": "year_2701"
                  },
                  {
                        "id": 2702,
                        "displayName": "year_2702"
                  },
                  {
                        "id": 2703,
                        "displayName": "year_2703"
                  },
                  {
                        "id": 2704,
                        "displayName": "year_2704"
                  },
                  {
                        "id": 2705,
                        "displayName": "year_2705"
                  },
                  {
                        "id": 2706,
                        "displayName": "year_2706"
                  },
                  {
                        "id": 2707,
                        "displayName": "year_2707"
                  },
                  {
                        "id": 2708,
                        "displayName": "year_2708"
                  },
                  {
                        "id": 2709,
                        "displayName": "year_2709"
                  },
                  {
                        "id": 2710,
                        "displayName": "year_2710"
                  },
                  {
                        "id": 2711,
                        "displayName": "year_2711"
                  },
                  {
                        "id": 2712,
                        "displayName": "year_2712"
                  },
                  {
                        "id": 2713,
                        "displayName": "year_2713"
                  },
                  {
                        "id": 2714,
                        "displayName": "year_2714"
                  },
                  {
                        "id": 2715,
                        "displayName": "year_2715"
                  },
                  {
                        "id": 2716,
                        "displayName": "year_2716"
                  },
                  {
                        "id": 2717,
                        "displayName": "year_2717"
                  },
                  {
                        "id": 2718,
                        "displayName": "year_2718"
                  },
                  {
                        "id": 2719,
                        "displayName": "year_2719"
                  },
                  {
                        "id": 2720,
                        "displayName": "year_2720"
                  },
                  {
                        "id": 2721,
                        "displayName": "year_2721"
                  },
                  {
                        "id": 2722,
                        "displayName": "year_2722"
                  },
                  {
                        "id": 2723,
                        "displayName": "year_2723"
                  },
                  {
                        "id": 2724,
                        "displayName": "year_2724"
                  },
                  {
                        "id": 2725,
                        "displayName": "year_2725"
                  },
                  {
                        "id": 2726,
                        "displayName": "year_2726"
                  },
                  {
                        "id": 2727,
                        "displayName": "year_2727"
                  },
                  {
                        "id": 2728,
                        "displayName": "year_2728"
                  },
                  {
                        "id": 2729,
                        "displayName": "year_2729"
                  },
                  {
                        "id": 2730,
                        "displayName": "year_2730"
                  },
                  {
                        "id": 2731,
                        "displayName": "year_2731"
                  },
                  {
                        "id": 2732,
                        "displayName": "year_2732"
                  },
                  {
                        "id": 2733,
                        "displayName": "year_2733"
                  },
                  {
                        "id": 2734,
                        "displayName": "year_2734"
                  },
                  {
                        "id": 2735,
                        "displayName": "year_2735"
                  },
                  {
                        "id": 2736,
                        "displayName": "year_2736"
                  },
                  {
                        "id": 2737,
                        "displayName": "year_2737"
                  },
                  {
                        "id": 2738,
                        "displayName": "year_2738"
                  },
                  {
                        "id": 2739,
                        "displayName": "year_2739"
                  },
                  {
                        "id": 2740,
                        "displayName": "year_2740"
                  },
                  {
                        "id": 2741,
                        "displayName": "year_2741"
                  },
                  {
                        "id": 2742,
                        "displayName": "year_2742"
                  },
                  {
                        "id": 2743,
                        "displayName": "year_2743"
                  },
                  {
                        "id": 2744,
                        "displayName": "year_2744"
                  },
                  {
                        "id": 2745,
                        "displayName": "year_2745"
                  },
                  {
                        "id": 2746,
                        "displayName": "year_2746"
                  },
                  {
                        "id": 2747,
                        "displayName": "year_2747"
                  },
                  {
                        "id": 2748,
                        "displayName": "year_2748"
                  },
                  {
                        "id": 2749,
                        "displayName": "year_2749"
                  },
                  {
                        "id": 2750,
                        "displayName": "year_2750"
                  },
                  {
                        "id": 2751,
                        "displayName": "year_2751"
                  },
                  {
                        "id": 2752,
                        "displayName": "year_2752"
                  },
                  {
                        "id": 2753,
                        "displayName": "year_2753"
                  },
                  {
                        "id": 2754,
                        "displayName": "year_2754"
                  },
                  {
                        "id": 2755,
                        "displayName": "year_2755"
                  },
                  {
                        "id": 2756,
                        "displayName": "year_2756"
                  },
                  {
                        "id": 2757,
                        "displayName": "year_2757"
                  },
                  {
                        "id": 2758,
                        "displayName": "year_2758"
                  },
                  {
                        "id": 2759,
                        "displayName": "year_2759"
                  },
                  {
                        "id": 2760,
                        "displayName": "year_2760"
                  },
                  {
                        "id": 2761,
                        "displayName": "year_2761"
                  },
                  {
                        "id": 2762,
                        "displayName": "year_2762"
                  },
                  {
                        "id": 2763,
                        "displayName": "year_2763"
                  },
                  {
                        "id": 2764,
                        "displayName": "year_2764"
                  },
                  {
                        "id": 2765,
                        "displayName": "year_2765"
                  },
                  {
                        "id": 2766,
                        "displayName": "year_2766"
                  },
                  {
                        "id": 2767,
                        "displayName": "year_2767"
                  },
                  {
                        "id": 2768,
                        "displayName": "year_2768"
                  },
                  {
                        "id": 2769,
                        "displayName": "year_2769"
                  },
                  {
                        "id": 2770,
                        "displayName": "year_2770"
                  },
                  {
                        "id": 2771,
                        "displayName": "year_2771"
                  },
                  {
                        "id": 2772,
                        "displayName": "year_2772"
                  },
                  {
                        "id": 2773,
                        "displayName": "year_2773"
                  },
                  {
                        "id": 2774,
                        "displayName": "year_2774"
                  },
                  {
                        "id": 2775,
                        "displayName": "year_2775"
                  },
                  {
                        "id": 2776,
                        "displayName": "year_2776"
                  },
                  {
                        "id": 2777,
                        "displayName": "year_2777"
                  },
                  {
                        "id": 2778,
                        "displayName": "year_2778"
                  },
                  {
                        "id": 2779,
                        "displayName": "year_2779"
                  },
                  {
                        "id": 2780,
                        "displayName": "year_2780"
                  },
                  {
                        "id": 2781,
                        "displayName": "year_2781"
                  },
                  {
                        "id": 2782,
                        "displayName": "year_2782"
                  },
                  {
                        "id": 2783,
                        "displayName": "year_2783"
                  },
                  {
                        "id": 2784,
                        "displayName": "year_2784"
                  },
                  {
                        "id": 2785,
                        "displayName": "year_2785"
                  },
                  {
                        "id": 2786,
                        "displayName": "year_2786"
                  },
                  {
                        "id": 2787,
                        "displayName": "year_2787"
                  },
                  {
                        "id": 2788,
                        "displayName": "year_2788"
                  },
                  {
                        "id": 2789,
                        "displayName": "year_2789"
                  },
                  {
                        "id": 2790,
                        "displayName": "year_2790"
                  },
                  {
                        "id": 2791,
                        "displayName": "year_2791"
                  },
                  {
                        "id": 2792,
                        "displayName": "year_2792"
                  },
                  {
                        "id": 2793,
                        "displayName": "year_2793"
                  },
                  {
                        "id": 2794,
                        "displayName": "year_2794"
                  },
                  {
                        "id": 2795,
                        "displayName": "year_2795"
                  },
                  {
                        "id": 2796,
                        "displayName": "year_2796"
                  },
                  {
                        "id": 2797,
                        "displayName": "year_2797"
                  },
                  {
                        "id": 2798,
                        "displayName": "year_2798"
                  },
                  {
                        "id": 2799,
                        "displayName": "year_2799"
                  },
                  {
                        "id": 2800,
                        "displayName": "year_2800"
                  },
                  {
                        "id": 2801,
                        "displayName": "year_2801"
                  },
                  {
                        "id": 2802,
                        "displayName": "year_2802"
                  },
                  {
                        "id": 2803,
                        "displayName": "year_2803"
                  },
                  {
                        "id": 2804,
                        "displayName": "year_2804"
                  },
                  {
                        "id": 2805,
                        "displayName": "year_2805"
                  },
                  {
                        "id": 2806,
                        "displayName": "year_2806"
                  },
                  {
                        "id": 2807,
                        "displayName": "year_2807"
                  },
                  {
                        "id": 2808,
                        "displayName": "year_2808"
                  },
                  {
                        "id": 2809,
                        "displayName": "year_2809"
                  },
                  {
                        "id": 2810,
                        "displayName": "year_2810"
                  },
                  {
                        "id": 2811,
                        "displayName": "year_2811"
                  },
                  {
                        "id": 2812,
                        "displayName": "year_2812"
                  },
                  {
                        "id": 2813,
                        "displayName": "year_2813"
                  },
                  {
                        "id": 2814,
                        "displayName": "year_2814"
                  },
                  {
                        "id": 2815,
                        "displayName": "year_2815"
                  },
                  {
                        "id": 2816,
                        "displayName": "year_2816"
                  },
                  {
                        "id": 2817,
                        "displayName": "year_2817"
                  },
                  {
                        "id": 2818,
                        "displayName": "year_2818"
                  },
                  {
                        "id": 2819,
                        "displayName": "year_2819"
                  },
                  {
                        "id": 2820,
                        "displayName": "year_2820"
                  },
                  {
                        "id": 2821,
                        "displayName": "year_2821"
                  },
                  {
                        "id": 2822,
                        "displayName": "year_2822"
                  },
                  {
                        "id": 2823,
                        "displayName": "year_2823"
                  },
                  {
                        "id": 2824,
                        "displayName": "year_2824"
                  },
                  {
                        "id": 2825,
                        "displayName": "year_2825"
                  },
                  {
                        "id": 2826,
                        "displayName": "year_2826"
                  },
                  {
                        "id": 2827,
                        "displayName": "year_2827"
                  },
                  {
                        "id": 2828,
                        "displayName": "year_2828"
                  },
                  {
                        "id": 2829,
                        "displayName": "year_2829"
                  },
                  {
                        "id": 2830,
                        "displayName": "year_2830"
                  },
                  {
                        "id": 2831,
                        "displayName": "year_2831"
                  },
                  {
                        "id": 2832,
                        "displayName": "year_2832"
                  },
                  {
                        "id": 2833,
                        "displayName": "year_2833"
                  },
                  {
                        "id": 2834,
                        "displayName": "year_2834"
                  },
                  {
                        "id": 2835,
                        "displayName": "year_2835"
                  },
                  {
                        "id": 2836,
                        "displayName": "year_2836"
                  },
                  {
                        "id": 2837,
                        "displayName": "year_2837"
                  },
                  {
                        "id": 2838,
                        "displayName": "year_2838"
                  },
                  {
                        "id": 2839,
                        "displayName": "year_2839"
                  },
                  {
                        "id": 2840,
                        "displayName": "year_2840"
                  },
                  {
                        "id": 2841,
                        "displayName": "year_2841"
                  },
                  {
                        "id": 2842,
                        "displayName": "year_2842"
                  },
                  {
                        "id": 2843,
                        "displayName": "year_2843"
                  },
                  {
                        "id": 2844,
                        "displayName": "year_2844"
                  },
                  {
                        "id": 2845,
                        "displayName": "year_2845"
                  },
                  {
                        "id": 2846,
                        "displayName": "year_2846"
                  },
                  {
                        "id": 2847,
                        "displayName": "year_2847"
                  },
                  {
                        "id": 2848,
                        "displayName": "year_2848"
                  },
                  {
                        "id": 2849,
                        "displayName": "year_2849"
                  },
                  {
                        "id": 2850,
                        "displayName": "year_2850"
                  },
                  {
                        "id": 2851,
                        "displayName": "year_2851"
                  },
                  {
                        "id": 2852,
                        "displayName": "year_2852"
                  },
                  {
                        "id": 2853,
                        "displayName": "year_2853"
                  },
                  {
                        "id": 2854,
                        "displayName": "year_2854"
                  },
                  {
                        "id": 2855,
                        "displayName": "year_2855"
                  },
                  {
                        "id": 2856,
                        "displayName": "year_2856"
                  },
                  {
                        "id": 2857,
                        "displayName": "year_2857"
                  },
                  {
                        "id": 2858,
                        "displayName": "year_2858"
                  },
                  {
                        "id": 2859,
                        "displayName": "year_2859"
                  },
                  {
                        "id": 2860,
                        "displayName": "year_2860"
                  },
                  {
                        "id": 2861,
                        "displayName": "year_2861"
                  },
                  {
                        "id": 2862,
                        "displayName": "year_2862"
                  },
                  {
                        "id": 2863,
                        "displayName": "year_2863"
                  },
                  {
                        "id": 2864,
                        "displayName": "year_2864"
                  },
                  {
                        "id": 2865,
                        "displayName": "year_2865"
                  },
                  {
                        "id": 2866,
                        "displayName": "year_2866"
                  },
                  {
                        "id": 2867,
                        "displayName": "year_2867"
                  },
                  {
                        "id": 2868,
                        "displayName": "year_2868"
                  },
                  {
                        "id": 2869,
                        "displayName": "year_2869"
                  },
                  {
                        "id": 2870,
                        "displayName": "year_2870"
                  },
                  {
                        "id": 2871,
                        "displayName": "year_2871"
                  },
                  {
                        "id": 2872,
                        "displayName": "year_2872"
                  },
                  {
                        "id": 2873,
                        "displayName": "year_2873"
                  },
                  {
                        "id": 2874,
                        "displayName": "year_2874"
                  },
                  {
                        "id": 2875,
                        "displayName": "year_2875"
                  },
                  {
                        "id": 2876,
                        "displayName": "year_2876"
                  },
                  {
                        "id": 2877,
                        "displayName": "year_2877"
                  },
                  {
                        "id": 2878,
                        "displayName": "year_2878"
                  },
                  {
                        "id": 2879,
                        "displayName": "year_2879"
                  },
                  {
                        "id": 2880,
                        "displayName": "year_2880"
                  },
                  {
                        "id": 2881,
                        "displayName": "year_2881"
                  },
                  {
                        "id": 2882,
                        "displayName": "year_2882"
                  },
                  {
                        "id": 2883,
                        "displayName": "year_2883"
                  },
                  {
                        "id": 2884,
                        "displayName": "year_2884"
                  },
                  {
                        "id": 2885,
                        "displayName": "year_2885"
                  },
                  {
                        "id": 2886,
                        "displayName": "year_2886"
                  },
                  {
                        "id": 2887,
                        "displayName": "year_2887"
                  },
                  {
                        "id": 2888,
                        "displayName": "year_2888"
                  },
                  {
                        "id": 2889,
                        "displayName": "year_2889"
                  },
                  {
                        "id": 2890,
                        "displayName": "year_2890"
                  },
                  {
                        "id": 2891,
                        "displayName": "year_2891"
                  },
                  {
                        "id": 2892,
                        "displayName": "year_2892"
                  },
                  {
                        "id": 2893,
                        "displayName": "year_2893"
                  },
                  {
                        "id": 2894,
                        "displayName": "year_2894"
                  },
                  {
                        "id": 2895,
                        "displayName": "year_2895"
                  },
                  {
                        "id": 2896,
                        "displayName": "year_2896"
                  },
                  {
                        "id": 2897,
                        "displayName": "year_2897"
                  },
                  {
                        "id": 2898,
                        "displayName": "year_2898"
                  },
                  {
                        "id": 2899,
                        "displayName": "year_2899"
                  },
                  {
                        "id": 2900,
                        "displayName": "year_2900"
                  },
                  {
                        "id": 2901,
                        "displayName": "year_2901"
                  },
                  {
                        "id": 2902,
                        "displayName": "year_2902"
                  },
                  {
                        "id": 2903,
                        "displayName": "year_2903"
                  },
                  {
                        "id": 2904,
                        "displayName": "year_2904"
                  },
                  {
                        "id": 2905,
                        "displayName": "year_2905"
                  },
                  {
                        "id": 2906,
                        "displayName": "year_2906"
                  },
                  {
                        "id": 2907,
                        "displayName": "year_2907"
                  },
                  {
                        "id": 2908,
                        "displayName": "year_2908"
                  },
                  {
                        "id": 2909,
                        "displayName": "year_2909"
                  },
                  {
                        "id": 2910,
                        "displayName": "year_2910"
                  },
                  {
                        "id": 2911,
                        "displayName": "year_2911"
                  },
                  {
                        "id": 2912,
                        "displayName": "year_2912"
                  },
                  {
                        "id": 2913,
                        "displayName": "year_2913"
                  },
                  {
                        "id": 2914,
                        "displayName": "year_2914"
                  },
                  {
                        "id": 2915,
                        "displayName": "year_2915"
                  },
                  {
                        "id": 2916,
                        "displayName": "year_2916"
                  },
                  {
                        "id": 2917,
                        "displayName": "year_2917"
                  },
                  {
                        "id": 2918,
                        "displayName": "year_2918"
                  },
                  {
                        "id": 2919,
                        "displayName": "year_2919"
                  },
                  {
                        "id": 2920,
                        "displayName": "year_2920"
                  },
                  {
                        "id": 2921,
                        "displayName": "year_2921"
                  },
                  {
                        "id": 2922,
                        "displayName": "year_2922"
                  },
                  {
                        "id": 2923,
                        "displayName": "year_2923"
                  },
                  {
                        "id": 2924,
                        "displayName": "year_2924"
                  },
                  {
                        "id": 2925,
                        "displayName": "year_2925"
                  },
                  {
                        "id": 2926,
                        "displayName": "year_2926"
                  },
                  {
                        "id": 2927,
                        "displayName": "year_2927"
                  },
                  {
                        "id": 2928,
                        "displayName": "year_2928"
                  },
                  {
                        "id": 2929,
                        "displayName": "year_2929"
                  },
                  {
                        "id": 2930,
                        "displayName": "year_2930"
                  },
                  {
                        "id": 2931,
                        "displayName": "year_2931"
                  },
                  {
                        "id": 2932,
                        "displayName": "year_2932"
                  },
                  {
                        "id": 2933,
                        "displayName": "year_2933"
                  },
                  {
                        "id": 2934,
                        "displayName": "year_2934"
                  },
                  {
                        "id": 2935,
                        "displayName": "year_2935"
                  },
                  {
                        "id": 2936,
                        "displayName": "year_2936"
                  },
                  {
                        "id": 2937,
                        "displayName": "year_2937"
                  },
                  {
                        "id": 2938,
                        "displayName": "year_2938"
                  },
                  {
                        "id": 2939,
                        "displayName": "year_2939"
                  },
                  {
                        "id": 2940,
                        "displayName": "year_2940"
                  },
                  {
                        "id": 2941,
                        "displayName": "year_2941"
                  },
                  {
                        "id": 2942,
                        "displayName": "year_2942"
                  },
                  {
                        "id": 2943,
                        "displayName": "year_2943"
                  },
                  {
                        "id": 2944,
                        "displayName": "year_2944"
                  },
                  {
                        "id": 2945,
                        "displayName": "year_2945"
                  },
                  {
                        "id": 2946,
                        "displayName": "year_2946"
                  },
                  {
                        "id": 2947,
                        "displayName": "year_2947"
                  },
                  {
                        "id": 2948,
                        "displayName": "year_2948"
                  },
                  {
                        "id": 2949,
                        "displayName": "year_2949"
                  },
                  {
                        "id": 2950,
                        "displayName": "year_2950"
                  },
                  {
                        "id": 2951,
                        "displayName": "year_2951"
                  },
                  {
                        "id": 2952,
                        "displayName": "year_2952"
                  },
                  {
                        "id": 2953,
                        "displayName": "year_2953"
                  },
                  {
                        "id": 2954,
                        "displayName": "year_2954"
                  },
                  {
                        "id": 2955,
                        "displayName": "year_2955"
                  },
                  {
                        "id": 2956,
                        "displayName": "year_2956"
                  },
                  {
                        "id": 2957,
                        "displayName": "year_2957"
                  },
                  {
                        "id": 2958,
                        "displayName": "year_2958"
                  },
                  {
                        "id": 2959,
                        "displayName": "year_2959"
                  },
                  {
                        "id": 2960,
                        "displayName": "year_2960"
                  },
                  {
                        "id": 2961,
                        "displayName": "year_2961"
                  },
                  {
                        "id": 2962,
                        "displayName": "year_2962"
                  },
                  {
                        "id": 2963,
                        "displayName": "year_2963"
                  },
                  {
                        "id": 2964,
                        "displayName": "year_2964"
                  },
                  {
                        "id": 2965,
                        "displayName": "year_2965"
                  },
                  {
                        "id": 2966,
                        "displayName": "year_2966"
                  },
                  {
                        "id": 2967,
                        "displayName": "year_2967"
                  },
                  {
                        "id": 2968,
                        "displayName": "year_2968"
                  },
                  {
                        "id": 2969,
                        "displayName": "year_2969"
                  },
                  {
                        "id": 2970,
                        "displayName": "year_2970"
                  },
                  {
                        "id": 2971,
                        "displayName": "year_2971"
                  },
                  {
                        "id": 2972,
                        "displayName": "year_2972"
                  },
                  {
                        "id": 2973,
                        "displayName": "year_2973"
                  },
                  {
                        "id": 2974,
                        "displayName": "year_2974"
                  },
                  {
                        "id": 2975,
                        "displayName": "year_2975"
                  },
                  {
                        "id": 2976,
                        "displayName": "year_2976"
                  },
                  {
                        "id": 2977,
                        "displayName": "year_2977"
                  },
                  {
                        "id": 2978,
                        "displayName": "year_2978"
                  },
                  {
                        "id": 2979,
                        "displayName": "year_2979"
                  },
                  {
                        "id": 2980,
                        "displayName": "year_2980"
                  },
                  {
                        "id": 2981,
                        "displayName": "year_2981"
                  },
                  {
                        "id": 2982,
                        "displayName": "year_2982"
                  },
                  {
                        "id": 2983,
                        "displayName": "year_2983"
                  },
                  {
                        "id": 2984,
                        "displayName": "year_2984"
                  },
                  {
                        "id": 2985,
                        "displayName": "year_2985"
                  },
                  {
                        "id": 2986,
                        "displayName": "year_2986"
                  },
                  {
                        "id": 2987,
                        "displayName": "year_2987"
                  },
                  {
                        "id": 2988,
                        "displayName": "year_2988"
                  },
                  {
                        "id": 2989,
                        "displayName": "year_2989"
                  },
                  {
                        "id": 2990,
                        "displayName": "year_2990"
                  },
                  {
                        "id": 2991,
                        "displayName": "year_2991"
                  },
                  {
                        "id": 2992,
                        "displayName": "year_2992"
                  },
                  {
                        "id": 2993,
                        "displayName": "year_2993"
                  },
                  {
                        "id": 2994,
                        "displayName": "year_2994"
                  },
                  {
                        "id": 2995,
                        "displayName": "year_2995"
                  },
                  {
                        "id": 2996,
                        "displayName": "year_2996"
                  },
                  {
                        "id": 2997,
                        "displayName": "year_2997"
                  },
                  {
                        "id": 2998,
                        "displayName": "year_2998"
                  },
                  {
                        "id": 2999,
                        "displayName": "year_2999"
                  },
                  {
                        "id": 3000,
                        "displayName": "year_3000"
                  },
                  {
                        "id": 3001,
                        "displayName": "year_3001"
                  },
                  {
                        "id": 3002,
                        "displayName": "year_3002"
                  },
                  {
                        "id": 3003,
                        "displayName": "year_3003"
                  },
                  {
                        "id": 3004,
                        "displayName": "year_3004"
                  },
                  {
                        "id": 3005,
                        "displayName": "year_3005"
                  },
                  {
                        "id": 3006,
                        "displayName": "year_3006"
                  },
                  {
                        "id": 3007,
                        "displayName": "year_3007"
                  },
                  {
                        "id": 3008,
                        "displayName": "year_3008"
                  },
                  {
                        "id": 3009,
                        "displayName": "year_3009"
                  },
                  {
                        "id": 3010,
                        "displayName": "year_3010"
                  },
                  {
                        "id": 3011,
                        "displayName": "year_3011"
                  },
                  {
                        "id": 3012,
                        "displayName": "year_3012"
                  },
                  {
                        "id": 3013,
                        "displayName": "year_3013"
                  },
                  {
                        "id": 3014,
                        "displayName": "year_3014"
                  },
                  {
                        "id": 3015,
                        "displayName": "year_3015"
                  },
                  {
                        "id": 3016,
                        "displayName": "year_3016"
                  },
                  {
                        "id": 3017,
                        "displayName": "year_3017"
                  },
                  {
                        "id": 3018,
                        "displayName": "year_3018"
                  },
                  {
                        "id": 3019,
                        "displayName": "year_3019"
                  },
                  {
                        "id": 3020,
                        "displayName": "year_3020"
                  },
                  {
                        "id": 3021,
                        "displayName": "year_3021"
                  },
                  {
                        "id": 3022,
                        "displayName": "year_3022"
                  },
                  {
                        "id": 3023,
                        "displayName": "year_3023"
                  },
                  {
                        "id": 3024,
                        "displayName": "year_3024"
                  },
                  {
                        "id": 3025,
                        "displayName": "year_3025"
                  },
                  {
                        "id": 3026,
                        "displayName": "year_3026"
                  },
                  {
                        "id": 3027,
                        "displayName": "year_3027"
                  },
                  {
                        "id": 3028,
                        "displayName": "year_3028"
                  },
                  {
                        "id": 3029,
                        "displayName": "year_3029"
                  },
                  {
                        "id": 3030,
                        "displayName": "year_3030"
                  },
                  {
                        "id": 3031,
                        "displayName": "year_3031"
                  },
                  {
                        "id": 3032,
                        "displayName": "year_3032"
                  },
                  {
                        "id": 3033,
                        "displayName": "year_3033"
                  },
                  {
                        "id": 3034,
                        "displayName": "year_3034"
                  },
                  {
                        "id": 3035,
                        "displayName": "year_3035"
                  },
                  {
                        "id": 3036,
                        "displayName": "year_3036"
                  },
                  {
                        "id": 3037,
                        "displayName": "year_3037"
                  },
                  {
                        "id": 3038,
                        "displayName": "year_3038"
                  },
                  {
                        "id": 3039,
                        "displayName": "year_3039"
                  },
                  {
                        "id": 3040,
                        "displayName": "year_3040"
                  },
                  {
                        "id": 3041,
                        "displayName": "year_3041"
                  },
                  {
                        "id": 3042,
                        "displayName": "year_3042"
                  },
                  {
                        "id": 3043,
                        "displayName": "year_3043"
                  },
                  {
                        "id": 3044,
                        "displayName": "year_3044"
                  },
                  {
                        "id": 3045,
                        "displayName": "year_3045"
                  },
                  {
                        "id": 3046,
                        "displayName": "year_3046"
                  },
                  {
                        "id": 3047,
                        "displayName": "year_3047"
                  },
                  {
                        "id": 3048,
                        "displayName": "year_3048"
                  },
                  {
                        "id": 3049,
                        "displayName": "year_3049"
                  },
                  {
                        "id": 3050,
                        "displayName": "year_3050"
                  },
                  {
                        "id": 3051,
                        "displayName": "year_3051"
                  },
                  {
                        "id": 3052,
                        "displayName": "year_3052"
                  },
                  {
                        "id": 3053,
                        "displayName": "year_3053"
                  },
                  {
                        "id": 3054,
                        "displayName": "year_3054"
                  },
                  {
                        "id": 3055,
                        "displayName": "year_3055"
                  },
                  {
                        "id": 3056,
                        "displayName": "year_3056"
                  },
                  {
                        "id": 3057,
                        "displayName": "year_3057"
                  },
                  {
                        "id": 3058,
                        "displayName": "year_3058"
                  },
                  {
                        "id": 3059,
                        "displayName": "year_3059"
                  },
                  {
                        "id": 3060,
                        "displayName": "year_3060"
                  },
                  {
                        "id": 3061,
                        "displayName": "year_3061"
                  },
                  {
                        "id": 3062,
                        "displayName": "year_3062"
                  },
                  {
                        "id": 3063,
                        "displayName": "year_3063"
                  },
                  {
                        "id": 3064,
                        "displayName": "year_3064"
                  },
                  {
                        "id": 3065,
                        "displayName": "year_3065"
                  },
                  {
                        "id": 3066,
                        "displayName": "year_3066"
                  },
                  {
                        "id": 3067,
                        "displayName": "year_3067"
                  },
                  {
                        "id": 3068,
                        "displayName": "year_3068"
                  },
                  {
                        "id": 3069,
                        "displayName": "year_3069"
                  },
                  {
                        "id": 3070,
                        "displayName": "year_3070"
                  },
                  {
                        "id": 3071,
                        "displayName": "year_3071"
                  },
                  {
                        "id": 3072,
                        "displayName": "year_3072"
                  },
                  {
                        "id": 3073,
                        "displayName": "year_3073"
                  },
                  {
                        "id": 3074,
                        "displayName": "year_3074"
                  },
                  {
                        "id": 3075,
                        "displayName": "year_3075"
                  },
                  {
                        "id": 3076,
                        "displayName": "year_3076"
                  },
                  {
                        "id": 3077,
                        "displayName": "year_3077"
                  },
                  {
                        "id": 3078,
                        "displayName": "year_3078"
                  },
                  {
                        "id": 3079,
                        "displayName": "year_3079"
                  },
                  {
                        "id": 3080,
                        "displayName": "year_3080"
                  },
                  {
                        "id": 3081,
                        "displayName": "year_3081"
                  },
                  {
                        "id": 3082,
                        "displayName": "year_3082"
                  },
                  {
                        "id": 3083,
                        "displayName": "year_3083"
                  },
                  {
                        "id": 3084,
                        "displayName": "year_3084"
                  },
                  {
                        "id": 3085,
                        "displayName": "year_3085"
                  },
                  {
                        "id": 3086,
                        "displayName": "year_3086"
                  },
                  {
                        "id": 3087,
                        "displayName": "year_3087"
                  },
                  {
                        "id": 3088,
                        "displayName": "year_3088"
                  },
                  {
                        "id": 3089,
                        "displayName": "year_3089"
                  },
                  {
                        "id": 3090,
                        "displayName": "year_3090"
                  },
                  {
                        "id": 3091,
                        "displayName": "year_3091"
                  },
                  {
                        "id": 3092,
                        "displayName": "year_3092"
                  },
                  {
                        "id": 3093,
                        "displayName": "year_3093"
                  },
                  {
                        "id": 3094,
                        "displayName": "year_3094"
                  },
                  {
                        "id": 3095,
                        "displayName": "year_3095"
                  },
                  {
                        "id": 3096,
                        "displayName": "year_3096"
                  },
                  {
                        "id": 3097,
                        "displayName": "year_3097"
                  },
                  {
                        "id": 3098,
                        "displayName": "year_3098"
                  },
                  {
                        "id": 3099,
                        "displayName": "year_3099"
                  },
                  {
                        "id": 3100,
                        "displayName": "year_3100"
                  },
                  {
                        "id": 3101,
                        "displayName": "year_3101"
                  },
                  {
                        "id": 3102,
                        "displayName": "year_3102"
                  },
                  {
                        "id": 3103,
                        "displayName": "year_3103"
                  },
                  {
                        "id": 3104,
                        "displayName": "year_3104"
                  },
                  {
                        "id": 3105,
                        "displayName": "year_3105"
                  },
                  {
                        "id": 3106,
                        "displayName": "year_3106"
                  },
                  {
                        "id": 3107,
                        "displayName": "year_3107"
                  },
                  {
                        "id": 3108,
                        "displayName": "year_3108"
                  },
                  {
                        "id": 3109,
                        "displayName": "year_3109"
                  },
                  {
                        "id": 3110,
                        "displayName": "year_3110"
                  },
                  {
                        "id": 3111,
                        "displayName": "year_3111"
                  },
                  {
                        "id": 3112,
                        "displayName": "year_3112"
                  },
                  {
                        "id": 3113,
                        "displayName": "year_3113"
                  },
                  {
                        "id": 3114,
                        "displayName": "year_3114"
                  },
                  {
                        "id": 3115,
                        "displayName": "year_3115"
                  },
                  {
                        "id": 3116,
                        "displayName": "year_3116"
                  },
                  {
                        "id": 3117,
                        "displayName": "year_3117"
                  },
                  {
                        "id": 3118,
                        "displayName": "year_3118"
                  },
                  {
                        "id": 3119,
                        "displayName": "year_3119"
                  },
                  {
                        "id": 3120,
                        "displayName": "year_3120"
                  },
                  {
                        "id": 3121,
                        "displayName": "year_3121"
                  },
                  {
                        "id": 3122,
                        "displayName": "year_3122"
                  },
                  {
                        "id": 3123,
                        "displayName": "year_3123"
                  },
                  {
                        "id": 3124,
                        "displayName": "year_3124"
                  },
                  {
                        "id": 3125,
                        "displayName": "year_3125"
                  },
                  {
                        "id": 3126,
                        "displayName": "year_3126"
                  },
                  {
                        "id": 3127,
                        "displayName": "year_3127"
                  },
                  {
                        "id": 3128,
                        "displayName": "year_3128"
                  },
                  {
                        "id": 3129,
                        "displayName": "year_3129"
                  },
                  {
                        "id": 3130,
                        "displayName": "year_3130"
                  },
                  {
                        "id": 3131,
                        "displayName": "year_3131"
                  },
                  {
                        "id": 3132,
                        "displayName": "year_3132"
                  },
                  {
                        "id": 3133,
                        "displayName": "year_3133"
                  },
                  {
                        "id": 3134,
                        "displayName": "year_3134"
                  },
                  {
                        "id": 3135,
                        "displayName": "year_3135"
                  },
                  {
                        "id": 3136,
                        "displayName": "year_3136"
                  },
                  {
                        "id": 3137,
                        "displayName": "year_3137"
                  },
                  {
                        "id": 3138,
                        "displayName": "year_3138"
                  },
                  {
                        "id": 3139,
                        "displayName": "year_3139"
                  },
                  {
                        "id": 3140,
                        "displayName": "year_3140"
                  },
                  {
                        "id": 3141,
                        "displayName": "year_3141"
                  },
                  {
                        "id": 3142,
                        "displayName": "year_3142"
                  },
                  {
                        "id": 3143,
                        "displayName": "year_3143"
                  },
                  {
                        "id": 3144,
                        "displayName": "year_3144"
                  },
                  {
                        "id": 3145,
                        "displayName": "year_3145"
                  },
                  {
                        "id": 3146,
                        "displayName": "year_3146"
                  },
                  {
                        "id": 3147,
                        "displayName": "year_3147"
                  },
                  {
                        "id": 3148,
                        "displayName": "year_3148"
                  },
                  {
                        "id": 3149,
                        "displayName": "year_3149"
                  },
                  {
                        "id": 3150,
                        "displayName": "year_3150"
                  },
                  {
                        "id": 3151,
                        "displayName": "year_3151"
                  },
                  {
                        "id": 3152,
                        "displayName": "year_3152"
                  },
                  {
                        "id": 3153,
                        "displayName": "year_3153"
                  },
                  {
                        "id": 3154,
                        "displayName": "year_3154"
                  },
                  {
                        "id": 3155,
                        "displayName": "year_3155"
                  },
                  {
                        "id": 3156,
                        "displayName": "year_3156"
                  },
                  {
                        "id": 3157,
                        "displayName": "year_3157"
                  },
                  {
                        "id": 3158,
                        "displayName": "year_3158"
                  },
                  {
                        "id": 3159,
                        "displayName": "year_3159"
                  },
                  {
                        "id": 3160,
                        "displayName": "year_3160"
                  },
                  {
                        "id": 3161,
                        "displayName": "year_3161"
                  },
                  {
                        "id": 3162,
                        "displayName": "year_3162"
                  },
                  {
                        "id": 3163,
                        "displayName": "year_3163"
                  },
                  {
                        "id": 3164,
                        "displayName": "year_3164"
                  },
                  {
                        "id": 3165,
                        "displayName": "year_3165"
                  },
                  {
                        "id": 3166,
                        "displayName": "year_3166"
                  },
                  {
                        "id": 3167,
                        "displayName": "year_3167"
                  },
                  {
                        "id": 3168,
                        "displayName": "year_3168"
                  },
                  {
                        "id": 3169,
                        "displayName": "year_3169"
                  },
                  {
                        "id": 3170,
                        "displayName": "year_3170"
                  },
                  {
                        "id": 3171,
                        "displayName": "year_3171"
                  },
                  {
                        "id": 3172,
                        "displayName": "year_3172"
                  },
                  {
                        "id": 3173,
                        "displayName": "year_3173"
                  },
                  {
                        "id": 3174,
                        "displayName": "year_3174"
                  },
                  {
                        "id": 3175,
                        "displayName": "year_3175"
                  },
                  {
                        "id": 3176,
                        "displayName": "year_3176"
                  },
                  {
                        "id": 3177,
                        "displayName": "year_3177"
                  },
                  {
                        "id": 3178,
                        "displayName": "year_3178"
                  },
                  {
                        "id": 3179,
                        "displayName": "year_3179"
                  },
                  {
                        "id": 3180,
                        "displayName": "year_3180"
                  },
                  {
                        "id": 3181,
                        "displayName": "year_3181"
                  },
                  {
                        "id": 3182,
                        "displayName": "year_3182"
                  },
                  {
                        "id": 3183,
                        "displayName": "year_3183"
                  },
                  {
                        "id": 3184,
                        "displayName": "year_3184"
                  },
                  {
                        "id": 3185,
                        "displayName": "year_3185"
                  },
                  {
                        "id": 3186,
                        "displayName": "year_3186"
                  },
                  {
                        "id": 3187,
                        "displayName": "year_3187"
                  },
                  {
                        "id": 3188,
                        "displayName": "year_3188"
                  },
                  {
                        "id": 3189,
                        "displayName": "year_3189"
                  },
                  {
                        "id": 3190,
                        "displayName": "year_3190"
                  },
                  {
                        "id": 3191,
                        "displayName": "year_3191"
                  },
                  {
                        "id": 3192,
                        "displayName": "year_3192"
                  },
                  {
                        "id": 3193,
                        "displayName": "year_3193"
                  },
                  {
                        "id": 3194,
                        "displayName": "year_3194"
                  },
                  {
                        "id": 3195,
                        "displayName": "year_3195"
                  },
                  {
                        "id": 3196,
                        "displayName": "year_3196"
                  },
                  {
                        "id": 3197,
                        "displayName": "year_3197"
                  },
                  {
                        "id": 3198,
                        "displayName": "year_3198"
                  },
                  {
                        "id": 3199,
                        "displayName": "year_3199"
                  },
                  {
                        "id": 3200,
                        "displayName": "year_3200"
                  },
                  {
                        "id": 3201,
                        "displayName": "year_3201"
                  },
                  {
                        "id": 3202,
                        "displayName": "year_3202"
                  },
                  {
                        "id": 3203,
                        "displayName": "year_3203"
                  },
                  {
                        "id": 3204,
                        "displayName": "year_3204"
                  },
                  {
                        "id": 3205,
                        "displayName": "year_3205"
                  },
                  {
                        "id": 3206,
                        "displayName": "year_3206"
                  },
                  {
                        "id": 3207,
                        "displayName": "year_3207"
                  },
                  {
                        "id": 3208,
                        "displayName": "year_3208"
                  },
                  {
                        "id": 3209,
                        "displayName": "year_3209"
                  },
                  {
                        "id": 3210,
                        "displayName": "year_3210"
                  },
                  {
                        "id": 3211,
                        "displayName": "year_3211"
                  },
                  {
                        "id": 3212,
                        "displayName": "year_3212"
                  },
                  {
                        "id": 3213,
                        "displayName": "year_3213"
                  },
                  {
                        "id": 3214,
                        "displayName": "year_3214"
                  },
                  {
                        "id": 3215,
                        "displayName": "year_3215"
                  },
                  {
                        "id": 3216,
                        "displayName": "year_3216"
                  },
                  {
                        "id": 3217,
                        "displayName": "year_3217"
                  },
                  {
                        "id": 3218,
                        "displayName": "year_3218"
                  },
                  {
                        "id": 3219,
                        "displayName": "year_3219"
                  },
                  {
                        "id": 3220,
                        "displayName": "year_3220"
                  },
                  {
                        "id": 3221,
                        "displayName": "year_3221"
                  },
                  {
                        "id": 3222,
                        "displayName": "year_3222"
                  },
                  {
                        "id": 3223,
                        "displayName": "year_3223"
                  },
                  {
                        "id": 3224,
                        "displayName": "year_3224"
                  },
                  {
                        "id": 3225,
                        "displayName": "year_3225"
                  },
                  {
                        "id": 3226,
                        "displayName": "year_3226"
                  },
                  {
                        "id": 3227,
                        "displayName": "year_3227"
                  },
                  {
                        "id": 3228,
                        "displayName": "year_3228"
                  },
                  {
                        "id": 3229,
                        "displayName": "year_3229"
                  },
                  {
                        "id": 3230,
                        "displayName": "year_3230"
                  },
                  {
                        "id": 3231,
                        "displayName": "year_3231"
                  },
                  {
                        "id": 3232,
                        "displayName": "year_3232"
                  },
                  {
                        "id": 3233,
                        "displayName": "year_3233"
                  },
                  {
                        "id": 3234,
                        "displayName": "year_3234"
                  },
                  {
                        "id": 3235,
                        "displayName": "year_3235"
                  },
                  {
                        "id": 3236,
                        "displayName": "year_3236"
                  },
                  {
                        "id": 3237,
                        "displayName": "year_3237"
                  },
                  {
                        "id": 3238,
                        "displayName": "year_3238"
                  },
                  {
                        "id": 3239,
                        "displayName": "year_3239"
                  },
                  {
                        "id": 3240,
                        "displayName": "year_3240"
                  },
                  {
                        "id": 3241,
                        "displayName": "year_3241"
                  },
                  {
                        "id": 3242,
                        "displayName": "year_3242"
                  },
                  {
                        "id": 3243,
                        "displayName": "year_3243"
                  },
                  {
                        "id": 3244,
                        "displayName": "year_3244"
                  },
                  {
                        "id": 3245,
                        "displayName": "year_3245"
                  },
                  {
                        "id": 3246,
                        "displayName": "year_3246"
                  },
                  {
                        "id": 3247,
                        "displayName": "year_3247"
                  },
                  {
                        "id": 3248,
                        "displayName": "year_3248"
                  },
                  {
                        "id": 3249,
                        "displayName": "year_3249"
                  },
                  {
                        "id": 3250,
                        "displayName": "year_3250"
                  },
                  {
                        "id": 3251,
                        "displayName": "year_3251"
                  },
                  {
                        "id": 3252,
                        "displayName": "year_3252"
                  },
                  {
                        "id": 3253,
                        "displayName": "year_3253"
                  },
                  {
                        "id": 3254,
                        "displayName": "year_3254"
                  },
                  {
                        "id": 3255,
                        "displayName": "year_3255"
                  },
                  {
                        "id": 3256,
                        "displayName": "year_3256"
                  },
                  {
                        "id": 3257,
                        "displayName": "year_3257"
                  },
                  {
                        "id": 3258,
                        "displayName": "year_3258"
                  },
                  {
                        "id": 3259,
                        "displayName": "year_3259"
                  },
                  {
                        "id": 3260,
                        "displayName": "year_3260"
                  },
                  {
                        "id": 3261,
                        "displayName": "year_3261"
                  },
                  {
                        "id": 3262,
                        "displayName": "year_3262"
                  },
                  {
                        "id": 3263,
                        "displayName": "year_3263"
                  },
                  {
                        "id": 3264,
                        "displayName": "year_3264"
                  },
                  {
                        "id": 3265,
                        "displayName": "year_3265"
                  },
                  {
                        "id": 3266,
                        "displayName": "year_3266"
                  },
                  {
                        "id": 3267,
                        "displayName": "year_3267"
                  },
                  {
                        "id": 3268,
                        "displayName": "year_3268"
                  },
                  {
                        "id": 3269,
                        "displayName": "year_3269"
                  },
                  {
                        "id": 3270,
                        "displayName": "year_3270"
                  },
                  {
                        "id": 3271,
                        "displayName": "year_3271"
                  },
                  {
                        "id": 3272,
                        "displayName": "year_3272"
                  },
                  {
                        "id": 3273,
                        "displayName": "year_3273"
                  },
                  {
                        "id": 3274,
                        "displayName": "year_3274"
                  },
                  {
                        "id": 3275,
                        "displayName": "year_3275"
                  },
                  {
                        "id": 3276,
                        "displayName": "year_3276"
                  },
                  {
                        "id": 3277,
                        "displayName": "year_3277"
                  },
                  {
                        "id": 3278,
                        "displayName": "year_3278"
                  },
                  {
                        "id": 3279,
                        "displayName": "year_3279"
                  },
                  {
                        "id": 3280,
                        "displayName": "year_3280"
                  },
                  {
                        "id": 3281,
                        "displayName": "year_3281"
                  },
                  {
                        "id": 3282,
                        "displayName": "year_3282"
                  },
                  {
                        "id": 3283,
                        "displayName": "year_3283"
                  },
                  {
                        "id": 3284,
                        "displayName": "year_3284"
                  },
                  {
                        "id": 3285,
                        "displayName": "year_3285"
                  },
                  {
                        "id": 3286,
                        "displayName": "year_3286"
                  },
                  {
                        "id": 3287,
                        "displayName": "year_3287"
                  },
                  {
                        "id": 3288,
                        "displayName": "year_3288"
                  },
                  {
                        "id": 3289,
                        "displayName": "year_3289"
                  },
                  {
                        "id": 3290,
                        "displayName": "year_3290"
                  },
                  {
                        "id": 3291,
                        "displayName": "year_3291"
                  },
                  {
                        "id": 3292,
                        "displayName": "year_3292"
                  },
                  {
                        "id": 3293,
                        "displayName": "year_3293"
                  },
                  {
                        "id": 3294,
                        "displayName": "year_3294"
                  },
                  {
                        "id": 3295,
                        "displayName": "year_3295"
                  },
                  {
                        "id": 3296,
                        "displayName": "year_3296"
                  },
                  {
                        "id": 3297,
                        "displayName": "year_3297"
                  },
                  {
                        "id": 3298,
                        "displayName": "year_3298"
                  },
                  {
                        "id": 3299,
                        "displayName": "year_3299"
                  },
                  {
                        "id": 3300,
                        "displayName": "year_3300"
                  },
                  {
                        "id": 3301,
                        "displayName": "year_3301"
                  },
                  {
                        "id": 3302,
                        "displayName": "year_3302"
                  },
                  {
                        "id": 3303,
                        "displayName": "year_3303"
                  },
                  {
                        "id": 3304,
                        "displayName": "year_3304"
                  },
                  {
                        "id": 3305,
                        "displayName": "year_3305"
                  },
                  {
                        "id": 3306,
                        "displayName": "year_3306"
                  },
                  {
                        "id": 3307,
                        "displayName": "year_3307"
                  },
                  {
                        "id": 3308,
                        "displayName": "year_3308"
                  },
                  {
                        "id": 3309,
                        "displayName": "year_3309"
                  },
                  {
                        "id": 3310,
                        "displayName": "year_3310"
                  },
                  {
                        "id": 3311,
                        "displayName": "year_3311"
                  },
                  {
                        "id": 3312,
                        "displayName": "year_3312"
                  },
                  {
                        "id": 3313,
                        "displayName": "year_3313"
                  },
                  {
                        "id": 3314,
                        "displayName": "year_3314"
                  },
                  {
                        "id": 3315,
                        "displayName": "year_3315"
                  },
                  {
                        "id": 3316,
                        "displayName": "year_3316"
                  },
                  {
                        "id": 3317,
                        "displayName": "year_3317"
                  },
                  {
                        "id": 3318,
                        "displayName": "year_3318"
                  },
                  {
                        "id": 3319,
                        "displayName": "year_3319"
                  },
                  {
                        "id": 3320,
                        "displayName": "year_3320"
                  },
                  {
                        "id": 3321,
                        "displayName": "year_3321"
                  },
                  {
                        "id": 3322,
                        "displayName": "year_3322"
                  },
                  {
                        "id": 3323,
                        "displayName": "year_3323"
                  },
                  {
                        "id": 3324,
                        "displayName": "year_3324"
                  },
                  {
                        "id": 3325,
                        "displayName": "year_3325"
                  },
                  {
                        "id": 3326,
                        "displayName": "year_3326"
                  },
                  {
                        "id": 3327,
                        "displayName": "year_3327"
                  },
                  {
                        "id": 3328,
                        "displayName": "year_3328"
                  },
                  {
                        "id": 3329,
                        "displayName": "year_3329"
                  },
                  {
                        "id": 3330,
                        "displayName": "year_3330"
                  },
                  {
                        "id": 3331,
                        "displayName": "year_3331"
                  },
                  {
                        "id": 3332,
                        "displayName": "year_3332"
                  },
                  {
                        "id": 3333,
                        "displayName": "year_3333"
                  },
                  {
                        "id": 3334,
                        "displayName": "year_3334"
                  },
                  {
                        "id": 3335,
                        "displayName": "year_3335"
                  },
                  {
                        "id": 3336,
                        "displayName": "year_3336"
                  },
                  {
                        "id": 3337,
                        "displayName": "year_3337"
                  },
                  {
                        "id": 3338,
                        "displayName": "year_3338"
                  },
                  {
                        "id": 3339,
                        "displayName": "year_3339"
                  },
                  {
                        "id": 3340,
                        "displayName": "year_3340"
                  },
                  {
                        "id": 3341,
                        "displayName": "year_3341"
                  },
                  {
                        "id": 3342,
                        "displayName": "year_3342"
                  },
                  {
                        "id": 3343,
                        "displayName": "year_3343"
                  },
                  {
                        "id": 3344,
                        "displayName": "year_3344"
                  },
                  {
                        "id": 3345,
                        "displayName": "year_3345"
                  },
                  {
                        "id": 3346,
                        "displayName": "year_3346"
                  },
                  {
                        "id": 3347,
                        "displayName": "year_3347"
                  },
                  {
                        "id": 3348,
                        "displayName": "year_3348"
                  },
                  {
                        "id": 3349,
                        "displayName": "year_3349"
                  },
                  {
                        "id": 3350,
                        "displayName": "year_3350"
                  },
                  {
                        "id": 3351,
                        "displayName": "year_3351"
                  },
                  {
                        "id": 3352,
                        "displayName": "year_3352"
                  },
                  {
                        "id": 3353,
                        "displayName": "year_3353"
                  },
                  {
                        "id": 3354,
                        "displayName": "year_3354"
                  },
                  {
                        "id": 3355,
                        "displayName": "year_3355"
                  },
                  {
                        "id": 3356,
                        "displayName": "year_3356"
                  },
                  {
                        "id": 3357,
                        "displayName": "year_3357"
                  },
                  {
                        "id": 3358,
                        "displayName": "year_3358"
                  },
                  {
                        "id": 3359,
                        "displayName": "year_3359"
                  },
                  {
                        "id": 3360,
                        "displayName": "year_3360"
                  },
                  {
                        "id": 3361,
                        "displayName": "year_3361"
                  },
                  {
                        "id": 3362,
                        "displayName": "year_3362"
                  },
                  {
                        "id": 3363,
                        "displayName": "year_3363"
                  },
                  {
                        "id": 3364,
                        "displayName": "year_3364"
                  },
                  {
                        "id": 3365,
                        "displayName": "year_3365"
                  },
                  {
                        "id": 3366,
                        "displayName": "year_3366"
                  },
                  {
                        "id": 3367,
                        "displayName": "year_3367"
                  },
                  {
                        "id": 3368,
                        "displayName": "year_3368"
                  },
                  {
                        "id": 3369,
                        "displayName": "year_3369"
                  },
                  {
                        "id": 3370,
                        "displayName": "year_3370"
                  },
                  {
                        "id": 3371,
                        "displayName": "year_3371"
                  },
                  {
                        "id": 3372,
                        "displayName": "year_3372"
                  },
                  {
                        "id": 3373,
                        "displayName": "year_3373"
                  },
                  {
                        "id": 3374,
                        "displayName": "year_3374"
                  },
                  {
                        "id": 3375,
                        "displayName": "year_3375"
                  },
                  {
                        "id": 3376,
                        "displayName": "year_3376"
                  },
                  {
                        "id": 3377,
                        "displayName": "year_3377"
                  },
                  {
                        "id": 3378,
                        "displayName": "year_3378"
                  },
                  {
                        "id": 3379,
                        "displayName": "year_3379"
                  },
                  {
                        "id": 3380,
                        "displayName": "year_3380"
                  },
                  {
                        "id": 3381,
                        "displayName": "year_3381"
                  },
                  {
                        "id": 3382,
                        "displayName": "year_3382"
                  },
                  {
                        "id": 3383,
                        "displayName": "year_3383"
                  },
                  {
                        "id": 3384,
                        "displayName": "year_3384"
                  },
                  {
                        "id": 3385,
                        "displayName": "year_3385"
                  },
                  {
                        "id": 3386,
                        "displayName": "year_3386"
                  },
                  {
                        "id": 3387,
                        "displayName": "year_3387"
                  },
                  {
                        "id": 3388,
                        "displayName": "year_3388"
                  },
                  {
                        "id": 3389,
                        "displayName": "year_3389"
                  },
                  {
                        "id": 3390,
                        "displayName": "year_3390"
                  },
                  {
                        "id": 3391,
                        "displayName": "year_3391"
                  },
                  {
                        "id": 3392,
                        "displayName": "year_3392"
                  },
                  {
                        "id": 3393,
                        "displayName": "year_3393"
                  },
                  {
                        "id": 3394,
                        "displayName": "year_3394"
                  },
                  {
                        "id": 3395,
                        "displayName": "year_3395"
                  },
                  {
                        "id": 3396,
                        "displayName": "year_3396"
                  },
                  {
                        "id": 3397,
                        "displayName": "year_3397"
                  },
                  {
                        "id": 3398,
                        "displayName": "year_3398"
                  },
                  {
                        "id": 3399,
                        "displayName": "year_3399"
                  },
                  {
                        "id": 3400,
                        "displayName": "year_3400"
                  },
                  {
                        "id": 3401,
                        "displayName": "year_3401"
                  },
                  {
                        "id": 3402,
                        "displayName": "year_3402"
                  },
                  {
                        "id": 3403,
                        "displayName": "year_3403"
                  },
                  {
                        "id": 3404,
                        "displayName": "year_3404"
                  },
                  {
                        "id": 3405,
                        "displayName": "year_3405"
                  },
                  {
                        "id": 3406,
                        "displayName": "year_3406"
                  },
                  {
                        "id": 3407,
                        "displayName": "year_3407"
                  },
                  {
                        "id": 3408,
                        "displayName": "year_3408"
                  },
                  {
                        "id": 3409,
                        "displayName": "year_3409"
                  },
                  {
                        "id": 3410,
                        "displayName": "year_3410"
                  },
                  {
                        "id": 3411,
                        "displayName": "year_3411"
                  },
                  {
                        "id": 3412,
                        "displayName": "year_3412"
                  },
                  {
                        "id": 3413,
                        "displayName": "year_3413"
                  },
                  {
                        "id": 3414,
                        "displayName": "year_3414"
                  },
                  {
                        "id": 3415,
                        "displayName": "year_3415"
                  },
                  {
                        "id": 3416,
                        "displayName": "year_3416"
                  },
                  {
                        "id": 3417,
                        "displayName": "year_3417"
                  },
                  {
                        "id": 3418,
                        "displayName": "year_3418"
                  },
                  {
                        "id": 3419,
                        "displayName": "year_3419"
                  },
                  {
                        "id": 3420,
                        "displayName": "year_3420"
                  },
                  {
                        "id": 3421,
                        "displayName": "year_3421"
                  },
                  {
                        "id": 3422,
                        "displayName": "year_3422"
                  },
                  {
                        "id": 3423,
                        "displayName": "year_3423"
                  },
                  {
                        "id": 3424,
                        "displayName": "year_3424"
                  },
                  {
                        "id": 3425,
                        "displayName": "year_3425"
                  },
                  {
                        "id": 3426,
                        "displayName": "year_3426"
                  },
                  {
                        "id": 3427,
                        "displayName": "year_3427"
                  },
                  {
                        "id": 3428,
                        "displayName": "year_3428"
                  },
                  {
                        "id": 3429,
                        "displayName": "year_3429"
                  },
                  {
                        "id": 3430,
                        "displayName": "year_3430"
                  },
                  {
                        "id": 3431,
                        "displayName": "year_3431"
                  },
                  {
                        "id": 3432,
                        "displayName": "year_3432"
                  },
                  {
                        "id": 3433,
                        "displayName": "year_3433"
                  },
                  {
                        "id": 3434,
                        "displayName": "year_3434"
                  },
                  {
                        "id": 3435,
                        "displayName": "year_3435"
                  },
                  {
                        "id": 3436,
                        "displayName": "year_3436"
                  },
                  {
                        "id": 3437,
                        "displayName": "year_3437"
                  },
                  {
                        "id": 3438,
                        "displayName": "year_3438"
                  },
                  {
                        "id": 3439,
                        "displayName": "year_3439"
                  },
                  {
                        "id": 3440,
                        "displayName": "year_3440"
                  },
                  {
                        "id": 3441,
                        "displayName": "year_3441"
                  },
                  {
                        "id": 3442,
                        "displayName": "year_3442"
                  },
                  {
                        "id": 3443,
                        "displayName": "year_3443"
                  },
                  {
                        "id": 3444,
                        "displayName": "year_3444"
                  },
                  {
                        "id": 3445,
                        "displayName": "year_3445"
                  },
                  {
                        "id": 3446,
                        "displayName": "year_3446"
                  },
                  {
                        "id": 3447,
                        "displayName": "year_3447"
                  },
                  {
                        "id": 3448,
                        "displayName": "year_3448"
                  },
                  {
                        "id": 3449,
                        "displayName": "year_3449"
                  },
                  {
                        "id": 3450,
                        "displayName": "year_3450"
                  },
                  {
                        "id": 3451,
                        "displayName": "year_3451"
                  },
                  {
                        "id": 3452,
                        "displayName": "year_3452"
                  },
                  {
                        "id": 3453,
                        "displayName": "year_3453"
                  },
                  {
                        "id": 3454,
                        "displayName": "year_3454"
                  },
                  {
                        "id": 3455,
                        "displayName": "year_3455"
                  },
                  {
                        "id": 3456,
                        "displayName": "year_3456"
                  },
                  {
                        "id": 3457,
                        "displayName": "year_3457"
                  },
                  {
                        "id": 3458,
                        "displayName": "year_3458"
                  },
                  {
                        "id": 3459,
                        "displayName": "year_3459"
                  },
                  {
                        "id": 3460,
                        "displayName": "year_3460"
                  },
                  {
                        "id": 3461,
                        "displayName": "year_3461"
                  },
                  {
                        "id": 3462,
                        "displayName": "year_3462"
                  },
                  {
                        "id": 3463,
                        "displayName": "year_3463"
                  },
                  {
                        "id": 3464,
                        "displayName": "year_3464"
                  },
                  {
                        "id": 3465,
                        "displayName": "year_3465"
                  },
                  {
                        "id": 3466,
                        "displayName": "year_3466"
                  },
                  {
                        "id": 3467,
                        "displayName": "year_3467"
                  },
                  {
                        "id": 3468,
                        "displayName": "year_3468"
                  },
                  {
                        "id": 3469,
                        "displayName": "year_3469"
                  },
                  {
                        "id": 3470,
                        "displayName": "year_3470"
                  },
                  {
                        "id": 3471,
                        "displayName": "year_3471"
                  },
                  {
                        "id": 3472,
                        "displayName": "year_3472"
                  },
                  {
                        "id": 3473,
                        "displayName": "year_3473"
                  },
                  {
                        "id": 3474,
                        "displayName": "year_3474"
                  },
                  {
                        "id": 3475,
                        "displayName": "year_3475"
                  },
                  {
                        "id": 3476,
                        "displayName": "year_3476"
                  },
                  {
                        "id": 3477,
                        "displayName": "year_3477"
                  },
                  {
                        "id": 3478,
                        "displayName": "year_3478"
                  },
                  {
                        "id": 3479,
                        "displayName": "year_3479"
                  },
                  {
                        "id": 3480,
                        "displayName": "year_3480"
                  },
                  {
                        "id": 3481,
                        "displayName": "year_3481"
                  },
                  {
                        "id": 3482,
                        "displayName": "year_3482"
                  },
                  {
                        "id": 3483,
                        "displayName": "year_3483"
                  },
                  {
                        "id": 3484,
                        "displayName": "year_3484"
                  },
                  {
                        "id": 3485,
                        "displayName": "year_3485"
                  },
                  {
                        "id": 3486,
                        "displayName": "year_3486"
                  },
                  {
                        "id": 3487,
                        "displayName": "year_3487"
                  },
                  {
                        "id": 3488,
                        "displayName": "year_3488"
                  },
                  {
                        "id": 3489,
                        "displayName": "year_3489"
                  },
                  {
                        "id": 3490,
                        "displayName": "year_3490"
                  },
                  {
                        "id": 3491,
                        "displayName": "year_3491"
                  },
                  {
                        "id": 3492,
                        "displayName": "year_3492"
                  },
                  {
                        "id": 3493,
                        "displayName": "year_3493"
                  },
                  {
                        "id": 3494,
                        "displayName": "year_3494"
                  },
                  {
                        "id": 3495,
                        "displayName": "year_3495"
                  },
                  {
                        "id": 3496,
                        "displayName": "year_3496"
                  },
                  {
                        "id": 3497,
                        "displayName": "year_3497"
                  },
                  {
                        "id": 3498,
                        "displayName": "year_3498"
                  },
                  {
                        "id": 3499,
                        "displayName": "year_3499"
                  },
                  {
                        "id": 3500,
                        "displayName": "year_3500"
                  },
                  {
                        "id": 3501,
                        "displayName": "year_3501"
                  },
                  {
                        "id": 3502,
                        "displayName": "year_3502"
                  },
                  {
                        "id": 3503,
                        "displayName": "year_3503"
                  },
                  {
                        "id": 3504,
                        "displayName": "year_3504"
                  },
                  {
                        "id": 3505,
                        "displayName": "year_3505"
                  },
                  {
                        "id": 3506,
                        "displayName": "year_3506"
                  },
                  {
                        "id": 3507,
                        "displayName": "year_3507"
                  },
                  {
                        "id": 3508,
                        "displayName": "year_3508"
                  },
                  {
                        "id": 3509,
                        "displayName": "year_3509"
                  },
                  {
                        "id": 3510,
                        "displayName": "year_3510"
                  },
                  {
                        "id": 3511,
                        "displayName": "year_3511"
                  },
                  {
                        "id": 3512,
                        "displayName": "year_3512"
                  },
                  {
                        "id": 3513,
                        "displayName": "year_3513"
                  },
                  {
                        "id": 3514,
                        "displayName": "year_3514"
                  },
                  {
                        "id": 3515,
                        "displayName": "year_3515"
                  },
                  {
                        "id": 3516,
                        "displayName": "year_3516"
                  },
                  {
                        "id": 3517,
                        "displayName": "year_3517"
                  },
                  {
                        "id": 3518,
                        "displayName": "year_3518"
                  },
                  {
                        "id": 3519,
                        "displayName": "year_3519"
                  },
                  {
                        "id": 3520,
                        "displayName": "year_3520"
                  },
                  {
                        "id": 3521,
                        "displayName": "year_3521"
                  },
                  {
                        "id": 3522,
                        "displayName": "year_3522"
                  },
                  {
                        "id": 3523,
                        "displayName": "year_3523"
                  },
                  {
                        "id": 3524,
                        "displayName": "year_3524"
                  },
                  {
                        "id": 3525,
                        "displayName": "year_3525"
                  },
                  {
                        "id": 3526,
                        "displayName": "year_3526"
                  },
                  {
                        "id": 3527,
                        "displayName": "year_3527"
                  },
                  {
                        "id": 3528,
                        "displayName": "year_3528"
                  },
                  {
                        "id": 3529,
                        "displayName": "year_3529"
                  },
                  {
                        "id": 3530,
                        "displayName": "year_3530"
                  },
                  {
                        "id": 3531,
                        "displayName": "year_3531"
                  },
                  {
                        "id": 3532,
                        "displayName": "year_3532"
                  },
                  {
                        "id": 3533,
                        "displayName": "year_3533"
                  },
                  {
                        "id": 3534,
                        "displayName": "year_3534"
                  },
                  {
                        "id": 3535,
                        "displayName": "year_3535"
                  },
                  {
                        "id": 3536,
                        "displayName": "year_3536"
                  },
                  {
                        "id": 3537,
                        "displayName": "year_3537"
                  },
                  {
                        "id": 3538,
                        "displayName": "year_3538"
                  },
                  {
                        "id": 3539,
                        "displayName": "year_3539"
                  },
                  {
                        "id": 3540,
                        "displayName": "year_3540"
                  },
                  {
                        "id": 3541,
                        "displayName": "year_3541"
                  },
                  {
                        "id": 3542,
                        "displayName": "year_3542"
                  },
                  {
                        "id": 3543,
                        "displayName": "year_3543"
                  },
                  {
                        "id": 3544,
                        "displayName": "year_3544"
                  },
                  {
                        "id": 3545,
                        "displayName": "year_3545"
                  },
                  {
                        "id": 3546,
                        "displayName": "year_3546"
                  },
                  {
                        "id": 3547,
                        "displayName": "year_3547"
                  },
                  {
                        "id": 3548,
                        "displayName": "year_3548"
                  },
                  {
                        "id": 3549,
                        "displayName": "year_3549"
                  },
                  {
                        "id": 3550,
                        "displayName": "year_3550"
                  },
                  {
                        "id": 3551,
                        "displayName": "year_3551"
                  },
                  {
                        "id": 3552,
                        "displayName": "year_3552"
                  },
                  {
                        "id": 3553,
                        "displayName": "year_3553"
                  },
                  {
                        "id": 3554,
                        "displayName": "year_3554"
                  },
                  {
                        "id": 3555,
                        "displayName": "year_3555"
                  },
                  {
                        "id": 3556,
                        "displayName": "year_3556"
                  },
                  {
                        "id": 3557,
                        "displayName": "year_3557"
                  },
                  {
                        "id": 3558,
                        "displayName": "year_3558"
                  },
                  {
                        "id": 3559,
                        "displayName": "year_3559"
                  },
                  {
                        "id": 3560,
                        "displayName": "year_3560"
                  },
                  {
                        "id": 3561,
                        "displayName": "year_3561"
                  },
                  {
                        "id": 3562,
                        "displayName": "year_3562"
                  },
                  {
                        "id": 3563,
                        "displayName": "year_3563"
                  },
                  {
                        "id": 3564,
                        "displayName": "year_3564"
                  },
                  {
                        "id": 3565,
                        "displayName": "year_3565"
                  },
                  {
                        "id": 3566,
                        "displayName": "year_3566"
                  },
                  {
                        "id": 3567,
                        "displayName": "year_3567"
                  },
                  {
                        "id": 3568,
                        "displayName": "year_3568"
                  },
                  {
                        "id": 3569,
                        "displayName": "year_3569"
                  },
                  {
                        "id": 3570,
                        "displayName": "year_3570"
                  },
                  {
                        "id": 3571,
                        "displayName": "year_3571"
                  },
                  {
                        "id": 3572,
                        "displayName": "year_3572"
                  },
                  {
                        "id": 3573,
                        "displayName": "year_3573"
                  },
                  {
                        "id": 3574,
                        "displayName": "year_3574"
                  },
                  {
                        "id": 3575,
                        "displayName": "year_3575"
                  },
                  {
                        "id": 3576,
                        "displayName": "year_3576"
                  },
                  {
                        "id": 3577,
                        "displayName": "year_3577"
                  },
                  {
                        "id": 3578,
                        "displayName": "year_3578"
                  },
                  {
                        "id": 3579,
                        "displayName": "year_3579"
                  },
                  {
                        "id": 3580,
                        "displayName": "year_3580"
                  },
                  {
                        "id": 3581,
                        "displayName": "year_3581"
                  },
                  {
                        "id": 3582,
                        "displayName": "year_3582"
                  },
                  {
                        "id": 3583,
                        "displayName": "year_3583"
                  },
                  {
                        "id": 3584,
                        "displayName": "year_3584"
                  },
                  {
                        "id": 3585,
                        "displayName": "year_3585"
                  },
                  {
                        "id": 3586,
                        "displayName": "year_3586"
                  },
                  {
                        "id": 3587,
                        "displayName": "year_3587"
                  },
                  {
                        "id": 3588,
                        "displayName": "year_3588"
                  },
                  {
                        "id": 3589,
                        "displayName": "year_3589"
                  },
                  {
                        "id": 3590,
                        "displayName": "year_3590"
                  },
                  {
                        "id": 3591,
                        "displayName": "year_3591"
                  },
                  {
                        "id": 3592,
                        "displayName": "year_3592"
                  },
                  {
                        "id": 3593,
                        "displayName": "year_3593"
                  },
                  {
                        "id": 3594,
                        "displayName": "year_3594"
                  },
                  {
                        "id": 3595,
                        "displayName": "year_3595"
                  },
                  {
                        "id": 3596,
                        "displayName": "year_3596"
                  },
                  {
                        "id": 3597,
                        "displayName": "year_3597"
                  },
                  {
                        "id": 3598,
                        "displayName": "year_3598"
                  },
                  {
                        "id": 3599,
                        "displayName": "year_3599"
                  },
                  {
                        "id": 3600,
                        "displayName": "year_3600"
                  },
                  {
                        "id": 3601,
                        "displayName": "year_3601"
                  },
                  {
                        "id": 3602,
                        "displayName": "year_3602"
                  },
                  {
                        "id": 3603,
                        "displayName": "year_3603"
                  },
                  {
                        "id": 3604,
                        "displayName": "year_3604"
                  },
                  {
                        "id": 3605,
                        "displayName": "year_3605"
                  },
                  {
                        "id": 3606,
                        "displayName": "year_3606"
                  },
                  {
                        "id": 3607,
                        "displayName": "year_3607"
                  },
                  {
                        "id": 3608,
                        "displayName": "year_3608"
                  },
                  {
                        "id": 3609,
                        "displayName": "year_3609"
                  },
                  {
                        "id": 3610,
                        "displayName": "year_3610"
                  },
                  {
                        "id": 3611,
                        "displayName": "year_3611"
                  },
                  {
                        "id": 3612,
                        "displayName": "year_3612"
                  },
                  {
                        "id": 3613,
                        "displayName": "year_3613"
                  },
                  {
                        "id": 3614,
                        "displayName": "year_3614"
                  },
                  {
                        "id": 3615,
                        "displayName": "year_3615"
                  },
                  {
                        "id": 3616,
                        "displayName": "year_3616"
                  },
                  {
                        "id": 3617,
                        "displayName": "year_3617"
                  },
                  {
                        "id": 3618,
                        "displayName": "year_3618"
                  },
                  {
                        "id": 3619,
                        "displayName": "year_3619"
                  },
                  {
                        "id": 3620,
                        "displayName": "year_3620"
                  },
                  {
                        "id": 3621,
                        "displayName": "year_3621"
                  },
                  {
                        "id": 3622,
                        "displayName": "year_3622"
                  },
                  {
                        "id": 3623,
                        "displayName": "year_3623"
                  },
                  {
                        "id": 3624,
                        "displayName": "year_3624"
                  },
                  {
                        "id": 3625,
                        "displayName": "year_3625"
                  },
                  {
                        "id": 3626,
                        "displayName": "year_3626"
                  },
                  {
                        "id": 3627,
                        "displayName": "year_3627"
                  },
                  {
                        "id": 3628,
                        "displayName": "year_3628"
                  },
                  {
                        "id": 3629,
                        "displayName": "year_3629"
                  },
                  {
                        "id": 3630,
                        "displayName": "year_3630"
                  },
                  {
                        "id": 3631,
                        "displayName": "year_3631"
                  },
                  {
                        "id": 3632,
                        "displayName": "year_3632"
                  },
                  {
                        "id": 3633,
                        "displayName": "year_3633"
                  },
                  {
                        "id": 3634,
                        "displayName": "year_3634"
                  },
                  {
                        "id": 3635,
                        "displayName": "year_3635"
                  },
                  {
                        "id": 3636,
                        "displayName": "year_3636"
                  },
                  {
                        "id": 3637,
                        "displayName": "year_3637"
                  },
                  {
                        "id": 3638,
                        "displayName": "year_3638"
                  },
                  {
                        "id": 3639,
                        "displayName": "year_3639"
                  },
                  {
                        "id": 3640,
                        "displayName": "year_3640"
                  },
                  {
                        "id": 3641,
                        "displayName": "year_3641"
                  },
                  {
                        "id": 3642,
                        "displayName": "year_3642"
                  },
                  {
                        "id": 3643,
                        "displayName": "year_3643"
                  },
                  {
                        "id": 3644,
                        "displayName": "year_3644"
                  },
                  {
                        "id": 3645,
                        "displayName": "year_3645"
                  },
                  {
                        "id": 3646,
                        "displayName": "year_3646"
                  },
                  {
                        "id": 3647,
                        "displayName": "year_3647"
                  },
                  {
                        "id": 3648,
                        "displayName": "year_3648"
                  },
                  {
                        "id": 3649,
                        "displayName": "year_3649"
                  },
                  {
                        "id": 3650,
                        "displayName": "year_3650"
                  },
                  {
                        "id": 3651,
                        "displayName": "year_3651"
                  },
                  {
                        "id": 3652,
                        "displayName": "year_3652"
                  },
                  {
                        "id": 3653,
                        "displayName": "year_3653"
                  },
                  {
                        "id": 3654,
                        "displayName": "year_3654"
                  },
                  {
                        "id": 3655,
                        "displayName": "year_3655"
                  },
                  {
                        "id": 3656,
                        "displayName": "year_3656"
                  },
                  {
                        "id": 3657,
                        "displayName": "year_3657"
                  },
                  {
                        "id": 3658,
                        "displayName": "year_3658"
                  },
                  {
                        "id": 3659,
                        "displayName": "year_3659"
                  },
                  {
                        "id": 3660,
                        "displayName": "year_3660"
                  },
                  {
                        "id": 3661,
                        "displayName": "year_3661"
                  },
                  {
                        "id": 3662,
                        "displayName": "year_3662"
                  },
                  {
                        "id": 3663,
                        "displayName": "year_3663"
                  },
                  {
                        "id": 3664,
                        "displayName": "year_3664"
                  },
                  {
                        "id": 3665,
                        "displayName": "year_3665"
                  },
                  {
                        "id": 3666,
                        "displayName": "year_3666"
                  },
                  {
                        "id": 3667,
                        "displayName": "year_3667"
                  },
                  {
                        "id": 3668,
                        "displayName": "year_3668"
                  },
                  {
                        "id": 3669,
                        "displayName": "year_3669"
                  },
                  {
                        "id": 3670,
                        "displayName": "year_3670"
                  },
                  {
                        "id": 3671,
                        "displayName": "year_3671"
                  },
                  {
                        "id": 3672,
                        "displayName": "year_3672"
                  },
                  {
                        "id": 3673,
                        "displayName": "year_3673"
                  },
                  {
                        "id": 3674,
                        "displayName": "year_3674"
                  },
                  {
                        "id": 3675,
                        "displayName": "year_3675"
                  },
                  {
                        "id": 3676,
                        "displayName": "year_3676"
                  },
                  {
                        "id": 3677,
                        "displayName": "year_3677"
                  },
                  {
                        "id": 3678,
                        "displayName": "year_3678"
                  },
                  {
                        "id": 3679,
                        "displayName": "year_3679"
                  },
                  {
                        "id": 3680,
                        "displayName": "year_3680"
                  },
                  {
                        "id": 3681,
                        "displayName": "year_3681"
                  },
                  {
                        "id": 3682,
                        "displayName": "year_3682"
                  },
                  {
                        "id": 3683,
                        "displayName": "year_3683"
                  },
                  {
                        "id": 3684,
                        "displayName": "year_3684"
                  },
                  {
                        "id": 3685,
                        "displayName": "year_3685"
                  },
                  {
                        "id": 3686,
                        "displayName": "year_3686"
                  },
                  {
                        "id": 3687,
                        "displayName": "year_3687"
                  },
                  {
                        "id": 3688,
                        "displayName": "year_3688"
                  },
                  {
                        "id": 3689,
                        "displayName": "year_3689"
                  },
                  {
                        "id": 3690,
                        "displayName": "year_3690"
                  },
                  {
                        "id": 3691,
                        "displayName": "year_3691"
                  },
                  {
                        "id": 3692,
                        "displayName": "year_3692"
                  },
                  {
                        "id": 3693,
                        "displayName": "year_3693"
                  },
                  {
                        "id": 3694,
                        "displayName": "year_3694"
                  },
                  {
                        "id": 3695,
                        "displayName": "year_3695"
                  },
                  {
                        "id": 3696,
                        "displayName": "year_3696"
                  },
                  {
                        "id": 3697,
                        "displayName": "year_3697"
                  },
                  {
                        "id": 3698,
                        "displayName": "year_3698"
                  },
                  {
                        "id": 3699,
                        "displayName": "year_3699"
                  },
                  {
                        "id": 3700,
                        "displayName": "year_3700"
                  },
                  {
                        "id": 3701,
                        "displayName": "year_3701"
                  },
                  {
                        "id": 3702,
                        "displayName": "year_3702"
                  },
                  {
                        "id": 3703,
                        "displayName": "year_3703"
                  },
                  {
                        "id": 3704,
                        "displayName": "year_3704"
                  },
                  {
                        "id": 3705,
                        "displayName": "year_3705"
                  },
                  {
                        "id": 3706,
                        "displayName": "year_3706"
                  },
                  {
                        "id": 3707,
                        "displayName": "year_3707"
                  },
                  {
                        "id": 3708,
                        "displayName": "year_3708"
                  },
                  {
                        "id": 3709,
                        "displayName": "year_3709"
                  },
                  {
                        "id": 3710,
                        "displayName": "year_3710"
                  },
                  {
                        "id": 3711,
                        "displayName": "year_3711"
                  },
                  {
                        "id": 3712,
                        "displayName": "year_3712"
                  },
                  {
                        "id": 3713,
                        "displayName": "year_3713"
                  },
                  {
                        "id": 3714,
                        "displayName": "year_3714"
                  },
                  {
                        "id": 3715,
                        "displayName": "year_3715"
                  },
                  {
                        "id": 3716,
                        "displayName": "year_3716"
                  },
                  {
                        "id": 3717,
                        "displayName": "year_3717"
                  },
                  {
                        "id": 3718,
                        "displayName": "year_3718"
                  },
                  {
                        "id": 3719,
                        "displayName": "year_3719"
                  },
                  {
                        "id": 3720,
                        "displayName": "year_3720"
                  },
                  {
                        "id": 3721,
                        "displayName": "year_3721"
                  },
                  {
                        "id": 3722,
                        "displayName": "year_3722"
                  },
                  {
                        "id": 3723,
                        "displayName": "year_3723"
                  },
                  {
                        "id": 3724,
                        "displayName": "year_3724"
                  },
                  {
                        "id": 3725,
                        "displayName": "year_3725"
                  },
                  {
                        "id": 3726,
                        "displayName": "year_3726"
                  },
                  {
                        "id": 3727,
                        "displayName": "year_3727"
                  },
                  {
                        "id": 3728,
                        "displayName": "year_3728"
                  },
                  {
                        "id": 3729,
                        "displayName": "year_3729"
                  },
                  {
                        "id": 3730,
                        "displayName": "year_3730"
                  },
                  {
                        "id": 3731,
                        "displayName": "year_3731"
                  },
                  {
                        "id": 3732,
                        "displayName": "year_3732"
                  },
                  {
                        "id": 3733,
                        "displayName": "year_3733"
                  },
                  {
                        "id": 3734,
                        "displayName": "year_3734"
                  },
                  {
                        "id": 3735,
                        "displayName": "year_3735"
                  },
                  {
                        "id": 3736,
                        "displayName": "year_3736"
                  },
                  {
                        "id": 3737,
                        "displayName": "year_3737"
                  },
                  {
                        "id": 3738,
                        "displayName": "year_3738"
                  },
                  {
                        "id": 3739,
                        "displayName": "year_3739"
                  },
                  {
                        "id": 3740,
                        "displayName": "year_3740"
                  },
                  {
                        "id": 3741,
                        "displayName": "year_3741"
                  },
                  {
                        "id": 3742,
                        "displayName": "year_3742"
                  },
                  {
                        "id": 3743,
                        "displayName": "year_3743"
                  },
                  {
                        "id": 3744,
                        "displayName": "year_3744"
                  },
                  {
                        "id": 3745,
                        "displayName": "year_3745"
                  },
                  {
                        "id": 3746,
                        "displayName": "year_3746"
                  },
                  {
                        "id": 3747,
                        "displayName": "year_3747"
                  },
                  {
                        "id": 3748,
                        "displayName": "year_3748"
                  },
                  {
                        "id": 3749,
                        "displayName": "year_3749"
                  },
                  {
                        "id": 3750,
                        "displayName": "year_3750"
                  },
                  {
                        "id": 3751,
                        "displayName": "year_3751"
                  },
                  {
                        "id": 3752,
                        "displayName": "year_3752"
                  },
                  {
                        "id": 3753,
                        "displayName": "year_3753"
                  },
                  {
                        "id": 3754,
                        "displayName": "year_3754"
                  },
                  {
                        "id": 3755,
                        "displayName": "year_3755"
                  },
                  {
                        "id": 3756,
                        "displayName": "year_3756"
                  },
                  {
                        "id": 3757,
                        "displayName": "year_3757"
                  },
                  {
                        "id": 3758,
                        "displayName": "year_3758"
                  },
                  {
                        "id": 3759,
                        "displayName": "year_3759"
                  },
                  {
                        "id": 3760,
                        "displayName": "year_3760"
                  },
                  {
                        "id": 3761,
                        "displayName": "year_3761"
                  },
                  {
                        "id": 3762,
                        "displayName": "year_3762"
                  },
                  {
                        "id": 3763,
                        "displayName": "year_3763"
                  },
                  {
                        "id": 3764,
                        "displayName": "year_3764"
                  },
                  {
                        "id": 3765,
                        "displayName": "year_3765"
                  },
                  {
                        "id": 3766,
                        "displayName": "year_3766"
                  },
                  {
                        "id": 3767,
                        "displayName": "year_3767"
                  },
                  {
                        "id": 3768,
                        "displayName": "year_3768"
                  },
                  {
                        "id": 3769,
                        "displayName": "year_3769"
                  },
                  {
                        "id": 3770,
                        "displayName": "year_3770"
                  },
                  {
                        "id": 3771,
                        "displayName": "year_3771"
                  },
                  {
                        "id": 3772,
                        "displayName": "year_3772"
                  },
                  {
                        "id": 3773,
                        "displayName": "year_3773"
                  },
                  {
                        "id": 3774,
                        "displayName": "year_3774"
                  },
                  {
                        "id": 3775,
                        "displayName": "year_3775"
                  },
                  {
                        "id": 3776,
                        "displayName": "year_3776"
                  },
                  {
                        "id": 3777,
                        "displayName": "year_3777"
                  },
                  {
                        "id": 3778,
                        "displayName": "year_3778"
                  },
                  {
                        "id": 3779,
                        "displayName": "year_3779"
                  },
                  {
                        "id": 3780,
                        "displayName": "year_3780"
                  },
                  {
                        "id": 3781,
                        "displayName": "year_3781"
                  },
                  {
                        "id": 3782,
                        "displayName": "year_3782"
                  },
                  {
                        "id": 3783,
                        "displayName": "year_3783"
                  },
                  {
                        "id": 3784,
                        "displayName": "year_3784"
                  },
                  {
                        "id": 3785,
                        "displayName": "year_3785"
                  },
                  {
                        "id": 3786,
                        "displayName": "year_3786"
                  },
                  {
                        "id": 3787,
                        "displayName": "year_3787"
                  },
                  {
                        "id": 3788,
                        "displayName": "year_3788"
                  },
                  {
                        "id": 3789,
                        "displayName": "year_3789"
                  },
                  {
                        "id": 3790,
                        "displayName": "year_3790"
                  },
                  {
                        "id": 3791,
                        "displayName": "year_3791"
                  },
                  {
                        "id": 3792,
                        "displayName": "year_3792"
                  },
                  {
                        "id": 3793,
                        "displayName": "year_3793"
                  },
                  {
                        "id": 3794,
                        "displayName": "year_3794"
                  },
                  {
                        "id": 3795,
                        "displayName": "year_3795"
                  },
                  {
                        "id": 3796,
                        "displayName": "year_3796"
                  },
                  {
                        "id": 3797,
                        "displayName": "year_3797"
                  },
                  {
                        "id": 3798,
                        "displayName": "year_3798"
                  },
                  {
                        "id": 3799,
                        "displayName": "year_3799"
                  },
                  {
                        "id": 3800,
                        "displayName": "year_3800"
                  },
                  {
                        "id": 3801,
                        "displayName": "year_3801"
                  },
                  {
                        "id": 3802,
                        "displayName": "year_3802"
                  },
                  {
                        "id": 3803,
                        "displayName": "year_3803"
                  },
                  {
                        "id": 3804,
                        "displayName": "year_3804"
                  },
                  {
                        "id": 3805,
                        "displayName": "year_3805"
                  },
                  {
                        "id": 3806,
                        "displayName": "year_3806"
                  },
                  {
                        "id": 3807,
                        "displayName": "year_3807"
                  },
                  {
                        "id": 3808,
                        "displayName": "year_3808"
                  },
                  {
                        "id": 3809,
                        "displayName": "year_3809"
                  },
                  {
                        "id": 3810,
                        "displayName": "year_3810"
                  },
                  {
                        "id": 3811,
                        "displayName": "year_3811"
                  },
                  {
                        "id": 3812,
                        "displayName": "year_3812"
                  },
                  {
                        "id": 3813,
                        "displayName": "year_3813"
                  },
                  {
                        "id": 3814,
                        "displayName": "year_3814"
                  },
                  {
                        "id": 3815,
                        "displayName": "year_3815"
                  },
                  {
                        "id": 3816,
                        "displayName": "year_3816"
                  },
                  {
                        "id": 3817,
                        "displayName": "year_3817"
                  },
                  {
                        "id": 3818,
                        "displayName": "year_3818"
                  },
                  {
                        "id": 3819,
                        "displayName": "year_3819"
                  },
                  {
                        "id": 3820,
                        "displayName": "year_3820"
                  },
                  {
                        "id": 3821,
                        "displayName": "year_3821"
                  },
                  {
                        "id": 3822,
                        "displayName": "year_3822"
                  },
                  {
                        "id": 3823,
                        "displayName": "year_3823"
                  },
                  {
                        "id": 3824,
                        "displayName": "year_3824"
                  },
                  {
                        "id": 3825,
                        "displayName": "year_3825"
                  },
                  {
                        "id": 3826,
                        "displayName": "year_3826"
                  },
                  {
                        "id": 3827,
                        "displayName": "year_3827"
                  },
                  {
                        "id": 3828,
                        "displayName": "year_3828"
                  },
                  {
                        "id": 3829,
                        "displayName": "year_3829"
                  },
                  {
                        "id": 3830,
                        "displayName": "year_3830"
                  },
                  {
                        "id": 3831,
                        "displayName": "year_3831"
                  },
                  {
                        "id": 3832,
                        "displayName": "year_3832"
                  },
                  {
                        "id": 3833,
                        "displayName": "year_3833"
                  },
                  {
                        "id": 3834,
                        "displayName": "year_3834"
                  },
                  {
                        "id": 3835,
                        "displayName": "year_3835"
                  },
                  {
                        "id": 3836,
                        "displayName": "year_3836"
                  },
                  {
                        "id": 3837,
                        "displayName": "year_3837"
                  },
                  {
                        "id": 3838,
                        "displayName": "year_3838"
                  },
                  {
                        "id": 3839,
                        "displayName": "year_3839"
                  },
                  {
                        "id": 3840,
                        "displayName": "year_3840"
                  },
                  {
                        "id": 3841,
                        "displayName": "year_3841"
                  },
                  {
                        "id": 3842,
                        "displayName": "year_3842"
                  },
                  {
                        "id": 3843,
                        "displayName": "year_3843"
                  },
                  {
                        "id": 3844,
                        "displayName": "year_3844"
                  },
                  {
                        "id": 3845,
                        "displayName": "year_3845"
                  },
                  {
                        "id": 3846,
                        "displayName": "year_3846"
                  },
                  {
                        "id": 3847,
                        "displayName": "year_3847"
                  },
                  {
                        "id": 3848,
                        "displayName": "year_3848"
                  },
                  {
                        "id": 3849,
                        "displayName": "year_3849"
                  },
                  {
                        "id": 3850,
                        "displayName": "year_3850"
                  },
                  {
                        "id": 3851,
                        "displayName": "year_3851"
                  },
                  {
                        "id": 3852,
                        "displayName": "year_3852"
                  },
                  {
                        "id": 3853,
                        "displayName": "year_3853"
                  },
                  {
                        "id": 3854,
                        "displayName": "year_3854"
                  },
                  {
                        "id": 3855,
                        "displayName": "year_3855"
                  },
                  {
                        "id": 3856,
                        "displayName": "year_3856"
                  },
                  {
                        "id": 3857,
                        "displayName": "year_3857"
                  },
                  {
                        "id": 3858,
                        "displayName": "year_3858"
                  },
                  {
                        "id": 3859,
                        "displayName": "year_3859"
                  },
                  {
                        "id": 3860,
                        "displayName": "year_3860"
                  },
                  {
                        "id": 3861,
                        "displayName": "year_3861"
                  },
                  {
                        "id": 3862,
                        "displayName": "year_3862"
                  },
                  {
                        "id": 3863,
                        "displayName": "year_3863"
                  },
                  {
                        "id": 3864,
                        "displayName": "year_3864"
                  },
                  {
                        "id": 3865,
                        "displayName": "year_3865"
                  },
                  {
                        "id": 3866,
                        "displayName": "year_3866"
                  },
                  {
                        "id": 3867,
                        "displayName": "year_3867"
                  },
                  {
                        "id": 3868,
                        "displayName": "year_3868"
                  },
                  {
                        "id": 3869,
                        "displayName": "year_3869"
                  },
                  {
                        "id": 3870,
                        "displayName": "year_3870"
                  },
                  {
                        "id": 3871,
                        "displayName": "year_3871"
                  },
                  {
                        "id": 3872,
                        "displayName": "year_3872"
                  },
                  {
                        "id": 3873,
                        "displayName": "year_3873"
                  },
                  {
                        "id": 3874,
                        "displayName": "year_3874"
                  },
                  {
                        "id": 3875,
                        "displayName": "year_3875"
                  },
                  {
                        "id": 3876,
                        "displayName": "year_3876"
                  },
                  {
                        "id": 3877,
                        "displayName": "year_3877"
                  },
                  {
                        "id": 3878,
                        "displayName": "year_3878"
                  },
                  {
                        "id": 3879,
                        "displayName": "year_3879"
                  },
                  {
                        "id": 3880,
                        "displayName": "year_3880"
                  },
                  {
                        "id": 3881,
                        "displayName": "year_3881"
                  },
                  {
                        "id": 3882,
                        "displayName": "year_3882"
                  },
                  {
                        "id": 3883,
                        "displayName": "year_3883"
                  },
                  {
                        "id": 3884,
                        "displayName": "year_3884"
                  },
                  {
                        "id": 3885,
                        "displayName": "year_3885"
                  },
                  {
                        "id": 3886,
                        "displayName": "year_3886"
                  },
                  {
                        "id": 3887,
                        "displayName": "year_3887"
                  },
                  {
                        "id": 3888,
                        "displayName": "year_3888"
                  },
                  {
                        "id": 3889,
                        "displayName": "year_3889"
                  },
                  {
                        "id": 3890,
                        "displayName": "year_3890"
                  },
                  {
                        "id": 3891,
                        "displayName": "year_3891"
                  },
                  {
                        "id": 3892,
                        "displayName": "year_3892"
                  },
                  {
                        "id": 3893,
                        "displayName": "year_3893"
                  },
                  {
                        "id": 3894,
                        "displayName": "year_3894"
                  },
                  {
                        "id": 3895,
                        "displayName": "year_3895"
                  },
                  {
                        "id": 3896,
                        "displayName": "year_3896"
                  },
                  {
                        "id": 3897,
                        "displayName": "year_3897"
                  },
                  {
                        "id": 3898,
                        "displayName": "year_3898"
                  },
                  {
                        "id": 3899,
                        "displayName": "year_3899"
                  },
                  {
                        "id": 3900,
                        "displayName": "year_3900"
                  },
                  {
                        "id": 3901,
                        "displayName": "year_3901"
                  },
                  {
                        "id": 3902,
                        "displayName": "year_3902"
                  },
                  {
                        "id": 3903,
                        "displayName": "year_3903"
                  },
                  {
                        "id": 3904,
                        "displayName": "year_3904"
                  },
                  {
                        "id": 3905,
                        "displayName": "year_3905"
                  },
                  {
                        "id": 3906,
                        "displayName": "year_3906"
                  },
                  {
                        "id": 3907,
                        "displayName": "year_3907"
                  },
                  {
                        "id": 3908,
                        "displayName": "year_3908"
                  },
                  {
                        "id": 3909,
                        "displayName": "year_3909"
                  },
                  {
                        "id": 3910,
                        "displayName": "year_3910"
                  },
                  {
                        "id": 3911,
                        "displayName": "year_3911"
                  },
                  {
                        "id": 3912,
                        "displayName": "year_3912"
                  },
                  {
                        "id": 3913,
                        "displayName": "year_3913"
                  },
                  {
                        "id": 3914,
                        "displayName": "year_3914"
                  },
                  {
                        "id": 3915,
                        "displayName": "year_3915"
                  },
                  {
                        "id": 3916,
                        "displayName": "year_3916"
                  },
                  {
                        "id": 3917,
                        "displayName": "year_3917"
                  },
                  {
                        "id": 3918,
                        "displayName": "year_3918"
                  },
                  {
                        "id": 3919,
                        "displayName": "year_3919"
                  },
                  {
                        "id": 3920,
                        "displayName": "year_3920"
                  },
                  {
                        "id": 3921,
                        "displayName": "year_3921"
                  },
                  {
                        "id": 3922,
                        "displayName": "year_3922"
                  },
                  {
                        "id": 3923,
                        "displayName": "year_3923"
                  },
                  {
                        "id": 3924,
                        "displayName": "year_3924"
                  },
                  {
                        "id": 3925,
                        "displayName": "year_3925"
                  },
                  {
                        "id": 3926,
                        "displayName": "year_3926"
                  },
                  {
                        "id": 3927,
                        "displayName": "year_3927"
                  },
                  {
                        "id": 3928,
                        "displayName": "year_3928"
                  },
                  {
                        "id": 3929,
                        "displayName": "year_3929"
                  },
                  {
                        "id": 3930,
                        "displayName": "year_3930"
                  },
                  {
                        "id": 3931,
                        "displayName": "year_3931"
                  },
                  {
                        "id": 3932,
                        "displayName": "year_3932"
                  },
                  {
                        "id": 3933,
                        "displayName": "year_3933"
                  },
                  {
                        "id": 3934,
                        "displayName": "year_3934"
                  },
                  {
                        "id": 3935,
                        "displayName": "year_3935"
                  },
                  {
                        "id": 3936,
                        "displayName": "year_3936"
                  },
                  {
                        "id": 3937,
                        "displayName": "year_3937"
                  },
                  {
                        "id": 3938,
                        "displayName": "year_3938"
                  },
                  {
                        "id": 3939,
                        "displayName": "year_3939"
                  },
                  {
                        "id": 3940,
                        "displayName": "year_3940"
                  },
                  {
                        "id": 3941,
                        "displayName": "year_3941"
                  },
                  {
                        "id": 3942,
                        "displayName": "year_3942"
                  },
                  {
                        "id": 3943,
                        "displayName": "year_3943"
                  },
                  {
                        "id": 3944,
                        "displayName": "year_3944"
                  },
                  {
                        "id": 3945,
                        "displayName": "year_3945"
                  },
                  {
                        "id": 3946,
                        "displayName": "year_3946"
                  },
                  {
                        "id": 3947,
                        "displayName": "year_3947"
                  },
                  {
                        "id": 3948,
                        "displayName": "year_3948"
                  },
                  {
                        "id": 3949,
                        "displayName": "year_3949"
                  },
                  {
                        "id": 3950,
                        "displayName": "year_3950"
                  },
                  {
                        "id": 3951,
                        "displayName": "year_3951"
                  },
                  {
                        "id": 3952,
                        "displayName": "year_3952"
                  },
                  {
                        "id": 3953,
                        "displayName": "year_3953"
                  },
                  {
                        "id": 3954,
                        "displayName": "year_3954"
                  },
                  {
                        "id": 3955,
                        "displayName": "year_3955"
                  },
                  {
                        "id": 3956,
                        "displayName": "year_3956"
                  },
                  {
                        "id": 3957,
                        "displayName": "year_3957"
                  },
                  {
                        "id": 3958,
                        "displayName": "year_3958"
                  },
                  {
                        "id": 3959,
                        "displayName": "year_3959"
                  },
                  {
                        "id": 3960,
                        "displayName": "year_3960"
                  },
                  {
                        "id": 3961,
                        "displayName": "year_3961"
                  },
                  {
                        "id": 3962,
                        "displayName": "year_3962"
                  },
                  {
                        "id": 3963,
                        "displayName": "year_3963"
                  },
                  {
                        "id": 3964,
                        "displayName": "year_3964"
                  },
                  {
                        "id": 3965,
                        "displayName": "year_3965"
                  },
                  {
                        "id": 3966,
                        "displayName": "year_3966"
                  },
                  {
                        "id": 3967,
                        "displayName": "year_3967"
                  },
                  {
                        "id": 3968,
                        "displayName": "year_3968"
                  },
                  {
                        "id": 3969,
                        "displayName": "year_3969"
                  },
                  {
                        "id": 3970,
                        "displayName": "year_3970"
                  },
                  {
                        "id": 3971,
                        "displayName": "year_3971"
                  },
                  {
                        "id": 3972,
                        "displayName": "year_3972"
                  },
                  {
                        "id": 3973,
                        "displayName": "year_3973"
                  },
                  {
                        "id": 3974,
                        "displayName": "year_3974"
                  },
                  {
                        "id": 3975,
                        "displayName": "year_3975"
                  },
                  {
                        "id": 3976,
                        "displayName": "year_3976"
                  },
                  {
                        "id": 3977,
                        "displayName": "year_3977"
                  },
                  {
                        "id": 3978,
                        "displayName": "year_3978"
                  },
                  {
                        "id": 3979,
                        "displayName": "year_3979"
                  },
                  {
                        "id": 3980,
                        "displayName": "year_3980"
                  },
                  {
                        "id": 3981,
                        "displayName": "year_3981"
                  },
                  {
                        "id": 3982,
                        "displayName": "year_3982"
                  },
                  {
                        "id": 3983,
                        "displayName": "year_3983"
                  },
                  {
                        "id": 3984,
                        "displayName": "year_3984"
                  },
                  {
                        "id": 3985,
                        "displayName": "year_3985"
                  },
                  {
                        "id": 3986,
                        "displayName": "year_3986"
                  },
                  {
                        "id": 3987,
                        "displayName": "year_3987"
                  },
                  {
                        "id": 3988,
                        "displayName": "year_3988"
                  },
                  {
                        "id": 3989,
                        "displayName": "year_3989"
                  },
                  {
                        "id": 3990,
                        "displayName": "year_3990"
                  },
                  {
                        "id": 3991,
                        "displayName": "year_3991"
                  },
                  {
                        "id": 3992,
                        "displayName": "year_3992"
                  },
                  {
                        "id": 3993,
                        "displayName": "year_3993"
                  },
                  {
                        "id": 3994,
                        "displayName": "year_3994"
                  },
                  {
                        "id": 3995,
                        "displayName": "year_3995"
                  },
                  {
                        "id": 3996,
                        "displayName": "year_3996"
                  },
                  {
                        "id": 3997,
                        "displayName": "year_3997"
                  },
                  {
                        "id": 3998,
                        "displayName": "year_3998"
                  },
                  {
                        "id": 3999,
                        "displayName": "year_3999"
                  },
                  {
                        "id": 4000,
                        "displayName": "year_4000"
                  },
                  {
                        "id": 4001,
                        "displayName": "year_4001"
                  },
                  {
                        "id": 4002,
                        "displayName": "year_4002"
                  },
                  {
                        "id": 4003,
                        "displayName": "year_4003"
                  },
                  {
                        "id": 4004,
                        "displayName": "year_4004"
                  },
                  {
                        "id": 4005,
                        "displayName": "year_4005"
                  },
                  {
                        "id": 4006,
                        "displayName": "year_4006"
                  },
                  {
                        "id": 4007,
                        "displayName": "year_4007"
                  },
                  {
                        "id": 4008,
                        "displayName": "year_4008"
                  },
                  {
                        "id": 4009,
                        "displayName": "year_4009"
                  },
                  {
                        "id": 4010,
                        "displayName": "year_4010"
                  },
                  {
                        "id": 4011,
                        "displayName": "year_4011"
                  },
                  {
                        "id": 4012,
                        "displayName": "year_4012"
                  },
                  {
                        "id": 4013,
                        "displayName": "year_4013"
                  },
                  {
                        "id": 4014,
                        "displayName": "year_4014"
                  },
                  {
                        "id": 4015,
                        "displayName": "year_4015"
                  },
                  {
                        "id": 4016,
                        "displayName": "year_4016"
                  },
                  {
                        "id": 4017,
                        "displayName": "year_4017"
                  },
                  {
                        "id": 4018,
                        "displayName": "year_4018"
                  },
                  {
                        "id": 4019,
                        "displayName": "year_4019"
                  },
                  {
                        "id": 4020,
                        "displayName": "year_4020"
                  },
                  {
                        "id": 4021,
                        "displayName": "year_4021"
                  },
                  {
                        "id": 4022,
                        "displayName": "year_4022"
                  },
                  {
                        "id": 4023,
                        "displayName": "year_4023"
                  },
                  {
                        "id": 4024,
                        "displayName": "year_4024"
                  },
                  {
                        "id": 4025,
                        "displayName": "year_4025"
                  },
                  {
                        "id": 4026,
                        "displayName": "year_4026"
                  },
                  {
                        "id": 4027,
                        "displayName": "year_4027"
                  },
                  {
                        "id": 4028,
                        "displayName": "year_4028"
                  },
                  {
                        "id": 4029,
                        "displayName": "year_4029"
                  },
                  {
                        "id": 4030,
                        "displayName": "year_4030"
                  },
                  {
                        "id": 4031,
                        "displayName": "year_4031"
                  },
                  {
                        "id": 4032,
                        "displayName": "year_4032"
                  },
                  {
                        "id": 4033,
                        "displayName": "year_4033"
                  },
                  {
                        "id": 4034,
                        "displayName": "year_4034"
                  },
                  {
                        "id": 4035,
                        "displayName": "year_4035"
                  },
                  {
                        "id": 4036,
                        "displayName": "year_4036"
                  },
                  {
                        "id": 4037,
                        "displayName": "year_4037"
                  },
                  {
                        "id": 4038,
                        "displayName": "year_4038"
                  },
                  {
                        "id": 4039,
                        "displayName": "year_4039"
                  },
                  {
                        "id": 4040,
                        "displayName": "year_4040"
                  },
                  {
                        "id": 4041,
                        "displayName": "year_4041"
                  },
                  {
                        "id": 4042,
                        "displayName": "year_4042"
                  },
                  {
                        "id": 4043,
                        "displayName": "year_4043"
                  },
                  {
                        "id": 4044,
                        "displayName": "year_4044"
                  },
                  {
                        "id": 4045,
                        "displayName": "year_4045"
                  },
                  {
                        "id": 4046,
                        "displayName": "year_4046"
                  },
                  {
                        "id": 4047,
                        "displayName": "year_4047"
                  },
                  {
                        "id": 4048,
                        "displayName": "year_4048"
                  },
                  {
                        "id": 4049,
                        "displayName": "year_4049"
                  },
                  {
                        "id": 4050,
                        "displayName": "year_4050"
                  },
                  {
                        "id": 4051,
                        "displayName": "year_4051"
                  },
                  {
                        "id": 4052,
                        "displayName": "year_4052"
                  },
                  {
                        "id": 4053,
                        "displayName": "year_4053"
                  },
                  {
                        "id": 4054,
                        "displayName": "year_4054"
                  },
                  {
                        "id": 4055,
                        "displayName": "year_4055"
                  },
                  {
                        "id": 4056,
                        "displayName": "year_4056"
                  },
                  {
                        "id": 4057,
                        "displayName": "year_4057"
                  },
                  {
                        "id": 4058,
                        "displayName": "year_4058"
                  },
                  {
                        "id": 4059,
                        "displayName": "year_4059"
                  },
                  {
                        "id": 4060,
                        "displayName": "year_4060"
                  },
                  {
                        "id": 4061,
                        "displayName": "year_4061"
                  },
                  {
                        "id": 4062,
                        "displayName": "year_4062"
                  },
                  {
                        "id": 4063,
                        "displayName": "year_4063"
                  },
                  {
                        "id": 4064,
                        "displayName": "year_4064"
                  },
                  {
                        "id": 4065,
                        "displayName": "year_4065"
                  },
                  {
                        "id": 4066,
                        "displayName": "year_4066"
                  },
                  {
                        "id": 4067,
                        "displayName": "year_4067"
                  },
                  {
                        "id": 4068,
                        "displayName": "year_4068"
                  },
                  {
                        "id": 4069,
                        "displayName": "year_4069"
                  },
                  {
                        "id": 4070,
                        "displayName": "year_4070"
                  },
                  {
                        "id": 4071,
                        "displayName": "year_4071"
                  },
                  {
                        "id": 4072,
                        "displayName": "year_4072"
                  },
                  {
                        "id": 4073,
                        "displayName": "year_4073"
                  },
                  {
                        "id": 4074,
                        "displayName": "year_4074"
                  },
                  {
                        "id": 4075,
                        "displayName": "year_4075"
                  },
                  {
                        "id": 4076,
                        "displayName": "year_4076"
                  },
                  {
                        "id": 4077,
                        "displayName": "year_4077"
                  },
                  {
                        "id": 4078,
                        "displayName": "year_4078"
                  },
                  {
                        "id": 4079,
                        "displayName": "year_4079"
                  },
                  {
                        "id": 4080,
                        "displayName": "year_4080"
                  },
                  {
                        "id": 4081,
                        "displayName": "year_4081"
                  },
                  {
                        "id": 4082,
                        "displayName": "year_4082"
                  },
                  {
                        "id": 4083,
                        "displayName": "year_4083"
                  },
                  {
                        "id": 4084,
                        "displayName": "year_4084"
                  },
                  {
                        "id": 4085,
                        "displayName": "year_4085"
                  },
                  {
                        "id": 4086,
                        "displayName": "year_4086"
                  },
                  {
                        "id": 4087,
                        "displayName": "year_4087"
                  },
                  {
                        "id": 4088,
                        "displayName": "year_4088"
                  },
                  {
                        "id": 4089,
                        "displayName": "year_4089"
                  },
                  {
                        "id": 4090,
                        "displayName": "year_4090"
                  },
                  {
                        "id": 4091,
                        "displayName": "year_4091"
                  },
                  {
                        "id": 4092,
                        "displayName": "year_4092"
                  },
                  {
                        "id": 4093,
                        "displayName": "year_4093"
                  },
                  {
                        "id": 4094,
                        "displayName": "year_4094"
                  },
                  {
                        "id": 4095,
                        "displayName": "year_4095"
                  },
                  {
                        "id": 4096,
                        "displayName": "year_4096"
                  },
                  {
                        "id": 4097,
                        "displayName": "year_4097"
                  },
                  {
                        "id": 4098,
                        "displayName": "year_4098"
                  },
                  {
                        "id": 4099,
                        "displayName": "year_4099"
                  },
                  {
                        "id": 4100,
                        "displayName": "year_4100"
                  },
                  {
                        "id": 4101,
                        "displayName": "year_4101"
                  },
                  {
                        "id": 4102,
                        "displayName": "year_4102"
                  },
                  {
                        "id": 4103,
                        "displayName": "year_4103"
                  },
                  {
                        "id": 4104,
                        "displayName": "year_4104"
                  },
                  {
                        "id": 4105,
                        "displayName": "year_4105"
                  },
                  {
                        "id": 4106,
                        "displayName": "year_4106"
                  },
                  {
                        "id": 4107,
                        "displayName": "year_4107"
                  },
                  {
                        "id": 4108,
                        "displayName": "year_4108"
                  },
                  {
                        "id": 4109,
                        "displayName": "year_4109"
                  },
                  {
                        "id": 4110,
                        "displayName": "year_4110"
                  },
                  {
                        "id": 4111,
                        "displayName": "year_4111"
                  },
                  {
                        "id": 4112,
                        "displayName": "year_4112"
                  },
                  {
                        "id": 4113,
                        "displayName": "year_4113"
                  },
                  {
                        "id": 4114,
                        "displayName": "year_4114"
                  },
                  {
                        "id": 4115,
                        "displayName": "year_4115"
                  },
                  {
                        "id": 4116,
                        "displayName": "year_4116"
                  },
                  {
                        "id": 4117,
                        "displayName": "year_4117"
                  },
                  {
                        "id": 4118,
                        "displayName": "year_4118"
                  },
                  {
                        "id": 4119,
                        "displayName": "year_4119"
                  },
                  {
                        "id": 4120,
                        "displayName": "year_4120"
                  },
                  {
                        "id": 4121,
                        "displayName": "year_4121"
                  },
                  {
                        "id": 4122,
                        "displayName": "year_4122"
                  },
                  {
                        "id": 4123,
                        "displayName": "year_4123"
                  },
                  {
                        "id": 4124,
                        "displayName": "year_4124"
                  },
                  {
                        "id": 4125,
                        "displayName": "year_4125"
                  },
                  {
                        "id": 4126,
                        "displayName": "year_4126"
                  },
                  {
                        "id": 4127,
                        "displayName": "year_4127"
                  },
                  {
                        "id": 4128,
                        "displayName": "year_4128"
                  },
                  {
                        "id": 4129,
                        "displayName": "year_4129"
                  },
                  {
                        "id": 4130,
                        "displayName": "year_4130"
                  },
                  {
                        "id": 4131,
                        "displayName": "year_4131"
                  },
                  {
                        "id": 4132,
                        "displayName": "year_4132"
                  },
                  {
                        "id": 4133,
                        "displayName": "year_4133"
                  },
                  {
                        "id": 4134,
                        "displayName": "year_4134"
                  },
                  {
                        "id": 4135,
                        "displayName": "year_4135"
                  },
                  {
                        "id": 4136,
                        "displayName": "year_4136"
                  },
                  {
                        "id": 4137,
                        "displayName": "year_4137"
                  },
                  {
                        "id": 4138,
                        "displayName": "year_4138"
                  },
                  {
                        "id": 4139,
                        "displayName": "year_4139"
                  },
                  {
                        "id": 4140,
                        "displayName": "year_4140"
                  },
                  {
                        "id": 4141,
                        "displayName": "year_4141"
                  },
                  {
                        "id": 4142,
                        "displayName": "year_4142"
                  },
                  {
                        "id": 4143,
                        "displayName": "year_4143"
                  },
                  {
                        "id": 4144,
                        "displayName": "year_4144"
                  },
                  {
                        "id": 4145,
                        "displayName": "year_4145"
                  },
                  {
                        "id": 4146,
                        "displayName": "year_4146"
                  },
                  {
                        "id": 4147,
                        "displayName": "year_4147"
                  },
                  {
                        "id": 4148,
                        "displayName": "year_4148"
                  },
                  {
                        "id": 4149,
                        "displayName": "year_4149"
                  },
                  {
                        "id": 4150,
                        "displayName": "year_4150"
                  },
                  {
                        "id": 4151,
                        "displayName": "year_4151"
                  },
                  {
                        "id": 4152,
                        "displayName": "year_4152"
                  },
                  {
                        "id": 4153,
                        "displayName": "year_4153"
                  },
                  {
                        "id": 4154,
                        "displayName": "year_4154"
                  },
                  {
                        "id": 4155,
                        "displayName": "year_4155"
                  },
                  {
                        "id": 4156,
                        "displayName": "year_4156"
                  },
                  {
                        "id": 4157,
                        "displayName": "year_4157"
                  },
                  {
                        "id": 4158,
                        "displayName": "year_4158"
                  },
                  {
                        "id": 4159,
                        "displayName": "year_4159"
                  },
                  {
                        "id": 4160,
                        "displayName": "year_4160"
                  },
                  {
                        "id": 4161,
                        "displayName": "year_4161"
                  },
                  {
                        "id": 4162,
                        "displayName": "year_4162"
                  },
                  {
                        "id": 4163,
                        "displayName": "year_4163"
                  },
                  {
                        "id": 4164,
                        "displayName": "year_4164"
                  },
                  {
                        "id": 4165,
                        "displayName": "year_4165"
                  },
                  {
                        "id": 4166,
                        "displayName": "year_4166"
                  },
                  {
                        "id": 4167,
                        "displayName": "year_4167"
                  },
                  {
                        "id": 4168,
                        "displayName": "year_4168"
                  },
                  {
                        "id": 4169,
                        "displayName": "year_4169"
                  },
                  {
                        "id": 4170,
                        "displayName": "year_4170"
                  },
                  {
                        "id": 4171,
                        "displayName": "year_4171"
                  },
                  {
                        "id": 4172,
                        "displayName": "year_4172"
                  },
                  {
                        "id": 4173,
                        "displayName": "year_4173"
                  },
                  {
                        "id": 4174,
                        "displayName": "year_4174"
                  },
                  {
                        "id": 4175,
                        "displayName": "year_4175"
                  },
                  {
                        "id": 4176,
                        "displayName": "year_4176"
                  },
                  {
                        "id": 4177,
                        "displayName": "year_4177"
                  },
                  {
                        "id": 4178,
                        "displayName": "year_4178"
                  },
                  {
                        "id": 4179,
                        "displayName": "year_4179"
                  },
                  {
                        "id": 4180,
                        "displayName": "year_4180"
                  },
                  {
                        "id": 4181,
                        "displayName": "year_4181"
                  },
                  {
                        "id": 4182,
                        "displayName": "year_4182"
                  },
                  {
                        "id": 4183,
                        "displayName": "year_4183"
                  },
                  {
                        "id": 4184,
                        "displayName": "year_4184"
                  },
                  {
                        "id": 4185,
                        "displayName": "year_4185"
                  },
                  {
                        "id": 4186,
                        "displayName": "year_4186"
                  },
                  {
                        "id": 4187,
                        "displayName": "year_4187"
                  },
                  {
                        "id": 4188,
                        "displayName": "year_4188"
                  },
                  {
                        "id": 4189,
                        "displayName": "year_4189"
                  },
                  {
                        "id": 4190,
                        "displayName": "year_4190"
                  },
                  {
                        "id": 4191,
                        "displayName": "year_4191"
                  },
                  {
                        "id": 4192,
                        "displayName": "year_4192"
                  },
                  {
                        "id": 4193,
                        "displayName": "year_4193"
                  },
                  {
                        "id": 4194,
                        "displayName": "year_4194"
                  },
                  {
                        "id": 4195,
                        "displayName": "year_4195"
                  },
                  {
                        "id": 4196,
                        "displayName": "year_4196"
                  },
                  {
                        "id": 4197,
                        "displayName": "year_4197"
                  },
                  {
                        "id": 4198,
                        "displayName": "year_4198"
                  },
                  {
                        "id": 4199,
                        "displayName": "year_4199"
                  },
                  {
                        "id": 4200,
                        "displayName": "year_4200"
                  },
                  {
                        "id": 4201,
                        "displayName": "year_4201"
                  },
                  {
                        "id": 4202,
                        "displayName": "year_4202"
                  },
                  {
                        "id": 4203,
                        "displayName": "year_4203"
                  },
                  {
                        "id": 4204,
                        "displayName": "year_4204"
                  },
                  {
                        "id": 4205,
                        "displayName": "year_4205"
                  },
                  {
                        "id": 4206,
                        "displayName": "year_4206"
                  },
                  {
                        "id": 4207,
                        "displayName": "year_4207"
                  },
                  {
                        "id": 4208,
                        "displayName": "year_4208"
                  },
                  {
                        "id": 4209,
                        "displayName": "year_4209"
                  },
                  {
                        "id": 4210,
                        "displayName": "year_4210"
                  },
                  {
                        "id": 4211,
                        "displayName": "year_4211"
                  },
                  {
                        "id": 4212,
                        "displayName": "year_4212"
                  },
                  {
                        "id": 4213,
                        "displayName": "year_4213"
                  },
                  {
                        "id": 4214,
                        "displayName": "year_4214"
                  },
                  {
                        "id": 4215,
                        "displayName": "year_4215"
                  },
                  {
                        "id": 4216,
                        "displayName": "year_4216"
                  },
                  {
                        "id": 4217,
                        "displayName": "year_4217"
                  },
                  {
                        "id": 4218,
                        "displayName": "year_4218"
                  },
                  {
                        "id": 4219,
                        "displayName": "year_4219"
                  },
                  {
                        "id": 4220,
                        "displayName": "year_4220"
                  },
                  {
                        "id": 4221,
                        "displayName": "year_4221"
                  },
                  {
                        "id": 4222,
                        "displayName": "year_4222"
                  },
                  {
                        "id": 4223,
                        "displayName": "year_4223"
                  },
                  {
                        "id": 4224,
                        "displayName": "year_4224"
                  },
                  {
                        "id": 4225,
                        "displayName": "year_4225"
                  },
                  {
                        "id": 4226,
                        "displayName": "year_4226"
                  },
                  {
                        "id": 4227,
                        "displayName": "year_4227"
                  },
                  {
                        "id": 4228,
                        "displayName": "year_4228"
                  },
                  {
                        "id": 4229,
                        "displayName": "year_4229"
                  },
                  {
                        "id": 4230,
                        "displayName": "year_4230"
                  },
                  {
                        "id": 4231,
                        "displayName": "year_4231"
                  },
                  {
                        "id": 4232,
                        "displayName": "year_4232"
                  },
                  {
                        "id": 4233,
                        "displayName": "year_4233"
                  },
                  {
                        "id": 4234,
                        "displayName": "year_4234"
                  },
                  {
                        "id": 4235,
                        "displayName": "year_4235"
                  },
                  {
                        "id": 4236,
                        "displayName": "year_4236"
                  },
                  {
                        "id": 4237,
                        "displayName": "year_4237"
                  },
                  {
                        "id": 4238,
                        "displayName": "year_4238"
                  },
                  {
                        "id": 4239,
                        "displayName": "year_4239"
                  },
                  {
                        "id": 4240,
                        "displayName": "year_4240"
                  },
                  {
                        "id": 4241,
                        "displayName": "year_4241"
                  },
                  {
                        "id": 4242,
                        "displayName": "year_4242"
                  },
                  {
                        "id": 4243,
                        "displayName": "year_4243"
                  },
                  {
                        "id": 4244,
                        "displayName": "year_4244"
                  },
                  {
                        "id": 4245,
                        "displayName": "year_4245"
                  },
                  {
                        "id": 4246,
                        "displayName": "year_4246"
                  },
                  {
                        "id": 4247,
                        "displayName": "year_4247"
                  },
                  {
                        "id": 4248,
                        "displayName": "year_4248"
                  },
                  {
                        "id": 4249,
                        "displayName": "year_4249"
                  },
                  {
                        "id": 4250,
                        "displayName": "year_4250"
                  },
                  {
                        "id": 4251,
                        "displayName": "year_4251"
                  },
                  {
                        "id": 4252,
                        "displayName": "year_4252"
                  },
                  {
                        "id": 4253,
                        "displayName": "year_4253"
                  },
                  {
                        "id": 4254,
                        "displayName": "year_4254"
                  },
                  {
                        "id": 4255,
                        "displayName": "year_4255"
                  },
                  {
                        "id": 4256,
                        "displayName": "year_4256"
                  },
                  {
                        "id": 4257,
                        "displayName": "year_4257"
                  },
                  {
                        "id": 4258,
                        "displayName": "year_4258"
                  },
                  {
                        "id": 4259,
                        "displayName": "year_4259"
                  },
                  {
                        "id": 4260,
                        "displayName": "year_4260"
                  },
                  {
                        "id": 4261,
                        "displayName": "year_4261"
                  },
                  {
                        "id": 4262,
                        "displayName": "year_4262"
                  },
                  {
                        "id": 4263,
                        "displayName": "year_4263"
                  },
                  {
                        "id": 4264,
                        "displayName": "year_4264"
                  },
                  {
                        "id": 4265,
                        "displayName": "year_4265"
                  },
                  {
                        "id": 4266,
                        "displayName": "year_4266"
                  },
                  {
                        "id": 4267,
                        "displayName": "year_4267"
                  },
                  {
                        "id": 4268,
                        "displayName": "year_4268"
                  },
                  {
                        "id": 4269,
                        "displayName": "year_4269"
                  },
                  {
                        "id": 4270,
                        "displayName": "year_4270"
                  },
                  {
                        "id": 4271,
                        "displayName": "year_4271"
                  },
                  {
                        "id": 4272,
                        "displayName": "year_4272"
                  },
                  {
                        "id": 4273,
                        "displayName": "year_4273"
                  },
                  {
                        "id": 4274,
                        "displayName": "year_4274"
                  },
                  {
                        "id": 4275,
                        "displayName": "year_4275"
                  },
                  {
                        "id": 4276,
                        "displayName": "year_4276"
                  },
                  {
                        "id": 4277,
                        "displayName": "year_4277"
                  },
                  {
                        "id": 4278,
                        "displayName": "year_4278"
                  },
                  {
                        "id": 4279,
                        "displayName": "year_4279"
                  },
                  {
                        "id": 4280,
                        "displayName": "year_4280"
                  },
                  {
                        "id": 4281,
                        "displayName": "year_4281"
                  },
                  {
                        "id": 4282,
                        "displayName": "year_4282"
                  },
                  {
                        "id": 4283,
                        "displayName": "year_4283"
                  },
                  {
                        "id": 4284,
                        "displayName": "year_4284"
                  },
                  {
                        "id": 4285,
                        "displayName": "year_4285"
                  },
                  {
                        "id": 4286,
                        "displayName": "year_4286"
                  },
                  {
                        "id": 4287,
                        "displayName": "year_4287"
                  },
                  {
                        "id": 4288,
                        "displayName": "year_4288"
                  },
                  {
                        "id": 4289,
                        "displayName": "year_4289"
                  },
                  {
                        "id": 4290,
                        "displayName": "year_4290"
                  },
                  {
                        "id": 4291,
                        "displayName": "year_4291"
                  },
                  {
                        "id": 4292,
                        "displayName": "year_4292"
                  },
                  {
                        "id": 4293,
                        "displayName": "year_4293"
                  },
                  {
                        "id": 4294,
                        "displayName": "year_4294"
                  },
                  {
                        "id": 4295,
                        "displayName": "year_4295"
                  },
                  {
                        "id": 4296,
                        "displayName": "year_4296"
                  },
                  {
                        "id": 4297,
                        "displayName": "year_4297"
                  },
                  {
                        "id": 4298,
                        "displayName": "year_4298"
                  },
                  {
                        "id": 4299,
                        "displayName": "year_4299"
                  },
                  {
                        "id": 4300,
                        "displayName": "year_4300"
                  },
                  {
                        "id": 4301,
                        "displayName": "year_4301"
                  },
                  {
                        "id": 4302,
                        "displayName": "year_4302"
                  },
                  {
                        "id": 4303,
                        "displayName": "year_4303"
                  },
                  {
                        "id": 4304,
                        "displayName": "year_4304"
                  },
                  {
                        "id": 4305,
                        "displayName": "year_4305"
                  },
                  {
                        "id": 4306,
                        "displayName": "year_4306"
                  },
                  {
                        "id": 4307,
                        "displayName": "year_4307"
                  },
                  {
                        "id": 4308,
                        "displayName": "year_4308"
                  },
                  {
                        "id": 4309,
                        "displayName": "year_4309"
                  },
                  {
                        "id": 4310,
                        "displayName": "year_4310"
                  },
                  {
                        "id": 4311,
                        "displayName": "year_4311"
                  },
                  {
                        "id": 4312,
                        "displayName": "year_4312"
                  },
                  {
                        "id": 4313,
                        "displayName": "year_4313"
                  },
                  {
                        "id": 4314,
                        "displayName": "year_4314"
                  },
                  {
                        "id": 4315,
                        "displayName": "year_4315"
                  },
                  {
                        "id": 4316,
                        "displayName": "year_4316"
                  },
                  {
                        "id": 4317,
                        "displayName": "year_4317"
                  },
                  {
                        "id": 4318,
                        "displayName": "year_4318"
                  },
                  {
                        "id": 4319,
                        "displayName": "year_4319"
                  },
                  {
                        "id": 4320,
                        "displayName": "year_4320"
                  },
                  {
                        "id": 4321,
                        "displayName": "year_4321"
                  },
                  {
                        "id": 4322,
                        "displayName": "year_4322"
                  },
                  {
                        "id": 4323,
                        "displayName": "year_4323"
                  },
                  {
                        "id": 4324,
                        "displayName": "year_4324"
                  },
                  {
                        "id": 4325,
                        "displayName": "year_4325"
                  },
                  {
                        "id": 4326,
                        "displayName": "year_4326"
                  },
                  {
                        "id": 4327,
                        "displayName": "year_4327"
                  },
                  {
                        "id": 4328,
                        "displayName": "year_4328"
                  },
                  {
                        "id": 4329,
                        "displayName": "year_4329"
                  },
                  {
                        "id": 4330,
                        "displayName": "year_4330"
                  },
                  {
                        "id": 4331,
                        "displayName": "year_4331"
                  },
                  {
                        "id": 4332,
                        "displayName": "year_4332"
                  },
                  {
                        "id": 4333,
                        "displayName": "year_4333"
                  },
                  {
                        "id": 4334,
                        "displayName": "year_4334"
                  },
                  {
                        "id": 4335,
                        "displayName": "year_4335"
                  },
                  {
                        "id": 4336,
                        "displayName": "year_4336"
                  },
                  {
                        "id": 4337,
                        "displayName": "year_4337"
                  },
                  {
                        "id": 4338,
                        "displayName": "year_4338"
                  },
                  {
                        "id": 4339,
                        "displayName": "year_4339"
                  },
                  {
                        "id": 4340,
                        "displayName": "year_4340"
                  },
                  {
                        "id": 4341,
                        "displayName": "year_4341"
                  },
                  {
                        "id": 4342,
                        "displayName": "year_4342"
                  },
                  {
                        "id": 4343,
                        "displayName": "year_4343"
                  },
                  {
                        "id": 4344,
                        "displayName": "year_4344"
                  },
                  {
                        "id": 4345,
                        "displayName": "year_4345"
                  },
                  {
                        "id": 4346,
                        "displayName": "year_4346"
                  },
                  {
                        "id": 4347,
                        "displayName": "year_4347"
                  },
                  {
                        "id": 4348,
                        "displayName": "year_4348"
                  },
                  {
                        "id": 4349,
                        "displayName": "year_4349"
                  },
                  {
                        "id": 4350,
                        "displayName": "year_4350"
                  },
                  {
                        "id": 4351,
                        "displayName": "year_4351"
                  },
                  {
                        "id": 4352,
                        "displayName": "year_4352"
                  },
                  {
                        "id": 4353,
                        "displayName": "year_4353"
                  },
                  {
                        "id": 4354,
                        "displayName": "year_4354"
                  },
                  {
                        "id": 4355,
                        "displayName": "year_4355"
                  },
                  {
                        "id": 4356,
                        "displayName": "year_4356"
                  },
                  {
                        "id": 4357,
                        "displayName": "year_4357"
                  },
                  {
                        "id": 4358,
                        "displayName": "year_4358"
                  },
                  {
                        "id": 4359,
                        "displayName": "year_4359"
                  },
                  {
                        "id": 4360,
                        "displayName": "year_4360"
                  },
                  {
                        "id": 4361,
                        "displayName": "year_4361"
                  },
                  {
                        "id": 4362,
                        "displayName": "year_4362"
                  },
                  {
                        "id": 4363,
                        "displayName": "year_4363"
                  },
                  {
                        "id": 4364,
                        "displayName": "year_4364"
                  },
                  {
                        "id": 4365,
                        "displayName": "year_4365"
                  },
                  {
                        "id": 4366,
                        "displayName": "year_4366"
                  },
                  {
                        "id": 4367,
                        "displayName": "year_4367"
                  },
                  {
                        "id": 4368,
                        "displayName": "year_4368"
                  },
                  {
                        "id": 4369,
                        "displayName": "year_4369"
                  },
                  {
                        "id": 4370,
                        "displayName": "year_4370"
                  },
                  {
                        "id": 4371,
                        "displayName": "year_4371"
                  },
                  {
                        "id": 4372,
                        "displayName": "year_4372"
                  },
                  {
                        "id": 4373,
                        "displayName": "year_4373"
                  },
                  {
                        "id": 4374,
                        "displayName": "year_4374"
                  },
                  {
                        "id": 4375,
                        "displayName": "year_4375"
                  },
                  {
                        "id": 4376,
                        "displayName": "year_4376"
                  },
                  {
                        "id": 4377,
                        "displayName": "year_4377"
                  },
                  {
                        "id": 4378,
                        "displayName": "year_4378"
                  },
                  {
                        "id": 4379,
                        "displayName": "year_4379"
                  },
                  {
                        "id": 4380,
                        "displayName": "year_4380"
                  },
                  {
                        "id": 4381,
                        "displayName": "year_4381"
                  },
                  {
                        "id": 4382,
                        "displayName": "year_4382"
                  },
                  {
                        "id": 4383,
                        "displayName": "year_4383"
                  },
                  {
                        "id": 4384,
                        "displayName": "year_4384"
                  },
                  {
                        "id": 4385,
                        "displayName": "year_4385"
                  },
                  {
                        "id": 4386,
                        "displayName": "year_4386"
                  },
                  {
                        "id": 4387,
                        "displayName": "year_4387"
                  },
                  {
                        "id": 4388,
                        "displayName": "year_4388"
                  },
                  {
                        "id": 4389,
                        "displayName": "year_4389"
                  },
                  {
                        "id": 4390,
                        "displayName": "year_4390"
                  },
                  {
                        "id": 4391,
                        "displayName": "year_4391"
                  },
                  {
                        "id": 4392,
                        "displayName": "year_4392"
                  },
                  {
                        "id": 4393,
                        "displayName": "year_4393"
                  },
                  {
                        "id": 4394,
                        "displayName": "year_4394"
                  },
                  {
                        "id": 4395,
                        "displayName": "year_4395"
                  },
                  {
                        "id": 4396,
                        "displayName": "year_4396"
                  },
                  {
                        "id": 4397,
                        "displayName": "year_4397"
                  },
                  {
                        "id": 4398,
                        "displayName": "year_4398"
                  },
                  {
                        "id": 4399,
                        "displayName": "year_4399"
                  },
                  {
                        "id": 4400,
                        "displayName": "year_4400"
                  },
                  {
                        "id": 4401,
                        "displayName": "year_4401"
                  },
                  {
                        "id": 4402,
                        "displayName": "year_4402"
                  },
                  {
                        "id": 4403,
                        "displayName": "year_4403"
                  },
                  {
                        "id": 4404,
                        "displayName": "year_4404"
                  },
                  {
                        "id": 4405,
                        "displayName": "year_4405"
                  },
                  {
                        "id": 4406,
                        "displayName": "year_4406"
                  },
                  {
                        "id": 4407,
                        "displayName": "year_4407"
                  },
                  {
                        "id": 4408,
                        "displayName": "year_4408"
                  },
                  {
                        "id": 4409,
                        "displayName": "year_4409"
                  },
                  {
                        "id": 4410,
                        "displayName": "year_4410"
                  },
                  {
                        "id": 4411,
                        "displayName": "year_4411"
                  },
                  {
                        "id": 4412,
                        "displayName": "year_4412"
                  },
                  {
                        "id": 4413,
                        "displayName": "year_4413"
                  },
                  {
                        "id": 4414,
                        "displayName": "year_4414"
                  },
                  {
                        "id": 4415,
                        "displayName": "year_4415"
                  },
                  {
                        "id": 4416,
                        "displayName": "year_4416"
                  },
                  {
                        "id": 4417,
                        "displayName": "year_4417"
                  },
                  {
                        "id": 4418,
                        "displayName": "year_4418"
                  },
                  {
                        "id": 4419,
                        "displayName": "year_4419"
                  },
                  {
                        "id": 4420,
                        "displayName": "year_4420"
                  },
                  {
                        "id": 4421,
                        "displayName": "year_4421"
                  },
                  {
                        "id": 4422,
                        "displayName": "year_4422"
                  },
                  {
                        "id": 4423,
                        "displayName": "year_4423"
                  },
                  {
                        "id": 4424,
                        "displayName": "year_4424"
                  },
                  {
                        "id": 4425,
                        "displayName": "year_4425"
                  },
                  {
                        "id": 4426,
                        "displayName": "year_4426"
                  },
                  {
                        "id": 4427,
                        "displayName": "year_4427"
                  },
                  {
                        "id": 4428,
                        "displayName": "year_4428"
                  },
                  {
                        "id": 4429,
                        "displayName": "year_4429"
                  },
                  {
                        "id": 4430,
                        "displayName": "year_4430"
                  },
                  {
                        "id": 4431,
                        "displayName": "year_4431"
                  },
                  {
                        "id": 4432,
                        "displayName": "year_4432"
                  },
                  {
                        "id": 4433,
                        "displayName": "year_4433"
                  },
                  {
                        "id": 4434,
                        "displayName": "year_4434"
                  },
                  {
                        "id": 4435,
                        "displayName": "year_4435"
                  },
                  {
                        "id": 4436,
                        "displayName": "year_4436"
                  },
                  {
                        "id": 4437,
                        "displayName": "year_4437"
                  },
                  {
                        "id": 4438,
                        "displayName": "year_4438"
                  },
                  {
                        "id": 4439,
                        "displayName": "year_4439"
                  },
                  {
                        "id": 4440,
                        "displayName": "year_4440"
                  },
                  {
                        "id": 4441,
                        "displayName": "year_4441"
                  },
                  {
                        "id": 4442,
                        "displayName": "year_4442"
                  },
                  {
                        "id": 4443,
                        "displayName": "year_4443"
                  },
                  {
                        "id": 4444,
                        "displayName": "year_4444"
                  },
                  {
                        "id": 4445,
                        "displayName": "year_4445"
                  },
                  {
                        "id": 4446,
                        "displayName": "year_4446"
                  },
                  {
                        "id": 4447,
                        "displayName": "year_4447"
                  },
                  {
                        "id": 4448,
                        "displayName": "year_4448"
                  },
                  {
                        "id": 4449,
                        "displayName": "year_4449"
                  },
                  {
                        "id": 4450,
                        "displayName": "year_4450"
                  },
                  {
                        "id": 4451,
                        "displayName": "year_4451"
                  },
                  {
                        "id": 4452,
                        "displayName": "year_4452"
                  },
                  {
                        "id": 4453,
                        "displayName": "year_4453"
                  },
                  {
                        "id": 4454,
                        "displayName": "year_4454"
                  },
                  {
                        "id": 4455,
                        "displayName": "year_4455"
                  },
                  {
                        "id": 4456,
                        "displayName": "year_4456"
                  },
                  {
                        "id": 4457,
                        "displayName": "year_4457"
                  },
                  {
                        "id": 4458,
                        "displayName": "year_4458"
                  },
                  {
                        "id": 4459,
                        "displayName": "year_4459"
                  },
                  {
                        "id": 4460,
                        "displayName": "year_4460"
                  },
                  {
                        "id": 4461,
                        "displayName": "year_4461"
                  },
                  {
                        "id": 4462,
                        "displayName": "year_4462"
                  },
                  {
                        "id": 4463,
                        "displayName": "year_4463"
                  },
                  {
                        "id": 4464,
                        "displayName": "year_4464"
                  },
                  {
                        "id": 4465,
                        "displayName": "year_4465"
                  },
                  {
                        "id": 4466,
                        "displayName": "year_4466"
                  },
                  {
                        "id": 4467,
                        "displayName": "year_4467"
                  },
                  {
                        "id": 4468,
                        "displayName": "year_4468"
                  },
                  {
                        "id": 4469,
                        "displayName": "year_4469"
                  },
                  {
                        "id": 4470,
                        "displayName": "year_4470"
                  },
                  {
                        "id": 4471,
                        "displayName": "year_4471"
                  },
                  {
                        "id": 4472,
                        "displayName": "year_4472"
                  },
                  {
                        "id": 4473,
                        "displayName": "year_4473"
                  },
                  {
                        "id": 4474,
                        "displayName": "year_4474"
                  },
                  {
                        "id": 4475,
                        "displayName": "year_4475"
                  },
                  {
                        "id": 4476,
                        "displayName": "year_4476"
                  },
                  {
                        "id": 4477,
                        "displayName": "year_4477"
                  },
                  {
                        "id": 4478,
                        "displayName": "year_4478"
                  },
                  {
                        "id": 4479,
                        "displayName": "year_4479"
                  },
                  {
                        "id": 4480,
                        "displayName": "year_4480"
                  },
                  {
                        "id": 4481,
                        "displayName": "year_4481"
                  },
                  {
                        "id": 4482,
                        "displayName": "year_4482"
                  },
                  {
                        "id": 4483,
                        "displayName": "year_4483"
                  },
                  {
                        "id": 4484,
                        "displayName": "year_4484"
                  },
                  {
                        "id": 4485,
                        "displayName": "year_4485"
                  },
                  {
                        "id": 4486,
                        "displayName": "year_4486"
                  },
                  {
                        "id": 4487,
                        "displayName": "year_4487"
                  },
                  {
                        "id": 4488,
                        "displayName": "year_4488"
                  },
                  {
                        "id": 4489,
                        "displayName": "year_4489"
                  },
                  {
                        "id": 4490,
                        "displayName": "year_4490"
                  },
                  {
                        "id": 4491,
                        "displayName": "year_4491"
                  },
                  {
                        "id": 4492,
                        "displayName": "year_4492"
                  },
                  {
                        "id": 4493,
                        "displayName": "year_4493"
                  },
                  {
                        "id": 4494,
                        "displayName": "year_4494"
                  },
                  {
                        "id": 4495,
                        "displayName": "year_4495"
                  },
                  {
                        "id": 4496,
                        "displayName": "year_4496"
                  },
                  {
                        "id": 4497,
                        "displayName": "year_4497"
                  },
                  {
                        "id": 4498,
                        "displayName": "year_4498"
                  },
                  {
                        "id": 4499,
                        "displayName": "year_4499"
                  },
                  {
                        "id": 4500,
                        "displayName": "year_4500"
                  },
                  {
                        "id": 4501,
                        "displayName": "year_4501"
                  },
                  {
                        "id": 4502,
                        "displayName": "year_4502"
                  },
                  {
                        "id": 4503,
                        "displayName": "year_4503"
                  },
                  {
                        "id": 4504,
                        "displayName": "year_4504"
                  },
                  {
                        "id": 4505,
                        "displayName": "year_4505"
                  },
                  {
                        "id": 4506,
                        "displayName": "year_4506"
                  },
                  {
                        "id": 4507,
                        "displayName": "year_4507"
                  },
                  {
                        "id": 4508,
                        "displayName": "year_4508"
                  },
                  {
                        "id": 4509,
                        "displayName": "year_4509"
                  },
                  {
                        "id": 4510,
                        "displayName": "year_4510"
                  },
                  {
                        "id": 4511,
                        "displayName": "year_4511"
                  },
                  {
                        "id": 4512,
                        "displayName": "year_4512"
                  },
                  {
                        "id": 4513,
                        "displayName": "year_4513"
                  },
                  {
                        "id": 4514,
                        "displayName": "year_4514"
                  },
                  {
                        "id": 4515,
                        "displayName": "year_4515"
                  },
                  {
                        "id": 4516,
                        "displayName": "year_4516"
                  },
                  {
                        "id": 4517,
                        "displayName": "year_4517"
                  },
                  {
                        "id": 4518,
                        "displayName": "year_4518"
                  },
                  {
                        "id": 4519,
                        "displayName": "year_4519"
                  },
                  {
                        "id": 4520,
                        "displayName": "year_4520"
                  },
                  {
                        "id": 4521,
                        "displayName": "year_4521"
                  },
                  {
                        "id": 4522,
                        "displayName": "year_4522"
                  },
                  {
                        "id": 4523,
                        "displayName": "year_4523"
                  },
                  {
                        "id": 4524,
                        "displayName": "year_4524"
                  },
                  {
                        "id": 4525,
                        "displayName": "year_4525"
                  },
                  {
                        "id": 4526,
                        "displayName": "year_4526"
                  },
                  {
                        "id": 4527,
                        "displayName": "year_4527"
                  },
                  {
                        "id": 4528,
                        "displayName": "year_4528"
                  },
                  {
                        "id": 4529,
                        "displayName": "year_4529"
                  },
                  {
                        "id": 4530,
                        "displayName": "year_4530"
                  },
                  {
                        "id": 4531,
                        "displayName": "year_4531"
                  },
                  {
                        "id": 4532,
                        "displayName": "year_4532"
                  },
                  {
                        "id": 4533,
                        "displayName": "year_4533"
                  },
                  {
                        "id": 4534,
                        "displayName": "year_4534"
                  },
                  {
                        "id": 4535,
                        "displayName": "year_4535"
                  },
                  {
                        "id": 4536,
                        "displayName": "year_4536"
                  },
                  {
                        "id": 4537,
                        "displayName": "year_4537"
                  },
                  {
                        "id": 4538,
                        "displayName": "year_4538"
                  },
                  {
                        "id": 4539,
                        "displayName": "year_4539"
                  },
                  {
                        "id": 4540,
                        "displayName": "year_4540"
                  },
                  {
                        "id": 4541,
                        "displayName": "year_4541"
                  },
                  {
                        "id": 4542,
                        "displayName": "year_4542"
                  },
                  {
                        "id": 4543,
                        "displayName": "year_4543"
                  },
                  {
                        "id": 4544,
                        "displayName": "year_4544"
                  },
                  {
                        "id": 4545,
                        "displayName": "year_4545"
                  },
                  {
                        "id": 4546,
                        "displayName": "year_4546"
                  },
                  {
                        "id": 4547,
                        "displayName": "year_4547"
                  },
                  {
                        "id": 4548,
                        "displayName": "year_4548"
                  },
                  {
                        "id": 4549,
                        "displayName": "year_4549"
                  },
                  {
                        "id": 4550,
                        "displayName": "year_4550"
                  },
                  {
                        "id": 4551,
                        "displayName": "year_4551"
                  },
                  {
                        "id": 4552,
                        "displayName": "year_4552"
                  },
                  {
                        "id": 4553,
                        "displayName": "year_4553"
                  },
                  {
                        "id": 4554,
                        "displayName": "year_4554"
                  },
                  {
                        "id": 4555,
                        "displayName": "year_4555"
                  },
                  {
                        "id": 4556,
                        "displayName": "year_4556"
                  },
                  {
                        "id": 4557,
                        "displayName": "year_4557"
                  },
                  {
                        "id": 4558,
                        "displayName": "year_4558"
                  },
                  {
                        "id": 4559,
                        "displayName": "year_4559"
                  },
                  {
                        "id": 4560,
                        "displayName": "year_4560"
                  },
                  {
                        "id": 4561,
                        "displayName": "year_4561"
                  },
                  {
                        "id": 4562,
                        "displayName": "year_4562"
                  },
                  {
                        "id": 4563,
                        "displayName": "year_4563"
                  },
                  {
                        "id": 4564,
                        "displayName": "year_4564"
                  },
                  {
                        "id": 4565,
                        "displayName": "year_4565"
                  },
                  {
                        "id": 4566,
                        "displayName": "year_4566"
                  },
                  {
                        "id": 4567,
                        "displayName": "year_4567"
                  },
                  {
                        "id": 4568,
                        "displayName": "year_4568"
                  },
                  {
                        "id": 4569,
                        "displayName": "year_4569"
                  },
                  {
                        "id": 4570,
                        "displayName": "year_4570"
                  },
                  {
                        "id": 4571,
                        "displayName": "year_4571"
                  },
                  {
                        "id": 4572,
                        "displayName": "year_4572"
                  },
                  {
                        "id": 4573,
                        "displayName": "year_4573"
                  },
                  {
                        "id": 4574,
                        "displayName": "year_4574"
                  },
                  {
                        "id": 4575,
                        "displayName": "year_4575"
                  },
                  {
                        "id": 4576,
                        "displayName": "year_4576"
                  },
                  {
                        "id": 4577,
                        "displayName": "year_4577"
                  },
                  {
                        "id": 4578,
                        "displayName": "year_4578"
                  },
                  {
                        "id": 4579,
                        "displayName": "year_4579"
                  },
                  {
                        "id": 4580,
                        "displayName": "year_4580"
                  },
                  {
                        "id": 4581,
                        "displayName": "year_4581"
                  },
                  {
                        "id": 4582,
                        "displayName": "year_4582"
                  },
                  {
                        "id": 4583,
                        "displayName": "year_4583"
                  },
                  {
                        "id": 4584,
                        "displayName": "year_4584"
                  },
                  {
                        "id": 4585,
                        "displayName": "year_4585"
                  },
                  {
                        "id": 4586,
                        "displayName": "year_4586"
                  },
                  {
                        "id": 4587,
                        "displayName": "year_4587"
                  },
                  {
                        "id": 4588,
                        "displayName": "year_4588"
                  },
                  {
                        "id": 4589,
                        "displayName": "year_4589"
                  },
                  {
                        "id": 4590,
                        "displayName": "year_4590"
                  },
                  {
                        "id": 4591,
                        "displayName": "year_4591"
                  },
                  {
                        "id": 4592,
                        "displayName": "year_4592"
                  },
                  {
                        "id": 4593,
                        "displayName": "year_4593"
                  },
                  {
                        "id": 4594,
                        "displayName": "year_4594"
                  },
                  {
                        "id": 4595,
                        "displayName": "year_4595"
                  },
                  {
                        "id": 4596,
                        "displayName": "year_4596"
                  },
                  {
                        "id": 4597,
                        "displayName": "year_4597"
                  },
                  {
                        "id": 4598,
                        "displayName": "year_4598"
                  },
                  {
                        "id": 4599,
                        "displayName": "year_4599"
                  },
                  {
                        "id": 4600,
                        "displayName": "year_4600"
                  },
                  {
                        "id": 4601,
                        "displayName": "year_4601"
                  },
                  {
                        "id": 4602,
                        "displayName": "year_4602"
                  },
                  {
                        "id": 4603,
                        "displayName": "year_4603"
                  },
                  {
                        "id": 4604,
                        "displayName": "year_4604"
                  },
                  {
                        "id": 4605,
                        "displayName": "year_4605"
                  },
                  {
                        "id": 4606,
                        "displayName": "year_4606"
                  },
                  {
                        "id": 4607,
                        "displayName": "year_4607"
                  },
                  {
                        "id": 4608,
                        "displayName": "year_4608"
                  },
                  {
                        "id": 4609,
                        "displayName": "year_4609"
                  },
                  {
                        "id": 4610,
                        "displayName": "year_4610"
                  },
                  {
                        "id": 4611,
                        "displayName": "year_4611"
                  },
                  {
                        "id": 4612,
                        "displayName": "year_4612"
                  },
                  {
                        "id": 4613,
                        "displayName": "year_4613"
                  },
                  {
                        "id": 4614,
                        "displayName": "year_4614"
                  },
                  {
                        "id": 4615,
                        "displayName": "year_4615"
                  },
                  {
                        "id": 4616,
                        "displayName": "year_4616"
                  },
                  {
                        "id": 4617,
                        "displayName": "year_4617"
                  },
                  {
                        "id": 4618,
                        "displayName": "year_4618"
                  },
                  {
                        "id": 4619,
                        "displayName": "year_4619"
                  },
                  {
                        "id": 4620,
                        "displayName": "year_4620"
                  },
                  {
                        "id": 4621,
                        "displayName": "year_4621"
                  },
                  {
                        "id": 4622,
                        "displayName": "year_4622"
                  },
                  {
                        "id": 4623,
                        "displayName": "year_4623"
                  },
                  {
                        "id": 4624,
                        "displayName": "year_4624"
                  },
                  {
                        "id": 4625,
                        "displayName": "year_4625"
                  },
                  {
                        "id": 4626,
                        "displayName": "year_4626"
                  },
                  {
                        "id": 4627,
                        "displayName": "year_4627"
                  },
                  {
                        "id": 4628,
                        "displayName": "year_4628"
                  },
                  {
                        "id": 4629,
                        "displayName": "year_4629"
                  },
                  {
                        "id": 4630,
                        "displayName": "year_4630"
                  },
                  {
                        "id": 4631,
                        "displayName": "year_4631"
                  },
                  {
                        "id": 4632,
                        "displayName": "year_4632"
                  },
                  {
                        "id": 4633,
                        "displayName": "year_4633"
                  },
                  {
                        "id": 4634,
                        "displayName": "year_4634"
                  },
                  {
                        "id": 4635,
                        "displayName": "year_4635"
                  },
                  {
                        "id": 4636,
                        "displayName": "year_4636"
                  },
                  {
                        "id": 4637,
                        "displayName": "year_4637"
                  },
                  {
                        "id": 4638,
                        "displayName": "year_4638"
                  },
                  {
                        "id": 4639,
                        "displayName": "year_4639"
                  },
                  {
                        "id": 4640,
                        "displayName": "year_4640"
                  },
                  {
                        "id": 4641,
                        "displayName": "year_4641"
                  },
                  {
                        "id": 4642,
                        "displayName": "year_4642"
                  },
                  {
                        "id": 4643,
                        "displayName": "year_4643"
                  },
                  {
                        "id": 4644,
                        "displayName": "year_4644"
                  },
                  {
                        "id": 4645,
                        "displayName": "year_4645"
                  },
                  {
                        "id": 4646,
                        "displayName": "year_4646"
                  },
                  {
                        "id": 4647,
                        "displayName": "year_4647"
                  },
                  {
                        "id": 4648,
                        "displayName": "year_4648"
                  },
                  {
                        "id": 4649,
                        "displayName": "year_4649"
                  },
                  {
                        "id": 4650,
                        "displayName": "year_4650"
                  },
                  {
                        "id": 4651,
                        "displayName": "year_4651"
                  },
                  {
                        "id": 4652,
                        "displayName": "year_4652"
                  },
                  {
                        "id": 4653,
                        "displayName": "year_4653"
                  },
                  {
                        "id": 4654,
                        "displayName": "year_4654"
                  },
                  {
                        "id": 4655,
                        "displayName": "year_4655"
                  },
                  {
                        "id": 4656,
                        "displayName": "year_4656"
                  },
                  {
                        "id": 4657,
                        "displayName": "year_4657"
                  },
                  {
                        "id": 4658,
                        "displayName": "year_4658"
                  },
                  {
                        "id": 4659,
                        "displayName": "year_4659"
                  },
                  {
                        "id": 4660,
                        "displayName": "year_4660"
                  },
                  {
                        "id": 4661,
                        "displayName": "year_4661"
                  },
                  {
                        "id": 4662,
                        "displayName": "year_4662"
                  },
                  {
                        "id": 4663,
                        "displayName": "year_4663"
                  },
                  {
                        "id": 4664,
                        "displayName": "year_4664"
                  },
                  {
                        "id": 4665,
                        "displayName": "year_4665"
                  },
                  {
                        "id": 4666,
                        "displayName": "year_4666"
                  },
                  {
                        "id": 4667,
                        "displayName": "year_4667"
                  },
                  {
                        "id": 4668,
                        "displayName": "year_4668"
                  },
                  {
                        "id": 4669,
                        "displayName": "year_4669"
                  },
                  {
                        "id": 4670,
                        "displayName": "year_4670"
                  },
                  {
                        "id": 4671,
                        "displayName": "year_4671"
                  },
                  {
                        "id": 4672,
                        "displayName": "year_4672"
                  },
                  {
                        "id": 4673,
                        "displayName": "year_4673"
                  },
                  {
                        "id": 4674,
                        "displayName": "year_4674"
                  },
                  {
                        "id": 4675,
                        "displayName": "year_4675"
                  },
                  {
                        "id": 4676,
                        "displayName": "year_4676"
                  },
                  {
                        "id": 4677,
                        "displayName": "year_4677"
                  },
                  {
                        "id": 4678,
                        "displayName": "year_4678"
                  },
                  {
                        "id": 4679,
                        "displayName": "year_4679"
                  },
                  {
                        "id": 4680,
                        "displayName": "year_4680"
                  },
                  {
                        "id": 4681,
                        "displayName": "year_4681"
                  },
                  {
                        "id": 4682,
                        "displayName": "year_4682"
                  },
                  {
                        "id": 4683,
                        "displayName": "year_4683"
                  },
                  {
                        "id": 4684,
                        "displayName": "year_4684"
                  },
                  {
                        "id": 4685,
                        "displayName": "year_4685"
                  },
                  {
                        "id": 4686,
                        "displayName": "year_4686"
                  },
                  {
                        "id": 4687,
                        "displayName": "year_4687"
                  },
                  {
                        "id": 4688,
                        "displayName": "year_4688"
                  },
                  {
                        "id": 4689,
                        "displayName": "year_4689"
                  },
                  {
                        "id": 4690,
                        "displayName": "year_4690"
                  },
                  {
                        "id": 4691,
                        "displayName": "year_4691"
                  },
                  {
                        "id": 4692,
                        "displayName": "year_4692"
                  },
                  {
                        "id": 4693,
                        "displayName": "year_4693"
                  },
                  {
                        "id": 4694,
                        "displayName": "year_4694"
                  },
                  {
                        "id": 4695,
                        "displayName": "year_4695"
                  },
                  {
                        "id": 4696,
                        "displayName": "year_4696"
                  },
                  {
                        "id": 4697,
                        "displayName": "year_4697"
                  },
                  {
                        "id": 4698,
                        "displayName": "year_4698"
                  },
                  {
                        "id": 4699,
                        "displayName": "year_4699"
                  },
                  {
                        "id": 4700,
                        "displayName": "year_4700"
                  },
                  {
                        "id": 4701,
                        "displayName": "year_4701"
                  },
                  {
                        "id": 4702,
                        "displayName": "year_4702"
                  },
                  {
                        "id": 4703,
                        "displayName": "year_4703"
                  },
                  {
                        "id": 4704,
                        "displayName": "year_4704"
                  },
                  {
                        "id": 4705,
                        "displayName": "year_4705"
                  },
                  {
                        "id": 4706,
                        "displayName": "year_4706"
                  },
                  {
                        "id": 4707,
                        "displayName": "year_4707"
                  },
                  {
                        "id": 4708,
                        "displayName": "year_4708"
                  },
                  {
                        "id": 4709,
                        "displayName": "year_4709"
                  },
                  {
                        "id": 4710,
                        "displayName": "year_4710"
                  },
                  {
                        "id": 4711,
                        "displayName": "year_4711"
                  },
                  {
                        "id": 4712,
                        "displayName": "year_4712"
                  },
                  {
                        "id": 4713,
                        "displayName": "year_4713"
                  },
                  {
                        "id": 4714,
                        "displayName": "year_4714"
                  },
                  {
                        "id": 4715,
                        "displayName": "year_4715"
                  },
                  {
                        "id": 4716,
                        "displayName": "year_4716"
                  },
                  {
                        "id": 4717,
                        "displayName": "year_4717"
                  },
                  {
                        "id": 4718,
                        "displayName": "year_4718"
                  },
                  {
                        "id": 4719,
                        "displayName": "year_4719"
                  },
                  {
                        "id": 4720,
                        "displayName": "year_4720"
                  },
                  {
                        "id": 4721,
                        "displayName": "year_4721"
                  },
                  {
                        "id": 4722,
                        "displayName": "year_4722"
                  },
                  {
                        "id": 4723,
                        "displayName": "year_4723"
                  },
                  {
                        "id": 4724,
                        "displayName": "year_4724"
                  },
                  {
                        "id": 4725,
                        "displayName": "year_4725"
                  },
                  {
                        "id": 4726,
                        "displayName": "year_4726"
                  },
                  {
                        "id": 4727,
                        "displayName": "year_4727"
                  },
                  {
                        "id": 4728,
                        "displayName": "year_4728"
                  },
                  {
                        "id": 4729,
                        "displayName": "year_4729"
                  },
                  {
                        "id": 4730,
                        "displayName": "year_4730"
                  },
                  {
                        "id": 4731,
                        "displayName": "year_4731"
                  },
                  {
                        "id": 4732,
                        "displayName": "year_4732"
                  },
                  {
                        "id": 4733,
                        "displayName": "year_4733"
                  },
                  {
                        "id": 4734,
                        "displayName": "year_4734"
                  },
                  {
                        "id": 4735,
                        "displayName": "year_4735"
                  },
                  {
                        "id": 4736,
                        "displayName": "year_4736"
                  },
                  {
                        "id": 4737,
                        "displayName": "year_4737"
                  },
                  {
                        "id": 4738,
                        "displayName": "year_4738"
                  },
                  {
                        "id": 4739,
                        "displayName": "year_4739"
                  },
                  {
                        "id": 4740,
                        "displayName": "year_4740"
                  },
                  {
                        "id": 4741,
                        "displayName": "year_4741"
                  },
                  {
                        "id": 4742,
                        "displayName": "year_4742"
                  },
                  {
                        "id": 4743,
                        "displayName": "year_4743"
                  },
                  {
                        "id": 4744,
                        "displayName": "year_4744"
                  },
                  {
                        "id": 4745,
                        "displayName": "year_4745"
                  },
                  {
                        "id": 4746,
                        "displayName": "year_4746"
                  },
                  {
                        "id": 4747,
                        "displayName": "year_4747"
                  },
                  {
                        "id": 4748,
                        "displayName": "year_4748"
                  },
                  {
                        "id": 4749,
                        "displayName": "year_4749"
                  },
                  {
                        "id": 4750,
                        "displayName": "year_4750"
                  },
                  {
                        "id": 4751,
                        "displayName": "year_4751"
                  },
                  {
                        "id": 4752,
                        "displayName": "year_4752"
                  },
                  {
                        "id": 4753,
                        "displayName": "year_4753"
                  },
                  {
                        "id": 4754,
                        "displayName": "year_4754"
                  },
                  {
                        "id": 4755,
                        "displayName": "year_4755"
                  },
                  {
                        "id": 4756,
                        "displayName": "year_4756"
                  },
                  {
                        "id": 4757,
                        "displayName": "year_4757"
                  },
                  {
                        "id": 4758,
                        "displayName": "year_4758"
                  },
                  {
                        "id": 4759,
                        "displayName": "year_4759"
                  },
                  {
                        "id": 4760,
                        "displayName": "year_4760"
                  },
                  {
                        "id": 4761,
                        "displayName": "year_4761"
                  },
                  {
                        "id": 4762,
                        "displayName": "year_4762"
                  },
                  {
                        "id": 4763,
                        "displayName": "year_4763"
                  },
                  {
                        "id": 4764,
                        "displayName": "year_4764"
                  },
                  {
                        "id": 4765,
                        "displayName": "year_4765"
                  },
                  {
                        "id": 4766,
                        "displayName": "year_4766"
                  },
                  {
                        "id": 4767,
                        "displayName": "year_4767"
                  },
                  {
                        "id": 4768,
                        "displayName": "year_4768"
                  },
                  {
                        "id": 4769,
                        "displayName": "year_4769"
                  },
                  {
                        "id": 4770,
                        "displayName": "year_4770"
                  },
                  {
                        "id": 4771,
                        "displayName": "year_4771"
                  },
                  {
                        "id": 4772,
                        "displayName": "year_4772"
                  },
                  {
                        "id": 4773,
                        "displayName": "year_4773"
                  },
                  {
                        "id": 4774,
                        "displayName": "year_4774"
                  },
                  {
                        "id": 4775,
                        "displayName": "year_4775"
                  },
                  {
                        "id": 4776,
                        "displayName": "year_4776"
                  },
                  {
                        "id": 4777,
                        "displayName": "year_4777"
                  },
                  {
                        "id": 4778,
                        "displayName": "year_4778"
                  },
                  {
                        "id": 4779,
                        "displayName": "year_4779"
                  },
                  {
                        "id": 4780,
                        "displayName": "year_4780"
                  },
                  {
                        "id": 4781,
                        "displayName": "year_4781"
                  },
                  {
                        "id": 4782,
                        "displayName": "year_4782"
                  },
                  {
                        "id": 4783,
                        "displayName": "year_4783"
                  },
                  {
                        "id": 4784,
                        "displayName": "year_4784"
                  },
                  {
                        "id": 4785,
                        "displayName": "year_4785"
                  },
                  {
                        "id": 4786,
                        "displayName": "year_4786"
                  },
                  {
                        "id": 4787,
                        "displayName": "year_4787"
                  },
                  {
                        "id": 4788,
                        "displayName": "year_4788"
                  },
                  {
                        "id": 4789,
                        "displayName": "year_4789"
                  },
                  {
                        "id": 4790,
                        "displayName": "year_4790"
                  },
                  {
                        "id": 4791,
                        "displayName": "year_4791"
                  },
                  {
                        "id": 4792,
                        "displayName": "year_4792"
                  },
                  {
                        "id": 4793,
                        "displayName": "year_4793"
                  },
                  {
                        "id": 4794,
                        "displayName": "year_4794"
                  },
                  {
                        "id": 4795,
                        "displayName": "year_4795"
                  },
                  {
                        "id": 4796,
                        "displayName": "year_4796"
                  },
                  {
                        "id": 4797,
                        "displayName": "year_4797"
                  },
                  {
                        "id": 4798,
                        "displayName": "year_4798"
                  },
                  {
                        "id": 4799,
                        "displayName": "year_4799"
                  },
                  {
                        "id": 4800,
                        "displayName": "year_4800"
                  },
                  {
                        "id": 4801,
                        "displayName": "year_4801"
                  },
                  {
                        "id": 4802,
                        "displayName": "year_4802"
                  },
                  {
                        "id": 4803,
                        "displayName": "year_4803"
                  },
                  {
                        "id": 4804,
                        "displayName": "year_4804"
                  },
                  {
                        "id": 4805,
                        "displayName": "year_4805"
                  },
                  {
                        "id": 4806,
                        "displayName": "year_4806"
                  },
                  {
                        "id": 4807,
                        "displayName": "year_4807"
                  },
                  {
                        "id": 4808,
                        "displayName": "year_4808"
                  },
                  {
                        "id": 4809,
                        "displayName": "year_4809"
                  },
                  {
                        "id": 4810,
                        "displayName": "year_4810"
                  },
                  {
                        "id": 4811,
                        "displayName": "year_4811"
                  },
                  {
                        "id": 4812,
                        "displayName": "year_4812"
                  },
                  {
                        "id": 4813,
                        "displayName": "year_4813"
                  },
                  {
                        "id": 4814,
                        "displayName": "year_4814"
                  },
                  {
                        "id": 4815,
                        "displayName": "year_4815"
                  },
                  {
                        "id": 4816,
                        "displayName": "year_4816"
                  },
                  {
                        "id": 4817,
                        "displayName": "year_4817"
                  },
                  {
                        "id": 4818,
                        "displayName": "year_4818"
                  },
                  {
                        "id": 4819,
                        "displayName": "year_4819"
                  },
                  {
                        "id": 4820,
                        "displayName": "year_4820"
                  },
                  {
                        "id": 4821,
                        "displayName": "year_4821"
                  },
                  {
                        "id": 4822,
                        "displayName": "year_4822"
                  },
                  {
                        "id": 4823,
                        "displayName": "year_4823"
                  },
                  {
                        "id": 4824,
                        "displayName": "year_4824"
                  },
                  {
                        "id": 4825,
                        "displayName": "year_4825"
                  },
                  {
                        "id": 4826,
                        "displayName": "year_4826"
                  },
                  {
                        "id": 4827,
                        "displayName": "year_4827"
                  },
                  {
                        "id": 4828,
                        "displayName": "year_4828"
                  },
                  {
                        "id": 4829,
                        "displayName": "year_4829"
                  },
                  {
                        "id": 4830,
                        "displayName": "year_4830"
                  },
                  {
                        "id": 4831,
                        "displayName": "year_4831"
                  },
                  {
                        "id": 4832,
                        "displayName": "year_4832"
                  },
                  {
                        "id": 4833,
                        "displayName": "year_4833"
                  },
                  {
                        "id": 4834,
                        "displayName": "year_4834"
                  },
                  {
                        "id": 4835,
                        "displayName": "year_4835"
                  },
                  {
                        "id": 4836,
                        "displayName": "year_4836"
                  },
                  {
                        "id": 4837,
                        "displayName": "year_4837"
                  },
                  {
                        "id": 4838,
                        "displayName": "year_4838"
                  },
                  {
                        "id": 4839,
                        "displayName": "year_4839"
                  },
                  {
                        "id": 4840,
                        "displayName": "year_4840"
                  },
                  {
                        "id": 4841,
                        "displayName": "year_4841"
                  },
                  {
                        "id": 4842,
                        "displayName": "year_4842"
                  },
                  {
                        "id": 4843,
                        "displayName": "year_4843"
                  },
                  {
                        "id": 4844,
                        "displayName": "year_4844"
                  },
                  {
                        "id": 4845,
                        "displayName": "year_4845"
                  },
                  {
                        "id": 4846,
                        "displayName": "year_4846"
                  },
                  {
                        "id": 4847,
                        "displayName": "year_4847"
                  },
                  {
                        "id": 4848,
                        "displayName": "year_4848"
                  },
                  {
                        "id": 4849,
                        "displayName": "year_4849"
                  },
                  {
                        "id": 4850,
                        "displayName": "year_4850"
                  },
                  {
                        "id": 4851,
                        "displayName": "year_4851"
                  },
                  {
                        "id": 4852,
                        "displayName": "year_4852"
                  },
                  {
                        "id": 4853,
                        "displayName": "year_4853"
                  },
                  {
                        "id": 4854,
                        "displayName": "year_4854"
                  },
                  {
                        "id": 4855,
                        "displayName": "year_4855"
                  },
                  {
                        "id": 4856,
                        "displayName": "year_4856"
                  },
                  {
                        "id": 4857,
                        "displayName": "year_4857"
                  },
                  {
                        "id": 4858,
                        "displayName": "year_4858"
                  },
                  {
                        "id": 4859,
                        "displayName": "year_4859"
                  },
                  {
                        "id": 4860,
                        "displayName": "year_4860"
                  },
                  {
                        "id": 4861,
                        "displayName": "year_4861"
                  },
                  {
                        "id": 4862,
                        "displayName": "year_4862"
                  },
                  {
                        "id": 4863,
                        "displayName": "year_4863"
                  },
                  {
                        "id": 4864,
                        "displayName": "year_4864"
                  },
                  {
                        "id": 4865,
                        "displayName": "year_4865"
                  },
                  {
                        "id": 4866,
                        "displayName": "year_4866"
                  },
                  {
                        "id": 4867,
                        "displayName": "year_4867"
                  },
                  {
                        "id": 4868,
                        "displayName": "year_4868"
                  },
                  {
                        "id": 4869,
                        "displayName": "year_4869"
                  },
                  {
                        "id": 4870,
                        "displayName": "year_4870"
                  },
                  {
                        "id": 4871,
                        "displayName": "year_4871"
                  },
                  {
                        "id": 4872,
                        "displayName": "year_4872"
                  },
                  {
                        "id": 4873,
                        "displayName": "year_4873"
                  },
                  {
                        "id": 4874,
                        "displayName": "year_4874"
                  },
                  {
                        "id": 4875,
                        "displayName": "year_4875"
                  },
                  {
                        "id": 4876,
                        "displayName": "year_4876"
                  },
                  {
                        "id": 4877,
                        "displayName": "year_4877"
                  },
                  {
                        "id": 4878,
                        "displayName": "year_4878"
                  },
                  {
                        "id": 4879,
                        "displayName": "year_4879"
                  },
                  {
                        "id": 4880,
                        "displayName": "year_4880"
                  },
                  {
                        "id": 4881,
                        "displayName": "year_4881"
                  },
                  {
                        "id": 4882,
                        "displayName": "year_4882"
                  },
                  {
                        "id": 4883,
                        "displayName": "year_4883"
                  },
                  {
                        "id": 4884,
                        "displayName": "year_4884"
                  },
                  {
                        "id": 4885,
                        "displayName": "year_4885"
                  },
                  {
                        "id": 4886,
                        "displayName": "year_4886"
                  },
                  {
                        "id": 4887,
                        "displayName": "year_4887"
                  },
                  {
                        "id": 4888,
                        "displayName": "year_4888"
                  },
                  {
                        "id": 4889,
                        "displayName": "year_4889"
                  },
                  {
                        "id": 4890,
                        "displayName": "year_4890"
                  },
                  {
                        "id": 4891,
                        "displayName": "year_4891"
                  },
                  {
                        "id": 4892,
                        "displayName": "year_4892"
                  },
                  {
                        "id": 4893,
                        "displayName": "year_4893"
                  },
                  {
                        "id": 4894,
                        "displayName": "year_4894"
                  },
                  {
                        "id": 4895,
                        "displayName": "year_4895"
                  },
                  {
                        "id": 4896,
                        "displayName": "year_4896"
                  },
                  {
                        "id": 4897,
                        "displayName": "year_4897"
                  },
                  {
                        "id": 4898,
                        "displayName": "year_4898"
                  },
                  {
                        "id": 4899,
                        "displayName": "year_4899"
                  },
                  {
                        "id": 4900,
                        "displayName": "year_4900"
                  },
                  {
                        "id": 4901,
                        "displayName": "year_4901"
                  },
                  {
                        "id": 4902,
                        "displayName": "year_4902"
                  },
                  {
                        "id": 4903,
                        "displayName": "year_4903"
                  },
                  {
                        "id": 4904,
                        "displayName": "year_4904"
                  },
                  {
                        "id": 4905,
                        "displayName": "year_4905"
                  },
                  {
                        "id": 4906,
                        "displayName": "year_4906"
                  },
                  {
                        "id": 4907,
                        "displayName": "year_4907"
                  },
                  {
                        "id": 4908,
                        "displayName": "year_4908"
                  },
                  {
                        "id": 4909,
                        "displayName": "year_4909"
                  },
                  {
                        "id": 4910,
                        "displayName": "year_4910"
                  },
                  {
                        "id": 4911,
                        "displayName": "year_4911"
                  },
                  {
                        "id": 4912,
                        "displayName": "year_4912"
                  },
                  {
                        "id": 4913,
                        "displayName": "year_4913"
                  },
                  {
                        "id": 4914,
                        "displayName": "year_4914"
                  },
                  {
                        "id": 4915,
                        "displayName": "year_4915"
                  },
                  {
                        "id": 4916,
                        "displayName": "year_4916"
                  },
                  {
                        "id": 4917,
                        "displayName": "year_4917"
                  },
                  {
                        "id": 4918,
                        "displayName": "year_4918"
                  },
                  {
                        "id": 4919,
                        "displayName": "year_4919"
                  },
                  {
                        "id": 4920,
                        "displayName": "year_4920"
                  },
                  {
                        "id": 4921,
                        "displayName": "year_4921"
                  },
                  {
                        "id": 4922,
                        "displayName": "year_4922"
                  },
                  {
                        "id": 4923,
                        "displayName": "year_4923"
                  },
                  {
                        "id": 4924,
                        "displayName": "year_4924"
                  },
                  {
                        "id": 4925,
                        "displayName": "year_4925"
                  },
                  {
                        "id": 4926,
                        "displayName": "year_4926"
                  },
                  {
                        "id": 4927,
                        "displayName": "year_4927"
                  },
                  {
                        "id": 4928,
                        "displayName": "year_4928"
                  },
                  {
                        "id": 4929,
                        "displayName": "year_4929"
                  },
                  {
                        "id": 4930,
                        "displayName": "year_4930"
                  },
                  {
                        "id": 4931,
                        "displayName": "year_4931"
                  },
                  {
                        "id": 4932,
                        "displayName": "year_4932"
                  },
                  {
                        "id": 4933,
                        "displayName": "year_4933"
                  },
                  {
                        "id": 4934,
                        "displayName": "year_4934"
                  },
                  {
                        "id": 4935,
                        "displayName": "year_4935"
                  },
                  {
                        "id": 4936,
                        "displayName": "year_4936"
                  },
                  {
                        "id": 4937,
                        "displayName": "year_4937"
                  },
                  {
                        "id": 4938,
                        "displayName": "year_4938"
                  },
                  {
                        "id": 4939,
                        "displayName": "year_4939"
                  },
                  {
                        "id": 4940,
                        "displayName": "year_4940"
                  },
                  {
                        "id": 4941,
                        "displayName": "year_4941"
                  },
                  {
                        "id": 4942,
                        "displayName": "year_4942"
                  },
                  {
                        "id": 4943,
                        "displayName": "year_4943"
                  },
                  {
                        "id": 4944,
                        "displayName": "year_4944"
                  },
                  {
                        "id": 4945,
                        "displayName": "year_4945"
                  },
                  {
                        "id": 4946,
                        "displayName": "year_4946"
                  },
                  {
                        "id": 4947,
                        "displayName": "year_4947"
                  },
                  {
                        "id": 4948,
                        "displayName": "year_4948"
                  },
                  {
                        "id": 4949,
                        "displayName": "year_4949"
                  },
                  {
                        "id": 4950,
                        "displayName": "year_4950"
                  },
                  {
                        "id": 4951,
                        "displayName": "year_4951"
                  },
                  {
                        "id": 4952,
                        "displayName": "year_4952"
                  },
                  {
                        "id": 4953,
                        "displayName": "year_4953"
                  },
                  {
                        "id": 4954,
                        "displayName": "year_4954"
                  },
                  {
                        "id": 4955,
                        "displayName": "year_4955"
                  },
                  {
                        "id": 4956,
                        "displayName": "year_4956"
                  },
                  {
                        "id": 4957,
                        "displayName": "year_4957"
                  },
                  {
                        "id": 4958,
                        "displayName": "year_4958"
                  },
                  {
                        "id": 4959,
                        "displayName": "year_4959"
                  },
                  {
                        "id": 4960,
                        "displayName": "year_4960"
                  },
                  {
                        "id": 4961,
                        "displayName": "year_4961"
                  },
                  {
                        "id": 4962,
                        "displayName": "year_4962"
                  },
                  {
                        "id": 4963,
                        "displayName": "year_4963"
                  },
                  {
                        "id": 4964,
                        "displayName": "year_4964"
                  },
                  {
                        "id": 4965,
                        "displayName": "year_4965"
                  },
                  {
                        "id": 4966,
                        "displayName": "year_4966"
                  },
                  {
                        "id": 4967,
                        "displayName": "year_4967"
                  },
                  {
                        "id": 4968,
                        "displayName": "year_4968"
                  },
                  {
                        "id": 4969,
                        "displayName": "year_4969"
                  },
                  {
                        "id": 4970,
                        "displayName": "year_4970"
                  },
                  {
                        "id": 4971,
                        "displayName": "year_4971"
                  },
                  {
                        "id": 4972,
                        "displayName": "year_4972"
                  },
                  {
                        "id": 4973,
                        "displayName": "year_4973"
                  },
                  {
                        "id": 4974,
                        "displayName": "year_4974"
                  },
                  {
                        "id": 4975,
                        "displayName": "year_4975"
                  },
                  {
                        "id": 4976,
                        "displayName": "year_4976"
                  },
                  {
                        "id": 4977,
                        "displayName": "year_4977"
                  },
                  {
                        "id": 4978,
                        "displayName": "year_4978"
                  },
                  {
                        "id": 4979,
                        "displayName": "year_4979"
                  },
                  {
                        "id": 4980,
                        "displayName": "year_4980"
                  },
                  {
                        "id": 4981,
                        "displayName": "year_4981"
                  },
                  {
                        "id": 4982,
                        "displayName": "year_4982"
                  },
                  {
                        "id": 4983,
                        "displayName": "year_4983"
                  },
                  {
                        "id": 4984,
                        "displayName": "year_4984"
                  },
                  {
                        "id": 4985,
                        "displayName": "year_4985"
                  },
                  {
                        "id": 4986,
                        "displayName": "year_4986"
                  },
                  {
                        "id": 4987,
                        "displayName": "year_4987"
                  },
                  {
                        "id": 4988,
                        "displayName": "year_4988"
                  },
                  {
                        "id": 4989,
                        "displayName": "year_4989"
                  },
                  {
                        "id": 4990,
                        "displayName": "year_4990"
                  },
                  {
                        "id": 4991,
                        "displayName": "year_4991"
                  },
                  {
                        "id": 4992,
                        "displayName": "year_4992"
                  },
                  {
                        "id": 4993,
                        "displayName": "year_4993"
                  },
                  {
                        "id": 4994,
                        "displayName": "year_4994"
                  },
                  {
                        "id": 4995,
                        "displayName": "year_4995"
                  },
                  {
                        "id": 4996,
                        "displayName": "year_4996"
                  },
                  {
                        "id": 4997,
                        "displayName": "year_4997"
                  },
                  {
                        "id": 4998,
                        "displayName": "year_4998"
                  },
                  {
                        "id": 4999,
                        "displayName": "year_4999"
                  },
                  {
                        "id": 5000,
                        "displayName": "year_5000"
                  },
                  {
                        "id": 5001,
                        "displayName": "year_5001"
                  },
                  {
                        "id": 5002,
                        "displayName": "year_5002"
                  },
                  {
                        "id": 5003,
                        "displayName": "year_5003"
                  },
                  {
                        "id": 5004,
                        "displayName": "year_5004"
                  },
                  {
                        "id": 5005,
                        "displayName": "year_5005"
                  },
                  {
                        "id": 5006,
                        "displayName": "year_5006"
                  },
                  {
                        "id": 5007,
                        "displayName": "year_5007"
                  },
                  {
                        "id": 5008,
                        "displayName": "year_5008"
                  },
                  {
                        "id": 5009,
                        "displayName": "year_5009"
                  },
                  {
                        "id": 5010,
                        "displayName": "year_5010"
                  },
                  {
                        "id": 5011,
                        "displayName": "year_5011"
                  },
                  {
                        "id": 5012,
                        "displayName": "year_5012"
                  },
                  {
                        "id": 5013,
                        "displayName": "year_5013"
                  },
                  {
                        "id": 5014,
                        "displayName": "year_5014"
                  },
                  {
                        "id": 5015,
                        "displayName": "year_5015"
                  },
                  {
                        "id": 5016,
                        "displayName": "year_5016"
                  },
                  {
                        "id": 5017,
                        "displayName": "year_5017"
                  },
                  {
                        "id": 5018,
                        "displayName": "year_5018"
                  },
                  {
                        "id": 5019,
                        "displayName": "year_5019"
                  },
                  {
                        "id": 5020,
                        "displayName": "year_5020"
                  },
                  {
                        "id": 5021,
                        "displayName": "year_5021"
                  },
                  {
                        "id": 5022,
                        "displayName": "year_5022"
                  },
                  {
                        "id": 5023,
                        "displayName": "year_5023"
                  },
                  {
                        "id": 5024,
                        "displayName": "year_5024"
                  },
                  {
                        "id": 5025,
                        "displayName": "year_5025"
                  },
                  {
                        "id": 5026,
                        "displayName": "year_5026"
                  },
                  {
                        "id": 5027,
                        "displayName": "year_5027"
                  },
                  {
                        "id": 5028,
                        "displayName": "year_5028"
                  },
                  {
                        "id": 5029,
                        "displayName": "year_5029"
                  },
                  {
                        "id": 5030,
                        "displayName": "year_5030"
                  },
                  {
                        "id": 5031,
                        "displayName": "year_5031"
                  },
                  {
                        "id": 5032,
                        "displayName": "year_5032"
                  },
                  {
                        "id": 5033,
                        "displayName": "year_5033"
                  },
                  {
                        "id": 5034,
                        "displayName": "year_5034"
                  },
                  {
                        "id": 5035,
                        "displayName": "year_5035"
                  },
                  {
                        "id": 5036,
                        "displayName": "year_5036"
                  },
                  {
                        "id": 5037,
                        "displayName": "year_5037"
                  },
                  {
                        "id": 5038,
                        "displayName": "year_5038"
                  },
                  {
                        "id": 5039,
                        "displayName": "year_5039"
                  },
                  {
                        "id": 5040,
                        "displayName": "year_5040"
                  },
                  {
                        "id": 5041,
                        "displayName": "year_5041"
                  },
                  {
                        "id": 5042,
                        "displayName": "year_5042"
                  },
                  {
                        "id": 5043,
                        "displayName": "year_5043"
                  },
                  {
                        "id": 5044,
                        "displayName": "year_5044"
                  },
                  {
                        "id": 5045,
                        "displayName": "year_5045"
                  },
                  {
                        "id": 5046,
                        "displayName": "year_5046"
                  },
                  {
                        "id": 5047,
                        "displayName": "year_5047"
                  },
                  {
                        "id": 5048,
                        "displayName": "year_5048"
                  },
                  {
                        "id": 5049,
                        "displayName": "year_5049"
                  },
                  {
                        "id": 5050,
                        "displayName": "year_5050"
                  },
                  {
                        "id": 5051,
                        "displayName": "year_5051"
                  },
                  {
                        "id": 5052,
                        "displayName": "year_5052"
                  },
                  {
                        "id": 5053,
                        "displayName": "year_5053"
                  },
                  {
                        "id": 5054,
                        "displayName": "year_5054"
                  },
                  {
                        "id": 5055,
                        "displayName": "year_5055"
                  },
                  {
                        "id": 5056,
                        "displayName": "year_5056"
                  },
                  {
                        "id": 5057,
                        "displayName": "year_5057"
                  },
                  {
                        "id": 5058,
                        "displayName": "year_5058"
                  },
                  {
                        "id": 5059,
                        "displayName": "year_5059"
                  },
                  {
                        "id": 5060,
                        "displayName": "year_5060"
                  },
                  {
                        "id": 5061,
                        "displayName": "year_5061"
                  },
                  {
                        "id": 5062,
                        "displayName": "year_5062"
                  },
                  {
                        "id": 5063,
                        "displayName": "year_5063"
                  },
                  {
                        "id": 5064,
                        "displayName": "year_5064"
                  },
                  {
                        "id": 5065,
                        "displayName": "year_5065"
                  },
                  {
                        "id": 5066,
                        "displayName": "year_5066"
                  },
                  {
                        "id": 5067,
                        "displayName": "year_5067"
                  },
                  {
                        "id": 5068,
                        "displayName": "year_5068"
                  },
                  {
                        "id": 5069,
                        "displayName": "year_5069"
                  },
                  {
                        "id": 5070,
                        "displayName": "year_5070"
                  },
                  {
                        "id": 5071,
                        "displayName": "year_5071"
                  },
                  {
                        "id": 5072,
                        "displayName": "year_5072"
                  },
                  {
                        "id": 5073,
                        "displayName": "year_5073"
                  },
                  {
                        "id": 5074,
                        "displayName": "year_5074"
                  },
                  {
                        "id": 5075,
                        "displayName": "year_5075"
                  },
                  {
                        "id": 5076,
                        "displayName": "year_5076"
                  },
                  {
                        "id": 5077,
                        "displayName": "year_5077"
                  },
                  {
                        "id": 5078,
                        "displayName": "year_5078"
                  },
                  {
                        "id": 5079,
                        "displayName": "year_5079"
                  },
                  {
                        "id": 5080,
                        "displayName": "year_5080"
                  },
                  {
                        "id": 5081,
                        "displayName": "year_5081"
                  },
                  {
                        "id": 5082,
                        "displayName": "year_5082"
                  },
                  {
                        "id": 5083,
                        "displayName": "year_5083"
                  },
                  {
                        "id": 5084,
                        "displayName": "year_5084"
                  },
                  {
                        "id": 5085,
                        "displayName": "year_5085"
                  },
                  {
                        "id": 5086,
                        "displayName": "year_5086"
                  },
                  {
                        "id": 5087,
                        "displayName": "year_5087"
                  },
                  {
                        "id": 5088,
                        "displayName": "year_5088"
                  },
                  {
                        "id": 5089,
                        "displayName": "year_5089"
                  },
                  {
                        "id": 5090,
                        "displayName": "year_5090"
                  },
                  {
                        "id": 5091,
                        "displayName": "year_5091"
                  },
                  {
                        "id": 5092,
                        "displayName": "year_5092"
                  },
                  {
                        "id": 5093,
                        "displayName": "year_5093"
                  },
                  {
                        "id": 5094,
                        "displayName": "year_5094"
                  },
                  {
                        "id": 5095,
                        "displayName": "year_5095"
                  },
                  {
                        "id": 5096,
                        "displayName": "year_5096"
                  },
                  {
                        "id": 5097,
                        "displayName": "year_5097"
                  },
                  {
                        "id": 5098,
                        "displayName": "year_5098"
                  },
                  {
                        "id": 5099,
                        "displayName": "year_5099"
                  },
                  {
                        "id": 5100,
                        "displayName": "year_5100"
                  },
                  {
                        "id": 5101,
                        "displayName": "year_5101"
                  },
                  {
                        "id": 5102,
                        "displayName": "year_5102"
                  },
                  {
                        "id": 5103,
                        "displayName": "year_5103"
                  },
                  {
                        "id": 5104,
                        "displayName": "year_5104"
                  },
                  {
                        "id": 5105,
                        "displayName": "year_5105"
                  },
                  {
                        "id": 5106,
                        "displayName": "year_5106"
                  },
                  {
                        "id": 5107,
                        "displayName": "year_5107"
                  },
                  {
                        "id": 5108,
                        "displayName": "year_5108"
                  },
                  {
                        "id": 5109,
                        "displayName": "year_5109"
                  },
                  {
                        "id": 5110,
                        "displayName": "year_5110"
                  },
                  {
                        "id": 5111,
                        "displayName": "year_5111"
                  },
                  {
                        "id": 5112,
                        "displayName": "year_5112"
                  },
                  {
                        "id": 5113,
                        "displayName": "year_5113"
                  },
                  {
                        "id": 5114,
                        "displayName": "year_5114"
                  },
                  {
                        "id": 5115,
                        "displayName": "year_5115"
                  },
                  {
                        "id": 5116,
                        "displayName": "year_5116"
                  },
                  {
                        "id": 5117,
                        "displayName": "year_5117"
                  },
                  {
                        "id": 5118,
                        "displayName": "year_5118"
                  },
                  {
                        "id": 5119,
                        "displayName": "year_5119"
                  },
                  {
                        "id": 5120,
                        "displayName": "year_5120"
                  },
                  {
                        "id": 5121,
                        "displayName": "year_5121"
                  },
                  {
                        "id": 5122,
                        "displayName": "year_5122"
                  },
                  {
                        "id": 5123,
                        "displayName": "year_5123"
                  },
                  {
                        "id": 5124,
                        "displayName": "year_5124"
                  },
                  {
                        "id": 5125,
                        "displayName": "year_5125"
                  },
                  {
                        "id": 5126,
                        "displayName": "year_5126"
                  },
                  {
                        "id": 5127,
                        "displayName": "year_5127"
                  },
                  {
                        "id": 5128,
                        "displayName": "year_5128"
                  },
                  {
                        "id": 5129,
                        "displayName": "year_5129"
                  },
                  {
                        "id": 5130,
                        "displayName": "year_5130"
                  },
                  {
                        "id": 5131,
                        "displayName": "year_5131"
                  },
                  {
                        "id": 5132,
                        "displayName": "year_5132"
                  },
                  {
                        "id": 5133,
                        "displayName": "year_5133"
                  },
                  {
                        "id": 5134,
                        "displayName": "year_5134"
                  },
                  {
                        "id": 5135,
                        "displayName": "year_5135"
                  },
                  {
                        "id": 5136,
                        "displayName": "year_5136"
                  },
                  {
                        "id": 5137,
                        "displayName": "year_5137"
                  },
                  {
                        "id": 5138,
                        "displayName": "year_5138"
                  },
                  {
                        "id": 5139,
                        "displayName": "year_5139"
                  },
                  {
                        "id": 5140,
                        "displayName": "year_5140"
                  },
                  {
                        "id": 5141,
                        "displayName": "year_5141"
                  },
                  {
                        "id": 5142,
                        "displayName": "year_5142"
                  },
                  {
                        "id": 5143,
                        "displayName": "year_5143"
                  },
                  {
                        "id": 5144,
                        "displayName": "year_5144"
                  },
                  {
                        "id": 5145,
                        "displayName": "year_5145"
                  },
                  {
                        "id": 5146,
                        "displayName": "year_5146"
                  },
                  {
                        "id": 5147,
                        "displayName": "year_5147"
                  },
                  {
                        "id": 5148,
                        "displayName": "year_5148"
                  },
                  {
                        "id": 5149,
                        "displayName": "year_5149"
                  },
                  {
                        "id": 5150,
                        "displayName": "year_5150"
                  },
                  {
                        "id": 5151,
                        "displayName": "year_5151"
                  },
                  {
                        "id": 5152,
                        "displayName": "year_5152"
                  },
                  {
                        "id": 5153,
                        "displayName": "year_5153"
                  },
                  {
                        "id": 5154,
                        "displayName": "year_5154"
                  },
                  {
                        "id": 5155,
                        "displayName": "year_5155"
                  },
                  {
                        "id": 5156,
                        "displayName": "year_5156"
                  },
                  {
                        "id": 5157,
                        "displayName": "year_5157"
                  },
                  {
                        "id": 5158,
                        "displayName": "year_5158"
                  },
                  {
                        "id": 5159,
                        "displayName": "year_5159"
                  },
                  {
                        "id": 5160,
                        "displayName": "year_5160"
                  },
                  {
                        "id": 5161,
                        "displayName": "year_5161"
                  },
                  {
                        "id": 5162,
                        "displayName": "year_5162"
                  },
                  {
                        "id": 5163,
                        "displayName": "year_5163"
                  },
                  {
                        "id": 5164,
                        "displayName": "year_5164"
                  },
                  {
                        "id": 5165,
                        "displayName": "year_5165"
                  },
                  {
                        "id": 5166,
                        "displayName": "year_5166"
                  },
                  {
                        "id": 5167,
                        "displayName": "year_5167"
                  },
                  {
                        "id": 5168,
                        "displayName": "year_5168"
                  },
                  {
                        "id": 5169,
                        "displayName": "year_5169"
                  },
                  {
                        "id": 5170,
                        "displayName": "year_5170"
                  },
                  {
                        "id": 5171,
                        "displayName": "year_5171"
                  },
                  {
                        "id": 5172,
                        "displayName": "year_5172"
                  },
                  {
                        "id": 5173,
                        "displayName": "year_5173"
                  },
                  {
                        "id": 5174,
                        "displayName": "year_5174"
                  },
                  {
                        "id": 5175,
                        "displayName": "year_5175"
                  },
                  {
                        "id": 5176,
                        "displayName": "year_5176"
                  },
                  {
                        "id": 5177,
                        "displayName": "year_5177"
                  },
                  {
                        "id": 5178,
                        "displayName": "year_5178"
                  },
                  {
                        "id": 5179,
                        "displayName": "year_5179"
                  },
                  {
                        "id": 5180,
                        "displayName": "year_5180"
                  },
                  {
                        "id": 5181,
                        "displayName": "year_5181"
                  },
                  {
                        "id": 5182,
                        "displayName": "year_5182"
                  },
                  {
                        "id": 5183,
                        "displayName": "year_5183"
                  },
                  {
                        "id": 5184,
                        "displayName": "year_5184"
                  },
                  {
                        "id": 5185,
                        "displayName": "year_5185"
                  },
                  {
                        "id": 5186,
                        "displayName": "year_5186"
                  },
                  {
                        "id": 5187,
                        "displayName": "year_5187"
                  },
                  {
                        "id": 5188,
                        "displayName": "year_5188"
                  },
                  {
                        "id": 5189,
                        "displayName": "year_5189"
                  },
                  {
                        "id": 5190,
                        "displayName": "year_5190"
                  },
                  {
                        "id": 5191,
                        "displayName": "year_5191"
                  },
                  {
                        "id": 5192,
                        "displayName": "year_5192"
                  },
                  {
                        "id": 5193,
                        "displayName": "year_5193"
                  },
                  {
                        "id": 5194,
                        "displayName": "year_5194"
                  },
                  {
                        "id": 5195,
                        "displayName": "year_5195"
                  },
                  {
                        "id": 5196,
                        "displayName": "year_5196"
                  },
                  {
                        "id": 5197,
                        "displayName": "year_5197"
                  },
                  {
                        "id": 5198,
                        "displayName": "year_5198"
                  },
                  {
                        "id": 5199,
                        "displayName": "year_5199"
                  },
                  {
                        "id": 5200,
                        "displayName": "year_5200"
                  },
                  {
                        "id": 5201,
                        "displayName": "year_5201"
                  },
                  {
                        "id": 5202,
                        "displayName": "year_5202"
                  },
                  {
                        "id": 5203,
                        "displayName": "year_5203"
                  },
                  {
                        "id": 5204,
                        "displayName": "year_5204"
                  },
                  {
                        "id": 5205,
                        "displayName": "year_5205"
                  },
                  {
                        "id": 5206,
                        "displayName": "year_5206"
                  },
                  {
                        "id": 5207,
                        "displayName": "year_5207"
                  },
                  {
                        "id": 5208,
                        "displayName": "year_5208"
                  },
                  {
                        "id": 5209,
                        "displayName": "year_5209"
                  },
                  {
                        "id": 5210,
                        "displayName": "year_5210"
                  },
                  {
                        "id": 5211,
                        "displayName": "year_5211"
                  },
                  {
                        "id": 5212,
                        "displayName": "year_5212"
                  },
                  {
                        "id": 5213,
                        "displayName": "year_5213"
                  },
                  {
                        "id": 5214,
                        "displayName": "year_5214"
                  },
                  {
                        "id": 5215,
                        "displayName": "year_5215"
                  },
                  {
                        "id": 5216,
                        "displayName": "year_5216"
                  },
                  {
                        "id": 5217,
                        "displayName": "year_5217"
                  },
                  {
                        "id": 5218,
                        "displayName": "year_5218"
                  },
                  {
                        "id": 5219,
                        "displayName": "year_5219"
                  },
                  {
                        "id": 5220,
                        "displayName": "year_5220"
                  },
                  {
                        "id": 5221,
                        "displayName": "year_5221"
                  },
                  {
                        "id": 5222,
                        "displayName": "year_5222"
                  },
                  {
                        "id": 5223,
                        "displayName": "year_5223"
                  },
                  {
                        "id": 5224,
                        "displayName": "year_5224"
                  },
                  {
                        "id": 5225,
                        "displayName": "year_5225"
                  },
                  {
                        "id": 5226,
                        "displayName": "year_5226"
                  },
                  {
                        "id": 5227,
                        "displayName": "year_5227"
                  },
                  {
                        "id": 5228,
                        "displayName": "year_5228"
                  },
                  {
                        "id": 5229,
                        "displayName": "year_5229"
                  },
                  {
                        "id": 5230,
                        "displayName": "year_5230"
                  },
                  {
                        "id": 5231,
                        "displayName": "year_5231"
                  },
                  {
                        "id": 5232,
                        "displayName": "year_5232"
                  },
                  {
                        "id": 5233,
                        "displayName": "year_5233"
                  },
                  {
                        "id": 5234,
                        "displayName": "year_5234"
                  },
                  {
                        "id": 5235,
                        "displayName": "year_5235"
                  },
                  {
                        "id": 5236,
                        "displayName": "year_5236"
                  },
                  {
                        "id": 5237,
                        "displayName": "year_5237"
                  },
                  {
                        "id": 5238,
                        "displayName": "year_5238"
                  },
                  {
                        "id": 5239,
                        "displayName": "year_5239"
                  },
                  {
                        "id": 5240,
                        "displayName": "year_5240"
                  },
                  {
                        "id": 5241,
                        "displayName": "year_5241"
                  },
                  {
                        "id": 5242,
                        "displayName": "year_5242"
                  },
                  {
                        "id": 5243,
                        "displayName": "year_5243"
                  },
                  {
                        "id": 5244,
                        "displayName": "year_5244"
                  },
                  {
                        "id": 5245,
                        "displayName": "year_5245"
                  },
                  {
                        "id": 5246,
                        "displayName": "year_5246"
                  },
                  {
                        "id": 5247,
                        "displayName": "year_5247"
                  },
                  {
                        "id": 5248,
                        "displayName": "year_5248"
                  },
                  {
                        "id": 5249,
                        "displayName": "year_5249"
                  },
                  {
                        "id": 5250,
                        "displayName": "year_5250"
                  },
                  {
                        "id": 5251,
                        "displayName": "year_5251"
                  },
                  {
                        "id": 5252,
                        "displayName": "year_5252"
                  },
                  {
                        "id": 5253,
                        "displayName": "year_5253"
                  },
                  {
                        "id": 5254,
                        "displayName": "year_5254"
                  },
                  {
                        "id": 5255,
                        "displayName": "year_5255"
                  },
                  {
                        "id": 5256,
                        "displayName": "year_5256"
                  },
                  {
                        "id": 5257,
                        "displayName": "year_5257"
                  },
                  {
                        "id": 5258,
                        "displayName": "year_5258"
                  },
                  {
                        "id": 5259,
                        "displayName": "year_5259"
                  },
                  {
                        "id": 5260,
                        "displayName": "year_5260"
                  },
                  {
                        "id": 5261,
                        "displayName": "year_5261"
                  },
                  {
                        "id": 5262,
                        "displayName": "year_5262"
                  },
                  {
                        "id": 5263,
                        "displayName": "year_5263"
                  },
                  {
                        "id": 5264,
                        "displayName": "year_5264"
                  },
                  {
                        "id": 5265,
                        "displayName": "year_5265"
                  },
                  {
                        "id": 5266,
                        "displayName": "year_5266"
                  },
                  {
                        "id": 5267,
                        "displayName": "year_5267"
                  },
                  {
                        "id": 5268,
                        "displayName": "year_5268"
                  },
                  {
                        "id": 5269,
                        "displayName": "year_5269"
                  },
                  {
                        "id": 5270,
                        "displayName": "year_5270"
                  },
                  {
                        "id": 5271,
                        "displayName": "year_5271"
                  },
                  {
                        "id": 5272,
                        "displayName": "year_5272"
                  },
                  {
                        "id": 5273,
                        "displayName": "year_5273"
                  },
                  {
                        "id": 5274,
                        "displayName": "year_5274"
                  },
                  {
                        "id": 5275,
                        "displayName": "year_5275"
                  },
                  {
                        "id": 5276,
                        "displayName": "year_5276"
                  },
                  {
                        "id": 5277,
                        "displayName": "year_5277"
                  },
                  {
                        "id": 5278,
                        "displayName": "year_5278"
                  },
                  {
                        "id": 5279,
                        "displayName": "year_5279"
                  },
                  {
                        "id": 5280,
                        "displayName": "year_5280"
                  },
                  {
                        "id": 5281,
                        "displayName": "year_5281"
                  },
                  {
                        "id": 5282,
                        "displayName": "year_5282"
                  },
                  {
                        "id": 5283,
                        "displayName": "year_5283"
                  },
                  {
                        "id": 5284,
                        "displayName": "year_5284"
                  },
                  {
                        "id": 5285,
                        "displayName": "year_5285"
                  },
                  {
                        "id": 5286,
                        "displayName": "year_5286"
                  },
                  {
                        "id": 5287,
                        "displayName": "year_5287"
                  },
                  {
                        "id": 5288,
                        "displayName": "year_5288"
                  },
                  {
                        "id": 5289,
                        "displayName": "year_5289"
                  },
                  {
                        "id": 5290,
                        "displayName": "year_5290"
                  },
                  {
                        "id": 5291,
                        "displayName": "year_5291"
                  },
                  {
                        "id": 5292,
                        "displayName": "year_5292"
                  },
                  {
                        "id": 5293,
                        "displayName": "year_5293"
                  },
                  {
                        "id": 5294,
                        "displayName": "year_5294"
                  },
                  {
                        "id": 5295,
                        "displayName": "year_5295"
                  },
                  {
                        "id": 5296,
                        "displayName": "year_5296"
                  },
                  {
                        "id": 5297,
                        "displayName": "year_5297"
                  },
                  {
                        "id": 5298,
                        "displayName": "year_5298"
                  },
                  {
                        "id": 5299,
                        "displayName": "year_5299"
                  },
                  {
                        "id": 5300,
                        "displayName": "year_5300"
                  },
                  {
                        "id": 5301,
                        "displayName": "year_5301"
                  },
                  {
                        "id": 5302,
                        "displayName": "year_5302"
                  },
                  {
                        "id": 5303,
                        "displayName": "year_5303"
                  },
                  {
                        "id": 5304,
                        "displayName": "year_5304"
                  },
                  {
                        "id": 5305,
                        "displayName": "year_5305"
                  },
                  {
                        "id": 5306,
                        "displayName": "year_5306"
                  },
                  {
                        "id": 5307,
                        "displayName": "year_5307"
                  },
                  {
                        "id": 5308,
                        "displayName": "year_5308"
                  },
                  {
                        "id": 5309,
                        "displayName": "year_5309"
                  },
                  {
                        "id": 5310,
                        "displayName": "year_5310"
                  },
                  {
                        "id": 5311,
                        "displayName": "year_5311"
                  },
                  {
                        "id": 5312,
                        "displayName": "year_5312"
                  },
                  {
                        "id": 5313,
                        "displayName": "year_5313"
                  },
                  {
                        "id": 5314,
                        "displayName": "year_5314"
                  },
                  {
                        "id": 5315,
                        "displayName": "year_5315"
                  },
                  {
                        "id": 5316,
                        "displayName": "year_5316"
                  },
                  {
                        "id": 5317,
                        "displayName": "year_5317"
                  },
                  {
                        "id": 5318,
                        "displayName": "year_5318"
                  },
                  {
                        "id": 5319,
                        "displayName": "year_5319"
                  },
                  {
                        "id": 5320,
                        "displayName": "year_5320"
                  },
                  {
                        "id": 5321,
                        "displayName": "year_5321"
                  },
                  {
                        "id": 5322,
                        "displayName": "year_5322"
                  },
                  {
                        "id": 5323,
                        "displayName": "year_5323"
                  },
                  {
                        "id": 5324,
                        "displayName": "year_5324"
                  },
                  {
                        "id": 5325,
                        "displayName": "year_5325"
                  },
                  {
                        "id": 5326,
                        "displayName": "year_5326"
                  },
                  {
                        "id": 5327,
                        "displayName": "year_5327"
                  },
                  {
                        "id": 5328,
                        "displayName": "year_5328"
                  },
                  {
                        "id": 5329,
                        "displayName": "year_5329"
                  },
                  {
                        "id": 5330,
                        "displayName": "year_5330"
                  },
                  {
                        "id": 5331,
                        "displayName": "year_5331"
                  },
                  {
                        "id": 5332,
                        "displayName": "year_5332"
                  },
                  {
                        "id": 5333,
                        "displayName": "year_5333"
                  },
                  {
                        "id": 5334,
                        "displayName": "year_5334"
                  },
                  {
                        "id": 5335,
                        "displayName": "year_5335"
                  },
                  {
                        "id": 5336,
                        "displayName": "year_5336"
                  },
                  {
                        "id": 5337,
                        "displayName": "year_5337"
                  },
                  {
                        "id": 5338,
                        "displayName": "year_5338"
                  },
                  {
                        "id": 5339,
                        "displayName": "year_5339"
                  },
                  {
                        "id": 5340,
                        "displayName": "year_5340"
                  },
                  {
                        "id": 5341,
                        "displayName": "year_5341"
                  },
                  {
                        "id": 5342,
                        "displayName": "year_5342"
                  },
                  {
                        "id": 5343,
                        "displayName": "year_5343"
                  },
                  {
                        "id": 5344,
                        "displayName": "year_5344"
                  },
                  {
                        "id": 5345,
                        "displayName": "year_5345"
                  },
                  {
                        "id": 5346,
                        "displayName": "year_5346"
                  },
                  {
                        "id": 5347,
                        "displayName": "year_5347"
                  },
                  {
                        "id": 5348,
                        "displayName": "year_5348"
                  },
                  {
                        "id": 5349,
                        "displayName": "year_5349"
                  },
                  {
                        "id": 5350,
                        "displayName": "year_5350"
                  },
                  {
                        "id": 5351,
                        "displayName": "year_5351"
                  },
                  {
                        "id": 5352,
                        "displayName": "year_5352"
                  },
                  {
                        "id": 5353,
                        "displayName": "year_5353"
                  },
                  {
                        "id": 5354,
                        "displayName": "year_5354"
                  },
                  {
                        "id": 5355,
                        "displayName": "year_5355"
                  },
                  {
                        "id": 5356,
                        "displayName": "year_5356"
                  },
                  {
                        "id": 5357,
                        "displayName": "year_5357"
                  },
                  {
                        "id": 5358,
                        "displayName": "year_5358"
                  },
                  {
                        "id": 5359,
                        "displayName": "year_5359"
                  },
                  {
                        "id": 5360,
                        "displayName": "year_5360"
                  },
                  {
                        "id": 5361,
                        "displayName": "year_5361"
                  },
                  {
                        "id": 5362,
                        "displayName": "year_5362"
                  },
                  {
                        "id": 5363,
                        "displayName": "year_5363"
                  },
                  {
                        "id": 5364,
                        "displayName": "year_5364"
                  },
                  {
                        "id": 5365,
                        "displayName": "year_5365"
                  },
                  {
                        "id": 5366,
                        "displayName": "year_5366"
                  },
                  {
                        "id": 5367,
                        "displayName": "year_5367"
                  },
                  {
                        "id": 5368,
                        "displayName": "year_5368"
                  },
                  {
                        "id": 5369,
                        "displayName": "year_5369"
                  },
                  {
                        "id": 5370,
                        "displayName": "year_5370"
                  },
                  {
                        "id": 5371,
                        "displayName": "year_5371"
                  },
                  {
                        "id": 5372,
                        "displayName": "year_5372"
                  },
                  {
                        "id": 5373,
                        "displayName": "year_5373"
                  },
                  {
                        "id": 5374,
                        "displayName": "year_5374"
                  },
                  {
                        "id": 5375,
                        "displayName": "year_5375"
                  },
                  {
                        "id": 5376,
                        "displayName": "year_5376"
                  },
                  {
                        "id": 5377,
                        "displayName": "year_5377"
                  },
                  {
                        "id": 5378,
                        "displayName": "year_5378"
                  },
                  {
                        "id": 5379,
                        "displayName": "year_5379"
                  },
                  {
                        "id": 5380,
                        "displayName": "year_5380"
                  },
                  {
                        "id": 5381,
                        "displayName": "year_5381"
                  },
                  {
                        "id": 5382,
                        "displayName": "year_5382"
                  },
                  {
                        "id": 5383,
                        "displayName": "year_5383"
                  },
                  {
                        "id": 5384,
                        "displayName": "year_5384"
                  },
                  {
                        "id": 5385,
                        "displayName": "year_5385"
                  },
                  {
                        "id": 5386,
                        "displayName": "year_5386"
                  },
                  {
                        "id": 5387,
                        "displayName": "year_5387"
                  },
                  {
                        "id": 5388,
                        "displayName": "year_5388"
                  },
                  {
                        "id": 5389,
                        "displayName": "year_5389"
                  },
                  {
                        "id": 5390,
                        "displayName": "year_5390"
                  },
                  {
                        "id": 5391,
                        "displayName": "year_5391"
                  },
                  {
                        "id": 5392,
                        "displayName": "year_5392"
                  },
                  {
                        "id": 5393,
                        "displayName": "year_5393"
                  },
                  {
                        "id": 5394,
                        "displayName": "year_5394"
                  },
                  {
                        "id": 5395,
                        "displayName": "year_5395"
                  },
                  {
                        "id": 5396,
                        "displayName": "year_5396"
                  },
                  {
                        "id": 5397,
                        "displayName": "year_5397"
                  },
                  {
                        "id": 5398,
                        "displayName": "year_5398"
                  },
                  {
                        "id": 5399,
                        "displayName": "year_5399"
                  },
                  {
                        "id": 5400,
                        "displayName": "year_5400"
                  },
                  {
                        "id": 5401,
                        "displayName": "year_5401"
                  },
                  {
                        "id": 5402,
                        "displayName": "year_5402"
                  },
                  {
                        "id": 5403,
                        "displayName": "year_5403"
                  },
                  {
                        "id": 5404,
                        "displayName": "year_5404"
                  },
                  {
                        "id": 5405,
                        "displayName": "year_5405"
                  },
                  {
                        "id": 5406,
                        "displayName": "year_5406"
                  },
                  {
                        "id": 5407,
                        "displayName": "year_5407"
                  },
                  {
                        "id": 5408,
                        "displayName": "year_5408"
                  },
                  {
                        "id": 5409,
                        "displayName": "year_5409"
                  },
                  {
                        "id": 5410,
                        "displayName": "year_5410"
                  },
                  {
                        "id": 5411,
                        "displayName": "year_5411"
                  },
                  {
                        "id": 5412,
                        "displayName": "year_5412"
                  },
                  {
                        "id": 5413,
                        "displayName": "year_5413"
                  },
                  {
                        "id": 5414,
                        "displayName": "year_5414"
                  },
                  {
                        "id": 5415,
                        "displayName": "year_5415"
                  },
                  {
                        "id": 5416,
                        "displayName": "year_5416"
                  },
                  {
                        "id": 5417,
                        "displayName": "year_5417"
                  },
                  {
                        "id": 5418,
                        "displayName": "year_5418"
                  },
                  {
                        "id": 5419,
                        "displayName": "year_5419"
                  },
                  {
                        "id": 5420,
                        "displayName": "year_5420"
                  },
                  {
                        "id": 5421,
                        "displayName": "year_5421"
                  },
                  {
                        "id": 5422,
                        "displayName": "year_5422"
                  },
                  {
                        "id": 5423,
                        "displayName": "year_5423"
                  },
                  {
                        "id": 5424,
                        "displayName": "year_5424"
                  },
                  {
                        "id": 5425,
                        "displayName": "year_5425"
                  },
                  {
                        "id": 5426,
                        "displayName": "year_5426"
                  },
                  {
                        "id": 5427,
                        "displayName": "year_5427"
                  },
                  {
                        "id": 5428,
                        "displayName": "year_5428"
                  },
                  {
                        "id": 5429,
                        "displayName": "year_5429"
                  },
                  {
                        "id": 5430,
                        "displayName": "year_5430"
                  },
                  {
                        "id": 5431,
                        "displayName": "year_5431"
                  },
                  {
                        "id": 5432,
                        "displayName": "year_5432"
                  },
                  {
                        "id": 5433,
                        "displayName": "year_5433"
                  },
                  {
                        "id": 5434,
                        "displayName": "year_5434"
                  },
                  {
                        "id": 5435,
                        "displayName": "year_5435"
                  },
                  {
                        "id": 5436,
                        "displayName": "year_5436"
                  },
                  {
                        "id": 5437,
                        "displayName": "year_5437"
                  },
                  {
                        "id": 5438,
                        "displayName": "year_5438"
                  },
                  {
                        "id": 5439,
                        "displayName": "year_5439"
                  },
                  {
                        "id": 5440,
                        "displayName": "year_5440"
                  },
                  {
                        "id": 5441,
                        "displayName": "year_5441"
                  },
                  {
                        "id": 5442,
                        "displayName": "year_5442"
                  },
                  {
                        "id": 5443,
                        "displayName": "year_5443"
                  },
                  {
                        "id": 5444,
                        "displayName": "year_5444"
                  },
                  {
                        "id": 5445,
                        "displayName": "year_5445"
                  },
                  {
                        "id": 5446,
                        "displayName": "year_5446"
                  },
                  {
                        "id": 5447,
                        "displayName": "year_5447"
                  },
                  {
                        "id": 5448,
                        "displayName": "year_5448"
                  },
                  {
                        "id": 5449,
                        "displayName": "year_5449"
                  },
                  {
                        "id": 5450,
                        "displayName": "year_5450"
                  },
                  {
                        "id": 5451,
                        "displayName": "year_5451"
                  },
                  {
                        "id": 5452,
                        "displayName": "year_5452"
                  },
                  {
                        "id": 5453,
                        "displayName": "year_5453"
                  },
                  {
                        "id": 5454,
                        "displayName": "year_5454"
                  },
                  {
                        "id": 5455,
                        "displayName": "year_5455"
                  },
                  {
                        "id": 5456,
                        "displayName": "year_5456"
                  },
                  {
                        "id": 5457,
                        "displayName": "year_5457"
                  },
                  {
                        "id": 5458,
                        "displayName": "year_5458"
                  },
                  {
                        "id": 5459,
                        "displayName": "year_5459"
                  },
                  {
                        "id": 5460,
                        "displayName": "year_5460"
                  },
                  {
                        "id": 5461,
                        "displayName": "year_5461"
                  },
                  {
                        "id": 5462,
                        "displayName": "year_5462"
                  },
                  {
                        "id": 5463,
                        "displayName": "year_5463"
                  },
                  {
                        "id": 5464,
                        "displayName": "year_5464"
                  },
                  {
                        "id": 5465,
                        "displayName": "year_5465"
                  },
                  {
                        "id": 5466,
                        "displayName": "year_5466"
                  },
                  {
                        "id": 5467,
                        "displayName": "year_5467"
                  },
                  {
                        "id": 5468,
                        "displayName": "year_5468"
                  },
                  {
                        "id": 5469,
                        "displayName": "year_5469"
                  },
                  {
                        "id": 5470,
                        "displayName": "year_5470"
                  },
                  {
                        "id": 5471,
                        "displayName": "year_5471"
                  },
                  {
                        "id": 5472,
                        "displayName": "year_5472"
                  },
                  {
                        "id": 5473,
                        "displayName": "year_5473"
                  },
                  {
                        "id": 5474,
                        "displayName": "year_5474"
                  },
                  {
                        "id": 5475,
                        "displayName": "year_5475"
                  },
                  {
                        "id": 5476,
                        "displayName": "year_5476"
                  },
                  {
                        "id": 5477,
                        "displayName": "year_5477"
                  },
                  {
                        "id": 5478,
                        "displayName": "year_5478"
                  },
                  {
                        "id": 5479,
                        "displayName": "year_5479"
                  },
                  {
                        "id": 5480,
                        "displayName": "year_5480"
                  },
                  {
                        "id": 5481,
                        "displayName": "year_5481"
                  },
                  {
                        "id": 5482,
                        "displayName": "year_5482"
                  },
                  {
                        "id": 5483,
                        "displayName": "year_5483"
                  },
                  {
                        "id": 5484,
                        "displayName": "year_5484"
                  },
                  {
                        "id": 5485,
                        "displayName": "year_5485"
                  },
                  {
                        "id": 5486,
                        "displayName": "year_5486"
                  },
                  {
                        "id": 5487,
                        "displayName": "year_5487"
                  },
                  {
                        "id": 5488,
                        "displayName": "year_5488"
                  },
                  {
                        "id": 5489,
                        "displayName": "year_5489"
                  },
                  {
                        "id": 5490,
                        "displayName": "year_5490"
                  },
                  {
                        "id": 5491,
                        "displayName": "year_5491"
                  },
                  {
                        "id": 5492,
                        "displayName": "year_5492"
                  },
                  {
                        "id": 5493,
                        "displayName": "year_5493"
                  },
                  {
                        "id": 5494,
                        "displayName": "year_5494"
                  },
                  {
                        "id": 5495,
                        "displayName": "year_5495"
                  },
                  {
                        "id": 5496,
                        "displayName": "year_5496"
                  },
                  {
                        "id": 5497,
                        "displayName": "year_5497"
                  },
                  {
                        "id": 5498,
                        "displayName": "year_5498"
                  },
                  {
                        "id": 5499,
                        "displayName": "year_5499"
                  },
                  {
                        "id": 5500,
                        "displayName": "year_5500"
                  },
                  {
                        "id": 5501,
                        "displayName": "year_5501"
                  },
                  {
                        "id": 5502,
                        "displayName": "year_5502"
                  },
                  {
                        "id": 5503,
                        "displayName": "year_5503"
                  },
                  {
                        "id": 5504,
                        "displayName": "year_5504"
                  },
                  {
                        "id": 5505,
                        "displayName": "year_5505"
                  },
                  {
                        "id": 5506,
                        "displayName": "year_5506"
                  },
                  {
                        "id": 5507,
                        "displayName": "year_5507"
                  },
                  {
                        "id": 5508,
                        "displayName": "year_5508"
                  },
                  {
                        "id": 5509,
                        "displayName": "year_5509"
                  },
                  {
                        "id": 5510,
                        "displayName": "year_5510"
                  },
                  {
                        "id": 5511,
                        "displayName": "year_5511"
                  },
                  {
                        "id": 5512,
                        "displayName": "year_5512"
                  },
                  {
                        "id": 5513,
                        "displayName": "year_5513"
                  },
                  {
                        "id": 5514,
                        "displayName": "year_5514"
                  },
                  {
                        "id": 5515,
                        "displayName": "year_5515"
                  },
                  {
                        "id": 5516,
                        "displayName": "year_5516"
                  },
                  {
                        "id": 5517,
                        "displayName": "year_5517"
                  },
                  {
                        "id": 5518,
                        "displayName": "year_5518"
                  },
                  {
                        "id": 5519,
                        "displayName": "year_5519"
                  },
                  {
                        "id": 5520,
                        "displayName": "year_5520"
                  },
                  {
                        "id": 5521,
                        "displayName": "year_5521"
                  },
                  {
                        "id": 5522,
                        "displayName": "year_5522"
                  },
                  {
                        "id": 5523,
                        "displayName": "year_5523"
                  },
                  {
                        "id": 5524,
                        "displayName": "year_5524"
                  },
                  {
                        "id": 5525,
                        "displayName": "year_5525"
                  },
                  {
                        "id": 5526,
                        "displayName": "year_5526"
                  },
                  {
                        "id": 5527,
                        "displayName": "year_5527"
                  },
                  {
                        "id": 5528,
                        "displayName": "year_5528"
                  },
                  {
                        "id": 5529,
                        "displayName": "year_5529"
                  },
                  {
                        "id": 5530,
                        "displayName": "year_5530"
                  },
                  {
                        "id": 5531,
                        "displayName": "year_5531"
                  },
                  {
                        "id": 5532,
                        "displayName": "year_5532"
                  },
                  {
                        "id": 5533,
                        "displayName": "year_5533"
                  },
                  {
                        "id": 5534,
                        "displayName": "year_5534"
                  },
                  {
                        "id": 5535,
                        "displayName": "year_5535"
                  },
                  {
                        "id": 5536,
                        "displayName": "year_5536"
                  },
                  {
                        "id": 5537,
                        "displayName": "year_5537"
                  },
                  {
                        "id": 5538,
                        "displayName": "year_5538"
                  },
                  {
                        "id": 5539,
                        "displayName": "year_5539"
                  },
                  {
                        "id": 5540,
                        "displayName": "year_5540"
                  },
                  {
                        "id": 5541,
                        "displayName": "year_5541"
                  },
                  {
                        "id": 5542,
                        "displayName": "year_5542"
                  },
                  {
                        "id": 5543,
                        "displayName": "year_5543"
                  },
                  {
                        "id": 5544,
                        "displayName": "year_5544"
                  },
                  {
                        "id": 5545,
                        "displayName": "year_5545"
                  },
                  {
                        "id": 5546,
                        "displayName": "year_5546"
                  },
                  {
                        "id": 5547,
                        "displayName": "year_5547"
                  },
                  {
                        "id": 5548,
                        "displayName": "year_5548"
                  },
                  {
                        "id": 5549,
                        "displayName": "year_5549"
                  },
                  {
                        "id": 5550,
                        "displayName": "year_5550"
                  },
                  {
                        "id": 5551,
                        "displayName": "year_5551"
                  },
                  {
                        "id": 5552,
                        "displayName": "year_5552"
                  },
                  {
                        "id": 5553,
                        "displayName": "year_5553"
                  },
                  {
                        "id": 5554,
                        "displayName": "year_5554"
                  },
                  {
                        "id": 5555,
                        "displayName": "year_5555"
                  },
                  {
                        "id": 5556,
                        "displayName": "year_5556"
                  },
                  {
                        "id": 5557,
                        "displayName": "year_5557"
                  },
                  {
                        "id": 5558,
                        "displayName": "year_5558"
                  },
                  {
                        "id": 5559,
                        "displayName": "year_5559"
                  },
                  {
                        "id": 5560,
                        "displayName": "year_5560"
                  },
                  {
                        "id": 5561,
                        "displayName": "year_5561"
                  },
                  {
                        "id": 5562,
                        "displayName": "year_5562"
                  },
                  {
                        "id": 5563,
                        "displayName": "year_5563"
                  },
                  {
                        "id": 5564,
                        "displayName": "year_5564"
                  },
                  {
                        "id": 5565,
                        "displayName": "year_5565"
                  },
                  {
                        "id": 5566,
                        "displayName": "year_5566"
                  },
                  {
                        "id": 5567,
                        "displayName": "year_5567"
                  },
                  {
                        "id": 5568,
                        "displayName": "year_5568"
                  },
                  {
                        "id": 5569,
                        "displayName": "year_5569"
                  },
                  {
                        "id": 5570,
                        "displayName": "year_5570"
                  },
                  {
                        "id": 5571,
                        "displayName": "year_5571"
                  },
                  {
                        "id": 5572,
                        "displayName": "year_5572"
                  },
                  {
                        "id": 5573,
                        "displayName": "year_5573"
                  },
                  {
                        "id": 5574,
                        "displayName": "year_5574"
                  },
                  {
                        "id": 5575,
                        "displayName": "year_5575"
                  },
                  {
                        "id": 5576,
                        "displayName": "year_5576"
                  },
                  {
                        "id": 5577,
                        "displayName": "year_5577"
                  },
                  {
                        "id": 5578,
                        "displayName": "year_5578"
                  },
                  {
                        "id": 5579,
                        "displayName": "year_5579"
                  },
                  {
                        "id": 5580,
                        "displayName": "year_5580"
                  },
                  {
                        "id": 5581,
                        "displayName": "year_5581"
                  },
                  {
                        "id": 5582,
                        "displayName": "year_5582"
                  },
                  {
                        "id": 5583,
                        "displayName": "year_5583"
                  },
                  {
                        "id": 5584,
                        "displayName": "year_5584"
                  },
                  {
                        "id": 5585,
                        "displayName": "year_5585"
                  },
                  {
                        "id": 5586,
                        "displayName": "year_5586"
                  },
                  {
                        "id": 5587,
                        "displayName": "year_5587"
                  },
                  {
                        "id": 5588,
                        "displayName": "year_5588"
                  },
                  {
                        "id": 5589,
                        "displayName": "year_5589"
                  },
                  {
                        "id": 5590,
                        "displayName": "year_5590"
                  },
                  {
                        "id": 5591,
                        "displayName": "year_5591"
                  },
                  {
                        "id": 5592,
                        "displayName": "year_5592"
                  },
                  {
                        "id": 5593,
                        "displayName": "year_5593"
                  },
                  {
                        "id": 5594,
                        "displayName": "year_5594"
                  },
                  {
                        "id": 5595,
                        "displayName": "year_5595"
                  },
                  {
                        "id": 5596,
                        "displayName": "year_5596"
                  },
                  {
                        "id": 5597,
                        "displayName": "year_5597"
                  },
                  {
                        "id": 5598,
                        "displayName": "year_5598"
                  },
                  {
                        "id": 5599,
                        "displayName": "year_5599"
                  },
                  {
                        "id": 5600,
                        "displayName": "year_5600"
                  },
                  {
                        "id": 5601,
                        "displayName": "year_5601"
                  },
                  {
                        "id": 5602,
                        "displayName": "year_5602"
                  },
                  {
                        "id": 5603,
                        "displayName": "year_5603"
                  },
                  {
                        "id": 5604,
                        "displayName": "year_5604"
                  },
                  {
                        "id": 5605,
                        "displayName": "year_5605"
                  },
                  {
                        "id": 5606,
                        "displayName": "year_5606"
                  },
                  {
                        "id": 5607,
                        "displayName": "year_5607"
                  },
                  {
                        "id": 5608,
                        "displayName": "year_5608"
                  },
                  {
                        "id": 5609,
                        "displayName": "year_5609"
                  },
                  {
                        "id": 5610,
                        "displayName": "year_5610"
                  },
                  {
                        "id": 5611,
                        "displayName": "year_5611"
                  },
                  {
                        "id": 5612,
                        "displayName": "year_5612"
                  },
                  {
                        "id": 5613,
                        "displayName": "year_5613"
                  },
                  {
                        "id": 5614,
                        "displayName": "year_5614"
                  },
                  {
                        "id": 5615,
                        "displayName": "year_5615"
                  },
                  {
                        "id": 5616,
                        "displayName": "year_5616"
                  },
                  {
                        "id": 5617,
                        "displayName": "year_5617"
                  },
                  {
                        "id": 5618,
                        "displayName": "year_5618"
                  },
                  {
                        "id": 5619,
                        "displayName": "year_5619"
                  },
                  {
                        "id": 5620,
                        "displayName": "year_5620"
                  },
                  {
                        "id": 5621,
                        "displayName": "year_5621"
                  },
                  {
                        "id": 5622,
                        "displayName": "year_5622"
                  },
                  {
                        "id": 5623,
                        "displayName": "year_5623"
                  },
                  {
                        "id": 5624,
                        "displayName": "year_5624"
                  },
                  {
                        "id": 5625,
                        "displayName": "year_5625"
                  },
                  {
                        "id": 5626,
                        "displayName": "year_5626"
                  },
                  {
                        "id": 5627,
                        "displayName": "year_5627"
                  },
                  {
                        "id": 5628,
                        "displayName": "year_5628"
                  },
                  {
                        "id": 5629,
                        "displayName": "year_5629"
                  },
                  {
                        "id": 5630,
                        "displayName": "year_5630"
                  },
                  {
                        "id": 5631,
                        "displayName": "year_5631"
                  },
                  {
                        "id": 5632,
                        "displayName": "year_5632"
                  },
                  {
                        "id": 5633,
                        "displayName": "year_5633"
                  },
                  {
                        "id": 5634,
                        "displayName": "year_5634"
                  },
                  {
                        "id": 5635,
                        "displayName": "year_5635"
                  },
                  {
                        "id": 5636,
                        "displayName": "year_5636"
                  },
                  {
                        "id": 5637,
                        "displayName": "year_5637"
                  },
                  {
                        "id": 5638,
                        "displayName": "year_5638"
                  },
                  {
                        "id": 5639,
                        "displayName": "year_5639"
                  },
                  {
                        "id": 5640,
                        "displayName": "year_5640"
                  },
                  {
                        "id": 5641,
                        "displayName": "year_5641"
                  },
                  {
                        "id": 5642,
                        "displayName": "year_5642"
                  },
                  {
                        "id": 5643,
                        "displayName": "year_5643"
                  },
                  {
                        "id": 5644,
                        "displayName": "year_5644"
                  },
                  {
                        "id": 5645,
                        "displayName": "year_5645"
                  },
                  {
                        "id": 5646,
                        "displayName": "year_5646"
                  },
                  {
                        "id": 5647,
                        "displayName": "year_5647"
                  },
                  {
                        "id": 5648,
                        "displayName": "year_5648"
                  },
                  {
                        "id": 5649,
                        "displayName": "year_5649"
                  },
                  {
                        "id": 5650,
                        "displayName": "year_5650"
                  },
                  {
                        "id": 5651,
                        "displayName": "year_5651"
                  },
                  {
                        "id": 5652,
                        "displayName": "year_5652"
                  },
                  {
                        "id": 5653,
                        "displayName": "year_5653"
                  },
                  {
                        "id": 5654,
                        "displayName": "year_5654"
                  },
                  {
                        "id": 5655,
                        "displayName": "year_5655"
                  },
                  {
                        "id": 5656,
                        "displayName": "year_5656"
                  },
                  {
                        "id": 5657,
                        "displayName": "year_5657"
                  },
                  {
                        "id": 5658,
                        "displayName": "year_5658"
                  },
                  {
                        "id": 5659,
                        "displayName": "year_5659"
                  },
                  {
                        "id": 5660,
                        "displayName": "year_5660"
                  },
                  {
                        "id": 5661,
                        "displayName": "year_5661"
                  },
                  {
                        "id": 5662,
                        "displayName": "year_5662"
                  },
                  {
                        "id": 5663,
                        "displayName": "year_5663"
                  },
                  {
                        "id": 5664,
                        "displayName": "year_5664"
                  },
                  {
                        "id": 5665,
                        "displayName": "year_5665"
                  },
                  {
                        "id": 5666,
                        "displayName": "year_5666"
                  },
                  {
                        "id": 5667,
                        "displayName": "year_5667"
                  },
                  {
                        "id": 5668,
                        "displayName": "year_5668"
                  },
                  {
                        "id": 5669,
                        "displayName": "year_5669"
                  },
                  {
                        "id": 5670,
                        "displayName": "year_5670"
                  },
                  {
                        "id": 5671,
                        "displayName": "year_5671"
                  },
                  {
                        "id": 5672,
                        "displayName": "year_5672"
                  },
                  {
                        "id": 5673,
                        "displayName": "year_5673"
                  },
                  {
                        "id": 5674,
                        "displayName": "year_5674"
                  },
                  {
                        "id": 5675,
                        "displayName": "year_5675"
                  },
                  {
                        "id": 5676,
                        "displayName": "year_5676"
                  },
                  {
                        "id": 5677,
                        "displayName": "year_5677"
                  },
                  {
                        "id": 5678,
                        "displayName": "year_5678"
                  },
                  {
                        "id": 5679,
                        "displayName": "year_5679"
                  },
                  {
                        "id": 5680,
                        "displayName": "year_5680"
                  },
                  {
                        "id": 5681,
                        "displayName": "year_5681"
                  },
                  {
                        "id": 5682,
                        "displayName": "year_5682"
                  },
                  {
                        "id": 5683,
                        "displayName": "year_5683"
                  },
                  {
                        "id": 5684,
                        "displayName": "year_5684"
                  },
                  {
                        "id": 5685,
                        "displayName": "year_5685"
                  },
                  {
                        "id": 5686,
                        "displayName": "year_5686"
                  },
                  {
                        "id": 5687,
                        "displayName": "year_5687"
                  },
                  {
                        "id": 5688,
                        "displayName": "year_5688"
                  },
                  {
                        "id": 5689,
                        "displayName": "year_5689"
                  },
                  {
                        "id": 5690,
                        "displayName": "year_5690"
                  },
                  {
                        "id": 5691,
                        "displayName": "year_5691"
                  },
                  {
                        "id": 5692,
                        "displayName": "year_5692"
                  },
                  {
                        "id": 5693,
                        "displayName": "year_5693"
                  },
                  {
                        "id": 5694,
                        "displayName": "year_5694"
                  },
                  {
                        "id": 5695,
                        "displayName": "year_5695"
                  },
                  {
                        "id": 5696,
                        "displayName": "year_5696"
                  },
                  {
                        "id": 5697,
                        "displayName": "year_5697"
                  },
                  {
                        "id": 5698,
                        "displayName": "year_5698"
                  },
                  {
                        "id": 5699,
                        "displayName": "year_5699"
                  },
                  {
                        "id": 5700,
                        "displayName": "year_5700"
                  },
                  {
                        "id": 5701,
                        "displayName": "year_5701"
                  },
                  {
                        "id": 5702,
                        "displayName": "year_5702"
                  },
                  {
                        "id": 5703,
                        "displayName": "year_5703"
                  },
                  {
                        "id": 5704,
                        "displayName": "year_5704"
                  },
                  {
                        "id": 5705,
                        "displayName": "year_5705"
                  },
                  {
                        "id": 5706,
                        "displayName": "year_5706"
                  },
                  {
                        "id": 5707,
                        "displayName": "year_5707"
                  },
                  {
                        "id": 5708,
                        "displayName": "year_5708"
                  },
                  {
                        "id": 5709,
                        "displayName": "year_5709"
                  },
                  {
                        "id": 5710,
                        "displayName": "year_5710"
                  },
                  {
                        "id": 5711,
                        "displayName": "year_5711"
                  },
                  {
                        "id": 5712,
                        "displayName": "year_5712"
                  },
                  {
                        "id": 5713,
                        "displayName": "year_5713"
                  },
                  {
                        "id": 5714,
                        "displayName": "year_5714"
                  },
                  {
                        "id": 5715,
                        "displayName": "year_5715"
                  },
                  {
                        "id": 5716,
                        "displayName": "year_5716"
                  },
                  {
                        "id": 5717,
                        "displayName": "year_5717"
                  },
                  {
                        "id": 5718,
                        "displayName": "year_5718"
                  },
                  {
                        "id": 5719,
                        "displayName": "year_5719"
                  },
                  {
                        "id": 5720,
                        "displayName": "year_5720"
                  },
                  {
                        "id": 5721,
                        "displayName": "year_5721"
                  },
                  {
                        "id": 5722,
                        "displayName": "year_5722"
                  },
                  {
                        "id": 5723,
                        "displayName": "year_5723"
                  },
                  {
                        "id": 5724,
                        "displayName": "year_5724"
                  },
                  {
                        "id": 5725,
                        "displayName": "year_5725"
                  },
                  {
                        "id": 5726,
                        "displayName": "year_5726"
                  },
                  {
                        "id": 5727,
                        "displayName": "year_5727"
                  },
                  {
                        "id": 5728,
                        "displayName": "year_5728"
                  },
                  {
                        "id": 5729,
                        "displayName": "year_5729"
                  },
                  {
                        "id": 5730,
                        "displayName": "year_5730"
                  },
                  {
                        "id": 5731,
                        "displayName": "year_5731"
                  },
                  {
                        "id": 5732,
                        "displayName": "year_5732"
                  },
                  {
                        "id": 5733,
                        "displayName": "year_5733"
                  },
                  {
                        "id": 5734,
                        "displayName": "year_5734"
                  },
                  {
                        "id": 5735,
                        "displayName": "year_5735"
                  },
                  {
                        "id": 5736,
                        "displayName": "year_5736"
                  },
                  {
                        "id": 5737,
                        "displayName": "year_5737"
                  },
                  {
                        "id": 5738,
                        "displayName": "year_5738"
                  },
                  {
                        "id": 5739,
                        "displayName": "year_5739"
                  },
                  {
                        "id": 5740,
                        "displayName": "year_5740"
                  },
                  {
                        "id": 5741,
                        "displayName": "year_5741"
                  },
                  {
                        "id": 5742,
                        "displayName": "year_5742"
                  },
                  {
                        "id": 5743,
                        "displayName": "year_5743"
                  },
                  {
                        "id": 5744,
                        "displayName": "year_5744"
                  },
                  {
                        "id": 5745,
                        "displayName": "year_5745"
                  },
                  {
                        "id": 5746,
                        "displayName": "year_5746"
                  },
                  {
                        "id": 5747,
                        "displayName": "year_5747"
                  },
                  {
                        "id": 5748,
                        "displayName": "year_5748"
                  },
                  {
                        "id": 5749,
                        "displayName": "year_5749"
                  },
                  {
                        "id": 5750,
                        "displayName": "year_5750"
                  },
                  {
                        "id": 5751,
                        "displayName": "year_5751"
                  },
                  {
                        "id": 5752,
                        "displayName": "year_5752"
                  },
                  {
                        "id": 5753,
                        "displayName": "year_5753"
                  },
                  {
                        "id": 5754,
                        "displayName": "year_5754"
                  },
                  {
                        "id": 5755,
                        "displayName": "year_5755"
                  },
                  {
                        "id": 5756,
                        "displayName": "year_5756"
                  },
                  {
                        "id": 5757,
                        "displayName": "year_5757"
                  },
                  {
                        "id": 5758,
                        "displayName": "year_5758"
                  },
                  {
                        "id": 5759,
                        "displayName": "year_5759"
                  },
                  {
                        "id": 5760,
                        "displayName": "year_5760"
                  },
                  {
                        "id": 5761,
                        "displayName": "year_5761"
                  },
                  {
                        "id": 5762,
                        "displayName": "year_5762"
                  },
                  {
                        "id": 5763,
                        "displayName": "year_5763"
                  },
                  {
                        "id": 5764,
                        "displayName": "year_5764"
                  },
                  {
                        "id": 5765,
                        "displayName": "year_5765"
                  },
                  {
                        "id": 5766,
                        "displayName": "year_5766"
                  },
                  {
                        "id": 5767,
                        "displayName": "year_5767"
                  },
                  {
                        "id": 5768,
                        "displayName": "year_5768"
                  },
                  {
                        "id": 5769,
                        "displayName": "year_5769"
                  },
                  {
                        "id": 5770,
                        "displayName": "year_5770"
                  },
                  {
                        "id": 5771,
                        "displayName": "year_5771"
                  },
                  {
                        "id": 5772,
                        "displayName": "year_5772"
                  },
                  {
                        "id": 5773,
                        "displayName": "year_5773"
                  },
                  {
                        "id": 5774,
                        "displayName": "year_5774"
                  },
                  {
                        "id": 5775,
                        "displayName": "year_5775"
                  },
                  {
                        "id": 5776,
                        "displayName": "year_5776"
                  },
                  {
                        "id": 5777,
                        "displayName": "year_5777"
                  },
                  {
                        "id": 5778,
                        "displayName": "year_5778"
                  },
                  {
                        "id": 5779,
                        "displayName": "year_5779"
                  },
                  {
                        "id": 5780,
                        "displayName": "year_5780"
                  },
                  {
                        "id": 5781,
                        "displayName": "year_5781"
                  },
                  {
                        "id": 5782,
                        "displayName": "year_5782"
                  },
                  {
                        "id": 5783,
                        "displayName": "year_5783"
                  },
                  {
                        "id": 5784,
                        "displayName": "year_5784"
                  },
                  {
                        "id": 5785,
                        "displayName": "year_5785"
                  },
                  {
                        "id": 5786,
                        "displayName": "year_5786"
                  },
                  {
                        "id": 5787,
                        "displayName": "year_5787"
                  },
                  {
                        "id": 5788,
                        "displayName": "year_5788"
                  },
                  {
                        "id": 5789,
                        "displayName": "year_5789"
                  },
                  {
                        "id": 5790,
                        "displayName": "year_5790"
                  },
                  {
                        "id": 5791,
                        "displayName": "year_5791"
                  },
                  {
                        "id": 5792,
                        "displayName": "year_5792"
                  },
                  {
                        "id": 5793,
                        "displayName": "year_5793"
                  },
                  {
                        "id": 5794,
                        "displayName": "year_5794"
                  },
                  {
                        "id": 5795,
                        "displayName": "year_5795"
                  },
                  {
                        "id": 5796,
                        "displayName": "year_5796"
                  },
                  {
                        "id": 5797,
                        "displayName": "year_5797"
                  },
                  {
                        "id": 5798,
                        "displayName": "year_5798"
                  },
                  {
                        "id": 5799,
                        "displayName": "year_5799"
                  },
                  {
                        "id": 5800,
                        "displayName": "year_5800"
                  },
                  {
                        "id": 5801,
                        "displayName": "year_5801"
                  },
                  {
                        "id": 5802,
                        "displayName": "year_5802"
                  },
                  {
                        "id": 5803,
                        "displayName": "year_5803"
                  },
                  {
                        "id": 5804,
                        "displayName": "year_5804"
                  },
                  {
                        "id": 5805,
                        "displayName": "year_5805"
                  },
                  {
                        "id": 5806,
                        "displayName": "year_5806"
                  },
                  {
                        "id": 5807,
                        "displayName": "year_5807"
                  },
                  {
                        "id": 5808,
                        "displayName": "year_5808"
                  },
                  {
                        "id": 5809,
                        "displayName": "year_5809"
                  },
                  {
                        "id": 5810,
                        "displayName": "year_5810"
                  },
                  {
                        "id": 5811,
                        "displayName": "year_5811"
                  },
                  {
                        "id": 5812,
                        "displayName": "year_5812"
                  },
                  {
                        "id": 5813,
                        "displayName": "year_5813"
                  },
                  {
                        "id": 5814,
                        "displayName": "year_5814"
                  },
                  {
                        "id": 5815,
                        "displayName": "year_5815"
                  },
                  {
                        "id": 5816,
                        "displayName": "year_5816"
                  },
                  {
                        "id": 5817,
                        "displayName": "year_5817"
                  },
                  {
                        "id": 5818,
                        "displayName": "year_5818"
                  },
                  {
                        "id": 5819,
                        "displayName": "year_5819"
                  },
                  {
                        "id": 5820,
                        "displayName": "year_5820"
                  },
                  {
                        "id": 5821,
                        "displayName": "year_5821"
                  },
                  {
                        "id": 5822,
                        "displayName": "year_5822"
                  },
                  {
                        "id": 5823,
                        "displayName": "year_5823"
                  },
                  {
                        "id": 5824,
                        "displayName": "year_5824"
                  },
                  {
                        "id": 5825,
                        "displayName": "year_5825"
                  },
                  {
                        "id": 5826,
                        "displayName": "year_5826"
                  },
                  {
                        "id": 5827,
                        "displayName": "year_5827"
                  },
                  {
                        "id": 5828,
                        "displayName": "year_5828"
                  },
                  {
                        "id": 5829,
                        "displayName": "year_5829"
                  },
                  {
                        "id": 5830,
                        "displayName": "year_5830"
                  },
                  {
                        "id": 5831,
                        "displayName": "year_5831"
                  },
                  {
                        "id": 5832,
                        "displayName": "year_5832"
                  },
                  {
                        "id": 5833,
                        "displayName": "year_5833"
                  },
                  {
                        "id": 5834,
                        "displayName": "year_5834"
                  },
                  {
                        "id": 5835,
                        "displayName": "year_5835"
                  },
                  {
                        "id": 5836,
                        "displayName": "year_5836"
                  },
                  {
                        "id": 5837,
                        "displayName": "year_5837"
                  },
                  {
                        "id": 5838,
                        "displayName": "year_5838"
                  },
                  {
                        "id": 5839,
                        "displayName": "year_5839"
                  },
                  {
                        "id": 5840,
                        "displayName": "year_5840"
                  },
                  {
                        "id": 5841,
                        "displayName": "year_5841"
                  },
                  {
                        "id": 5842,
                        "displayName": "year_5842"
                  },
                  {
                        "id": 5843,
                        "displayName": "year_5843"
                  },
                  {
                        "id": 5844,
                        "displayName": "year_5844"
                  },
                  {
                        "id": 5845,
                        "displayName": "year_5845"
                  },
                  {
                        "id": 5846,
                        "displayName": "year_5846"
                  },
                  {
                        "id": 5847,
                        "displayName": "year_5847"
                  },
                  {
                        "id": 5848,
                        "displayName": "year_5848"
                  },
                  {
                        "id": 5849,
                        "displayName": "year_5849"
                  },
                  {
                        "id": 5850,
                        "displayName": "year_5850"
                  },
                  {
                        "id": 5851,
                        "displayName": "year_5851"
                  },
                  {
                        "id": 5852,
                        "displayName": "year_5852"
                  },
                  {
                        "id": 5853,
                        "displayName": "year_5853"
                  },
                  {
                        "id": 5854,
                        "displayName": "year_5854"
                  },
                  {
                        "id": 5855,
                        "displayName": "year_5855"
                  },
                  {
                        "id": 5856,
                        "displayName": "year_5856"
                  },
                  {
                        "id": 5857,
                        "displayName": "year_5857"
                  },
                  {
                        "id": 5858,
                        "displayName": "year_5858"
                  },
                  {
                        "id": 5859,
                        "displayName": "year_5859"
                  },
                  {
                        "id": 5860,
                        "displayName": "year_5860"
                  },
                  {
                        "id": 5861,
                        "displayName": "year_5861"
                  },
                  {
                        "id": 5862,
                        "displayName": "year_5862"
                  },
                  {
                        "id": 5863,
                        "displayName": "year_5863"
                  },
                  {
                        "id": 5864,
                        "displayName": "year_5864"
                  },
                  {
                        "id": 5865,
                        "displayName": "year_5865"
                  },
                  {
                        "id": 5866,
                        "displayName": "year_5866"
                  },
                  {
                        "id": 5867,
                        "displayName": "year_5867"
                  },
                  {
                        "id": 5868,
                        "displayName": "year_5868"
                  },
                  {
                        "id": 5869,
                        "displayName": "year_5869"
                  },
                  {
                        "id": 5870,
                        "displayName": "year_5870"
                  },
                  {
                        "id": 5871,
                        "displayName": "year_5871"
                  },
                  {
                        "id": 5872,
                        "displayName": "year_5872"
                  },
                  {
                        "id": 5873,
                        "displayName": "year_5873"
                  },
                  {
                        "id": 5874,
                        "displayName": "year_5874"
                  },
                  {
                        "id": 5875,
                        "displayName": "year_5875"
                  },
                  {
                        "id": 5876,
                        "displayName": "year_5876"
                  },
                  {
                        "id": 5877,
                        "displayName": "year_5877"
                  },
                  {
                        "id": 5878,
                        "displayName": "year_5878"
                  },
                  {
                        "id": 5879,
                        "displayName": "year_5879"
                  },
                  {
                        "id": 5880,
                        "displayName": "year_5880"
                  },
                  {
                        "id": 5881,
                        "displayName": "year_5881"
                  },
                  {
                        "id": 5882,
                        "displayName": "year_5882"
                  },
                  {
                        "id": 5883,
                        "displayName": "year_5883"
                  },
                  {
                        "id": 5884,
                        "displayName": "year_5884"
                  },
                  {
                        "id": 5885,
                        "displayName": "year_5885"
                  },
                  {
                        "id": 5886,
                        "displayName": "year_5886"
                  },
                  {
                        "id": 5887,
                        "displayName": "year_5887"
                  },
                  {
                        "id": 5888,
                        "displayName": "year_5888"
                  },
                  {
                        "id": 5889,
                        "displayName": "year_5889"
                  },
                  {
                        "id": 5890,
                        "displayName": "year_5890"
                  },
                  {
                        "id": 5891,
                        "displayName": "year_5891"
                  },
                  {
                        "id": 5892,
                        "displayName": "year_5892"
                  },
                  {
                        "id": 5893,
                        "displayName": "year_5893"
                  },
                  {
                        "id": 5894,
                        "displayName": "year_5894"
                  },
                  {
                        "id": 5895,
                        "displayName": "year_5895"
                  },
                  {
                        "id": 5896,
                        "displayName": "year_5896"
                  },
                  {
                        "id": 5897,
                        "displayName": "year_5897"
                  },
                  {
                        "id": 5898,
                        "displayName": "year_5898"
                  },
                  {
                        "id": 5899,
                        "displayName": "year_5899"
                  },
                  {
                        "id": 5900,
                        "displayName": "year_5900"
                  },
                  {
                        "id": 5901,
                        "displayName": "year_5901"
                  },
                  {
                        "id": 5902,
                        "displayName": "year_5902"
                  },
                  {
                        "id": 5903,
                        "displayName": "year_5903"
                  },
                  {
                        "id": 5904,
                        "displayName": "year_5904"
                  },
                  {
                        "id": 5905,
                        "displayName": "year_5905"
                  },
                  {
                        "id": 5906,
                        "displayName": "year_5906"
                  },
                  {
                        "id": 5907,
                        "displayName": "year_5907"
                  },
                  {
                        "id": 5908,
                        "displayName": "year_5908"
                  },
                  {
                        "id": 5909,
                        "displayName": "year_5909"
                  },
                  {
                        "id": 5910,
                        "displayName": "year_5910"
                  },
                  {
                        "id": 5911,
                        "displayName": "year_5911"
                  },
                  {
                        "id": 5912,
                        "displayName": "year_5912"
                  },
                  {
                        "id": 5913,
                        "displayName": "year_5913"
                  },
                  {
                        "id": 5914,
                        "displayName": "year_5914"
                  },
                  {
                        "id": 5915,
                        "displayName": "year_5915"
                  },
                  {
                        "id": 5916,
                        "displayName": "year_5916"
                  },
                  {
                        "id": 5917,
                        "displayName": "year_5917"
                  },
                  {
                        "id": 5918,
                        "displayName": "year_5918"
                  },
                  {
                        "id": 5919,
                        "displayName": "year_5919"
                  },
                  {
                        "id": 5920,
                        "displayName": "year_5920"
                  },
                  {
                        "id": 5921,
                        "displayName": "year_5921"
                  },
                  {
                        "id": 5922,
                        "displayName": "year_5922"
                  },
                  {
                        "id": 5923,
                        "displayName": "year_5923"
                  },
                  {
                        "id": 5924,
                        "displayName": "year_5924"
                  },
                  {
                        "id": 5925,
                        "displayName": "year_5925"
                  },
                  {
                        "id": 5926,
                        "displayName": "year_5926"
                  },
                  {
                        "id": 5927,
                        "displayName": "year_5927"
                  },
                  {
                        "id": 5928,
                        "displayName": "year_5928"
                  },
                  {
                        "id": 5929,
                        "displayName": "year_5929"
                  },
                  {
                        "id": 5930,
                        "displayName": "year_5930"
                  },
                  {
                        "id": 5931,
                        "displayName": "year_5931"
                  },
                  {
                        "id": 5932,
                        "displayName": "year_5932"
                  },
                  {
                        "id": 5933,
                        "displayName": "year_5933"
                  },
                  {
                        "id": 5934,
                        "displayName": "year_5934"
                  },
                  {
                        "id": 5935,
                        "displayName": "year_5935"
                  },
                  {
                        "id": 5936,
                        "displayName": "year_5936"
                  },
                  {
                        "id": 5937,
                        "displayName": "year_5937"
                  },
                  {
                        "id": 5938,
                        "displayName": "year_5938"
                  },
                  {
                        "id": 5939,
                        "displayName": "year_5939"
                  },
                  {
                        "id": 5940,
                        "displayName": "year_5940"
                  },
                  {
                        "id": 5941,
                        "displayName": "year_5941"
                  },
                  {
                        "id": 5942,
                        "displayName": "year_5942"
                  },
                  {
                        "id": 5943,
                        "displayName": "year_5943"
                  },
                  {
                        "id": 5944,
                        "displayName": "year_5944"
                  },
                  {
                        "id": 5945,
                        "displayName": "year_5945"
                  },
                  {
                        "id": 5946,
                        "displayName": "year_5946"
                  },
                  {
                        "id": 5947,
                        "displayName": "year_5947"
                  },
                  {
                        "id": 5948,
                        "displayName": "year_5948"
                  },
                  {
                        "id": 5949,
                        "displayName": "year_5949"
                  },
                  {
                        "id": 5950,
                        "displayName": "year_5950"
                  },
                  {
                        "id": 5951,
                        "displayName": "year_5951"
                  },
                  {
                        "id": 5952,
                        "displayName": "year_5952"
                  },
                  {
                        "id": 5953,
                        "displayName": "year_5953"
                  },
                  {
                        "id": 5954,
                        "displayName": "year_5954"
                  },
                  {
                        "id": 5955,
                        "displayName": "year_5955"
                  },
                  {
                        "id": 5956,
                        "displayName": "year_5956"
                  },
                  {
                        "id": 5957,
                        "displayName": "year_5957"
                  },
                  {
                        "id": 5958,
                        "displayName": "year_5958"
                  },
                  {
                        "id": 5959,
                        "displayName": "year_5959"
                  },
                  {
                        "id": 5960,
                        "displayName": "year_5960"
                  },
                  {
                        "id": 5961,
                        "displayName": "year_5961"
                  },
                  {
                        "id": 5962,
                        "displayName": "year_5962"
                  },
                  {
                        "id": 5963,
                        "displayName": "year_5963"
                  },
                  {
                        "id": 5964,
                        "displayName": "year_5964"
                  },
                  {
                        "id": 5965,
                        "displayName": "year_5965"
                  },
                  {
                        "id": 5966,
                        "displayName": "year_5966"
                  },
                  {
                        "id": 5967,
                        "displayName": "year_5967"
                  },
                  {
                        "id": 5968,
                        "displayName": "year_5968"
                  },
                  {
                        "id": 5969,
                        "displayName": "year_5969"
                  },
                  {
                        "id": 5970,
                        "displayName": "year_5970"
                  },
                  {
                        "id": 5971,
                        "displayName": "year_5971"
                  },
                  {
                        "id": 5972,
                        "displayName": "year_5972"
                  },
                  {
                        "id": 5973,
                        "displayName": "year_5973"
                  },
                  {
                        "id": 5974,
                        "displayName": "year_5974"
                  },
                  {
                        "id": 5975,
                        "displayName": "year_5975"
                  },
                  {
                        "id": 5976,
                        "displayName": "year_5976"
                  },
                  {
                        "id": 5977,
                        "displayName": "year_5977"
                  },
                  {
                        "id": 5978,
                        "displayName": "year_5978"
                  },
                  {
                        "id": 5979,
                        "displayName": "year_5979"
                  },
                  {
                        "id": 5980,
                        "displayName": "year_5980"
                  },
                  {
                        "id": 5981,
                        "displayName": "year_5981"
                  },
                  {
                        "id": 5982,
                        "displayName": "year_5982"
                  },
                  {
                        "id": 5983,
                        "displayName": "year_5983"
                  },
                  {
                        "id": 5984,
                        "displayName": "year_5984"
                  },
                  {
                        "id": 5985,
                        "displayName": "year_5985"
                  },
                  {
                        "id": 5986,
                        "displayName": "year_5986"
                  },
                  {
                        "id": 5987,
                        "displayName": "year_5987"
                  },
                  {
                        "id": 5988,
                        "displayName": "year_5988"
                  },
                  {
                        "id": 5989,
                        "displayName": "year_5989"
                  },
                  {
                        "id": 5990,
                        "displayName": "year_5990"
                  },
                  {
                        "id": 5991,
                        "displayName": "year_5991"
                  },
                  {
                        "id": 5992,
                        "displayName": "year_5992"
                  },
                  {
                        "id": 5993,
                        "displayName": "year_5993"
                  },
                  {
                        "id": 5994,
                        "displayName": "year_5994"
                  },
                  {
                        "id": 5995,
                        "displayName": "year_5995"
                  },
                  {
                        "id": 5996,
                        "displayName": "year_5996"
                  },
                  {
                        "id": 5997,
                        "displayName": "year_5997"
                  },
                  {
                        "id": 5998,
                        "displayName": "year_5998"
                  },
                  {
                        "id": 5999,
                        "displayName": "year_5999"
                  },
                  {
                        "id": 6000,
                        "displayName": "year_6000"
                  },
                  {
                        "id": 6001,
                        "displayName": "year_6001"
                  },
                  {
                        "id": 6002,
                        "displayName": "year_6002"
                  },
                  {
                        "id": 6003,
                        "displayName": "year_6003"
                  },
                  {
                        "id": 6004,
                        "displayName": "year_6004"
                  },
                  {
                        "id": 6005,
                        "displayName": "year_6005"
                  },
                  {
                        "id": 6006,
                        "displayName": "year_6006"
                  },
                  {
                        "id": 6007,
                        "displayName": "year_6007"
                  },
                  {
                        "id": 6008,
                        "displayName": "year_6008"
                  },
                  {
                        "id": 6009,
                        "displayName": "year_6009"
                  },
                  {
                        "id": 6010,
                        "displayName": "year_6010"
                  },
                  {
                        "id": 6011,
                        "displayName": "year_6011"
                  },
                  {
                        "id": 6012,
                        "displayName": "year_6012"
                  },
                  {
                        "id": 6013,
                        "displayName": "year_6013"
                  },
                  {
                        "id": 6014,
                        "displayName": "year_6014"
                  },
                  {
                        "id": 6015,
                        "displayName": "year_6015"
                  },
                  {
                        "id": 6016,
                        "displayName": "year_6016"
                  },
                  {
                        "id": 6017,
                        "displayName": "year_6017"
                  },
                  {
                        "id": 6018,
                        "displayName": "year_6018"
                  },
                  {
                        "id": 6019,
                        "displayName": "year_6019"
                  },
                  {
                        "id": 6020,
                        "displayName": "year_6020"
                  },
                  {
                        "id": 6021,
                        "displayName": "year_6021"
                  },
                  {
                        "id": 6022,
                        "displayName": "year_6022"
                  },
                  {
                        "id": 6023,
                        "displayName": "year_6023"
                  },
                  {
                        "id": 6024,
                        "displayName": "year_6024"
                  },
                  {
                        "id": 6025,
                        "displayName": "year_6025"
                  },
                  {
                        "id": 6026,
                        "displayName": "year_6026"
                  },
                  {
                        "id": 6027,
                        "displayName": "year_6027"
                  },
                  {
                        "id": 6028,
                        "displayName": "year_6028"
                  },
                  {
                        "id": 6029,
                        "displayName": "year_6029"
                  },
                  {
                        "id": 6030,
                        "displayName": "year_6030"
                  },
                  {
                        "id": 6031,
                        "displayName": "year_6031"
                  },
                  {
                        "id": 6032,
                        "displayName": "year_6032"
                  },
                  {
                        "id": 6033,
                        "displayName": "year_6033"
                  },
                  {
                        "id": 6034,
                        "displayName": "year_6034"
                  },
                  {
                        "id": 6035,
                        "displayName": "year_6035"
                  },
                  {
                        "id": 6036,
                        "displayName": "year_6036"
                  },
                  {
                        "id": 6037,
                        "displayName": "year_6037"
                  },
                  {
                        "id": 6038,
                        "displayName": "year_6038"
                  },
                  {
                        "id": 6039,
                        "displayName": "year_6039"
                  },
                  {
                        "id": 6040,
                        "displayName": "year_6040"
                  },
                  {
                        "id": 6041,
                        "displayName": "year_6041"
                  },
                  {
                        "id": 6042,
                        "displayName": "year_6042"
                  },
                  {
                        "id": 6043,
                        "displayName": "year_6043"
                  },
                  {
                        "id": 6044,
                        "displayName": "year_6044"
                  },
                  {
                        "id": 6045,
                        "displayName": "year_6045"
                  },
                  {
                        "id": 6046,
                        "displayName": "year_6046"
                  },
                  {
                        "id": 6047,
                        "displayName": "year_6047"
                  },
                  {
                        "id": 6048,
                        "displayName": "year_6048"
                  },
                  {
                        "id": 6049,
                        "displayName": "year_6049"
                  },
                  {
                        "id": 6050,
                        "displayName": "year_6050"
                  },
                  {
                        "id": 6051,
                        "displayName": "year_6051"
                  },
                  {
                        "id": 6052,
                        "displayName": "year_6052"
                  },
                  {
                        "id": 6053,
                        "displayName": "year_6053"
                  },
                  {
                        "id": 6054,
                        "displayName": "year_6054"
                  },
                  {
                        "id": 6055,
                        "displayName": "year_6055"
                  },
                  {
                        "id": 6056,
                        "displayName": "year_6056"
                  },
                  {
                        "id": 6057,
                        "displayName": "year_6057"
                  },
                  {
                        "id": 6058,
                        "displayName": "year_6058"
                  },
                  {
                        "id": 6059,
                        "displayName": "year_6059"
                  },
                  {
                        "id": 6060,
                        "displayName": "year_6060"
                  },
                  {
                        "id": 6061,
                        "displayName": "year_6061"
                  },
                  {
                        "id": 6062,
                        "displayName": "year_6062"
                  },
                  {
                        "id": 6063,
                        "displayName": "year_6063"
                  },
                  {
                        "id": 6064,
                        "displayName": "year_6064"
                  },
                  {
                        "id": 6065,
                        "displayName": "year_6065"
                  },
                  {
                        "id": 6066,
                        "displayName": "year_6066"
                  },
                  {
                        "id": 6067,
                        "displayName": "year_6067"
                  },
                  {
                        "id": 6068,
                        "displayName": "year_6068"
                  },
                  {
                        "id": 6069,
                        "displayName": "year_6069"
                  },
                  {
                        "id": 6070,
                        "displayName": "year_6070"
                  },
                  {
                        "id": 6071,
                        "displayName": "year_6071"
                  },
                  {
                        "id": 6072,
                        "displayName": "year_6072"
                  },
                  {
                        "id": 6073,
                        "displayName": "year_6073"
                  },
                  {
                        "id": 6074,
                        "displayName": "year_6074"
                  },
                  {
                        "id": 6075,
                        "displayName": "year_6075"
                  },
                  {
                        "id": 6076,
                        "displayName": "year_6076"
                  },
                  {
                        "id": 6077,
                        "displayName": "year_6077"
                  },
                  {
                        "id": 6078,
                        "displayName": "year_6078"
                  },
                  {
                        "id": 6079,
                        "displayName": "year_6079"
                  },
                  {
                        "id": 6080,
                        "displayName": "year_6080"
                  },
                  {
                        "id": 6081,
                        "displayName": "year_6081"
                  },
                  {
                        "id": 6082,
                        "displayName": "year_6082"
                  },
                  {
                        "id": 6083,
                        "displayName": "year_6083"
                  },
                  {
                        "id": 6084,
                        "displayName": "year_6084"
                  },
                  {
                        "id": 6085,
                        "displayName": "year_6085"
                  },
                  {
                        "id": 6086,
                        "displayName": "year_6086"
                  },
                  {
                        "id": 6087,
                        "displayName": "year_6087"
                  },
                  {
                        "id": 6088,
                        "displayName": "year_6088"
                  },
                  {
                        "id": 6089,
                        "displayName": "year_6089"
                  },
                  {
                        "id": 6090,
                        "displayName": "year_6090"
                  },
                  {
                        "id": 6091,
                        "displayName": "year_6091"
                  },
                  {
                        "id": 6092,
                        "displayName": "year_6092"
                  },
                  {
                        "id": 6093,
                        "displayName": "year_6093"
                  },
                  {
                        "id": 6094,
                        "displayName": "year_6094"
                  },
                  {
                        "id": 6095,
                        "displayName": "year_6095"
                  },
                  {
                        "id": 6096,
                        "displayName": "year_6096"
                  },
                  {
                        "id": 6097,
                        "displayName": "year_6097"
                  },
                  {
                        "id": 6098,
                        "displayName": "year_6098"
                  },
                  {
                        "id": 6099,
                        "displayName": "year_6099"
                  },
                  {
                        "id": 6100,
                        "displayName": "year_6100"
                  },
                  {
                        "id": 6101,
                        "displayName": "year_6101"
                  },
                  {
                        "id": 6102,
                        "displayName": "year_6102"
                  },
                  {
                        "id": 6103,
                        "displayName": "year_6103"
                  },
                  {
                        "id": 6104,
                        "displayName": "year_6104"
                  },
                  {
                        "id": 6105,
                        "displayName": "year_6105"
                  },
                  {
                        "id": 6106,
                        "displayName": "year_6106"
                  },
                  {
                        "id": 6107,
                        "displayName": "year_6107"
                  },
                  {
                        "id": 6108,
                        "displayName": "year_6108"
                  },
                  {
                        "id": 6109,
                        "displayName": "year_6109"
                  },
                  {
                        "id": 6110,
                        "displayName": "year_6110"
                  },
                  {
                        "id": 6111,
                        "displayName": "year_6111"
                  },
                  {
                        "id": 6112,
                        "displayName": "year_6112"
                  },
                  {
                        "id": 6113,
                        "displayName": "year_6113"
                  },
                  {
                        "id": 6114,
                        "displayName": "year_6114"
                  },
                  {
                        "id": 6115,
                        "displayName": "year_6115"
                  },
                  {
                        "id": 6116,
                        "displayName": "year_6116"
                  },
                  {
                        "id": 6117,
                        "displayName": "year_6117"
                  },
                  {
                        "id": 6118,
                        "displayName": "year_6118"
                  },
                  {
                        "id": 6119,
                        "displayName": "year_6119"
                  },
                  {
                        "id": 6120,
                        "displayName": "year_6120"
                  },
                  {
                        "id": 6121,
                        "displayName": "year_6121"
                  },
                  {
                        "id": 6122,
                        "displayName": "year_6122"
                  },
                  {
                        "id": 6123,
                        "displayName": "year_6123"
                  },
                  {
                        "id": 6124,
                        "displayName": "year_6124"
                  },
                  {
                        "id": 6125,
                        "displayName": "year_6125"
                  },
                  {
                        "id": 6126,
                        "displayName": "year_6126"
                  },
                  {
                        "id": 6127,
                        "displayName": "year_6127"
                  },
                  {
                        "id": 6128,
                        "displayName": "year_6128"
                  },
                  {
                        "id": 6129,
                        "displayName": "year_6129"
                  },
                  {
                        "id": 6130,
                        "displayName": "year_6130"
                  },
                  {
                        "id": 6131,
                        "displayName": "year_6131"
                  },
                  {
                        "id": 6132,
                        "displayName": "year_6132"
                  },
                  {
                        "id": 6133,
                        "displayName": "year_6133"
                  },
                  {
                        "id": 6134,
                        "displayName": "year_6134"
                  },
                  {
                        "id": 6135,
                        "displayName": "year_6135"
                  },
                  {
                        "id": 6136,
                        "displayName": "year_6136"
                  },
                  {
                        "id": 6137,
                        "displayName": "year_6137"
                  },
                  {
                        "id": 6138,
                        "displayName": "year_6138"
                  },
                  {
                        "id": 6139,
                        "displayName": "year_6139"
                  },
                  {
                        "id": 6140,
                        "displayName": "year_6140"
                  },
                  {
                        "id": 6141,
                        "displayName": "year_6141"
                  },
                  {
                        "id": 6142,
                        "displayName": "year_6142"
                  },
                  {
                        "id": 6143,
                        "displayName": "year_6143"
                  },
                  {
                        "id": 6144,
                        "displayName": "year_6144"
                  },
                  {
                        "id": 6145,
                        "displayName": "year_6145"
                  },
                  {
                        "id": 6146,
                        "displayName": "year_6146"
                  },
                  {
                        "id": 6147,
                        "displayName": "year_6147"
                  },
                  {
                        "id": 6148,
                        "displayName": "year_6148"
                  },
                  {
                        "id": 6149,
                        "displayName": "year_6149"
                  },
                  {
                        "id": 6150,
                        "displayName": "year_6150"
                  },
                  {
                        "id": 6151,
                        "displayName": "year_6151"
                  },
                  {
                        "id": 6152,
                        "displayName": "year_6152"
                  },
                  {
                        "id": 6153,
                        "displayName": "year_6153"
                  },
                  {
                        "id": 6154,
                        "displayName": "year_6154"
                  },
                  {
                        "id": 6155,
                        "displayName": "year_6155"
                  },
                  {
                        "id": 6156,
                        "displayName": "year_6156"
                  },
                  {
                        "id": 6157,
                        "displayName": "year_6157"
                  },
                  {
                        "id": 6158,
                        "displayName": "year_6158"
                  },
                  {
                        "id": 6159,
                        "displayName": "year_6159"
                  },
                  {
                        "id": 6160,
                        "displayName": "year_6160"
                  },
                  {
                        "id": 6161,
                        "displayName": "year_6161"
                  },
                  {
                        "id": 6162,
                        "displayName": "year_6162"
                  },
                  {
                        "id": 6163,
                        "displayName": "year_6163"
                  },
                  {
                        "id": 6164,
                        "displayName": "year_6164"
                  },
                  {
                        "id": 6165,
                        "displayName": "year_6165"
                  },
                  {
                        "id": 6166,
                        "displayName": "year_6166"
                  },
                  {
                        "id": 6167,
                        "displayName": "year_6167"
                  },
                  {
                        "id": 6168,
                        "displayName": "year_6168"
                  },
                  {
                        "id": 6169,
                        "displayName": "year_6169"
                  },
                  {
                        "id": 6170,
                        "displayName": "year_6170"
                  },
                  {
                        "id": 6171,
                        "displayName": "year_6171"
                  },
                  {
                        "id": 6172,
                        "displayName": "year_6172"
                  },
                  {
                        "id": 6173,
                        "displayName": "year_6173"
                  },
                  {
                        "id": 6174,
                        "displayName": "year_6174"
                  },
                  {
                        "id": 6175,
                        "displayName": "year_6175"
                  },
                  {
                        "id": 6176,
                        "displayName": "year_6176"
                  },
                  {
                        "id": 6177,
                        "displayName": "year_6177"
                  },
                  {
                        "id": 6178,
                        "displayName": "year_6178"
                  },
                  {
                        "id": 6179,
                        "displayName": "year_6179"
                  },
                  {
                        "id": 6180,
                        "displayName": "year_6180"
                  },
                  {
                        "id": 6181,
                        "displayName": "year_6181"
                  },
                  {
                        "id": 6182,
                        "displayName": "year_6182"
                  },
                  {
                        "id": 6183,
                        "displayName": "year_6183"
                  },
                  {
                        "id": 6184,
                        "displayName": "year_6184"
                  },
                  {
                        "id": 6185,
                        "displayName": "year_6185"
                  },
                  {
                        "id": 6186,
                        "displayName": "year_6186"
                  },
                  {
                        "id": 6187,
                        "displayName": "year_6187"
                  },
                  {
                        "id": 6188,
                        "displayName": "year_6188"
                  },
                  {
                        "id": 6189,
                        "displayName": "year_6189"
                  },
                  {
                        "id": 6190,
                        "displayName": "year_6190"
                  },
                  {
                        "id": 6191,
                        "displayName": "year_6191"
                  },
                  {
                        "id": 6192,
                        "displayName": "year_6192"
                  },
                  {
                        "id": 6193,
                        "displayName": "year_6193"
                  },
                  {
                        "id": 6194,
                        "displayName": "year_6194"
                  },
                  {
                        "id": 6195,
                        "displayName": "year_6195"
                  },
                  {
                        "id": 6196,
                        "displayName": "year_6196"
                  },
                  {
                        "id": 6197,
                        "displayName": "year_6197"
                  },
                  {
                        "id": 6198,
                        "displayName": "year_6198"
                  },
                  {
                        "id": 6199,
                        "displayName": "year_6199"
                  },
                  {
                        "id": 6200,
                        "displayName": "year_6200"
                  },
                  {
                        "id": 6201,
                        "displayName": "year_6201"
                  },
                  {
                        "id": 6202,
                        "displayName": "year_6202"
                  },
                  {
                        "id": 6203,
                        "displayName": "year_6203"
                  },
                  {
                        "id": 6204,
                        "displayName": "year_6204"
                  },
                  {
                        "id": 6205,
                        "displayName": "year_6205"
                  },
                  {
                        "id": 6206,
                        "displayName": "year_6206"
                  },
                  {
                        "id": 6207,
                        "displayName": "year_6207"
                  },
                  {
                        "id": 6208,
                        "displayName": "year_6208"
                  },
                  {
                        "id": 6209,
                        "displayName": "year_6209"
                  },
                  {
                        "id": 6210,
                        "displayName": "year_6210"
                  },
                  {
                        "id": 6211,
                        "displayName": "year_6211"
                  },
                  {
                        "id": 6212,
                        "displayName": "year_6212"
                  },
                  {
                        "id": 6213,
                        "displayName": "year_6213"
                  },
                  {
                        "id": 6214,
                        "displayName": "year_6214"
                  },
                  {
                        "id": 6215,
                        "displayName": "year_6215"
                  },
                  {
                        "id": 6216,
                        "displayName": "year_6216"
                  },
                  {
                        "id": 6217,
                        "displayName": "year_6217"
                  },
                  {
                        "id": 6218,
                        "displayName": "year_6218"
                  },
                  {
                        "id": 6219,
                        "displayName": "year_6219"
                  },
                  {
                        "id": 6220,
                        "displayName": "year_6220"
                  },
                  {
                        "id": 6221,
                        "displayName": "year_6221"
                  },
                  {
                        "id": 6222,
                        "displayName": "year_6222"
                  },
                  {
                        "id": 6223,
                        "displayName": "year_6223"
                  },
                  {
                        "id": 6224,
                        "displayName": "year_6224"
                  },
                  {
                        "id": 6225,
                        "displayName": "year_6225"
                  },
                  {
                        "id": 6226,
                        "displayName": "year_6226"
                  },
                  {
                        "id": 6227,
                        "displayName": "year_6227"
                  },
                  {
                        "id": 6228,
                        "displayName": "year_6228"
                  },
                  {
                        "id": 6229,
                        "displayName": "year_6229"
                  },
                  {
                        "id": 6230,
                        "displayName": "year_6230"
                  },
                  {
                        "id": 6231,
                        "displayName": "year_6231"
                  },
                  {
                        "id": 6232,
                        "displayName": "year_6232"
                  },
                  {
                        "id": 6233,
                        "displayName": "year_6233"
                  },
                  {
                        "id": 6234,
                        "displayName": "year_6234"
                  },
                  {
                        "id": 6235,
                        "displayName": "year_6235"
                  },
                  {
                        "id": 6236,
                        "displayName": "year_6236"
                  },
                  {
                        "id": 6237,
                        "displayName": "year_6237"
                  },
                  {
                        "id": 6238,
                        "displayName": "year_6238"
                  },
                  {
                        "id": 6239,
                        "displayName": "year_6239"
                  },
                  {
                        "id": 6240,
                        "displayName": "year_6240"
                  },
                  {
                        "id": 6241,
                        "displayName": "year_6241"
                  },
                  {
                        "id": 6242,
                        "displayName": "year_6242"
                  },
                  {
                        "id": 6243,
                        "displayName": "year_6243"
                  },
                  {
                        "id": 6244,
                        "displayName": "year_6244"
                  },
                  {
                        "id": 6245,
                        "displayName": "year_6245"
                  },
                  {
                        "id": 6246,
                        "displayName": "year_6246"
                  },
                  {
                        "id": 6247,
                        "displayName": "year_6247"
                  },
                  {
                        "id": 6248,
                        "displayName": "year_6248"
                  },
                  {
                        "id": 6249,
                        "displayName": "year_6249"
                  },
                  {
                        "id": 6250,
                        "displayName": "year_6250"
                  },
                  {
                        "id": 6251,
                        "displayName": "year_6251"
                  },
                  {
                        "id": 6252,
                        "displayName": "year_6252"
                  },
                  {
                        "id": 6253,
                        "displayName": "year_6253"
                  },
                  {
                        "id": 6254,
                        "displayName": "year_6254"
                  },
                  {
                        "id": 6255,
                        "displayName": "year_6255"
                  },
                  {
                        "id": 6256,
                        "displayName": "year_6256"
                  },
                  {
                        "id": 6257,
                        "displayName": "year_6257"
                  },
                  {
                        "id": 6258,
                        "displayName": "year_6258"
                  },
                  {
                        "id": 6259,
                        "displayName": "year_6259"
                  },
                  {
                        "id": 6260,
                        "displayName": "year_6260"
                  },
                  {
                        "id": 6261,
                        "displayName": "year_6261"
                  },
                  {
                        "id": 6262,
                        "displayName": "year_6262"
                  },
                  {
                        "id": 6263,
                        "displayName": "year_6263"
                  },
                  {
                        "id": 6264,
                        "displayName": "year_6264"
                  },
                  {
                        "id": 6265,
                        "displayName": "year_6265"
                  },
                  {
                        "id": 6266,
                        "displayName": "year_6266"
                  },
                  {
                        "id": 6267,
                        "displayName": "year_6267"
                  },
                  {
                        "id": 6268,
                        "displayName": "year_6268"
                  },
                  {
                        "id": 6269,
                        "displayName": "year_6269"
                  },
                  {
                        "id": 6270,
                        "displayName": "year_6270"
                  },
                  {
                        "id": 6271,
                        "displayName": "year_6271"
                  },
                  {
                        "id": 6272,
                        "displayName": "year_6272"
                  },
                  {
                        "id": 6273,
                        "displayName": "year_6273"
                  },
                  {
                        "id": 6274,
                        "displayName": "year_6274"
                  },
                  {
                        "id": 6275,
                        "displayName": "year_6275"
                  },
                  {
                        "id": 6276,
                        "displayName": "year_6276"
                  },
                  {
                        "id": 6277,
                        "displayName": "year_6277"
                  },
                  {
                        "id": 6278,
                        "displayName": "year_6278"
                  },
                  {
                        "id": 6279,
                        "displayName": "year_6279"
                  },
                  {
                        "id": 6280,
                        "displayName": "year_6280"
                  },
                  {
                        "id": 6281,
                        "displayName": "year_6281"
                  },
                  {
                        "id": 6282,
                        "displayName": "year_6282"
                  },
                  {
                        "id": 6283,
                        "displayName": "year_6283"
                  },
                  {
                        "id": 6284,
                        "displayName": "year_6284"
                  },
                  {
                        "id": 6285,
                        "displayName": "year_6285"
                  },
                  {
                        "id": 6286,
                        "displayName": "year_6286"
                  },
                  {
                        "id": 6287,
                        "displayName": "year_6287"
                  },
                  {
                        "id": 6288,
                        "displayName": "year_6288"
                  },
                  {
                        "id": 6289,
                        "displayName": "year_6289"
                  },
                  {
                        "id": 6290,
                        "displayName": "year_6290"
                  },
                  {
                        "id": 6291,
                        "displayName": "year_6291"
                  },
                  {
                        "id": 6292,
                        "displayName": "year_6292"
                  },
                  {
                        "id": 6293,
                        "displayName": "year_6293"
                  },
                  {
                        "id": 6294,
                        "displayName": "year_6294"
                  },
                  {
                        "id": 6295,
                        "displayName": "year_6295"
                  },
                  {
                        "id": 6296,
                        "displayName": "year_6296"
                  },
                  {
                        "id": 6297,
                        "displayName": "year_6297"
                  },
                  {
                        "id": 6298,
                        "displayName": "year_6298"
                  },
                  {
                        "id": 6299,
                        "displayName": "year_6299"
                  },
                  {
                        "id": 6300,
                        "displayName": "year_6300"
                  },
                  {
                        "id": 6301,
                        "displayName": "year_6301"
                  },
                  {
                        "id": 6302,
                        "displayName": "year_6302"
                  },
                  {
                        "id": 6303,
                        "displayName": "year_6303"
                  },
                  {
                        "id": 6304,
                        "displayName": "year_6304"
                  },
                  {
                        "id": 6305,
                        "displayName": "year_6305"
                  },
                  {
                        "id": 6306,
                        "displayName": "year_6306"
                  },
                  {
                        "id": 6307,
                        "displayName": "year_6307"
                  },
                  {
                        "id": 6308,
                        "displayName": "year_6308"
                  },
                  {
                        "id": 6309,
                        "displayName": "year_6309"
                  },
                  {
                        "id": 6310,
                        "displayName": "year_6310"
                  },
                  {
                        "id": 6311,
                        "displayName": "year_6311"
                  },
                  {
                        "id": 6312,
                        "displayName": "year_6312"
                  },
                  {
                        "id": 6313,
                        "displayName": "year_6313"
                  },
                  {
                        "id": 6314,
                        "displayName": "year_6314"
                  },
                  {
                        "id": 6315,
                        "displayName": "year_6315"
                  },
                  {
                        "id": 6316,
                        "displayName": "year_6316"
                  },
                  {
                        "id": 6317,
                        "displayName": "year_6317"
                  },
                  {
                        "id": 6318,
                        "displayName": "year_6318"
                  },
                  {
                        "id": 6319,
                        "displayName": "year_6319"
                  },
                  {
                        "id": 6320,
                        "displayName": "year_6320"
                  },
                  {
                        "id": 6321,
                        "displayName": "year_6321"
                  },
                  {
                        "id": 6322,
                        "displayName": "year_6322"
                  },
                  {
                        "id": 6323,
                        "displayName": "year_6323"
                  },
                  {
                        "id": 6324,
                        "displayName": "year_6324"
                  },
                  {
                        "id": 6325,
                        "displayName": "year_6325"
                  },
                  {
                        "id": 6326,
                        "displayName": "year_6326"
                  },
                  {
                        "id": 6327,
                        "displayName": "year_6327"
                  },
                  {
                        "id": 6328,
                        "displayName": "year_6328"
                  },
                  {
                        "id": 6329,
                        "displayName": "year_6329"
                  },
                  {
                        "id": 6330,
                        "displayName": "year_6330"
                  },
                  {
                        "id": 6331,
                        "displayName": "year_6331"
                  },
                  {
                        "id": 6332,
                        "displayName": "year_6332"
                  },
                  {
                        "id": 6333,
                        "displayName": "year_6333"
                  },
                  {
                        "id": 6334,
                        "displayName": "year_6334"
                  },
                  {
                        "id": 6335,
                        "displayName": "year_6335"
                  },
                  {
                        "id": 6336,
                        "displayName": "year_6336"
                  },
                  {
                        "id": 6337,
                        "displayName": "year_6337"
                  },
                  {
                        "id": 6338,
                        "displayName": "year_6338"
                  },
                  {
                        "id": 6339,
                        "displayName": "year_6339"
                  },
                  {
                        "id": 6340,
                        "displayName": "year_6340"
                  },
                  {
                        "id": 6341,
                        "displayName": "year_6341"
                  },
                  {
                        "id": 6342,
                        "displayName": "year_6342"
                  },
                  {
                        "id": 6343,
                        "displayName": "year_6343"
                  },
                  {
                        "id": 6344,
                        "displayName": "year_6344"
                  },
                  {
                        "id": 6345,
                        "displayName": "year_6345"
                  },
                  {
                        "id": 6346,
                        "displayName": "year_6346"
                  },
                  {
                        "id": 6347,
                        "displayName": "year_6347"
                  },
                  {
                        "id": 6348,
                        "displayName": "year_6348"
                  },
                  {
                        "id": 6349,
                        "displayName": "year_6349"
                  },
                  {
                        "id": 6350,
                        "displayName": "year_6350"
                  },
                  {
                        "id": 6351,
                        "displayName": "year_6351"
                  },
                  {
                        "id": 6352,
                        "displayName": "year_6352"
                  },
                  {
                        "id": 6353,
                        "displayName": "year_6353"
                  },
                  {
                        "id": 6354,
                        "displayName": "year_6354"
                  },
                  {
                        "id": 6355,
                        "displayName": "year_6355"
                  },
                  {
                        "id": 6356,
                        "displayName": "year_6356"
                  },
                  {
                        "id": 6357,
                        "displayName": "year_6357"
                  },
                  {
                        "id": 6358,
                        "displayName": "year_6358"
                  },
                  {
                        "id": 6359,
                        "displayName": "year_6359"
                  },
                  {
                        "id": 6360,
                        "displayName": "year_6360"
                  },
                  {
                        "id": 6361,
                        "displayName": "year_6361"
                  },
                  {
                        "id": 6362,
                        "displayName": "year_6362"
                  },
                  {
                        "id": 6363,
                        "displayName": "year_6363"
                  },
                  {
                        "id": 6364,
                        "displayName": "year_6364"
                  },
                  {
                        "id": 6365,
                        "displayName": "year_6365"
                  },
                  {
                        "id": 6366,
                        "displayName": "year_6366"
                  },
                  {
                        "id": 6367,
                        "displayName": "year_6367"
                  },
                  {
                        "id": 6368,
                        "displayName": "year_6368"
                  },
                  {
                        "id": 6369,
                        "displayName": "year_6369"
                  },
                  {
                        "id": 6370,
                        "displayName": "year_6370"
                  },
                  {
                        "id": 6371,
                        "displayName": "year_6371"
                  },
                  {
                        "id": 6372,
                        "displayName": "year_6372"
                  },
                  {
                        "id": 6373,
                        "displayName": "year_6373"
                  },
                  {
                        "id": 6374,
                        "displayName": "year_6374"
                  },
                  {
                        "id": 6375,
                        "displayName": "year_6375"
                  },
                  {
                        "id": 6376,
                        "displayName": "year_6376"
                  },
                  {
                        "id": 6377,
                        "displayName": "year_6377"
                  },
                  {
                        "id": 6378,
                        "displayName": "year_6378"
                  },
                  {
                        "id": 6379,
                        "displayName": "year_6379"
                  },
                  {
                        "id": 6380,
                        "displayName": "year_6380"
                  },
                  {
                        "id": 6381,
                        "displayName": "year_6381"
                  },
                  {
                        "id": 6382,
                        "displayName": "year_6382"
                  },
                  {
                        "id": 6383,
                        "displayName": "year_6383"
                  },
                  {
                        "id": 6384,
                        "displayName": "year_6384"
                  },
                  {
                        "id": 6385,
                        "displayName": "year_6385"
                  },
                  {
                        "id": 6386,
                        "displayName": "year_6386"
                  },
                  {
                        "id": 6387,
                        "displayName": "year_6387"
                  },
                  {
                        "id": 6388,
                        "displayName": "year_6388"
                  },
                  {
                        "id": 6389,
                        "displayName": "year_6389"
                  },
                  {
                        "id": 6390,
                        "displayName": "year_6390"
                  },
                  {
                        "id": 6391,
                        "displayName": "year_6391"
                  },
                  {
                        "id": 6392,
                        "displayName": "year_6392"
                  },
                  {
                        "id": 6393,
                        "displayName": "year_6393"
                  },
                  {
                        "id": 6394,
                        "displayName": "year_6394"
                  },
                  {
                        "id": 6395,
                        "displayName": "year_6395"
                  },
                  {
                        "id": 6396,
                        "displayName": "year_6396"
                  },
                  {
                        "id": 6397,
                        "displayName": "year_6397"
                  },
                  {
                        "id": 6398,
                        "displayName": "year_6398"
                  },
                  {
                        "id": 6399,
                        "displayName": "year_6399"
                  },
                  {
                        "id": 6400,
                        "displayName": "year_6400"
                  },
                  {
                        "id": 6401,
                        "displayName": "year_6401"
                  },
                  {
                        "id": 6402,
                        "displayName": "year_6402"
                  },
                  {
                        "id": 6403,
                        "displayName": "year_6403"
                  },
                  {
                        "id": 6404,
                        "displayName": "year_6404"
                  },
                  {
                        "id": 6405,
                        "displayName": "year_6405"
                  },
                  {
                        "id": 6406,
                        "displayName": "year_6406"
                  },
                  {
                        "id": 6407,
                        "displayName": "year_6407"
                  },
                  {
                        "id": 6408,
                        "displayName": "year_6408"
                  },
                  {
                        "id": 6409,
                        "displayName": "year_6409"
                  },
                  {
                        "id": 6410,
                        "displayName": "year_6410"
                  },
                  {
                        "id": 6411,
                        "displayName": "year_6411"
                  },
                  {
                        "id": 6412,
                        "displayName": "year_6412"
                  },
                  {
                        "id": 6413,
                        "displayName": "year_6413"
                  },
                  {
                        "id": 6414,
                        "displayName": "year_6414"
                  },
                  {
                        "id": 6415,
                        "displayName": "year_6415"
                  },
                  {
                        "id": 6416,
                        "displayName": "year_6416"
                  },
                  {
                        "id": 6417,
                        "displayName": "year_6417"
                  },
                  {
                        "id": 6418,
                        "displayName": "year_6418"
                  },
                  {
                        "id": 6419,
                        "displayName": "year_6419"
                  },
                  {
                        "id": 6420,
                        "displayName": "year_6420"
                  },
                  {
                        "id": 6421,
                        "displayName": "year_6421"
                  },
                  {
                        "id": 6422,
                        "displayName": "year_6422"
                  },
                  {
                        "id": 6423,
                        "displayName": "year_6423"
                  },
                  {
                        "id": 6424,
                        "displayName": "year_6424"
                  },
                  {
                        "id": 6425,
                        "displayName": "year_6425"
                  },
                  {
                        "id": 6426,
                        "displayName": "year_6426"
                  },
                  {
                        "id": 6427,
                        "displayName": "year_6427"
                  },
                  {
                        "id": 6428,
                        "displayName": "year_6428"
                  },
                  {
                        "id": 6429,
                        "displayName": "year_6429"
                  },
                  {
                        "id": 6430,
                        "displayName": "year_6430"
                  },
                  {
                        "id": 6431,
                        "displayName": "year_6431"
                  },
                  {
                        "id": 6432,
                        "displayName": "year_6432"
                  },
                  {
                        "id": 6433,
                        "displayName": "year_6433"
                  },
                  {
                        "id": 6434,
                        "displayName": "year_6434"
                  },
                  {
                        "id": 6435,
                        "displayName": "year_6435"
                  },
                  {
                        "id": 6436,
                        "displayName": "year_6436"
                  },
                  {
                        "id": 6437,
                        "displayName": "year_6437"
                  },
                  {
                        "id": 6438,
                        "displayName": "year_6438"
                  },
                  {
                        "id": 6439,
                        "displayName": "year_6439"
                  },
                  {
                        "id": 6440,
                        "displayName": "year_6440"
                  },
                  {
                        "id": 6441,
                        "displayName": "year_6441"
                  },
                  {
                        "id": 6442,
                        "displayName": "year_6442"
                  },
                  {
                        "id": 6443,
                        "displayName": "year_6443"
                  },
                  {
                        "id": 6444,
                        "displayName": "year_6444"
                  },
                  {
                        "id": 6445,
                        "displayName": "year_6445"
                  },
                  {
                        "id": 6446,
                        "displayName": "year_6446"
                  },
                  {
                        "id": 6447,
                        "displayName": "year_6447"
                  },
                  {
                        "id": 6448,
                        "displayName": "year_6448"
                  },
                  {
                        "id": 6449,
                        "displayName": "year_6449"
                  },
                  {
                        "id": 6450,
                        "displayName": "year_6450"
                  },
                  {
                        "id": 6451,
                        "displayName": "year_6451"
                  },
                  {
                        "id": 6452,
                        "displayName": "year_6452"
                  },
                  {
                        "id": 6453,
                        "displayName": "year_6453"
                  },
                  {
                        "id": 6454,
                        "displayName": "year_6454"
                  },
                  {
                        "id": 6455,
                        "displayName": "year_6455"
                  },
                  {
                        "id": 6456,
                        "displayName": "year_6456"
                  },
                  {
                        "id": 6457,
                        "displayName": "year_6457"
                  },
                  {
                        "id": 6458,
                        "displayName": "year_6458"
                  },
                  {
                        "id": 6459,
                        "displayName": "year_6459"
                  },
                  {
                        "id": 6460,
                        "displayName": "year_6460"
                  },
                  {
                        "id": 6461,
                        "displayName": "year_6461"
                  },
                  {
                        "id": 6462,
                        "displayName": "year_6462"
                  },
                  {
                        "id": 6463,
                        "displayName": "year_6463"
                  },
                  {
                        "id": 6464,
                        "displayName": "year_6464"
                  },
                  {
                        "id": 6465,
                        "displayName": "year_6465"
                  },
                  {
                        "id": 6466,
                        "displayName": "year_6466"
                  },
                  {
                        "id": 6467,
                        "displayName": "year_6467"
                  },
                  {
                        "id": 6468,
                        "displayName": "year_6468"
                  },
                  {
                        "id": 6469,
                        "displayName": "year_6469"
                  },
                  {
                        "id": 6470,
                        "displayName": "year_6470"
                  },
                  {
                        "id": 6471,
                        "displayName": "year_6471"
                  },
                  {
                        "id": 6472,
                        "displayName": "year_6472"
                  },
                  {
                        "id": 6473,
                        "displayName": "year_6473"
                  },
                  {
                        "id": 6474,
                        "displayName": "year_6474"
                  },
                  {
                        "id": 6475,
                        "displayName": "year_6475"
                  },
                  {
                        "id": 6476,
                        "displayName": "year_6476"
                  },
                  {
                        "id": 6477,
                        "displayName": "year_6477"
                  },
                  {
                        "id": 6478,
                        "displayName": "year_6478"
                  },
                  {
                        "id": 6479,
                        "displayName": "year_6479"
                  },
                  {
                        "id": 6480,
                        "displayName": "year_6480"
                  },
                  {
                        "id": 6481,
                        "displayName": "year_6481"
                  },
                  {
                        "id": 6482,
                        "displayName": "year_6482"
                  },
                  {
                        "id": 6483,
                        "displayName": "year_6483"
                  },
                  {
                        "id": 6484,
                        "displayName": "year_6484"
                  },
                  {
                        "id": 6485,
                        "displayName": "year_6485"
                  },
                  {
                        "id": 6486,
                        "displayName": "year_6486"
                  },
                  {
                        "id": 6487,
                        "displayName": "year_6487"
                  },
                  {
                        "id": 6488,
                        "displayName": "year_6488"
                  },
                  {
                        "id": 6489,
                        "displayName": "year_6489"
                  },
                  {
                        "id": 6490,
                        "displayName": "year_6490"
                  },
                  {
                        "id": 6491,
                        "displayName": "year_6491"
                  },
                  {
                        "id": 6492,
                        "displayName": "year_6492"
                  },
                  {
                        "id": 6493,
                        "displayName": "year_6493"
                  },
                  {
                        "id": 6494,
                        "displayName": "year_6494"
                  },
                  {
                        "id": 6495,
                        "displayName": "year_6495"
                  },
                  {
                        "id": 6496,
                        "displayName": "year_6496"
                  },
                  {
                        "id": 6497,
                        "displayName": "year_6497"
                  },
                  {
                        "id": 6498,
                        "displayName": "year_6498"
                  },
                  {
                        "id": 6499,
                        "displayName": "year_6499"
                  },
                  {
                        "id": 6500,
                        "displayName": "year_6500"
                  },
                  {
                        "id": 6501,
                        "displayName": "year_6501"
                  },
                  {
                        "id": 6502,
                        "displayName": "year_6502"
                  },
                  {
                        "id": 6503,
                        "displayName": "year_6503"
                  },
                  {
                        "id": 6504,
                        "displayName": "year_6504"
                  },
                  {
                        "id": 6505,
                        "displayName": "year_6505"
                  },
                  {
                        "id": 6506,
                        "displayName": "year_6506"
                  },
                  {
                        "id": 6507,
                        "displayName": "year_6507"
                  },
                  {
                        "id": 6508,
                        "displayName": "year_6508"
                  },
                  {
                        "id": 6509,
                        "displayName": "year_6509"
                  },
                  {
                        "id": 6510,
                        "displayName": "year_6510"
                  },
                  {
                        "id": 6511,
                        "displayName": "year_6511"
                  },
                  {
                        "id": 6512,
                        "displayName": "year_6512"
                  },
                  {
                        "id": 6513,
                        "displayName": "year_6513"
                  },
                  {
                        "id": 6514,
                        "displayName": "year_6514"
                  },
                  {
                        "id": 6515,
                        "displayName": "year_6515"
                  },
                  {
                        "id": 6516,
                        "displayName": "year_6516"
                  },
                  {
                        "id": 6517,
                        "displayName": "year_6517"
                  },
                  {
                        "id": 6518,
                        "displayName": "year_6518"
                  },
                  {
                        "id": 6519,
                        "displayName": "year_6519"
                  },
                  {
                        "id": 6520,
                        "displayName": "year_6520"
                  },
                  {
                        "id": 6521,
                        "displayName": "year_6521"
                  },
                  {
                        "id": 6522,
                        "displayName": "year_6522"
                  },
                  {
                        "id": 6523,
                        "displayName": "year_6523"
                  },
                  {
                        "id": 6524,
                        "displayName": "year_6524"
                  },
                  {
                        "id": 6525,
                        "displayName": "year_6525"
                  },
                  {
                        "id": 6526,
                        "displayName": "year_6526"
                  },
                  {
                        "id": 6527,
                        "displayName": "year_6527"
                  },
                  {
                        "id": 6528,
                        "displayName": "year_6528"
                  },
                  {
                        "id": 6529,
                        "displayName": "year_6529"
                  },
                  {
                        "id": 6530,
                        "displayName": "year_6530"
                  },
                  {
                        "id": 6531,
                        "displayName": "year_6531"
                  },
                  {
                        "id": 6532,
                        "displayName": "year_6532"
                  },
                  {
                        "id": 6533,
                        "displayName": "year_6533"
                  },
                  {
                        "id": 6534,
                        "displayName": "year_6534"
                  },
                  {
                        "id": 6535,
                        "displayName": "year_6535"
                  },
                  {
                        "id": 6536,
                        "displayName": "year_6536"
                  },
                  {
                        "id": 6537,
                        "displayName": "year_6537"
                  },
                  {
                        "id": 6538,
                        "displayName": "year_6538"
                  },
                  {
                        "id": 6539,
                        "displayName": "year_6539"
                  },
                  {
                        "id": 6540,
                        "displayName": "year_6540"
                  },
                  {
                        "id": 6541,
                        "displayName": "year_6541"
                  },
                  {
                        "id": 6542,
                        "displayName": "year_6542"
                  },
                  {
                        "id": 6543,
                        "displayName": "year_6543"
                  },
                  {
                        "id": 6544,
                        "displayName": "year_6544"
                  },
                  {
                        "id": 6545,
                        "displayName": "year_6545"
                  },
                  {
                        "id": 6546,
                        "displayName": "year_6546"
                  },
                  {
                        "id": 6547,
                        "displayName": "year_6547"
                  },
                  {
                        "id": 6548,
                        "displayName": "year_6548"
                  },
                  {
                        "id": 6549,
                        "displayName": "year_6549"
                  },
                  {
                        "id": 6550,
                        "displayName": "year_6550"
                  },
                  {
                        "id": 6551,
                        "displayName": "year_6551"
                  },
                  {
                        "id": 6552,
                        "displayName": "year_6552"
                  },
                  {
                        "id": 6553,
                        "displayName": "year_6553"
                  },
                  {
                        "id": 6554,
                        "displayName": "year_6554"
                  },
                  {
                        "id": 6555,
                        "displayName": "year_6555"
                  },
                  {
                        "id": 6556,
                        "displayName": "year_6556"
                  },
                  {
                        "id": 6557,
                        "displayName": "year_6557"
                  },
                  {
                        "id": 6558,
                        "displayName": "year_6558"
                  },
                  {
                        "id": 6559,
                        "displayName": "year_6559"
                  },
                  {
                        "id": 6560,
                        "displayName": "year_6560"
                  },
                  {
                        "id": 6561,
                        "displayName": "year_6561"
                  },
                  {
                        "id": 6562,
                        "displayName": "year_6562"
                  },
                  {
                        "id": 6563,
                        "displayName": "year_6563"
                  },
                  {
                        "id": 6564,
                        "displayName": "year_6564"
                  },
                  {
                        "id": 6565,
                        "displayName": "year_6565"
                  },
                  {
                        "id": 6566,
                        "displayName": "year_6566"
                  },
                  {
                        "id": 6567,
                        "displayName": "year_6567"
                  },
                  {
                        "id": 6568,
                        "displayName": "year_6568"
                  },
                  {
                        "id": 6569,
                        "displayName": "year_6569"
                  },
                  {
                        "id": 6570,
                        "displayName": "year_6570"
                  },
                  {
                        "id": 6571,
                        "displayName": "year_6571"
                  },
                  {
                        "id": 6572,
                        "displayName": "year_6572"
                  },
                  {
                        "id": 6573,
                        "displayName": "year_6573"
                  },
                  {
                        "id": 6574,
                        "displayName": "year_6574"
                  },
                  {
                        "id": 6575,
                        "displayName": "year_6575"
                  },
                  {
                        "id": 6576,
                        "displayName": "year_6576"
                  },
                  {
                        "id": 6577,
                        "displayName": "year_6577"
                  },
                  {
                        "id": 6578,
                        "displayName": "year_6578"
                  },
                  {
                        "id": 6579,
                        "displayName": "year_6579"
                  },
                  {
                        "id": 6580,
                        "displayName": "year_6580"
                  },
                  {
                        "id": 6581,
                        "displayName": "year_6581"
                  },
                  {
                        "id": 6582,
                        "displayName": "year_6582"
                  },
                  {
                        "id": 6583,
                        "displayName": "year_6583"
                  },
                  {
                        "id": 6584,
                        "displayName": "year_6584"
                  },
                  {
                        "id": 6585,
                        "displayName": "year_6585"
                  },
                  {
                        "id": 6586,
                        "displayName": "year_6586"
                  },
                  {
                        "id": 6587,
                        "displayName": "year_6587"
                  },
                  {
                        "id": 6588,
                        "displayName": "year_6588"
                  },
                  {
                        "id": 6589,
                        "displayName": "year_6589"
                  },
                  {
                        "id": 6590,
                        "displayName": "year_6590"
                  },
                  {
                        "id": 6591,
                        "displayName": "year_6591"
                  },
                  {
                        "id": 6592,
                        "displayName": "year_6592"
                  },
                  {
                        "id": 6593,
                        "displayName": "year_6593"
                  },
                  {
                        "id": 6594,
                        "displayName": "year_6594"
                  },
                  {
                        "id": 6595,
                        "displayName": "year_6595"
                  },
                  {
                        "id": 6596,
                        "displayName": "year_6596"
                  },
                  {
                        "id": 6597,
                        "displayName": "year_6597"
                  },
                  {
                        "id": 6598,
                        "displayName": "year_6598"
                  },
                  {
                        "id": 6599,
                        "displayName": "year_6599"
                  },
                  {
                        "id": 6600,
                        "displayName": "year_6600"
                  },
                  {
                        "id": 6601,
                        "displayName": "year_6601"
                  },
                  {
                        "id": 6602,
                        "displayName": "year_6602"
                  },
                  {
                        "id": 6603,
                        "displayName": "year_6603"
                  },
                  {
                        "id": 6604,
                        "displayName": "year_6604"
                  },
                  {
                        "id": 6605,
                        "displayName": "year_6605"
                  },
                  {
                        "id": 6606,
                        "displayName": "year_6606"
                  },
                  {
                        "id": 6607,
                        "displayName": "year_6607"
                  },
                  {
                        "id": 6608,
                        "displayName": "year_6608"
                  },
                  {
                        "id": 6609,
                        "displayName": "year_6609"
                  },
                  {
                        "id": 6610,
                        "displayName": "year_6610"
                  },
                  {
                        "id": 6611,
                        "displayName": "year_6611"
                  },
                  {
                        "id": 6612,
                        "displayName": "year_6612"
                  },
                  {
                        "id": 6613,
                        "displayName": "year_6613"
                  },
                  {
                        "id": 6614,
                        "displayName": "year_6614"
                  },
                  {
                        "id": 6615,
                        "displayName": "year_6615"
                  },
                  {
                        "id": 6616,
                        "displayName": "year_6616"
                  },
                  {
                        "id": 6617,
                        "displayName": "year_6617"
                  },
                  {
                        "id": 6618,
                        "displayName": "year_6618"
                  },
                  {
                        "id": 6619,
                        "displayName": "year_6619"
                  },
                  {
                        "id": 6620,
                        "displayName": "year_6620"
                  },
                  {
                        "id": 6621,
                        "displayName": "year_6621"
                  },
                  {
                        "id": 6622,
                        "displayName": "year_6622"
                  },
                  {
                        "id": 6623,
                        "displayName": "year_6623"
                  },
                  {
                        "id": 6624,
                        "displayName": "year_6624"
                  },
                  {
                        "id": 6625,
                        "displayName": "year_6625"
                  },
                  {
                        "id": 6626,
                        "displayName": "year_6626"
                  },
                  {
                        "id": 6627,
                        "displayName": "year_6627"
                  },
                  {
                        "id": 6628,
                        "displayName": "year_6628"
                  },
                  {
                        "id": 6629,
                        "displayName": "year_6629"
                  },
                  {
                        "id": 6630,
                        "displayName": "year_6630"
                  },
                  {
                        "id": 6631,
                        "displayName": "year_6631"
                  },
                  {
                        "id": 6632,
                        "displayName": "year_6632"
                  },
                  {
                        "id": 6633,
                        "displayName": "year_6633"
                  },
                  {
                        "id": 6634,
                        "displayName": "year_6634"
                  },
                  {
                        "id": 6635,
                        "displayName": "year_6635"
                  },
                  {
                        "id": 6636,
                        "displayName": "year_6636"
                  },
                  {
                        "id": 6637,
                        "displayName": "year_6637"
                  },
                  {
                        "id": 6638,
                        "displayName": "year_6638"
                  },
                  {
                        "id": 6639,
                        "displayName": "year_6639"
                  },
                  {
                        "id": 6640,
                        "displayName": "year_6640"
                  },
                  {
                        "id": 6641,
                        "displayName": "year_6641"
                  },
                  {
                        "id": 6642,
                        "displayName": "year_6642"
                  },
                  {
                        "id": 6643,
                        "displayName": "year_6643"
                  },
                  {
                        "id": 6644,
                        "displayName": "year_6644"
                  },
                  {
                        "id": 6645,
                        "displayName": "year_6645"
                  },
                  {
                        "id": 6646,
                        "displayName": "year_6646"
                  },
                  {
                        "id": 6647,
                        "displayName": "year_6647"
                  },
                  {
                        "id": 6648,
                        "displayName": "year_6648"
                  },
                  {
                        "id": 6649,
                        "displayName": "year_6649"
                  },
                  {
                        "id": 6650,
                        "displayName": "year_6650"
                  },
                  {
                        "id": 6651,
                        "displayName": "year_6651"
                  },
                  {
                        "id": 6652,
                        "displayName": "year_6652"
                  },
                  {
                        "id": 6653,
                        "displayName": "year_6653"
                  },
                  {
                        "id": 6654,
                        "displayName": "year_6654"
                  },
                  {
                        "id": 6655,
                        "displayName": "year_6655"
                  },
                  {
                        "id": 6656,
                        "displayName": "year_6656"
                  },
                  {
                        "id": 6657,
                        "displayName": "year_6657"
                  },
                  {
                        "id": 6658,
                        "displayName": "year_6658"
                  },
                  {
                        "id": 6659,
                        "displayName": "year_6659"
                  },
                  {
                        "id": 6660,
                        "displayName": "year_6660"
                  },
                  {
                        "id": 6661,
                        "displayName": "year_6661"
                  },
                  {
                        "id": 6662,
                        "displayName": "year_6662"
                  },
                  {
                        "id": 6663,
                        "displayName": "year_6663"
                  },
                  {
                        "id": 6664,
                        "displayName": "year_6664"
                  },
                  {
                        "id": 6665,
                        "displayName": "year_6665"
                  },
                  {
                        "id": 6666,
                        "displayName": "year_6666"
                  },
                  {
                        "id": 6667,
                        "displayName": "year_6667"
                  },
                  {
                        "id": 6668,
                        "displayName": "year_6668"
                  },
                  {
                        "id": 6669,
                        "displayName": "year_6669"
                  },
                  {
                        "id": 6670,
                        "displayName": "year_6670"
                  },
                  {
                        "id": 6671,
                        "displayName": "year_6671"
                  },
                  {
                        "id": 6672,
                        "displayName": "year_6672"
                  },
                  {
                        "id": 6673,
                        "displayName": "year_6673"
                  },
                  {
                        "id": 6674,
                        "displayName": "year_6674"
                  },
                  {
                        "id": 6675,
                        "displayName": "year_6675"
                  },
                  {
                        "id": 6676,
                        "displayName": "year_6676"
                  },
                  {
                        "id": 6677,
                        "displayName": "year_6677"
                  },
                  {
                        "id": 6678,
                        "displayName": "year_6678"
                  },
                  {
                        "id": 6679,
                        "displayName": "year_6679"
                  },
                  {
                        "id": 6680,
                        "displayName": "year_6680"
                  },
                  {
                        "id": 6681,
                        "displayName": "year_6681"
                  },
                  {
                        "id": 6682,
                        "displayName": "year_6682"
                  },
                  {
                        "id": 6683,
                        "displayName": "year_6683"
                  },
                  {
                        "id": 6684,
                        "displayName": "year_6684"
                  },
                  {
                        "id": 6685,
                        "displayName": "year_6685"
                  },
                  {
                        "id": 6686,
                        "displayName": "year_6686"
                  },
                  {
                        "id": 6687,
                        "displayName": "year_6687"
                  },
                  {
                        "id": 6688,
                        "displayName": "year_6688"
                  },
                  {
                        "id": 6689,
                        "displayName": "year_6689"
                  },
                  {
                        "id": 6690,
                        "displayName": "year_6690"
                  },
                  {
                        "id": 6691,
                        "displayName": "year_6691"
                  },
                  {
                        "id": 6692,
                        "displayName": "year_6692"
                  },
                  {
                        "id": 6693,
                        "displayName": "year_6693"
                  },
                  {
                        "id": 6694,
                        "displayName": "year_6694"
                  },
                  {
                        "id": 6695,
                        "displayName": "year_6695"
                  },
                  {
                        "id": 6696,
                        "displayName": "year_6696"
                  },
                  {
                        "id": 6697,
                        "displayName": "year_6697"
                  },
                  {
                        "id": 6698,
                        "displayName": "year_6698"
                  },
                  {
                        "id": 6699,
                        "displayName": "year_6699"
                  },
                  {
                        "id": 6700,
                        "displayName": "year_6700"
                  },
                  {
                        "id": 6701,
                        "displayName": "year_6701"
                  },
                  {
                        "id": 6702,
                        "displayName": "year_6702"
                  },
                  {
                        "id": 6703,
                        "displayName": "year_6703"
                  },
                  {
                        "id": 6704,
                        "displayName": "year_6704"
                  },
                  {
                        "id": 6705,
                        "displayName": "year_6705"
                  },
                  {
                        "id": 6706,
                        "displayName": "year_6706"
                  },
                  {
                        "id": 6707,
                        "displayName": "year_6707"
                  },
                  {
                        "id": 6708,
                        "displayName": "year_6708"
                  },
                  {
                        "id": 6709,
                        "displayName": "year_6709"
                  },
                  {
                        "id": 6710,
                        "displayName": "year_6710"
                  },
                  {
                        "id": 6711,
                        "displayName": "year_6711"
                  },
                  {
                        "id": 6712,
                        "displayName": "year_6712"
                  },
                  {
                        "id": 6713,
                        "displayName": "year_6713"
                  },
                  {
                        "id": 6714,
                        "displayName": "year_6714"
                  },
                  {
                        "id": 6715,
                        "displayName": "year_6715"
                  },
                  {
                        "id": 6716,
                        "displayName": "year_6716"
                  },
                  {
                        "id": 6717,
                        "displayName": "year_6717"
                  },
                  {
                        "id": 6718,
                        "displayName": "year_6718"
                  },
                  {
                        "id": 6719,
                        "displayName": "year_6719"
                  },
                  {
                        "id": 6720,
                        "displayName": "year_6720"
                  },
                  {
                        "id": 6721,
                        "displayName": "year_6721"
                  },
                  {
                        "id": 6722,
                        "displayName": "year_6722"
                  },
                  {
                        "id": 6723,
                        "displayName": "year_6723"
                  },
                  {
                        "id": 6724,
                        "displayName": "year_6724"
                  },
                  {
                        "id": 6725,
                        "displayName": "year_6725"
                  },
                  {
                        "id": 6726,
                        "displayName": "year_6726"
                  },
                  {
                        "id": 6727,
                        "displayName": "year_6727"
                  },
                  {
                        "id": 6728,
                        "displayName": "year_6728"
                  },
                  {
                        "id": 6729,
                        "displayName": "year_6729"
                  },
                  {
                        "id": 6730,
                        "displayName": "year_6730"
                  },
                  {
                        "id": 6731,
                        "displayName": "year_6731"
                  },
                  {
                        "id": 6732,
                        "displayName": "year_6732"
                  },
                  {
                        "id": 6733,
                        "displayName": "year_6733"
                  },
                  {
                        "id": 6734,
                        "displayName": "year_6734"
                  },
                  {
                        "id": 6735,
                        "displayName": "year_6735"
                  },
                  {
                        "id": 6736,
                        "displayName": "year_6736"
                  },
                  {
                        "id": 6737,
                        "displayName": "year_6737"
                  },
                  {
                        "id": 6738,
                        "displayName": "year_6738"
                  },
                  {
                        "id": 6739,
                        "displayName": "year_6739"
                  },
                  {
                        "id": 6740,
                        "displayName": "year_6740"
                  },
                  {
                        "id": 6741,
                        "displayName": "year_6741"
                  },
                  {
                        "id": 6742,
                        "displayName": "year_6742"
                  },
                  {
                        "id": 6743,
                        "displayName": "year_6743"
                  },
                  {
                        "id": 6744,
                        "displayName": "year_6744"
                  },
                  {
                        "id": 6745,
                        "displayName": "year_6745"
                  },
                  {
                        "id": 6746,
                        "displayName": "year_6746"
                  },
                  {
                        "id": 6747,
                        "displayName": "year_6747"
                  },
                  {
                        "id": 6748,
                        "displayName": "year_6748"
                  },
                  {
                        "id": 6749,
                        "displayName": "year_6749"
                  },
                  {
                        "id": 6750,
                        "displayName": "year_6750"
                  },
                  {
                        "id": 6751,
                        "displayName": "year_6751"
                  },
                  {
                        "id": 6752,
                        "displayName": "year_6752"
                  },
                  {
                        "id": 6753,
                        "displayName": "year_6753"
                  },
                  {
                        "id": 6754,
                        "displayName": "year_6754"
                  },
                  {
                        "id": 6755,
                        "displayName": "year_6755"
                  },
                  {
                        "id": 6756,
                        "displayName": "year_6756"
                  },
                  {
                        "id": 6757,
                        "displayName": "year_6757"
                  },
                  {
                        "id": 6758,
                        "displayName": "year_6758"
                  },
                  {
                        "id": 6759,
                        "displayName": "year_6759"
                  },
                  {
                        "id": 6760,
                        "displayName": "year_6760"
                  },
                  {
                        "id": 6761,
                        "displayName": "year_6761"
                  },
                  {
                        "id": 6762,
                        "displayName": "year_6762"
                  },
                  {
                        "id": 6763,
                        "displayName": "year_6763"
                  },
                  {
                        "id": 6764,
                        "displayName": "year_6764"
                  },
                  {
                        "id": 6765,
                        "displayName": "year_6765"
                  },
                  {
                        "id": 6766,
                        "displayName": "year_6766"
                  },
                  {
                        "id": 6767,
                        "displayName": "year_6767"
                  },
                  {
                        "id": 6768,
                        "displayName": "year_6768"
                  },
                  {
                        "id": 6769,
                        "displayName": "year_6769"
                  },
                  {
                        "id": 6770,
                        "displayName": "year_6770"
                  },
                  {
                        "id": 6771,
                        "displayName": "year_6771"
                  },
                  {
                        "id": 6772,
                        "displayName": "year_6772"
                  },
                  {
                        "id": 6773,
                        "displayName": "year_6773"
                  },
                  {
                        "id": 6774,
                        "displayName": "year_6774"
                  },
                  {
                        "id": 6775,
                        "displayName": "year_6775"
                  },
                  {
                        "id": 6776,
                        "displayName": "year_6776"
                  },
                  {
                        "id": 6777,
                        "displayName": "year_6777"
                  },
                  {
                        "id": 6778,
                        "displayName": "year_6778"
                  },
                  {
                        "id": 6779,
                        "displayName": "year_6779"
                  },
                  {
                        "id": 6780,
                        "displayName": "year_6780"
                  },
                  {
                        "id": 6781,
                        "displayName": "year_6781"
                  },
                  {
                        "id": 6782,
                        "displayName": "year_6782"
                  },
                  {
                        "id": 6783,
                        "displayName": "year_6783"
                  },
                  {
                        "id": 6784,
                        "displayName": "year_6784"
                  },
                  {
                        "id": 6785,
                        "displayName": "year_6785"
                  },
                  {
                        "id": 6786,
                        "displayName": "year_6786"
                  },
                  {
                        "id": 6787,
                        "displayName": "year_6787"
                  },
                  {
                        "id": 6788,
                        "displayName": "year_6788"
                  },
                  {
                        "id": 6789,
                        "displayName": "year_6789"
                  },
                  {
                        "id": 6790,
                        "displayName": "year_6790"
                  },
                  {
                        "id": 6791,
                        "displayName": "year_6791"
                  },
                  {
                        "id": 6792,
                        "displayName": "year_6792"
                  },
                  {
                        "id": 6793,
                        "displayName": "year_6793"
                  },
                  {
                        "id": 6794,
                        "displayName": "year_6794"
                  },
                  {
                        "id": 6795,
                        "displayName": "year_6795"
                  },
                  {
                        "id": 6796,
                        "displayName": "year_6796"
                  },
                  {
                        "id": 6797,
                        "displayName": "year_6797"
                  },
                  {
                        "id": 6798,
                        "displayName": "year_6798"
                  },
                  {
                        "id": 6799,
                        "displayName": "year_6799"
                  },
                  {
                        "id": 6800,
                        "displayName": "year_6800"
                  },
                  {
                        "id": 6801,
                        "displayName": "year_6801"
                  },
                  {
                        "id": 6802,
                        "displayName": "year_6802"
                  },
                  {
                        "id": 6803,
                        "displayName": "year_6803"
                  },
                  {
                        "id": 6804,
                        "displayName": "year_6804"
                  },
                  {
                        "id": 6805,
                        "displayName": "year_6805"
                  },
                  {
                        "id": 6806,
                        "displayName": "year_6806"
                  },
                  {
                        "id": 6807,
                        "displayName": "year_6807"
                  },
                  {
                        "id": 6808,
                        "displayName": "year_6808"
                  },
                  {
                        "id": 6809,
                        "displayName": "year_6809"
                  },
                  {
                        "id": 6810,
                        "displayName": "year_6810"
                  },
                  {
                        "id": 6811,
                        "displayName": "year_6811"
                  },
                  {
                        "id": 6812,
                        "displayName": "year_6812"
                  },
                  {
                        "id": 6813,
                        "displayName": "year_6813"
                  },
                  {
                        "id": 6814,
                        "displayName": "year_6814"
                  },
                  {
                        "id": 6815,
                        "displayName": "year_6815"
                  },
                  {
                        "id": 6816,
                        "displayName": "year_6816"
                  },
                  {
                        "id": 6817,
                        "displayName": "year_6817"
                  },
                  {
                        "id": 6818,
                        "displayName": "year_6818"
                  },
                  {
                        "id": 6819,
                        "displayName": "year_6819"
                  },
                  {
                        "id": 6820,
                        "displayName": "year_6820"
                  },
                  {
                        "id": 6821,
                        "displayName": "year_6821"
                  },
                  {
                        "id": 6822,
                        "displayName": "year_6822"
                  },
                  {
                        "id": 6823,
                        "displayName": "year_6823"
                  },
                  {
                        "id": 6824,
                        "displayName": "year_6824"
                  },
                  {
                        "id": 6825,
                        "displayName": "year_6825"
                  },
                  {
                        "id": 6826,
                        "displayName": "year_6826"
                  },
                  {
                        "id": 6827,
                        "displayName": "year_6827"
                  },
                  {
                        "id": 6828,
                        "displayName": "year_6828"
                  },
                  {
                        "id": 6829,
                        "displayName": "year_6829"
                  },
                  {
                        "id": 6830,
                        "displayName": "year_6830"
                  },
                  {
                        "id": 6831,
                        "displayName": "year_6831"
                  },
                  {
                        "id": 6832,
                        "displayName": "year_6832"
                  },
                  {
                        "id": 6833,
                        "displayName": "year_6833"
                  },
                  {
                        "id": 6834,
                        "displayName": "year_6834"
                  },
                  {
                        "id": 6835,
                        "displayName": "year_6835"
                  },
                  {
                        "id": 6836,
                        "displayName": "year_6836"
                  },
                  {
                        "id": 6837,
                        "displayName": "year_6837"
                  },
                  {
                        "id": 6838,
                        "displayName": "year_6838"
                  },
                  {
                        "id": 6839,
                        "displayName": "year_6839"
                  },
                  {
                        "id": 6840,
                        "displayName": "year_6840"
                  },
                  {
                        "id": 6841,
                        "displayName": "year_6841"
                  },
                  {
                        "id": 6842,
                        "displayName": "year_6842"
                  },
                  {
                        "id": 6843,
                        "displayName": "year_6843"
                  },
                  {
                        "id": 6844,
                        "displayName": "year_6844"
                  },
                  {
                        "id": 6845,
                        "displayName": "year_6845"
                  },
                  {
                        "id": 6846,
                        "displayName": "year_6846"
                  },
                  {
                        "id": 6847,
                        "displayName": "year_6847"
                  },
                  {
                        "id": 6848,
                        "displayName": "year_6848"
                  },
                  {
                        "id": 6849,
                        "displayName": "year_6849"
                  },
                  {
                        "id": 6850,
                        "displayName": "year_6850"
                  },
                  {
                        "id": 6851,
                        "displayName": "year_6851"
                  },
                  {
                        "id": 6852,
                        "displayName": "year_6852"
                  },
                  {
                        "id": 6853,
                        "displayName": "year_6853"
                  },
                  {
                        "id": 6854,
                        "displayName": "year_6854"
                  },
                  {
                        "id": 6855,
                        "displayName": "year_6855"
                  },
                  {
                        "id": 6856,
                        "displayName": "year_6856"
                  },
                  {
                        "id": 6857,
                        "displayName": "year_6857"
                  },
                  {
                        "id": 6858,
                        "displayName": "year_6858"
                  },
                  {
                        "id": 6859,
                        "displayName": "year_6859"
                  },
                  {
                        "id": 6860,
                        "displayName": "year_6860"
                  },
                  {
                        "id": 6861,
                        "displayName": "year_6861"
                  },
                  {
                        "id": 6862,
                        "displayName": "year_6862"
                  },
                  {
                        "id": 6863,
                        "displayName": "year_6863"
                  },
                  {
                        "id": 6864,
                        "displayName": "year_6864"
                  },
                  {
                        "id": 6865,
                        "displayName": "year_6865"
                  },
                  {
                        "id": 6866,
                        "displayName": "year_6866"
                  },
                  {
                        "id": 6867,
                        "displayName": "year_6867"
                  },
                  {
                        "id": 6868,
                        "displayName": "year_6868"
                  },
                  {
                        "id": 6869,
                        "displayName": "year_6869"
                  },
                  {
                        "id": 6870,
                        "displayName": "year_6870"
                  },
                  {
                        "id": 6871,
                        "displayName": "year_6871"
                  },
                  {
                        "id": 6872,
                        "displayName": "year_6872"
                  },
                  {
                        "id": 6873,
                        "displayName": "year_6873"
                  },
                  {
                        "id": 6874,
                        "displayName": "year_6874"
                  },
                  {
                        "id": 6875,
                        "displayName": "year_6875"
                  },
                  {
                        "id": 6876,
                        "displayName": "year_6876"
                  },
                  {
                        "id": 6877,
                        "displayName": "year_6877"
                  },
                  {
                        "id": 6878,
                        "displayName": "year_6878"
                  },
                  {
                        "id": 6879,
                        "displayName": "year_6879"
                  },
                  {
                        "id": 6880,
                        "displayName": "year_6880"
                  },
                  {
                        "id": 6881,
                        "displayName": "year_6881"
                  },
                  {
                        "id": 6882,
                        "displayName": "year_6882"
                  },
                  {
                        "id": 6883,
                        "displayName": "year_6883"
                  },
                  {
                        "id": 6884,
                        "displayName": "year_6884"
                  },
                  {
                        "id": 6885,
                        "displayName": "year_6885"
                  },
                  {
                        "id": 6886,
                        "displayName": "year_6886"
                  },
                  {
                        "id": 6887,
                        "displayName": "year_6887"
                  },
                  {
                        "id": 6888,
                        "displayName": "year_6888"
                  },
                  {
                        "id": 6889,
                        "displayName": "year_6889"
                  },
                  {
                        "id": 6890,
                        "displayName": "year_6890"
                  },
                  {
                        "id": 6891,
                        "displayName": "year_6891"
                  },
                  {
                        "id": 6892,
                        "displayName": "year_6892"
                  },
                  {
                        "id": 6893,
                        "displayName": "year_6893"
                  },
                  {
                        "id": 6894,
                        "displayName": "year_6894"
                  },
                  {
                        "id": 6895,
                        "displayName": "year_6895"
                  },
                  {
                        "id": 6896,
                        "displayName": "year_6896"
                  },
                  {
                        "id": 6897,
                        "displayName": "year_6897"
                  },
                  {
                        "id": 6898,
                        "displayName": "year_6898"
                  },
                  {
                        "id": 6899,
                        "displayName": "year_6899"
                  },
                  {
                        "id": 6900,
                        "displayName": "year_6900"
                  },
                  {
                        "id": 6901,
                        "displayName": "year_6901"
                  },
                  {
                        "id": 6902,
                        "displayName": "year_6902"
                  },
                  {
                        "id": 6903,
                        "displayName": "year_6903"
                  },
                  {
                        "id": 6904,
                        "displayName": "year_6904"
                  },
                  {
                        "id": 6905,
                        "displayName": "year_6905"
                  },
                  {
                        "id": 6906,
                        "displayName": "year_6906"
                  },
                  {
                        "id": 6907,
                        "displayName": "year_6907"
                  },
                  {
                        "id": 6908,
                        "displayName": "year_6908"
                  },
                  {
                        "id": 6909,
                        "displayName": "year_6909"
                  },
                  {
                        "id": 6910,
                        "displayName": "year_6910"
                  },
                  {
                        "id": 6911,
                        "displayName": "year_6911"
                  },
                  {
                        "id": 6912,
                        "displayName": "year_6912"
                  },
                  {
                        "id": 6913,
                        "displayName": "year_6913"
                  },
                  {
                        "id": 6914,
                        "displayName": "year_6914"
                  },
                  {
                        "id": 6915,
                        "displayName": "year_6915"
                  },
                  {
                        "id": 6916,
                        "displayName": "year_6916"
                  },
                  {
                        "id": 6917,
                        "displayName": "year_6917"
                  },
                  {
                        "id": 6918,
                        "displayName": "year_6918"
                  },
                  {
                        "id": 6919,
                        "displayName": "year_6919"
                  },
                  {
                        "id": 6920,
                        "displayName": "year_6920"
                  },
                  {
                        "id": 6921,
                        "displayName": "year_6921"
                  },
                  {
                        "id": 6922,
                        "displayName": "year_6922"
                  },
                  {
                        "id": 6923,
                        "displayName": "year_6923"
                  },
                  {
                        "id": 6924,
                        "displayName": "year_6924"
                  },
                  {
                        "id": 6925,
                        "displayName": "year_6925"
                  },
                  {
                        "id": 6926,
                        "displayName": "year_6926"
                  },
                  {
                        "id": 6927,
                        "displayName": "year_6927"
                  },
                  {
                        "id": 6928,
                        "displayName": "year_6928"
                  },
                  {
                        "id": 6929,
                        "displayName": "year_6929"
                  },
                  {
                        "id": 6930,
                        "displayName": "year_6930"
                  },
                  {
                        "id": 6931,
                        "displayName": "year_6931"
                  },
                  {
                        "id": 6932,
                        "displayName": "year_6932"
                  },
                  {
                        "id": 6933,
                        "displayName": "year_6933"
                  },
                  {
                        "id": 6934,
                        "displayName": "year_6934"
                  },
                  {
                        "id": 6935,
                        "displayName": "year_6935"
                  },
                  {
                        "id": 6936,
                        "displayName": "year_6936"
                  },
                  {
                        "id": 6937,
                        "displayName": "year_6937"
                  },
                  {
                        "id": 6938,
                        "displayName": "year_6938"
                  },
                  {
                        "id": 6939,
                        "displayName": "year_6939"
                  },
                  {
                        "id": 6940,
                        "displayName": "year_6940"
                  },
                  {
                        "id": 6941,
                        "displayName": "year_6941"
                  },
                  {
                        "id": 6942,
                        "displayName": "year_6942"
                  },
                  {
                        "id": 6943,
                        "displayName": "year_6943"
                  },
                  {
                        "id": 6944,
                        "displayName": "year_6944"
                  },
                  {
                        "id": 6945,
                        "displayName": "year_6945"
                  },
                  {
                        "id": 6946,
                        "displayName": "year_6946"
                  },
                  {
                        "id": 6947,
                        "displayName": "year_6947"
                  },
                  {
                        "id": 6948,
                        "displayName": "year_6948"
                  },
                  {
                        "id": 6949,
                        "displayName": "year_6949"
                  },
                  {
                        "id": 6950,
                        "displayName": "year_6950"
                  },
                  {
                        "id": 6951,
                        "displayName": "year_6951"
                  },
                  {
                        "id": 6952,
                        "displayName": "year_6952"
                  },
                  {
                        "id": 6953,
                        "displayName": "year_6953"
                  },
                  {
                        "id": 6954,
                        "displayName": "year_6954"
                  },
                  {
                        "id": 6955,
                        "displayName": "year_6955"
                  },
                  {
                        "id": 6956,
                        "displayName": "year_6956"
                  },
                  {
                        "id": 6957,
                        "displayName": "year_6957"
                  },
                  {
                        "id": 6958,
                        "displayName": "year_6958"
                  },
                  {
                        "id": 6959,
                        "displayName": "year_6959"
                  },
                  {
                        "id": 6960,
                        "displayName": "year_6960"
                  },
                  {
                        "id": 6961,
                        "displayName": "year_6961"
                  },
                  {
                        "id": 6962,
                        "displayName": "year_6962"
                  },
                  {
                        "id": 6963,
                        "displayName": "year_6963"
                  },
                  {
                        "id": 6964,
                        "displayName": "year_6964"
                  },
                  {
                        "id": 6965,
                        "displayName": "year_6965"
                  },
                  {
                        "id": 6966,
                        "displayName": "year_6966"
                  },
                  {
                        "id": 6967,
                        "displayName": "year_6967"
                  },
                  {
                        "id": 6968,
                        "displayName": "year_6968"
                  },
                  {
                        "id": 6969,
                        "displayName": "year_6969"
                  },
                  {
                        "id": 6970,
                        "displayName": "year_6970"
                  },
                  {
                        "id": 6971,
                        "displayName": "year_6971"
                  },
                  {
                        "id": 6972,
                        "displayName": "year_6972"
                  },
                  {
                        "id": 6973,
                        "displayName": "year_6973"
                  },
                  {
                        "id": 6974,
                        "displayName": "year_6974"
                  },
                  {
                        "id": 6975,
                        "displayName": "year_6975"
                  },
                  {
                        "id": 6976,
                        "displayName": "year_6976"
                  },
                  {
                        "id": 6977,
                        "displayName": "year_6977"
                  },
                  {
                        "id": 6978,
                        "displayName": "year_6978"
                  },
                  {
                        "id": 6979,
                        "displayName": "year_6979"
                  },
                  {
                        "id": 6980,
                        "displayName": "year_6980"
                  },
                  {
                        "id": 6981,
                        "displayName": "year_6981"
                  },
                  {
                        "id": 6982,
                        "displayName": "year_6982"
                  },
                  {
                        "id": 6983,
                        "displayName": "year_6983"
                  },
                  {
                        "id": 6984,
                        "displayName": "year_6984"
                  },
                  {
                        "id": 6985,
                        "displayName": "year_6985"
                  },
                  {
                        "id": 6986,
                        "displayName": "year_6986"
                  },
                  {
                        "id": 6987,
                        "displayName": "year_6987"
                  },
                  {
                        "id": 6988,
                        "displayName": "year_6988"
                  },
                  {
                        "id": 6989,
                        "displayName": "year_6989"
                  },
                  {
                        "id": 6990,
                        "displayName": "year_6990"
                  },
                  {
                        "id": 6991,
                        "displayName": "year_6991"
                  },
                  {
                        "id": 6992,
                        "displayName": "year_6992"
                  },
                  {
                        "id": 6993,
                        "displayName": "year_6993"
                  },
                  {
                        "id": 6994,
                        "displayName": "year_6994"
                  },
                  {
                        "id": 6995,
                        "displayName": "year_6995"
                  },
                  {
                        "id": 6996,
                        "displayName": "year_6996"
                  },
                  {
                        "id": 6997,
                        "displayName": "year_6997"
                  },
                  {
                        "id": 6998,
                        "displayName": "year_6998"
                  },
                  {
                        "id": 6999,
                        "displayName": "year_6999"
                  },
                  {
                        "id": 7000,
                        "displayName": "year_7000"
                  },
                  {
                        "id": 7001,
                        "displayName": "year_7001"
                  },
                  {
                        "id": 7002,
                        "displayName": "year_7002"
                  },
                  {
                        "id": 7003,
                        "displayName": "year_7003"
                  },
                  {
                        "id": 7004,
                        "displayName": "year_7004"
                  },
                  {
                        "id": 7005,
                        "displayName": "year_7005"
                  },
                  {
                        "id": 7006,
                        "displayName": "year_7006"
                  },
                  {
                        "id": 7007,
                        "displayName": "year_7007"
                  },
                  {
                        "id": 7008,
                        "displayName": "year_7008"
                  },
                  {
                        "id": 7009,
                        "displayName": "year_7009"
                  },
                  {
                        "id": 7010,
                        "displayName": "year_7010"
                  },
                  {
                        "id": 7011,
                        "displayName": "year_7011"
                  },
                  {
                        "id": 7012,
                        "displayName": "year_7012"
                  },
                  {
                        "id": 7013,
                        "displayName": "year_7013"
                  },
                  {
                        "id": 7014,
                        "displayName": "year_7014"
                  },
                  {
                        "id": 7015,
                        "displayName": "year_7015"
                  },
                  {
                        "id": 7016,
                        "displayName": "year_7016"
                  },
                  {
                        "id": 7017,
                        "displayName": "year_7017"
                  },
                  {
                        "id": 7018,
                        "displayName": "year_7018"
                  },
                  {
                        "id": 7019,
                        "displayName": "year_7019"
                  },
                  {
                        "id": 7020,
                        "displayName": "year_7020"
                  },
                  {
                        "id": 7021,
                        "displayName": "year_7021"
                  },
                  {
                        "id": 7022,
                        "displayName": "year_7022"
                  },
                  {
                        "id": 7023,
                        "displayName": "year_7023"
                  },
                  {
                        "id": 7024,
                        "displayName": "year_7024"
                  },
                  {
                        "id": 7025,
                        "displayName": "year_7025"
                  },
                  {
                        "id": 7026,
                        "displayName": "year_7026"
                  },
                  {
                        "id": 7027,
                        "displayName": "year_7027"
                  },
                  {
                        "id": 7028,
                        "displayName": "year_7028"
                  },
                  {
                        "id": 7029,
                        "displayName": "year_7029"
                  },
                  {
                        "id": 7030,
                        "displayName": "year_7030"
                  },
                  {
                        "id": 7031,
                        "displayName": "year_7031"
                  },
                  {
                        "id": 7032,
                        "displayName": "year_7032"
                  },
                  {
                        "id": 7033,
                        "displayName": "year_7033"
                  },
                  {
                        "id": 7034,
                        "displayName": "year_7034"
                  },
                  {
                        "id": 7035,
                        "displayName": "year_7035"
                  },
                  {
                        "id": 7036,
                        "displayName": "year_7036"
                  },
                  {
                        "id": 7037,
                        "displayName": "year_7037"
                  },
                  {
                        "id": 7038,
                        "displayName": "year_7038"
                  },
                  {
                        "id": 7039,
                        "displayName": "year_7039"
                  },
                  {
                        "id": 7040,
                        "displayName": "year_7040"
                  },
                  {
                        "id": 7041,
                        "displayName": "year_7041"
                  },
                  {
                        "id": 7042,
                        "displayName": "year_7042"
                  },
                  {
                        "id": 7043,
                        "displayName": "year_7043"
                  },
                  {
                        "id": 7044,
                        "displayName": "year_7044"
                  },
                  {
                        "id": 7045,
                        "displayName": "year_7045"
                  },
                  {
                        "id": 7046,
                        "displayName": "year_7046"
                  },
                  {
                        "id": 7047,
                        "displayName": "year_7047"
                  },
                  {
                        "id": 7048,
                        "displayName": "year_7048"
                  },
                  {
                        "id": 7049,
                        "displayName": "year_7049"
                  },
                  {
                        "id": 7050,
                        "displayName": "year_7050"
                  },
                  {
                        "id": 7051,
                        "displayName": "year_7051"
                  },
                  {
                        "id": 7052,
                        "displayName": "year_7052"
                  },
                  {
                        "id": 7053,
                        "displayName": "year_7053"
                  },
                  {
                        "id": 7054,
                        "displayName": "year_7054"
                  },
                  {
                        "id": 7055,
                        "displayName": "year_7055"
                  },
                  {
                        "id": 7056,
                        "displayName": "year_7056"
                  },
                  {
                        "id": 7057,
                        "displayName": "year_7057"
                  },
                  {
                        "id": 7058,
                        "displayName": "year_7058"
                  },
                  {
                        "id": 7059,
                        "displayName": "year_7059"
                  },
                  {
                        "id": 7060,
                        "displayName": "year_7060"
                  },
                  {
                        "id": 7061,
                        "displayName": "year_7061"
                  },
                  {
                        "id": 7062,
                        "displayName": "year_7062"
                  },
                  {
                        "id": 7063,
                        "displayName": "year_7063"
                  },
                  {
                        "id": 7064,
                        "displayName": "year_7064"
                  },
                  {
                        "id": 7065,
                        "displayName": "year_7065"
                  },
                  {
                        "id": 7066,
                        "displayName": "year_7066"
                  },
                  {
                        "id": 7067,
                        "displayName": "year_7067"
                  },
                  {
                        "id": 7068,
                        "displayName": "year_7068"
                  },
                  {
                        "id": 7069,
                        "displayName": "year_7069"
                  },
                  {
                        "id": 7070,
                        "displayName": "year_7070"
                  },
                  {
                        "id": 7071,
                        "displayName": "year_7071"
                  },
                  {
                        "id": 7072,
                        "displayName": "year_7072"
                  },
                  {
                        "id": 7073,
                        "displayName": "year_7073"
                  },
                  {
                        "id": 7074,
                        "displayName": "year_7074"
                  },
                  {
                        "id": 7075,
                        "displayName": "year_7075"
                  },
                  {
                        "id": 7076,
                        "displayName": "year_7076"
                  },
                  {
                        "id": 7077,
                        "displayName": "year_7077"
                  },
                  {
                        "id": 7078,
                        "displayName": "year_7078"
                  },
                  {
                        "id": 7079,
                        "displayName": "year_7079"
                  },
                  {
                        "id": 7080,
                        "displayName": "year_7080"
                  },
                  {
                        "id": 7081,
                        "displayName": "year_7081"
                  },
                  {
                        "id": 7082,
                        "displayName": "year_7082"
                  },
                  {
                        "id": 7083,
                        "displayName": "year_7083"
                  },
                  {
                        "id": 7084,
                        "displayName": "year_7084"
                  },
                  {
                        "id": 7085,
                        "displayName": "year_7085"
                  },
                  {
                        "id": 7086,
                        "displayName": "year_7086"
                  },
                  {
                        "id": 7087,
                        "displayName": "year_7087"
                  },
                  {
                        "id": 7088,
                        "displayName": "year_7088"
                  },
                  {
                        "id": 7089,
                        "displayName": "year_7089"
                  },
                  {
                        "id": 7090,
                        "displayName": "year_7090"
                  },
                  {
                        "id": 7091,
                        "displayName": "year_7091"
                  },
                  {
                        "id": 7092,
                        "displayName": "year_7092"
                  },
                  {
                        "id": 7093,
                        "displayName": "year_7093"
                  },
                  {
                        "id": 7094,
                        "displayName": "year_7094"
                  },
                  {
                        "id": 7095,
                        "displayName": "year_7095"
                  },
                  {
                        "id": 7096,
                        "displayName": "year_7096"
                  },
                  {
                        "id": 7097,
                        "displayName": "year_7097"
                  },
                  {
                        "id": 7098,
                        "displayName": "year_7098"
                  },
                  {
                        "id": 7099,
                        "displayName": "year_7099"
                  },
                  {
                        "id": 7100,
                        "displayName": "year_7100"
                  },
                  {
                        "id": 7101,
                        "displayName": "year_7101"
                  },
                  {
                        "id": 7102,
                        "displayName": "year_7102"
                  },
                  {
                        "id": 7103,
                        "displayName": "year_7103"
                  },
                  {
                        "id": 7104,
                        "displayName": "year_7104"
                  },
                  {
                        "id": 7105,
                        "displayName": "year_7105"
                  },
                  {
                        "id": 7106,
                        "displayName": "year_7106"
                  },
                  {
                        "id": 7107,
                        "displayName": "year_7107"
                  },
                  {
                        "id": 7108,
                        "displayName": "year_7108"
                  },
                  {
                        "id": 7109,
                        "displayName": "year_7109"
                  },
                  {
                        "id": 7110,
                        "displayName": "year_7110"
                  },
                  {
                        "id": 7111,
                        "displayName": "year_7111"
                  },
                  {
                        "id": 7112,
                        "displayName": "year_7112"
                  },
                  {
                        "id": 7113,
                        "displayName": "year_7113"
                  },
                  {
                        "id": 7114,
                        "displayName": "year_7114"
                  },
                  {
                        "id": 7115,
                        "displayName": "year_7115"
                  },
                  {
                        "id": 7116,
                        "displayName": "year_7116"
                  },
                  {
                        "id": 7117,
                        "displayName": "year_7117"
                  },
                  {
                        "id": 7118,
                        "displayName": "year_7118"
                  },
                  {
                        "id": 7119,
                        "displayName": "year_7119"
                  },
                  {
                        "id": 7120,
                        "displayName": "year_7120"
                  },
                  {
                        "id": 7121,
                        "displayName": "year_7121"
                  },
                  {
                        "id": 7122,
                        "displayName": "year_7122"
                  },
                  {
                        "id": 7123,
                        "displayName": "year_7123"
                  },
                  {
                        "id": 7124,
                        "displayName": "year_7124"
                  },
                  {
                        "id": 7125,
                        "displayName": "year_7125"
                  },
                  {
                        "id": 7126,
                        "displayName": "year_7126"
                  },
                  {
                        "id": 7127,
                        "displayName": "year_7127"
                  },
                  {
                        "id": 7128,
                        "displayName": "year_7128"
                  },
                  {
                        "id": 7129,
                        "displayName": "year_7129"
                  },
                  {
                        "id": 7130,
                        "displayName": "year_7130"
                  },
                  {
                        "id": 7131,
                        "displayName": "year_7131"
                  },
                  {
                        "id": 7132,
                        "displayName": "year_7132"
                  },
                  {
                        "id": 7133,
                        "displayName": "year_7133"
                  },
                  {
                        "id": 7134,
                        "displayName": "year_7134"
                  },
                  {
                        "id": 7135,
                        "displayName": "year_7135"
                  },
                  {
                        "id": 7136,
                        "displayName": "year_7136"
                  },
                  {
                        "id": 7137,
                        "displayName": "year_7137"
                  },
                  {
                        "id": 7138,
                        "displayName": "year_7138"
                  },
                  {
                        "id": 7139,
                        "displayName": "year_7139"
                  },
                  {
                        "id": 7140,
                        "displayName": "year_7140"
                  },
                  {
                        "id": 7141,
                        "displayName": "year_7141"
                  },
                  {
                        "id": 7142,
                        "displayName": "year_7142"
                  },
                  {
                        "id": 7143,
                        "displayName": "year_7143"
                  },
                  {
                        "id": 7144,
                        "displayName": "year_7144"
                  },
                  {
                        "id": 7145,
                        "displayName": "year_7145"
                  },
                  {
                        "id": 7146,
                        "displayName": "year_7146"
                  },
                  {
                        "id": 7147,
                        "displayName": "year_7147"
                  },
                  {
                        "id": 7148,
                        "displayName": "year_7148"
                  },
                  {
                        "id": 7149,
                        "displayName": "year_7149"
                  },
                  {
                        "id": 7150,
                        "displayName": "year_7150"
                  },
                  {
                        "id": 7151,
                        "displayName": "year_7151"
                  },
                  {
                        "id": 7152,
                        "displayName": "year_7152"
                  },
                  {
                        "id": 7153,
                        "displayName": "year_7153"
                  },
                  {
                        "id": 7154,
                        "displayName": "year_7154"
                  },
                  {
                        "id": 7155,
                        "displayName": "year_7155"
                  },
                  {
                        "id": 7156,
                        "displayName": "year_7156"
                  },
                  {
                        "id": 7157,
                        "displayName": "year_7157"
                  },
                  {
                        "id": 7158,
                        "displayName": "year_7158"
                  },
                  {
                        "id": 7159,
                        "displayName": "year_7159"
                  },
                  {
                        "id": 7160,
                        "displayName": "year_7160"
                  },
                  {
                        "id": 7161,
                        "displayName": "year_7161"
                  },
                  {
                        "id": 7162,
                        "displayName": "year_7162"
                  },
                  {
                        "id": 7163,
                        "displayName": "year_7163"
                  },
                  {
                        "id": 7164,
                        "displayName": "year_7164"
                  },
                  {
                        "id": 7165,
                        "displayName": "year_7165"
                  },
                  {
                        "id": 7166,
                        "displayName": "year_7166"
                  },
                  {
                        "id": 7167,
                        "displayName": "year_7167"
                  },
                  {
                        "id": 7168,
                        "displayName": "year_7168"
                  },
                  {
                        "id": 7169,
                        "displayName": "year_7169"
                  },
                  {
                        "id": 7170,
                        "displayName": "year_7170"
                  },
                  {
                        "id": 7171,
                        "displayName": "year_7171"
                  },
                  {
                        "id": 7172,
                        "displayName": "year_7172"
                  },
                  {
                        "id": 7173,
                        "displayName": "year_7173"
                  },
                  {
                        "id": 7174,
                        "displayName": "year_7174"
                  },
                  {
                        "id": 7175,
                        "displayName": "year_7175"
                  },
                  {
                        "id": 7176,
                        "displayName": "year_7176"
                  },
                  {
                        "id": 7177,
                        "displayName": "year_7177"
                  },
                  {
                        "id": 7178,
                        "displayName": "year_7178"
                  },
                  {
                        "id": 7179,
                        "displayName": "year_7179"
                  },
                  {
                        "id": 7180,
                        "displayName": "year_7180"
                  },
                  {
                        "id": 7181,
                        "displayName": "year_7181"
                  },
                  {
                        "id": 7182,
                        "displayName": "year_7182"
                  },
                  {
                        "id": 7183,
                        "displayName": "year_7183"
                  },
                  {
                        "id": 7184,
                        "displayName": "year_7184"
                  },
                  {
                        "id": 7185,
                        "displayName": "year_7185"
                  },
                  {
                        "id": 7186,
                        "displayName": "year_7186"
                  },
                  {
                        "id": 7187,
                        "displayName": "year_7187"
                  },
                  {
                        "id": 7188,
                        "displayName": "year_7188"
                  },
                  {
                        "id": 7189,
                        "displayName": "year_7189"
                  },
                  {
                        "id": 7190,
                        "displayName": "year_7190"
                  },
                  {
                        "id": 7191,
                        "displayName": "year_7191"
                  },
                  {
                        "id": 7192,
                        "displayName": "year_7192"
                  },
                  {
                        "id": 7193,
                        "displayName": "year_7193"
                  },
                  {
                        "id": 7194,
                        "displayName": "year_7194"
                  },
                  {
                        "id": 7195,
                        "displayName": "year_7195"
                  },
                  {
                        "id": 7196,
                        "displayName": "year_7196"
                  },
                  {
                        "id": 7197,
                        "displayName": "year_7197"
                  },
                  {
                        "id": 7198,
                        "displayName": "year_7198"
                  },
                  {
                        "id": 7199,
                        "displayName": "year_7199"
                  },
                  {
                        "id": 7200,
                        "displayName": "year_7200"
                  },
                  {
                        "id": 7201,
                        "displayName": "year_7201"
                  },
                  {
                        "id": 7202,
                        "displayName": "year_7202"
                  },
                  {
                        "id": 7203,
                        "displayName": "year_7203"
                  },
                  {
                        "id": 7204,
                        "displayName": "year_7204"
                  },
                  {
                        "id": 7205,
                        "displayName": "year_7205"
                  },
                  {
                        "id": 7206,
                        "displayName": "year_7206"
                  },
                  {
                        "id": 7207,
                        "displayName": "year_7207"
                  },
                  {
                        "id": 7208,
                        "displayName": "year_7208"
                  },
                  {
                        "id": 7209,
                        "displayName": "year_7209"
                  },
                  {
                        "id": 7210,
                        "displayName": "year_7210"
                  },
                  {
                        "id": 7211,
                        "displayName": "year_7211"
                  },
                  {
                        "id": 7212,
                        "displayName": "year_7212"
                  },
                  {
                        "id": 7213,
                        "displayName": "year_7213"
                  },
                  {
                        "id": 7214,
                        "displayName": "year_7214"
                  },
                  {
                        "id": 7215,
                        "displayName": "year_7215"
                  },
                  {
                        "id": 7216,
                        "displayName": "year_7216"
                  },
                  {
                        "id": 7217,
                        "displayName": "year_7217"
                  },
                  {
                        "id": 7218,
                        "displayName": "year_7218"
                  },
                  {
                        "id": 7219,
                        "displayName": "year_7219"
                  },
                  {
                        "id": 7220,
                        "displayName": "year_7220"
                  },
                  {
                        "id": 7221,
                        "displayName": "year_7221"
                  },
                  {
                        "id": 7222,
                        "displayName": "year_7222"
                  },
                  {
                        "id": 7223,
                        "displayName": "year_7223"
                  },
                  {
                        "id": 7224,
                        "displayName": "year_7224"
                  },
                  {
                        "id": 7225,
                        "displayName": "year_7225"
                  },
                  {
                        "id": 7226,
                        "displayName": "year_7226"
                  },
                  {
                        "id": 7227,
                        "displayName": "year_7227"
                  },
                  {
                        "id": 7228,
                        "displayName": "year_7228"
                  },
                  {
                        "id": 7229,
                        "displayName": "year_7229"
                  },
                  {
                        "id": 7230,
                        "displayName": "year_7230"
                  },
                  {
                        "id": 7231,
                        "displayName": "year_7231"
                  },
                  {
                        "id": 7232,
                        "displayName": "year_7232"
                  },
                  {
                        "id": 7233,
                        "displayName": "year_7233"
                  },
                  {
                        "id": 7234,
                        "displayName": "year_7234"
                  },
                  {
                        "id": 7235,
                        "displayName": "year_7235"
                  },
                  {
                        "id": 7236,
                        "displayName": "year_7236"
                  },
                  {
                        "id": 7237,
                        "displayName": "year_7237"
                  },
                  {
                        "id": 7238,
                        "displayName": "year_7238"
                  },
                  {
                        "id": 7239,
                        "displayName": "year_7239"
                  },
                  {
                        "id": 7240,
                        "displayName": "year_7240"
                  },
                  {
                        "id": 7241,
                        "displayName": "year_7241"
                  },
                  {
                        "id": 7242,
                        "displayName": "year_7242"
                  },
                  {
                        "id": 7243,
                        "displayName": "year_7243"
                  },
                  {
                        "id": 7244,
                        "displayName": "year_7244"
                  },
                  {
                        "id": 7245,
                        "displayName": "year_7245"
                  },
                  {
                        "id": 7246,
                        "displayName": "year_7246"
                  },
                  {
                        "id": 7247,
                        "displayName": "year_7247"
                  },
                  {
                        "id": 7248,
                        "displayName": "year_7248"
                  },
                  {
                        "id": 7249,
                        "displayName": "year_7249"
                  },
                  {
                        "id": 7250,
                        "displayName": "year_7250"
                  },
                  {
                        "id": 7251,
                        "displayName": "year_7251"
                  },
                  {
                        "id": 7252,
                        "displayName": "year_7252"
                  },
                  {
                        "id": 7253,
                        "displayName": "year_7253"
                  },
                  {
                        "id": 7254,
                        "displayName": "year_7254"
                  },
                  {
                        "id": 7255,
                        "displayName": "year_7255"
                  },
                  {
                        "id": 7256,
                        "displayName": "year_7256"
                  },
                  {
                        "id": 7257,
                        "displayName": "year_7257"
                  },
                  {
                        "id": 7258,
                        "displayName": "year_7258"
                  },
                  {
                        "id": 7259,
                        "displayName": "year_7259"
                  },
                  {
                        "id": 7260,
                        "displayName": "year_7260"
                  },
                  {
                        "id": 7261,
                        "displayName": "year_7261"
                  },
                  {
                        "id": 7262,
                        "displayName": "year_7262"
                  },
                  {
                        "id": 7263,
                        "displayName": "year_7263"
                  },
                  {
                        "id": 7264,
                        "displayName": "year_7264"
                  },
                  {
                        "id": 7265,
                        "displayName": "year_7265"
                  },
                  {
                        "id": 7266,
                        "displayName": "year_7266"
                  },
                  {
                        "id": 7267,
                        "displayName": "year_7267"
                  },
                  {
                        "id": 7268,
                        "displayName": "year_7268"
                  },
                  {
                        "id": 7269,
                        "displayName": "year_7269"
                  },
                  {
                        "id": 7270,
                        "displayName": "year_7270"
                  },
                  {
                        "id": 7271,
                        "displayName": "year_7271"
                  },
                  {
                        "id": 7272,
                        "displayName": "year_7272"
                  },
                  {
                        "id": 7273,
                        "displayName": "year_7273"
                  },
                  {
                        "id": 7274,
                        "displayName": "year_7274"
                  },
                  {
                        "id": 7275,
                        "displayName": "year_7275"
                  },
                  {
                        "id": 7276,
                        "displayName": "year_7276"
                  },
                  {
                        "id": 7277,
                        "displayName": "year_7277"
                  },
                  {
                        "id": 7278,
                        "displayName": "year_7278"
                  },
                  {
                        "id": 7279,
                        "displayName": "year_7279"
                  },
                  {
                        "id": 7280,
                        "displayName": "year_7280"
                  },
                  {
                        "id": 7281,
                        "displayName": "year_7281"
                  },
                  {
                        "id": 7282,
                        "displayName": "year_7282"
                  },
                  {
                        "id": 7283,
                        "displayName": "year_7283"
                  },
                  {
                        "id": 7284,
                        "displayName": "year_7284"
                  },
                  {
                        "id": 7285,
                        "displayName": "year_7285"
                  },
                  {
                        "id": 7286,
                        "displayName": "year_7286"
                  },
                  {
                        "id": 7287,
                        "displayName": "year_7287"
                  },
                  {
                        "id": 7288,
                        "displayName": "year_7288"
                  },
                  {
                        "id": 7289,
                        "displayName": "year_7289"
                  },
                  {
                        "id": 7290,
                        "displayName": "year_7290"
                  },
                  {
                        "id": 7291,
                        "displayName": "year_7291"
                  },
                  {
                        "id": 7292,
                        "displayName": "year_7292"
                  },
                  {
                        "id": 7293,
                        "displayName": "year_7293"
                  },
                  {
                        "id": 7294,
                        "displayName": "year_7294"
                  },
                  {
                        "id": 7295,
                        "displayName": "year_7295"
                  },
                  {
                        "id": 7296,
                        "displayName": "year_7296"
                  },
                  {
                        "id": 7297,
                        "displayName": "year_7297"
                  },
                  {
                        "id": 7298,
                        "displayName": "year_7298"
                  },
                  {
                        "id": 7299,
                        "displayName": "year_7299"
                  },
                  {
                        "id": 7300,
                        "displayName": "year_7300"
                  },
                  {
                        "id": 7301,
                        "displayName": "year_7301"
                  },
                  {
                        "id": 7302,
                        "displayName": "year_7302"
                  },
                  {
                        "id": 7303,
                        "displayName": "year_7303"
                  },
                  {
                        "id": 7304,
                        "displayName": "year_7304"
                  },
                  {
                        "id": 7305,
                        "displayName": "year_7305"
                  },
                  {
                        "id": 7306,
                        "displayName": "year_7306"
                  },
                  {
                        "id": 7307,
                        "displayName": "year_7307"
                  },
                  {
                        "id": 7308,
                        "displayName": "year_7308"
                  },
                  {
                        "id": 7309,
                        "displayName": "year_7309"
                  },
                  {
                        "id": 7310,
                        "displayName": "year_7310"
                  },
                  {
                        "id": 7311,
                        "displayName": "year_7311"
                  },
                  {
                        "id": 7312,
                        "displayName": "year_7312"
                  },
                  {
                        "id": 7313,
                        "displayName": "year_7313"
                  },
                  {
                        "id": 7314,
                        "displayName": "year_7314"
                  },
                  {
                        "id": 7315,
                        "displayName": "year_7315"
                  },
                  {
                        "id": 7316,
                        "displayName": "year_7316"
                  },
                  {
                        "id": 7317,
                        "displayName": "year_7317"
                  },
                  {
                        "id": 7318,
                        "displayName": "year_7318"
                  },
                  {
                        "id": 7319,
                        "displayName": "year_7319"
                  },
                  {
                        "id": 7320,
                        "displayName": "year_7320"
                  },
                  {
                        "id": 7321,
                        "displayName": "year_7321"
                  },
                  {
                        "id": 7322,
                        "displayName": "year_7322"
                  },
                  {
                        "id": 7323,
                        "displayName": "year_7323"
                  },
                  {
                        "id": 7324,
                        "displayName": "year_7324"
                  },
                  {
                        "id": 7325,
                        "displayName": "year_7325"
                  },
                  {
                        "id": 7326,
                        "displayName": "year_7326"
                  },
                  {
                        "id": 7327,
                        "displayName": "year_7327"
                  },
                  {
                        "id": 7328,
                        "displayName": "year_7328"
                  },
                  {
                        "id": 7329,
                        "displayName": "year_7329"
                  },
                  {
                        "id": 7330,
                        "displayName": "year_7330"
                  },
                  {
                        "id": 7331,
                        "displayName": "year_7331"
                  },
                  {
                        "id": 7332,
                        "displayName": "year_7332"
                  },
                  {
                        "id": 7333,
                        "displayName": "year_7333"
                  },
                  {
                        "id": 7334,
                        "displayName": "year_7334"
                  },
                  {
                        "id": 7335,
                        "displayName": "year_7335"
                  },
                  {
                        "id": 7336,
                        "displayName": "year_7336"
                  },
                  {
                        "id": 7337,
                        "displayName": "year_7337"
                  },
                  {
                        "id": 7338,
                        "displayName": "year_7338"
                  },
                  {
                        "id": 7339,
                        "displayName": "year_7339"
                  },
                  {
                        "id": 7340,
                        "displayName": "year_7340"
                  },
                  {
                        "id": 7341,
                        "displayName": "year_7341"
                  },
                  {
                        "id": 7342,
                        "displayName": "year_7342"
                  },
                  {
                        "id": 7343,
                        "displayName": "year_7343"
                  },
                  {
                        "id": 7344,
                        "displayName": "year_7344"
                  },
                  {
                        "id": 7345,
                        "displayName": "year_7345"
                  },
                  {
                        "id": 7346,
                        "displayName": "year_7346"
                  },
                  {
                        "id": 7347,
                        "displayName": "year_7347"
                  },
                  {
                        "id": 7348,
                        "displayName": "year_7348"
                  },
                  {
                        "id": 7349,
                        "displayName": "year_7349"
                  },
                  {
                        "id": 7350,
                        "displayName": "year_7350"
                  },
                  {
                        "id": 7351,
                        "displayName": "year_7351"
                  },
                  {
                        "id": 7352,
                        "displayName": "year_7352"
                  },
                  {
                        "id": 7353,
                        "displayName": "year_7353"
                  },
                  {
                        "id": 7354,
                        "displayName": "year_7354"
                  },
                  {
                        "id": 7355,
                        "displayName": "year_7355"
                  },
                  {
                        "id": 7356,
                        "displayName": "year_7356"
                  },
                  {
                        "id": 7357,
                        "displayName": "year_7357"
                  },
                  {
                        "id": 7358,
                        "displayName": "year_7358"
                  },
                  {
                        "id": 7359,
                        "displayName": "year_7359"
                  },
                  {
                        "id": 7360,
                        "displayName": "year_7360"
                  },
                  {
                        "id": 7361,
                        "displayName": "year_7361"
                  },
                  {
                        "id": 7362,
                        "displayName": "year_7362"
                  },
                  {
                        "id": 7363,
                        "displayName": "year_7363"
                  },
                  {
                        "id": 7364,
                        "displayName": "year_7364"
                  },
                  {
                        "id": 7365,
                        "displayName": "year_7365"
                  },
                  {
                        "id": 7366,
                        "displayName": "year_7366"
                  },
                  {
                        "id": 7367,
                        "displayName": "year_7367"
                  },
                  {
                        "id": 7368,
                        "displayName": "year_7368"
                  },
                  {
                        "id": 7369,
                        "displayName": "year_7369"
                  },
                  {
                        "id": 7370,
                        "displayName": "year_7370"
                  },
                  {
                        "id": 7371,
                        "displayName": "year_7371"
                  },
                  {
                        "id": 7372,
                        "displayName": "year_7372"
                  },
                  {
                        "id": 7373,
                        "displayName": "year_7373"
                  },
                  {
                        "id": 7374,
                        "displayName": "year_7374"
                  },
                  {
                        "id": 7375,
                        "displayName": "year_7375"
                  },
                  {
                        "id": 7376,
                        "displayName": "year_7376"
                  },
                  {
                        "id": 7377,
                        "displayName": "year_7377"
                  },
                  {
                        "id": 7378,
                        "displayName": "year_7378"
                  },
                  {
                        "id": 7379,
                        "displayName": "year_7379"
                  },
                  {
                        "id": 7380,
                        "displayName": "year_7380"
                  },
                  {
                        "id": 7381,
                        "displayName": "year_7381"
                  },
                  {
                        "id": 7382,
                        "displayName": "year_7382"
                  },
                  {
                        "id": 7383,
                        "displayName": "year_7383"
                  },
                  {
                        "id": 7384,
                        "displayName": "year_7384"
                  },
                  {
                        "id": 7385,
                        "displayName": "year_7385"
                  },
                  {
                        "id": 7386,
                        "displayName": "year_7386"
                  },
                  {
                        "id": 7387,
                        "displayName": "year_7387"
                  },
                  {
                        "id": 7388,
                        "displayName": "year_7388"
                  },
                  {
                        "id": 7389,
                        "displayName": "year_7389"
                  },
                  {
                        "id": 7390,
                        "displayName": "year_7390"
                  },
                  {
                        "id": 7391,
                        "displayName": "year_7391"
                  },
                  {
                        "id": 7392,
                        "displayName": "year_7392"
                  },
                  {
                        "id": 7393,
                        "displayName": "year_7393"
                  },
                  {
                        "id": 7394,
                        "displayName": "year_7394"
                  },
                  {
                        "id": 7395,
                        "displayName": "year_7395"
                  },
                  {
                        "id": 7396,
                        "displayName": "year_7396"
                  },
                  {
                        "id": 7397,
                        "displayName": "year_7397"
                  },
                  {
                        "id": 7398,
                        "displayName": "year_7398"
                  },
                  {
                        "id": 7399,
                        "displayName": "year_7399"
                  },
                  {
                        "id": 7400,
                        "displayName": "year_7400"
                  },
                  {
                        "id": 7401,
                        "displayName": "year_7401"
                  },
                  {
                        "id": 7402,
                        "displayName": "year_7402"
                  },
                  {
                        "id": 7403,
                        "displayName": "year_7403"
                  },
                  {
                        "id": 7404,
                        "displayName": "year_7404"
                  },
                  {
                        "id": 7405,
                        "displayName": "year_7405"
                  },
                  {
                        "id": 7406,
                        "displayName": "year_7406"
                  },
                  {
                        "id": 7407,
                        "displayName": "year_7407"
                  },
                  {
                        "id": 7408,
                        "displayName": "year_7408"
                  },
                  {
                        "id": 7409,
                        "displayName": "year_7409"
                  },
                  {
                        "id": 7410,
                        "displayName": "year_7410"
                  },
                  {
                        "id": 7411,
                        "displayName": "year_7411"
                  },
                  {
                        "id": 7412,
                        "displayName": "year_7412"
                  },
                  {
                        "id": 7413,
                        "displayName": "year_7413"
                  },
                  {
                        "id": 7414,
                        "displayName": "year_7414"
                  },
                  {
                        "id": 7415,
                        "displayName": "year_7415"
                  },
                  {
                        "id": 7416,
                        "displayName": "year_7416"
                  },
                  {
                        "id": 7417,
                        "displayName": "year_7417"
                  },
                  {
                        "id": 7418,
                        "displayName": "year_7418"
                  },
                  {
                        "id": 7419,
                        "displayName": "year_7419"
                  },
                  {
                        "id": 7420,
                        "displayName": "year_7420"
                  },
                  {
                        "id": 7421,
                        "displayName": "year_7421"
                  },
                  {
                        "id": 7422,
                        "displayName": "year_7422"
                  },
                  {
                        "id": 7423,
                        "displayName": "year_7423"
                  },
                  {
                        "id": 7424,
                        "displayName": "year_7424"
                  },
                  {
                        "id": 7425,
                        "displayName": "year_7425"
                  },
                  {
                        "id": 7426,
                        "displayName": "year_7426"
                  },
                  {
                        "id": 7427,
                        "displayName": "year_7427"
                  },
                  {
                        "id": 7428,
                        "displayName": "year_7428"
                  },
                  {
                        "id": 7429,
                        "displayName": "year_7429"
                  },
                  {
                        "id": 7430,
                        "displayName": "year_7430"
                  },
                  {
                        "id": 7431,
                        "displayName": "year_7431"
                  },
                  {
                        "id": 7432,
                        "displayName": "year_7432"
                  },
                  {
                        "id": 7433,
                        "displayName": "year_7433"
                  },
                  {
                        "id": 7434,
                        "displayName": "year_7434"
                  },
                  {
                        "id": 7435,
                        "displayName": "year_7435"
                  },
                  {
                        "id": 7436,
                        "displayName": "year_7436"
                  },
                  {
                        "id": 7437,
                        "displayName": "year_7437"
                  },
                  {
                        "id": 7438,
                        "displayName": "year_7438"
                  },
                  {
                        "id": 7439,
                        "displayName": "year_7439"
                  },
                  {
                        "id": 7440,
                        "displayName": "year_7440"
                  },
                  {
                        "id": 7441,
                        "displayName": "year_7441"
                  },
                  {
                        "id": 7442,
                        "displayName": "year_7442"
                  },
                  {
                        "id": 7443,
                        "displayName": "year_7443"
                  },
                  {
                        "id": 7444,
                        "displayName": "year_7444"
                  },
                  {
                        "id": 7445,
                        "displayName": "year_7445"
                  },
                  {
                        "id": 7446,
                        "displayName": "year_7446"
                  },
                  {
                        "id": 7447,
                        "displayName": "year_7447"
                  },
                  {
                        "id": 7448,
                        "displayName": "year_7448"
                  },
                  {
                        "id": 7449,
                        "displayName": "year_7449"
                  },
                  {
                        "id": 7450,
                        "displayName": "year_7450"
                  },
                  {
                        "id": 7451,
                        "displayName": "year_7451"
                  },
                  {
                        "id": 7452,
                        "displayName": "year_7452"
                  },
                  {
                        "id": 7453,
                        "displayName": "year_7453"
                  },
                  {
                        "id": 7454,
                        "displayName": "year_7454"
                  },
                  {
                        "id": 7455,
                        "displayName": "year_7455"
                  },
                  {
                        "id": 7456,
                        "displayName": "year_7456"
                  },
                  {
                        "id": 7457,
                        "displayName": "year_7457"
                  },
                  {
                        "id": 7458,
                        "displayName": "year_7458"
                  },
                  {
                        "id": 7459,
                        "displayName": "year_7459"
                  },
                  {
                        "id": 7460,
                        "displayName": "year_7460"
                  },
                  {
                        "id": 7461,
                        "displayName": "year_7461"
                  },
                  {
                        "id": 7462,
                        "displayName": "year_7462"
                  },
                  {
                        "id": 7463,
                        "displayName": "year_7463"
                  },
                  {
                        "id": 7464,
                        "displayName": "year_7464"
                  },
                  {
                        "id": 7465,
                        "displayName": "year_7465"
                  },
                  {
                        "id": 7466,
                        "displayName": "year_7466"
                  },
                  {
                        "id": 7467,
                        "displayName": "year_7467"
                  },
                  {
                        "id": 7468,
                        "displayName": "year_7468"
                  },
                  {
                        "id": 7469,
                        "displayName": "year_7469"
                  },
                  {
                        "id": 7470,
                        "displayName": "year_7470"
                  },
                  {
                        "id": 7471,
                        "displayName": "year_7471"
                  },
                  {
                        "id": 7472,
                        "displayName": "year_7472"
                  },
                  {
                        "id": 7473,
                        "displayName": "year_7473"
                  },
                  {
                        "id": 7474,
                        "displayName": "year_7474"
                  },
                  {
                        "id": 7475,
                        "displayName": "year_7475"
                  },
                  {
                        "id": 7476,
                        "displayName": "year_7476"
                  },
                  {
                        "id": 7477,
                        "displayName": "year_7477"
                  },
                  {
                        "id": 7478,
                        "displayName": "year_7478"
                  },
                  {
                        "id": 7479,
                        "displayName": "year_7479"
                  },
                  {
                        "id": 7480,
                        "displayName": "year_7480"
                  },
                  {
                        "id": 7481,
                        "displayName": "year_7481"
                  },
                  {
                        "id": 7482,
                        "displayName": "year_7482"
                  },
                  {
                        "id": 7483,
                        "displayName": "year_7483"
                  },
                  {
                        "id": 7484,
                        "displayName": "year_7484"
                  },
                  {
                        "id": 7485,
                        "displayName": "year_7485"
                  },
                  {
                        "id": 7486,
                        "displayName": "year_7486"
                  },
                  {
                        "id": 7487,
                        "displayName": "year_7487"
                  },
                  {
                        "id": 7488,
                        "displayName": "year_7488"
                  },
                  {
                        "id": 7489,
                        "displayName": "year_7489"
                  },
                  {
                        "id": 7490,
                        "displayName": "year_7490"
                  },
                  {
                        "id": 7491,
                        "displayName": "year_7491"
                  },
                  {
                        "id": 7492,
                        "displayName": "year_7492"
                  },
                  {
                        "id": 7493,
                        "displayName": "year_7493"
                  },
                  {
                        "id": 7494,
                        "displayName": "year_7494"
                  },
                  {
                        "id": 7495,
                        "displayName": "year_7495"
                  },
                  {
                        "id": 7496,
                        "displayName": "year_7496"
                  },
                  {
                        "id": 7497,
                        "displayName": "year_7497"
                  },
                  {
                        "id": 7498,
                        "displayName": "year_7498"
                  },
                  {
                        "id": 7499,
                        "displayName": "year_7499"
                  },
                  {
                        "id": 7500,
                        "displayName": "year_7500"
                  },
                  {
                        "id": 7501,
                        "displayName": "year_7501"
                  },
                  {
                        "id": 7502,
                        "displayName": "year_7502"
                  },
                  {
                        "id": 7503,
                        "displayName": "year_7503"
                  },
                  {
                        "id": 7504,
                        "displayName": "year_7504"
                  },
                  {
                        "id": 7505,
                        "displayName": "year_7505"
                  },
                  {
                        "id": 7506,
                        "displayName": "year_7506"
                  },
                  {
                        "id": 7507,
                        "displayName": "year_7507"
                  },
                  {
                        "id": 7508,
                        "displayName": "year_7508"
                  },
                  {
                        "id": 7509,
                        "displayName": "year_7509"
                  },
                  {
                        "id": 7510,
                        "displayName": "year_7510"
                  },
                  {
                        "id": 7511,
                        "displayName": "year_7511"
                  },
                  {
                        "id": 7512,
                        "displayName": "year_7512"
                  },
                  {
                        "id": 7513,
                        "displayName": "year_7513"
                  },
                  {
                        "id": 7514,
                        "displayName": "year_7514"
                  },
                  {
                        "id": 7515,
                        "displayName": "year_7515"
                  },
                  {
                        "id": 7516,
                        "displayName": "year_7516"
                  },
                  {
                        "id": 7517,
                        "displayName": "year_7517"
                  },
                  {
                        "id": 7518,
                        "displayName": "year_7518"
                  },
                  {
                        "id": 7519,
                        "displayName": "year_7519"
                  },
                  {
                        "id": 7520,
                        "displayName": "year_7520"
                  },
                  {
                        "id": 7521,
                        "displayName": "year_7521"
                  },
                  {
                        "id": 7522,
                        "displayName": "year_7522"
                  },
                  {
                        "id": 7523,
                        "displayName": "year_7523"
                  },
                  {
                        "id": 7524,
                        "displayName": "year_7524"
                  },
                  {
                        "id": 7525,
                        "displayName": "year_7525"
                  },
                  {
                        "id": 7526,
                        "displayName": "year_7526"
                  },
                  {
                        "id": 7527,
                        "displayName": "year_7527"
                  },
                  {
                        "id": 7528,
                        "displayName": "year_7528"
                  },
                  {
                        "id": 7529,
                        "displayName": "year_7529"
                  },
                  {
                        "id": 7530,
                        "displayName": "year_7530"
                  },
                  {
                        "id": 7531,
                        "displayName": "year_7531"
                  },
                  {
                        "id": 7532,
                        "displayName": "year_7532"
                  },
                  {
                        "id": 7533,
                        "displayName": "year_7533"
                  },
                  {
                        "id": 7534,
                        "displayName": "year_7534"
                  },
                  {
                        "id": 7535,
                        "displayName": "year_7535"
                  },
                  {
                        "id": 7536,
                        "displayName": "year_7536"
                  },
                  {
                        "id": 7537,
                        "displayName": "year_7537"
                  },
                  {
                        "id": 7538,
                        "displayName": "year_7538"
                  },
                  {
                        "id": 7539,
                        "displayName": "year_7539"
                  },
                  {
                        "id": 7540,
                        "displayName": "year_7540"
                  },
                  {
                        "id": 7541,
                        "displayName": "year_7541"
                  },
                  {
                        "id": 7542,
                        "displayName": "year_7542"
                  },
                  {
                        "id": 7543,
                        "displayName": "year_7543"
                  },
                  {
                        "id": 7544,
                        "displayName": "year_7544"
                  },
                  {
                        "id": 7545,
                        "displayName": "year_7545"
                  },
                  {
                        "id": 7546,
                        "displayName": "year_7546"
                  },
                  {
                        "id": 7547,
                        "displayName": "year_7547"
                  },
                  {
                        "id": 7548,
                        "displayName": "year_7548"
                  },
                  {
                        "id": 7549,
                        "displayName": "year_7549"
                  },
                  {
                        "id": 7550,
                        "displayName": "year_7550"
                  },
                  {
                        "id": 7551,
                        "displayName": "year_7551"
                  },
                  {
                        "id": 7552,
                        "displayName": "year_7552"
                  },
                  {
                        "id": 7553,
                        "displayName": "year_7553"
                  },
                  {
                        "id": 7554,
                        "displayName": "year_7554"
                  },
                  {
                        "id": 7555,
                        "displayName": "year_7555"
                  },
                  {
                        "id": 7556,
                        "displayName": "year_7556"
                  },
                  {
                        "id": 7557,
                        "displayName": "year_7557"
                  },
                  {
                        "id": 7558,
                        "displayName": "year_7558"
                  },
                  {
                        "id": 7559,
                        "displayName": "year_7559"
                  },
                  {
                        "id": 7560,
                        "displayName": "year_7560"
                  },
                  {
                        "id": 7561,
                        "displayName": "year_7561"
                  },
                  {
                        "id": 7562,
                        "displayName": "year_7562"
                  },
                  {
                        "id": 7563,
                        "displayName": "year_7563"
                  },
                  {
                        "id": 7564,
                        "displayName": "year_7564"
                  },
                  {
                        "id": 7565,
                        "displayName": "year_7565"
                  },
                  {
                        "id": 7566,
                        "displayName": "year_7566"
                  },
                  {
                        "id": 7567,
                        "displayName": "year_7567"
                  },
                  {
                        "id": 7568,
                        "displayName": "year_7568"
                  },
                  {
                        "id": 7569,
                        "displayName": "year_7569"
                  },
                  {
                        "id": 7570,
                        "displayName": "year_7570"
                  },
                  {
                        "id": 7571,
                        "displayName": "year_7571"
                  },
                  {
                        "id": 7572,
                        "displayName": "year_7572"
                  },
                  {
                        "id": 7573,
                        "displayName": "year_7573"
                  },
                  {
                        "id": 7574,
                        "displayName": "year_7574"
                  },
                  {
                        "id": 7575,
                        "displayName": "year_7575"
                  },
                  {
                        "id": 7576,
                        "displayName": "year_7576"
                  },
                  {
                        "id": 7577,
                        "displayName": "year_7577"
                  },
                  {
                        "id": 7578,
                        "displayName": "year_7578"
                  },
                  {
                        "id": 7579,
                        "displayName": "year_7579"
                  },
                  {
                        "id": 7580,
                        "displayName": "year_7580"
                  },
                  {
                        "id": 7581,
                        "displayName": "year_7581"
                  },
                  {
                        "id": 7582,
                        "displayName": "year_7582"
                  },
                  {
                        "id": 7583,
                        "displayName": "year_7583"
                  },
                  {
                        "id": 7584,
                        "displayName": "year_7584"
                  },
                  {
                        "id": 7585,
                        "displayName": "year_7585"
                  },
                  {
                        "id": 7586,
                        "displayName": "year_7586"
                  },
                  {
                        "id": 7587,
                        "displayName": "year_7587"
                  },
                  {
                        "id": 7588,
                        "displayName": "year_7588"
                  },
                  {
                        "id": 7589,
                        "displayName": "year_7589"
                  },
                  {
                        "id": 7590,
                        "displayName": "year_7590"
                  },
                  {
                        "id": 7591,
                        "displayName": "year_7591"
                  },
                  {
                        "id": 7592,
                        "displayName": "year_7592"
                  },
                  {
                        "id": 7593,
                        "displayName": "year_7593"
                  },
                  {
                        "id": 7594,
                        "displayName": "year_7594"
                  },
                  {
                        "id": 7595,
                        "displayName": "year_7595"
                  },
                  {
                        "id": 7596,
                        "displayName": "year_7596"
                  },
                  {
                        "id": 7597,
                        "displayName": "year_7597"
                  },
                  {
                        "id": 7598,
                        "displayName": "year_7598"
                  },
                  {
                        "id": 7599,
                        "displayName": "year_7599"
                  },
                  {
                        "id": 7600,
                        "displayName": "year_7600"
                  },
                  {
                        "id": 7601,
                        "displayName": "year_7601"
                  },
                  {
                        "id": 7602,
                        "displayName": "year_7602"
                  },
                  {
                        "id": 7603,
                        "displayName": "year_7603"
                  },
                  {
                        "id": 7604,
                        "displayName": "year_7604"
                  },
                  {
                        "id": 7605,
                        "displayName": "year_7605"
                  },
                  {
                        "id": 7606,
                        "displayName": "year_7606"
                  },
                  {
                        "id": 7607,
                        "displayName": "year_7607"
                  },
                  {
                        "id": 7608,
                        "displayName": "year_7608"
                  },
                  {
                        "id": 7609,
                        "displayName": "year_7609"
                  },
                  {
                        "id": 7610,
                        "displayName": "year_7610"
                  },
                  {
                        "id": 7611,
                        "displayName": "year_7611"
                  },
                  {
                        "id": 7612,
                        "displayName": "year_7612"
                  },
                  {
                        "id": 7613,
                        "displayName": "year_7613"
                  },
                  {
                        "id": 7614,
                        "displayName": "year_7614"
                  },
                  {
                        "id": 7615,
                        "displayName": "year_7615"
                  },
                  {
                        "id": 7616,
                        "displayName": "year_7616"
                  },
                  {
                        "id": 7617,
                        "displayName": "year_7617"
                  },
                  {
                        "id": 7618,
                        "displayName": "year_7618"
                  },
                  {
                        "id": 7619,
                        "displayName": "year_7619"
                  },
                  {
                        "id": 7620,
                        "displayName": "year_7620"
                  },
                  {
                        "id": 7621,
                        "displayName": "year_7621"
                  },
                  {
                        "id": 7622,
                        "displayName": "year_7622"
                  },
                  {
                        "id": 7623,
                        "displayName": "year_7623"
                  },
                  {
                        "id": 7624,
                        "displayName": "year_7624"
                  },
                  {
                        "id": 7625,
                        "displayName": "year_7625"
                  },
                  {
                        "id": 7626,
                        "displayName": "year_7626"
                  },
                  {
                        "id": 7627,
                        "displayName": "year_7627"
                  },
                  {
                        "id": 7628,
                        "displayName": "year_7628"
                  },
                  {
                        "id": 7629,
                        "displayName": "year_7629"
                  },
                  {
                        "id": 7630,
                        "displayName": "year_7630"
                  },
                  {
                        "id": 7631,
                        "displayName": "year_7631"
                  },
                  {
                        "id": 7632,
                        "displayName": "year_7632"
                  },
                  {
                        "id": 7633,
                        "displayName": "year_7633"
                  },
                  {
                        "id": 7634,
                        "displayName": "year_7634"
                  },
                  {
                        "id": 7635,
                        "displayName": "year_7635"
                  },
                  {
                        "id": 7636,
                        "displayName": "year_7636"
                  },
                  {
                        "id": 7637,
                        "displayName": "year_7637"
                  },
                  {
                        "id": 7638,
                        "displayName": "year_7638"
                  },
                  {
                        "id": 7639,
                        "displayName": "year_7639"
                  },
                  {
                        "id": 7640,
                        "displayName": "year_7640"
                  },
                  {
                        "id": 7641,
                        "displayName": "year_7641"
                  },
                  {
                        "id": 7642,
                        "displayName": "year_7642"
                  },
                  {
                        "id": 7643,
                        "displayName": "year_7643"
                  },
                  {
                        "id": 7644,
                        "displayName": "year_7644"
                  },
                  {
                        "id": 7645,
                        "displayName": "year_7645"
                  },
                  {
                        "id": 7646,
                        "displayName": "year_7646"
                  },
                  {
                        "id": 7647,
                        "displayName": "year_7647"
                  },
                  {
                        "id": 7648,
                        "displayName": "year_7648"
                  },
                  {
                        "id": 7649,
                        "displayName": "year_7649"
                  },
                  {
                        "id": 7650,
                        "displayName": "year_7650"
                  },
                  {
                        "id": 7651,
                        "displayName": "year_7651"
                  },
                  {
                        "id": 7652,
                        "displayName": "year_7652"
                  },
                  {
                        "id": 7653,
                        "displayName": "year_7653"
                  },
                  {
                        "id": 7654,
                        "displayName": "year_7654"
                  },
                  {
                        "id": 7655,
                        "displayName": "year_7655"
                  },
                  {
                        "id": 7656,
                        "displayName": "year_7656"
                  },
                  {
                        "id": 7657,
                        "displayName": "year_7657"
                  },
                  {
                        "id": 7658,
                        "displayName": "year_7658"
                  },
                  {
                        "id": 7659,
                        "displayName": "year_7659"
                  },
                  {
                        "id": 7660,
                        "displayName": "year_7660"
                  },
                  {
                        "id": 7661,
                        "displayName": "year_7661"
                  },
                  {
                        "id": 7662,
                        "displayName": "year_7662"
                  },
                  {
                        "id": 7663,
                        "displayName": "year_7663"
                  },
                  {
                        "id": 7664,
                        "displayName": "year_7664"
                  },
                  {
                        "id": 7665,
                        "displayName": "year_7665"
                  },
                  {
                        "id": 7666,
                        "displayName": "year_7666"
                  },
                  {
                        "id": 7667,
                        "displayName": "year_7667"
                  },
                  {
                        "id": 7668,
                        "displayName": "year_7668"
                  },
                  {
                        "id": 7669,
                        "displayName": "year_7669"
                  },
                  {
                        "id": 7670,
                        "displayName": "year_7670"
                  },
                  {
                        "id": 7671,
                        "displayName": "year_7671"
                  },
                  {
                        "id": 7672,
                        "displayName": "year_7672"
                  },
                  {
                        "id": 7673,
                        "displayName": "year_7673"
                  },
                  {
                        "id": 7674,
                        "displayName": "year_7674"
                  },
                  {
                        "id": 7675,
                        "displayName": "year_7675"
                  },
                  {
                        "id": 7676,
                        "displayName": "year_7676"
                  },
                  {
                        "id": 7677,
                        "displayName": "year_7677"
                  },
                  {
                        "id": 7678,
                        "displayName": "year_7678"
                  },
                  {
                        "id": 7679,
                        "displayName": "year_7679"
                  },
                  {
                        "id": 7680,
                        "displayName": "year_7680"
                  },
                  {
                        "id": 7681,
                        "displayName": "year_7681"
                  },
                  {
                        "id": 7682,
                        "displayName": "year_7682"
                  },
                  {
                        "id": 7683,
                        "displayName": "year_7683"
                  },
                  {
                        "id": 7684,
                        "displayName": "year_7684"
                  },
                  {
                        "id": 7685,
                        "displayName": "year_7685"
                  },
                  {
                        "id": 7686,
                        "displayName": "year_7686"
                  },
                  {
                        "id": 7687,
                        "displayName": "year_7687"
                  },
                  {
                        "id": 7688,
                        "displayName": "year_7688"
                  },
                  {
                        "id": 7689,
                        "displayName": "year_7689"
                  },
                  {
                        "id": 7690,
                        "displayName": "year_7690"
                  },
                  {
                        "id": 7691,
                        "displayName": "year_7691"
                  },
                  {
                        "id": 7692,
                        "displayName": "year_7692"
                  },
                  {
                        "id": 7693,
                        "displayName": "year_7693"
                  },
                  {
                        "id": 7694,
                        "displayName": "year_7694"
                  },
                  {
                        "id": 7695,
                        "displayName": "year_7695"
                  },
                  {
                        "id": 7696,
                        "displayName": "year_7696"
                  },
                  {
                        "id": 7697,
                        "displayName": "year_7697"
                  },
                  {
                        "id": 7698,
                        "displayName": "year_7698"
                  },
                  {
                        "id": 7699,
                        "displayName": "year_7699"
                  },
                  {
                        "id": 7700,
                        "displayName": "year_7700"
                  },
                  {
                        "id": 7701,
                        "displayName": "year_7701"
                  },
                  {
                        "id": 7702,
                        "displayName": "year_7702"
                  },
                  {
                        "id": 7703,
                        "displayName": "year_7703"
                  },
                  {
                        "id": 7704,
                        "displayName": "year_7704"
                  },
                  {
                        "id": 7705,
                        "displayName": "year_7705"
                  },
                  {
                        "id": 7706,
                        "displayName": "year_7706"
                  },
                  {
                        "id": 7707,
                        "displayName": "year_7707"
                  },
                  {
                        "id": 7708,
                        "displayName": "year_7708"
                  },
                  {
                        "id": 7709,
                        "displayName": "year_7709"
                  },
                  {
                        "id": 7710,
                        "displayName": "year_7710"
                  },
                  {
                        "id": 7711,
                        "displayName": "year_7711"
                  },
                  {
                        "id": 7712,
                        "displayName": "year_7712"
                  },
                  {
                        "id": 7713,
                        "displayName": "year_7713"
                  },
                  {
                        "id": 7714,
                        "displayName": "year_7714"
                  },
                  {
                        "id": 7715,
                        "displayName": "year_7715"
                  },
                  {
                        "id": 7716,
                        "displayName": "year_7716"
                  },
                  {
                        "id": 7717,
                        "displayName": "year_7717"
                  },
                  {
                        "id": 7718,
                        "displayName": "year_7718"
                  },
                  {
                        "id": 7719,
                        "displayName": "year_7719"
                  },
                  {
                        "id": 7720,
                        "displayName": "year_7720"
                  },
                  {
                        "id": 7721,
                        "displayName": "year_7721"
                  },
                  {
                        "id": 7722,
                        "displayName": "year_7722"
                  },
                  {
                        "id": 7723,
                        "displayName": "year_7723"
                  },
                  {
                        "id": 7724,
                        "displayName": "year_7724"
                  },
                  {
                        "id": 7725,
                        "displayName": "year_7725"
                  },
                  {
                        "id": 7726,
                        "displayName": "year_7726"
                  },
                  {
                        "id": 7727,
                        "displayName": "year_7727"
                  },
                  {
                        "id": 7728,
                        "displayName": "year_7728"
                  },
                  {
                        "id": 7729,
                        "displayName": "year_7729"
                  },
                  {
                        "id": 7730,
                        "displayName": "year_7730"
                  },
                  {
                        "id": 7731,
                        "displayName": "year_7731"
                  },
                  {
                        "id": 7732,
                        "displayName": "year_7732"
                  },
                  {
                        "id": 7733,
                        "displayName": "year_7733"
                  },
                  {
                        "id": 7734,
                        "displayName": "year_7734"
                  },
                  {
                        "id": 7735,
                        "displayName": "year_7735"
                  },
                  {
                        "id": 7736,
                        "displayName": "year_7736"
                  },
                  {
                        "id": 7737,
                        "displayName": "year_7737"
                  },
                  {
                        "id": 7738,
                        "displayName": "year_7738"
                  },
                  {
                        "id": 7739,
                        "displayName": "year_7739"
                  },
                  {
                        "id": 7740,
                        "displayName": "year_7740"
                  },
                  {
                        "id": 7741,
                        "displayName": "year_7741"
                  },
                  {
                        "id": 7742,
                        "displayName": "year_7742"
                  },
                  {
                        "id": 7743,
                        "displayName": "year_7743"
                  },
                  {
                        "id": 7744,
                        "displayName": "year_7744"
                  },
                  {
                        "id": 7745,
                        "displayName": "year_7745"
                  },
                  {
                        "id": 7746,
                        "displayName": "year_7746"
                  },
                  {
                        "id": 7747,
                        "displayName": "year_7747"
                  },
                  {
                        "id": 7748,
                        "displayName": "year_7748"
                  },
                  {
                        "id": 7749,
                        "displayName": "year_7749"
                  },
                  {
                        "id": 7750,
                        "displayName": "year_7750"
                  },
                  {
                        "id": 7751,
                        "displayName": "year_7751"
                  },
                  {
                        "id": 7752,
                        "displayName": "year_7752"
                  },
                  {
                        "id": 7753,
                        "displayName": "year_7753"
                  },
                  {
                        "id": 7754,
                        "displayName": "year_7754"
                  },
                  {
                        "id": 7755,
                        "displayName": "year_7755"
                  },
                  {
                        "id": 7756,
                        "displayName": "year_7756"
                  },
                  {
                        "id": 7757,
                        "displayName": "year_7757"
                  },
                  {
                        "id": 7758,
                        "displayName": "year_7758"
                  },
                  {
                        "id": 7759,
                        "displayName": "year_7759"
                  },
                  {
                        "id": 7760,
                        "displayName": "year_7760"
                  },
                  {
                        "id": 7761,
                        "displayName": "year_7761"
                  },
                  {
                        "id": 7762,
                        "displayName": "year_7762"
                  },
                  {
                        "id": 7763,
                        "displayName": "year_7763"
                  },
                  {
                        "id": 7764,
                        "displayName": "year_7764"
                  },
                  {
                        "id": 7765,
                        "displayName": "year_7765"
                  },
                  {
                        "id": 7766,
                        "displayName": "year_7766"
                  },
                  {
                        "id": 7767,
                        "displayName": "year_7767"
                  },
                  {
                        "id": 7768,
                        "displayName": "year_7768"
                  },
                  {
                        "id": 7769,
                        "displayName": "year_7769"
                  },
                  {
                        "id": 7770,
                        "displayName": "year_7770"
                  },
                  {
                        "id": 7771,
                        "displayName": "year_7771"
                  },
                  {
                        "id": 7772,
                        "displayName": "year_7772"
                  },
                  {
                        "id": 7773,
                        "displayName": "year_7773"
                  },
                  {
                        "id": 7774,
                        "displayName": "year_7774"
                  },
                  {
                        "id": 7775,
                        "displayName": "year_7775"
                  },
                  {
                        "id": 7776,
                        "displayName": "year_7776"
                  },
                  {
                        "id": 7777,
                        "displayName": "year_7777"
                  },
                  {
                        "id": 7778,
                        "displayName": "year_7778"
                  },
                  {
                        "id": 7779,
                        "displayName": "year_7779"
                  },
                  {
                        "id": 7780,
                        "displayName": "year_7780"
                  },
                  {
                        "id": 7781,
                        "displayName": "year_7781"
                  },
                  {
                        "id": 7782,
                        "displayName": "year_7782"
                  },
                  {
                        "id": 7783,
                        "displayName": "year_7783"
                  },
                  {
                        "id": 7784,
                        "displayName": "year_7784"
                  },
                  {
                        "id": 7785,
                        "displayName": "year_7785"
                  },
                  {
                        "id": 7786,
                        "displayName": "year_7786"
                  },
                  {
                        "id": 7787,
                        "displayName": "year_7787"
                  },
                  {
                        "id": 7788,
                        "displayName": "year_7788"
                  },
                  {
                        "id": 7789,
                        "displayName": "year_7789"
                  },
                  {
                        "id": 7790,
                        "displayName": "year_7790"
                  },
                  {
                        "id": 7791,
                        "displayName": "year_7791"
                  },
                  {
                        "id": 7792,
                        "displayName": "year_7792"
                  },
                  {
                        "id": 7793,
                        "displayName": "year_7793"
                  },
                  {
                        "id": 7794,
                        "displayName": "year_7794"
                  },
                  {
                        "id": 7795,
                        "displayName": "year_7795"
                  },
                  {
                        "id": 7796,
                        "displayName": "year_7796"
                  },
                  {
                        "id": 7797,
                        "displayName": "year_7797"
                  },
                  {
                        "id": 7798,
                        "displayName": "year_7798"
                  },
                  {
                        "id": 7799,
                        "displayName": "year_7799"
                  },
                  {
                        "id": 7800,
                        "displayName": "year_7800"
                  },
                  {
                        "id": 7801,
                        "displayName": "year_7801"
                  },
                  {
                        "id": 7802,
                        "displayName": "year_7802"
                  },
                  {
                        "id": 7803,
                        "displayName": "year_7803"
                  },
                  {
                        "id": 7804,
                        "displayName": "year_7804"
                  },
                  {
                        "id": 7805,
                        "displayName": "year_7805"
                  },
                  {
                        "id": 7806,
                        "displayName": "year_7806"
                  },
                  {
                        "id": 7807,
                        "displayName": "year_7807"
                  },
                  {
                        "id": 7808,
                        "displayName": "year_7808"
                  },
                  {
                        "id": 7809,
                        "displayName": "year_7809"
                  },
                  {
                        "id": 7810,
                        "displayName": "year_7810"
                  },
                  {
                        "id": 7811,
                        "displayName": "year_7811"
                  },
                  {
                        "id": 7812,
                        "displayName": "year_7812"
                  },
                  {
                        "id": 7813,
                        "displayName": "year_7813"
                  },
                  {
                        "id": 7814,
                        "displayName": "year_7814"
                  },
                  {
                        "id": 7815,
                        "displayName": "year_7815"
                  },
                  {
                        "id": 7816,
                        "displayName": "year_7816"
                  },
                  {
                        "id": 7817,
                        "displayName": "year_7817"
                  },
                  {
                        "id": 7818,
                        "displayName": "year_7818"
                  },
                  {
                        "id": 7819,
                        "displayName": "year_7819"
                  },
                  {
                        "id": 7820,
                        "displayName": "year_7820"
                  },
                  {
                        "id": 7821,
                        "displayName": "year_7821"
                  },
                  {
                        "id": 7822,
                        "displayName": "year_7822"
                  },
                  {
                        "id": 7823,
                        "displayName": "year_7823"
                  },
                  {
                        "id": 7824,
                        "displayName": "year_7824"
                  },
                  {
                        "id": 7825,
                        "displayName": "year_7825"
                  },
                  {
                        "id": 7826,
                        "displayName": "year_7826"
                  },
                  {
                        "id": 7827,
                        "displayName": "year_7827"
                  },
                  {
                        "id": 7828,
                        "displayName": "year_7828"
                  },
                  {
                        "id": 7829,
                        "displayName": "year_7829"
                  },
                  {
                        "id": 7830,
                        "displayName": "year_7830"
                  },
                  {
                        "id": 7831,
                        "displayName": "year_7831"
                  },
                  {
                        "id": 7832,
                        "displayName": "year_7832"
                  },
                  {
                        "id": 7833,
                        "displayName": "year_7833"
                  },
                  {
                        "id": 7834,
                        "displayName": "year_7834"
                  },
                  {
                        "id": 7835,
                        "displayName": "year_7835"
                  },
                  {
                        "id": 7836,
                        "displayName": "year_7836"
                  },
                  {
                        "id": 7837,
                        "displayName": "year_7837"
                  },
                  {
                        "id": 7838,
                        "displayName": "year_7838"
                  },
                  {
                        "id": 7839,
                        "displayName": "year_7839"
                  },
                  {
                        "id": 7840,
                        "displayName": "year_7840"
                  },
                  {
                        "id": 7841,
                        "displayName": "year_7841"
                  },
                  {
                        "id": 7842,
                        "displayName": "year_7842"
                  },
                  {
                        "id": 7843,
                        "displayName": "year_7843"
                  },
                  {
                        "id": 7844,
                        "displayName": "year_7844"
                  },
                  {
                        "id": 7845,
                        "displayName": "year_7845"
                  },
                  {
                        "id": 7846,
                        "displayName": "year_7846"
                  },
                  {
                        "id": 7847,
                        "displayName": "year_7847"
                  },
                  {
                        "id": 7848,
                        "displayName": "year_7848"
                  },
                  {
                        "id": 7849,
                        "displayName": "year_7849"
                  },
                  {
                        "id": 7850,
                        "displayName": "year_7850"
                  },
                  {
                        "id": 7851,
                        "displayName": "year_7851"
                  },
                  {
                        "id": 7852,
                        "displayName": "year_7852"
                  },
                  {
                        "id": 7853,
                        "displayName": "year_7853"
                  },
                  {
                        "id": 7854,
                        "displayName": "year_7854"
                  },
                  {
                        "id": 7855,
                        "displayName": "year_7855"
                  },
                  {
                        "id": 7856,
                        "displayName": "year_7856"
                  },
                  {
                        "id": 7857,
                        "displayName": "year_7857"
                  },
                  {
                        "id": 7858,
                        "displayName": "year_7858"
                  },
                  {
                        "id": 7859,
                        "displayName": "year_7859"
                  },
                  {
                        "id": 7860,
                        "displayName": "year_7860"
                  },
                  {
                        "id": 7861,
                        "displayName": "year_7861"
                  },
                  {
                        "id": 7862,
                        "displayName": "year_7862"
                  },
                  {
                        "id": 7863,
                        "displayName": "year_7863"
                  },
                  {
                        "id": 7864,
                        "displayName": "year_7864"
                  },
                  {
                        "id": 7865,
                        "displayName": "year_7865"
                  },
                  {
                        "id": 7866,
                        "displayName": "year_7866"
                  },
                  {
                        "id": 7867,
                        "displayName": "year_7867"
                  },
                  {
                        "id": 7868,
                        "displayName": "year_7868"
                  },
                  {
                        "id": 7869,
                        "displayName": "year_7869"
                  },
                  {
                        "id": 7870,
                        "displayName": "year_7870"
                  },
                  {
                        "id": 7871,
                        "displayName": "year_7871"
                  },
                  {
                        "id": 7872,
                        "displayName": "year_7872"
                  },
                  {
                        "id": 7873,
                        "displayName": "year_7873"
                  },
                  {
                        "id": 7874,
                        "displayName": "year_7874"
                  },
                  {
                        "id": 7875,
                        "displayName": "year_7875"
                  },
                  {
                        "id": 7876,
                        "displayName": "year_7876"
                  },
                  {
                        "id": 7877,
                        "displayName": "year_7877"
                  },
                  {
                        "id": 7878,
                        "displayName": "year_7878"
                  },
                  {
                        "id": 7879,
                        "displayName": "year_7879"
                  },
                  {
                        "id": 7880,
                        "displayName": "year_7880"
                  },
                  {
                        "id": 7881,
                        "displayName": "year_7881"
                  },
                  {
                        "id": 7882,
                        "displayName": "year_7882"
                  },
                  {
                        "id": 7883,
                        "displayName": "year_7883"
                  },
                  {
                        "id": 7884,
                        "displayName": "year_7884"
                  },
                  {
                        "id": 7885,
                        "displayName": "year_7885"
                  },
                  {
                        "id": 7886,
                        "displayName": "year_7886"
                  },
                  {
                        "id": 7887,
                        "displayName": "year_7887"
                  },
                  {
                        "id": 7888,
                        "displayName": "year_7888"
                  },
                  {
                        "id": 7889,
                        "displayName": "year_7889"
                  },
                  {
                        "id": 7890,
                        "displayName": "year_7890"
                  },
                  {
                        "id": 7891,
                        "displayName": "year_7891"
                  },
                  {
                        "id": 7892,
                        "displayName": "year_7892"
                  },
                  {
                        "id": 7893,
                        "displayName": "year_7893"
                  },
                  {
                        "id": 7894,
                        "displayName": "year_7894"
                  },
                  {
                        "id": 7895,
                        "displayName": "year_7895"
                  },
                  {
                        "id": 7896,
                        "displayName": "year_7896"
                  },
                  {
                        "id": 7897,
                        "displayName": "year_7897"
                  },
                  {
                        "id": 7898,
                        "displayName": "year_7898"
                  },
                  {
                        "id": 7899,
                        "displayName": "year_7899"
                  },
                  {
                        "id": 7900,
                        "displayName": "year_7900"
                  },
                  {
                        "id": 7901,
                        "displayName": "year_7901"
                  },
                  {
                        "id": 7902,
                        "displayName": "year_7902"
                  },
                  {
                        "id": 7903,
                        "displayName": "year_7903"
                  },
                  {
                        "id": 7904,
                        "displayName": "year_7904"
                  },
                  {
                        "id": 7905,
                        "displayName": "year_7905"
                  },
                  {
                        "id": 7906,
                        "displayName": "year_7906"
                  },
                  {
                        "id": 7907,
                        "displayName": "year_7907"
                  },
                  {
                        "id": 7908,
                        "displayName": "year_7908"
                  },
                  {
                        "id": 7909,
                        "displayName": "year_7909"
                  },
                  {
                        "id": 7910,
                        "displayName": "year_7910"
                  },
                  {
                        "id": 7911,
                        "displayName": "year_7911"
                  },
                  {
                        "id": 7912,
                        "displayName": "year_7912"
                  },
                  {
                        "id": 7913,
                        "displayName": "year_7913"
                  },
                  {
                        "id": 7914,
                        "displayName": "year_7914"
                  },
                  {
                        "id": 7915,
                        "displayName": "year_7915"
                  },
                  {
                        "id": 7916,
                        "displayName": "year_7916"
                  },
                  {
                        "id": 7917,
                        "displayName": "year_7917"
                  },
                  {
                        "id": 7918,
                        "displayName": "year_7918"
                  },
                  {
                        "id": 7919,
                        "displayName": "year_7919"
                  },
                  {
                        "id": 7920,
                        "displayName": "year_7920"
                  },
                  {
                        "id": 7921,
                        "displayName": "year_7921"
                  },
                  {
                        "id": 7922,
                        "displayName": "year_7922"
                  },
                  {
                        "id": 7923,
                        "displayName": "year_7923"
                  },
                  {
                        "id": 7924,
                        "displayName": "year_7924"
                  },
                  {
                        "id": 7925,
                        "displayName": "year_7925"
                  },
                  {
                        "id": 7926,
                        "displayName": "year_7926"
                  },
                  {
                        "id": 7927,
                        "displayName": "year_7927"
                  },
                  {
                        "id": 7928,
                        "displayName": "year_7928"
                  },
                  {
                        "id": 7929,
                        "displayName": "year_7929"
                  },
                  {
                        "id": 7930,
                        "displayName": "year_7930"
                  },
                  {
                        "id": 7931,
                        "displayName": "year_7931"
                  },
                  {
                        "id": 7932,
                        "displayName": "year_7932"
                  },
                  {
                        "id": 7933,
                        "displayName": "year_7933"
                  },
                  {
                        "id": 7934,
                        "displayName": "year_7934"
                  },
                  {
                        "id": 7935,
                        "displayName": "year_7935"
                  },
                  {
                        "id": 7936,
                        "displayName": "year_7936"
                  },
                  {
                        "id": 7937,
                        "displayName": "year_7937"
                  },
                  {
                        "id": 7938,
                        "displayName": "year_7938"
                  },
                  {
                        "id": 7939,
                        "displayName": "year_7939"
                  },
                  {
                        "id": 7940,
                        "displayName": "year_7940"
                  },
                  {
                        "id": 7941,
                        "displayName": "year_7941"
                  },
                  {
                        "id": 7942,
                        "displayName": "year_7942"
                  },
                  {
                        "id": 7943,
                        "displayName": "year_7943"
                  },
                  {
                        "id": 7944,
                        "displayName": "year_7944"
                  },
                  {
                        "id": 7945,
                        "displayName": "year_7945"
                  },
                  {
                        "id": 7946,
                        "displayName": "year_7946"
                  },
                  {
                        "id": 7947,
                        "displayName": "year_7947"
                  },
                  {
                        "id": 7948,
                        "displayName": "year_7948"
                  },
                  {
                        "id": 7949,
                        "displayName": "year_7949"
                  },
                  {
                        "id": 7950,
                        "displayName": "year_7950"
                  },
                  {
                        "id": 7951,
                        "displayName": "year_7951"
                  },
                  {
                        "id": 7952,
                        "displayName": "year_7952"
                  },
                  {
                        "id": 7953,
                        "displayName": "year_7953"
                  },
                  {
                        "id": 7954,
                        "displayName": "year_7954"
                  },
                  {
                        "id": 7955,
                        "displayName": "year_7955"
                  },
                  {
                        "id": 7956,
                        "displayName": "year_7956"
                  },
                  {
                        "id": 7957,
                        "displayName": "year_7957"
                  },
                  {
                        "id": 7958,
                        "displayName": "year_7958"
                  },
                  {
                        "id": 7959,
                        "displayName": "year_7959"
                  },
                  {
                        "id": 7960,
                        "displayName": "year_7960"
                  },
                  {
                        "id": 7961,
                        "displayName": "year_7961"
                  },
                  {
                        "id": 7962,
                        "displayName": "year_7962"
                  },
                  {
                        "id": 7963,
                        "displayName": "year_7963"
                  },
                  {
                        "id": 7964,
                        "displayName": "year_7964"
                  },
                  {
                        "id": 7965,
                        "displayName": "year_7965"
                  },
                  {
                        "id": 7966,
                        "displayName": "year_7966"
                  },
                  {
                        "id": 7967,
                        "displayName": "year_7967"
                  },
                  {
                        "id": 7968,
                        "displayName": "year_7968"
                  },
                  {
                        "id": 7969,
                        "displayName": "year_7969"
                  },
                  {
                        "id": 7970,
                        "displayName": "year_7970"
                  },
                  {
                        "id": 7971,
                        "displayName": "year_7971"
                  },
                  {
                        "id": 7972,
                        "displayName": "year_7972"
                  },
                  {
                        "id": 7973,
                        "displayName": "year_7973"
                  },
                  {
                        "id": 7974,
                        "displayName": "year_7974"
                  },
                  {
                        "id": 7975,
                        "displayName": "year_7975"
                  },
                  {
                        "id": 7976,
                        "displayName": "year_7976"
                  },
                  {
                        "id": 7977,
                        "displayName": "year_7977"
                  },
                  {
                        "id": 7978,
                        "displayName": "year_7978"
                  },
                  {
                        "id": 7979,
                        "displayName": "year_7979"
                  },
                  {
                        "id": 7980,
                        "displayName": "year_7980"
                  },
                  {
                        "id": 7981,
                        "displayName": "year_7981"
                  },
                  {
                        "id": 7982,
                        "displayName": "year_7982"
                  },
                  {
                        "id": 7983,
                        "displayName": "year_7983"
                  },
                  {
                        "id": 7984,
                        "displayName": "year_7984"
                  },
                  {
                        "id": 7985,
                        "displayName": "year_7985"
                  },
                  {
                        "id": 7986,
                        "displayName": "year_7986"
                  },
                  {
                        "id": 7987,
                        "displayName": "year_7987"
                  },
                  {
                        "id": 7988,
                        "displayName": "year_7988"
                  },
                  {
                        "id": 7989,
                        "displayName": "year_7989"
                  },
                  {
                        "id": 7990,
                        "displayName": "year_7990"
                  },
                  {
                        "id": 7991,
                        "displayName": "year_7991"
                  },
                  {
                        "id": 7992,
                        "displayName": "year_7992"
                  },
                  {
                        "id": 7993,
                        "displayName": "year_7993"
                  },
                  {
                        "id": 7994,
                        "displayName": "year_7994"
                  },
                  {
                        "id": 7995,
                        "displayName": "year_7995"
                  },
                  {
                        "id": 7996,
                        "displayName": "year_7996"
                  },
                  {
                        "id": 7997,
                        "displayName": "year_7997"
                  },
                  {
                        "id": 7998,
                        "displayName": "year_7998"
                  },
                  {
                        "id": 7999,
                        "displayName": "year_7999"
                  },
                  {
                        "id": 8000,
                        "displayName": "year_8000"
                  },
                  {
                        "id": 8001,
                        "displayName": "year_8001"
                  },
                  {
                        "id": 8002,
                        "displayName": "year_8002"
                  },
                  {
                        "id": 8003,
                        "displayName": "year_8003"
                  },
                  {
                        "id": 8004,
                        "displayName": "year_8004"
                  },
                  {
                        "id": 8005,
                        "displayName": "year_8005"
                  },
                  {
                        "id": 8006,
                        "displayName": "year_8006"
                  },
                  {
                        "id": 8007,
                        "displayName": "year_8007"
                  },
                  {
                        "id": 8008,
                        "displayName": "year_8008"
                  },
                  {
                        "id": 8009,
                        "displayName": "year_8009"
                  },
                  {
                        "id": 8010,
                        "displayName": "year_8010"
                  },
                  {
                        "id": 8011,
                        "displayName": "year_8011"
                  },
                  {
                        "id": 8012,
                        "displayName": "year_8012"
                  },
                  {
                        "id": 8013,
                        "displayName": "year_8013"
                  },
                  {
                        "id": 8014,
                        "displayName": "year_8014"
                  },
                  {
                        "id": 8015,
                        "displayName": "year_8015"
                  },
                  {
                        "id": 8016,
                        "displayName": "year_8016"
                  },
                  {
                        "id": 8017,
                        "displayName": "year_8017"
                  },
                  {
                        "id": 8018,
                        "displayName": "year_8018"
                  },
                  {
                        "id": 8019,
                        "displayName": "year_8019"
                  },
                  {
                        "id": 8020,
                        "displayName": "year_8020"
                  },
                  {
                        "id": 8021,
                        "displayName": "year_8021"
                  },
                  {
                        "id": 8022,
                        "displayName": "year_8022"
                  },
                  {
                        "id": 8023,
                        "displayName": "year_8023"
                  },
                  {
                        "id": 8024,
                        "displayName": "year_8024"
                  },
                  {
                        "id": 8025,
                        "displayName": "year_8025"
                  },
                  {
                        "id": 8026,
                        "displayName": "year_8026"
                  },
                  {
                        "id": 8027,
                        "displayName": "year_8027"
                  },
                  {
                        "id": 8028,
                        "displayName": "year_8028"
                  },
                  {
                        "id": 8029,
                        "displayName": "year_8029"
                  },
                  {
                        "id": 8030,
                        "displayName": "year_8030"
                  },
                  {
                        "id": 8031,
                        "displayName": "year_8031"
                  },
                  {
                        "id": 8032,
                        "displayName": "year_8032"
                  },
                  {
                        "id": 8033,
                        "displayName": "year_8033"
                  },
                  {
                        "id": 8034,
                        "displayName": "year_8034"
                  },
                  {
                        "id": 8035,
                        "displayName": "year_8035"
                  },
                  {
                        "id": 8036,
                        "displayName": "year_8036"
                  },
                  {
                        "id": 8037,
                        "displayName": "year_8037"
                  },
                  {
                        "id": 8038,
                        "displayName": "year_8038"
                  },
                  {
                        "id": 8039,
                        "displayName": "year_8039"
                  },
                  {
                        "id": 8040,
                        "displayName": "year_8040"
                  },
                  {
                        "id": 8041,
                        "displayName": "year_8041"
                  },
                  {
                        "id": 8042,
                        "displayName": "year_8042"
                  },
                  {
                        "id": 8043,
                        "displayName": "year_8043"
                  },
                  {
                        "id": 8044,
                        "displayName": "year_8044"
                  },
                  {
                        "id": 8045,
                        "displayName": "year_8045"
                  },
                  {
                        "id": 8046,
                        "displayName": "year_8046"
                  },
                  {
                        "id": 8047,
                        "displayName": "year_8047"
                  },
                  {
                        "id": 8048,
                        "displayName": "year_8048"
                  },
                  {
                        "id": 8049,
                        "displayName": "year_8049"
                  },
                  {
                        "id": 8050,
                        "displayName": "year_8050"
                  },
                  {
                        "id": 8051,
                        "displayName": "year_8051"
                  },
                  {
                        "id": 8052,
                        "displayName": "year_8052"
                  },
                  {
                        "id": 8053,
                        "displayName": "year_8053"
                  },
                  {
                        "id": 8054,
                        "displayName": "year_8054"
                  },
                  {
                        "id": 8055,
                        "displayName": "year_8055"
                  },
                  {
                        "id": 8056,
                        "displayName": "year_8056"
                  },
                  {
                        "id": 8057,
                        "displayName": "year_8057"
                  },
                  {
                        "id": 8058,
                        "displayName": "year_8058"
                  },
                  {
                        "id": 8059,
                        "displayName": "year_8059"
                  },
                  {
                        "id": 8060,
                        "displayName": "year_8060"
                  },
                  {
                        "id": 8061,
                        "displayName": "year_8061"
                  },
                  {
                        "id": 8062,
                        "displayName": "year_8062"
                  },
                  {
                        "id": 8063,
                        "displayName": "year_8063"
                  },
                  {
                        "id": 8064,
                        "displayName": "year_8064"
                  },
                  {
                        "id": 8065,
                        "displayName": "year_8065"
                  },
                  {
                        "id": 8066,
                        "displayName": "year_8066"
                  },
                  {
                        "id": 8067,
                        "displayName": "year_8067"
                  },
                  {
                        "id": 8068,
                        "displayName": "year_8068"
                  },
                  {
                        "id": 8069,
                        "displayName": "year_8069"
                  },
                  {
                        "id": 8070,
                        "displayName": "year_8070"
                  },
                  {
                        "id": 8071,
                        "displayName": "year_8071"
                  },
                  {
                        "id": 8072,
                        "displayName": "year_8072"
                  },
                  {
                        "id": 8073,
                        "displayName": "year_8073"
                  },
                  {
                        "id": 8074,
                        "displayName": "year_8074"
                  },
                  {
                        "id": 8075,
                        "displayName": "year_8075"
                  },
                  {
                        "id": 8076,
                        "displayName": "year_8076"
                  },
                  {
                        "id": 8077,
                        "displayName": "year_8077"
                  },
                  {
                        "id": 8078,
                        "displayName": "year_8078"
                  },
                  {
                        "id": 8079,
                        "displayName": "year_8079"
                  },
                  {
                        "id": 8080,
                        "displayName": "year_8080"
                  },
                  {
                        "id": 8081,
                        "displayName": "year_8081"
                  },
                  {
                        "id": 8082,
                        "displayName": "year_8082"
                  },
                  {
                        "id": 8083,
                        "displayName": "year_8083"
                  },
                  {
                        "id": 8084,
                        "displayName": "year_8084"
                  },
                  {
                        "id": 8085,
                        "displayName": "year_8085"
                  },
                  {
                        "id": 8086,
                        "displayName": "year_8086"
                  },
                  {
                        "id": 8087,
                        "displayName": "year_8087"
                  },
                  {
                        "id": 8088,
                        "displayName": "year_8088"
                  },
                  {
                        "id": 8089,
                        "displayName": "year_8089"
                  },
                  {
                        "id": 8090,
                        "displayName": "year_8090"
                  },
                  {
                        "id": 8091,
                        "displayName": "year_8091"
                  },
                  {
                        "id": 8092,
                        "displayName": "year_8092"
                  },
                  {
                        "id": 8093,
                        "displayName": "year_8093"
                  },
                  {
                        "id": 8094,
                        "displayName": "year_8094"
                  },
                  {
                        "id": 8095,
                        "displayName": "year_8095"
                  },
                  {
                        "id": 8096,
                        "displayName": "year_8096"
                  },
                  {
                        "id": 8097,
                        "displayName": "year_8097"
                  },
                  {
                        "id": 8098,
                        "displayName": "year_8098"
                  },
                  {
                        "id": 8099,
                        "displayName": "year_8099"
                  },
                  {
                        "id": 8100,
                        "displayName": "year_8100"
                  },
                  {
                        "id": 8101,
                        "displayName": "year_8101"
                  },
                  {
                        "id": 8102,
                        "displayName": "year_8102"
                  },
                  {
                        "id": 8103,
                        "displayName": "year_8103"
                  },
                  {
                        "id": 8104,
                        "displayName": "year_8104"
                  },
                  {
                        "id": 8105,
                        "displayName": "year_8105"
                  },
                  {
                        "id": 8106,
                        "displayName": "year_8106"
                  },
                  {
                        "id": 8107,
                        "displayName": "year_8107"
                  },
                  {
                        "id": 8108,
                        "displayName": "year_8108"
                  },
                  {
                        "id": 8109,
                        "displayName": "year_8109"
                  },
                  {
                        "id": 8110,
                        "displayName": "year_8110"
                  },
                  {
                        "id": 8111,
                        "displayName": "year_8111"
                  },
                  {
                        "id": 8112,
                        "displayName": "year_8112"
                  },
                  {
                        "id": 8113,
                        "displayName": "year_8113"
                  },
                  {
                        "id": 8114,
                        "displayName": "year_8114"
                  },
                  {
                        "id": 8115,
                        "displayName": "year_8115"
                  },
                  {
                        "id": 8116,
                        "displayName": "year_8116"
                  },
                  {
                        "id": 8117,
                        "displayName": "year_8117"
                  },
                  {
                        "id": 8118,
                        "displayName": "year_8118"
                  },
                  {
                        "id": 8119,
                        "displayName": "year_8119"
                  },
                  {
                        "id": 8120,
                        "displayName": "year_8120"
                  },
                  {
                        "id": 8121,
                        "displayName": "year_8121"
                  },
                  {
                        "id": 8122,
                        "displayName": "year_8122"
                  },
                  {
                        "id": 8123,
                        "displayName": "year_8123"
                  },
                  {
                        "id": 8124,
                        "displayName": "year_8124"
                  },
                  {
                        "id": 8125,
                        "displayName": "year_8125"
                  },
                  {
                        "id": 8126,
                        "displayName": "year_8126"
                  },
                  {
                        "id": 8127,
                        "displayName": "year_8127"
                  },
                  {
                        "id": 8128,
                        "displayName": "year_8128"
                  },
                  {
                        "id": 8129,
                        "displayName": "year_8129"
                  },
                  {
                        "id": 8130,
                        "displayName": "year_8130"
                  },
                  {
                        "id": 8131,
                        "displayName": "year_8131"
                  },
                  {
                        "id": 8132,
                        "displayName": "year_8132"
                  },
                  {
                        "id": 8133,
                        "displayName": "year_8133"
                  },
                  {
                        "id": 8134,
                        "displayName": "year_8134"
                  },
                  {
                        "id": 8135,
                        "displayName": "year_8135"
                  },
                  {
                        "id": 8136,
                        "displayName": "year_8136"
                  },
                  {
                        "id": 8137,
                        "displayName": "year_8137"
                  },
                  {
                        "id": 8138,
                        "displayName": "year_8138"
                  },
                  {
                        "id": 8139,
                        "displayName": "year_8139"
                  },
                  {
                        "id": 8140,
                        "displayName": "year_8140"
                  },
                  {
                        "id": 8141,
                        "displayName": "year_8141"
                  },
                  {
                        "id": 8142,
                        "displayName": "year_8142"
                  },
                  {
                        "id": 8143,
                        "displayName": "year_8143"
                  },
                  {
                        "id": 8144,
                        "displayName": "year_8144"
                  },
                  {
                        "id": 8145,
                        "displayName": "year_8145"
                  },
                  {
                        "id": 8146,
                        "displayName": "year_8146"
                  },
                  {
                        "id": 8147,
                        "displayName": "year_8147"
                  },
                  {
                        "id": 8148,
                        "displayName": "year_8148"
                  },
                  {
                        "id": 8149,
                        "displayName": "year_8149"
                  },
                  {
                        "id": 8150,
                        "displayName": "year_8150"
                  },
                  {
                        "id": 8151,
                        "displayName": "year_8151"
                  },
                  {
                        "id": 8152,
                        "displayName": "year_8152"
                  },
                  {
                        "id": 8153,
                        "displayName": "year_8153"
                  },
                  {
                        "id": 8154,
                        "displayName": "year_8154"
                  },
                  {
                        "id": 8155,
                        "displayName": "year_8155"
                  },
                  {
                        "id": 8156,
                        "displayName": "year_8156"
                  },
                  {
                        "id": 8157,
                        "displayName": "year_8157"
                  },
                  {
                        "id": 8158,
                        "displayName": "year_8158"
                  },
                  {
                        "id": 8159,
                        "displayName": "year_8159"
                  },
                  {
                        "id": 8160,
                        "displayName": "year_8160"
                  },
                  {
                        "id": 8161,
                        "displayName": "year_8161"
                  },
                  {
                        "id": 8162,
                        "displayName": "year_8162"
                  },
                  {
                        "id": 8163,
                        "displayName": "year_8163"
                  },
                  {
                        "id": 8164,
                        "displayName": "year_8164"
                  },
                  {
                        "id": 8165,
                        "displayName": "year_8165"
                  },
                  {
                        "id": 8166,
                        "displayName": "year_8166"
                  },
                  {
                        "id": 8167,
                        "displayName": "year_8167"
                  },
                  {
                        "id": 8168,
                        "displayName": "year_8168"
                  },
                  {
                        "id": 8169,
                        "displayName": "year_8169"
                  },
                  {
                        "id": 8170,
                        "displayName": "year_8170"
                  },
                  {
                        "id": 8171,
                        "displayName": "year_8171"
                  },
                  {
                        "id": 8172,
                        "displayName": "year_8172"
                  },
                  {
                        "id": 8173,
                        "displayName": "year_8173"
                  },
                  {
                        "id": 8174,
                        "displayName": "year_8174"
                  },
                  {
                        "id": 8175,
                        "displayName": "year_8175"
                  },
                  {
                        "id": 8176,
                        "displayName": "year_8176"
                  },
                  {
                        "id": 8177,
                        "displayName": "year_8177"
                  },
                  {
                        "id": 8178,
                        "displayName": "year_8178"
                  },
                  {
                        "id": 8179,
                        "displayName": "year_8179"
                  },
                  {
                        "id": 8180,
                        "displayName": "year_8180"
                  },
                  {
                        "id": 8181,
                        "displayName": "year_8181"
                  },
                  {
                        "id": 8182,
                        "displayName": "year_8182"
                  },
                  {
                        "id": 8183,
                        "displayName": "year_8183"
                  },
                  {
                        "id": 8184,
                        "displayName": "year_8184"
                  },
                  {
                        "id": 8185,
                        "displayName": "year_8185"
                  },
                  {
                        "id": 8186,
                        "displayName": "year_8186"
                  },
                  {
                        "id": 8187,
                        "displayName": "year_8187"
                  },
                  {
                        "id": 8188,
                        "displayName": "year_8188"
                  },
                  {
                        "id": 8189,
                        "displayName": "year_8189"
                  },
                  {
                        "id": 8190,
                        "displayName": "year_8190"
                  },
                  {
                        "id": 8191,
                        "displayName": "year_8191"
                  },
                  {
                        "id": 8192,
                        "displayName": "year_8192"
                  },
                  {
                        "id": 8193,
                        "displayName": "year_8193"
                  },
                  {
                        "id": 8194,
                        "displayName": "year_8194"
                  },
                  {
                        "id": 8195,
                        "displayName": "year_8195"
                  },
                  {
                        "id": 8196,
                        "displayName": "year_8196"
                  },
                  {
                        "id": 8197,
                        "displayName": "year_8197"
                  },
                  {
                        "id": 8198,
                        "displayName": "year_8198"
                  },
                  {
                        "id": 8199,
                        "displayName": "year_8199"
                  },
                  {
                        "id": 8200,
                        "displayName": "year_8200"
                  },
                  {
                        "id": 8201,
                        "displayName": "year_8201"
                  },
                  {
                        "id": 8202,
                        "displayName": "year_8202"
                  },
                  {
                        "id": 8203,
                        "displayName": "year_8203"
                  },
                  {
                        "id": 8204,
                        "displayName": "year_8204"
                  },
                  {
                        "id": 8205,
                        "displayName": "year_8205"
                  },
                  {
                        "id": 8206,
                        "displayName": "year_8206"
                  },
                  {
                        "id": 8207,
                        "displayName": "year_8207"
                  },
                  {
                        "id": 8208,
                        "displayName": "year_8208"
                  },
                  {
                        "id": 8209,
                        "displayName": "year_8209"
                  },
                  {
                        "id": 8210,
                        "displayName": "year_8210"
                  },
                  {
                        "id": 8211,
                        "displayName": "year_8211"
                  },
                  {
                        "id": 8212,
                        "displayName": "year_8212"
                  },
                  {
                        "id": 8213,
                        "displayName": "year_8213"
                  },
                  {
                        "id": 8214,
                        "displayName": "year_8214"
                  },
                  {
                        "id": 8215,
                        "displayName": "year_8215"
                  },
                  {
                        "id": 8216,
                        "displayName": "year_8216"
                  },
                  {
                        "id": 8217,
                        "displayName": "year_8217"
                  },
                  {
                        "id": 8218,
                        "displayName": "year_8218"
                  },
                  {
                        "id": 8219,
                        "displayName": "year_8219"
                  },
                  {
                        "id": 8220,
                        "displayName": "year_8220"
                  },
                  {
                        "id": 8221,
                        "displayName": "year_8221"
                  },
                  {
                        "id": 8222,
                        "displayName": "year_8222"
                  },
                  {
                        "id": 8223,
                        "displayName": "year_8223"
                  },
                  {
                        "id": 8224,
                        "displayName": "year_8224"
                  },
                  {
                        "id": 8225,
                        "displayName": "year_8225"
                  },
                  {
                        "id": 8226,
                        "displayName": "year_8226"
                  },
                  {
                        "id": 8227,
                        "displayName": "year_8227"
                  },
                  {
                        "id": 8228,
                        "displayName": "year_8228"
                  },
                  {
                        "id": 8229,
                        "displayName": "year_8229"
                  },
                  {
                        "id": 8230,
                        "displayName": "year_8230"
                  },
                  {
                        "id": 8231,
                        "displayName": "year_8231"
                  },
                  {
                        "id": 8232,
                        "displayName": "year_8232"
                  },
                  {
                        "id": 8233,
                        "displayName": "year_8233"
                  },
                  {
                        "id": 8234,
                        "displayName": "year_8234"
                  },
                  {
                        "id": 8235,
                        "displayName": "year_8235"
                  },
                  {
                        "id": 8236,
                        "displayName": "year_8236"
                  },
                  {
                        "id": 8237,
                        "displayName": "year_8237"
                  },
                  {
                        "id": 8238,
                        "displayName": "year_8238"
                  },
                  {
                        "id": 8239,
                        "displayName": "year_8239"
                  },
                  {
                        "id": 8240,
                        "displayName": "year_8240"
                  },
                  {
                        "id": 8241,
                        "displayName": "year_8241"
                  },
                  {
                        "id": 8242,
                        "displayName": "year_8242"
                  },
                  {
                        "id": 8243,
                        "displayName": "year_8243"
                  },
                  {
                        "id": 8244,
                        "displayName": "year_8244"
                  },
                  {
                        "id": 8245,
                        "displayName": "year_8245"
                  },
                  {
                        "id": 8246,
                        "displayName": "year_8246"
                  },
                  {
                        "id": 8247,
                        "displayName": "year_8247"
                  },
                  {
                        "id": 8248,
                        "displayName": "year_8248"
                  },
                  {
                        "id": 8249,
                        "displayName": "year_8249"
                  },
                  {
                        "id": 8250,
                        "displayName": "year_8250"
                  },
                  {
                        "id": 8251,
                        "displayName": "year_8251"
                  },
                  {
                        "id": 8252,
                        "displayName": "year_8252"
                  },
                  {
                        "id": 8253,
                        "displayName": "year_8253"
                  },
                  {
                        "id": 8254,
                        "displayName": "year_8254"
                  },
                  {
                        "id": 8255,
                        "displayName": "year_8255"
                  },
                  {
                        "id": 8256,
                        "displayName": "year_8256"
                  },
                  {
                        "id": 8257,
                        "displayName": "year_8257"
                  },
                  {
                        "id": 8258,
                        "displayName": "year_8258"
                  },
                  {
                        "id": 8259,
                        "displayName": "year_8259"
                  },
                  {
                        "id": 8260,
                        "displayName": "year_8260"
                  },
                  {
                        "id": 8261,
                        "displayName": "year_8261"
                  },
                  {
                        "id": 8262,
                        "displayName": "year_8262"
                  },
                  {
                        "id": 8263,
                        "displayName": "year_8263"
                  },
                  {
                        "id": 8264,
                        "displayName": "year_8264"
                  },
                  {
                        "id": 8265,
                        "displayName": "year_8265"
                  },
                  {
                        "id": 8266,
                        "displayName": "year_8266"
                  },
                  {
                        "id": 8267,
                        "displayName": "year_8267"
                  },
                  {
                        "id": 8268,
                        "displayName": "year_8268"
                  },
                  {
                        "id": 8269,
                        "displayName": "year_8269"
                  },
                  {
                        "id": 8270,
                        "displayName": "year_8270"
                  },
                  {
                        "id": 8271,
                        "displayName": "year_8271"
                  },
                  {
                        "id": 8272,
                        "displayName": "year_8272"
                  },
                  {
                        "id": 8273,
                        "displayName": "year_8273"
                  },
                  {
                        "id": 8274,
                        "displayName": "year_8274"
                  },
                  {
                        "id": 8275,
                        "displayName": "year_8275"
                  },
                  {
                        "id": 8276,
                        "displayName": "year_8276"
                  },
                  {
                        "id": 8277,
                        "displayName": "year_8277"
                  },
                  {
                        "id": 8278,
                        "displayName": "year_8278"
                  },
                  {
                        "id": 8279,
                        "displayName": "year_8279"
                  },
                  {
                        "id": 8280,
                        "displayName": "year_8280"
                  },
                  {
                        "id": 8281,
                        "displayName": "year_8281"
                  },
                  {
                        "id": 8282,
                        "displayName": "year_8282"
                  },
                  {
                        "id": 8283,
                        "displayName": "year_8283"
                  },
                  {
                        "id": 8284,
                        "displayName": "year_8284"
                  },
                  {
                        "id": 8285,
                        "displayName": "year_8285"
                  },
                  {
                        "id": 8286,
                        "displayName": "year_8286"
                  },
                  {
                        "id": 8287,
                        "displayName": "year_8287"
                  },
                  {
                        "id": 8288,
                        "displayName": "year_8288"
                  },
                  {
                        "id": 8289,
                        "displayName": "year_8289"
                  },
                  {
                        "id": 8290,
                        "displayName": "year_8290"
                  },
                  {
                        "id": 8291,
                        "displayName": "year_8291"
                  },
                  {
                        "id": 8292,
                        "displayName": "year_8292"
                  },
                  {
                        "id": 8293,
                        "displayName": "year_8293"
                  },
                  {
                        "id": 8294,
                        "displayName": "year_8294"
                  },
                  {
                        "id": 8295,
                        "displayName": "year_8295"
                  },
                  {
                        "id": 8296,
                        "displayName": "year_8296"
                  },
                  {
                        "id": 8297,
                        "displayName": "year_8297"
                  },
                  {
                        "id": 8298,
                        "displayName": "year_8298"
                  },
                  {
                        "id": 8299,
                        "displayName": "year_8299"
                  },
                  {
                        "id": 8300,
                        "displayName": "year_8300"
                  },
                  {
                        "id": 8301,
                        "displayName": "year_8301"
                  },
                  {
                        "id": 8302,
                        "displayName": "year_8302"
                  },
                  {
                        "id": 8303,
                        "displayName": "year_8303"
                  },
                  {
                        "id": 8304,
                        "displayName": "year_8304"
                  },
                  {
                        "id": 8305,
                        "displayName": "year_8305"
                  },
                  {
                        "id": 8306,
                        "displayName": "year_8306"
                  },
                  {
                        "id": 8307,
                        "displayName": "year_8307"
                  },
                  {
                        "id": 8308,
                        "displayName": "year_8308"
                  },
                  {
                        "id": 8309,
                        "displayName": "year_8309"
                  },
                  {
                        "id": 8310,
                        "displayName": "year_8310"
                  },
                  {
                        "id": 8311,
                        "displayName": "year_8311"
                  },
                  {
                        "id": 8312,
                        "displayName": "year_8312"
                  },
                  {
                        "id": 8313,
                        "displayName": "year_8313"
                  },
                  {
                        "id": 8314,
                        "displayName": "year_8314"
                  },
                  {
                        "id": 8315,
                        "displayName": "year_8315"
                  },
                  {
                        "id": 8316,
                        "displayName": "year_8316"
                  },
                  {
                        "id": 8317,
                        "displayName": "year_8317"
                  },
                  {
                        "id": 8318,
                        "displayName": "year_8318"
                  },
                  {
                        "id": 8319,
                        "displayName": "year_8319"
                  },
                  {
                        "id": 8320,
                        "displayName": "year_8320"
                  },
                  {
                        "id": 8321,
                        "displayName": "year_8321"
                  },
                  {
                        "id": 8322,
                        "displayName": "year_8322"
                  },
                  {
                        "id": 8323,
                        "displayName": "year_8323"
                  },
                  {
                        "id": 8324,
                        "displayName": "year_8324"
                  },
                  {
                        "id": 8325,
                        "displayName": "year_8325"
                  },
                  {
                        "id": 8326,
                        "displayName": "year_8326"
                  },
                  {
                        "id": 8327,
                        "displayName": "year_8327"
                  },
                  {
                        "id": 8328,
                        "displayName": "year_8328"
                  },
                  {
                        "id": 8329,
                        "displayName": "year_8329"
                  },
                  {
                        "id": 8330,
                        "displayName": "year_8330"
                  },
                  {
                        "id": 8331,
                        "displayName": "year_8331"
                  },
                  {
                        "id": 8332,
                        "displayName": "year_8332"
                  },
                  {
                        "id": 8333,
                        "displayName": "year_8333"
                  },
                  {
                        "id": 8334,
                        "displayName": "year_8334"
                  },
                  {
                        "id": 8335,
                        "displayName": "year_8335"
                  },
                  {
                        "id": 8336,
                        "displayName": "year_8336"
                  },
                  {
                        "id": 8337,
                        "displayName": "year_8337"
                  },
                  {
                        "id": 8338,
                        "displayName": "year_8338"
                  },
                  {
                        "id": 8339,
                        "displayName": "year_8339"
                  },
                  {
                        "id": 8340,
                        "displayName": "year_8340"
                  },
                  {
                        "id": 8341,
                        "displayName": "year_8341"
                  },
                  {
                        "id": 8342,
                        "displayName": "year_8342"
                  },
                  {
                        "id": 8343,
                        "displayName": "year_8343"
                  },
                  {
                        "id": 8344,
                        "displayName": "year_8344"
                  },
                  {
                        "id": 8345,
                        "displayName": "year_8345"
                  },
                  {
                        "id": 8346,
                        "displayName": "year_8346"
                  },
                  {
                        "id": 8347,
                        "displayName": "year_8347"
                  },
                  {
                        "id": 8348,
                        "displayName": "year_8348"
                  },
                  {
                        "id": 8349,
                        "displayName": "year_8349"
                  },
                  {
                        "id": 8350,
                        "displayName": "year_8350"
                  },
                  {
                        "id": 8351,
                        "displayName": "year_8351"
                  },
                  {
                        "id": 8352,
                        "displayName": "year_8352"
                  },
                  {
                        "id": 8353,
                        "displayName": "year_8353"
                  },
                  {
                        "id": 8354,
                        "displayName": "year_8354"
                  },
                  {
                        "id": 8355,
                        "displayName": "year_8355"
                  },
                  {
                        "id": 8356,
                        "displayName": "year_8356"
                  },
                  {
                        "id": 8357,
                        "displayName": "year_8357"
                  },
                  {
                        "id": 8358,
                        "displayName": "year_8358"
                  },
                  {
                        "id": 8359,
                        "displayName": "year_8359"
                  },
                  {
                        "id": 8360,
                        "displayName": "year_8360"
                  },
                  {
                        "id": 8361,
                        "displayName": "year_8361"
                  },
                  {
                        "id": 8362,
                        "displayName": "year_8362"
                  },
                  {
                        "id": 8363,
                        "displayName": "year_8363"
                  },
                  {
                        "id": 8364,
                        "displayName": "year_8364"
                  },
                  {
                        "id": 8365,
                        "displayName": "year_8365"
                  },
                  {
                        "id": 8366,
                        "displayName": "year_8366"
                  },
                  {
                        "id": 8367,
                        "displayName": "year_8367"
                  },
                  {
                        "id": 8368,
                        "displayName": "year_8368"
                  },
                  {
                        "id": 8369,
                        "displayName": "year_8369"
                  },
                  {
                        "id": 8370,
                        "displayName": "year_8370"
                  },
                  {
                        "id": 8371,
                        "displayName": "year_8371"
                  },
                  {
                        "id": 8372,
                        "displayName": "year_8372"
                  },
                  {
                        "id": 8373,
                        "displayName": "year_8373"
                  },
                  {
                        "id": 8374,
                        "displayName": "year_8374"
                  },
                  {
                        "id": 8375,
                        "displayName": "year_8375"
                  },
                  {
                        "id": 8376,
                        "displayName": "year_8376"
                  },
                  {
                        "id": 8377,
                        "displayName": "year_8377"
                  },
                  {
                        "id": 8378,
                        "displayName": "year_8378"
                  },
                  {
                        "id": 8379,
                        "displayName": "year_8379"
                  },
                  {
                        "id": 8380,
                        "displayName": "year_8380"
                  },
                  {
                        "id": 8381,
                        "displayName": "year_8381"
                  },
                  {
                        "id": 8382,
                        "displayName": "year_8382"
                  },
                  {
                        "id": 8383,
                        "displayName": "year_8383"
                  },
                  {
                        "id": 8384,
                        "displayName": "year_8384"
                  },
                  {
                        "id": 8385,
                        "displayName": "year_8385"
                  },
                  {
                        "id": 8386,
                        "displayName": "year_8386"
                  },
                  {
                        "id": 8387,
                        "displayName": "year_8387"
                  },
                  {
                        "id": 8388,
                        "displayName": "year_8388"
                  },
                  {
                        "id": 8389,
                        "displayName": "year_8389"
                  },
                  {
                        "id": 8390,
                        "displayName": "year_8390"
                  },
                  {
                        "id": 8391,
                        "displayName": "year_8391"
                  },
                  {
                        "id": 8392,
                        "displayName": "year_8392"
                  },
                  {
                        "id": 8393,
                        "displayName": "year_8393"
                  },
                  {
                        "id": 8394,
                        "displayName": "year_8394"
                  },
                  {
                        "id": 8395,
                        "displayName": "year_8395"
                  },
                  {
                        "id": 8396,
                        "displayName": "year_8396"
                  },
                  {
                        "id": 8397,
                        "displayName": "year_8397"
                  },
                  {
                        "id": 8398,
                        "displayName": "year_8398"
                  },
                  {
                        "id": 8399,
                        "displayName": "year_8399"
                  },
                  {
                        "id": 8400,
                        "displayName": "year_8400"
                  },
                  {
                        "id": 8401,
                        "displayName": "year_8401"
                  },
                  {
                        "id": 8402,
                        "displayName": "year_8402"
                  },
                  {
                        "id": 8403,
                        "displayName": "year_8403"
                  },
                  {
                        "id": 8404,
                        "displayName": "year_8404"
                  },
                  {
                        "id": 8405,
                        "displayName": "year_8405"
                  },
                  {
                        "id": 8406,
                        "displayName": "year_8406"
                  },
                  {
                        "id": 8407,
                        "displayName": "year_8407"
                  },
                  {
                        "id": 8408,
                        "displayName": "year_8408"
                  },
                  {
                        "id": 8409,
                        "displayName": "year_8409"
                  },
                  {
                        "id": 8410,
                        "displayName": "year_8410"
                  },
                  {
                        "id": 8411,
                        "displayName": "year_8411"
                  },
                  {
                        "id": 8412,
                        "displayName": "year_8412"
                  },
                  {
                        "id": 8413,
                        "displayName": "year_8413"
                  },
                  {
                        "id": 8414,
                        "displayName": "year_8414"
                  },
                  {
                        "id": 8415,
                        "displayName": "year_8415"
                  },
                  {
                        "id": 8416,
                        "displayName": "year_8416"
                  },
                  {
                        "id": 8417,
                        "displayName": "year_8417"
                  },
                  {
                        "id": 8418,
                        "displayName": "year_8418"
                  },
                  {
                        "id": 8419,
                        "displayName": "year_8419"
                  },
                  {
                        "id": 8420,
                        "displayName": "year_8420"
                  },
                  {
                        "id": 8421,
                        "displayName": "year_8421"
                  },
                  {
                        "id": 8422,
                        "displayName": "year_8422"
                  },
                  {
                        "id": 8423,
                        "displayName": "year_8423"
                  },
                  {
                        "id": 8424,
                        "displayName": "year_8424"
                  },
                  {
                        "id": 8425,
                        "displayName": "year_8425"
                  },
                  {
                        "id": 8426,
                        "displayName": "year_8426"
                  },
                  {
                        "id": 8427,
                        "displayName": "year_8427"
                  },
                  {
                        "id": 8428,
                        "displayName": "year_8428"
                  },
                  {
                        "id": 8429,
                        "displayName": "year_8429"
                  },
                  {
                        "id": 8430,
                        "displayName": "year_8430"
                  },
                  {
                        "id": 8431,
                        "displayName": "year_8431"
                  },
                  {
                        "id": 8432,
                        "displayName": "year_8432"
                  },
                  {
                        "id": 8433,
                        "displayName": "year_8433"
                  },
                  {
                        "id": 8434,
                        "displayName": "year_8434"
                  },
                  {
                        "id": 8435,
                        "displayName": "year_8435"
                  },
                  {
                        "id": 8436,
                        "displayName": "year_8436"
                  },
                  {
                        "id": 8437,
                        "displayName": "year_8437"
                  },
                  {
                        "id": 8438,
                        "displayName": "year_8438"
                  },
                  {
                        "id": 8439,
                        "displayName": "year_8439"
                  },
                  {
                        "id": 8440,
                        "displayName": "year_8440"
                  },
                  {
                        "id": 8441,
                        "displayName": "year_8441"
                  },
                  {
                        "id": 8442,
                        "displayName": "year_8442"
                  },
                  {
                        "id": 8443,
                        "displayName": "year_8443"
                  },
                  {
                        "id": 8444,
                        "displayName": "year_8444"
                  },
                  {
                        "id": 8445,
                        "displayName": "year_8445"
                  },
                  {
                        "id": 8446,
                        "displayName": "year_8446"
                  },
                  {
                        "id": 8447,
                        "displayName": "year_8447"
                  },
                  {
                        "id": 8448,
                        "displayName": "year_8448"
                  },
                  {
                        "id": 8449,
                        "displayName": "year_8449"
                  },
                  {
                        "id": 8450,
                        "displayName": "year_8450"
                  },
                  {
                        "id": 8451,
                        "displayName": "year_8451"
                  },
                  {
                        "id": 8452,
                        "displayName": "year_8452"
                  },
                  {
                        "id": 8453,
                        "displayName": "year_8453"
                  },
                  {
                        "id": 8454,
                        "displayName": "year_8454"
                  },
                  {
                        "id": 8455,
                        "displayName": "year_8455"
                  },
                  {
                        "id": 8456,
                        "displayName": "year_8456"
                  },
                  {
                        "id": 8457,
                        "displayName": "year_8457"
                  },
                  {
                        "id": 8458,
                        "displayName": "year_8458"
                  },
                  {
                        "id": 8459,
                        "displayName": "year_8459"
                  },
                  {
                        "id": 8460,
                        "displayName": "year_8460"
                  },
                  {
                        "id": 8461,
                        "displayName": "year_8461"
                  },
                  {
                        "id": 8462,
                        "displayName": "year_8462"
                  },
                  {
                        "id": 8463,
                        "displayName": "year_8463"
                  },
                  {
                        "id": 8464,
                        "displayName": "year_8464"
                  },
                  {
                        "id": 8465,
                        "displayName": "year_8465"
                  },
                  {
                        "id": 8466,
                        "displayName": "year_8466"
                  },
                  {
                        "id": 8467,
                        "displayName": "year_8467"
                  },
                  {
                        "id": 8468,
                        "displayName": "year_8468"
                  },
                  {
                        "id": 8469,
                        "displayName": "year_8469"
                  },
                  {
                        "id": 8470,
                        "displayName": "year_8470"
                  },
                  {
                        "id": 8471,
                        "displayName": "year_8471"
                  },
                  {
                        "id": 8472,
                        "displayName": "year_8472"
                  },
                  {
                        "id": 8473,
                        "displayName": "year_8473"
                  },
                  {
                        "id": 8474,
                        "displayName": "year_8474"
                  },
                  {
                        "id": 8475,
                        "displayName": "year_8475"
                  },
                  {
                        "id": 8476,
                        "displayName": "year_8476"
                  },
                  {
                        "id": 8477,
                        "displayName": "year_8477"
                  },
                  {
                        "id": 8478,
                        "displayName": "year_8478"
                  },
                  {
                        "id": 8479,
                        "displayName": "year_8479"
                  },
                  {
                        "id": 8480,
                        "displayName": "year_8480"
                  },
                  {
                        "id": 8481,
                        "displayName": "year_8481"
                  },
                  {
                        "id": 8482,
                        "displayName": "year_8482"
                  },
                  {
                        "id": 8483,
                        "displayName": "year_8483"
                  },
                  {
                        "id": 8484,
                        "displayName": "year_8484"
                  },
                  {
                        "id": 8485,
                        "displayName": "year_8485"
                  },
                  {
                        "id": 8486,
                        "displayName": "year_8486"
                  },
                  {
                        "id": 8487,
                        "displayName": "year_8487"
                  },
                  {
                        "id": 8488,
                        "displayName": "year_8488"
                  },
                  {
                        "id": 8489,
                        "displayName": "year_8489"
                  },
                  {
                        "id": 8490,
                        "displayName": "year_8490"
                  },
                  {
                        "id": 8491,
                        "displayName": "year_8491"
                  },
                  {
                        "id": 8492,
                        "displayName": "year_8492"
                  },
                  {
                        "id": 8493,
                        "displayName": "year_8493"
                  },
                  {
                        "id": 8494,
                        "displayName": "year_8494"
                  },
                  {
                        "id": 8495,
                        "displayName": "year_8495"
                  },
                  {
                        "id": 8496,
                        "displayName": "year_8496"
                  },
                  {
                        "id": 8497,
                        "displayName": "year_8497"
                  },
                  {
                        "id": 8498,
                        "displayName": "year_8498"
                  },
                  {
                        "id": 8499,
                        "displayName": "year_8499"
                  },
                  {
                        "id": 8500,
                        "displayName": "year_8500"
                  },
                  {
                        "id": 8501,
                        "displayName": "year_8501"
                  },
                  {
                        "id": 8502,
                        "displayName": "year_8502"
                  },
                  {
                        "id": 8503,
                        "displayName": "year_8503"
                  },
                  {
                        "id": 8504,
                        "displayName": "year_8504"
                  },
                  {
                        "id": 8505,
                        "displayName": "year_8505"
                  },
                  {
                        "id": 8506,
                        "displayName": "year_8506"
                  },
                  {
                        "id": 8507,
                        "displayName": "year_8507"
                  },
                  {
                        "id": 8508,
                        "displayName": "year_8508"
                  },
                  {
                        "id": 8509,
                        "displayName": "year_8509"
                  },
                  {
                        "id": 8510,
                        "displayName": "year_8510"
                  },
                  {
                        "id": 8511,
                        "displayName": "year_8511"
                  },
                  {
                        "id": 8512,
                        "displayName": "year_8512"
                  },
                  {
                        "id": 8513,
                        "displayName": "year_8513"
                  },
                  {
                        "id": 8514,
                        "displayName": "year_8514"
                  },
                  {
                        "id": 8515,
                        "displayName": "year_8515"
                  },
                  {
                        "id": 8516,
                        "displayName": "year_8516"
                  },
                  {
                        "id": 8517,
                        "displayName": "year_8517"
                  },
                  {
                        "id": 8518,
                        "displayName": "year_8518"
                  },
                  {
                        "id": 8519,
                        "displayName": "year_8519"
                  },
                  {
                        "id": 8520,
                        "displayName": "year_8520"
                  },
                  {
                        "id": 8521,
                        "displayName": "year_8521"
                  },
                  {
                        "id": 8522,
                        "displayName": "year_8522"
                  },
                  {
                        "id": 8523,
                        "displayName": "year_8523"
                  },
                  {
                        "id": 8524,
                        "displayName": "year_8524"
                  },
                  {
                        "id": 8525,
                        "displayName": "year_8525"
                  },
                  {
                        "id": 8526,
                        "displayName": "year_8526"
                  },
                  {
                        "id": 8527,
                        "displayName": "year_8527"
                  },
                  {
                        "id": 8528,
                        "displayName": "year_8528"
                  },
                  {
                        "id": 8529,
                        "displayName": "year_8529"
                  },
                  {
                        "id": 8530,
                        "displayName": "year_8530"
                  },
                  {
                        "id": 8531,
                        "displayName": "year_8531"
                  },
                  {
                        "id": 8532,
                        "displayName": "year_8532"
                  },
                  {
                        "id": 8533,
                        "displayName": "year_8533"
                  },
                  {
                        "id": 8534,
                        "displayName": "year_8534"
                  },
                  {
                        "id": 8535,
                        "displayName": "year_8535"
                  },
                  {
                        "id": 8536,
                        "displayName": "year_8536"
                  },
                  {
                        "id": 8537,
                        "displayName": "year_8537"
                  },
                  {
                        "id": 8538,
                        "displayName": "year_8538"
                  },
                  {
                        "id": 8539,
                        "displayName": "year_8539"
                  },
                  {
                        "id": 8540,
                        "displayName": "year_8540"
                  },
                  {
                        "id": 8541,
                        "displayName": "year_8541"
                  },
                  {
                        "id": 8542,
                        "displayName": "year_8542"
                  },
                  {
                        "id": 8543,
                        "displayName": "year_8543"
                  },
                  {
                        "id": 8544,
                        "displayName": "year_8544"
                  },
                  {
                        "id": 8545,
                        "displayName": "year_8545"
                  },
                  {
                        "id": 8546,
                        "displayName": "year_8546"
                  },
                  {
                        "id": 8547,
                        "displayName": "year_8547"
                  },
                  {
                        "id": 8548,
                        "displayName": "year_8548"
                  },
                  {
                        "id": 8549,
                        "displayName": "year_8549"
                  },
                  {
                        "id": 8550,
                        "displayName": "year_8550"
                  },
                  {
                        "id": 8551,
                        "displayName": "year_8551"
                  },
                  {
                        "id": 8552,
                        "displayName": "year_8552"
                  },
                  {
                        "id": 8553,
                        "displayName": "year_8553"
                  },
                  {
                        "id": 8554,
                        "displayName": "year_8554"
                  },
                  {
                        "id": 8555,
                        "displayName": "year_8555"
                  },
                  {
                        "id": 8556,
                        "displayName": "year_8556"
                  },
                  {
                        "id": 8557,
                        "displayName": "year_8557"
                  },
                  {
                        "id": 8558,
                        "displayName": "year_8558"
                  },
                  {
                        "id": 8559,
                        "displayName": "year_8559"
                  },
                  {
                        "id": 8560,
                        "displayName": "year_8560"
                  },
                  {
                        "id": 8561,
                        "displayName": "year_8561"
                  },
                  {
                        "id": 8562,
                        "displayName": "year_8562"
                  },
                  {
                        "id": 8563,
                        "displayName": "year_8563"
                  },
                  {
                        "id": 8564,
                        "displayName": "year_8564"
                  },
                  {
                        "id": 8565,
                        "displayName": "year_8565"
                  },
                  {
                        "id": 8566,
                        "displayName": "year_8566"
                  },
                  {
                        "id": 8567,
                        "displayName": "year_8567"
                  },
                  {
                        "id": 8568,
                        "displayName": "year_8568"
                  },
                  {
                        "id": 8569,
                        "displayName": "year_8569"
                  },
                  {
                        "id": 8570,
                        "displayName": "year_8570"
                  },
                  {
                        "id": 8571,
                        "displayName": "year_8571"
                  },
                  {
                        "id": 8572,
                        "displayName": "year_8572"
                  },
                  {
                        "id": 8573,
                        "displayName": "year_8573"
                  },
                  {
                        "id": 8574,
                        "displayName": "year_8574"
                  },
                  {
                        "id": 8575,
                        "displayName": "year_8575"
                  },
                  {
                        "id": 8576,
                        "displayName": "year_8576"
                  },
                  {
                        "id": 8577,
                        "displayName": "year_8577"
                  },
                  {
                        "id": 8578,
                        "displayName": "year_8578"
                  },
                  {
                        "id": 8579,
                        "displayName": "year_8579"
                  },
                  {
                        "id": 8580,
                        "displayName": "year_8580"
                  },
                  {
                        "id": 8581,
                        "displayName": "year_8581"
                  },
                  {
                        "id": 8582,
                        "displayName": "year_8582"
                  },
                  {
                        "id": 8583,
                        "displayName": "year_8583"
                  },
                  {
                        "id": 8584,
                        "displayName": "year_8584"
                  },
                  {
                        "id": 8585,
                        "displayName": "year_8585"
                  },
                  {
                        "id": 8586,
                        "displayName": "year_8586"
                  },
                  {
                        "id": 8587,
                        "displayName": "year_8587"
                  },
                  {
                        "id": 8588,
                        "displayName": "year_8588"
                  },
                  {
                        "id": 8589,
                        "displayName": "year_8589"
                  },
                  {
                        "id": 8590,
                        "displayName": "year_8590"
                  },
                  {
                        "id": 8591,
                        "displayName": "year_8591"
                  },
                  {
                        "id": 8592,
                        "displayName": "year_8592"
                  },
                  {
                        "id": 8593,
                        "displayName": "year_8593"
                  },
                  {
                        "id": 8594,
                        "displayName": "year_8594"
                  },
                  {
                        "id": 8595,
                        "displayName": "year_8595"
                  },
                  {
                        "id": 8596,
                        "displayName": "year_8596"
                  },
                  {
                        "id": 8597,
                        "displayName": "year_8597"
                  },
                  {
                        "id": 8598,
                        "displayName": "year_8598"
                  },
                  {
                        "id": 8599,
                        "displayName": "year_8599"
                  },
                  {
                        "id": 8600,
                        "displayName": "year_8600"
                  },
                  {
                        "id": 8601,
                        "displayName": "year_8601"
                  },
                  {
                        "id": 8602,
                        "displayName": "year_8602"
                  },
                  {
                        "id": 8603,
                        "displayName": "year_8603"
                  },
                  {
                        "id": 8604,
                        "displayName": "year_8604"
                  },
                  {
                        "id": 8605,
                        "displayName": "year_8605"
                  },
                  {
                        "id": 8606,
                        "displayName": "year_8606"
                  },
                  {
                        "id": 8607,
                        "displayName": "year_8607"
                  },
                  {
                        "id": 8608,
                        "displayName": "year_8608"
                  },
                  {
                        "id": 8609,
                        "displayName": "year_8609"
                  },
                  {
                        "id": 8610,
                        "displayName": "year_8610"
                  },
                  {
                        "id": 8611,
                        "displayName": "year_8611"
                  },
                  {
                        "id": 8612,
                        "displayName": "year_8612"
                  },
                  {
                        "id": 8613,
                        "displayName": "year_8613"
                  },
                  {
                        "id": 8614,
                        "displayName": "year_8614"
                  },
                  {
                        "id": 8615,
                        "displayName": "year_8615"
                  },
                  {
                        "id": 8616,
                        "displayName": "year_8616"
                  },
                  {
                        "id": 8617,
                        "displayName": "year_8617"
                  },
                  {
                        "id": 8618,
                        "displayName": "year_8618"
                  },
                  {
                        "id": 8619,
                        "displayName": "year_8619"
                  },
                  {
                        "id": 8620,
                        "displayName": "year_8620"
                  },
                  {
                        "id": 8621,
                        "displayName": "year_8621"
                  },
                  {
                        "id": 8622,
                        "displayName": "year_8622"
                  },
                  {
                        "id": 8623,
                        "displayName": "year_8623"
                  },
                  {
                        "id": 8624,
                        "displayName": "year_8624"
                  },
                  {
                        "id": 8625,
                        "displayName": "year_8625"
                  },
                  {
                        "id": 8626,
                        "displayName": "year_8626"
                  },
                  {
                        "id": 8627,
                        "displayName": "year_8627"
                  },
                  {
                        "id": 8628,
                        "displayName": "year_8628"
                  },
                  {
                        "id": 8629,
                        "displayName": "year_8629"
                  },
                  {
                        "id": 8630,
                        "displayName": "year_8630"
                  },
                  {
                        "id": 8631,
                        "displayName": "year_8631"
                  },
                  {
                        "id": 8632,
                        "displayName": "year_8632"
                  },
                  {
                        "id": 8633,
                        "displayName": "year_8633"
                  },
                  {
                        "id": 8634,
                        "displayName": "year_8634"
                  },
                  {
                        "id": 8635,
                        "displayName": "year_8635"
                  },
                  {
                        "id": 8636,
                        "displayName": "year_8636"
                  },
                  {
                        "id": 8637,
                        "displayName": "year_8637"
                  },
                  {
                        "id": 8638,
                        "displayName": "year_8638"
                  },
                  {
                        "id": 8639,
                        "displayName": "year_8639"
                  },
                  {
                        "id": 8640,
                        "displayName": "year_8640"
                  },
                  {
                        "id": 8641,
                        "displayName": "year_8641"
                  },
                  {
                        "id": 8642,
                        "displayName": "year_8642"
                  },
                  {
                        "id": 8643,
                        "displayName": "year_8643"
                  },
                  {
                        "id": 8644,
                        "displayName": "year_8644"
                  },
                  {
                        "id": 8645,
                        "displayName": "year_8645"
                  },
                  {
                        "id": 8646,
                        "displayName": "year_8646"
                  },
                  {
                        "id": 8647,
                        "displayName": "year_8647"
                  },
                  {
                        "id": 8648,
                        "displayName": "year_8648"
                  },
                  {
                        "id": 8649,
                        "displayName": "year_8649"
                  },
                  {
                        "id": 8650,
                        "displayName": "year_8650"
                  },
                  {
                        "id": 8651,
                        "displayName": "year_8651"
                  },
                  {
                        "id": 8652,
                        "displayName": "year_8652"
                  },
                  {
                        "id": 8653,
                        "displayName": "year_8653"
                  },
                  {
                        "id": 8654,
                        "displayName": "year_8654"
                  },
                  {
                        "id": 8655,
                        "displayName": "year_8655"
                  },
                  {
                        "id": 8656,
                        "displayName": "year_8656"
                  },
                  {
                        "id": 8657,
                        "displayName": "year_8657"
                  },
                  {
                        "id": 8658,
                        "displayName": "year_8658"
                  },
                  {
                        "id": 8659,
                        "displayName": "year_8659"
                  },
                  {
                        "id": 8660,
                        "displayName": "year_8660"
                  },
                  {
                        "id": 8661,
                        "displayName": "year_8661"
                  },
                  {
                        "id": 8662,
                        "displayName": "year_8662"
                  },
                  {
                        "id": 8663,
                        "displayName": "year_8663"
                  },
                  {
                        "id": 8664,
                        "displayName": "year_8664"
                  },
                  {
                        "id": 8665,
                        "displayName": "year_8665"
                  },
                  {
                        "id": 8666,
                        "displayName": "year_8666"
                  },
                  {
                        "id": 8667,
                        "displayName": "year_8667"
                  },
                  {
                        "id": 8668,
                        "displayName": "year_8668"
                  },
                  {
                        "id": 8669,
                        "displayName": "year_8669"
                  },
                  {
                        "id": 8670,
                        "displayName": "year_8670"
                  },
                  {
                        "id": 8671,
                        "displayName": "year_8671"
                  },
                  {
                        "id": 8672,
                        "displayName": "year_8672"
                  },
                  {
                        "id": 8673,
                        "displayName": "year_8673"
                  },
                  {
                        "id": 8674,
                        "displayName": "year_8674"
                  },
                  {
                        "id": 8675,
                        "displayName": "year_8675"
                  },
                  {
                        "id": 8676,
                        "displayName": "year_8676"
                  },
                  {
                        "id": 8677,
                        "displayName": "year_8677"
                  },
                  {
                        "id": 8678,
                        "displayName": "year_8678"
                  },
                  {
                        "id": 8679,
                        "displayName": "year_8679"
                  },
                  {
                        "id": 8680,
                        "displayName": "year_8680"
                  },
                  {
                        "id": 8681,
                        "displayName": "year_8681"
                  },
                  {
                        "id": 8682,
                        "displayName": "year_8682"
                  },
                  {
                        "id": 8683,
                        "displayName": "year_8683"
                  },
                  {
                        "id": 8684,
                        "displayName": "year_8684"
                  },
                  {
                        "id": 8685,
                        "displayName": "year_8685"
                  },
                  {
                        "id": 8686,
                        "displayName": "year_8686"
                  },
                  {
                        "id": 8687,
                        "displayName": "year_8687"
                  },
                  {
                        "id": 8688,
                        "displayName": "year_8688"
                  },
                  {
                        "id": 8689,
                        "displayName": "year_8689"
                  },
                  {
                        "id": 8690,
                        "displayName": "year_8690"
                  },
                  {
                        "id": 8691,
                        "displayName": "year_8691"
                  },
                  {
                        "id": 8692,
                        "displayName": "year_8692"
                  },
                  {
                        "id": 8693,
                        "displayName": "year_8693"
                  },
                  {
                        "id": 8694,
                        "displayName": "year_8694"
                  },
                  {
                        "id": 8695,
                        "displayName": "year_8695"
                  },
                  {
                        "id": 8696,
                        "displayName": "year_8696"
                  },
                  {
                        "id": 8697,
                        "displayName": "year_8697"
                  },
                  {
                        "id": 8698,
                        "displayName": "year_8698"
                  },
                  {
                        "id": 8699,
                        "displayName": "year_8699"
                  },
                  {
                        "id": 8700,
                        "displayName": "year_8700"
                  },
                  {
                        "id": 8701,
                        "displayName": "year_8701"
                  },
                  {
                        "id": 8702,
                        "displayName": "year_8702"
                  },
                  {
                        "id": 8703,
                        "displayName": "year_8703"
                  },
                  {
                        "id": 8704,
                        "displayName": "year_8704"
                  },
                  {
                        "id": 8705,
                        "displayName": "year_8705"
                  },
                  {
                        "id": 8706,
                        "displayName": "year_8706"
                  },
                  {
                        "id": 8707,
                        "displayName": "year_8707"
                  },
                  {
                        "id": 8708,
                        "displayName": "year_8708"
                  },
                  {
                        "id": 8709,
                        "displayName": "year_8709"
                  },
                  {
                        "id": 8710,
                        "displayName": "year_8710"
                  },
                  {
                        "id": 8711,
                        "displayName": "year_8711"
                  },
                  {
                        "id": 8712,
                        "displayName": "year_8712"
                  },
                  {
                        "id": 8713,
                        "displayName": "year_8713"
                  },
                  {
                        "id": 8714,
                        "displayName": "year_8714"
                  },
                  {
                        "id": 8715,
                        "displayName": "year_8715"
                  },
                  {
                        "id": 8716,
                        "displayName": "year_8716"
                  },
                  {
                        "id": 8717,
                        "displayName": "year_8717"
                  },
                  {
                        "id": 8718,
                        "displayName": "year_8718"
                  },
                  {
                        "id": 8719,
                        "displayName": "year_8719"
                  },
                  {
                        "id": 8720,
                        "displayName": "year_8720"
                  },
                  {
                        "id": 8721,
                        "displayName": "year_8721"
                  },
                  {
                        "id": 8722,
                        "displayName": "year_8722"
                  },
                  {
                        "id": 8723,
                        "displayName": "year_8723"
                  },
                  {
                        "id": 8724,
                        "displayName": "year_8724"
                  },
                  {
                        "id": 8725,
                        "displayName": "year_8725"
                  },
                  {
                        "id": 8726,
                        "displayName": "year_8726"
                  },
                  {
                        "id": 8727,
                        "displayName": "year_8727"
                  },
                  {
                        "id": 8728,
                        "displayName": "year_8728"
                  },
                  {
                        "id": 8729,
                        "displayName": "year_8729"
                  },
                  {
                        "id": 8730,
                        "displayName": "year_8730"
                  },
                  {
                        "id": 8731,
                        "displayName": "year_8731"
                  },
                  {
                        "id": 8732,
                        "displayName": "year_8732"
                  },
                  {
                        "id": 8733,
                        "displayName": "year_8733"
                  },
                  {
                        "id": 8734,
                        "displayName": "year_8734"
                  },
                  {
                        "id": 8735,
                        "displayName": "year_8735"
                  },
                  {
                        "id": 8736,
                        "displayName": "year_8736"
                  },
                  {
                        "id": 8737,
                        "displayName": "year_8737"
                  },
                  {
                        "id": 8738,
                        "displayName": "year_8738"
                  },
                  {
                        "id": 8739,
                        "displayName": "year_8739"
                  },
                  {
                        "id": 8740,
                        "displayName": "year_8740"
                  },
                  {
                        "id": 8741,
                        "displayName": "year_8741"
                  },
                  {
                        "id": 8742,
                        "displayName": "year_8742"
                  },
                  {
                        "id": 8743,
                        "displayName": "year_8743"
                  },
                  {
                        "id": 8744,
                        "displayName": "year_8744"
                  },
                  {
                        "id": 8745,
                        "displayName": "year_8745"
                  },
                  {
                        "id": 8746,
                        "displayName": "year_8746"
                  },
                  {
                        "id": 8747,
                        "displayName": "year_8747"
                  },
                  {
                        "id": 8748,
                        "displayName": "year_8748"
                  },
                  {
                        "id": 8749,
                        "displayName": "year_8749"
                  },
                  {
                        "id": 8750,
                        "displayName": "year_8750"
                  },
                  {
                        "id": 8751,
                        "displayName": "year_8751"
                  },
                  {
                        "id": 8752,
                        "displayName": "year_8752"
                  },
                  {
                        "id": 8753,
                        "displayName": "year_8753"
                  },
                  {
                        "id": 8754,
                        "displayName": "year_8754"
                  },
                  {
                        "id": 8755,
                        "displayName": "year_8755"
                  },
                  {
                        "id": 8756,
                        "displayName": "year_8756"
                  },
                  {
                        "id": 8757,
                        "displayName": "year_8757"
                  },
                  {
                        "id": 8758,
                        "displayName": "year_8758"
                  },
                  {
                        "id": 8759,
                        "displayName": "year_8759"
                  },
                  {
                        "id": 8760,
                        "displayName": "year_8760"
                  },
                  {
                        "id": 8761,
                        "displayName": "year_8761"
                  },
                  {
                        "id": 8762,
                        "displayName": "year_8762"
                  },
                  {
                        "id": 8763,
                        "displayName": "year_8763"
                  },
                  {
                        "id": 8764,
                        "displayName": "year_8764"
                  },
                  {
                        "id": 8765,
                        "displayName": "year_8765"
                  },
                  {
                        "id": 8766,
                        "displayName": "year_8766"
                  },
                  {
                        "id": 8767,
                        "displayName": "year_8767"
                  },
                  {
                        "id": 8768,
                        "displayName": "year_8768"
                  },
                  {
                        "id": 8769,
                        "displayName": "year_8769"
                  },
                  {
                        "id": 8770,
                        "displayName": "year_8770"
                  },
                  {
                        "id": 8771,
                        "displayName": "year_8771"
                  },
                  {
                        "id": 8772,
                        "displayName": "year_8772"
                  },
                  {
                        "id": 8773,
                        "displayName": "year_8773"
                  },
                  {
                        "id": 8774,
                        "displayName": "year_8774"
                  },
                  {
                        "id": 8775,
                        "displayName": "year_8775"
                  },
                  {
                        "id": 8776,
                        "displayName": "year_8776"
                  },
                  {
                        "id": 8777,
                        "displayName": "year_8777"
                  },
                  {
                        "id": 8778,
                        "displayName": "year_8778"
                  },
                  {
                        "id": 8779,
                        "displayName": "year_8779"
                  },
                  {
                        "id": 8780,
                        "displayName": "year_8780"
                  },
                  {
                        "id": 8781,
                        "displayName": "year_8781"
                  },
                  {
                        "id": 8782,
                        "displayName": "year_8782"
                  },
                  {
                        "id": 8783,
                        "displayName": "year_8783"
                  },
                  {
                        "id": 8784,
                        "displayName": "year_8784"
                  },
                  {
                        "id": 8785,
                        "displayName": "year_8785"
                  },
                  {
                        "id": 8786,
                        "displayName": "year_8786"
                  },
                  {
                        "id": 8787,
                        "displayName": "year_8787"
                  },
                  {
                        "id": 8788,
                        "displayName": "year_8788"
                  },
                  {
                        "id": 8789,
                        "displayName": "year_8789"
                  },
                  {
                        "id": 8790,
                        "displayName": "year_8790"
                  },
                  {
                        "id": 8791,
                        "displayName": "year_8791"
                  },
                  {
                        "id": 8792,
                        "displayName": "year_8792"
                  },
                  {
                        "id": 8793,
                        "displayName": "year_8793"
                  },
                  {
                        "id": 8794,
                        "displayName": "year_8794"
                  },
                  {
                        "id": 8795,
                        "displayName": "year_8795"
                  },
                  {
                        "id": 8796,
                        "displayName": "year_8796"
                  },
                  {
                        "id": 8797,
                        "displayName": "year_8797"
                  },
                  {
                        "id": 8798,
                        "displayName": "year_8798"
                  },
                  {
                        "id": 8799,
                        "displayName": "year_8799"
                  },
                  {
                        "id": 8800,
                        "displayName": "year_8800"
                  },
                  {
                        "id": 8801,
                        "displayName": "year_8801"
                  },
                  {
                        "id": 8802,
                        "displayName": "year_8802"
                  },
                  {
                        "id": 8803,
                        "displayName": "year_8803"
                  },
                  {
                        "id": 8804,
                        "displayName": "year_8804"
                  },
                  {
                        "id": 8805,
                        "displayName": "year_8805"
                  },
                  {
                        "id": 8806,
                        "displayName": "year_8806"
                  },
                  {
                        "id": 8807,
                        "displayName": "year_8807"
                  },
                  {
                        "id": 8808,
                        "displayName": "year_8808"
                  },
                  {
                        "id": 8809,
                        "displayName": "year_8809"
                  },
                  {
                        "id": 8810,
                        "displayName": "year_8810"
                  },
                  {
                        "id": 8811,
                        "displayName": "year_8811"
                  },
                  {
                        "id": 8812,
                        "displayName": "year_8812"
                  },
                  {
                        "id": 8813,
                        "displayName": "year_8813"
                  },
                  {
                        "id": 8814,
                        "displayName": "year_8814"
                  },
                  {
                        "id": 8815,
                        "displayName": "year_8815"
                  },
                  {
                        "id": 8816,
                        "displayName": "year_8816"
                  },
                  {
                        "id": 8817,
                        "displayName": "year_8817"
                  },
                  {
                        "id": 8818,
                        "displayName": "year_8818"
                  },
                  {
                        "id": 8819,
                        "displayName": "year_8819"
                  },
                  {
                        "id": 8820,
                        "displayName": "year_8820"
                  },
                  {
                        "id": 8821,
                        "displayName": "year_8821"
                  },
                  {
                        "id": 8822,
                        "displayName": "year_8822"
                  },
                  {
                        "id": 8823,
                        "displayName": "year_8823"
                  },
                  {
                        "id": 8824,
                        "displayName": "year_8824"
                  },
                  {
                        "id": 8825,
                        "displayName": "year_8825"
                  },
                  {
                        "id": 8826,
                        "displayName": "year_8826"
                  },
                  {
                        "id": 8827,
                        "displayName": "year_8827"
                  },
                  {
                        "id": 8828,
                        "displayName": "year_8828"
                  },
                  {
                        "id": 8829,
                        "displayName": "year_8829"
                  },
                  {
                        "id": 8830,
                        "displayName": "year_8830"
                  },
                  {
                        "id": 8831,
                        "displayName": "year_8831"
                  },
                  {
                        "id": 8832,
                        "displayName": "year_8832"
                  },
                  {
                        "id": 8833,
                        "displayName": "year_8833"
                  },
                  {
                        "id": 8834,
                        "displayName": "year_8834"
                  },
                  {
                        "id": 8835,
                        "displayName": "year_8835"
                  },
                  {
                        "id": 8836,
                        "displayName": "year_8836"
                  },
                  {
                        "id": 8837,
                        "displayName": "year_8837"
                  },
                  {
                        "id": 8838,
                        "displayName": "year_8838"
                  },
                  {
                        "id": 8839,
                        "displayName": "year_8839"
                  },
                  {
                        "id": 8840,
                        "displayName": "year_8840"
                  },
                  {
                        "id": 8841,
                        "displayName": "year_8841"
                  },
                  {
                        "id": 8842,
                        "displayName": "year_8842"
                  },
                  {
                        "id": 8843,
                        "displayName": "year_8843"
                  },
                  {
                        "id": 8844,
                        "displayName": "year_8844"
                  },
                  {
                        "id": 8845,
                        "displayName": "year_8845"
                  },
                  {
                        "id": 8846,
                        "displayName": "year_8846"
                  },
                  {
                        "id": 8847,
                        "displayName": "year_8847"
                  },
                  {
                        "id": 8848,
                        "displayName": "year_8848"
                  },
                  {
                        "id": 8849,
                        "displayName": "year_8849"
                  },
                  {
                        "id": 8850,
                        "displayName": "year_8850"
                  },
                  {
                        "id": 8851,
                        "displayName": "year_8851"
                  },
                  {
                        "id": 8852,
                        "displayName": "year_8852"
                  },
                  {
                        "id": 8853,
                        "displayName": "year_8853"
                  },
                  {
                        "id": 8854,
                        "displayName": "year_8854"
                  },
                  {
                        "id": 8855,
                        "displayName": "year_8855"
                  },
                  {
                        "id": 8856,
                        "displayName": "year_8856"
                  },
                  {
                        "id": 8857,
                        "displayName": "year_8857"
                  },
                  {
                        "id": 8858,
                        "displayName": "year_8858"
                  },
                  {
                        "id": 8859,
                        "displayName": "year_8859"
                  },
                  {
                        "id": 8860,
                        "displayName": "year_8860"
                  },
                  {
                        "id": 8861,
                        "displayName": "year_8861"
                  },
                  {
                        "id": 8862,
                        "displayName": "year_8862"
                  },
                  {
                        "id": 8863,
                        "displayName": "year_8863"
                  },
                  {
                        "id": 8864,
                        "displayName": "year_8864"
                  },
                  {
                        "id": 8865,
                        "displayName": "year_8865"
                  },
                  {
                        "id": 8866,
                        "displayName": "year_8866"
                  },
                  {
                        "id": 8867,
                        "displayName": "year_8867"
                  },
                  {
                        "id": 8868,
                        "displayName": "year_8868"
                  },
                  {
                        "id": 8869,
                        "displayName": "year_8869"
                  },
                  {
                        "id": 8870,
                        "displayName": "year_8870"
                  },
                  {
                        "id": 8871,
                        "displayName": "year_8871"
                  },
                  {
                        "id": 8872,
                        "displayName": "year_8872"
                  },
                  {
                        "id": 8873,
                        "displayName": "year_8873"
                  },
                  {
                        "id": 8874,
                        "displayName": "year_8874"
                  },
                  {
                        "id": 8875,
                        "displayName": "year_8875"
                  },
                  {
                        "id": 8876,
                        "displayName": "year_8876"
                  },
                  {
                        "id": 8877,
                        "displayName": "year_8877"
                  },
                  {
                        "id": 8878,
                        "displayName": "year_8878"
                  },
                  {
                        "id": 8879,
                        "displayName": "year_8879"
                  },
                  {
                        "id": 8880,
                        "displayName": "year_8880"
                  },
                  {
                        "id": 8881,
                        "displayName": "year_8881"
                  },
                  {
                        "id": 8882,
                        "displayName": "year_8882"
                  },
                  {
                        "id": 8883,
                        "displayName": "year_8883"
                  },
                  {
                        "id": 8884,
                        "displayName": "year_8884"
                  },
                  {
                        "id": 8885,
                        "displayName": "year_8885"
                  },
                  {
                        "id": 8886,
                        "displayName": "year_8886"
                  },
                  {
                        "id": 8887,
                        "displayName": "year_8887"
                  },
                  {
                        "id": 8888,
                        "displayName": "year_8888"
                  },
                  {
                        "id": 8889,
                        "displayName": "year_8889"
                  },
                  {
                        "id": 8890,
                        "displayName": "year_8890"
                  },
                  {
                        "id": 8891,
                        "displayName": "year_8891"
                  },
                  {
                        "id": 8892,
                        "displayName": "year_8892"
                  },
                  {
                        "id": 8893,
                        "displayName": "year_8893"
                  },
                  {
                        "id": 8894,
                        "displayName": "year_8894"
                  },
                  {
                        "id": 8895,
                        "displayName": "year_8895"
                  },
                  {
                        "id": 8896,
                        "displayName": "year_8896"
                  },
                  {
                        "id": 8897,
                        "displayName": "year_8897"
                  },
                  {
                        "id": 8898,
                        "displayName": "year_8898"
                  },
                  {
                        "id": 8899,
                        "displayName": "year_8899"
                  },
                  {
                        "id": 8900,
                        "displayName": "year_8900"
                  },
                  {
                        "id": 8901,
                        "displayName": "year_8901"
                  },
                  {
                        "id": 8902,
                        "displayName": "year_8902"
                  },
                  {
                        "id": 8903,
                        "displayName": "year_8903"
                  },
                  {
                        "id": 8904,
                        "displayName": "year_8904"
                  },
                  {
                        "id": 8905,
                        "displayName": "year_8905"
                  },
                  {
                        "id": 8906,
                        "displayName": "year_8906"
                  },
                  {
                        "id": 8907,
                        "displayName": "year_8907"
                  },
                  {
                        "id": 8908,
                        "displayName": "year_8908"
                  },
                  {
                        "id": 8909,
                        "displayName": "year_8909"
                  },
                  {
                        "id": 8910,
                        "displayName": "year_8910"
                  },
                  {
                        "id": 8911,
                        "displayName": "year_8911"
                  },
                  {
                        "id": 8912,
                        "displayName": "year_8912"
                  },
                  {
                        "id": 8913,
                        "displayName": "year_8913"
                  },
                  {
                        "id": 8914,
                        "displayName": "year_8914"
                  },
                  {
                        "id": 8915,
                        "displayName": "year_8915"
                  },
                  {
                        "id": 8916,
                        "displayName": "year_8916"
                  },
                  {
                        "id": 8917,
                        "displayName": "year_8917"
                  },
                  {
                        "id": 8918,
                        "displayName": "year_8918"
                  },
                  {
                        "id": 8919,
                        "displayName": "year_8919"
                  },
                  {
                        "id": 8920,
                        "displayName": "year_8920"
                  },
                  {
                        "id": 8921,
                        "displayName": "year_8921"
                  },
                  {
                        "id": 8922,
                        "displayName": "year_8922"
                  },
                  {
                        "id": 8923,
                        "displayName": "year_8923"
                  },
                  {
                        "id": 8924,
                        "displayName": "year_8924"
                  },
                  {
                        "id": 8925,
                        "displayName": "year_8925"
                  },
                  {
                        "id": 8926,
                        "displayName": "year_8926"
                  },
                  {
                        "id": 8927,
                        "displayName": "year_8927"
                  },
                  {
                        "id": 8928,
                        "displayName": "year_8928"
                  },
                  {
                        "id": 8929,
                        "displayName": "year_8929"
                  },
                  {
                        "id": 8930,
                        "displayName": "year_8930"
                  },
                  {
                        "id": 8931,
                        "displayName": "year_8931"
                  },
                  {
                        "id": 8932,
                        "displayName": "year_8932"
                  },
                  {
                        "id": 8933,
                        "displayName": "year_8933"
                  },
                  {
                        "id": 8934,
                        "displayName": "year_8934"
                  },
                  {
                        "id": 8935,
                        "displayName": "year_8935"
                  },
                  {
                        "id": 8936,
                        "displayName": "year_8936"
                  },
                  {
                        "id": 8937,
                        "displayName": "year_8937"
                  },
                  {
                        "id": 8938,
                        "displayName": "year_8938"
                  },
                  {
                        "id": 8939,
                        "displayName": "year_8939"
                  },
                  {
                        "id": 8940,
                        "displayName": "year_8940"
                  },
                  {
                        "id": 8941,
                        "displayName": "year_8941"
                  },
                  {
                        "id": 8942,
                        "displayName": "year_8942"
                  },
                  {
                        "id": 8943,
                        "displayName": "year_8943"
                  },
                  {
                        "id": 8944,
                        "displayName": "year_8944"
                  },
                  {
                        "id": 8945,
                        "displayName": "year_8945"
                  },
                  {
                        "id": 8946,
                        "displayName": "year_8946"
                  },
                  {
                        "id": 8947,
                        "displayName": "year_8947"
                  },
                  {
                        "id": 8948,
                        "displayName": "year_8948"
                  },
                  {
                        "id": 8949,
                        "displayName": "year_8949"
                  },
                  {
                        "id": 8950,
                        "displayName": "year_8950"
                  },
                  {
                        "id": 8951,
                        "displayName": "year_8951"
                  },
                  {
                        "id": 8952,
                        "displayName": "year_8952"
                  },
                  {
                        "id": 8953,
                        "displayName": "year_8953"
                  },
                  {
                        "id": 8954,
                        "displayName": "year_8954"
                  },
                  {
                        "id": 8955,
                        "displayName": "year_8955"
                  },
                  {
                        "id": 8956,
                        "displayName": "year_8956"
                  },
                  {
                        "id": 8957,
                        "displayName": "year_8957"
                  },
                  {
                        "id": 8958,
                        "displayName": "year_8958"
                  },
                  {
                        "id": 8959,
                        "displayName": "year_8959"
                  },
                  {
                        "id": 8960,
                        "displayName": "year_8960"
                  },
                  {
                        "id": 8961,
                        "displayName": "year_8961"
                  },
                  {
                        "id": 8962,
                        "displayName": "year_8962"
                  },
                  {
                        "id": 8963,
                        "displayName": "year_8963"
                  },
                  {
                        "id": 8964,
                        "displayName": "year_8964"
                  },
                  {
                        "id": 8965,
                        "displayName": "year_8965"
                  },
                  {
                        "id": 8966,
                        "displayName": "year_8966"
                  },
                  {
                        "id": 8967,
                        "displayName": "year_8967"
                  },
                  {
                        "id": 8968,
                        "displayName": "year_8968"
                  },
                  {
                        "id": 8969,
                        "displayName": "year_8969"
                  },
                  {
                        "id": 8970,
                        "displayName": "year_8970"
                  },
                  {
                        "id": 8971,
                        "displayName": "year_8971"
                  },
                  {
                        "id": 8972,
                        "displayName": "year_8972"
                  },
                  {
                        "id": 8973,
                        "displayName": "year_8973"
                  },
                  {
                        "id": 8974,
                        "displayName": "year_8974"
                  },
                  {
                        "id": 8975,
                        "displayName": "year_8975"
                  },
                  {
                        "id": 8976,
                        "displayName": "year_8976"
                  },
                  {
                        "id": 8977,
                        "displayName": "year_8977"
                  },
                  {
                        "id": 8978,
                        "displayName": "year_8978"
                  },
                  {
                        "id": 8979,
                        "displayName": "year_8979"
                  },
                  {
                        "id": 8980,
                        "displayName": "year_8980"
                  },
                  {
                        "id": 8981,
                        "displayName": "year_8981"
                  },
                  {
                        "id": 8982,
                        "displayName": "year_8982"
                  },
                  {
                        "id": 8983,
                        "displayName": "year_8983"
                  },
                  {
                        "id": 8984,
                        "displayName": "year_8984"
                  },
                  {
                        "id": 8985,
                        "displayName": "year_8985"
                  },
                  {
                        "id": 8986,
                        "displayName": "year_8986"
                  },
                  {
                        "id": 8987,
                        "displayName": "year_8987"
                  },
                  {
                        "id": 8988,
                        "displayName": "year_8988"
                  },
                  {
                        "id": 8989,
                        "displayName": "year_8989"
                  },
                  {
                        "id": 8990,
                        "displayName": "year_8990"
                  },
                  {
                        "id": 8991,
                        "displayName": "year_8991"
                  },
                  {
                        "id": 8992,
                        "displayName": "year_8992"
                  },
                  {
                        "id": 8993,
                        "displayName": "year_8993"
                  },
                  {
                        "id": 8994,
                        "displayName": "year_8994"
                  },
                  {
                        "id": 8995,
                        "displayName": "year_8995"
                  },
                  {
                        "id": 8996,
                        "displayName": "year_8996"
                  },
                  {
                        "id": 8997,
                        "displayName": "year_8997"
                  },
                  {
                        "id": 8998,
                        "displayName": "year_8998"
                  },
                  {
                        "id": 8999,
                        "displayName": "year_8999"
                  },
                  {
                        "id": 9000,
                        "displayName": "year_9000"
                  },
                  {
                        "id": 9001,
                        "displayName": "year_9001"
                  },
                  {
                        "id": 9002,
                        "displayName": "year_9002"
                  },
                  {
                        "id": 9003,
                        "displayName": "year_9003"
                  },
                  {
                        "id": 9004,
                        "displayName": "year_9004"
                  },
                  {
                        "id": 9005,
                        "displayName": "year_9005"
                  },
                  {
                        "id": 9006,
                        "displayName": "year_9006"
                  },
                  {
                        "id": 9007,
                        "displayName": "year_9007"
                  },
                  {
                        "id": 9008,
                        "displayName": "year_9008"
                  },
                  {
                        "id": 9009,
                        "displayName": "year_9009"
                  },
                  {
                        "id": 9010,
                        "displayName": "year_9010"
                  },
                  {
                        "id": 9011,
                        "displayName": "year_9011"
                  },
                  {
                        "id": 9012,
                        "displayName": "year_9012"
                  },
                  {
                        "id": 9013,
                        "displayName": "year_9013"
                  },
                  {
                        "id": 9014,
                        "displayName": "year_9014"
                  },
                  {
                        "id": 9015,
                        "displayName": "year_9015"
                  },
                  {
                        "id": 9016,
                        "displayName": "year_9016"
                  },
                  {
                        "id": 9017,
                        "displayName": "year_9017"
                  },
                  {
                        "id": 9018,
                        "displayName": "year_9018"
                  },
                  {
                        "id": 9019,
                        "displayName": "year_9019"
                  },
                  {
                        "id": 9020,
                        "displayName": "year_9020"
                  },
                  {
                        "id": 9021,
                        "displayName": "year_9021"
                  },
                  {
                        "id": 9022,
                        "displayName": "year_9022"
                  },
                  {
                        "id": 9023,
                        "displayName": "year_9023"
                  },
                  {
                        "id": 9024,
                        "displayName": "year_9024"
                  },
                  {
                        "id": 9025,
                        "displayName": "year_9025"
                  },
                  {
                        "id": 9026,
                        "displayName": "year_9026"
                  },
                  {
                        "id": 9027,
                        "displayName": "year_9027"
                  },
                  {
                        "id": 9028,
                        "displayName": "year_9028"
                  },
                  {
                        "id": 9029,
                        "displayName": "year_9029"
                  },
                  {
                        "id": 9030,
                        "displayName": "year_9030"
                  },
                  {
                        "id": 9031,
                        "displayName": "year_9031"
                  },
                  {
                        "id": 9032,
                        "displayName": "year_9032"
                  },
                  {
                        "id": 9033,
                        "displayName": "year_9033"
                  },
                  {
                        "id": 9034,
                        "displayName": "year_9034"
                  },
                  {
                        "id": 9035,
                        "displayName": "year_9035"
                  },
                  {
                        "id": 9036,
                        "displayName": "year_9036"
                  },
                  {
                        "id": 9037,
                        "displayName": "year_9037"
                  },
                  {
                        "id": 9038,
                        "displayName": "year_9038"
                  },
                  {
                        "id": 9039,
                        "displayName": "year_9039"
                  },
                  {
                        "id": 9040,
                        "displayName": "year_9040"
                  },
                  {
                        "id": 9041,
                        "displayName": "year_9041"
                  },
                  {
                        "id": 9042,
                        "displayName": "year_9042"
                  },
                  {
                        "id": 9043,
                        "displayName": "year_9043"
                  },
                  {
                        "id": 9044,
                        "displayName": "year_9044"
                  },
                  {
                        "id": 9045,
                        "displayName": "year_9045"
                  },
                  {
                        "id": 9046,
                        "displayName": "year_9046"
                  },
                  {
                        "id": 9047,
                        "displayName": "year_9047"
                  },
                  {
                        "id": 9048,
                        "displayName": "year_9048"
                  },
                  {
                        "id": 9049,
                        "displayName": "year_9049"
                  },
                  {
                        "id": 9050,
                        "displayName": "year_9050"
                  },
                  {
                        "id": 9051,
                        "displayName": "year_9051"
                  },
                  {
                        "id": 9052,
                        "displayName": "year_9052"
                  },
                  {
                        "id": 9053,
                        "displayName": "year_9053"
                  },
                  {
                        "id": 9054,
                        "displayName": "year_9054"
                  },
                  {
                        "id": 9055,
                        "displayName": "year_9055"
                  },
                  {
                        "id": 9056,
                        "displayName": "year_9056"
                  },
                  {
                        "id": 9057,
                        "displayName": "year_9057"
                  },
                  {
                        "id": 9058,
                        "displayName": "year_9058"
                  },
                  {
                        "id": 9059,
                        "displayName": "year_9059"
                  },
                  {
                        "id": 9060,
                        "displayName": "year_9060"
                  },
                  {
                        "id": 9061,
                        "displayName": "year_9061"
                  },
                  {
                        "id": 9062,
                        "displayName": "year_9062"
                  },
                  {
                        "id": 9063,
                        "displayName": "year_9063"
                  },
                  {
                        "id": 9064,
                        "displayName": "year_9064"
                  },
                  {
                        "id": 9065,
                        "displayName": "year_9065"
                  },
                  {
                        "id": 9066,
                        "displayName": "year_9066"
                  },
                  {
                        "id": 9067,
                        "displayName": "year_9067"
                  },
                  {
                        "id": 9068,
                        "displayName": "year_9068"
                  },
                  {
                        "id": 9069,
                        "displayName": "year_9069"
                  },
                  {
                        "id": 9070,
                        "displayName": "year_9070"
                  },
                  {
                        "id": 9071,
                        "displayName": "year_9071"
                  },
                  {
                        "id": 9072,
                        "displayName": "year_9072"
                  },
                  {
                        "id": 9073,
                        "displayName": "year_9073"
                  },
                  {
                        "id": 9074,
                        "displayName": "year_9074"
                  },
                  {
                        "id": 9075,
                        "displayName": "year_9075"
                  },
                  {
                        "id": 9076,
                        "displayName": "year_9076"
                  },
                  {
                        "id": 9077,
                        "displayName": "year_9077"
                  },
                  {
                        "id": 9078,
                        "displayName": "year_9078"
                  },
                  {
                        "id": 9079,
                        "displayName": "year_9079"
                  },
                  {
                        "id": 9080,
                        "displayName": "year_9080"
                  },
                  {
                        "id": 9081,
                        "displayName": "year_9081"
                  },
                  {
                        "id": 9082,
                        "displayName": "year_9082"
                  },
                  {
                        "id": 9083,
                        "displayName": "year_9083"
                  },
                  {
                        "id": 9084,
                        "displayName": "year_9084"
                  },
                  {
                        "id": 9085,
                        "displayName": "year_9085"
                  },
                  {
                        "id": 9086,
                        "displayName": "year_9086"
                  },
                  {
                        "id": 9087,
                        "displayName": "year_9087"
                  },
                  {
                        "id": 9088,
                        "displayName": "year_9088"
                  },
                  {
                        "id": 9089,
                        "displayName": "year_9089"
                  },
                  {
                        "id": 9090,
                        "displayName": "year_9090"
                  },
                  {
                        "id": 9091,
                        "displayName": "year_9091"
                  },
                  {
                        "id": 9092,
                        "displayName": "year_9092"
                  },
                  {
                        "id": 9093,
                        "displayName": "year_9093"
                  },
                  {
                        "id": 9094,
                        "displayName": "year_9094"
                  },
                  {
                        "id": 9095,
                        "displayName": "year_9095"
                  },
                  {
                        "id": 9096,
                        "displayName": "year_9096"
                  },
                  {
                        "id": 9097,
                        "displayName": "year_9097"
                  },
                  {
                        "id": 9098,
                        "displayName": "year_9098"
                  },
                  {
                        "id": 9099,
                        "displayName": "year_9099"
                  },
                  {
                        "id": 9100,
                        "displayName": "year_9100"
                  },
                  {
                        "id": 9101,
                        "displayName": "year_9101"
                  },
                  {
                        "id": 9102,
                        "displayName": "year_9102"
                  },
                  {
                        "id": 9103,
                        "displayName": "year_9103"
                  },
                  {
                        "id": 9104,
                        "displayName": "year_9104"
                  },
                  {
                        "id": 9105,
                        "displayName": "year_9105"
                  },
                  {
                        "id": 9106,
                        "displayName": "year_9106"
                  },
                  {
                        "id": 9107,
                        "displayName": "year_9107"
                  },
                  {
                        "id": 9108,
                        "displayName": "year_9108"
                  },
                  {
                        "id": 9109,
                        "displayName": "year_9109"
                  },
                  {
                        "id": 9110,
                        "displayName": "year_9110"
                  },
                  {
                        "id": 9111,
                        "displayName": "year_9111"
                  },
                  {
                        "id": 9112,
                        "displayName": "year_9112"
                  },
                  {
                        "id": 9113,
                        "displayName": "year_9113"
                  },
                  {
                        "id": 9114,
                        "displayName": "year_9114"
                  },
                  {
                        "id": 9115,
                        "displayName": "year_9115"
                  },
                  {
                        "id": 9116,
                        "displayName": "year_9116"
                  },
                  {
                        "id": 9117,
                        "displayName": "year_9117"
                  },
                  {
                        "id": 9118,
                        "displayName": "year_9118"
                  },
                  {
                        "id": 9119,
                        "displayName": "year_9119"
                  },
                  {
                        "id": 9120,
                        "displayName": "year_9120"
                  },
                  {
                        "id": 9121,
                        "displayName": "year_9121"
                  },
                  {
                        "id": 9122,
                        "displayName": "year_9122"
                  },
                  {
                        "id": 9123,
                        "displayName": "year_9123"
                  },
                  {
                        "id": 9124,
                        "displayName": "year_9124"
                  },
                  {
                        "id": 9125,
                        "displayName": "year_9125"
                  },
                  {
                        "id": 9126,
                        "displayName": "year_9126"
                  },
                  {
                        "id": 9127,
                        "displayName": "year_9127"
                  },
                  {
                        "id": 9128,
                        "displayName": "year_9128"
                  },
                  {
                        "id": 9129,
                        "displayName": "year_9129"
                  },
                  {
                        "id": 9130,
                        "displayName": "year_9130"
                  },
                  {
                        "id": 9131,
                        "displayName": "year_9131"
                  },
                  {
                        "id": 9132,
                        "displayName": "year_9132"
                  },
                  {
                        "id": 9133,
                        "displayName": "year_9133"
                  },
                  {
                        "id": 9134,
                        "displayName": "year_9134"
                  },
                  {
                        "id": 9135,
                        "displayName": "year_9135"
                  },
                  {
                        "id": 9136,
                        "displayName": "year_9136"
                  },
                  {
                        "id": 9137,
                        "displayName": "year_9137"
                  },
                  {
                        "id": 9138,
                        "displayName": "year_9138"
                  },
                  {
                        "id": 9139,
                        "displayName": "year_9139"
                  },
                  {
                        "id": 9140,
                        "displayName": "year_9140"
                  },
                  {
                        "id": 9141,
                        "displayName": "year_9141"
                  },
                  {
                        "id": 9142,
                        "displayName": "year_9142"
                  },
                  {
                        "id": 9143,
                        "displayName": "year_9143"
                  },
                  {
                        "id": 9144,
                        "displayName": "year_9144"
                  },
                  {
                        "id": 9145,
                        "displayName": "year_9145"
                  },
                  {
                        "id": 9146,
                        "displayName": "year_9146"
                  },
                  {
                        "id": 9147,
                        "displayName": "year_9147"
                  },
                  {
                        "id": 9148,
                        "displayName": "year_9148"
                  },
                  {
                        "id": 9149,
                        "displayName": "year_9149"
                  },
                  {
                        "id": 9150,
                        "displayName": "year_9150"
                  },
                  {
                        "id": 9151,
                        "displayName": "year_9151"
                  },
                  {
                        "id": 9152,
                        "displayName": "year_9152"
                  },
                  {
                        "id": 9153,
                        "displayName": "year_9153"
                  },
                  {
                        "id": 9154,
                        "displayName": "year_9154"
                  },
                  {
                        "id": 9155,
                        "displayName": "year_9155"
                  },
                  {
                        "id": 9156,
                        "displayName": "year_9156"
                  },
                  {
                        "id": 9157,
                        "displayName": "year_9157"
                  },
                  {
                        "id": 9158,
                        "displayName": "year_9158"
                  },
                  {
                        "id": 9159,
                        "displayName": "year_9159"
                  },
                  {
                        "id": 9160,
                        "displayName": "year_9160"
                  },
                  {
                        "id": 9161,
                        "displayName": "year_9161"
                  },
                  {
                        "id": 9162,
                        "displayName": "year_9162"
                  },
                  {
                        "id": 9163,
                        "displayName": "year_9163"
                  },
                  {
                        "id": 9164,
                        "displayName": "year_9164"
                  },
                  {
                        "id": 9165,
                        "displayName": "year_9165"
                  },
                  {
                        "id": 9166,
                        "displayName": "year_9166"
                  },
                  {
                        "id": 9167,
                        "displayName": "year_9167"
                  },
                  {
                        "id": 9168,
                        "displayName": "year_9168"
                  },
                  {
                        "id": 9169,
                        "displayName": "year_9169"
                  },
                  {
                        "id": 9170,
                        "displayName": "year_9170"
                  },
                  {
                        "id": 9171,
                        "displayName": "year_9171"
                  },
                  {
                        "id": 9172,
                        "displayName": "year_9172"
                  },
                  {
                        "id": 9173,
                        "displayName": "year_9173"
                  },
                  {
                        "id": 9174,
                        "displayName": "year_9174"
                  },
                  {
                        "id": 9175,
                        "displayName": "year_9175"
                  },
                  {
                        "id": 9176,
                        "displayName": "year_9176"
                  },
                  {
                        "id": 9177,
                        "displayName": "year_9177"
                  },
                  {
                        "id": 9178,
                        "displayName": "year_9178"
                  },
                  {
                        "id": 9179,
                        "displayName": "year_9179"
                  },
                  {
                        "id": 9180,
                        "displayName": "year_9180"
                  },
                  {
                        "id": 9181,
                        "displayName": "year_9181"
                  },
                  {
                        "id": 9182,
                        "displayName": "year_9182"
                  },
                  {
                        "id": 9183,
                        "displayName": "year_9183"
                  },
                  {
                        "id": 9184,
                        "displayName": "year_9184"
                  },
                  {
                        "id": 9185,
                        "displayName": "year_9185"
                  },
                  {
                        "id": 9186,
                        "displayName": "year_9186"
                  },
                  {
                        "id": 9187,
                        "displayName": "year_9187"
                  },
                  {
                        "id": 9188,
                        "displayName": "year_9188"
                  },
                  {
                        "id": 9189,
                        "displayName": "year_9189"
                  },
                  {
                        "id": 9190,
                        "displayName": "year_9190"
                  },
                  {
                        "id": 9191,
                        "displayName": "year_9191"
                  },
                  {
                        "id": 9192,
                        "displayName": "year_9192"
                  },
                  {
                        "id": 9193,
                        "displayName": "year_9193"
                  },
                  {
                        "id": 9194,
                        "displayName": "year_9194"
                  },
                  {
                        "id": 9195,
                        "displayName": "year_9195"
                  },
                  {
                        "id": 9196,
                        "displayName": "year_9196"
                  },
                  {
                        "id": 9197,
                        "displayName": "year_9197"
                  },
                  {
                        "id": 9198,
                        "displayName": "year_9198"
                  },
                  {
                        "id": 9199,
                        "displayName": "year_9199"
                  },
                  {
                        "id": 9200,
                        "displayName": "year_9200"
                  },
                  {
                        "id": 9201,
                        "displayName": "year_9201"
                  },
                  {
                        "id": 9202,
                        "displayName": "year_9202"
                  },
                  {
                        "id": 9203,
                        "displayName": "year_9203"
                  },
                  {
                        "id": 9204,
                        "displayName": "year_9204"
                  },
                  {
                        "id": 9205,
                        "displayName": "year_9205"
                  },
                  {
                        "id": 9206,
                        "displayName": "year_9206"
                  },
                  {
                        "id": 9207,
                        "displayName": "year_9207"
                  },
                  {
                        "id": 9208,
                        "displayName": "year_9208"
                  },
                  {
                        "id": 9209,
                        "displayName": "year_9209"
                  },
                  {
                        "id": 9210,
                        "displayName": "year_9210"
                  },
                  {
                        "id": 9211,
                        "displayName": "year_9211"
                  },
                  {
                        "id": 9212,
                        "displayName": "year_9212"
                  },
                  {
                        "id": 9213,
                        "displayName": "year_9213"
                  },
                  {
                        "id": 9214,
                        "displayName": "year_9214"
                  },
                  {
                        "id": 9215,
                        "displayName": "year_9215"
                  },
                  {
                        "id": 9216,
                        "displayName": "year_9216"
                  },
                  {
                        "id": 9217,
                        "displayName": "year_9217"
                  },
                  {
                        "id": 9218,
                        "displayName": "year_9218"
                  },
                  {
                        "id": 9219,
                        "displayName": "year_9219"
                  },
                  {
                        "id": 9220,
                        "displayName": "year_9220"
                  },
                  {
                        "id": 9221,
                        "displayName": "year_9221"
                  },
                  {
                        "id": 9222,
                        "displayName": "year_9222"
                  },
                  {
                        "id": 9223,
                        "displayName": "year_9223"
                  },
                  {
                        "id": 9224,
                        "displayName": "year_9224"
                  },
                  {
                        "id": 9225,
                        "displayName": "year_9225"
                  },
                  {
                        "id": 9226,
                        "displayName": "year_9226"
                  },
                  {
                        "id": 9227,
                        "displayName": "year_9227"
                  },
                  {
                        "id": 9228,
                        "displayName": "year_9228"
                  },
                  {
                        "id": 9229,
                        "displayName": "year_9229"
                  },
                  {
                        "id": 9230,
                        "displayName": "year_9230"
                  },
                  {
                        "id": 9231,
                        "displayName": "year_9231"
                  },
                  {
                        "id": 9232,
                        "displayName": "year_9232"
                  },
                  {
                        "id": 9233,
                        "displayName": "year_9233"
                  },
                  {
                        "id": 9234,
                        "displayName": "year_9234"
                  },
                  {
                        "id": 9235,
                        "displayName": "year_9235"
                  },
                  {
                        "id": 9236,
                        "displayName": "year_9236"
                  },
                  {
                        "id": 9237,
                        "displayName": "year_9237"
                  },
                  {
                        "id": 9238,
                        "displayName": "year_9238"
                  },
                  {
                        "id": 9239,
                        "displayName": "year_9239"
                  },
                  {
                        "id": 9240,
                        "displayName": "year_9240"
                  },
                  {
                        "id": 9241,
                        "displayName": "year_9241"
                  },
                  {
                        "id": 9242,
                        "displayName": "year_9242"
                  },
                  {
                        "id": 9243,
                        "displayName": "year_9243"
                  },
                  {
                        "id": 9244,
                        "displayName": "year_9244"
                  },
                  {
                        "id": 9245,
                        "displayName": "year_9245"
                  },
                  {
                        "id": 9246,
                        "displayName": "year_9246"
                  },
                  {
                        "id": 9247,
                        "displayName": "year_9247"
                  },
                  {
                        "id": 9248,
                        "displayName": "year_9248"
                  },
                  {
                        "id": 9249,
                        "displayName": "year_9249"
                  },
                  {
                        "id": 9250,
                        "displayName": "year_9250"
                  },
                  {
                        "id": 9251,
                        "displayName": "year_9251"
                  },
                  {
                        "id": 9252,
                        "displayName": "year_9252"
                  },
                  {
                        "id": 9253,
                        "displayName": "year_9253"
                  },
                  {
                        "id": 9254,
                        "displayName": "year_9254"
                  },
                  {
                        "id": 9255,
                        "displayName": "year_9255"
                  },
                  {
                        "id": 9256,
                        "displayName": "year_9256"
                  },
                  {
                        "id": 9257,
                        "displayName": "year_9257"
                  },
                  {
                        "id": 9258,
                        "displayName": "year_9258"
                  },
                  {
                        "id": 9259,
                        "displayName": "year_9259"
                  },
                  {
                        "id": 9260,
                        "displayName": "year_9260"
                  },
                  {
                        "id": 9261,
                        "displayName": "year_9261"
                  },
                  {
                        "id": 9262,
                        "displayName": "year_9262"
                  },
                  {
                        "id": 9263,
                        "displayName": "year_9263"
                  },
                  {
                        "id": 9264,
                        "displayName": "year_9264"
                  },
                  {
                        "id": 9265,
                        "displayName": "year_9265"
                  },
                  {
                        "id": 9266,
                        "displayName": "year_9266"
                  },
                  {
                        "id": 9267,
                        "displayName": "year_9267"
                  },
                  {
                        "id": 9268,
                        "displayName": "year_9268"
                  },
                  {
                        "id": 9269,
                        "displayName": "year_9269"
                  },
                  {
                        "id": 9270,
                        "displayName": "year_9270"
                  },
                  {
                        "id": 9271,
                        "displayName": "year_9271"
                  },
                  {
                        "id": 9272,
                        "displayName": "year_9272"
                  },
                  {
                        "id": 9273,
                        "displayName": "year_9273"
                  },
                  {
                        "id": 9274,
                        "displayName": "year_9274"
                  },
                  {
                        "id": 9275,
                        "displayName": "year_9275"
                  },
                  {
                        "id": 9276,
                        "displayName": "year_9276"
                  },
                  {
                        "id": 9277,
                        "displayName": "year_9277"
                  },
                  {
                        "id": 9278,
                        "displayName": "year_9278"
                  },
                  {
                        "id": 9279,
                        "displayName": "year_9279"
                  },
                  {
                        "id": 9280,
                        "displayName": "year_9280"
                  },
                  {
                        "id": 9281,
                        "displayName": "year_9281"
                  },
                  {
                        "id": 9282,
                        "displayName": "year_9282"
                  },
                  {
                        "id": 9283,
                        "displayName": "year_9283"
                  },
                  {
                        "id": 9284,
                        "displayName": "year_9284"
                  },
                  {
                        "id": 9285,
                        "displayName": "year_9285"
                  },
                  {
                        "id": 9286,
                        "displayName": "year_9286"
                  },
                  {
                        "id": 9287,
                        "displayName": "year_9287"
                  },
                  {
                        "id": 9288,
                        "displayName": "year_9288"
                  },
                  {
                        "id": 9289,
                        "displayName": "year_9289"
                  },
                  {
                        "id": 9290,
                        "displayName": "year_9290"
                  },
                  {
                        "id": 9291,
                        "displayName": "year_9291"
                  },
                  {
                        "id": 9292,
                        "displayName": "year_9292"
                  },
                  {
                        "id": 9293,
                        "displayName": "year_9293"
                  },
                  {
                        "id": 9294,
                        "displayName": "year_9294"
                  },
                  {
                        "id": 9295,
                        "displayName": "year_9295"
                  },
                  {
                        "id": 9296,
                        "displayName": "year_9296"
                  },
                  {
                        "id": 9297,
                        "displayName": "year_9297"
                  },
                  {
                        "id": 9298,
                        "displayName": "year_9298"
                  },
                  {
                        "id": 9299,
                        "displayName": "year_9299"
                  },
                  {
                        "id": 9300,
                        "displayName": "year_9300"
                  },
                  {
                        "id": 9301,
                        "displayName": "year_9301"
                  },
                  {
                        "id": 9302,
                        "displayName": "year_9302"
                  },
                  {
                        "id": 9303,
                        "displayName": "year_9303"
                  },
                  {
                        "id": 9304,
                        "displayName": "year_9304"
                  },
                  {
                        "id": 9305,
                        "displayName": "year_9305"
                  },
                  {
                        "id": 9306,
                        "displayName": "year_9306"
                  },
                  {
                        "id": 9307,
                        "displayName": "year_9307"
                  },
                  {
                        "id": 9308,
                        "displayName": "year_9308"
                  },
                  {
                        "id": 9309,
                        "displayName": "year_9309"
                  },
                  {
                        "id": 9310,
                        "displayName": "year_9310"
                  },
                  {
                        "id": 9311,
                        "displayName": "year_9311"
                  },
                  {
                        "id": 9312,
                        "displayName": "year_9312"
                  },
                  {
                        "id": 9313,
                        "displayName": "year_9313"
                  },
                  {
                        "id": 9314,
                        "displayName": "year_9314"
                  },
                  {
                        "id": 9315,
                        "displayName": "year_9315"
                  },
                  {
                        "id": 9316,
                        "displayName": "year_9316"
                  },
                  {
                        "id": 9317,
                        "displayName": "year_9317"
                  },
                  {
                        "id": 9318,
                        "displayName": "year_9318"
                  },
                  {
                        "id": 9319,
                        "displayName": "year_9319"
                  },
                  {
                        "id": 9320,
                        "displayName": "year_9320"
                  },
                  {
                        "id": 9321,
                        "displayName": "year_9321"
                  },
                  {
                        "id": 9322,
                        "displayName": "year_9322"
                  },
                  {
                        "id": 9323,
                        "displayName": "year_9323"
                  },
                  {
                        "id": 9324,
                        "displayName": "year_9324"
                  },
                  {
                        "id": 9325,
                        "displayName": "year_9325"
                  },
                  {
                        "id": 9326,
                        "displayName": "year_9326"
                  },
                  {
                        "id": 9327,
                        "displayName": "year_9327"
                  },
                  {
                        "id": 9328,
                        "displayName": "year_9328"
                  },
                  {
                        "id": 9329,
                        "displayName": "year_9329"
                  },
                  {
                        "id": 9330,
                        "displayName": "year_9330"
                  },
                  {
                        "id": 9331,
                        "displayName": "year_9331"
                  },
                  {
                        "id": 9332,
                        "displayName": "year_9332"
                  },
                  {
                        "id": 9333,
                        "displayName": "year_9333"
                  },
                  {
                        "id": 9334,
                        "displayName": "year_9334"
                  },
                  {
                        "id": 9335,
                        "displayName": "year_9335"
                  },
                  {
                        "id": 9336,
                        "displayName": "year_9336"
                  },
                  {
                        "id": 9337,
                        "displayName": "year_9337"
                  },
                  {
                        "id": 9338,
                        "displayName": "year_9338"
                  },
                  {
                        "id": 9339,
                        "displayName": "year_9339"
                  },
                  {
                        "id": 9340,
                        "displayName": "year_9340"
                  },
                  {
                        "id": 9341,
                        "displayName": "year_9341"
                  },
                  {
                        "id": 9342,
                        "displayName": "year_9342"
                  },
                  {
                        "id": 9343,
                        "displayName": "year_9343"
                  },
                  {
                        "id": 9344,
                        "displayName": "year_9344"
                  },
                  {
                        "id": 9345,
                        "displayName": "year_9345"
                  },
                  {
                        "id": 9346,
                        "displayName": "year_9346"
                  },
                  {
                        "id": 9347,
                        "displayName": "year_9347"
                  },
                  {
                        "id": 9348,
                        "displayName": "year_9348"
                  },
                  {
                        "id": 9349,
                        "displayName": "year_9349"
                  },
                  {
                        "id": 9350,
                        "displayName": "year_9350"
                  },
                  {
                        "id": 9351,
                        "displayName": "year_9351"
                  },
                  {
                        "id": 9352,
                        "displayName": "year_9352"
                  },
                  {
                        "id": 9353,
                        "displayName": "year_9353"
                  },
                  {
                        "id": 9354,
                        "displayName": "year_9354"
                  },
                  {
                        "id": 9355,
                        "displayName": "year_9355"
                  },
                  {
                        "id": 9356,
                        "displayName": "year_9356"
                  },
                  {
                        "id": 9357,
                        "displayName": "year_9357"
                  },
                  {
                        "id": 9358,
                        "displayName": "year_9358"
                  },
                  {
                        "id": 9359,
                        "displayName": "year_9359"
                  },
                  {
                        "id": 9360,
                        "displayName": "year_9360"
                  },
                  {
                        "id": 9361,
                        "displayName": "year_9361"
                  },
                  {
                        "id": 9362,
                        "displayName": "year_9362"
                  },
                  {
                        "id": 9363,
                        "displayName": "year_9363"
                  },
                  {
                        "id": 9364,
                        "displayName": "year_9364"
                  },
                  {
                        "id": 9365,
                        "displayName": "year_9365"
                  },
                  {
                        "id": 9366,
                        "displayName": "year_9366"
                  },
                  {
                        "id": 9367,
                        "displayName": "year_9367"
                  },
                  {
                        "id": 9368,
                        "displayName": "year_9368"
                  },
                  {
                        "id": 9369,
                        "displayName": "year_9369"
                  },
                  {
                        "id": 9370,
                        "displayName": "year_9370"
                  },
                  {
                        "id": 9371,
                        "displayName": "year_9371"
                  },
                  {
                        "id": 9372,
                        "displayName": "year_9372"
                  },
                  {
                        "id": 9373,
                        "displayName": "year_9373"
                  },
                  {
                        "id": 9374,
                        "displayName": "year_9374"
                  },
                  {
                        "id": 9375,
                        "displayName": "year_9375"
                  },
                  {
                        "id": 9376,
                        "displayName": "year_9376"
                  },
                  {
                        "id": 9377,
                        "displayName": "year_9377"
                  },
                  {
                        "id": 9378,
                        "displayName": "year_9378"
                  },
                  {
                        "id": 9379,
                        "displayName": "year_9379"
                  },
                  {
                        "id": 9380,
                        "displayName": "year_9380"
                  },
                  {
                        "id": 9381,
                        "displayName": "year_9381"
                  },
                  {
                        "id": 9382,
                        "displayName": "year_9382"
                  },
                  {
                        "id": 9383,
                        "displayName": "year_9383"
                  },
                  {
                        "id": 9384,
                        "displayName": "year_9384"
                  },
                  {
                        "id": 9385,
                        "displayName": "year_9385"
                  },
                  {
                        "id": 9386,
                        "displayName": "year_9386"
                  },
                  {
                        "id": 9387,
                        "displayName": "year_9387"
                  },
                  {
                        "id": 9388,
                        "displayName": "year_9388"
                  },
                  {
                        "id": 9389,
                        "displayName": "year_9389"
                  },
                  {
                        "id": 9390,
                        "displayName": "year_9390"
                  },
                  {
                        "id": 9391,
                        "displayName": "year_9391"
                  },
                  {
                        "id": 9392,
                        "displayName": "year_9392"
                  },
                  {
                        "id": 9393,
                        "displayName": "year_9393"
                  },
                  {
                        "id": 9394,
                        "displayName": "year_9394"
                  },
                  {
                        "id": 9395,
                        "displayName": "year_9395"
                  },
                  {
                        "id": 9396,
                        "displayName": "year_9396"
                  },
                  {
                        "id": 9397,
                        "displayName": "year_9397"
                  },
                  {
                        "id": 9398,
                        "displayName": "year_9398"
                  },
                  {
                        "id": 9399,
                        "displayName": "year_9399"
                  },
                  {
                        "id": 9400,
                        "displayName": "year_9400"
                  },
                  {
                        "id": 9401,
                        "displayName": "year_9401"
                  },
                  {
                        "id": 9402,
                        "displayName": "year_9402"
                  },
                  {
                        "id": 9403,
                        "displayName": "year_9403"
                  },
                  {
                        "id": 9404,
                        "displayName": "year_9404"
                  },
                  {
                        "id": 9405,
                        "displayName": "year_9405"
                  },
                  {
                        "id": 9406,
                        "displayName": "year_9406"
                  },
                  {
                        "id": 9407,
                        "displayName": "year_9407"
                  },
                  {
                        "id": 9408,
                        "displayName": "year_9408"
                  },
                  {
                        "id": 9409,
                        "displayName": "year_9409"
                  },
                  {
                        "id": 9410,
                        "displayName": "year_9410"
                  },
                  {
                        "id": 9411,
                        "displayName": "year_9411"
                  },
                  {
                        "id": 9412,
                        "displayName": "year_9412"
                  },
                  {
                        "id": 9413,
                        "displayName": "year_9413"
                  },
                  {
                        "id": 9414,
                        "displayName": "year_9414"
                  },
                  {
                        "id": 9415,
                        "displayName": "year_9415"
                  },
                  {
                        "id": 9416,
                        "displayName": "year_9416"
                  },
                  {
                        "id": 9417,
                        "displayName": "year_9417"
                  },
                  {
                        "id": 9418,
                        "displayName": "year_9418"
                  },
                  {
                        "id": 9419,
                        "displayName": "year_9419"
                  },
                  {
                        "id": 9420,
                        "displayName": "year_9420"
                  },
                  {
                        "id": 9421,
                        "displayName": "year_9421"
                  },
                  {
                        "id": 9422,
                        "displayName": "year_9422"
                  },
                  {
                        "id": 9423,
                        "displayName": "year_9423"
                  },
                  {
                        "id": 9424,
                        "displayName": "year_9424"
                  },
                  {
                        "id": 9425,
                        "displayName": "year_9425"
                  },
                  {
                        "id": 9426,
                        "displayName": "year_9426"
                  },
                  {
                        "id": 9427,
                        "displayName": "year_9427"
                  },
                  {
                        "id": 9428,
                        "displayName": "year_9428"
                  },
                  {
                        "id": 9429,
                        "displayName": "year_9429"
                  },
                  {
                        "id": 9430,
                        "displayName": "year_9430"
                  },
                  {
                        "id": 9431,
                        "displayName": "year_9431"
                  },
                  {
                        "id": 9432,
                        "displayName": "year_9432"
                  },
                  {
                        "id": 9433,
                        "displayName": "year_9433"
                  },
                  {
                        "id": 9434,
                        "displayName": "year_9434"
                  },
                  {
                        "id": 9435,
                        "displayName": "year_9435"
                  },
                  {
                        "id": 9436,
                        "displayName": "year_9436"
                  },
                  {
                        "id": 9437,
                        "displayName": "year_9437"
                  },
                  {
                        "id": 9438,
                        "displayName": "year_9438"
                  },
                  {
                        "id": 9439,
                        "displayName": "year_9439"
                  },
                  {
                        "id": 9440,
                        "displayName": "year_9440"
                  },
                  {
                        "id": 9441,
                        "displayName": "year_9441"
                  },
                  {
                        "id": 9442,
                        "displayName": "year_9442"
                  },
                  {
                        "id": 9443,
                        "displayName": "year_9443"
                  },
                  {
                        "id": 9444,
                        "displayName": "year_9444"
                  },
                  {
                        "id": 9445,
                        "displayName": "year_9445"
                  },
                  {
                        "id": 9446,
                        "displayName": "year_9446"
                  },
                  {
                        "id": 9447,
                        "displayName": "year_9447"
                  },
                  {
                        "id": 9448,
                        "displayName": "year_9448"
                  },
                  {
                        "id": 9449,
                        "displayName": "year_9449"
                  },
                  {
                        "id": 9450,
                        "displayName": "year_9450"
                  },
                  {
                        "id": 9451,
                        "displayName": "year_9451"
                  },
                  {
                        "id": 9452,
                        "displayName": "year_9452"
                  },
                  {
                        "id": 9453,
                        "displayName": "year_9453"
                  },
                  {
                        "id": 9454,
                        "displayName": "year_9454"
                  },
                  {
                        "id": 9455,
                        "displayName": "year_9455"
                  },
                  {
                        "id": 9456,
                        "displayName": "year_9456"
                  },
                  {
                        "id": 9457,
                        "displayName": "year_9457"
                  },
                  {
                        "id": 9458,
                        "displayName": "year_9458"
                  },
                  {
                        "id": 9459,
                        "displayName": "year_9459"
                  },
                  {
                        "id": 9460,
                        "displayName": "year_9460"
                  },
                  {
                        "id": 9461,
                        "displayName": "year_9461"
                  },
                  {
                        "id": 9462,
                        "displayName": "year_9462"
                  },
                  {
                        "id": 9463,
                        "displayName": "year_9463"
                  },
                  {
                        "id": 9464,
                        "displayName": "year_9464"
                  },
                  {
                        "id": 9465,
                        "displayName": "year_9465"
                  },
                  {
                        "id": 9466,
                        "displayName": "year_9466"
                  },
                  {
                        "id": 9467,
                        "displayName": "year_9467"
                  },
                  {
                        "id": 9468,
                        "displayName": "year_9468"
                  },
                  {
                        "id": 9469,
                        "displayName": "year_9469"
                  },
                  {
                        "id": 9470,
                        "displayName": "year_9470"
                  },
                  {
                        "id": 9471,
                        "displayName": "year_9471"
                  },
                  {
                        "id": 9472,
                        "displayName": "year_9472"
                  },
                  {
                        "id": 9473,
                        "displayName": "year_9473"
                  },
                  {
                        "id": 9474,
                        "displayName": "year_9474"
                  },
                  {
                        "id": 9475,
                        "displayName": "year_9475"
                  },
                  {
                        "id": 9476,
                        "displayName": "year_9476"
                  },
                  {
                        "id": 9477,
                        "displayName": "year_9477"
                  },
                  {
                        "id": 9478,
                        "displayName": "year_9478"
                  },
                  {
                        "id": 9479,
                        "displayName": "year_9479"
                  },
                  {
                        "id": 9480,
                        "displayName": "year_9480"
                  },
                  {
                        "id": 9481,
                        "displayName": "year_9481"
                  },
                  {
                        "id": 9482,
                        "displayName": "year_9482"
                  },
                  {
                        "id": 9483,
                        "displayName": "year_9483"
                  },
                  {
                        "id": 9484,
                        "displayName": "year_9484"
                  },
                  {
                        "id": 9485,
                        "displayName": "year_9485"
                  },
                  {
                        "id": 9486,
                        "displayName": "year_9486"
                  },
                  {
                        "id": 9487,
                        "displayName": "year_9487"
                  },
                  {
                        "id": 9488,
                        "displayName": "year_9488"
                  },
                  {
                        "id": 9489,
                        "displayName": "year_9489"
                  },
                  {
                        "id": 9490,
                        "displayName": "year_9490"
                  },
                  {
                        "id": 9491,
                        "displayName": "year_9491"
                  },
                  {
                        "id": 9492,
                        "displayName": "year_9492"
                  },
                  {
                        "id": 9493,
                        "displayName": "year_9493"
                  },
                  {
                        "id": 9494,
                        "displayName": "year_9494"
                  },
                  {
                        "id": 9495,
                        "displayName": "year_9495"
                  },
                  {
                        "id": 9496,
                        "displayName": "year_9496"
                  },
                  {
                        "id": 9497,
                        "displayName": "year_9497"
                  },
                  {
                        "id": 9498,
                        "displayName": "year_9498"
                  },
                  {
                        "id": 9499,
                        "displayName": "year_9499"
                  },
                  {
                        "id": 9500,
                        "displayName": "year_9500"
                  },
                  {
                        "id": 9501,
                        "displayName": "year_9501"
                  },
                  {
                        "id": 9502,
                        "displayName": "year_9502"
                  },
                  {
                        "id": 9503,
                        "displayName": "year_9503"
                  },
                  {
                        "id": 9504,
                        "displayName": "year_9504"
                  },
                  {
                        "id": 9505,
                        "displayName": "year_9505"
                  },
                  {
                        "id": 9506,
                        "displayName": "year_9506"
                  },
                  {
                        "id": 9507,
                        "displayName": "year_9507"
                  },
                  {
                        "id": 9508,
                        "displayName": "year_9508"
                  },
                  {
                        "id": 9509,
                        "displayName": "year_9509"
                  },
                  {
                        "id": 9510,
                        "displayName": "year_9510"
                  },
                  {
                        "id": 9511,
                        "displayName": "year_9511"
                  },
                  {
                        "id": 9512,
                        "displayName": "year_9512"
                  },
                  {
                        "id": 9513,
                        "displayName": "year_9513"
                  },
                  {
                        "id": 9514,
                        "displayName": "year_9514"
                  },
                  {
                        "id": 9515,
                        "displayName": "year_9515"
                  },
                  {
                        "id": 9516,
                        "displayName": "year_9516"
                  },
                  {
                        "id": 9517,
                        "displayName": "year_9517"
                  },
                  {
                        "id": 9518,
                        "displayName": "year_9518"
                  },
                  {
                        "id": 9519,
                        "displayName": "year_9519"
                  },
                  {
                        "id": 9520,
                        "displayName": "year_9520"
                  },
                  {
                        "id": 9521,
                        "displayName": "year_9521"
                  },
                  {
                        "id": 9522,
                        "displayName": "year_9522"
                  },
                  {
                        "id": 9523,
                        "displayName": "year_9523"
                  },
                  {
                        "id": 9524,
                        "displayName": "year_9524"
                  },
                  {
                        "id": 9525,
                        "displayName": "year_9525"
                  },
                  {
                        "id": 9526,
                        "displayName": "year_9526"
                  },
                  {
                        "id": 9527,
                        "displayName": "year_9527"
                  },
                  {
                        "id": 9528,
                        "displayName": "year_9528"
                  },
                  {
                        "id": 9529,
                        "displayName": "year_9529"
                  },
                  {
                        "id": 9530,
                        "displayName": "year_9530"
                  },
                  {
                        "id": 9531,
                        "displayName": "year_9531"
                  },
                  {
                        "id": 9532,
                        "displayName": "year_9532"
                  },
                  {
                        "id": 9533,
                        "displayName": "year_9533"
                  },
                  {
                        "id": 9534,
                        "displayName": "year_9534"
                  },
                  {
                        "id": 9535,
                        "displayName": "year_9535"
                  },
                  {
                        "id": 9536,
                        "displayName": "year_9536"
                  },
                  {
                        "id": 9537,
                        "displayName": "year_9537"
                  },
                  {
                        "id": 9538,
                        "displayName": "year_9538"
                  },
                  {
                        "id": 9539,
                        "displayName": "year_9539"
                  },
                  {
                        "id": 9540,
                        "displayName": "year_9540"
                  },
                  {
                        "id": 9541,
                        "displayName": "year_9541"
                  },
                  {
                        "id": 9542,
                        "displayName": "year_9542"
                  },
                  {
                        "id": 9543,
                        "displayName": "year_9543"
                  },
                  {
                        "id": 9544,
                        "displayName": "year_9544"
                  },
                  {
                        "id": 9545,
                        "displayName": "year_9545"
                  },
                  {
                        "id": 9546,
                        "displayName": "year_9546"
                  },
                  {
                        "id": 9547,
                        "displayName": "year_9547"
                  },
                  {
                        "id": 9548,
                        "displayName": "year_9548"
                  },
                  {
                        "id": 9549,
                        "displayName": "year_9549"
                  },
                  {
                        "id": 9550,
                        "displayName": "year_9550"
                  },
                  {
                        "id": 9551,
                        "displayName": "year_9551"
                  },
                  {
                        "id": 9552,
                        "displayName": "year_9552"
                  },
                  {
                        "id": 9553,
                        "displayName": "year_9553"
                  },
                  {
                        "id": 9554,
                        "displayName": "year_9554"
                  },
                  {
                        "id": 9555,
                        "displayName": "year_9555"
                  },
                  {
                        "id": 9556,
                        "displayName": "year_9556"
                  },
                  {
                        "id": 9557,
                        "displayName": "year_9557"
                  },
                  {
                        "id": 9558,
                        "displayName": "year_9558"
                  },
                  {
                        "id": 9559,
                        "displayName": "year_9559"
                  },
                  {
                        "id": 9560,
                        "displayName": "year_9560"
                  },
                  {
                        "id": 9561,
                        "displayName": "year_9561"
                  },
                  {
                        "id": 9562,
                        "displayName": "year_9562"
                  },
                  {
                        "id": 9563,
                        "displayName": "year_9563"
                  },
                  {
                        "id": 9564,
                        "displayName": "year_9564"
                  },
                  {
                        "id": 9565,
                        "displayName": "year_9565"
                  },
                  {
                        "id": 9566,
                        "displayName": "year_9566"
                  },
                  {
                        "id": 9567,
                        "displayName": "year_9567"
                  },
                  {
                        "id": 9568,
                        "displayName": "year_9568"
                  },
                  {
                        "id": 9569,
                        "displayName": "year_9569"
                  },
                  {
                        "id": 9570,
                        "displayName": "year_9570"
                  },
                  {
                        "id": 9571,
                        "displayName": "year_9571"
                  },
                  {
                        "id": 9572,
                        "displayName": "year_9572"
                  },
                  {
                        "id": 9573,
                        "displayName": "year_9573"
                  },
                  {
                        "id": 9574,
                        "displayName": "year_9574"
                  },
                  {
                        "id": 9575,
                        "displayName": "year_9575"
                  },
                  {
                        "id": 9576,
                        "displayName": "year_9576"
                  },
                  {
                        "id": 9577,
                        "displayName": "year_9577"
                  },
                  {
                        "id": 9578,
                        "displayName": "year_9578"
                  },
                  {
                        "id": 9579,
                        "displayName": "year_9579"
                  },
                  {
                        "id": 9580,
                        "displayName": "year_9580"
                  },
                  {
                        "id": 9581,
                        "displayName": "year_9581"
                  },
                  {
                        "id": 9582,
                        "displayName": "year_9582"
                  },
                  {
                        "id": 9583,
                        "displayName": "year_9583"
                  },
                  {
                        "id": 9584,
                        "displayName": "year_9584"
                  },
                  {
                        "id": 9585,
                        "displayName": "year_9585"
                  },
                  {
                        "id": 9586,
                        "displayName": "year_9586"
                  },
                  {
                        "id": 9587,
                        "displayName": "year_9587"
                  },
                  {
                        "id": 9588,
                        "displayName": "year_9588"
                  },
                  {
                        "id": 9589,
                        "displayName": "year_9589"
                  },
                  {
                        "id": 9590,
                        "displayName": "year_9590"
                  },
                  {
                        "id": 9591,
                        "displayName": "year_9591"
                  },
                  {
                        "id": 9592,
                        "displayName": "year_9592"
                  },
                  {
                        "id": 9593,
                        "displayName": "year_9593"
                  },
                  {
                        "id": 9594,
                        "displayName": "year_9594"
                  },
                  {
                        "id": 9595,
                        "displayName": "year_9595"
                  },
                  {
                        "id": 9596,
                        "displayName": "year_9596"
                  },
                  {
                        "id": 9597,
                        "displayName": "year_9597"
                  },
                  {
                        "id": 9598,
                        "displayName": "year_9598"
                  },
                  {
                        "id": 9599,
                        "displayName": "year_9599"
                  },
                  {
                        "id": 9600,
                        "displayName": "year_9600"
                  },
                  {
                        "id": 9601,
                        "displayName": "year_9601"
                  },
                  {
                        "id": 9602,
                        "displayName": "year_9602"
                  },
                  {
                        "id": 9603,
                        "displayName": "year_9603"
                  },
                  {
                        "id": 9604,
                        "displayName": "year_9604"
                  },
                  {
                        "id": 9605,
                        "displayName": "year_9605"
                  },
                  {
                        "id": 9606,
                        "displayName": "year_9606"
                  },
                  {
                        "id": 9607,
                        "displayName": "year_9607"
                  },
                  {
                        "id": 9608,
                        "displayName": "year_9608"
                  },
                  {
                        "id": 9609,
                        "displayName": "year_9609"
                  },
                  {
                        "id": 9610,
                        "displayName": "year_9610"
                  },
                  {
                        "id": 9611,
                        "displayName": "year_9611"
                  },
                  {
                        "id": 9612,
                        "displayName": "year_9612"
                  },
                  {
                        "id": 9613,
                        "displayName": "year_9613"
                  },
                  {
                        "id": 9614,
                        "displayName": "year_9614"
                  },
                  {
                        "id": 9615,
                        "displayName": "year_9615"
                  },
                  {
                        "id": 9616,
                        "displayName": "year_9616"
                  },
                  {
                        "id": 9617,
                        "displayName": "year_9617"
                  },
                  {
                        "id": 9618,
                        "displayName": "year_9618"
                  },
                  {
                        "id": 9619,
                        "displayName": "year_9619"
                  },
                  {
                        "id": 9620,
                        "displayName": "year_9620"
                  },
                  {
                        "id": 9621,
                        "displayName": "year_9621"
                  },
                  {
                        "id": 9622,
                        "displayName": "year_9622"
                  },
                  {
                        "id": 9623,
                        "displayName": "year_9623"
                  },
                  {
                        "id": 9624,
                        "displayName": "year_9624"
                  },
                  {
                        "id": 9625,
                        "displayName": "year_9625"
                  },
                  {
                        "id": 9626,
                        "displayName": "year_9626"
                  },
                  {
                        "id": 9627,
                        "displayName": "year_9627"
                  },
                  {
                        "id": 9628,
                        "displayName": "year_9628"
                  },
                  {
                        "id": 9629,
                        "displayName": "year_9629"
                  },
                  {
                        "id": 9630,
                        "displayName": "year_9630"
                  },
                  {
                        "id": 9631,
                        "displayName": "year_9631"
                  },
                  {
                        "id": 9632,
                        "displayName": "year_9632"
                  },
                  {
                        "id": 9633,
                        "displayName": "year_9633"
                  },
                  {
                        "id": 9634,
                        "displayName": "year_9634"
                  },
                  {
                        "id": 9635,
                        "displayName": "year_9635"
                  },
                  {
                        "id": 9636,
                        "displayName": "year_9636"
                  },
                  {
                        "id": 9637,
                        "displayName": "year_9637"
                  },
                  {
                        "id": 9638,
                        "displayName": "year_9638"
                  },
                  {
                        "id": 9639,
                        "displayName": "year_9639"
                  },
                  {
                        "id": 9640,
                        "displayName": "year_9640"
                  },
                  {
                        "id": 9641,
                        "displayName": "year_9641"
                  },
                  {
                        "id": 9642,
                        "displayName": "year_9642"
                  },
                  {
                        "id": 9643,
                        "displayName": "year_9643"
                  },
                  {
                        "id": 9644,
                        "displayName": "year_9644"
                  },
                  {
                        "id": 9645,
                        "displayName": "year_9645"
                  },
                  {
                        "id": 9646,
                        "displayName": "year_9646"
                  },
                  {
                        "id": 9647,
                        "displayName": "year_9647"
                  },
                  {
                        "id": 9648,
                        "displayName": "year_9648"
                  },
                  {
                        "id": 9649,
                        "displayName": "year_9649"
                  },
                  {
                        "id": 9650,
                        "displayName": "year_9650"
                  },
                  {
                        "id": 9651,
                        "displayName": "year_9651"
                  },
                  {
                        "id": 9652,
                        "displayName": "year_9652"
                  },
                  {
                        "id": 9653,
                        "displayName": "year_9653"
                  },
                  {
                        "id": 9654,
                        "displayName": "year_9654"
                  },
                  {
                        "id": 9655,
                        "displayName": "year_9655"
                  },
                  {
                        "id": 9656,
                        "displayName": "year_9656"
                  },
                  {
                        "id": 9657,
                        "displayName": "year_9657"
                  },
                  {
                        "id": 9658,
                        "displayName": "year_9658"
                  },
                  {
                        "id": 9659,
                        "displayName": "year_9659"
                  },
                  {
                        "id": 9660,
                        "displayName": "year_9660"
                  },
                  {
                        "id": 9661,
                        "displayName": "year_9661"
                  },
                  {
                        "id": 9662,
                        "displayName": "year_9662"
                  },
                  {
                        "id": 9663,
                        "displayName": "year_9663"
                  },
                  {
                        "id": 9664,
                        "displayName": "year_9664"
                  },
                  {
                        "id": 9665,
                        "displayName": "year_9665"
                  },
                  {
                        "id": 9666,
                        "displayName": "year_9666"
                  },
                  {
                        "id": 9667,
                        "displayName": "year_9667"
                  },
                  {
                        "id": 9668,
                        "displayName": "year_9668"
                  },
                  {
                        "id": 9669,
                        "displayName": "year_9669"
                  },
                  {
                        "id": 9670,
                        "displayName": "year_9670"
                  },
                  {
                        "id": 9671,
                        "displayName": "year_9671"
                  },
                  {
                        "id": 9672,
                        "displayName": "year_9672"
                  },
                  {
                        "id": 9673,
                        "displayName": "year_9673"
                  },
                  {
                        "id": 9674,
                        "displayName": "year_9674"
                  },
                  {
                        "id": 9675,
                        "displayName": "year_9675"
                  },
                  {
                        "id": 9676,
                        "displayName": "year_9676"
                  },
                  {
                        "id": 9677,
                        "displayName": "year_9677"
                  },
                  {
                        "id": 9678,
                        "displayName": "year_9678"
                  },
                  {
                        "id": 9679,
                        "displayName": "year_9679"
                  },
                  {
                        "id": 9680,
                        "displayName": "year_9680"
                  },
                  {
                        "id": 9681,
                        "displayName": "year_9681"
                  },
                  {
                        "id": 9682,
                        "displayName": "year_9682"
                  },
                  {
                        "id": 9683,
                        "displayName": "year_9683"
                  },
                  {
                        "id": 9684,
                        "displayName": "year_9684"
                  },
                  {
                        "id": 9685,
                        "displayName": "year_9685"
                  },
                  {
                        "id": 9686,
                        "displayName": "year_9686"
                  },
                  {
                        "id": 9687,
                        "displayName": "year_9687"
                  },
                  {
                        "id": 9688,
                        "displayName": "year_9688"
                  },
                  {
                        "id": 9689,
                        "displayName": "year_9689"
                  },
                  {
                        "id": 9690,
                        "displayName": "year_9690"
                  },
                  {
                        "id": 9691,
                        "displayName": "year_9691"
                  },
                  {
                        "id": 9692,
                        "displayName": "year_9692"
                  },
                  {
                        "id": 9693,
                        "displayName": "year_9693"
                  },
                  {
                        "id": 9694,
                        "displayName": "year_9694"
                  },
                  {
                        "id": 9695,
                        "displayName": "year_9695"
                  },
                  {
                        "id": 9696,
                        "displayName": "year_9696"
                  },
                  {
                        "id": 9697,
                        "displayName": "year_9697"
                  },
                  {
                        "id": 9698,
                        "displayName": "year_9698"
                  },
                  {
                        "id": 9699,
                        "displayName": "year_9699"
                  },
                  {
                        "id": 9700,
                        "displayName": "year_9700"
                  },
                  {
                        "id": 9701,
                        "displayName": "year_9701"
                  },
                  {
                        "id": 9702,
                        "displayName": "year_9702"
                  },
                  {
                        "id": 9703,
                        "displayName": "year_9703"
                  },
                  {
                        "id": 9704,
                        "displayName": "year_9704"
                  },
                  {
                        "id": 9705,
                        "displayName": "year_9705"
                  },
                  {
                        "id": 9706,
                        "displayName": "year_9706"
                  },
                  {
                        "id": 9707,
                        "displayName": "year_9707"
                  },
                  {
                        "id": 9708,
                        "displayName": "year_9708"
                  },
                  {
                        "id": 9709,
                        "displayName": "year_9709"
                  },
                  {
                        "id": 9710,
                        "displayName": "year_9710"
                  },
                  {
                        "id": 9711,
                        "displayName": "year_9711"
                  },
                  {
                        "id": 9712,
                        "displayName": "year_9712"
                  },
                  {
                        "id": 9713,
                        "displayName": "year_9713"
                  },
                  {
                        "id": 9714,
                        "displayName": "year_9714"
                  },
                  {
                        "id": 9715,
                        "displayName": "year_9715"
                  },
                  {
                        "id": 9716,
                        "displayName": "year_9716"
                  },
                  {
                        "id": 9717,
                        "displayName": "year_9717"
                  },
                  {
                        "id": 9718,
                        "displayName": "year_9718"
                  },
                  {
                        "id": 9719,
                        "displayName": "year_9719"
                  },
                  {
                        "id": 9720,
                        "displayName": "year_9720"
                  },
                  {
                        "id": 9721,
                        "displayName": "year_9721"
                  },
                  {
                        "id": 9722,
                        "displayName": "year_9722"
                  },
                  {
                        "id": 9723,
                        "displayName": "year_9723"
                  },
                  {
                        "id": 9724,
                        "displayName": "year_9724"
                  },
                  {
                        "id": 9725,
                        "displayName": "year_9725"
                  },
                  {
                        "id": 9726,
                        "displayName": "year_9726"
                  },
                  {
                        "id": 9727,
                        "displayName": "year_9727"
                  },
                  {
                        "id": 9728,
                        "displayName": "year_9728"
                  },
                  {
                        "id": 9729,
                        "displayName": "year_9729"
                  },
                  {
                        "id": 9730,
                        "displayName": "year_9730"
                  },
                  {
                        "id": 9731,
                        "displayName": "year_9731"
                  },
                  {
                        "id": 9732,
                        "displayName": "year_9732"
                  },
                  {
                        "id": 9733,
                        "displayName": "year_9733"
                  },
                  {
                        "id": 9734,
                        "displayName": "year_9734"
                  },
                  {
                        "id": 9735,
                        "displayName": "year_9735"
                  },
                  {
                        "id": 9736,
                        "displayName": "year_9736"
                  },
                  {
                        "id": 9737,
                        "displayName": "year_9737"
                  },
                  {
                        "id": 9738,
                        "displayName": "year_9738"
                  },
                  {
                        "id": 9739,
                        "displayName": "year_9739"
                  },
                  {
                        "id": 9740,
                        "displayName": "year_9740"
                  },
                  {
                        "id": 9741,
                        "displayName": "year_9741"
                  },
                  {
                        "id": 9742,
                        "displayName": "year_9742"
                  },
                  {
                        "id": 9743,
                        "displayName": "year_9743"
                  },
                  {
                        "id": 9744,
                        "displayName": "year_9744"
                  },
                  {
                        "id": 9745,
                        "displayName": "year_9745"
                  },
                  {
                        "id": 9746,
                        "displayName": "year_9746"
                  },
                  {
                        "id": 9747,
                        "displayName": "year_9747"
                  },
                  {
                        "id": 9748,
                        "displayName": "year_9748"
                  },
                  {
                        "id": 9749,
                        "displayName": "year_9749"
                  },
                  {
                        "id": 9750,
                        "displayName": "year_9750"
                  },
                  {
                        "id": 9751,
                        "displayName": "year_9751"
                  },
                  {
                        "id": 9752,
                        "displayName": "year_9752"
                  },
                  {
                        "id": 9753,
                        "displayName": "year_9753"
                  },
                  {
                        "id": 9754,
                        "displayName": "year_9754"
                  },
                  {
                        "id": 9755,
                        "displayName": "year_9755"
                  },
                  {
                        "id": 9756,
                        "displayName": "year_9756"
                  },
                  {
                        "id": 9757,
                        "displayName": "year_9757"
                  },
                  {
                        "id": 9758,
                        "displayName": "year_9758"
                  },
                  {
                        "id": 9759,
                        "displayName": "year_9759"
                  },
                  {
                        "id": 9760,
                        "displayName": "year_9760"
                  },
                  {
                        "id": 9761,
                        "displayName": "year_9761"
                  },
                  {
                        "id": 9762,
                        "displayName": "year_9762"
                  },
                  {
                        "id": 9763,
                        "displayName": "year_9763"
                  },
                  {
                        "id": 9764,
                        "displayName": "year_9764"
                  },
                  {
                        "id": 9765,
                        "displayName": "year_9765"
                  },
                  {
                        "id": 9766,
                        "displayName": "year_9766"
                  },
                  {
                        "id": 9767,
                        "displayName": "year_9767"
                  },
                  {
                        "id": 9768,
                        "displayName": "year_9768"
                  },
                  {
                        "id": 9769,
                        "displayName": "year_9769"
                  },
                  {
                        "id": 9770,
                        "displayName": "year_9770"
                  },
                  {
                        "id": 9771,
                        "displayName": "year_9771"
                  },
                  {
                        "id": 9772,
                        "displayName": "year_9772"
                  },
                  {
                        "id": 9773,
                        "displayName": "year_9773"
                  },
                  {
                        "id": 9774,
                        "displayName": "year_9774"
                  },
                  {
                        "id": 9775,
                        "displayName": "year_9775"
                  },
                  {
                        "id": 9776,
                        "displayName": "year_9776"
                  },
                  {
                        "id": 9777,
                        "displayName": "year_9777"
                  },
                  {
                        "id": 9778,
                        "displayName": "year_9778"
                  },
                  {
                        "id": 9779,
                        "displayName": "year_9779"
                  },
                  {
                        "id": 9780,
                        "displayName": "year_9780"
                  },
                  {
                        "id": 9781,
                        "displayName": "year_9781"
                  },
                  {
                        "id": 9782,
                        "displayName": "year_9782"
                  },
                  {
                        "id": 9783,
                        "displayName": "year_9783"
                  },
                  {
                        "id": 9784,
                        "displayName": "year_9784"
                  },
                  {
                        "id": 9785,
                        "displayName": "year_9785"
                  },
                  {
                        "id": 9786,
                        "displayName": "year_9786"
                  },
                  {
                        "id": 9787,
                        "displayName": "year_9787"
                  },
                  {
                        "id": 9788,
                        "displayName": "year_9788"
                  },
                  {
                        "id": 9789,
                        "displayName": "year_9789"
                  },
                  {
                        "id": 9790,
                        "displayName": "year_9790"
                  },
                  {
                        "id": 9791,
                        "displayName": "year_9791"
                  },
                  {
                        "id": 9792,
                        "displayName": "year_9792"
                  },
                  {
                        "id": 9793,
                        "displayName": "year_9793"
                  },
                  {
                        "id": 9794,
                        "displayName": "year_9794"
                  },
                  {
                        "id": 9795,
                        "displayName": "year_9795"
                  },
                  {
                        "id": 9796,
                        "displayName": "year_9796"
                  },
                  {
                        "id": 9797,
                        "displayName": "year_9797"
                  },
                  {
                        "id": 9798,
                        "displayName": "year_9798"
                  },
                  {
                        "id": 9799,
                        "displayName": "year_9799"
                  },
                  {
                        "id": 9800,
                        "displayName": "year_9800"
                  },
                  {
                        "id": 9801,
                        "displayName": "year_9801"
                  },
                  {
                        "id": 9802,
                        "displayName": "year_9802"
                  },
                  {
                        "id": 9803,
                        "displayName": "year_9803"
                  },
                  {
                        "id": 9804,
                        "displayName": "year_9804"
                  },
                  {
                        "id": 9805,
                        "displayName": "year_9805"
                  },
                  {
                        "id": 9806,
                        "displayName": "year_9806"
                  },
                  {
                        "id": 9807,
                        "displayName": "year_9807"
                  },
                  {
                        "id": 9808,
                        "displayName": "year_9808"
                  },
                  {
                        "id": 9809,
                        "displayName": "year_9809"
                  },
                  {
                        "id": 9810,
                        "displayName": "year_9810"
                  },
                  {
                        "id": 9811,
                        "displayName": "year_9811"
                  },
                  {
                        "id": 9812,
                        "displayName": "year_9812"
                  },
                  {
                        "id": 9813,
                        "displayName": "year_9813"
                  },
                  {
                        "id": 9814,
                        "displayName": "year_9814"
                  },
                  {
                        "id": 9815,
                        "displayName": "year_9815"
                  },
                  {
                        "id": 9816,
                        "displayName": "year_9816"
                  },
                  {
                        "id": 9817,
                        "displayName": "year_9817"
                  },
                  {
                        "id": 9818,
                        "displayName": "year_9818"
                  },
                  {
                        "id": 9819,
                        "displayName": "year_9819"
                  },
                  {
                        "id": 9820,
                        "displayName": "year_9820"
                  },
                  {
                        "id": 9821,
                        "displayName": "year_9821"
                  },
                  {
                        "id": 9822,
                        "displayName": "year_9822"
                  },
                  {
                        "id": 9823,
                        "displayName": "year_9823"
                  },
                  {
                        "id": 9824,
                        "displayName": "year_9824"
                  },
                  {
                        "id": 9825,
                        "displayName": "year_9825"
                  },
                  {
                        "id": 9826,
                        "displayName": "year_9826"
                  },
                  {
                        "id": 9827,
                        "displayName": "year_9827"
                  },
                  {
                        "id": 9828,
                        "displayName": "year_9828"
                  },
                  {
                        "id": 9829,
                        "displayName": "year_9829"
                  },
                  {
                        "id": 9830,
                        "displayName": "year_9830"
                  },
                  {
                        "id": 9831,
                        "displayName": "year_9831"
                  },
                  {
                        "id": 9832,
                        "displayName": "year_9832"
                  },
                  {
                        "id": 9833,
                        "displayName": "year_9833"
                  },
                  {
                        "id": 9834,
                        "displayName": "year_9834"
                  },
                  {
                        "id": 9835,
                        "displayName": "year_9835"
                  },
                  {
                        "id": 9836,
                        "displayName": "year_9836"
                  },
                  {
                        "id": 9837,
                        "displayName": "year_9837"
                  },
                  {
                        "id": 9838,
                        "displayName": "year_9838"
                  },
                  {
                        "id": 9839,
                        "displayName": "year_9839"
                  },
                  {
                        "id": 9840,
                        "displayName": "year_9840"
                  },
                  {
                        "id": 9841,
                        "displayName": "year_9841"
                  },
                  {
                        "id": 9842,
                        "displayName": "year_9842"
                  },
                  {
                        "id": 9843,
                        "displayName": "year_9843"
                  },
                  {
                        "id": 9844,
                        "displayName": "year_9844"
                  },
                  {
                        "id": 9845,
                        "displayName": "year_9845"
                  },
                  {
                        "id": 9846,
                        "displayName": "year_9846"
                  },
                  {
                        "id": 9847,
                        "displayName": "year_9847"
                  },
                  {
                        "id": 9848,
                        "displayName": "year_9848"
                  },
                  {
                        "id": 9849,
                        "displayName": "year_9849"
                  },
                  {
                        "id": 9850,
                        "displayName": "year_9850"
                  },
                  {
                        "id": 9851,
                        "displayName": "year_9851"
                  },
                  {
                        "id": 9852,
                        "displayName": "year_9852"
                  },
                  {
                        "id": 9853,
                        "displayName": "year_9853"
                  },
                  {
                        "id": 9854,
                        "displayName": "year_9854"
                  },
                  {
                        "id": 9855,
                        "displayName": "year_9855"
                  },
                  {
                        "id": 9856,
                        "displayName": "year_9856"
                  },
                  {
                        "id": 9857,
                        "displayName": "year_9857"
                  },
                  {
                        "id": 9858,
                        "displayName": "year_9858"
                  },
                  {
                        "id": 9859,
                        "displayName": "year_9859"
                  },
                  {
                        "id": 9860,
                        "displayName": "year_9860"
                  },
                  {
                        "id": 9861,
                        "displayName": "year_9861"
                  },
                  {
                        "id": 9862,
                        "displayName": "year_9862"
                  },
                  {
                        "id": 9863,
                        "displayName": "year_9863"
                  },
                  {
                        "id": 9864,
                        "displayName": "year_9864"
                  },
                  {
                        "id": 9865,
                        "displayName": "year_9865"
                  },
                  {
                        "id": 9866,
                        "displayName": "year_9866"
                  },
                  {
                        "id": 9867,
                        "displayName": "year_9867"
                  },
                  {
                        "id": 9868,
                        "displayName": "year_9868"
                  },
                  {
                        "id": 9869,
                        "displayName": "year_9869"
                  },
                  {
                        "id": 9870,
                        "displayName": "year_9870"
                  },
                  {
                        "id": 9871,
                        "displayName": "year_9871"
                  },
                  {
                        "id": 9872,
                        "displayName": "year_9872"
                  },
                  {
                        "id": 9873,
                        "displayName": "year_9873"
                  },
                  {
                        "id": 9874,
                        "displayName": "year_9874"
                  },
                  {
                        "id": 9875,
                        "displayName": "year_9875"
                  },
                  {
                        "id": 9876,
                        "displayName": "year_9876"
                  },
                  {
                        "id": 9877,
                        "displayName": "year_9877"
                  },
                  {
                        "id": 9878,
                        "displayName": "year_9878"
                  },
                  {
                        "id": 9879,
                        "displayName": "year_9879"
                  },
                  {
                        "id": 9880,
                        "displayName": "year_9880"
                  },
                  {
                        "id": 9881,
                        "displayName": "year_9881"
                  },
                  {
                        "id": 9882,
                        "displayName": "year_9882"
                  },
                  {
                        "id": 9883,
                        "displayName": "year_9883"
                  },
                  {
                        "id": 9884,
                        "displayName": "year_9884"
                  },
                  {
                        "id": 9885,
                        "displayName": "year_9885"
                  },
                  {
                        "id": 9886,
                        "displayName": "year_9886"
                  },
                  {
                        "id": 9887,
                        "displayName": "year_9887"
                  },
                  {
                        "id": 9888,
                        "displayName": "year_9888"
                  },
                  {
                        "id": 9889,
                        "displayName": "year_9889"
                  },
                  {
                        "id": 9890,
                        "displayName": "year_9890"
                  },
                  {
                        "id": 9891,
                        "displayName": "year_9891"
                  },
                  {
                        "id": 9892,
                        "displayName": "year_9892"
                  },
                  {
                        "id": 9893,
                        "displayName": "year_9893"
                  },
                  {
                        "id": 9894,
                        "displayName": "year_9894"
                  },
                  {
                        "id": 9895,
                        "displayName": "year_9895"
                  },
                  {
                        "id": 9896,
                        "displayName": "year_9896"
                  },
                  {
                        "id": 9897,
                        "displayName": "year_9897"
                  },
                  {
                        "id": 9898,
                        "displayName": "year_9898"
                  },
                  {
                        "id": 9899,
                        "displayName": "year_9899"
                  },
                  {
                        "id": 9900,
                        "displayName": "year_9900"
                  },
                  {
                        "id": 9901,
                        "displayName": "year_9901"
                  },
                  {
                        "id": 9902,
                        "displayName": "year_9902"
                  },
                  {
                        "id": 9903,
                        "displayName": "year_9903"
                  },
                  {
                        "id": 9904,
                        "displayName": "year_9904"
                  },
                  {
                        "id": 9905,
                        "displayName": "year_9905"
                  },
                  {
                        "id": 9906,
                        "displayName": "year_9906"
                  },
                  {
                        "id": 9907,
                        "displayName": "year_9907"
                  },
                  {
                        "id": 9908,
                        "displayName": "year_9908"
                  },
                  {
                        "id": 9909,
                        "displayName": "year_9909"
                  },
                  {
                        "id": 9910,
                        "displayName": "year_9910"
                  },
                  {
                        "id": 9911,
                        "displayName": "year_9911"
                  },
                  {
                        "id": 9912,
                        "displayName": "year_9912"
                  },
                  {
                        "id": 9913,
                        "displayName": "year_9913"
                  },
                  {
                        "id": 9914,
                        "displayName": "year_9914"
                  },
                  {
                        "id": 9915,
                        "displayName": "year_9915"
                  },
                  {
                        "id": 9916,
                        "displayName": "year_9916"
                  },
                  {
                        "id": 9917,
                        "displayName": "year_9917"
                  },
                  {
                        "id": 9918,
                        "displayName": "year_9918"
                  },
                  {
                        "id": 9919,
                        "displayName": "year_9919"
                  },
                  {
                        "id": 9920,
                        "displayName": "year_9920"
                  },
                  {
                        "id": 9921,
                        "displayName": "year_9921"
                  },
                  {
                        "id": 9922,
                        "displayName": "year_9922"
                  },
                  {
                        "id": 9923,
                        "displayName": "year_9923"
                  },
                  {
                        "id": 9924,
                        "displayName": "year_9924"
                  },
                  {
                        "id": 9925,
                        "displayName": "year_9925"
                  },
                  {
                        "id": 9926,
                        "displayName": "year_9926"
                  },
                  {
                        "id": 9927,
                        "displayName": "year_9927"
                  },
                  {
                        "id": 9928,
                        "displayName": "year_9928"
                  },
                  {
                        "id": 9929,
                        "displayName": "year_9929"
                  },
                  {
                        "id": 9930,
                        "displayName": "year_9930"
                  },
                  {
                        "id": 9931,
                        "displayName": "year_9931"
                  },
                  {
                        "id": 9932,
                        "displayName": "year_9932"
                  },
                  {
                        "id": 9933,
                        "displayName": "year_9933"
                  },
                  {
                        "id": 9934,
                        "displayName": "year_9934"
                  },
                  {
                        "id": 9935,
                        "displayName": "year_9935"
                  },
                  {
                        "id": 9936,
                        "displayName": "year_9936"
                  },
                  {
                        "id": 9937,
                        "displayName": "year_9937"
                  },
                  {
                        "id": 9938,
                        "displayName": "year_9938"
                  },
                  {
                        "id": 9939,
                        "displayName": "year_9939"
                  },
                  {
                        "id": 9940,
                        "displayName": "year_9940"
                  },
                  {
                        "id": 9941,
                        "displayName": "year_9941"
                  },
                  {
                        "id": 9942,
                        "displayName": "year_9942"
                  },
                  {
                        "id": 9943,
                        "displayName": "year_9943"
                  },
                  {
                        "id": 9944,
                        "displayName": "year_9944"
                  },
                  {
                        "id": 9945,
                        "displayName": "year_9945"
                  },
                  {
                        "id": 9946,
                        "displayName": "year_9946"
                  },
                  {
                        "id": 9947,
                        "displayName": "year_9947"
                  },
                  {
                        "id": 9948,
                        "displayName": "year_9948"
                  },
                  {
                        "id": 9949,
                        "displayName": "year_9949"
                  },
                  {
                        "id": 9950,
                        "displayName": "year_9950"
                  },
                  {
                        "id": 9951,
                        "displayName": "year_9951"
                  },
                  {
                        "id": 9952,
                        "displayName": "year_9952"
                  },
                  {
                        "id": 9953,
                        "displayName": "year_9953"
                  },
                  {
                        "id": 9954,
                        "displayName": "year_9954"
                  },
                  {
                        "id": 9955,
                        "displayName": "year_9955"
                  },
                  {
                        "id": 9956,
                        "displayName": "year_9956"
                  },
                  {
                        "id": 9957,
                        "displayName": "year_9957"
                  },
                  {
                        "id": 9958,
                        "displayName": "year_9958"
                  },
                  {
                        "id": 9959,
                        "displayName": "year_9959"
                  },
                  {
                        "id": 9960,
                        "displayName": "year_9960"
                  },
                  {
                        "id": 9961,
                        "displayName": "year_9961"
                  },
                  {
                        "id": 9962,
                        "displayName": "year_9962"
                  },
                  {
                        "id": 9963,
                        "displayName": "year_9963"
                  },
                  {
                        "id": 9964,
                        "displayName": "year_9964"
                  },
                  {
                        "id": 9965,
                        "displayName": "year_9965"
                  },
                  {
                        "id": 9966,
                        "displayName": "year_9966"
                  },
                  {
                        "id": 9967,
                        "displayName": "year_9967"
                  },
                  {
                        "id": 9968,
                        "displayName": "year_9968"
                  },
                  {
                        "id": 9969,
                        "displayName": "year_9969"
                  },
                  {
                        "id": 9970,
                        "displayName": "year_9970"
                  },
                  {
                        "id": 9971,
                        "displayName": "year_9971"
                  },
                  {
                        "id": 9972,
                        "displayName": "year_9972"
                  },
                  {
                        "id": 9973,
                        "displayName": "year_9973"
                  },
                  {
                        "id": 9974,
                        "displayName": "year_9974"
                  },
                  {
                        "id": 9975,
                        "displayName": "year_9975"
                  },
                  {
                        "id": 9976,
                        "displayName": "year_9976"
                  },
                  {
                        "id": 9977,
                        "displayName": "year_9977"
                  },
                  {
                        "id": 9978,
                        "displayName": "year_9978"
                  },
                  {
                        "id": 9979,
                        "displayName": "year_9979"
                  },
                  {
                        "id": 9980,
                        "displayName": "year_9980"
                  },
                  {
                        "id": 9981,
                        "displayName": "year_9981"
                  },
                  {
                        "id": 9982,
                        "displayName": "year_9982"
                  },
                  {
                        "id": 9983,
                        "displayName": "year_9983"
                  },
                  {
                        "id": 9984,
                        "displayName": "year_9984"
                  },
                  {
                        "id": 9985,
                        "displayName": "year_9985"
                  },
                  {
                        "id": 9986,
                        "displayName": "year_9986"
                  },
                  {
                        "id": 9987,
                        "displayName": "year_9987"
                  },
                  {
                        "id": 9988,
                        "displayName": "year_9988"
                  },
                  {
                        "id": 9989,
                        "displayName": "year_9989"
                  },
                  {
                        "id": 9990,
                        "displayName": "year_9990"
                  },
                  {
                        "id": 9991,
                        "displayName": "year_9991"
                  },
                  {
                        "id": 9992,
                        "displayName": "year_9992"
                  },
                  {
                        "id": 9993,
                        "displayName": "year_9993"
                  },
                  {
                        "id": 9994,
                        "displayName": "year_9994"
                  },
                  {
                        "id": 9995,
                        "displayName": "year_9995"
                  },
                  {
                        "id": 9996,
                        "displayName": "year_9996"
                  },
                  {
                        "id": 9997,
                        "displayName": "year_9997"
                  },
                  {
                        "id": 9998,
                        "displayName": "year_9998"
                  },
                  {
                        "id": 9999,
                        "displayName": "year_9999"
                  }
            ],
            "relationLabels": [
                  {
                        "id": "criterion",
                        "displayName": "Criterion"
                  },
                  {
                        "id": "value",
                        "displayName": "Value"
                  },
                  {
                        "id": "operator",
                        "displayName": "Operator"
                  }
            ]
      },
      "samples": [
            {
                  "document": "Inclusion Criteria:\n\nAge \u2265 18 years.\nWilling and able to give written informed consent.\nDiagnosis of primary AML or AML secondary to myelodysplastic syndrome (MDS) according to World Health Organization classification.\nRelapsed after or refractory to first-line AML therapy.\nPositive for FLT3 mutation in bone marrow or whole blood.\nEastern Cooperative Oncology Group performance status \u2264 2 with no deterioration during screening period.\nAdequate hepatic and renal function.\nRecovery from non-hematologic AEs associated with prior therapy to baseline CTCAE v5 Grade 0 or 1, except for AEs not considered a safety risk (eg, alopecia or vitiligo).\nAble to take oral medication with no medical conditions that prevent swallowing and absorbing oral medications.\nWilling to comply with all protocol-required visits, assessments, and procedures.\n\nExclusion Criteria:\n\nDiagnosis of AML secondary to prior chemotherapy or other neoplasms (except for MDS).\nDiagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia (chronic myeologenous leukemia in blast crisis).\nClinically active central nervous system leukemia.\nSecond or later hematologic relapse or prior salvage therapy for refractory disease.\nFor participants being considered for ERAS-007+gilteritinib treatment: prior therapy with ERK inhibitor.\nFor participants being considered for ERAS-601+gilteritinib treatment: prior therapy with SHP2 inhibitor.\nAnticancer therapy \u226414 days prior to first dose (except hydroxyurea given for controlling blast count), or \u22645 half-lives prior to first dose, whichever is shorter.\nPalliative radiation \u22647 days prior to first dose.\nMajor surgery within 28 days of enrollment.\nContraindication to gilteritinib use as per local label.\nKnown hypersensitivity to any of the components of ERAS-007 or ERAS-601.\nClinically active infection, requiring systemic therapy.\nImpaired cardiovascular function or clinically significant cardiovascular disease.\nHistory of thromboembolic or cerebrovascular events \u22646 months prior to first dose.\nHistory of other malignancy \u22643 years prior to first dose.\nHistory of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or risk factors to RPED or RVO.\nHistory of or clinically active interstitial lung disease (ILD), drug induced ILD, or radiation pneumonitis that required steroid treatment.\nAny evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that renders the participant inappropriate to participate in the study.\nPregnant or breastfeeding women."
            },
            {
                  "document": "Inclusion Criteria:\n\nSubject must be 18 to 75 years of age, inclusive.\n\nSubject must have a World Health Organization (WHO)-defined diagnosis of R/R AML and meet one of the following criteria:\n\nThe subject has experienced primary AML induction failure\n\nOR the subject has a WHO-defined diagnosis of MDS-EB and has failed/is refractory to HMA\n\nAcute myeloid leukemia or MDS-EB must be CD117+\nSubject must have an identified HSC donor (related donor or unrelated donor), haplo-identical transplant donor, or umbilical blood donor.\nSubject must sign an Institutional Review Board (IRB)-approved informed consent form (ICF)\nSubject's Eastern Cooperative Oncology Group (ECOG) performance status must be \u22642.\nSubject must have adequate baseline hepatic function. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) \u22642 x upper limit of normal (ULN), and serum bilirubin \u22641.5 x ULN.\nEstimated creatinine clearance \u226560 mL/min\nAdequate cardiac function as demonstrated by cardiac left ventricular ejection fraction \u226540%\nFemale subjects must not be pregnant or lactating. Both male subjects and female subjects of childbearing potential must agree to use at least 2 means of contraception from the time of signing the ICF until 6 months after dosing with MGTA-117.\nToxicities from all prior therapies must have resolved to less than or equal to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1 or baseline prior to MGTA-117 dosing (except alopecia and hematological).\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia (APL).\nKnown active central nervous system (CNS) leukemia or chloroma (granulocyte sarcoma).\nReceived HSCT within 6 months of study entry or has active graft-versus-host disease (GVHD).\nActive hepatitis B (Hep-B) or hepatitis C (Hep-C) infection or history of human immunodeficiency virus (HIV).\nSubject with a QTc value >470 msec\nSubject has received another investigational drug or device within 30 days.\nSubject has any clinically significant medical condition, which in the opinion of the Investigator may place the subject at an unacceptable risk.\nActive uncontrolled systemic bacterial, fungal, or viral infection\nSubject has a history of serious allergic reactions, which in the opinion of the Investigator may pose an increased risk of serious infusion reactions.\nSubject has had any systemic antileukemia treatment within 14 days except hydroxyurea, which is permitted until 24 hours prior to MGTA-117 dosing.\nSubject has received prior ADC treatment or anti-CD117 antibody treatment.\nSubject has received recent monoclonal antibody therapy within the last 30 days.\nSubject has received recent vaccination within the last 14 days.\nSubject has Grade 2 or higher electrolyte abnormality at screening"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge \u2265 18 years\n\nAll subjects must have histologically or pathologically confirmed diagnosis of their malignancy and/or measurable R/R disease, as follows:\n\nCohort 1 only: Refractory or relapsed acute leukemia defined as > 5% blasts in the bone marrow or reappearance of blasts in the peripheral blood\nCohort 2 only: Previously treated, pathologically confirmed de novo DLBCL, or DLBCL transformed from previously indolent lymphoma (e.g., follicular lymphoma) with documented clinical or radiological evidence of progressive or persistent disease. At study entry, subjects must have measurable disease as per the revised criteria for response assessment of lymphoma.\nCohort 3 only: Measurable MM based on IMWG (International Myeloma Working Group) guidelines\n\nPatients must be refractory or must have progressed on, or following discontinuation of the most recent anti-cancer therapy, with the following considerations:\n\nCohort 1 only: Have failed or are ineligible for any approved standard of care therapies, including HSCT (Hematopoietic Stem Cell Transplantation)\nCohort 2 only: Must have received at least 2 but no more than 5 previous systemic regimens for the treatment of their de novo or transformed DLBCL (i.e., transformed from a previously diagnosed indolent lymphoma [e.g., follicular lymphoma])\nCohort 3 only: Must have received at least 3 but no more than 6 prior anti-MM regimens including proteasome inhibitor (e.g., bortezomib or carfilzomib) and immunomodulatory drug (IMiD) (e.g., lenalidomide or pomalidomide) therapy.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will not be enrolled in the study (all cohorts, unless otherwise indicated):\n\nCertain disease subtypes or occurrences, as follows:\n\nCohort 1: acute promyelocytic leukemia (APL), chronic myeloid leukemia (CML) in blast crisis, isolated extramedullary relapse (iEMR).\nCohort 2: Primary mediastinal B-cell lymphoma (PMBCL), DLBCL transformed from diseases other than indolent non-Hodgkin's Lymphoma (NHL)\nCohort 3: Active plasma cell leukemia, myeloma with amyloidosis, systemic light chain amyloidosis\nWhite Blood Count (WBC) > 25,000/ \u00b5L (uncontrollable with cytoreductive therapy)\n\nKnown central nervous involvement, as follows:\n\nCohort 1: Clinically active central nervous system (CNS) leukemia. Previously controlled CNS leukemia is acceptable\nCohort 2: Active CNS lymphoma or meningeal involvement\nPrior menin inhibitor therapy\nKnown positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen\nSubjects with a pre-existing disorder predisposing them to a serious or life-threatening infection (e.g., cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias not related to acute leukemia, DLBCL, or MM)\nAn active uncontrolled acute or chronic systemic fungal, bacterial, or viral infection"
            },
            {
                  "document": "Inclusion Criteria:\n\nDemonstration of understanding and voluntarily signing of an informed consent form\nAge \u2265 18 years\nPart A - Relapsed or refractory AML, according to the World Health Organization (WHO) classification (Arber, Orazi, et al., 2016). Subjects must be ineligible for or have exhausted standard therapeutic options that would otherwise be likely to provide clinical benefit. Part B - B cell NHL that is refractory to or intolerant of all standard therapy or for which no standard therapy is available or histologically or cytologically documented, incurable or metastatic solid tumor that has failed all available standard therapies with known benefit.\nSubjects with solid tumors must have measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). NHL subjects must have bi-dimensionally measurable disease on cross sectional imaging by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by Lugano criteria (Cheson, Fisher, et al., 2014).\nAdequate organ function\nFemales must avoid pregnancy for at least 4 weeks before beginning BTX-1188 therapy, during therapy, during dose interruptions, and for at least 4 weeks after completing therapy and agree to either abstain from sexual intercourse or use two highly effective methods of contraception (for up to 4 weeks after last dose of study drug)\nMales sexually active with a woman of childbearing age must agree to use barrier method of birth control during and after the study and not donate sperm (for up to 4 weeks after last dose of study drug).\n\nExclusion Criteria:\n\nLife expectancy <3 months, as determined by the Investigator.\nTreatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 3 weeks prior to first dose of BTX-1188\nImmediate life-threatening severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation\nMajor trauma or major surgery within 4 weeks prior to first dose of BTX-1188.\nAdverse events from prior anti-cancer therapy that have not resolved to Grade \u22641 except for alopecia or Grade \u22642 immunotherapy-related thyroid toxicity.\nHistory of, or known, central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade \u22653 drug-related CNS toxicity.\nClinically significant cardiac disease\nActive uncontrolled systemic fungal, bacterial, mycobacterial, or viral infection\nKnown positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)\nActive hepatitis C virus (HCV) or hepatitis B virus (HBV)\nSecond primary malignancy that has not been in remission for greater than 3 years\nAny serious underlying medical (e.g., pulmonary, renal, hepatic, gastrointestinal, or neurological) or psychiatric condition (e.g., alcohol or drug abuse, dementia or altered mental status) or any issue that would limit compliance with study requirements\nPregnant, lactating, or breastfeeding.\nParticipation or plans to participate in another interventional clinical study."
            },
            {
                  "document": "Inclusion Criteria:\n\nMales or females aged > 18 years of age.\nWilling and able to give written informed consent and adhere to protocol requirements; written informed consent and any locally required authorization must be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations, and serial samples of bone marrow and peripheral blood.\n\nConfirmed diagnosis of recurrent or refractory AML as defined below.\n\nAML either de novo or secondary that either: are in relapse to standard therapy following an initial response or failed primary induction therapy (PIF) with no complete response (CR [failed \u22652 induction attempts]) and for whom no other approved therapy is available.\nFor adults who have comorbidities that preclude use of intensive induction chemotherapy, PIF is defined as AML refractory to one of the following, less intensive regimens:\n\ni. Patient has received 2 or more cycles of B-cell lymphoma 2 (bcl-2) inhibitors in combination with azacitidine, decitabine, or low dose cytarabine.\n\nPatient has received, and has progressed, recurred, or is intolerant of approved therapeutic options that are available, or declines treatment with these therapies.\nWhite blood cell (WBC) count at the time of the first dose is < 20,000/uL (microliter) (hydroxyurea is permitted according to standard institutional practice).\nEastern Cooperative Oncology Group (ECOG) performance status is 0 to 2.\nToxicities related to prior study therapy should have resolved to Grade 1 or less according to criteria of NCI CTCAE v5.0, except for alopecia, lymphopenia, neutropenia, leukopenia, anemia, thrombocytopenia. Patients with chronic but stable toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.\n\nThe patient's laboratory values meet the following criteria:\n\nCreatinine clearance (CrCl) as calculated by the Cockcroft-Gault formula (Section 15.1) must be \u2265 60 mL/min;\nTotal bilirubin \u2264 1.5 \u00d7 ULN (upper limit of normal). This does not apply for patients with confirmed Gilbert's Syndrome, hemolysis, or chronic blood transfusions, for whom total bilirubin must be less than 3.0 mg/dL with a conjugated bilirubin less than 0.5 mg/dL;\nAST (aspartate aminotransferase) and ALT (alanine aminotransferase) \u2264 3.0 \u00d7 ULN (upper limit of normal) (unless attributed to leukemic involvement).\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL)\nActive central nervous system (CNS) leukemia. For patients with a history of CNS leukemia, a lumbar puncture should be performed during screening to exclude the presence of active CNS involvement.\nIsolated extramedullary relapse\nPrior organ allograft\nAllogeneic hematopoietic transplantation\n\nTreatment with any of the following:\n\nRadiation therapy (XRT) within 28 days of the first dose of CLN-049, or craniospinal XRT within 8 weeks of the first dose of CLN-049, or history of total body irradiation (TBI).\nPrior immunotherapy with checkpoint inhibitors, \u2264 42 days prior to the first dose of CLN-049.\nPrior history of chimeric antigen receptor (CAR-T) cell therapy or other modified T cell therapy.\nAnti-leukemic therapy except hydroxyurea for cytoreduction, and intrathecal chemotherapy \u2264 14 days or 5 half-lives, whichever is shorter, prior to the first dose of CLN-049.\nShort-acting hematopoietic growth factors \u2264 7 days prior to the first dose of CLN-049\nLong-acting growth factors \u2264 14 days prior to the first dose of CLN-049.\nSystemic glucocorticoid therapy (except equivalent of < 10 mg prednisone daily) or other immune-suppressive drugs \u2264 14 days prior to the first dose of CLN-049 (see separate guidelines for patients who are post allogeneic hematopoietic transplantation). The transient use of corticosteroids for transfusion premedication or the treatment of infusion or transfusion reactions will not be considered for this criterion. Topical corticosteroids and steroid eye drops are allowed, and will not exclude the patient from eligibility.\nPrior treatment with a FLT3-directed bispecific molecule, or a FLT3-targeted antibody.\nCurrently participating/previously participated in an interventional study and received an investigational drug within 14 days (or five half-lives, whichever is longer) prior to the first dose of CLN-049.\nPatients with concomitant second malignancies requiring active treatment in the past 12 months, or if additional therapy is required or anticipated during study participation.\nPatients with any active autoimmune disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or immunosuppressive medications, except for patients with vitiligo, psoriasis (in consultation with the Sponsor), resolved childhood asthma/atopy or autoimmune thyroid disorders on stable thyroid hormone supplementation.\n\nA serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy or whose control may be jeopardized by the complications of this therapy. These criteria include, but are not limited to the following:\n\nUncontrolled airway hyper-reactivity;\nType 1 diabetes mellitus. Type 2 diabetes mellitus patients are allowed if patient is under stable glycemic control as per Investigator assessment;\nUncontrolled, clinically significant pulmonary disease;\nRequirement for supplemental oxygen;\nSymptomatic congestive heart failure as per Investigator assessment or documented cardiac ejection fraction less than 45%. Note: Patients with prior anthracycline exposure or a history of ventricular dysfunction should have a baseline assessment of cardiac function with an ejection fraction > 45% and no clinically significant pericardial effusion.\nHistory of unstable angina or myocardial infarction within six months of the first dose of CLN-049;\nUnstable cardiac arrhythmia or clinically significant ventricular arrhythmia; presence of intracardiac defibrillator;\nUncontrolled hypertension;\nHistory of stroke or cerebral hemorrhage within one year of the first dose of CLN-049;\nPoorly controlled seizure disorder;\nRecent major surgery within three months of the first dose of CLN-049 (with the exception of indwelling catheter or port placement) or major surgery with unresolved complications that could interfere with study treatment.\nAny concurrent condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug.\nTreatment with systemic antiviral, antibacterial, or antifungal agents for acute infection within 7 days of the first dose of CLN-049. Use of these agents for treatment of chronic, controlled infection or as prophylaxis is permitted.\nHas a history of, or a positive test for Human Immunodeficiency Virus (HIV) 1/2 or primary immunodeficiency disease such as HIV.\nKnown history of hepatitis B (with positive testing for either hepatitis B surface antigen [HBsAg] or hepatitis B core Ag), hepatitis C (HCV) infection (with positive testing for HCV antibody and/or HCV ribonucleic acid [RNA] in serum), or acute hepatitis A (with positive testing for hepatitis A IgM). Note: patients with chronic HCV with undetectable viral load defined by sustained virologic response 24 weeks (SVR24) after completion of anti-hepatitis C treatment.\nActive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection including history of positive SARS-CoV-2 testing without subsequent documentation of negative test results, patients with results that are pending but not yet known, or patients with suspected active infection based on clinical features\nHistory of the following events in conjunction with prior treatment with immunotherapy: Grade 3 or greater neurotoxicity, ocular toxicity, pneumonitis, myocarditis, or colitis; liver dysfunction meeting the laboratory criteria for Hy's Law.\nLive virus vaccines within 28 days of the first dose of CLN-049, during treatment, and until the end of last dose of CLN-049.\n\nWoman of child-bearing potential (WOCBP) who is pregnant or breast-feeding, plans to become pregnant within 120 days of last study drug administration, or declines to use an acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration (Section 15.2).\n\nA WOCBP is defined as:\n\nNot surgically sterile, ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy, or;\nNot post-menopausal, defined as amenorrhea for \u2265 2 years without an alternative medical cause.\n\nNote: Women with amenorrhea for < 2 years and who are not surgically sterile ie, tubal ligation, bilateral oophorectomy, or complete hysterectomy will only be considered not to be of reproductive potential if patient have a documented follicle stimulating hormone (FSH) value in the postmenopausal range.\n\nMale patient who plans to father a child or donate sperm within 120 days of last study drug administration, or who has a partner who is a WOCBP, and declines to use acceptable method to prevent pregnancy during study treatment and for 120 days after the last dose of study drug administration (Section 15.2).\nQT interval corrected for heart rate using Fridericia's formula (QTcF) of \u2265 480 milliseconds.\nPatient has history of drug-related anaphylactic reactions to any components of CLN-049. History of Grade 4 anaphylactic reaction to any bispecific molecule or monoclonal antibody therapy.\nKnown history of prior human anti-human antibody response. Patients will not be screened for human anti-human antibody prior to study participation.\nKnown active alcohol or drug abuse.\nPatients who are incapacitated or involuntarily incarcerated."
            },
            {
                  "document": "Inclusion Criteria:\n\nEastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 2\nAdequate organ function (bone marrow, hepatic, renal, cardiovascular)\nLeft ventricular ejection fraction of \u2265 50%\nAll patients must have recovered from the effects of any prior cancer related therapy, radiotherapy, or surgery (toxicity no greater than Grade 1).\nAll patients on prior investigational agents must wait at least 5 half-lives of the agent in question, or 14 days, whichever is longer before enrollment into the trial, and until any toxicities of the prior investigational agent have resolved to Grade 1 or a baseline state\nFemale patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use a highly effective method of contraception during the trial\n\nAML patients only: Pathologically confirmed diagnosis of AML as defined by the WHO Classification and patients with targeted mutations must have been treated with appropriate therapy for their disease\n\na. White blood cell count < 25 \u00d7 10^9/L. Hydroxyurea or leukapheresis are permitted to meet this criterion\n\nCMML patients only: intermediate-2 or high risk per CMML-specific prognostic scoring system (CPSS) or clinical/molecular CPSS (CPSS-mol) criteria. Must have failed at least 4-6 cycles of prior therapy with a hypomethylating agent\nHigh Risk MDS - MDS/MPN Overlap Syndrome: intermediate, high, or very high risk by International Prognostic Scoring System-Revised [IPSS-R] criteria that is relapsed or refractory to approved therapies, including at least 4-6 cycles of a hypomethylating agent, or MDS/MPN Overlap Syndrome (displaying both fibrosis and dysplastic features)\n\nExclusion Criteria:\n\nKnown hypersensitivity to any of the components of PRT1419\nFemale patients who are pregnant or lactating\nActive inflammatory disorders of the gastrointestinal tract, or patients with GI malabsorption\nMean QTcF interval of > 480 msec\nHistory of heart failure, additional risk factors for arrhythmias or requiring concomitant medications that prolong the QT/QTc interval\nElevated cardiac troponin or evidence of recent cardiac injury\nHIV positive; known active hepatitis B or C\nHematopoietic stem-cell transplantation within the last 90 days or have GVHD Grade > 1 at study entry\nUncontrolled intercurrent illnesses\nTreatment with either OATP1B1, OATP1B3 substrates or strong inhibitors of CYP2C8\nPrior exposure to an MCL1 inhibitor\n\nHistory of another malignancy except for:\n\nMalignancy treated with curative intent with no known active disease for > 2 years prior to study start\nAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\nAdequately treated carcinoma in situ without evidence of disease\nOther concurrent low-grade malignancies (i.e., chronic lymphocytic leukemia (CLL) (Rai 0)) may be considered after consultation with Sponsor"
            },
            {
                  "document": "Inclusion Criteria:\n\nSubject age \u2264 28 years. The first three enrolled subjects must be \u2265 18 years of age.\n\nAML that expresses CD33 by flow cytometry and meets one of the below definitions:\n\nFor subjects who have previously received an allogeneic HCT, any evidence of AML re-emergence post HCT detectable by flow cytometry\nFirst relapse of AML \u2264 6 months of initial diagnosis\nFirst relapse of AML > 6 months after initial diagnosis, with MRD of >0.1% by flow cytometry (MPF) after at least one re-induction (single cycle) attempt\nSecond or greater relapse AML\nRefractory AML, defined as >1% leukemic cells determined by flow cytometry after 2 cycles of induction chemotherapy\nAble to tolerate apheresis, or subject with sufficient existing apheresis product or T cells for manufacturing investigational product.\nLife expectancy \u2265 8 weeks\nHas an appropriate stem cell donor source identified\nLansky performance status score of \u2265 50 for subjects <16 years of age or Karnofsky score \u2265 50 for subjects \u2265 16 years. Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for purposes of assessing performance status\n\nIf a subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of DARIC T cells, the subject must discontinue all anticancer agents and radiotherapy and, in the opinion of the investigator, have fully recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy:\n\na. Chemotherapy and biologic agents: All chemotherapy and biologic therapy not specifically mentioned below must be discontinued \u2265 7 days prior to enrollment, with the exception of intrathecal chemotherapy for which there is not a required washout period b. Must be \u2265 30 days from last gemtuzumab ozogamicin dose. c. Steroid use: All corticosteroid therapy (unless physiologic replacement dosing) must be discontinued \u2265 7 days prior to enrollment d. Tyrosine Kinase Inhibitor (TKI) use: All TKIs must be discontinued \u2265 3 days prior to enrollment e. Hydroxyurea: must be discontinued \u2265 1 day prior to enrollment. f. Gene Modified cellular therapy: i. must be at least 30 days from most recent gene modified cell therapy infusion and document no evidence of modified cells in the peripheral blood OR ii. must be at least 60 days from most recent gene modified cell therapy\n\nAdequate organ function as indicated by:\n\nRenal: Serum creatinine \u2264 1.5 X the upper limit of normal (ULN)\nHepatic: Total bilirubin \u2264 3 times ULN for age OR conjugated bilirubin \u2264 2 mg/dL AND ALT (SGPT) \u2264 5 times ULN\nCardiac: Shortening fraction \u2265 28% OR ejection fraction \u2265 50% as measured by echocardiogram\nRespiratory: Oxygen saturation \u2265 92% on room air without supplemental oxygen or mechanical ventilation\n\nLaboratory values meet the following criteria:\n\na. Subjects requiring apheresis: Absolute Lymphocyte Count (ALC) \u2265 100 cells/uL b. Virology Testing negative within 3 months prior to enrollment, to include: i. HIV antigen & antibody ii. Hepatitis B surface antigen iii. Hepatitis C antibody OR if positive, Hepatitis C PCR is negative\n\nIf subject is of childbearing or child-fathering potential, must agree to use highly effective contraception from the time of initial consent through 12 months following the infusion of investigational product on this trial.\nSubject and/or legally authorized representative has signed the Informed Consent Form for this study\n\nExclusion Criteria:\n\nActive malignancy other than acute myeloid leukemia\nHistory of symptomatic non-AML CNS disease or ongoing symptomatic CNS disease requiring medical intervention, including paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder (subjects with non-febrile seizure disorder controlled on anti-epileptic medication and without seizure activity within 1 month are eligible).\nCNS AML involvement that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and DARIC T cell infusion\nIf history of allogeneic stem cell transplant: active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment\n\nPresence of active severe infection, defined as:\n\ni. positive blood culture within 48 hours of enrollment, OR ii. fever above 38.2\u00b0 C, AND clinical signs of infection within 48 hours of enrollment\n\nPrimary immunodeficiency syndrome\nSubject has received prior virotherapy\nPregnant or breastfeeding\nSubject and/or legally authorized representative unwilling to provide consent/assent for participation in the 15-year follow-up period, required if DARIC T cell therapy is administered\nPresence of any condition that, in the opinion of the investigator, would prohibit the subject from undergoing treatment under this protocol\nConsidered by the investigator to be unable to tolerate a lymphodepleting regimen\nSubject has a contraindication to receiving rapamycin"
            },
            {
                  "document": "Inclusion Criteria (abbreviated):\n\nHas AML as defined by World Health Organization\nHas detectable disease following first-line therapy\nIs \u2265 18 years of age.\nCarries the human leukocyte antigen-A0201 (HLA-A*02:01) allele.\nHas ECOG performance status of 0 to 1.\nHas adequate absolute total lymphocyte count\nHas adequate cardiac, renal, and liver organ function\n\nExclusion Criteria (abbreviated):\n\nHas received AML-directed therapy or immunomodulatory therapy within a specified window prior to study entry.\nHas received allogeneic hematopoietic cell transplant within 84 days, with ongoing GVHD, with recent DLI, or on active immunosuppression.\nHas CNS involvement by tumor.\nHas severe autoimmunity requiring immunomodulatory therapy.\nHas active disseminated intravascular coagulation (DIC), bleeding or coagulopathy.\nHas leukocytosis \u2265 20,000 blasts/\u03bcL despite hydroxyurea or has rapidly progressive disease\nHas human immunodeficiency virus (HIV) infection, or any uncontrolled infection.\nFemale subjects are pregnant or breastfeeding; or are of childbearing potential and are unwilling to use protocol specified method of contraception.\nMale subjects who have female partners of childbearing potential and are unwilling to use protocol specified method of contraception."
            },
            {
                  "document": "Inclusion Criteria:\n\nAged 18 and older\nAdvanced hematologic malignancies\nHospice eligible as determined by their primary hematologist\nHave opted to forego further cancer-directed therapy.\nTransfusion Dependent: Requiring at least 2 units of blood products\n\nExclusion Criteria:\n\nPatients with major psychiatric illness\nPatients without the ability to speak and read English"
            },
            {
                  "document": "Inclusion Criteria:\n\n-Has confirmed diagnosis of AML with myelomonocytic or monoblastic/monocytic differentiation per World Health Organization (WHO) 2016 criteria and with confirmed refractory or relapsed disease (i.e., \u22655% blast in bone marrow or in peripheral blood) after treatment with available therapies known to benefit participant's AML subtypes.\n\nExclusion Criteria:\n\nHas active central nervous system (CNS) leukemia.\nHas isolated extramedullary disease, i.e., no leukemic involvement in bone marrow or peripheral blood.\nHas diagnosis of acute promyelocytic leukemia.\nHas received previous allogeneic stem cell transplant or organ transplant within 60 days of screening.\nHas a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 1 year.\nHas a history of any of the following cardiovascular conditions within 6 months of screening: myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, coronary artery bypass graft, or pulmonary embolism; has New York Heart Association (NYHA) Class III or IV congestive heart failure.\nHas had a severe hypersensitivity reaction to treatment with a monoclonal antibody (mAB) and or any components of the study intervention, MK-0482.\nHas an active uncontrolled infection requiring directed therapy.\nHas immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, or disseminated intravascular coagulation.\nHas known human immunodeficiency virus (HIV) and/or hepatitis B or C infections, or is known to be positive for HBsAg/ Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) or hepatitis C antibody or Ribonucleic acid (RNA).\nHas known psychiatric or substance abuse disorders (verbally reported) that would interfere with the participant's ability to cooperate with the requirements of the study.\nIs pregnant or breast feeding or expecting to conceive or father children within the projected duration of the study, starting with the Screening Visit through 120 days after the last dose of study intervention.\nHas received systemic anticancer therapy, radiotherapy, or surgery within 2 weeks before the start of study treatment.\nHas received hematopoietic cytokines (Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte Macrophage (GM)-CSF, or erythropoietin) within 2 weeks prior to start of study treatment.\nHas received a live or live attenuated vaccine within 30 days before the first dose of study medication.\nIs currently participating and receiving study intervention in a study of an investigational agent or has participated and received study intervention in a study of an investigational agent or has used an investigational device within 28 days of administration of MK-0482.\nHas a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication."
            },
            {
                  "document": "Inclusion Criteria:\n\nVoluntary written consent must be given before performance of any study-related procedure not part of standard medical care.\nMale or female subjects 18 years or older.\nMorphologically documented T-ALL, AML (including undifferentiated leukemia and bi-phenotypic leukemia, or T-LBL in relapsed/refractory status (at least one line of prior therapy). Subjects with measurable residual disease by flow cytometry, molecular testing or cytogenetics will be eligible for the trial.\nCD38 expression \u2265 20% by flow cytometry or immunohistochemistry at time of relapse.\n\nAdequate organ system function as outlined below:\n\nTotal bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 3 \u00d7 ULN. If total bilirubin > 1.5 \u00d7 ULN then check direct bilirubin. Subject will be eligible if direct bilirubin is < 1.5 \u00d7 ULN.\nCalculated creatinine clearance \u2265 40 mL/min (calculated by Cockcroft-Gault formula) for subjects with creatinine levels above institutional normal.\nEjection > 40% by echocardiogram or multiple-gated acquisition (MUGA) scan.\nEastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n\nFemale subjects who:\n\nAre postmenopausal for at least one year before the screening visit, OR\nAre surgically sterile, OR\nIf they are of childbearing potential:\n\ni. Agree to practice one highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through four months after the last dose of study drug (female and male condoms should not be used together), OR ii. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception).\n\nMale subjects, even if surgically sterilized (i.e., status postvasectomy), who:\n\nAgree to practice effective barrier contraception during the entire study drug treatment period from the time of signing the informed consent through four months after the last dose of study drug (female and male condoms should not be used together), OR\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia.\nTreatment with systemic antineoplastic therapy within 5 half-lives from the last dose before cycle one day one of therapy. Radiation within 7 days before C1D1 of therapy. The use of hydroxyurea, steroids, or vincristine for leukoreduction is permitted.\nPrior treatment with an anti-CD38 antibody in last 6 months.\nHematopoietic stem cell transplantation within 6 months of enrollment, or evidence of veno-occlusive disease at any time post-transplant, or active graft-versus-host disease requiring immunosuppressive therapy.\nAny serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of study procedures.\nActive, significant, uncontrolled infection. Subjects with infections that are controlled by antibiotics, antiviral or antifungal therapy can be enrolled in the study.\n\nPresence of another active malignancy (requiring treatment) treated within 12 months with the exception of:\n\nAdequately treated non-melanoma skin cancer,\nAdequately treated melanoma Grade 2 or less,\nCervical intraepithelial neoplasia,\nAdequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast,\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin,\nAdequately treated prostate cancer.\nLife-threatening illness with life expectancy < 6 months unrelated to cancer.\nSubjects with active central nervous system (CNS) disease. Subjects with adequately treated CNS disease may enroll on the study.\nKnown hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection. Note: Subjects who have isolated positive hepatitis B core antibody (i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Subjects who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load.\n\nKnown cardiopulmonary disease defined as:\n\nUnstable angina,\nCongestive heart failure (New York Heart Association [NYHA] Class III or IV;\nMyocardial infarction (MI) within six months prior to enrollment (subjects who had ischemic heart disease such as acute coronary syndrome, MI, and/or revascularization > 6 months before Screening and who are without cardiac symptoms may enroll),\nClinically significant pulmonary hypertension requiring pharmacologic therapy,\nClinically significant arrhythmia:\n\ni. History of polymorphic ventricular fibrillation or torsade de pointes, ii. Uncontrolled permanent atrial fibrillation (A-Fib), defined as continuous A-Fib for \u2265 6 months and not well controlled with adequate A-Fib therapy, iii. Uncontrolled persistent A-Fib, defined as sustained A-Fib lasting > 7 days and/or requiring cardioversion in the four weeks before Screening and not well controlled with A-Fib therapy, iv. Grade 3 A-Fib defined as symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation, and v. Subjects with paroxysmal A-Fib or < Grade 3 A-Fib for a period of at least 6 months are permitted to enroll provided that their rate is controlled on a stable regimen.\n\nSubject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, gastrointestinal or any other medical condition that in the opinion of the Investigator would adversely affect his/her participating in this study.\nUncontrolled high blood pressure as determined by the treating physician (i.e., systolic blood pressure > 180 mm Hg, diastolic blood pressure > 100 mm Hg).\nSubjects with uncontrolled coagulopathy or bleeding disorder.\nKnown moderate-to-severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis.\nMajor surgery within 14 days before the enrollment or a prescheduled major surgery during study period.\nFemale subjects who are both lactating and breastfeeding or of childbearing potential who have a positive serum or urine test during Screening.\nFemale subjects who intend to donate eggs (ova) during the course of this study or four months after receiving their last dose of study drug(s).\nMale subjects who intend to donate sperm during the course of this study or four months after receiving their last dose of study drug(s)."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients diagnosed with new or recurrent myeloid leukemia\nAged >= 18 years old\nEastern Cooperative Oncology Group (ECOG) performance status < 4\nPatient have measurable and amenable to biopsy under local anesthesia without the need for imaging directed procedure\nAbility to understand and provide signed informed consent\nFemales must be surgically or biologically sterile or postmenopausal (amenorrhoeic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment. Women of childbearing potential must agree to use an adequate method of contraception during the study and until the last radiation treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study and until the last radiation treatment\n\nExclusion Criteria:\n\nPatients who are unwilling to participate\nPatients unwilling to undergo the biopsy before or after radiotherapy"
            },
            {
                  "document": "Inclusion Criteria:\n\nRadiation-based cohort diagnoses:\n\nAcute myeloid leukemia\nAcute lymphoid leukemia in remission\nMyelodysplasia (MDS)\nChronic lymphocytic leukemia (CLL) with no or minimal lymph node involvement\nMultiple myeloma\nChronic myeloid leukemia\nMyelofibrosis\nMyeloid malignancy not otherwise specified\nChronic myelomonocytic leukemia\nEssential thrombocytopenia or polycythemia vera\nT cell leukemia\nT cell lymphoma without significant lymph node disease burden\nAny hematological malignancy or dyscrasia not cited above in which HSCT is potentially curable * Any patient who has a hematological disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history. Examples are patients with previous treatment with radiation therapy precluding total-body irradiation (TBI), or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen.\nPatients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)\n\nChemotherapy-based cohort diagnoses:\n\nHodgkin or non-Hodgkin lymphoma\nSmall lymphocytic lymphoma/CLL\nAny other diagnosis in which chemotherapy is thought to be superior to radiotherapy for treatment of the disease\nHematological malignancy in patients who cannot receive > 2 Gy radiation * Aplastic anemia and other non-malignant hematologic dyscrasias\nPatients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)\n\nHLA identical cohort diagnoses:\n\n* Patients in this group will be treated in parallel to the radiation-based cohort or the chemotherapy-based group based on what category their diagnosis falls into. However, these patients will have HLA identical related donors (one-antigen cross-over event included).\n\nLeft ventricular ejection fraction of >= 50%\nDiffusion lung capacity of oxygen >= 50% and forced expiratory volume at 1 second >= 50% of predicted corrected for hemoglobin\nAdequate liver function as defined by a serum bilirubin =< 1.8, aspartate aminotransferase or alanine aminotransferase =< 2.5 x upper limit of normal\nCreatinine clearance of >= 60 mL/min\n\nPatients must have adequate Karnofsky performance status (KPS) and hematopoietic cell transplantation-comorbidity index (HCT-CI) scores:\n\nPatients < age 60 years must have a KPS of >= 80% and an HCT-CI score of 5 or less\nPatients aged 60 to 65 years must have a KPS of >= 80% and an HCT-CI score of 4 or less\nPatients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less * Patients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less\n(Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the principal investigator and at least 1 co-investigator not on the primary care team of the patient). This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than guideline HCT-CI points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities\nPatients must be willing to use contraception if they have childbearing potential\nPatient or patient's guardian is able to give informed consent\nPatients should have a life expectancy of >= 6 months for reasons other than their underlying hematologic/oncologic disorder\n\nExclusion Criteria:\n\nPatients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol\n\nPatients should not be:\n\nHuman immunodeficiency virus positive\nHave active involvement of the central nervous system with malignancy. This can be documented by a normal neurological exam, magnetic resonance imaging (MRI) of the head, and/or a negative cerebral spinal fluid analysis\nPregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nAdults \u226518 years of age with acute myeloid leukemia (AML) and at least 1 prior line of therapy\nFMS-like tyrosine kinase 3 (FLT3)-mutated disease documented in a local reference laboratory\nHave the ability to understand the requirements and procedures of the study and sign a written informed consent form\nEastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2\nAdequate hepatic and renal function\nProthrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) \u22641.5x upper limit of normal (ULN) unless receiving therapeutic anticoagulation\nNegative serum \u00df-human chorionic gonadotropin (HCG) test in women of child-bearing potential (WOCBP)\nLeft ventricular ejection fraction \u226550% confirmed by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\n\nExclusion Criteria:\n\nKnown central nervous system (CNS) involvement with leukemia\nFailure to achieve at least a partial response (PR) or have relapsed following prior exposure to gilteritinib or other next-generation FLT3 inhibitor monotherapy (eg. quizartinib, crenolanib)\nClinical signs/symptoms of leukostasis that have failed therapy including hydroxyurea and/or leukapheresis of at least 3 days duration\nPregnant or breastfeeding women\nActive infection with hepatitis B, C or known human immunodeficiency virus (HIV) infection\nDisseminated intravascular coagulation with active bleeding or signs of thrombosis\nKnown active coronavirus disease 2019 (COVID-19)\nAdministration of a live attenuated virus vaccine within 35 days before Cycle 1 Day 1 (C1D1)\nHistory of non-myeloid malignancy except for the following: adequately treated localized basal cell or squamous cell carcinoma of the skin; cervical carcinoma in situ; superficial bladder cancer; asymptomatic prostate cancer without known metastatic disease, with no requirement for therapy or requiring only hormonal therapy and with normal prostate specific antigen for > 1 year prior to start of study therapy; or any other cancer that has been in complete remission without treatment for \u22653 years prior to enrollment\nClinically significant heart disease\nProlongation of the congenital long measure between Q wave and T wave in the electrocardiogram (QT) interval at baseline\nEvidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection at the time of study treatment initiation\nCurrent (within 30 days of study enrollment) drug-induced liver injury, chronic active hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, orportal hypertension\nOngoing (within 6 weeks of study enrollment) hepatic encephalopathy\nOngoing immunosuppressive therapy, including systemic chemotherapy for treatment of leukemia"
            },
            {
                  "document": "Inclusion Criteria:\n\n1. Subject is \u2265 18 years of age at the time of signing informed consent 2. Subject is willing and able to adhere to the study visit schedule and other protocol requirements. 3. Subject has relapsed or refractory MDS, AML or CMML with a previously defined hotspot splicing factor mutation in SF3B1, SRSF2, U2AF1, or U2AF2 (with hotspot mutations as defined by OncoKB) or a nonsense or frameshift mutation in ZRSR2. A splicing factor mutation is required to be detected on next generation sequencing from bone marrow aspirate or peripheral blood at any timepoint within the 6 months prior to screening for the study.\n\na. Relapsed AML is defined as: i. The appearance of 5% or greater myeloblasts in the bone marrow or peripheral blood after achieving a CR (MRD positive or negative), CRh, or CRi\n\n1. Patients with mutations in FLT3, IDH1 or IDH2 must have failed or been intolerant of an FDA approved FLT3, IDH1 or IDH2 inhibitor before enrolling on study.\n\nb. Refractory AML is defined as failure to achieve a CR, CRh, or CRi after one of the following regimens: i. Two cycles of intensive induction chemotherapy with a cytarabine containing regimen (e.g. 7+3, MEC, HIDAC, etc.) ii. Two cycles of HMA/venetoclax or LDAC/glasdegib iii. 4 cycles of HMA monotherapy c. Relapsed MDS is defined as: i. Any relapse after achieving an IWG defined response. d. Refractory MDS is defined as: i. For patients with intermediate, high or very high risk disease by IPSS-R, the failure to achieve a response (as per IWG 2006 criteria) after 4 cycles of HMA monotherapy or 2 cycles of HMA + venetoclax.\n\nii. For patients with very low and low risk disease by IPSS-R failure to achieve hematologic improvement or loss of hematologic improvement after treatment with standard of care agents such as ESAs, Luspatercept (for MDS with ringed sideroblasts) and lenalidomide (for pts with a 5q-).\n\ne. Relapsed CMML is defined as: i. Any relapse after achieving an IWG defined response. f. Refractory CMML is defined as: i. Failure to achieve a response (as per IWG 2006 criteria) after 4 cycles of HMA monotherapy or 2 cycles of HMA + venetoclax.\n\n4. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 5. Subject has adequate organ function defined as:\n\nSerum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) \u2264 3 x ULN, unless considered due to organ involvement by the patient's myeloid malignancy (in that case a cut off of \u2264 5 x ULN will be used)\nSerum direct bilirubin < 1.5 x ULN.\nCreatinine clearance \u2265 60 mL/min based on the Cockroft-Gault glomerular filtration rate (GFR) estimation.\n\nFemales of childbearing potential may participate provided they have a negative serum pregnancy test at screening and a negative serum OR urine pregnancy test within 72 hours of starting on treatment. Females and male participants with female partners of childbearing potential also must agree to either abstain from sexual intercourse or use a highly effective method of contraception while on study and for 4 months after completing the study treatment.\n\n6. There are no limits on transfusion and/or growth factor support for enrollment.\n\n7. In case of leukemic organ involvement, patients with creatinine clearance > 30 ml/min and bilirubin \u2264 2.0 x ULN will be eligible to be included.\n\nExclusion Criteria:\n\nPatients with acute promyelocytic leukemia\nSubject has immediate life-threatening, severe complications of their myeloid malignancy such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation\nSubject has significant active cardiac disease within 6 months prior to the start of study treatment, including New York Heart Association (NYHA) class III or IV congestive heart failure; acute coronary syndrome (ACS); and/or stroke or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment.\nSubject has active viral infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients with HIV that is controlled with HAART are eligible to participate.\nSubject is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.\nSubject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).\nSubject has QTc interval (i.e., Fridericia's correction [QTcF]) \u2265 480 ms or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure family history of long QT interval syndrome) at screening. Patients with left bundle branch block or right bundle branch block with prolonged QTc will be allowed to enroll on the trial with medical monitor approval.\nFemale subject who is pregnant or lactating.\nSubject with known hypersensitivity to sulfa medications"
            },
            {
                  "document": "Inclusion Criteria:\n\nProvision of signed and dated informed consent form\nStated willingness to comply with all study procedures and availability for the duration of the study\nEastern Cooperative Oncology Group (ECOG) performance status \u22642\nFLT3-ITD or FLT3-TKD mutated AML (non-M3) in 1st or greater relapse or refractory to at least one prior line of AML directed therapy\nFLT3 testing must be confirmed at the time of disease relapse\nAdequate organ function\nLeft ventricular ejection fraction (LVEF) \u226550%\nPrior anthracycline exposure \u2264368 mg/m2 daunorubicin (or equivalent)\nAbility to take oral medication and willingness to adhere to the medication regimen\nFor females of reproductive potential: use of highly effective contraception including double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices and tubal ligation.\nFor females of reproductive potential: negative serum or urine pregnancy test with a sensitivity of at least 50mIU/mL within 10 days and again within 24 hours of beginning study treatment\nFor males of reproductive potential: use of condoms\nBreastfeeding mothers must agree to discontinue nursing\n\nExclusion Criteria:\n\nPatients may not be receiving any other investigational agents\nPatients with documented central nervous system involvement of AML\nAny prior use of gilteritinib\nPatients must not have evidence of GI tract abnormalities that would alter the absorption of oral medications\nMajor surgery within two weeks of first dose of study drug. Patients must have recovered from the effects of any surgery performed greater than two weeks prior\nWBC count \u226550,000 at the time study treatment begins. Use of hydroxyurea to maintain WBC <50,000 is allowed up to the time that study treatment begins\nPredicted inability to tolerate standard induction chemotherapy\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nNo other malignancies in addition to AML that are currently requiring treatment with the exception of: 1) basal cell or squamous cell carcinoma or the skin; 2) carcinoma in situ of the cervix or breast; 3) a history of breast cancer that is currently being managed with adjuvant endocrine therapy\nPatients may not have undergone an allogeneic stem cell transplant at any time in the past"
            },
            {
                  "document": "Inclusion Criteria:\n\nAdults 18 to 75 years with previously untreated de novo acute myeloid leukemia (AML), AML with myelodysplastic syndromes (MDS) features, or therapy-related AML.\n\nNucleophosmin-1 (NPM1)-mutated disease documented in a local or the Sponsor's central testing facility.\n\nNote: Participants with concurrent FMS-like tyrosine kinase 3 (FLT3) mutation but without access to midostaurin (eg, either for lack of health authority approval or reimbursement) may also enroll; participants with a concurrent FLT3 mutation will not be allowed to receive a FLT3 inhibitor at any time during the study treatment period.\n\nNote: Participants with local test results for nucleophosmin-1 mutated (NPM1-m) (and/or FLT3 mutational status) may enroll, provided appropriate samples are sent to the Sponsor's central testing facility for NPM1-m companion diagnostic development.\n\nEastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0, 1, or 2.\n\nAdequate hepatic and renal function defined as:\n\nSerum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times the upper limit of normal (ULN), except those with hepatic involvement by AML, as documented by either computed tomography (CT) or ultrasound, in whom levels of AST and ALT < 5 times ULN are acceptable; total bilirubin < 1.5 times ULN unless elevated due to Gilbert's Disease or hemolysis.\nCalculated creatinine clearance > 40 mL/min or serum creatinine < 1.5 times ULN.\nProthrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR) \u2264 1.5 x ULN unless receiving therapeutic anticoagulation.\nLeft ventricular ejection fraction \u2265 45% confirmed by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan.\n\nExclusion Criteria:\n\nIsolated myeloid sarcoma (ie, participants must have peripheral blood and/or bone marrow involvement by AML) or acute promyelocytic leukemia.\nKnown central nervous system (CNS) involvement with leukemia.\nActive infection with hepatitis B, C, or known human immunodeficiency virus (HIV).\n\nKnown active coronavirus disease 2019 (COVID-19) either symptomatic or asymptomatic, as determined by nasopharyngeal swab for severe acute respiratory syndrome (SARS) coronavirus 2 (SARS CoV-2) ribonucleic acid (RNA) or antigen.\n\nNote: Participants with a history of SARS-CoV-2 nasopharyngeal carriage (either with or without symptoms), who have subsequently tested negative on follow-up nasopharyngeal swab and are without signs or symptoms of COVID-19 may enroll. Participants who are fully vaccinated against SARS-CoV-2 may enroll.\n\nDisseminated intravascular coagulation with active bleeding or signs of thrombosis.\nHistory of prior allogeneic hematopoietic stem cell transplant or solid organ transplant.\n\nTreatment with proton pump inhibitors (PPIs) from 7 days prior to enrollment until 48 hours after completion of entospletinib (ENTO) or placebo.\n\nNote: PPIs are likely to interfere with ENTO absorption, thus requiring a 7-day washout period. Histamine (H2) receptor antagonists and antacids are allowed for use during the study treatment period.\n\nOngoing immunosuppressive therapy, including systemic chemotherapy for treatment of leukemia.\n\nNote: Participants may not receive AML-directed therapy prior to enrollment other than hydroxyurea or leukapheresis for acute management of hyperleukocytosis.\n\nClinical signs/symptoms of leukostasis that have failed therapy including hydroxyurea and/or leukapheresis of at least 3 days duration.\n\nClinically significant heart disease defined as:\n\nNew York Heart Association Class 3 or 4 congestive heart failure,\nAcute myocardial infarction \u2264 6 months before enrollment,\nSymptomatic cardiac ischemia/unstable angina \u2264 3 months before enrollment,\nHistory of clinically significant arrhythmias (eg, ventricular tachycardia or fibrillation; Torsades de Pointe) including Mobitz type II 2nd degree or 3rd degree heart block without a permanent pacemaker in place.\nParticipants with a corrected congenital long measure between Q wave and T wave in the electrocardiogram (QT) interval (using the Fredericia formula, Fridericia correction of the QT measure [QTcF]) > 480 msec or Long QT Syndrome.\nEvidence of ongoing, uncontrolled systemic bacterial, fungal, or viral infection at the time of study treatment initiation, including but not limited to persistent fever or positive cultures in the setting of appropriate antimicrobial therapy.\nUnable to swallow tablets or concurrent disease affecting gastrointestinal function such as, malabsorption syndrome, gastric or small bowel resection, bariatric surgery, inflammatory bowel disease, or bowel obstruction."
            },
            {
                  "document": "Inclusion Criteria:\n\nMale or female, aged between 18 and 75 years of age undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) or the treatment of Acute Myeloid Leukemia (AML) with detectable minimal residual disease (MRD) either before or after alloHCT\nHave < 5% blasts in bone marrow by morphology at the time of transplantation but pre-alloHCT flow cytometric or molecular evidence of MRD\nKarnofsky performance status (KPS) \u2265 70% during the study screening.\nFree of symptomatic congestive heart failure or uncontrolled arrhythmia\nAdequate organ function as defined per protocol\nNegative serum pregnancy test\nNote: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for at least 30 days following study treatment (T-cell infusion); should a woman subject or female partner of a male subject become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.\nProvision of signed and dated informed consent form\nStated willingness to comply with all study procedures and availability for the duration of the study.\nAgreement to adhere to Lifestyle Considerations throughout study duration\n\nExclusion Criteria:\n\nCurrent use of concomitant systemic glucocorticoid for any reason will not be allowed in order to avoid their immunosuppressive effects on \u03b3\u03b4 T-cell function.\nActive grade II-IV acute GVHD (patients with prior GVHD should be off prednisone for at least 14 days prior to infusion of the study cell product).\nUncontrolled serious infection.\nMorphologic relapse of leukemia at any timepoint after HCT.\nActive central nervous system malignancy.\nPregnancy or lactation.\nTreatment with another investigational drug or other intervention within 14 days of T-cell infusion"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients aged >= 18 years AML who have achieved their FIRST complete response (CR) or complete response with incomplete bone marrow recovery (CRi) and are not immediately candidates for allogeneic stem cell transplant\nPatients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be designated as COHORT 1 (intensive induction cohort)\nPatients who have received lower intensity therapy (defined as receiving low-dose cytarabine [LDAC] or hypomethylating agent [HMA]-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be designated as COHORT 2 (lower intensity induction cohort)\nFor either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement\nEastern Cooperative Oncology Group (ECOG) performance status of < or = 3\nSerum total bilirubin < or = to 1.5 x the upper limit of normal (ULN)\nSerum creatinine < or = to 2.5 x ULN\nAbsolute neutrophil count (ANC) > 0.5 x k/uL\nPlatelet count > or = 50 x k/uL\n\nFor females of childbearing age, they may participate if they:\n\nHave a negative serum or urine pregnancy test within 10 to 14 days of enrolling\nAgree to either abstinence or 2 effective contraceptive methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment\nFor male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment\nAbility to understand and sign informed consent\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL), AML - M3 by French-American-British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies\nDiagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor\nUncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPatients with active CNS (central nervous system) disease\nPatients with documented hypersensitivity to any components of the study program\nFemales who are pregnant or lactating or intending to become pregnant during the study\nPatients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment\nPatient should be removed from current trial if they wish to participate and get treatment on another trial"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis:\n\nPhase I cohort: Adults >= 18 years with relapsed/refractory FLT3-mutated AML or myelodysplastic syndrome (MDS) that is intermediate-2 or high-risk by the International Prognostic Scoring System\n\nPhase II cohort A: Adults >= 18 years with newly diagnosed FLT3-mutated AML. Patients should meet the following criteria:\n\nConfirmed newly diagnosed AML with FLT3 mutation\n\nIneligible for induction therapy defined as\n\nEither age >= 75\nOr 18-74 with at least one comorbidity (congestive heart failure [CHF] requiring therapy or ejection fraction [EF] =< 50%, diffusion capacity of the lung for carbon monoxide [DLCO] =< 65% or forced expiratory volume in 1 second [FEV1] =< 65%, or Eastern Cooperative Oncology Group [ECOG] 2 or 3, or other significant co-morbidity precluding use of cytotoxic chemotherapy as approved by the principal investigator (PI)\nPhase II cohort B: Adults >= 18 years with relapsed/refractory FLT3-mutated AML or MDS that is intermediate-2 or high-risk by the International Prognostic Scoring System who have received 1 prior therapy\nFor all cohorts, patients with either FLT3-ITD or FLT3 D835 mutations will be eligible\nPerformance status =< 3 (Eastern Cooperative Oncology Group [ECOG] scale)\nTotal serum bilirubin =< 2.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the PI\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x ULN, unless due to the underlying leukemia approved by the PI\nCreatinine clearance >= 30 mL/min\nAbility to swallow\nSigned informed consent\nHydroxyurea or one dose of cytarabine up to 1000 mg is allowed to reduce the white blood cell (WBC) to less than 25 x 10^9/L prior to initiation of study treatment\n\nExclusion Criteria:\n\nPrior therapies\n\nPhase I cohort: No restriction based on prior therapies\nPhase II cohort A: Patients with prior therapy for AML are not eligible. Prior therapy for antecedent hematologic disorder is allowed including prior hypomethylating agent (HMA) therapy for MDS. Prior hydroxyurea or cytarabine given for purposes of cytoreduction is also allowed. Prior all trans-retinoic acid given for presumed acute promyelocytic leukemia is also allowed\nPhase II cohort B: Patients with >= 3 prior lines of therapy are not eligible. Stem cell transplantation, treatment given only for cytoreductive purposes (e.g. hydroxyurea), and growth factors do not count as lines of therapy for this purpose. Prior therapy with venetoclax is allowed\nPrior treatment with gilteritinib\nPatients suitable for and willing to receive intensive induction chemotherapy (for Phase II cohort A only)\nCongenital long QT syndrome or corrected QT (QTc) > 450 msec. Repeat electrocardiograms (EKGs) after correction of electrolytes or discontinuation of QT prolonging medications are allowed to meet entry criteria\nActive serious infection not controlled by oral or intravenous antibiotics (e.g. persistent fever or lack of improvement despite antimicrobial treatment)\nActive grade III-V cardiac failure as defined by the New York Heart Association Criteria\nActive central nervous system leukemia\nKnown history of human immunodeficiency virus (HIV) seropositive\n\nKnown hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection\n\nNote: Patients who have isolated positive hepatitis B core antibody (i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load\nPatients with a prior or concurrent malignancy whose natural history or treatment is not anticipated to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the PI\nConsumed strong inducer of CYP3A or p-glycoprotein within 3 days of study enrollment. Agents include but are not limited to: carbamazepine, phenytoin, rifampin, and St. John's wart\nTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator. Prior recent treatment with corticosteroids, hydroxyurea and/or cytarabine (given for cytoreduction) permitted. Use of hydroxyurea or one dose cytarabine to reduce WBC below 25 prior to initiation of study treatment is recommended\nPregnant women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to use effective methods of contraception throughout the study period and for at least 6 months after the last dose of study drugs. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control throughout the study period and for at least 4 months after the last dose of study drugs. Lactating women (or those planning to breastfeed) should not breastfeed during treatment of gilteritinib and for at least 2 months after the last dose of gilteritinib"
            },
            {
                  "document": "Inclusion Criteria:\n\n\u2265 18 years old\nWeight \u2265 40 kg\nAnticipated life expectancy > 3 months prior to lymphodepletion\nKarnofsky Performance Score \u2265 70%\nHistologically confirmed diagnosis of AML\nIn complete response (CR) (including CRi/CRp); patients in first, second or subsequent CR (including CRi/CRp) are permitted\nMRD detected in bone marrow by MFC\nNegative pregnancy test (females of childbearing potential only)\nAgree to use effective birth control\nLeft ventricular ejection fraction (LVEF) \u2265 50%\nPlatelet Count \u2265 20 x 109/L\nProthrombin Time or INR \u2264 1.5 x ULN (unless receiving therapeutic anticoagulation)\nPartial Thromboplastin Time \u2264 1.5 x ULN (unless receiving therapeutic anticoagulation)\nHemoglobin \u2265 8.0 g/dL\nCreatinine Clearance \u2265 40mL/min\nSerum Total Bilirubin \u2264 1.5 x ULN (unless documented Gilbert's Syndrome with Direct Bilirubin < 35% of Total Bilirubin)\nALT \u2264 2.5 x ULN\n\nExclusion Criteria:\n\nCytotoxic chemotherapy within 3 weeks\nImmune therapy within 4 weeks\nImmunosuppressive therapy within 2 weeks (with exceptions)\nInvestigational treatment or interventional clinical trial within 4 weeks or 5 half-lives (if known), whichever is longer\nMajor surgery within 4 weeks and/or not fully recovered from surgery-related toxicities\nKnown hypersensitivity to chemotherapy, other agents, or excipients used in this study\nFemale patient that is pregnant or lactating/breastfeeding\nOngoing toxicity from prior anti-cancer therapy that have not recovered to \u2264 Grade 1 (with exceptions)\nHistory of chronic or recurrent autoimmune or immune-mediated disease requiring steroids or other immunosuppressive treatments (including anti-tumor necrosis factor agents)\nActive CNS involvement (i.e. leukemic infiltration)\nAny other malignancy that requires active therapy\nUncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months)\nActive infection with HIV, Hepatitis B or Hepatitis C\n\nNOTE: other protocol defined inclusion/exclusion criteria may apply."
            },
            {
                  "document": "Inclusion Criteria:\n\nNewly diagnosed patients > 18 years of age\nPatients must be in CR or CRh (complete remission with partial count recovery).\nMust have received ANY induction treatment with standard consolidation or hypomethylating agent (HMA) + venetoclax, for up to 6 cycles or no more than one year of treatment.\nMust be able to start therapy within 3 months of last documented CR\nDe novo or secondary AML/treatment related AML (non-M3) including AML with myelodysplasia-related changes (MRC), histologically confirmed\nPatients must be ineligible for allogeneic BMT (for any reason including poor performance status, patient's preference, favorable AML not a candidate for transplant, or comorbidities and age precluding from transplant etc)\nCardiac ejection fraction \u2265 50% by transthoracic echocardiography or MUGA scan\n\nAdequate hepatic and renal function defined as:\n\nSerum aspartate transaminase (AST) or alanine transaminase (ALT) \u2264 3 x upper limit of normal (ULN)\nSerum aspartate transaminase (AST) or alanine transaminase (ALT) \u2264 3 is permissible if due to disease.\nBilirubin \u22643 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)\nEstimated Creatinine Clearance \u226530 ml/min (Cockcroft-Gault based on actual weight) (See Appendix A)\nEastern Cooperative Oncology Group (ECOG) performance status of \u2264 3 (Appendix A)\nFemale subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for \u22651 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry.\nMale and female subjects who agree to use highly effective methods of birth control (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], sexual abstinence, or sterilized partner) during the period of therapy and for at least 6 months after the last dose of study drug\n\nExclusion Criteria:\n\nPrior allogeneic transplant\nPrevious cumulative anthracycline (doxorubicin equivalent) dose equal to or greater than 345 mg/m2, and for patients with prior mediastinal XRT, anthracycline dose equal to or greater than 295 mg/m2\nAcute promyelocytic leukemia [t(15;17)]\nIf patient is unable to sign informed consent due to any serious medical condition, laboratory abnormality or psychiatric illness\nPatients with evidence of uncontrolled current myocardial impairment (e.g. unstable ischemic heart disease, uncontrolled arrhythmia, symptomatic valvular dysfunction not controlled on medical therapy, uncontrolled hypertensive heart disease, and uncontrolled congestive heart failure)\nHistory of Wilson's disease or other copper-related disorders\nHistory of allergic reactions attributed to compounds of similar composition to cytarabine and daunorubicin or liposomal products\n\nHistory of other malignancies, except:\n\nMalignancy treated with curative intent and with no known active disease present for \u2265 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.\nAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\nAdequately treated carcinoma in situ without evidence of disease.\nUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade \u22641, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia.\nKnown bleeding disorders (e.g., von Willebrand's disease) or hemophilia\nKnown active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).\nSubjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, hepatitis C antibody, must have a negative polymerase chain reaction (PCR) result for the respective disease before enrollment. Those who are PCR positive will be excluded.\nAny uncontrolled active systemic infection.\nAny life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.\nCurrently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.\nKnown CNS involvement by leukemia\nErythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome\nLactating or pregnant.\nUnwilling or unable to participate in all required study evaluations and procedures.\nUnable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).\nCurrently active, clinically significant hepatic impairment (\u2265 moderate hepatic impairment according to the Child Pugh classification (class B or C))"
            },
            {
                  "document": "Inclusion Criteria Patient\n\nPatient with a clinical suspicion for a new diagnosis of AML or MDS for whom the diagnostic molecular testing via the hematologic molecular algorithm (HMA) at BJH is requested or planned to be requested.\nAdult patients 18 years or older.\nAbility to understand and willingness to sign an IRB approved written informed consent document.\n\nInclusion Criteria Physician\n\nTreating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.\nAble and willing to complete standardized questionnaires about usability, and stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process.\n\nExclusion Criteria Patient\n\nYounger than 18 years of age\n\nExclusion Criteria Physician\n\nDoes not treat patients at Washington University School of Medicine"
            },
            {
                  "document": "Inclusion Criteria:\n\nSigned informed consent obtained prior to conducting any study-specific screening procedures.\nWilling and able to understand the nature of this study and to comply with both the study as well as follow-up procedures for the duration of the study.\nAge \u2265 18 years old with newly-diagnosed Acute Myeloid Leukemia (AML)\nECOG performance status must be \u2264 2\nPeripheral white blood cell (WBC) count < 30,000/\u00b5L. For those patients with a WBC count above this threshold who are requiring cytoreduction, hydroxyurea is permitted during screening and through Cycle 1, Day 7 in order to reduce WBC count to < 30,000/\u00b5L.\n\nAdequate organ function as evidenced by the following laboratory findings:\n\nTotal bilirubin \u2264 1.5 x upper limit of normal (ULN) or < 3 x ULN for patients with Gilbert's Syndrome\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 x ULN\nCreatinine clearance > 60 mL/min\nAbility to take oral medication and a willingness to adhere to the beta blocker and lisinopril regimen\nQT interval corrects to < 480ms on one electrocardiogram (ECG) at screening\nEchocardiogram demonstrating an ejection fraction \u2265 50% prior to the initiation of induction chemotherapy\n\nExclusion Criteria:\n\nOngoing use of any beta blocker, ACEi, or angiotensin II receptor agonist (ARB) at the time of pre-enrollment screening.\nUncontrolled, intercurrent illnesses including but not limited to symptomatic unstable angina pectoris, cardiac arrhythmias not well controlled with medications, myocardial infarction in the 6 months preceding registration or psychiatric illness/social situations that would limit compliance with study requirements as determined by the study personnel, all at the discretion of the treating oncologist.\nPatient receiving concurrent investigational agents, or those who have received an investigational agent within one week of registration.\nFemales who are pregnant or lactating.\nFor females of reproductive potential: a negative pregnancy test is traditionally required prior to initiation of induction chemotherapy, due to the risk of teratogenicity to the fetus, and patients are advised to either abstain from sexual activity or use reliable contraception while undergoing treatment. All patients will additionally be counseled on the teratogenic effects of ACE inhibitors, in addition to their induction chemotherapy, and counseled to adhere to the recommendations outlined above.\nHistory of other malignancies in the 12 months preceding registration with the exception of in-situ cancers, non-muscle invasive bladder cancer, prostate cancer basal or squamous cell skin cancers.\nLife-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction that, in the investigator's opinion, could compromise the patient's safety or study outcomes.\nRadiographic evidence of extramedullary disease\nAcute Promyelocytic Leukemia (APL) or AML with active central nervous system (CNS) involvement.\nActive, untreated and/or severe infections as determined by the treating oncologist.\nActive and uncontrolled HIV infection, defined as infection possessing a PCR-detectable viral load\nActive infection with the Hepatitis B Virus, defined as having a positive Hepatitis B surface antigen or PCR-detectable viral load\nActive infection with the Hepatitis C Virus, defined as having a PCR-detectable viral load.\nHistory of hematopoietic stem cell transplant (HSCT) with active graft vs host disease, immunosuppression other than low-dose prednisone (\u2264 5mg) or calcineurin inhibitors within the four weeks preceding registration\nModerate or severe mitral or aortic valve disease, as determined by echocardiography\nCongestive heart failure as clinically diagnosed by treating oncologist at the time of presentation for induction chemotherapy, or documented diagnosed by a previous physician.\nHistory of (repaired or unrepaired) congenital heart disease\nSignificant liver disease, including cirrhosis or history of transplant or hepatorenal syndrome)\nBradycardia (defined as baseline resting heart rate \u2264 60 beats per minute) or third degree atrioventricular heart block at presentation for induction chemotherapy.\nBaseline resting systolic blood pressure < 95mmHg at presentation for induction chemotherapy.\nDocumented allergy to beta blockers or ACE inhibitors."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of relapsed or refractory AML (or biphenotypic or bilineage leukemia including a myeloid component). Patients with isolated extramedullary AML are eligible\nAge >= 18 years\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nCreatinine < 2 unless related to the disease\nDirect bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement\nIn the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents. Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principal investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\nMale subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug\nWilling and able to provide informed consent\n\nExclusion Criteria:\n\nPatients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)\nPatients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI)\nPatients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications as determined by the investigator\nPatients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia\nActive and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician\nKnown active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection\nSubject has a white blood cell count > 10 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion)\nAny other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\n\nNursing women, women of childbearing potential (WOCBP) with positive urine or serum pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception\n\nAppropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)"
            },
            {
                  "document": "Inclusion Criteria:\n\nAbility to understand and the willingness to sign a written informed consent\nDiagnosis of AML by World Health Organization (WHO) 2016 criteria (Arber 2016)\nAge >= 18 years\n\nTreatment naive and eligible for venetoclax plus hypomethylating agents (HMA)\n\nAge >= 75 OR\n\nAge 18-74 with at least one of the following co-morbidities:\n\nEastern Cooperative Oncology Group (ECOG) performance status of 2 or 3\nCardiac history of congestive heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) =< 50% or chronic stable angina\nCarbon monoxide diffusing capability test (DLCO) =< 65% or forced expiratory volume in 1 second (FEV1) =< 65%\nAny other situation that the investigator judges to be incompatible with intensive chemotherapy must be reviewed with the study chair before study enrollment\n\nECOG performance status of:\n\n0 to 2 for subjects >= 75 years of age OR\n0 to 3 for subjects 18-74 years of age\nWhite blood cell (WBC) =< 25,000/mm^3 at the start of study therapy (leukapheresis and hydroxyurea are allowed to meet this criteria). No other hematologic parameters\nTotal bilirubin =< 1.5 x institution's upper limit of normal (ULN) unless related to AML or Gilbert's syndrome\nAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum pyruvic glutamic transaminase (SPGT) =< 3 x institutional ULN unless related to AML\n\nCreatinine clearance >= 45 mL/min (calculated by the Cockcroft Gault formula or measured by 24-hour urine collection)\n\nNote, if >= 65 years of age, creatinine clearance or serum creatinine can be used for determining eligibility with creatinine clearance >= 45 mL/min (calculated by the Cockcroft Gault formula or measured by 24-hour urine collection) or serum creatinine =< institution's ULN considered eligible\n\nWomen of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (non-estrogen hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman or female partner of a male subject become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n\nA woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\nHas not undergone a hysterectomy or bilateral oophorectomy; or\nHas not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\nWomen of child-bearing potential has negative pregnancy test prior to initiating study drug dosing\nAble to swallow and retain oral medication\n\nExclusion Criteria:\n\nCurrent or anticipated use of other investigational agents\nDiagnosis of acute promyelocytic leukemia\nActive central nervous system involvement by AML\nAML must be treatment naive. Prior treatment with hypomethylating agent (azacitidine or decitabine), venetoclax or uproleselan, including for antecedent hematologic disorders. Prior allogeneic hematopoietic transplant for antecedent hematologic disorder is allowed if done at least 3 months prior to enrollment and there is no evidence of active graft versus host disease (GVHD) or requirement for systemic immune suppression\nAnticancer therapies, including investigational therapy, chemotherapy, targeted small molecule agents, or radiotherapy within 14 days or 5 half-lives (whichever is shorter) prior to the first dose and throughout venetoclax administration. Biologic agents (e.g. monoclonal antibodies) given for anti-neoplastic intent within 30 days prior to the first dose and throughout venetoclax administration\nKnown diagnosis of human immunodeficiency virus (HIV) infection or known active hepatitis A, B or C infection with the exception of those with an undetectable viral load within 3 months of starting study treatment\nKnown strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment\nSubject has consumed grapefruit, grapefruit products, Seville oranges or Starfruit within 3 days prior to the initiation of study treatment\nSevere or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness/social situations that would limit compliance with study requirements)\nHistory of other malignancies, except for malignancy treated with curative intent with no known active disease present for >= 1 year; treated non-melanoma skin cancer; and localized, cured prostate and cervical cancer\nEvidence of uncontrolled active systemic infection requiring therapy (viral, bacterial, or fungal). Fever of unknown origin is not an exclusion criterion, as this may be disease related\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study\nSubject has a malabsorption syndrome of other condition that precludes enteral route of administration\nSubjects with a cardiovascular disability status of New York Heart Association class greater than 2\nPregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatient is male or female aged \u226518 years.\nPatient provided signed and dated informed consent prior to initiation of any study procedures.\nPatient has relapsed AML after complete remission of any duration as evidenced by presence of neoplastic blasts in the bone marrow confirmed by flow cytometry OR has refractory AML, defined as primary refractory to at least 2 cycles of induction therapy.\nNo other therapy exists or patient has received all standard therapies that would be potentially curative or might provide significant benefit.\nPatient has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2.\nPatient has a predicted life expectancy of \u22653 months.\nPatient has a total white blood cell count of count \u2264 25.0 x 10^9/L at screening and on C1D1. (Patient may have received hydroxyurea prior to the screening sample for elevated WBC but must have discontinued the therapy at least 72 hours prior to screening, and not be treated with hydroxyurea after the screening sample has been taken).\nPatient has adequate renal function (creatinine \u22642 \u00d7 the upper limit of the normal range (ULN) and an estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73 m^2).\n\nPatient has adequate hepatic function, as evidenced by a total bilirubin \u22642 \u00d7 ULN, aspartate aminotransferase (AST) \u22645 \u00d7 ULN and /or alanine aminotransferase (ALT)\n\n\u22645 \u00d7 ULN, unless due to leukemia involvement in the judgement of the Principal Investigator in consultation with the Medical Monitor.\n\nPatient has adequate cardiac function with an ejection fraction (EF) \u226545%, as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO) and corrected QT interval by Fridericia's correction formula (QTcF) <450 msec for males and <470 msec for females. The eligibility of patients with ventricular pacemakers for whom the QT interval may not be accurately measurable will be determined on a case-by-case basis by the Sponsor in consultation with the Medical Monitor.\n\nPatient and his/her partner agree to use adequate contraception after providing written informed consent through 3 months after the last dose of fosciclopirox, as follows:\n\nFor women: Negative pregnancy test during Screening and at Day 1 of each treatment cycle and compliant with a medically-approved contraceptive regimen during, and for 3 months after, the Treatment period or documented to be surgically sterile or postmenopausal.\nFor men: Compliant with a medically-approved contraceptive regimen during, and for 3 months after, the Treatment period or documented to be surgically sterile. Men whose sexual partners are of child-bearing potential must agree to use 2 methods of contraception prior to study entry, during the study, and for 3 months after the Treatment period. Men must also agree not to donate sperm during the Treatment period and for 3 months after the Treatment period.\nPatient is willing and able to participate in the study and comply with all study requirements.\nPrior allogeneic stem cell transplant is allowed as long as patient is more than 100 days post-transplant and has no active graft versus host disease.\n\nExclusion Criteria:\n\nPatients who meet any of the following exclusion criteria are not to be enrolled in this study.\n\nPatient has another active malignancy.\nPatient has acute promyelocytic leukemia (APL) or Ph+ AML.\nPatient has total white blood cell count >25.0 x 10^9/L at C1D1.\nPatient has clinically significant cardiac disease.\nPatient has known chronic active liver disease or evidence of acute or chronic Hepatitis B Virus (HBV) or Hepatitis C (HCV).\nPatient has known diagnosis of human immunodeficiency virus (HIV) infection. Testing is not required in absence of clinical suspicion.\nPatients has any serious and/or uncontrolled concurrent medical conditions (e.g., uncontrolled infection, uncontrolled diabetes) or psychiatric illness that could, in the investigator's opinion, cause unacceptable safety risks or potentially interfere with the completion of the treatment according to the protocol.\nPatient has received any live viral vaccine used for prevention of infectious diseases within 4 weeks prior to Baseline.\nIf female, patient is pregnant or breast-feeding.\nPatient is taking warfarin.\nPatient has known allergy or hypersensitivity to any component of fosciclopirox.\nPatient is taking any iron replacement therapy administered IV, intramuscularly, or orally due to the potential for loss of anticancer activity due to drug and/or metabolites chelating iron.\nPatient is taking Hydrea (hydroxyurea) within 72 hours prior to the screening visit."
            },
            {
                  "document": "Inclusion Criteria:\n\nA histologically or pathologically confirmed diagnosis of AML based on WHO classification. Patients with myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) evolving into AML who are candidates for AML induction therapy are eligible for enrollment.\nAge 18-65 years old.\nECOG performance status < 3.\n\nPatients must have normal organ function as defined below:\n\nTotal bilirubin \u22642X the institutional upper limit of normal (ULN) (except in patients with leukemic infiltration of the liver)\nAST(SGOT)/ALT(SGPT) \u22643X ULN (except if attributable to leukemic infiltration of the liver)\nCreatinine Clearance (CrCl) \u2265 40 mL/min (except in patients with evidence of tumor lysis syndrome)\nLeft ventricular ejection fraction (LVEF) \u226550%\nFemale patients of childbearing potential must have a negative pregnancy test <1 week before enrollment. Female patients of childbearing potential who are sexually active and male patients who are sexually active and have female partners of childbearing potential must agree to use a highly effective method of non-hormonal contraception. Contraception should be used during treatment and for at least 3 months after the last dose of Calaspargase pegol-mknl.\nAbility to understand and willingness to sign a written informed consent document.\nAgree to comply with the study requirements and agrees to come to the clinic/hospital for required study visits\n\nExclusion Criteria:\n\nPatients with the following clinical histories are excluded:\n\nsevere pancreatitis not related to cholelithiasis. Severe acute pancreatitis as defined by lipase elevation >5X ULN and with signs or symptoms\nunprovoked DVT\nPE\nserious or life-threatening thrombosis in any location of the body\nhemorrhagic or thromboembolic stroke\nmajor hemorrhagic event within three weeks before signing ICF; hemorrhage due to thrombocytopenia from underlying AML is excluded\npatients with hemorrhagic diathesis\nneurologic/cerebellar disorders that may confound the toxicity monitoring of HiDAC\nhistory of serious hypersensitivity reactions to pegylated L-asparaginase therapy\nPatients receiving any other investigational agents or concurrent chemotherapy or immunotherapy. Hydroxyurea for blast count control is permitted before starting treatment and up to a maximum of 10 days after starting treatment on the study.\nPatients with AML with any of the following cytogenetic abnormalities: t(15;17), t(8;21), inv(16), t(16;16).\nPregnant women and female patients who are lactating and do not agree to stop breast-feeding.\nUncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements"
            },
            {
                  "document": "Inclusion Criteria:\n\nEastern Cooperative Oncology Group (ECOG) Performance Status 0-2\nWhite Blood Cell count < 20 x 109/L.\nAdequate organ function\nRelapsed/refractory AML or MDS/CMML patients who have failed up to 2 prior therapeutic regimens.\n\nExclusion Criteria:\n\nAcute Promyelocytic leukemia\nSymptomatic central nervous system (CNS) leukemia or patients with poorly controlled CNS leukemia\nLife-threatening (grade 4) immune-mediated adverse event related to prior immunotherapy\nImmune-mediated adverse reaction that required discontinuation of prior immunotherapy\nPast or current history of autoimmune disease or immune deficiency\nHistory of severe interstitial lung disease or severe pneumonitis or active pneumonitis\nClinically significant and poorly compensated liver disease\nPrior organ allografts (such as renal transplant) requiring active immunosuppression\nActive graft versus host disease\nTreatment with systemic immunostimulatory within 4 weeks prior to initiation of study treatment\nTreatment with any CD47/SIRP\u03b1 targeting agent or immune agonists\nKnown allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product\nReceived live, attenuated vaccine within 4 weeks prior to first dose of study treatment\nActive Hepatitis B or C infection\nHistory or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease\nPregnant or breast feeding or planning to become pregnant while enrolled in the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nPediatric patients with diagnosis of CD33 positive (> 3%),\n\nNewly diagnosed secondary AML\nRelapsed refractory acute myeloid leukemia by World Health Organization (WHO) criteria Patients must have >= 5% blasts in the bone marrow as assessed by morphology or flow cytometry. However, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with >= 5% blasts in the peripheral blood\nPediatric Patients with myelodysplastic syndrome (MDS) who progress to AML are eligible at the time of diagnosis of AML regardless of any prior therapy for MDS\nPerformance status: Lansky >= 50 for patients who are =< 16 years old and Karnofsky >= 50% for patients who are > 16 years old\nAge =< 21 years of age\nTotal serum bilirubin =< 2 x upper limit of normal (ULN). Patients with known Gilbert's syndrome may have a total bilirubin up to =< 3 x ULN\nSerum creatinine =< 2.0 mg/dl\nAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN; =< 5 x ULN in case of suspected leukemic liver involvement\n\nFemales of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and for 30 days following the last dose of study drug. Effective methods of birth control include:\n\nBirth control pills, skin patches, shots, implants (placed under the skin by a health care provider)\nIntrauterine devices (IUDs)\nCondom or occlusive cap (diaphragm or cervical/vault caps) used with Spermicide\nAbstinence\nMales, need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment\n\nExclusion Criteria:\n\nHistory of another primary invasive malignancy that has not been definitively treated and in remission. Patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)\nPresence of clinically significant uncontrolled central nervous system (CNS) pathology such as epilepsy, childhood seizure, paresis, aphasia, stroke, severe brain injuries, organic brain syndrome, or psychosis\nEvidence of active cerebral/meningeal disease. Patients may have history of CNS leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of consent with at least 2 consecutive spinal fluid negative assessments for residual leukemia and negative imaging (imaging required only if previously showing evidence of CNS leukemia not otherwise documented by spinal fluid assessment)\nPatients with a cardiac ejection fraction (as measured by either multigated acquisition scan [MUGA] or echocardiogram) < 50% are excluded\nPatients with total cumulative doses of non-liposomal daunorubicin, or other anthracycline equivalent, greater than 450 mg/m^2\nPatients with uncontrolled, active infections (viral, bacterial, or fungal). Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable\nKnown active hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)\nLiver cirrhosis or other serious active liver disease or with suspected active alcohol abuse\nActive acute/chronic graft-versus-host disease (GvHD) requiring systemic treatment; or receiving immunosuppression for GvHD prophylaxis within 2 weeks from the start of study therapy\n\nPrior chemotherapy/radiotherapy/investigational therapy within 2 weeks before the start of study drugs with the following exception:\n\nTo reduce the circulating blast count or palliation: Single dose intravenous cytarabine or hydroxyurea. No washout necessary for these agents\nFemales who are pregnant or lactating\nMale or female subjects of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with institution's standards\nOther severe, uncontrolled acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the Investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study\nPatients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, or bone marrow failure syndromes are not eligible"
            },
            {
                  "document": "Inclusion Criteria:\n\nWritten informed consent obtained prior to any study related procedures required solely for this research study.\nAge \u226518 years.\nPatients with WHO-confirmed non-APL AML who have not responded to or relapsed after at least one prior therapy and for whom no standard therapy that may provide clinical benefit is available.\nEastern Cooperative Oncology Group (ECOG) performance status of \u2264 2.\n\nAdequate hepatic function:\n\nTotal bilirubin < 1.5 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia]; in the case of Gilbert's syndrome the direct bilirubin must be \u22642.0 times the ULN).\n\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 times ULN (except patients with known liver involvement of their AML who must have AST and ALT \u2264 5.0 times ULN).\n\nAdequate renal function: estimated creatinine clearance of \u2265 60 mL/min, calculated using the formula of Cockroft and Gault (140-Age) \u2022 Mass (kg)/(72 \u2022 creatinine mg/dL); multiply by 0.85 if female.\nFemale patients of child-bearing potential must agree to use dual methods of contraception (including one highly effective and one effective method of contraception) and have a negative serum pregnancy test at Screening. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose.\nMale patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose.\n\nExclusion Criteria:\n\nFemale patients who are pregnant or lactating.\nRadiation, chemotherapy, immunotherapy or any other anticancer therapy, including investigational anti-cancer therapy \u2264 2 weeks prior to C1D1. Hydroxyurea is not considered an anti-cancer therapy.\nPatients who have not recovered or stabilized (Grade 1 or to their baseline for non-hematologic toxicities) from toxicities related to their previous treatment, except for alopecia.\nWhite blood cell count \u226525x109/L (hydroxyurea or leukapheresis permitted to reduce to below the exclusion criteria threshold and allow eligibility)\nPatients with known active central nervous system (CNS) disease\nClinically significant severe heart disease\nSubjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment.\nKnown, active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen). Testing is not required.\nPatients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea that could interfere with the absorption of KPT-9274.\nSerious psychiatric or medical conditions that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give consent."
            },
            {
                  "document": "Inclusion Criteria:\n\nDocumented confirmation of acute myeloid leukemia (AML) according to the World Health Organization (WHO) criteria, previously untreated [OR]\nDocumented diagnosis of previously untreated de novo myelodysplastic syndrome (MDS) according to the 2017 WHO classification with presence of < 20% bone marrow blasts per marrow biopsy/aspirate.\n\nParticipants with documented MDS must meet the following disease activity criteria:\n\nOverall revised international prognostic scoring system (IPSS-R) score > 3 (intermediate, high, or very high);\nEastern cooperative oncology group (ECOG) performance status of 0 to 2;\nHematopoietic stem cell transplant (HSCT) ineligible, or participant who chooses not to undergo HSCT.\n\nParticipants with documented AML with adverse cytogenetic and/or molecular risk, and must be considered ineligible for induction therapy defined by the following:\n\n>= 75 years of age; [OR]\n\n>= 18 to 74 years of age with at least one of the following comorbidities:\n\nEastern cooperative oncology group (ECOG) performance status of 2 to 3;\nCardiac history of congestive heart failure requiring treatment or ejection fraction <= 50% or chronic stable angina;\nDiffusion capacity of lung (DLCO) <= 65% or forced expiratory volume during the first second (FEV1) <= 65%;\nCreatinine clearance >= 30 mL/min to < 45 mL/min;\nModerate hepatic impairment with total bilirubin > 1.5 to <= 3.0 \u00d7 upper limit of normal (ULN);\nAny other comorbidity that the physician judges to be incompatible with intensive chemotherapy or the participant declines to receive intensive chemotherapy.\n\nExclusion Criteria:\n\nParticipants with documented AML with acute promyelocytic leukemia and considered eligible for induction therapy.\n\nParticipant with documented AML having prior diagnosis of:\n\nChronic myeloid leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation;\nknown active central nervous system involvement with AML.\n\nParticipants with documented MDS having prior diagnosis of:\n\nTherapy-related MDS;\nMDS evolving from a pre-existing myeloproliferative neoplasm (MPN);\nMDS/MPN including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia and unclassifiable MDS/MPN.\nHistory of allogeneic HSCT or solid organ transplantation.\nPrevious exposure to azacitidine or venetoclax or anti-CD47 therapies.\n\nHistory of an active malignancy within the past 2 years prior to Screening, with the exception of:\n\nAdequately treated carcinoma in situ of the cervix uteri or carcinoma in situ of the breast;\nAdequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin;\nAsymptomatic prostate cancer without known metastatic disease and with no requirement for therapy;\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent.\nConditions that could interfere with drug absorption including but not limited to short bowel syndrome."
            },
            {
                  "document": "Inclusion Criteria:\n\nAbility to understand and the willingness to sign a written informed consent\nDiagnosis of AML by World Health Organization (WHO) 2016 criteria (Arber 2016)\nAge >= 18 years\nTreatment na\u00efve and eligible for venetoclax plus HMA: * Age >= 75 OR * Age >= 18-74 with at least one of the following co-morbidities: ** Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3 ** Cardiac history of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) =< 50% or chronic unstable angina ** Carbon monoxide diffusing capability (DLCO) =< 65% or forced expiratory volume in 1 second (FEV1) =< 65% ** Creatinine clearance >= 30 mL/min to =< 45 mL/min ** Moderate hepatic impairment with total bilirubin > 1.5 to =< 3 x upper limit of normal (ULN) ** Any other situation that the investigator judges to be incompatible with intensive chemotherapy must be reviewed with the study chair before study enrollment\nPatient experienced HMA failure for an antecedent hematologic disorder (e.g. myelodysplastic syndrome) prior to study entry (Santini 2019), defined as: * Disease progression or stable disease as best response to >= 4 cycles of HMA or >= 2 cycles of HMA combination therapy (primary resistance) OR * Relapse or progression after prior response to HMA (secondary resistance)\nPrior decitabine and/or azacitidine, including oral formulations, for antecedent hematologic disorder is required. The patient should be treatment na\u00efve for the AML diagnosis\nPrior allogeneic hematopoietic transplant for antecedent hematologic disorder is allowed if done at least 3 months prior to enrollment and there is no evidence of active graft versus host disease (GVHD) or requirement for systemic immune suppression\nECOG performance status of: * 0 to 2 for subjects >= 75 years of age OR * 0 to 3 for subjects >= 18-74 years of age\nWhole blood cell (WBC) >= 25,000/mm^3 at the start of study therapy (leukapheresis and hydroxyurea areallowed to meet this criteria)\nTotal bilirubin =, 1.5 x institution's ULN unless related to AML or Gilbert's syndrome (subjects who are >= 18-74 may have a total bilirubin of =< 3 x institution's ULN)\nAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SPGT) =< 3 x institutional ULN unless related to AML\nCreatinine clearance >= 30 mL/min (calculated by the Cockcroft Gault formula or measured by 24-hours urine collection)\nWomen of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: ** Has not undergone a hysterectomy or bilateral oophorectomy; or ** Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\nWomen of child-bearing potential has negative pregnancy test prior to initiating study drug dosing\nAble to swallow and retain oral medication\n\nExclusion Criteria:\n\nCurrent or anticipated use of other investigational agents within 14 days or 5 half-lives (whichever is shorter) prior to the first dose and throughout venetoclax administration\nDiagnosis of acute promyelocytic leukemia\nActive central nervous system involvement by AML\nAnticancer therapies, including investigational therapy, chemotherapy, targeted small molecule agents, or radiotherapy within 14 days or 5 half-lives (whichever is shorter) prior to the first dose and throughout venetoclax administration. Biologic agents (e.g. monoclonal antibodies) given for anti-neoplastic intent within 30 days prior to the first dose and throughout venetoclax administration\nPrior therapy with venetoclax\nKnown diagnosis of human immunodeficiency virus (HIV) infection or known active hepatitis A, B or C infection with the exception of those with an undetectable viral load and CD4+ T-cell (CD4+) counts >= 350 cells/\u03bcL within 3 months of starting study treatment. Should have no titers within 28d of day 1. Patients with hepatitis C virus (HCV) infection should have completed curative antiviral treatment\nKnown strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment\nSubject has consumed grapefruit, grapefruit products, Seville oranges or starfruit within 3 days prior to the initiation of study treatment\nSevere or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness/social situations that would limit compliance with study requirements)\nHistory of other malignancies, except for malignancy treated with curative intent with no known active disease present for >= 1 year; treated non-melanoma skin cancer; and localized, cured prostate and cervical cancer\nEvidence of uncontrolled active systemic infection requiring therapy (viral, bacterial, or fungal). Fever of unknown origin is not an exclusion criterion, as this may be disease related\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study\nSubject has a malabsorption syndrome of other condition that precludes enteral route of administration\nSubjects with a cardiovascular disability status of New York Heart Association class greater than 2\nPregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must be RARA-positive based on the investigational assay.\n\nParticipants must have newly diagnosed, previously untreated non-acute promyelocytic leukemia (APL) AML with a bone marrow or peripheral blood blast count \u226520% and must be unlikely to tolerate standard intensive chemotherapy at the time of study entry due to age, performance status, or comorbidities based on at least one of the following criteria:\n\nage \u226575 years old, or\n\nage <75 years old, with at least one of the following:\n\nEastern Cooperative Oncology Group (ECOG) performance status of 3\ncardiac history of congestive heart failure (CHF) or documented ejection fraction (EF) \u226450%\npulmonary disease with diffusing capacity of the lungs for carbon monoxide (DLCO) \u226465% or forced expiratory volume in one second (FEV1) \u226465%\ncreatinine clearance \u226530 milliliters (mL)/minute (min) to <45 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation\nhepatic impairment with total bilirubin >1.5 to \u22643.0 * upper limit of normal (ULN)\nany other comorbidity that the investigator judges to be incompatible with intensive chemotherapy, and reviewed and approved by the sponsor prior to enrollment.\n\nExclusion Criteria:\n\nParticipants have APL.\nParticipants have known active central nervous system involvement with AML.\nPrior treatment for the diagnosis of AML, myelodysplastic syndromes (MDS), or antecedent hematologic malignancy with any hypomethylating agent, venetoclax, chemotherapy, or hematopoietic stem cell transplantation (HSCT), with the exception of prior treatment with hydroxyurea."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients \u2265 18 years of age and weighing at least 40 kg, inclusive, with persistence or relapse/progression of AML, MDS, or MDS/MPN overlap (within 28 days of enrollment) and:\n\na diagnosis of persistence or relapse/progression of AML and \u2265 5% blasts in the marrow or blood following at least 1 cycle of induction therapy, or\na diagnosis of intermediate, high, or very high-risk MDS according to IPSS-R classification (Greenberg et al., 2012) who are resistant or refractory to at least one course of therapy including demethylating agents (having had at least 4 cycles) with \u2265 5% blasts in the marrow or blood, or\na diagnosis of overlap of an MPN with MDS features and also are resistant or refractory to at least one course of therapy including demethylating agents (having had at least 4 cycles) with \u2265 5% blasts in the marrow or blood.\nWritten informed consent in accordance with federal, local, and institutional guidelines.\nMust be able to adhere to the study visit schedule and other protocol requirements.\nHave an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nMeet the following laboratory criteria within 7 days of enrollment:\n\nALT/SGPT and AST/SGOT < 3x the upper limit of normal (ULN) unless due to underlying disease state\nCalculated creatinine clearance \u2265 45.0 mL/min as estimated by Cockcroft Gault and dialysis independent (Cockcroft et al., 1976)\nTotal bilirubin \u2264 2.0 mg/dL (Patients with Gilbert's or Meulengracht Syndrome must have a total bilirubin < 5.0 mg/dL).\nFemales cannot be pregnant or breast-feeding from time of enrollment or for 3 months post final infusion.\nWomen of childbearing potential is willing to use 2 highly effective methods of contraception while receiving study treatment and for an additional 3 months after the last dose of protocol-specified therapy. Men who have a female partner of childbearing potential are together willing to use 2 highly effective forms of contraception for at least an additional 3 months after the last dose of protocol- specified therapy.\nPatients status post allogeneic BMT or other donor lymphocyte infusions are eligible, but they must be at least 60 days from the last infusion of cell therapy products.\nPatients must have other anti-leukemia therapies stopped 2 weeks prior to infusion on this study. Hydroxyurea and/or pheresis ARE allowed prior to this study until 1 day prior to infusion.\n\nExclusion Criteria:\n\nWeight less than 40 kg.\nPatients with progressive infections at time of first infusion (patients with treated infections documented as controlled by the treating team are eligible).\nPatients with history of active seizure disorder (having a documented seizure within the prior year) or any autoimmune disease with CNS involvement.\nMajor surgery, chemotherapy, systemic therapy (excluding hydroxyurea, steroids, and any targeted small molecules or biologics), or radiotherapy within 14 days or 5 half-lives (whichever is shorter) prior to Cycle 1.\n\nPatients with proven, progressive severe autoimmune disease such as multiple sclerosis, active Guillain Barr\u00e9 syndrome, poliomyelitis, Sjogren's are not eligible.\n\nGiven the immediate, life threatening nature of the relapsed cancer in this patient population, those with other stable and non-immediate non-threatening autoimmune disorders (such as thyroid disease or diabetes and others) are eligible.\n\nDiagnosis of any other malignancy within 3 years, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention other than hormonal therapy, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms.\nAny of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism.\nAny active acute Graft-versus-Host Disease (GvHD) > Grade 1 overall or systemic treatment of more than 10 mg prednisone daily (or equivalent); patients must have been off any calcineurin inhibitors for at least 28 days prior to starting therapy on this study.\n\nCurrent use of immunosuppressive medications at the time of study enrollment and within 2 weeks of any study treatments, except:\n\nIntranasal, inhaled, topical steroids, or local steroid injection\nSystemic corticosteroids at physiologic doses \u2264 10 mg/day of prednisone or equivalent\nSteroids as premedication for hypersensitivity reactions at physiologic doses \u2264 10 mg/day of prednisone or equivalent"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must have a diagnosis of AML or ALAL and meet the criteria below:\n\nRefractory leukemia, defined as persistent leukemia after at least two courses of induction chemotherapy, OR\nEarly relapsed leukemia, defined as the re-appearance of leukemia after the achievement of remission and within one year of diagnosis, OR\nRelapsed leukemia that is refractory to at least one course of salvage therapy (i.e., therapy given after the relapse has occurred), OR\nRelapsed leukemia following HCT, OR\nSecond or greater relapse\nPatients with late first relapses, defined as the re-appearance of leukemia after the achievement of remission and greater than one year of diagnosis, may be enrolled in the dose expansion portion of the study after safety data from the dose escalation portion is available.\n\nPatients must have \u2265 5% blasts in the bone marrow as assessed by morphology or flow cytometry. However, if flow cytometry cannot be performed or if an adequate bone marrow sample cannot be obtained (e.g., in a patient with acute megakaryoblastic leukemia with marrow fibrosis), patients may be enrolled if there is unequivocal evidence of leukemia with \u2265 5% blasts in the blood.\n\nIn addition, patients in all categories must not be eligible to undergo curative therapy, such as immediate HCT, because of disease burden, time to identify a stem cell donor, or other reasons.\n\nAdequate organ function defined as the following:\n\nDirect bilirubin \u2264 1.5 x institutional upper limit of normal (ULN)\nNormal creatinine for age or a calculated creatinine clearance \u2265 30 mL/min/1.73m^2\nLeft ventricular ejection fraction \u2265 40% or shortening fraction \u2265 25%\nPatients must be \u2264 30 years old. The upper age limit may be defined by each institution, but may not exceed 30 years. Patients treated at St. Jude Children's Research Hospital must be \u2264 24 years old.\nPerformance status: Lansky \u2265 50 for patients who are \u2264 16 years old and Karnofsky \u2265 50% for patients who are > 16 years old.\nAt least 14 days must have elapsed since the completion of myelosuppressive therapy or hypomethylating agents and the first doses of venetoclax and selinexor.\nAt least 24 hours must have elapsed since the completion of low-dose or non- myelosuppressive therapy, such as hydroxyurea or low-dose cytarabine (up to 100 mg/m^2/day), or leukapheresis, and the first doses of venetoclax and selinexor.\nFor patients who have received prior HCT, there can be no evidence of GVHD and greater than 60 days must have elapsed since the HCT.\nAt least 14 days must have elapsed since the completion of any calcineurin inhibitors (e.g. tacrolimus, cyclosporine).\nPatients may not receive strong or moderate CYP3A inducers, such as rifampin, within 3 days of the first dose of venetoclax or during the administration of venetoclax. During the dose-escalation portion of the trial, we discourage the use of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, voriconazole, posaconazole) within 3 days of the first dose of venetoclax or during the administration of venetoclax. However, if an azole is required for the treatment or prevention of fungal infection during any phase of the trial, venetoclax dosing will be reduced to 60 mg/m^2 (100 mg max) in patients who require treatment with voriconazole and reduced to 40 mg/m^2 (70 mg max) in patients who require posaconazole.\n\nExclusion Criteria:\n\nMust not be pregnant or breastfeeding. Male or female of reproductive potential must agree to use effective contraception for the duration of study participation.\nPatients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, or bone marrow failure syndromes are not eligible.\nUncontrolled infection. Patients with infections that are controlled on concurrent anti-microbial agents are eligible.\nImpairment of GI function or GI disease that, in the opinion of the treating physician, may significantly alter the absorption of venetoclax or selinexor.\nHistory of cerebellar toxicity or cerebellar neurological findings on exam.\nPrevious toxicity or hypersensitivity directly attributed to venetoclax."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge: 18 years old or older, male or female.\nPatients must have histologically or cytologically confirmed tumors of the following types.\n\nDose Escalation Phase: Patients with PMF, PV/ET-MF\n\nIntermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis which failed standard treatment.\nSymptomatic splenomegaly\nNot undergone splenectomy or splenic radiation therapy within 6 months prior to screening.\nDose expansion phase: Patients with PMF, PV/ET-MF who relapsed or are intolerant to standard treatment, and relapsed/refractory AML\nPlatelet count \u2265 100 \u00d7 10e9/L within 14 days before study drug administration\nAbsolute neutrophil count (ANC) \u2265 1.5 \u00d7 10e9/L within 14 days before study drug administration\nWomen of childbearing potential negative pregnancy test at screening. Female patients of childbearing potential, or male patients and their partners should agree to effective contraception from signing ICF until 6 months after the last dose of study drug.\n\nExclusion Criteria:\n\nPatients who meet any of the following exclusion criteria will be excluded from the clinical study:\n\nAllergic to any component of LNK01002.\nSerum total bilirubin greater than 1.5 times the upper limit of the normal (ULN) reference range, except patients diagnosed as Gilbert's disease\nALT or AST higher than 3 times the ULN reference range without hepatic involvement by leukemia, which are excluded if higher than 5 times the ULN\nGlomerular filtration rate or estimated creatinine clearance < 50 mL/min according to the Cockcroft-Gault formula;\nSerum amylase or lipase levels higher than the ULN and considered clinically significant\nInternational normalized ratio (INR) or partial activated prothrombin time (aPTT) above 1.5 times the ULN reference range\n\nKnown history of clinically significant liver disease, including viral or other hepatitis:\n\na) Patients with hepatitis B or hepatitis C may be enrolled if they have a negative polymerase chain reaction (PCR)\n\nKnown human immunodeficiency virus (HIV) infection;\nClinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass surgery within 6 months before enrollment, congestive heart failure with New York Heart Association (NYHA) classification of III or above, left ventricular ejection fraction (LVEF) < 50%, or uncontrolled hypertension, cardiac arrhythmia;\nPatients with history or presence of clinically relevant non-malignant CNS disease requiring treatment\nPatients who have received systemic antineoplastic therapy or radiotherapy within 2 weeks prior to start of study treatment:\nPatients who have received hematopoietic stem cell transplantation (HSCT) within 60 days prior to the start of study treatment, or are receiving immunosuppressive therapy after HSCT at screening, or have graft-versus-host disease (GVHD) requiring drug control:\nReceived anti-tumor Chinese herbal medicine treatment within 1 week before the start of study treatment;\nReceived CYP3A substrates, CYP2B6 substrates, CYP2C substrates, OATP1B3 substrates, UGT1A1 inhibitors, or UGT1A3 inhibitors less than one week or 5 half-lives (whichever is longer) prior to the start of study treatment;\nUncontrolled, active infections requiring intravenous antibiotic treatment;"
            },
            {
                  "document": "Inclusion Criteria:\n\nSubject must be \u2265 18 years of age.\n\nSubject must have a confirmed diagnosis of an advanced hematologic malignancy, specified as follows:\n\nR/R AML (subjects who relapse after transplantation; subjects in second or later relapse; subjects who are refractory to initial induction or reinduction treatment; subjects who relapse within 1 year of initial treatment). Subjects with AML must have previously failed all prior therapies known to be active for treatment of their diagnosed hematologic disease.\nR/R MDS. Subjects with MDS must have previously failed treatment with at least 4 cycles of a hypomethylating agent, known to be active for treatment of their diagnosed hematologic disease.\nSubject must be able to understand and be willing to sign an informed consent.\nSubject must be willing and able to comply with scheduled study visits and treatment plans.\nSubject must be willing to undergo all study procedures (fresh bone marrow biopsy and/or aspirate at baseline within 28 days of first dose plus bone marrow evaluations every 4 weeks for the first 24 weeks, then every 8 weeks for the next 48 weeks of treatment, as clinically indicated thereafter, and 1 EOT bone marrow evaluation (unless contraindicated due to medical risk; other exceptions to this are at the discretion of the Sponsor's Medical Monitor), peripheral blood and tissue sampling, and urine sampling during the study.\nSubject must have an ECOG PS of \u2264 2.\nSubject must have a life expectancy of \u2265 3 months.\n\nSubject must have adequate hepatic function as evidenced by:\n\nSerum total bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN), unless considered due to leukemic involvement following approval by the study Sponsor Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) \u2264 3.0 \u00d7 ULN, unless considered due to leukemic involvement following approval by the study Sponsor\nProthrombin time (PT) \u2264 1.5 \u00d7 ULN or international normalized ratio (INR) \u2264 1.4\nActivated partial thromboplastin time (aPTT) \u2264 ULN\nNo known portal vein thrombosis\n\nSubject must have adequate renal function as evidenced by:\n\n\u2022 Creatinine clearance > 60 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR) estimation\n\nSubject must have an adequate platelet level, defined as:\n\n\u2022 Platelets > 50 \u00d7 109/L (transfusions to achieve this level are allowed.) Subjects with a baseline platelet count of \u2264 50 \u00d7 109/L due to underlying malignancy are eligible with Medical Monitor approval.\n\nSubject must have adequate cardiovascular, respiratory, and immune system function as evidenced by the below criteria and in the opinion of the Investigator:\n\n\u2022 LVEF of \u2265 40% by ECHO\n\nSubjects must agree to discontinue intake of beverages, herbal supplements, or food known to inhibit or induce cytochrome P450 (CYP) 3A such as grapefruit juice, St John's wort, echinacea, and goldenseal from 72 hours before admission until 72 hours following final dose of study drug.\n\nTiming requirements with respect to prior therapy and surgery are as follows:\n\n2 weeks and/or at least 5 half-lives, whichever is shorter, must have elapsed since administration of the last dose of any prior systemic anticancer therapy. Hydroxyurea is allowed prior to enrollment and after the start of FHD-286 for the control of peripheral leukemic blasts in subjects with leukocytosis (eg, white blood cell [WBC] counts > 30 \u00d7 109/L) with approval of the Medical Monitor. (Patients must either be intolerant to and/or have experienced disease progression on their prior therapy in the opinion of the treating physician.)\n4 weeks must have elapsed since the last dose of post-transplant calcineurin inhibitors.\n4 weeks must have elapsed since the last major surgery, 2 weeks for minor surgery (eg, port placement).\n2 weeks must have elapsed since the last radiotherapy. Exceptions may be made in the case of palliative radiotherapy at the discretion of the Medical Monitor.\nToxicity related to prior therapy must have returned to \u2264 Grade 2 by CTCAE at least 14 days prior to study start or be deemed irreversible by the Investigator. Exceptions include alopecia, neuropathy, appropriately controlled endocrine toxicities, and other toxicities similar to these with discussion with the Medical Monitor.\n\nFemale subjects must be:\n\npostmenopausal, defined as at least 12 months post cessation of menses (without an alternative medical cause), or\npermanently sterile following documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation or having a male partner with vasectomy as affirmed by the subject, or\nnonpregnant, nonlactating, and if sexually active having agreed to use a highly effective method of contraception (ie, hormonal contraceptives associated with inhibition of ovulation or intrauterine device [IUD], or intrauterine hormone-releasing system [IUS], or sexual abstinence) from Screening Visit until 90 days after the final dose of the study drug.\n\nNote: The potential risk to female fertility posed by FHD-286 is unknown; it is recommended that subjects discuss options for fertility preservation with their doctor prior to study start.\n\nMale subjects must have documented vasectomy or if sexually active must agree to use a highly effective method of contraception with their partners of childbearing potential (ie, hormonal contraceptives associated with the inhibition of ovulation or IUD, or IUS, or sexual abstinence) from Screening until 90 days after the final dose of the study drug. Male subjects must agree to refrain from donating sperm during this time period.\n\nNote: The potential risk to male fertility posed by FHD-286 is unknown; it is recommended that subjects discuss options for fertility preservation with their doctor prior to study start.\n\nExclusion Criteria:\n\nSubject is unable to provide informed consent and/or to follow protocol requirements.\nSubject has undergone HSCT within 60 days of the first dose of FHD-286, or subject is on immunosuppressive therapy post-HSCT at the time of screening, or subject has clinically significant graft-versus-host disease (GVHD). The use of a stable dose of oral steroids post-HSCT is permitted with Medical Monitor approval.\nSubject has clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of the cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during screening.\nSubject has an immediately life-threatening, severe complications of leukemia, such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.\nSubject has other malignancy which may interfere with the diagnosis and/or treatment of advanced hematologic malignancies.\nSubject has active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections; subjects with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted. Subject has known positive human immunodeficiency virus (HIV)antibody results, or acquired immunodeficiency syndrome (AIDS)-related illness; subjects with CD4+ T-cell counts \u2265 350 cells/\u03bcL will be permitted as will subjects who have not had an AIDS-related illness within the past 12 months.\nSubject has an active severe infection that requires anti-infective therapy or has an unexplained temperature of > 38.5\u00b0C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, subjects with tumor fever may be enrolled).\nSubject has an uncontrolled intercurrent illness.\nSubjects with corrected QT interval (QTc) using Fridericia's formula (QTcF) > 470 msecs or other factors that increase the risk of QTc prolongation or arrhythmic events (eg, heart failure, hypokalemia, family history of long QT interval syndrome) including heart failure that meets New York Heart Association (NYHA) class III and IV definitions are excluded.\nSubject has any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate, or participate in the study.\nSubject has known allergies or hypersensitivities to components of the FHD-286 formulation.\nSubject is unable to tolerate the administration of oral medication or has GI dysfunction that could interfere with absorption of FHD-286 (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, partial bowel resections).\nSubject is receiving any other investigational agents.\nSubject has participated in any other clinical trials within 2 weeks or at least 5 half-lives of a prior investigational drug at the start of study treatment. Exceptions include participation in any observational or nontherapeutic clinical trials.\nSubject is on medications that are strong CYP3A inhibitors, are strong CYP3A inducers, or are sensitive CYP3A substrates with narrow TIs. Exceptions may be made for therapy in the case of life-threatening infections, for example a triazole anti-fungal agent to reduce the risk of invasive fungal infections, at the discretion of the Medical Monitor.\nSubject is on medications with narrow TIs that are sensitive P-gp or breast cancer BCRP substrates and are administered orally, such as digoxin or on medications that are strong inhibitors of P-gp or BCRP.\nSubject on medications that are acid-reducing agents (ARA) such as histamine H2-receptor antagonists (H2 blockers), and proton pump inhibitors (PPIs). The last dose of PPIs must be administered 7 days prior to administration of study drug. Antacids are acceptable when administered in a staggered dosing manner with FHD-286.\nSubject is receiving systemic steroid therapy or any other systemic immunosuppressive medication. The use of a stable dose of oral steroids post-HSCT is permitted with Medical Monitor approval. Local steroid therapies (inhaled or topical steroids) are acceptable. Appropriate steroid replacement to manage endocrine toxicities resulting from prior anticancer systemic therapy is permitted.\nSubject has undergone any prior treatment with a BRG1/BRM inhibitor.\nSubject is pregnant or breastfeeding or is planning to become pregnant within 1 year of study start. Subject is a woman or man of childbearing capabilities who is unwilling to use effective contraception."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of relapsed or refractory acute myeloid leukemia (AML) (or biphenotypic or bilineage leukemia including a myeloid component) or myelodysplastic syndrome\nFor myelodysplastic syndrome (MDS) patients, patients must have no response, progression, or relapse following at least 4 cycles of azacytidine or decitabine; and/or intolerance defined as grade >= 3 drug-related toxicity precluding continued therapy\nAge >= 18 years\nSubjects must have documented RUNX1 gene mutation\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nCreatinine < 2 unless related to the disease\nDirect bilirubin < 2x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3x ULN unless considered due to leukemic involvement\nIn the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (i.e. immunotherapy) agents. Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principal investigator (PI)\nMale subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug\nWilling and able to provide informed consent\n\nExclusion Criteria:\n\nPatients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)\nPatients with any concurrent uncontrolled clinically significant medical condition including active infection or psychiatric illness, which could place the patient at unacceptable risk of study treatment\nPatients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI)\nPatients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications\nKnown active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or known human immunodeficiency virus (HIV) infection\nSubject has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion.)\n\nNursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception\n\nAppropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients receiving first peripheral blood mobilized ex-vivo CD34-selected T cell depleted allo-HCT for the following hematologic malignant conditions:\n\nAcute myeloid leukemia (AML) with intermediate or high-risk features in CR1 or Relapse AML in \u2265 CR2.\nMust have MRD <5% (flow cytometry, molecular and/or cytogenetics accepted).\nAcute leukemias of ambiguous lineage in \u2265 CR1.\nMust have MRD <5% (flow cytometry, molecular and/or cytogenetics accepted).\nAcute lymphoid leukemia (ALL) in CR1 with clinical, flow cytometric, or molecular features indicating a high risk for relapse, or ALL in \u2265 CR2.\nAdult Patients - recommended but not required to be MRDnegative (by flow cytometry, molecular and/or cytogenetics).\nPediatric Patients - Must be MRD-negative by flow cytometry, molecular and/or cytogenetics.\nMyelodysplastic syndromes (MDS) with least one of the following:\nRevised International Prognostic Scoring System risk score of intermediate or higher at the time of transplant evaluation.\nLife-threatening cytopenia.\nKaryotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.\nTherapy related disease or disease evolving from other malignant processes.\nAble to tolerate cytoreduction\n\nPatients age:\n\nRegimen A: 4 - 60 years\nRegimen B - no age restriction\n\nAdequate organ function is required, defined as follows:\n\nHepatic: Serum bilirubin \u2264 2 mg/dL, unless benign congenital hyperbilirubinemia. Patients with hyperbilirubinemia related to paroxysmal nocturnal hemoglobinuria or other hemolytic disorders are eligible with PI approval.\nHepatic: AST, ALT, and alkaline phosphatase < 2.5 times the upper limit of normal unless thought to be disease-related.\nRenal: serum creatinine <1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.\n\nNormal GFR by Age\n\n1 week 40.6 + / - 14.8\n\n2 - 8 weeks 65.8 + / - 24.8\n\n\u00b0> 8 weeks 95.7 +/- 21.7\n\n2 - 12 years 133 +/- 27\n13 - 21 years (males) 140 +/- 30\n13 - 21 years (females) 126.0 + / - 22.0\nCardiac: LVEF \u2265 50% by MUGA or resting echocardiogram.\nPulmonary: Pulmonary function testing (FEV1 and corrected DLCO) \u2265 50% predicted (pediatric patients unable to complete PFTs will need oxygen saturation as recorded by pulse oximetry of \u226592% on room air).\n\nAdequate performance status:\n\nAge \u2265 16 years: ECOG \u2264 1 or Karnofsky 70%\nAge < 16 years: Lansky 70%\nEach patient must be willing to participate as a research subject and must sign an informed consent form or legal guardian with assent as appropriate.\n\nExclusion Criteria:\n\nPatients with active extramedullary disease.\nPatients with active central nervous system malignancy.\nUncontrolled infection at the time of allo-HCT.\nPatients who have undergone previous allo-HCT.\nPatient seropositivity for HIV I/II and/or HTLV I/II.\nFemales who are pregnant or breastfeeding.\nPatients unwilling to use contraception during the study period.\nPatient or parent or guardian unable to give informed consent or unable to comply with the treatment protocol including research tests.\n\nDonor Inclusion Criteria:\n\nRelated Donors:\n\n\u00b08/8 or 7/8 HLA matched at A, B, C, and DRB1 loci, as tested by DNA analysis.\n\nUnrelated Donors:\n\n\u00b08/8 or 7/8 matched at A, B, C, and DRB1 loci, as tested by DNA analysis.\n\nAble to provide informed consent for the donation process per institutional standards.\nMeet standard criteria for donor collection (e.g. National Marrow Donor Program Guidelines or collecting center guidelines as approved by treating physician).\nProvide GSCF mobilized peripheral blood stem cells"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of treated secondary-AML (TS-AML) who have not received therapy for their AML will be eligible\nTS-AML is defined as AML arising from a previously treated antecedent myeloid neoplasm (myelodysplastic syndrome or myeloproliferative neoplasm)\nAge >= 18 years\nTotal bilirubin =< 2mg/dL\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) - or < 5 x ULN if related to leukemic involvement\nCreatinine =< 1.5 x ULN\nKnown cardiac ejection fraction of > or = 45% within the past 6 months\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2\nA negative urine or serum pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial\nPatient must have the ability to understand the requirements of the study and informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol\n\nExclusion Criteria:\n\nPregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided\nUncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPatients with documented hypersensitivity to any of the components of the chemotherapy program\nMen and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation\nPrior treatment with uproleselan\nPatients with a diagnosis of acute promyelocytic leukemia (AML-M3) will be excluded from this study"
            },
            {
                  "document": "Inclusion Criteria:\n\nSubjects must be between 18-65 years of age at the time of signing the Informed Consent Form (ICF) and must be able to meet all study requirements. AML patients under the age of 18 are excluded as is being studied in in patients under 18 years of age in different venues\nMorphologically confirmed diagnosis of AML in accordance with World Health Organization (WHO) diagnostic criteria\nAdverse risk AML per 2017 European LeukemiaNet (ELN) recommendations\nSubjects must be either treatment naive defined by =< 1 cycle of deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) therapy, no history of cytotoxic chemotherapy for their AML; prior treatment with lenalidomide, hydroxyurea or ESAs is allowed (prior treatment for myelodysplastic syndrome [MDS] with > 1 cycle of DNMTi is not allowed)\nA bone marrow aspirate and biopsy must be performed, and tissue collected for entrance to the trial\nEastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\nRecovery to =< grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia\nWhite blood cell count (WBC) < 25,000 (may be reduced with leukopheresis or hydroxyurea prior to study start)\nDirect bilirubin =< 2 x institutional upper limit of normal (ULN)\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional ULN\nCreatinine clearance >= 30 mL/min (per the Cockcroft-Gault formula)\nHuman immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\nFor patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\nPatients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment or have received treatment, they are eligible if they have an undetectable HCV viral load\nTumor lysis present prior to therapy must be treated accordingly prior to start of therapy\nThe effects of venetoclax and ASTX727 on the developing human fetus are unknown. For this reason and because BCL2 inhibitor and DNMTi agents as well as other therapeutic agents used in this trial (cytarabine and daunorubicin) are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal method of birth control or abstinence) prior to study entry and for the duration of study participation, and for 6 months following completion of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception (latex or synthetic condom or abstinence) prior to the study, for the duration of study participation, and 3 months after completion of venetoclax and ASTX727 administration\nAbility to understand and the willingness to sign a written informed consent document\nAdequate cardiac systolic function as measured by ejection fraction (EF) >= 50%\n\nExclusion Criteria:\n\nFavorable or intermediate risk AML as defined by 2017 ELN criteria\nPresence of FLT3 TKD or FLT-ITD mutations\nInability to tolerate oral medication or keep a pill diary\nActive documented central nervous system (CNS) leukemia\nConcurrent treatment with a non-permitted concomitant medication\nConcurrent anticancer treatment, major surgery, or use of any investigational drug within 28 days before the start of trial treatment\nOther malignancy currently being treated or likely to be treated in next 6 months with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ and patients receiving hormonal therapy for prevention of hormone-sensitive cancers\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to venetoclax, ASTX727, or other agents used in study\nPatient must not have received known moderate or strong CYP3A inducers within 7 days of enrollment. Patient must not have known medical conditions requiring chronic therapy of moderate CYP3A inducers. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\nPatients with uncontrolled intercurrent illness\nPatients with psychiatric illness/social situations (including substance abuse) that would limit compliance with study requirements\nPregnant women are excluded from this study because venetoclax and ASTX727 have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax. These potential risks may also apply to other agents used in this study\nPrevious exposure to either venetoclax or > 1 cycle of DNMTi (e.g. azacitidine, decitabine, ASTX727, CC486)\nActive, uncontrolled infection as determined by the investigator. Patients with infection under active treatment and controlled with antibiotics are eligible\nAny condition deemed by the investigator to make the patient a poor candidate for clinical trial and/or treatment with investigational agents"
            },
            {
                  "document": "Inclusion Criteria:\n\nRelapsed or refractory acute leukemia and has exhausted, or is ineligible for, available therapeutic options\nAcute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A) or nucleophosmin 1 gene (NPM1) alterations\nPretreatment clinical laboratory values meeting the following criteria: (a) Hematology: white blood cell (WBC) count less than or equal to (<=) 30 * 10^9/liter (L) (hydroxyurea may be used to lower WBC count at screening and during study; (b) Chemistry: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5 * upper limit of normal (ULN), total serum bilirubin <= 1.5 * ULN (participants with elevated bilirubinemia, such as Gilbert's syndrome, may enroll if conjugated bilirubin is within normal range) and renal function; Estimated or measured glomerular filtration rate greater than or equal to (>=) 60 milliliter per minute (mL/min)/1.73 meter square (m^2) per four variable modified diet in renal disease (MDRD) equation\nEastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1, or 2\nA woman of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment\nA male must agree to all the following during the study and for 90 days after the last dose of study treatment: A male must agree to all the following during the study and for 90 days after the last dose of study treatment: (a) wear a condom when engaging in any activity that allows for passage of ejaculate to another person; (b) not to donate sperm or freeze for future use for the purpose of reproduction. In addition, the participant should be advised of the benefit for a female partner to use a highly effective method of contraception as condom may break or leak\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia according to World Health Organization (WHO) 2016 criteria\nKnown central nervous system (CNS) involvement\nPrior solid organ transplantation\nQTc according to Fridericia's formula (QTcF) for males >= 450 millisecond (msec) or for females >= 470 msec. Participants with a family history of Long QT syndrome are excluded\nExclusion criteria related to stem cell transplant: a. Willing and able to undergo allogeneic stem cell transplant (if clinically indicated); b. Received prior treatment with allogenic bone marrow or stem cell transplant <=3 months before the first dose of study treatment; c. Has evidence of graft versus host disease; d. Received donor lymphocyte infusion <=1 month before the first dose of study treatment; e. Requires immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)\nChemotherapy, targeted therapy, immunotherapy, or radiotherapy within 4 weeks or 5 half-lives (whichever is shorter) before the planned first dose of study treatment"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge \u2265 18 years\n\nParticipants must have pathologically confirmed, newly diagnosed acute myeloid leukemia (AML). The AML may be either:\n\nDe Novo: AML in patients with no clinical history of prior myelodysplastic syndrome (MDS), myeloproliferative disorder, or exposure to potentially leukemogenic therapies or agents\nSecondary AML (sAML): refers to an acute leukemic process (1) evolving from known prior myelodysplasia, myeloproliferative disorder, or aplastic anemia with or without treatment or; (2) as a product of previous exposure to a proven leukemogenic chemotherapeutic agent\nEligible for intensive induction chemotherapy, according to their treating physician\nECOG performance status \u22642 (Karnofsky \u226560%, see Appendix A)\nLeft ventricular ejection fraction > 50% as measured by echocardiogram or MUGA scan\nMust not have received systemic prior antineoplastic therapy for treatment for the newly diagnosed AML, including radiation therapy, except hydroxyurea for the purposes of cytoreduction. Patients may also have received all-trans retinoic acid (ATRA) if there is an early suspicion of acute promyelocytic leukemia (APL, M3-AML), although if confirmed to have APL these patients will be excluded from the study.\n\nAdequate hepatic function per local laboratory reference ranges as follows:\n\nAspartate transaminase (AST) and alanine transaminase (ALT) \u2264 3.0X ULN\nTotal bilirubin \u2264 2.0 x ULN (unless bilirubin rise is known to be due to Gilbert's syndrome or of non-hepatic origin)\nThe effects of venetoclax on the developing human fetus are unknown. For this reason and because other chemotherapeutic agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women should use contraceptives for at least 30 days following the last dose of venetoclax. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of therapy.\nAbility to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nDiagnosis of Acute promyelocytic leukemia (APL) or AML with favorable cytogenetics [t(8;21), inv(16), t(16;16)]\nPatients < 60 years old with NPM1-mutated AML:\nPatients with FLT3-mutated AML (TKD or ITD).\nPatients with acute leukemia with ambiguous lineage or mixed phenotype\nPatients that have received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment.\nSubject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.\nPatients who have had prior systemic cytotoxic chemotherapy or radiotherapy for AML (excluding patients with therapy-related AML), except for hydroxyurea or 6-MP as noted. Empiric intrathecal chemotherapy during a diagnostic lumbar puncture is allowed, as long as CNS disease is not suspected.\nPatients treated with prior hypomethylating therapy (such as azacitidine or decitabine).\nPatients who will exceed a lifetime anthracycline exposure of >550 mg/m2 daunorubicin or equivalent (or >400 mg/m2 daunorubicin or equivalent in the event of prior mediastinal radiation) if they receive the maximum potential exposure to anthracyclines per protocol (including both induction and consolidation cycles.\nIndividuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, breast DCIS, and basal cell or squamous cell carcinoma of the skin.\nCurrent clinical central nervous system (CNS) symptoms deemed by the investigator to be related to leukemic CNS involvement (no lumbar puncture required, clinical assessment per investigator's judgment is sufficient).\nPrior bone marrow transplantation for a myeloid malignancy\nParticipants who are receiving any other investigational agents within the prior 14 days.\nCurrently clinically active hepatitis C or hepatitis B infection, as suggested by serology or viral load.\nHuman immunodeficiency virus (HIV)-infected participants. Patients with no detectable viral load on a stable anti-viral regimen may be eligible, after discussion with the study overall PI.\nCurrent or history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF <50%, as measured by MUGA scan or echocardiogram). Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.\nKnown hypersensitivity to the trial drugs or other contraindication to standard \"7+3\" induction chemotherapy.\nWBC > 25 x 109/L. Note: hydroxyurea is permitted to meet this criterion\nPatients who might refuse to receive blood products and/or have a hypersensitivity to blood products\nPatients with clinically significant persistent electrolyte abnormalities such as hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia of Grade > 1 per NCI CTCAE, v5.0. Treatment for correction of above electrolyte imbalances is permitted during screening to meet eligibility.\nUncontrolled intercurrent illness including, but not limited to, clinically ongoing or active infection requiring intravenous antibiotics (IV antibiotics are allowed if infection is deemed to be controlled), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nKnown GI disease or GI procedures that could interfere with the oral absorption or tolerance of the study drugs. Examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease.\nPregnant women are excluded from this study because venetoclax and azacitidine, along with standard induction chemotherapy, carries the potential for teratogenic or abortifacient effects. Because there is potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax as well as azacitidine, cytarabine, daunorubicin and idarubicin, breastfeeding should be avoided. Confirmation that the subject is not pregnant must be established by a negative serum \u00df-human chorionic gonadotropin (\u00df-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.\nPatients with psychological, familial, social, or geographic factors that otherwise preclude them from giving informed consent, following the protocol, or potentially hamper compliance with study treatment and follow-up.\nPatients who are otherwise felt unable to comply with the protocol, in the opinion of the investigator."
            },
            {
                  "document": "Inclusion Criteria:\n\nAcute myeloid leukemia (per the World Health Organization [WHO] 2016 classification) or high-grade myeloid neoplasm (>= 10% myeloid blasts in peripheral blood or marrow)\n\nNewly diagnosed patients must have adverse risk disease as per the European LeukemiaNet 2017 guidelines\nRelapsed/refractory patients must require first or subsequent salvage therapy\nPatients with biphenotypic or mixed phenotype acute leukemia are eligible\nAge >= 18 years\nAspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 X upper limit of normal (ULN)\nBilirubin =< 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)\nSubject must have adequate renal function as demonstrated by a creatinine clearance >= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection\nLeft ventricular ejection fraction (LVEF) >= 45%, assessed by multigated acquisition (MUGA) or echocardiogram (ECHO) within 3 months prior to study day 0 or after most recent anthracycline administration if appropriate\nEastern Cooperative Oncology Group (ECOG) =< 2\nTreatment-related mortality (TRM) score < 13.1\nFemale subjects of childbearing potential must have negative results for pregnancy test\nAbility to understand and the willingness to sign a written informed consent document\nWhite blood cell count in peripheral blood must be < 25,000/ul prior to initiation of study therapy (CLAG-M plus venetoclax). Cytoreduction with hydroxyurea and/or cytarabine (e.g., 500 mg/m^2 per dose) is allowed to decrease the risk of tumor lysis syndrome\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia or chronic myeloid leukemia in myeloid blast crisis\nKnown active central nervous system (CNS) involvement with acute myeloid leukemia (AML)\nConcomitant illness associated with a likely survival of < 1 year\nActive systemic infection, unless disease is under treatment with antimicrobials and considered controlled or stable; patients with fever thought to be likely secondary to leukemia are eligible. Patients with chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment would be excluded. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface [HBs] antigen negative-, anti-HBs antibody positive and anti-hepatitis B core [HBc] antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate\nActive or clinically significant (or symptomatic) cardiac disease, including active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin within the last 3 months, unstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before study day 0\nKnown hypersensitivity to any study drug\nPregnancy or lactation because of the unknown risks of this combination\nConcurrent treatment with any other investigational agent\nSubject is known to be positive for human immunodeficiency virus (HIV)\n\nTreatment with any of the following within 7 days prior to the first dose of venetoclax\n\nSteroid therapy for anti-neoplastic intent\n\nAdministration or consumption of any of the following within 3 days prior to the first dose of venetoclax:\n\nGrapefruit or grapefruit products\nSeville oranges (including marmalade containing Seville oranges)\nStar fruit"
            },
            {
                  "document": "Key Inclusion Criteria:\n\nRelapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML)\nMorphological disease in the bone marrow and/or peripheral blood within 28 days before enrollment\nPrior exposure to the relevant agent class for individuals with AML characterized by a mutation targeted by an approved therapy\nInstitutional criteria for allo-SCT fitness must be met: individuals must have an identified stem-cell donor readily available for potential allo-SCT after therapy with KITE-222\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nAdequate hematologic status, defined as:\n\nAbsolute neutrophil count (ANC) \u2265 1000/\u00b5L unless, in the opinion of the investigator, cytopenia is due to underlying leukemia\nPlatelet count \u2265 50,000/\u00b5L unless, in the opinion of the investigator, thrombocytopenia is due to underlying leukemia\nAbsolute lymphocyte count (ALC) \u2265 100/\u00b5L\n\nAdequate renal, hepatic, pulmonary and cardiac function defined as:\n\nCreatinine clearance (as estimated by the Cockcroft Gault formula) \u2265 60 mL/min\nSerum alanine aminotransferase/aspartate aminotransferase \u2264 2.5 x upper limit of normal\nTotal bilirubin \u2264 1.5 mg/dL, except in individuals with Gilbert's syndrome\nCardiac ejection fraction \u2265 50%, no clinically significant pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings\nBaseline oxygen saturation > 92% on room air and no clinically significant pleural effusion as determined by chest imaging\nContraception: males and females of childbearing potential must agree to use an effective method of contraception\nPregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test\n\nKey Exclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia\nAuto-SCT within the 6 weeks before enrollment\nDonor Lymphocyte Infusions (DLI) within 28 days prior to enrollment\nAny drug used for graft-versus-host-disease (GVHD) within 4 weeks prior to enrollment\nAcute GVHD grade II-IV by Mount Sinai Acute GVHD International Consortium criteria\nActive central nervous system (CNS) disease involvement\nRequirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) or the possible requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, spinal cord compression, bowel obstruction, leukostasis, or TLS) at the time of enrollment or KITE-222 infusion\nHistory of C-type lectin-like molecule-1 (CLL-1)-directed therapy or genetically modified T-cell therapy\nHistory of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder, or breast) unless disease free for at least 3 years after the last definitive therapy\nHistory of severe hypersensitivity reaction to aminoglycosides\nHistory of concomitant genetic syndrome associated with bone marrow failure\nIndividuals with a genetic syndrome that increases the risk of allo-SCT, including Down syndrome (trisomy 21)\nHistory of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment\nIndividuals with cardiac atrial or ventricular leukemia involvement\nHistory of symptomatic deep vein thrombosis (DVT) or a pulmonary embolism within 6 months of enrollment. History of upper extremity line related DVT within the 3 months of conditioning chemotherapy.\nPrimary immunodeficiency disorders\nHistory of a human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection\nHistory of an autoimmune disease resulting in end-organ injury or requiring systemic immunosuppression or systemic disease modifying agents within the last 2 years\nHistory or presence of a CNS disorder\nPresence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management\nLive vaccine received within the \u2264 4 weeks before enrollment, or anticipation of the need for a live vaccination during the course of the study\nInability to tolerate prophylactic antifungal and antibacterial therapy\nPresence of any indwelling line or drain\nOngoing Grade 2 or higher toxicities from previous therapies, excluding hematologic toxicities\nFemales of childbearing potential who are pregnant or breastfeeding\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply."
            },
            {
                  "document": "Individuals with histological confirmation of AML by World Health Organization criteria, previously untreated for AML, and who have presence of at least 1 TP53 gene mutation that is not benign or likely benign based on evaluation by central laboratory (individuals with biallelic 17p deletions, loss of both 17p alleles, are eligible based on locally evaluated cytogenetics/karyotype/fluorescence in situ hybridization (FISH) report)\nIndividuals with white blood cell (WBC) count \u2264 20\u00d710^3/microliter (\u03bcL) prior to randomization. If the individual's WBC is > 20\u00d710^3/\u03bcL prior to randomization, the individual can be enrolled, assuming all other eligibility criteria are met. However, the WBC should be \u2264 20\u00d710^3/\u03bcL prior to the first dose of study treatment and prior to each magrolimab dose for the first 4 weeks (if the individual is randomized to the experimental arm) Note: Individuals can be treated with hydroxyurea throughout the study or prior to randomization to reduce the WBC to \u2264 20\u00d710^3/\u03bcL to enable eligibility for study drug dosing. Oral etoposide (up to 200 mg orally per day) may be given as an alternative to hydroxyurea for individuals who are intolerant to hydroxyurea or cannot achieve sufficient WBC lowering on hydroxyurea.\nThe hemoglobin must be \u2265 9 grams per deciliter (g/dL) prior to initial dose of study treatment. Note:Transfusions are allowed to meet hemoglobin eligibility\nIndividual has provided informed consent\nIndividual is willing and able to comply with clinic visits and procedure outlined in the study protocol\nIndividuals must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, except for individuals less than 75 years of age and appropriate for non-intensive treatment. For these individuals, the ECOG performance status score may be 0 to 3\nIndividuals must have adequate renal function as demonstrated by a creatinine clearance \u2265 30 milliliters per minute (mL/min); calculated by the Cockcroft Gault formula\n\nAdequate cardiac function as demonstrated by:\n\n\u2022"
            },
            {
                  "document": "Inclusion Criteria:\n\nAble to read, speak and consent in English\nIndividuals newly diagnosed with either acute myelogenous (AML) or chronic lymphocytic leukemia (CLL), defined as within three months of diagnosis\nInternet access via smart phone, tablet, a computer, or another device with the capacity to receive calls, texts, or e-mails, as well as the electronic study assessments\nIndividuals with a prior history of myelodysplastic syndrome (MDS) will be allowed to enroll\n\nExclusion Criteria:\n\nIndividuals who are terminally ill, defined as individuals identified by their physician as likely having 6 months or less to live, or those individuals transitioned to comfort measures only (meaning only supportive care measures without curative focused treatment)\nIndividuals who have undergone treatment for previous diagnoses of leukemia\nIndividuals for whom there is documentation of inability to provide consent in the medical record"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of relapsed or refractory acute myeloid leukemia (AML) (including biphenotypic or bilineage leukemia including a myeloid component or isolated extramedullary AML); OR\nPatients (> 60 year old) with newly diagnosed AML not eligible for intensive chemotherapy are also eligible\nAge >= 18 years\nSubjects must have documented IDH1 or IDH2 gene mutation\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nAdequate renal function including creatinine < 2 unless related to the disease\nDirect bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5 x ULN will be considered eligible)\nIn the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy agent(s). Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principle investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\nMale subjects who are sexually active with a women of childbearing potential (WOCBP) and who have not had vasectomies must be willing to use a barrier method of contraception and refrain from sperm donation from initial study drug until 90 days after last dose of study drug\nWilling and able to provide informed consent\n\nExclusion Criteria:\n\nPatients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)\nPatients with any concurrent uncontrolled clinically significant medical condition including life-threatening severe infection, or psychiatric illness, which could place the patient at unacceptable risk of study treatment\nPatients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI)\nPatients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications\nCorrected QT (QTc) interval using Fridericia's formula (QTcF) >= 450 msec. Bundle branch block and prolonged QTc interval are permitted after discussion with the PI\nKnown active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection\nSubject has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion)\n\nNursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception\n\nAppropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)"
            },
            {
                  "document": "Inclusion Criteria:\n\nMale or female subjects, \u2265 18 years of age at the time of Screening with the following exception as outlined below:\n\n\u2022 For T cell ALL subjects with age between 13 - 18 years, their body weight shall be \u2265 40 kg (for Phase 1b only).\n\nEligible subject must have an advanced hematologic malignancy including:\n\nRelapsed or refractory NHL (NHL histologies [MZL, FL, WM, DLBCL, ATLL, PTCL, AITL, ALCL, MCL] are to be included per the 2016 World Health Organization [WHO] criteria) subjects, must have histologically documented diagnosis of a non-Hodgkin lymphoma as defined in the WHO classification scheme. Subjects have received at least 2 prior therapies and have no available therapies known to provide clinical benefits; For subjects with indolent NHL (Grade 1~3a FL, MZL) who have received two prior systemic therapies and have relapsed or progressed according to 2014 Lugano; NHL subjects with high risk for Tumor Lysis Syndrome (TLS) are not eligible until an MTD or RP2D is reached in subjects with low or medium risk for TLS;\nTransformed, follicular, MZL, WM (to large cell or aggressive lymphoma) subjects who must have received at least one prior systemic therapy for the transformed lymphoma (unless combination chemotherapy is not appropriate);\nRichter transformation (RT): previously treated CLL and biopsy-proven Richter transformation with DLBCL histology after receiving at least one regimen for RT\nT-cell prolymphocytic leukemia (T-PLL) subjects who have received one therapy for this and are relapsed or refractory; T-PLL subjects with high risk for TLS are not eligible until an MTD or RP2D is reached at subjects with low or medium risk for TLS;\nRelapsed or refractory multiple myeloma (MM) subjects who have received a PI, an IMiD, and an anti-CD38 and have no treatment options available known to provide clinical benefits; MM subjects with high risk for TLS are not eligible until an MTD or RP2D is reached in subjects with low or medium risk for TLS;\nMDS subjects with refractory anemia with excess blasts (RAEB; subtype RAEB-1 or RAEB-2) as defined by WHO 2016 revised criteria and/or MDS with high- or very high-risk (risk score > 4.5) per the Revised International Prognostic Scoring System (IPSS-R) who have no available therapies known to provide clinical benefit;\nMorphologically confirmed diagnosis of MDS/MPN, excluding juvenile myelomonocytic leukemia (JMML), in accordance with WHO 2016 revised criteria, that is relapsed and/or refractory and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits;\nMorphologically confirmed diagnosis of MF in accordance with the WHO 2016 revised criteria, that is relapsed, intolerant and/or refractory and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits;\nRelapsed or primary refractory AML subjects (including de novo AML, secondary AML evolving from MDS or MPN, and therapy-related AML) as defined by WHO 2016 revised criteria, subjects who have no available therapies known to provide clinical benefits; subjects with prior BCL-2 inhibitor therapy are permitted;\nRelapsed or refractory ALL subjects with B cell phenotype who have received at least two prior regimens (such as multi-agent chemotherapy and/or tyrosine kinase inhibitors including bosutinib, dasatinib, imatinib, nilotinib or ponatinib) and failed, or are currently ineligible/intolerant for CD19-based target therapy (e.g. Blinatumomab); Relapsed or refractory ALL subjects with T cell phenotype who have received at least one prior therapy and failed.\nFor Group 2 AML and ALL subjects only, white blood cell (WBC) count \u2264 25 \u00d7 109 cells/L at the time of enrollment (glucocorticoids or hydroxyurea is permitted to control WBC count prior to and during therapy).\nAdequate cardiac function defined as shortening fraction of \u2265 27% by echocardiogram, or ejection fraction of \u2265 50% by echocardiogram or radionuclide angiogram (nuclear medicine analysis) if there is history of anthracycline exposure.\n\nSubject must have adequate bone marrow (independent of growth factor support), coagulation, renal, and hepatic function, per laboratory reference ranges at Screening as follows:\n\nBone marrow criteria: Group 1 (r/r NHL, RT, MM, T-PLL):\n\nAbsolute Neutrophil Count (ANC) \u2265 1 x 109/L (An exception is for subjects with an ANC<1 x 109/L and bone marrow heavily infiltrated with underlying disease [approximately 60% or more] may use growth factor to achieve the ANC eligibility criteria per discussion between the Investigator and the Medical Monitor),\nPlatelets \u2265 50 x 109/L on day of screening (entry platelet count must be independent of transfusion with 14 days of screening);\nHemostasis criteria: Activated partial thromboplastin time (APPT) and prothrombin time (PT) \u2264 1.5 \u00d7 the upper limit of normal (ULN);\nRenal function criteria: Serum creatinine \u2264 ULN (per local institution reference range) or Calculated creatinine clearance (Cr Cl) \u2265 60 mL/min using 24-hour CrCl OR by Cockcroft-Gault formula using actual body weight.\nHepatic function criteria: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 3.0 \u00d7 ULN; bilirubin \u2264 1.5 \u00d7 ULN (except subjects with Gilbert's Syndrome, who may have a bilirubin > 1.5 \u00d7 ULN, per discussion between the Investigator and the Medical Monitor).\n\nExclusion Criteria:\n\nA subject will not be eligible for study participation if he/she meets any of the following criteria.\n\nSubjects who have undergone autologous/allogeneic hematopoietic stem cell transplantation (HSCT) therapy within 60 days of the first dose of LP-118, or subjects on immunosuppressive therapy post-HSCT at the time of Screening, or currently with clinically significant graft-versus-host disease (GVHD) as per treating physician (Subjects in relapse after allogeneic transplantation must be off treatment with systemic immunosuppressive agents for at least 4 weeks. The use of topical steroids and/or up to 20 mg/day prednisone or equivalent systemic steroids for ongoing GVHD is permitted).\n\nSubject has a history of other malignancies within past 12 months that are active and could result in competing risks. These cases shall be discussed with the Medical Monitor with exception below\n\nSubject with breast cancer or prostate cancer on endocrine therapy with stable disease;\nAdequately treated in situ carcinoma of the cervix uteri;\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent.\n\nSubject has received any of the following therapies within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of LP-118, or has not recovered to \u2264 Grade 2 clinically significant AEs of the previous therapy (excluding alopecia or neuropathy):\n\nAny anti-neoplastic therapy including chemotherapy, hormonal therapy, radiotherapy, biologic or immunotherapy, targeted small molecule agents, etc. (corticosteroid therapy < 20 mg/day prednisone equivalent and hydroxyurea cytoreduction therapy according to institutional guidelines to treat disease associated symptoms are permitted);\n\nFor MF subjects who come off JAK2 antagonists, allow washout for 2 days as these subjects progress quickly after treatment discontinuation and remain eligible (steroids may be given during these two days to allow disease control).\nSubjects in need of immediate cytoreduction should be excluded.\nAny investigational therapy.\nLive vaccines\n\nSubject has received the following medications, therapies or natural products within 7 days prior to the first dose of LP-118:\n\nCytochrome P450, family 3, subfamily A (CYP3A) strong inhibitors (itraconazole, etc) or inducers (phenytoin, rifampin, etc);\nInhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).\nSubject has baseline prolongation of the heart rate-corrected QT (QTc) interval \u2265 480 ms (calculated per Fridericia's formula [QTc = QT/RR(1/3)]) ), a cardiovascular disability status of New York Heart Association Class \u2265 2 or associated other significant screening ECG or ultrasonic cardiogram abnormalities, per Investigator's judgement.\nSubject has significant a history of congenital long QT syndrome or Torsades de pointes, uncontrolled or symptomatic arrhythmias, congestive heart failure, myocardial infarction, stroke or intracranial hemorrhage within 6 months prior to the first dose of LP-118.\n\nSubject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:\n\nUncontrolled active systemic infection (bacterial, fungal, viral);\nKnown poorly controlled of human immunodeficiency virus (HIV) or active hepatitis B or C infection (active hepatitis B defined as HBsAg positive, or HBcAb positive with detectable HBV DNA load; active hepatitis C defined as HCV antibody positive with HCV RNA positive);\nUnexplained fever > 38.5\u00b0C within 7 days prior to the first dose of study drug administration (at the discretion of the Investigator, if the fever is considered attributed to the subject's malignancy or an explained infection may be enrolled).\nSubjects with known and active central nervous system (CNS) involvement at Screening."
            },
            {
                  "document": "Inclusion Criteria:\n\nCytologically or histologically confirmed diagnosis of relapsed/refractory or newly diagnosed AML per WHO 2016 classification.\nPhase 1a: AML that is relapsed/refractory or that is previously untreated in patients not considered suitable for intensive induction therapy.\nPhase 1b: AML that is relapsed/refractory after prior treatment with a HMA-based regimen.\nPhase 2: Previously untreated AML in patients who are not considered suitable candidates for intensive induction therapy.\nAdequate renal and liver function.\nAge \u226518 years.\nAdequate performance status.\n\nExclusion Criteria:\n\nIn Phase 1a and 1b, patients that have undergone prior allo-HSCT must be at least 3 months post-HSCT, without uncontrolled graft-versus-host disease (GVHD). For Phase 2, patients that have undergone prior allo-HSCT are excluded.\nPatients with newly diagnosed AML with favorable risk cytogenetics such as t(8;21), inv(16), or t(16;16) as per the NCCN Guidelines Version 3, 2019 for AML.\nPatients with acute promyelocytic leukemia (APL).\nPrior treatment with any anti-CD47 or anti-SIRPalpha (signal regulatory protein alpha) agent.\nKnown active viral infections, including hepatitis B and C, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)."
            },
            {
                  "document": "Inclusion Criteria:\n\nProvision of written (signed) informed consent form (ICF) by the subject or legal guardian prior to the performance of any study-specific procedures, according to International Council on Harmonisation (ICH) and local regulatory requirements. Subject must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible toxicities) and must sign and date an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form (ICF)(including Health Insurance Portability and Accountability Act authorization [HIPAA], if applicable) before performance of any study-specific procedures or examinations\nSubjects must be willing and able to comply with the protocol\nSubjects with AML or ALL, diagnosed according to the 2016 criteria by the World Health Organization (WHO) who are refractory or relapsed (any salvage) with no available therapies or not candidates for available therapies. For subjects with prior MDS or chronic myelomonocytic leukemia (CMML) or MPN who transformed to AML, therapy received for MDS, CMML, or MPN is NOT considered as prior therapy for AML except for MDS or CMML treated with HMAs. Subjects with MDS or CMML treated with HMA therapies who progress to AML and have no available therapies or are not candidates for available therapies, will be eligible at the time of progression to AML. In Phase 1: all R/R AML or R/R ALL subjects irrespective of mutations will be eligible. In Phase 2 Cohort A only R/R AML with MLLr will be eligible. In Phase 2 Cohort B only R/R AML with NPM1m will be eligible. In Phase 2 Cohorts C and D: Only R/R AML or R/R ALL subjects with an MLLr or NPM1m will be eligible\nPrior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is permitted\nAge 18 years or older\nEastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\nTotal bilirubin =< 1.5 times upper limit of normal (x ULN)\nAspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (aspartate aminotransferase or alanine aminotransferase =< 5.0 x ULN if deemed related to leukemia by the treating physician)\nCreatinine clearance >= 50 mL/min as calculated using the modified Cockcroft-Gault equation\nSerum electrolytes within the institution's normal limits: potassium, calcium (total calcium, calcium corrected for serum albumin in case of hypoalbuminemia or ionized calcium) and magnesium. If outside of the institution's normal range, subject will be eligible when electrolytes are corrected\nIn the absence of rapidly progressive disease, the interval from prior treatment to the time of initiation of protocol therapy will be at least 14 days for prior anti-leukemic therapy with the exception of hydroxyurea as noted below OR at least 5 half-lives for cytotoxic/noncytotoxic agents, whichever is shorter. The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochure's, or drug-administration manuals) and will be documented in the protocol eligibility document. Since the effect of therapy may be delayed, use of hydroxyurea for subjects with rapidly proliferative disease is allowed before the start of study therapy and on study and hydroxyurea will not require a washout\nConcurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted. Subjects with a known history of CNS disease or leukemic brain metastasis must have been treated locally, have at least 3 consecutive lumbar punctures (LPs) with no evidence of CNS leukemia, and must be clinically stable for at least 4 weeks prior to enrollment and have no ongoing neurological symptoms that in the opinion of the treating physician are related to the CNS disease (sequelae that are a consequence of the treatment of the CNS disease are acceptable)\nFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment\n\nWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 4 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment. Adequate methods of contraception include:\n\nTotal abstinence when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.\nFemale sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment\nMale sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject\n\nCombination of any of the two following (a+b or a+c or b+c)\n\na. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.\nb. Placement of an intrauterine device (IUD) or intrauterine system (IUS).\nc. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.\nIn case of use of oral contraception, women should have been stable on the same pill before taking study treatment.\nNote: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction. Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential\n\nExclusion Criteria:\n\nSubjects with a known allergy, hypersensitivity, or contraindication to the protocol therapies or any of their components to be used in the arm the subject is to be enrolled on\n\nUncontrolled or significant cardiovascular disease, including any of the following:\n\nBradycardia of less than 50 beats per minute, unless the subject has a pacemaker;\nCorrected QT interval Fridericia's Correction Formula (QTcF) interval > 450 msec;\nDiagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);\nSystolic blood pressure >=180 mmHg or diastolic blood pressure >=110 mmHg;\nHistory of clinically relevant ventricular arrhythmias within 6 months prior to screening (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);\nHistory of second (Mobitz II) or third-degree heart block (subjects with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);\nHistory of uncontrolled angina pectoris, unstable angina or myocardial infarction, coronary artery bypass graft (CABG), cerebrovascular accident (CVA), transient ischemia attack (TIA), symptomatic pulmonary emboli within 6 months prior to screening;\nNew York Heart Association Class 3 or 4 heart failure;\nLeft ventricular ejection fraction (LVEF) =< 50 or less than the institutional lower limit of normal;\nComplete left bundle branch block (right bundle branch block is permitted, but requires manual reading of the QTc interval);\nActive cardiac dysrhythmias of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 (eg, atrial fibrillation)\nPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 5.0; however, alopecia and sensory neuropathy grade 2 or lower is acceptable\nUnderwent HSCT within 90 days of the first dose of protocol therapy, or subjects with clinically significant (grade 2 or greater) graft-versus-host disease (GVHD) (the use of topical steroids for ongoing cutaneous GVHD is permitted)\nSubjects with symptomatic CNS leukemia or subjects with poorly controlled CNS leukemia\nActive and uncontrolled disease (active infection requiring systemic therapy, fever likely secondary to infection within prior 48 hours, uncontrolled hypertension despite adequate medical therapy as judged by the treating physician)\nActive (uncontrolled, metastatic) other malignancies\nMajor surgery within 28 days prior to the first dose of protocol therapy\nKnown dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally\nKnown history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (test at screening only if required by local regulations)\nKnown history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection with active Hepatitis B or C infection at screening (positive HBV surface antigen or HCV ribonucleic acid [RNA] if anti-HCV antibody screening test positive)\nVaccination within 4 weeks of the first dose of study drug and while on trials is prohibited except for administration of inactivated vaccines\n\nSubjects who are currently receiving treatment with medication that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of DS-1594b treatment:\n\nMedications that may prolong QTc interval and have a known risk of inducing Torsades de Pointes unless it is vital for the care of the subjects\nStrong inhibitors or inducers of CYP3A\nCYP3A and CYP2C19 substrates with narrow therapeutic index\nSubjects who consume grapefruit products, Seville oranges, or star fruit within 3 days prior to the first DS-1594b administration and until the last day of DS-1594b is completed\nSUB-STUDIES: Subjects who are currently receiving moderate inhibitors or inducers of CYP3A who cannot discontinue at least one week prior to the start of DS-1594b treatment till the end of sub-study period\nSUB-STUDIES: Subjects who are currently receiving proton pump inhibitors who cannot discontinue at least 2 days prior to the start of DS-1594b treatment till the end of sub-study period\nOther severe acute or chronic medical conditions that is active and not well controlled including renal, skeletal muscle, adrenal insufficiency, colitis, inflammatory bowel disease, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study\n\nSubjects unwilling or unable to comply with the protocol, including:\n\nPregnant or breastfeeding women or women of childbearing potential who are unable to comply with appropriate contraception as outlined in or who plan to become pregnant while in the study or for at least 6-7 months after last administration of study treatment\nKnown alcohol or drug abuse within the last 1 year\nIn a man whose sexual partner is a woman of childbearing potential, unwillingness or inability to use an acceptable contraceptive method for the entire study period and for at least 3 months after study completion\nAcute promyelocytic leukemia (APL)\nUncontrolled or poorly controlled adrenal or pituitary disease (including adrenal insufficiency, Addison's disease, Cushing's disease)"
            },
            {
                  "document": "Documented diagnosis of MDS, according to World Health Organization (WHO) classification and Revised International Prognostic Scoring System (IPSS-R) overall score \u2265 4.5 Or\n\nDiagnosed AML according to the 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia: \u226520% blasts in peripheral blood or bone marrow\n\nAdult \u226518 years of age\n\nMDS relapse following treatment with azacitidine or decitabine Or\n\nMDS failure to achieve complete or partial response or stable disease with hematologic improvement after at least 4 cycles of azacitidine or decitabine, all within the last 1 year Or\n\nMDS progression while on azacitidine or decitabine treatment irrespective of the number of cycles the patient has received Or\n\nAML relapse after initial CR/CRi/CRh following treatment with: azacitidine, decitabine, Low-Dose Ara-C (LDAC) , venetoclax+HMA, or venetoclax+LDAC Or\n\nAML failure to achieve CR, CRh or CRi following at least 4 cycles of azacitidine or decitabine or 2 cycles of venetoclax+HMA or venetoclax+LDAC within the last 1 year.\n\nOr\n\nAML progression while on azacitidine, decitabine, LDAC, venetoclax+HMA, venetoclax+LDAC, irrespective of the number of cycles the patient has received.\n\nNot able to receive an allogeneic bone marrow transplantation (BMT) at the time of study enrolment.\n\nNot eligible for intensive chemotherapy;\n\nAge \u226575 years Or\nAge \u226518 years with at least one of the following comorbidities:\nSignificant heart or lung comorbidities, as reflected by at least one of the following:\nLeft ventricular ejection fraction (LVEF) \u226450%\nLung diffusing capacity for carbon monoxide (DLCO) \u226465% of expected\nForced expiratory volume in 1 second (FEV1) \u226465% of expected\nChronic stable angina or congestive heart failure controlled with medication\nOther comorbidity or conditions that the Investigator judges as incompatible with intensive chemotherapy, which must be documented\nECOG=2\nCreatinine clearance (estimated by the Modification of Diet in Renal Disease (MDRD) equation or measured by 24 hours urine collection) \u226545 mL/min\nLiver enzymes (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \u22642.5 times the upper limits of normal (ULN), unless attributed to leukemia (in AML patients)\nTotal bilirubin \u22643 XULN unless due to Gilbert disease\nEastern Cooperative Oncology Group (ECOG) performance status \u2264 2\nWomen of reproductive potential must have a negative serum pregnancy test within 48 hours prior to the first day of any BST-236 treatment course\nWomen of reproductive potential must use two forms of effective birth control methods starting from at least 1 month prior to BST-236 first dose and until 3 months following the last BST-236 administration day (acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptives, or double-barrier method condom or diaphragm with spermicide)\nMale subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 3 months following the last dose of study drug\nSubject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures\nPatient must be able to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\nMDS or AML evolving from a pre-existing myeloproliferative neoplasm (MPN)\nMDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN\nAcute promyelocytic leukemia\nPrevious treatment for AML or MDS with drugs other than HMA or LDAC or combinations of venetoclax with either HMA or LDAC\nPrevious allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation\nParticipation in a previous clinical trial involving use of an investigational drug within 30 days or at least 5 half-lives of tested drug (whichever is shorter) of study day 1\nPeripheral White Blood Cell (WBC) count >30,000 /\u00b5L in the 48 hours prior to first BST-236 dose administration. Hydroxyurea administration or leukapheresis is permitted to meet this criterion\nAdministration of HMA, LDAC, or venetoclax within 14 days prior to Study Day 1\nPrevious treatment with cytarabine at a dose higher than 20 mg/ m2/d\nUncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment)\nAny medical or surgical condition, presence of laboratory abnormalities or psychiatric illness that may preclude safe and complete study participation based on the Investigator's judgment\nDiagnosis of malignant disease (other than AML) within the previous 12 months (excluding basal cell carcinoma of the skin without complications, \"in-situ\" carcinoma, or other local malignancy excised or irradiated with a high probability of cure and not treated with systemic or topical chemotherapy)\nSurgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) in the 14 days prior to first BST-236 dose administration\nHistory of allergic reactions attributed to compounds of similar chemical composition as BST-236 and/or cytarabine\nLife expectancy shorter than 3 months attributed to any known medical condition other than AML/MDS\nIn 12 leads ECG, corrected QT interval (QTc)>480msec or history of QT prolongation or Torsades de pointes"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with AML by the World Health Organization (WHO) classification who have failed prior therapy, refractory to it or relapsed after prior response. Patients with isolated extramedullary AML are eligible (cohort 1)\nAge >= 18 years\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\n\nFor cohort 2 (frontline elderly or unfit AML AML), the following inclusion criteria:\n\nConfirmed newly diagnosed AML\n\nIneligible for induction therapy defined as\n\nEither age >= 75 years\nOr 18-74 years of age with at least one comorbidity (chronic heart failure [CHF] requiring therapy or eject fraction [EF] =< 50%, carbon monoxide diffusing capability [DLCO] =< 65% or forced expiratory volume in 1 second [FEV1] =< 65%, or ECOG 2 or 3)\nCreatinine < 2 x upper limit of normal unless related to the disease (e.g. infiltration)\nTotal bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\nAlanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement (by biopsy or imaging)\nAble to give written informed consent\nOral hydroxyurea and/or one dose of cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy and hydroxyurea while the patient is on active study treatment through cycle 1, as needed, for clinical benefit and after discussion with the principal investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\nFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment\nWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia\nPrior therapy with a BCL2 inhibitor\nSymptomatic or uncontrolled CNS leukemia\nActive and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician\nKnown infection with human immunodeficiency virus (HIV) or active hepatitis B or C\nAny other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\nPregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must be >18 years of age\n\nFor Parts 1A and 1B, the following malignancy types will be included:\n\nRelapsed or refractory AML.\nMDS, after prior hypomethylating agents.\nCMML, with progressive disease/lack of response after hypomethylating agents\n\nFor Parts 1A and 1B, Patients may have relapsed or refractory disease.\n\nFor Parts 2A and 2B, the following malignancy types will be included:\n\nRelapsed or Refractory AML.\nMDS patients should be limited to high risk disease\nMDS or CMML should be previously untreated and patients with AML may have relapsed or refractory disease;\nHave clinically acceptable laboratory screening results (i.e., clinical chemistry, hematology, and urinalysis) within certain limits per protocol.\nHave an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\nPatients who have received investigational therapy, radiotherapy, immunotherapy, monoclonal antibodies, or chemotherapy within 14 days or 5 half-lives (whichever is shorter)\nAllogeneic or autologous transplant for AML with infusion of stem cells within 90 days before Cycle 1 Day 1, or on active immunosuppressive therapy for graft-versus-host disease (GVHD) or GVHD prophylaxis within 2 weeks of Cycle 1 Day 1.\nAny Grade \u2265 2 persistent non-hematological toxicity related to allogeneic transplant, such as those requiring systemic immunosuppressive therapy."
            },
            {
                  "document": "Disease specific Inclusion Criteria:\n\nAcute myeloid leukemia relapsed/refractory after 2 lines of therapy; with CD38 expression\n\nCD38 expression is defined by \u226520% of malignant cells with CD38 expression by flow cytometry on the most recent marrow biopsy (within 30 days of enrollment - archived or fresh).\nRelapsed/refractory is defined as failure to achieve at least a Morphological Leukemia Free State (MLFS) or reverting from MLFS.\n\nLines of therapy are defined as (must have had 2 prior therapies):\n\nOne cycle of Intensive induction chemotherapy such as 7+3, 5+2, MEC, FLAG, FLAG-Ida, CLAG \u00b1 small molecule inhibitor\nFour weeks of HMA-based induction \u00b1 small molecule inhibitor\nHematopoietic stem cell transplantation (HSCT) if relapse that occurs > 90 days after HSCT\nGemtuzumab Ozogamicin\nLDAC + glasdegib\nBiomarker-specific targeted agents (FLT3 inhibitors, IDH1/2 inhibitors, others if available)\nOther treatments could be considered after discussion with the PI\n\nInclusion Criteria:\n\nAge 12 years or older at the time of consent - Please note, enrollment of minors will be begin until permission to proceed is received from the FDA. At that time, the protocol will be updated to open enrollment to minors.\nWeight \u2265 50 kg due to FT538 fixed cell dosing and FT538 product pre-dose packaging\nKarnofsky performance status of 80-100% for 16 years and older or Lansky Play Score of 80-100 for \u226512 and < 16 years of age\n\nEvidence of adequate organ function within 14 days of starting study treatment defined as:\n\nEstimated Glomerular Filtration Rate (estimated creatinine clearance) \u226550 mL/min/1.73m^2\nTotal bilirubin \u2264 5 \u00d7 upper limit normal (ULN), not applicable for patients with Gilbert's syndrome\nAST \u22643 \u00d7 ULN and ALT \u2264 3 \u00d7 ULN, not applicable if determined to be directly due to underlying malignancy\nLVEF \u2265 40% by echocardiogram or MUGA\n\nContraceptive use by men or women\n\nFemale subjects: Women of childbearing potential (WOCBP) must use a highly effective form of contraception from the screening visit until at least 12 months after the final dose of cyclophosphamide (CY), at least 4 months after the final dose of FT538, and at least 3 months after the final dose of daratumumab, whichever is latest.\nMale subjects: Males with a female partner of childbearing potential or a pregnant female partner must be sterile (biologically or surgically) or use a highly effective method of contraception from the screening visit until at least 4 months after the final dose of CY and at least 4 months after the final dose of FT538, and at least 3 months after the final dose of daratumumab, whichever is latest.\nMust agree to and sign the consent for the companion Long-Term Follow-Up study (UMN CPRC #2020LS166) to fulfill the FDA required 15 years of follow-up for a genetically modified cell product.\nMust agree to and sign the consent for the companion Long-Term Follow-Up study (UMN CPRC #2020LS166) to fulfill the FDA required 15 years of follow-up for a genetically modified cell product.\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL)\nPregnant or breastfeeding, Menstruating females of child-bearing potential must have a negative pregnancy test within 14 days of study treatment start\nKnown allergy to any of study drugs or their components\nClinically significant cardiovascular disease including any of the following: myocardial infarction within 6 months prior to first study treatment; unstable angina or congestive heart failure of New York Heart Association Grade 2 or higher or cardiac ejection fraction <40%\nAny known condition that requires systemic immunosuppressive therapy (> 5mg prednisone daily or equivalent) during the FT538 dosing period (3 days before the 1st dose through 14 days after the last dose) excluding pre-medications - inhaled and topical steroids are permitted\nReceipt of any biological therapy, chemotherapy, or radiation therapy, except for palliative purposes, within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to the to the first dose of daratumumab. Maintenance hydroxyurea for blast control up to the initiation of lympho-conditioning is permitted\nKnown active central nervous system (CNS) involvement or treated CNS disease that has not cleared. If prior disease related CNS involvement must have completed effective treatment of their CNS disease at least 2 months prior to Day 1 with no evidence of disease clinically and at least stable findings on relevant CNS imaging\nNon-malignant CNS disease such as epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions in the 2-year period leading up to study enrollment\nClinically significant untreated/uncontrolled infection\nLive vaccine <6 weeks prior to start of lympho-conditioning\nKnown seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR\nPrior solid organ transplant\nAllogeneic HSCT relapse occurring <90 days after HSCT\nActive graft-versus-host-disease (GvHD) requiring systemic immunosuppression within 14 days prior to enrollment\nPresence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to the participant."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge >= 18 and =< 70 years\n\nPatients with acute myeloid leukemia who have previously received induction therapy and one of the following high-risk features:\n\nELN17 adverse risk prognostic group irrespective of remission status\nMeasurable residual disease positive (MRD +)\nNot in complete remission including complete remission without count recovery (Cri), primary refractory, or relapsed disease or\n\nPatients with myelodysplastic syndrome or chronic myelomonocytic leukemia (CMML) and one of the following high-risk features:\n\nPoor or very poor cytogenetic risk group as per Revised International Prognostic Scoring System (IPSS-R)\nMutated P53 or Ras pathway genes (CBL, NRAS, KRAS, NF1, PTPN1) or DNMT 3a or ASXL1 or RUNX1\nIPSS-R > 3.5 at diagnosis\n\n>= 5% bone marrow (BM) blasts at transplant\n\nHLA-identical sibling or a 7/8 matched unrelated donor, or a haploidentical related donor available\nSubject must voluntarily sign an informed consent\nFemale subjects of childbearing potential must have negative results for pregnancy test\nAspartate transaminase (AST) and alanine transaminase (ALT) < 3.0 x upper limit of normal (ULN)\nBilirubin < 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)\nSubject must have adequate renal function as demonstrated by a creatinine clearance >= 50 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection\n\nExclusion Criteria:\n\nSubject is known to be positive for human immunodeficiency virus (HIV)\nSubject has acute promyelocytic leukemia\nSubject has known active central nervous system (CNS) involvement with acute myeloblastic leukemia (AML)\n\nEvidence of other clinically significant uncontrolled condition(s) including, but not limited to:\n\nUncontrolled and/or active systemic infection (viral, bacterial or fungal)\nChronic hepatitis B virus (HBV) or hepatitis C (hepatitis C virus [HCV]) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface [HBs] antigen negative-, anti-HBs antibody positive and anti-hepatitis B core [HBc] antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate\nCardiac history of congestive heart failure (CHF) requiring treatment or ejection fraction < 50% or unstable angina\nCorrected diffusion capacity of the lung for carbon monoxide (DLCO) < 65% or forced expiratory volume in 1 second (FEV1) < 65%\n\nTreatment with any of the following within 7 days prior to the first dose of study drug:\n\nSteroid therapy for anti-neoplastic intent\nModerate or strong cytochrome P450 3A (CYP3A) inhibitors, moderate or strong CYP3A inducers. These agents may be used once venetoclax is discontinued\n\nAdministration or consumption of any of the following within 3 days prior to the first dose of study drug:\n\nGrapefruit or grapefruit products\nSeville oranges (including marmalade containing Seville oranges)\nStar fruit\nPrior gemtuzumab ozogamicin and/or inotuzumab ozogamicin use"
            },
            {
                  "document": "Select Inclusion Criteria:\n\nSubject is \u226518 years of age on the day Informed Consent is signed and dated.\nSubject must have received only one allogeneic HSCT from a related or unrelated donor prior to administration of Mana 312.\nSubject has a donor who has agreed to donate leukocytes for manufacture of Mana 312 and who is the same donor who provided cells for the subject's current HSCT.\na. Prior to HSCT, for Escalation Cohort 1, subject has AML/MDS b. Prior to HSCT, for Escalation Cohorts after Cohort 1 and for the Expansion Cohort, a subject must have high risk of relapse AML/MDS\n\nMana 312 product is available\n\nThe following Inclusion Criteria apply only during the Pre-Infusion Screening Phase, prior to the time of the planned first infusion of Mana 312.\n\nSubject has Eastern Cooperative Oncology Group (ECOG) performance status \u2264 3 or Karnofsky/Lansky score of \u2265 50.\nSubjects in the Expansion Cohort must have a relapse of AML/MDS (MRD+ or morphologic relapse)\nSubject has adequate organ function\n\nSelect Exclusion Criteria:\n\nSubject has received antibody that affects T-cell number or function\nSubject has received a donor lymphocyte infusion (DLI) for the current HSCT.\nEvidence of GVHD \u2265 Grade 2 in any organ system, or active bronchiolitis obliterans syndrome, sclerotic GVHD, or symptomatic serositis.\nSubject has undergone major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, apheresis, or biopsy) < 21 days prior to the first planned infusion of Mana 312.\nSubject has an active and clinically relevant infection\nSubject has symptomatic or uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression (radiation therapy to local site for disease control is allowed if \u2265 14 days prior to Screening and all AE from radiation therapy have resolved to \u2264 Grade 1 prior to the planned first Mana 312 infusion).\nSubject has any other medical condition not listed above or social condition that, in the opinion of the Investigator, might place the subject at increased risk, adversely affect compliance, or confound safety or other clinical study data interpretation."
            },
            {
                  "document": "Inclusion Criteria:\n\nMale and female patients \u2265 1 and \u2264 29 years of age at time of consent.\n\nAML in second or greater relapse, post-transplant relapse, or chemotherapy-refractory disease. Specifically:\n\nSecond or greater relapse defined as flow cytometric confirmation of myeloid leukemia of at least 0.1% after second documented complete remission; OR\nAny detectable disease post-allogeneic transplant with flow cytometric confirmation (MRD) of myeloid leukemia of at least 0.1%; OR\nRefractory disease, defined as persistent bone marrow involvement with >5% blasts after two courses of induction chemotherapy for patients at initial presentation or >5% bone marrow blasts after one course of re-induction chemotherapy for patients who have relapsed after previously achieving a CR.\nSubjects must have a suitable stem cell donor available who may donate cells in the event the subject needs to undergo an allogeneic HCT. Donor may be matched or mismatched and must be found to be suitable according to the institution's standard criteria; donors must be fully cleared to proceed as the donor.\n\nAdequate organ function defined as:\n\na. A serum creatinine based on age/gender b. Adequate liver function i. ALT \u2264 5 x ULN ii. Total bilirubin \u2264 3 x ULN iii. ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to ALL infiltration of the liver.\n\nc. Must have a minimum level of pulmonary reserve defined as \u2264 Grade 1 dyspnea and < Grade 3 hypoxia; DLCO \u2265 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the treating investigator d. Left Ventricular Shortening Fraction (LVSF) \u2265 28% or Ejection Fraction (LVEF) \u2265 45% confirmed by ECHO, or adequate ventricular function documented by a scan or a cardiologist. In cases where quantitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualitatively normal ventricular function will suffice.\n\nAdequate performance status defined as Lansky or Karnofsky score \u2265 50\nSigned informed consent must be obtained.\nNo contraindications for leukapheresis (unless apheresis product previously acquired).\nSubjects of reproductive potential must agree to use acceptable birth control methods.\n\nExclusion Criteria:\n\nPregnant or lactating (nursing) women.\nPatients with relapsed AML with t(15:17).\nPatients must be > 6 months from alloHSCT.\nHIV infection.\nActive hepatitis B or hepatitis C infection.\nActive acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy\nConcurrent use of systemic steroids at the time of cell infusion or cell collection or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well.\nAny uncontrolled active medical disorder that would preclude participation as outlined.\nUncontrolled active infection\nSubjects with CNS3 disease that is progressive on therapy or with CNS parenchymal lesions that may increase the risk of CNS toxicity. Subjects with adequately treated CNS leukemia are eligible.\nKnown history of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).\nPatients with any prior history of myeloproliferative neoplasm.\nPatients with somatic JAK2 V617F mutation by PCR or next generation sequencing."
            },
            {
                  "document": "Inclusion Criteria:\n\nTP53 wildtype AML\nRelapsed/Refractory to at least one prior therapy, one of which must have included a FLT-3 inhibitor\nFLT3 mutation (FLT3-TKD or FLT3-ITD)\nECOG 0-2\nAdequate hematologic, hepatic, and renal functions\n\nExclusion Criteria:\n\nAML subtype 3\nPrior treatment with MDM2 antagonist therapies\nEligible for HSCT"
            },
            {
                  "document": "Inclusion Criteria:\n\nA histologically or pathologically confirmed diagnosis of AML based on 2016 WHO classification. Patients with Complex Karyotype AML (CK-AML) and TP53-mutated AML are eligible for this study.\nAML has relapsed after or is refractory to, first-line therapy, with a maximum of three prior lines of therapy. Patients whose AML has FLT3 or IDH1/IDH2 mutations should have received at least one available FLT3 or IDH1/IDH2 inhibitors\nAge 18 years and older\nECOG performance status \u2264 2\nPatients who have undergone allo-HSCT are eligible if they are \u2265 30 days post stem cell infusion, have no evidence of graft versus hose disease ( GVHD ) > Grade 1, and are \u2265 10 days off all immunosuppressive therapy\nPrevious cytotoxic chemotherapy must have been completed at least 10 days prior to day 1 of treatment on the study and all AEs (excluding alopecia, acne, rash) due to agents administered earlier should have recovered to < Grade 1. Patients with hematologic malignancies are expected to have hematologic abnormalities at study entry. These abnormalities which are thought to be primarily related to the underlying leukemia, are not considered to be toxicities (AE) and do not need to resolve to < Grade 1\nAll biologic agents including hematopoietic growth factors must have been stopped at least 1 week prior to day 1 of treatment on the study\n\nPatients must have adequate organ function as defined below:\n\nDirect bilirubin \u22642X the institutional upper limit of normal (ULN) (except in patients with leukemic infiltration of the liver)\nAST(SGOT)/ALT(SGPT) \u22643X ULN (except if attributable to leukemic infiltration of the liver)\nAlkaline phosphatase \u22645X ULN\nCreatinine Clearance (CrCl) \u2265 45 mL/min (except in patients with evidence of tumor lysis syndrome)\nPatients with a history of CNS leukemia must be stable with clear CSF for > 2 months prior to day 1 of treatment (patient can receive intrathecal maintenance chemotherapy)\nFemale patients of childbearing potential must have a negative pregnancy test <1 week prior to enrollment. Female patients of childbearing potential who are sexually active and male patients who are sexually active and have female partners of childbearing potential must agree to use highly effective method of contraception with their partners during exposure to study drugs and for 30 days after the last dose of study drugs.\nAbility to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nPatients receiving any other investigational agents, or concurrent chemotherapy or immunotherapy\nPatients with acute promyelocytic leukemia (APL) confirmed with t(15;17) (i.e. FAB subtype M3 and M3 variant)\nPrior treatment with any asparaginase product. Patients who received \u226412 weeks of a BCL-2 inhibitor including venetoclax are eligible.\nAbsolute peripheral blast > 100,000/\u03bcL. Hydroxyurea for blast count control is permitted before starting treatment and up to maximum of 10 days after starting treatment on the study. The decision to start hydroxyurea during this time is at the discretion of the treating physician.\n\nPatients with the following clinical histories are excluded:\n\nsevere pancreatitis not related to cholelithiasis. Severe acute pancreatitis is defined by lipase elevation >5X ULN and with signs or symptoms\nunprovoked deep venous thrombosis (DVT)\npulmonary emboli\nhemorrhagic or thromboembolic stroke\nother malignancies requiring systemic chemotherapy, immunotherapy or targeted therapy in the last three months\nActive, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible\nUncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements\nPregnant women and female patients who are lactating and do not agree to stop breast- feeding.\nUncontrolled active seizure\nAny other clinical conditions that in the opinion of the investigator would make the subject unsuitable for the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nPRE-SCREENING INCLUSION CRITERIA:\nAbility to understand and the willingness to sign a written informed consent document\nAge >= 18 years at time of informed consent. Both men and women of all races and ethnic groups will be included\nParticipants must consent to a bone marrow aspirate/biopsy that will be collected prior to start of planned 7+3 induction therapy. Patients with known favorable risk AML (ELN Guidelines) or FLT3 mutations should not be pre-screened. If the risk category is unknown, then it is okay to pre-screen patients for study. Adverse or intermediate risk needs to be confirmed prior to treatment with pemigatinib (during screening period) as outlined below\nTREATMENT INCLUSION CRITERIA:\nEastern Cooperative Oncology Group (ECOG) performance status 0-2\n\nFor dose-determining portion of study, study population is limited to: Newly diagnosed, morphologically documented primary AML, based on the World Health Organization (WHO) 2008 classification, with cytogenetics associated with the adverse prognostic risk group per European Leukemia Net (ELN) guidelines. These include:\n\nt(6;9)(p23;q34.1); DEK-NUP214\nt(v;11q23.3); KMT2A rearranged\nt(9;22)(q34.1;q11.2); BCR-ABL1\ninv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)\n-5 or del(5q); -7; -17/abn(17p)\nComplex karyotype - defined as three or more unrelated chromosome abnormalities in the absence of 1 of the WHO-designated recurring translocations or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCR-ABL1\nMonosomal karyotype - defined by the presence of 1 single monosomy (excluding loss of X or Y) in association with at least 1 additional monosomy or structural chromosome abnormality (excluding core-binding factor AML)\nMutated RUNX1\nMutated ASXL1\nMutated TP53\n\nFor the dose-expansion portion of the study, study population is limited to: Newly diagnosed, morphologically documented primary AML, based on the World Health Organization (WHO) 2008 classification, with a cytogenetic profile encompassing the intermediate prognostic risk groups per European Leukemia Net (ELN) guidelines.2 These include:\n\nWild-type or NPM1\nt(9;11)(p21.3;q23.3); MLLT3-KMT2A\nCytogenetic abnormalities not classified as favorable or adverse\nSerum creatinine clearance >= 30 mL/min (as calculated by Cockcroft-Gault formula) (on or by day 8 of induction therapy, prior to starting pemigatinib)\nSerum phosphate within institutional upper limit of normal (ULN) or can be corrected with supplementation/ phosphate binders to be within institutional ULN (on or by day 8 of induction therapy, prior to starting pemigatinib)\nSerum electrolytes within institutional ULN: potassium, calcium (total, or corrected for serum albumin in case of hypoalbuminemia) and magnesium. If outside of normal limits, participant will be eligible when electrolytes are corrected (on or by day 8 of induction therapy, prior to starting pemigatinib)\nTotal serum bilirubin =< 3 x ULN (on or by day 8 of induction therapy, prior to starting pemigatinib)\nSerum aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 3 x ULN (on or by day 8 of induction therapy, prior to starting pemigatinib)\nParticipants must consent to standard of care bone marrow aspirate/biopsies during treatment. Bone marrow biopsies will be obtained prior to study, on day 14 (+3 days, if considered institutional standard of care), after recovery from induction therapy, and at the end of consolidation and/or prior to allogeneic stem cell transplant\nFemale participants of childbearing potential must agree to use effective contraception (2 forms of contraception or abstinence) from the screening visit until 6 months following the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\nMale patients of childbearing potential having intercourse with females of childbearing potential must agree to abstain from heterosexual intercourse or have their partner use 2 forms of contraception from the screening visit until 3 months following the last dose of study treatment. The male participant must also refrain from sperm donation from the screening visit until 3 months following the last dose of study treatment\n\nExclusion Criteria:\n\nPRE-SCREENING EXCLUSION CRITERIA:\nDiagnosis of acute promyelocytic leukemia (APL, or AML M3 subtype) per WHO classification\nAML with FLT3 mutations\nFavorable risk AML: inv(16), t(8;21) or NPM1 mutations without FLT3 ITD mutations\nAny cancer-directed therapy within 2 weeks prior to starting planned 7+3 induction regimen, with the exception of hydroxyurea, which is allowed to control white blood cell count, or empiric all-trans retinoic acid (ATRA) for suspected APL\nPrior receipt of a selective FGFR inhibitor\nKnown liver disease\n\nHistory of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues\n\nExcept for commonly observed calcifications in soft tissues such as the skin, kidney tendon, or vessels due to injury, disease, or aging in the absence of systemic mineral imbalance)\nHistory of hypovitaminosis D requiring supraphysiologic doses (e.g., 50,000 IU/weekly) to replenish the deficiency. Vitamin D supplements are allowed\n\nUntreated human immunodeficiency virus (HIV) or active hepatitis C detectable by PCR, or chronic hepatitis B\n\nIndividuals positive for hepatitis B core antibody who are receiving intravenous immunoglobulin (IVIg) are eligible if HepB PCR is negative\nHistory of cerebrovascular accident or intracranial hemorrhage within 2 months of enrollment\nUnwillingness to receive infusion of blood products\nInability to take oral medication\nGastrointestinal condition/disorders that may raise gastric and/or small intestinal pH that could interfere with absorption, metabolism, or excretion of pemigatinib\nKnown history and/or current evidence of ectopic mineralization/calcification, including (but not limited to): soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcification\nCurrent evidence of corneal disorder/keratopathy, including (but not limited to): bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis, etc., as confirmed by ophthalmologic examination\nConcurrent active malignancy with expected survival of < 1 year\nTREATMENT EXCLUSION CRITERIA:\nClinically significant coagulation abnormality (e.g., disseminated intravascular coagulation) that is present on or by day 8 of induction therapy prior to starting pemigatinib\n\nClinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months from day 1 of planned induction therapy, New York Heart Association class III or IV congestive heart failure, and uncontrolled arrhythmia (participants with pacemaker or with atrial fibrillation and well controlled heart rate are allowed). History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.\n\nA screening QT interval by Fridericia's Correction Formula (QTcF) interval > 480 ms will result in exclusion.\nFor participants with an intraventricular conduction delay (QRS interval > 120 ms), the JTc interval may be used in place of the QTc with approval from Sponsor-Investigator. The JTc must be =< 340 ms if JTc is used in place of the QTc.\nLeft ventricular ejection fraction (LVEF) by echocardiogram < 45% prior to initiating pemigatinib\nActive infection that is not well-controlled by antibacterial or antiviral therapy\n\nCurrent use of prohibited medications including use of any potent CYP3A4 inducers within 14 days or five half-lives (whichever is longer) before the first dose of study drug.\n\nUse of CYP3A4 inhibitors should be avoided but, if medically necessary, is permitted with a dose reduction of study drug\nUse of moderate CYP3A4 inhibitors are permitted.\nBased on the low overall bioavailability of topical ketoconazole, there are no restrictions on topical ketoconazole\nCurrent use of prohibited medication\nHypersensitivity to pemigatinib, or its excipients, when administered alone\nPregnancy or breastfeeding at the time of enrollment\nAny concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the protocol"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipant must be 18 years of age or older.\nHistological confirmation of newly diagnosed AML by World Health Organization (WHO) 2016 criteria.\nProjected life expectancy of at least 3 months.\nParticipants must be considered ineligible for intensive induction chemotherapy defined by the following: a) Age 75 years or older, or b) Age 18 to 74 years with at least one of the following comorbidities: i) Severe cardiac disorder (eg, congestive heart failure requiring treatment, ejection fraction \u226450%, or chronic stable angina), ii) Severe pulmonary disorder (eg, diffusing lung capacity for carbon monoxide DLCO \u226465% or forced expiratory volume in 1 second [FEV1] \u226465%), iii) Creatinine clearance \u226530 mL/min to <45 mL/min, iv) Moderate hepatic impairment with total bilirubin >1.5 to \u22643.0 \u00d7 upper limit of normal (ULN), v) Phase 1: Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 (participants with ECOG \u22653 are not eligible); Phase 2: ECOG Performance Status of 2 or 3 (participants with ECOG 4 are not eligible).\nPhase 1: ECOG Performance Status of 0-2; Phase 2 ECOG 0-3.\nWomen of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.\nParticipants and their partners with reproductive potential must agree to use a highly effective contraceptive measure during the study and for 3 months after the last dose of study treatment, including refraining from sperm donation. Effective contraception includes methods such as oral contraceptives or double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\nCapable of giving legally effective informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and protocol, and willing to participate in the study.\n\nExclusion Criteria:\n\nHistory of myeloproliferative neoplasm including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.\nThe following karyotype abnormalities: t(8;21), inv(16) or t(15;17), or other acute promyelocytic leukemia variants that remain sensitive to all-trans retinoic acid (ATRA) therapy.\nKnown active central nervous system involvement from AML.\nKnown human immunodeficiency virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). Human immunodeficiency virus testing will be performed at Screening, only if indicated per local guidelines or institutional standards.\nKnown active hepatitis B or C infection (detectable viral load). Hepatitis B or C testing will be performed at Screening, only if indicated per local guidelines or institutional standards.\nSevere hepatic impairment defined as: bilirubin >1.5\u00d7upper limit of normal (ULN) for participants \u226575 years or >3\u00d7ULN for participants <75 years; or aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) >3\u00d7ULN (unless considered to be due to leukemic organ involvement).\nSevere renal impairment defined as: calculated creatinine clearance or glomerular filtration rate <30 mL/min.\nA malabsorption syndrome or other condition that precludes enteral route of administration.\nCardiovascular disability status of New York Heart Association Class >2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.\nChronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications that in the opinion of the investigator would adversely affect his/her participating in this study.\nClinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal).\nHistory of other malignancies prior to study entry, with the exception of adequately treated in situ carcinoma of the breast or cervix uteri; localized basal cell carcinoma or squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or adequately treated and controlled with other modalities); and any early stage malignancy for which no definitive therapy is required.\nWhite blood cell (WBC) count >25,000/\u03bcL (Hydroxyurea treatment is permitted to meet this criterion).\nTreatment with the following: a) A hypomethylating agent (azacitidine or decitabine), or venetoclax including prior treatment for myelodysplastic syndrome (MDS), b) Chimeric Antigen Receptor (CAR)-T cell therapy, c) Investigational therapies for MDS or AML.\nParticipants who cannot discontinue concomitant prophylactic antifungal therapy with CYP3A inhibitor activity or other concomitant medications with moderate or strong CYP3A inhibitor activity \u22657 days or 5 half-lives, whichever is greater, prior to cycle 1 day 1 (C1D1).\nParticipants who cannot discontinue concomitant drugs that are strong CYP3A or P-gp inhibitors \u22657 days or 5 half-lives, whichever is greater, prior to C1D1.\nParticipants who cannot avoid concomitant drugs known as moderate or strong CYP3A inducers.\nCurrent participation in another research study requiring interventions such as drug therapy or study procedures.\nKnown or suspected hypersensitivity to decitabine, cedazuridine, venetoclax, or any of their excipients.\nKnown significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol.\nParticipants who consume grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit \u22647 days prior to C1D1."
            },
            {
                  "document": "[Patient]\n\nInclusion Criteria:\n\n\u2265 60 years of age\ndiagnosis of AML\nReceive 1) low-dose cytarabine or hypomethylating agent (HMA) in combination with Venetoclax chemotherapy OR 2) low-dose cytarabine or hypomethylating agent (HMA) in combination with Venetoclax chemotherapy and any investigational drugs\nhave caregiver(s) willing to participate\nparticipate in the parent study (PACT study, NCT04570709)\n\nExclusion Criteria:\n\nreferred to hospice care\n\n[Caregiver]\n\nInclusion criteria:\n\nidentified by patient as a caregiver\n\u226518 years of age\nspeak and read English"
            },
            {
                  "document": "Participant Inclusion Criteria:\n\nAge and Donor Status:\n\nPatients with age \u2264 21 years at time of consent with no available and suitably matched related or unrelated donor in the required time period.\n\nDiagnoses :\n\nI. Acute myelogenous leukemia (AML) :\n\nComplete first remission (CR1) at high risk for relapse such as any of the following:\n\nKnown prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder (MPS).\nTherapy-related AML (t-AML).\nWhite cell count at presentation > 100,000.\nPresence of extramedullary leukemia at diagnosis.\nAny unfavorable subtype by FAB or WHO classification.\nHigh-risk cytogenetics (e.g. those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) or high-risk molecular abnormalities.\nRequirement for 2 or more inductions to achieve CR1.\nPresence of Minimal Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods after induction.\nAny patient with newly diagnosed AML with intermediate risk cytogenetics who elects allograft with curative intent over consolidation chemotherapy.\nAny patient unable to tolerate consolidation chemotherapy as would have been deemed appropriate by the treating physician.\nOther high-risk features not defined above.\nComplete second remission (CR2).\nPrimary refractory or relapsed AML with less than 10% blasts by bone marrow morphology. Patients with cytogenetic, flow cytometric, or molecular abnormalities in \u2264 10% of cells are eligible.\n\nII. Acute lymphoblastic leukemia (ALL):\n\nComplete first remission (CR1) at high risk for relapse such as any of the following:\n\nWhite cell count at presentation > 30,000 for B-cell lineage and > 100,000 for T-cell lineage.\nPresence of any high-risk cytogenetic abnormalities such as t (9;22), t (1;19), t (4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality.\nFailure to achieve complete remission (CR) after four weeks of induction therapy.\nPersistence or recurrence of MRD on therapy.\nAny patient unable to tolerate consolidation and/or maintenance chemotherapy as would have been deemed appropriate by the treating physician.\nOther high-risk features not defined above.\nComplete second remission (CR2).\nPrimary refractory or relapsed ALL with MRD disease after antibody therapy (e.g., blinatumomab, inotuzumab, other) and/or CAR-T cell therapy.\n\nIII. Other acute leukemias:\n\nLeukemias of ambiguous lineage or of other types (e.g. blastic plasmacytoid dendritic cell neoplasm) with less than 5% blasts by BM morphology. Patients with persistent/relapsed disease with cytogenetic, flow cytometric or molecular aberrations in \u2264 5% of cells are eligible.\n\nIV. Myelodysplastic Syndrome (MDS) / Myeloproliferative Disorders (MPD) other than myelofibrosis:\n\nInternational prognostic scoring system (IPSS) risk score of INT-2 or high risk at the time of diagnosis.\nAny IPSS risk category if life-threatening cytopenia(s) exists.\nAny IPSS risk category with karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia.\nMDS/ myeloproliferative disorder overlap syndromes without myelofibrosis.\nMDS/ MPD patients must have less than 10% bone marrow myeloblasts and ANC \u2265 0.2 (growth factor supported if necessary) at transplant work-up.\n\nV. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high-risk of relapse or progression if not in remission:\n\nEligible patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histology) in CR.\nEligible patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/ CR/ PR with no single lesion equal to or more than 5 cm.\nEligible patients with HL will be those without progression of disease (POD) after salvage chemotherapy with no single lesion \u2265 5 cm.\n\nVI. Inherited Metabolic Disorders [also see EBMT Handbook for discussion on patient eligibility for allogeneic transplant; in general, patients are considered early in the disease course, before they develop neurologic symptoms (46)]:\n\nHurler Syndrome\nHunter (MPS 2 - early disease)\nSly syndrome (MPSVIII)\n\u03b1-Mannosidosis\nX- ALD\nOsteopetrosis\nMetachromatic Leukodystrophy\nGloboid (GLD)\n\nVII. Non-Malignant disorders (other) [also see EBMT Handbook for criteria for transplant (46)]\n\nHemoglobinopathies\nBone Marrow Failure syndromes\nImmunodeficiencies, including HLH\n\nOrgan Function and Performance Status Criteria:\n\nKarnofsky or Lansky score \u2265 70% (see Appendix)\nBilirubin \u2264 1.5 mg/dL (unless benign congenital hyperbilirubinemia).\nALT \u2264 3 x upper limit of normal.\nPulmonary function (spirometry and corrected DLCO) \u2265 50% predicted (corrected for hemoglobin) .\nLeft ventricular ejection fraction \u2265 50%.\nAge-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) less than or equal to 7.\nRenal: serum creatinine \u2264 1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.\n\nNormal GFR in Children and Young Adults (Age) : Mean GFR +- SD (mL/min/1.73 m2)\n\n1 week: 40.6 + / - 14.8 2-8 weeks: 65.8 + / - 24.8 >8 weeks: 95.7 + / - 21.7 2-12 years: 133.0 + / - 27.0 13-21 years (males): 140.0 + / - 30.0 13-21 years (females: 126.0 + / - 22.0\n\nGFR, glomerular filtration rate; SD, standard deviation greater than 2 years old: Normal GFR is 100 mL/ min. Infants: GFR must be corrected for body surf ace area.\n\nFor metabolic diseases: disease status to be evaluated according to EBMT Handbook [45].\n\nGraft Criteria\n\nCB units will be selected according to the current MSKCC unit selection algorithm. High resolution 8 allele HLA typing and recipient HLA antibody profile will be performed. Cord unit selection will occur based on HLA-match, total nucleated cell (TNC) and CD34+ cell dose adjusted per patient body weight. The cord bank of origin will also be considered. Donor specific HLA antibodies, if present, will also be taken into consideration and may influence the selection of the graft. CB graft will consist of one or two CB units (CBU) based on MSKCC selection algorithm.\n\nEach CB unit must be at least 3/8 HLA-matched to the patient considering high-resolution 8-allele HLA typing.\nFor malignant diseases follow MSKCC CBU selection algorithm\nFor non-malignant diseases, CBU will be required to have > 5 x 107 TNC/kg; high HLA allele level match is preferable\n\nParticipant Exclusion Criteria:\n\nInadequate performance status/ organ function.\nAdvanced metabolic disease (EBMT handbook).\nActive CNS leukemic involvement.\nIndolent NHL or Hodgkin lymphoma with progression of disease after most recent salvage chemotherapy.\nDiagnosis of myelofibrosis or other malignancy with moderate-severe bone marrow fibrosis.\nAutologous stem cell transplant within the preceding 6 months.\nAny prior allogeneic stem cell transplant.\nActive and uncontrolled infection (bacterial/fungal/viral) at time of transplantation.\nHIV infection.\nSeropositivity for HTLV-1.\nPregnancy or breast feeding.\nPatient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients \u2267 18 years of age with persistence or relapse/progression AML, MDS, or MDS/MPN,\n\nfollowing allogeneic stem cell transplantation.\n\ngrade 1 overall GVHD at time of inclusion with stable immune suppression for at least 2 weeks pre infusion on study and planned stable immune suppression dose for at least 8 weeks (the safety evaluation period)\nCalculated creatinine clearance \u2265 60ml/min as estimated by Cockcroft Gault and not dialysis dependent.\nAST, ALT <3 x ULN unless documented due to medications (ie azole or other common therapy for such patients). Total bilirubin \u22643.0 mg/dl unless there is a history of Gilbert's syndrome in which case the T bili hould be < 5.0 mg/dl.\nFemales cannot be pregnant or breast-feeding from time of enrollment till 16 weeks post final agent exposure on this study.\nImmune suppression not greater than 20mg prednisone daily or equivalent dosing of alternative GVHD prophylaxis/therapy\nPatients are at least 30 days from most recent allogeneic stem cell infusion\nPatients may have had other therapy post alloBMT and other donor lymphocyte infusions but they must be at least 60 days from the last infusion of cell therapy products\nPatients must have other anti-leukemia therapies stopped 2 weeks prior to infusion on this study. Hydrea or pheresis ARE allowed prior to this study and may continue until 14 days following the first infusion on this study if deemed to be needed to assist in count control.\n\nExclusion Criteria:\n\nPatients with progressive infections at time of first infusion (patients with treated infections documented as controlled by the treating team are eligible).\nKnown active CNS disease at time of enrollment\nPatients with other cancers treated within 3 years\nKnown history of immunogenicity or hypersensitivity to a CD25 antibody or a component of ADCT-301\nMajor surgery, chemotherapy, systemic therapy (excluding hydroxyurea, steroids, and any targeted small molecules or biologics), or radiotherapy within 14 days or 5 half-lives (whichever is shorter) prior to Cycle 1, Day 1 treatment, except if approved by Dr. Rizzieri.\nPatients with proven, progressive severe autoimmune disease such as multiple sclerosis, active Guillain Barr\u00e9 syndrome, poliomyelitis, sjogren's are not eligible. Given the immediate, life threatening nature of the relapsed cancer in this patient population, those with other stable and non-immediate non-threatening autoimmune disorders such as thyroid disease or diabetes and others are eligible.\nPatients with a known infection/reactivation of any of the following within 28 days of the first dose of this agent on study are not eligible: HSV1, HSV2, VZV, EBV, CMV, measles, influenza A, Zika, Chikungunya, mycoplasma pneumonia, Campylobacter jejuni, enterovirus B68, or SARS-CoV-2. Patients will have evaluation for HSV1, HSV2, VZV, EBV, CMV as part of screening studies. Patients will have SARS-CoV-2 screening performed if at all possible during the screening process. If screening is not available, then screening based on symptoms will be documented. Additionally, screening based on clinical concern and/or symptoms will be conducted for measles, influenza A, Zika, Chikungunya, mycoplasma pneumonia, Campylobacter jejuni, enterovirus B68."
            },
            {
                  "document": "Inclusion Criteria:\n\nCapable of giving signed informed consent.\nParticipant must be 18 years of age or older, at the time of signing the informed consent.\nLife expectancy of at least 12 weeks as assessed by the investigator.\nParticipants with R/R AML or other myeloid neoplasms where approved therapies have failed or for whom known life-prolonging therapies are not available. The AML population includes de novo AML, secondary AML, and MDS transformed into AML. Other myeloid neoplasms include accelerated phase MPN, and chronic or accelerated phase MPN-U and MDS-MPN. Blast crisis phase of MPN, MPN-U, and MDS-MPN are considered secondary AML and will be included in the AML cohort.\nHave an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\nHave platelet count \u226510,000/\u03bcL (transfusions to achieve this level are allowed).\nHave adequate renal function as demonstrated by a 24-hour urine measured creatinine clearance \u226560 mL/min.\n\nAdequate hepatic function as evidenced by:\n\naspartate aminotransferase (AST) \u22643\u00d7 upper limit of normal (ULN)\nalanine aminotransferase (ALT) \u22643\u00d7ULN\ntotal bilirubin \u22641.5\u00d7ULN.\nParticipants must be amenable to serial bone marrow biopsies, peripheral blood sampling, and urine sampling during the study.\nWomen of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.\n\nExclusion Criteria:\n\nParticipants who have MPN, MPN-U, or MDS/MPN and display hypoplastic bone marrow and would also not ordinarily benefit from cytoreductive therapy such as hydroxyurea (HU).\n\nParticipants with highly proliferative disease are excluded as follows:\n\nPart 1/AML: white blood cells (WBC) >20,000/\u03bcL and >50% blasts in blood. Measures to reduce WBC, such as HU treatment within the last 2 weeks and cytotoxic chemotherapy within the last 4 weeks are not allowed to meet this eligibility criterion.\nPart 1/other myeloid neoplasms: WBC >20,000/\u03bcL. A short course of HU may be used to meet this eligibility criterion, as long as HU is discontinued 96 hours and any encountered drug-related toxicity must be resolved to Grade \u22641 before the first dose of study treatment.\nPart 2/Cohort 1, AML: WBC>20,000/\u03bcL and >50% blasts in blood. A short course of HU may be used to meet this eligibility criterion, as long as HU is discontinued 96 hours, and any encountered drug-related toxicity must be resolved to Grade \u22641 before the first dose of study treatment.\nPart 2/Cohort 2, other myeloid neoplasms: Specific WBC exclusion criterion not defined. A short course of HU may be used to reduce WBC if judged to be necessary by the investigator, as long as HU is discontinued 96 hours and any encountered drug-related toxicity must be resolved to Grade \u22641 before the first dose of study treatment.\nKnown clinically active central nervous system (CNS) leukemia.\nDiagnosis of BCR-ABL-positive leukemia, acute promyelocytic leukemia (M3 AML or APML), or juvenile myelomonocytic leukemia (JMML).\nSecond malignancy requiring active systemic therapy, except breast or prostate cancer stable on or responding to endocrine therapy.\nOngoing Grade \u22653 Graft Versus Host Disease (GVHD), or any grade GVHD requiring active treatment (for example, calcineurin inhibitors, \u22655mg/day prednisone or other steroid equivalent, or other immunosuppressive agents). (Note: Prednisone at any dose for other indications is allowed).\nAdvanced human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; Inactive hepatitis carrier status and participants with laboratory evidence of no active replication and participants on antiviral medication(s) who have a viral load below limit of detection will be permitted.\nKnown significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of non-compliance with the protocol.\nActive infection resistant to antibiotics; or non-leukemia-associated pulmonary disease requiring >2 liters per minute oxygen or any other condition that puts the participant at an imminent risk of death.\n24-hour urinary protein excretion \u22651g or urinalysis of 2+proteinuria.\n\nHistory of, or at risk for, cardiac disease, as evidenced by any of the following conditions:\n\nAbnormal left ventricular ejection fraction (LVEF; <50%) on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan at Screening.\nCongestive cardiac failure of Class \u2265III severity according to New York Heart Association (NYHA) functional classification defined as patients with marked limitation of activity and who are comfortable at rest, while Class IV patients have symptoms of heart failure at rest.\nUnstable cardiac disease including unstable angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).\nVentricular arrhythmias including ventricular bigeminy, clinically significant brady arrhythmias such as sick sinus syndrome, third-degree atrioventricular (AV) block, presence of cardiac pacemaker or defibrillator, or other clinically significant arrhythmias.\nScreening 12-lead electrocardiogram (ECG) with measurable QTcF interval of \u2265470 msec (Fridericia's formula should be used).\nKnown hypersensitivity to TAS1553 or any of its components.\nAllogenic hematopoietic stem cell transplantation (HSCT) within 180 days of the first dose of TAS1553, or participants on immunosuppressive therapy post HSCT at the time of screening (calcineurin inhibitors or similar must be discontinued \u22654 weeks prior to the time of study drug initiation).\nTreated with any systemic anticancer therapy within 2 weeks of the first dose of study treatment. Any encountered treatment-related toxicities (excepting alopecia) must be resolved to Grade 1 or less.\nPhase 1 Part 1 only: participants who require concomitant use of strong CYP3A4 inducers.\nInability to swallow oral medication."
            },
            {
                  "document": "Inclusion Criteria:\n\nAgreement to adhere to Lifestyle Considerations(prebiotic diet) throughout study duration\nAdults (\u226518 yrs of age)\nAble to provide informed consent\nAre willing/able to incorporate the required foods in their diet\n\nEligible, suitable and planning to undergo a stem cell transplant:\n\nEither allogeneic or autologous\nWith any conditioning regimen (e.g. both myeloablative and reduced intensity conditioning)\nMatched related, matched unrelated, haplo-identical and cord blood transplants will be included.\n\nExclusion Criteria:\n\nPatients undergoing a second allogeneic or autologous transplant or an allogeneic transplant after an autologous transplant.\nAnticipation of requirement of broad spectrum antibiotics 1 week prior to admission for HSCT (through HSCT)\nPatients with any prior history of C.Diff infection"
            },
            {
                  "document": "Inclusion Criteria:\n\nGeneral:\n\nECOG performance status \u22642\nHaplo-matched related subjects require a suitable haplo-matched related donor, who is able and willing to undergo leukapheresis\n\nDisease related:\n\nFor AML subjects:\n\nPreviously treated relapsed/refractory AML, including subjects with MRD+ disease\nWhite blood cell count of \u226425 \u00d7 10^9/L\n\nFor MDS subjects:\n\nIntermediate-, high-, or very high-risk MDS\nPreviously treated relapsed/refractory MDS\nAdequate Organ Function\nPlatelet count \u226530,000/uL (platelet transfusions acceptable)\n\nOther:\n\nSigned informed consent\nAgree to use an effective barrier method of birth control\n\nExclusion Criteria:\n\nDisease related:\n\nAcute promyelocytic leukemia with t(15;17) (q22;q12); or abnormal promyelocytic leukemia/retinoic acid receptor alpha (APML-RARA)\nEvidence of leukemic meningitis or known active central nervous system disease\nUse of any anti-AML/MDS chemotherapeutic or targeted small molecule drug within protocol specified window prior to the first dose of NKX101\nPresence of residual non-hematologic toxicity from prior therapies that has not resolved to \u2264 Grade 1\nAny hematopoietic cell transplantation within 16 weeks\nOther comorbid conditions and concomitant medications prohibited as per study protocol\n\nOther:\n\nPregnant or lactating female"
            },
            {
                  "document": "Inclusion Criteria:\n\nMyelodysplastic Syndrome (MDS) having failed hypomethylating agent (HMA) therapy cohort:\n\nAge 18-79 years, inclusive\nPathologically confirmed MDS or myelodysplastic/myeloproliferative overlap (MDS/MPN)\nIPSS-R score intermediate, high or very high\nMust have failed therapy with an HMA (defined as lack of response by International Working Group criteria (1) or intolerance of the drug)\n\nSecondary Acute Myeloid Leukemia (sAML):\n\nPathologically confirmed AML according to World Health Organization (WHO) criteria\nEvidence of an antecedent hematologic disorder (AHD) prior to acute leukemia including a known prior diagnosis of MDS, MPN or MDS/MPN or data suggestive of an AHD such as cytopenias, fibrosis, macrocytic anemia, cellular or dysplasia at or prior to the time of diagnosis. If available, MDS-defining karyotypes (-7/del(7q), -5/del(5q), del(13q), del(11q), del(12p), t(12p), del(9q), idic(X)(q13), t(17p) (unbalanced translocations) or i(17q) (ie, loss of 17p), t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21), t(2;11)(p21;q23), inv(3)(q21q26.2), t(6;9)(p23;q34)) or somatic mutations in multiple genes including p53, TET2, JAK2, CALR, MPL, ASXL1, RUNX1, SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 would also confirm eligibility.\nAge 60-79 years, inclusive\nMay be previously untreated\n\nFor both cohorts:\n\nEastern Cooperative Oncology Group (ECOG) performance status of 0-2\nDeemed eligible to receive cytotoxic chemotherapy\nCreatinine clearance (CrCl)>50ml/min\nTotal bilirubin <2 mg/dL (except for patients with Gilbert's disease), AST and ALT < 3x ULN\nLeft Ventricular Ejection Fraction \u2265 50%\nWilling and able to participate in study assessments\n\nExclusion Criteria:\n\nPatients who have had systemic chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Hydroxyurea during this period may be given as a bridging therapy to maintain disease stability while awaiting treatment. Intrathecal chemotherapy within this time frame is permitted. Intrathecal chemotherapy may be continued during protocol therapy in order to consolidate or maintain a central nervous system (CNS) remission, but not to treat active CNS disease\nAcute promyelocytic leukemia, or the presence of t(15;17)\nPatients receiving any other investigational agents\nUncontrolled concurrent illness including, but not limited to, ongoing and uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPregnant women are excluded from this study because there is an unknown but potential risk for adverse events in the fetus. Breastfeeding should be discontinued if the mother is treated. These potential risks may also apply to other agents used in this study\nPatients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow-up\nPatients with a poor functional status of ECOG 3-4, or otherwise deemed unfit to tolerate induction chemotherapy.\nPatients with blastic transformation of chronic myelogenous leukemia are ineligible\nExposure to a humanized mouse chimeric antibody, as this could sensitize patients to components of the CD8 depletion column that may be present in small amounts in the cell product\nPrior allogenic hematopoietic cell transplant"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of one of the following by treatment regimen:\n\nRegimen A (FT538 monotherapy in r/r AML)\n\nPrimary refractory AML, or\nRelapsed AML, defined as not in CR after one or more re-induction attempts; if >60 years of age, prior re-induction therapy is not required\n\nRegimens B or C (FT538 + mAb in r/r MM)\n\nRegimen B only: MM that has relapsed or progressed after at least two lines of therapies, including a proteasome inhibitor and an immunomodulatory drug\nRegimen C only: MM that has relapsed or progressed after proteasome inhibitor therapy, and immunomodulatory therapy\nRegimen B and Regimen C: Measurable disease as defined in the protocol\nCapable of giving signed informed consent\nAge \u226518 years old\nAgreement to comply with study procedures as described in the Schedule of Activities\nContraceptive use as described in the protocol\n\nExclusion Criteria:\n\nFemales who are pregnant or breastfeeding\nECOG Performance Status \u2265 2\nEvidence of insufficient hematologic function as defined in the protocol\nEvidence of insufficient organ function defined as defined by the protocol\nClinically significant cardiovascular disease as defined by the protocol\nKnown active central nervous system (CNS) involvement by malignancy\nNon-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions in the 2-year period leading up to study enrollment\nCurrently receiving or likely to require systemic immunosuppressive therapy for any reason during the treatment period\nClinically significant infections including HIV, HBV and HCV\nLive vaccine <6 weeks prior to start of lympho-conditioning\nReceipt of an allograft organ transplant\nPrior allogeneic HSCT or allogeneic CAR-T within 6 months of Day 1, or ongoing requirement for systemic graft-versus-host therapy\nKnown allergy to albumin (human) or DMSO\nPresence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject\n\nAny medical condition or clinical laboratory abnormality that per investigator or Medical Monitor judgement precludes safe participation in and completion of the study, or which could affect compliance with protocol conduct or interpretation of results\n\nExclusion Criteria Specific to Regimen A (r/r AML)\n\nDiagnosis of promyelocytic leukemia with t(15;17) translocation\n\nReceipt of any biological therapy, chemotherapy, or radiation therapy, except for palliative purposes, within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Day 1\n\nExclusion Criteria Specific to Regimens B and C (r/r MM)\n\nPlasma cell leukemia defined as a plasma cell count >2000/mm3\nLeptomeningeal involvement of MM\nReceipt of any biological therapy, chemotherapy, or radiation therapy, except for palliative purposes, within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to the first dose of mAb\nAllergy or hypersensitivity to antibodies or antibody-related proteins"
            },
            {
                  "document": "Inclusion Criteria:\n\nA diagnosis of: Arms A and C: Acute Myeloid Leukemia (AML) according to the World Health Organization (WHO) 2016 criteria with relapsed or refractory disease and have exhausted or are ineligible for standard therapeutic options; or newly transformed secondary AML according to the WHO 2016 criteria and have exhausted standard therapeutic options for AML during their treatment prior to transformation; or high-risk or very high-risk Myelodysplastic Syndrome (MDS) according to the WHO 2016 criteria and the revised International Prognostic Scoring System (IPSS-R) with relapsed or refractory disease and have exhausted or are ineligible for standard therapeutic options; or Arm A only: chronic myelomonocytic leukemia-2 (CMML-2) according to the WHO 2016 criteria with relapsed or refractory disease and have exhausted or are ineligible for standard therapeutic options; Arm B: Eligible participants must be considered unsuitable for intensive treatment with a curative intent (including stem cell transplantation), but eligible to receive Azacitidine (AZA) treatment with the following underlying diseases: AML (newly diagnosed or relapsed/refractory) according to the 2016 WHO classification only if Venetoclax (VEN) + hypomethylating agent (HMA) (or low-dose cytarabine) is not indicated or available; or high-risk or very high-risk MDS according to the 2016 WHO classification and IPSS-R; or CMML-2 according to the WHO 2016 criteria; Arm D: Very low, low, or intermediate-risk MDS according to the 2016 WHO classification and IPSS-R and the following: Transfusion dependence defined as requiring at least 3 red blood cell (RBC) units transfused within 16 weeks prior to C1D1; pre-transfusion hemoglobin (Hb) should be less than (<) 9.0 grams per decilitre (g/dL) to count towards the 3 units total, Relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment or endogenous serum erythropoietin (EPO) level greater than (>) 500 milliunits per milliliter (mU/mL). Exception: Del(5q) karyotype is allowed, provided prior treatment with lenalidomide has failed or participant was ineligible to receive lenalidomide\nEastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1\nWomen of childbearing potential (WOCBP) must have a negative highly sensitive serum (beta-human chorionic gonadotropin) at screening and again within 48 hours prior to the first dose of study treatment. A urine or serum test is acceptable at subsequent time points\nA WOCBP must agree to all the following during the study and for 6 months after the last dose of study treatment: a) use a barrier method of contraception; b) use a highly effective preferably user-independent method of contraception; c) not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction; d) not plan to become pregnant; e) not breast-feeding\nA male must agree to all the following during the study and for 90 days after the last dose of study treatment: a) wear a condom when engaging in any activity that allows for passage of ejaculate to another person; b) not to donate sperm or freeze for future use for the purpose of reproduction; c) not plan to father a child. In addition, the participant should be advised of the benefit for a female partner to use a highly effective method of contraception as condom may break or leak\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia according to World Health Organization 2016 criteria\nKnown central nervous system involvement\nPrior treatment with a dihydroorotate dehydrogenase (DHODH) inhibitor for an oncology indication or intolerance to a DHODH inhibitor given for non-oncology indication\nToxicities (except for alopecia, peripheral neuropathy, thrombocytopenia, neutropenia, anemia) from previous anticancer therapies that have not resolved to baseline or to Grade 1 or less\nKnown allergies, hypersensitivity, or intolerance to JNJ-74856665, AZA, or VEN or the excipients of these treatments"
            },
            {
                  "document": "Inclusion Criteria:\n\nAdvanced IDH mutant hematologic malignancy\nPatients must have received prior therapy\nBlasts at least 5% in bone marrow.\nPatients must have a qualifying IDH1 R132, IDH2 R140 or IDH2 R172 mutation\nEastern Cooperative Oncology Group (ECOG) 0-2\nAdequate organ function\nAbility to swallow capsules or tablets\nAbility to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation\nWillingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment.\n\nExclusion Criteria:\n\nInvestigational agent or anticancer therapy within 2 weeks or 5 half-lives, whichever is shorter; or investigational monoclonal antibody within 4 weeks prior to planned start of LY3410738\nMajor surgery within 4 weeks prior to planned start of LY3410738.\nActive, uncontrolled clinically significant systemic bacterial, viral, fungal or parasitic infection or an unexplained fever > 38.5\u00baC during screening or on the first day of study drug administration.\nAnother concurrent malignancy requiring active therapy.\nActive central nervous system involvement\nAny unresolved toxicities from prior therapy greater than CTCAE v5.0 Grade 2 at the time of starting study treatment except for alopecia.\nHistory of hematopoietic stem cell transplant (HSCT) or CAR-T therapy within 60 days of the first dose of LY3410738\nClinically significant cardiovascular disease\nActive hepatitis B virus (HBV)\nActive hepatitis C virus (HCV)\nClinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug\nCurrent treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and/or P-gp inhibitor, with the exception of patients being treated with allowed antifungal inhibitors of CYP3A4\nTreatment with proton pump inhibitor (PPIs) within 7 days of starting LY3410738\nAny serious underlying medical or psychiatric condition (e.g. alcohol or drug abuse), dementia or altered mental status or any issue that would impair the ability of the patient to understand informed consent or that in the opinion of the investigator would contraindicate the patient's participation in the study or confound the results of the study\nKnown human immunodeficiency virus (HIV), excluded due to potential drug-drug interactions between anti-retroviral medications and LY3410738\nPregnancy, lactation or plan to breastfeeding during the study or within 90 days of the last dose of study intervention\nKnown hypersensitivity to any of the components of LY3410738 or its formulation"
            },
            {
                  "document": "Recipient Inclusion Criteria:\n\nHistologically or cytologically confirmed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including any AML subtype, except acute promyelocytic leukemia (APL), and including AML that has evolved from a previous MDS or MPN.\nPatients must have peripheral blast count \u2264 20,000/mm3. Use of hydroxyurea to control blast count is permitted.\nPatients must be status post allo-HCT (including: matched related, matched unrelated, haploidentical, mismatched unrelated; and cord blood HCT).\nEastern Cooperative Oncology Group (ECOG) performance status (PS) \u2264 2\n\nAdequate organ function, defined as:\n\nHepatic transaminase (both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels \u22642.5 times the institutional upper limit of normal (ULN),\nTotal bilirubin level \u22641.5 times the ULN (unless the patient has a history of Gilbert's Syndrome, in which case, total bilirubin must be \u22642.5 times the ULN),\nCreatinine clearance of \u226550 ml/min\nAdequate organ reserve including cardiovascular (ejection fraction within institutional normal limits), pulmonary (baseline pulmonary function test [PFT]: carbon monoxide diffusion capacity in the lung [DLCO] > 50%, forced expiratory volume in 1 second [FEV1] > 70%), renal, and hepatic functioning sufficient, in the judgment of the Investigator, to undergo therapy.\nNormal thyroid function or stable thyroid tests on supplementation, except euthyroid sick syndrome.\nRecovery from toxicities of clinical consequence attributed to previous chemotherapy to CTCAE v4.0 Grade \u2264 1 (i.e., certain toxicities such as alopecia will not be considered in this category).\nFemale patients of childbearing potential must test negative for pregnancy at enrollment and during the study. Sexually active women of child-bearing potential, unless surgically sterile, must be willing to use a highly effective method of birth control defined as those which result in a low failure rate (i.e., less than 1% per year) such as implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs) or vasectomized partner. Male patients with partners of childbearing potential must be either vasectomized or agree to use a condom in addition to having their partners use another method of contraception resulting in a highly effective method of birth control defined as those which result in a low failure rate (i.e., less than 1% per year) such as implants, injectables, combined oral contraceptives, or IUDs. Patients should not have sexual intercourse with females who are either pregnant or lactating without a condom. Contraception should be employed from the time of consent through 12 weeks after MGD006 administration. Patients should also abstain from sperm/egg donation during the course of the study.\nAble to have corticosteroids weaned to \u22640.5mg/kg prednisone/day (or equivalent)\n\nAble to have non-steroidal immunosuppression discontinued, including:\n\nmycophenolate (MMF)\n\ncalcineurin inhibitors (tacrolimus, cyclosporine)\n\n**calcineurin inhibitors must be able to be discontinued at least 14 days prior to enrolling on study.\n\nJAK inhibitors (ruxolitinib)\nMTOR inhibitors (sirolimus)\nAt least 18 years of age.\nAbility to understand and willingness to sign an IRB approved written informed consent document\n\nRecipient Exclusion Criteria:\n\nActive GVHD requiring systemic immunosuppresion with more than 0.5 mg/day prednisone\nCurrently receiving any other investigational agents.\nAny active untreated autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid clinically and with stable supplementation).\nSecond primary malignancy that requires active therapy (adjuvant hormonal therapy is allowed).\nAntitumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular- targeted therapy, retinoid therapy, or investigational agent) within 14 days or 5 half-lives of Cycle 1 Day 1, whichever is longer.\nAt the time of study entry, steroids >0.5mg/kg of prednisone or equivalent (except steroid inhaler, nasal spray or ophthalmic solution which are allowed).\nUse of immunosuppressant medications (other than steroids as noted) in the 2 weeks prior to study drug administration (Cycle 1 Day 1).\nIsolated extramedullary relapse (i.e., no evidence of bone marrow involvement).\nKnown central nervous system (CNS) leukemia. Patients with suspected CNS leukemia must be evaluated by lumbar puncture and be free of CNS disease prior to study entry. Previously treated CNS leukemia is allowed provided adequate treatment has been provided and the patient is free of CNS disease.\n\nAny medical or psychiatric condition limiting full compliance or increasing the safety risk, at the discretion of the PI, such as:\n\nactive uncontrolled infection (including, but not limited to viral, bacterial, fungal, or mycobacterial infection),\nknown human immunodeficiency virus infection,\nknown, active, or chronic hepatitis B or C infection (appropriately treated HBV/HCV infections with documented clearance of viral titer are allowed),\nGrade 3 or 4 bleeding,\nsignificant pulmonary compromise including the requirement for supplemental oxygen, history of non-infectious pneumonitis (including radiation pneumonitis), pulmonary fibrosis, or severe chronic obstructive pulmonary disease (COPD),\nuncontrolled (persistent) hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 100 mm Hg\nclinically significant arrhythmia, clinically significant baseline QTcF >480 msec,\nunstable angina,\nrecent myocardial infarction within 6 months prior to study drug administration (Cycle 1 Day 1),\nclinically significant heart disease, such as, congestive heart failure, history of pericarditis, myocarditis,\nhistory of stroke or transient ischemic event within 3 months prior to study drug administration (Cycle 1 Day 1),\nuntreated pulmonary embolism, or non-catheter-related deep-vein thrombosis in the 3 months prior to study drug administration (Cycle 1 Day 1),\npregnancy, or breast feeding,\nmajor surgery or trauma within 4 weeks before enrollment.\nKnown hypersensitivity to murine, yeast, or recombinant proteins; polysorbate 80; recombinant human serum albumin; benzyl alcohol; or any excipient contained in the MGD006 drug formulation.\nDementia or altered mental status that would preclude sufficient understanding to provide informed consent."
            },
            {
                  "document": "Inclusion Criteria:\n\nWith confirmed diagnosis of primary or secondary AML according to WHO classification 2016, with measurable disease. Eligible participants need to have received standard-of-care (SOC) and have no other SOC options available Participants who are not willing to receive SOC will be not eligible. Two groups of participants (Group I - hematologic relapsed/refractory and Group II - molecular relapsed/refractory) will be included\nParticipants who have received hematopoietic stem cell transplant (HSCT) must have the HSCT performed \u2265 90 days prior to the first dose of RO7283420 on Cycle 1 Day 1, having demonstrated hematological engraftment and do not have an active Graft versus Host Disease, not requiring immunosuppressive treatment (including but not limited to cyclosporine, tacrolimus, sirolimus, and mycophenolate), which must be stopped at least 28 days prior to the first dose of RO7283420 on Cycle 1 Day 1\nEastern Cooperative Oncology Group (ECOG) performance status 0-2\nPeripheral blast counts =< 20,000/mm3 on Cycle 1 Day 1 prior to the first dosing\nConfirmed genotype of HLA-A*02\nAdequate renal (a creatinine clearance of >=50 mL/min as calculated according to the Cockroft-Gault formula) and adequate liver test results\nMale or female participants agree to use contraception and the abstinence requirements to prevent exposure of an embryo to the study treatment\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia (APL)\nCore Binding Factor (CBF)-AML Note: participants with r/r CBF-AML after at least 2 salvage attempts can be enrolled into the study\nGroup II only: participants with normal karyotype and a favorable molecular profile according to ELN guideline 2017\nParticipants with active bacterial, fungal or viral infection considered by the Investigator to be clinically uncontrolled or of unacceptable risk upon the induction of neutropenia (i.e. participants who are or should be on antimicrobial agents for the treatment of active infection)\nGrade >= 2 glomerular proteinuria at screening or on Cycle 1 Day 1 prior to the first dosing.\nAnother primary malignancy (other than AML) that requires active therapy. Adjuvant hormonal therapy is allowed\nClinical evidence or history of central nervous system (CNS) leukemia\nPresence of extramedullary disease at screening\nCurrent or past history of CNS disease, such as stroke, CNS inflammation, epilepsy, CNS vasculitis, or neurodegenerative disease\nParticipants who have a history of clinically significant liver disease, including liver cirrhosis (e.g. Child-Pugh class B and C) or participants who have a history of active or chronic infectious hepatitis unless serology demonstrates clearance of infection\nParticipants who might refuse to receive blood products and/or have known hypersensitivity to any of the components of RO7283420, tocilizumab, or dasatinib"
            },
            {
                  "document": "Inclusion Criteria:\n\nNewly diagnosed, previously untreated AML (according to World Health Organization criteria) with at least 20% blasts in the peripheral blood or bone marrow.\nAge \u2265 18 with Intermediate or Adverse genetic risk (per ELN criteria).\nEastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia (t(15;17)), myeloid sarcoma without bone marrow involvement, or blast transformation of chronic myelogenous leukemia.\nClinical evidence of active central nervous system leukemia.\nAML treatment, including Vyxeos (CPX-351, liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin, or any other prohibited concomitant AML therapy previously received or anticipated to start during the study.\nReceiving any form of anticoagulant therapy (e.g., unfractionated heparin, low molecular weight heparin, coumadin, factor Xa inhibitors). Heparin flush of indwelling catheters is permitted.\nTreatment with any other investigational agent within 28 days, or 5 half-lives, whichever is longer, prior to baseline.\nAny major surgery or radiation therapy within 28 days prior to baseline.\nImmediately life threatening, severe complications of leukemia such as pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.\nActive or uncontrolled bleeding at the time of randomization; a bleeding disorder, either inherited or caused by disease; history of known arterial-venous malformation, intracranial hemorrhage, or suspected or known cerebral aneurysm; or clinically significant gastrointestinal bleeding within the 3 weeks prior to randomization.\nPresence of significant active or uncontrolled infection, including HIV or hepatitis B or C.\nActive (uncontrolled, metastatic) second malignancy.\nHistory of severe congestive heart failure or other cardiac disease that contraindicates the use of idarubicin or daunorubicin (e.g., cardiac ejection fraction <45%).\nQTc >480 msec.\nSevere renal impairment, as determined by calculated creatinine clearance <30 mL/min or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2.\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x upper limit of normal (ULN) or total bilirubin >2x ULN."
            },
            {
                  "document": "[Patient]\n\nInclusion Criteria:\n\n\u226760 years of age\nDiagnosis of acute myeloid leukemia\nReceive 1) low-dose cytarabine or hypomethylating agent (HMA) in combination with Venetoclax chemotherapy OR 2) low-dose cytarabine or hypomethylating agent (HMA) in combination with Venetoclax chemotherapy and any investigational drugs\nSpeak and read English\n\nExclusion Criteria:\n\n1. Patients receiving hospice care\n\n[Caregiver]\n\nInclusion Criteria:\n\n\u226718 years of age\nIdentified by patient as caregiver\nSpeak and read English"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with pathologically confirmed ALL or AML, whose disease is refractory to two induction therapeutic attempts, or who are in 2nd or greater relapse, or who are in 1st relapse or refractory to a single therapeutic attempt but are unable to receive intensive therapy at the time of consent.\nAll prior upfront therapies including bone marrow transplant are acceptable. Pulse steroids (of 5 days duration or less in the prior month) administered as part of a routine maintenance therapy are acceptable.\nAge 1 to 21 years of age, inclusive\nEstablished central catheter IV access\n\nExclusion Criteria:\n\nFemales who are known to be pregnant or lactating\nAny Grade 3 or higher Cardiac Disorder per CTCAE version 5\nPatients with echocardiographic evidence of cardiomyopathy (shortening fraction <27% or ejection fraction <50%)\nUncontrolled sepsis\nAbsolute Blast Count >50 x10(3)/mcL at enrollment or on day 1 of study\nDirect hyperbilirubinemia >5mg/dL\nGrade 3 or higher anaphylaxis to daunorubicin\nNon-English speaking\nPatients, who in the opinion of the PI, are unable to tolerate any study-specific procedures\nPatients who have received cyclosporine, tacrolimus or other agents to prevent or treat graft-vs-host disease post bone marrow transplant in the last 14 days\nConcurrent investigational drugs or other chemotherapeutic agents (excluding hydroxyurea), immunotherapies or biosimilars during the 5 days of daunorubicin.\nPrior cumulative doses of anthracyclines will not be an exclusion regardless of the total cumulative dose previously received."
            },
            {
                  "document": "Inclusion Criteria:\n\nEastern Cooperative Oncology Group (ECOG) performance status of \u2264 2\nAdequate organ function (bone marrow, hepatic, renal, cardiovascular)\nLeft ventricular ejection fraction of \u226550%\nFemale patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use a highly effective method of contraception during the trial\nPatients must have recovered from the effects of any prior cancer related therapy, radiotherapy or surgery (toxicity \u2264 Grade 1)\nAll patients on prior investigational agents must wait at least 5 half-lives of the agent in question, or 14 days, whichever is longer before study entry\n\nAML patients only: Pathologically confirmed diagnosis of AML as defined by the WHO Classification and patients with targeted mutations must have been treated with appropriate therapy for their disease\n\nWhite blood cell count < 25 x 10^9/L. Hydrea or leukapheresis are permitted to meet this criterion.\nCMML patients only: intermediate-2 or high risk per CMML-specific prognostic scoring system (CPSS) or clinical/molecular CPSS (CPSS-mol) criteria. Must have failed prior therapy with a hypomethylating agent.\nMDS patients only: Intermediate, high, or very high risk by International Prognostic Scoring System-Revised [IPSS-R] criteria that is relapsed or refractory to approved therapies or MDS/MPN Overlap Syndrome (displaying both fibrosis and dysplastic features).\nNHL patients only: Histologically or cytologically confirmed NHL, including B- and T-cell lymphomas that is relapsed or refractory or intolerant to approved therapies. Must have one lesion that can be measured for response\nMM patients only: Measurable disease defined by one or more of the following: Serum M-protein \u2265 0.5 g/dL, Urine M-protein \u2265 200 mg/24 hours, Serum Free Light Chain (sFLC) > 10 mg/dL with normal serum FLC ratio. Presence of soft tissue plasmacytoma confirmed by imaging\n\nNHL and MM patients only: must have the following lab values within 14 days prior to study Day 1:\n\nANC \u22651.0 x 10^3 \u03bcL\nPlatelet count \u226550,000 \u03bcL\n\nExclusion Criteria:\n\nKnown hypersensitivity to any of the components of PRT1419\nFemale patients who are pregnant or lactating\nMean QTcF interval of >480 msec\nHistory of heart failure, additional risk factors for arryhthmias or requiring concomitant medications that prolong the QT/QTc interval\nHematopoietic stem-cell transplant < 90 days or have GVHD Grade >1 at study entry\nUncontrolled intercurrent illnesses\nTreatment with strong inhibitors of CYP2C8 and/or P-glycoprotein for which there are no therapeutic substitutions\nInflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption\nHIV positive; known active hepatitis B or C\nPrior exposure to an MCL1 inhibitor\n\nHistory of another malignancy except:\n\nMalignancy treated with curative intent with no known active disease for >2 years at study entry\nAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\nAdequately treated carcinoma in situ without evidence of disease\nOther concurrent low-grade malignancies (i.e chronic lymphocytic leukemia (Rai 0)) may be considered after consultation with Sponsor."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of relapsed or refractory leukemia including, but not limited to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), T-cell prolymphocytic leukemia, biphenotypic acute leukemia, or blast-phase of chronic myeloid Leukemia (CML) will be allowed during the safety lead-in phase\nFor cohort A of the expansion phase: Patients with a diagnosis untreated adverse-risk AML (as defined by ELN [European Leukemia Net Classification] 2017) will be enrolled\nFor cohort B of the expansion phase: Patients with a diagnosis of relapsed or refractory AML will be enrolled\nBilirubin =< 2 mg/dL\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)\nCreatinine =< 1.5 x ULN\nCardiac ejection fraction of > or = 45% within the past 3 months\nAmylase and lipase =< 1.5 x ULN\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2\nA negative urine pregnancy test is required within one week (7 days) for all women of childbearing potential prior to being registered on this trial\nPatient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol\n\nExclusion Criteria:\n\nPregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided\nUncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPatient with documented hypersensitivity to any of the components of the chemotherapy program\nPrior treatment with pegylated asparaginase\nPatients with a diagnoses of acute promyelocytic leukemia (AML-M3) will be excluded from this trial\n\nMen and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation. Effective methods of birth control include:\n\nBirth control pills, shots, implants or patches\nIntrauterine devices (IUDs)\nCondom or occlusive cap (diaphragm or cervical/vault caps) used with spermicide\nAbstinence\nFemales of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation, oophorectomy, and/or hysterectomy\nPatients with history of clinically significant venous thromboembolism"
            },
            {
                  "document": "Inclusion Criteria:\n\nAcute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL), myelodysplastic syndrome with excess blasts-2 (MDS-EB2), or another high-risk myeloid neoplasm (>= 10% blasts in the blood or marrow), having completed at least one cycle of chemotherapy intended to induce remission\n\nSubjects must have MRD, defined as the presence of original disease detected by multi-parameter flow cytometry and cytogenetic/molecular assessment within 90 days of chemotherapy intended to induce remission:\n\nAbnormal cells identified by multiparameter flow cytometry, present at a frequency of between 0% and 5% of total nucleated cells, judged in the opinion of the hematopathologist to represent continued presence of malignant cells\nAbnormal karyotype; present in any number of metaphase cells\nAbnormal fluorescence in-situ hybridization; judged in the opinion of the hematopathologist to represent continued presence of malignant cells\nThe presence of any leukemia associated mutation as detected by DNA sequencing, except mutations in DNMT3A, TET2, or ASXL1. This includes (but is not limited to) the following genes: CBL (CDS), CSF3R (exons 14, 15, 17), EZH2 (exons 15-20), FBXW7 (CDS), FGFR1 (exons 4, 11-17, partial 18), FLT3 (p.D835H), GATA1 (exons 2-3), GATA2 (exons 3-5), HRAS (exon 1-2), IDH1(p.R132), IDH2 (exon 4), JAK2 (exon 12, 14, 16), KIT (8-18), KMT2A (CDS), KRAS (CDS), MAP2K1 (exons 2, 3, 6), MPL (exon 10), MYD88 (exon 3-5), NOTCH1 (exons 20, 26, 27), NPM1 (exon 12), NRAS (CDS), PDGFRA (exons 12-18), PHF6 (CDS), PTEN (CDS), RB1 (CDS), RUNX1 (exon 4-8), SF3B1 (exon 14-16), SRSF2 (exon 1), STAG2 (CDS), STAT3 (exons 20-21), TP53 (CDS), U2AF1 (exons 2, 6), WT1 (CDS), and ZRSR2 (CDS)\n\nAllowable prior therapy:\n\nFor the purposes of this study intensive chemotherapy will include regimens listed below. Additional regimens may be included at the discretion of the study principal investigator (PI)\n\nAny regimen including cytarabine at a dose of 100 mg/m^2/day for at least 7 days and an anthracycline at any dose +/- gemtuzumab ozogamicin (GO)\nAny regimen including cytarabine at a dose of at least 100 mg/m^2/day for at least 5 days and a purine analog at any dose (e.g. clofarabine, fludarabine, cladribine) +/- GO\nAbility to understand and voluntarily sign a written informed consent document (ICF)\nAbsence of a concomitant illness with a likely survival of < 1 year\nMedically fit, defined as a treatment related mortality score (TRM) of =< 13.1 calculated according to Walter et al, Journal of Clinical Oncology (JCO) 2011\nAdditionally, subjects should be eligible in the opinion of their treating physician for allogeneic transplantation\nBilirubin =< 2.5 x institutional upper limit of normal, unless elevation is thought to be due to Gilberts syndrome or hemolysis (within 14 days of study start [unless otherwise noted] to be enrolled in the study)\nLeft ventricular ejection fraction >= 40% assessed by multiple gated acquisition scan (MUGA), echocardiography or other appropriate diagnostic modality within 12 months of enrollment with no clinical evidence of decompensated congestive heart failure\nCreatinine clearance of >= 30 mL/min as measured by Cockcroft Gault equation (within 14 days of study start [unless otherwise noted] to be enrolled in the study)\nConsent of female patients with a negative serum or urine pregnancy test to use a medically acceptable method of contraception throughout the entire study period and for 6 months following the last dose of CPX-351\nMale patients must be willing to refrain from sperm donation for 6 months following the last dose of CPX-351 and must use adequate contraception throughout the entire study period and for 6 months following the last dose of CPX-351\nPatients enrolling in this trial should intend to complete the treatments described and should be eligible in the opinion of the treating physician for allogeneic transplantation\nPatients must have a caregiver capable of providing post-HCT care, who will be present once conditioning therapy begins\nThe informed consent document (ICF) must be signed and dated by the subject or by the subject's legally authorized representative if the subject is unable to sign\n\nExclusion Criteria:\n\nAllogeneic myeloablative hematopoietic cell transplant within 6 months\nAutologous hematopoietic cell transplant within 6 months\n\nKnown Hypersensitivity to CPX-351\n\nPatients may not have known hypersensitivity to CPX-351, daunorubicin, cytarabine, or liposomal products\nPrior treatment with two or more cycles of CPX-351\nTreatment within the last 30 days of other investigational antineoplastic agents\n\nEvidence of organ dysfunction likely to preclude safe transplantation including the following:\n\nSymptomatic coronary artery disease or uncontrolled arrhythmia within the prior 3 months and since most recent anthracycline exposure\nMyocardial impairment of any cause resulting in heart failure as determined by New York (NY) Heart Association Criteria (class III or IV)\nCorrected diffusion capacity of the lung for carbon monoxide (DLCOc) < 40% or forced expiratory volume in 1 second (FEV1) < 50%\nNeed for supplemental oxygen\nActive systemic fungal, bacterial, viral or other infection, unless under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)])\nFemale patients who are pregnant, nursing, or lactating\nPatients with an inability to accept blood transfusions\nInability to give informed consent, or unable to comply with the treatment protocol including appropriate supportive care, follow-up and tests\nAny other condition that would cause a risk to patients if they participate in the trial"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with AML and the presence of FLT3-ITD mutation\nPatients with secondary AML or therapy related disease (t-AML) are eligible\nIf the patient has co-morbid medical illness, life expectancy attributed to this must be greater than 6 months\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nTotal bilirubin < 2.0mg/dL unless due to Gilbert's disease\nAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal\nCreatinine (Cr) clearance > 50 mL/min by Cockcroft-Gault calculation\nNew York Heart Association (NYHA) Congestive Heart Failure (CHF) class II or better\nCardiac ejection fraction \u226540%\nFemale patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose\nAbility to understand and willingness to sign the written informed consent document\nHuman immunodeficiency virus (HIV) infection without history of acquired immunodeficiency syndrome (AIDS) and sufficiently high CD4 cells (> 400/mm^3) and low HIV viral loads (< 30,000 copies/ml plasma) not requiring anti-HIV therapy are eligible\n\nExclusion Criteria:\n\nPatients with acute promyelocytic leukemia\nPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Treatment with hydoxyurea is permitted during cycle 1 to maintain white blood cell (WBC) < 40,000/uL\nPatients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment\nPatients with active central nervous system (CNS) malignancy\nMajor surgery within 2 weeks before day 1\nUncontrolled active infection. Patients with infection requiring parenteral antibiotics are eligible if the infection is controlled\nPatients with significantly diseased or obstructed gastrointestinal tract\nUncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, myocardial infarction within 6 months prior to enrollment, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant\nPatients with serious medical or psychiatric illness likely to interfere with participation in this clinical study\nPregnant women or women who are breastfeeding are excluded from this study. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women\nPatients with advanced malignant solid tumors\nPatients who are not able to swallow capsules or tablets"
            },
            {
                  "document": "Inclusion Criteria:\n\nPathologically confirmed AML or CLL, otherwise eligible for VEN-containing therapy at Screening\n\nNewly diagnosed patients with AML deemed ineligible for intensive induction chemotherapy (age 75 and older or < 75 years of age with comorbidities that preclude the use of intensive induction therapy) eligible to receive VEN at Screening. VEN may be combined with azacitidine or decitabine at the discretion of the treating Investigator.\nRelapsed/refractory CLL eligible to receive single-agent VEN or VEN in combination with rituximab at Screening.\nNewly-diagnosed CLL eligible to receive VEN in combination with obinatuzumab at Screening.\nPatients who have been receiving stable doses of VEN for at least 5 days prior to initiation of PIT add-on therapy.\nAge \u2265 18 years.\nPatients who are already on statins for dyslipidemias are eligible if their previous statin is stopped at least 72 hour prior to starting VEN-based therapy; administration of other statins is prohibited during the study.\nECOG performance status \u2264 2 at baseline.\nCreatinine clearance 30 mL/min or higher; patients assigned to the highest dose level of PIT add-on therapy must have creatinine clearance 60 mL/min or higher.\n\nLiver Function tests within the following ranges:\n\nAspartate aminotransferase (AST) \u2264 3.0 \u00d7 ULN\nAlanine aminotransferase (ALT) \u2264 3.0 \u00d7 ULN\nBilirubin \u2264 1.5 \u00d7 ULN (unless elevated bilirubin due to leukemic involvement in the liver or Gilbert's disease)\nAbility to understand and willingness to sign the informed consent.\nFor the duration of the study treatment period and for at least 90 days following the last dose of study drug female of childbearing potential (FCBP) who are sexually active must agree to employ effective contraceptive methods. Effective contraceptive methods include use of hormonal contraception or an intrauterine device (IUD) by the female partner, or use of condoms by the male partner. An FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).\nFor the duration of the study treatment period and for at least 90 days following the last dose of study drug, male patients must agree to use effective contraceptive methods during sexual contact with a female of childbearing potential (FCBP) and must agree to refrain from semen or sperm donation during the same timeframe.\n\nExclusion Criteria:\n\nPatients who are receiving any investigational agents during the previous 30 days or at any time during the study.\nPatients who have previously received VEN.\nPatients who satisfy any of the contraindications for PIT.\nPatients with AML who received prior therapy other than hydroxyurea including those starting hypomethylating therapy for MDS after AML diagnosis.\nPatients with acute promyelocytic leukemia are excluded\nPatients with known CNS involvement with leukemia are excluded\nPatients with active hepatitis B (HBV) or hepatitis C (HCV) infection are excluded. Patients with prior HBV or HCV exposure and those on antiviral medications with negative HBV or HCV viral loads are eligible, as long as the antiretroviral drugs being used do not have significant CYP3A4 interactions.\nPatients with uncontrolled HIV are excluded. Patients with known HIV and undetectable viral loads are eligible as long as the antiretroviral drugs being used do not have significant CYP3A4 interactions.\nPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PEN, PIT, or other statins are excluded.\nPatients receiving are strong inhibitors or inducers of CYP3A4 within 7 days prior to initiation of VEN therapy are excluded. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. An exception to this is made for patients with AML who require anti-fungal therapy with appropriate dose reduction in VEN (see Section 5.10.2.3).\nPatients who have consumed grapefruit, grapefruit juice or Seville oranges within 72 hours of initiation of VEN therapy. Consumption of grapefruit, grapefruit juice, Seville oranges, or orange marmalade should be avoided for the duration of the study, as these affect CYP3A4 activity.\nPatients with certain uncontrolled intercurrent illness are excluded. These include, but are not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illnesses, or social situations that would limit compliance with study requirements.\nPatients who are pregnant or breastfeeding are excluded.\nPatients who are unable to swallow pills are excluded.\nPatients having a malabsorption syndrome or other condition that precludes the oral/enteral route of administration are excluded\nPatients with an active concurrent malignancy other than CLL or AML are excluded. Patients with a history of definitively treated prior malignancy with low risk of recurrence, skin cancers that have been excised, or on prolonged adjuvant hormonal therapy (ie, for breast or prostate cancer) but are otherwise considered in remission are eligible."
            },
            {
                  "document": "Inclusion Criteria\n\nFirst allogeneic HSCT, in \u2264 CR2, and MRD negative prior to transplant (including matched sibling, MUD with at least 6 of 8 HLA markers, or haploidentical with at least 5 of 10 HLA markers) as:\n\nAdjuvant therapy for AML (Group 1) at 90 days (\u00b110 days) post-HSCT defined as patients with CRMRD; or\n\nTreatment for refractory/relapsed AML (first relapse post-HSCT) when disease occurs after transplant (Group 2) defined as\n\nFirst relapse (MRD+ or frank relapse) post-HSCT\nPatients in Arm 1B (SOC) who experience first relapse (MRD+ or frank relapse) post HSCT\nSafety Lead-in defined as patients who fit all the criteria for Group 2 only\nAre \u226518 years of age\nKarnofsky/Lansky score of \u226560\nLife expectancy \u226512 weeks\n\nAdequate blood, liver, and renal function\n\nBlood: Hemoglobin \u22657.0 g/dL (can be transfused)\nLiver: Bilirubin \u22642X upper limit of normal; aspartate aminotransferase \u22643X upper limit of normal\nRenal: Serum creatinine \u22642X upper limit of normal or measured or calculated creatinine clearance \u226545mL/min\n\n7. Patients are allowed to be on experimental conditioning regimens prior to transplant if no planned maintenance therapy post-transplant.\n\n8. In Group 2, patients may receive bridging therapy at the investigators' discretion in situations where MT-401 is not ready for administration or the treating physician believes the patient would benefit\n\nExclusion Criteria\n\nClinically significant or severely symptomatic intercurrent infection\nPregnant or lactating\nFor Group 1, anti-neoplastic therapy after HSCT and prior to or during dosing of MT-401\nFor Group 2, concomitant anti-neoplastic therapy during or after dosing of MT-401\nEvidence of acute or chronic GVHD \u2265Grade 2 (exception: acute or chronic Grade 2 GVHD of skin allowed if stable) within one week prior to receiving MT-401"
            },
            {
                  "document": "Inclusion Criteria:\n\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2\nIDH1-R132 mutated disease status as assessed by local laboratory. 2HG-producing IDH1 variants outside of R132 (i.e. R100) may be eligible after discussion with the principal investigator (PI)\nTreatment naive or relapsed/refractory AML who are eligible for intensive chemotherapy. Patients with high-risk MDS or MPN (defined as >= 10% bone marrow blasts, or intermediate or high risk by International Prognostic Scoring System [IPSS], revised [R]-IPSS or dynamic [D]-IPSS) may also be eligible after discussion with the PI\nDirect bilirubin =< 2 x upper limit of normal (ULN) unless deemed to be related to underlying leukemia\nAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN unless deemed to be related to underlying leukemia\nCreatinine clearance >= 30 ml/min based on the Cockcroft-Gault equation\nWilling and able to provide informed consent\nIn the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents\nMale subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug\n\nExclusion Criteria:\n\nPatients who have previously received either ivosidenib or CPX-351\nPatients with any concurrent uncontrolled clinically significant medical condition including infection, laboratory abnormality, or psychiatric illness, which could place the patient at unacceptable risk of study treatment\nThe use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions (1) intrathecal chemotherapy for prophylactic use or for controlled central nervous system (CNS) leukemia. (2) use of hydroxyurea, and/or cytarabine (1 or 2 doses; up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy\nPatients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI)\nPatients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications\nPatients with symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina, or an ejection fraction < 45%\nPatients with prior anthracycline exposure of > 360 mg/m^2 daunorubicin (or equivalent) or > 210 mg/m^2 daunorubicin (or equivalent) in patients with prior mediastinal radiation\nCorrected QT (QTc) interval using Fridericia's formula (QTcF) >= 470 msec. A prolonged QTc interval in the setting of right bundle branch block is permitted after discussion with the PI\n\nNursing women, women of childbearing potential (WOCBP) with positive urine or serum pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception\n\nAppropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)\nSubjects with a known medical history of progressive multifocal leukoencephalopathy (PML)\nSubjects taking strong CYP3A4 inducers are excluded from the study unless they can be transferred to other medications within >= 5 half lives prior to dosing\nPatients with a diagnosis of acute promyelocytic leukemia (APL)\nUnresolved toxicities > grade 1 from prior treatment including chemotherapy, targeted therapy, immunotherapy, experimental agents, radiation, or surgery"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis:\n\nCohort A (frontline): Newly diagnosed AML\nCohort B (relapsed/refractory): Relapsed/refractory AML or relapsed/refractory MDS or chronic myelomonocytic leukemia (CMML) that is intermediate-2 or high-risk by the International Prognostic Scoring System with >= 10% blasts harboring a Ras pathway-activating mutation. Eligible mutations include: activating mutations of KIT, HRAS/NRAS/KRAS, BRAF, CBL or PTPN11 or loss of function mutation of NF1. Other mutations not listed here that are anticipated to activate Ras signaling may be considered for enrollment after discussion with the principal investigator (PI)\nPerformance status =< 2 (Eastern Cooperative Oncology Group [ECOG] scale)\nTotal serum bilirubin =< 2.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the PI\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x ULN, unless due to the underlying leukemia approved by the PI\nCreatinine clearance >= 30 mL/min\nAbility to swallow\nSigned informed consent\n\nExclusion Criteria:\n\nPatients suitable for and willing to receive intensive induction chemotherapy (cohort A only)\nActive serious infection not controlled by oral or intravenous antibiotics (e.g. persistent fever or lack of improvement despite antimicrobial treatment)\nPatients with a prior or concurrent malignancy whose natural history or treatment is not anticipated to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the PI\nConsumed strong inducer of CYP3A or p-glycoprotein within 3 days of study enrollment. Agents include but are not limited to: carbamazepine, phenytoin, rifampin, and St. John's wart\nTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator. Prior recent treatment with corticosteroids, hydroxyurea and/or cytarabine (given for cytoreduction) permitted\nPregnant women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception throughout the study period and for at least 6 months after the last dose of study drugs. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control throughout the study period and for at least 4 months after the last dose of study drugs. Lactating women (or those planning to breastfeed) should not breastfeed during treatment of trametinib and for at least 2 months after the last dose of trametinib"
            },
            {
                  "document": "Inclusion Criteria:\n\nAbility to provide informed consent\nStated willingness to comply with all study procedures and availability for the duration of the study\n\nAny of the following:\n\nPatients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 and older.\n\nOR\n\nPatients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 and older.\n\nOR\n\nPatients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 and older.\n\nRefractory AML/ALL will be defined as persistent leukemia despite two or more cycles of induction chemotherapy.\n\nRefractory MDS will be defined according to the 2006 IWG response criteria Refractory CMML will be based on the assessment of the treating investigator.\n\nExclusion Criteria:\n\n1. Participants must not have a diagnosis of Acute Promyelocytic Leukemia (APL)"
            },
            {
                  "document": "Key Inclusion Criteria:\n\nAge \u226518 years\nLife expectancy of at least 3 months\nECOG Performance Status \u2264 2\nPatients must be able to swallow capsules\nAdequate hematologic parameters, unless cytopenias are disease caused\nAdequate renal, liver and cardiac functions\n\nKey Exclusion Criteria:\n\nPatients with GVHD requiring systemic immunosuppressive therapy\nUncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinically significant disease related metabolic disorder\nClinically significant leukostasis\nTreatment with other investigational drugs or receipt of cytotoxic therapy within 14 days prior to first study treatment administration\nReceipt of cellular immunotherapeutic agents within 4 weeks prior to first study treatment administration"
            },
            {
                  "document": "Inclusion Criteria:\n\nMen or women \u2265 18 and \u2264 80 years old\n\nDiagnosis of hematological malignancy:\n\nAcute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in morphologic complete remission\nMyelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), or chronic myelomonocytic leukemic (CMML) with < 5% blasts in blood or bone marrow\nChemosensitive Hodgkin lymphoma (HL) or Non-Hodgkin lymphoma (NHL)\nPatients must be undergoing haploidentical allogeneic hematopoietic cell transplantation, defined as 1st or 2nd degree relative with at least 5/10 matching at HLA-A, -B, -C, DR, and DQ.\nECOG performance status \u22642\n\nPatients with adequate physical function as measured by:\n\nCardiac: Left ventricular ejection fraction at rest must be \u2265 40%, or shortening fraction >25%\n\nHepatic:\n\nBilirubin \u2264 2.5 mg/dL, except for patients with Gilbert's syndrome or hemolysis\nALT, AST, and Alkaline Phosphatase < 5 x ULN\nRenal: Serum creatinine within normal range, or if serum creatinine is outside normal range, then renal function (measured or estimated creatinine clearance or GFR) \u2265 40mL/min/1.73m2\nPulmonary: DLCO (corrected for hemoglobin), FEV1 and FVC \u2265 50% predicted\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nPrior allogeneic hematopoietic stem cell transplantation. (Patients may have received a prior autologous hematopoietic stem cell transplant.)\nParticipants who are receiving any other investigational agents within 14 days prior to RGI-2001 dosing. Thus, participants must stop investigational agents by Day -9 prior to transplant.\nUncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, recent myocardial infarction or stroke, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nPatients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.\nPlanned use of prophylactic donor lymphocyte infusion (DLI) therapy.\nPregnant and breast-feeding women are ineligible because they are not eligible for hematopoietic stem cell transplantation.\nHIV-positive participants and patients with active Hepatitis B or C are ineligible"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of 1) Pathology diagnosis of AML (excluding acute promyelocytic leukemia [APL])\nPhase Ib dose finding cohort: Patients aged >= 18 years old with relapsed/refractory AML are eligible if they are not eligible for potentially curative therapy such as effective salvage therapy or hematopoietic stem cell transplantation or who refuse these options at the time of enrollment. Patients must have received at least one prior therapy for AML\nPhase Ib dose finding cohort: Patients may have received up to 2 prior therapies for AML (i.e. up to salvage 2 status allowed)\nPhase Ib dose finding cohort: Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n\nPhase II (frontline cohort): Patients with newly diagnosed AML who are chemonaive who are ineligible for intensive chemotherapy based on EITHER:\n\n>= 75 years of age OR\n\n< 75 years of age with at least 1 of the following relevant comorbidities:\n\nPoor performance status (ECOG) score of 2.\n\nClinically significant heart or lung comorbidities, as reflected by at least 1 of:\n\nLeft ventricular ejection fraction (LVEF) =< 50%.\nLung diffusing capacity for carbon monoxide (DLCO) =< 65% of expected.\nForced expiratory volume in 1 second (FEV1) =< 65% of expected.\nChronic stable angina or congestive heart failure controlled with medication.\nOther contraindication(s) to anthracycline therapy (must be documented).\nOther comorbidity the investigator judges incompatible with intensive remission induction chemotherapy, which must be documented and approved by the principal investigator (PI)\nPhase II (frontline cohort): For patients with prior MDS or chronic myelomonocytic leukemia (CMML) or MPN who transformed to AML, therapy received for MDS, CMML, or MPN is NOT considered as prior therapy for AML. Patients with MDS or CMML treated with hypomethylating agent (HMA) therapies who progress to AML, and have no available therapies or are not candidates for available therapies, will be eligible at the time of progression to AML. Temporary prior measures such as apheresis, ATRA, steroids while diagnostic work-up of AML is being performed are allowed and not counted as a prior salvage\nPhase II (relapsed/refractory prior venetoclax naive cohort): Patients aged >= 18 years old with relapsed/refractory AML are eligible if they are not eligible for potentially curative therapy such as effective salvage therapy or hematopoietic stem cell transplantation or who refuse these options at the time of enrollment. Patients must have received at least one prior therapy for AML. Patients may have received up to 2 prior therapies for AML (i.e. up to salvage 2 status allowed). Eastern Cooperative Oncology Group (ECOG) performance status =< 2. Patients must not have received prior venetoclax for MDS or AML\nPhase II (relapsed/refractory prior venetoclax exposed cohort): Patients aged >= 18 years old with relapsed/refractory AML are eligible if they are not eligible for potentially curative therapy such as effective salvage therapy, targeted therapies, or hematopoietic stem cell transplantation or who refuse these options at the time of enrollment. Patients must have received at least one prior therapy for AML. Patients may have received up to 2 prior therapies for AML (i.e. up to salvage 2 status allowed). Eastern Cooperative Oncology Group (ECOG) performance status =< 2. Patients may have received prior venetoclax for MDS or AML\nPatients with newly diagnosed AML with poor risk karyotype or complex karyotype and/or TP53 deletions/mutations younger than 75 year old will be eligible for the Phase II (frontline cohort) regardless of eligibility or fitness for intensive chemotherapy\nFor Phase II (frontline cohort): Patients must be chemonaive, i.e., not have received any chemotherapy (except hydrea or 1-2 doses of ara-C for transient control of hyperleukocytosis) for AML. They may have received transfusions, hematopoietic growth factors or vitamins for an antecedent hematological disorder (AHD) or for AML. Temporary prior measures such as apheresis, ATRA, steroids or hydrea while diagnostic work-up is being performed are allowed and not counted as a prior salvage. Supportive care therapy for MDS (growth factors, transfusions) will not be considered as prior therapy for MDS/AML and these patients will be enrolled to the frontline cohort of the study if they are otherwise eligible\nIn the absence of rapidly progressing disease, the interval from prior treatment to time of initiation of protocol therapy will be at least 2 weeks or at least 5 half-lives (whichever is shorter). The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochure's, or drug-administration manuals) and will be documented in the protocol eligibility document. The toxicity from prior therapy should have resolved to grade =< 1, however alopecia and sensory neuropathy grade =< 2 not constituting a safety risk based on investigators judgement is acceptable. The use of chemotherapeutic or anti-leukemic agents is not permitted during the study with the following exceptions: (1) intrathecal (IT) therapy for patients with controlled central nervous system (CNS) leukemia at the discretion of the PI. (2) Use of 1-2 doses of cytarabine (up to 2 g/m^2 each dose) for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy. Since the effect of most immuno-oncology (IO)-agents, HMA-therapies, venetoclax may be delayed, use of hydroxyurea for patients with rapidly proliferative disease is allowed on study and before the start of study therapy and will not require a washout. These medications will be recorded in the case-report form\nConcurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS disease is permitted. Patients with a known history of CNS disease or leukemic brain metastasis must have been treated locally, have at least 2 consecutive LPs with no evidence of CNS leukemia, and must be clinically stable for at least 4 weeks prior to enrollment and have no ongoing neurological symptoms that in the opinion of the treating physician are related to the CNS disease (sequelae that are a consequence of the treatment of the CNS disease are acceptable)\n\nCreatinine clearance (CrCl) >= 30 mL/min calculated by the Cockcroft-Gault formula or measured by 24 hours' urine collection.\n\nFor patients with body mass index (BMI) > 23, adjusted body weight and not ideal body weight is the recommended parameter\nDirect bilirubin < 1.5 x ULN unless considered due to Gilbert's syndrome\nAspartate aminotransferase or alanine aminotransferase =< 2.0 x ULN (aspartate aminotransferase or alanine aminotransferase =< 3.0 x ULN if deemed related to leukemia by the treating physician)\nWhite blood cell count < 15 x 10^9/L. Patients must have a white blood cell (WBC) count < 15 x 10^9/L prior to each dose of magrolimab in cycle 1. Hydroxyurea may be used to reduce the WBC count to =< 15 x 10^9/L\nAbility to understand and provide signed informed consent\nFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment\n\nWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 4 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment. Adequate methods of contraception include:\n\nTotal abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\nFemale sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment\nMale sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient\n\nCombination of any of the two following (a+b or a+c or b+c)\n\nUse of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception\nPlacement of an intrauterine device (IUD) or intrauterine system (IUS)\nBarrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository\nIn case of use of oral contraception, women should have been stable on the same pill before taking study treatment\nNote: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction.\nWomen are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.\nMale patients who are sexually active with a WOCBP and who have not had vasectomies must be willing to use a barrier method of contraception during the study and for 3 months after the last dose of magrolimab, venetoclax or azacitidine, whichever ends later.\nWomen who are pregnant or breastfeeding will not be eligible\n\nExclusion Criteria:\n\nPatients with known allergy or hypersensitivity to magrolimab, venetoclax, azacitidine or any of their components\nPatients with any other known concurrent severe and/or uncontrolled medical condition including but not limited to diabetes, cardiovascular disease including hypertension, renal disease, or active uncontrolled infection, which could compromise participation in the study. Patients on active antineoplastic or radiation therapy for a concurrent malignancy at the time of screening. Maintenance therapy, hormonal therapy, or steroid therapy for well-controlled malignancy is allowed\nPrior organ transplantation including allogenic stem-cell transplantation within 3 months prior to planned enrollment, active graft versus host disease (GVHD) > grade 1, or requiring transplant-related immunosuppression\nKnown inherited or acquired bleeding disorders\nPrior treatment with a CD47 or SIRPalpha targeting agent\nPatients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia\nPatients with a known human immunodeficiency virus (HIV) infection that is not well controlled (i.e. any detectable circulating viral load) at the time of enrollment\nPatients with known positive hepatitis B or C infection by serology, with the exception of those with an undetectable viral load within 3 months (hepatitis B or C testing is not required prior to study entry). Subjects with serologic evidence of prior vaccination to hepatitis B virus (HBV) [i.e., hepatitis B surface antigen (HBsAg)-, and anti-HBs+] may participate\nPatients who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit within 3 days prior to the initiation of study treatment\nPatients who have had any major surgical procedure within 14 days of day 1\nOther severe acute or chronic medical conditions that is active and not well controlled including colitis, inflammatory bowel disease, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study\nActive and uncontrolled disease (active infection requiring systemic therapy or fever likely secondary to infection within prior 48 hours): prophylactic antibiotics or prolonged course of IV antibiotics for controlled infection are allowed, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia) as judged by the treating physician\nPatients unwilling or unable to comply with the protocol"
            },
            {
                  "document": "Key Inclusion Criteria:\n\nAML/MDS as defined by specific criteria, including but not limited to the following subtypes:\n\nAML in CR\nMDS < 5% BM blasts\nMDS 5 - 10% BM blasts\nAML not in CR or MDS > 10% BM blasts\nPatients with human leukocyte antigen (HLA) matched related or unrelated donors\nAdequate end organ function as defined in study protocol\n\nKey Exclusion Criteria:\n\nPatients with any acute or uncontrolled infections\nPatients receiving any other investigational agents\nPatients with active non-hematologic malignancy\nPrior allogeneic hematologic cell transplantation"
            },
            {
                  "document": "Inclusion Criteria:\n\nHistologically confirmed de novo or secondary AML as defined by WHO criteria\nIntermediate- or poor-risk disease by ELN 2017 criteria\nAdults 18 years of age or older\nECOG performance status of 0, 1, or 2\nAble to give informed consent and follow study guidelines\n\nOrgan function requirements:\n\nAdequate renal function defined as creatinine clearance greater than 60 ml/min\nAdequate hepatic function defined by serum bilirubin less than or equal 2 mg/dL. If serum bilirubin greater than 2 mg/dl and direct bilirubin is less than 30 percent of total bilirubin contact study chair for eligibility exception for Gilbert's syndrome.\nALT/AST less than or equal to 3 times the upper limit of normal\nLVEF 50 percent by echocardiogram or MUGA\nPatients with history of second malignancies in complete remission and without history of metastasis are eligible if there is clinical evidence of disease stability for a period of greater than 6 months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening.\nWomen of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 120 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\nWomen of child-bearing potential has negative pregnancy test prior to initiating study drug dosing.\n\nExclusion Criteria:\n\nCurrent or anticipated use of additional investigational agents.\nAny prior treatment for AML with the exception of corticosteroids, hydroxyurea, and/or leukapheresis to prevent or treat early complications prior to starting study therapy. Permitted prior therapy must be stopped 24 hours prior to starting study therapy.\nPrior use of hypomethylating agents is permitted for patients with history of antecedent MDS. Last dose of hypomethylating therapy must have been 15 or more days prior to starting study therapy. Toxicities associated with prior MDS therapy must have recovered to grade 1 or less prior to start of treatment.\nFavorable risk cytogenetics as defined by 2017 ELN risk stratification including acute promyelocytic leukemia\nChronic myeloid leukemia in myeloid blast crisis\nExcept for CMML, patients with history of myeloproliferative neoplasms (MPN) (defined as a history of essential thrombocytosis or polycythemia vera, or idiopathic myelofibrosis prior to the diagnosis of AML) or combined MDS/MPN are not eligible\nClinical evidence of active CNS leukemia\nActive or metastatic second malignancy\nAny major surgery or radiation therapy within four weeks.\nPatients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent).\nAny serious medical condition, laboratory abnormality or psychiatric illness that would prevent obtaining informed consent\nPatients with myocardial impairment of any cause (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging)\nActive or uncontrolled infection. Patients with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for greater than or equal to 72 hrs.\nCurrent evidence of invasive fungal infection (blood or tissue culture); patients with recent fungal infection must have subsequent negative culture(s) to be eligible\nKnown HIV infection\nActive hepatitis B or hepatitis C infection\nHypersensitivity to cytarabine, daunorubicin or liposomal products\nHistory of Wilson's disease or copper-metabolism disorder\nPregnant or breastfeeding\nAny condition which in the opinion of the investigator will interfere with the ability of the subject to comply with the requirements of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nMale or female and \u2265 18 years of age at the time of signing the consent form\n\nOne of the following advanced hematologic malignancies including:\n\nRelapsed or refractory AML as defined by 2016 WHO criteria and are not candidates for curative therapies such as allogeneic hematopoietic cell transplant or for whom there is no standard of care therapy available that is likely to lead to disease remission according the investigator\nMDS high-very high risk by the revised international scoring system for evaluating prognosis in myelodysplastic syndromes that is recurrent or refractory or the participant is intolerant to established therapy known to provide clinical benefit for their condition (e.g., relapsed following treatment with hypomethylating agent or lack of response after > 4 cycles), according to treating physician. Potential participants who meet the criteria for intermediate risk may be considered with approval by the medical monitor if the participant has severe cytopenia(s) and/or elevated bone marrow blast counts.\n\nAdequate organ function defined as:\n\nSerum creatinine \u22641.5 mg/dL or an estimated glomerular filtration rate of \u226560 mL/min as calculated by the Cockcroft-Gault glomerular filtration rate equation\nTotal bilirubin \u2264 1.5 \u00d7 the upper limit of normal (ULN) unless considered due to Gilbert's disease or leukemic disease\nAspartate aminotransferase (AST) \u22643 \u00d7 the ULN; alanine aminotransferase (ALT) \u22643 \u00d7 the ULN. Levels of AST and/or ALT \u22645 \u00d7 the ULN may be acceptable for participants with known leukemic involvement of the liver after discussion with the study medical monitor\nEastern Cooperative Oncology Group (ECOG) performance status \u22642.\nContraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If of childbearing potential, agree to use an effective barrier method of birth control (i.e., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy during the study and 90 days after the last dose of CB-5339. Female participants of childbearing potential need a negative serum or urine pregnancy test within 7 days of study enrollment. Non-childbearing is defined as \u2265 1 year postmenopausal or surgically sterilized\nCapable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia with t(15;17)(q22;q12); or abnormal promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA).\nParticipants with clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during screening.\nParticipants with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.\n\nConcomitant malignancy, requiring active treatment, except for basal-cell or squamous cell carcinoma of the skin, carcinoma-in-situ of the uterine cervix, or localized prostate cancer.\n\n\u2022 Adjuvant therapy for breast cancer or prostate cancer is allowed.\n\nActive, uncontrolled, systemic infection or severe localized infection during screening or prior to Cycle 1 Day 1 (C1D1; unless considered due to tumor by the investigator).\n\n\u2022 Note, participants receiving prophylactic anti-infectives are allowed on study.\n\nKnown human immunodeficiency virus (HIV) infection with CD4+ T cell counts <350 cells/\u03bcL, initiation of antiretroviral therapy within 4 weeks before C1D1, or acquired immunodeficiency syndrome (AIDS)-related infection within 12 months before C1D1.\nHepatitis B virus (HBV) or hepatitis C virus (HCV) infection with viral load above the limit of quantification\nMajor cardiac abnormalities as defined but not limited to the following: uncontrolled angina or unstable life-threatening arrhythmias, history of myocardial infarction within 12 weeks prior to Baseline, Class 3 or higher New York Heart Association (NYHA) congestive heart failure, or left ventricular ejection fraction (LVEF) <45% as measured by echocardiogram (ECHO) within 28 days of C1D1\nPersistent (3 consecutive ECGs performed \u22655 minutes apart) prolongation of the corrected QT interval by Fredericia's method (QTcF) to > 480 msec\nGastrointestinal conditions that may interfere with the absorption of orally-administered drugs including but not limited to short gut syndrome, gastroparesis, inflammatory bowel disease, or acute pancreatitis.\nAny other severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or CB-5339 administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, may interfere with the interpretation of the study results and, in the Investigator's opinion, or would make the participant inappropriate for entry into this study\nA condition that is expected to require concomitant use of any medication listed as prohibited while on study.\nKnown hypersensitivity to any components of CB-5339.\nUse of chemotherapy (except hydroxyurea), radiation or monoclonal antibodies within 14 days or 5 half-lives for small molecule inhibitors prior to first dose of CB-5339\n\nParticipants who have undergone a hematopoietic cell transplant (HCT) within 100 days of the first dose of CB-5339, or participants on immunosuppressive therapy post-HCT at the time of screening, use of calcineurin inhibitors within 4 weeks prior to first dose of CB-5339, or with clinically significant graft-versus-host disease (GVHD).\n\n\u2022 Note: The use of topical steroids or <10mg oral prednisone for ongoing skin GVHD is permitted.\n\nMajor surgery within 4 weeks prior to first dose of CB-5339. Participant must have recovered from surgery and be without current complications of infection or dehiscence\nEnrollment in other clinical trials unless approved by Medical Monitor"
            },
            {
                  "document": "Inclusion Criteria:\n\nHematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) =< 5 for patients over 60 years\nAcute myeloid leukemia (AML) (2016 World Health Organization [WHO] criteria) that is either primary refractory (as defined by failure of 2 cycles of 7+3-like chemotherapy, 1 cycle of high-dose cytarabine-based chemotherapy, or at least 2 cycles of venetoclax in combination with either low-dose cytarabine or an azanucleoside), or is in early (remission duration =< 6 months) untreated relapse. Patients in morphological remission (i.e. < 5% blasts in the bone marrow) but evidence of minimal residual disease (MRD) by multiparameter flow cytometry, cytogenetics/fluorescence in situ hybridization (FISH), or molecular means will be eligible for trial participation. Patients with refractory acute leukemia of ambiguous lineage (acute undifferentiated leukemia, mixed phenotype acute leukemia) are eligible\nSubjects with previously treated MDS and CMML, defined as prior treatment with at least one hypomethylating agent (HMA; azacitidine and/or decitabine) whose disease progressed, relapsed, or was refractory to HMA treatment as follows: 1) patients who have failed at least 4 cycles of monotherapy with Azacitidine or Decitabine, 2) patients who received at least 2 cycles of HMA in combination with another therapeutic agent. Subjects with MDS and CMML who failed at least 1 cycle of induction chemotherapy will be also eligible\nThe use of hydroxyurea prior to initiation of study treatment is allowed. Patients with symptoms/signs of hyperleukocytosis, WBC > 100,000/uL or with concern for other complications of high tumor burden (e.g. disseminated intravascular coagulation) can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2 per dose) prior to start of study treatment\nKarnofsky score >= 70; Eastern Cooperative Oncology Group (ECOG) 0-1\nAdequate cardiac function defined as absence of decompensated congestive heart failure and/or uncontrolled arrhythmia and left ventricular ejection fraction >= 45%\nBilirubin =< 2.5 x institutional upper limit of normal unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis\nAdequate pulmonary function defined as absence of oxygen (O2) requirements and either carbon monoxide diffusing capability test (DLCO) correct >= 70% mmHg or DLCO corrected 60-69% mmHg and partial pressure of oxygen (pO2) >= 70 mmHg\nSerum creatinine =< 1.5 mg/dL\nPrior autologous HCT is permissible if relapse occurred > 3 months but =< 6 months after HCT\nPrior TBI-containing allogeneic HCT up to 3 Gy is permissible if > 6 months after HCT\nA human leukocyte antigen (HLA)-matched or near-matched related or unrelated donor for collection of stimulated peripheral blood stem cells must be identified and readily available\nWomen of childbearing potential and men must agree to use adequate contraception beginning at the signing of the consent until at least 12 months post-transplant\nPatients may have previously received chemotherapy with a mitoxantrone- or cladribine-based regimen for MDS or AML. If the patient has received CLAG-M before and has been sensitive to this regimen, eligibility will be determined on a case-by-case basis by the study principal investigator (PI)\nAbility to understand and sign a written informed consent document (or legal representative)\n\nDONOR: Patients must have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard SCCA and/or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) donation as follows:\n\nRelated donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1. Phenotypic identity must be confirmed by high-resolution typing\n\nUnrelated donor:\n\nMatched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR\nMismatched for a single allele without antigen mismatching at HLA-A, B, or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing\nDonors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment. The recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT. If the PRA shows > 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor should be excluded if any of the cytotoxic cross match assays are positive. For those patients with an HLA class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results. A positive anti-donor cytotoxic crossmatch is an absolute donor exclusion\nPatient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0102, and this type of mismatch is not allowed\n\nExclusion Criteria:\n\nPatients >= 18 years being treated at Seattle Children's Hospital\nActive central nervous system (CNS) disease\nConcomitant illness associated with a likely survival of < 1 year\nActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable. Patients with fever thought to be likely secondary to myeloid malignancy are eligible\nKnown hypersensitivity or contraindication to any study drug used in this trial\nPregnancy or lactation\nConcurrent treatment with any other approved or investigational anti-leukemia agent"
            },
            {
                  "document": "Inclusion Criteria:\n\nSigned written informed consent obtained prior to study procedures\nPatients \u226518 years with an ECOG 0 or 1 (Parts 1, 2 and 4) or 0-2 (Part 3).\nRelapsed/Refractory (R/R) or locally advanced, unresectable solid tumor for which no standard therapy exists (Parts 1, 2 and 4), or for which the patient is ineligible or has declined standard therapy or R/R, cytologically confirmed AML (Part 3).\nDisease must be measurable per Response Evaluation Criteria\nThe shorter of 28 days or 5 half-lives must have elapsed since the completion of prior therapy, before initiation of study treatment.\n\nAdequate Organ Function and Blood Cell Counts (Parts 1, 2, and 4) as Defined by the protocol:\n\nGFR \u2265 50 mL/min/1.73,\nAST and ALT \u2264 3 \u00d7 the ULN and total bilirubin \u2264 1.5 \u00d7 ULN, in the absence of cancer within the liver\nOr AST and ALT \u2264 5 \u00d7 ULN and total bilirubin \u2264 3 \u00d7 ULN, in the setting of primary or metastatic liver tumors.\nANC \u2265 10 \u00d7 103/\u03bcL and platelet count \u2265 100 \u00d7 103/\u03bcL without myeloid growth factor support or transfusion, respectively, for at least one week.\nHemoglobin should be \u2265 9 g/dL without red blood cell transfusion for at least two weeks.\nPatients must have LVEF \u2265 45%\n\nPatients enrolling into Part 2 of the study must be diagnosed with a solid tumor that has been selected for an expansion cohort\n\nPatients must have LVEF \u2265 45%\nPatients enrolling into Part 4 must have relapsed following or have been refractory to a prior PD 1 or PD L1 blocking antibody.\n\nExclusion Criteria:\n\nPrimary central nervous system (CNS) malignancy or CNS involvement, unless asymptomatic, previously treated, and stable without steroids (Parts 1, 2 and 4) or known CNS leukemia (Part 3).\nKnown hypersensitivity to any component of study treatment or excipients.\nPositive antibody screen using institution's standard type and screen test.\nClinically significant, active and uncontrolled infection, including human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).\nClinically significant coagulopathy, uncontrolled hypertension or autoimmune hemolytic anemia\nLeukemic blast count \u226525 x 103/\u00b5L (Part 3)\nConcomitant conditions requiring active immunosuppression\nGrade 3 immune related Adverse Event (irAE)\nPrior malignancy within the past 3 years, with protocol specified exceptions\nHistory of severe hypersensitivity to a PD 1/PD L1 blocking Ab unless previously rechallenged successfully (Part 4)\nCurrent noninfectious pneumonitis or a history of radiation pneumonitis or pneumonitis that required steroids or greater immune related pneumonitis, hepatitis, hypophysitis, or other endocrinopathy (Part 4)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must be \u226518.\n\nFor the Part 1 Dose-Escalation Phase, patients must be diagnosed with the following:\n\nRelapsed or refractory AML with myelomonocytic or monoblastic/monocytic differentiation according to the World Health Organization 2016 criteria and has failed treatment with available therapies known to be active for AML.\nRelapsed or refractory CMML and has failed treatment with available therapies known to be active for CMML\n\nPart 2 Expansion Phase:\n\na) Relapsed or refractory AML with myelomonocytic or monoblastic/monocytic differentiation and has failed treatment with available therapies known to be active for AML.\n\nPatients must be amenable to serial BM aspirates/biopsies and peripheral blood sampling during the study.\nPatients must be able to understand and willing to sign an informed consent. A legally authorized representative may consent on behalf of a patient who is otherwise unable to provide informed consent, if acceptable to and approved by the site and/or site's Institutional Review Board (IRB) or Ethics Committee.\nPatients must have an ECOG performance status of 0 to 2\nPatients must have adequate hepatic function\nPatients must have adequate renal function\nPatients must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer (patients with residual Grade 1 toxicity, or any grade of alopecia, are allowed; patients with peripheral neuropathy that is not more than Grade 2 and stable are allowed).\nPatients must be off systemic calcineurin inhibitors (e.g., cyclosporine, tacrolimus) for at least 4 weeks prior to study drug treatment.\nFemale patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy.\n\nExclusion Criteria:\n\nPatients who have previously received IO-202.\nPatients who have undergone HSCT within 60 days of the first dose of IO-202, or patients on immunosuppressive therapy post human stem cell transplantation (HSCT) at the time of screening, or with clinically significant graft-versus-host disease (GVHD) (the use of a stable dose of oral steroids post-HSCT of <10 mg prednisone/day or dose equivalent of other corticosteroid and/or topical steroids for ongoing skin GVHD is permitted with Medical Monitor approval).\nPatients who received systemic anti-cancer therapy or radiotherapy <7 days prior to their first day of study drug administration (Hydroxyurea or leukapheresis is allowed up to 24 hours prior to the first dose. However, hydroxyurea must be ceased 24 hours prior to the first dose of IO-202 treatment in Cycle 1); it may be initiated again if necessary 24 hours after the first dose of IO-202 treatment in Cycle 1).\nPatients who received an investigational agent <7 days prior to their first day of study drug administration. In addition, the first dose of IO-202 should not occur before a period \u22655 half-lives of the investigational agent has elapsed.\nPatients for whom potentially curative anti-cancer therapy is available.\nPatients who are pregnant or breast feeding.\nPatients with uncontrolled, active infection.\nPatients with known hypersensitivity to any of the components of the IO-202 formulation.\n\nActive known malignancy with the exception of any of the following:\n\nAdequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer;\nLow-risk prostate cancer for which observation or hormonal therapy only is indicated;\nAny other malignancy treated with curative intent with the last treatment completed \u22656 months before study initiation (with the exception of hormonal therapies when indicated).\nPatients with New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan \u226428 days prior to Cycle 1, Day 1.\nAny of the following in the previous 6 months: myocardial infarction, congenital long QT syndrome, Torsades de pointes, clinically significant arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), and left anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF (NYHA class III or IV), cerebrovascular accident, transient ischemic attack, or pulmonary embolism. Patients with asymptomatic right bundle branch block or controlled atrial fibrillation are allowed.\nOngoing cardiac dysrhythmias Grade 2 or higher per of NCI CTCAE, Version 5.0, Grade \u22652.\nKnown or suspected hypersensitivity to recombinant human proteins.\nKnown active bacterial, viral, and/or fungal infection including hepatitis B (HBV), hepatitis C, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS)-related illness, or active Covid-19 infection. . Hepatitis B and C and HIV testing are not required for asymptomatic patients; however, for patients who have previously tested positive or have a known history of hepatitis B and C, HIV, and/or tuberculosis, clinical laboratory assessments at screening will include repeat testing for the previous infection. A sample for SARS-CoV-2 should be obtained during the screening period, and results must be available prior to C1D1.\nPatients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before trial entry.\nPatients with clinical signs and/or symptoms suggesting active, uncontrolled central nervous system (CNS) leukemia or known active, uncontrolled CNS leukemia (a lumbar puncture is not required in patients without signs or symptoms that are suggestive of CNS leukemia). Note: Patients with controlled CNS leukemia (documented by 2 consecutive assessments of zero blast count in cerebrospinal fluid), and who are still receiving intrathecal (IT) therapy at study entry are considered eligible and will continue to receive IT therapy.\nPatients with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, or disseminated intravascular coagulation.\nDonor Lymphocyte Infusion within 30 days prior to first IO-202 administration.\nCurrent active treatment in another interventional therapeutic clinical study.\nChronic systemic corticosteroid treatment with a dose of \u226510 mg prednisone/day or dose equivalent of another corticosteroid. Topical applications, inhaled sprays, eye drops, local injections of corticosteroids, and systemic steroids required for acute medical interventions are allowed.\nOther severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.\nAcute Promyelocytic Leukemia patients or patients with known Philadelphia chromosome (Ph+) positive AML or chronic myelogenous leukemia (CML) blast crisis.\nHyperleukocytosis (leukocytes \u226525 x 10e9/L) at first dose of IO-202. These patients may be treated with hydroxyurea or receive leukapheresis treatment according to routine practice, and enrolled in the study when the leukocyte count falls below 25 x 10e9/L.\nPatients who are investigational site staff members or relatives of those site staff members or patients who are Immune-Onc employees directly involved in the conduct of the trial."
            },
            {
                  "document": "Inclusion Criteria:\n\nConfirmed diagnosis of one of the following:\n\nRelapsed/refractory Acute Myelogenous Leukemia (AML) where no alternative life prolonging therapy exists. Adverse genetic risk treatment na\u00efve patients may also be considered eligible if, in the opinion of the investigator, these patients are unlikely to benefit from alternative therapy (e.g., an older patient with adverse risk MDS who progresses to AML after failing treatment for MDS (i.e. hypomethylating agent (HMA) or HMA and Venetoclax and is not a candidate for traditional AML induction chemotherapy).\nRelapsed/refractory Myelodysplastic Syndrome (MDS) those who fail to achieve a complete remission (CR) with at least 4 cycles of HMA (e.g. decitabine or azacitidine); or those who have progressive disease or have intolerance of HMA therapy after at least 2 cycles. Intolerance to HMA includes those patients forced to stop the HMA after at least 2 cycles due to severe infections/worsening cytopenias and are otherwise considered eligible. Patients with MDS have to have intermediate, high, or very high risk disease by International Prognostic Scoring System - Revised (IPSS-R score).\nAdult male or female patients 18 years of age or older.\nEastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.\n\nPatients must satisfy the following laboratory criteria:\n\nPre-treatment bone marrow staining must demonstrate expression of the ST2 receptor by IHC (low or high expression is allowed).\nTotal bilirubin < 1.5 x greater upper limit of normal (UNL). Elevated indirect bilirubin associated with post-transfusion hemolysis is allowed.\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be < 3 x UNL\nCreatinine < 2 x UNL or calculated creatinine clearance > 40 ml/min; or Estimated Glomerular Filtration Rate (eGFR) <50 according to MDRD (Modification of Diet in Renal Disease) method.\nWhite blood cell count (WBC) < 25,000/uL before the administration of NEROFE on Cycle 1 Day 1. Use of hydroxyurea to control the level of circulating leukemic blast cell counts is allowed before and during the study.\nSuitable venous access to allow for all study related blood sampling (safety and research).\nEstimated life expectancy, in the judgment of the investigator, which will permit receipt of at least 8 weeks of treatment.\nVoluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without jeopardy to future medical care.\n\nFemale patients who are:\n\nPostmenopausal for at least one year before the screening visit, OR\nSurgically sterile, OR\nIf they are of childbearing potential:\n\nAgree to practice one highly effective method and one additional effective (barrier) method of contraception, at the same time, form the time of signing the informed consent through 4 months after the last does of study drug (female and male condoms should not be used together), OR Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence e.g. calendar, ovulation, symptothermal, postovulation methods; withdrawal; spermicides only; and lactational amenorrhea are not acceptable methods of contraception).\n\nMale patients even if surgically sterilized (e.g. status post vasectomy), who:\n\nAgree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug (female and male condoms should not be used together), OR\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence e.g. calendar, ovulation, symptothermal, postovulation methods; withdrawal; spermicides only; and lactational amenorrhea are not acceptable methods of contraception).\nAble to undergo bone marrow examination at screening\n\nExclusion Criteria:\n\nPatients with a diagnosis of acute promyelocytic leukemia (APL).\nScreening bone marrow slide without staining for ST2 receptor. (Low or High expression by Immunohistochemistry [IHC] allowed on study).\nTherapy with any investigational products, anti-neoplastic therapy, or radiotherapy within 14 days of Cycle 1 Day 1. Patients actively receiving hydroxyurea are eligible and may continue to receive this medication during treatment on this protocol.\nCandidates for standard and/or potentially curative treatments. (A candidate is defined as a patient that is both eligible and willing to have these treatments.)\nMajor surgery within 30 days of the first dose of any study drug or a scheduled surgery during study period.\nGrade 2 or higher diarrhea (as defined by NCI CTCAE Version 5.0) despite optimal anti-diarrheal supportive care within 7 days prior to Cycle 1 Day 1.\n\nKnown cardiopulmonary disease as defined by one of the following:\n\nClinically significant arrhythmia including: history of polymorphic ventricular fibrillation or torsade de pointes; atrial fibrillation > 7 days and requiring cardioversion in the 4 weeks before screening; incompletely controlled, symptomatic atrial fibrillation. Patients with Afib are permitted to enroll if it is < Grade 3 for a period of 6 months or greater and the rate is controlled with a stable regimen.\n\nCongestive heart failure (New York Heart Association (NYHA) Class III or IV; or Class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within four weeks of screening; myocardial infarction (MI) and/or revascularization (e.g.\n\ncoronary bypass graft/stent) within 6 months of first dose of study drug.;\n\nPatients with ischemic heart disease who have had acute coronary syndrome (ACS), MI< and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll.\nModerate to severe aortic and/or mitral valve stenosis or other ongoing valvulopathy;\nPulmonary hypertension (symptomatic)\nProlonged rate corrected QT (QTc) interval >480 msec, calculated according to institutional guidelines;\nKnown, active left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography (not required at screening);\nKnown moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease and/or pulmonary fibrosis (e.g., requiring home O2 therapy).\nActive and uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia (stable or resolving infection on antibiotics is allowed).\nKnown human immunodeficiency virus (HIV) seropositive.\nKnown Hepatitis B surface antigen seropositive (note: patients who have isolated positive hepatitis B core antibody [e.g. in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody] must have an undetectable hepatitis viral load).\nKnown or suspected active hepatitis C infection. Patients with treated Hep C treated with a negative viral load are eligible.\nFemales of child bearing potential who refuse to practice two effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing consent through four months after the last dose of study drug.\nMales of child bearing potential who refuse to practice effective barrier methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing consent through four months after the last dose of study drug.\nFemale patients who are both lactating or breastfeeding, or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before the first dose of study drug.\nFemale patients who intend to donate eggs (ova) during the course of this study or within four months after receiving their last dose of study drug.\nMale patients who intend to donate sperm during the course of this study or within four months after receiving their last dose of study drug.\nAny serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures.\nSymptomatic central nervous system (CNS) involvement.\nDiagnosed or treated for another malignancy within 2 years with evidence of residual disease.\nKnown hepatic cirrhosis or severe pre-existing hepatic impairment.\nPatients with uncontrolled coagulopathy or bleeding disorder.\nUse of systemic steroids (prednisone) >10mg/day or any equivalent corticosteroids within 7 days of Cycle 1 Day 1. Patients on other immunosuppression (such as post-transplant) and also ineligible. Patients with active, uncontrolled GVHD (Graft Versus Host Disease) are also ineligible. Otherwise patients are eligible post-bone marrow transplantation.\nLife-threatening illnesses unrelated to cancer."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of histologically confirmed relapsed or refractory AML, CMML, or high-risk MDS (overall revised international prognostic scoring system (IPSS-R) score > 3, including intermediate, high, or very high risk) by World Health Organization (WHO) classification for which no available standard therapies are indicated or anticipated to result in a durable response.\n\nAdequate organ function as defined below:\n\nLiver function (total bilirubin < or = 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) <3 x ULN\nKidney function (defined as a calculated creatinine clearance \u2265 60 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula)\nKnown cardiac ejection fraction of > or = 45% within the past 3 months\nEastern Cooperative Oncology Group (ECOG) performance status of \u2264 2\nA negative serum pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.\nPatient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or legally authorized representative is required prior to their enrollment on the protocol.\nSubject must have a projected life expectancy of at least 12 weeks.\nSubject has a white blood cell count < 25 \u00d7 10\u02c49/L. Note: Hydroxyurea is permitted to meet this criteria.\n\nExclusion:\n\nPregnant women are excluded.\nUncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nHave had leukemia therapy for 14 days prior to starting investigational drug. However, patients with rapidly proliferative disease may receive hydroxyurea as needed until 24 hours prior to starting therapy on this protocol and during the first cycle of study.\nHave acute promyelocytic leukemia.\nActive infection requiring systemic antibiotic/antifungal medication, known clinically active hepatitis B or C, or HIV infection.\nHave received allogeneic hematopoietic stem cell transplant (HSCT) within 12 months prior to the first dose, or who have active/ongoing graft-versus host disease (GVHD), or require continued treatment with systemic immunosuppressive agents (calcineurin inhibitors within 4 weeks prior to the first dose), or received autologous hematopoietic stem cell transplantation within 6 months prior to the first dose.\nDocumented hypersensitivity to any of the components of the therapy program\nActive, uncontrolled central nervous system (CNS) leukemia will not be eligible.\nMen and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use at least 1 form of barrier birth control (such as condom) prior to study entry and for the duration of study participation.\nAny prior systemic MDM2-p53 inhibitor treatment\nAny other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.\n\nHistory of other malignancies within 2 years prior to study entry, with the exception of:\n\nAdequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intention: requires discussion with sponsor\nFailure to have recovered (Grade > 1) from prior treatment (including chemotherapy, targeted therapy, immunotherapy, experimental agents, radiation, or surgery)\nSignificant screening electrocardiogram (ECG) abnormalities including left bundle branch block, 2nd degree atrioventricular (AV) block type II, 3rd degree block, or corrected QT interval (QTc) \u2265470 msec"
            },
            {
                  "document": "Inclusion Criteria for Procurement and T-cell Production:\n\nAge \u226421 years old\nRelapsed/refractory CD123+ disease defined as follows:\n\nAML\n\nRelapsed disease: Patients developing recurrent disease after a first complete remission (CR)\nRefractory disease: Patients not achieving a CR after 2 cycles of induction chemotherapy\n\nB-cell ALL\n\nRelapsed disease that is CD123 positive and CD19 negative/dim or patients otherwise ineligible for CD19 directed therapies including\n\nPatients in 2nd or greater relapse\nPatients with relapse after allogeneic HSCT\nRefractory disease that is CD123 positive and CD19 negative/dim or patients otherwise ineligible for CD19 directed therapies\n\nT-cell All \u2022 Relapsed refractory disease that is CD123 positive\n\nBPDCN\n\n\u2022 Relapsed/refractory disease that has failed front-line therapy\n\nEstimated life expectancy of >12 weeks\nKarnofsky or Lansky (age-dependent) performance score \u226550\nPatients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis\nPatient must have an identified, suitable HCT donor\nFor females of child-bearing age:\nNot lactating with intent to breastfeed\nNot pregnant with negative serum pregnancy test within 7 days prior to enrollment\nMeets eligibility criteria to undergo autologous apheresis, or have previously undergone autologous apheresis\n\nExclusion Criteria:\n\nKnown primary immunodeficiency\nHistory of HIV infection\nSevere intercurrent uncontrolled bacterial, viral or fungal infection (e.g. active hepatitis B or C infection or adenovirus infection)\nHistory of hypersensitivity reactions to murine protein-containing products\nPatients with acute promyelocytic leukemia (APL, t (15;17))\nKnown contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/cyclophosphamide.\n\nInclusion Criteria for Treatment:\n\nAge\u226421 years old\nDetectable disease that is CD123+ (at least MRD+ disease)\nEstimated life expectancy of >8 weeks\nKarnofsky or Lansky (age-dependent) performance score\u226550\nPatients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion\nPatient must have an identified, suitable HCT donor\nAdequate cardiac function defined as left ventricular ejection fraction >40%, or shortening fraction \u226525%\nEKG without evidence of clinically significant arrhythmia\nAdequate renal function defined as creatinine clearance or radioisotope GFR \u226550 ml/min/1.73m2 (GFR \u226540 ml/min/1.73m2 if < 2 years of age)\nAdequate pulmonary function defined as forced vital capacity (FVC)\u226550% of predicted value; or pulse oximetry\u226592% on room air if patient is unable to perform pulmonary function testing\nTotal Bilirubin\u22643 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) \u22645 times the upper limit of normal for age\nHas recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n\nFor females of child-bearing age\n\nNot lactating with intent to breastfeed\nNot pregnant with negative serum pregnancy test within 7 days prior to enrollment\nIf sexually active, agreement to use birth control until 3 months after T- cell infusion. Male partners should use a condom.\nAvailable autologous transduced T-cell product that has met GMP release criteria\n\nExclusion Criteria:\n\nKnown primary immunodeficiency\nHistory of HIV infection\nSevere intercurrent uncontrolled bacterial, viral or fungal infection\nHistory of hypersensitivity reactions to murine protein-containing products\nHistory of severe hypersensitivity reactions to cornstarch or hydroxyethyl starch.\nReceiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to CD123-CAR T- cell infusion\nReceiving systemic therapy in the 14 days prior to CD123-CAR T-cell infusion, which will interfere with the activity of the CD123-CAR T cells in vivo (in the opinion of the study PI(s))\nReceiving rituximab therapy in the 30 days prior to CD123-CAR T cell infusion. (This exclusion criterion is intended to prevent premature exposure of CD123-CAR Tcells to rituximab, which would activate the safety switch and promote CAR T-cell apoptosis).\nReceiving intrathecal chemotherapy in the 7 days prior to CD123-CAR T cell infusion.\nKnown contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/cyclophosphamide.\nActive CNS disease"
            },
            {
                  "document": "Treatment Eligibility Screening Patient Inclusion Criteria\n\nPatients must satisfy the following criteria to be enrolled in the study:\n\nPatient has eligible disease status:\n\nPrimary or Secondary acute myeloid leukemia (AML) Patients in first of second Morphological Complete Remission (CR), Morphological Complete Remission with incomplete hematologic recovery (CRi), or Morphologic Leukemia-free State (MLFS) as defined by the European LeukemiaNet (ELN) recommendations for AML Response Criteria (Dohner, 2017).\n\nR/R diagnosis based on confirmed diagnosis with local pathology report following any reinduction/ salvage therapy ELN guidelines.\n\nRelapsed AML are defined as having relapsed after achieving \u2265 1 CR, including relapse after allogeneic stem cell transplantation (\u2265 2 months after transplant).\nRefractory AML, defined as not achieving CR, CRi, or MLFS after 2 or more cycles of induction therapy (primary refractory) or not achieving CR after treatment for relapsed AML.\nSecondary AML (MDS transformation): Secondary AML patients are eligible to participate if they have received a minimum of one prior line of treatment for AML.\nTreatment-related AML: Treatment-related AML patients are eligible to participate if they have received a minimum of one prior line of treatment for AML.\nPatient with prior central nervous system involvement by malignancy are eligible provided that it has been treated and cerebral spinal fluid is clear for at least 2 weeks prior to start of Lymphodepletion Regimen.\n(MRD positive population only): Patient is minimal residual disease (MRD) positive, as assessed on bone marrow aspirate (BMA) by Multiparameter Flow Cytometry (MFC) at time of Treatment Eligibility assessment.\n\nFor the purposes of this study, MRD positivity is defined as greater than or equal to 0.1% blasts detected by MFC on BMA by the Sponsor-selected Central MRD analysis laboratory, where assay sensitivity allows for a Lower Limit of Detection (LOD) of 1 x 10-4 (0.01%) or lower.\n\nPatient is \u2265 18 and \u2264 80 years of age at the time of signing the Study informed consent form (ICF).\nPatient understands and voluntarily signs the Study ICF prior to any study-related assessments/procedures are conducted.\nPatient is willing and able to adhere to the study schedule and other protocol requirements.\nPerformance status of Eastern Cooperative Oncology Group (ECOG) \u2264 2.\nAbility to be off immunosuppressive drugs for at least 3 days prior to the CYNK-001 infusion. Steroids at the equivalent of no more than 7.5 mg prednisone per day are permissible.\n\nFemale of childbearing potential (FCBP)* must not be pregnant and agree to not becoming pregnant for at least 28 days following the CYNK-001. FCBP must agree to use an adequate method of contraception during the treatment period.\n\nFCBP is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).\nMale Patients must agree to use a condom during sexual contact for at least 28 days following the last infusion of CYNK-001, even if he has undergone a successful vasectomy.\n\nTreatment Eligibility Screening Patient Exclusion Criteria\n\nThe presence of any of the following will exclude the Patient from enrollment:\n\nPatient has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the Patient from participating in the study.\nPatient has any condition including the presence of laboratory abnormalities which places the Patient at unacceptable risk if he or she were to participate in the study.\nPatient has any condition that confounds the ability to interpret data from the study.\nPatient has bi-phenotypic acute leukemia.\nPatient has acute promyelocytic leukemia (APL).\n\nPatient has inadequate organ function as defined below at time of Treatment Eligibility Period:\n\nPatient has aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase \u2265 2.5 x the upper limit of normal (ULN).\nEstimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 as calculated using the Modification of Diet in Renal Disease Study equation (Levey, 2006) or history of an abnormal eGFR < 60 and a decline of > 15 mL/min/1.73 m2 below normal in the past year.\nPatient has a bilirubin level > 2 mg/dL (unless Patient has known Gilbert's disease).\nPatient has had prior treatment with biologic antineoplastic agents less than 7 days before first CYNK-001 infusion and at least 5 half-lives. (Exception will be granted for monoclonal antibodies that are known to have long half-lives, in which case a minimum of 2 weeks from last dose will be required). For agents that have known AEs occurring beyond these specified days after administration, this period must be extended beyond the time during which acute AEs are known to occur. Treating physicians are encouraged to discuss cases with the Medical Monitor.\nPatient is pregnant or breastfeeding.\nPatient has new or progressive pulmonary infiltrates or pleural effusion large enough to be detected by chest x-ray or CT scan within 2 weeks of first CYNK-001 infusion.\nPatient has active autoimmune disease other than controlled connective tissue disorder or those who are not on active therapy.\nPatient has had a Bone Marrow transplant < 60 days prior to screening or plans to have a transplant within the 28 day period following the first CYNK-001 infusion.\n\nPatient has a history of malignancy other than AML or other underlying hematologic conditions such as myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) unless the Patient has been free of disease for greater than 3 years prior to CYNK 001 infusion. Exceptions will include the following malignancies:\n\nBasal cell carcinoma of the skin\nSquamous cell carcinoma of the skin\nCarcinoma in situ of the cervix\nCarcinoma in situ of the breast\nIncidental biological finding of prostate cancer (TNM stage of T1a or T1b)\nSuperficial bladder cancer\nFor patients with therapy-related AML, the underlying malignancy which led to secondary AML must be stabilized (not progressing) and not under active treatment.\nPatient has a history of severe asthma and is presently on chronic medications or has a history of other symptomatic pulmonary disease.\nPatient has uncontrolled graft versus host disease (GVHD) or GVHD requiring treatment with corticosteroids.\nPatient has an untreated chronic infection or has received treatment of any uncontrolled or progressive infection with systemic antibiotics within 2 weeks prior to first CYNK-001 infusion. Prophylactic antibiotic, antiviral, and antifungal medication are permissible.\nPatient has any other organ dysfunction (CTCAE Version 5.0 Grade 3 or greater) that will interfere with the administration of the therapy according to this protocol.\nPatient has a resting left ventricular ejection fraction (LVEF) of < 40% obtained by echocardiography or multi-gated acquisition scan (MUGA).\nPatient was treated with an investigational product within 28 days of first CYNK-001 infusion. Patient must no longer be a participant in the previous interventional study at the time of CYNK-001 infusion. (Patients who are under survival follow-up or observation associated with a study are permitted, and if treatment information is collected for this period, \"Investigational Study\" must be used to capture the study treatment.)."
            },
            {
                  "document": "Inclusion Criteria:\n\nAll patients must be enrolled on APEC14B1 and consented to Eligibility Screening (Part A) prior to enrollment and treatment on AAML1831. Submission of diagnostic specimens must be done according to the Manual of Procedures). Risk stratification will not be possible without the submission of viable samples. Given there are multiple required samples, bone marrow acquisition techniques such as frequent repositioning or performing bilateral bone marrow testing should be considered to avoid insufficient material for required studies. Consider a repeat marrow prior to starting treatment if there is insufficient diagnostic material for the required studies\nPatients must be less than 22 years of age at the time of study enrollment\n\nPatient must be newly diagnosed with de novo AML according to the 2016 World Health Organization (WHO) classification with or without extramedullary disease\n\nPatient must have 1 of the following:\n\n>= 20% bone marrow blasts (obtained within 14 days prior to enrollment)\n\nIn cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy\n< 20% bone marrow blasts with one or more of the genetic abnormalities (sample obtained within 14 days prior to enrollment)\nA complete blood count (CBC) documenting the presence of at least 1,000/uL (i.e., a white blood cell [WBC] count >= 10,000/uL with >= 10% blasts or a WBC count of >= 5,000/uL with >= 20% blasts) circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed within 7 days prior to enrollment)\nARM C: Patient must be >= 2 years of age at the time of Late Callback\nARM C: Patient must have FLT3/ITD allelic ratio > 0.1 as reported by Molecular Oncology\nARM C: Patient does not have any congenital long QT syndrome or congenital heart block\nARM C: Females of reproductive potential must agree to use effective contraception during treatment and for at least 6 months after the last dose of gilteritinib\nARM C: Lactating women must agree not to breastfeed during treatment with gilteritinib and for 2 months after the last dose of gilteritinib\nARM C: Males of reproductive potential must agree to use effective contraception during treatment and for at least 4 months after the last dose of gilteritinib\nARM D: Patient must be >= 2 years of age at the time of Late Callback\nARM D: Patient must have one of the clinically relevant non-ITD FLT3 activating mutations as reported by Foundation Medicine\nARM D: Females of reproductive potential must agree to use effective contraception during treatment and for at least 6 months after the last dose of gilteritinib\nARM D: Lactating women must agree not to breastfeed during treatment with gilteritinib and for 2 months after the last dose of gilteritinib\nARM D: Males of reproductive potential must agree to use effective contraception during treatment and for at least 4 months after the last dose of gilteritinib\nNEUROPSYCHOLOGICAL TESTING: Patient must be enrolled on Arm A or Arm B. Patients who transfer to Arm C or Arm D are not eligible\nNEUROPSYCHOLOGICAL TESTING: Patient must be 5 years or older at the time of enrollment\nNEUROPSYCHOLOGICAL TESTING: English-, French- or Spanish-speaking\nNEUROPSYCHOLOGICAL TESTING: No known history of neurodevelopmental disorder prior to diagnosis of AML (e.g., Down syndrome, fragile X, William syndrome, mental retardation)\nNEUROPSYCHOLOGICAL TESTING: No significant visual or motor impairment that would prevent computer use or recognition of visual test stimuli\nAll patients and/or their parents or legal guardians must sign a written informed consent\nAll institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.\n\nExclusion Criteria:\n\nPatients with myeloid neoplasms with germline predisposition are not eligible\nFanconi anemia\nShwachman Diamond syndrome\nPatients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21\nAny other known bone marrow failure syndrome\nAny concurrent malignancy\nJuvenile myelomonocytic leukemia (JMML)\nPhiladelphia chromosome positive AML\nMixed phenotype acute leukemia\nAcute promyelocytic leukemia\nAcute myeloid leukemia arising from myelodysplasia\nTherapy-related myeloid neoplasms\n\nAdministration of prior anti-cancer therapy except as outlined below:\n\nHydroxyurea\nAll-trans retinoic acid (ATRA)\nCorticosteroids (any route)\nIntrathecal therapy given at diagnosis\nIn particular, strong inducers of CYP3A4 and/or P-glycoprotein (P-gp) should be avoided from the time of enrollment until it is determined whether the patient will receive gilteritinib. Patients receiving gilteritinib will be required to avoid strong CYP3A4 inducers and/or strong P-gp inducers for the duration of the study treatment\nFemale patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential\nLactating females who plan to breastfeed their infants\nSexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation\nARM D: Patients with congenital long QT syndrome or congenital heart block are not eligible for this treatment arm"
            },
            {
                  "document": "Inclusion Criteria:\n\nGeneral\n\nAbility to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard-of-care for the patient's disease. Patients must also be willing and able to comply with study procedures, including the acquisition of specified research specimens\nAge \u2265 18 years old\nExpression of HLA-A*0201 as determined by high resolution sequence-based typing method (e.g. TruSight HLA v2 Sequence Panel)\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nPatients must have a confirmed diagnosis of AML (according to World Health Organization (WHO) classification) or MDS with evidence of MRD or morphological relapse after HLA-matched allogeneic HCT\n\nMRD includes:\n\nDetection of blasts <5% in bone marrow\nDetection of a clonal abnormal blast population via multi-color flow cytometry\nDetection of known or new myeloid gene mutations\n\nDonor match at 10 of 10 loci for HLA-A, -B, -C, -DRB1 and DQB1, with each typed at high resolution by DNA-based methods.\n\na. Patients who have had prior HLA-mismatched or haploidentical allogeneic HCT will not be eligible\n\nT-cell chimerism \u2265 50% to donor (by PCR analysis)\n\nAcceptable laboratory parameters as follows:\n\nAspartate aminotransferase (AST)/alanine aminotransferase (ALT) \u2264 2.5 \u00d7 upper limit of normal (ULN)\nTotal bilirubin \u2264 1.5 \u00d7 ULN, except patients with Gilbert's syndrome, who may enroll if the conjugated bilirubin is within normal limits\nCreatinine < 1.5 mg/dL or a calculated or measured creatinine clearance (CL) \u2265 50 mL/min per standard calculation\nRecovery to Grade 1 or baseline of non-hematologic toxicities from prior treatments, excluding alopecia\nFemale patients of childbearing potential must test negative for pregnancy at enrollment and during the study. Sexually active women of child-bearing potential, unless surgically sterile, must be willing to use a highly effective method of birth control defined as those which result in a low failure rate (i.e., less than 1% per year) such as implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs) or vasectomized partner\nMale patients with partners of childbearing potential must be either vasectomized or agree to use a condom in addition to having their partners use another method of contraception resulting in a highly effective method of birth control defined as those which result in a low failure rate (i.e., less than 1% per year) such as implants, injectables, combined oral contraceptives, or IUDs. Patients should not have sexual intercourse with females who are either pregnant or lactating without double-barrier contraception Is not pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the prescreening or screening visit through one year from administration of NEXI-001 cells\n\nExclusion Criteria:\n\nActive acute or chronic graft versus host disease (GvHD)\n\nEligible patients will not be on any steroids \u226510 mg per day prednisone or equivalent or other immunosuppressants such as tacrolimus, cyclosporine, etc.\nIntermittent topical, inhaled or intranasal corticosteroids are allowed\nHave active or uncontrolled infections with positive cultures and/or requiring treatment with IV anti-infective agents\n\nHistory of clinically significant cardiovascular disease including but not limited to:\n\nMyocardial infarction or unstable angina within the 6 months prior to the initiation of study\nStroke or transient ischemic attack within 6 months prior to initiation of study\nClinically significant cardiac arrhythmia\nUncontrolled hypertension: systolic blood pressure (SBP) > 180 mmHg, diastolic blood pressure (DBP) > 100 mmHg\nCongestive heart failure (New York Heart Association [NYHA] class III-IV)\nPericarditis or clinically significant pericardial effusion\nMyocarditis\nClinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation\nHistory of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus erythematosus, etc.) resulting in end organ injury or requiring systemic immunosuppression / systemic disease modifying agents within the last 2 years prior to enrollment. Subjects with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and subjects with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for the study\nHuman immunodeficiency virus (HIV) seropositive; HIV testing within 2 years of enrollment\n\nSeropositive for and with evidence of active viral infection with hepatitis B virus (HBV). Patients who are hepatitis B surface antigen (HBsAg) negative and HBV viral DNA negative are eligible\n\nPatients who had HBV but have received an antiviral treatment and show non-detectable viral DNA for 6 months are eligible\nPatients who are seropositive because of HBV vaccine are eligible\n\nSeropositive for and with active viral infection with hepatitis C virus (HCV)\n\na. Patients who had HCV but have received an antiviral treatment and show no detectable HCV viral DNA for 6 months are eligible\n\nSecond primary invasive malignancy that has not been in remission for greater than 2 years. Exceptions that do not require a 2-year remission include: resected non-melanoma skin cancer; carcinoma in situ (cervix, bladder, breast, etc.) or squamous intraepithelial lesion on Pap smear; localized prostate cancer (Gleason score < 6); or resected melanoma in situ\nHistory of trauma or major surgery within 4 weeks prior to the study enrollment\nAny serious underlying medical or psychiatric condition that would impair the ability of the patient to receive or tolerate the planned treatment and follow up\nKnown hypersensitivity to any component of NEXI-001 T cells, cyclophosphamide, fludarabine or tocilizumab\nVaccination with any live virus vaccine is not permitted prior to the initiation of study treatment. Inactivated annual influenza vaccination is allowed.\nDementia or altered mental status that would preclude understanding and rendering of informed consent\n\nHistory of seizures, aphasia, psychosis or other chronic clinically significant neurologic disorders\n\na. Patients with remote history of seizures that are well controlled on anti-seizure medications and without any seizure episode for 6 months are eligible\n\nAny issue that in the opinion of the investigator, would contraindicate the patient's participation in the study or confound the results of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nHave a projected life expectancy of at least 12 weeks and be in stable condition to complete 1 full cycle (4 weeks) of treatment.\nHave histological confirmation of AML by World Health Organization (WHO) 2016 criteria and who have failed all other available conventional therapies.\nHave a peripheral blood or bone marrow blast count >5% at the time of enrollment.\n\nHave disease that:\n\nis refractory to standard induction chemotherapy, including but not limited to anthracycline and cytarabine combination therapy, or\nhas relapsed after anthracycline and cytarabine therapy or stem cell transplant (SCT), or\nis refractory to or has relapsed after a front-line regimen containing a hypomethylating agent, alone or in combination.\nHave an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 1.\nHave adequate renal function as demonstrated by a serum creatinine \u22641.5 \u00d7 upper limit of normal (ULN) or calculated creatinine clearance (by the standard Cockcroft-Gault formula) of \u226560 mL/min.\n\nHave adequate liver function as demonstrated by the following:\n\naspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 \u00d7 upper limit of normal (ULN)\nAST and ALT <5 \u00d7 ULN (if considered due to leukemic organ involvement).\nWomen of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.\n\nExclusion Criteria:\n\nKnown clinically active central nervous system leukemia.\nBCR-ABL-positive leukemia.\nDiagnosis of acute promyelocytic leukemia (M3 AML or APML or APL).\nSecond malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.\n\nGrade 3 or higher graft versus host disease (GVHD), or GVHD requiring treatment with either:\n\na calcineurin inhibitor, or\nprednisone more than 5 mg/day (Note: Prednisone at any dose for other indications is allowed).\nTotal serum bilirubin \u22651.5 \u00d7 ULN (except for subjects with Gilbert's Syndrome for whom direct bilirubin is >2.5 \u00d7 ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.\nKnown active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer being treated with antivirals is allowed. For subjects considered at risk of viral exposure, serologies should be used to establish negativity.\nKnown significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of non-compliance with the protocol.\nMyocardial impairment of any cause (eg, cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, or congestive heart failure) resulting in heart failure by New York Heart Association (NYHA) Criteria (Class III or IV staging).\nScreening 12-lead echocardiogram with measurable QTc interval (according to either Fridericia's or Bazett's correction) of >480 milliseconds.\nActive, uncontrolled infection. Participants with an infection receiving treatment (antibiotic, antifungal, or antiviral treatment) must be afebrile and hemodynamically stable for \u226572 hours before enrollment.\nNon-AML-associated pulmonary disease requiring >2 liters per minute (LPM) oxygen.\nProliferative AML with total white blood cells > 20,000/uL\nAny other condition that puts the participant at an imminent risk of death.\nTreated with any investigational therapy within 2 weeks of the first dose of study treatment.\nInability to swallow oral medication.\nKnown hypersensitivity to ATRA, any of its components, or other retinoids.\nKnown sensitivity to parabens."
            },
            {
                  "document": "Inclusion Criteria:\n\nPathologically confirmed diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with >= 5% myeloblasts in either bone marrow or peripheral blood felt to be transformed out of an MPN as defined by the 2016 World Health Organization criteria, consisting of polycythemia vera, essential thrombocythemia, primary myelofibrosis, secondary myelofibrosis, MPN-unclassifiable, or MDS/MPN overlap\nOutside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution by pathology. Flow cytometric analysis of peripheral blood and/or bone marrow should be performed according to institutional practice guidelines\nEastern Cooperative Oncology Group (ECOG) performance status 0-2 or Karnofsky >= 60%\nSerum creatinine clearance >= 50 ml/min calculated by the Cockcroft-Gault Equation (assessed within 14 days of study day 1)\nTotal bilirubin =< 3 unless due to Gilbert's disease or hemolysis (total bilirubin > 3 is allowable if thought due to Gilbert's disease, hemolysis, or MPN disease) (assessed within 14 days of study day 1)\nAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN) unless thought to be due to MPN disease process (AST/ALT > 3 is allowable if thought due to MPN disease) (assessed within 14 days of study day 1)\nFor patient receiving fedratinib, thiamine level should be above the laboratory lower limit of normal (>= 70 nmol/L in the University of Washington [UW]/Seattle Cancer Care Alliance [SCCA] lab). If it is low, it may be repleted but should be rechecked and demonstrated to normalize prior to initiation of therapy\nPatient is considered a potential transplant candidate. The attending/treating physician will determine transplant candidacy at the time of consent\nThe use of hydroxyurea prior to study registration is allowed. Patients with symptoms/signs of hyperleukocytosis, white blood count (WBC) > 100,000/uL, or with concern for other complications of high tumor burden or leukostasis (e.g. hypoxia, disseminated intravascular coagulation) can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2 /dose) anytime prior to enrollment\nCapable of providing valid informed consent\n\nExclusion Criteria:\n\nPrevious treatment with chemotherapy (e.g. hypomethylating agents or cytarabine-based regimens) for MPN progressed to MDS or AML. Prior temporary measures to control blood counts is allowed. Prior treatment with hydroxyurea, interferons or JAK inhibitor therapy is allowed\nActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)])\nKnown hypersensitivity to any study drug\nFemales who are pregnant or breastfeeding\nTreatment with any other anti-MDS/leukemia investigational agent within 2 weeks of start of study drugs\nFor patients planning to receive fedratinib: concurrent use of strong and moderate CYP3A4 inducers or dual CYP3A4 and CYP2C19 inhibitors that cannot be discontinued\nFor patients planned to receive ruxolitinib AND platelets < 50,000/mm^2: concurrent use of a strong CYP3A4 inhibitor that cannot be discontinued"
            },
            {
                  "document": "Inclusion Criteria:\n\nNewly diagnosed:\n\nTherapy-related acute myeloid leukemia (AML)\nAML with antecedent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)\nAML with MDS-related changes (as per World Health Organization [WHO])\nHave an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2\nPlasma creatinine =< 1.5 x upper limit of normal (ULN)\nTotal bilirubin < 2.0 mg/dL\nSerum alanine aminotransferase and aspartate aminotransferase < 3 x ULN\nLeft ventricular ejection fraction by echocardiogram or multiple-gated acquisition >= 50%\nParticipants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\nWomen of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to enrollment and commit to two forms of birth control\nMen must use a latex condom during any sexual contact with women of childbearing potential\nWilling to adhere to protocol specific requirements\nParticipant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\nPrior treatment of AML\nKnown clinically active central nervous system (CNS) leukemia\nCore-binding factor leukemia\nAcute promyelocytic leukemia\nUncontrolled other malignancy\nPrior anthracycline exposure > 368 mg/m^2 of daunorubicin or equivalent\nCardiovascular disease resulting in heart failure (New York Heart Association class III or IV), unstable angina (angina symptoms at rest), or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months\nHypersensitivity to cytarabine, daunorubicin, or liposomal drugs\nKnown active HIV infection\nKnown history of active hepatitis B or C infection\nPre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)\nEvidence of ongoing, uncontrolled systemic infection\nPregnant or breastfeeding women\nSubject with concurrent severe and/or uncontrolled medical or psychiatric conditions that in the opinion of the investigator may impair the participation in the study or the evaluation of safety and/or efficacy\nHistory of Wilson disease or other copper-handling disorders\nAny condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug"
            },
            {
                  "document": "Inclusion Criteria:\n\nHas morphologically confirmed diagnosis of AML (World Health Organization [WHO] criteria 2008). Participants may have newly diagnosed primary de novo AML or secondary AML (sAML), defined as AML after myelodysplastic syndromes (MDS) or myeloproliferative neoplasm (MPN), or therapy-related AML (t-AML) following cytotoxic therapy, and/or radiotherapy for a malignant or nonmalignant disease.\n\nIs unfit for treatment with a standard Ara-C and anthracycline induction regimen due to age or co-morbidities defined by 1 of the following:\n\n\u226575 years of age. OR\n\u226518 to <75 years of age with at least one of the following:\nEastern Cooperative Oncology Group (ECOG) performance status of 2 or 3.\nSevere cardiac disorder (e.g., congestive heart failure requiring treatment, ejection fraction \u226450%, or chronic stable angina).\nSevere pulmonary disorder (e.g., carbon monoxide lung diffusion capacity \u226465% or forced expiratory volume in 1 second \u226465%).\nCreatinine clearance (CrCl) <45 mL/min (but \u226530 mL/min as part of general eligibility criteria).\nHepatic disorder with total bilirubin >1.5 times the upper limit of the normal range (ULN).\n\nHas clinical laboratory values within the following parameters (repeat within 3 days before the first dose of study drug if laboratory values used for randomization were obtained more than 3 days before the first dose of study drug):\n\nTotal bilirubin \u22641.5 times the ULN except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll with direct bilirubin \u22643 times the ULN of the direct bilirubin. Elevated indirect bilirubin due to posttransfusion hemolysis is allowed.\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22643.0 times the ULN.\nCreatinine clearance (CrCl) \u226530 mL/min (calculated by the Modification of Diet in Renal Disease [MDRD] Study equation).\nAlbumin >2.7 g/dL.\nWBC count <25 \u00d7 10^9/L. Participants who are cytoreduced with leukapheresis or with hydroxyurea may be enrolled if they meet the eligibility criteria before starting therapy.\n\nExclusion Criteria:\n\nHas history of MPN with BCR-ABL1 translocation or AML with BCR-ABL1 translocation.\nHas genetic diagnosis of acute promyelocytic leukemia.\nIs eligible for intensive chemotherapy and/or allogeneic stem cell transplantation.\nHas extramedullary AML without evidence of bone marrow involvement.\nHad prior treatment with hypomethylating agents for AML (hypomethylating agent treatment for prior MDS is not exclusionary).\nHas clinical evidence of or history of central nervous system involvement by AML.\nHad diagnosed or treated for another malignancy (except for adequately treated carcinoma in situ of any organ or nonmelanoma skin cancer) within 1 year before randomization or previously diagnosed with another malignancy and have any evidence of residual disease that may compromise the administration of pevonedistat, venetoclax or azacitidine. Prior MDS is also allowed, but the participant cannot have received treatment for MDS within 14 days before first dose of any study drug.\nHas a WBC count \u226525 \u00d7 10^9/L\n\nHas uncontrolled human immunodeficiency virus (HIV) infection. Note: Known HIV positive participants who meet the following criteria will be considered eligible:\n\nCluster difference 4 (CD4) count >350 cells/mm^3.\nUndetectable viral load.\nMaintained on modern therapeutic regimens utilizing non-cytochrome P (CYP)-interactive agents.\nNo history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections.\nParticipant is known to be positive for hepatitis B or C infection, with the exception of those with an undetectable viral load within 3 months (hepatitis B or C testing is not required for eligibility assessment).\nHas hepatic cirrhosis.\nHas uncontrolled coagulopathy or bleeding disorder.\nHas high blood pressure which cannot be controlled by standard treatments.\nHas prolonged rate QTc interval \u2265500 msec, calculated according to institutional guidelines.\nHas left ventricular ejection fraction (LVEF) <40%, based on echocardiogram or multi gated acquisition (MUGA) scan at screening (data to be available within last 3 months of screening).\nAs infection is a common feature of AML, participants with active infection are permitted to enroll provided that the infection is under control and no signs of systemic inflammatory response beyond low grade fever that makes participant clinically unstable in the opinion of the investigator. Participants with uncontrolled infection shall not be enrolled until infection is treated and brought under control."
            },
            {
                  "document": "Inclusion Criteria:\n\nDocumented informed consent of the participant and/or legally authorized representative\nKarnofsky performance status >= 70\n\nHistologically confirmed diagnosis of one the following:\n\nPatients with acute myelogenous leukemia\n\nIn first complete remission (CR1) with intermediate or poor risk cytogenetics according to National Comprehensive Cancer Network (NCCN) guidelines for acute myeloid leukemia (AML) or European LeukemiaNet (ELN) 2017\nIn second complete remission (CR2) or third complete remission (CR3)\nPatients with chemosensitive active disease\n\nPatients with acute lymphocytic leukemia\n\nIn CR1 with poor risk cytogenetics:\nFor adults according to NCCN guidelines for acute lymphoblastic leukemia (ALL): Patients older than 40 year of age; with high white blood cell count (WBC) at diagnosis (>= 30,000 for B lineage or >= 50,000 for T lineage), or with high risk cytogenetics including: hypoploidy (< 44 chromosomes); t(v;11q23): MLL rearranged; t(9;22) (q34;q11.2); complex cytogenetics (5 or more chromosomal abnormalities)\n\nFor pediatrics t(9;22), iAMP21loss of 13q, and abnormal 17p\n\nIn CR2 or CR3\nPatients with chemosensitive active disease\nMyelodysplastic syndrome in high-intermediate (int-2) and high risk categories by International Prognostic Scoring System (IPSS) or revised (R)-IPSS\nTotal bilirubin =< 2 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\nCreatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n\nEjection fraction measured by echocardiogram or multigated acquisition scan (MUGA) >= 50% (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n\nNote: To be performed within 28 days prior to day 1 of protocol therapy\n\nIf able to perform pulmonary function tests: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capability test (DLCO) (diffusion capacity) >= 50% of predicted (corrected for hemoglobin). If unable to perform pulmonary function tests: oxygen (O2) saturation > 92% on room air\n\nNote: To be performed within 28 days prior to day 1 of protocol therapy\n\nSeronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]) (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n\nIf positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed\n\nMeets other institutional and federal requirements for infectious disease titer requirements\n\nNote: Infectious disease testing to be performed within 28 days prior to Day 1 of protocol therapy\n\nWomen of childbearing potential (WOCBP): negative urine or serum pregnancy test\n\nIf the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n\nAgreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy\n\nChildbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nThe recipient must have a related donor genotypically human leukocyte antigen (HLA)-A, B,C and DRB1 loci haploidentical to the recipient\nNo HLA matched sibling or matched unrelated donor is available\n\nPatients should be off all previous intensive therapy, chemotherapy or radiotherapy for 3 weeks prior to commencing therapy on this study\n\n(NOTE: Low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted. These include: Hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors [TKIs]. FLT-3 inhibitors such as sorafenib, crenolanib, midostaurin can also be given up to 3 days before conditioning regimen.)\nDONOR: The donor must be examined and have specific tests performed according to existing institutional guidelines to evaluate his/her candidacy as a donor including the following:\nDONOR: Age =< 60 years of age\nDONOR: For younger donors, no more than 20 mL bone marrow may be harvested per kg of donor body weight\nDONOR: Medical history and physical examination confirm good health status as defined by institutional standards\nDONOR: Seronegative for HIV Ag, HIV 1+2 Ab, HTLV I/II Ab, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) (IgM and IgG), HCV Ab, RPR for syphilis within 30 days of apheresis collection\nDONOR: Genotypically haploidentical as determined by HLA typing, preferably a nonmaternal HLA haploidentical relative due to data of high incidence of graft failure with use of maternal HLA haploidentical cells. Eligible donors include biological parents, siblings or half siblings, or children\nDONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within seven days of mobilization\nDONOR: The donor must have been informed of the investigational nature of this study and have signed a consent form in accordance with Federal Guidelines and the guidelines of the participating institution\nDONOR: Selection of a haploidentical donor will require absence of pre-existing donor-directed anti-HLA antibodies in the recipient\n\nExclusion Criteria:\n\nPatients should not have any uncontrolled illness including ongoing or active bacterial, viral or fungal infection\n\nPatient may not be receiving any other investigational agents or concurrent biological, intensive chemotherapy or radiation therapy for the previous three weeks from conditioning\n\n(NOTE: Low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted. These include: Hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors [TKIs]. FLT-3 inhibitors such as sorafenib, crenolanib, midostaurin can also be given up to 3 days before conditioning regimen.)\nHerbal medications dependency\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\nNo intercurrent illness or other malignancy (other than non-melanoma skin cancer)\nActive infection requiring antibiotics\nKnown history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection\nFemales only: Pregnant or breastfeeding\nAny other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\nPatients who had a prior autologous or allogeneic transplant\nPatients who had prior radiation therapy of more than 20% of bone marrow containing areas or to any area exceeding 2000 cGy\nPatients with HLA-matched or partially matched (7/8 or 8/8) related or fully matched unrelated donor available to donate\nPatients who have received more than 3 prior regimens, where the regimen intent was to induce remission\nPatients with treatment history including anti-CD33 monoclonal antibody therapy (e.g., SGN-CD33 or Mylotarg)\nProspective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)\nDONOR: Evidence of active infection\nDONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis\nDONOR: Factors which place the donor at increased risk for complications from leukapheresis or granulocyte colony-stimulating factor (G-CSF) therapy\nDONOR: HIV positive"
            },
            {
                  "document": "Inclusion Criteria:\n\nConfirmed MDS, CMML, MDS/MPN, or AML who are candidates to receive and benefit from single agent azacitidine as follows and as applicable according to local country approvals and/or local institution standard practice:\n\nFrench-American-British myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), or MDS with intermediate-2 or high risk MDS according to the International Prognostic Scoring System (IPSS). MDS/MPN patients including CMML according to the World Health Organization (WHO) 2016 classification are also eligible if they are candidates to receive single agent azacitidine per local institution standards; or\nPreviously untreated AML with 20% to 30% blasts present in bone marrow and multi-lineage dysplasia (Phase 2 and 3 only); or\nPreviously untreated AML with >30% blasts present in bone marrow, who are not eligible for stem cell transplant and unfit for intensive chemotherapy induction (Phase 2 and 3 only).\nParticipants with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\nParticipants with adequate organ function defined as:\n\nHepatic: Total or direct bilirubin \u22642 \u00d7 upper limit of normal (ULN); aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) \u22642.5 \u00d7 ULN.\nRenal: Calculated creatinine clearance >50 mL/min/1.73 m^2 by Cockcroft-Gault formula or other medically acceptable formulas.\nFor participants with prior allogeneic stem cell transplant, no evidence of graft-versus-host disease (GVHD) and must be \u22652 weeks off systemic immunosuppressive therapy before start of study treatment.\nParticipants with no major surgery within 2 weeks before first study treatment.\nParticipants with no cytotoxic chemotherapy within 4 weeks before first study treatment.\nAble to swallow the number of tablets/capsules required for the treatment assignment within a 10-minute period and tolerate 4 hours of fasting.\nParticipants with projected life expectancy of at least 12 weeks.\nWomen of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.\n\nExclusion Criteria:\n\nActive uncontrolled gastric or duodenal ulcer.\nPoor medical risk because of other conditions such as uncontrolled systemic diseases or active uncontrolled bacterial, viral, or fungal infections.\nLife-threatening illness (e.g., uncontrolled bleeding and patients at risk for or are experiencing leukostasis [AML]), uncontrolled medical condition or organ system dysfunction, or other reasons, which, in the investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of oral cedazuridine + azacitidine or compromise the integrity of the study outcomes.\nPrior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer or breast cancer under control with hormone therapy, or other cancer from which the participant has been disease free for at least 2 years.\nParticipants with MDS/MPN who have clinical extramedullary disease including clinically palpable hepatomegaly or splenomegaly.\nPrevious treatment with more than 1 cycles of decitabine, azacitidine, or guadecitabine (Phases 2 and 3 only).\nTreated with any investigational drug or therapy within 2 weeks, or 5 half lives, whichever is longer, before the protocol-defined first dose of study treatment, or ongoing clinically significant adverse events from previous treatment with investigational drug or therapy.\nKnown or suspected hypersensitivity to cedazuridine or azacitidine, or any of their excipients."
            },
            {
                  "document": "Inclusion Criteria:\n\nDemonstration of understanding and voluntarily signing of an informed consent form\nAge \u2265 18 years\nDiagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) according to the World Health Organization classification and, with respect to MDS, that is high risk; participants must have refractory or relapsed disease and be ineligible for or have exhausted standard therapeutic options that would otherwise be likely to provide clinical benefit\nEastern Cooperative Oncology Group performance status \u2264 2 and life expectancy of \u2265 6 weeks\nAdequate organ function (Grade 1 serum creatinine; Grade 1 total bilirubin; aspartate aminotransferase and/or alanine transaminase \u2264 2 \u00d7 ULN)\nFemales of childbearing age must not be pregnant at time of Screening/beginning of treatment and agree to either abstain from sexual intercourse or use highly effective methods of contraception (for up to 3 months after last dose of study drug)\nMales sexually active with a woman of childbearing age must agree to use barrier method of birth control during and after the study (up to 3 months after last dose of study drug)\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia\nWhite blood cell count > 20 x 10^9/L\nReceipt of cancer chemotherapy (other than hydroxyurea) within 2 weeks prior to the start of study drug\nIn participants who have undergone autologous or allogeneic stem cell transplantation: transplantation within the 3 months prior to Screening; active graft-versus-host disease requiring anything other than topical corticosteroids and budesonide; treatment with systemic immunosuppressive medications including high-dose steroids (\u2265 20 mg prednisolone or equivalent per day), or calcineurin inhibitors (e.g., cyclosporine, tacrolimus) for at least 1 week prior to Screening, and sirolimus, mycophenylate mofetil, azathioprine, or ruxolitinib for at least 2 weeks prior to Screening\nImmediate life-threatening severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation\nPersistent toxicities from prior treatment of Grade 2 or higher\nActive uncontrolled systemic fungal, bacterial, mycobacterial, or viral infection\nClinically significant cardiac disease\nKnown dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally\nAny other concurrent medical condition or disease that is likely to interfere with study procedures or results, or that, in the opinion of the Investigator, would constitute a hazard for participating in this study\nIf female, pregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nSubject is aged \u2265 6 months and < 21 years of age* at the time of signing informed consent and/or assent, as applicable.\n\n*For phase 2: Enrollment of subjects from 6 months to less than 1 year and 1 year to less than 2 years will be dependent on the establishment of recommended phase 2 dose (RP2D) in the respective age groups during phase 1.\n\nSubject has a diagnosis of acute myeloid leukemia (AML) according to The French-American-British (FAB) classification with \u2265 5% blasts in the bone marrow, with or without extramedullary disease (except subjects with active central nervous system [CNS] leukemia).\n\nIn the phase 1 portion of the study, subject must be in first or greater relapse or refractory to induction therapy with no more than 1 attempt at remission induction (up to 2 induction cycles).\nFor the phase 2 portion of the study, subject must be in first relapse.\n\nSubject has fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.\n\nMyelosuppressive chemotherapy:\n\nFor subject who relapses while receiving cytotoxic therapy, at least 21 days must have elapsed since the completion of cytotoxic therapy and prior to screening, unless the subject has recovered earlier than 21 days.\n\nCytoreduction with the following can be initiated and continued for up to 24 hours prior to the start of systemic protocol therapy (cycle 1 day -1).\n\nhydroxyurea,\nlow dose cytarabine (100 mg/m^2 per dose once daily for 5 days) or\nother low dose/maintenance therapies as per local site practice.\nSubject who has received other FLT3 inhibitors (e.g., lestaurtinib, sorafenib, etc) is eligible for this study.\nHematopoietic growth factors: at least 7 days must have elapsed since the completion of therapy with a growth factor and prior to screening.\nBiologic (anti-neoplastic agent): at least 7 days must have elapsed since the completion of therapy with a biologic agent and prior to screening. For agents that have known adverse events (AEs) occurring beyond 7 days after administration, this period must be extended beyond the time during which AEs are known to occur.\n\nX-ray treatment (XRT):\n\n14 days must have elapsed for local palliative XRT for CNS chloromas and prior to screening; no washout period is necessary for other chloromas;\nPrior to screening, 90 days must have elapsed if the subject had a prior traumatic brain injury or has received craniospinal XRT.\nFor subject undergoing hematopoietic stem cell transplant (HSCT), at least 90 days must have elapsed since HSCT and subject must not have active graft-versus-host disease (GVHD).\nSubject has Karnofsky score \u2265 50 (if the subject is of \u2265 16 years of age) or Lansky score of \u2265 50 (if the subject is < 16 years of age). A score < 50 is acceptable if related to the subject's leukemia.\n\nSubject must meet the following criteria as indicated on the clinical laboratory tests.\n\nSerum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 3.0 x upper limit normal (ULN) for age\nTotal serum bilirubin \u2264 1.5 x ULN for age\nSerum creatinine \u2264 1.5 x ULN for age or an estimated glomerular filtration rate of > 60 mL/min/1.73 m^2.\n\nA female subject is eligible to participate if she is not pregnant and at least 1 of the following conditions applies:\n\nNot a woman of childbearing potential (WOCBP) OR\nWOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 180 days after the final study drug administration.\nFemale subject must agree not to breastfeed starting at Screening, and throughout the study period and for 60 days after the final study drug administration.\nFemale subject must not donate ova starting at Screening and throughout the study, and for 180 days after the final study drug administration.\nA male subject with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 180 days after the final study drug administration.\nA male subject must not donate sperm during the treatment period and for at least 120 days after the final study drug administration.\nMale subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 180 days after the final study drug administration.\nSubject and subject's parent(s) or legal guardian agrees not to participate in another interventional study while on treatment.\nLive Vaccines - At least 6 weeks must have elapsed since the administration of the last dose of a live vaccine and prior to the initiation of study treatment (cycle 1, day -1)\nPhase 1: Subject is positive for FLT3 (ITD and/or tyrosine kinase domain [TKD]) mutation in bone marrow or blood as determined by the local institution.\nPhase 2: Subject is positive for the FLT3 (ITD) mutation in bone marrow or blood as determined by the local institution.\n\nExclusion Criteria:\n\nSubject has active CNS leukemia.\n\nSubject has uncontrolled or significant cardiovascular disease, including:\n\nDiagnosed or suspected congenital long QT syndrome or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes (TdP)); any history of arrhythmia will be discussed with the sponsor prior to subject's entry into the study\nProlonged Fridericia's Correction Formula (QTcF) interval on pre-entry electrocardiogram (ECG) (\u2265 450 ms)\nAny history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)\nHeart rate < 50 beats/minute on pre-entry ECG\nUncontrolled hypertension\nComplete left bundle branch block\nSubject has systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The subject needs to be off pressors and have negative blood cultures for 48 hours.\nSubject is receiving or plans to receive concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.\nSubject has active clinically significant graft-versus-host disease (GVHD) or is on treatment with systemic corticosteroids and is receiving > 0.5 mg/kg of prednisone (or equivalent) daily dose for GVHD.\nSubject has active malignant tumors other than AML.\nSubject has any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise subject safety or compliance; interfere with consent, study participation, follow-up or interpretation of study results.\nSubject has hypokalemia and/or hypomagnesemia at Screening (defined as values below institutional lower limit of normal [LLN]). Repletion of potassium and magnesium levels during the screening period is allowed.\nSubject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A/P-glycoprotein (P-gp).\nSubject is known to have human immunodeficiency virus infection.\n\nSubject has active hepatitis B or C, or other active hepatic disorder.\n\nSubjects with positive hepatitis B surface antigen (HBsAg) or detectable hepatitis B DNA are not eligible.\nSubjects with negative HBsAg, positive hepatitis B core antibody and negative hepatitis B surface antibody will be eligible if hepatitis B DNA is undetectable.\nSubjects with antibodies to hepatitis C virus will be eligible if hepatitis C RNA is undetectable.\nSubject must wait for at least 5 half-lives after stopping therapy with any investigational agent and before starting gilteritinib.\nSubject has a known or suspected hypersensitivity to gilteritinib, cytarabine, fludarabine, granulocyte colony-stimulating factor (G-CSF) or any components of the formulation used."
            },
            {
                  "document": "Inclusion Criteria:\n\nPreviously untreated therapy-related AML or AML with myelodysplastic related changes as described by World Health Organization (WHO) 2016\n\nAML arising in MDS (including CMML) or MDS/MPN syndrome\nAML with MDS-related cytogenetic abnormalities (Appendix A, metaphase FISH allowable as surrogate for cytogenetics)\nAML with multi-lineage dysplasia involving the presence of 50% or more dysplastic cells in at least two cell lines and in the absence of mutation in NPM1 or biallelic CEBPA (as per WHO 2016)\nAdults 18 years of age or older\nECOG performance status 0 to 2\n\nAdequate organ function as defined as:\n\nLeft Ventricular Ejection Fraction (LVEF) > 50%\nSerum total bilirubin < 2.0 mg/dL, unless considered due to Gilbert's disease or leukemic involvement\nAST, ALT and alkaline phosphatase < 3 times the upper limit of normal, unless considered due to leukemic involvement\nSerum creatinine < 2.0 mg/dL, or creatinine clearance > 40 mL/min based on Cockcroft-Gault GFR\nAbsence of unstable cardiac disease defined as myocardial infarction within 6 months, uncontrolled heart failure, or uncontrolled cardiac arrhythmia\nAbility to understand and the willingness to sign a written informed consent or subject's legally authorize representative (LAR) has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent\n\nWomen of child-bearing potential and men with partners of child-bearing potential must agree to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication\n\nA woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\nHas not undergone a hysterectomy or bilateral oophorectomy; or\nHas not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\nWomen of child-bearing potential has negative pregnancy test within 72 hours of initiating study drug dosing\nMale subjects must agree to use a latex condom during sexual contact with females of childbearing potential even if they have had a successful vasectomy starting with the first dose of study therapy through 120 days after the last dose of study therapy\nLeukapheresis, corticosteroid and hydroxyurea are permitted as initial management of hyperleukocytosis at the investigator's discretion for up to 7 days after starting study therapy. Hyperleukocytosis is defined as greater than 30k WBC. When possible, a bone marrow biopsy for screening should be performed prior to the initiation hyperleukocytosis\n\nExclusion Criteria:\n\nPrior treatment with Glasdegib or CPX-351\nPreviously treated AML except for initial management of hyperleukocytosis. Treatment with hypomethylating therapy for MDS is allowable but not since their diagnosis of AML. No prior treatment with cytarabine or daunorubicin are allowed\nConcurrent FLT3 mutation that the treating physician deems necessary to treat with midostaurin, whereas patients with FLT3-mutated AML not treated with midostaurin can be enrolled. Patients with known Core Binding Factor -t(8;21), inv(16), t(16;16) are allowed for study participation at the treating investigator's discretion\nActive CNS or testicular involvement by leukemia; diagnostic lumbar puncture is not required\nHistory of neurologic disorder including but not limited to: prior seizure, epilepsy, structural brain abnormality, benign brain tumor, stroke, brain injuries, dementia, movement disorder or other significant CNS abnormalities\nBaseline QT corrected interval based on Fridericia's formula (QTcF) interval > 450 ms\nAcute coronary syndrome in the past 12 months, NYHA class III or VI\nKnown history of Wilson's disease or other copper handling disorder\nHistory of GI malabsorptive disease\nHas a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy\nKnown HIV infection\nActive hepatitis B or hepatitis C infection (patients who successfully completed curative hepatitis C therapy can be enrolled)\nAny uncontrolled infection, active bacterial or viral infection manifesting as fevers or hemodynamic instability within the past 72 hours\nProven active invasive fungal infection\nIs pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\nSevere or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness/social situations that would limit compliance with study requirements\nCurrent or anticipated use of other investigational agents\nFor patients with prior anthracycline exposure, the cumulative life-time dose should not exceed 386mg/m2 at the time of study entry (to convert different anthracycline to daunorubicin-equivalent, see Appendix H for conversion factors)"
            },
            {
                  "document": "Inclusion Criteria:\n\nWilling and able to understand and provide signed informed consent for the study that fulfills Institution Review Board (IRB) guidelines\nMale or female patients > 18 years of age on the day of signing informed consent\nMust have a diagnosis of AML according to the WHO criteria (primary/de novo or secondary, including treatment-related [e.g., due to prior anthracycline use], as well as cases due to progression of antecedent hematological disorder [e.g., MDS, MPN, or MDS/MPN 'overlap' syndrome).\n\nMust be in second morphological complete remission (with or without platelet recovery; CR2/CR2p) for relapsed (but not refractory AML) based upon the International Working Group (IWG) 2003 criteria as follows:\n\n<5% myeloblasts in bone marrow.\nAbsence of circulating peripheral blasts.\nPeripheral blood absolute neutrophil count (ANC) >1000 cells/\u00b5L. d. Peripheral blood platelet count >60,000/\u00b5L\nabsence of extramedullary disease.\nLeukemic blasts must express WT1\nFree of any requirement for red blood cell transfusions.\nAre not candidates at the time of study entry for allogeneic stem cell transplant (Allo-SCT) due to intercurrent medical conditions or lack of an available donor.\nReceived the last dose of antileukemic therapy at least 3 months prior to study enrolment.\nMust be within 3 months of having achieved CR2/CR2p\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\nEstimated life expectancy >6 months.\nIf female, is postmenopausal (at least 12 sequential months of amenorrhea) or surgically sterile.\nFemales of childbearing potential must have a negative pregnancy test\nFemale patients of childbearing potential who are heterosexually active and male patients with female sexual partners of childbearing potential must agree to use an effective method of contraception (e.g., oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device) during the study and for 4 months following the last dose of study medication, or to abstain from sexual intercourse for this time; a woman not of childbearing potential is one who has undergone bilateral oophorectomies or who is post- menopausal, defined as the absence of menstrual periods for 12 consecutive months.\nRecovered to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5 Grade 0 or 1 after completion of prior AML therapy with the exception of the platelet count requirements (i.e., as long as peripheral blood platelet count is >60,000/\u00b5L).\nAdequate renal function defined as a serum creatinine <2 \u00d7 upper limit of normal (ULN) or calculated creatinine clearance > 30 mL/min based on the Cockroft-Gault equation.\nAdequate hepatic function defined as a serum total bilirubin <2 \u00d7 ULN (except for Gilbert's syndrome, which will allow bilirubin \u22643.0 mg/dL), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22643 \u00d7 ULN.\nWilling and able to return to the clinical site for adequate follow-up and to comply with the protocol as required.\n\nExclusion Criteria:\n\nFor subjects randomized to GPS maintenance monotherapy:\n\nContinuation of any agents administered as part of induction of CR2/CR2p\nReceiving any concurrent anti-AML systemic therapy\nPrior clinically significant allergic reaction to Montanide, sargramostim (GM-CSF) or filgrastim (granulocyte colony stimulating factor [G-CSF]).\nReceived any investigational agent, systemic corticosteroid therapy, or other immunosuppressive therapy within 4 weeks prior to enrolment within the study. Corticosteroids for chronic conditions (at doses \u22647.5 mg/day of prednisone or equivalent) or permitted, as are inhalational, intra-ocular, intra-articular and topical corticosteroids.\nComplete remission with incomplete hematologic recovery (CRi).\nComplete remission with partial haematologic recovery (CRh).\nImminently planned hematopoietic stem cell transplant (autologous or allogeneic, with any degree of match donor).\nAcute promyelocytic leukemia or any morphologic and molecular variants, inclusive.\nSerious concurrent illness that in the opinion of the Investigator would pose an undue risk to the subject being participating in the clinical study.\nHistory of, or who currently have, central nervous system leukemia.\nReceived a live vaccine within 30 days prior to the first dose of study drug.\nCurrently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\nUndergone prior allogeneic hematopoietic stem cell transplantation\nDiagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.\nAdditional malignancy that is progressing or has required active treatment within the past 5 years, even if currently inactive or unapparent.\nActive CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.\nHypersensitivity to Montanide or vaccine adjuvants.\nPrevious clinically significant systemic allergic reaction to Montanide, sargramostim (GM-CSF), or filgrastim (G-CSF).\nActive autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\nActive infection requiring systemic therapy.\nHistory or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator. This includes any serious, intercurrent, chronic, or acute illness, such as cardiac disease (New York Heart Association [NYHA] class III or IV), hepatic disease, or other illness considered by the investigator as an unwarranted high risk for investigational drug treatment.20.Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.\nPregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 30 days after the last dose of study treatment.\nHad an allogeneic tissue/solid organ transplant.\nReceived transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (excluding GM-CSF, but including G CSF or recombinant erythropoietin) within 4 weeks prior to first study treatment."
            },
            {
                  "document": "Part A Inclusion Criteria\n\nParticipants with cytologically/histologically confirmed myelodysplastic syndrome (MDS) according to the 2016 World Health Organization (WHO) classification with the following:\n\nMeasurable disease per WHO MDS with excess blasts criteria as defined either:\n\n5%-9% blasts in the bone marrow or 2%-4% blasts in the peripheral blood or\n10%-19% blasts in the bone marrow or 5%-19% blasts in the peripheral blood\nMDS that is relapsed or refractory and must not have other therapeutic options known to provide clinical benefit in MDS available.\n\nTreatment failure after prior hypomethylating agent (HMA) therapy for MDS, defined as one of the following:\n\nProgression (per 2006 International Working Group [IWG] criteria) at any time after initiation of HMA therapy.\nLack of response (failure to achieve complete remission [CR], partial response [PR], or hematologic improvement [HI] per 2006 IWG criteria) after at least 6 cycles of azacitidine (or equivalent HMA) or 4 cycles of decitabine (or equivalent HMA).\nRelapse after achievement of CR, PR, or HI (per 2006 IWG criteria).\nIntolerance of HMA (Grade 3 or higher non-hematologic toxicity leading to treatment discontinuation).\nParticipants with isolated 5q-/5q- syndrome must have progressed, failed, relapsed, or not tolerated lenalidomide in addition to HMA.\nMust be off HMA therapy \u2265 2 weeks and must be off any other treatments for MDS for \u2265 4 weeks prior to first dose of SEA-CD70; growth factors and transfusions are allowed before and during the study as clinically indicated\nEastern Cooperative Oncology Group (ECOG) performance status of 0-1\n\nPart B Inclusion Criteria\n\nParticipants with cytologically/histologically confirmed MDS according to the WHO classification with the following:\n\nMeasurable disease per WHO MDS with excess blasts (MDS-EB) criteria as defined either:\n\n5%-9% blasts in the bone marrow or 2%-4% blasts in the peripheral blood, or\n10%-19% blasts in the bone marrow or 5%-19% in the peripheral blood\nMDS that is relapsed or refractory and must not have other therapeutic options known to provide clinical benefit in MDS available.\n\nTreatment failure after prior HMA therapy for MDS defined as one of the following:\n\nProgression (per 2006 IWG criteria) at any time after initiation of HMA therapy.\nLack of response (failure to achieve CR, PR, or HI per 2006 IWG criteria) after at least 6 cycles of azacitidine or 4 cycles of decitabine.\nRelapse after achievement of CR, PR, or HI (per 2006 IWG criteria).\nIntolerance of HMA (Grade 3 or higher non-hematologic toxicity leading to treatment discontinuation).\nParticipants with isolated 5q-/5q- syndrome must have progressed, failed, relapsed, or not tolerated lenalidomide in addition to HMA.\nMust be off HMA therapy \u2265 2 weeks and must be off any other systemic treatments for MDS for \u2265 4 weeks prior to first dose of SEA-CD70; growth factors (e.g., G-CSF, erythropoietin and thrombopoietin) and transfusions are allowed before and during the study as clinically indicated.\nECOG Performance Status of 0-2\n\nPart C Inclusion Criteria\n\nParticipants with relapsed or refractory acute myeloid leukemia (AML) according to the WHO 2016 classification (except for acute promyelocytic leukemia [APL]):\n\nWho have received either 2 or 3 previous regimens to treat active disease. Post-remission treatments, intrathecal chemotherapy, and radiotherapy are not considered previous regimens.\n\nWho have received 1 previous regimen to treat active disease and have at least one of the following:\n\nAge > 60 and \u226475 years.\nPrimary resistant AML (defined as failure to achieve CR after 1-2 courses of induction therapy)\nFirst CR duration <6 months\nAdverse-risk per European Leukemia Net (ELN) genetic risk stratification\nSecondary AML (prior history of MDS or therapy-related)\nAge 18-75 years\nECOG performance status of 0-2\n\nExclusion Criteria (All Parts)\n\nHistory of another malignancy within 3 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.\nPrevious exposure to CD70-targeted agents\nPrior allogeneic hematopoietic stem cell transplant, for any condition\nCentral nervous system leukemia based on imaging or documented positive cytology in cerebral spinal fluid\nHistory of clinically significant sickle cell anemia, autoimmune hemolytic anemia, or idiopathic thrombocytopenic purpura"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatient Inclusion Criteria for Induction Phase\n\nPrimary Relapsed AML including\nRelapsed AML after allogeneic stem cells\nIsolated CNS or extramedullary disease (Note: a response monitoring plan must be developed a priori for subjects with extramedullary disease)\n1-3 prior lines of therapy which includes chemotherapy, hypomethylating agents, venetoclax or targeted therapy.\nPatient weight \u2265 42 kg\nPerformance status: Karnofsky or Lansky Performance Scale (PS) greater or equal to 70, or, ECOG score 0-2.\nRenal function: Serum creatinine \u2264 2 mg/dl and/or creatinine clearance greater or equal than 40 cc/min.\nPulmonary function: FEV1, FVC and DLCO \u2265 50% of expected, corrected for hemoglobin.\nLiver function: Total bilirubin \u2264 2 mg/dl or \u2264 2.5 x ULN for age (unless Gilbert's syndrome) and SGPT (ALT) \u2264 2.5 x ULN for age.\nCardiac function: left ventricular ejection fraction \u2265 40%.\nCNS: Patients with seizure disorder are eligible if seizures well controlled.\nNegative serum test to rule out pregnancy within 2 weeks prior to enrollment in females of childbearing potential (non-childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized).\nSexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator.\nAbility to understand and willingness to sign the written informed consent document.\nNegative serology for human immunodeficiency virus (HIV).\nPatients on hydrocortisone for adrenal insufficiency or on inhaled or topical steroids are eligible.\n\nMaintenance Phase: Patients that complete induction therapy and who achieve a CR/CRi/PR within the designated follow-up period and who are ineligible, unable or unwilling to undergo HSCT; these patients will not receive fludarabine or cytarabine.\n\nExclusion Criteria for Induction Phase:\n\nInvestigational therapies in the 3 weeks prior to beginning treatment on this protocol.\nPatients receiving any concurrent therapy including but not limited to chemotherapy, targeted therapy, radiation therapy, or immunotherapy for R/R AML.\nAny comorbidities that in the opinion of the investigator will preclude receiving fludarabine or cytarabine.\nUncontrolled infection, defined as an infection which has not resolved spontaneously or does not show evidence of significant resolution after initiating appropriate therapy. Asymptomatic viremia such as CMV, HPV, BK virus, HCV, HBV etc. is NOT considered as an exclusion criteria.\nUncontrolled arrhythmias or uncontrolled symptomatic cardiac disease.\nActive GVHD\nPrednisone dose is > 20 mg/day or >0.25mg/kg, whichever is higher will be excluded.\nPatients with donor-specific antibodies with MFI > 5000 will be ineligible\nMaintenance Phase: Patients must continue to meet exclusion criteria as defined in Section 4.4."
            },
            {
                  "document": "PROCUREMENT\n\nInclusion Criteria:\n\nDiagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML) with the exception of acute promyelocytic leukemia (APL) AND suitable for consideration of allogeneic Hematopoietic Stem Cell Transplant with confirmation of an identified eligible donor by a FACT accredited transplant center\nCLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory\nAge \u226475 years NOTE: The first six (6) patients treated on the study will be adults (\u226518 yrs of age).\nHgb \u2265 7.0 g/dL(can be transfused)\nLife expectancy greater than 12 wks\n\nIf apheresis required to collect blood\n\nPT and APTT <1.5x ULN\nSerum Creatinine < 1.5 x ULN\nAST < 1.5 x ULN\nInformed consent\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL)\nActive infection (bacterial, fungal or viral) requiring ongoing treatment without improvement.\nActive infection with HIV or HTLV\nActive second cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer)or other cancer treated \u2264 2 years prior to enrollment\nOngoing treatment with immune suppression for prophylaxis or treatment of GVHD including high dose steroids (e.g. prednisone > 0.25mg/kg)\n\nTREATMENT\n\nInclusion Criteria:\n\nDiagnosis of primary refractory or relapsed Acute Myeloid Leukemia (AML) with the exception of acute promyelocytic leukemia (APL). Patients with targetable mutations should have failed or be ineligible for targeted therapies (e.g. FLT3 inhibitors, IDH inhibitors, or anti-CD33 drug conjugate). AND patients should be suitable for consideration of allogeneic Hematopoietic Stem Cell Transplant with confirmation of an identified eligible donor by a FACT accredited transplant center and with confirmation that the center plans to proceed with transplant if CLL-1.CAR treatment induces a response they consider adequate to proceed to allogeneic HSCT.\nCLL-1 positive tumor with at least 30% CLL-1 blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory\nAge \u226475 years NOTE: The first six (6) patients treated on the study will be adults (\u226518 yrs of age).\nAST/ALT less than 5 times the upper limit of normal\nBilirubin less than 3 times the upper limit of normal\nEstimated GFR \u2265 60ml/min\nPulse oximetry of > 92% on room air\nKarnofsky/Lansky \u2265 60\nRecovered from all acute toxic effects of prior chemotherapy at least one week before study entry and off systemic chemotherapy at least 2 weeks prior to study entry\nAvailable autologous transduced activated peripheral blood T-cell product with \u2265 20% expression of CLL-1.CAR.28z by flow cytometry\nLife expectancy > 12 weeks\nSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom\nInformed consent explained to, understood by, and signed by patient/guardian. Patient/guardian given copy of informed consent.\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL)\nCurrently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks.\nHistory of hypersensitivity reactions to murine protein-containing products.\nPregnant or lactating.\nActive infection with HIV or HTLV.\nClinically significant bacterial, viral or fungal infection requiring ongoing antifungal therapy without improvement,.\nFever of unknown origin without complete work-up including imaging (CT head, sinus, chest, abdomen/pelvis)\nCardiac criteria: Prolonged QTc with maximum interval as defined by age with ; Uncontrolled atrial fibrillation/flutter; Myocardial infarction within the last 6 months; Cardiac echocardiography with LVSF<30% or LVEF<50% or clinically significant pericardial effusion; Cardiac dysfunction NYHA III or IV; CNS abnormalities: Presence of CNS disease defined as detectable cerebrospinal blast cells in a sample of CSF with \u2265 5 WBCs per mm3 or chloroma on imaging, History or presence of an underlying CNS disorder such as a seizure disorder requiring current use of antiepileptic medications, cerebrovascular ischemia/hemorrhage within prior 6 months, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.\n\n8) Use of serotherapy with Campath or Anti-Thymocyte Globulin (ATG) within the last 28 days 9) Use of Donor Lymphocyte Infusion (DLI) or other cellular therapy product within 30 days 10) Acute GVHD \u2265 Grade 2 or moderate to severe (formerly extensive) chronic GVHD 11) Aministration of high dose steroids >1 mg/kg within the preceding 5 days or currently receiving > 0.25 mg/kg of Prednisone equivalent 12) Hyperleukocytosis (WBC \u226550K) or rapidly progressive disease that in the estimation of the investigator would compromise the ability of the patient to complete the study."
            },
            {
                  "document": "Inclusion Criteria:\n\nNewly diagnosed and pathologically-confirmed AML, confirmed by a bone marrow aspirate and/or biopsy and/or peripheral blood with >= 20% myeloid blasts. Bone marrow biopsy, or aspirate or peripheral blood that were obtained up to 3 weeks before signing consent are allowed for purposes of confirming AML diagnosis for eligibility purposes. Secondary AML (that is arising from prior myelodysplastic syndrome [MDS]/AML, therapy-related [t]-AML) are also allowed. AML arising from myeloproliferative neoplasms (MPN), MPN/MDS overlap (including chronic myelomonocytic leukemia [CMML]) or another malignancy are NOT allowed. Note 1: Patients must have evidence of bone marrow involvement on aspirate or biopsy. Patients with only extramedullary disease and no bone marrow involvement will be excluded. Note 2: Every effort should be made to get an aspirate for central flow assessment at screening and all subsequent required time points, but in cases where an aspirate cannot be collected-including dry taps-the patient will not be excluded and assessments will be performed on peripheral blood (PB) which should be collected at every time that bone marrow (BM) is collected. Note 3: Some patients with AML require initiation of therapy quickly after diagnosis, and full metaphase karyotype results in some centers can take 2-3 weeks to result. To avoid this issue being an impediment to accrual to study or to cause delays in initiation of therapy in patients who need fast initiation of therapy, we allow use of karyotype and/or fluorescence in situ hybridization (FISH) results (as well as FLT3 results) on samples from blood or marrow that were obtained up to 3 weeks before signing consent for purposes of eligibility and stratification. In any case, results from FISH or karyotype should show if CBF abnormalities are present by time of randomization as the presence of core-binding factor (CBF) abnormalities is a required stratification factor.\n\nAge > = 18 and =< 75 years\n\nBecause no dosing or AE data are currently available on the use of pembrolizumab (MK-3475) in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials\nEastern Cooperative Oncology Group (ECOG) performance status =< -2\nThe patient has to be eligible to receive intensive \"7+3\" induction chemotherapy as judged by the treating physician\nPrior use of hypomethylating agents (HMA), lenalidomide, erythropoiesis-stimulating agents (ESAs), and growth factors is allowed if used to treat prior MDS. AML must be previously untreated except as outlined below (hydroxyurea, or tretinoin [ATRA], or leukapheresis). Note: One dose of prophylactic intrathecal therapy is allowed during or before screening if a lumbar puncture is performed to rule out central nervous system (CNS) involvement.\nHydroxyurea/leukapheresis allowed for control of hyperleukocytosis but hydroxyurea must be discontinued day prior to start of chemotherapy\n\nCreatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (CrCl) >= 60 mL/min for patient with creatinine levels > 1.5 x institutional ULN (within 3 days prior to the first day of 7+3)\n\nCreatinine clearance (CrCl) should be calculated per institutional standard\nGlomerular filtration rate (GFR) can also be used in place of creatinine or CrCl\nTotal bilirubin =< 1.5 x ULN or direct bilirubin =< ULN for patients with total bilirubin levels > 1.5 x ULN (within 3 days prior to the first day of 7+3)\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN OR =< 5 x ULN for patients with liver metastases (within 3 days prior to the first day of 7+3)\nInternational normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (within 3 days prior to the first day of 7+3)\nActivated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 3 days prior to the first day of 7+3)\n\nPatients with a known history of being human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\n\nThey must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\nPatients must have an undetectable HIV viral load\nPatients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\nPatients who have undergone major surgery must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\nPatients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better\n\nFemale patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of 7+3 treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication. Male patients with female partners of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\n\nNOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient\nAbility to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible\n\nExclusion Criteria:\n\nPatients with a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. Prior treatment with the following are not allowed:\n\nPatients who have received anthracyclines for treatment of a prior, unrelated, curatively-treated malignancy which would limit their ability to receive 7 + 3 chemotherapy treatment on study\nAnti-PD-1, anti-PD-L1, or anti-PD-L2, for a prior, unrelated, curatively-treated malignancy, within last 3 months of enrollment in the study\nAnti-cancer monoclonal antibody (mAb) within 4 weeks, for a prior, unrelated, curatively-treated malignancy, prior to study registration or have not recovered (recovery defined as baseline or =< grade 1) from adverse events (AEs) due to agents administered more than 4 weeks earlier\nExperimental treatment within 4 weeks prior to study registration\nPatients who have had chemotherapy (except hydroxyurea and all trans retinoic acid [ATRA] which are allowed but have to be stopped the day before induction therapy starts), targeted small molecule therapy (aside from imatinib, dasatinib, or nilotinib), or curative-intent radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C), for a prior curatively treated malignancy, prior to entering the study\nPatients who have received prior anthracyclines not to exceed 150 mg/m^2 of daunorubicin or equivalent for treatment of a prior, unrelated, curatively-treated malignancy which would limit their ability to receive 7 + 3 chemotherapy treatment on study\nPatients with a cardiac ejection fraction less than 50% as determined by Echocardiogram or radionuclide ventriculogram scan (MUGA) scan.\n\nOther active primary malignancy (other than non-melanomatous skin cancer or carcinoma in situ of the cervix) requiring treatment or limiting expected survival to =< 2 years\n\nNOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy for their cancer)\n\nPatients who have FLT3-mutated AML\n\nFLT3-ITD or TKD mutations are defined as a mutation with a ratio of mutant to wild-type allele >= 0.05 or variant allele fraction of >= 5% by polymerase chain reaction (PCR) or next generation sequencing from either bone marrow or peripheral blood\nNote 1: FLT3, karyotype, or FISH results from bone marrow or peripheral blood that were performed up to 3 weeks before initiation of trial therapy are acceptable for eligibility determination or therapy stratification as long as they are performed in a Clinical Laboratory Improvement Act (CLIA) certified laboratory. Note 2: Patients are stratified based on age (younger than 65 verses (vs) 65 and older), presence of core-binding abnormalities by FISH or karyotype (yes/no), and by having t- AML or AML arising from prior/antecedent MDS (yes/no)\n\nPatients who have not recovered from AEs due to prior anti-cancer therapy (i.e., have not returned to baseline or have residual toxicities > grade 1) with the exception of =< grade 2 neuropathy and alopecia\n\nNOTE: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease\nPatients currently participating and receiving study therapy or have participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment are ineligible\nHistory of hypersensitivity to MK-3475 (pembrolizumab) or any of its excipients, or other agents used in this study\n\nCurrent use of corticosteroids\n\nEXCEPTION: Low doses of steroids (< 10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g., chronic adrenal insufficiency) is permitted\nPatients who underwent prior allogenic transplant\nPatients with a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) who are not on appropriate suppressive therapy\nPatient with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\nPatient with known active CNS disease and/or carcinomatous meningitis before study enrollment. Assessment of the cerebral spinal fluid (CSF) as per investigator judgement. Up to one dose of prophylactic intrathecal chemotherapy is allowed prior to study enrollment is not required to enroll in the study unless there is clinical suspicion for CNS involvement. However, if CSF assessment is performed for any reason, there should be no evidence of active leukemia in the CSF. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of protocol treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to protocol treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability\nPatients with active autoimmune disease except for patients with hypothyroidism and vitiligo that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\nPatients with a known history of non-infectious pneumonitis that required the use of steroids or current pneumonitis\nPatients with active infection requiring systemic therapy\nPatients with a known history of active TB (Bacillus tuberculosis)\nPatients with uncontrolled intercurrent illness\nPatients with psychiatric illness/social situations that would limit compliance with study requirements\nPregnant women are excluded from this study because MK-3475 (pembrolizumab) is humanized antibody with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MK-3475 (pembrolizumab), breastfeeding should be discontinued if the mother is treated with MK-3475 (pembrolizumab). These potential risks may also apply to other agents used in this study\n\nPatient who have received a live vaccine within 30 days of planned start of study therapy\n\nNOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed\nActive hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment. Patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participation\nPatients with clinically significant disseminated intravascular coagulation (DIC), which cannot be managed with supportive care including transfusions, as assessed by treating physician, will be excluded from study\nPatients with no bone marrow involvement will be excluded (i.e., those with only extramedullary disease)\nPatients with acute promyelocytic leukemia will be excluded"
            },
            {
                  "document": "Inclusion Criteria:\n\nEastern Cooperative Oncology Group performance status between 0-1\nCreatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance (Cockcroft and Gault ) > 30 mL/min (performed on plasma unless otherwise indicated)\nAlanine aminotransferase (ALT) =< 2.5 x ULN (performed on plasma unless otherwise indicated)\nDirect bilirubin < 1.5 mg/dL (performed on plasma unless otherwise indicated)\nLeft ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan performed within 28 days of enrollment\nDiagnosis of CD33+ acute myeloid leukemia (AML) with evidence of >= 5% myeloblasts in the bone marrow, peripheral blood, or in an extramedullary site by pathology. Any CD33 receptor expression level > 0.01% by institute flow cytometric analysis will suffice\n\nRelapsed or refractory disease, defined as:\n\nAny bone marrow relapse after allogeneic HSCT: subjects must be at least 1 month from HSCT at the time of screening and off immunosuppressive medication for at least 2 weeks at time of initial treatment (with the exception of low-dose steroids =< 20 mg prednisone equivalent) and have no active graft versus (vs.) host disease (GVHD)\nAML with no prior CR/CRi after at least 1 prior cycle of remission induction chemotherapy (i.e. cytarabine or hypomethylating based regimen(s) allowed)\nAML recurring after prior CR/CRi, which was achieved following at least one prior chemotherapy cycle (i.e. cytarabine or hypomethylating based regimen(s) allowed)\nPeripheral white blood cell (WBC) counts <25,000/mcL. Patients are allowed to receive hydroxyurea and/or leukapheresis to control and maintain WBC count prior to enrollment and can continue on hydroxyurea through Cycle 1 Day 28 or until first disease assessment\nParticipants of childbearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\nParticipant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia (APL, FAB M3) with t(15-17) and/or evidence of promyelocytic leukemia/retinoic acid receptor alpha (PML-RAR alpha)\nBlast phase of prior chronic phase chronic myeloid leukemia with t(9;22)\nReceipt of chemotherapy (except for hydroxyurea), radiotherapy, or investigational drug therapy within 2 weeks prior to treatment on study or those who have not recovered from adverse events due to agents administered > 2 weeks earlier\nKnown active central nervous system involvement; patients who have a history of central nervous system (CNS) disease which has been effectively treated as defined by at least one negative cerebrospinal sample prior to screening are eligible\n\nActive uncontrolled malignancy requiring ongoing chemotherapy and/or radiation. Examples of eligible patients include individuals with a prior history of malignancy treated with curative intent with no current evidence of active disease such as:\n\nSubjects with stage I breast cancer that has been completely and successfully treated, requiring no therapy or only anti-hormonal therapy\nSubjects with T1N0M0 or T2N0M0 colorectal cancer who have been completely and successfully resected and who are disease-free for > 2 years prior to screening\nSubjects with indolent prostate cancer, defined as clinical stage T1 or T2a, Gleason score =< 6, and prostate specific antigen (PSA) < 10 ng/mL, requiring no therapy or only anti-hormonal therapy\nSubjects with a history of basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix, fully resected, and with no evidence of active disease\nOther prior or concurrent malignancies will be considered on a case-by-case basis after discussion with the principal investigator (PI)\n\nUncontrolled current medical illness including, but not limited to:\n\nSevere cardiac disorder (symptomatic congestive heart failure requiring treatment, chronic unstable angina pectoris, myocardial infarction, cardiac arrhythmia, torsades de pointes,\nNeurologic impairment (cerebrovascular accident, transient ischemic attack)\nSevere pulmonary disorder (e.g. DLCO of 65% or less or a forced expiratory volume in 1 second [FEV1]) of 65% of less)\nModerate hepatic impairment with total bilirubin >1.5 x upper limit of normal (ULN),\nEastern Cooperative Oncology (ECOG ) Performance Status \u2265 2,\nAny other psychiatric illness/social situations that in the opinion of the investigator would limit compliance with study requirements\nKnown malabsorption syndrome or other condition that may impair the absorption of the study drug and/or inability and/or unwillingness to swallow capsules\nUncontrolled active systemic fungal, bacterial, viral, or other infection with patient still exhibiting ongoing signs and symptoms due to infection despite appropriate anti-infective therapy at time of screening\nPregnant or breastfeeding female participants\nKnown active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening which requires therapy\nPresence of grade II-IV acute or extensive chronic GVHD at time of screening\nUnwilling or unable to follow protocol requirements\nAny condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug including, but not limited to, medical, psychological, familial, social or geographical considerations"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatient must have AML with an IDH2 mutation identified from a peripheral blood or bone marrow sample at the time of diagnosis and/or relapsed/refractory disease\n\nPatient must have bone marrow assessment (aspiration or biopsy) with > 5% leukemic blasts by morphology and/or flow cytometry in at least one of the following clinical scenarios:\n\nSecond or greater relapse after chemotherapy or hematopoietic stem cell transplant (HSCT)\nRefractory after >= 2 attempts at induction therapy\n\nRelapsed patients\n\nMust not have received prior re-induction therapy for this relapse\nEach block of chemotherapy (i.e., cytarabine, daunorubicin and etoposide [ADE], cytarabine and mitoxantrone [MA]) is a separate re-induction attempt\nDonor lymphocyte infusion (DLI) is considered a re-induction attempt\n\nRefractory patients\n\nEach attempt at induction therapy may include up to two chemotherapy courses\nKarnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score\nPatient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life\nEvaluation of cerebrospinal fluid (CSF) is only required if there is a clinical suspicion of central nervous system (CNS) involvement by leukemia during eligibility screening. Should a patient be found to have CNS2 or CNS3 status by CSF prior to eligibility screening, patient may receive intrathecal chemotherapy > 72 hours prior to starting study drug. CNS1 status must be established before starting study drug\n\nPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, e.g., blood count criteria, the patient is considered to have recovered adequately\n\nCytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive. The duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment\n\n>= 14 days must have elapsed after the completion of other cytotoxic therapy with the exception of hydroxyurea. Additionally, patients must have fully recovered from all acute toxic effects of prior therapy. NOTE: Cytoreduction with hydroxyurea must be discontinued >= 24 hours prior to the start of protocol therapy\nIntrathecal chemotherapy must be completed >= 72 hours prior to the start of the first cycle of treatment\nAnti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent. The duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment\nAntibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1\nCorticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\nHematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study research coordinator\nInterleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)\n\nStem cell Infusions (with or without total body irradiation [TBI]):\n\nAllogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including DLI or boost infusion:\n\n>= 60 days after infusion for bone marrow or stem cell transplant and\n>= 4 weeks after infusion for any stem cell infusion including DLI or boost infusion\nThere must be no evidence of graft versus host disease (GVHD)\nAutologous stem cell infusion including boost infusion: >= 42 days\nCellular Therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)\nXRT/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation\nRadiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-metaiodobenzylguanidine [MIBG]): >= 42 days after systemically administered radiopharmaceutical therapy\nStudy-specific limitations on prior therapy: small molecule investigational agents: >= 14 days or > 5 half-lives must have elapsed from the last dose of the agent, whichever is greater\nPlatelet count >= 20,000/mm^3 (may receive platelet transfusions). These patients must not be known to be refractory to red cell or platelet transfusion\nHemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)\n\nCreatinine clearance or radioisotope glomerular filtration rate [GFR] >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\n\nAge: Maximum serum creatinine (mg/dL)\n\n2 to < 6 years: 0.8 (male and female)\n6 to < 10 years: 1 (male and female)\n10 to < 13 years: 1.2 (male and female)\n13 to < 16 years: 1.5 (male); 1.4 (female\n>= 16 years: 1.7 (male); 1.4 (female)\nBilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age\nSerum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 225 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L\nSerum albumin >= 2 g/dL\nLeft ventricular ejection fraction of >= 50% by echocardiogram\n\nRegulatory Requirements\n\nAll patients and/or their parents or legal authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines\nAll institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\n\nExclusion Criteria:\n\nAML associated with Down syndrome or t(15;17) is not eligible for study\nPregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy and for 4 months after the last dose of enasidenib. Abstinence is an acceptable method of birth control. It is not known if enasidenib is present in breast milk. Breastfeeding is not recommended during therapy or for at least 30 days after the last dose of enasidenib\n\nConcomitant Medications:\n\nCorticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible. If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid. The use of corticosteroids to manage the side effect of IDH inhibitor-associated differentiation syndrome (IDH-DS), is permitted on study\nInvestigational drugs: Patients who are currently receiving another investigational drug are not eligible\nAnti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy; the use of hydroxyurea to manage the side effect of IDH-DS, is permitted on study)\nAnti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\n\nPatients must be able to swallow intact tablets whole.\n\nPatients with known hypersensitivity to any of the components of enasidenib are not eligible.\nPatients with prior exposure to enasidenib or another IDH2 inhibitor are not eligible.\n\nPatients taking the following drugs will be excluded from study entry unless these drugs are discontinued or patients are transferred to a medically acceptable alternative > 5 half-lives before the first dose of enasidenib.\n\nDrugs with a narrow therapeutic range that are sensitive substrates of the following cytochrome P450 (CYP) enzymes: CYP2C8 (e.g. paclitaxel), 2C9 (e.g. phenytoin and warfarin), 2C19 (e.g. s-mephenytoin), 2D6 (e.g. thioridazine), and 1A2 (e.g. theophylline and tizanidine).\nBreast cancer resistant protein (BCRP) transporter-sensitive substrate rosuvastatin\n\nPatients with the following leukemia complications are not eligible for this trial:\n\nNo intrathecal chemotherapy is permitted on study. Prior to study enrollment, cerebrospinal fluid (CSF) evaluation is only required if there is a clinical suspicion for CNS leukemia. Clinical signs of CNS leukemia (such as facial nerve palsy, brain/eye involvement or hypothalamic syndrome) are not eligible for this trial\nImmediately life-threatening, severe complications of leukemia including uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation\nInfection: Patients who have an uncontrolled infection or patients with known human immunodeficiency virus (HIV) or active hepatitis B or C are not eligible\nPatients who have received a prior solid organ transplantation are not eligible\nPatients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of untreated \"high-grade\" myeloid neoplasm (>=10% blasts in blood or bone marrow) or AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2016 World Health Organization (WHO) classification. Outside diagnostic material is acceptable to establish diagnosis; submission of peripheral blood specimen for flow cytometry performed at the study institution should be considered. Diagnostic material must have been submitted for cytogenetic and/or molecular testing as clinically appropriate\nTreatment-related mortality (TRM) score >= 13.1 as calculated with simplified model\nThe use of hydroxyurea before enrollment is permitted; hydroxyurea should be discontinued prior to start of study treatment. Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL or with concern for other complications of high tumor burden or leukostasis (e.g. hypoxia, disseminated intravascular coagulation) can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2) any time prior to enrollment\nPatients may have received low-intensity treatment (e.g. azacitidine/decitabine, lenalidomide, growth factors) for antecedent low-grade myeloid neoplasm (i.e. < 10% blasts in blood and bone marrow)\nBilirubin < 2.0 mg/mL unless elevation is thought to be due to hepatic infiltration by neoplastic cells, Gilbert's syndrome, or hemolysis (assessed within 14 days prior to study day 0)\nLeft ventricular ejection fraction (LVEF) >= 45%, assessed within 12 months prior to registration, e.g. by multigated acquisition scan (MUGA) scan or echocardiography or another appropriate diagnostic modality\nWomen of childbearing potential and men must agree to use adequate contraception beginning at the signing of the consent until at least 4 weeks after the last dose of study drug\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nMyeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatment\nConcomitant illness associated with a likely survival of < 1 year\nActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable. Patients with fever thought to be likely secondary to leukemia are eligible\nKnown hypersensitivity to any study drug used in this trial\nPregnancy or active breast feeding\nConcurrent treatment with any other approved or investigational anti-leukemia agent. Treatment with a FLT3-inhibitor for FLT3-mutated AML is permissible"
            },
            {
                  "document": "Inclusion Criteria:\n\nAcute leukemia (AL) that includes acute myeloid leukemia (AML) / acute lymphoblastic leukemia (ALL) / mixed phenotype leukemia (MPAL) in complete morphological remission (CR) with or without detectable minimal residual disease (MRD); complete morphological remission is defined by the presence of less than 5% of detectable blasts in bone marrow specimen, evaluated no earlier than one month before conditioning regimen start. Patients with documented CR but without hematologic recovery since last chemotherapy are considered eligible to the study\nChronic myelogenous leukemia (CML), except refractory blast crisis. To be eligible in first chronic phase, patients must have failed or be intolerant to at least one tyrosine-kinase inhibitor\nChronic myelomonocytic leukemia (CMML)\nMyelodysplastic syndromes (MDS)\n\nLymphoblastic, Burkitt's and other high-grade lymphoma in any complete (CR) or partial (PR) response\n\nCR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\n\nLow grade lymphoma (chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL], marginal zone lymphoma, follicular lymphoma) progressed after two treatment regimens, in CR/PR\n\nFor CLL/SLL, CR and PR are defined according to: International Workshop on CLL (iwCLL) guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL\nCR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\n\nLarge cell lymphoma in > second CR (CR2)/ >= PR2\n\nCR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\n\nMantle cell lymphoma, lymphoplasmacytic lymphoma and prolymphocytic leukemia may be eligible after initial therapy if in CR/PR\n\nCR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\nFor prolymphocytic leukemia (PLL), CR is defined as a normalization of lymphadenopathies (long-axis diameter < 1 cm) and splenomegaly (< 13 cm), absence of constitutional symptoms, PLL cells < 5% in bone marrow and circulating lymphocytes count < 4 x 10^9/L. Patients without hematopoietic recovery are considered eligible to the study. PR is defined as a decrease of >= 30% of the sum of lymphadenopathies' long-axis diameters, a decrease of >= 50% in spleen vertical length beyond normal from baseline, peripheral blood (PB) lymphocytes =< 30 x 10^9/L (and a decrease of >= 50% from baseline)\n\nHodgkin Lymphoma in > CR2/PR2\n\nCR and PR are defined according to Lugano classification: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification\nSubjects must be >= 6 months old\nKarnofsky >= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1 (for adults)\nLansky score >= 50 (for children)\nAdequate cardiac function defined as absence of decompensated congestive heart failure or uncontrolled arrhythmia AND left ventricular ejection fraction >= 40% or shortening fraction > 22%\n\nAdequate pulmonary function defined as absence of oxygen (O2) requirements and one of the following:\n\nDiffusion capacity of the lung for carbon monoxide (DLCO) corrected >= 70% mm Hg\nDLCO corrected between 60% - 69% mm Hg and partial pressure of oxygen (pO2) >= 70 mm Hg\nDLCO corrected between 50% - 59% mm Hg and pO2 >= 80 mm Hg Pediatric patients unable to perform pulmonary function tests must have O2 saturation >= 92% on room air. May not be on supplemental oxygen\nTotal bilirubin < 2 x upper limit of normal (ULN) unless felt to be related to Gilbert's disease or hemolysis\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN\nAlkaline phosphatase =< 5 x ULN\n\nCreatinine < 2.0 mg/dl (adults) or estimated creatinine clearance > 40 ml/min (pediatrics)\n\nAll adults with a creatinine > 1.2 or a history of renal dysfunction must have estimated creatinine clearance > 40 ml/min\nIf recent mold infection, e.g., aspergillus, must be cleared by infectious disease to proceed\nPatients who have undergone prior allogeneic hematopoietic cell transplant are eligible, but the prior transplant must have been performed at least 3 months prior to enrollment, unless in case of graft failure from the prior transplant\nWritten and signed informed consent\nDONOR: Donors must be haploidentical relatives of the patients. Donor-recipient compatibility will be tested through HLA typing at high resolution for the HLA loci (-A, -B, -C, -DRB1, -DQB1). Donor and recipient should share at least 5/10 HLA loci\nDONOR: Age >= 12 years\nDONOR: Weight >= 40 Kg\nDONOR: Ability of donors younger than 18 years of age to undergo apheresis without use of a vascular access device. Vein check must be performed and verified by an apheresis nurse prior to arrival at the Seattle Cancer Care Alliance (SCCA)\nDONOR: Donor must meet selection criteria as defined by the Foundation of the Accreditation of Cell Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB) guidelines\n\nDONOR: In case of more available haploidentical donors, selection criteria should include, in this order:\n\nFor cytomegalovirus (CMV) seronegative recipients, a CMV seronegative donor\n\nRed blood cell compatibility\n\nRed blood cell (RBC) cross match compatible\nMinor ABO incompatibility\nMajor ABO incompatibility\n\nExclusion Criteria:\n\nActive, uncontrolled, life-threatening viral, bacterial or fungal infection requiring treatment at time of conditioning regiment administration and transplantation\nPresence of a malignancy other than the one for which the transplant is being performed, with an expected survival less than 75% at 5 years\nPregnant or breastfeeding\nKnown hypersensitivity to treosulfan, fludarabine or cyclophosphamide\nDosing with another investigational agent within 30 days prior to entry in the study\nCentral nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and/or cranial radiation prior to initiation of conditioning (day -6)\nDONOR: Since detection of anti-donor-specific-antigen antibodies (anti-DSA) is associated with higher graft rejection rate, patients will be screened for anti-DSA pre-transplant. Patients with DSA will be reviewed by the principal investigator and considered for desensitization treatment."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge \u2265 55 years or HCT Co-Morbidity score (HCT-CI) >/=3\nLack of a suitable 8/8 HLA-matched sibling donor\nAdequate performance status is defined as Karnofsky score \u2265 70%\nPatients and selected donor must be HLA typed at high resolution using DNA based typing at the following HLA-loci: HLA-A, -B, -C and DRB1. Donors must be HLA-haploidentical relatives including, but not limited to, children, siblings, or parents, defined as having a shared HLA haplotype between donor and patient at HLA-A, -B, -C, and -DRB1.\nAcute Myeloid Leukemia (AML): Must be in remission with morphology (<5% blasts)\nAcute Lymphoblastic Leukemia (ALL)/lymphoma second or greater complete remission (CR) first CR unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities, first CR high-risk ALL\nBiphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR\nMyelodysplastic syndrome: any subtype including refractory anemia (RA) if severe pancytopenia or complex cytogenetics. Blasts must be less than 5%. If 5% of more requires chemotherapy for cytoreduction to </=5% prior to transplantation.\nChronic Myelogenous leukemia in accelerated phase: patient must have failed at least two different Tyrosine Kinase Inhibitor (TKI)s, been intolerant to all TKIs, or have T315l mutation\nMyeloproliferative neoplasms/myelofibrosis: Blasts must be less than 5%. If 5% or more requires chemotherapy for cytoreduction to </=5% prior to transplantation\nRelapsed large-cell lymphoma, mantle-cell lymphoma or Hodgkin lymphoma that is chemotherapy sensitive and has failed or ineligible for an autologous transplant\nBurkitt's lymphoma in second CR or subsequent CR\nRelapsed T-cell lymphoma that is chemotherapy sensitive in CR/Partial Response (PR) that has failed or ineligible for an autologous transplant\nNatural killer cell malignancies\nRelapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma with any of the following:\nProgressed within 12 months of achieving a partial or complete remission Patients who had remissions lasting up\nPatients who had remission lasting > 12 months are eligible after at least two prior therapies\nPatients with primary, refractory disease. Bulky disease and an estimated tumor doubling time of less than one month require debulking therapy prior to transplant.\nLymphoplasmacytic lymphoma is eligible after initial therapy if chemotherapy sensitive\nAdequate organ function as defined per protocol\nSexually active females of child bearing potential and males with partners of child bearing potential must agree to use adequate birth control during study treatment\n\nExclusion Criteria:\n\nPregnant or breastfeeding\nUntreated active infection\nActive HIV infection\nPrior allogenic transplant at any time prior or less than 6 months since prior autologous transplant (if applicable)\nActive central nervous system malignancy\nFavorable risk AML defined as per protocol\nActive central nervous system malignancy\nFavorable risk AML defined as having one of the following:\nt(8,21) without cKIT mutation or evidence of immunophenotypic, cytogenetic or molecular minimal residual disease (MRD)\ninv(16) or t(16;16) without cKIT mutation or evidence of MRD\nNormal karyotype with mutated NPM1 but FLT3-ITD wild type without evidence of MRD\nNormal karyatype with double mutated CEBPA without evidence of MRD"
            },
            {
                  "document": "Inclusion Criteria:\n\nNewly diagnosed and previously untreated AML (except acute promyelocytic leukemia [APL]) (>= 20% blasts in bone marrow or extramedullary leukemia) according to the World Health Organization (WHO), 2016 criteria. Note that patients who have received treatment with hypomethylating agents alone or in combination with venetoclax, ivosidenib or enasidenib for myelodysplastic syndrome (MDS) and have now transformed to AML are eligible.\nEligible patients must show evidence of wild-type (WT) p53 as assessed by deoxyribonucleic acid (DNA) sequencing before initiation of KRT-232 (AMG 232).\nPatients must be considered candidates for intensive chemotherapy treatment with standard doses of cytarabine and idarubicin (\"7+3 regimen\").\nLeft ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram or radionuclide angiography.\nAll non-hematological adverse events of any prior chemotherapy, surgery, or radiotherapy, except alopecia, must have resolved to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade =< 2 prior to starting therapy.\nPatient must be willing to submit the blood sampling and bone marrow sampling for the PK and PD analyses and exploratory biomarkers.\nEastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%).\nProthrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN), OR international normalized ratio (INR) < 1.5.\nTotal bilirubin =< 2 mg/dl, unless from hemolysis, Gilbert's syndrome or liver infiltration with leukemia.\nAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional ULN (=< 5 x ULN if liver infiltration with leukemia).\nAlkaline phosphatase (ALP) < 2.0 x ULN (if liver or bone metastases are present, < 3.0 x ULN)\nCreatinine within reference laboratory ranges OR glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2 (by the Cockcroft Gault equation), with normalization to the patient's body surface area.\nHuman immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\nPatients with known leukemic involvement of the central nervous system (CNS) are eligible if, in the opinion of the treating physician, they are eligible for induction chemotherapy. These patients can receive the intrathecal treatment concurrently with the study treatment on protocol.\nPatients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\nThe effects of KRT-232 (AMG 232) on the developing human fetus are unknown. For this reason and because MDM2 inhibiting agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation through 5 weeks (women) after receiving the last dose of KRT-232 (AMG 232). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of KRT-232 (AMG 232) administration. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug. Adequate methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women).\nFemale patients with child-bearing potential must have a negative serum pregnancy test within 72 hours prior to the first study drug administration.\nAbility to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible.\n\nExclusion Criteria:\n\nPatients with evidence of p53 mutation or deletion (e.g. chromosome 17p deletion).\nPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 2) with the exception of alopecia.\nPatients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug with the exception of: Hydroxyurea (HU) in patients who need to continue this agent to maintain white blood cell (WBC) count =< 50,000/mm^3.\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to KRT-232 (AMG 232) or other agents used in study.\nPatients with uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia; patients receiving an anti-microbial agent may be eligible if the patient remains hemodynamically stable for 72 hours; patients with myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association [NYHA] class III and higher), unstable angina, or cardiac arrhythmia requiring medication are excluded.\nPatients with psychiatric illness/social situations that would limit compliance with study requirements.\nPregnant women are excluded from this study because KRT-232 (AMG 232) is an MDM2 inhibiting agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with KRT-232 (AMG 232), breastfeeding should be discontinued if the mother is treated with KRT-232 (AMG 232). These potential risks may also apply to other agents used in this study.\nPatients with reproductive potential not willing to use effective methods of contraception.\nPatients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis).\nPatients with history of bleeding diathesis.\nPositive hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B), positive hepatitis total core antibody with negative HBsAG (suggestive of occult hepatitis B), or detectable hepatitis C virus ribonucleic acid (RNA) by a polymerase-chain reaction (PCR) assay (indicative of active hepatitis C - screening is generally done by hepatitis C antibody [HepCAb], followed by hepatitis C virus RNA by PCR if HepCAb is positive).\nAll herbal medicines (e.g., St. John's wort), vitamins, and supplements consumed by the subject within the 30 days prior to receiving the first dose of AMG 232, and continuing use, if applicable, will be reviewed by the principal investigator. Patients may continue to take all herbal medicines (e.g., St. John's wort), vitamins, and supplements if approved by the principal investigator.\nUse of any known CYP3A4 substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfanide) within the 14 days prior to receiving the first dose of AMG 232 is not permitted. Other medications (such as fentanyl and oxycodone) may be allowed per investigator's assessment/evaluation. Use of any known CYP2C8 substrates with a narrow therapeutic window within the 14 days prior to receiving the first dose of KRT-232 (AMG 232) is not permitted.\nUse of any medications considered inhibitors or substrates of UGT1A1, or inhibitors or inducers of P-glycoprotein (gp) are not permitted. Caution should be used with concomitant antacids or proton pump inhibitor (PPI) products.\nMajor surgery within 28 days of study day 1.\nCurrent use of warfarin, factor Xa inhibitors and direct thrombin inhibitors. Note: Low molecular weight heparin and prophylactic low dose warfarin are permitted. PT/PTT must meet the inclusion criteria. Subjects taking warfarin must have their INR followed closely."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with Philadelphia (Ph)+ acute myeloid leukemia (AML) or myeloid accelerated phase (AP)-chronic myelogenous leukemia (CML) or blast phase (BP)-CML (either t[9;22] and/or BCR-ABL1 positive by fluorescent in situ hybridization or polymerase chain reaction). Both untreated and relapsed/refractory patients are eligible\nPerformance status =< 3 (Eastern Cooperative Oncology Group [ECOG] scale)\nTotal serum bilirubin =< 2 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the principal investigator (PI)\nAlanine aminotransferase (ALT) =< 1.5 x ULN, unless due to the underlying leukemia approved by the PI\nAspartate aminotransferase (AST) =< 1.5 x ULN unless due to the underlying leukemia approved by the PI\nCreatinine clearance >= 30 mL/min\nSerum lipase =< 1.5 x ULN\nAmylase =< 1.5 x ULN\nAbility to swallow\nSigned informed consent\n\nExclusion Criteria:\n\nActive serious infection not controlled by oral or intravenous antibiotics (e.g. persistent fever or lack of improvement despite antimicrobial treatment)\nHistory of acute pancreatitis within 6 months of study or history of chronic pancreatitis\nUncontrolled hypertriglyceridemia (triglycerides > 450 mg/dL)\nActive secondary malignancy that in the investigator's opinion will shorten survival to less than 1 year\nActive grade III-V cardiac failure as defined by the New York Heart Association criteria\n\nClinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:\n\nMyocardial infarction (MI), stroke, revascularization, unstable angina or transient ischemic attack within 6 months\nLeft ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards prior to enrollment\nDiagnosed or suspected congenital long QT syndrome\nClinically significant atrial or ventricular arrhythmias (such as uncontrolled, clinically significant atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or torsades de pointes) as determined by the treating physician\nProlonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 480 msec) unless corrected after electrolyte replacement\nHistory of venous thromboembolism including deep venous thrombosis or pulmonary embolism within the past 3 months, excluding line-associated deep venous thrombosis (DVT) of the upper extremity\nUncontrolled hypertension (diastolic blood pressure > 100 mmHg; systolic > 150 mmHg)\nConsumed grapefruit, grapefruit products, Seville oranges, or star fruit within 3 days prior to starting venetoclax\nTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator. Prior recent treatment with corticosteroids, hydroxyurea, or a Food and Drug Administration (FDA)-approved BCR-ABL tyrosine kinase inhibitor (TKI) is permitted\nPregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception throughout the study period. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control"
            },
            {
                  "document": "Inclusion Criteria:\n\nAble to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before the first study-specific procedure.\n\nMen or women \u226518 years with one of the following conditions that is relapsed or refractory to at least one line of therapy:\n\nAcute myeloid leukemia as long as with myeloblast percentage in the marrow is \u2264 30% or the peripheral white blood cell count is less than 20,000 cells/\u03bcL in the absence of leukoreducing therapy (e.g., hydroxyurea, leukapheresis)\nMDS classified as intermediate, high, or very high risk by International Prognostic Scoring System-Revised [IPSS-R] criteria\nCMML classified as intermediate-2 or high risk per CMML-specific prognostic scoring system (CPSS) or clinical/molecular CPSS (CPSS-mol) criteria\nECOG performance status of 0, 1, or 2\n\nAdequate organ function at screening defined as follows [reasonably minor changes pre-first dose are acceptable if deemed so by the investigator]:\n\na) Hepatic:\n\nTotal bilirubin \u22642 \u00d7 upper limit of normal (ULN); isolated bilirubin > 2 is acceptable if participant has a diagnosis of Gilbert's syndrome\n\nAspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT) \u22643 \u00d7 ULN.\n\nb) Renal:\n\nestimated glomerular filtration rate (by CKD-EPI method) \u2265 40 mL/min/1.73 m2 c) Cardiac:\nLeft ventricular ejection fraction greater than 45% or the institutional lower limit of normal by either ECHO or MUGA at entry.\nPatients must have recovered to grade 1 or less from prior toxicity or adverse events (exception of myelosuppression - neutropenia, anemia, thrombocytopenia - and alopecia). Note: Participants with treatment-related toxicities that are unlikely to resolve per the investigator may be enrolled on a case-by-case basis after discussion with the medical monitor\nPatients must have completed any chemotherapy, radiation therapy, or biologic therapy specific to their myeloid neoplasm \u2265 2 weeks or 5 half-lives (whichever is longer)\nAble to swallow, retain, and absorb orally administered medication\nExpected life \u2265 4 months\n\nParticipants with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed if all of the following are met:\n\n90 days or more have elapsed from the time of transplant\nsubject has been off systemic immunosuppressive medications (including but not limited to: cyclosporine, tacrolimus, mycophenolate mofetil, or corticosteroids) for at least 30 days prior to the first dose of NTX-301. Topical steroids are permitted\nno signs or symptoms of acute graft versus host disease, other than Grade 1 skin involvement.\nthere are no signs or symptoms of chronic graft versus host disease requiring systemic therapy\nWomen of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG], CTFG 2014) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. A woman is considered of childbearing potential (ie, fertile) following menarche and until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.\nSubjects and their partners with reproductive potential must agree to use 2 highly effective contraceptive measures during the study and must agree not to become pregnant or father a child for 3 months after the last dose of study treatment. Contraceptive measures that may be considered highly effective comprise combined hormonal contraception (oral, vaginal, or transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence, and surgically successful vasectomy. Abstinence is acceptable only if it is consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of birth control.\n\nExclusion Criteria:\n\nDiagnosis or presence of any of the following:\n\nacute promyelocytic leukemia\ncore-binding factor AML in first relapse\nextramedullary leukemia\nsymptomatic or untreated Central Nervous System (CNS) disease [note that lumbar puncture (LP) is not required for study enrollment unless there is clinical suspicion for CNS disease; patients with history of CNS disease are permitted to enroll if they have previously received appropriate therapy and CNS remission has been; participants on maintenance intrathecal chemotherapy may be enrolled and continue to receive therapy]\nPatients who are receiving any other investigational agents.\nPregnant women and women who are breastfeeding are excluded from this study.\n\nPatients with clinically significant illnesses which would compromise participation in the study, including, but not limited to:\n\nsevere or uncontrolled infection\nknown HIV infection requiring protease inhibitor therapy\nknown Hepatitis B; defined as presence of hepatitis B surface antigen (HBsAg)\nknown Hepatitis C; if Hepatitis C antibody is positive, then this is defined as positive Hepatitis C RNA polymerase chain reaction (PCR) (or comparable test)\nuncontrolled diabetes and/or hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator\nMalabsorption syndrome or other conditions that would interfere with intestinal absorption.\nHistory of a second malignancy, excluding non-melanoma skin cell cancer, within the last three years. Participants with second malignancies that were indolent, in situ or definitively treated may be enrolled even if less than three years have elapsed since treatment. Consult the monitor if there are any queries.\nHistory of prior solid organ transplant\nHistory of prior sensitivity reaction to any cytidine derivates"
            },
            {
                  "document": "Inclusion Criteria (main):\n\nThe patient must not be eligible for standard of care therapy and have one of the following hematological malignancy:\n\nA confirmed relapsed or refractory acute AML (i.e. \u2265 5% blasts in bone marrow or in peripheral blood) with revised European LeukemiaNet (ELN) 2017 risk stratification for favorable, intermediate or adverse groups, after at least one prior therapy defined as either\n\nRecurrence of disease after a first complete remission and not eligible for a second course of induction therapy, or\nRecurrence of disease after a second complete remission, or\nFailure to achieve a Complete Response after induction chemotherapy.\n\nA confirmed MDS as defined by revised International Prognostic Scoring System criteria for intermediate, high-risk or very high-risk disease or MDS with Tumor Protein 53 mutation as detected by next-generation sequencing, after failure of prior treatment with at least 4 cycles of azacitidine or decitabine defined as:\n\nNo response to treatment,\nLoss of response at any time point, or\nIntolerance to therapy.\n\nThe patient must have evaluable disease as defined by:\n\nRevised Recommendations of the International Working Group (IWG) for Diagnosis, Standardization of Response Criteria for AML patients,\nIWG 2006 Uniform Response Criteria for patients with MDS.\nThe absolute peripheral blast count should be < 15,000/L.\nThe patient must have adequate hepatic and renal functions, as assessed by standard laboratory criteria.\nThe patient must have a left ventricular ejection fraction of \u2265 40 %, as determined by echocardiography or a multigated acquisition scan.\nThe patient must have a Forced Expiratory Volume (FEV) in the first second /Forced Vital Capacity = 0.7 with FEV-1 at 50 % predicted (GOLD 1 or 2 severity) as determined by spirometry\n\nExclusion Criteria (main):\n\nPatients with a confirmed or history of tumor involvement in the central nervous system\nPatients who have received any cancer therapy with therapeutic intent (investigational agent or not)\nPatients with any positive serology test results at baseline\nPatients who plan to receive, are concurrently receiving or have received any investigational agent within 3 weeks before the planned day for the first CYAD-02 infusion\nPatients with uncontrolled intercurrent illness or serious uncontrolled medical disorder\nPatients with significant coagulation disorder or who are receiving treatment with warfarin derivatives, heparin or direct oral anticoagulants\nPatients who have active infections\nPatients with documented history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis and/or active or acute exacerbation of chronic obstructive pulmonary disease"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must be at least 18 years old for Part 1 and, at least 12 years old for Part 2.\nParticipant must be diagnosed with Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria (2017) and either be planning for allogeneic stem cell transplantation or have received allogeneic stem cell transplantation within the past 30 days.\nBlast percentage in bone marrow before transplant must be < 10%.\nBlast count in peripheral blood must be \"0\" and Blast percentage in bone marrow must be < 5% after transplant.\nParticipant meet adequate renal, hepatic and hematologic criteria as described in the protocol.\nParticipants >= 17 years old must have a Karnofsky Performance Scale (KPS) score > 50 and participants between 12 to 16 years old must have a Lansky Play Performance Scale score > 40.\n\nExclusion Criteria:\n\nHistory of disease progression during prior treatment with venetoclax.\nHistory of any other malignancy within 2 years prior to study entry, except for: Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; Myelodysplastic Syndrome, Myeloproliferative neoplasm (only allowed if it transformed to AML and AML should be the indication for marrow transplantation).\nParticipant has known infection with HIV or history of being positive for hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\nPresence of clinical or laboratory symptoms/signs of extramedullary myeloid malignancy."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must weigh >/= 17 kg\n\nWeight limit is due to constraints related to the concentration of the current drug formulation. If a new formulation of flotetuzumab becomes available to allow dosing of smaller patients, the protocol will be amended\nPatients with recurrent or refractory AML are eligible. Patients must have histologic verification of malignancy at relapse\n\nPatients with leukemia must have >/= M2 marrow by morphology and/or flow cytometry and one of the following:\n\nSecond or greater relapse\nRefractory after 2 or more chemotherapy cycles\nFirst relapse after primary chemotherapy-refractory disease\nFirst relapse after hematopoietic stem cell transplantation (HSCT)\n\nCentral nervous system (CNS) disease:\n\nPatients must have the status of CNS1 and no clinical signs or neurologic symptoms suggestive of CNS leukemia, such as cranial palsy.\nPatients with CNS3 or CNS2 status may receive antecedent intrathecal chemotherapy to achieve CNS1 status prior to study entry.\nPatients with a history of CNS chloromatous disease are required to have no radiographic evidence of disease prior to enrollment.\nPatient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.\nPatients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =/< 16 years of age. Use appropriate score for study population. NOTE: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n\nPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, e.g., blood count criteria, the patient is considered to have recovered adequately.\n\nCytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive.\n\n>/= 14 days must have elapsed after the completion of other cytotoxic therapy with the exception of hydroxyurea. Additionally, patients must have fully recovered from all acute toxic effects of prior therapy.\n\nNOTE: Cytoreduction with hydroxyurea is recommended to be discontinued >/= 24 hours prior to the start of protocol therapy. No waiting period is required for patients having received intrathecal cytarabine, methotrexate, and/or hydrocortisone.\nAnti-cancer agents not known to be myelosuppressive (e.g., not associated with reduced platelet or absolute neutrophil count [ANC] counts): >/= 7 days after the last dose of agent.\nAntibodies: >/= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =/< 1.\nCorticosteroids: If used to modify immune adverse events related to prior therapy, >/= 14 days must have elapsed since last dose of corticosteroid.\nHematopoietic growth factors: >/= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study-assigned research coordinator.\nInterleukins, interferons and cytokines (other than hematopoietic growth factors): >/= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors).\n\nStem cell infusions (with or without total body irradiation [TBI]):\n\nAllogeneic (non-autologous) bone marrow or stem cell transplant, or stem cell boost: >/= 84 days after infusion and no evidence of graft versus host disease (GVHD)\nDonor leukocyte infusion: >/= 42 days\nAutologous stem cell infusion including boost infusion: >/= 42 days\nCellular therapy: >/= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)\nRadiation therapy (XRT)/external beam irradiation including protons: >/= 14 days after local XRT; >/= 84 days after TBI, craniospinal XRT or if radiation to >/= 50% of the pelvis; >/= 42 days if other substantial bone marrow (BM) radiation\nRadiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >/= 42 days after systemically administered radiopharmaceutical therapy\nPatients must not have received prior exposure to flotetuzumab.\n\nPlatelet count >/= 20,000/mm^3 (may receive platelet transfusions)\n\nThese patients must not be known to be refractory to red cell or platelet transfusion\n\nHemoglobin >/= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)\n\nThese patients must not be known to be refractory to red cell or platelet transfusion.\nCreatinine clearance or radioisotope glomerular filtration rate (GFR) >/= 70 ml/min/1.73 m^2 or\n\nA serum creatinine based on age/gender as follows:\n\nAge: Maximum serum creatinine (mg/dL)\n\n1 to < 2 years: male - 0.6; female - 0.6\n2 to < 6 years: male - 0.8; female - 0.8\n6 to < 10 years: male - 1; female - 1\n10 to < 13 years: male - 1.2; female - 1.2\n13 to < 16 years: male - 1.5; female - 1.4\n>/= 16 years: male - 1.7; female - 1.4\nBilirubin (sum of conjugated + unconjugated) =/< 1.5 x upper limit of normal (ULN) for age regardless of baseline\nSerum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =/< 3 x ULN. For the purpose of this study, the ULN for SGPT is 45 U/L regardless of baseline.\nSerum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST/< 3 x ULN. For the purpose of this study, the ULN for SGPT is 50 U/L regardless of baseline.\nSerum albumin >/= 2 g/dL\nShortening fraction of >/= 27% by echocardiogram, or\nEjection fraction of >/= 50% by gated radionuclide study\nPatients with seizure disorder may be enrolled if on anticonvulsants and well controlled\nNervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5) resulting from prior therapy must be =/< grade 2 with the exception of decreased tendon reflex (DTR). Any grade of DTR is eligible.\nAll patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.\nPermanent central access should be established with a central line. A central line that contains 2 lumens is preferred\n\nExclusion Criteria:\n\nPregnant or breast-feeding women will not be entered on this study because there is yet no available information regarding human fetal or teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy and for 12 weeks after flotetuzumab discontinuation.\nPatients must be off steroids (unless physiologic replacement dosing) for at least 7 days prior to enrollment. If used to modify immune adverse events related to prior therapy, >/= 14 days must have elapsed since last dose of corticosteroid.\nPatients who are currently receiving another investigational drug are not eligible.\nPatients who are currently receiving other anti-cancer agents are not eligible (except hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy).\nPatients who are receiving cyclosporine, tacrolimus or other agents to treat graft-versus-host disease post bone marrow transplant are not eligible for this trial.\nPatient has French-American-British classification (FAB) type M3 leukemia (acute promyelocytic leukemia) or identification of t(15;17).\nPatient has isolated CNS involvement or isolated extramedullary relapse.\nPatient with known human immunodeficiency virus (HIV) infection are eligible if he or she has a negative HIV serology and an undetectable viral load.\nPatient known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down syndrome ARE eligible for the study.\nPatients must not weigh < 17 kg.\nPatients must not have received prior therapy with a CD123 directed antibody or CD123 directed chimeric antigen receptor (CAR) T cells.\nPatients who have an uncontrolled infection are not eligible.\nPatients who have received a prior solid organ transplantation are not eligible.\nPatients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.\nKnown hypersensitivity to murine, yeast, or recombinant proteins; polysorbate 80; recombinant human serum albumin; benzyl alcohol; or any excipient contained in the flotetuzumab drug formulation. Additionally, those patients who have had a hypersensitivity reaction to etoposide that is considered likely related to polysorbate 80 are not eligible.\nPatients must refrain from driving a motor vehicle or operating heavy machinery while receiving flotetuzumab and for 30 days from the date of last study drug administration"
            },
            {
                  "document": "Inclusion Criteria:\n\nHave a projected life expectancy of at least 12 weeks, as assessed by the Investigator.\n\nHave histological confirmation of AML by World Health Organization (WHO) 2016 criteria and are either:\n\nrefractory to intensive induction chemotherapy OR\nrelapsed after intensive induction chemotherapy or stem cell transplant OR\nrelapsed after or refractory to treatment with molecularly targeted and/or low-intensity chemotherapeutic regimens.\nHave an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2.\nHave adequate renal function as demonstrated by measured or calculated creatinine clearance \u226560 mL/min.\n\nHave adequate liver function as demonstrated by:\n\nAspartate aminotransferase (AST) \u22642.5 \u00d7 upper limit of normal (ULN)\nAlanine aminotransferase (ALT) \u22642.5 \u00d7 ULN\nBilirubin \u22641.5 \u00d7 ULN - unless considered due to leukemic organ involvement.\nWomen of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.\n\nExclusion Criteria:\n\nPoor medical risk in the investigator's opinion because of systemic diseases in addition to the cancer under study, for example, uncontrolled infections.\nKnown clinically active central nervous system (CNS) leukemia.\nBCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).\nDiagnosis of acute promyelocytic leukemia (M3 AML or APML).\nSecond malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.\nGraft Versus Host Disease (GVHD), or any GVHD requiring treatment with immunosuppression. Any GVHD treatment (including calcineurin inhibitors) must be discontinued at least 28 days prior to Day 1 of study treatment.\nPresence of persistent toxicities of Grade >1 from prior treatment including chemotherapy, targeted therapy, immunotherapy, experimental agents, radiation, and surgery (except for alopecia).\nHypersensitivity to decitabine, ASTX727, ASTX660, or any of their excipients.\nLiver cirrhosis, or chronic liver disease Child-Pugh Class B or C.\nLife-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise participant safety, or the integrity of study outcomes, or interfere with the absorption or metabolism of ASTX660 or ASTX727.\nHistory of, or at risk for, cardiac disease.\nKnown human immunodeficiency virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV) infection (participants with laboratory evidence of no active replication will be permitted).\nKnown significant mental illness or other conditions, such as active alcohol or other substance abuse that, in the opinion of the investigator, predispose the participant to high risk of noncompliance with the protocol treatment or assessments.\nTreated with any investigational therapy within 2 weeks of the first dose of study treatment or treatment with a myelosuppressive therapy within 4 weeks of the first dose of study treatment.\nIn Parts 1 and 2, prior treatment with decitabine for more than 2 cycles. In Part 3, any treatment with an HMA (azacitidine or decitabine, for more than one cycle).\nInability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to ASTX660-02 (Note: G-tube administration is not allowed)."
            },
            {
                  "document": "Inclusion Criteria:\n\nSigned informed consent must be obtained prior to participation in the study.\nAge \u2265 18 years at the date of signing the informed consent form (ICF)\nNewly diagnosed with AML based on 2016 WHO classification (Arber et al 2016) and not suitable for intensive chemotherapy defined as: age \u226575, ECOG performance Status 2 or 3, or any of the following comomorbitities: severe cardiac comorbities (including congestive heart failure, LVEF \u2264 50%, chronic stable Angina) , pulmonary comorbidity (DLCO \u2264 65% or FEVI \u2264 65%). moderate hepatic impairment (with total Bilirubin >1.5 to 3x ULN) , renal impairment (eGFR\u2265 30 ml/min/1.73m^2 to 45 30 ml/min/1.73m^2), or other comorbidity incompatible with intensive chemotherapy per Investigator assessement and approved by the Novartis Medical monitor)\n.Not planned for hematopoietic stem-cell transplantation (HSCT)\n.Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 , 2 or 3\n\nExclusion Criteria:\n\nPrior exposure to TIM-3 directed therapy\nHistory of severe hypersensitivity reactions to any ingredient of study drug(s) (azacitidine, venetoclax or MGB453) or monoclonal antibodies (mAbs) and/or their excipients\nCurrent use or use within 14 days prior to randomization of systemic, steroid therapy (> 10 mg/day prednisone or equivalent) or any immunosuppressive therapy. Topical, inhaled, nasal, ophthalmic steroids are allowed. Replacement therapy, steroids given in the context of a transfusion are allowed and not considered a form of systemic treatment.\nPrevious treatment at any time, with any of the following antineoplastic agents, approved or investigational; checkpoint inhibitors, venetoclax and hypomethylating agents (HMAs) such as decitabine or azacitidine.\nActive autoimmune disease requiring systemic therapy (e.g.corticosteroids).\nLive vaccine administered within 30 Days prior to randomization\n\nOther protocol-defined Inclusion/Exclusion may apply."
            },
            {
                  "document": "Inclusion Criteria:\n\nHistologically proven acute myelogenous leukemia (AML) or advanced myeloid malignancy [myelodysplasia; chronic myelomonocytic leukemia (CMML); or chronic myeloproliferative disease (MPD) each with >= 10% myeloblasts in blood or bone marrow]\nFor patients with de novo AML: must not be a candidate for standard induction therapy based upon age, co-morbidities, patient choice, high risk features known to have poor outcomes with standard induction therapy (ELN high risk disease by cytogenetics, deoxyribonucleic acid [DNA] mutation profile or TP53 mutation)\nPatients with advanced myelodysplastic syndrome (MDS), secondary AML, relapsed/refractory AML, prior hypomethylating agent are eligible\nPatients must give informed consent\nPatients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2\nTotal bilirubin < 2 x upper limit of normal (ULN)\nAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional ULN\nCreatinine < 2 mg/dL\n\nExclusion Criteria:\n\nWhite blood cell (WBC) uncontrolled (> 15,000/uL) despite hydroxyurea or cytarabine x 3 days. Known central nervous system (CNS) AML\nSerious concomitant systemic disorders (including active infections) that would compromise the safety of the patient or compromise the patient?s ability to complete the study, at the discretion of the investigator. Pregnant patients are excluded\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Salsalate or other agents used in the study. Examples include aspirin\nThe effects of venetoclax and decitabine or 5-azacytidine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 24 weeks after. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\nPatients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, therefore, known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with treatment medications or other agents administered during the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis:\n\nPhase I cohort: Adults >= 18 years with relapsed/refractory FLT3-mutated AML or CMML or other MDS/MPN that is intermediate-2 or high-risk by the International Prognostic Scoring System\nPhase II cohort A: Adults >= 18 years with newly diagnosed FLT3-mutated AML\nPhase II cohort B: Adults >= 18 years with relapsed/refractory FLT3-mutated AML or CMML or other MDS/MPN that is intermediate-2 or high-risk by the International Prognostic Scoring System\nFor all cohorts, patients with either FLT3-internal tandem duplication (FLT3-ITD) or FLT3 D835 mutations will be eligible\nPerformance status =< 3 (Eastern Cooperative Oncology Group [ECOG] scale)\nTotal serum bilirubin =< 2.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the principal investigator (PI)\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x ULN, unless due to the underlying leukemia approved by the PI\nCreatinine clearance >= 30 mL/min\nAbility to swallow\nSigned informed consent\n\nExclusion Criteria:\n\nPrior therapies:\n\nPhase I cohort: No restriction based on prior therapies\nPhase II cohort A: Patients with prior therapy for AML are not eligible. Prior therapy for antecedent hematologic disorder is allowed. Prior hydroxyurea or cytarabine given for purposes of cytoreduction is also allowed. Prior all trans-retinoic acid given for presumed acute promyelocytic leukemia is also allowed\nPhase II cohort B: No restriction on number of prior therapies\nPatients suitable for and willing to receive intensive induction chemotherapy (for Phase II cohort A only)\nCongenital long QT syndrome or corrected QT interval by Fridericia (QTcF) > 450 msec. Repeat electrocardiograms (EKGs) after correction of electrolytes or discontinuation of QT prolonging medications are allowed to meet entry criteria. In cases where QTcF > 450 msec is considered to be falsely increased due to inaccurate automated reading and not clinically significant (e.g. due to bundle branch block), patients are still eligible if cardiologist reviews and documents that QTcF is =< 450 msec when manually measured\nActive serious infection not controlled by oral or intravenous antibiotics (e.g. persistent fever or lack of improvement despite antimicrobial treatment)\nActive grade III-V cardiac failure as defined by the New York Heart Association criteria\nActive central nervous system leukemia\nKnown human immunodeficiency virus (HIV) seropositive\n\nKnown hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection\n\nNote: Patients who have isolated positive hepatitis B core antibody (i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load\nPatients with a prior or concurrent malignancy whose natural history or treatment is not anticipated to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the PI\nConsumed strong inducer of cytochrome P450, family 3, subfamily A (CYP3A) or p-glycoprotein within 3 days of study enrollment. Agents include but are not limited to: carbamazepine, phenytoin, rifampin, and St. John's wort\nTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator. Prior recent treatment with corticosteroids, hydroxyurea and/or cytarabine (given for cytoreduction) permitted\nPregnant women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception throughout the study period and for at least 6 months after the last dose of study drugs. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control throughout the study period and for at least 4 months after the last dose of study drugs. Lactating women (or those planning to breastfeed) should not breastfeed during treatment of gilteritinib and for at least 2 months after the last dose of gilteritinib"
            },
            {
                  "document": "Inclusion Criteria:\n\nA subject will be eligible for study participation if the subject meets the following criteria:\n\nEligible subject must have an advanced hematologic malignancy including:\n\nMDS with refractory anemia with excess blasts (RAEB; subtype RAEB-1 or RAEB-2) as defined by World Health Organization (WHO) 2016 revised criteria and/or MDS with high- or very high-risk (risk score > 4.5) per the Revised International Prognostic Scoring System (IPSS-R) (Greenberg et al. 2012) that is relapsed or refractory to prior therapy for MDS, or the subject is intolerant to established therapy known to provide clinical benefit for their condition in the opinion of the Investigator; Or relapsed and/or refractory MDS subjects in whom the Investigators feel would benefit from Arm 2.\nRelapsed and/or primary refractory AML as defined by WHO 2016 revised criteria; Or frontline older and/or unfit AML subjects in whom the Investigators feel would benefit from Arm 2.\nCMML (with \u2265 5% blasts in bone marrow) as defined by WHO 2016 revised criteria that is relapsed and/or refractory and that, in the opinion of the Investigator, requires treatment or that has exhausted treatment options that would be considered standard of care.\nSubject's prior therapies may include other BCL2 inhibitors and other HMA agents for Arm 2.\nBlast count \u2264 30 \u00d7 10^9 cells/L at the time of initiating investigational therapy (hydroxyurea is allowed to control blast count prior to and during therapy).\n\nSubject must have adequate coagulation, renal, and hepatic function.\n\nActivated partial thromboplastin time and prothrombin time not to exceed 1.5 \u00d7 the upper limit of normal (ULN);\nCalculated creatinine clearance (Cr Cl) \u2265 30 mL/min using 24-hour CrCl OR Cockcroft-Gault formula (using actual body weight)\nUK and EU only: Estimated glomerular filtration rate (GFR) \u2265 30 mL/min/1.73m2 using the modification of diet in renal disease (MDRD) equation.\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 3.0 \u00d7ULN; bilirubin \u2264 1.5 \u00d7 ULN (except subjects with Gilbert's Syndrome, who may have a bilirubin > 1.5 \u00d7 ULN, per discussion between the Investigator and the Medical Monitor).\nAdequate cardiac function defined as: shortening fraction of \u2265 27% by echocardiogram, or ejection fraction of \u2265 50% by 2D echocardiogram without Doppler.\n\nExclusion Criteria:\n\nA subject will not be eligible for study participation if he/she meets any of the following criteria.\n\nSubjects with a diagnosis of promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) or non-PML-RARA rearranged acute promyelocytic leukemia (APL).\nSubjects who have undergone hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of LP-108, or subjects on immunosuppressive therapy post-HSCT at the time of Screening, or with clinically significant graft-versus-host disease (GVHD). (Subjects in relapse after allogeneic transplantation must be off calcineurin inhibitors for at least 4 weeks. The use of topical steroids and/or up to 20 mg/day prednisone or equivalent systemic steroids for ongoing GVHD is permitted).\n\nSubject has received any of the following therapies within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug, or has not recovered to \u2264 Grade 1 clinically significant adverse effect(s) of the previous therapy:\n\nAny anti-cancer therapy including chemotherapy, hormonal therapy, biologic or immunotherapy, targeted small molecule agents, etc. (corticosteroid therapy < 20 mg/day prednisone equivalent for < 14 days at time of study treatment and hydroxyurea cytoreduction therapy according to institutional guidelines to treat disease associated symptoms are permitted).\nAny investigational therapy.\nThere is 28-day washout period required for subject who have had prior CAR-T treatment if there is no evidence of cytokine release syndrome (CRS) or other adverse events related to the CAR-T treatment per discussion with the Medical Monitor.\n\nSubject has received the following medications or therapies within 7 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug:\n\nCytochrome P450, family 3, subfamily A (CYP3A4) strong inhibitors (see Appendix 10 for strong CYP3A4 inhibitors). In Phase 1b of this trial, the criterion regarding CYP3A4 strong inhibitors will be removed at time of amendment of the trial when Phase 1b is to be initiated. The amendment will include recommendations on concomitant dosing of LP-108 and strong CYP3A4 inhibitors such as azole antifungal agents, PK monitoring for the initial weeks on study, as well as closer safety monitoring for subjects.\nStrong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.\nInhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (see Appendix 11 for P gp and BCRP inhibitors).\nImmunosuppressive drugs (equivalent to >10mg prednisone) for underlying autoimmune or rheumatologic conditions.\nAll statins as they could inhibit bilirubin uptake transporter OATP1B1 and OATP1B3 (the washout period should always be 5 half-lives) (see Appendix 11)\nSubject has baseline prolongation of the corrected QTc > 480 ms (calculated per Fridericia's formula [QTc = QT/RR (1/3)].\n\nSubject has a history of other malignancies other than the eligible hematologic malignancy within the past 1 year prior to study entry, with the exception of:\n\nSubject with breast cancer or prostrate cancer on endocrine therapy with stable disease.\nAdequately treated in situ carcinoma of the cervix uteri;\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\nPrevious malignancy confined and surgically resected (or treated with other\n\nSubject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:\n\nUncontrolled systemic infection (bacterial, fungal, viral)\nKnown active or poorly controlled human immunodeficiency virus or active hepatitis B or C infection\nUnexplained fever > 38.5 \u00b0C during the Screening period or on their first day of study drug administration (at the discretion of the Investigator, if the fever is considered related to the subject's malignancy may be enrolled).\nSubjects with known and active central nervous system (CNS) involvement (radiographic or cytologic) at Screening; subjects with history of CNS involvement who have no symptoms suggestive of CNS disease and have had at least 2 successful lumbar punctures without cytologic evidence of leukemia may be included after discussion and approval of the Medical Monitor. (Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during screening in subjects without a history of CNS involvement).\nSubjects with immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.\n\nRequires ongoing treatment with\n\nSystemic acid-reducing agents including H-2-receptor antagonists and proton pump inhibitors\nSensitive CYP2C8 substrates (such as montelukast, pioglitazone, repaglinide, rosiglitazone) or CYP2C8 substrates with a narrow therapeutic index (e.g., amiodarone, fosphenytoin, paclitaxel, penprocoumon, phenytoin)"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of 1) AML (World Health Organization [WHO] classification definition of >= 20% blasts, excluding acute promyelocytic leukemia [APL]), or 2) high risk MDS (> 10% bone marrow blasts)\nFor frontline cohort: Patients aged >= 60 years old\nFor relapsed or refractory cohort: Patients aged >= 18 years old\nFor frontline cohort: Patients must be chemonaive, i.e., not have received any chemotherapy (except hydrea or 1-2 doses of ara-C for transient control of hyperleukocytosis) for AML or MDS. They may have received transfusions, hematopoietic growth factors or vitamins for an antecedent hematological disorder (AHD) or for AML. Temporary prior measures such as apheresis, ATRA (all-trans retinoic acid), steroids or hydrea while diagnostic work-up is being performed are allowed and not counted as a prior salvage. Supportive care therapy for MDS (growth factors, transfusions) will not be considered as prior therapy for MDS/AML and these patients will be enrolled to the frontline cohort of the study if they are otherwise eligible\nFor relapsed or refractory cohort: Patients who have received at least one prior therapy for AML or for MDS (with > 10%) blasts will be eligible. Patients may have received up to 4 salvage regimens for AML and/or MDS (defined by the International Prognostic Scoring System [IPSS] classification). Patients who receive MDS directed therapies considered not purely supportive such as hypomethylating agents (HMAs), lenalidomide, investigational therapies, will be enrolled to the salvage cohort if they are otherwise eligible\nIn the absence of rapidly progressing disease, the interval from prior treatment to time of initiation of protocol therapy will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for cytotoxic/noncytotoxic agents (whichever is shorter). The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochure's, or drug-administration manuals) and will be documented in the protocol eligibility document. The use of chemotherapeutic or anti-leukemic agents is not permitted during the study with the following exceptions: (1) intrathecal (IT) therapy for patients with controlled central nervous system (CNS) leukemia at the discretion of the principal investigator (PI). (2) Use of cytarabine (up to 2 g/m^2) or hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy. These medications will be recorded in the case-report form\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nSerum biochemical values with the following limits unless considered due to leukemia\nCreatinine < 1.8 mg/dl\nTotal bilirubin < 1.8 mg/dL, unless increase is due to hemolysis or congenital disorder\nTransaminases (serum glutamate pyruvate transaminase [SGPT]) < 2.5x upper limit of normal (ULN)\nPotassium, magnesium, and calcium (normalized for albumin) levels should be within institutional normal limits\nAbility to take oral medication\nAbility to understand and provide signed informed consent\nBaseline left ventricular ejection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) >= 50%\nWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 7 days. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential\nWOCBP must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy until at 30 days after the last dose of investigational drug. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as men with azoospermia do not require contraception. Appropriate methods of birth control include: birth control pills, condoms, intrauterine device (IUD), or other Food and Drug Administration (FDA) approved birth control methods\nPatients may be concurrently enrolling in supportive care clinical trials. Other investigational agents that are used for treatment of other cancers will not be allowed\n\nExclusion Criteria:\n\nPatients with known allergy or hypersensitivity to quizartinib, mannitol, CPX-351 or any of their components\nPatients with electrolyte abnormalities at study entry defined as follows: (a) Serum potassium < 3.5 mEq/L despite supplementation, or > 5.5 mEq/L. (b) Serum magnesium above or below the institutional normal limit despite adequate management. (c) Serum calcium (corrected for albumin levels) above or below institutional normal limit despite adequate management\nPatients with known significant impairment of gastrointestinal (GI) function or GI disease as determined by the investigator that may significantly alter the absorption of quizartinib\nPatients with any other known concurrent severe and/or uncontrolled medical condition including but not limited to diabetes, cardiovascular disease including hypertension, renal disease, or active uncontrolled infection, which as determined by the investigator could compromise participation in the study. Patients on active antineoplastic or radiation therapy for a concurrent malignancy at the time of screening. Maintenance therapy, hormonal therapy, or steroid therapy for well-controlled malignancy is allowed\nPatients with a known human immunodeficiency virus (HIV) infection (HIV testing is not required prior to enrollment)\nPatients with known positive hepatitis B or C infection by serology, with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required prior to study entry). Subjects with serologic evidence of prior vaccination to hepatitis B virus (HBV) (i.e., hepatitis surface antigen [HBs Ag]-, and anti-HBs+) may participate\nPatients who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) within 3 days prior to the initiation of study treatment\nPatients who have had any major surgical procedure within 14 days of day 1\nImpaired cardiac function including any of the following: (a) screening electrocardiogram (ECG) with a corrected QT (QTc) > 450 msec. The QTc interval will be calculated by Fridericia's correction factor (QTcF) at screening and on day 6 prior to the first dose of quizartinib. The QTcF will be derived from the average QTcF in triplicate. If QTcF > 450 msec on day 6, quizartinib will not be given\nPatients with congenital long QT syndrome\nHistory or presence of sustained ventricular tachycardia requiring medical intervention\nAny history of clinically significant ventricular fibrillation or torsades de pointes\nKnown history of second or third degree heart block (may be eligible if the patient currently has a pacemaker)\nSustained heart rate of < 50/minute on pre-entry ECG\nRight bundle branch block + left anterior hemiblock (bifascicular block)\nComplete left bundle branch block\nPatients with myocardial infarction or unstable angina within 6 months prior to starting study drug\nCongestive heart failure (CHF) New York (NY) Heart Association class III or IV\nAtrial fibrillation documented within 2 weeks prior to first dose of study drug\nPatients who are actively taking a strong CYP3A4 inducing medication\nPatients who require treatment with concomitant drugs that prolong QT/QTc interval with the exception of antibiotics, antifungals, and antivirals that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject or if the Investigator believes that beginning therapy with a potentially QTc-prolonging medication (such as anti-emetic) is vital to an individual subject's care while on study\nKnown family history of congenital long QT syndrome"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with AML who are in morphological remission after allogeneic stem cell transplantation with peripheral blood stem cell (PBSC)s or bone marrow if they had at least one of the following disease characteristics:\n\nTherapy related AML\nCytogenetics and molecular features consistent with adverse risk group by European LeukemiaNet classification for AML\nPrimary induction failure defined as absence of complete remission after two different lines of anti-leukemia therapy following diagnosis\nPresence of minimal residual disease by multi-color flow cytometry or cytogenetics or molecular studies at the time of HSCT\nPresence of active disease defined as bone marrow blast count > 5% at the time of HSCT\nPatients transplanted beyond first remission\nPatients with biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) or T cell acute lymphoblastic leukemia who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow\nThe use of reduced intensity regimen with fludarabine/melphalan (100-140 mg/m^2) with or without total-body irradiation (TBI) with post-transplant Cytoxan\nThe use of myeloablative regimens including: sequential busulfan (area under curve [AUC] > 5000)/flurabine with post-transplant Cytoxan or TBI/etoposide with any GVHD regimen\n\nPatients who are in remission with no detectable minimal residual disease after allogeneic stem cell transplant should have:\n\nAdequate engraftment within 14 days prior to starting study drug\nAbsolute neutrophil count (ANC) >= 1.0 x 10^9/L without daily use of myeloid growth factor\nPlatelet >= 30 x 10^9/L without platelet transfusion within 1 week; and\nBe able to start the drug therapy between 42 to 100 days following HSCT\nPersistence or reappearance of minimal residual disease by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\nSerum creatinine =< 1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault equation\nSerum bilirubin =< 1.5 x upper limit of normal (ULN)\nAspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x ULN\nAlkaline phosphatase =< 2.5 x UL\nCapable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent\nNegative serum or urine pregnancy test for women with reproductive potential. The only subjects who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for > 12 months) or subjects who have been surgically sterilized or otherwise proven sterile\n\nExclusion Criteria:\n\nActive acute GVHD grade II or higher\nActive chronic GVHD that is extensive\nUncontrolled GVHD\nConcurrent use of systemic immune suppressive other than calcineurin inhibitors, mycophenolate mofetil (MMF) and sirolimus\nActive uncontrolled systemic fungal, bacterial or viral infection\nActive bleeding\nSymptomatic or uncontrolled arrhythmias\nSignificant active cardiac disease within the previous 6 months, including: New York Heart Association (NYHA) class III or IV congestive heart failure. Unstable angina or angina requiring surgical or medical intervention, and/or myocardial infarction\nKnown active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)\n\nPrior history of malignancies, other than leukemia, unless the subject has been free of the disease for >= 1 year. However, subjects with the following history/concurrent conditions are allowed:\n\nBasal or squamous cell carcinoma of the skin\nCarcinoma in situ of the cervix\nCarcinoma in situ of the breast\nIncidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system)"
            },
            {
                  "document": "Key Inclusion Criteria:\n\nPart A: Patients with relapsed or refractory AML, or newly-diagnosed AML secondary to MPN\nPart B:Patients with relapsed or refractory AML secondary to MPN (myelofibrosis [MF], polycythemia vera [PV], or essential thrombocythemia [ET]); patients may have been treated with \u22651 prior lines of therapy for their AML secondary to MPN.\nAdequate hepatic and renal function\nAppropriate prior treatment with an FLT3 or IDH1/2 inhibitor where applicable\n\nKey Exclusion Criteria:\n\nPatients who are TP53 mutation positive\nPrior treatment with an MDM2 antagonist therapy\nPatients treated with \u2265 18 g/m2 of cytarabine within the prior 90 days are not eligible to be treated with cytarabine on this study but may be treated with decitabine (for Part A) .\nPatients previously treated with decitabine are not eligible to receive decitabine on this study but may be treated with cytarabine (for Part A) .\nPatients who have received an allogeneic HSCT within 90 days of enrollment or who have active graft-versus-host disease requiring active therapy (for Part A)\nAllogeneic stem cell transplant within 3 months; autologous stem cell transplant within 3 months or active graft-versus-host disease prior to first dose of study treatment (for Part B)\nPatients who have received immunosuppressive therapy for graft-versus-host disease within 1 month prior to enrollment into this study\nPatients who are eligible for an allogeneic HSCT per the opinion of the investigator and have a donor. Patients who are HSCT-eligible in the opinion of the investigator, but who refuse a transplant, are eligible for the study.\nPatients with known CNS involvement with AML, acute promyelocytic leukemia (APL), or a history of bleeding diathesis\nPatients who have had major surgery within 28 days prior to the first treatment with KRT-232\nWomen who are pregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of newly diagnosed acute myeloid leukemia (AML).\n\nParticipant meets the following disease activity criteria:\n\nConfirmation of AML by World Health Organization (WHO) criteria (2016) and have confirmed complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following completion of intensive induction and consolidation chemotherapies.\nAchieved first CR + CRi within 120days of first dose of study drug or be no more than 75 days since last dose of intensive conventional chemotherapies.\nAML has intermediate or poor risk cytogenetics per National Comprehensive Cancer Network (NCCN) 2016 criteria.\nEastern Cooperative Oncology Group (ECOG) performance status <= 2.\nParticipant must have adequate hematologic, renal, and liver function laboratory values as described in the protocol.\n\nExclusion Criteria:\n\nHistory of acute promyelocytic leukemia (APL).\nHistory of active central nervous system involvement with acute myeloid leukemia (AML)."
            },
            {
                  "document": "Patient Inclusion Criteria\n\nPatient must be \u2265 18 years of age.\nPatients must have confirmed diagnosis of AML (excluding acute promyelocytic leukemia) based on World Health Organization classification (Arber 2016).\n\nDisease characteristics and allowable prior therapy:\n\nPatients must be evaluated for any available standard of care therapies and, in the opinion of the treating physician, be deemed appropriate for this experimental therapy.\nTreatment-na\u00efve (untreated) patients will be allowed in the Expansion Phase for Regimens A (IMGN632 + azacitidine) and C (IMGN632 + azacitidine + venetoclax). No prior treatments with HMAs for MDS are allowed. Note: Patients who are MRD+ following frontline treatment are eligible for the Regimen D Cohorts D1 and D2 (Expansion Phase).\nPatients must have CD123-positive AML as confirmed by local flow cytometry (or immunohistochemistry [IHC]).\nPatients may have received prior CD123-targeted therapies, except IMGN632, as long as CD123 remains detectable during screening.\nRelapsed or refractory CD123-positive AML patients will be allowed to enroll in the Escalation Phase of Regimens A, B, and C (Triplet) (IMGN632 + azacitidine, venetoclax, or azacitidine + venetoclax, respectively) and relapsed CD123-positive AML patients will be allowed to enroll the Expansion Phase of Regimens A-C.\nPatients enrolling in Regimen D must be in CR (CR/CRi) for no more than 6 months and be MRD+, confirmed by central laboratory testing, after intensive induction/consolidation therapy. Note: Fit patients who previously received intensive treatment (eg 3+7, HiDAC, etc.) are eligible for Regimen D Cohort D1. Unfit patients who previously received non-intensive treatment (eg, HMA, low dose cytarabine, etc.) are eligible for Regimen D Cohort D2.\nPatients enrolling on Regimen D (MRD+ AML), must first have an evaluable screening bone marrow sample confirmed as MRD+ by central flow testing of MRD.\nEastern Cooperative Oncology Group performance status \u2264 1. If nonambulatory due to a chronic disability, must be Karnofsky performance status > 70.\nPrevious treatment-related toxicities must have resolved to Grade 1 or baseline (excluding alopecia).\nTotal white blood cell count must be less than 25 x 10^9 cells/L. Hydroxyurea may be used to control blood counts before Cycle 1 Day 1, at the discretion of the treating physician, according to institutional practice. During the Escalation Phase in Regimens A-C, hydroxyurea may also be used during Cycle 1.\nLiver enzymes (AST and ALT) \u2264 3 \u00d7 the upper limit of normal (ULN).\nTotal bilirubin \u2264 1.5 \u00d7 the ULN within 14 days of enrollment.\nSerum creatinine \u2264 1.5 mg/dL within 14 days of enrollment.\nEchocardiogram or other modality demonstrating an ejection fraction \u2265 45%.\nPatients with prior autologous and allogeneic bone marrow transplant are eligible. Patients with an allogeneic transplant must meet the following conditions: The transplant must have been performed more than 120 days before the date of dosing on this study, the patient must not have active \u2265 Grade 2 graft versus host disease, and the patient must be off all systemic immunosuppression for at least 2 weeks before dosing.\nVoluntary written informed consent before performance of any study-related procedure not part of normal medical care.\nWomen of childbearing potential (WCBP), defined as sexually mature women who have not undergone surgical sterilization or who have not been naturally postmenopausal for at least 12 consecutive months (ie, who have had menses any time in the preceding 12 consecutive months), must agree to use highly effective contraceptive methods (examples include oral, parenteral, or implantable hormonal contraceptive, intrauterine device, barrier contraceptive with spermicide, partner's latex condom or vasectomy) while on study drug and for at least 7 months after the last dose of study drug.\nWCBP must have a negative pregnancy test within 3 days before the first dose of study drug.\nA male patient must agree to use a latex condom even if he has had a successful vasectomy and must continue to follow these requirements for at least 12 weeks after the last dose of study drug.\nPatients with prior malignancy are eligible; however, the patient must be in remission from the prior malignancy and have completed all chemotherapy and radiotherapy for the prior malignancy at least 6 months before enrollment, and all treatment-related toxicities must have resolved to Grade 1 or less.\n\nPatient Exclusion Criteria\n\nPatients who have received any anticancer therapy, including investigational agents, within 14 days (or within 28 days for checkpoint inhibitors) before drug administration on this study (hydroxyurea is allowed before beginning study treatment). Patients must have recovered to baseline from all acute toxicity from this prior therapy.\nPatients who have been previously treated with IMGN632.\nPatients with myeloproliferative neoplasm-related secondary AML are excluded from the Dose Expansion Phase of the study.\nPatients with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgement. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor.\nPatients with a history of sinusoidal obstruction syndrome/venous occlusive disease of the liver.\nMyocardial infarction within 6 months before enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities before study entry.\nClinically relevant active infection including known active hepatitis B or C, HIV infection, or cytomegalovirus or any other known concurrent infectious disease that, in the judgment of the investigator, would make a patient inappropriate for enrollment into this study (testing not required).\nPatients who have undergone a major surgery within 4 weeks (or longer if not fully recovered) before study enrollment.\nSerious or poorly controlled medical conditions that could be exacerbated by treatment or that would seriously compromise safety assessment or compliance with the protocol, in the judgment of the investigator.\nWomen who are pregnant or breastfeeding.\nPrior known hypersensitivity reactions to monoclonal antibodies (\u2265 Grade 3).\nPrior known hypersensitivity reactions to study drugs and/or any of their excipients"
            },
            {
                  "document": "Inclusion Criteria:\n\nTreatment with combination antiretroviral therapy (cART) for at least 1 month before enrollment\nViral load < 5000 copies/ml plasma on cART\n\nDisease criteria\n\nAcute myeloid leukemia\n\nHigh risk in first complete remission (CR1), >= 2 cycles to obtain complete remission (CR), erythroblastic or megakaryocytic leukemia; >= in second complete remission (CR2)\nAll patients must be in CR as defined by hematologic recovery and < 5% blasts by morphology within the bone marrow and a cellularity of >= 15%\nPatients for whom adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible. Specimen for morphologic assessment, including possible repeat procedures will be obtained (as possible). These patients must be discussed with the lead principal investigator, Filippo Milano prior to enrollment\n\nAcute lymphoblastic leukemia\n\nHigh risk CR1 (for example, but not limited to: t(9;22), t(1;19), t(4;11) or other mixed-lineage leukemia [MLL] rearrangements, hypodiploid); greater than 1 cycle to obtain CR; >= CR2\nAll patients must be in CR as defined by hematologic recovery and < 5% blasts by morphology within the bone marrow and a cellularity of >= 15%\nPatients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible. Specimen for morphologic assessment, including possible repeat procedures will be obtained (as possible). These patients must be discussed with the lead principal investigator, Filippo Milano prior to enrollment\nChronic myelogenous leukemia excluding refractory blast crisis. To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate\nMyelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (i.e., refractory anemia with excess blasts [RAEB], refractory anemia with excess blasts in transformation [RAEBt]) or refractory anemia with severe pancytopenia or high-risk cytogenetics. Blasts must be < 10% by a representative bone marrow aspirate morphology\nOther hematologic malignancy such as non-Hodgkin lymphomas. Fred Hutch site: These patients must be presented at Patient Care Conference (PCC) prior to enrollment, given potential competing eligibility on auto-transplant protocols. Participating centers: These patients must be discussed with the lead principal investigator, Filippo Milano prior to enrollment\nKarnofsky (>= 16 years old) >= 70%\nLansky (< 16 years old) >= 50%\nAdults: Calculated creatinine clearance must be > 60 mL and serum creatinine =< 2 mg/dL\nChildren (< 18 years old): Calculated creatinine clearance must be > 60 mL/min\nTotal serum bilirubin must be < 3 mg/dL\nTransaminases must be < 3 x the upper limit of normal\nDiffusion capacity of the lung for carbon monoxide (DLCO) corrected > 50% normal or for pediatric patients in whom DLCO cannot be measured has adequate pulmonary function\nLeft ventricular ejection fraction > 45% OR\nShortening fraction > 26%\nAbility to understand and the willingness to sign a written informed consent document (adult subject or parent/legal guardian of minor subject)\n\nExclusion Criteria:\n\nUncontrolled viral or bacterial infection at the time of study enrollment\nActive or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval\nPregnant or breastfeeding\nPrior myeloablative transplant within the last 6 months\nExtensive prior therapy including > 12 months alkylator therapy or > 6 months alkylator therapy with extensive radiation\nCentral nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy. Diagnostic lumbar puncture to be performed"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must have histologically confirmed acute myeloid leukemia (AML) diagnosed per WHO criteria.\nParticipants must have relapsed or refractory AML.\nAge \u2265 18 years.\nECOG performance status \u2264 2\n\nParticipants must have adequate organ function as defined below:\n\nDirect Bilirubin \u2264 1.5 \u00d7 institutional upper limit of normal (ULN)\nAST (SGOT) and ALT(SGPT) \u2264 2.5 \u00d7 institutional ULN, OR\nAST (SGOT) and ALT (SGPT) \u2264 5 \u00d7 institutional ULN if elevation is a result of leukemia\nCreatinine Clearance \u2265 60 mL/min/1.73 m2 (calculated via the Cockcroft-Gault equation)\nThe effects of LY3214996 on the developing human fetus are unknown. For this reason and because anti-cancer agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men and women treated or enrolled on this protocol must agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of LY3214996 administration.\nAbility to understand and the willingness to sign a written informed consent document.\nAbility to swallow and retain oral medication.\nParticipants must have resolution of adverse events related to prior anti-cancer therapies to \u2264 CTCAE Grade 2 or baseline\nConsiderations of concurrent use of CYP3A4 inhibitors\n\nDose escalation phase:\n\nARM A: Participants must not be receiving any concurrent antifungal agents that are moderate/strong CYP3A4 inhibitors. These include but are not limited to: isavuconazole, itraconazole, fluconazole, ketoconazole, posaconazole, and voriconazole.\nARM B: Participants must be receiving concurrent antifungal agents that are moderate/strong CYP3A4 inhibitors. These include but are not limited to: isavuconazole, itraconazole, fluconazole, ketoconazole, posaconazole, and voriconazole.\n\nExpansion Phase:\n\nParticipants not receiving concurrent antifungal agents that are moderate/strong CYP3A4 inhibitors are eligible to enroll at MTD determined upon completion of dose-escalation cohort Arm A. Participants receiving concurrent antifungal agents that are moderate/strong CYP3A4 inhibitors are eligible to enroll at MTD determined upon completion of dose-escalation cohort Arm B.\n\nExclusion Criteria:\n\nParticipants who have had chemotherapy, other investigational therapy, immunotherapy, or radiotherapy within 2 weeks prior to the first dose of study medication. ATRA treatment is permitted with no required washout if treatment duration was for less than 1 week. Hydroxyurea is allowed with no required washout. For participants with an absolute peripheral blast count > 20 K/\u00b5L, hydroxyurea may be administered up to day 14 of protocol therapy with a maximum allowed dose of 6 g per day.\nParticipants who have received oral tyrosine kinase inhibitors (TKIs) within 5 half-lives of the first dose of study medication.\nParticipants who have had major surgery within 4 weeks prior to the first dose of study medication.\nParticipants who have had a prior stem cell transplant (SCT) within 90 days prior to the first dose of study medication. Additionally, participants having undergone prior SCT must be off calcineurin inhibitor therapy for at least 28 days prior to the first dose of study medication.\nParticipants with active > Grade 1 acute or chronic Graft v. Host Disease (GvHD) who are receiving immunosuppressive therapy other than prednisone. Use of prednisone is permitted only if participants have been maintained at a steady dose of < 20 mg/day for at least 5 days prior to the first dose of study medication.\nParticipants with known active CNS leukemia involvement. Participants with no known history of CNS leukemia are not required to undergo lumbar puncture (LP) for trial eligibility unless the participant is symptomatic as judged by the treating investigator. Participants with a history of CNS leukemia involvement are eligible provided that the CNS disease has been adequately treated and cleared prior to study enrollment as judged by the treating investigator.\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to LY3214996.\nUncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nPregnant women are excluded from this study because LY3214996 is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LY3214996, breastfeeding should be discontinued if the mother is treated with LY3214996. A negative serum pregnancy test is required for women of childbearing potential prior to study entry.\nParticipants who are known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B or C. Testing is not required for eligibility.\nParticipants with a history or findings of central or branch retinal artery or venous occlusion with significant vision less, or other retinal diseases causing visual impairment as determined by an ophthalmologist."
            },
            {
                  "document": "Inclusion Criteria:\n\nWritten informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\nMale or female patients 18 years or older at the time of consent.\nPatients must have a diagnosis of primary or secondary AML with relapsed or refractory disease (WHO update 2016, [34]) other than acute promyelocytic leukemia, or complex karyotype or monosomy 7 (or containing monosomy 7) for whom no standard therapies are anticipated to result in a durable remission according to the clinical judgment of the treating physician, or in a patient who refuses standard therapies.\nMust have submitted for Next Generation Sequencing (NGS) testing by: 1) (preferred) having submitted a tumor sample for commercial myeloid NGS from Foundation One, Mayo, Tempus, Quest, ARUP or an institutional CLIA-certified laboratory and/or 2) obtaining a bone marrow aspirate during screening for submission to Foundation One, Mayo, Tempus, Quest, ARUP or an institutional CLIA-certified laboratory and ordered as standard of care. If bone marrow aspiration has failed, a peripheral blood sample with circulating blasts may be substituted. Screening reports on tumor cytogenetics and/or mutation assays (eg, FLT-3, and NGS) performed as part of the standard of care will be recorded in the study database or obtained at the time of screening if not previously available.\nPatient's disease must be characterized for the presence/absence of Flt3ITD/TKD mutation from an FDA-approved vendor (ex. LabPMM).\n\nIn addition, patients for the phase 2 portion of the study must meet the following:\n\nPatients, if relapsed/ refractory, must have exposure to no more than 2 prior chemotherapy regimens. Re-induction with the same regimen or stem cell transplant will not be considered a separate regimen.\nPatients must not have prior exposure to any investigational Flt3 inhibitors (midostaurin or gilteritinib are allowed)\nEastern Cooperative Oncology Group (ECOG) performance status 0-2\nLife expectancy of greater than 3 months as determined by the treating physician.\n\nFemale patients who:\n\nAre postmenopausal for at least 1 year before the screening visit, OR\nAre surgically sterile, OR\nIf they are of childbearing potential, agree to practice 2 effective methods of contraception at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, or\nAgree to practice true abstinence, when is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)\nAgree not to donate eggs (ova) during the course of this study or 180 days after receiving their last dose of study drug.\n\nMale patients, even if surgically sterilized (i.e., status post-vasectomy), who:\n\nAgree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, or\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception. Female and male condoms should not be used together.)\nAgree not to donate sperm during the course of this study or within 180 days after receiving their last dose of study drug.\nVoluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care\nIn the absence of rapid progressive disease, the interval from prior systemic anticancer treatment to time of TAK-659/Ixazomib administration should be at least 2 weeks for cytotoxic agents (other than hydroxyurea), or at least 5 half-lives for noncytotoxic agents, and patients have to have recovered from acute toxicities of these therapies. Patients who are on hydroxyurea may be included in the study and may continue on hydroxyurea for the first 21 days while participating in this study. NOTE: For patients with a white blood cell count >50,000/uL, hydroxyurea may be used to control the level of circulating leukemic blast cell counts prior to study entry, and, if needed, concomitantly while on TAK-659 treatment during the first 21 days of the study.\nSuitable venous access for the study-required blood sampling, and transfusion support.\nDemonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 28 days prior to registration.\n\nExclusion Criteria:\n\nClinically active central nervous system leukemia.\nFemale patients who are lactating and breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)\nFemale patients who have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.\nAny serious medical or psychiatric illness, including drug or alcohol abuse, that could, in the investigator's opinion, potentially jeopardize the safety of the patient or interfere with the objectives of the study.\nPrior treatment with investigational agents \u2264 21 days or \u2264 5 half-lives (whichever is shorter) before the first dose of study treatment. A minimum of 10 days should elapse from prior investigational therapy to initiating protocol therapy.\nPersistent clinically significant toxicity from prior chemotherapy that is Grade 2 or higher by the NCI CTCAE (v5).\nReceipt of HSCT within 60 days of the first dose of TAK-659/Ixazomib; clinically significant graft-versus-host disease (GVHD) requiring ongoing immunosuppressive therapy post HSCT at the time of screening (use of topical steroids for ongoing skin GVHD is permitted).\nActive, systemic infection requiring intravenous (IV) antibiotic, antifungal, or antiviral therapy or other serious infection within 10 days before the first dose of study drug.\nMajor surgery within 14 days before the first dose of study drug and have not recovered fully from any complications from surgery.\nRadiotherapy less than 2 weeks before the first dose of study treatment or have not recovered from acute toxic effects from radiotherapy.\nKnown human immunodeficiency virus (HIV) positive.\nKnown hepatitis B surface antigen positive, or known or suspected active hepatitis C infection (testing not required).\n\nAny of the following cardiovascular conditions:\n\nAcute myocardial infarction within 6 months before starting study drug.\nCurrent or history of New York Heart Association Class III or IV heart failure (see Study Procedures Manual [SPM]).\nEvidence of current, uncontrolled cardiovascular conditions including cardiac arrhythmias, angina, pulmonary hypertension, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.\nFridericia corrected QT interval (QTcF) >450 milliseconds (msec) (men) or >475 msec (women) on a 12-lead ECG during the Screening period.\nAbnormalities on 12-lead ECG including, but not limited to, changes in rhythm and intervals that, in the opinion of the treating physician, are considered to be clinically significant.\nKnown gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance to study drugs, including difficulty swallowing tablets, diarrhea > Grade I despite supportive therapy.\n\nUse or consumption of any of the following medications, supplements, or foods/beverages that are inhibitors or inducers of P-gp or strong reversible inhibitors or inducers of CYP3A within the indicated timeframes below. Note that use or consumption of these substances is not permitted during the study.\n\nInhibitors of P-gp and/or strong reversible inhibitors of CYP3A within 5 times the inhibitor half-life (if a reasonable half-life estimate is known), or within 7 days (if a reasonable half-life estimate is unknown), before the first dose of study drug. In general, the use of these agents is not permitted during the study except in cases where an AE must be managed. See SPM for a nonexhaustive list of strong CYP3A reversible inhibitors and/ or Pgp inhibitors based on the FDA Draft DDI Guidance.\nStrong CYP3A mechanism-based inhibitors or strong CYP3A inducers and/or P-gp inducers within 7 days, or within 5 times the inhibitor or inducer half-life (whichever is longer), before the first dose of study drug. However, if a patient has a strong indication for fungal prophylaxis, then the moderate CYP3A inhibitors fluconazole or isovuconazole (mold-active) is recommended for prophylaxis, and the TAK-659 dose should be reduced to 60mg, along with increased scrutiny for toxicity. Similarly, if the patient develops a fungal infection during a productive intervention with TAK-659/Ixazomib combination, isovuconazole (mold-active) should be used, along with increased scrutiny for toxicity. In general, the use of these agents is not recommended during the study except in cases where such an AE must be managed, and the intermittent schedule of TAK-659/Ixazomib combination will not prevent profound neutropenia. See SPM for a non-exhaustive list of strong CYP3A mechanism-based inhibitors or strong CYP3A inducers and/or P-gp inducers based on the FDA Draft DDI Guidance.\nGrapefruit-containing food or beverages within 5 days before the first dose of study drug.\nLack of suitable venous access for the study-required blood sampling.\nDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.\nPatient has Grade 3 peripheral neuropathy, or Grade 2 with pain on clinical examination during the screening period.\nKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent."
            },
            {
                  "document": "Inclusion Criteria:\n\nSubject diagnosed with R/R AML or R/R higher risk MDS is defined as:\n\nR/R AML: Morphologically documented primary or secondary AML by the WHO criteria (2016); and refractory to at least 2 cycles of induction chemotherapy/not a candidate for re-induction or relapsed after achieving remission with a prior therapy; and received all standard therapies including targeted therapies (unless the therapy is contraindicated or intolerable) which are known to provide clinical benefit in the opinion of the treating investigator; and received salvage therapy or is not a candidate for salvage therapy.\nR/R higher risk MDS: Has MDS by the WHO criteria (2016); and either relapsed after achieving remission or refractory to standard therapies, including \u2265 4 cycles of hypomethylating agents (unless the therapy is contraindicated or intolerable); and is classified as higher risk MDS with a score of > 3.5 by Revised International Prognostic Scoring System (IPSS-R) in MDS.\nSubject has an Eastern Cooperative Oncology Group performance status of \u2264 2.\n\nSubject must meet the following criteria as indicated on the clinical laboratory tests during screening period:\n\nSerum aspartate aminotransferase and alanine aminotransferase \u2264 2.5 \u00d7 upper limit of normal (ULN).\nSerum total bilirubin \u2264 1.5 \u00d7 ULN.\nSerum creatinine \u2264 1.5 \u00d7 ULN or an estimated glomerular filtration rate of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.\nPlatelets \u2265 50,000/\u03bcL at cycle 1 day 1 (C1D1) in the dose escalation cohorts only.\nSubject has a life expectancy of \u2265 12 weeks at the time of screening.\nSubjects with AML must have peripheral blood absolute blast count of < 20,000/\u03bcL at C1D1. Note: Blast count can be controlled by hydroxyurea during screening period.\n\nFemale subject is not pregnant and at least 1 of the following conditions apply:\n\nNot a woman of childbearing potential (WOCBP).\nWOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 180 days after final study treatment administration.\nFemale subject must agree not to breastfeed starting at screening and throughout the study period and for 180 days after the final study treatment administration.\nFemale subject must not donate ova starting at first dose of investigational product (IP) and throughout the study period and for 180 days after final study treatment administration.\nMale subject with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 180 day after final study treatment administration.\nMale subject must not donate sperm during the treatment period and for 180 days after the final study treatment administration.\nMale subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 180 days after final study treatment administration.\nSubject agrees not to participate in another interventional study while receiving study treatment in the present study.\n\nExclusion Criteria:\n\nSubject was diagnosed with acute promyelocytic leukemia.\nSubject has breakpoint cluster region-Abelson-positive leukemia (BCR-ABL).\nSubject has persistent non-hematological toxicities of \u2265 grade 2 (National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI-CTCAE], version 5.0), with symptoms and objective findings from prior AML or MDS treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation or surgery).\n\nSubject has received any of the following therapies:\n\nSystemic immunomodulators or immunosuppressive drugs including steroids \u2264 28 days prior to C1D1 (steroids can be used if not intended for treatment of AML or MDS; steroids for AML/MDS related symptoms can be used at low doses [less than 10 mg/day dexamethasone]).\nCytotoxic agents (except hydroxyurea given for controlling blast cells) \u2264 28 days prior to C1D1.\nInvestigational products for the treatment of AML or MDS within 5 half-lives prior to screening visit.\nHematopoietic stem cell transplant (HSCT).\nRadiation therapy \u2264 28 days prior to C1D1.\nSubject has clinically active nervous system leukemia.\nSubject has active or prior documented autoimmune or inflammatory disorders requiring systemic treatment.\n\nSubject has ongoing, untreated malignancy with the exception of the following:\n\nSubjects with treated non-melanoma skin cancer, in situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.\nSubjects with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed or treated with definitive radiotherapy.\nSubject with left ventricular ejection fraction of < 45% on echocardiogram or multigated acquisition scan (MUGA) performed within 28 days of screening.\nSubject has laboratory abnormalities, or clinical evidence of disseminated intravascular coagulation, or ongoing history of coagulation disorder manifested by bleeding or clotting.\nSubject has an active uncontrolled infection.\nSubject is known to have human immunodeficiency virus infection.\nSubject has active hepatitis B or C or other active hepatic disorder.\nSubject has any condition which makes the subject unsuitable for study participation.\nSubject has a known or suspected hypersensitivity to bovine-derived protein or has suspected hypersensitivity to any ingredients of ASP7517.\nSubject is eligible for HSCT."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge \u2265 18 to \u2264 75 years at the time of informed consent.\nNewly diagnosed AML according to World Health Organization (WHO) pathological criteria (with at least 20% blasts in the peripheral blood or bone marrow).\nECOG performance status of 0 to 2.\n\nLaboratory values fulfilling the following:\n\nSerum creatinine < 2.0 mg/dL.\nSerum total bilirubin < 2.0 mg/dL. (For subjects with Gilbert's Syndrome and serum total bilirubin \u2265 2.0 mg/dL, the medical monitor should be contacted.)\nSerum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 3 times the upper limit of normal (ULN). (Note: If elevated liver enzymes > ULN are related to disease, contact medical monitor to discuss.)\nCardiac ejection fraction \u2265 50% by echocardiography or multiple gated acquisition scan (MUGA).\nSubjects with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period > 6 months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Subjects maintained on long-term nonchemotherapy treatment (eg, hormonal therapy) are eligible.\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia [t(15;17)].\nSubject has favorable risk cytogenetics ((t8;21), inv(16), t(16;16), or t15;17) karyotype abnormalities) as categorized by the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2014 for AML (NCCN 2014).\nClinical evidence of active central nervous system (CNS) leukemia.\nSubjects with active (uncontrolled, metastatic) second malignancies.\nSubjects who have received prior treatment intended for induction therapy of AML; only hydroxyurea is permitted for control of blood cell counts. (For example, a subject with myelodysplastic syndrome [MDS] who changes hypomethylating agent [HMA] dose and schedule after the diagnosis of AML is excluded. AML-type therapy, such as cytarabine alone [> 1g/m2/day] or cytarabine plus an anthracycline as well as prior HSCT are also excluded.)\nSubjects receiving administration of any therapy for MDS (conventional or investigational) must be completed by 2 weeks prior to the first dose of study drug. In the event of rapidly proliferative disease, use of hydroxyurea is permitted until 24 hours before the start of study treatment. Toxicities associated with prior MDS therapy must have recovered to Grade 1 or less prior to start of treatment.\nSubjects with myocardial impairment of any cause (eg, cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging).\nSubjects with active or uncontrolled infection. Subjects with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for \u2265 72 hours.\nCurrent evidence of invasive fungal infection (blood or tissue culture). Subjects with recent fungal infection must have a subsequent negative culture to be eligible.\nSubjects with known human immunodeficiency virus (new testing not required) or evidence of active hepatitis B or C infection.\nSubjects with known history of Wilson's disease or other known copper-metabolism disorder.\nSubjects with other comorbidity that the investigator judges to be incompatible with conventional ICT, and / or the targeted agent."
            },
            {
                  "document": "Inclusion Criteria\n\nSubjects must meet all of the following applicable inclusion criteria to participate in this study:\n\nWritten informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\nAges 18 to 75 years at the time of consent.\nECOG Performance Status of 0-2 within 7 days prior to registration; see Appendix I.\nPatients must have AML, as defined, that is relapsed or refractory. Prior therapy including chemotherapy, immunotherapy, biological or targeted therapy (e.g. FMS-like tyrosine kinase-3 (FLT3) inhibitors, other kinase inhibitors, azacitidine, ATRA) is allowed.\nCD33 expression (by flow or IHC) in at least 20% of the leukemia blasts per local pathologist.\nPrior cancer treatment must be completed at least 21 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to \u2264Grade 1 or baseline.\nDemonstrate adequate organ function as defined in the table in the protocol; all screening labs to be obtained within 28 days prior to registration.\nFemales of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to registration. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months\nFemales of childbearing potential and males must be willing to use effective contraception during treatment and for at least 30 days after the last dose of Venetoclax. Females will be advised to use effective contraception for at least 6 months after the last dose of Gemtuzumab and males for at least 3 months after the last dose of Gemtuzumab.\nAs determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria\n\nSubjects meeting any of the criteria below may not participate in the study:\n\nPatients with history of prior use of GO or Venetoclax NOTE: Starting with dose cohort 3, prior therapy with venetoclax is allowed, provided patients do not have evidence of p53 deletion or mutations. If the dose cohort is de-escalated to dose cohort 2 due to toxicity in cohort 3, prior exposure to venetoclax will continue to be allowed, provided patients do not have evidence of p53 deletion/mutations.\nHistory of myeloproliferative neoplasm [MPN] including myelofibrosis, essential thrombocythemia, polycythemia vera, CML with or without BCR-ABL1 translocation, and AML with BCR-ABL1 translocation.\nMore than three lines of prior therapy. A line of therapy consists of \u22651 complete cycle of a single agent, a regimen consisting of a combination of several drugs, or a planned sequential therapy of various regimens (e.g., 3-6 cycles of initial therapy with bortezomib-dexamethasone [VD] followed by stem cell transplantation [SCT], consolidation, and lenalidomide maintenance is considered 1 line).\nWBC >25 \u00d7 109/L. Cytoreduction is required (hydroxyurea as per local standard of care).\nAcute promyelocytic leukemia.\nUnresolved \u2265grade 2 clinically significant nonhematologic toxicities from prior anticancer therapy or unresolved disseminated intravascular coagulation \u2265 grade 2 per CTCAE v5 criteria.\nHistory of other malignancies within 1 year prior to study entry, with the exception of: adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities), with curative intent.\nInvestigational drug within 4 weeks of study entry.\nHistory of CHF requiring treatment, left ventricular ejection fraction \u2264 50%, cardiac insufficiency grade III or IV per New York Heart Association classification (NYHA; see Appendix II), or chronic stable angina\nPatients who are HIV positive.\nKnown CNS involvement with AML.\nPrevious hematopoietic stem cell transplant within 2 months.\nPrevious history of veno-occlusive disease/sinusoidal obstruction syndrome.\nPatients who are positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. Subjects with serologic evidence of prior vaccination to HBV [i.e., HBs Ag-, and anti-HBs+] may participate.\nActive uncontrolled infection or severe systemic infection. Enrollment is possible after control of infection, at discretion of the treating physician.\nPregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\nPatients who have received strong and/or moderate CYP3A inducers or inhibitors within 7 days prior to the initiation of study treatment unless deemed necessary by the treating physician. (See protocol)\nPatients who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.\nMalabsorption syndrome or other condition that precludes enteral route of administration.\nPsychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up.\nUnable or unwilling to undergo a screening bone marrow study.\nOther severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrollment in this study."
            },
            {
                  "document": "Key Inclusion Criteria:\n\nRefractory or relapsed AML defined as the reappearance of > 5% blasts in the bone marrow and who have also failed or are ineligible for any approved standard of care therapies, including HSCT.\n\u2265 18 years of age.\nEastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\nAdequate liver and kidney function according to protocol requirements.\nPeripheral white blood cell (WBC) counts \u2264 30,000/\u03bcL. Patients are allowed to receive hydroxyurea to control and maintain WBC count prior to enrollment.\nBoth men and women (of childbearing potential) enrolled in this trial must use adequate birth control measures during the course of the trial and for at least 90 days after their last dose of study treatment.\n\nKey Exclusion Criteria:\n\nDonor lymphocyte infusion < 30 days prior to study entry.\nClinically active central nervous system (CNS) leukemia.\nUndergone HSCT and have not had adequate hematologic recovery (i.e. ANC >1000 and platelet count > 100,000).\nReceiving immunosuppressive therapy post HSCT at the time of screening (must be off all immunosuppression therapy for at least 2 weeks). The use of topical steroids for cutaneous GVHD is allowed and stable steroid doses less than or equal to 20 mg of prednisone daily is permitted.\nGrade > 2 active graft-versus-host disease (GVHD), moderate or severe limited chronic GVHD, or extensive chronic GVHD of any severity.\nReceived chemotherapy immunotherapy, or radiotherapy or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation) < 14 days prior to the first dose of KO-539 or within 5 drug half-lives (whichever is longer) prior to the first dose of study drug.\nTreatment with concomitant drugs that are strong inhibitors or inducers of cytochrome P450-isozyme 3A4 (CYP3A4) with the exception of antibiotics, antifungals, and antivirals that are used as standard of care or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient.\nKnown detectable viral load for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen indicative of active infection.\nActive uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection.\nSignificant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension or arrhythmia, history of cerebrovascular accident including transient ischemic attack within the past 6 months, congestive heart failure (NYHA Class III or IV) related to primary cardiac disease, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the first dose of study treatment.\nQTcF >480 ms.\nMajor surgery within 4 weeks prior to the first dose of study treatment.\nWomen who are pregnant or lactating. All female patients with reproductive potential must have a negative pregnancy test prior to starting treatment."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have active acute leukemia (bone marrow blasts \u2265 5% or reappearance of blasts in peripheral blood) as defined by the National Comprehensive Cancer Network (NCCN) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Lymphoblastic Leukemia (Version 1.2020) and Acute Myeloid Leukemia (Version 3.2020).\n\nPhase 1: Documented R/R acute leukemia harboring MLL rearrangement or NPM1c mutation.\n\nArm A: Patients not receiving any strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducers.\nArm B: Patients receiving strong cytochrome P450 3A4 inhibitors for antifungal prophylaxis.\nArm C: Patients receiving SNDX-5613 in combination with cobicistat.\n\nPhase 2:\n\nCohort 2A: Documented R/R ALL/MPAL with an MLLr translocation.\nCohort 2B: Documented R/R AML with an MLLr translocation.\nCohort 2C: Documented R/R AML with NPM1c.\nWBC must be below 50,000/ \u03bcL at time of enrollment. Patients may receive cytoreduction prior to enrollment.\nMale or female patient aged \u226530 days old.\nEastern Cooperative Oncology Group (ECOG) performance status score 0-2 or Karnofsky/Lansky score \u226540.\nAny prior treatment-related toxicities resolved to \u2264Grade 1 prior to enrollment, with the exception of \u2264Grade 2 neuropathy or alopecia.\nRadiation Therapy: At least 60 days from prior total body irradiation (TBI), craniospinal radiation and/or \u226550% radiation of the pelvis, or at least 14 days from local palliative radiation therapy (small port).\nStem Cell Infusion: At least 60 days must have elapsed from HSCT and at least 4 weeks (from first dose) must have elapsed from donor lymphocyte infusion (DLI) without conditioning.\nImmunotherapy: At least 42 days since prior immunotherapy, including tumor vaccines and checkpoint inhibitors, and at least 21 days since receipt of chimeric antigen receptor therapy or other modified T cell therapy.\nMyelosuppressive Chemotherapy: At least 14 days since the completion of cytotoxic/myelosuppressive therapy.\nHematopoietic Growth Factors: At least 7 days since the completion of therapy with short-acting hematopoietic growth factors and 14 days with long-acting growth factors.\nBiologics: At least 7 days or 5 half-lives, whichever is longer, since the completion of therapy with a biologic agent.\nSteroids: At least 7 days since systemic glucocorticoid therapy, unless receiving physiologic dosing (equivalent to \u226410 mg prednisone daily) or cytoreductive therapy.\nAdequate organ function.\nIf of childbearing potential, willing to use a highly effective method of contraception or double barrier method from the time of enrollment through 120 days following the last study drug dose.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria are not eligible for study participation:\n\nActive diagnosis of acute promyelocytic leukemia.\nIsolated extramedullary relapse.\nKnown CNS involvement (cytologic or radiographic).\nDetectable human immunodeficiency virus (HIV) viral load within the previous 6 months. Patients with a known history of HIV 1/2 antibodies must have viral load testing prior to study enrollment.\nHepatitis B or C.\nPregnant or nursing women.\n\nCardiac Disease:\n\nAny of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class \u2265II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack.\n\n- QTc >450 msec for males and QTc >450 msec for females.\n\nGastrointestinal Disease:\n\nChronic diarrhea or other gastrointestinal issue that might affect oral drug absorption or ingestion (ie, short-gut syndrome, gastroparesis, etc).\nCirrhosis with a Child-Pugh score of B or C.\nGraft-Versus-Host Disease (GVHD): Signs or symptoms of acute or chronic GVHD >Grade 0 within 4 weeks of enrollment. All transplant patients must have been off all systemic immunosuppressive therapy and calcineurin inhibitors for at least 4 weeks prior to enrollment. Patients may be on physiological doses of steroids.\nConcurrent malignancy in the previous 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy. Concurrent malignancy must be in complete remission or no evidence of disease during this timeframe.\nParticipation in another therapeutic interventional clinical study within 30 days of enrollment."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients aged >/= 18 years AML who have achieved their FIRST CR or CRi and are not immediately candidates for allogeneic stem cell transplant.\nPatients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be enrolled in COHORT 1.\nPatients who have received lower intensity therapy (defined as receiving low-dose cytarabine (LDAC) or hypomethylating agent (HMA)-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be treated on COHORT 2.\nFor either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement.\nECOG performance status of < or = 3\n\nAdequate organ function as follows:\n\nSerum total bilirubin < or = to 1.5 X the Upper Limit of Normal (ULN)\nSerum creatinine < or = to 2.5 x ULN\n\nAdequate BM reserve:\n\nAbsolute neutrophil count (ANC) > 0.5 x k/uL\nPlatelet count > or = 30 x k/uL\n\nFor females of childbearing age, they may participate if they:\n\nHave a negative serum or urine pregnancy test within 10 to 14 days of enrolling\nAgree to either abstinence or 2 effective contraceptive methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment.\nFor male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment.\nAbility to understand and sign informed consent.\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL), AML - M3 by FAB classification based on morphology, immunophenotype, molecular, or cytogenetic s studies.\nDiagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor.\nUncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nPatients with active CNS (central nervous system) disease.\nPatients with documented hypersensitivity to any components of the study program.\nFemales who are pregnant or lactating or intending to become pregnant during the study.\nPatients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment.\nPatient should be removed from current trial if they wish to participate and get treatment on another trial."
            },
            {
                  "document": "Inclusion Criteria:\n\nAll subjects must have the ability to understand and the willingness to sign a written informed consent\nParticipant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT\n\nPlanned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies:\n\nLymphoma (Hodgkin and non-Hodgkin)\nMyelodysplastic syndrome\nAcute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. Persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography [PET] scan without progression is allowed.)\nAcute myeloid leukemia in first or second remission\nChronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase\n\nOther hematologic malignancies judged appropriate by the clinical principal investigators (PIs), including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\n\nAdult cases of multiple myeloma (MM) are excluded as HCT is not standard of care for MM, and is only performed in very advanced cases with an associated high risk of relapse and NRM. Adults with aplastic anemia are excluded because their standard management includes T cell depletion with agents such as anti-thymocyte globulin (ATG), which is not permissible on this protocol. Patients undergoing a second haploHCT are not eligible (patients who have undergone a previous autologous HCT are eligible)\nPatients receiving myeloablative (MA) or reduced intensity conditioning (RIC) are allowed\nCMV seropositive (recipient)\nPlanned related HCT with molecular 3/6 (haploidentical) intermediate/high resolution HLA donor allele matching\nPlanned HCT with minimal to no-T cell depletion of graft\nConditioning and immunosuppressive regimens according to institutional guidelines are permitted\nNegative serum or urine beta human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration\nSeronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease\nAgreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to d90 post-HCT. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n\nExclusion Criteria:\n\nAny prior investigational CMV vaccine\nExperimental anti-CMV chemotherapy in the last 6 months\nLive attenuated vaccines (from the time of HCT to d70 post-HCT)\nMedically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections) (from the time of HCT to d70 post-HCT)\nAllergy treatment with antigen injections (from the time of HCT to d70 post-HCT)\nAlemtuzumab or any equivalent in vivo T-cell depleting agent (or CD34+ selection) (from the time of HCT to d70 post-HCT)\nAntiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valganciclovir (VAL), foscarnet (FOS), cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV) (from the time of HCT to d70 post-HCT)\nProphylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment EXCEPT Prevymis prophylaxis (prior to d100) (from the time of HCT to d70 post-HCT)\nConditioning regimens d30 prior to trial participation and up to d180 post-HCT\nDisease-based radiation therapy (not total body irradiation) (from the time of HCT to d70 post-HCT)\nOther investigational product - concurrent enrollment in other clinical trials using any investigational new drugs (IND) with unknown effects on CMV or with unknown toxicity profiles is prohibited (from the time of HCT to d70 post-HCT)\nOther medications that might interfere with the evaluation of the investigational product (from the time of HCT to d70 post-HCT)\nPatients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible\nPatients considered by PIs/protocol team to have a complicated prior therapy or HCT regimen, or who have a low survival probability (e.g., refractory leukemia and/or undergoing 2nd HCT)\nPoor risk disease/disease status including: chronic myeloid leukemia (CML) in blast crisis, acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) beyond 2nd remission, multiple myeloma, and aplastic anemia\nPregnant women and women who are lactating. Triplex risks to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the administered vaccine, also breastfeeding should be discontinued if the mother is enrolled on this study\nAny other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/ psychological issues, etc.\nProspective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)"
            },
            {
                  "document": "Patient Inclusion Criteria:\n\nAge \u226512 years\nHave undergone first allo-HCT from a 6/6 matched sibling donor, 8/8 matched unrelated donor, or an HLA haploidentical donor.\nHistory of AML or MDS for which allo-HCT was performed. Overlap MPN/MDS is included.\nUntreated relapse of the underlying malignancy as defined by >5% of malignant blasts (by morphology and/or flow cytometry) in the bone marrow, or myeloid sarcoma.\nAdditional cells sufficient for the first DLI available from the same donor, or the donor must be willing to donate. Both G-CSF mobilized and unmobilized products are allowed and the choice is at the discretion of the treating physician.\nPartial (or better) engraftment from the bone marrow showing relapse, defined as >50% donor chimerism on non-split RFLP. Patients with chimerism of 25-50% may be enrolled with approval of the site PI and Sponsor/Investigator\nKarnofsky performance status \u2265 50%\n\nAdequate organ function within 14 days of study registration defined as:\n\nTotal bilirubin < 1.5 x upper limit of institutional normal, unless a diagnosis of Gilbert's disease\nAST/ALT < 2.5 x upper limit of institutional normal\nCreatinine clearance \u226540 mL/minute as calculated by the Cockcroft-Gault formula. Cockcroft-Gault CrCl = (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr).\nPeripheral white blood cell count <50 x 10^9/L. The use of hydroxyurea for cytoreduction is allowed and may continue until cycle 2 day 1\n\nSubjects and spouse/partner who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (at least 1 of which must be a barrier method) starting at Screening and continuing through the entire study (for at least 3 months after the last dose of ruxolitinib if study treatment is stopped early or subject withdraws consent). Highly effective contraception is defined as:\n\nEstablished use of oral, injected or implanted hormonal methods of contraception.\nPlacement of an intrauterine device or intrauterine system.\nDouble barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository (double barrier method will count as 2 forms of contraception).\nMale subjects must not donate sperm during the Screening and Treatment Periods, and for at least 3 months after the last dose of ruxolitinib.\nSubjects are willing and able to give written informed consent and to comply with all study visits and procedures. Parents or legal guardians will consent for minors and minors will be asked to assent.\n\nPatient Exclusion Criteria:\n\nActive uncontrolled infection at the time of consent. An active uncontrolled infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without signs or symptoms of infection will not be interpreted as an active uncontrolled infection. Subjects with a controlled infection receiving definitive therapy for 72 hours prior to enrollment are eligible.\nHistory of infection with human immunodeficiency virus (HIV), unresolved hepatitis B, or hepatitis C.\nUntreated CNS leukemia\nUntreated or active GVHD (acute or chronic)\nHistory of grade III-IV acute GVHD at any point in time\nAny form of iatrogenic immunosuppression except <0.5 mg/kg/day of prednisone or equivalent at the time of consent.\nUnresolved veno-occlusive disease of the liver, defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction (renal, ascites).\nSubjects who are pregnant, breast feeding or sexually active and unwilling to use effective birth control for the duration of the study, as agents in this study are in pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, and category D: there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans.\nRadiation therapy within 14 days prior to consent.\nAny prior therapy for relapse after allo-HCT.\nPrior DLI. CD34-selected boost is allowed\nExposure to any other investigational agent, device or procedure within 14 days prior to consent\nPatients or donors with any medical or psychological condition that, in the opinion of the Investigator, might interfere with the subject's participation in the trial, pose any additional risk for the patient/donor, or confounds the assessments of the subject.\nSubjects with known allergies, hypersensitivity or intolerance to ruxolitinib or similar compounds."
            },
            {
                  "document": "Inclusion Criteria:\n\nAdult patients age 18 years or older, with a pathologically confirmed diagnosis of AML [excluding acute promyelocytic leukemia (APL)] according to WHO criteria. AML may be de novo, or following a prior hematologic disease and/or therapy-related.\nPatients must have relapsed after or be refractory to at least one course of an intensive chemotherapy regimen, for example anthracycline/cytarabine (\"7+3\" or daunorubicin and cytarabine liposome). Patients with residual disease on day 13-22 of initial induction chemotherapy are eligible, provided the bone marrow cellularity is \u2265 30% AND bone marrow blasts are \u2265 20%. Hypomethylating agents such as azacitidine or decitabine are allowed as a prior therapy, but are not considered an intensive chemotherapy regimen.\nEastern Cooperative Oncology Group performance status of 0-2.\nAny systemic chemotherapy and any radiotherapy must be completed at least 7 days prior to initiation of protocol therapy, with the exception of hydroxyurea or 6-mercaptopurine for cytoreduction.\nAt least 20% expression of CD33 as determined by flow cytometry or immunohistochemical staining.\nAdequate renal function, defined as a serum creatinine less than 1.8 mg/dL.\nAdequate hepatic function, defined as a direct bilirubin less than 2 times the institutional upper limit of normal (ULN) and AST, ALT and Alkaline Phosphatase less than 3 times the ULN.\nPatients who relapse after allogeneic hematopoietic stem cell transplantation are eligible, provided they are at least 60 days from stem cell infusion, do not have > grade 1 graft versus host disease, and have been off all immunosuppressive therapy for at least 2 weeks.\nFemale patients of childbearing potential must have a negative pregnancy test and agree to use an adequate method of contraception as defined by the protocol. This must persist through the treatment period until at least 6 months after the last dose of chemotherapy or GO.\nMale subjects who are able to father children and are having intercourse with females of childbearing potential must also agree to an acceptable method of contraception through the treatment period until at least 3 months after the last dose of chemotherapy or GO, and must refrain from sperm donation during this period.\nAbility to give written informed consent.\n\nExclusion Criteria:\n\nPatients with acute promyelocytic leukemia (FAB-M3) or chronic myelogenous leukemia in blast phase.\nIsolated myeloid sarcoma. Patients must have marrow involvement with AML to enter the study.\nPatients with known active AML involvement of the central nervous system.\nPrior treatment with gemtuzumab ozogamicin or cladribine for AML. Prior treatment with cytarabine is permitted.\nAs patients will be receiving G-CSF prior to chemotherapy, patients presenting with symptomatic leukostasis (as judged by the investigator) are excluded. Hydroxyurea, 6-mercaptopurine and/or leukapheresis for blast count control (see inclusion criterion #4) for patients with asymptomatic hyperleukocytosis is permitted before starting treatment, but must be stopped for at least 24 hours prior to starting protocol treatment.\nActive uncontrolled infection. Patients on prophylactic antibacterial, antifungal, and/or antiviral agents and patients whose infections are controlled with these agents are eligible.\nKnown active hepatitis B or C or other known active hepatic disorder.\nAny history of veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS).\nActive concurrent malignancy, unless disease-free for at least 3 years. Subjects with treated non-melanoma skin cancer, in situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been treated surgically or with definitive radiotherapy.\nUncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that per investigator's judgment would limit compliance with study requirements."
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of\n\nAML (World Health Organization [WHO] classification definition of >= 20% blasts, excluding Acute promyelocytic leukemia),\nAcute biphenotypic leukemia or\nHigh-risk MDS (> 10% bone marrow blasts)\nFrontline cohort: Patients aged 18 to 65 years\nRelapse cohort: Patients aged >=18 years old\n\nPatients may be newly diagnosed (Frontline cohort) or with prior therapy (Relapsed cohort) as follows:\n\nFor frontline cohort: Patients must be chemonaive, i.e., not have received any chemotherapy (except hydroxyurea [Hydrea] [no dose limit], tretinoin [atra] [no dose limit] or ara-C [one or two doses (max 2 gr/m^2 per dose)] for transient control of hyperleukocytosis) for AML or MDS. They may have received hypomethylating agents for prior MDS and transfusions, hematopoietic growth factors or vitamins. Temporary prior measures such as apheresis or Hydrea are allowed\nFor relapsed cohort: Patients with previously treated, relapsed or refractory AML, acute biphenotypic leukemia or high-risk MDS (> 10% bone marrow blasts)\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nCreatinine < 1.5 mg/dl\nTotal bilirubin < 1.5 mg/dL, unless increase is due to hemolysis or congenital disorder\nTransaminases (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x upper limit of normal (ULN)\nPotassium, magnesium, and calcium (normalized for albumin) levels should be at least within institutional normal limits\nAbility to take oral medication\nAbility to understand and provide signed informed consent\nBaseline test of left ventricular ejection fraction >= 50%\nWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 7 days\nWOCBP must use appropriate method(s) of contraception such as oral contraceptive pills (OCP), birth control shots, intrauterine device (IUD) etc. WOCBP should use an adequate method to avoid pregnancy until 30 days after the last dose of investigational drug. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as men with known azoospermia do not require contraception\n\nExclusion Criteria:\n\nAny coexisting medical condition that in the judgment of the treating physician is likely to interfere with study procedures or results\nBreastfeeding women\nPatients with current active malignancies or any remission for < 6 months, except patients with carcinoma in situ or with non-melanoma skin cancer who may be in remission for less than 6 months or have active disease\nActive clinically serious and uncontrolled infection. Patients with recent infections must have no temperature of >= 101 degrees Fahrenheit (F) for at least 48 hours (hrs)\nPatients with known significant impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of quizartinib\nDocumented active central nervous system leukemia (patients with history of central nervous system [CNS] leukemia without active disease are allowed)\nPatients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis\nPatients who have had any major surgical procedure within 14 days of day 1\n\nImpaired cardiac function including any of the following:\n\nScreening electrocardiography (ECG) with a corrected QT (QTc) > 450 msec. The QTc interval will be calculated by Fridericia's correction factor (QTcF) at screening and prior to the first dose of quizartinib (on day 6 during induction and day 4 during consolidation). The QTcF will be derived from the average QTcF in triplicate. If QTcF > 450 msec prior to the first dose, quizartinib will not be given until corrected\nPatients with congenital long QT syndrome\nSustained ventricular tachycardia requiring medical intervention\nAny history of clinically significant ventricular fibrillation or torsades de pointes\nKnown history of second or third degree heart block (may be eligible if the patient currently has a pacemaker)\nSustained heart rate of < 50/minute on pre-entry ECG\nLeft bundle branch block\nRight bundle branch block + left anterior hemiblock (bifascicular block)\nPatients with myocardial infarction or unstable angina within 6 months prior to starting study drug\nCongestive heart failure (CHF) New York (NY) Heart Association class III or IV\nAtrial fibrillation documented within 2 weeks prior to first dose of study drug\nKnown family history of congenital long QT syndrome\nPatients who are actively taking a strong CYP3A4 inducing medication"
            },
            {
                  "document": "Inclusion Criteria:\n\n\u2022 Subject must have newly diagnosed AML with histological confirmation by World Health Organization (WHO) criteria.\n\nDefinition of subjects who are unfit for ICT:\n\n\u2022 Each subject must meet the following criteria characterizing him / her as unfit to receive ICT within 21 days prior to the first day of therapy to be enrolled in the study:\n\n\u2265 75 years of age OR\n\n\u2265 18 to 74 years of age and fulfilling at least 1 criteria associated with lack of fitness for ICT as follows:\n\nEastern Cooperative Oncology Group (ECOG) Performance Status of 2 to 3;\nCardiac history of Congestive Heart Failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) \u2264 50%.\nDiffusing Capacity of the Lung for Carbon Monoxide (DLCO) \u2264 65% or Forced Expiratory Volume in 1 second (FEV1) \u2264 65%;\nCreatinine clearance (CrCl) \u2265 30 mL/min to < 45 mL/min calculated by the Cockcroft-Gault formula;\nModerate hepatic impairment with total bilirubin > 1.5 to \u2264 3.0 \u00d7 Upper Limit of Normal (ULN);\nOther comorbidity that the physician judges to be incompatible with conventional intensive chemotherapy which must be reviewed and approved by the study medical monitor before study enrollment.\n\nIn addition, all subjects must meet the following criteria:\n\nIf the subject is \u2265 75 years of age, then ECOG Performance Status must be 0-2.\nSubject must have adequate renal function as demonstrated by a CrCl \u2265 30 mL/min (calculated by the Cockcroft Gault formula or measured by 24-hour urine collection).\n\nSubject must have adequate liver function as demonstrated by:\n\nAspartate aminotransferase (AST) \u2264 3.0 \u00d7 ULN*\nAlanine aminotransferase (ALT) \u2264 3.0 \u00d7 ULN*\nBilirubin \u2264 1.5 \u00d7 ULN (subjects who are < 75 years of age may have bilirubin of \u2264 3.0 \u00d7 ULN)* *Unless considered to be due to leukemic organ involvement.\n\nFemale subjects must be either postmenopausal defined as:\n\nAge > 55 years with no menses for \u2265 2 years without an alternative medical cause.\nOR\nAge \u2264 55 years with no menses for \u2265 12 months without an alternative medical cause AND a follicle-stimulating hormone level > 40 IU/L;\nOR\nPermanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); OR\nA woman of childbearing potential practicing at least 1 protocol specified method of birth control starting at Study Day 1 through at least 6 months after the last dose of study treatment.\n\nA woman of childbearing potential must have negative results for pregnancy test performed:\n\nAt Pretreatment with a serum sample obtained within 14 days prior to the first study treatment administration, and\nPrior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.\nSubjects with borderline pregnancy tests at Pretreatment must have a serum pregnancy test \u2265 3 days later to document continued lack of a positive result.\nMale subjects who are sexually active, must agree, from Study Day 1 through at least 6 months after the last dose of study treatment, to practice protocol specified methods of contraception. Male subjects must agree to refrain from sperm donation from initial study treatment administration through at least 6 months after the last dose of study treatment.\nSubject must have a white blood cell count \u2264 25 \u00d7 109/L. (Note: subjects who have undergone hydroxyurea administration or leukapheresis for therapeutic cytoreduction will be considered eligible).\n\nExclusion Criteria:\n\nSubject has ECOG Performance Status > 3, regardless of age.\nSubject has known Human Immunodeficiency Virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Pretreatment, if required per local guidelines or institutional standards.\nSubject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within 3 days prior to the initiation of study treatment."
            },
            {
                  "document": "Inclusion Criteria:\n\nThe participants ages are < 18 for part 1a, < 30 for Parts 1b. 2 and 3\nStudy Part 1 (single-agent therapy dose escalation): histologically confirmed diagnosis of neuroblastoma or other solid tumor that has progressed or recurred despite standard therapy, and for which there is no therapy proven to prolong survival with an acceptable quality of life\nStudy Part 1 (combination safety run-in), Study Part 2 (initial expansion), and Study Part 3 (additional expansion): histologically confirmed diagnosis of neuroblastoma, AML, or precursor-B ALL that has progressed or recurred despite, or is refractory to, standard therapy\nAdequate performance status: Participants <16 years of age: Lansky greater than or equal to (\u2265)50%; Patients \u226516 years of age: Karnofsky \u226550%\nAdequate end-organ function, as defined in the protocol\nFor females of childbearing potential: agreement to remain abstinent, use contraception, agreement to refrain from donating eggs. Females must remain abstinent or use two methods of contraception with a failure rate of <1% per year during the treatment and follow-up period (variable depending on the combination agent) or in accordance with national prescribing information guidance regarding abstinence, contraception\nFor males: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm, with a female partner of childbearing potential or pregnant female partner, males must remain abstinent or use a condom during the treatment period and for follow-up period (variable, depending on the combination agent) or in accordance with national prescribing information guidance regarding abstinence, contraception\n\nAdditional Inclusion Criteria for Participants with Solid Tumors (including Neuroblastoma)\n\nAt least one evaluable or measurable radiological site of disease as defined by standard criteria for the participant's tumor type, or measurable bone marrow disease by morphology\nAdequate hematologic end-organ function, as defined in the protocol\nTumor tissue from relapsed disease\n\nAdditional Inclusion Criteria for Patients with Leukemia\n\nBone marrow with \u22655% lymphoblasts by morphologic assessment at screening\nAvailable bone marrow aspirate or biopsy from screening\n\nExclusion Criteria:\n\nPrimary Central Nervous System (CNS) tumors\nSymptomatic CNS metastases that result in a neurologically unstable clinical state or require increasing doses of corticosteroids or local CNS-directed therapy to control the CNS disease\nCNS3 leukemia\nAcute promyelocytic leukemia\nWhite blood cell count >50 \u00d7 10^9 cells/Liter (L)\nDown syndrome, Li-Fraumeni syndrome, history of severe aplastic anemia, or any known bone marrow failure predisposition syndrome\nBurkitt-type acute lymphoblastic leukemia\nT-cell lymphoblastic leukemia\nPrior treatment with a MDM2 antagonist\nPrior treatment with venetoclax (if potential for enrollment in a venetoclax arm)\nInfection considered by the investigator to be clinically uncontrolled or of unacceptable risk to the participant\nAny uncontrolled medical condition or other identified abnormality that precludes the patient's safe participation in and completion of the study\nSystemic anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to initiation of study treatment\nTreatment with monoclonal antibodies, antibody drug conjugates, or cellular therapy for anti-neoplastic intent within 30 days prior to initiation of study treatment\nI-131 meta-iodobenzylguanidine (MIBG) therapy within 6 weeks prior to initiation of study treatment\nMyeloablative therapy with autologous or allogeneic hematopoietic stem cell rescue within 100 days of study treatment initiation\nImmunosuppressive therapy for treatment of graft-versus-host disease within 2 weeks of study treatment initiation\nRadiotherapy within 3 weeks prior to study treatment initiation\nSpecific restrictions are applicable for patients treated with drugs interacting with CYP2C8, CYP3A4, OATP1B1/B3, and P-gp\nReceived anti-coagulant or anti-platelet agent within 7 days or 5 half-lives prior to study treatment initiation\nUnderwent major surgical procedure within 21 days of study treatment initiation, or anticipate need for major surgical procedure during the course of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nRelapse or post-transplant persistence of AML, MDS (including JMML) or MPN (CMML, myelofibrosis or MDS/MPN). Disease relapse or persistence will be defined as any measurable disease by morphology, flow-cytometry, validated tests for minimal residual disease or disease-defining mutations in the bone marrow, or non-immune privileged extramedullary sites\n\nPersistence of disease* within 4 weeks before planned NK cell infusion and at least 2 weeks after completion of immune suppression taper as long as it is > 2 months after stem cell transplantation for both adult and pediatric patients. If 2 weeks after completion of the immune suppression taper is still within 2 months of the most recent stem cell transplant, then chemotherapy with Fludarabine/Cyclophosphamide would need to start no earlier than at least 2 months after the transplant. For adults, disease persistence after a second transplant is allowed as long as the most recent transplant was a haploidentical stem cell transplant. In the pediatric cohort, disease persistence or recurrence after a second transplant is allowed as long as the most recent transplant was a haploidentical or matched related donor SCT.\n\n*Disease persistence is defined as the presence of any residual disease using standard morphological assessment, immunohistochemistry or cytogenetics, or the presence of any identifiable disease clone using either a high sensitivity flow cytometry or high sensitivity next-generation sequencing assay.\n\nAvailable original donor (same donor as used for the most recent haploidentical stem cell transplant for adults, or for the most recent matched related donor or related haploidentical donor for pediatrics) that is willing and eligible for non-mobilized collection.\nAge \u226512 years.\nECOG performance status \u22642\nT cell chimerism \u226520% donor-derived within the 4 weeks prior to cell infusion.\nPatient with \u226480% bone marrow involvement within 4 weeks prior to cell infusion. Medications like hydroxyurea, decitabine or cytarabine are allowed to control rising blasts between study enrollment and cell infusion.\nNo systemic corticosteroid therapy for GVHD (\u2264 5mg of prednisone or equivalent dose of systemic steroids for non-GVHD, non-autoimmune indications are allowed) for at least 4 weeks prior to cell infusion. Patients on systemic GVHD prophylaxis medications such as tacrolimus or sirolimus need to be off these medications for at least 4 weeks prior to cell infusion.\nNo other systemic medications/treatments (e.g. ECP) for GVHD for at least 4 weeks prior to cell infusion.\nAbility of the patient or legal guardian to understand and the willingness to sign a written informed consent document.\n\nAdequate organ function within 2 weeks of NK cell infusion as defined below:\n\nTotal bilirubin: \u22641.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then < 3 x ULN)\nAST(SGOT)/ALT(SGPT): \u22643 x institutional ULN\nSerum creatinine \u22642.0mg/dL\nO2 saturation: \u226590% on room air\nLVEF >40%. If there is no clinical evidence of a change in cardiovascular function from the time of pre-transplantation ECHO, then there is no need to repeat it. Otherwise, an ECHO will need to be repeated within 2 weeks of NK cell infusion.\nNegative pregnancy test for women of childbearing potential only.\nThe effects of CIML NK cells and IL-2 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after the last IL-2 dose administration.\n\nExclusion Criteria:\n\nExtramedullary relapse involving immuno-privileged sites (e.g. CNS, testes, eyes). Other sites of extramedullary relapse (e.g. leukemia cutis, granulocytic sarcoma) are acceptable.\nParticipants who have had other investigational agents within 4 weeks prior to cell infusion (6 weeks for nitrosoureas or mitomycin C), or immunotherapy within 8 weeks prior, or those who have not recovered from adverse events due to agents administered more than 4 weeks prior. Use of hydroxyurea to control counts within 4 weeks prior to cell infusion is permitted with study PI approval but would need to be stopped 1 day prior to administration of Fludarabine and Cyclophosphamide preceding the NK cell infusion. Patients on standard of care FLT-3, IDH1, and IDH2 inhibitors can stay on this treatment. Therapy with BCR-ABL inhibitors must be stopped 2 weeks before NK cell infusion and may be resumed after the end of the DLT period.\nPrior history of treatment with anti-CTLA-4 or anti-PD-1 pathway therapy, or CD137 agonist therapy for post-transplant relapse.\nPrior history of Donor Lymphocyte Infusion (DLI).\nPrior history of severe (grade 3 or 4) acute GVHD, or ongoing active GVHD requiring systemic treatment.\nSolid organ transplant recipient. Prior allogeneic HLA matched or mismatched stem cell transplant is allowed in the pediatric cohort. Prior HLA matched related donor or HLA matched unrelated donor stem cell transplant is allowed in the adult cohort. However, the most recent transplant must be a haploidentical stem cell transplant in adults.\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to IL2 or other agents used in study.\nAutoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]) and motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis). Patients with Hashimoto's thyroiditis are eligible to go on study.\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nPatients who develop a critical illness prior to NK cell infusion that would contraindicate the administration of Fludarabine and Cyclophosphamide conditioning. Patients who recover from such illness may still be eligible, but this must be reviewed with the study PI. A repeat bone marrow examination may be required depending on the timing of recovery. Patients who become critically ill on the planned day of NK cell infusion are excluded if the NK cell infusion cannot be given within 48 hours of the planned day 0.\nPregnant women are excluded from this study because of the unknown teratogenic risk of CIML NK cells and IL-2 and with the potential for teratogenic or abortifacient effects by Flu/Cy chemotherapy regimen. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CIML NK cells and IL-2, breastfeeding should be discontinued if the mother is treated on this study.\nHIV-positive participants are ineligible because of the potential for pharmacokinetic interactions with anti-retroviral agents used in this study. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy.\nIndividuals with active uncontrolled hepatitis B or C, HIV, or HTLV-1 are ineligible as they are at high risk of lethal treatment-related hepatotoxicity after HSCT."
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of\n\nAML (World Health Organization [WHO] classification definition of >= 20% blasts), or\nMDS intermediate-2 score or with > 10% blasts, to include: MDS, myeloproliferative neoplasm (MPN) with 10% blasts or more, or MDS/MPN 10% blasts or more\nPatients who have received at least one prior therapy for AML or for MDS will be eligible. Any prior therapy for AML or MDS will be counted as a prior salvage\n\nIn the absence of rapidly progressing disease, the interval from prior treatment to time of initiation of protocol therapy will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for cytotoxic/non-cytotoxic agents. The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochures, or drug-administration manuals) and will be documented in the protocol eligibility document. The use of chemotherapeutic or anti-leukemic agents is not permitted during the study with the following exceptions:\n\nIntrathecal (IT) therapy for patients with controlled central nervous system (CNS) leukemia at the discretion of the principal investigator (PI). Controlled CNS leukemia is defined by the absence of active clinical signs of CNS disease and no evidence of CNS leukemia on the most recent 2 simultaneous cerebrospinal fluid (CSF) evaluations\nUse of one dose of cytarabine (up to 2 g/m^2) or hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy. These medications will be recorded in the case-report form.\nEastern Cooperative Oncology Group (ECOG) performance status 0-2\nMeasured or calculated creatinine clearance >= 60 mL/min (unless considered due to leukemia)\nTotal bilirubin < 1.8 mg/dL (unless increase is due to hemolysis, congenital disorder, or leukemia)\nTransaminases (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x upper limit of normal (ULN) (unless considered due to leukemia)\nPotassium levels should be within institutional normal limits (unless considered due to leukemia)\nMagnesium levels should be within institutional normal limits (unless considered due to leukemia)\nCalcium (normalized for albumin) levels should be within institutional normal limits (unless considered due to leukemia)\nAbility to take oral medication\nAbility to understand and provide signed informed consent prior to any study-related procedures and to comply with all study requirements\nBaseline left ventricular ejection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) >= 50%\nWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 7 days. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential\nWOCBP must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy until after the last dose of investigational drug. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as men with azoospermia do not require contraception\n\nExclusion Criteria:\n\nPatients with known significant impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PLX51107\nPatients with any other known concurrent severe and/or uncontrolled medical condition including but not limited to diabetes, cardiovascular disease including hypertension, renal disease, or active uncontrolled infection, which could compromise participation in the study. Patients on active antineoplastic or radiation therapy for a concurrent malignancy at the time of screening. Maintenance therapy, hormonal therapy, or steroid therapy for well-controlled malignancy is allowed\nPatients with known positive human immunodeficiency virus (HIV), hepatitis B or C infection by serology, with the exception of those with an undetectable viral load within 3 months. (HIV testing and hepatitis B or C testing is not required prior to study entry). Subjects with serologic evidence of prior vaccination to hepatitis B virus (HBV) (i.e., hepatitis B virus surface antigen negative [HBs Ag-], and hepatitis B surface antibody positive [HBs+]) may participate\nPatients with advanced malignant hepatic tumors\nPatients with known hypersensitivity to AZA or mannitol\nWomen who are pregnant or are breast-feeding\nPatients who receive strong CYP3A4 and CYP2C8 inhibitors or inducers or CYP3A4 substrate drugs with a narrow therapeutic range, taken within 14 days or 5 drug half-lives, whichever is longer, before start of study drug\nPatients who have received anti-cancer therapy within 14 days (or 5 half-lives) with all toxicities resolved to grade 1 or less. No immune therapy or other biologic therapy (other monoclonal antibodies or antibody-drug conjugates [ADCs]) within 28 days of cycle 1 day 1"
            },
            {
                  "document": "Inclusion Criteria:\n\nAll the following criteria must be met for a patient to be eligible for the study:\n\nWritten informed consent provided prior to any study-related procedure.\nAge \u226518 years.\nAML diagnosis according to the 2016 World Health Organisation (WHO) classification (Arber et al. 2016) with relapsed or refractory disease who have received no more than 3 prior lines of therapy and with no available therapy who have exhausted the applicable standard of care; or Myelodysplastic Syndrome (MDS) diagnosis according to the 2016 WHO classification (Arber et al. 2016) with high-risk disease per the Revised International Prognostic Scoring System and with relapsed or refractory disease, who have received no more than 3 prior lines of therapy and with no available therapy who have exhausted the applicable standard of care.\nEastern Cooperative Oncology Group (ECOG) performance score of 0-2.\nPatients must have been off anti-cancer treatment for 2 weeks or 5 half-lives, whichever is longer. Note: Hydroxyurea is exempted if used to reduce total white blood cell (WBC) count (see below); radiation must have been completed at least 4 weeks prior to first dose of study drug.\nPatients must have recovered from the toxic effects of previous treatments to at least Grade 1, for neurotoxicity or alopecia to Grade 2.\n\nClinical laboratory parameters as follows:\n\nPeripheral white blood cell (WBC) count, no upper limit at Screening, but must be <10x10^9/L on Day 1 prior to first dose of study drug. Note: Patients with excessive blasts may be treated with hydroxyurea until 2 days prior to first dose of study drug to reduce WBC;\nPlatelet count >10,000/\u00b5L; Platelet transfusion prior to first dose is permitted\nSerum albumin \u2265 30g/L (3.0g/dL)\nNormal coagulation (elevated INR, prothrombin time or APTT <1.3 x ULN acceptable);\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22643x the upper limit of normal (ULN);\nTotal bilirubin \u22641.5 x ULN; and\nCreatinine clearance \u226560 mL/min (Cockcroft-Gault formula)\nUrine protein \u2264 2+ (as measured by dipstick) or \u2264100 mg/24 hours urine\nAdequate cardiac function confirmed by left ventricular ejection fraction \u226540% as per echocardiography or MUGA (Multiple Gated Acquisition) scan.\nLife expectancy of at least 12 weeks.\nFor females of childbearing potential (FCBP), a negative pregnancy test must be confirmed before enrolment. FCBP must commit to using two medically accepted forms of effective contraception during study participation and until 6 months after the last dose of study drug. Note: Where oral contraceptives are considered, please contact the Medical Monitor. Females must also refrain from donating blood during the same time-period.\nFor males, an effective barrier method of contraception must be used during study participation until 6 months after the last dose of study drug, if the patient is sexually active with a FCBP. Males must also refrain from donating blood or sperm during the same time-period.\n\nInvestigator considers the patient to be suitable for participation in the clinical study by assessing that they:\n\nUnderstand the requirements of the clinical study and can give informed consent;\nCan comply with study medication dosing requirements and all study-related procedures and evaluations; and\nAre not considered to be potentially unreliable and/or not cooperative.\n\nExclusion Criteria:\n\nAny of the following will exclude a patient from enrolment:\n\nActive central nervous system (CNS) leukemia.\nPrevious treatment with CDK8-targeted therapy.\nPatients who have undergone major surgery within 28 days prior to first dose of study drug.\nHematopoietic stem cell transplant within 120 days prior to first dose of study drug.\nActive Grade 2-4 acute graft versus host disease (GVHD), active moderate-to-severe chronic GVHD, or requirement for systemic immunosuppressive medications for GVHD.\nEvidence of ongoing and uncontrolled systemic bacterial, fungal, or viral infection and acute inflammatory conditions (including pancreatitis).\nKnown seropositivity or history of active viral infection with human immunodeficiency virus (HIV) or known active positive test of /or known active diagnosis of COVID-19 viral infection.\nOngoing significant liver disease such as cirrhosis, drug-induced liver injury, active hepatitis or chronic persistent hepatitis B and/or C.\nImpairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RVU120 (SEL120) (e.g. active inflammatory bowel disease, ulcerative disease, malabsorption syndrome, short bowel syndrome, uncontrolled nausea, vomiting or diarrhea).\nOngoing drug-induced pneumonitis.\nConcurrent participation in another investigational clinical trial.\nTaking any medications, herbal supplements or other substances (including smoking) that are known to be strong inhibitors or inducers of CYP1A2 or that can prolong Q wave to T wave (QT) interval and/or cause torsade de pointes within less than 2 weeks or 5 half-lives, whichever is shorter, prior to first dose of study drug. Any exception should be discussed with the Study Sponsor Medical Director.\nSignificant cardiac dysfunction defined as myocardial infarction within 12 months of first dose of study drug, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, or poorly controlled angina.\n\nCurrently taking drugs that are documented, in the drug package insert, to have a risk of causing prolonged QTc or torsades de pointes (TdP) within 2 weeks or 5 half-lives, whichever is shorter, prior to first dose of study drug. Please also consult the following\n\nCredible Meds web page:\n\nhttps://crediblemeds.org/index.php/login/dlcheck (Appendix F). Any exception should be discussed with the Study Sponsor Medical Director\n\nPersonal or family history of serious ventricular arrhythmia, or QT interval corrected for heart rate (QTc) \u2265450 ms (Bazett's formula).\nAny other prior or current medical condition, intercurrent illness, surgical history, physical or electrocardiogram (ECG) findings, laboratory abnormalities, or extenuating circumstance (e.g. alcohol or drug addiction) that, in the Investigator's opinion, could jeopardize patient safety or interfere with the objectives of the study.\n\nPrior history of malignancies other than AML or MDS, unless the patient has been free of the disease for 5 years or more prior to Screening. Exceptions to the \u22655-year time limit include history of the following:\n\nbasal cell carcinoma of the skin;\nnon-metastatic squamous cell carcinoma of the skin;\ncarcinoma in situ of the cervix;\ncarcinoma in situ of the breast;\ncarcinoma in situ of the bladder; and\nincidental histological finding of prostate cancer (Tumor/Node/Metastasis [TNM] stage of T1a or T1b).\nPregnant or breast-feeding females."
            },
            {
                  "document": "Key Inclusion Criteria:\n\nRecipients must meet all of the following criteria:\n\nPatients must diagnosed with one of the following histopathologically confirmed diseases, for which a myeloablative hematopoietic stem cell transplant (HCT) is planned:\n\nacute myeloid, lymphoid or mixed phenotype leukemia\nhigh or very high risk myelodysplastic syndromes\nMyelofibrosis\nBlastic Plasmacytoid Dendritic Cell Neoplasm\nPatients with active acute leukemia (i.e. not in morphologic complete response) must have bone marrow infiltration by leukemic blasts of <= 10%,\nPatients must be matched to a related or unrelated donor\nEstimated glomerular filtration rate (eGFR) > 50 mL/minute\nCardiac ejection fraction at rest \u2265 45% or shortening fraction of \u2265 27% by echocardiogram or radionuclide scan (MUGA)\nDiffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) \u2265 50%\nTotal bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included where hemolysis has been excluded) and ALT/AST < 3 times ULN\n\nKey Exclusion Criteria:\n\nRecipients meeting any of the following exclusion criteria will not be eligible:\n\nHistory of prior allogeneic HCT\nCurrently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.\nPre-planned donor lymphocyte infusion (DLI)\nPlanned pharmaceutical in vivo or ex vivo T cell depletion\nPositive for anti-donor HLA antibodies against an allele in the selected donor\nKarnofsky performance score < 70%\nHematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) > 4\nUncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment\nSeropositive for HIV-1 or -2 antibody, HTLV-1 or -2 antibody, Hepatitis B sAg, or Hepatitis C antibody\nAny uncontrolled autoimmune disease requiring active immunosuppressive treatment\nConcurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected\nWomen who are pregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nAt least age 18\nCapacity to give consent\nDiagnosis of acute myeloid leukemia (AML)\nFluent in English\nStarting a new line of in-patient chemotherapy at Duke (in the last 4 days)\n\nExclusion Criteria:\n\nPatients too sick to participate per clinician discretion\nPatients that are not able to read or understand English"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnostic criteria of AML, induction failure without having achieved remission after at least 2 attempts at induction chemotherapy, or relapsed after any complete remission (CR).\n18 to 75 years of age.\nPlanned or scheduled to receive an allogeneic HSCT from haploidentical related donors, matched and mismatched unrelated donors.\n\nAll organ function testing should be done within 28 days of study registration.\n\nPerformance status: Karnofsky \u2265 70% (Appendix A).\nCardiac: LVEF \u2265 50% by MUGA or echocardiogram.\nPulmonary: FEV1 and FVC \u2265 50% predicted, DLCO (corrected for hemoglobin) \u2265 50% of predicted.\nRenal: Creatinine clearance (CrCl) \u2265 60 mL/min/1.73 m2\nHepatic: Serum bilirubin \u22641.5 x upper limit of normal (ULN); (AST)/(ALT) \u2264 2.5 x ULN; Alkaline phosphatase \u2264 2.5 x ULN.\nBoth men and women need to use an approved method of birth control and/or abstinence due to unknown risks to the fetus.\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia (APL)\nKnown history of non-compliance with medication regimens, scheduled clinic visits, or self-care.\nIn the opinion of the investigator, no appropriate caregivers identified.\nHIV1 (Human Immunodeficiency Virus-1) or HIV2 positive\nActive Hepatitis B and Hepatitis C.\nIn the opinion of the physician investigator, uncontrolled medical or psychiatric disorders.\nUncontrolled infections requiring treatment within 14 days of registration.\nActive central nervous system (CNS) leukemia.\nCord blood transplant excluded.\nPrior allogeneic HSCT within last 6 months.\nPatients with >= grade 2 acute GVHD.\nPatients with >=moderate chronic GVHD.\nPregnant or Breastfeeding. Women of child bearing potential (WCBP) are required to have a negative serum or urine pregnancy test prior to initiation of conditioning regimen.\nHaploidentical related donors who are positive for DSA \u2265 5000 MFI by solid phase microarray method (Luminex)."
            },
            {
                  "document": "Inclusion Criteria:\n\nAn established and confirmed diagnosis of AML by World Health Organization criteria, excluding acute promyelocytic leukemia (APL) (with promyelocytic leukemia -retinoic acid receptor alpha [PML-RARA])\n\nPatients with R/R AML, defined as:\n\nRelapsed: >= 5% bone marrow blasts by morphology, reappearance of peripheral blood blasts, or development of extramedullary leukemia after achieving prior CR or CRi. First or second relapse is eligible. First relapse is restricted to participants with CR 1 duration of less than 9-12 months\nRefractory: no CR or CRi after one or more cycles of induction. Induction cycles include regimens with the intent to achieve remission and can include high intensity and/or low intensity regimens\nAge >= 18 years. Because no dosing or adverse event data are currently available on the use of M3814 in combination with mitoxantrone, etoposide, and cytarabine in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials\nEastern Cooperative Oncology Group (ECOG) performance status =< 1 (or Karnofsky >= 60%)\nSerum bilirubin =< 1.5 institutional upper limit of normal (ULN) (For patients with hemolysis, Gilbert's syndrome or liver infiltration with leukemia, serum bilirubin =< 3 x institutional ULN)\nAspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN (For patients with liver infiltration with leukemia, AST[SGOT]/ALT[SGPT] =< 5 x institutional ULN)\nGlomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula\nPatients must be medically eligible to receive MEC, including acceptable pre-study cardiac function (left ventricular ejection fraction of >= 45%) and lifetime anthracycline exposure (=< 360 mg/m^2 daunorubicin equivalents)\nPatients may have had prior allogeneic hematopoietic cell transplant at least 3 months prior to enrollment but should not have evidence of active graft versus host disease or require systemic immune suppression\nPatients must be willing to submit the blood sampling and bone marrow sampling for any mandatory PK and pharmacodynamics analyses and exploratory biomarkers\nFemale patients with child bearing potential must have a negative serum pregnancy test within 72 hours prior to the first study drug administration and all patients must be willing to use effective methods of contraception during the treatment period and 3 months after study completion\nHuman immunodeficiency virus (HIV)-infected patients will be eligible for this trial if they are on effective antiretroviral regimens utilizing non-CYP-interacting agents, they have an undetectable viral load, they have a CD4 count > 350 cells/mm^3, and they have no history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections. If there is evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy, if indicated. If there is history of hepatitis C virus (HCV) infection, the patient must have been treated and have undetectable HCV viral load\nPatients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\nAbility to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible\nAll non-hematologic adverse events (AEs) of prior chemotherapy, surgery, or radiotherapy, except alopecia, must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade =< 1 prior to starting therapy\n\nExclusion Criteria:\n\nPatients must not have had prior treatment with MEC\nPatients must not have documented active central nervous system (CNS) involvement by leukemia. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)\nPatients must not have received any other investigational or commercial agents or therapies administered with the intention to treat their leukemia within 14 days or 5 elimination half-lives (whichever is shorter) of first receipt of study drug, with the exception of hydroxyurea and/or leukapheresis used to control white blood cell counts\n\nPatients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9 and CYP2C19 during treatment with M3814. Concomitant use of CYP1A2, CYP2B6 and CYP3A4/5 substrates with a narrow therapeutic index are also excluded during treatment with M3814. Patients may confer with the study doctor to determine if alternative medications can be used. The following categories of medications and herbal supplements must be discontinued for at least the specified period of time prior to the first dose of M3814:\n\nStrong inducers of CYP3A4/5, CYP2C9 and CYP2C19: >= 3 weeks or 5 elimination half-lives (whichever is shorter) prior to the first dose of M3814\nStrong inhibitors of CYP3A4/5, CYP2C9 and CYP2C19: >= 1 week or 5 elimination half-lives (whichever is shorter) prior to the first dose of M3814\nSubstrates of CYP1A2, CYP2B6 and CYP3A4/5 with a narrow therapeutic index: >= 1 day prior to the first dose of M3814\nPatients who cannot discontinue concomitant proton-pump inhibitors (PPIs). Patients may confer with the study doctor to determine if such medications can be discontinued. These must be discontinued >= 5 days or 5 elimination half-lives (whichever is shorter) prior to the first dose of M3814. Patients do not need to discontinue calcium carbonate or H2 blockers\nPatients receiving sorivudine or any chemically related analogues (such as brivudine) are excluded\nPatients who require oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes (including coumadin and warfarin), or who received such agents within 5 days of the first dose of M3814. Low and high-molecular weight heparins are permitted provided the platelets are maintained at greater than 30,000/mm^3\nPatients with ongoing active infection or who have received a live attenuated vaccine within 30 days of dosing with M3814\n\nPatients must not have known significant cardiopulmonary disease defined as:\n\nUnstable angina;\nCongestive heart failure (New York Heart Association [NYHA] class III or IV;\nMyocardial infarction (MI) within 6 months prior to first dose. Patients who had ischemic heart disease such as acute coronary syndrome (ACS), MI, and/or revascularization more than 6 months before screening and who are without cardiac symptoms or those with a prior non-ST elevation MI (NSTEM) due to demand-supply mismatch (NSTEM Type II) may enroll\nPatients should not have severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator, could affect their participation in the study\nPatients with psychiatric illness/social situations that would limit compliance with study requirements\nPatients should not be pregnant or breastfeeding\nA marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 480 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT correction formula\nA history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT syndrome)\nThe use of concomitant medications that prolong the QT/corrected QT (QTc) interval\nGastrointestinal disorders that may affect the M3814 absorption\nPatients will need to avoid any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days before the first administration of M3814 and throughout the duration of M3814 treatment"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients who are considered appropriate candidates for myeloablative, TBI-containing allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses:\n\nAcute lymphocytic leukemia (ALL) in first or subsequent morphological remission (< 5% marrow blasts by morphology).\nAcute myeloid leukemia (AML) in first or subsequent morphological remission (< 5% marrow blasts by morphology).\nOther acute leukemia or related neoplasm (including but not limited to 'mixed phenotype' 'biphenotypic', 'acute undifferentiated' or 'ambiguous lineage' acute leukemia, blastic plasmacytoid dendritic cell neoplasm or lymphoblastic lymphoma) in first or subsequent morphological remission (< 5% marrow blasts by morphology).\n\nPatient age 1-60 years old (inclusive) at the time of informed consent\n\nPatients aged 1-50 years old (inclusive) are eligible for TBI-based conditioning regimens\nPatients aged 1-60 years old (inclusive) are eligible for busulfan-based conditioning regimens (with or without TBI 4 Gy)\nPatient with an HLA-matched (HLA-A, B, C, DRB1, and DQB1 matched) related or unrelated donor capable of donating PBSC.\nRecipient informed consent/assent and/or legal guardian permission must be obtained.\nDONOR: HLA-matched related and unrelated donors (HLA-A, B, C, DRB1 and DQB1 matched based on high-resolution typing).\nDONOR: >= 18 years old.\nDONOR: Willing to donate PBSC.\n\nDONOR: Matched related donors:\n\nMust give informed consent using the related donor informed consent form.\nMust meet institutional donor eligibility criteria or be ineligible with statement that the donor is a first or second degree relative (exception 21 Code of Federal Regulations [CFR] 1271.65(b)(i)).\n\nDONOR: Matched unrelated donors:\n\nMust consent according to the applicable National Marrow Donor Program (NMDP) donor regulatory requirements.\nMust meet eligibility criteria as defined by the NMDP or be ineligible with statement of urgent medical need (exception 21 CFR 1271.65(b)(iii)).\n\nExclusion Criteria:\n\nPatients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation. A patient may have a history of CNS disease. However, any CNS disease must be cleared by the end of the pre-conditioning evaluation time frame. If CNS disease is identified on cerebrospinal fluid (CSF) evaluation within 30 days of the start of the preparative regimen a repeat CSF evaluation must be performed and show no evidence of disease in order for the patient to be eligible for the protocol.\nPatients on other experimental protocols for prevention of GVHD.\n\nPatient weight:\n\nPatients with HLA-matched related donors will be excluded if they weigh >= 100 kg.\nPatients with HLA-matched unrelated donors will be excluded if they weigh >= 100 kg and must be discussed with the Fred Hutch protocol principal investigator (PI) if they weigh >= 80 kg.\nPatients who are positive for human immunodeficiency virus (HIV)-1, HIV-2, human T-cell lymphotropic virus (HTLV)1 or HTLV2.\nPatients with uncontrolled infections for whom myeloablative HCT is considered contraindicated by the consulting infectious disease physician; i.e. patients with active infections require infectious disease consultation and documentation by the infectious disease team that myeloablative HCT is not considered to be contraindicated. Upper respiratory tract infection is not considered to represent an uncontrolled infection in this context.\n\nPatients with organ dysfunction, including:\n\nRenal insufficiency (creatinine > 1.5 mg/dl) at the time of evaluation for the protocol. Patients with a known history of creatinine > 1.5 mg/dl or a current serum creatinine above the normal range for age must have a current creatinine clearance of > 60 ml/min/1.73 m^2 (measured by 24-hr urine specimen or nuclear glomerular filtration rate [GFR]).\nLeft ventricular ejection fraction < 45%.\nCarbon monoxide diffusing capability (DLCO) corrected < 60%. Patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the oxygen (O2) saturation is < 92% on room air.\nLiver function abnormality. Patients who have liver function test (LFT)s (specifically, total bilirubin, aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) >= twice the upper limit of normal should be evaluated by a gastrointestinal (GI) physician unless there is a clear precipitating factor (such as an azole, MTX, trimethoprim-sulfamethoxazole, or another drug). If the GI physician considers that HCT on the protocol is contraindicated, that patient will be excluded from the protocol. Patients with Gilbert's syndrome and no other known liver function abnormality or with reversible drug-related transaminitis do not necessarily require GI consultation and may be included on the protocol.\nPatients who have received previous myeloablative allogeneic or autologous transplantation.\nPatients with a life expectancy < 12 months from co-existing disease other than the leukemia.\nPatients who are pregnant or breast-feeding.\nPatients of childbearing age who are presumed to be fertile and are unwilling to use an effective birth control method or refrain from sexual intercourse during and for 12 months post-HCT.\nPatients with any other significant medical conditions that would make them unsuitable for transplantation, as determined by the PI.\nPatients with a known hypersensitivity to tacrolimus or MTX\nPatients who have received checkpoint inhibitors within three months of transplantation unless an exception is made by the PI\nDONOR: Donors who are HIV-1, HIV-2, HTLV-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection. Test must be performed using Food and Drug Administration (FDA) licensed, cleared, and approved test kits (serological and/or nucleic acid amplification test [NAT] and/or other approved testing) in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory."
            },
            {
                  "document": "Inclusion Criteria:\n\nDocumented informed consent of the participant and/or legally authorized representative\nAgreement to allow the use of archival blood samples and marrow from diagnostic tumor biopsies. If unavailable, exceptions may be granted with study principal investigator (PI) approval\nEastern Cooperative Oncology Group (ECOG) status of 0-1\nHistologically confirmed AML or MDS with the following characteristics\n\nPatients diagnosed with AML by World Health Organization (WHO) classification, meeting one of following criteria:\n\nAge 60 or older, newly diagnosed, untreated, who are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines\nAge 60 or older with relapsed or refractory disease\nAdult patients < 60 with previously untreated high-risk disease (complex karyotype, inv(3) or t(3;3), t(6;9), monosomal karyotype, therapy-related and secondary disease) that are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines and/or allogeneic stem cell transplantation\nAdult patients < 60 with refractory/relapsed AML who are otherwise not candidates for allogeneic stem cell transplantation\nPatients with extramedullary disease who meet one of the above criteria may be included\n\nPatients with a diagnosis of MDS as per WHO Classification that meets one of the following treatment history criteria\n\nNewly diagnosed high-risk MDS (International Prognostic Scoring System [IPSS]: intermediate 2 and high risk)\nRefractory to or relapsed after previous therapies\nHuman leukocyte antigen (HLA)-DR15-positive MDS that has failed immunosuppressive therapies\nMust have a life expectancy of >= 3 months\nFully recovered (=< grade 1) from the acute toxic effects (except alopecia) of prior anti-cancer therapy\nCannot be a candidate for allogeneic hematopoietic cell transplantation (alloHCT) within 90 days of starting treatment on the protocol and should be off pembrolizumab for at least 30 days to become eligible for alloHCT post-protocol therapy\nTotal bilirubin =< 1.5 x upper limit of normal (ULN) (unless has Gilbert?s disease)\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN\nCreatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula\nInternational normalized ratio (INR) OR prothrombin time (PT) =< 1.5 x ULN\nActivated partial thromboplastin time (aPTT) =< 1.5 x ULN\nLeft ventricular ejection fraction (LVEF) >= 50%\nCorrected QT (QTc) =< 480 ms, Note: electrocardiogram (ECG) to be performed within 14 days prior to day 1 of protocol therapy\n\nSeronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]) (within 28 days prior to day 1 of protocol therapy)\n\nIf positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed\n\nMeets other institutional and federal requirements for infectious disease titer requirements\n\nNote: Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy\nWomen of childbearing potential (WOCBP): negative urine or serum pregnancy test\n\nAgreement by males and females of childbearing potential to use an effective birth control method of low user dependency or abstain from heterosexual activity from 4 weeks prior to first dose of treatment throughout the study treatment period and 3 (males) to 4 (females) months from the last dose of treatment\n\nChildbearing potential is defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nAlso, male subjects should refrain from sperm donation from the start of treatment throughout the study treatment period and for 6 months following the last dose of treatment\n\nExclusion Criteria:\n\nPrevious allogeneic cell transplantation for at least 1 year (yr) prior, have no history of graft versus host disease (GVHD) and been off all immunosuppression for at least 3 months\nPrevious treatment with pembrolizumab\nSystemic steroid therapy or any other form of immunosuppressive medication\nReceived a live-virus vaccination within 30 days of planned treatment start\nPrior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or PD ligand-1 (PD-L1) or PD ligand-2 (PD-L2) agent or an antibody targeting other immuno-regulatory receptors or mechanisms\nPrior therapy with an anti-CD137, anti-CTLA-4 antibody (including ipilimumab), denosumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways\nCurrent or planned use of other investigational agents, or concurrent biological, chemotherapy, or radiation therapy during the study treatment period, or within 4 weeks prior to day 1 of protocol therapy\nSystemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within 4 weeks prior to day 1 of protocol therapy\nConcurrent use of corticosteroids (exception: nasal or topical corticosteroids or physiologic levels for steroid replacement are allowed)\nConcurrent use of granulocyte-macrophage colony-stimulating factor (GMCSF) or granulocyte colony stimulating factor (GCSF), or within 7 days prior to start of study treatment\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\nSevere hypersensitivity reaction to treatment with another monoclonal antibody (mAb)\nActive central nervous system (CNS) disease\nHistory of (non-infectious) pneumonitis that required steroids or has current pneumonitis\nActive autoimmune disease that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed)\nUncontrolled active infection requiring therapy\n\nSeronegative for HIV Ag/Ab combo, HCV, active HBV (surface antigen negative), and syphilis (RPR).\n\nIf positive, hepatitis C RNA quantitation must be performed\nKnown history of active TB (Bacillus tuberculosis)\nHistory of deep venous thrombosis (DVT) or pulmonary embolism\nSymptomatic ascites or pleural effusion\nClinically significant uncontrolled illness\nFemales only: Pregnant or breastfeeding\nAny other condition that would, in the investigator?s judgment, contraindicate the patient?s participation in the clinical study due to safety concerns with clinical study procedures\nProspective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)"
            },
            {
                  "document": "Inclusion Criteria:\n\nVoluntary written informed consent\nMen or women, age \u2265 18 years of age, with upper limit of 75 years old.\nSubjects with acute myeloid leukemia (AML) or Myelodysplastic Syndrome (MDS) for cohort 1.\nSubjects with chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), CML, chronic neutrophilic leukemia (CNL), myelofibrosis, and myelodysplastic/myeloproliferative (MDS/MPN) overlap syndrome for cohort 2.\nKarnofsky performance status (KPS) of \u2265 70%\nPatients should have New York Heart Association (NYHA) Functional Classification, Class I (ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain) or Class II (ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain).\nAdequate hepatic, renal, cardiac and pulmonary function to be eligible for transplant. Minimum criteria include: Hepatic: ALT, AST < 4x IULN and serum total bilirubin \u2264 2.0 mg/dL; Renal: serum creatinine: \u2264 2.0 mg/dL; Left ventricular ejection fraction \u2265 45% measured by 2D-ECHO or MUGA scan; EKG with no clinically significant arrhythmia; FEV1, FVC and DLCO \u2265 50% of predicted value (corrected to serum hemoglobin)\nWomen of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman or partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and the investigator immediately.\nA woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\nWomen of child-bearing potential should have a negative urine or serum pregnancy test within 4 weeks of starting preparative regimen\n\nExclusion Criteria:\n\nPregnant or breastfeeding\nSevere chronic obstructive pulmonary disease requiring oxygen supplementation\nHistory of spontaneous pneumothorax, prior chest surgery requiring thoracotomy or direct chest irradiation to the lungs\nEvidence of pneumothorax or significant pulmonary fibrosis on chest imaging within 60 days of transplant.\nActive malignancy excluding AML, MDS, CMML, aCML CML, CNL, MF and MDS/MPN overlap syndrome.\nActive ear/sinus infection. Patients with chronic sinusitis or sinus headaches are excluded unless cleared by ear, nose, and throat specialist.\nRecent sinus surgery (within the last 5 years).\nEar surgery excluding myringotomy or ear tubes\nSubjects must agree to refrain from active tobacco or e-cigarette use 72 hours prior to transplant until complete transplant recovery. Nicotine replacement therapy is allowed.\nClaustrophobia\nHistory of recurrent seizures within 5 years of study enrollment.\nUncontrolled asthma\nUncontrolled viral or bacterial infection at the time of study enrollment\nActive or recent (prior 6 months) invasive fungal infection without interdisciplinary (ID) consult and approval\nPatients who had intrathecal chemotherapy within 2 weeks of starting preparative regimen or cranial irradiation within 4 weeks of starting preparative regimen"
            },
            {
                  "document": "Inclusion Criteria:\n\nWritten informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.\nAge \u2265 18 years\nLife expectancy > 12 weeks.\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nHistologically confirmed diagnosis of one of the following, in accordance with WHO diagnostic criteria:\n\nEscalation:\nDiffuse Large B-cell Lymphoma (DLBCL, including primary mediastinal large B cell lymphoma, T cell rich B cell lymphoma, and high-grade B cell lymphoma NOS). Patients with Burkitt's, lymphoblastic lymphoma, follicular lymphoma, and mantle cell lymphoma are not included. OR\nAcute Myeloid Leukemia (AML)\nExpansion:\nDiffuse Large B-cell Lymphoma and acute myeloid leukemia as above.\nVEN Refractory expansion cohort (Diffuse Large B-cell Lymphoma and acute myeloid leukemia only): Patients must have previously received and failed venetoclax therapy (either monotherapy or combination) during their treatment course (i.e., patients may receive non-VEN therapy immediately prior to enrollment on this study). Treatment failure is defined as evidence of disease progression after \u2265 1 cycle (four weeks) of full-intensity venetoclax-based therapy (i.e., 28 days exclusive of ramp-up. Patients that require dose reductions due to intolerance may be considered for this cohort after discussion with the sponsor.)\nRelapsed or refractory following \u2265 1 line(s) of prior therapy\nPatients that relapse \u2265 3 months after allogeneic hematopoietic cell transplantation (HCT) are eligible.\nFemale patients of childbearing potential must agree to use two methods of contraception (including one highly effective and one effective method of contraception) and have a negative serum pregnancy test at screening. Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatment.\nFor leukemia and DLBCL with known or suspected marrow involvement, patients must have at least 10-15 mL of bone marrow aspirate material obtained within 14 days of beginning treatment on this study. Patients with DLBCL must have 3-5 unstained slides, or tissue block, available for evaluation within 14 days of study enrollment in the expansion cohorts. DLBCL patients enrolled during the escalation phase must have blocks available for submission within 28 days of beginning treatment.\n\nCBC testing must confirm adequate marrow reserve, as demonstrated by:\n\nDLBCL: Hgb \u2265 10g/dL, platelets \u2265 75,000 cells/mm3 , ANC \u2265 1,000 cells/mm3\n\nAdequate organ function, as demonstrated by:\n\nTotal bilirubin < 1.5 x upper limit of normal (ULN) (except patients with Gilbert's syndrome (hereditary indirect hyperbilirubinemia), who must have a total bilirubin of < 3 x ULN, and\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to < 2 x ULN\nCalculated creatinine clearance > 50 mL/min (per the Cockcroft-Gault formula).\nPatients with laboratory evidence of liver or kidney dysfunction secondary to underlying disease, that is expected to reverse with treatment, may be enrolled after discussion with the sponsor/investigator.\n\nExclusion Criteria:\n\nPatients who are pregnant or lactating\nPatients who received any systemic anticancer therapy including investigational agents or radiation \u22643 weeks (or \u22645 half-lives of the drug [whichever is shorter]) prior to C1D1. Hydroxyurea is permitted for up to 14 days in AML patients\nInadequate recovery from toxicity attributed to prior anti-cancer therapy. With the exception of alopecia or fatigue, patients must have recovered to baseline or \u2264 Grade 1 (NCI-CTCAE v4.03) residual toxicity prior to first dose of protocol-indicated treatment.\nParticipation in another clinical trial with any investigational drug within 14 days prior to study enrollment.\nPatients included in the VEN refractory cohort that have discontinued venetoclax therapy (either monotherapy or combination) due to toxicity or hypersensitivity, including prior history of grade 3/4 TLS during prior VEN exposure\nIn dose expansion cohorts, except venetoclax refractory cohort, no prior treatment with SINE compounds, another XPO1 inhibitor, or BCL-2 inhibitors.\nActive GVHD requiring calcineurin inhibitors or steroid dosing \u2265 10mg/day prednisone (or equivalent) or < 3 months from allogenic hematopoietic cell transplant (HCT).\nUncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral.\nMajor surgery within 2 weeks of first dose of study drug.\nAny life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety.\n\nUnstable cardiovascular function:\n\nSymptomatic ischemia, or\nUncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on anti-arrhythmia therapy are excluded; 1st degree AV block or asymptomatic LAFB/RBBB will not be excluded), or\nCongestive heart failure (CHF) of NYHA Class \u22653, or\nMyocardial infarction (MI) within 3 months.\nKnown active Hepatitis B or Hepatitis C infection (Hepatitis testing is not required as part of this study).\nKnown human immunodeficiency virus (HIV) infection (HIV testing is not required as part of this study).\nSubject has received the following \u2264 7 days prior to Cycle 1, Day 1: Strong and moderate CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.\nSubject has received the following \u2264 5 days prior to Cycle 1, Day 1: Strong and moderate CYP3A inhibitors such as fluconazole, ketoconazole, and clarithromycin.\nSubject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit \u2264 3 days prior to Cycle 1, Day 1.\nInability to swallow oral medication; or the presence of a poorly controlled gastrointestinal disease, disorder, syndrome, or dysfunction that could significantly affect the absorption of oral study drug - e.g. Crohn's disease, ulcerative colitis, chronic diarrhea (defined as > 4 loose stools per day), malabsorption syndrome, or bowel obstruction.\nInability or unwillingness to take required and recommended medications intended to prevent and treat potential adverse events of tumor lysis syndrome (TLS), nausea and vomiting, loss of appetite, and fatigue.\nPatients unwilling to comply with the protocol"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge >= 18 years. Because no dosing or adverse event (AE) data are currently available on the use of olaparib in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials\nDiagnosis of MDS or AML per World Health Organization 2016 classification. AML may be de novo, or following a prior hematologic disorder, including MDS or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-related.\n\nPatients must have a documented IDH1 or IDH2 mutation within 30 days of inclusion based on mutational testing. Only specific mutations that lead to a neomorphic phenotype will be eligible for enrollment, and include those listed below:\n\nIDH1: R132V, R132G, R132S, R132L, R132C and R132H\nIDH2: R140W, R140L, R140Q, R172W, R172G, R172S, R172M, R172K.\nPatients with AML or MDS should have disease that has relapsed after, or is refractory to, first-line therapy, with or without subsequent additional therapy.\nPatients with MDS should have at least a MDS-excess blasts (EB)1 at the inclusion and have a revised International Prognostic Symptom Score risk stratification of intermediate, high, or very high risk.\nHuman immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\nFor patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\nPatients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\nPatients may or may not have been previously treated with IDH targeted therapies.\nPatients who have undergone allogeneic stem cell transplant (alloSCT) are eligible if they are >= 180 days from stem cell infusion, have no evidence of graft versus host disease (GVHD) > grade 1, and are >= 2 weeks off all immunosuppressive therapy.\nPrevious cytotoxic chemotherapy must have been completed at least 3 weeks and radiotherapy at least 2 weeks prior to Day 1 of treatment on the study, and all adverse events (AEs) (excluding alopecia) due to agents administered more than 4 weeks earlier should have recovered to < grade 1. Patients with hematologic malignancies are expected to have hematologic abnormalities at study entry. Hematologic abnormalities that are thought to be primarily related to leukemia are not considered to be toxicities (AEs) and do not need to resolve to < grade 1.\nEastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky >= 60%).\nPatient must have recovered from toxicities of any prior treatment regimen (no Common Terminology Criteria for Adverse Events [CTCAE] grading over 1 for non-hematological toxicities, return to baseline for hematological values).\nAbility to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity may have a close relative, guardian, caregiver, or legally authorized representative consent on their behalf.\nTotal bilirubin =< 1.5 x institutional upper limit of normal (ULN) unless considered due to Gilbert's syndrome (measured within 28 days prior to administration of study treatment).\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless considered due to organ leukemic involvement (measured within 28 days prior to administration of study treatment). If liver metastases are present in which case they must be =< 5 x ULN.\nCreatinine clearance of > 30 ml/min (measured within 28 days prior to administration of study treatment).\nPatients are eligible for this study if low blood count and transfusion support are due to the MDS/AML.\nPatients must have, in the best estimate of the treating physician, a life expectance of at least 12-16 weeks.\n\nPostmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1. Postmenopausal is defined as:\n\nAmenorrheic for 1 year or more following cessation of exogenous hormonal treatments\nLuteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50\nRadiation-induced oophorectomy with last menses > 1 year ago\nChemotherapy-induced menopause with > 1 year interval since last menses\nSurgical sterilization (bilateral oophorectomy or hysterectomy)\nMale patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.\n\nExclusion Criteria:\n\nPatients with acute promyelocytic leukemia.\nPatients with active central nervous system (CNS) leukemia or requiring maintenance intrathecal chemotherapy.\nPatients receiving concurrent chemotherapy, radiation therapy, or immunotherapy for AML/MDS.\nPatients actively receiving any other investigational agents.\nManagement of treatment for patients with co-occurring mutations, like FLT3, will be prioritized by the treating physician after discussion of treatment options with the patient.\nHyperleukocytosis with > 50,000 white blood cell (WBC)/mcl. Hydroxyurea for WBC count control is permitted before starting treatment and may be continued until day 28 of cycle 1. The maximum dose of hydrea will be 6 grams per day. Patients will be withdrawn from the study if > 50,000 WBC/mcl occur or recur > 14 days after starting treatment on the study.\nActive, uncontrolled infection. Patients with infection controlled with antibiotics are eligible.\nPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.\nPatients who are pregnant or nursing. Pregnant women are excluded from this study because olaparib is a PARP inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with olaparib, breastfeeding should be discontinued if the mother is treated with olaparib. These potential risks may also apply to other agents used in this study.\nResting electrocardiogram indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, corrected QT by Fridericia's formula (QTcF) prolongation > 500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.\nPatients with symptomatic uncontrolled CNS disease. Imaging to confirm the absence of brain metastases is not required. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.\nThe patient can receive a stable dose of corticosteroids, up to 20 mg by mouth (PO) prednisone daily, before and during the study as long as these were started at least 4 weeks prior to treatment.\nPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\nAny previous treatment with PARP inhibitor, including olaparib.\nConcomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.\nMajor surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\nPatients with a known hypersensitivity to olaparib or any of the excipients of the product.\nPatient with active malignancies requiring active treatment that interferes with protocol therapy and/or with significant risk of clinical relapse within 12 months that would require treatment interfering with protocol therapy are excluded.\nPersistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy, excluding alopecia.\nPatients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment.\nConcomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks. Patients without reasonable alternative may be included in the trial after discussion with the medical monitor.\nPrevious double umbilical cord blood transplantation (dUCBT).\nBreast feeding women."
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipant has confirmation of acute myeloid leukemia (AML) by World Health Organization (WHO) criteria.\nParticipant is deemed by the investigator to be an appropriate candidate for outpatient ramp-up of venetoclax.\nParticipant is not eligible to receive treatment with standard cytarabine and anthracycline induction regimens.\nParticipant has not received prior treatment for AML (treatment na\u00efve) with the exception of hydroxyurea.\nParticipant has no evidence of spontaneous tumor lysis syndrome (TLS) at Screening.\nParticipant can have progressed from myelodysplastic syndrome (MDS) or be considered to have secondary AML and could have been treated with growth factors or other agents with the exception of hypomethylating agents.\nParticipant has adequate kidney, liver and hematology laboratory values as detailed in the protocol.\nHas an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 3.\n\nExclusion Criteria:\n\nHas a history of the following conditions:\n\nAcute promyelocytic leukemia\nKnown active central nervous system involvement with AML\nPositive for HIV (HIV testing is not required)\nPositive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months\nCardiovascular disability status of New York Heart Association Class > 2\nChronic respiratory disease that requires continuous oxygen or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study\nMalabsorption syndrome or other condition that precludes enteral route of administration\n\nHas a history of other malignancies within 2 years prior to study entry, with the exception of:\n\nAdequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatient post a cord blood transplant (CBT) with documented absolute neutrophil engraftment and no evidence of GVHD or no history of acute or chronic GVHD requiring systemic steroids\nPatients with documented engraftment but require granulocyte-colony stimulating factor (G-CSF) to treat myelosuppression induced by drugs used to treat or prevent infection are eligible\nKarnofsky performance status (KPS) > 60%\nAbsence of dyspnea or hypoxia (< 90% of saturation by pulse oximetry on room air)\nBilirubin =< 1.5 x upper limit of normal (ULN)\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and/or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN\nProthrombin time (PT)/partial prothrombin time (PTT) < 1.5 x ULN\nCalculated creatinine clearance > 60 mL/min/1.73 m^2\nDiagnosis of acute myeloid leukemia; myelodysplastic syndrome; chronic myeloid leukemia or myeloproliferative disease\n\nExclusion Criteria:\n\nPregnant or nursing\nHistory of lymphoid malignancy (including Hodgkin disease, non-Hodgkin lymphoma, acute lymphoblastic leukemia and chronic lymphocytic leukemia) or acute biphenotypic leukemia\nHistory of Epstein-Barr virus (EBV) associated lymphoproliferation\nActive uncontrolled viral, bacterial or fungal infection\nDocumented human immunodeficiency virus (HIV)-1 or -2, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection at any time before or after transplant. (A positive hepatitis B serology indicative of a previous immunization is not an exclusion criteria)\nEBV viremia equal to or greater than 500 copies EBV deoxyribonucleic acid (DNA)/mL of blood by quantitative polymerase chain reaction (PCR)\nPositive cytomegalovirus (CMV) antigenemia\nHistory of autoimmune disease\nReceiving systemic corticosteroid therapy\nReceiving concurrent treatment with another investigational drug and/or biological agent\nReceiving anticoagulant therapy\nUncontrolled hypertension\nCorrected QT (QTc) prolongation (QTc > 470 ms) or prior history of significant arrhythmia or electrocardiogram (ECG) abnormalities\nActive drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements\nAny past or current psychiatric illness that, in the opinion of the investigator, would interfere with adherence to study requirements or the ability and willingness to give written informed consent"
            },
            {
                  "document": "Main Inclusion Criteria:\n\nMale or female patients \u2265 18 years of age at the date of ICF signature who present with one of the following:\n\nRelapsed/refractory AML following \u22651 prior therapies (but \u22643 prior therapies) who have relapsed or exhibited refractory disease (primary failure) and are deemed by the Investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)\nFirst line AML patient unfit for standard induction chemotherapy (includes both de novo and secondary AML), except in countries where approved therapies are available. Patients who are suitable for hematopoietic stem cell transplantation and willing to receive it are excluded.\nHigh-risk MDS patient (high and very high-risk groups according to rIPSS) who have failed hypomethylating agent therapy.\nECOG performance status \u2264 1\nTP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and determined to contain no mutations. The TP53 status must be obtained from a bone-marrow sample, collected no longer than 3 months before signing the main ICF.\nPatient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutional guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis.\n\nMain Exclusion Criteria:\n\nPatients eligible for this study must not meet any of the following criteria:\n\nPrior combination treatment with compounds having the same mode of action:\n\nmdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in treatment arm1)\nmdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in treatment arm2)\nHistory of severe hypersensitivity reactions to any ingredient of study drug(s) and other monoclonal antibodies (mAbs) and/or their excipients.\nPatients with acute promyelocytic leukemia with PML-RARA.\nAllogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD requiring systemic immunosuppressive therapy.\nGI disorders impacting absorption of oral HDM201 or venetoclax.\nEvidence of active bleeding or bleeding diathesis or major coagulopathy (including familial).\nPatients with active, known or suspected autoimmune disease (treatment arm 1 only).\n\nOther eligibility criteria apply."
            },
            {
                  "document": "Inclusion Criteria:\n\nA history of AML or MDS with at least one of the following features:\n\nAML: High-risk AML as defined by the 2017 European LeukemiaNet criteria (e.g. complex karyotype with \u22653 changes), AML with high-risk mutations (e.g. TP53, RUNX1, or ASXL1 mutations), transplant being performed in second remission or beyond, or AML with active disease or minimal residual disease positivity before or after transplant.\n\nMDS: MDS with high or very-high risk cytogenetic changes as used indefined by the Revised International Prognostic Scoring System (e.g. complex karyotype with \u22653 changes),53 the presence of TP53 mutation, high-risk or very high-risk MDS not responding to 4 cycles of hypomethylating agents, MDS progressing following initial response, persistence of MDS after transplant, or transplant being performed in second remission or beyond.\n\nReceipt of allogeneic hematopoietic stem cell transplant 6-20 weeks prior to enrollment\nDisease status: <5% bone marrow blast at the time of enrollment\nAll donor sources and conditioning regimens are allowed\nAdults, Age \u226519 years (for the state of Nebraska)\nKarnofsky Performance Status (KPS) of \u226570\nAbsolute neutrophil count (ANC) greater than 1000/\u00b5L without the use of granulocyte colony stimulating factor in the past 2 weeks, and platelet count 50,000/\u00b5L without platelet transfusion in the past 2 weeks.\nAble to take oral medication.\nFemale patient of reproductive potential must have a negative serum or urine pregnancy test \u22647 days prior to starting the study drug.\nMale and female patients of reproductive potential must be willing to avoid pregnancy or fathering children from enrollment to two months after the end of study treatment. This will require either a total abstinence, OR exclusively non-heterosexual activity (when this is in line with the preferred and usual lifestyle of the subject), OR two methods of contraception\nWritten informed consent to participate in the study.\n\nExclusion Criteria:\n\nA history of acute graft-versus-host disease grade III/IV or initiation of any new immunosuppressive agent for treatment of graft-versus-host disease within 4 weeks prior to enrollment. Oral beclomethasone or budesonide, empirically used for possible but not biopsy-proven graft-versus-host disease, will not be considered an exclusion criterion.\nUse of prednisone at a dose of \u22650.25 mg/kg/day (or equivalent dose of another glucocorticoid) at the time of enrollment\nActive uncontrolled bacterial, fungal, parasitic, or viral infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of infection progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection\nPresence of known HIV infection, active hepatitis B or C infection.\nTotal bilirubin, aspartate transaminase, alanine transaminase 2 X the upper limit of the normal range. Patients with elevated bilirubin secondary to Gilbert syndrome will not be excluded.\nCreatinine clearance <30 mL/min\nPresence of uncontrolled cardiopulmonary conditions such as ongoing cardiac arrhythmias, unstable angina or myocardial infarction, New York Heart Association class III/IV congestive heart failure, or severe chronic obstructive pulmonary disease or other pulmonary condition resulting in a requirement of supplemental oxygen or having a resting O2 saturation <90% by pulse oximetry\nPregnancy or breastfeeding.\nKnown hypersensitivity, or intolerance to any of the study medications, or excipients.\nTreatment with any other investigational agent, device, or procedure, within 21 days (or 5 half-lives, whichever is greater)\nPatients on dopamine antagonists for treatment of psychotic disorder or Parkinson's disease will be excluded. A brief use of drugs such as clozapine or haloperidol for a few days for treatment of nausea or other indication will not be prohibited. The use of tricyclic antidepressants does not constitute an exclusion criterion.\nAny other condition that is judged by the physician to potentially interfere with compliance to the study protocol or pose a significant risk to the patient."
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must be diagnosed with either relapsed or refractory AML (including extramedullary disease) or higher risk MDS/CMML.\nAbsolute lymphocyte count \u2265 0.2 k/\u03bcL.\nKarnofsky performance status score \u226560%.\nLife expectancy \u2265 12 weeks from the time of enrollment.\nPretreatment calculated or measured creatinine clearance (absolute value) of \u2265 40 mL/minute or Cr > 2x upper limit of normal (ULN).\nSerum bilirubin \u2264 2.0 mg/dL or total bilirubin \u2264 3.0 x IULN with direct bilirubin within normal range in participants with well documented Gilbert's syndrome or hemolysis or who require regular blood transfusions\nAlanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 3.0 x IULN.\nEjection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) > 45%.\nParticipant does not require supplemental oxygen or mechanical ventilation AND has an oxygen saturation by pulse oximetry of \u2265 92% or higher on room air.\nNegative serum pregnancy test. Note: Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for at least 1 year following study treatment (T cell infusion); should a woman participant or female partner of a male participant become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.\nParticipant has a matched bone marrow donor and is otherwise able to receive a bone marrow transplant (dose escalation part only)\nParticipants who have undergone allo-SCT are eligible if they are at least 3 months post SCT, have relapsed AML/MDS as defined above, are not on treatment or prophylaxis for GVHD for at least 6 weeks before administration of CAR T cells, and have no active GVHD.\nAll participants must have the ability to understand and willingness to sign a written informed consent.\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.\nKnown central nervous system (CNS) leukemic involvement that is refractory to intrathecal chemotherapy and/or cranio-spinal radiation; participants with a history of CNS disease that have been effectively treated to complete remission ( i.e. no blasts in cerebrospinal fluid [CSF] by cytology and flow cytometry) will be eligible.\nPrior treatment with investigational CAR T therapy for any disease.\nParticipants enrolled in another investigational therapy protocol for their disease within 14 days or 5 half-lives of enrollment, whichever is shorter.\nOngoing uncontrolled serious infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements.\nHuman immunodeficiency virus (HIV) seropositivity, or active hepatitis B or C infection based on testing performed within 28 days of enrollment.\nParticipants requiring agents other than hydroxyurea to control blast counts within 14 days of study enrollment.\nParticipants with presence of other active malignancy within 1 year of study entry;\nParticipants with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis.\nPregnant and lactating women are excluded from this study\nHistory of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab (anti-EGFR).\nActive autoimmune disease requiring systemic immunosuppressive therapy (i.e. >10mg of prednisone daily or equivalent).\nParticipant, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study."
            },
            {
                  "document": "Inclusion Criteria:\n\nHistologically or cytologically confirmed relapse of AML, MDS or MPN (CMML or myelofibrosis or MDS/MPN with \u22655% blasts in the marrow).\nRelapse at \u22652 months after first 8/8 HLA-matched HCT\nAvailable original stem cell donor.\nAge \u226518 years. Because no dosing or adverse event data are currently available on the use of Ipilimumab in participants <18 years of age, children are excluded from this study.\nECOG performance status \u22642 (Karnofsky performance status \u226560, see Appendix A).\nRecipient donor T cell chimerism \u226520% within 4 weeks prior to cell infusion.\n<50% bone marrow involvement within 4 weeks prior to cell infusion.\nNo systemic corticosteroid therapy for GVHD (\u22645 mg of prednisone or equivalent doses of other systemic steroids for non-GVHD, non-autoimmune indications for at least 4 weeks prior to cell infusion).\nNo other systemic medications/treatments (e.g. ECP) for GVHD for at least 4 weeks prior to cell infusion.\nAbility to understand and willingness to sign written informed consents.\n\nAdequate organ function as defined below:\n\nTotal bilirubin: \u22641.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then < 3 x ULN)\nAST(SGOT)/ALT(SGPT): \u22643 x institutional ULN\ncreatinine clearance: \u22641.5 x institutional ULN\nO2 saturation: \u226590% on room air\nLVEF >40%\nThe effects of CD25/Treg-depleted DLI and Ipilimumab on the developing human fetus are unknown. For this reason and because immunomodulatory agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study or within 23 weeks after the last dose of study drug, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for at least 31 weeks after completion of Ipilimumab administration.\nNegative pregnancy test for females of childbearing potential only\n\nExclusion Criteria:\n\nExtramedullary relapse involving immuno-privileged sites (e.g. CNS, testes, eyes). Other sites of extramedullary relapse (e.g. leukemia cutis, granulocytic sarcoma) are acceptable.\nParticipants who have had anti-tumor chemotherapy or other investigational agents within 4 weeks prior to cell infusion (6 weeks for nitrosoureas or mitomycin C), or immunotherapy within 8 weeks prior, or those who have not recovered from adverse events due to agents administered more than 4 weeks prior. Use of hydroxyurea to control counts within 4 weeks prior to cell infusion is permitted.\nPrior history of DLI\nPrior history of treatment with anti-CTLA-4 or anti-PD-1 pathway therapy, or CD137 agonist therapy.\nPrior history of severe (grade 3 or 4) acute GVHD, or ongoing active GVHD requiring systemic treatment.\nOrgan transplant (allograft) recipient.\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to Ipilimumab or other agents used in study.\nAutoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]) and motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis). Patients with Hashimoto's thyroiditis are eligible to go on study.\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nPregnant women are excluded from this study because of the unknown teratogenic risk. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated on this study.\nHIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with agents used in this study. In addition, these participants are at increased risk of lethal infections when treated with marrow- suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.\nIndividuals with active uncontrolled hepatitis B or C are ineligible as they are at high risk of lethal treatment-related hepatotoxicity after HCT."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients fulfilling the inclusion criteria will be eligible for enrollment in this study. Of those who consent, only patients who lack a suitable HLA-identical or 1 allele or antigen mismatched related donors are evaluable. Patients with an HLA-identical sibling or 1 allele or antigen mismatched family member donor are evaluable as long as the center deems the family member donor as unsuitable for other reasons. Patients may co-enroll with other interventional or observational studies.\n\nPatients of all ages with AML, ALL, MDS, NHL, HL, AA, or SCD are eligible.\nAny planned conditioning regimen and GVHD prophylaxis approach is eligible.\nPatients must be considered suitable allogeneic transplant candidates at the time of enrollment based on medical history, physical examination, and available laboratory tests. Specific testing for organ function is not required for eligibility but, if available, these tests should be used by the treating physician to judge transplant suitability.\nPatient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified.\nCenter plans to follow the algorithm for alternative donor identification: (a) for subjects who are Very Likely to find a MUD, attempt to identify a matched unrelated donor; (b) for a subjects who are Very Unlikely to find a MUD, proceed expeditiously to a haploidentical, cord blood or mismatched unrelated donor.\nSigned informed consent, and assent if applicable. Consent may be signed prior to completion of family typing but patients will only be considered evaluable upon confirmation that there is no suitable HLA-identical or 1 allele or antigen mismatched related donor available.\n\nExclusion Criteria:\n\nPrior allogeneic HCT (prior autologous transplant is allowed)\nPrevious formal unrelated donor search"
            },
            {
                  "document": "Inclusion Criteria:\n\nMetastatic or advanced solid tumor; or advanced diffuse large B-cell lymphoma; or advanced mantle cell lymphoma; or relapsed myelodysplastic syndrome, acute myeloid leukemia or chronic myelomonocytic leukemia; or relapsed myelofibrosis. All malignancies must be refractory to established therapies\nBiomarker-selected solid tumors\nEastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1\nAdequate organ function (bone marrow, hepatic, renal, cardiovascular)\nFemale patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial\n\nExclusion Criteria:\n\nPrimary malignancies of the Central Nervous System(CNS) or uncontrolled CNS metastases\nRequirement of pharmacologic doses of glucocorticoids\nPrior treatment with chimeric antigen receptor T cells (CAR-T cells)\nHIV positive; known active hepatitis B or C\nKnown hypersensitivity to any of the components of PRT543\nPrior allogeneic bone marrow transplant; autologous hematopoietic transplantation less than 100 days since transplantation"
            },
            {
                  "document": "Key Inclusion Criteria:\n\nAbility to understand and the willingness to sign a written informed consent document\nParticipants, both men and women, must agree to use an adequate method of contraception prior to study entry, for the duration of study participation, and for 4 months after completion of study\nWomen of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration\n\nPatients must have a histologically or cytologically-confirmed metastatic solid tumor or hematological malignancy that has progressed as follows:\n\nPatients with a solid tumor must have metastatic disease and have progressed on at least 1 line of established therapy that is known to provide clinical benefit, or for whom no standard curative therapy exists. Participants with newly diagnosed, unresectable, locally-advanced or metastatic pancreatic adenocarcinoma and are beginning first-line treatment with a course of chemotherapy are eligible OR\n\nParticipants must have a hematological malignancy that is advanced, relapsed, or refractory to at least 1 line of established therapy that is known to provide clinical for the treatment of their disease. Hematological disease included in this study are as follows:\n\nAcute myelogenous leukemia (AML), or\nMyelodysplastic syndrome (MDS), or\nMDS/myeloproliferative neoplasms (MDS/MPN), or\nPrimary myelofibrosis (PMF)\nAcute lymphoblastic leukemia (ALL)\nChronic myelogenous leukemia (CML)\nNon-Hodgkin lymphoma (NHL) or Hodgkin's disease (HD)\nChronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)\nMultiple myeloma (MM)\n\nParticipants with a metastatic solid tumor or advanced hematological malignancy whom, due to medical issues cannot receive standard therapy shown to prolong survival, will be eligible, if other eligibility criteria are met\n\nPatients with a metastatic solid tumor or advanced hematological malignancy that actively refuse chemotherapy that is considered standard treatment for their cancer, despite being informed by the investigator about the treatment options, are eligible for this study on a case-by-case basis (in consultation with the principal investigator [PI]). Potential participants actively refusing chemotherapy must have had progression or refractory disease prior to starting study treatment, and their refusal must be documented\n\nParticipants must have measurable disease:\n\nPatients with solid tumors must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. At least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, per RECIST (v1.1)\nNote: Participants with lesions on a bone scan that are considered distinctly metastatic will also be included\nPatients with lymphoma must have at least one non-irradiated tumor mass > 15 mm (long axis of lymph node) or > 10 mm (short axis of lymph node or extranodal lesions) on spiral CT-scan\nPatients with CLL must have presence of radiographically measurable lymphadenopathy (defined as the presence of >= 1 nodal lesion that measures >= 2.0 cm in the longest diameter [LD] and >= 1.0 cm in the longest perpendicular diameter [LPD] as assessed by CT or magnetic resonance imaging [MRI])\nPatients with MM must have at least one of the following: serum monoclonal component > 1 g/dL (IgG), or > 0.5 g/dL (IgA), or Bence-Jones (BJ) proteinuria > 200 mg/24 hour, or measurable plasmacytoma (not previously irradiated)\nParticipants with a hematological malignancy must have their bone marrow biopsy and aspirate reviewed at Oregon Health & Science University (OHSU)\nParticipants with a solid tumor must have lesions meeting the above criteria also and must be amenable to biopsy procedures performed per institutional standards\nParticipants must not currently be receiving any other investigational agents\nParticipants must have Eastern Cooperative Oncology Group (ECOG) performance status =< 2 and a physician assessed life expectancy of >= 6 months\n\nAbsolute neutrophil count (ANC) >= 1,500/mcL (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\n\nWaived for those with hematological malignancy; and may be waived on a case-by-case basis for patient populations recognized to have normal baseline values below this level\n\nPlatelets >= 100,000/mcL (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\n\nWaived for those with hematological malignancy\n\nHemoglobin >= 9 g/dL or >= 5.6 mmol/L (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\n\nWaived for those with hematological malignancy\n\nCreatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min/1.73 m^2 for participants with creatinine levels > 1 x institutional ULN (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\n\nWaived for those with hematological malignancy; and may be waived on a case-by-case basis for patient populations recognized to have normal baseline values below this level\n\nTotal bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for participants with total bilirubin levels > 1.5 x ULN (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\n\nCreatinine clearance should be calculated per institutional standard. For participants with a baseline calculated creatinine clearance below normal institutional laboratory values, a measured baseline creatinine clearance should be determined. Individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\nInternational normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\nActivated partial thromboplastin time (aPTT) or PTT =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\n\nBody mass index (BMI) > > 16.0 and < 35.0 kg/m^2 (at time of registration and within 4 weeks prior to initiating on-protocol treatment)\n\nParticipants with a BMI of >= 30.0 will use ideal body weight indices in calculating the delivery of agents that are dosed based upon body surface area (i.e., mg agent/meter squared) or weight (i.e., mg agent/kg body weight)\nAny prior therapy, radiotherapy (except palliative radiation therapy of 30 Gy or less), or major surgery must have been completed >= 4 weeks prior to start of study treatment. All adverse events due to prior therapy must have resolved to a grade 1 or better (except alopecia and lymphopenia for all disease cohorts, and hematologic toxicity for those with a hematological malignancy) by start of treatment. Palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment. The radiotherapy must not be to a lesion that is included as measurable disease\nAdditional cancer-specific inclusion criteria must also be met\n\nKey Exclusion Criteria:\n\nParticipants with metastases to the central nervous system that are considered uncontrolled and/or were diagnosed within the past 4 weeks of screening for this study\nParticipants cannot have an active malignancy of another cancer. Those with a history of prior malignancy will be considered on a case-by-case basis. Guiding examples for those who can be enrolled include: individuals who have been disease free for > 5 years; individuals who are considered to have a high likelihood of being cured (e.g., prior history of stage 1 rectal cancer and currently otherwise disease free); adequately treated localized non-melanomatous skin cancer\n\nParticipants cannot be on other forms of anti-cancer therapy at the same time, except as described within this protocol. There must be at least a washout period that accounts for 5 half-lives (or >= 21 days, whichever is longer) of last therapy\n\nParticipants with prostate cancer (PCa) will continue treatment with androgen deprivation therapy, either by prior castration or treatment with luteinizing hormone-releasing hormone (LHRH) antagonists or agonists, as is standard practice\nParticipants with breast cancer (BCa) who are HER2 positive may continue to receive anti-HER2 therapy per standard practice guidelines, while participants who are hormone receptor positive may continue to receive hormone therapy per standard practice guidelines\nParticipants with a hematological malignancy may continue to receive hydroxyurea or other hypomethylating agent for two cycles of SMMART-PRIME therapy, as described in this protocol\nUncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure\nChronic graft versus host disease (GVHD) or on immunosuppressive therapy for the control of GVHD\nParticipants with uncontrolled infection will not be enrolled until infection is treated\n\nParticipant is seropositive with human immunodeficiency virus (HIV) or has active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)\n\nHIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\nFor patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\nIndividuals with a history of HCV infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\nParticipants with medical conditions, inclusive of psychiatric, that in the opinion of the investigators would jeopardize the patient or the study will be excluded\nParticipants that are pregnant or breast feeding\nON-TREATMENT: Individuals that have medical and/or psychiatric conditions that in the opinion of investigators would jeopardize participant safety or study integrity if they were to receive on-study treatment will not proceed further treatment and will be removed from study\nON-TREATMENT: If performance status is ECOG > 2\nON-TREATMENT: History of allergic reaction to a recommended study agent or its excipients\nAdditional cancer-specific exclusion criteria requirements"
            },
            {
                  "document": "Inclusion Criteria:\n\nAbility to understand and the willingness to sign a written informed consent document\nMorphologically documented relapsed/refractory acute myeloid leukemia (AML) as defined by World Health Organization (WHO) criteria after at least 1 prior therapy for AML with the exception of hydroxyurea. Patients with myelodysplastic syndrome (MDS) transformed to AML that have been treated with hypomethylating agents may be considered if they fulfill one or more of the following criteria: 1) patient has a left ventricular ejection fraction of 45% or less; 2) patient has a serum creatinine of >= 1.4 gm/dl; 3) patient is age 75 or older\nEastern Cooperative Oncology Group (ECOG) performance status 0 to 2\nWomen must not be pregnant or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration\nParticipants must agree to use an adequate method of contraception\nMust be able to take oral medications\nCreatinine clearance >= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection\nTotal serum bilirubin =< 1.5 x upper limit of normal (ULN) unless thought to be due to leukemic involvement\nSerum aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 3.0 x ULN unless thought to be due to leukemic involvement\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL, or AML M3 subtype)\nActive central nervous system involvement with AML\nConcurrent active malignancy with expected survival of less than 1 year. For example, candidates with treated skin cancers, prostate cancer, breast cancer, etc. without metastatic disease are candidates for therapy since their expected survival exceeds that of relapsed or refractory AML. All subjects with concurrent malignancies will be reviewed by the principal investigator (PI) prior to enrollment\nClinically significant graft versus host disease (GVHD) or active GVHD requiring initiation or escalation of treatment within 28 day screening period\nParticipants with rapidly progressive disease (defined by blast count doubles within 48 hours) or organ dysfunction\nClinically significant coagulation abnormality, such as disseminated intravascular coagulation\nParticipants who are currently receiving any other investigational agents\nKnown clinically significant liver disease defined as ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis\nUntreated human immunodeficiency virus (HIV) or active hepatitis C detectable by polymerase chain reaction (PCR), or chronic hepatitis B (patients positive for hepatitis B core antibody who are receiving intravenous immunoglobulin [IVIG] are eligible if hepatitis [Hep]B PCR is negative)\nKnown history of cerebrovascular accident, myocardial infarction, or intracranial hemorrhage within 2 months of enrollment\nClinically significant surgery within 2 weeks of enrollment\n\nPer PI discretion, active infection that is not well controlled by antibacterial or antiviral therapy\n\nParticipants with known history of tuberculosis (TB; Mycobacterium tuberculosis) are not eligible for participation. At investigator discretion, latent TB test should be performed for individuals considered to be at high-risk (e.g., immune compromised, persons that have traveled to, or emigrated from, regions with high rates of TB)\nCancer-directed therapy within 1 week prior to starting treatment, with the exception of hydroxyurea, which is allowed to control white blood cell count\nUnwillingness to receive infusion of blood products\n\nParticipant on any of the following therapies need to be discussed with the sponsor investigator:\n\nStrong and moderate CYP3A inhibitors\nStrong and moderate CYP3A inducers\nPatients with uncontrolled white blood cell count (defined as > 50 K/mm^3 not controlled with hydroxyurea)\nPatients with known sensitivity to ruxolitinib or venetoclax"
            },
            {
                  "document": "Inclusion Criteria:\n\nRefractory or relapsed AML which will include:\n\nRefractory disease will be defined as at least 1 prior treatment with no remission.\nRelapsed disease will be defined as 5% or more blasts in bone marrow seen after remission.\nPatients with AML arising from myelodysplastic syndromes (including CMML) or myeloproliferative neoplasms (secondary AML, ts-AML) are also eligible.\nCirculating blast count \u2264 200/\u03bcL within 10 days prior to first cycle of treatment. Hydroxyurea should be used to keep the peripheral blast count \u2264 200/\u03bcL until the first day of protocol treatment, to the extent that this is possible\nECOG \u2264 2\nEstimated creatinine clearance \u2265 50 mL/min\nAST and ALT \u2264 3.0 x ULN\nBilirubin \u2264 3.0 x ULN\n\nExclusion Criteria:\n\nActive CNS Leukemia.\nKnown HIV infection or known hepatitis B or hepatitis C infection (with a detectable viral load).\nParticipant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment.\n\nSecondary refractory AML (e.g., treated for current relapse without achieving remission);\n\na. With the exception that single agent FLT3 inhibitors, IDH1/IDH2 inhibitors are allowed for current relapse without achieving remission.\n\nHave received prior radiation to maximally tolerated levels to any critical normal organ.\nClinically significant cardiac disease.\nActive, uncontrolled serious infection.\nHave other non-myeloid malignancy within 2 years of entry (with exceptions).\nPsychiatric disorder that would preclude study participation\nPrevious solid organ transplant (prior treatment with SCT is allowed but not if patient has GVHD or is still receiving immunosuppression/GVHD therapy)."
            },
            {
                  "document": "Inclusion Criteria:\n\nAML COHORT ONLY: Patients must have a new diagnosis (i.e., no prior therapy for AML) of AML per World Health Organization (WHO) 2016 criteria and any one of the following (i.e. therapy-related AML or AML with myelodysplastic-related changes per WHO):\n\nA history of MDS\nA history of a myeloproliferative neoplasm (MPN) including polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF, whether primary [pre-fibrotic or overt] or post-polycythemia vera [PV]/essential [E]), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), MPN-unclassifiable (MPN-U) or myeloid neoplasm with a rearrangement of PDGFRA, PDGFRB or FGFR1\nA history of MDS/MPN such as chronic myelomonocytic leukemia (CMML), MDS/MPN-unclassifiable (MDS/MPN-U), MDS/MPN with ringed sideroblasts and thrombocytosis (MDS/MPN-RS-T) or atypical chronic myeloid leukemia (aCML), BCR-ABL negative\nAn MDS-related cytogenetic abnormality other than del9q\nThe presence of dysplasia in >= 50% cells in >= 2 myeloid lineages, unless accompanied by mutant NPM1 or biallelic CEBPA mutations\nExposure to prior chemotherapy or radiation therapy for another malignancy\nNEWLY DIAGNOSED MDS/CMML COHORT ONLY: Diagnosis of MDS or CMML with intermediate-2 or high-risk disease by the International Prognostic Scoring System (IPSS)\nMDS/CMML POST-HMA FAILURE COHORT ONLY: Diagnosis of MDS or CMML with intermediate-1, intermediate-2, or high-risk disease by the IPSS who have no responded, progressed, or relapsed after treatment with at least 4 cycles of azacitidine and/or decitabine\nEastern Cooperative Oncology Group (ECOG) performance status from 0-2\nTotal bilirubin =< 1.5 x upper limit of normal (ULN) except in patients with Gilbert's syndrome or if elevation is attributed to underlying leukemia. Patients with Gilbert's syndrome or with elevated bilirubin attributed to underlying leukemia may enroll if direct bilirubin =< 1.5 x ULN of the direct bilirubin (repeat if more than 3 days before the first dose)\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (repeat if more than 3 days before the first dose)\nCreatinine clearance >= 30 mL/min (repeat if more than 3 days before the first dose)\nWhite blood cell (WBC) count < 50,000/uL. Note: Hydroxyurea may be used to control leukocytosis for the first 28 days of study treatment (i.e., cycle 1). Use of hydroxyurea beyond this point may be permitted as clinically indicated, on a case-by-case basis and after discussion with the principal investigator (PI). (repeat if more than 3 days before the first dose)\n\nFemale patients who:\n\nAre postmenopausal for at least 1 year before the screening visit, OR\nAre surgically sterile, OR\n\nIf they are of childbearing potential:\n\nAgree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), or\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception)\n\nMale patients, even if surgically sterilized (i.e., status postvasectomy), who:\n\nAgree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug (female and male condoms should not be used together), or\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)\nVoluntary written consent must be given before performance of any study related procedure\n\nExclusion Criteria:\n\nTreatment with any investigational anti-neoplastic drugs within 2 weeks before the first dose of any study drug (cycle 1 day 1 [C1D1])\nAML COHORT ONLY: Patients who are suitable for and agreeable to receive intensive induction chemotherapy\nNEWLY DIAGNOSED MDS/CMML COHORT ONLY: Prior treatment with hypomethylating agents\nMDS/CMML POST-HMA FAILURE COHORT ONLY: Prior treatment with venetoclax or pevonedistat\nPatients whose only site of disease is extramedullary\nAcute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis\nAny serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures\nActive uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia\nMajor surgery within 14 days before the first dose of any study drug\nPatients with a prior or concurrent malignancy whose natural history or treatment is not anticipated to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the PI\nLife-threatening illness unrelated to cancer, leading to expected life expectancy (unrelated to leukemia) < 1 year\nPatients with severe, uncontrolled coagulopathy or bleeding disorder not related to leukemia\n\nKnown human immunodeficiency virus (HIV) positive patients who meet the following criteria will be considered eligible:\n\nCD4 count > 350 cells/mm^3\nUndetectable viral load\nMaintained on modern therapeutic regimens utilizing non-CYP-interactive agents\nNo history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections\n\nKnown hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection\n\nNote: Patients who have isolated positive hepatitis B core antibody (i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load\nKnown hepatic cirrhosis or severe pre-existing hepatic impairment\n\nKnown cardiopulmonary disease defined as:\n\nUnstable angina within 6 months\nCongestive heart failure (New York Heart Association [NYHA] class III or IV)\nMyocardial infarction (MI) within 6 months prior to first dose (patients who had ischemic heart disease such as an acute coronary syndrome [ACS], MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll)\nSymptomatic cardiomyopathy\nClinically significant arrhythmia\nHistory of polymorphic ventricular fibrillation or torsade de pointes\nPersistent atrial fibrillation (a fib) requiring cardioversion in the 4 weeks before screening\nGrade 3 a fib defined as symptomatic and incompletely controlled medically , or controlled with device (e.g. pacemaker), or ablation in the past 6 months\nModerate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing)\nSymptomatic pulmonary hypertension requiring pharmacologic therapy\nUncontrolled high blood pressure (i.e., systolic blood pressure > 180 mm Hg, diastolic blood pressure > 100 mm Hg documented on two consecutive blood pressure evaluations)\nProlonged rate corrected QT (QTc) interval >= 500 msec, calculated according to institutional guidelines\nLeft ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography\nKnown severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis\nKnown central nervous system (CNS) involvement\nTreatment with strong CYP3A4 inducers within 14 days (or 3 half-lives, whichever is shorter) before the first dose of the study drug. Strong CYP3A4 inducers are not permitted during this study\nSystemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days (or 3 half-lives, whichever is shorter) before the first dose of any study drug, except for hydroxyurea or up to 2 total grams of intravenous cytarabine for cytoreduction. Prior hypomethylating agent (HMA) therapy is allowed, unless given for AML\nFemale patients who are either lactating and/or breastfeeding or have a positive serum pregnancy test during the screening period\nFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)\nMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)\nKnown hypersensitivity to azacitidine, mannitol or pevonedistat, any of their components, or compounds of similar chemical composition"
            },
            {
                  "document": "Inclusion criteria:\n\nParticipant must be 28 days to less than 18 years of age, at the time of signing the informed consent.\nParticipants must have a confirmed diagnosis of relapsed Acute Lymphoblastic Leukemia (ALL) of T- or B-cell origin including T-lymphoblastic lymphoma (LBL), or relapsed Acute Myeloblastic Leukemia (AML) including participants with history of myelodysplasia.\nParticipants must be previously treated for their disease and have relapsed or are refractory to most recent treatment. Participants in first or second relapse will be eligible regardless of the remission duration.\nParticipants with no more than 1 prior salvage therapy.\nWBC counts below 20 x109/L on Day 1 before isatuximab administration\n\nExclusion criteria:\n\nAny serious active disease or co-morbid condition which, in the opinion of the Investigator, may interfere with the safety of the study treatment or the compliance with the study protocol.\nParticipants must have been off prior treatment with immunotherapy/investigational agents and chemotherapy for >2 weeks and must have recovered from acute toxicity before the first study treatment administration. Exceptions are participants who need to receive cytoreductive chemotherapy in order to decrease tumor burden (the study treatment may start earlier if necessitated by the patient's medical condition (eg, rapidly progressive disease) following discussion with the Sponsor).\nPrior stem cell transplant within 3 months and/or evidence of active systemic Graft versus Host Disease (GVHD) and/or immunosuppressive therapy for GVHD within 1 week before the first study treatment administration.\nParticipants with LBL with bone marrow blasts <5%.\nParticipants with Burkitt-type ALL.\nAcute leukemia with testicular or central nerve system involvement alone.\nParticipants who have developed therapy related acute leukemia.\nLive vaccine(s) within 30 days prior to the first IMP administration or plans to receive such vaccines during the study until 90 days after the last IMP administration.\nParticipants with white blood cell count > 50 x109/L at the time of screening visit.\nParticipants who have been exposed to anti-CD38 therapies within 6 months prior to Day-1.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."
            },
            {
                  "document": "Inclusion Criteria:\n\nInstitutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent including privacy language as per national regulations (e.g., HIPAA Authorization for U.S. site) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).\nPatient is \u2265 18 years of age (or country's legal age of majority if the legal age was > 18 years) at the time of obtaining informed consent.\n\nPatient is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2016) and fulfills one of the following:\n\nRefractory to at least 1 cycle of prior therapy\nRelapsed after achieving remission with a prior therapy\nPatient has an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2.\nPatient's interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells), or at least 5 half-lives for prior experimental agents or noncytotoxic agents, including immunosuppressive therapy post hematopoietic stem cell transplantation (HSCT). (upon discussion with the Medical Monitor, shorter than stated washout period may be considered provided that the patient has recovered from any clinically relevant safety issue and recovered to Grade \u2264 1 toxicity from prior therapies)\n\nPatient must meet the following criteria as indicated on the clinical laboratory tests\n\nSerum aspartate aminotransferase(AST) and alanine aminotransferase(ALT) \u2264 2.5\u00d7 institutional upper limit normal (ULN)\nTotal serum bilirubin \u2264 1.5\u00d7 institutional ULN\nSerum creatinine \u2264 1.5\u00d7 institutional ULN or an estimated glomerular filtration rate (eGFR) of > 60 ml/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation.\nPatient is suitable for oral administration of study drug and has minimum life expectancy (\u2265 3 months)\nFemale patient must be either:\n\nOf non-child bearing potential\n\nPost-menopausal (defined as at least 1 year without any menses) prior to screening, or\nDocumented surgically sterile or status post hysterectomy (at least 1 month prior to screening)\n\nOr, if of childbearing potential,\n\nMust have a negative serum or urine pregnancy test at screening, and\nMust use two forms of birth control\u00a3 (at least one of which must be a barrier method) starting at screening and throughout the study period and for 90 days after the final study drug administration.\nFemale patient must not be breastfeeding at screening and during the study period, and for 90 days after the final study drug administration\nFemale patient must not donate ova starting at screening and throughout the study period, and for 90 days after the final study drug administration.\nMale patient and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control\u00a3 (one of which must be a barrier method) starting at screening and continue throughout the study period and for 90 days after the final study drug administration.\nMale patient must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.\nPatient agrees not to participate in another interventional study while on treatment\n\nExclusion Criteria:\n\nPatients must not enter the study if any of the following exclusion criteria are fulfilled.\n\nPatient was diagnosed as acute promyelocytic leukemia (APL)\nPatient has BCR-ABL-positive leukemia\nPatient has active malignant tumors other than AML, or Myelodysplastic Syndrome (MDS).\nPatient has persistent non-hematological toxicities of \u2265 Grade 2 (CTCAE v4.03), with symptoms and objective findings, from prior AML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)\n\nPatient has had hematopoietic stem cell transplant (HSCT) and meets any of the following:\n\nHas undergone HSCT within the 2 month period prior to the first study dose\nHas clinically significant graft-versus-host-disease(GVHD) requiring treatment\nHas \u2265 Grade 2 persistent non-hematological toxicity related to the transplant Donor lymphocytes infusion (DLI) is not permitted \u2264 30 days prior to the first study dose or during the first two cycle of treatment on the study in Part A and Part B\nPatient with symptomatic central nervous system (CNS) involvement of leukemia or other CNS diseases related to underlying and secondary effects of malignancy.\nPatient has disseminated intravascular coagulation abnormality (DIC).\nPatient has had major surgery within 4 weeks prior to the first study dose.\nPatient has had radiation therapy within 4 weeks prior to the first study dose.\nPatient has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or patient with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is \u2265 45%.\n\nAny of the following cardiac abnormalities of history\n\nPatient has any clinically important abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval > 250milliseconds (ms).\nPatient has a mean QT interval (QTc) by Friderica's method (QTcF) > 450ms in three successive Screening measurements.\nPatient has any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as congenital long QT, syndrome, family history of long QT syndrome.\nPatient is unable or unwilling to discontinue concomitant use of drugs that are known to prolong the QT interval.\nPatient is known to have active infection including any identified active COVID-19 infection.\nPatient is known to have human immunodeficiency virus infection.\nPatient has known active hepatitis B or C, or other active hepatic disorder.\nPatient has any condition which, in the investigator's opinion, makes the patient unsuitable for study participation."
            },
            {
                  "document": "Inclusion Criteria for Transplant Recipient\n\nAge less than or equal to 21 years.\nDoes not have a suitable HLA-matched sibling donor (MSD) or volunteer 10/10 HLA-matched unrelated donor (MUD) available in the necessary time for progenitor cell donation.\nHas a suitable single haplotype matched (\u2265 3 of 6) family member donor.\n\nHigh risk hematologic malignancy. High risk ALL in CR1. Examples include, but not limited to: t(9;22) with persistent or recurrent transcript, hypodiploid cytogenetics, MRD >1% at the end of induction, M2 or greater marrow at the end of induction, recurrent or rising MRD after induction, Infants with MLL fusion or t(4;11), relapse after prior CART therapy.\n\nALL in High risk CR2. Examples include, but not limited to t(9;22), BM relapse <36 mo CR1 or <6mo after completion of therapy, any T-ALL, very early (< 6mo CR1) isolated CNS relapse, late BM relapse with poor response to standard reinduction therapy(e.g. MRD positive or recurrence after two blocks), relapse after prior CART therapy.\n\nALL in CR3 or subsequent.\n\nAML in high risk CR1 (diagnosis of AML includes myeloid sarcoma). Examples include but not limited to: preceding MDS or MDS-related AML, FAB M0, FAB M6, FAB M7 with high risk genetics such as ML not t(1;22), MRD > 0.1% after two cycles of induction, MRD > 1% after one cycle of induction, FLT3-ITD in combination with NUP98-NSD1 fusion or WT1 mutation, any high risk cytogenetics such as: DEK-NUP214 [t(6;9)], KAT6A-CREBBP [t(8;16)], RUNX1-CBFA2T3 [t(16;21)], -7, -5, 5q-, KMT2A-MLLT10 [t(6;11)], KMT2A-MLLT4 [t(10;11)], inv(3)(q21q26.2), CBFA2T3-GLIS2 [inv(16)(p13.3q24.3)], NUP98-KDM5A [t(11;12)(p15;p13)], ETV6-HLXB [t(7;12)(q36;p13)], NUP98-HOXA9 [t(7;11)(p15.4;p15)], NUP98-NSD1.\n\nAML in CR2 or subsequent.\n\nTherapy related AML, with prior malignancy in CR > 12mo\nMDS, primary or secondary\nNK cell, biphenotypic, or undifferentiated leukemia in CR1 or subsequent.\nCML in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor.\nHodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize progenitor cells for autologous HCT.\nNon-Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize progenitor cells for autologous HCT.\nJMML\nIf prior CNS leukemia, it must be treated and in CNS CR\nDoes not have any other active malignancy other than the one for which this HCT is indicated.\nNo prior allogeneic HCT, and no autologous HCT within the previous 12 months.\n\nPatient must fulfill pre-transplant organ function criteria:\n\nLeft ventricular ejection fraction > 40%, or shortening fraction \u2265 25%.\nCreatinine clearance (CrCl) or glomerular filtration rate (GFR) \u2265 50 ml/min/1.73m2.\nForced vital capacity (FVC) \u2265 50% of predicted value; or pulse oximetry \u2265 92% on room air if patient is unable to perform pulmonary function testing.\nKarnofsky or Lansky (age-dependent) performance score \u2265 50 (See APPENDIX A).\nBilirubin \u2264 3 times the upper limit of normal for age.\nAlanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \u2264 5 times the upper limit of normal for age.\nNot pregnant. If female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment.\nNot breast feeding\nDoes not have current uncontrolled bacterial, fungal, or viral infection.\n\nInclusion Criteria for Haploidentical Donor\n\nAt least single haplotype matched (\u2265 3 of 6) family member\nAt least 18 years of age.\nHIV negative.\nNot pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).\nNot breast feeding.\n\nRegarding donation eligibility, is identified as either:\n\nCompleted the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR\nDoes not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.\n\nExclusion Criteria:\n\n-"
            },
            {
                  "document": "Inclusion Criteria:\n\nMorphologically documented AML or secondary AML [from prior conditions such as myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN)] or therapy related AML (t-AML), as defined by World Health Organization (WHO) criteria.\nAge \u226560 years, with relapsed/refractory AML to at least one line of therapy. Patients with antecedent MDS who progressed to AML while on hypomethylating agent therapy will also be eligible.\nAge 18-59 years with relapsed/refractory AML to at least two lines of intensive induction chemotherapy, or one line of therapy if deemed unsuitable for further intensive chemotherapy.\nPatients aged 18 years or older with relapsed AML after allogeneic hematopoietic cell transplantation, if deemed unsuitable for further intensive chemotherapy.\nDetectable CD33 expression on AML blasts confirmed by flow cytometry.\nKarnofsky performance status \u2265 60 (or Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 2 or less).\n\nAdequate organ system function as outlined below:\n\nTotal bilirubin \u2264 2 x upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 x ULN.\nSerum creatinine \u2264 2 or a serum creatinine clearance \u2264 1.5 x ULN.\nBaseline EKG with QT-interval corrected (QTcF) \u2264 450ms.\n\nFemales should be using adequate contraception, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential. Male patient should avoid impregnating a female partner.\n\nIt is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below.\n\nFemale patients must meet one of the following:\n\nPostmenopausal for at least one year before the screening visit, or\nSurgically sterile, or\nIf they are of childbearing potential, agree to practice two effective methods of contraception from the time of signing of the informed consent form through three months after the last dose of study drug, AND\nMust also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, or\nAgree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable contraception methods.)\n\nMale patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:\n\nPractice effective barrier contraception during the entire study treatment period and through 90 days after the last study drug dose, OR\nMust also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR\nAgree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)\nAbility to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia (APL).\n\nPrior chemotherapy, radiotherapy, or investigative agent within 14 days, or within five half-lives of study entry.\n\nSubjects must have recovered from side effects of prior treatment.\nThe use of hydroxyurea for leukoreduction prior to start of dosing is permitted.\nHematopoietic Stem Cell Transplantation (HCT) within 60 days of enrollment, or evidence of veno-occlusive disease (VOD) at any time post-transplant, or active graft-versus-host disease requiring systemic immunosuppressive therapy.\nLife-threatening illness unrelated to AML, or any serious medical or psychiatric illness that could potentially interfere with participation in this study.\nActive and uncontrolled human immunodeficiency virus (HIV), or chronic Hepatitis B, or Hepatitis C."
            },
            {
                  "document": "Inclusion Criteria:\n\nNewly diagnosed acute myeloid leukemia according to 2016 WHO criteria(excluding APL [AML-M3]).\nEastern Cooperative Oncology Group (ECOG) Performance Status <2\nSubjects must have normal organ function as defined below:\nTotal bilirubin <2 times upper limit of normal ((\u2264 3 x ULN if considered to be due to leukemic involvement or Gilbert's syndrome) or if higher than 2 times upper limit of normal with approval from the PI\nSerum Creatinine <2 x ULNor if higher than 2 times upper limit of normal with approval from the PI\nLeft ventricular ejection fraction of \u226545%\nPatients with secondary AML arising out of MDS (all subtypes under WHO classification), chronic myelomonocytic leukemia (CMML) and therapy-related AML are eligible.\nWomen of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment. All men and women of childbearing potential must use acceptable methods of birth control throughout the study\nSubjects must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nPrior treatment with CPX-351, Palbociclib or other cell cycle inhibitors.\nAny serious medical condition, laboratory abnormality, or psychiatric illness that, in the view of the treating physician, would place the participant at an unacceptable risk if he or she were to participate in the study or would prevent that person from giving informed consent.\nAny active malignancy (unrelated, non-hematological malignancy) diagnosed within the past 6 months of starting the study drug (other than curatively treated carcinoma-in-situ of the cervix or non-melanoma skin cancer).\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to CPX-351, Palbociclib or other cell cycle inhibitors.\nSubjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nKnown history of HIV or active hepatitis B or C.\nNo major surgery within 2 weeks prior to study enrollment.\nPregnancy or breast feeding\nMale and female patients who are fertile who do not agree to use an effective barrier methods of birth control (i.e. abstinence) to avoid pregnancy while receiving study treatment.\nAcute promyelocytic leukemia (APL)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPhase 1: Dose Escalation Phase\n\nHigh risk AML, including any of the following:\n\nRelapsed or refractory disease\nTP53 mutant AML\nAdverse risk cytogenetics including any of the following: 3 or more abnormalities; deletions involving chromosomes 5, 7, or 17; abnormalities in chromosome 11 involving MLL; t(6;9); inv(3) or t(3;3)\nECOG performance status 0-2\nAge 18 years or older\n\nAdequate organ function as defined by all of the following:\n\nCreatinine clearance \u226530 mL/min, determined by the Cockroft-Gault formula, or measured by a 24 hour urine collection\nAST and ALT \u22643 x ULN and bilirubin \u22641.5 x ULN (unless considered due to Gilbert's syndrome or of non-hepatic origin i.e. leukemic involvement).\nPatients must be at least 2 weeks from major surgery, radiation therapy, or participation in other investigational trials, and must have recovered from clinically significant toxicities related to these prior treatments.\nPatients must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the i initiation of any screening or study specific procedures.\nFemale patients of childbearing potential must have negative results for a pregnancy test\nPatients must be willing to use appropriate contraception\nPhase 2: Dose Expansion Phase During the Phase 2 portion of the study, the subject population will be limited to patients with previously untreated AML with a mutation in TP53. All other inclusion criteria described above will apply.\n\nExclusion Criteria:\n\n- Key exclusion criteria (apply to both Phase 1 and Phase 2 portions of the study):\n\nConcomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in this protocol\nPatients suitable for and willing to receive intensive induction chemotherapy\nUse of investigational agents and/or anticancer therapy within 2 weeks of study entry (with the exception of hydroxyurea, which is permitted before and during Cycle 1 of therapy until D10, at the discretion of the investigator)\nPrior treatment with venetoclax, decitabine, or azacitidine\nDiagnosis of acute promyelocytic leukemia\nPregnant or breastfeeding patients\nPatient known to be positive for HIV\nKnown CNS involvement with AML\n\nEvidence of other clinically significant uncontrolled condition(s) including, but not limited to:\n\nUncontrolled and/or active systemic infection (viral, bacterial or fungal)\nChronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.\nAn active second cancer that requires treatment within 6 months of study entry\n\nCardiac history including the following:\n\nHistory of CHF requiring treatment or Ejection Fraction \u2264 50%\nSubject has a cardiovascular disability status of New York Heart Association\n\nClass > 2, defined as:\n\ni. Cardiac disease in which patients are comfortable at rest but ordinary physical activity ii. Results in fatigue, palpitations, dyspnea, or anginal pain c. Chronic stable angina\n\nTreatment with any of the following within 7 days prior to the first dose of study drug:\n\nSteroid therapy for anti-neoplastic intent\nModerate or strong cytochrome P450 3A (CYP3A) inducers\n\nAdministration or consumption of any of the following within 3 days prior to the first dose of study drug:\n\nGrapefruit or grapefruit products\nSeville oranges (including marmalade containing Seville oranges)\nStar fruit"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatient is 1 year to 21 years of age.\nPatient has a diagnosis of AML, MDS, MDS/AML, MPAL, or JMML. Note: patients are allowed to have received a HMA or HDACi prior to undergoing alloHCT.\nPatient has undergone allogeneic hematopoietic cell transplantation (no restrictions on conditioning regimen, donor or stem cell source, or GVHD prophylaxis regimen).\nPatient and/or parent(s) or legal guardian(s) are capable of understanding the study, including potential benefits and risks, and sign written informed consent. Age-appropriate assent will be obtained.\nFemale patient of childbearing potential has a negative screening pregnancy test (urine or serum, as per local institutional standard).\nFemale patient with infant(s) agrees not to breastfeed her infant(s) while on study.\nPatient of child-bearing potential (male and female) agrees to use effective method of contraception during the study.\n\nExclusion Criteria:\n\nPatient is enrolled on a clinical trial with investigational post-transplant medications. Note: trials involving defibrotide, post-transplant cyclophosphamide, and Lactobacillus plantarum are permitted. Other trials involving investigational medications that aren't leukemia or GVHD-directed may also be permitted after consultation with the overall PI.\nPatient has a planned administration of non-protocol chemotherapy, radiation therapy, donor leukocyte infusion, or immunotherapy during the planned study period.\nPatient has a known allergy to azacitidine or vorinostat.\nPatient has chronic myelogenous leukemia.\n\nConcomitant use of coumarin-derived anticoagulants or valproic acid.\n\n-"
            },
            {
                  "document": "Inclusion Criteria:\n\nAble to understand and have the ability to provide written consent.\nAge: \u226518 and \u226475 years-old\nPatients with newly diagnosed AML based on the World Health Organization classification who have persistent disease after their first course treatment with an anthracycline and cytarabine (the diagnosis of persistent disease, which is defined as \u226510% blasts by morphology for this trial or >5% blasts if they have had an increase in blasts from the last bone marrow biopsy, will be based on their assessment after bone marrow aspiration and/or biopsy after initial treatment).\nPatients with myelodysplastic syndrome (MDS) based on the World Health Organization classification who have persistent disease after their treatment with an anthracycline and cytarabine (the diagnosis of persistent disease, which is defined as \u226510% blasts by morphology for this trial or >5% blasts if they have had an increase in blasts from the last bone marrow biopsy, will be based on their assessment after bone marrow aspiration and/or biopsy after initial treatment).\nCD33 expression in \u2265 30% of leukemic blasts on the bone marrow.\nEastern Cooperative Oncology Group Performance Status of 0 -2 (see Appendix I).\n\nPatients must have the following laboratory values prior to beginning protocol treatment:\n\nCalculated creatinine clearance \u2265 30 mL/min (using the Cockcroft-Gault equation CL creatinine = ((140-age) x body mass X 0.85 if female)/72 x creatinine where age is given in years, body mass is given in Kg and creatinine is given in mg/dl).\nAspartate aminotransferase (AST) \u2264 2.5 x upper normal limit.\nAlanine aminotransferase (ALT) \u2264 2.5 x upper normal limit.\nTotal bilirubin \u2264 2 x upper normal limit. Note: As many eligible patients will be pancytopenic secondary to their disease or prior treatments, hematologic abnormalities will not be used as criteria for entry or exclusion.\nLeft ventricular ejection fraction (LVEF) \u226550 %.\n\nFemales of child-bearing potential must have a negative pregnancy test during screening and all subjects must agree to use an effective method of contraception. A woman is eligible to enter and participate in the study if she is of:\n\nNon-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who has had a hysterectomy or has had a bilateral oophorectomy (ovariectomy).\nChildbearing potential, has a negative serum pregnancy test during the screening period and agrees to avoid sexual activity or use contraception from screening through follow-up (method of birth control if the patient is not neutropenic include the use of a diaphragm, intrauterine device, contraceptive sponge and/or usage of male condom with a spermicide from the partner). A man with a female partner of childbearing potential is eligible to enter and participate in the study if he has either had a prior vasectomy or agrees to avoid sexual activity or use adequate contraception (as described above) from screening through follow-up.\n\nExclusion Criteria:\n\nPatients with a diagnosis of Acute Promyelocytic Leukemia (APL) as defined by the World Health Organization.\nRelapsed acute leukemia.\nBi-lineage or bi-phenotypic leukemia.\nPrior use of mitoxantrone or etoposide or GO.\nPrevious allogeneic hematopoietic cell transplantation.\nFirst induction course of acute myeloid leukemia with CPX-351.\nHas a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of treating investigator.\nHas known history of active Hepatitis B (HBsAg reactive) or Hepatitis C (detectable HCV RNA).\nUncontrolled, life-threatening infection that is not responding to antimicrobial therapy.\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\nPatient may have not received any other investigational anti-neoplastic agents within 4 weeks from the start of therapy.\nConcurrent active malignancy; exceptions include patients who have been disease free for 5 years, patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, or patients with another malignancy with better prognosis than AML.\nWomen who are pregnant or breastfeeding.\nEvidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory or cardiac disease)."
            },
            {
                  "document": "Registration Criteria:\n\nAny patient undergoing bone marrow biopsy with suspicion of or known diagnosis of acute myeloid leukemia (AML) will be asked to sign a Prescreening Consent to allow for centralized testing of bone marrow/peripheral blood samples.\n\nRandomization Eligibility Criteria:\n\nPatient must have previously untreated FLT3 mutated Non M3 AML (FLT3-TKD or FLT3-ITD allowed).\n\n\u00b0 Standard of care induction 7+3 chemotherapy may start prior to randomization using same regimen and doses as defined in the protocol while awaiting prescreening test results.\n\nPatient must have had no prior systemic therapy for AML, except as noted below:\n\nHydroxyurea and emergent leukapheresis or preemptive treatment with retinoic acid prior to exclusion of Acute Promyelocytic Leukemia (APL) allowed.\nPrior therapy for myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN) (e.g., thalidomide or lenalidomide, interferon, jakafi, cytokines, 5-azacytidine or decitabine, histone deacetylase inhibitors).\nInitiation of standard of care 7+3 induction chemotherapy using same regimen and doses as defined in protocol while awaiting prescreening test results\nPatient may not have received hypomethylating agent within 21 days.\nPatient may not have M3 AML.\nPatient may not have AML with known Core Binding Factor -t(8;21), inv(16), t(16;16).\n\nPatient may not have known active Central Nervous System (CNS) leukemia.\n\n\u00b0 Prophylaxis with intrathecal chemotherapy is allowed prior to or during induction/consolidation.\n\nPatient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\nPatient must be age \u2265 18 years to \u2264 70 years.\nPatient must be able to understand and willing to sign Institutional Review Board (IRB)-approved informed consent.\nPatient must be willing to provide mandatory bone marrow and blood samples for research.\n\nPatient must have adequate organ function as measured by the following criteria, obtained \u2264 48 hours prior to randomization except ECG and left ventricular ejection fraction (LVEF) which can be done \u2264 2 weeks prior to randomization:\n\nSerum creatinine \u2264 1.5x institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) >40 mL/min as measured by Cockcroft-Gault formula.\nAlanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) \u2264 3x ULN, unless secondary to leukemia.\nSerum total or direct bilirubin <2 mg/dL, unless due to Gilbert's, hemolysis or leukemic infiltration.\nFridericia-Corrected QT Interval (QTcF) interval \u2264 500 msec (using Friderica's correction).\nLeft Ventricular Ejection Fraction >45%.\nThe patient may not be known to have hypokalemia and/or hypomagnesemia that does not respond to supplementation.\n\nA female patient is eligible to participate if she is not pregnant and at least one of the following conditions apply:\n\nNot a woman of childbearing potential (WOCBP) OR\nWOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 180 days after the final study drug administration.\nFemale patient must agree not to breastfeed or donate ova starting at treatment and throughout the study period, and for at least 180 days after the final study drug administration.\nA male patient must agree not to donate sperm starting at treatment and throughout the study period, and for at least 120 days after the final study drug administration.\nA male patient with female partner(s) of child-bearing potential must agree to use contraception during the treatment period, and for at least 120 days after the final study drug administration.\nMale patient with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the treatment period, and for at least 120 days after the final study drug administration.\nPatient may not have another malignancy that could interfere with the evaluation of safety or efficacy of this combination.\nPatient may not have a history of Long QT Syndrome.\nPatient may not have evidence of uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or congestive heart failure (CHF) New York Heart Association (NYHA) Class 3 or 4. Patient may also not have a history of CHF NYHA Class 3 or 4 in the past, unless a prescreening echocardiogram (ECHO) or multigated acquisition scan (MUGA) performed within 2 weeks prior to study entry with results of left ventricular ejection fraction >45%.\nPatient may not have had major surgery or radiation therapy within 4 weeks of registration.\nPatient may not require treatment with concomitant drugs that are strong inducers of CYP3A.\nPatient with a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligible.\nPatient with known gastrointestinal (GI) disease or prior GI procedure that could interfere with the oral absorption or tolerance of gilteritinib or midostaurin including difficulty swallowing are not eligible.\nPatient with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of the treatment according to the protocol are not eligible.\nPatient may not participate in any other therapeutic clinical trials, including those with other investigational agents not included in this trial during treatment on this study without prior approval from PrECOG."
            },
            {
                  "document": "Inclusion Criteria:\n\nMen or women of age \u226518 years.\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\nHistological diagnosis of CLL/SLL, MCL, FL, MZL, DLBCL, RTL, BL, LPL/WM, T-cell NHL, ALL, or AML as documented in medical records.\nHematological cancer has been previously treated and has progressed during or relapsed after prior systemic therapy.\nHematological cancer is unlikely to be responsive to established therapies known to provide clinical benefit or the study candidate has developed an intolerance to established therapies known to provide clinical benefit.\nPresence of measurable cancer including CLL/SLL, MCL, FL, MZL, DLBCL, RTL, BL, LPL/WM, T-cell NHL, ALL, and AML.\nCurrent medical need for therapy due to disease-related symptoms or complications, cytopenias, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease.\nAvailability of pretreatment tumor tissue.\nCompletion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer \u22651 week before the start of study therapy.\nAll acute toxic effects of any prior antitumor therapy (not including hydroxyurea, cytarabine, and/or cyclophosphamide used in subjects with acute leukemia) resolved to \u2264Grade 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted] or selected laboratory parameters [Grade 1 or Grade 2 permitted with exceptions.\nAdequate bone marrow function.\nAdequate hepatic profile.\nAdequate renal function.\nAdequate coagulation profile.\nNegative antiviral serology.\nFor female participants of childbearing potential, a negative serum pregnancy test.\nFor both male and female participants, willingness to use protocol-recommended method of contraception from the start of the screening period until \u22656 months after the final dose of study therapy.\nWillingness and ability of the participant to comply with study activities.\nEvidence of a personally signed informed consent document.\nPrevious treatment with an MMAE-containing drug is allowed.\n\nExclusion Criteria:\n\nPresence of malignancy involving the central nervous system.\nPresence of another cancer with disease manifestations or therapy that could adversely affect participant safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.\nSignificant cardiovascular disease within 3 months prior to start of study therapy.\nSignificant screening electrocardiogram (ECG) abnormalities.\nUncontrolled ongoing systemic bacterial, fungal, or viral infection.\nKnown diagnosis of liver cirrhosis.\nPregnancy or breastfeeding.\nCandidacy for hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR)-T-cell therapy with access to HSCT or CAR-T cells and a willingness to undergo such therapy.\nIn participants with prior HSCT, evidence of graft-versus-host disease (GVHD) with Grade \u22652 serum bilirubin, Grade \u22653 skin involvement, or Grade \u22653 diarrhea.\nPrior solid organ transplantation.\nMajor surgery within 4 weeks before the start of study therapy.\nPrior therapy with a receptor tyrosine kinase-like orphan receptor 1 (ROR1)-directed therapy.\nHas ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent). Prednisone equivalent dosing must have been stable for at least 4 weeks prior to Cycle 1 Day 1 (C1D1). If corticosteroid treatment is required for lymphoma symptom control prior to C1D1, up to 100 mg per day of prednisone equivalent can be given for up to 5 days. In that case, all tumor assessments must have been completed prior to the start of corticosteroid treatment.\nUse of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4.\nUse within 7 days prior to the start of study therapy of a drug known to prolong the QT interval.\nConcurrent participation in another therapeutic or imaging clinical trial.\nPresence of a medical condition that (in the judgement of the investigator) interferes with the ability of the participant to participate in the study.\nHas baseline peripheral neuropathy >Grade 1."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge Patients must be \u2265 1 and \u226430 years of age.\n\nDiagnosis\n\nRelapsed or refractory AML with \u22655% blasts (by morphology) in the bone marrow.\n\n1st or greater relapse, OR\nFailed to go into remission (i.e. refractory) after first or greater relapse, OR\nFailed to go into remission from original diagnosis after two or more induction attempts.\nRelapsed or refractory AML with \u2264 5% blasts (by morphology) and MRD positive disease (M1/MRD+): Two serial marrows demonstrating stable or rising MRD \u2265 0.1 % (i.e. not declining). MRD will be determined by multiparameter flow cytometry using AML-associated phenotype markers, or real-time quantitative PCR for AML-associated genetic lesions\nPatients may have CNS 1 or 2 or other sites of extramedullary disease. No cranial irradiation is allowed during the protocol therapy.\nPatients with secondary AML are eligible.\nPatients with DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded.\nPatients with Down Syndrome will be eligible and will be included as an observation cohort\n\nPerformance Level Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients \u2264 16 years of age.\n\nPrior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.\n\nA. Myelosuppressive chemotherapy\n\nPrior chemotherapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. At least 14 days must have elapsed since the completion of the cytotoxic therapy, except Intrathecal chemotherapy.\nCytoreduction with hydroxyurea Hydroxyurea can be initiated and continued for up to 24 hours prior to the start of day 1 nivolumab and azacytidine. It is recommended to use hydroxyurea in patients with significant leukocytosis (WBC > 50,000/L) to control blast count before initiation of systemic protocol therapy.\n\nB. Hematopoietic stem cell transplant: Patients who have experienced their relapse after a HSCT are eligible provided they have no evidence of active GVHD, no past history of grade 3 or greater GVHD, and are at least 100 days post-transplant at the time of enrollment. Patients should be off immune suppression for at least 2 weeks (excluding physiologic replacement steroids).\n\nC. Hematopoietic growth factors: It must have been at least 7 days since the completion of therapy with GCSF or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta\u00ae).\n\nD. Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair\n\nE. Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after the last dose of monoclonal antibody. (i.e. Gemtuzumab = 36 days)\n\nF. Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines or CAR T-cells.\n\nG. XRT: XRT is prohibited during protocol therapy. No washout period is necessary for radiation given to non-CNS chloromas; \u2265 90 days must have elapsed if prior TBI or craniospinal XRT.\n\nRenal and hepatic function\n\nPatients must have adequate renal and hepatic functions as indicated by the following laboratory values:\n\nA. Adequate renal function defined as: Patient must have a calculated creatinine clearance or radioisotope GFR \u2265 70ml/min/1.73m2 OR a normal serum creatinine based on age/gender in the chart below:\n\nB. Adequate Liver Function Defined as: Direct bilirubin < 1.5 x upper limit of normal (ULN) for age or normal, AND alanine transaminase (ALT) < 5 x ULN for age. The hepatic requirements are waived for patients with known or suspected liver involvement by leukemia. This must be reviewed by and approved by the study chair or vice chair.\n\nAdequate Cardiac Function Defined as: Shortening fraction of \u2265 27% OR ejection fraction of \u2265 50%.\n\nReproductive Function A. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 24 hours prior to first dose.\n\nB. Female patients with infants must agree not to breastfeed their infants while on this study.\n\nC. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 7 months after study treatment. Women of childbearing potential (WOCBP) receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of nivolumab. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of nivolumab.\n\nInformed Consent Patients and/or their parents or legal guardians must be capable of understanding the investigational nature, potential risks and benefits of the study. All patients and/or their parents or legal guardians must sign a written informed consent. Age appropriate assent will be obtained per institutional guidelines. To allow non-English speaking patients to participate in this study, bilingual health services will be provided in the appropriate language when feasible.\n\nProtocol Approval All institutional, FDA, and OHRP requirements for human studies must be met.\n\nExclusion Criteria:\n\nPatients will be excluded if they have a known allergy or hypersensitivity to nivolumab or AZA used in the study.\n\nPatients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The patient needs to be off pressors and have negative blood cultures for 48 hours.\n\nPatients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.\n\nPatients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results.\n\nPatients with DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded.\n\nPatients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis that is uncontrolled in the opinion of the treating physician.\n\nPatients who have previously been treated with nivolumab will be excluded.\n\nPatients with a known history of any of the following autoimmune diseases are excluded: (a) patients with a history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis) (b) patients with a history of rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]).\n\nPatients with organ allografts (such as renal transplant) are excluded.\n\nPatients with known Human Immunodeficiency Virus seropositivity will be excluded.\n\nKnown to be positive for hepatitis B by surface antigen expression. Known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months).\n\nPregnant or breastfeeding.\n\nAcute promyelocytic leukemia (APL).\n\nCNS 3 disease.\n\nPatients who have experienced their relapse after a HSCT and are less than 100 days post-transplant at the time of enrollment, have active GVHD at time of enrollment, have past history of grade 3 or greater GVHD, Patients on immune suppression (excluding physiologic replacement steroids)."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have had histologic verification of AML at the original diagnosis. Patients must have one of the following:\n\nRecurrent disease in >= 1st relapse with >= 5% blasts in the bone marrow (M2/M3) marrow OR immunophenotypic evidence of disease with >= 0.1% blasts detected by flow cytometry, OR evidence of recurrent cytogenetic or molecular abnormalities consistent with relapse, with or without extramedullary disease\nRefractory AML is defined as >= 5% blasts in the bone marrow (M2/M3) after >= 2 induction attempts (i.e., 2 cycles of chemotherapy)\nPatients with advanced MDS, including MDS that has progressed to AML, and have experienced relapse or are refractory after >= 1 course of induction therapy, are eligible\nKarnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age\n\nPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, e.g., blood count criteria, the patient is considered to have recovered adequately\n\nCytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive\n\n>= 14 days must have elapsed after the completion of other cytotoxic therapy, with the exception of hydroxyurea, for patients not receiving standard maintenance therapy. Additionally, patients must have recovered from all acute toxic effects of prior therapy\n\nNOTE: Cytoreduction with hydroxyurea must be discontinued >= 24 hours prior to the start of protocol therapy\nAnti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil [ANC] counts): >= 7 days after the last dose of agent\nAntibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1\nHematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study-assigned research coordinator\nInterleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)\n\nStem cell Infusions (with or without traumatic brain injury [TBI]):\n\nAllogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)\nAutologous stem cell infusion including boost infusion: >= 42 days\nCellular Therapy: >= 30 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)\nRadiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 42 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial brain metastases (BM) radiation\nRadiopharmaceutical therapy (e.g., radiolabeled antibody, 131 iodine [I]-metaiodobenzylguanidine [MIBG]): >= 42 days after systemically administered radiopharmaceutical therapy\nPatients must not have received prior exposure to MLN4924 (pevonedistat)\n\nCreatinine clearance or radioisotope glomerular filtration rate (GFR) >= 60 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\n\n1 month to < 6 months; 0.4 (male and female)\n6 months to < 1 year; 0.5 (male and female)\n1 to < 2 years; 0.6 (male and female)\n2 to < 6 years; 0.8 (male and female)\n6 to < 10 years; 1 (male and female)\n10 to < 13 years; 1.2 (male and female)\n13 to < 16 years; 1.5 (male) and 1.4 (female)\n>= 16 years; 1.7 (male) and 1.4 (female)\nBilirubin (sum of conjugated + unconjugated) =< upper limit of normal (ULN) for age\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN. For the purpose of this study, the ULN for serum glutamate pyruvate transaminase (SGPT) is 45 U/L\nShortening fraction of >= 27% by echocardiogram, or\nEjection fraction of >= 50% by echocardiogram or radionuclide angiogram\nNo ventricular or supraventricular arrhythmia on electrocardiogram (EKG)\nProlonged rate corrected QT (QTc) interval < 500 msec\nPulse oximetry > 94% on room air if there is clinical indication for determination (e.g. dyspnea at rest)\nInternational normalized ratio (INR) =< 1.5\nHemoglobin > 8.0 g/dL (may receive red blood cell [RBC] transfusions)\nAll patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines\n\nExclusion Criteria:\n\nPregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies, OR because there is yet no available information regarding human fetal or teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use 1 highly effective and 1 additional effective (barrier) method of contraception at the same time for the duration of study therapy and for 4 months after the completion of MLN4924 (pevonedistat) administration. True abstinence, when this is in line with the preferred and usual lifestyle of the subject, is acceptable. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception\nInvestigational drugs: Patients who are currently receiving another investigational drug are not eligible\nAnti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible (except hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy)\nAnti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other systemic agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial. Topical immunosuppressive agents (e.g. topical steroids) are allowed. Physiologic replacement of hydrocortisone is allowed\nPatients who are taking drugs that are strong CYP3A4 inducers and cannot be switched to alternative drugs 14 days prior to enrollment are not eligible. Strong inducers of CYP34 are not permitted during the study\nPatients with known hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection are not eligible. NOTE: Patients who have isolated positive hepatitis B core antibody (i.e. in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load\nPatients with known hepatic cirrhosis or severe pre-existing hepatic impairment are not eligible\nPatients with uncontrolled high blood pressure (i.e., >= 99% for age) are not eligible\n\nPatients with any of the following diagnoses:\n\nAcute promyelocytic leukemia\nDown syndrome\nJuvenile myelomonocytic leukemia\nPatients who have a documented active uncontrolled infection are not eligible\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition as the study agent\n\nPatients with human immunodeficiency virus (HIV) are not eligible unless they meet all of the following criteria:\n\nCD4 count > 350 cell/mm^3\nUndetectable viral load\nMaintained on modern therapeutic regimens utilizing non-CYP-interactive agents\nNo history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections\nFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s) are not eligible\nMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s) are not eligible"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge: Patients <25 years.\nFirst allogeneic HSCT only.\nDisease eligibility: Acute leukemias at high risk for relapse including positive minimal residual disease at end consolidation, high risk cytogenetics, or relapse. Hematologic malignancies including: acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, mixed lineage or bi-phenotypic leukemia, lymphoblastic or Burkitts, juvenile myelomonocytic leukemia\nEvaluation of organ and infectious status as per our Bone Marrow Transplant standard operating procedure (BMT SOP).\nSigned consent by parent/guardian or able to give consent if >18 years.\n\nExclusion Criteria:\n\nPatients who do not meet institutional disease, organ or infectious criteria\nNo suitable donor available for mobilized peripheral stem cells\nPatients with genetic disorders including Fanconi anemia, Kostmann syndrome, dyskeratosis congenital or other DNA repair defects.\nPatients with Hodgkin lymphoma or non-Burkitts, non-lymphoblastic lymphoma\n\nDonor selection and eligibility\n\nUnrelated donor meets National Marrow Donor Program criteria for donation\nHLA testing/matching\nDonor must be willing to undergo granulocyte colony stimulating factor (GCSF) mobilization and peripheral blood stem cell collection"
            },
            {
                  "document": "Key Inclusion Criteria:\n\nAge \u2265 18 and \u2264 65 years at the time of enrollment\nDiagnosed acute myeloid, lymphoid or mixed phenotype leukemia, or high or very high risk myelodysplasic syndrome (MDS) or Myelofibrosis\nPlanned to undergo myeloablative allogeneic hematopoietic stem cell transplant (HCT)\nMatched to a related or unrelated donor or to a haploidentical donor\nEstimated glomerular filtration rate (eGFR) > 50 mL/minute\nCardiac ejection fraction at rest \u2265 45% or shortening fraction of \u2265 27% by echocardiogram or radionuclide scan (MUGA)\nDiffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) \u2265 50%\nTotal bilirubin < 1.5 times upper limit of normal (ULN) (< 3 times if attributed to Gilbert's syndrome) and ALT/AST < 3 times ULN\n\nKey Exclusion Criteria:\n\nPrior allogeneic HCT\nCurrently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.\nPlanned donor lymphocyte infusion (DLI)\nPositive anti-donor HLA antibodies against a mismatched allele in the selected donor\nKarnofsky performance score < 70% (Appendix 12.7)\nHematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) > 4 (Appendix 12.8)\nUncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment\nSeropositive for HIV-1 or -2, HTLV-1 or -2\nAny uncontrolled autoimmune disease requiring active immunosuppressive treatment\nConcurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected\nHistory of idiopathic or secondary myelofibrosis\nWomen who are pregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nHas diagnosis of AML according to the World Health Organization (WHO) 2008 classification with \u22655% blasts in bone marrow, with or without extramedullary disease\nIs in first relapse or refractory to first-line high-dose chemotherapy with no more than 1 attempt (1 to 2 cycles of induction chemotherapy) at remission induction - prior HSCT is permitted\nHas presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood as defined in the protocol\nIs between 1 month and 21 years of age at the time the Informed Consent/Assent form is signed\nHas protocol-defined adequate performance status score\nHas fully recovered from the acute clinically significant toxicity effects of all prior chemotherapy, immunotherapy, or radiotherapy, per protocol guidelines\nHas protocol-defined adequate renal, hepatic and cardiac functions\nIf of reproductive potential, is permanently sterile or agrees to use highly effective birth control upon enrollment, during the period of therapy, and for 6 months following the last dose of study drug or cytarabine, whichever is later\nIf female of child-bearing potential, tests negative for pregnancy and agrees not to breast feed\nParticipant/legal representative is capable of understanding the investigational nature of the study, potential risks, and benefits, and the patient (and/or legal representative) signs a written assent/informed consent\nMeets protocol-specified guidelines before inclusion in the continuation therapy phase\n\nExclusion Criteria:\n\nHas been diagnosed with isolated central nervous system relapse, certain kinds of leukemia, or with myeloid proliferations related to Down syndrome\nHas uncontrolled or pre-defined significant cardiovascular disease as detailed in the protocol\nHas systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The patient must be off vasopressors and have negative blood cultures for at least 48 hours prior to the start of systematic protocol therapy.\nHas known active clinically relevant liver disease (e.g., active hepatitis B or active hepatitis C)\nHas known history of human immunodeficiency virus (HIV)\nHas history of hypersensitivity to any of the study medications or their excipients\nIs receiving or is anticipated to receive concomitant chemotherapy, radiation, or immunotherapy other than as specified in the protocol\nHas any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise subject safety or compliance, interfere with consent/assent, study participation, follow up, or interpretation of study results\nIs currently participating in another investigative interventional procedure (observational or long-term interventional follow-up is allowed)\nIs otherwise considered inappropriate for the study by the Investigator"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have one of the following, histologically or cytologically confirmed:\n\nAML (non- acute promyelocytic leukemia [APL] AML)\n\nAML that is relapsed or refractory to at least one prior line of therapy\n\nMDS, must meet all of the following at the time of enrollment:\n\nHigher risk MDS (intermediate-2 or high risk by the original International Prognostic Scoring System [IPSS]), and\nRelapsed, refractory, or intolerant to at least one prior line of therapy containing a hypomethylating agent (deoxyribonucleic acid [DNA] methyltransferase inhibitor)\nEastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\nTotal bilirubin =< upper limit of normal (ULN) for the laboratory except in patients with Gilbert's syndrome. Patients with Gilbert's syndrome may enroll if direct bilirubin =< 1.5 x ULN for the laboratory of the direct bilirubin\nAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN\nCreatinine clearance within normal limits for the laboratory OR estimated glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 appropriate to race for patients with creatinine levels above institutional normal\n\nKnown human immunodeficiency virus (HIV) positive patients who meet the following criteria will be considered eligible:\n\nCD4 count > 350 cells/mm^3\nUndetectable viral load\nMaintained on modern therapeutic regimens utilizing non-CYP-interactive agents\nNo history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections\nIf evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy, if indicated\nIf history of hepatitis C virus (HCV) infection, patients must be treated and have an undetectable HCV viral load\nThe effects of belinostat and/or MLN4924 (pevonedistat) on the developing human fetus are unknown. For this reason and because histone deacetylase inhibitors and NEDD8-activating enzyme (NAE) inhibitory agents are known to be teratogenic, women of child-bearing potential and men must use 1 highly effective method and 1 additional (barrier) method of contraception at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of MLN4924 (pevonedistat) and belinostat administration\nAbility to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible\n\nExclusion Criteria:\n\nClinical picture indicative of leukostasis or evidence of disseminated intravascular coagulopathy\nPatients with uncontrolled coagulopathy or bleeding disorder\nSystemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug, except for hydroxyurea\nUncontrolled high blood pressure (i.e., systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg)\nFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)\nMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)\nOngoing toxicities >= grade 2 from prior therapy, except those related to hydroxyurea (which is permitted through the first 5 days of study treatment)\nAPL (M3)\nActive central nervous system (CNS) leukemia\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN4924 (pevonedistat) or belinostat\nStem cell transplant within previous 3 months prior to initiation of study therapy\nMajor surgical procedures =< 28 days before beginning study treatment or minor surgical procedures =< 7 days before beginning study treatment. No waiting required after placement of a vascular access device\nUncontrolled intercurrent illness or infection\nCirculating blast count > 50,000 mm^3 within 7 days preceding enrollment\nCurrent candidacy for a potentially curative allogeneic stem cell transplant, unless declined\nLeft ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography\n\nProlongation of the heart-rate corrected QT (QTc) interval >= 450 ms (i.e., grade 1 or higher) on electrocardiogram (ECG) prior to initiation of study treatment.\n\nIf baseline QTc on screening ECG is >= 450 ms (i.e., grade 1 or higher):\n\nCheck potassium and magnesium serum levels, and\nCorrect any identified hypokalemia and/or hypomagnesemia and repeat ECG to confirm QTc interval\n\nFor patients with baseline heart rate < 60 beats per minute (bpm) or > 100 bpm, manual measurement of QT interval by cardiologist is required, with Fridericia correction applied to that manual measurement to determine the QTc for eligibility consideration\n\nNote: For patients with a heart rate of 60-100 bpm, manual measurement of QT interval and use of the Fridericia formula to determine QTc is NOT required\n\nKnown cardiopulmonary disease defined as:\n\nUnstable angina\nCongestive heart failure (New York Heart Association [NYHA] class III or IV)\nMyocardial infarction (MI) within 6 months prior to first dose (patients who had ischemic heart disease such as acute chest syndrome [ACS], MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll)\nSymptomatic cardiomyopathy\nClinically significant pulmonary hypertension requiring pharmacologic therapy\n\nClinically significant arrhythmia defined as any of the following:\n\nHistory of polymorphic ventricular fibrillation or torsade de pointes\nPermanent atrial fibrillation (a fib), defined as continuous a fib for >= 6 months\nPersistent a fib, defined as sustaining a fib lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening\nGrade 3 a fib defined as symptomatic and incompletely controlled medically, or controlled with device (e.g., pace maker), or ablation in the past 6 months\nPatients with paroxysmal a fib or < grade 3 a fib for a period of at least 6 months are permitted to enroll provided that their rate is controlled on a stable regimen\nKnown congenital long QT syndrome\nSecond degree atrioventricular (AV) block type II or third degree AV block\nVentricular rate < 50 bpm or > 120 bpm\n\nTreatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of the study drug.\n\nNote: Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\nOngoing or planned treatment with strong inhibitors of UGT1A1\nAny known UGT1A polymorphism, heterozygous or homozygous\nHistory of prior therapy with belinostat or MLN4924 (pevonedistat)\nActive gastrointestinal (GI) conditions that might predispose to drug intolerance or poor drug absorption\nKnown hepatic cirrhosis\nKnown moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis\n\nNo other prior malignancy is allowed except for the following:\n\nIn situ cervical cancer,\nAdequately treated basal cell or squamous cell skin cancer,\nAdequately treated stage I or II cancer from which the patient is currently in complete remission, and\nAny other cancer from which the patient has been disease-free for at least 1 year\nMedical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk, interfere with the patient's participation in the study, or hinder evaluation of study results\n\nPregnant or nursing. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study therapy.\n\nNote: Pregnant women are excluded from this study because MLN4924 (pevonedistat) is a NEDD8 inhibitor with the potential for teratogenic or abortifacient effects and because belinostat may cause teratogenicity and/or embryo-fetal lethality by virtue of targeting actively dividing cells. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with MLN4924 (pevonedistat) or belinostat, breastfeeding should be discontinued if the mother is treated with MLN4924 (pevonedistat)/belinostat"
            },
            {
                  "document": "Inclusion Criteria:\n\nMale or female subjects 18 years of age or older\n\nSubjects with active acute myeloid leukemia (AML) with no available curative treatment options using currently available therapies. Specifically:\n\nAML that has not achieved a complete remission or morphologic leukemia free state by ELN criteria (D\u00f6hner et al., 2017 Blood, 129(4):424-447); partial remission or refractory disease (including primary refractory) are eligible. Or:\nAML relapsed following allogeneic stem cell transplantation (including MDS evolved to AML post-allogeneic stem cell transplantation). Note: morphologic relapse is not required; persistent/recurrent disease-associated molecular, phenotypic or cytogenetic abnormalities (measurable residual disease, MRD) at any time after allogeneic HCT is eligible\n\nSubjects with relapsed disease after prior transplant must meet one of the following:\n\na. Subjects with relapsed disease after prior allogeneic HCT (myeloablative or non-myeloablative) will be eligible if they meet all other inclusion criteria and i. Have no residual donor cells (by STR analysis on 2 occasions separated by at least 1 month), OR: ii. Donor cells are present but there is no active GVHD (>Gr II), subject does not require systemic immunosuppression and is more than 3 months from transplant, and at least 1 month off GVHD prophylaxis.\n\nb. Subjects with relapsed disease after prior autologous or syngeneic HCT will be eligible if they meet all other inclusion criteria and it has been more than 3 months from transplant.\n\nSubjects must have a suitable stem cell donor available who may donate cells in the event the subject needs to undergo an allogeneic HCT. Donor may be matched or mismatched and must be found to be suitable according to the institution's standard criteria; donors must be fully cleared to proceed as the donor.\n\nSatisfactory organ functions:\n\nCreatinine \u2264 1.6 mg/dl\nALT/AST must be \u22645 x upper limit of normal unless related to disease\nDirect bilirubin or total bilirubin < 2.0mg/dl, unless subject has Gilbert's syndrome (\u22643.0 mg/dL);\nLeft ventricular ejection fraction \u2265 40% as confirmed by ECHO/MUGA\nECOG Performance status 0-2.\nWritten informed consent is given.\nNo contraindications for leukapheresis.\nSubjects of reproductive potential must agree to use acceptable birth control methods (as described in protocol Section 4.3).\n\nExclusion Criteria:\n\nPregnant or lactating (nursing women) women.\nPatients with relapsed AML with t(15:17).\nHIV infection.\nActive hepatitis B or hepatitis C infection.\nConcurrent use of systemic steroids or immunosuppressant medications. Recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary. For additional details regarding use of steroids while on study, please see Section 5.5.\nAny uncontrolled active medical disorder that would preclude participation as outlined.\nSubjects with signs or symptoms indicative of CNS involvement. A CNS evaluation should be performed as clinically appropriate to rule out CNS involvement.\nKnown history of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).\nClass III/IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 3).\nPatients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to leukemia or previous leukemia treatment.\nSubjects with clinically apparent arrhythmia, or arrhythmias that are not stable on medical management, within 2 weeks of the Screening/Enrollment visit.\nPatients with any prior history of myeloproliferative neoplasm.\nPatients with the JAK2 V617F mutation by PCR or next generation sequencing."
            },
            {
                  "document": "Inclusion Criteria:\n\nAdults ages 18 years or older.\nParticipant must have relapsed or refractory acute myeloid leukemia (AML) (excluding acute promyelocytic leukemia).\nRelapsed patients must have received at least 1 induction chemotherapy regimen or two cycles of a hypomethylating agent and achieved a Complete Response (CR), followed by relapse of disease.\nRefractory patients must have received at least 1 induction chemotherapy regimen or two cycles of hypomethylating agent without achieving a CR.\nEastern Cooperative Oncology Group (ECOG) performance status <2.\nParticipants must have acceptable organ function.\nBe able and willing to adhere to the study visit schedule and other protocol requirements.\nMust be able to swallow capsules and have no evidence of GI tract abnormality that would alter the absorption of oral medications.\nThe effects of Minnelide on the developing human fetus are unknown. For this reason, women of child-bearing potential must have a negative serum or urine pregnancy test within 24 hours prior to beginning study treatment.\nParticipants of childbearing potential must practice contraception. Females of childbearing potential: Recommendation is for 2 effective contraceptive methods during the study. Male participants with female partners who are of childbearing potential: Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, during the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\nBecause there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Minnelide, breastfeeding mothers must agree to discontinue nursing if the mother is treated with Minnelide.\nProvision of signed and dated informed consent document\nPatients with prior allogeneic stem cell transplant who experience relapse of AML are eligible if they are off of immunosuppressive therapy and without any evidence of graft-versus-host disease (GVHD)\n\nExclusion Criteria:\n\nParticipants may not have received any therapy with any investigational products, systemic anti-neoplastic therapy, or radiotherapy within 14 days prior to Cycle 1 Day 1. Patients actively receiving hydroxyurea are eligible and may continue to receive hydroxyurea during protocol treatment.\nCandidates for standard and/or potentially curative treatments.\nMajor surgery within 28 days prior to Cycle 1 Day 1.\nNew York Heart Association Class III or IV heart failure, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on an electrocardiogram (EKG)\nActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\nKnown, active HIV, Hepatitis A, B or C infection (prior Hepatitis C infection that has been treated and determined to be cured is allowed)\nSymptomatic central nervous system (CNS) involvement with leukemia\nA concurrent second active and non-stable malignancy with the exception of non-melanoma skin cancer or carcinoma in-situ."
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of AML or AML secondary to MDS (myelodysplastic syndrome) and lymphoma with fatigue >= 4/10 (0-10 scale) on the MDASI-AML/MDS.\nPresence of fatigue for at least 2 weeks.\nNormal cognition by Memorial Delirium Assessment Scale score of < 13 at baseline.\nHemoglobin > 8 g/L within 2 weeks of enrollment in the study; if the patient has not had blood drawn for a hemoglobin level in the past two weeks, one will be done to determine the eligibility.\nZubrod performance status =< 2.\nAble to communicate in English or Spanish.\nSeen at leukemia and lymphoma clinics at University of Texas (UT) MD Anderson Cancer Center, Houston, Texas and its affiliates in University of Texas.\n\nExclusion Criteria:\n\nHas received CBT (cognitive behavioral therapy) for any indication (e.g. depression, sleep disturbance) in the past 1 year.\nInability to comply with study protocol procedures.\nPrior cancer diagnosis other than noted in the inclusion criterion #1."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have an established and confirmed diagnosis of AML by World Health Organization (WHO) criteria, excluding acute promyelocytic leukemia (APL).\n\nPatients must have relapsed or refractory AML, defined as:\n\nRelapsed: >= 5% bone marrow blasts by morphology, reappearance of minimal residual disease (MRD) (> 0.1%) by flow cytometry, reappearance of peripheral blood blasts, or development of extramedullary leukemia after one or more prior lines of therapy. Consolidation regimens, including autologous and allogeneic HCT, do not count as a separate prior line of therapy, (e.g., 7+3 followed by cytarabine consolidation followed by allogeneic hematopoietic cell transplantation (HCT) would be considered one prior line of therapy). Note, there is no restriction on the prior number of relapses and prior treatment of relapsed disease is allowed.\nRefractory: no complete response (CR) or complete response with incomplete bone marrow recovery (CRi) after two courses of induction therapy (e.g. therapy with the intent to induce remission). Patients 75 years or older, or patients of any age with comorbidities that prevent the use of further intensive chemotherapy, will be eligible if they did not experience CR or CRi after one course of induction therapy.\nPatients must have Karnofsky >= 60%.\nPatients must have a white blood cell count (WBC) =< 25 x 10^9 cells/L. Hydroxyurea and leukapheresis are permitted to satisfy this criterion.\nTotal bilirubin =< institutional upper limit of normal (ULN) except in patients with Gilbert's syndrome or post-transfusion hemolysis. Patients with Gilbert's syndrome or post-transfusion hemolysis may enroll if direct bilirubin =< 1.5 x ULN of the direct bilirubin.\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN (unless resulting from liver infiltration with leukemia).\nCreatinine clearance >= 30 mL/min (If serum creatinine not =< institutional ULN).\nHemoglobin > 8 g/dL. Patients may be transfused to achieve this value.\nHuman immunodeficiency virus (HIV)-infected patients will be eligible for this trial if they are on effective antiretroviral regimens utilizing non-CYP-interacting agents, they have an undetectable viral load, they have a CD4 count > 350 cells/mm^3, and they have no history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections. If there is evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy, if indicated. If there is history of hepatitis C virus (HCV) infection, the patient must have been treated and have undetectable HCV viral load.\nPatients must be willing to submit blood samples for the integrated biomarker.\nFemale patients of childbearing potential (i.e. who are not postmenopausal for at least 1 year before screening or are not surgically sterile) must have a negative serum pregnancy test within 72 hours prior to the first study drug administration and must agree to practice one highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. Male patients, even if surgically sterilized, must agree to practice effective barrier contraception during the entire study treatment period through 4 months after the last dose of study drug, or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.\nPatients may have had prior allogeneic HCT at least 3 months prior to randomization but should not have evidence of active graft versus host disease or require systemic immune suppression.\nPatients must be able to understand and be willing to sign a written informed consent document.\nPatients with impaired decision-making capacity (IDMC) will be eligible if they have a legal guardian or a close family member available to assist them.\n\nExclusion Criteria:\n\nPatients must not have had prior treatment with MLN4924 (pevonedistat), azacitidine, or decitabine.\nPatients for whom, in the opinion of the treating physician, azacitidine alone is not an appropriate treatment will be excluded.\nPatients must not have documented active central nervous system (CNS) involvement by leukemia. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\nPatients must not have received any other investigational or commercial agents or therapies administered with the intention to treat their leukemia within 14 days or five half-lives (whichever is shorter) of first receipt of study drug, with the exception of hydroxyurea used to control WBCs.\nAll non-hematologic adverse events (AEs) of prior chemotherapy, surgery, or radiotherapy, except alopecia, must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade =< 2 prior to starting therapy.\n\nPatients must not have a history of other malignancies, except:\n\nAny malignancy that was treated with curative intent, has no known active disease present for >= 1 year before the first dose of study drug, and is felt to be at low risk of recurrence by the treating physician;\nAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease;\nAdequately treated carcinoma in situ without evidence of disease;\nLow-risk prostate cancer after curative surgery.\nPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN4924 (pevonedistat), azacitidine, or mannitol.\nClinically significant metabolic enzyme inducers are not permitted during this study, or within 14 days before the first dose of study drugs. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.\nPatients must not have severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator, could affect their participation in the study.\nPregnant women are ineligible because, as an Nedd8 activating enzyme (NAE) inhibitor, MLN4924 (pevonedistat) has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with MLN4924 (pevonedistat), breastfeeding must be discontinued if the mother is treated with MLN4924 (pevonedistat). These potential risks may also apply to azacitidine.\nPatients must not have had major surgery within 14 days before the first dose of any study drug or be scheduled for surgery during the study period.\nPatients must not have uncontrolled coagulopathy or a bleeding disorder unless directly attributable to their AML (e.g., disseminated intravascular coagulation).\nPatients must not have known hepatic cirrhosis or severe pre-existing hepatic impairment.\n\nPatients must not have known cardiopulmonary disease defined as:\n\nUnstable angina;\nCongestive heart failure (New York Heart Association [NYHA] class III or IV;\nMyocardial infarction (MI) within 6 months prior to first dose. Patients who had ischemic heart disease such as acute coronary syndrome (ACS), MI, and/or revascularization more than 6 months before screening and who are without cardiac symptoms or those with a prior non-ST elevation MI due to demand-supply mismatch (NSTEM type II) may enroll;\nSymptomatic cardiomyopathy;\n\nClinically significant arrhythmia:\n\nHistory of polymorphic ventricular fibrillation or torsade de pointes,\nPermanent atrial fibrillation, defined as continuous atrial fibrillation lasting for >= 6 months;\nPersistent atrial fibrillation, defined as sustained atrial fibrillation lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening;\nGrade 3 atrial fibrillation, defined as symptomatic and incompletely controlled medically, or controlled with a device (e.g., pacemaker) or by ablation;\nPatients with paroxysmal atrial fibrillation or < grade 3 atrial fibrillation for period of at least 6 months are permitted to enroll provided that their heart rate is controlled on a stable regimen;\nModerate or severe pulmonary hypertension.\nPatients must not have uncontrolled high blood pressure that cannot be controlled by standard therapies.\nPatients must not have any life-threatening illness unrelated to cancer.\nPatients must not have an active, uncontrolled infection or severe infectious disease, (e.g. severe pneumonia, meningitis, or septicemia). Patients with an uncontrolled infection must not be enrolled until they have received treatment and the infection is under control.\nPatients must not have prolonged rate-corrected QT (QTc) interval >= 480 msec, calculated according to institutional guidelines.\nPatients must not have left ventricular ejection fraction < 40% as assessed by a transthoracic echocardiogram or radionuclide angiography within one month prior to study entry.\nPatients must not have known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis.\nFemale patients who intend to donate eggs (ova) during the course of this study or within 4 months of receiving their last dose of study drugs are ineligible.\nMale patients who intend to donate sperm during the course of this study or within 4 months of receiving their last dose of study drugs are ineligible."
            },
            {
                  "document": "Inclusion Criteria:\n\nVoluntary written informed consent\nPatients who are considered for allogeneic transplantation based on their disease risk (see below) but lack matched sibling or unrelated donors or who are unable to proceed to allogeneic transplant within 8 weeks, will be considered for UCB transplantation on this study. Only patients for whom RIC will be considered are eligible. RIC is considered in those older than 45 or younger than 45 with Hematopoietic Cell Transplant (HCT) Comorbidity Index of 3 or higher (HCT) Comorbidity Index can be calculated using the following link: http://www.hctci.org/Home/Calculator\nPatients with acute myeloid leukemia (AML) in CR1 that is not considered favorable-risk (favorable risk is defined as patients with t(15;17)(q22;q21), t(8;21)(q22;q22), inv(16)(p13q22)/t(16;16)(p13;q22), NPM1 mutation without FLT3-ITD, and double-mutated CEBPA58,59), AML in CR2 or subsequent CR, high-risk acute lymphoblastic leukemia (ALL) in CR1, or ALL in CR2 or higher, biphenotypic leukemia defined as coexpression of B-lymphoid and myeloid markers or T-lymphoid and myeloid markers in the blast population60or undifferentiated leukemia in \u2265CR1. Myelodysplatic syndrome (MDS)/myeloproliferative neoplasm (MPN) patients with less than 10% bone marrow blasts and no peripheral blood blasts on pre-transplant bone marrow aspirate/biopsy are considered for FluCyTTBI regimen. Chemotherapy sensitive (achievement of at least a partial response according to Lugano classification61) Hodgkin's disease (HD) that relapsed following high-dose therapy. Chemotherapy sensitive (achievement of at least a partial response according to Lugano classification) non-Hodgkin's lymphoma (NHL) patients who relapsed post-high-dose therapy and autologous transplantation. Subjects should be enrolled within 30 days of transplant.\n\nFor ALL, high-risk features are defined using modified Hoelzer risk criteria62, these criteria are:\n\nHigh white blood cell count at diagnosis (ie, >30,000/microL in B-ALL or >100,000/microL in T-ALL).\nClonal cytogenetic abnormalities - t(4;11), t(1;19), t(9;22), or BCR-ABL gene positivity.\nProgenitor-B cell immunophenotype (eg, blasts expressing membrane CD19, CD79a, and cytoplasmic CD22).\nLength of time from start of induction therapy to attainment of CR greater than four weeks.\nOlder age - >60 years old is high risk, 30 to 59 years old is intermediate risk.\nMRD - a post-remission bone marrow MRD level \u226510-3 by molecular tests.\nSubjects must be \u2265 18 years old and \u2264 70 years old\nKarnofsky performance status (KPS) of \u2265 70% (Appendix A).\n\nAdequate hepatic, renal, cardiac and pulmonary function to be eligible for transplant. Minimum criteria include:\n\nALT, AST: < 4x IULN\nTotal bilirubin: \u2264 2.0 mg/dL\nCreatinine: \u2264 1.5 x ULN\nEF measured by 2D-ECHO or MUGA scan of \u2265 45%\nFEV1, FVC and DLCO \u2265 50% of predicted value (corrected to serum hemoglobin).\nEKG with no clinically significant arrhythmia.\nPatients should have New York Heart Association (NYHA) Functional Classification, class -1 (ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or angina pain) or class II (ordinary physical activity results in fatigue, palpitation, dyspnea, or angina pain).\nPatients should be evaluated for fitness for HBO by a hyperbaric oxygen trained medical professional who is not part of the study team prior to starting preparative regimen.\nWomen of child-bearing potential should have a negative urine pregnancy test within 4 weeks of starting preparative regimen.\nWomen of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman or partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and the investigator immediately.\n\nA woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\nHas not undergone a hysterectomy or bilateral oophorectomy; or\nHas not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\n\nExclusion Criteria:\n\nPregnant or breastfeeding\nSevere chronic obstructive pulmonary disease requiring oxygen supplementation\nHistory of spontaneous pneumothorax\nActive ear/sinus infection. Patients with chronic sinusitis or sinus headaches are excluded unless cleared by ear, nose, throat provider.\nEvidence of pneumothorax or significant pulmonary fibrosis on chest imaging within 60 days of transplant.\nPrior chest surgery requiring thoracotomy or direct chest irradiation.\nRecent of sinus or ear surgery, excluding myringotomy or ear tubes (within the last 5 years).\nClaustrophobia\nPatients who had intrathecal chemotherapy within 2 weeks of starting preparative regimen or cranial irradiation within 4 weeks of starting preparative regimen.\nHistory of seizures\nNo active tobacco use 72 hours prior to transplant until complete transplant recovery."
            },
            {
                  "document": "Inclusion Criteria:\n\nPrior diagnosis AML based on 2016 World Health Organization criteria. Acute promyelocytic leukemia (APL) and biphenotypic AML are not eligible.\nPatients must have MRD-level disease only and otherwise meet criteria for complete response (CR) or complete remission with incomplete hematologic recovery (CRi) per the 2017 European Leukemia Net response criteria (< 5% blasts in the marrow without a requirement for peripheral blood count recovery). MRD must be measurable by multiparameter flow cytometry (MPFC) and/or polymerase chain reaction (PCR)-based molecular markers and/or karyotypic markers (e.g., classical cytogenetics or fluorescence in situ hybridization). MRD status will be centrally confirmed by the UW/FHCRC clinical laboratory in order to standardize response assessment following administration of study therapy.\nPatients must have received at least 1 cycle of standard induction chemotherapy prior to enrollment on the study. However, adult patients (>= 18 years of age) are eligible for participation at any time point in treatment (after induction, during or after consolidation, pre-transplant, or post-transplant). Pediatric patients (2-18 years of age) must have MRD positivity during/after consolidation or post-transplant.\nAge >= 2 years of age\nEastern Cooperative Oncology Group (ECOG) performance status =< 3 (for adults) or Lansky performance status >= 40 (for children).\nPatient's AML blasts must have CD33 expression.\nFor adults (>= 18 years of age): Serum creatinine =< 2.0 mg/dL.\nFor adults (>= 18 years of age): Total bilirubin =< 2 x institutional upper limit of normal for age (unless known history of Gilbert's disease).\nFor adults (>= 18 years of age): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal for age (unless thought to be related to resolving infectious complications).\nFor children (< 18 years of age): Glomerular filtration rate (GFR) in ml/min (age 2: 63-175; age 3-12: 89-165; females 13 and older: 75-115; males 13 and older: 85-125).\nFor children (< 18 years of age): Total bilirubin =< 2 x institutional upper limit of normal for age (unless known history of Gilbert's disease).\nFor children (< 18 years of age): AST and ALT < 2.5 x institutional upper limit of normal for age (unless thought to be related to resolving infectious complications).\nAbility of patient or representative to provide written informed consent.\nFemales of childbearing potential must have a negative pregnancy test prior to receiving GO.\nPatients who re-enroll must have achieved an MRD-negative CR during their prior enrollment\n\nExclusion Criteria:\n\nSubjects who have had chemotherapy or radiation therapy within 14 days prior to entering the study.\nSubjects may not be receiving other investigational agents.\nUncontrolled or concurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."
            },
            {
                  "document": "Inclusion Criteria:\n\nFLT3-ITD mutated patients with relapsed/refractory AML (up to four prior therapeutic regimens for AML i.e. up to salvage 4 AML), including patients who may have been previously exposed to prior FLT3-inhibitor/s other than quizartinib (stem cell transplant [SCT] or stem cell therapy for patients who previously underwent SCT/stem cell therapy in remission will not be considered a salvage regimen)\nEastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\nPotassium, magnesium, and calcium (normalized for albumin) levels should be within institutional normal limits\nSerum direct bilirubin =< 1.5 x upper limit normal (ULN) (or =< 3.0 x ULN if deemed to be elevated due to leukemia)\nAlanine aminotransferase and/or aspartate aminotransferase (aspartate transaminase) =< 2.5 x ULN (or =< 5.0 x ULN if deemed elevated due to leukemia)\nSubjects with documented Gilbert's Syndrome may have a total bilirubin > 1.5 x ULN\nPotassium levels should be within institutional normal limits\nMagnesium levels should be within institutional normal limits\nCalcium (normalized for albumin) levels should be within institutional normal limits\nAdequate renal function as demonstrated by a serum creatinine =< 1.8\nPatients must provide written informed consent\n\nWith the exception of patients with rapidly proliferative disease, the interval from prior treatment to time of initiation of venetoclax and quizartinib administration will be at least 14 days or at least 5 half-lives (whichever is shorter) for cytotoxic/noncytotoxic agents. The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochures, or drug-administration manuals) and will be documented in the protocol eligibility document. The use of chemotherapeutic or anti-leukemic agents is not permitted during the study with the following exceptions:\n\nIntrathecal (IT) therapy for patients with controlled central nervous system (CNS) leukemia at the discretion of the principal investigator (PI). Controlled CNS leukemia is defined by the absence of active clinical signs of CNS disease and no evidence of CNS leukemia on the most recent 2 simultaneous cerebrospinal fluid (CSF) evaluations\nUse of one dose of cytarabine (up to 2 g/m^2) or hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and on therapy. These medications will be recorded in the case-report form\nBaseline ejection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) must be >= 50%\nWomen of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy\nWomen of childbearing potential must agree to have a negative serum or beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 7 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 90 days following the last dose of the study. Men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 90 days following the last dose of study drug\n\nExclusion Criteria:\n\nSubject has t(8;21) or inv(16) karyotype abnormalities\nSubject has acute promyelocytic leukemia (French-American-British Class M3 AML)\nPrior exposure to quizartinib at any time in the past\nSerum potassium < 3.5 mEq/L despite supplementation, or > 5.5 mEq/L. Serum magnesium above or below the institutional normal limit despite adequate management. Serum calcium (corrected for albumin levels) above or below institutional normal limit despite adequate management\nPatients with known allergy or hypersensitivity to quizartinib, venetoclax or any of their components\n\nSubject with a known history of being human immunodeficiency virus (HIV) positive (due to potential drug-drug interactions between antiretroviral medications and venetoclax, as well as anticipated venetoclax mechanism-based lymphopenia that may potentially increase the risk of opportunistic infections)\n\nNote: HIV testing is not required\nSubject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit within 3 days prior to the initiation of study treatment\nSubject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator and/or the PI would adversely affect his/her participating in this study. Patients who have had any major surgical procedure within 14 days of day 1\nSubject has a malabsorption syndrome or other condition that precludes enteral route of administration\nSubject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: a. Uncontrolled systemic infection requiring intravenous (IV) therapy (viral, bacterial or fungal). Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines is acceptable. Patients with neutropenic fever considered infection related should be afebrile for at least 72 hours prior to first dose\n\nSubject has a history of other malignancies within 1 year prior to study entry, with the exception of:\n\nAdequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent\nPatients on active antineoplastic or radiation therapy for a concurrent malignancy at the time of screening. Maintenance therapy, hormonal therapy, or steroid therapy for well-controlled malignancy is allowed\nPatients with a known positive hepatitis B or C infection by serology, with the exception of those with an undetectable viral load within 3 months (hepatitis B or C testing is not required prior to study entry). Subjects with serologic evidence of prior vaccination to hepatitis B virus (HBV) (i.e., hepatitis B surface antigen negative [HBs Ag-], and hepatitis B surface antibody positive [anti-HBs+]) may participate\nFemale subjects who are pregnant or breastfeeding\n\nImpaired cardiac function including any of the following:\n\nScreening electrocardiogram (ECG) with a corrected QT (QTc) > 450 msec. The QTc interval will be calculated by Fridericia's correction factor (QTcF) at screening and on day 1 prior to the first dose of quizartinib. The QTcF will be derived from the average QTcF in triplicate. If QTcF > 450 msec on day 1, quizartinib will not be given.\nPatients with congenital long QT syndrome\nHistory or presence of sustained ventricular tachycardia requiring medical intervention within 3 months prior to starting study drug\nAny history of clinically significant ventricular fibrillation or torsades de pointes\nKnown history of second or third degree heart block (may be eligible if the patient currently has a pacemaker) within 3 months prior to starting study drug\nSustained heart rate of < 50/minute on screening or day 1 ECG\nRight bundle branch block + left anterior hemiblock (i.e. bifascicular block)\nIsolated right bundle branch block (RBBB) will not be an exclusion criterion\nComplete left bundle branch block\nPatients with myocardial infarction or unstable angina within 6 months prior to starting study drug\nCongestive heart failure (CHF) New York (NY) Heart Association class III or IV within 3 months prior to starting study drug\nAtrial fibrillation documented within 2 weeks prior to first dose of study drug\nPatients who are actively taking CYP3A inducers. CYP3A4 inducers should be stopped at least 3 days prior to the first dose of quizartinib and are prohibited at any time on study. Moderate and strong CYP3A4 inhibitors should be stopped at least 3 days prior to the first dose of quizartinib and are prohibited during cycle 1. Moderate (but not strong) CYP3A4 inhibitors may be used with the below dose reductions of venetoclax after cycle 1. Patients may receive weak CYP3A4 inhibitors at any time on study. The venetoclax and quizartinib doses do not need to be adjusted for weak CYP3A4 inhibitors\nPatients who require treatment with concomitant drugs that prolong QT/QTc interval. QT/QTc prolonging drugs should be stopped at least 3 days prior to the first dose of quizartinib and are prohibited at any time on study\nKnown family history of congenital long QT syndrome"
            },
            {
                  "document": "Inclusion Criteria:\n\nDocumented informed consent of the participant and/or legally authorized representative\n\nAgreement to allow the use of archival tissue from diagnostic tumor biopsies\n\nIf unavailable, exceptions may be granted with study principal investigator (PI) approval\nEastern Cooperative Oncology Group (ECOG) =< 2 or Karnofsky performance status (KPS) >= 70\nRecipients of allogeneic HCT - all stem cell sources including sibling, unrelated, mismatched related/unrelated, cord and haploidentical transplant patients will be included\nConditioning regimen: Investigator's choice based on center guidelines\nGvHD prophylaxis: sirolimus + tacrolimus or tacrolimus + methotrexate or investigator choice\nPatients must have acute myeloid leukemia (AML) with IDH2 mutation at diagnosis. Day 30 marrow post HCT should show evidence of morphologic remission with < 5% bone marrow blasts. Patients with MRD either by flow cytometry or IDH2 mutation testing will be allowed\nPatients with previous therapy with IDH2 inhibitors will be included\nAbsolute neutrophil count (ANC) > 1000 (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\nHemoglobin >= 9.5 gm% (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\nPlatelets > 50,000/mm^3 (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n\nPlatelets >= 20,000/mm^3 (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n\nNOTE: Patients with lower counts can enroll if infection cytomegalovirus (CMV)/human herpesvirus 6 (HHV6) etc. is being treated actively\nTotal bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\nTotal bilirubin < 2.0 mg/dl-exception permitted in patients with Gilbert's Syndrome (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\nAspartate aminotransferases (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x ULN, patients with abnormal liver function tests (LFTs) in the context of active GVHD will not be included (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\nCreatinine clearance of >= 40/min/1.73 m^2 for participants with creatinine levels above institutional normal per 24 hour urine test or the Cockcroft-Gault formula (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n\nCorrected QT (QTc) =< 480 ms\n\nNote: To be performed within 28 days prior to day 1 of protocol therapy\n\nSeronegative for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR])\n\nIf positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed\n\nWomen of childbearing potential (WOCBP): negative urine or serum pregnancy test\n\nIf the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n\nAgreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy\n\nChildbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\n\nExclusion Criteria:\n\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\nActive diarrhea considered clinically significant and may impair oral drug administration\nClinically significant uncontrolled illness\n\nActive infection requiring antibiotics\n\nActive infection. Patients with treated viral, bacterial or fungal infections that are controlled on therapy will be allowed to participate\nKnown history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection\nDiagnosis of Gilbert's disease\nOther active malignancy. Participants with history of prior malignancy treated with curative intent who achieved complete response (CR) more than 2 years before study entry are eligible. This exclusion rule does not apply to non-melanoma skin tumors and in-situ cervical cancer\nFemales only: Pregnant or breastfeeding\nActive grade II-IV acute GVHD and/or requiring systemic steroids with prednisone dose equivalent of >= 0.25 mg/kg at end of 4 weeks\nAny other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\nProspective participants, who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have histologically confirmed acute myeloid leukemia by World Health Organization (WHO) criteria. Patients with treatment-related acute leukemia are eligible if they do not exceed lifetime anthracycline doses\nPresence of a cytogenetic rearrangement of KMT2A (MLL) by interphase fluorescent in-situ hybridization (FISH)\nPatients must have previously untreated (with exception of hydroxyurea for count control or all-trans retinoic acid [ATRA] for acute promyelocytic leukemia [APML] that was initially suspected but later ruled out) AML by World Health Organization (WHO) criteria. Treatment with hydroxyurea for count-control of hyperproliferative disease is permitted before and during treatment with pinometostat and chemotherapy\nAge >=14 years at time of screening, although individual sites may further restrict age eligibility in accordance with local Institutional Review Board (IRB) and hospital policy.\nEastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\nTotal bilirubin =< 1.5 x institutional upper limit of normal (ULN), unless elevated due to Gilbert syndrome, hemolysis, or leukemia (at the time of eligibility screening)\nAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN, unless due to leukemia in which case < 5 x ULN (at the time of eligibility screening)\nCreatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal (at the time of eligibility screening)\nGlomerular filtration rate (GFR) => 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\nProthrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (both) (at the time of eligibility screening)\nHuman immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial (at the time of eligibility screening)\nIf evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy if indicated (at the time of eligibility screening)\nIf history of hepatitis C virus (HCV) infection, must be treated with undetectable HCV viral load (at the time of eligibility screening)\n\nFor pediatric patients, a serum creatinine based on age/gender as follows:\n\n10 to < 13 years: male = 1.2; female = 1.2\n13 to < 16 years: male = 1.3; female = 1.4\n>= 16 years: male = 1.7; female = 1.4\nBe medically fit, in the opinion of the investigator, for intensive (7+3) induction chemotherapy\nLeft ventricular ejection fraction (LVEF) >= 45% confirmed by echocardiogram or multi-gated acquisition scan (MUGA), AND no symptoms of congestive heart failure exceeding New York Heart Association (NYHA) class II\nWillingness to comply with all study procedures, including scheduled visits, investigational and standard of care drug administration plans, imaging studies, laboratory tests (including all biomarkers), procedures, and study- and disease-related restrictions\nThe effects of pinometostat on the developing human fetus are unknown. For this reason and because other small molecule inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry for the duration of study participation, and for 4 weeks after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate barrier contraception prior to the study, for the duration of study participation, and for 90 days after completion of pinometostat administration\nAbility to understand and the willingness to sign a written informed consent document or, for patients with impaired decision-making capacity, the consent of a close legal guardian who is readily available\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia with t(15;17)(q22;q12) and/or PML-RARA molecular rearrangement, or other atypical RARA translocation partner\nPatients who have received prior chemotherapy for AML, excluding hydroxyurea for count control, or ATRA for APML that was initially suspected but later ruled out\nPatients who have received any prior investigational agent for acute myeloid leukemia\nPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study\nPatients who have a cumulative lifetime exposure (prior to study entry) of greater than 300 mg/m^2 doxorubicin equivalent anthracycline\nPatients who have received chest radiation (unless organ-sparing) and who have a cumulative lifetime exposure (prior to study entry) of greater than 240 mg/m^2 doxorubicin equivalent anthracycline\nPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia, or peripheral neuropathy (up to grade 2 is permitted)\nPatients who are receiving any other investigational agents\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pinometostat or other agents used in study\nPatients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible unless the offending medication can be safely stopped prior to enrollment. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring antibiotics (with exception), symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia not controllable with medications, electrocardiographic evidence of ischemia, or psychiatric illness/social situations that would limit compliance with study requirements. Patients receiving an anti-microbial agent may be eligible if the patient remains afebrile and hemodynamically stable for 72 hours\nPatients with an active bleeding diathesis\nPregnant women are excluded from this study because pinometostat is a small molecule inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pinometostat, breastfeeding should be discontinued if the mother is treated with pinometostat. These potential risks may also apply to other agents used in this study\nSubjects with known symptomatic leukemia of the central nervous system including leptomeningeal leukemic involvement\nHistory of active other malignancy that limits survival to less than 1 year\nOngoing viral or drug induced liver injury, including active chronic hepatitis C virus (HCV), chronic active hepatitis B, clinically known alcoholic liver disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, primary biliary cirrhosis, other cirrhosis of the liver, history of hepatic encephalopathy, or portal hypertension\nAny other prior condition that could, in the opinion of the investigator, compromise patient safety or evaluation of the primary outcome"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with AML who are newly diagnosed according to the WHO 2016 Classification and previously untreated with the exception of hydroxyurea. ATRA pretreatment for suspected APL for less than 5 days is allowed. Eligible patients with AML arising from an antecedent hematologic disease (AHD) including MDS, may have been treated for their prior hematologic disease (except for allogenic transplant).\n\nAML patients include de-novo AML, AML evolving from MDS or other AHD and AML after previous cytotoxic therapy or radiation (secondary AML).\n\nFor a diagnosis of AML, a bone marrow or peripheral blast count of 20% or more is required.\nIn AML with monocytic or myelomonocytic differentiation, monoblasts and promonocytes, but not abnormal mature monocytes, are counted as blast equivalents.\nPatients must be \u226518 and \u226460 years old.\nEastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2. (See protocol Appendix D.)\nLVEF \u2265 45% by MUGA or ECHO at screening.\nAdequate renal function as demonstrated by a calculated creatinine clearance \u2265 50 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula.\n\nAdequate liver function as demonstrated by:\n\naspartate aminotransferase (AST) \u2264 2.5 \u00d7 ULN*\nalanine aminotransferase (ALT) \u2264 2.5\u00d7 ULN*\ntotal bilirubin \u2264 1.5 \u00d7 ULN*\nUnless considered due to leukemic organ involvement.\nSubjects with Gilbert's Syndrome may have a total bilirubin > 1.5 \u00d7 ULN per discussion with the overall study PI\nMale subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug.\nFemales of childbearing potential (i.e., not postmenopausal for at least 1 year or not surgically sterile) must have negative results by a serum pregnancy test performed within 7 days of day 1.\nSubject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.\n\nExclusion Criteria:\n\nSubject has acute promyelocytic leukemia, inversion16, t(8;21) or FLT3 mutant AML as described below. Contact PI with questions.\n\nInversion 16 and t(8;21): CBF chromosomal abnormalities may be assessed by molecular (PCR), metaphase cytogenetics, or FISH\nFLT3: ITD or a point mutation in the TKD loop of variant allele fractions \u22655% by PCR, capillary electrophoresis, or NGS panel capable of defining FLT3 allelic burden\nSubject has known active CNS involvement with AML.\nSubject has tested positive for HIV (due to potential drug-drug interactions between antiretroviral medications and venetoclax, as well as anticipated venetoclax mechanism-based lymphopenia that may potentially increase the risk of opportunistic infections). Note: HIV testing is not required.\nSubject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required). Subjects with serologic evidence of prior vaccination to HBV [i.e., HBs Ag-, and anti-HBs+] are allowed.\n\nSubject has received the following within 7 days prior to the initiation of study treatment:\n\nStrong or moderate CYP3A inducers (see Appendix C)\nStrong and moderate CYP3A inhibitors (see Appendix C)\nSubject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within 3 days prior to the initiation of study treatment.\nSubject has a cardiovascular disability status of New York Heart Association Class \u2265 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.\nSubject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study.\nSubject has chronic respiratory disease that requires continuous oxygen use.\nSubject has a malabsorption syndrome or other condition that precludes enteral route of administration.\nSubject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection.\n\nSubject has a history of other malignancies prior to study entry, with the exception of:\n\nAdequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent.\nPrior malignancies treated with (surgery+/- chemotherapy+/- radiation) that have remained disease free for at least two years after completion of therapy\nSubject has a white blood cell count > 25 \u00d7 109/L. Note: Hydroxyurea is permitted to meet this criterion.\nSubject treated with any form of chemotherapy, immunotherapy, or investigative agent within 1 month of enrollment."
            },
            {
                  "document": "Inclusion Criteria:\n\nMale and female 18 years old and above\nAble to understand and sign informed consent form\nPatients with histologically or cytologically confirmed advanced solid tumors who have relapsed or refractory disease or relapsed/refractory AML for which no standard therapies expected to produce clinical benefit to the patient are available\nPatients with diagnosed solid tumors must have at least one lesion that is measurable per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria\nPatients with relapsed or refractory AML must be diagnosed with AML based on World Health Organization (WHO) criteria (\u2265 20% blasts in bone marrow). Patients with acute promyelocytic leukemia are excluded\nEastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1\nHave discontinued all previous cancer therapies for at least 21 days or 5 half-lives prior to study treatment, whichever is shorter, and recovered from the acute adverse effects of therapy\nExpected to survive at least 2 to 3 months\nLVEF \u2265 50% and QTc interval < 450 ms\nWomen shall meet either of the following conditions before enrollment\nInfertile, defined as having a bilateral oophorectomy (ovariectomy), or a bilateral tubal ligation, or being post-menopausal for at least 1 year.\nFor those of childbearing potential, they should have a negative serum pregnancy test during screening, agree to refrain from lactation, and use effective contraception such as hormonal methods associated with inhibition of ovulation, condom, intra-uterine device, surgical sterilization (including partner's vasectomy) or sexual abstinence during the study and 30 days after the last administration of study drug.\nMen who are engaging or plan to engage in sexual activity with a female of childbearing potential must either have a prior vasectomy or agree to use effective contraception such as condoms, sexual abstinence and appropriate methods taken by their partner(s) during the study and 90 days after the last dose.\nPatients must have adequate organ functions as indicated by the following screening laboratory values:\nSerum total bilirubin \u2264 1.5 \u00d7 upper limit normal (ULN) (Serum total bilirubin can be \u2264 3.0 \u00d7 ULN if patients have hemolysis or congenital hemolytic diseases)\nCreatinine < 1.5 \u00d7 ULN or estimated creatinine clearance \u2265 50 mL/min\n\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 \u00d7 ULN or\n\n5 X ULN for patient with liver metastases\nAbsolute neutrophil count (ANC) \u2265 1.5\u00d710^9/L\nPlatelets \u2265 100\u00d710^9/L\nHemoglobin \u2265 9 g/dL or \u2265 5.6 mmol/L (Note: Criteria must be met without a transfusion within 2 weeks of obtaining the sample) Note: Laboratory requirements for complete blood counts (hemoglobin, ANC, and platelets) do not apply to AML patients\n\nExclusion Criteria:\n\nParticipation in another therapeutic clinical trial within 3 weeks of enrollment\nA previous toxicity-related reaction towards cancer therapy have not recovered within 2 weeks of enrollment (>Grade 2 National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03)\nHaving received a major surgical operation within 4 weeks of enrollment or not yet completely recovered from a previous operation\nAny serious or uncontrollable systemic disease, including but not limited to: Hypertension (after treatment, systolic blood pressure (SBP) > 180 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg) and active hemorrhagic disorders; patients who are determined by investigators as otherwise not suitable for participation in this study.Note: Patients that in the judgment of the investigator have clinical signs of disease progression during the screening period (i.e.: febrile neutropenia, ascites requiring drainage, hospitalization due to worsening underlying disease, etc.) will not be eligible for participation.\nActive known infection, including hepatitis B, hepatitis C, and human immunodeficiency virus\nPrimary central nervous system (CNS) tumor or CNS metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with a history of CNS metastases or cord compression are allowable if they have been definitively treated and have been clinically stable for at least 3 months, and off steroids or anticonvulsants \u2265 2 weeks before first dose of study drug)\nSerious kidney injury, requiring dialysis\nSerious liver injury, and advanced liver diseases of Child-Pugh class B and C\nOn medications that are strong cytochrome P450(CYP)3A inhibitors or inducers unless patients are willing and able to change to use of an equivalent medication that is not a strong CYP3A inhibitor or inducer\nCardiac function and disease history which meets one or more of the following conditions:\nAny risk which may increase QTc interval prolongation, such as hypokalemia, hereditary long QT syndrome and taking drugs that can prolong QT interval\nAcute myocardial infarction \u2264 6 months prior to Day 1\nClinically significant arrhythmia \u2264 6 months prior to Day 1\nCongestive heart failure \u2265 Grade 3 by New York Heart Association (NYHA) \u2264 6 months prior to Day 1\nCerebral vascular accident (CVA) \u2264 6 months prior to Day 1\nAre pregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge\u2265 18 years\n\nCohort A: Patients undergoing intensive induction chemotherapy for acute myeloid leukemia (AML; newly diagnosed or relapsed/refractory).\n\n* Any intensive regimen with planned ~4 weeks of inpatient stay\n\nCohort B: Allo-HCT patients\n\n* Any allogeneic transplant regimen with planned GVHD prophylaxis containing generic IV Mycophenolate Mofetil (MMF) and tacrolimus (Tac)\n\nSexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least six months post-FMT/placebo\nVoluntary written consent signed before performance of any study-related procedure not part of normal medical care\n\nExclusion Criteria:\n\nPlanned continuation of antibacterial antibiotics after the first neutrophil recovery (ANC > 1,000)\nPatients who are currently receiving or recently received (within 28 days) other investigational agents.\nPregnant or breast feeding. The FDA has not classified this agent into a specified pregnancy category. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy"
            },
            {
                  "document": "Age, Unit Cell Dose and HLA Match Criteria\n\nSubjects must be \u226455 years of age\nSubjects must weigh >11 kg\nSubjects must have a partially HLA matched UCB unit with a pre-cryopreserved TNC dose >1.0 x 107 per kilogram recipient weight. HLA matching is initially based on a minimum of 5 of 8 HLA alleles at high resolution A, B, C, DRB1 typing; searches will be performed according to the current Magenta Cord Blood Search Algorithm.\n\nEligible Diseases:\n\nAcute myelogenous leukemia (AML) in morphological complete remission with:\n\nMinimal residual disease (MRD) by flow cytometry, or\n\nIntermediate to high risk leukemia in first (CR1) based on institutional criteria, eg. not favorable risk AML which is defined as having one of the following:\n\nt(8,21) without cKIT mutation\ninv(16) or t(16;16) without cKIT mutation\nNormal karyotype with mutated NPM1 but FLT3-ITD wild type\nNormal karyotype with double mutated CEBPA\nAcute promyelocytic leukemia (APL) in first molecular remission at the end of consolidation\nAny second or subsequent CR, or\n\nSecondary AML with prior malignancy that has been in remission for at least 12 months.\n\nAcute lymphocytic leukemia (ALL) at the following stages:\n\nHigh risk first morphological, cytogenetic and molecular CR with:\n\nMRD by flow cytometry, or\nDiagnosis of Philadelphia chromosome (Ph)+ ALL, or\nMLL rearrangement at diagnosis with slow early response at Day 14, or\nHypodiploidy (< 44 chromosomes or DNA index < 0.81) at diagnosis, or\nEnd of induction M3 bone marrow, or\nEnd of induction M2 with M2-3 at Day 42.\nHigh risk second CR based on institutional criteria (eg, for children, bone marrow relapse <36 months from induction or T-lineage bone marrow relapse or very early isolated central nervous system (CNS) relapse <6 months from diagnosis, or slow re-induction (stage M2-3 at day 28 after induction) regardless of length remission. All patients with MRD by flow cytometry.\nAny third or subsequent CR.\nSecondary ALL\nBiphenotypic/undifferentiated leukemia in morphological, cytogenetic and molecular CR .\nChronic Myelogenous Leukemia (CML) in high risk first chronic phase (failure of two tyrosine kinase inhibitors (TKI) or TKI intolerance), accelerated phase or second chronic phase.\nMyelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt <5% blasts) or other high risk features, including multiple cytopenias, high risk cytogenetics or lack of response to standard therapy..\nRelapsed large-cell lymphoma, mantle-cell lymphoma and Hodgkin lymphoma that is chemotherapy sensitive and ineligible for an autologous transplant.\nBurkitt's lymphoma in CR2 or subsequent CR.\nRelapsed T-cell lymphoma that is chemotherapy sensitive in CR/PR that is ineligible for an autologous transplant.\n\nOrgan Specific Inclusion Criteria\n\nKarnofsky score \u226570 (16 years and older), Lansky play score >50 (children 2-16 years, or 'adequate' score for children <2 years, as detailed in Appendix II.\n\nAdequate organ function defined as:\n\nRenal: Serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then creatinine clearance >40 ml/min or GFR \u226570 mL/min/1.73 m2.normal for age\nHepatic: Bilirubin <3x upper limit of normal (ULN) and AST, ALT and alkaline phosphatase <5x ULN.\nPulmonary function: DLCO, FEV1, FEC (diffusion capacity) >5030% of predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then O2 saturation >95% on room air.\nCardiac: No uncontrolled arrhythmia and left ventricular ejection fraction at rest must be >3545%.\nAvailable 'back-up' HSPC graft (e.g, second UCB unit, haploidentical related donor).\nFemales of child bearing potential and sexually active males must agree to use adequate birth control during study treatment.\nVoluntary written consent signed (adult or parental) before performance of any study-related procedure not part of normal medical care.\n\nExclusion Criteria\n\nPatients with a HLA matched sibling donor or a HLA matched unrelated donor who is available for marrow or peripheral blood stem cell collection at the desired time of transplant.\nPregnant or breast feeding. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Females of childbearing potential must have a blood test or urine study within 14 days prior to study enrollment to rule out pregnancy.\nEvidence of human immunodeficiency virus (HIV) infection or known HIV positive serology.\nActive bacterial, viral or fungal infection (currently taking medication and persistence of clinical signs and symptoms) with a minimum of 4 weeks of anti-fungal treatment\nPrior autologous or allogeneic transplant.\nOther active malignancy.\nSubjects >2 3 years of age unable to receive TBI 1320 cGy due to extensive prior therapy including >12 months alkylator therapy or >6 months alkylator therapy with extensive radiation, or prior Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar), as part of their salvage therapy."
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of CD33 positive (>= 3%), relapsed refractory acute myeloid leukemia by World Health Organization (WHO) criteria. Patients with post-hypomethylating agent (post-HMA) failure high-risk myelodysplastic syndrome (MDS), as defined by the presence of > 10% blasts, are also eligible.\nPatients with MDS or chronic myelomonocytic leukemia (CMML) who received hypomethylating agent based-therapy for the MDS or CMML and progress to AML are eligible at the time of diagnosis of AML regardless of any prior therapy for MDS or CMML. The WHO classification will be used for AML.\nEastern Cooperative Oncology Group (ECOG) performance status score of =< 2.\nTotal serum bilirubin =< 2 x upper limit of normal (ULN). Patients with known Gilbert's syndrome may have a total bilirubin up to =< 3 x ULN.\nSerum creatinine =< 2.0 mg/dl.\nAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN; =< 5 x ULN in case of suspected leukemic liver involvement.\nFemales of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (b-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and for 30 days following the last dose of study drug. Effective methods of birth control include: Birth control pills, shots, implants (placed under the skin by a health care provider) or patches (placed on the skin); intrauterine devices (IUDs); condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicide; abstinence.\nFemales of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation, oophorectomy, and/or hysterectomy.\nMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug.\nPatients or their legally authorized representative must provide written informed consent.\n\nExclusion Criteria:\n\nHistory of another primary invasive malignancy that has not been definitively treated and in remission. Patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses).\nPresence of clinically significant uncontrolled central nervous system (CNS) pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.\nEvidence of active cerebral/meningeal disease. Patients may have history of CNS leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of consent with at least 2 consecutive spinal fluid negative assessments for residual leukemia and negative imaging (imaging required only if previously showing evidence of CNS leukemia not otherwise documented by spinal fluid assessment).\nPatients with active unstable angina, concomitant clinically significant active arrhythmias, myocardial infarction within 6 months, or congestive heart failure New York Heart Association class III-IV. Patients with a cardiac ejection fraction (as measured by either multigated acquisition scan [MUGA] or echocardiogram) < 50% are excluded.\nPatients with total cumulative doses of non-liposomal daunorubicin, or other anthracycline equivalent, greater than 200 mg/m^2.\nPatients with uncontrolled, active infections (viral, bacterial, or fungal).\nKnown active hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV).\nPatients with liver cirrhosis or other serious active liver disease or with suspected active alcohol abuse.\nAllogeneic hematopoietic stem cell transplantation (HSCT) within 6 months before the start of protocol-specified therapy, or with active acute/chronic graft-versus-host disease (GvHD) requiring systemic treatment; or receiving immunosuppression for GvHD prophylaxis within 2 weeks from the start of study therapy.\nPrior chemotherapy/radiotherapy/investigational therapy within 2 weeks before the start of study drugs with the following exception: To reduce the circulating blast count or palliation; single dose intravenous cytarabine or hydroxyurea. No washout necessary for these agents.\nPatients must have recovered from acute non hematologic toxicity (to =< grade 1) of all previous therapy prior to enrollment.\nFemales who are pregnant or lactating.\nMale or female subjects of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with institution's standards.\nOther severe, uncontrolled acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study.\nPrior treatment with CPX-351 or gemtuzumab ozogamicin."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have AML, ALL, high-risk MDS, or MPAL (also known as biphenotypic) meeting one of the following descriptions:\n\nAML, ALL, or MPAL in first remission with evidence of measurable residual disease (MRD) by flow cytometry;\nAML, ALL, or MPAL beyond first remission (i.e., having relapsed at least one time after achieving remission in response to a treatment regimen);\nAML, ALL, or MPAL representing primary refractory disease (i.e., having failed to achieve remission at any time following one or more prior treatment regimens);\nAML evolved from myelodysplastic or myeloproliferative syndromes;\nMDS expressed as refractory anemia with excess blasts (RAEB)\nChronic myelomonocytic leukemia (CMML) by French-American-British (FAB) criteria.\nPatients not in remission must have CD45-expressing leukemic blasts. Patients in remission do not require phenotyping and may have leukemia previously documented to be CD45 negative (because in remission patients, virtually all antibody binding is to non-malignant cells which make up >= 95% of nucleated cells in the marrow).\nPatients should have a circulating blast count of less than 10,000/mm^3 (control with hydroxyurea or similar agent is allowed).\nPatients must have an estimated creatinine clearance greater than 50/ml per minute by the following formula (Cockcroft-Gault). Serum creatinine value must be within 28 days prior to registration.\nBilirubin < 2 times the upper limit of normal.\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal.\nEastern Cooperative Oncology Group (ECOG) < 2 or Karnofsky >= 70.\nPatients must be free of uncontrolled infection.\nPatients with prior non-myeloablative or reduced-intensity conditioning allogeneic-HCT must have no evidence of ongoing GVHD and be off all immunosuppression for at least 6 weeks at time of enrollment.\nPatients must not have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA) or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) or bone marrow donation.\nPatients must have a related donor who is identical for one HLA haplotype and mismatched at the HLA-A, -B or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches.\nDONOR: Donors must meet HLA matching criteria as well as standard Seattle Cancer Care Alliance (SCCA) criteria for PBSC or bone marrow donation. Preference should be given to donors who are mismatched at the HLA-A, -B and -DRB1 loci.\n\nExclusion Criteria:\n\nPatients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects.\nLeft ventricular ejection fraction < 45%.\nCorrected diffusion capacity of the lung for carbon monoxide (DLCO) < 35% or receiving supplemental continuous oxygen. When pulmonary function tests (PFTs) cannot be obtained, the 6-minute walk test (6MWT, also known as exercise oximetry) will be used: Any patient with oxygen saturation on room air of < 89% during a 6MWT will be excluded\nLiver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease.\nPatients who are known to be seropositive for human immunodeficiency virus (HIV).\nPerceived inability to tolerate diagnostic or therapeutic procedures.\nActive central nervous system (CNS) leukemia at time of treatment.\nPatients with prior myeloablative allogeneic-HCT.\nWomen of childbearing potential who are pregnant (beta human chorionic gonadotropin [B-HCG]+) or breast feeding.\nFertile men and women unwilling to use contraceptives during and for 12 months post-transplant.\nInability to understand or give an informed consent.\nAllergy to murine-based monoclonal antibodies.\nKnown contraindications to radiotherapy."
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of 1) AML (World Health Organization [WHO] classification definition of >= 20% blasts) excluding acute promyelocytic leukemia (APL) or 2) MDS with > 10% blasts (defined by the International Prognostic Scoring System [IPSS] classification).\nFor frontline Cohort: Patients aged >= 60 years old who are not candidates for intensive induction therapy and agree to receive the proposed combination therapy will be enrolled.\n\nNot considered candidates for intensive remission induction chemotherapy at time of enrollment based on EITHER:\n\n75 years of age OR\n\n< 75 years of age with at least 1 of the following:\n\nPoor performance status (Eastern Cooperative Oncology Group [ECOG]) score of 2-3.\n\nClinically significant heart or lung comorbidities, as reflected by at least 1 of:\n\nLeft ventricular ejection fraction (LVEF) =< 50%.\nLung diffusing capacity for carbon monoxide (DLCO) =< 65% of expected.\nForced expiratory volume in 1 second (FEV1) =< 65% of expected.\nChronic stable angina or congestive heart failure controlled with medication.\nLiver transaminases > 3 x upper limit of normal (ULN).\nOther contraindication(s) to anthracycline therapy (must be documented).\nOther comorbidity the investigator judges incompatible with intensive remission induction chemotherapy, which must be documented and approved by the principal investigator (PI).\nPatients with newly diagnosed AML with poor risk complex karyotype and/or TP53 deletions/mutations equal or younger than 60 year old\nFor relapsed cohort: Patients aged >= 18 years old. (Patients who are candidates for relapse cohort will be enrolled into the study regardless of their fitness for intensive chemotherapy). (a) Patients with relapsed/refractory AML are eligible if they are not eligible for potentially curative therapy such as effective salvage therapy or hematopoietic stem cell transplantation or who refuse these options at the time of enrollment.\nDetection of FLT3-ITD mutation or FLT3-ITD/TKD co-mutations in bone marrow and/or peripheral blood samples within 30 days prior to study enrollment.\nFor frontline cohort: Patients must be chemonaive, i.e. not have received any chemotherapy (except hydrea or 1-2 doses of ara-C for transient control of hyperleukocytosis) for AML or MDS. They may have received transfusions, hematopoietic growth factors or vitamins for an antecedent hematological disorder (AHD) or for AML. Temporary prior measures such as apheresis, all-trans-retinoic acid (ATRA), steroids or hydrea while diagnostic work-up is being performed are allowed and not counted as a prior salvage. Supportive care therapy for MDS (growth factors, transfusions) will not be considered as prior therapy for MDS/AML and these patients will be enrolled to the frontline cohort of the study if they are otherwise eligible.\nFor relapsed cohort: Patients who have received at least one prior therapy for AML or for MDS with > 10% blasts will be eligible. Patients may have received up to 4 prior salvages for AML and/or MDS (defined by the IPSS classification). Prior therapy for AML or MDS will be counted as a prior salvage. Patients who receive MDS directed therapies considered not purely supportive such as HMAs, lenalidomide, investigational therapies, will be enrolled to the salvage cohort if they are otherwise eligible.\nIn the absence of rapidly progressing disease, the interval from prior treatment to time of initiation of protocol therapy will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for cytotoxic/noncytotoxic agents. The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochure's, or drug-administration manuals) and will be documented in the protocol eligibility document\nThe use of chemotherapeutic or anti-leukemic agents is not permitted during the study with the following exceptions: (1) intrathecal (IT) therapy for patients with controlled central nervous system (CNS) leukemia at the discretion of the PI a (2) Use of one dose of cytarabine (up to 2 g/m^2) or hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy. These medications will be recorded in the case-report form.\nEastern Cooperative Oncology Group (ECOG) performance status =< 2.\nSerum biochemical values with the following limits unless considered due to leukemia, hemolysis or congenital disorder (creatinine < 1.8 mg/dl, total bilirubin < 1.8 mg/dL, [serum glutamate pyruvate transaminase (SGPT)] < 2.5 x upper limit of normal).\nWhite blood cell count < 25 x 10^9/L\nPotassium, magnesium, and calcium (normalized for albumin) levels should be within institutional normal limits.\nAbility to take oral medication.\nAbility to understand and provide signed informed consent.\nBaseline left ventricular ejection fraction by echocardiogram (ECHO) or multigated acquisition (MUGA) >= 50%.\nWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 7 days. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.\nWOCBP must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy until at least 3 months after the last dose of investigational drug. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as men with azoospermia do not require contraception.\nNegative urine or serum pregnancy test.\nInvestigational agents that are not used for treatment of the leukemia per se (e.g. anti-infective prophylaxis or therapy) will be allowed. Other supportive care studies are allowed, even if under an Investigational New Drug (IND).\n\nExclusion Criteria:\n\nPatients with known allergy or hypersensitivity to quizartinib, mannitol, decitabine or any of their components.\nPrior quizartinib use.\nPatients with known uncontrolled CNS leukemia.\nOnly for frontline cohort: patients who are fit for intensive chemotherapy.\nPatients with electrolyte abnormalities at study entry defined as follows: Serum potassium < 3.5 mEq/L despite supplementation, or > 5.5 mEq/L Serum magnesium above or below the institutional normal limit despite adequate management. Serum calcium (corrected for albumin levels) above or below institutional normal limit despite adequate management.\nPatients with known significant impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of quizartinib.\nPatients with any other known concurrent severe and/or uncontrolled medical condition including but not limited to diabetes, cardiovascular disease including hypertension, renal disease, or active uncontrolled infection, which could compromise participation in the study. Patients on active antineoplastic or radiation therapy for a concurrent malignancy at the time of screening. Maintenance therapy, hormonal therapy, or steroid therapy for well-controlled malignancy is allowed.\nPatients with a known human immunodeficiency virus (HIV) infection.\nPatients with known positive hepatitis B or C infection by serology, with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required prior to study entry). Subjects with serologic evidence of prior vaccination to HBV [i.e., hepatitis B surface antigen [HBs Ag]-, and anti-HBs+] may participate.\nPatients who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.\nPatients who have had any major surgical procedure within 14 days of day 1.\nImpaired cardiac function including any of the following: Screening ECG with a Fridericia's correction formula (QTcF) > 450 msec. The QTcF interval will be calculated by Fridericia's correction factor (QTcF). The QTcF will be derived from the average QTcF in triplicate. Patients are excluded if they have QTcF >= 450. Subjects with prolonged QTcF interval in the setting of RBBB (right bundle branch block) may participate upon review and approval by the medical monitor. RBBB for patients' triplicate EKGs can show false corrected QT (QTc) prolongation; therefore, the Cardiology collaborator for this study will manually review to provide an accurate reading of the QTc. Patients with congenital long QT syndrome. History or presence of sustained ventricular tachycardia requiring medical intervention. Any history of clinically significant ventricular fibrillation or torsades de pointes. Known history of second or third degree heart block (may be eligible if the patient currently has a pacemaker). Sustained heart rate of < 50/minute on pre-entry ECG. Right bundle branch block + left anterior hemiblock (bifascicular block). Complete left bundle branch block. Patients with myocardial infarction or unstable angina within 6 months prior to starting study drug. Congestive heart failure (CHF) New York (NY) Heart Association class III or IV. Atrial fibrillation documented within 2 weeks prior to first dose of study drug. Patients who are actively taking a strong CYP3A4 inducing medication.\nPatients who require treatment with concomitant drugs that prolong QT/QTc interval or strong CYP3A4 inhibitors with the exception of antibiotics, antifungals, and antivirals that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject or if the Investigator believes that beginning therapy with a potentially QTc-prolonging medication (such as anti-emetic except for prochlorperazine) is vital to an individual subject's care while on study.\nKnown family history of congenital long QT syndrome.\nPatients who are on strong CYP3A4 inhibitor will be excluded."
            },
            {
                  "document": "Inclusion Criteria for Part 1: Dose Escalation Phase:\n\nAll patients must meet the following criteria prior to the first dose of study drug:\n\nSigned informed consent. Consent must be obtained prior to any study-related procedure.\nAge \u2265 18 years\n\nHistologically confirmed AML or MDS:\n\nAML - relapsed or refractory AML and refuses or is not a candidate for intensive chemotherapy (due to prior failure or not eligible due to expected intolerance) or allogeneic transplant\nMDS - relapsed or refractory MDS with > 5% blasts in the marrow or any blasts in the peripheral blood. Patients must have failed prior treatment with an HMA (azacitidine, decitabine, or other HMA agent); failure is defined as intolerance to HMA, lack of response (no CR by at least 6 cycles), or have IWG-defined progressive disease during or after treatment with an HMA.\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\nLife expectancy of > 2 months in the Investigator's opinion\nWhite blood cells (WBC) \u2264 25,000 cells/mm3 (may receive hydroxyurea to bring WBC count down prior to and during the first cycle of treatment with study drug if necessary)\nCreatinine \u2264 2 \u00d7 upper limit of normal (ULN)\nAdequate liver test parameters: total bilirubin < 2.5 \u00d7 ULN (if disease related or secondary to Gilbert's disease, then total bilirubin < 3.5 mg/dL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) < 3 \u00d7 ULN\nProthrombin time (PT) / international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 \u00d7 ULN\nPatients and partners of childbearing potential must be willing to use adequate contraception during the study and for 2 months after last study drug administration. Adequate contraception means less than 1% chance of pregnancy may occur with proper use of the method(s).\n\nExclusion Criteria for Part 1: Dose Escalation Phase:\n\nA patient is not eligible to enroll into the study if they have any of the following:\n\nAny CNS (cerebral/meningeal) disease related to underlying malignancy\nHistory of seizures\nAcute promyelocytic leukemia\nPrior anti-CD123 therapy outside of this study\nAny clinically significant graft-versus-host disease (GVHD) secondary to prior allogenic transplant. Patients must be > 90 days from transplant and have been on no immunosuppressive therapy for > 30 days. Topical corticosteroids for minor skin rash (<5% body surface area) is acceptable. Prior solid organ transplant is acceptable provided the patient is on no immunosuppressive therapy.\nAny therapy or experimental treatment for MDS or AML within 7 days of the first dose of study drug. Must have recovered to Grade \u2264 1 from any Grade 2 to 4 toxicity from previous treatment. The use of hydroxyurea is acceptable and does not exclude the patient.\nActive, uncontrolled infection requiring systemic therapy. If the infection is controlled or has resolved, maintenance and/or prophylactic systemic antimicrobials are permitted.\nMajor surgery within 3 weeks prior to first dose of study drug\nKnown to be positive for HIV, hepatitis B virus surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV)\nPregnant or breast feeding\nAny other active systemic malignancies. Exceptions: noninvasive non-melanoma skin cancer, in situ carcinoma, cervical intraepithelial neoplasia, and breast or prostate cancer that is well controlled with anti-hormonal therapy\nAny current autoimmune disorder requiring immunosuppressive therapy\nRequires more than a replacement dose of corticosteroids (i.e., > 10 mg/day of prednisone or equivalent)\n\nAny uncontrolled medical condition, including but not limited to:\n\nSymptomatic congestive heart failure \u2265 Class III (New York Heart Association Functional Classification)\nUncontrolled hypertension\nUnstable angina\nMyocardial infarction within previous 6 months\nClinically significant arrhythmias not controlled by medication\nUncontrolled metabolic disorders such as hypercalcemia\nSubstance use disorder, psychiatric, cognitive, or any other condition that, in the opinion of the Investigator, would pose a risk to the patient's safety, may compromise the patient's ability to understand and comply with the protocol or provide informed consent, or interfere with the study evaluation\nAny difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration, or may cause a safety concern for the patient\n\nInclusion Criteria for Part 2: Dose Expansion Phase\n\nIndividuals eligible to participate in this study must meet all of the following:\n\nAll patients must meet the following criteria prior to the first dose of study drug:\n\nSigned informed consent. Consent must be obtained prior to any study-related procedure.\nAge: >18 years\nHistologically confirmed AML: Subjects must have de novo (primary) AML (any WHO 2016 classification excluding acute promyelocytic leukemia, AML with myelodysplasia-related features, and Therapy-related secondary AML (except in Cohort 1 or Cohort 2)\nCohort 1: Fit primary or secondary AML patients (Age: >18 years) in 1st or 2nd relapse with last CR <1 year or primary refractory disease; Relapsed patients must have relapsed a maximum of two times after standard induction therapy for AML;\nCohort 2: Poor prognostic but fit primary or secondary AML patients who are treatment-na\u00efve or in 1st relapse; patients in relapse must have relapsed only once after induction/consolidation therapy for AML, i.e., they must be in 1st relapse\nCohort 3: Fit primary AML patients with FLT3-negative intermediate or adverse risk AML (including but not limited to: TP53, RUNX1 and ASXL1 mutations and/or complex cytogenetics) who are treatment-na\u00efve or in 1st relapse with a duration of CR1<1 year\nCohort 3: Patients are required to be either not in CR or be in CR is MRD positive (\u226501% level) by MFC (Central Laboratory) post induction/consolidation to be eligible for APVO436 treatments.\nCohort 4: MRD+ (at \u22650.1% level by multicolor-multiparameter flow cytometry [MFC] in Central Lab) high-risk 1st remission AML patients\nCohort 4: Patients must be newly diagnosed AML patients in 1st remission who achieved their first remission after standard chemotherapy with a standard induction regimen with or without post-induction consolidation.\nCohort 5: Patients must be AML patients who were in 1st relapse and achieved a 2nd remission after standard chemotherapy with a standard induction regimen with or without post-induction consolidation.\nCohorts 1-5: If patient was treated with Cytarabine-containing induction or consolidation regimen, a minimum of 21 days must have passed since the last Cytarabine dose to allow for resolution of the side effects\nCohorts 1-3: Patients must have CD123-positive AML as confirmed by flow cytometry in Central Laboratory\nCohorts 4 and 5: Patients archived bone marrow or peripheral blood leukemic blast cells must be CD123-positive - local laboratory results are acceptable. If cells are available, the positivity should be confirmed by Central Laboratory.\nPatients with precedent MDS are not eligible\nMRD+ AML patients in Cohort 4 or Cohort 5 must be in CR (CR/CRi) for no more than 6 months and be MRD+, as determined by central hematopathology laboratory\nMRD+ AML patients in Cohort 4 or Cohort 5 must first have an evaluable screening bone marrow sample confirmed as MRD+ by central hematopathology laboratory\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\nLife expectancy of > 2 months in the Investigator's opinion\nCreatinine \u2264 2 \u00d7 upper limit of normal (ULN)\nAdequate liver test parameters: total bilirubin < 2.5 \u00d7 ULN (if disease related or secondary to Gilbert's disease, then total bilirubin < 3.5 mg/dL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) < 3 \u00d7 ULN\nProthrombin time (PT) / international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 \u00d7 ULN\n\nWomen of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) may participate, provided they meet the following conditions:\n\nMust agree to use physician-approved contraceptive methods (e.g., abstinence, intrauterine device, oral contraceptive, double barrier device) throughout the study and for 3 months following the last dose of APVO436; and\nMust have a negative serum or urine pregnancy test within 7 days prior to beginning treatment on this study.\nMales with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 3 months following the last dose of APVO436\n\nExclusion Criteria for Part 2: Dose Expansion Phase\n\nSubjects with any of the following will not be eligible for study participation:\n\nAcute promyelocytic leukemia (APL) with t(15;17) translocation\nAbsolute peripheral blood myeloblast count greater than 20,000/mm3 - may receive hydroxyurea to reduce and control the myeloblast count down prior to and during the first week of the first cycle of treatment with study drug if necessary if deemed medically necessary and appropriate by the treating physician\nPatients with active central nervous system (CNS) involvement by AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgement. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor.\nHistory of seizures\nPrior anti-CD123 therapy with APVO436; prior anti-CD123 therapy with bispecific antibodies, recombinant fusion proteins or antibody-drug conjugates is allowed.\nPrior allogeneic, unrelated or autologous hematopoietic stem cell transplantation is allowed only in Cohort 5. The transplant must have been performed more than 100 days before the date of dosing on this study without any Grade \u22652 graft-versus-host disease (GVHD) secondary to prior allogenic transplant. Patients must be > 100 days from transplant and have been on no immunosuppressive therapy for > 30 days. Topical corticosteroids for minor skin rash (<5% body surface area) is acceptable.\nPrior allogeneic, unrelated or autologous hematopoietic stem cell transplantation is not allowed for Cohorts 1 to 4\nPrior solid organ transplant is acceptable provided the patient is on no immunosuppressive therapy.\nAny therapy or experimental treatment for AML within 7 days of the first dose of study drug. Must have recovered to Grade \u2264 1 from any Grade 2 to 4 toxicity from previous treatment. The use of hydroxyurea is acceptable and does not exclude the patient.\nActive, uncontrolled infection requiring systemic therapy. If the infection is controlled or has resolved, maintenance and/or prophylactic systemic antimicrobials are permitted.\nMajor surgery within 3 weeks prior to first dose of study drug\nKnown to be positive for HIV, hepatitis B virus surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV)\nUncontrolled hypertension, defined as blood pressure \u2265 140/90 mm Hg despite maximum medical intervention\nHistory of congenital long QT syndrome or torsades de pointes\nPathologic bradycardia or heart block (excluding first degree heart block)\nProlonged baseline QTc, defined as QTcF (Fredericia correction) interval >480 msec (including subjects with a bundle branch block)\nHistory of ventricular arrhythmia (excluding PVCs)\nMajor surgery within 28 days prior to informed consent\nUnstable angina pectoris within 28 days\nMyocardial infarction and/or new ST elevation or depression or new Q wave on ECG within 6 months\nAny history of stroke\nSymptomatic congestive heart failure Class III or greater (New York Heart Association Functional Classification)\nOn full dose anti-coagulation defined as warfarin intended to raise the INR to 2-3\nMajor hemorrhagic event within 28 days requiring transfusion of packed red blood cells\nPrior history of hypertensive crisis or hypertensive encephalopathy\nClinical evidence suggestive of central nervous system (CNS) involvement with leukemia unless a lumbar puncture was performed to confirm the absence of leukemic blasts in the cerebrospinal fluid (CSF)\nSystemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)\nAny open wound\nPregnant and nursing subjects are excluded because the effects of APVO436 on a fetus or nursing child are unknown\nTreatment with any anticancer therapy (standard or investigational) within the previous 14 days prior to the first dose of study drug. In addition, subjects must have fully recovered (NCI CTCAE Grade 1) from the clinically significant toxic effects of that treatment. The use of hydroxyurea in subjects with rapidly proliferating disease is allowed only during Cycle 1. Hydroxyurea is allowed prior to starting the study, and may be used for two weeks after dosing in Cycle 1 (e.g., Days 1-14 dosed with hydroxyurea)\nSubstance use disorder, psychiatric, cognitive, or any other condition that, in the opinion of the Investigator, would pose a risk to the patient's safety, may compromise the patient's ability to understand and comply with the protocol or provide informed consent, or interfere with the study evaluation, study participation, or follow-up\nAny difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration, or may cause a safety concern for the patient\n\nAny uncontrolled medical condition, including but not limited to:\n\nUncontrolled hypertension\nUnstable angina\nClinically significant arrhythmias not controlled by medication\nUncontrolled metabolic disorders such as hypercalcemia\nAny other active systemic malignancies. Exceptions: noninvasive non-melanoma skin cancer, in situ carcinoma, cervical intraepithelial neoplasia, and breast or prostate cancer that is well controlled with anti-hormonal therapy\nAny current autoimmune disorder requiring immunosuppressive therapy with more than a replacement dose of corticosteroids (i.e., > 10 mg/day of prednisone or equivalent)"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of acute myeloid leukemia (AML) by World Health Organization (WHO) 2016 criteria. Patients will be divided into 2 arms during the phase 2 portion:\n\nArm A: Subjects must have newly diagnosed AML\nArm B: Subjects must have refractory or relapsed AML\nTP53 wild-type status on molecular testing performed within the last 3 months\nEastern Cooperative Oncology Group (ECOG) performance status =< 3\nCreatinine clearance >= 60 mL/min, as calculated using the modified Cockcroft-Gault equation OR creatinine =< 1.5 x upper limit of normal (ULN)\nAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN\nBilirubin =< 1.5 x ULN, unless resulting from hemolysis, Gilbert's disease or considered to be due to leukemic involvement\nNo gastrointestinal issues to interfere with oral medication absorption\nNo active uncontrolled infection or comorbidity that would interfere with therapy or place patient at increased risk\nSubject (male and female) of childbearing/reproductive potential must agree to use double-barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug\nSubject must sign and date an Institutional Review Board-approved informed consent form (including Health Insurance Portability and Accountability Act authorization, if applicable) before performance of any study-specific procedures or tests\nAble and willing to provide bone marrow biopsies/aspirates as requested by the protocol\nWilling to undergo malignancy genotyping for TP53 mutation, insertion, or deletion at screening\nUse of hydroxyurea is allowed prior to and during the first cycle of study treatment. 1-2 doses of cytarabine are also permitted if needed for cytoreduction prior to initiating study treatment\n\nExclusion Criteria:\n\nPatient with t(15;17) karyotypic abnormality or a diagnosis of acute promyelocytic leukemia\nPatient with other malignancy that contains a non-synonymous mutation, insertion, or deletion in the TP53 gene determined previously or at screening\nPrior treatment with an MDM2 inhibitor\nPresence of central nervous system involvement of leukemia. History of prior leptomeningeal leukemia/disease that has fully resolved is eligible\nA second concurrent primary malignancy that has required systemic anti-neoplastic treatment within the previous 6 months, except for localized cancers that have apparently been cured, for example non-melanoma skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast\nAny condition that would preclude adequate absorption of DS-3032b, including refractory vomiting, malabsorption, biliary shunt, significant bowel resection, and/or graft-versus-host disease (GVHD) affecting the gut\nAny active uncontrolled infection, known human immunodeficiency virus infection, or active hepatitis B or C infection\nAny concomitant medical condition that would in the opinion of the investigator increase the risk of toxicity\nUnresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5, grade =< 1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per discretion of the investigator and sponsor (e.g., grade 2 chemotherapy-induced neuropathy)\nPatient having received hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of DS-3032b, is on immuno-suppressive therapy post-HSCT at the time of screening, or has clinically significant GVHD (use of topical steroids for ongoing skin GVHD will be permitted)\nProlongation of corrected QT interval using Fridericia's method (QTcF) at rest, where the mean QTcF interval is >= 450 ms for males or >= 470 ms for females based on electrocardiograms (ECGs). Patients with right bundle branch block (RBBB) will be eligible after discussion with principal investigator (PI)\nPregnant or breastfeeding\nSubstance abuse or medical, psychological, or social conditions that, in the opinion of the investigator, may interfere with the subject's participation in the clinical study or evaluation of the clinical study results"
            },
            {
                  "document": "Inclusion Criteria:\n\nUnderstand and voluntarily sign an informed consent form\n\nDiagnosis of any of the following:\n\nNewly diagnosed (or untreated) AML with poor-risk cytogenetics, poor-risk molecular, or secondary AML (i.e. therapy-related or evolved from antecedent hematologic malignancy\nNewly diagnosed (or untreated) myeloid blast phase of myeloproliferative neoplasm (MPN) (including myeloid blast phase of chronic myeloid leukemia [CML])\nNewly diagnosed (or untreated) high-risk, very-high risk or secondary MDS\nNewly diagnosed (or untreated) MDS/MPN (regardless of cytogenetic/molecular status)\nRelapsed and/or refractory AML, MDS, MDS/MPN, myeloid blast phase of MPN (including myeloid blast phase of CML) who are either salvage 1 or salvage 2\nPatients on non-investigational regimens or on investigational new drug (IND)-exempt MD Anderson studies (for hematologic malignancies) of approved drugs are also eligible\nPatients on IND studies (for hematologic malignancies) utilizing Food and Drug Administration (FDA) approved commercially available drugs are eligible\nInvestigational agents that are not used for treatment of the leukemia per se (e.g. anti-infective prophylaxis or therapy) will be allowed. Other supportive care studies are allowed, even if under an IND\nNewly diagnosed MDS or AML, as well as MDS/MPN, myeloid blast phase of MPN (including myeloid blast phase of CML), patients can enroll on this study after start of non-investigational induction therapy, but must be within first 3 cycles of therapy and benefiting from their front-line therapy. Patients with relapsed and/or refractory AML, MDS, MDS/MPN, myeloid blast phase of MPN (including myeloid blast phase of CML) who are either salvage 1 or salvage 2 are eligible for these salvage cohorts if they are within the first 3 cycles of salvage 1 or salvage 2 therapy\nTransformed and untreated AML transformed from previously treated MDS, myeloproliferative neoplasm (MPN) or other types of secondary AML are allowed. Myeloid blast phase of MPN and chronic myeloid leukemia (CML) are allowed\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2 at study entry\nSerum creatinine =< 1.5 mg/dL (unless due to leukemia or other hematologic malignancy)\nTotal bilirubin =< 2.0 x upper limit of normal (ULN), unless the patient has Gilbert's (unless due to leukemia or other hematologic malignancy)\nAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and/or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.0 x ULN (unless due to leukemia or other hematologic malignancy)\nWomen of childbearing potential (WCBP) must have a negative urine pregnancy test within 7 days and must either commit to continued abstinence from heterosexual intercourse or adopting at least one highly effective method of contraception. These methods include intra-uterine device, tubal ligation, partner's vasectomy, and hormonal birth control pills. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential\nExtramedullary disease is allowed as long as it can be measured and followed for response\n\nExclusion Criteria:\n\nNursing and pregnant females. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\nUncontrolled inter-current illness including, but not limited to, uncontrolled active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or which judged by the investigator, places the patient at unacceptable risk\nAcute Promyelocytic leukemia (APL)"
            },
            {
                  "document": "Inclusion Criteria:\n\nFor the lead in phase: Patients >= 18 years of age with a diagnosis of relapsed and/or refractory AML will be eligible. Patients who have had prior treatment with venetoclax will be allowed to participate in the lead in phase and cohort A\nFor the dose expansion cohort A (relapsed/refractory [R/R] AML): Patients >= 18 years of age with a diagnosis of relapsed and/or refractory AML will be eligible\nFor the dose expansion cohort B (de novo AML): Patients >= 18 years to 69 years of age; patients in this cohort must have received no prior therapy for AML\nPrior therapy with hydroxyurea, hematopoietic growth factors, or tretinoin (ATRA) (for emergency use for stabilization) is allowed with no washout. A cumulative dose of ara-C of up to 3 g for emergency stabilization in patients with rapidly proliferating disease is also allowed provided it was administered > 48 hrs prior to enrollment\nBilirubin =< 2 mg/dL\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or < 5 x ULN if related to leukemic involvement\nCreatinine =< 1.5 x ULN\nKnown cardiac ejection fraction of > or = 45% within the past 3 months\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2\nA negative urine or serum pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial. A woman of childbearing potential is defined as a woman who has not been naturally postmenopausal for at least 12 consecutive months, or who had no previous surgical sterilization\nPatient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol\n\nExclusion Criteria:\n\nPregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided\nUncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPatient with documented hypersensitivity to any of the components of the chemotherapy program\nPatients with acute promyelocytic leukemia (M3) or core-binding factor AML\nPatients with active central nervous system (CNS) leukemia are excluded since the antileukemia activity of the treatment components against CNS leukemia are not known\nMen and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation\nPrior treatment with CPX-351 or venetoclax. Patients with prior treatment with venetoclax will be allowed in patients with relapsed/refractory (R/R) disease including those in the lead-in phase as well as those in cohort A"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge 12-75 years. The first 3 subjects will be 18 years of age to gain experience and observe safety. After 3 adult subjects have successfully engrafted and if the safety profile is tolerable, adolescents age 12 may be enrolled on to the trial\nPatients with a diagnosis either follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), chronic myeloid leukemia (CML), myelodysplastic syndrome, myeloproliferative syndromes (MPD), acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL).\n\nPatients with aplastic anemia and severe immune deficiency or nonmalignant bone marrow failure states. Patients with severe thalassemia requiring regular blood transfusions or sickle cell disease with severe clinical features (these include any clinically significant sickle genotype, for example, hemoglobin SS (Hb SS), hemoglobin SC (Hb SC), hemoglobin S beta thalassemia (Hb Sbeta), or Hemoglobin S-OArab genotype] with at least one of the following manifestations:\n\nClinically significant neurologic event (stroke) or neurological deficit lasting > 24 hours;\nHistory of two or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment or referral despite adequate supportive care measures (i.e. asthma therapy);\nAn average of three or more pain crises per year in the 2-year period preceding enrollment or referral (required intravenous pain management in the outpatient or inpatient hospital setting);\nAdministration of regular red blood cell (RBC) transfusion therapy, defined as 8 or more transfusion events per year (in the 12 months before enrollment) to prevent vaso-occlusive clinical complications (i.e. pain, stroke, or acute chest syndrome);\nAn echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity >= 2.7 m/sec.\nOngoing high impact1 chronic pain on a majority of days per month for >= 6 months as defined as ONE or more of the following: Chronic pain without contributory sickle cell disease (SCD) complications2, OR mixed pain type in which chronic pain is occurring at site(s) (arms, back, chest, or abdominal pain) unrelated to any sites associated with contributory SCD complications2 (e.g. leg ulcers and/or avascular necrosis)\nPatients with hematological malignancies must have had persistent or progressive disease despite initial chemotherapy and must have achieved stable disease or a partial or complete response to their most recent chemotherapy. Patients with low bulk or indolent relapse are eligible without additional treatment. Patients with high risk acute myeloid leukemia by European LeukemiaNet (ELN) criteria in first remission are eligible.\nAvailability of a haploidentical related donor.\nKarnofsky performance status >= 70%.\nLeft ventricular ejection fraction of at least 40%.\nPulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least 50% predicted value for hemoglobin concentration.\nSerum creatinine =< 1.5 mg/dl.\nSerum glutamic-pyruvic transaminase (SGPT) =< 200 IU/ml.\nBilirubin < 1.5 mg/dl (unless Gilbert's syndrome).\nNegative pregnancy test in a woman with child bearing potential.\n\nExclusion Criteria:\n\nHuman immune deficiency virus (HIV) seropositive.\nUncontrolled infection or serious medical or psychiatric condition that would limit tolerance to the protocol treatment.\nActive central nervous system (CNS) malignancy.\nAvailability of medically eligible, human leukocyte antigen (HLA)-matched related stem cell donor."
            },
            {
                  "document": "Inclusion Criteria:\n\n\u226518 years and \u226475 years in age\nPatients with relapsed or refractory AML\nNo more than one prior stem cell transplant\nHas not received the chemotherapy regimen to be used for induction on this trial\nIs considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial\n\nExclusion Criteria:\n\nPatients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.\nActive signs or symptoms of CNS involvement by malignancy.\nStem cell transplantation \u22644 months prior to dosing.\nAny immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.\nPrior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.\nInadequate organ function.\nAbnormal liver function.\nKnown active infection with hepatitis A, B, or C, or human immunodeficiency virus.\nModerate kidney dysfunction (glomerular filtration rate <45 mL/min).\nUncontrolled acute life-threatening bacterial, viral, or fungal infection.\nClinically significant cardiovascular disease.\nMajor surgery within 4 weeks of dosing."
            },
            {
                  "document": "Subject Inclusion Criteria:\n\nPatients with any of the following hematologic malignancies who are considered to be eligible for allogeneic transplantation:\n\nAcute lymphoid leukemia (ALL) in first complete remission (CR1) with high risk for relapse including:\n\nDetectable minimal residual disease by either multicolor flow cytometry or by genomic assay after initial induction therapy\nt(9;22) or detected BCR-ABL1 translocation by genomic methodologies\nBCR-ABL1-Like B-ALL [23] including mutations of IKZF1 or CRLF2\nTranslocations or mutations involving 11q23 (MLL) gene.\nHypodiploid karyotype\nDeletion of 9p\nLoss of 17p or TP53 mutation\nT-lymphocyte lineage antigen expression (T-ALL)\nPrior CNS or other extramedullary involvement\nWBC count \u2265 100,000 cells/\u03bcL at diagnosis\nAcute biphenotypic or bilineal leukemia in CR1\n\nAcute myeloid leukemia (AML) in CR1 with\n\nDetectable minimal residual disease (MRD) by either multicolor flow cytometry or by genomic assay after initial induction therapy\nIn the absence of MRD any intermediate or high risk features according to the European LeukemiaNet 2017 guidelines indlucing:\nMutated FL T3-ITD or FL T3-TKD\nCytogenetic abnormalities not classified as favorable\nCytogenetic abnormalities associated with myelodysplastic syndrome including abnormalities of chromosome 5, 7, or 17p\nComplex karyotype or monosomal karyotype\nt(9;11)(p21.1;q23.3); MLL-KMT2A or other rearrangements of KMT2A\nt(9;11); BCR-ABL1\nInversions or translocations of chromosome 3\nT(6;9)(p23;q34.1); DEK-NUP214\n\nSomatic mutation of RUNX1, ASX1 or TP53\n\nExtramedullary involvement\n\nWBC count \u2265100,000 cells/\u03bcL at diagnosis\n\nRelapsed acute leukemia with \u2264 5% blasts in the bone marrow prior to transplantation (i.e. CR2 or greater).\nMyelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome with \u2264 10% blasts and at least one of the following:\nRevised International Prognostic Scoring System risk score of INT, HIGH, or VERY HIGH at the time of transplant evaluation.\nLife-threatening cytopenias\nKaryotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.\n\nTherapy related disease or disease evolving from other malignant processes.\n\nChronic myelomonocytic leukemia (CMML) with \u2264 10% blasts prior to transplantation.\nChronic myeloid leukemia (CML) meeting one of the following criteria:\nFailed or are intolerant to BCR-ABL tyrosine kinase inhibitors.\nCML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g. T351I mutation).\n\nCML with accelerated or blast phase with <10% blasts after therapy.\n\nChronic lymphocytic leukemia (CLL) with high risk disease as defined by the EBMT consensus criteria\nHodgkin lymphoma meeting both of the following criteria:\nResponding to therapy prior to enrollment\n\nRelapse after autologous bone marrow transplant or are ineligible for autologous bone marrow transplant.\n\n\u00b0Non-Hodgkin lymphoma meeting both of the following criteria:\n\nResponding to therapy prior to enrollment.\nRelapse after prior autologous bone marrow transplant or are ineligible for autologous bone marrow transplant.\nPatients aged from birth through 65 years old are eligible.\nPatients must have Karnofsky/Lanksy performance status \u226570%.\nCardiac left ventricular ejection fraction \u226550% at rest.\nSerum bilirubin \u2264 2 mg/dL. Patients with Gilbert's disease or ongoing hemolytic anemia are acceptable if the direct bilirubin is \u2264 2 mg/dL.\nAST and ALT \u2264 2.5 x ULN unless thought to be disease related\nEstimated or measured creatinine clearance > 50 mL/min/1.73 m^2 body surface area.\nAdult patients and pediatric patients capable of performing pulmonary function studies must have hemoglobin adjusted pulmonary DLCO \u226550% of predicted.\n\nSubject Exclusion Criteria:\n\nPersons with a HLA matched sibling donor or a 8/8 allele level HLA-matched unrelated donor.\nFemale patients who are pregnant or breast-feeding.\nPersons with an infection that is not responding to antimicrobial therapy.\nPersons who are seropositive for HIV.\nPersons with active/detectable central nervous system malignancy.\nPersons who do not meet the age and organ function criteria specified above.\nPresence of psychiatric or neurologic disease, or lack of social support that limits the patient's ability to comply with the treatment protocol including supportive care, followup, and research tests.\nPrior allogeneic hematopoietic cell transplantation are ineligible.\nPatients with history of other malignancy within 5 years of study therapy are ineligible with the following exceptions: Low grade prostate cancer (Gleason's \u22646) treated with curative intent, breast ductal carcinoma in situ treated with curative intent, or nonmelanomatous skin carcinomas.\n\nDonor Inclusion and Exclusion Criteria:\n\nPartially HLA-matched unrelated volunteers (allele level matched at 6-7 of 8 HLA loci: -A, -B, -C, and -DRB1) are eligible.\nRelated, haploidentical donors are eligible.\nAble to provide informed consent to the donation process\nMeet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines."
            },
            {
                  "document": "Part 1 Inclusion Criteria:\n\nAge 18 years and older.\n\nPatients must have a prior diagnosis of one of the following:\n\n(Note: Mutational and cytogenetic studies performed at sites other than Dana-Farber Cancer Institute or Brigham and Women's Hospital will require review of the outside cytogenetic and/or molecular pathology reports by the overall PI.)\n\nHigh-risk MDS, which is defined as one of the following subsets:\n\nIPSS Intermediate-2 or higher\nPresence of a mutation in TP53\nPrescence of mutation in the RAS pathway including NRAS, KRAS, PTPN11, CBL, NF1, RIT1, FLT3, and KIT\nTherapy-related MDS\n\nHigh-risk AML, which is defined as one of the following subsets:\n\nAML with adverse risk disease according to ELN guidelines including one of the following features:\n\na history of mutation in TP53, RUNX1, or ASXL1\nt(6;9)(p23;q34.1); DEK-NUP214\nt(v;11q23.3); KMT2A rearranged\nt(9;22)(q34.1;q11.2); BCR-ABL1\ninv(3)(q21.3q26.2) or t(3;3)(q21.3;26.2); GATA2,MECOM(EVI1)\n-5 or del(5q)\n-7\n-17/abn(17p)\nComplex karyotype\nMonosomal karyotype\nWild-type NPM1 and FLT3-ITDhigh\nSecondary AML, which is defined as a history of antecedent hematologic disorder (an MPN or MDS), a diagnosis of therapy-related myeloid neoplasm including t-MDS and t-AML, or AML with myelodysplasia-related changes, OR\n\"Secondary-type\" AML, which is defined by the presence of a mutation in any of the following eight genes with high specificity for the presence of antecedent myelodysplastic syndrome including SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2\nPatients with AML with evidence of measurable residual disease by multiparameter flow cytometry (\u2265 0.1%) despite morphologic remission on the pre-transplant/screening bone marrow biopsy. Review required by overall PI.\nHigh-risk chronic myelomonocytic leukemia (CMML) or MDS/MPN unclassifiable (MDS/MPN-U), which is defined by the presence of trisomy 8, chromosome 7 abnormalities or complex karyotype (3 or more abnormalities); or by the presence of a mutation in ASXL1\nMeasurable disease is not required for eligibility.\nPatient is determined to be a suitable candidate for an allo-HCT using a reduced intensity conditioning (RIC) regimen using peripheral blood stem cell as stem cell source.\nPatient must have a matched related or an 8/8 unrelated donor option for his/her allo-HCT.\nPatient must have an ECOG performance status \u2264 2\nThere are no limitations or minimum on the amount of prior therapy for patient's advanced myeloid malignancy. Prior exposure to venetoclax is allowed.\n\nPatient must have normal organ function as defined below:\n\nTotal bilirubin \u2264 2.0 x institutional upper limit of normal (In patients with Gilbert's Syndrome, Total Bilirubin \u2265 2.0 is permitted.)\nAST(SGOT)/ALT(SGPT) \u2264 3 \u00d7 institutional upper limit of normal\nCreatinine clearance \u2265 30 mL/min using Cockcroft Gault formula\nThe effects of venetoclax on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of venetoclax administration. For women who are of child-bearing potential, they must have a negative serum beta-HCG (human chorionic gonadotropin) test to be eligible.\nAbility to understand and the willingness to sign a written informed consent document\n\nPart 1 Exclusion Criteria:\n\nPatients who have had chemotherapy (with the exception of hydroxyurea and/or dexamethasone) or radiotherapy or investigational therapy within 14 days prior to starting treatment on study. Exceptions: Patients already on venetoclax therapy prior to transplant need a three day wash out prior to first treatment dose on study. Patients on BCR-ABL, IDH and FLT3 small molecule inhibitors can stay on this treatment up until 5 days prior to first treatment dose on study.\nPatients with > 10% morphologic blasts on bone marrow biopsy if they have a diagnosis of MDS or MDS/MPN. Patients > 5% morphologic blasts on bone marrow biopsy if they have a diagnosis of AML.\nPatients recommended to receive a myeloablative conditioning regimen prior to transplantation (since there is a known survival advantage for AML using higher intensity).\nPatients who have a history of prior allogeneic stem cell transplantation.\nSymptomatic or untreated known CNS involvement of disease\nPatients with active heart disease (New York Heart Association class 3-4 as assessed by history and physical exam, or a critical event including unstable angina/stroke/myocardial infarction within the last 6 months prior to first dose on study).\nPatients who have consumed grapefruit, grapefruit products, Seville oranges or starfruit within 3 days prior to study treatment. Patients who a strong or moderate inducer within 7 days prior to the first dose of study drug.\nMalabsorption syndrome or other clinically significant condition that would preclude enteral administration.\nOther severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study.\nPatients with known active hepatitis B virus (HBV) infection should be excluded because of potential effects on immune function and/or drug interactions. However, if a patient has HBV history with an undetectable HBV load by polymerase chain reaction (PCR), no liver-related complications, and is on definitive HBV therapy that is not contraindicated on this study, then he/she would be eligible for study.\nPatients with known active hepatitis C virus (HCV) infection. However, if a patient with a history of HCV infection has received definitive therapy (and is now HCV viral load negative), or if a patient has a reactive HCV antibody test but has an undetectable viral load by PCR, then he/she would be eligible.\nPatients with known active HIV infection out of concern for the drug-drug interaction with venetoclax and HAART therapy.\nPregnant or breastfeeding women or those intending to become pregnant during the study or within 3 months after the final dose of study treatment are excluded from this study. Women of childbearing potential must have a negative serum pregnancy test resulted during screening and repeated within 7 days prior to study drug (local labs are allowed).\nVaccination with live, attenuated vaccines within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study.\nPatients with uncontrolled infection at time of first dose of treatment on study. Patients receiving anti-microbial agents including antibiotics, antiviral and antifungal therapies are allowed if hemodynamically stable.\nPart 2 and Part 3 only: Patients recommended to receive FLT3 inhibitor therapy or any other antileukemic therapy for AML as maintenance post allo-HCT.\n\nPart 2 and Part 3 Eligibility Criteria:\n\nNo DLT event (including delay in neutrophil engraftment) due to the addition of venetoclax to conditioning chemotherapy prior to start of maintenance therapy.\nNo morphologic evidence of relapse (defined as 5% or more morphologic blasts) prior to start of maintenance therapy confirmed by bone marrow biopsy after day +28.\n\nANC \u2265 1.0 K/uL without growth factor support and platelet level \u2265 50 K/uL without platelet transfusion within 7 days of starting maintenance therapy.\n\n--Exception: Patients without morphologic evidence of disease relapse but with evidence of persistent molecular or cytogenetic residual disease at the time of assessment can start maintenance therapy as long as ANC \u2265 0.75 K/uL without growth factor support and platelet level \u2265 25 K/uL.\n\nAbsence of overall grade II-IV acute GVHD per investigator. Upon acute GVHD resolution, patients are eligible. Patients that are on prednisone 0.5 mg/kg daily dose or lower are allowed to initiate maintenance.\nTotal bilirubin less than or equal to 2 x institutional ULN (unless has known Gilbert's disease).\nAST and ALT less than or equal to 3 x ULN.\nCr Cl \u2265 30 mL/min or higher (Cockgroft Gault formula).\nNo concurrent illnesses that would prevent taking oral therapy and interfere with safety assessment."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with evidence of relapsed or refractory AML or MDS following allogeneic stem cell transplantation\nPatients must have received preparative regimens to include either busulfan- or melphalan-based regimens\nPatient must have achieved myeloid engraftment as defined by an absolute neutrophil count >= 500 micro/L on 3 consecutive days\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nTotal bilirubin =< 2 times upper limit of normal (x ULN) (=< 3 x ULN if considered to be due to Gilbert's syndrome)\nAspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN\nSerum creatinine =< 2 x ULN or glomerular filtration rate (GFR) >= 50\nPatients must provide written informed consent\nThe interval from the infusion of stem cells to time of initiation of nivolumab or ipilimumab will be at least 6 weeks (42 days)\nFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment\nWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment\n\nExclusion Criteria:\n\nPatients with known allergy or hypersensitivity to nivolumab or ipilimumab or any of their components\nPatients with acute GVHD > grade 2 at any time during the post-transplant course\nPatients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis that is uncontrolled in the opinion of the treating physician\n\nPatients with a known history of any of the following autoimmune diseases are excluded:\n\nPatients with a history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis)\nPatients with a history of rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's granulomatosis)\nPatients with solid organ allografts (such as renal transplant) are excluded\nOngoing immunosuppressive therapy for the treatment of GVHD. Patients receiving GVHD prophylaxis will be allowed on this study\nPatients with symptomatic central nervous system (CNS) leukemia at the time of evaluation or patients with poorly controlled CNS leukemia\nActive and uncontrolled disease/(active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association [NYHA] class III/IV, clinically significant and uncontrolled arrhythmia) as judged by the treating physician\nPatients with known human immunodeficiency virus seropositivity will be excluded\nKnown to be positive for hepatitis B by surface antigen expression. Known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)\nAny other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\nPatients unwilling or unable to comply with the protocol\nPregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nDocumented Diagnosis of previously untreated de novo AML according to WHO 2016 criteria\nPresence of a FLT3 mutation status with results available prior first dose of Midostaurin\nPatients with Lansky or Karnofsky performance status equal or superior to 60\nPatient with the following laboratory value : AST and ALT \u2264 3times ULN\nSerum Total bilirubin \u2264 1.5times ULN\nEstimated creatinine clearance \u226530ml/min\n\nExclusion Criteria:\n\nAny concurrent malignancy, AML with Philadelphia Chromosome, AML-DS, JMML\nSymptomatic leukemic CNS involvement\nIsolated extramedullary leukemia, secondary AML and MDS\nAcute Promyelocytic Leukemia with the PML RARA rearrangement\nPatient who have received prior treatment with a FLT3 inhibitor.\n\nOther protocol-defined inclusion/exclusion criteria may apply"
            },
            {
                  "document": "Inclusion Criteria:\n\nBaseline left ventricular ejection fraction (LVEF) is greater than or equal to 50% by echocardiography (echo) or multigated acquisition (MUGA) scan.\nPatients of child bearing potential should use contraception.\nPatients with a diagnosis of acute myeloid leukemia (AML), or high risk myelodysplastic syndrome (MDS) (>= 10% blasts or International Prognostic Scoring System [IPSS] >= intermediate-2) or high-risk myeloproliferative neoplasm will be eligible.\nPatients with untreated or previously untreated chronic myeloid leukemia (CML) in myeloid blast phase or (Philadelphia chromosome-positive (Ph+) AML are also eligible.\nPatients with myeloproliferative neoplasms in blast phase will be eligible.\nPatients with isolated extramedullary myeloid neoplasm will be eligible.\nPatients with active CNS (central nervous system) disease are eligible.\nBilirubin < 2mg/dL.\nAST (aspartate aminotransferase) and/or ALT (alanine aminotransferase) < 3 x ULN (upper limit of normal) - or < 5 x ULN if related to leukemic involvement.\nCreatinine < 1.5 x ULN.\nHyperbilirubinemia is allowed if due to Gilbert's hyperbilirubinemia.\nA negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.\nWomen of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.\nPatient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol.\nPrior therapy for any of the cohorts may include with hydroxyurea, rescue doses of cytarabine, various combination-chemotherapy regimens, hematopoietic growth factors, azacytidine, decitabine, ATRA (all-trans retinoic acid).\nCohort 1: Frontline cohort patients are eligible in the frontline cohort if they are untreated or previously treated already in CR if they received 3 or fewer cycles of previous chemotherapy (including either 1 induction and 2 consolidations or 2 inductions and 1 consolidation).\nCohort 2: Salvage cohort in 1st and 2nd salvage patients are eligible in the salvage cohort 2 if they have active disease after first or second relapse or if they are in CR after previously documented first or second relapse as long as they if they have received 3 or fewer cycles of chemotherapy to achieve the most current CR.\nCohort 3: Salvage cohort in 3rd salvage and beyond patients may be eligible in salvage cohort 3 if they have active disease after 3rd or greater relapse or if they are in CR after a previously documented relapse (3rd or greater), but may have only received 3 or fewer cycles of chemotherapy to achieve the most current CR.\nCohort 4: Maintenance cohort: Patients in CR who are considered by treating physician to benefit from maintenance therapy are eligible for maintenance therapy with dexrazoxane combined with idarubicin plus cytarabine.\n\nExclusion Criteria:\n\nAny condition, including the presence of laboratory abnormalities, which judged by the investigator, places the patient at unacceptable risk.\nActive heart disease defined as: Unstable coronary syndromes, unstable or severe angina, recent myocardial infarction (MI) within 6 months.\nDecompensated heart failure (HF).\nClinically significant arrhythmias.\nSevere valvular disease.\nHistory of coronary artery disease (CAD).\nPregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.\nPsychiatric illness/social situations that would limit compliance with study requirements per the judgment of the investigator.\nPatient with documented hypersensitivity to any of the components of the chemotherapy program.\nMen and women of childbearing potential who do not practice contraception."
            },
            {
                  "document": "Inclusion Criteria:\n\nA subject will be eligible for study participation if he/she meets the following criteria within 28 days prior to the first day of therapy (bone marrow biopsy can be performed 28 days prior to the first day of therapy). Historical records are permitted per Investigator discretion.\n\nSubject must have confirmation of non-APL and AML by WHO criteria45\nSubject must have received no prior treatment for AML\nAge \u226518 years, \u226459 years\nWithout clinical signs of active central nervous system disease\nSubject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of \u22642\nSubject must have adequate renal function as demonstrated by a calculated creatinine clearance \u2265 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula\n\nSubject must have adequate liver function as demonstrated by:\n\naspartate aminotransferase (AST) \u2264 3.0 \u00d7 ULN*\nalanine aminotransferase (ALT) \u2264 3.0 \u00d7 ULN*\nbilirubin \u2264 3.0 \u00d7 ULN, unless due to Gilbert's syndrome* * Unless considered due to leukemic organ involvement\nNon-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug.\nFemale subjects who are pre-menopausal and have not had a hysterectomy or oophorectomy must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting therapy; 2) throughout the entire duration of treatment; 3) during dose interruptions; and 4) for at least 90 days after discontinuation of therapy (last dose of study drug).\nSubject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any research directed screening procedures.\nSubject must have adverse risk disease as defined by the European LeukemiaNet46 (Appendix B) 5.3.2 Exclusion Criteria\n\nA subject will not be eligible for study participation if he/she meets any of the following criteria:\n\nSubject has received disease modifying treatment for myelodysplastic syndrome (MDS) or AML. ATRA given for clinical suspicion of APL will not be exclusionary and no washout will be required in this scenario.\nSubject is known to be positive for HIV. HIV testing is not required.\nSubject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag-, anti-HBs+ and anti-HBc-) may participate\nSubject has received within 7 days prior to the first dose of study drug:steroid therapy for anti-neoplastic intent; strong and moderate CYP3A inhibitors; strong and moderate CYP3A inducers.\nSubject is informed that consumption of the following fruits is prohibited 3 days prior to the initiation of study treatment and throughout participation: grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit.\n\nSubject has any history of clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to:\n\nNew York Heart Association heart failure > class 2\nRenal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia\nSubject has a malabsorption syndrome or other condition that precludes enteral route of administration\nSubject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)\n\nSubject has a history of other malignancies prior to study entry, with the exception of:\n\nAdequately treated in situ carcinoma of the breast or cervix uteri\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin\nProstate cancer with no plans for therapy of any kind\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent.\nSubject has a white blood cell count >25 \u00d7 10^9/L or absolute blast count of >50 10^9/L. Hydroxyurea and leukapheresis are permitted, if clinically indicated.\nPatients willing to receive intensive induction chemotherapy\nPregnant and breastfeeding females."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge: Children \u22651 month and children and young adults < 21 years of age\n\nDiagnosis: Patients must be newly diagnosed with acute myelogenous leukemia\n\n2.1 Patients with previously untreated primary AML who meet the customary criteria for AML with \u2265 20% bone marrow blasts as set out in the 2008 World Health Organization (WHO) Myeloid Neoplasm Classification are eligible.\n\nAttempts to obtain bone marrow either by aspirate or biopsy must be made unless clinically prohibitive. In cases where it is clinically prohibitive, peripheral blood with an excess of 20% blasts and in which adequate flow cytometric and cytogenetics/Fluorescent in situ hybridization (FISH) testing is feasible can be substituted for the marrow exam at diagnosis\n\n2.2 Patients with < 20% bone marrow or peripheral blood blasts are eligible if they have:\n\nA karyotypic abnormality characteristic of de novo AML (t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22) or 11q23 abnormalities,\nThe unequivocal presence of megakaryoblasts, or\nBiopsy proven isolated myeloid sarcoma (myeloblastoma; chloroma, including leukemia cutis).\n\nPre-existing myelodysplastic syndrome:\n\nPatients with a history of myelodysplastic syndrome that has progressed to AML which meets the criteria above are eligible.\n\nTherapy-related or secondary AML Patients with AML which is thought to be therapy related but meet the criteria above are eligible.\n\nPrior Therapy:\n\nPrior therapy with hydroxyurea, all-trans retinoic acid (ATRA), corticosteroids (any route), and IT cytarabine given at diagnosis is allowed. Hydroxyurea and ATRA cannot be given concurrently with protocol therapy. There is no specific amount of time mandated between the last dose of hydroxyurea or ATRA and the start of protocol therapy.\n\nWith the exception of infants who had previously received low dose cytarabine to control disease, patients who have previously received any other antileukemic therapy (i.e. chemotherapy or radiation therapy) are not eligible for this protocol.\n\nOrgan Function Requirement:\n\nAdequate Liver Function Defined as:\n\nDirect Bilirubin \u22642x upper limit of normal (ULN) for age and institution (unless related to leukemic involvement), and\nserum glutamate-pyruvate transaminase (SGPT) (ALT) \u22642.5x ULN for age and institution (unless it is related to leukemic involvement)\nAbility to receive enteral medication:\n\nEligible patients should have no contraindication to enteral administration of medication (e.g. oral, Nasogastric (NG), G-tube, etc) as determined by the evaluating physician.\n\nExclusion Criteria:\n\nExcluded Constitutional Conditions\n\nPatients with a history of any of the following constitutional conditions are not eligible:\n\nFanconi anemia\nShwachman syndrome\nAny other known constitutional bone marrow failure syndrome\nPatients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 who are eligible to receive treatment for Down Syndrome (DS) related AML Note: Enrollment and initiation of therapy may occur pending results of clinically indicated studies to exclude these conditions. If a patient is found to have any of these conditions they should be removed from the study once results are received. Patients who are removed due to ineligibility after results are received will be replaced.\n\nOther Excluded Conditions\n\nPatients with any of the following oncologic diagnoses are not eligible:\n\nAny concurrent malignancy\nJuvenile myelomonocytic leukemia (JMML)\nPhiladelphia chromosome positive AML\nBiphenotypic or bilineal acute leukemia\nAcute promyelocytic leukemia Note: Enrollment and initiation of therapy may occur pending results of clinically indicated studies to exclude these conditions. If a patient is found to have any of these conditions they should be removed from the study once results are received. Patients who are removed due to ineligibility after results are received will be replaced.\nPrior receipt of anthracyclines Patients with treatment-related AML who have received more than 250mg/m2 of anthracyclines (in daunorubicin equivalents) are not eligible.\nKnown Allergy or Intolerance to Atovaquone Patients with a known allergy or intolerance to atovaquone are not eligible.\nEnrollment on another ongoing treatment study Patients who are enrolled on a treatment study are not eligible\nPregnancy or Breast-Feeding 6.1 Female patients who are pregnant are ineligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs.\n\n6.2 Lactating females are not eligible unless they have agreed not to breastfeed their infants.\n\n6.3 Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained."
            },
            {
                  "document": "Inclusion Criteria:\n\nAbility of participant to understand this study, and participant to sign a written informed consent. Legally authorized representative is not allowed to sign consent for participant.\nParticipants with tumor protein 53 (TP53) immunohistochemistry (IHC)-positive tumors\nParticipants whose screening IHC shows TP53-IHC-negative including wild type (WT) and null.\nParticipants with histologic or cytologic confirmation of any malignant disease who are planning and eligible to undergo surgical resection. For participants with Solid Tumors Only\nParticipants with previously treated acute myeloid leukemia (AML) are eligible if they relapse and are in between two treatment regimens\nNo concurrent or recent (within 30 days) use of systemic therapy including chemotherapy, immunotherapy, hormonal therapy, cancer vaccine, or local therapy for the cancer.\nFormalin-fixed paraffin-embedded (FFPE) tumor tissue deemed adequate for IHC analysis and next generation sequencing (NGS) are required. Bone marrow aspirate tissue samples from participants with AML are required.\nEastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\nAdequate organ and marrow function\nA negative urine or serum pregnancy test within 7 days before Day 1 dose of study medication, if female participant is of childbearing potential.\nWomen of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception (hormonal AND barrier method of birth control) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nExclusion Criteria:\n\nCurrent or anticipated use of other investigational agents while participating in this study.\nPregnant or breast feeding.\nDiagnosis of squamous cell cancer of the oropharynx\nPrevious malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast), unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period\nPrior use of statins in the past 30 days.\nHistory of rhabdomyolysis\nActive liver disease\nParticipants who currently consume substantial quantities of alcohol (Male, more than 4 drinks a day, Female, more than 2 drinks a day)\nConcurrent use of drugs associated with myopathy\nHypersensitivity to atorvastatin or any component of the formulation\nUntreated hypothyroidism\nInability to comply with study and follow-up procedures as judged by the Investigator"
            },
            {
                  "document": "Inclusion Criteria:\n\nDONOR: Ability to comprehend the investigational nature of the study and provide informed consent\nDONOR: Willing to receive Triplex vaccination, a minimum of 14 days prior to the PBSC collection\nDONOR VACCINATION: Donors are eligible to be vaccinated prior to the determination of their human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human T-cell lymphotropic virus (HTLV) status. The exclusion criteria for transplant is independent of eligibility for vaccination and is determined by the exclusion criteria for transplant from donors\nRECIPIENT: All subjects must have the ability to understand and the willingness to sign a written informed consent\nRECIPIENT: Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT\nRECIPIENT: Age 18 to 75 years\nRECIPIENT: Planned HCT for the treatment of the following hematologic malignancies: lymphoma (Hodgkin and non-Hodgkin), myelodysplastic syndrome, acute lymphoblastic leukemia in first or second remission, acute myeloid leukemia in first or second remission, chronic myelogenous leukemia (in first chronic or accelerated phase, or in second chronic phase), chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis (City of Hope [COH] only). Patients with multiple myeloma are excluded\nRECIPIENT: CMV seropositive\nRECIPIENT: Planned related HCT with 8/8 (A, B, C, DRB1) high resolution HLA donor allele matching\nRECIPIENT: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted\nRECIPIENT: Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration\nRECIPIENT: Seronegative for HIV, HCV and active HBV (surface antigen negative) within 2 months of registration\nRECIPIENT: Agreement by females of childbearing potential and males with partners of childbearing potential to use effective contraception (hormonal or barrier method or abstinence) prior to study entry and for up to 90 days post-HCT. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n\nExclusion Criteria:\n\nTRANSPLANT FROM DONOR: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension\nTRANSPLANT FROM DONOR: Sickling hemoglobinopathy including HbSS, HbAS, HbSC\nTRANSPLANT FROM DONOR: Positive for human immunodeficiency virus (HIV), active hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]) or human T-cell lymphotropic virus (HTLV-I/II). This holds true even if donors have been already vaccinated according to criteria for donor vaccination\nTRANSPLANT FROM DONOR: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus brachycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination\nTRANSPLANT FROM DONOR: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely, and making informed consent impossible\nRECIPIENT: Any prior investigational CMV vaccine\nRECIPIENT: Experimental anti-CMV chemotherapy in the last 6 months\nRECIPIENT: Planned medications from the time of HCT to day 70 post-HCT\nRECIPIENT: Live attenuated vaccines\nRECIPIENT: Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus [HPV]) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections)\nRECIPIENT: Allergy treatment with antigens injections\nRECIPIENT: Alemtuzumab or any equivalent in vivo T-cell depleting agent\nRECIPIENT: Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valganciclovir (VAL), FOS, Cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent Herpes simplex virus (HSV)\nRECIPIENT: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment (Letermovir is permitted). EXCEPT for low risk patients [8/8 high resolution HLA donor allele matching HCT])\nRECIPIENT: Other investigational product - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited\nRECIPIENT: Other medications that might interfere with the evaluation of the investigational product\nRECIPIENT: Diagnosis with autoimmune disease\nRECIPIENT: Pregnant women and women who are lactating. The risks of CMV-MVA-Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this study\nRECIPIENT: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/ psychological issues, etc\nRECIPIENT: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)"
            },
            {
                  "document": "Part-1 Dose Escalation [Key Inclusion]:\n\nHistologically or cytologically confirmed diagnosis of solid tumor malignancy or lymphoma that is not responsive to standard therapies, are unfit for standard chemotherapy or for which there is no approved or curative therapy.\nECOG score of 0 or 1.\nAble to swallow and retain oral medication.\nAdequate organ system function.\n\nParts 2-4 Cohort Expansion Only [Key Inclusion]:\n\nPart 1 inclusion criteria.\n\nSubjects must either have available archival tumor tissue samples, or consent to tumor tissue sampling prior to the first dose, that is sufficient for IHC analysis of TrkA expression, AND have a tumor or tumor type in one of the following categories:\n\n(i). Tumors showing a response or stable disease after at least 2 cycles of VMD-928 during Part 1;\n\n(ii). Tumor types associated with high TrkA protein overexpression, i.e.:\n\nThymic carcinoma and thymoma\nMesothelioma\nHead and neck squamous cell carcinoma (HNSCC)\nOvarian cancer (especially serous)\nHepatocellular carcinoma\nSquamous cell carcinoma of lung (squamous NSCLC)\nEsophageal cancer\nAdenoid cystic carcinoma\nProstate cancer\nCervical cancer\nGastric cancer\nMelanoma\nAcute myeloid leukemia\nPancreatic carcinoma\nNon-Hodgkins' lymphoma\n\n(iii). Tumors with documented NTRK1 gene fusions or amplifications, or TrkA protein overexpression, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor (e.g. larotrectinib or entrectinib)\n\nPart 3 Pharmacodynamic Activity only (Eligible subjects in Part 2 may enroll in Part 3):\n\nPart-2 inclusion criteria.\nTumor with readily accessible lesion that is amenable to biopsy and consent to pre-and post-dose biopsy.\n\nPart 4 Exploratory Comparative PK of Tablet vs. Capsule Formulations only (Eligible subjects in Part 2 or 3 will be encouraged to enroll in Part 4)\n\nKey Exclusion Criteria (Parts 1-4):\n\nReceived chemotherapy having delayed toxicity within the last 21 days (six weeks for prior nitrosourea or mitomycin C).\nReceived anticancer therapy with radiation, immunotherapy, a biologic, surgery and/or tumor embolization within the past 2 weeks.\nReceived an investigational anti-cancer drug within 21 days or 5 half-lives of the investigational agent prior, whichever is longer, to the first dose of VMD-928.\nUnresolved toxicity from previous anti-cancer therapy \u2265 CTCAE Grade 1 (except alopecia or anemia) unless agreed to by both the Investigator and Sponsor.\nNegative result on TrkA-specific or pan-Trk IHC assay (Parts 2-4 only).\nKnown active infections including HIV disease.\nCurrently pregnant, nursing, or planning to become pregnant during the course of the study.\nQTcF interval \u2265 480 msec.\nClass II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.\nAcute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.\nUnstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the patient's safety or interfere with assessment of the drug.\n\nPsychological, familial, sociological, geographical or other concurrent conditions that would interfere with safety evaluation, limit the subject's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Subjects with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded.\n\nKey Exclusion Criteria (For Parts 1 and 4 only):\n\nAny current medical condition that would alter the absorption, distribution, metabolism or excretion of VMD-928 including but not limited to:\n\nSevere uncontrolled nausea or vomiting\nSevere uncontrolled diarrhea\nWith a history of short bowel syndrome\nClinically diagnosed malabsorption secondary to bowel resection"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge \u226518 years\n\nHistologically-confirmed diagnosis of Follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia(CLL), diffuse large B-cell lymphoma (DLBCL), or AML\n\na. Subjects must have disease that has relapsed or is refractory to 2 or more prior regimens and in need of treatment due to progressive disease\n\nPresence of measurable disease defined per the 2008 International workshop on CLL guidelines, or by 2014 Lugano criteria for non-Hodgkin lymphoma (does not apply for AML subjects)\nAdequate hematologic parameters unless clearly due to the disease under study\nAdequate renal and hepatic function, per laboratory reference range at screening\n\nExclusion Criteria:\n\nHistory of pneumonitis of any cause\nFor CLL subjects: only known histological transformation to an aggressive lymphoma\n\nFor AML subjects:\n\nAcute promyelocytic leukemia\nPeripheral blast count > 25 \u00d7 10 9/L\nKnown central nervous system involvement\nSignificant cardiovascular disease\nSignificant screening ECG abnormalities\nSubjects who require warfarin, anti-cancer therapeutics or investigational agents\nEvidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of voruciclib therapy\nPrior solid organ transplantation\nReceipt of an allogeneic transplant within 6 months or an autologous transplant within the preceding 3 months; evidence of ongoing graft-versus-host disease (GVHD)\nPrior therapy with a cyclin-dependent kinase (CDK9) inhibitor\n\nOngoing immunosuppressive treatment at the time of the start of voruciclib therapy, including systemic or enteric corticosteroids except as follows:\n\nPrior to the start of voruciclib therapy, subjects may be using systemic corticosteroids (\u226420 mg/day of prednisone or equivalent), topical, or inhaled corticosteroids\nDuring study therapy, subjects may use systemic, topical, or enteric corticosteroids, if needed"
            },
            {
                  "document": "Inclusion Criteria:\n\nSubject has provided informed consent prior to initiation of any study-specific activities/procedures.\nSubjects greater than or equal to 18 years of age at the time of signing consent.\nAML as defined by the WHO Classification as persisting or recurring following 1 or more treatment courses (exceptions noted in exclusi\u00f3n criteria).\nMyeloblasts greater than or equal to 5% in bone marrow, as confirmed by immunophenotype by flow cytometry.\nEastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 2.\nRenal function as follows: serum creatinine less than 2.0 mg/dL (176.84 mol/L); estimated glomerular filtration rate (eGFR) greater than 30 mL/min/1.73 m2.\nHepatic function as follows: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3.0 x upper limit of normal (ULN); bilirubin less than or equal to 1.5 x ULN (unless considered due to Gilbert's syndrome or hemolysis).\n\nNo active tuberculosis in the setting of anti-TNF therapy - National guidelines should be followed for the appropriate tuberculosis screening in the setting of anti-TNF therapy, including a minimum of:\n\nSubject has a negative test for tuberculosis during screening defined as either:\n\nNegative purified protein derivative (PPD) (< 5 mm induration at 48 to 72 hours after test is placed) OR\nNegative quantiferon test\nSubjects with positive PPD and a history of bacillus Calmette-Gu\u00e9rin vaccination are allowed with a negative Quantiferon test.\n\nSubjects with a positive PPD test (without a history of bacillus Calmette-Gu\u00e9rin vaccination) or subjects with a positive or indeterminate Quantiferon test are allowed if they have all of the following:\n\nno symptoms, per tuberculosis worksheet provided by Amgen\ndocumented history of a completed course of adequate treatment or prophylaxis (per local standard of care) prior to the start of investigational product\nno known exposure to a case of active tuberculosis after most recent prophylaxis\nno evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of investigational product (substudy subjects only)\n\nExclusion Criteria:\n\nPatients with acute promyelocytic leukemia (APML).\nActive extramedullary AML in the central nervous system (CNS)\nKnown hypersensitivity to immunoglobulins.\nWhite blood cells (WBC) greater than 15,000 cells/mcL (15 cells x 10^9/L) at screening (hydroxyurea is permitted to enable eligibility).\nSubjects with a prior or concurrent malignancy whose natural history or treatment is anticipated to interfere with the safety or efficacy assessment of the investigational regimen. Exception: Subjects with prior or concurrent malignancy not anticipated to interfere with the safety or efficacy of the investigational regimen may be included only after discussion with the Amgen Medical Monitor.\nAutologous HSCT within 6 weeks prior to start of AMG 427 treatment.\nAllogeneic HSCT within 3 months prior to start of AMG 427 treatment.\nAny graft-versus-host disease requiring systemic therapy with immunomodulators.\nHistory or evidence of significant cardiovascular risk including any of the following: symptomatic congestive heart failure, unstable angina, clinically significant arrhythmias (eg, ventricular fibrillation, ventricular tachycardia etc.), recent coronary angioplasty, intra-cardiac defibrillators or any clinically relevant concurrent disorder that may pose a risk to subject safety or interfere with study evaluation, procedures, or completion.\nHistory of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 3 months.\nActive infection requiring intravenous antibiotics within 1 week of study enrollment (day 1). Antibiotics may be administered for prophylaxis as per institutional standards up to and after enrollment.\nKnown positive test for human immunodeficiency virus (HIV).\nPositive for hepatitis B surface antigen (HepBsAg).\nPositive for hepatitis C or chronic hepatitis C. Possible exceptions: acute hepatitis C and completely cleared of the virus (demonstrated by negative viral load), chronic hepatitis C with undetectable viral load defined by sustained virologic response 24 weeks (SVR24) after completion of anti-hepatitis C treatment.\nLive vaccination(s) within 4 weeks before the start of AMG 427 treatment on day 1, during treatment, and until the end of the last study dose.\nUnresolved toxicities from prior antitumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 grade 1 (with the exception of myelosuppression, eg, neutropenia, anemia, thrombocytopenia), or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from prior antitumor therapy that are considered irreversible (defined as having been present and stable for greater than 2 months) which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor.\nAntitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, or investigational agent) within 14 days of day 1. Exception: hydroxyurea to control peripheral blood leukemic cell counts is allowed until start of investigational product treatment. Exception: antitumor therapies with short half-lives only require passing of 5 half-lives from last dose, and after discussion with sponsor.\nTreatment with systemic immune modulators including, but not limited to, non-topical systemic corticosteroids, cyclosporine, and tacrolimus within 2 weeks before enrollment (day 1). Exceptions: physiologic replacement steroids or steroids for treatment of transfusion/hypersensitivity reactions.\nPrior treatment with a FLT3 targeting chimeric antigen receptor T cell (CAR-T)\nMajor surgery within 28 days of study day 1 with the exception of biopsy and insertion of central venous catheter.\nHistory or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the investigator or Amgen medical monitor would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.\nMales and females of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through 4 weeks after receiving the last dose of study drug. Acceptable methods of highly effective birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (men) in combination with hormonal birth control or intrauterine device (IUD) (women).\nFemales who are lactating/breastfeeding or who plan to breastfeed while on study through 4 weeks after receiving the last dose of study drug.\nFemales with a positive pregnancy test.\nFemales planning to become pregnant while on study through 4 weeks after receiving the last dose of study drug.\nSubjects likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge.\nHistory of multiple sclerosis or any other demyelinating disease.\nNo active hepatitis secondary to alcoholic hepatitis or nonalcoholic steatohepatitis."
            },
            {
                  "document": "Inclusion Criteria:\n\nThe following criteria are used to enroll patients in the study before transplant.\n\nPatients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:\n\nAcute myeloid leukemia [AML] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease\nChronic myeloid leukemia [CML] in any chronic phase.\nMyelodysplastic syndrome [MDS] with intermediate/high risk features or refractory disease (with bone marrow blast count <10%).\nAcute lymphoblastic leukemia [ALL] in morphologic complete remission with high-risk features or relapsed disease.\nNegative test for donor-specific antibody within 28 days of starting conditioning regimen.\nAge Criteria: 19-65 years.\n\nOrgan Function Criteria: The following organ function testing should be done within 35 days before study registration.\n\nCardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram.\nPulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected.\nRenal: serum creatinine level to be <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2.\nHepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN.\nPerformance status: Karnofsky performance score (KPS) or Lansky score: \u226580.\nHematopoietic cell transplant comorbidity index (HCT-CI) <3. Exception may be made on individual cases after discussion with the primary investigator.\nConsent: All patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.\n\nThe following criteria are required within 48 hours prior to infusion of the EAGD T cell product.\n\nAbsence of uncontrolled infection with sepsis syndrome (e.g persistent positive blood culture).\nNO hemodynamic instability (due to sepsis or organ dysfunction) or circulatory volume overload.\n\nNO clinically significant organ toxicity that are defined as follows:\n\nHeart failure with subnormal LVEF or clinical fluid overload.\nElevated serum creatinine or subnormal creatinine clearance (either estimated or measured).\nElevated total bilirubin \u22651.5 upper normal level (unless indirect hyperbilirubinemia attributed to non-hepatic pathology), or elevated liver enzymes (ALT, AST, ALP) >5 x ULN.\nHypoxemia requiring oxygen therapy\nNO acute graft versus host disease (any grade).\nNeutrophil engraftment.\n\nExclusion Criteria:\n\nNon-compliant patients.\nNo appropriate caregivers identified.\nUncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).\nActive central nervous system (CNS) neoplastic involvement.\nMorbid obesity with body mass index >35 (borderline cases may be considered on case-by-case basis after discussion with the primary investigator).\nPatients with known allergy to DMSO.\nHIV1 (Human Immunodeficiency Virus-1) or HIV2 positive.\nPregnant or breastfeeding women."
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of untreated \"high-grade\" myeloid neoplasm (\u2265 10% blasts in blood or bone marrow) or acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2016 World Health Organization (WHO) classification; outside diagnostic material is acceptable to establish diagnosis; submission of peripheral blood specimen for flow cytometry performed at the study institution should be considered; diagnostic material must have been submitted for cytogenetic and/or molecular testing as clinically appropriate\nMedically fit, as defined by treatment-related mortality (TRM) score \u226413.1 calculated with simplified model\nThe use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment\nPatients may have received low-intensity treatment (e.g. azacitidine/decitabine, lenalidomide, growth factors) for antecedent low-grade myeloid neoplasm (i.e. < 10% blasts in blood and bone marrow)\nBilirubin \u2264 2.5 x institutional upper limit of normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (assessed within 14 days prior to study day 0)\nSerum creatinine \u2264 2.0 mg/dL (assessed within 14 days prior to study day 0)\nLeft ventricular ejection fraction \u2265 45%, assessed within 12 months prior to study day 0, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure\nWomen of childbearing potential and men must agree to use adequate contraception\nProvide written informed consent\n\nExclusion Criteria:\n\nMyeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatment\nConcomitant illness associated with a likely survival of < 1 year\nActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials, and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. known chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligible\nKnown hypersensitivity to any study drug\nConfirmed or suspected pregnancy or active breast feeding\nTreatment with any other investigational anti-leukemia agent; in phase 2, treatment with a tyrosine kinase inhibitor for patients with FLT3-mutated AML is permissible"
            },
            {
                  "document": "Key Inclusion Criteria (Phase 1a and Phase 1b, all Cohorts):\n\nAvailable fresh or archived tumor tissue.\nEastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\nAdequate coagulation function.\nAdequate hepatic function.\nAdequate hematologic status.\nAdequate renal function.\nRecovery from non-hematopoietic toxicities of previous anticancer drugs or radiotherapy or previous surgeries to \u2264Grade 1 (or to baseline grade if condition was pre-existing).\n\nKey Inclusion Criteria (Phase 1a): Histologically confirmed relapsed/refractory lymphoma (Hodgkin or non-Hodgkin).\n\nKey Inclusion Criteria (Phase 1b Cohort A): Histologically confirmed, newly diagnosed TP53-mutated Acute Myeloid Leukemia (AML).\n\nKey Inclusion Criteria (Phase 1b Cohort B): Histologically confirmed, newly diagnosed TP53-wildtype AML, elderly or unfit for more aggressive treatment.\n\nInclusion Criteria (Phase 1b Cohort C): Histologically documented relapsed/refractory Multiple Myeloma (MM).\n\nKey Exclusion Criteria (Phase 1a and Phase 1b, all Cohorts):\n\nKnown, current central nervous system disease involvement.\nUse of any investigational agent or any anticancer drug within 14 days before planned start of study treatment (within 4 weeks for antibody-based therapies and within 8 weeks for cell-based therapies).\nSubjects who have undergone radiation therapy within 14 days of study treatment administration.\nHematopoietic stem cell transplant within 90 days before the planned start of study treatment or subjects with active graft-vs-host disease, with the exception of Grade 1 skin involvement.\nMajor surgery within 30 days before planned start of study treatment."
            },
            {
                  "document": "Inclusion Criteria:\n\nPathologically confirmed diagnosis of IDH2-mutant acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).\nIDH2 mutations will include any IDH2 R140 or R172 alterations\nEligibility and enrollment will be based on local IDH2 mutational testing performed at any center. The presence of an IDH2 mutation at the time of initial diagnosis or any other time thereafter is necessary and sufficient. The presence of an IDH2 mutation at time of enrollment is not necessary for the purposes of eligibility.\nBetween the ages of 18 and 75 years\nWill undergo first allogeneic hematopoietic stem cell transplantation (HSCT) for their malignancy. Conditioning may have been either conventional myeloablative (MAC) or reduced intensity conditioning (RIC).\n\nHSCT Donor will be one of the following:\n\n5/6 or 6/6 (HLA-A, B, DR) matched related donor\n7/8 or 8/8 (HLA-A, B, DR, C) matched unrelated donor. Matching in the unrelated setting must be at the allele level.\nHaploidentical related donor, defined as \u2265 3/6 (HLA-A, B, DR) matched --\u2265 4/6 (HLA-A, B, DR) umbilical cord blood (UCB). Matching in the UCB setting is at the antigen level. Recipients may receive either one or two UCB units. In the case of 2 UCB units, both units must have been at least 4/6 matched with the recipient.\nECOG performance status \u2264 2\n\nParticipants must have normal organ and marrow function as defined below:\n\nAbsolute neutrophil count \u2265 1000/\u00b5L without growth factor support (e.g. GCSF) in the previous 7 days\nPlatelet count \u2265 50,000/\u00b5L without transfusional support in the previous 7 days\nAST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional upper limit of normal (ULN)\nDirect bilirubin < 2.0 mg/dL\nCalculated creatinine clearance \u2265 40 mL/min (Cockcroft-Gault formula)\nLVEF must be equal to or greater than 50%, as measured by MUGA scan or echocardiogram\nFemale patients of childbearing potential must have a negative pregnancy test, as measured by serum or urine testing\nThe effects of enasidenib on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during the entire study treatment period and through 6 months after the last dose of treatment\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nPrior allogeneic hematopoietic stem cell transplants.\nEvidence of relapsed/recurrent/residual disease as assessed by bone marrow aspirate and biopsy performed within 42 days prior to study entry.\n\nHistory of other malignancy(ies) unless\n\nthe participant has been disease-free for at least 5 years and is deemed by the investigator to be at low risk of recurrence of that malignancy, or\nthe only prior malignancy was cervical cancer in situ and/or basal cell or squamous cell carcinoma of the skin\nKnown diagnosis of active hepatitis B or hepatitis C\nCurrent or history of congestive heart failure New York Heart Association (NHYA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF < 50%, as measured by MUGA scan or echocardiogram)\nCurrent or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome\nSystemic infection requiring IV antibiotic or antifungal or antiviral therapy within 7 days preceding the first dose of study drug, or other severe infection\nKnown dysphagia, short-gut syndrome, gastroparesis, or other condition(s) that limits the ingestion or gastrointestinal absorption of drugs administered orally\nUncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic BP > 100 mmHg)\nQTc interval (i.e., Friderica's correction [QTcF]) \u2265 450 ms or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) at screening\nConcomitant receipt of the following sensitive CYP substrate medications that have a narrow therapeutic range (unless the participant can be transferred to other medications at least 5 half-lives prior to the start of study treatment): paclitaxel and docetaxel (CYP2C8), phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6), theophylline, and tizanidine (CYP1A2)\nConcomitant receipt of the breast cancer resistance protein (BCRP) transporter-sensitive substrate rosuvastain (unless the participant can be transferred to another medication at least 5 half-lives prior to the start of study treatment)\nUncontrolled intercurrent illness that would limit compliance with study requirements.\nHIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with study drug. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy."
            },
            {
                  "document": "Inclusion Criteria:\n\nESCLATION COHORT: Patients must have a diagnosis of newly diagnosed and/ or relapsed/refractory AML with any of the following:\n\nConfirmed translocation involving 11q23\nPartial tandem duplication(PTD) of the MLL gene (on 11q23)\nFLT3-ITD (internal tandem duplication)\nIncreased Fgf2 in serum (2 standard deviations above control serum samples)\nHOX(A9/A10) over-expression in bone marrow ( 2 standard deviations above control values in CD34+ cells from normal subjects)\n\nNote: Relapsed or refractory AML is defined as either:\n\nRecurrence of disease after a complete remission (CR), or\nFailure to achieve CR with initial therapy\n\nEXPANSION COHORT: Patients must have a diagnosis of newly diagnosed AML with any of the following:\n\nConfirmed translocation involving 11q23\nPartial tandem duplication (PTD) of the MLL gene (on 11q23)\nFLT3-ITD (internal tandem duplication)\nIncreased Fgf2 in serum (2 standard deviations above control serum samples)\nHOX(A9/A10) over-expression in bone marrow (2 standard deviations above control values in CD34+ cells from normal subjects)\nNote: Patients with secondary AML are eligible for enrollment into the trial (in both cohorts); secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities, or myelodysplastic syndromes (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history of prior chemotherapy or radiation therapy for a disease other than AML\nPatients who are not candidates for, or decline, intensive therapy\nPatients must exhibit an ECOG performance status 0-3\nInternational normalized ratio (INR) ? 2 (If coagulopathy is related to disease, this criterion does not apply) within14 days prior to registration\nProthrombin time (PT) and partial thromboplastin time (PTT) ? 1.5 x of institutional upper limit of normal (ULN) (Note: If coagulopathy is related to disease, this criteria do not apply) within14 days prior to registration\nTotal bilirubin ? 1.5 x of institutional ULN within14 days prior to registration\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SPGT]) 1.5 X institutional upper limit of normal (ULN) within14 days prior to registration\nCreatinine 2 x ULN OR creatinine clearance > 30 mL/min based on the Cockroft-Gault glomerular filtration rate (GFR) estimation\n\nFemales of child-bearing potential (FOCBP) and males must agree to use medically acceptable method of contraception (e.g. a method which results in a low failure rate of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, latex condoms for participating males, sexual abstinence) prior to study entry, for the duration of study participation, and for 3 months following completion of therapy; should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; if the female partner of a male participant becomes pregnant he should inform the treating physician and the female partner should contact her treating physician immediately\n\nNOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\nHas not undergone a hysterectomy or bilateral oophorectomy\nHas had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)\nFOCBP must have a negative pregnancy test (beta-human chorionic gonadotropin [HCG] test in urine or serum) within 7 days prior to registration on study (Note: The test will have to be repeated if cycle 1 day1 is more than 3 days from registration)\nPatients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study\nPatients must agree/be able to comply with all protocol specific requirements\n\nExclusion Criteria:\n\nPatients who have received chemo-, hormone-, radio or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 14 days prior to start of treatment or those who have not recovered from adverse events attributed to the agent to grade 1 or baseline\n\nExceptions for prior treatments are:\n\nHydroxyurea for increased blast count (no washout period required; it can be continued throughout the first cycle of therapy)\n\nLeukapheresis for leukocytosis (no wash out period required; it can be continued during the study)\n\nNote: If patient is registered prior to completion of washout, start date of treatment will need to be confirmed prior to registration; please see assigned quality assurance monitor (QAM) with questions\n\nPatients who have received any other investigational product within14 days of treatment are not eligible for this study; a wash out period ? 14 days or 5 half- lives (whichever is greater) is required from investigational treatment, prior to start of study treatment; please Note:\n\nIf patient is registered prior to completion of washout, start date of treatment will need to be confirmed prior to registration; please see assigned QAM with questions\nThe ?5 half-lives? time period will be determined by investigational pharmacy\nIf half life is not known and cannot be predicted, then wash out of ? 14 days is required\nPatients who have had major injuries and/or surgery within the past 4 weeks (< 28 days) prior to registration with incomplete wound healing and/or planned surgery while the patient is on study treatment\nPatients who have proteinuria CTCAE version (v)4.03 grade 2 or greater within < 30 days of registration\n\nPatients who have significant cardiovascular diseases are not eligible; these are:\n\nUncontrolled hypertension\nUnstable angina\nHistory of infarction within the past 12 months prior to start of study treatment\nCongestive heart failure > New York Heart Association (NYHA) II\nSerious uncontrolled cardiac arrhythmia\nPericardial effusion\nPatients requiring therapeutic anticoagulation with drugs requiring INR monitoring or anti-platelet therapy, except for acetylsalicylic acid (aspirin) ? 325 mg per day, are not eligible\nPatients with acute promyelocytic leukemia (APL) are not eligible\nPatients with known or suspected central nervous system (CNS) leukemia are not eligible\nPatients with known extramedullary leukemia are not eligible\nPatients who have received prior treatment with nintedanib or any other VEGFR inhibitor are not eligible\nPatients with known hypersensitivity to nintedanib or 5-azacitidine or who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or 5-azacitidine are not eligible\nPatients with hypersensitivity to mannitol are not eligible; patients who have known hypersensitivity to peanut or soya, any other trial drug, or their excipients, or to contrast media are not eligible\nPatients with known active or history of chronic hepatitis C and/or B infection, known HIV infection and active alcohol or drug abuse are not eligible.\nPatient with HIV who require anti-viral or supportive care that interacts with the study drugs are not eligible\nPatients must not have a concurrent active malignancy for which they are receiving treatment\n\nPatients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible:\n\nActive uncontrolled infection\nSerious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study\nPsychiatric illness/social situations that would limit compliance with study requirements\nAny other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient?s safety or study endpoints\nFemale patients who are pregnant or nursing are not eligible\nPatients who are unable to swallow oral gel capsules are not eligible\nPatients who have gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug are not eligible"
            },
            {
                  "document": "Inclusion Criteria:\n\nEligible patients with a histopathological confirmed diagnosis of hematologic malignancy in one of the following categories:\n\nAcute myelogenous leukemia:\n\nPatients with de novo or secondary disease in unfavorable risk group including poor risk cytogenetics according to National Comprehensive Cancer Network (NCCN) guidelines for AML i.e., monosomal karyotype, -5, 5q-, -7, 7q-, 11q23-non t (9;11), inv (3), t (3;3),t (6;9), t (9;22) and complex karyotypes (\u2265 3 unrelated abnormalities), or all patient in intermediate risk groups accept patients with FLT3-NPM1+ disease\nPatients with active disease\nPatients with chemosensitive active disease\n\nAcute lymphocytic leukemia:\n\nPatients with de novo or secondary disease according to NCCN guidelines for ALL hypoploidy (< 44 chromosomes); t (v;11q23): MLL rearranged; t (9;22) (q34;q11.2); complex cytogenetics (5 or more chromosomal abnormalities); high white blood cell (WBC) at diagnosis (\u2265 30,000 for B lineage or \u2265 50,000 for T lineage); iAMP21loss of 13q, and abnormal 17p\nPatients with active disease\nPatients with chemosensitive active disease\nMyelodysplastic syndrome in high-intermediate (int-2) and high risk categories\nPatients \u2265 12 years and < 55 years are also included if they are not candidates for myeloablative conditioning regimens due to comorbidities\nKarnofsky or Lansky performance status of \u2265 70\nA pretreatment measured creatinine clearance (absolute value) of \u2265 60 ml/minute\nPatients must have a serum bilirubin \u2264 2.0 mg/dl\nSerum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) \u2264 2.5 times the institutional upper limits of normal\nEjection fraction measured by echocardiogram or multigated acquisition (MUGA) \u2265 50%\nCarbon monoxide diffusing capacity (DLCO) and forced expiratory volume FEV1 > 50% predicted\nPATIENT-SPECIFIC INCLUSION CRITERIA\n\nPatients should have discontinued all previous intensive therapy, chemotherapy or radiotherapy for 2 weeks prior to commencing therapy on this study\n\nNOTE: low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted; these include hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors (TKIs); FLT-3 inhibitors can also be given up to 3 days before conditioning regimen\nAll patients with prior radiation treatment to the lung, liver, and kidney will be excluded; for other scenarios of prior radiation treatment, up to 2000 cGY at 2 gray Gy per day will be allowed; inclusion of patients with previous radiation exposure will be determined based on the radiation oncologist MD evaluation and judgment\nDONOR: Arm A: All candidates for this study must have an human leukocyte antigen (HLA) (A, B, C, and DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 (A, B, C, DR and DQ) allele matched unrelated donor; DQ or DP mismatch is allowed per discretion of the principal investigator\nDONOR: Arm B: The recipient must have a related donor genotypically HLA-A, B, C and DRB1 loci haploidentical to the recipient; no HLA matched sibling or matched unrelated donor is available; DSA is allowed with desensitization done if recommended by donor selection committee (DSC) per City of Hope (COH) standard operating procedures (SOP)\nDONOR: Both arms: All donors in both arms should be evaluated and approved by DSC\n\nExclusion Criteria:\n\nHaving any uncontrolled illness including ongoing or active bacterial, viral or fungal infection\n\nReceiving any investigational agents or concurrent biological, intensive chemotherapy or radiation therapy for the previous 2 weeks from conditioning\n\nNOTE: low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted; these include: hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors (TKIs), FLT-3 inhibitors can also be given up to 3 days before conditioning regimen\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the regimen\nPatients with other malignancies are ineligible for this study, other than non-melanoma skin cancers\nThe recipient has another medical problem or neurologic/psychiatric dysfunction which would impair his/her ability to be compliant with the medical regimen and to tolerate transplantation or would prolong hematologic recovery in which the opinion of the principal investigator would place the recipient at unacceptable risk\nPatients may not have had a prior autologous or allogeneic transplant\nPatients may not have received more than 3 prior lines of intensive chemotherapy, where the regimen intent was to induce remission\nIn the opinion of the principal investigator (PI), the participant has a condition that will preclude them from complying with study treatment\nWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\nAll subjects must have the ability to understand and the willingness to sign a written informed consent; they are to give voluntary written informed consent before performance if any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care; cognitively impaired subjects will be included only if their guardian or legal representative agrees to sign the written informed consent\nDONOR: Donor selection for both arms must be approved by the donor selection committee\nDONOR: Evidence of active infection\nDONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy or leukapheresis\nDONOR: Factors which place the donor at increased risk for complications from leukapheresis or granulocyte-colony stimulating factor (G-CSF) therapy could be harvested for bone marrow (BM) if safer for the donor and if approved by the principal investigator (PI)\nDONOR: Human immunodeficiency virus (HIV) positive"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of acute myeloid leukemia (AML) by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3.\nEastern Cooperative Oncology Group (ECOG) performance status \u2264 2.\nParticipant must have adequate hematologic, renal, and liver function laboratory values as described in the protocol.\n\nExclusion Criteria:\n\nKnown central nervous system leukemia\nSevere chronic obstructive pulmonary disease (COPD) with hypoxemia\nHistory of any malignancy within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment.\nPrior allogeneic stem cell transplant within 6 months of study drug administration and no requirement for graft versus host therapy.\nHistory of clinically significant medical condition that, in the opinion of the investigator, would adversely affect participation in this study.\nKnown active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.\nHistory of tumor lysis syndrome (TLS) due to previous exposure to venetoclax."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have received some immunosuppressive chemotherapy in the preceding 3 months.\n\nAcute myelogenous leukemia (AML):\n\nComplete first remission (CR1) at high risk for relapse\nComplete second remission (CR2).\nNo documented myelofibrosis at screening marrow biopsy\n\nAcute lymphoblastic leukemia (ALL):\n\nComplete first remission (CR1) at high risk for relapse\nComplete second remission (CR2).\nOther acute leukemias that are of ambiguous lineage or of other types\nAny acute leukemia with marrow aplasia or without adequate count recovery.\nMyelodysplastic Syndrome (MDS)\nKarnofsky score > 70 %.\nCalculated creatinine clearance > 60 ml/min.\nBilirubin < 1.5 mg/dL, ALT < 3 x upper limit of normal\nPulmonary function (FVC, FEV1 and corrected DLCO) > 50% predicted.\nLeft ventricular ejection fraction > 50%.\nAlbumin > 3.0 g/dL.\nNegative antiviral serology:\nNegative human immunodeficiency virus (HIV) antibody.\nNegative human T-lymphotropic virus (HTLV)-1 and 2 antibodies.\nNegative hepatitis B surface antigen (HBsAg) and undetectable hepatitis B virus (HBV) DNA\nNegative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA)\n\nFor female subjects of childbearing potential:\n\nA negative serum pregnancy test\nWilling to use contraception throughout the study period.\nMale subjects must be willing to use a recommended method of contraception throughout the study period, and to refrain from sperm donation throughout the study period.\nTwo appropriate CB units identified for the subject.\nIn the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's cancer.\nWillingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.\nEvidence of a signed informed written consent\n\nExclusion Criteria:\n\nPregnancy or breastfeeding.\nCurrent active, uncontrolled bacterial, viral, or fungal infection\nPrior allogeneic or autologous HCT at any time.\nActive malignancy other than the one for which AB-110 transplant is being performed within 12 months of enrollment.\nAny identified and available 10/10 HLA-matched related donor or 10/10 HLA-matched unrelated donor.\nHave evidence of recipient donor specific anti-HLA antibodies.\nActive central nervous system (CNS) disease at time of screening.\nDocumented allergy to DMSO, mouse or bovine proteins, or iron.\nSubject has other conditions that in the opinion of the investigator would place the subject at increased risk for toxicity by participation in the study.\nPsychiatric condition making the patient unlikely to comply with protocol therapy, required tests and follow-up."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge: less than 75 years\nThe patient must be approved for transplant by the treating transplant physician. This includes completion of their pre-transplant workup, as directed by standard Dartmouth-Hitchcock Medical Center (DHMC) Standard Operating Procedure (SOP) (DHMC SOP - Pre-transplant Evaluation of allogeneic recipient (Appendix).\nThe patient must have a disease (listed below) with treatment-responsiveness that the treating transplant physician believes will benefit from an allogeneic stem cell transplant. The diseases include:\nAcute leukemia - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia\nChronic leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia\nMyelodysplasia\nMyeloproliferative disorder\nMyelofibrosis\nLymphoma - Non-Hodgkin's Lymphoma or Hodgkin's disease\nPlasma cell disorder, including myeloma, Waldenstrom's Macroglobulinemia\nDonor availability- the patient must have an identified RELATED haplo-identical donor\nNo Human Immunodeficiency Virus infection or active hepatitis B or C\nEastern Cooperative Oncology Group performance status: 0-2\nDiffusing capacity of carbon monoxide (DLCO) greater than or equal to 40 % predicted\nLeft ventricular ejection fraction greater than or equal to 40%\nSerum bilirubin < 2x upper limit of normal; transaminases < 3x normal at the time of transplant\nNo active or uncontrollable infection\nIn female, a negative pregnancy test if experiencing menstrual periods\nNo major organ dysfunction precluding transplantation\nNo evidence of an active malignancy that would limit the patient's survival to less than 2 years. (If there is any question, the PI can make a decision).\n\nExclusion Criteria:\n\nPsychiatric disorder or a mental deficiency of the patient that is sufficiently severe to make compliance with the treatment unlikely, and making informed consent impossible.\nMajor anticipated illness or organ failure incompatible with survival from bone marrow transplant.\nHistory of refractory systemic infection\n\nDONOR ELIGIBILITY\n\nHuman leukocyte antigen (HLA) haplo-identical matched related.\nThe donor must be healthy and must be willing to serve as a donor, based on standard National Marrow Donor Program (NMDP) guidelines and DHMC SOP - Donor Evaluation (Appendix)\nThe donor must have no significant co-morbidities that would put the donor at marked increased risk\nThere is no age restriction for the donor\nInformed consent must be signed by donor\n\nDONOR EXCLUSION CRITERIA\n\nThe NMDP guidelines for exclusion criteria will be used (Appendix). In addition, the following donors are NOT eligible:\nPregnant or lactating donor\nHIV or active Hep B or C in the donor\nDonor unfit to receive G-CSF and undergo apheresis\nA donor with a psychiatric disorder or mental deficiency that makes compliance with the procedure unlikely and informed consent impossible"
            },
            {
                  "document": "Inclusion Criteria:\n\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2.\nIDH1-R132 mutated disease status as assessed by local laboratory. 2HG-producing IDH1 variants outside of R132 (i.e. R100) may be eligible after discussion with the principal investigator (PI).\nRelapsed/refractory AML, or treatment-naive patients with AML who are not eligible for standard induction chemotherapy. Patients with high-risk myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) (defined as >= 10% bone marrow blasts, or intermediate or high risk by International Prostate Symptom Score [IPSS], Revised [R]-IPSS or Dynamic [D]-IPSS) may also be eligible after discussion with the PI\nDirect bilirubin =< 2 x upper limit of normal (ULN) unless deemed to be related to underlying leukemia.\nAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN unless deemed to be related to underlying leukemia.\nCreatinine clearance >= 30 ml/min based on the Cockcroft-Gault equation.\nWilling and able to provide informed consent.\nIn the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents.\nMale subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug.\n\nExclusion Criteria:\n\nPatients with known allergy or hypersensitivity to ivosidenib or venetoclax.\nPatients who have previously received either ivosidenib or venetoclax.\nPatients with any concurrent uncontrolled clinically significant medical condition including infection, laboratory abnormality, or psychiatric illness, which could place the patient at unacceptable risk of study treatment\nThe use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions (1) intrathecal chemotherapy for prophylactic use or for controlled central nervous system (CNS) leukemia. (2) use of hydroxyurea and/or one dose of cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.\nPatients receiving concomitant treatment with strong CYP3A4 inhibitors within 3 days of start of study therapy (including posaconazole and voriconazole).\nPatients receiving concomitant strong CYP3A inducers (avasimibe, carbamazepine, phenytoin, rifampin, rifabutin, St. John's wort) within 3 days of start of study therapy.\nPatients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI).\nPatients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications.\nPatients with a concurrent active malignancy under treatment.\nCorrected QT (QTc) interval using Fridericia's formula (QTcF) >= 450 msec. Bundle branch block and prolonged QTc interval are permitted after discussion with the PI.\nKnown active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection.\nSubject has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion.)\n\nNursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception.\n\nAppropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)."
            },
            {
                  "document": "Inclusion Criteria:\n\nThis study is open to patients with acute myeloid leukemia (AML) evaluated within 30 days of the start of conditioning regimen and in first or second complete remission (CR)\nKarnofsky performance status (KPS) >= 70%\nThe effects of radiation on the developing fetus are known to be teratogenic; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\nPatients with acute myelogenous leukemia (AML) who are in first or second complete remission\nAll candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 allele matched unrelated donor; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques; (red cell exchange or plasma exchange)\nA cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram\nPatients must have a serum creatinine of less than or equal to 1.3 mg/dL or creatinine clearance > 70 ml/min as calculated by the Cockcroft-Gault formula\nA bilirubin of less than or equal to 1.5 mg/dL, excluding patients with Gilbert's disease\nPatients should also have a serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than 5 times the upper limit of normal\nPulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV 1) and DLCO should be greater than 50% of predicted normal value\nAll subjects must have the ability to understand and the willingness to sign a written informed consent; signed informed consent form approved by the Institutional Review Board (IRB) is required; the patient, family member, and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting, all pertinent information with respect to risks and benefits to the donor and recipient will be presented; alternative treatment modalities will be discussed\nThe time from the end of last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days\nPrior therapy with etoposide and cyclophosphamide is allowed\nDONOR: donor evaluation and eligibility will be assessed as per current City of Hope standard operating procedure (SOP)\n\nExclusion Criteria:\n\nPatients should not have any uncontrolled illness including ongoing or active or poorly controlled infection\nPatients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; maintenance therapy with Food and Drug Administration (FDA)-approved targeted therapies (e.g. tyrosine kinase inhibitors for Philadelphia chromosome [Ph] positive [+] acute lymphoblastic leukemia [ALL], and FLT inhibitors for FLT3+ patients) will be allowed after day 60 disease assessment\nPrior radiation therapy that would exclude the use of TMLI\nRelapsed patients who have undergone autologous or allogeneic hematopoietic stem cell transplantation previously\nPatients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation\nElectrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction < 50%\nPatients who have been treated with chemotherapy or radiation for the purpose of induction, re-induction or consolidation, within two weeks of planned study enrollment\nPatients with other active malignancies are ineligible for this study, other than localized malignancies\nPatients that are pregnant or breastfeeding\nAny other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to, infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.\nSubjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge \u226518 years at the time of informed consent.\nMorphologically documented primary AML or secondary AML [from prior conditions such as Myelodysplastic Syndrome (MDS), myeloproliferative neoplasm (MPN)] or therapy related AML (t-AML), as defined by World Health Organization (WHO) criteria.\nIn first or subsequent relapse or refractory status after prior therapy, with or without prior hematopoietic stem cell transplant (HSCT). Patients with MDS and progression to AML on hypomethylating agents will also be included.\nEastern Cooperative Oncology Group (ECOG) performance score 0-2.\nGreater than 25% of blasts must be CD33 positive on flow cytometry using Phycoerythrin (PE) labeled anti-CD33 antibody.\n\nPatients must meet the following clinical laboratory criteria:\n\nTotal bilirubin \u2264 2 x the upper limit of the normal range (ULN)\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 5 x ULN.\nCalculated creatinine clearance \u2265 50 mL/min\nResting left ventricular ejection fraction (LVEF) > 40%\nFemale patients must agree to avoid becoming pregnant, and male patients should avoid impregnating a female partner.\n\nExclusion Criteria:\n\nAcute Promyelocytic Leukemia.\nActive severe infection not well controlled by antibacterial or antiviral therapy.\nKnown infection with human immunodeficiency virus.\nPatients with documented pulmonary disease, with a diffusing capacity of the lungs for carbon monoxide (DLCO) and/or forced expiratory volume in one second (FEV1) <65%, or history of dyspnea at rest, or requiring oxygen.\nPregnant or breast feeding women.\nPrior chemotherapy or radiotherapy within 14 days of study entry unless fully recovered from adverse effects due to treatment, at investigator's discretion.\nActive malignancy within 2 years of entry, except previously treated melanoma grade 2 or less, non-melanoma skin cancer, carcinoma in situ, or cervical intraepithelial neoplasia, and organ confined prostate cancer with no evidence of progressive disease based on prostate-specific antigen (PSA) levels and are not on active therapy. Active malignancy is malignancy receiving treatment."
            },
            {
                  "document": "Inclusion Criteria:\n\nAdult \u226518 years of age\n\nAML according to the 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: \u226520% blasts in peripheral blood or marrow\n\nde-novo AML or\nAML secondary to MDS or\nAML secondary to exposure to potentially leukemogenic therapies or agents (e.g. radiation therapy, alkylating agents, topoisomerase II inhibitors) with the primary malignancy in remission for at least 2 years\n\nNot eligible for standard induction chemotherapy;\n\nAge \u226575 years or\nAge \u226518 years with at least one of the following comorbidities:\n\ni. Clinically significant heart or lung comorbidities, as reflected by at least one of:\n\nLeft ventricular ejection fraction (LVEF) \u226450%\nLung diffusing capacity for carbon monoxide (DLCO) \u226465% of expected\nForced expiratory volume in 1 second (FEV1) \u226465% of expected ii. Chronic stable angina or congestive heart failure controlled with medication iii. Other contraindication(s) to anthracycline therapy (must be documented) iv. Other comorbidity that the Investigator judges as incompatible with intensive remission induction chemotherapy, which must be documented\nCreatinine clearance (estimated by the Cockroft-Gault (C-G) or measured by 24 hours urine collection) \u226545 mL/min\nLiver enzymes (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \u22642.5 times the upper limits of normal (ULN)\nTotal bilirubin \u22641.5 x ULN unless due to known history of Gilbert's disease\nEastern Cooperative Oncology Group (ECOG) performance status \u2264 2 at screening\nPrepared and able to give written (signed and dated) informed consent, which includes compliance with study requirements and restrictions prior to admission to the study\nWomen of reproductive potential must have a negative serum pregnancy test within 48 hours of the first day of any BST-236 treatment course\nWomen or men of reproductive potential must use (or have his/her partner use) two forms of effective birth control methods starting from 1 month prior to screening and until 3 months following the last BST-236 administration day (acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptives, partner's vasectomy, or double-barrier method condom or diaphragm with spermicide)\nPatient must voluntarily sign and date an ICF, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures\nPatient must be able to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\nPatient has relapsed or refractory AML\nPatient has acute promyelocytic leukemia\nAny previous treatment for AML (except for hydroxyurea or up to one treatment course with hypomethylating agents (HMA))\nPatient has history of myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation\nPrevious use (prior to study initiation) of drugs containing cytarabine as an active ingredient\nUse of any HMA for the treatment of MDS within 30 days of study Day 1\nParticipation in a previous clinical trial and/or use of an investigational drug within 90 days or at least 5 half-lives of tested drug (whichever is longer) of initial screening assessment\nPeripheral White Blood Cell (WBC) count >30,000 /\u00b5L in the 48 hours prior to first BST-236 dose administration. Hydroxyurea administration or leukapheresis is permitted to meet this criterion\nUncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment)\nAny medical or surgical condition, presence of laboratory abnormalities or psychiatric illness that may preclude safe and complete study participation based on the Investigator's judgment\nDiagnosis of malignant disease within the previous 12 months (excluding basal cell carcinoma of the skin without complications, \"in-situ\" carcinoma, or other local malignancy excised or irradiated with a high probability of cure and not treated with chemotherapy)\nActive malignant disease other than AML\nLeptomeningeal/central nervous system involvement of AML\nMyeloid sarcoma as a sole manifestation of AML\nSurgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) in the 14 days prior to BST-236 administration\nUnstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA) class 4 congestive heart failure\nShortness of breath requiring continuous oxygen treatment for at least 15 hours per day in chronically hypoxemic patients\nHistory of allergic reactions attributed to compounds of similar chemical composition as BST-236 and/or cytarabine\nLife expectancy shorter than 3 months attributed to any known medical condition other than AML\nActive/chronic Hepatitis B Virus (HBV) infection (based on positive surface antigen (HBsAg)), Hepatitis C Virus (HCV) infection (HCV) (based on positive HCV antibody (Ab)), or Human Immunodeficiency Virus (HIV)-1 or HIV-2 (based on positive HIV antibody)"
            },
            {
                  "document": "Inclusion Criteria:\n\nI. Acute myelogenous leukemia (AML)\n\nComplete first remission (CR1) at high risk for relapse such as any of the following:\nKnown prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder\nTherapy-related AML\nWhite cell count at presentation > 100,000\nPresence of extramedullary leukemia at diagnosis\nAny unfavorable subtype by FAB or WHO classification\nHigh-risk cytogenetics (e.g. those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) or high risk molecular abnormalities\nRequirement for 2 or more induction to achieve CR1\nAny patient with newly diagnosed AML with intermediate risk cytogenetics who elects allograft with curative intent over consolidation chemotherapy\nAny patient unable to tolerate consolidation chemotherapy as would have been deemed appropriate by the treating physician\nOther high risk features not defined above\nComplete second remission (CR2)\nPrimary refractory or relapsed AML with less than 10% blasts before transplant. Persistent/relapsed AML with cytogenetic, flow cytometric, or molecular aberrations in >/= 10% of cells are eligible\n\nII. Acute lymphoblastic leukemia (ALL)\n\nComplete first remission (CR1) at high risk for relapse such as any of the following:\nWhite cell count at presentation > 30,000 for B-cell lineage and > 100,00 for T-cell lineage\nPresence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality\nFailure to achieve complete remission after four weeks of induction therapy\nPersistence or recurrence of minimal residual disease on therapy\nAny patient with newly diagnosed ALL >/= 50 years-old\nAny patient unable to tolerate consolidation and/or maintenance chemotherapy as would have been deemed appropriate by the treating physician\nOther high risk features not defined above\nComplete second remission (CR2)\nPrimary refractory or relapsed ALL with less than 5% blasts before transplant. Persistent/relapsed ALL with cytogenetic, flow cytometric or molecular aberrations in >/=5% of cells are eligible.\n\nIII. Other acute leukemias: leukemias of ambiguous lineage or of other types e.g. blastic plasmacytoid dendritic cell neoplasm with less than 5% blasts. Persistent/relapsed disease with cytogenetic, flow cytometric or molecular aberrations in >/=5% of cells are eligible\n\nIV. Myelodysplastic Syndrome (MDS)/ Myeloproliferative Disorders (MPD) other than myelofibrosis:\n\nInternational prognostic scoring system (IPSS) risk score of INT-2 or high risk at the time of diagnosis\nAny IPSS risk category if life-threatening cytopenia(s) exists\nAny IPSS risk category with karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia\nMDS/ myeloproliferative disorder overlap syndromes without myelofibrosis\nMDS/ MPD patients must have less than 10% bone marrow myeloblasts and ANC >/= 0.2 (growth factor supported if necessary) at transplant work-up\n\nV. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high-risk of relapse or progression if not in remission:\n\nEligible patients with aggressive histologies (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histologies) in CR\nEligible patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/CR/PR with no single lesion equal to or more than 5 cm.\nEligible patients with HL will be without progression of disease (POD) after salvage chemotherapy with no single lesion equal to or more than 5cm.\n\nOrgan Function and Performance Status Criteria:\n\nKarnofsky score >/= 70% (inpatient Leukemia service transfers without discharge are acceptable provided patient has equivalent KPS as if were outpatient)\nCalculated creatinine clearance >/= 60 ml/min\nBilirubin < 1.5 mg/dL (unless benign congenital hyperbilirubinemia)\nALT </= 3 x upper limit of normal\nPulmonary function (spirometry and corrected DLCO) >/= 50% predicted\nLeft ventricular ejection fraction greater than 50%\nAlbumin >/= 3.0\nAge-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) less than or equal to 7\n\nGraft Criteria:\n\n2 CB units will be selected according to current MSKCC unit selection algorithm. High resolution 8 allele HLA typing and recipient HLA antibody profile will be performed. Unit selection will occur based on HLA-match, total nucleated cell (TNC) and CD34+ cell dose adjusted per patient body weight. The bank of origin will also be taken into account. Donor specific HLA antibodies, if present, will also be taken into consideration and may influence the selection of the graft.\n\nEach CB unit must be at least 3/8 HLA-matched to the patient considering high resolution 8-allele HLA typing\nEach CB unit will be required to have a cryopreserved TNC dose of at least 1.5 x 10^7 TNC/ recipient body weight (TNC/ kg)\nEach CB unit will be required to have a cryopreserved CD34+ cell dose of at least 1.0 x 10^5 CD34+ cells/ recipient body weight (CD34+/kg).\nA minimum of one domestic will be reserved as a backup unit.\n\nExclusion Criteria:\n\nIndolent NHL or Hodgkin lymphoma with POD after most recent salvage chemotherapy\nDiagnosis of myelofibrosis or other malignancy with moderate-severe bone marrow fibrosis\nAny diagnosis without prior immunosuppressive chemotherapy within 3 months of intended admission for transplant\nPrior checkpoint inhibitors/ blockade in the last 12 months\nTwo prior stem cell transplants of any kind\nOne prior autologous stem cell transplant within the preceding 12 months\nOne prior allogeneic stem cell transplant within the preceding 24 months\nPrior radiation therapy with 400cGy or more of TBI\nActive and uncontrolled infection at time of transplantation\nHIV infection\nSeropositivity for HTLV-1.\nInadequate performance status/ organ function.\nPregnancy or breast feeding\nPatient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests."
            },
            {
                  "document": "Inclusion Criteria:\n\nCohort TMLI+FLT: AML patients eligible for and enrolling on COH 14012 or IRB 17505 that agree to participate in optional FLT PET imaging\n\nNote: patients enrolling on IRB 19518 cannot enroll onto this cohort, but they may enroll on Cohort TMLI (below)\nCohort TMLI: AML or ALL patients eligible for and enrolling on COH 14012, IRB 17505 or IRB 19518\nCohort TBI: First or second remission AML or ALL patients that will receive TBI (13.2 Gy) plus chemotherapy (etoposide [VP16] 60 mg/kg or cyclophosphamide [Cy] 60 mg/kg for two days) as part of their standard of care\nCohort TBI: Documented written informed consent of participant\nCohort TBI: Age >= 18 to =< 60 years\nCohort TBI: Patients who have not received a prior transplant"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with AML, BPDCN, biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) who have failed prior therapy; patients with AML should have failed prior therapy or have relapsed after prior therapy; patients with isolated extramedullary AML are eligible\nElderly (> 60 year old) patients with newly diagnosed AML, BPDCN, or mixed phenotype acute leukemia (MPAL) not eligible for intensive chemotherapy\nPatients with newly diagnosed AML with poor risk complex karyotype and/or TP53 deletions/mutations equal or younger than 60 year old\nAML or BPDCN patients with prior history of MDS or CMML who received any therapy or no therapy for the MDS or CMML and progressed to AML, are eligible at the time of diagnosis of AML regardless of any prior therapy for MDS; the World Health Organization (WHO) classification will be used for AML\nPatients with high-risk MDS with bone marrow blasts between 10% and 20%, relapsed or refractory to prior hypomethylating agent (HMA) therapy, defined as prior receipt of 4 cycles of HMA therapy with failure to attain a response, or relapse after prior response to HMA therapy; patients with high risk chronic myelomonocytic leukemia (CMML) with bone marrow blasts >= 10% regardless of prior therapy\nEastern Cooperative Oncology Group (ECOG) performance status =< 3\nWhite blood cell count =< 10,000\nAdequate renal function including creatinine < 2 unless related to the disease\nAdequate hepatic function including total bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\nAlanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement\nProvision of written informed consent\nOral hydroxyurea and/or one dose of cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy and while the patient is on active study treatment through cycle 1, as needed, for clinical benefit and after discussion with the principal investigator (PI); concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\nFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment\nWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment\n\nExclusion Criteria:\n\nPatients having received any prior BCL2 inhibitor therapy\nPatients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)\nPatients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia\nActive and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician\nPatients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C\nAny other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\nPregnant or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria:\n\nARMS A-G: RR AML: Patients with AML who are refractory or relapsed (any salvage) with no available therapies or not candidates for available therapies. For patients with prior MDS or chronic myelomonocytic leukemia (CMML) or myeloproliferative neoplasm (MPN) who transformed to AML, therapy received for MDS, CMML, or MPN is NOT considered as prior therapy for AML with the exception of MDS or CMML treated with hypomethylating agents (HMAs). Patients with MDS or CMML treated with HMA therapies who progress to AML, and have no available therapies or are not candidates for available therapies, will be eligible at the time of progression to AML.\nPrior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is permitted.\nEastern Cooperative Oncology Group (ECOG) performance status =< 2.\nTotal bilirubin =< 2.0 times upper limit of normal (x ULN).\nAspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (aspartate aminotransferase or alanine aminotransferase =< 5.0 x ULN if deemed related to leukemia by the treating physician).\nAdequate renal function defined by an estimated creatinine clearance >= 40 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).\nPatients must provide written informed consent.\nIn the absence of rapidly progressive disease, the interval from prior treatment to the time of initiation of protocol therapy will be at least 14 days for prior anti-leukemic therapy, with the exception of hydroxyurea as noted below, OR at least 5 half-lives for cytotoxic/noncytotoxic agents, whichever is shorter. The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochure's, or drug-administration manuals) and will be documented in the protocol eligibility document. The toxicity from prior therapy should have resolved to grade =< 1, however alopecia and sensory neuropathy grade =< 2 not constituting a safety risk based on investigators judgement is acceptable. Since the effect of most IO-agents, HMA-therapies, SMO-inhibitors, venetoclax may be delayed, use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and will not require a washout.\nConcurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted. Patients with a known history of CNS disease or leukemic brain metastasis must have been treated locally, have at least 3 consecutive lumbar punctures (LPs) with no evidence of CNS leukemia, and must be clinically stable for at least 4 weeks prior to enrollment and have no ongoing neurological symptoms that in the opinion of the treating physician are related to the CNS disease (sequelae that are a consequence of the treatment of the CNS disease are acceptable).\nFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment.\n\nWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment. Adequate methods of contraception include:\n\nTotal abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\nFemale sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\nMale sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient.\n\nCombination of any of the two following:\n\nUse of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception.\nPlacement of an intrauterine device (IUD) or intrauterine system (IUS).\nBarrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository in case of use of oral contraception, women should have been stable on the same pill before taking study treatment.\nNote: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.\n\nExclusion Criteria:\n\nPatients with a known allergy or hypersensitivity to the protocol therapies or any of their components to be used in the arm the patient is to be enrolled on. Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).\nPatients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis/pneumonia or pulmonary pathology that is not well controlled in the opinion of the treating physician and/or principal investigator (PI).\nClinically significant (i.e., active) cardiovascular disease: acute cerebral vascular accident/stroke (< 6 months prior to enrollment) excluding transient ischemic attack (TIA), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication.\nEjection fraction < 50% on screening echocardiography (ECHO) or multigated acquisition scan (MUGA).\nPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy grade =< 2 is acceptable.\n\nActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent: * Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible\n\nCurrent use of immunosuppressive medication, EXCEPT for the following:\n\nIntranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection);\nSystemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent;\nSteroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication).\nPrior organ transplantation including allogenic stem-cell transplantation within 3 months prior to planned enrollment.\nPatients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia.\nActive and uncontrolled disease (active infection requiring systemic therapy, fever likely secondary to infection within prior 48 hours, uncontrolled hypertension despite adequate medical therapy as judged by the treating physician.\nKnown history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.\nKnown history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive.\nVaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.\nOther severe acute or chronic medical conditions that is active and not well controlled including colitis, inflammatory bowel disease, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.\nPatients unwilling or unable to comply with the protocol.\nPregnant or breastfeeding.\nKnown alcohol or drug abuse within the last 1 year.\nAcute promyelocytic leukemia (APL).\nCardiac exclusions specific to glasdegib and OX40 containing arms: Any one of the following ongoing or in the previous 6 months: congenital long QT syndrome, torsades de pointes or any clinically significant ventricular fibrillation, sustained ventricular tachyarrhythmia requiring medical intervention, right bundle branch block + left anterior hemiblock (i.e. bifascicular block): isolated RBBB without a bifascicular block will not be an exclusion criterion; complete left bundle branch block, unstable angina or myocardial infarction, coronary/peripheral artery bypass graft, cerebrovascular accident (CVA), transient ischemic attack or symptomatic pulmonary emboli, as well as bradycardia defined as < 50 bpms on screening or day 1 electrocardiography (EKG). Known history of second or third degree heart block (may be eligible if the patient currently has a pacemaker). Active cardiac dysrhythmias of NCI CTCAE grade >= 2 (eg, atrial fibrillation) or corrected QT interval by Fridericia's correction formula (QTcF) interval > 470 msec within 4 weeks prior to starting the study drug"
            },
            {
                  "document": "Inclusion Criteria:\n\nDisease Characteristics:\n\na. Confirmation of CD123 positivity by flow cytometry or IHC. Patients who received prior CD123-targeting agents will be allowed as long as the blasts still have detectable CD123 expression.\n\nExpansion inclusion:\n\nCohort 1 - Patients with relapsed or refractory BPDCN with 1-3 prior lines of therapy\nCohort 2 - Patients will have relapsed AML.\nCohort 3 - Patients will have relapsed or refractory ALL (including any subtypes: B-cell, T-cell, Ph+, and Ph-).\nCohort 4 - Patients will have relapsed or refractory \"other\" hematologic malignancies not included in the cohorts above (eg, high-risk/very high-risk MDS, MPN, CMML, BP- CML). Other CD123+ malignancies may be considered upon discussion with the Sponsor.\nCohort 5 - Patients will have relapsed or refractory (to non-intense therapies) AML.\nCohort 6 - Patients with frontline BPDCN who have not received prior systemic therapy.\n\nNote: Patients in Cohort 6 may have received local therapy (radiotherapy, surgical excision, photodynamic therapy). Eligible patients must have a recurrence or progression in the field of local therapy OR disease outside the field of local therapy.\n\nExclusion Criteria:\n\nPatients who, in the judgment of their treating physician, have appropriate standard of care therapies will be excluded from Cohorts 1 through 5.\nFrontline BPDCN patients with central nervous system (CNS) disease will be excluded. A lumbar puncture must be performed during the 28-day screening period, prior to drug administration. Relapsed or refractory BPDCN patients with a known history of CNS disease must have been treated locally, have at least 1 lumbar puncture with no evidence of CNS disease, and must be clinically stable prior to first dose. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS disease is permitted with the approval of the Sponsor.\nPatients with a history of veno-occlusive disease of the liver.\nPatients with a history of Grade 4 capillary leak syndrome, or non-cardiac Grade 4 edema are ineligible, eg, related to tagraxofusp-erzs or other etiology.\nInterval from prior cancer therapy: 1. For frontline BPDCN patients with prior local therapy (eg, radiotherapy), patients must not have received treatment within 14 days prior to drug administration on this study. 2. Relapsed or refractory BPDCN patients must not have received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational agents within 14 days prior to drug administration on this study. Patients must have recovered to baseline from all acute toxicity from this prior therapy.\n\nNote: the exception that patients who have received a checkpoint inhibitor must not have received that therapy within 28 days prior to drug administration on this study."
            },
            {
                  "document": "Inclusion Criteria:\n\nSigned, informed consent must be obtained prior to any study specific procedures\nSubjects with a histologically confirmed diagnosis of MDS, including both MDS and refractory anemia with excess blasts in transformation (RAEB-T) (acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria) by World Health Organization (WHO), and chronic myelomonocytic leukemia (CMML) are eligible\nSubjects must have an IDH2 gene mutation (IDH2-R140 or R172) as determined by local laboratory result\n(Arm A only): Subject must be hypomethylating agent naive (i.e. prior azacitidine, decitabine, SGI-110 is exclusionary). Receipt of other MDS-directed therapy such as lenalidomide is allowed\n(Arm A only): Subjects with high-risk MDS (i.e. International Prostate Symptom Score [IPSS] intermediate-2 or high-risk; or revised [R]-IPSS high or very-high risk). Patients with intermediate-1 risk by IPSS or intermediate risk by R-IPSS with high-risk molecular features including TP53, ASXL1, EZH2, and/or RUNX1 mutations are also eligible\n(Arm B only): Subject must be relapsed or refractory to prior hypomethylating agent therapy, defined as prior receipt of 6 cycles of HMA therapy with failure to attain a response, or relapse after prior response to HMA therapy\nEastern Cooperative Oncology Group (ECOG) performance status of 0-2\nSerum bilirubin =< 2 x the upper limit of normal (ULN) (except for patients with Gilbert's disease)\nAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x the laboratory ULN\nSerum creatinine =< 2 x the ULN\nAble to understand and voluntarily sign a written informed consent, and willing and able to comply with protocol requirements\nResolution of all clinically significant treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to =< grade 1 prior to the first dose of study treatment\nFemale patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug. Post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potential\n\nExclusion Criteria:\n\nAny prior or coexisting medical condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in the study\nSubject has received a prior targeted IDH2 inhibitor\nPsychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures\nActive uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection\nClinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy\nPatients with known active central nervous system (CNS) disease, including leptomeningeal involvement\nImpaired cardiac function, uncontrolled cardiac arrhythmia, or clinically significant cardiac disease including the following: a) New York Heart Association grade III or IV congestive heart failure, b) myocardial infarction within the last 6 months\nSubjects with a corrected QT (QTc) > 480 ms (QTc > 510 msec for subjects with a bundle branch block at baseline\nNursing or pregnant women\nSubjects with known hypersensitivity to study drugs or their excipients"
            },
            {
                  "document": "Inclusion Criteria of Recipient (patient):\n\nHistologic confirmation of acute myeloid leukemia (AML)\nRecurrence or progression (including refractory disease) of AML after at least 1 prior standard treatment with progression within 6 months from last treatment.\nNo curative treatment option is available\n\u2265 4-weeks since prior chemotherapy or radiation to cellular therapy infusion.\nAge equal to or greater than 18 years.\nPatients with a history of invasive second malignancy who are disease free for \u2265 2 years.\nPatients must have an expected life expectancy of at least 2 months at the time of initiation of treatment\nNo active systemic infections allowed.\nPatients who have relapsed after standard autologous stem cell infusion are eligible as long as they meet all inclusion criteria and no exclusion criteria. These patients must be out more than 6 months from cell infusion to be eligible for enrollment.\nDLCO \u2265 40% with no symptomatic pulmonary disease.\nLVEF \u2265 40% by MUGA or echocardiogram.\nCreatinine <1.5x ULN or any serum creatinine level associated with a measured or calculated creatinine clearance of >40 mL/min, AST and ALT < 2.5x ULN, Total Bilirubin < 1.5 x ULN\nWomen of childbearing potential and sexually active males must use 2 forms of effective contraception method from time of consent through 6 months after completing treatment (whether last treatment is infusion or drug).\nNot pregnant or nursing. Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment (drug). Post-menopausal women (surgical menopause or lack of menses \u226512 months) do not need to have a pregnancy test, please document status.\nPerformance status \u2264 2 (or KPS 70)\n\nExclusion Criteria of Recipient (patient):\n\nEvidence of HIV infection.\nAny uncontrolled severe, concurrent illness which in the opinion of the treating physician would make this protocol treatment unreasonably hazardous for the patient.\nOxygen dependent obstructive pulmonary disease.\nFailure to demonstrate adequate compliance with medical therapy and follow-up\nSignificant medical or psychiatric illness that would impair the ability to participate in protocol therapy.\nPrevious allogeneic stem cell transplant\nPatients who have had previous purine analog (fludarabine, pentostatin, 2-CDA) treatment or treatment with alemtuzumab within 1 year of entering the study\nPrevious history of Veno-occlusive disease/Sinusoidal Obstruction Syndrome\nActive hepatitis B or C\nPatients with known active central nervous system leukemia\nPatients with prior treatment of Gemtuzumab ozogamicin\nPatients eligible for allogeneic stem cell transplant\n\nDonor Eligibility Criteria * donor eligibility must be documented and assessed by a separate participating physician other than the treating physician of the recipient.\n\nDonors agree to up to 3 donor leukocyte collections as documented by assessing physician (although it is not required that the same donor is used for all leukocyte infusions it is preferable, therefore agreement is important at screening). This must be documented in writing by treating physician.\nTyping is required at the following loci: HLA A, B, C, and DRB1.\nPatients with a HLA 0/6 to 3/6(using loci A, B, DR) donor match will be able to participate in this protocol.\nDonors must be a first or second degree relative.\nIf the patient/recipient is CMV negative, only CMV negative donors are eligible. If the patient/recipient is CMV positive, CMV testing is not required for the donor.\nAlthough ABO blood type matching is not required given use of apheresis product preference will be made to ABO compatible donors\nDonors must be \u226518 years of age to donate.\nDonor with a history of malignancy other than non-melanoma skin cancers are eligible only if they had a history of a solid tumor malignancy more than five years prior to lymphocyte donation, and are considered to be in longstanding complete remission as documented by a physician. The donor must be healthy and have all testing criteria completed and meet all criteria for stem cell donation.\nThe donor will also be assessed by physician who will document behavioral risk for exposure to infectious agents and diseases. Testing will include the following: Human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease, communicable disease risks associated with xenotransplantation, Chlamydia trachomatis and for Neisseria gonorrhea, Treponema pallidum (syphilis).This will exclude the donor.\nThe donor must be in good general health and not have significant cardiopulmonary, renal, endocrine, or hepatic disease as documented in writing by physician.\nB-HCG urine or serum negative if donor is of childbearing potential within 7 days of PBMC procurement. Not applicable for donors who are Post-menopausal (surgical menopause or lack of menses \u226512 months).\nDonors must have adequate venous access so leukapheresis can be performed via standard peripheral IV without the need for placement of a central venous catheter.\n\nDonor Exclusion Criteria:\n\nEvidence of infection for HIV-1, HIV-2, syphilis, hepatitis B or C, HTLV 1 or 2, WNV, Chagas.\nUncontrolled diabetes mellitus. If donor has controlled diabetes this must be documented by physician.\nActive or congestive heart failure syndrome from any cause per donor medical history. Approval for participation by Cardiologist required to be sent to BrUOG.\nFull cardiac workup by a Cardiologist is required for any history of congestive heart failure syndrome, conduction abnormalities or history of arrhythmia other than treated atrial fibrillation.\nActive angina pectoris. To be documented by physician\nOxygen dependent pulmonary disease. To be documented by physician\nHistory of any lymphoid, myeloid or other non-solid malignancy. To be documented by physician\nFailure to receive full informed consent.\nInadequate renal and/or hepatic function per medical history. To be documented by physician\nKnown history of cirrhosis or active liver disease per medical history. To be documented by physician\nHistory of transplantation. To be documented by physician.\nA donor in whom plasma dilution sufficient to affect the results of communicable disease testing is suspected, unless: (A) You test a specimen taken from the donor before transfusion or infusion and up to 7 days before recovery of cells or tissue; or (B) You use an appropriate algorithm designed to evaluate volumes administered in the 48 hours before specimen collection, and the algorithm shows that plasma dilution sufficient to affect the results of communicable disease testing has not occurred.\n\nClinical situations in which you must suspect plasma dilution sufficient to affect the results of communicable disease testing will exclude the donor. Such situations include, but are not limited to the following:(A) Blood loss is known or suspected in a donor over 12 years of age, and the donor has received a transfusion or infusion of any of the following, alone or in combination:\n\nMore than 2,000 milliliters (mL) of blood (e.g., whole blood, red blood cells) or colloids within 48 hours before death or specimen collection, whichever occurred earlier, or\nMore than 2,000 mL of crystalloids within 1 hour before death or specimen collection, whichever occurred earlier."
            },
            {
                  "document": "Inclusion Criteria:\n\nAdult patients (\u226518 years).\nNew diagnosis of acute myeloid leukemia.\nAdmitted to Massachusetts General Hospital for intensive induction chemotherapy requiring 4-6-week hospitalization.\nThe ability to provide informed consent.\nAbility to comprehend and speak English.\n\nExclusion Criteria:\n\nSignificant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder,\nMajor depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits the ability to participate in study procedures"
            },
            {
                  "document": "Inclusion Criteria:\n\nAny disease that is considered transplant eligible per TCT standards\nDisease response noted (i.e. CR, non-CR, or not applicable): Assessed as per disease specific criteria\n\nSuitable related haploidentical donor identified per transplant service:\n\nRecipient should not have HLA antibodies to potential donor. If the recipient does have HLA antibodies to the potential donor, an alternative donor is preferred; however, if there are no suitable alternative donors, the anti-HLAt antibodies should be depleted per transplant service guidelines.\nHaploidentical donors that are ABO compatible with the recipient are preferred. Minor ABO incompatibility is preferred to major ABO incompatibility. Major ABO incompatibility between recipient and donor is the least preferred but still acceptable for this study.\nIt is preferred that the haploidentical donor must be available to donate on day -1 and day 0, so that fresh product can be processed by the Stem Cell lab and administered to the patient on day 0.While less preferable, cryopreserved product may be utilized with this product.\nDiffusing capacity of the lung for carbon monoxide (DLCO) > 40% predicted, corrected for hemoglobin and/or alveolar ventilation\nLeft ventricular ejection fraction > 40%\nBilirubin, liver alkaline phosphatase, serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 3 x upper limit of normal\nCalculated creatinine clearance > 40 cc/min by the modified Cockcroft-Gault formula for adults or the Schwartz formula for pediatrics\nHave a Karnofsky (adult) or Lansky (for =< 16 years) performance status >= 60%\nPatient must be able to pass radiation evaluation (i.e.: able to receive 200 cGy)\nPatients who have failed a prior autologous transplant are eligible; however, at least 90 days must have elapsed between the start of this reduced intensity conditioning regimen and the last transplant if patient had a prior autologous BMT\nParticipants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\nParticipant must understand the investigational nature of this study and sign an independent ethics committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\nIf patient is planned to use a fully matched donor, patient is excluded from trial; patient must be planned to undergo a haploidentical matched transplant to participate on study. Patient is still eligible for trial regardless of donor options if PI feels that haplo transplant is in the patient's best interest per clinical decision\nExclusion Criteria:\nParticipants who have had chemotherapy (not including molecularly targeted agents; examples include, but are not limited to, tyrosine kinase inhibitors such as FLT3 inhibitors and IDH2 inhibitors), radiation treatment and/or surgery 7 days prior to starting conditioning regimen. Those who have not recovered sufficiently from adverse events due to agents administered more than 2 weeks earlier are also ineligible. Exceptions may be made on a case-by-case basis after discussion with the PI\nUncontrolled central nervous system (CNS) disease (for hematologic malignancies) Per PI discretion\nChild-Pugh class B and C liver failure\nConcomitant active malignancy that would be expected to require chemotherapy within 3 years of transplant (other than non-melanoma skin cancer) Exception would include any concurrently existing malignancy that could be treated with a transplant per PI discretion (Example: Patient has AML but a history of mastocytosis)\nPatients who have received maximally allowed doses (given in 2 Gy fractionations, or equivalent) of previous radiation therapy to various organs; patients who previously have received a higher than allowed dose of radiation to a small lung, liver and brain volume, will be evaluated by the radiation oncologist to determine if the patient is eligible for study\nUncontrolled diabetes mellitus, cardiovascular disease, active serious infection or other condition which, in the opinion of treating physician, would make this protocol unreasonably hazardous for the patient\nKnown human immunodeficiency virus (HIV) positive\nPregnant or nursing female participants\nPatients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening\nPatients with donor specific HLA antibodies with a titer greater than 3000 MFI (whether or not they have undergone a desensitization protocol)\nPatients who have undergone a prior allogeneic hematopoietic or (other organ) transplant\nTreating physician considers the potential HLA haploidentical donor to be ineligible to receive G-CSF, and/or concern on the part of the treating physician for risk of harm to the potential donor with administration of G-CSF, and/or refusal by the potential donor (or donor's guardian) to receive G-CSF\nAny condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug\nReceived an investigational agent within 14 days prior to enrollment. Exceptions may be made on a case-by-case basis after discussion with PI"
            },
            {
                  "document": "Inclusion Criteria:\n\nVoluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care\n\nFemale patients who:\n\nAre postmenopausal for at least 1 year before the screening visit, OR\nAre surgically sterile, OR\nIf they are of childbearing potential, agree to practice 1 highly effective method and 1 additional (barrier) of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), or\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only and lactational amenorrhea are not acceptable methods of contraception)\n\nMale patients, even if surgically sterilized (ie, status postvasectomy), who:\n\nAgree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug (female and male condoms should not be used together), or\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only and lactational amenorrhea are not acceptable methods of contraception)\nEastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0-2\nExpected survival > 3 months from study enrollment\nWithin 3 days before the first dose of study drug: albumin > 2.7 g/dL\nWithin 3 days before the first dose of study drug: total bilirubin < upper limit of normal (ULN)\nWithin 3 days before the first dose of study drug: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN\nWithin 3 days before the first dose of study drug: creatinine clearance > 50 mL/min\nWithin 3 days before the first dose of study drug: hemoglobin > 8 g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed\n\nPatients with previously untreated AML (except acute promyelocytic leukemia [APL]) who have at least one of the following:\n\nAdverse genetic features as per the European Leukemia Net guidelines\nTreatment related AML or AML with antecedent myelodysplastic syndrome (MDS); (patient who have received treatment with hypomethylating agents for MDS and have now transformed to AML are eligible)\nAre over the age of 55 years and considered fit for chemotherapy\nPatients with AML with MDS-related changes\nPatients must be considered candidates for intensive chemotherapy treatment with standard doses of cytarabine and anthracycline regimen (?7+3 regimen?)\nWhite blood cell (WBC) count < 50,000/uL before administration of pevonedistat on cycle 1 day 1; Note: hydroxyurea may be used to control the level of circulating leukemic blast cell counts to not lower than 10,000/uL during the study\n\nExclusion Criteria:\n\nKnown cardiopulmonary disease defined as one of the following:\n\nUncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg)\nCardiomyopathy or history of ischemic heart disease\nArrhythmia (eg, history of polymorphic ventricular fibrillation or torsade de pointes); however, patients with < grade 3 atrial fibrillation (a fib) for a period of at least 6 months may enroll; grade 3 a fib is symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation; patients with paroxysmal a fib are permitted to enroll\nImplantable cardioverter defibrillator\nCongestive heart failure (New York Heart Association [NYHA] class III or IV; or class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within 4 weeks before screening), myocardial infarction and/or revascularization (eg, coronary artery bypass graft, stent) within 6 months of first dose of study drug\nPatients who had ischemic heart disease who have had acute coronary syndrome (ACS), myocardial infarction (MI), and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll\nModerate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing)\nPulmonary hypertension\nProlonged rate corrected QT (QTc) interval >= 500 msec, calculated according to institutional guidelines\nLeft ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography\nKnown moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis\nAny serious medical or psychiatric illness that could, in the investigator?s opinion, potentially interfere with the completion of study procedures\nTreatment with any investigational products within 14 days before the first dose of any study drug\nPatients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug with the exception of: hydroxyurea (HU) in patients who need to continue this agent to maintain WBC count =< 50,000/mm^3\nActive uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, septicemia, or methicillin resistant staphylococcus aureus infection\nMajor surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period\nDiagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection\nLife-threatening illness unrelated to cancer\nPatients with uncontrolled coagulopathy or bleeding disorder\nKnown central nervous system (CNS) involvement\nKnown human immunodeficiency virus (HIV) seropositive\n\nKnown hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection\n\nNote: patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load\nKnown hepatic cirrhosis or severe pre-existing hepatic impairment\nSystemic antineoplastic therapy or radiotherapy within 14 days before the first dose of any study drug, except for hydroxyurea\nTreatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of the study drug; clinically significant metabolic enzyme inducers are not permitted during this study\nPatients who refuse to potentially receive blood products and/or have a hypersensitivity to blood products\nPatients with history of allergic or toxic reactions attributed to cytarabine or a history of allergic reactions to components of the formulated product\nPatients with history of allergic or toxic reactions attributed to anthracyclines or a history of allergic reactions to components of the formulated product\nPatients who have had prior chemotherapy for AML\nFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)\nFemale patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drug (if applicable)\nMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatient age 0-75 years at the time of enrollment. Initially only patients who are >= 16 years old will receive HA-1-TCR T cell infusions on the protocol. Younger patients may be screened, enrolled in the protocol and monitored for relapse but will not be eligible for infusion until at least one patient >=16 years old has been treated and discussed with the Food and Drug Administration (FDA)\nPatients must express HLA-A*0201\nPatients must have the HA-1(H) genotype (RS_1801284: A/G, A/A)\n\nPatients must have an adult donor for HCT who is adequately HLA matched by institutional standards (includes HLA-matched related or unrelated donors, and HLA-mismatched family donors, including haploidentical donors) and is either:\n\nHLA-A*0201 positive and HA-1(H) negative (RS_1801284: G/G) or\nHLA-A*0201 negative\n\nPatients who are currently undergoing or who previously underwent allogeneic HCT for\n\nAcute myeloid leukemia (AML) of any subtype\nAcute lymphoid leukemia (ALL) of any subtype\nMixed phenotype/undifferentiated/any other type of acute leukemia, including blastic plasmacytoid dendritic cell neoplasm\n\nChronic myeloid leukemia with a history of blast crisis and:\n\nWith relapse or refractory disease (>= 5% marrow blasts, or circulating blasts) at any time after HCT\nWith persistent rising minimal residual disease (defined as detectable disease by morphology, flow cytometry, molecular or cytogenetic testing but < 5% marrow blasts by morphology, no circulating blasts on >= 2 of two consecutive tests), refractory or ineligible for treatment with tyrosine kinase inhibitors at any time after HCT\nMyelodysplastic syndrome (MDS) of any subtype\nChronic myelomonocytic leukemia (CMML)\nJuvenile myelomonocytic leukemia (JMML)\nPatients must be able to understand and be willing to give informed consent; decision-impaired adults may consent with their legally authorized representative; parent or legal representative will be asked to consent for patients younger than 18 years old\nPatients must agree to participate in long-term follow-up for up to 15 years if they are enrolled in the study and receive T cell infusion\nPatients who have relapsed or have MRD after HCT may receive other agents for treatment of disease and remain eligible for the protocol\nA specific performance status score is not required for enrolling on the protocol; a delay in infusion of the HA-1 TCR T cells may be required for patients with low performance status\n\nDONOR SELECTION INCLUSION\n\nDonor age >= 18 years\nDonors must be able to give informed consent\n\nPatients must have an adult donor for HCT who is adequately HLA matched by institutional standards (includes HLA-matched related or unrelated donors, and HLA-mismatched family donors, including haploidentical donors) and is either:\n\nHLA-A*0201 positive and HA-1(H) negative (RS_1801284: G/G) or\nHLA-A*0201 negative\n\nExclusion Criteria:\n\nMedical or psychological conditions that would make the patient unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)\nFertile patients unwilling to use contraception during and for 12 months after treatment\nPatients with a life expectancy < 3 months of enrollment from coexisting disease other than leukemia\nPatients who develop grade IV acute GVHD or severe chronic GVHD following most recent transplant prior to enrollment on the protocol\nThe presence of organ toxicities will not necessarily exclude patients from enrolling on the protocol at the discretion of the PI; however, a delay in the infusion of HA-1 TCR T cells may be required\n\nDONOR SELECTION EXCLUSION\n\nDonors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection\nUnrelated donor residing outside of the United States of America (USA) unless the donor screening, testing and leukapheresis occur at an NMDP-affiliated and qualified donor center and are facilitated by the NMDP."
            },
            {
                  "document": "-Inclusion Criteria:\n\nAge: \u2264 60 years of age\nPerformance Status: Karnofsky \u2265 80%, Lansky play score \u2265 70\nConsent: Voluntary written consent (adult or legally authorized representative; or parental/guardian)\n\nAdequate Organ Function:\n\nRenal: Creatinine <2x upper limit of normal. Patients above this limit must have creatinine clearance \u2265 40 ml/min/1.73m2 as determined by an age-appropriate method, such as cystatin C GFR.\nHepatic: Bilirubin, AST, alkaline phosphatase <4 times the upper limit of institutional normal\nPulmonary: Diffusion capacity of oxygen, corrected for hemoglobin, > 50% of predicted. For pediatric patients not able to undergo PFTs or diffusion testing: O2 sat of >95% on room air\nCardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 45%. For children not able to cooperate with MUGA or echocardiography, such should be clearly stated in the physician's documentation\nHIV Status: HIV infection with undetectable viral load. All HIV+ patients must be evaluated by Infectious Disease (ID) and a HIV management plan establish prior to transplantation\n\nOther Inclusion Criteria:\n\nWomen of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment.\nDonor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program\nEligible Diseases and Status: Patients are eligible unless their treatment is to be guided by a higher priority protocol.\nAcute Leukemias: Must be in remission by morphology (\u22645% blasts). Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse.\nAcute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in \u2264 60 years old that is NOT considered as favorable-risk.\n\nFavorable risk AML is defined as having one of the following:\n\nt(8,21) without cKIT mutation\ninv(16) or t(16;16) without cKIT mutation\nNormal karyotype with mutated NPM1 and wild type FLT-ITD\nNormal karyotype with double mutated CEBPA\nAcute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation\nVery high risk pediatric patients with AML: Patients <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy.\nAcute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL.\n\nHigh risk ALL is defined as having one of the following:\n\nEvidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1\n30 years of age or older at diagnosis\nWhite blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis\nCNS leukemia involvement during the course of disease\nSlow cytologic response (>10% lymphoblasts in bone marrow on Day 14 of induction therapy)\nEvidence of persistent immonophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapy\nVery high risk pediatric patients with ALL: patients <21 years are also considered high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction or M3 marrow at the end of induction. They are eligible once they achieve a complete remission.\nChronic Myelogenous Leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to one or more tyrosine kinase inhibitors.\nPlasma Cell Leukemia after initial therapy, in patients who have achieved at least a partial remission\nMyeloproliferative Neoplasms/Myelofibrosis, either primary as a result of polycythemia vera or essential thrombocythemia, with disease risk of intermediate or high-risk according to DIPSS criteria. Blasts must be <10% by bone marrow aspirate morphology.\nMyelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features. Blasts must be < 10% by a representative bone marrow aspirate morphology.\nChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone B-Cell Lymphoma or Follicular Lymphoma are eligible if there was disease progression/relapse within 12 of achieving a partial or complete remission. Patients who had remissions lasting > 12 months, are eligible after at least two prior therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before transplant.\nLymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy in CR1+ or PR1+.\nDiffuse large Cell NHL > CR/> PR: Patients in CR/PR with initial short remission (<6 months) are eligible, or those who have failed/or are not eligible for autologous transplant.\nLymphoblastic Lymphoma, Burkitt's Lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year.\nMultiple Myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or \u03b2-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapy.\nJuvenile myelomonocytic leukemia\nBiphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR.\nMRD positive leukemia (AML, ALL or accelerated/blast phase CML). Selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative status.\nNatural Killer Cell Malignancies\nAcquired Bone Marrow Failure Syndromes except for Fanconi Anemia or Dyskeratosis Congenita\nOther Leukemia Subtypes: A major effort in the field of hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee.\n\nExclusion Criteria:\n\nChemotherapy refractory large cell and high grade NHL (i.e., progressive disease after > 2 salvage regimens)\nCML in blast crisis\nLarge cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on salvage therapy.\nEvidence of progressive disease by imaging modalities or biopsy - persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression.\nActive central nervous system malignancy\nif \u2264 18 years old, prior myeloablative transplant within the last 6 months. If >18 years old prior myeloablative allotransplant or autologous transplant\nActive HIV infection or known HIV positive serology\nactive uncontrolled infection\nPregnant or breastfeeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with AML receiving non-intensive therapy including hypomethylating agents, single-agent chemotherapy, targeted therapy agents, or single or combination non-intensive agents offered on a clinical trial, including the following populations:\n\nNewly diagnosed AML\nRelapsed AML\nPrimary refractory AML\nThe ability to provide informed consent\nThe ability to comprehend English or complete questionnaires with minimal assistance of an interpreter\n\nExclusion Criteria:\n\nPatients not receiving care at MGH\nPatients receiving intensive chemotherapy (requiring 4-6 week hospitalization)\nPatients receiving supportive care alone\nMajor psychiatric illness or co-morbid conditions prohibiting compliance with study procedures\nPatients already receiving palliative care"
            },
            {
                  "document": "Inclusion Criteria:\n\nAble to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before the first study-specific procedure; specifically able to comply with the PK assessment schedule during the first 2 treatment cycles.\n\nMen or women \u226518 years who are candidates to receive IV decitabine according to FDA or European Medicines Agency (EMA) approved indications:\n\nIn North America: Participants with MDS previously treated or untreated with de novo or secondary MDS, including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic Scoring System (IPSS) int-1, -2, or high-risk MDS.\nIn Europe: Participants with de novo or secondary AML, as defined by the World Health Organization (WHO) criteria, who are not candidates for standard induction chemotherapy.\nEastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\nAdequate organ function defined as follows:\n\nHepatic: Total or direct bilirubin \u22642 \u00d7 upper limit of normal (ULN); aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) \u22642.5 \u00d7 ULN.\nRenal: serum creatinine \u22641.5 \u00d7 ULN or calculated creatinine clearance or glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.\nNo major surgery within 30 days of first study treatment.\nLife expectancy of at least 3 months.\nWomen of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of non-childbearing potential are those who have had a hysterectomy or bilateral oophorectomy, or who have completed menopause, defined as no menses for at least 1 year AND either age \u226565 years or follicle-stimulating hormone levels in the menopausal range.\nSubjects and their partners with reproductive potential must agree to use effective contraceptive measures during the study and for 3 months after the last dose of study treatment. Effective contraception includes methods such as oral contraceptives or double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\n\nExclusion Criteria:\n\nPrior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC) counts.\nHospitalization for more than 2 days for documented febrile neutropenia, pneumonia, sepsis, or systemic infection in the 30 days before screening.\nTreatment with any investigational drug or therapy within 2 weeks of study treatment, or 5 half-lives, whichever is longer, before the first dose of study treatment, or ongoing clinically significant adverse events (AEs) from previous treatment.\nCytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose of study treatment.\nConcurrent MDS therapies, including lenalidomide, erythropoietin, cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these agents is permitted, provided that completion is at least 1 week before the first dose of study treatment.)\nPoor medical risk because of other conditions such as uncontrolled systemic diseases, active uncontrolled infections, or comorbidities that may put the patient at risk of not being able to complete at least 2 cycles of treatment.\nKnown significant mental illness or other condition, such as active alcohol or other substance abuse or addiction, that in the opinion of the investigator predisposes the subject to high risk of noncompliance with the protocol.\nRapidly progressive or highly proliferative disease (total white blood cell count of >15 \u00d7 10^9/L) or other criteria that render the subject at high risk of requiring intensive cytotoxic chemotherapy within the next 3 months.\nLife-threatening illness or severe organ system dysfunction, such as uncontrolled congestive heart failure or chronic obstructive pulmonary disease, or other reasons including laboratory abnormalities, which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ASTX727, or compromise completion of the study or integrity of the study outcomes.\nPrior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer or breast cancer under control with hormone therapy, or other cancer from which the subject has been disease free for at least 2 years."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge > 1 month and < 26 years\nLife expectancy > 10 weeks\nSubjects deemed eligible for allogeneic stem cell transplantation.\nSubjects with life-threatening hematological malignancies (high-risk ALL in 1st CR, ALL in 2nd or subsequent CR, AML in 1st CR, AML in 2nd or subsequent CR, myelodysplastic syndromes, non-Hodgkin lymphomas in 2nd or subsequent CR, other hematologic malignancies eligible for stem cell transplantation per institutional standard);\n\nNon-malignant disorders amenable to cure by an allograft:\n\nprimary immune deficiencies,\nsevere aplastic anemia not responding to immune suppressive therapy,\nosteopetrosis,\nhemoglobinopathies, (thalassemias, and sickle cell anemia, and Diamond-Blackfan anemia among others)\ncongenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML) Note: Subjects will be eligible if they meet either item 4 OR item 5.\nLack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative or 10/10 unrelated donor evaluated using high resolution molecular typing) or presence of rapidly progressive disease not permitting time to identify an unrelated donor\nA minimum genotypic identical match of 5/ 10 is required.\nThe donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA- DRB1 and HLA-DQB1.\nLansky/Karnofsky score > 50\nSigned written informed consent\n\nExclusion Criteria:\n\nGreater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at the time of inclusion\nSubject receiving an immunosuppressive treatment for GVHD treatment due to a previous allograft at the time of inclusion\nDysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance < 30 mL / min)\nSevere cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)\nCurrent active infectious disease (including positive HIV serology or viral RNA)\nSerious concurrent uncontrolled medical disorder\nPregnant or breastfeeding subject\nFor subjects who have received more than 1 x 10E5 alpha/beta T cells/kg with the graft infusion the clinical trial site must contact the sponsor for approval to be eligible to receive BPX-501 infusion."
            },
            {
                  "document": "Inclusion Criteria:\n\nPRE-REGISTRATION ELIGIBILITY CRITERIA\nNewly diagnosed acute myeloid leukemia (AML) associated with antecedent myeloproliferative disorder (polycythemia vera, essential thrombocythemia, myelofibrosis, atypical chronic myeloid leukemia, chronic myelomonocytic leukemia and related undifferentiated myeloproliferative/myelodysplastic disorders)\nRelapsed/refractory AML associated with antecedent myeloproliferative disorder (polycythemia vera, essential thrombocythemia, myelofibrosis, atypical chronic myeloid leukemia, chronic myelomonocytic leukemia and related undifferentiated myeloproliferative/myelodysplastic disorders) who have received two or fewer prior induction chemotherapy courses\n\nAccelerated phase myeloproliferative disorders per Zeider et al with two or fewer prior therapies\n\nFor aggressive phase myeloproliferative disorders (MPD) (polycythemia vera, essential thrombocythemia, Philadelphia [Ph]-negative chronic myelogenous leukemia), one or more of the following criteria must be met: marrow blasts > 5%, peripheral blood blasts plus progranulocytes > 10%, new onset or increasing myelofibrosis, new onset or > 25% increase in hepatomegaly or splenomegaly, new onset constitutional symptoms (fever, weight loss, splenic pain, bone pain). Zeider et al\nFor chronic myelomonocytic leukemia (CMML), the following criteria must be met: 5-19% bone marrow blasts (aggressive) or >= 20% marrow blasts (transformation)\nBone marrow and/or peripheral blood specimens will be submitted for correlative studies; patients with a dry tap will still be eligible\nRANDOMIZATION ELIGIBILITY CRITERIA\nBone marrow aspirate and/or peripheral blood specimens were submitted to the central lab and site has confirmation by the local institution that the patient meets one of the criteria specified above\nEastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofsky >= 60%\nTotal bilirubin less than 2.0 mg/dL unless due to Gilbert's syndrome, then less than 5.0 mg/dL\nAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) less than 5 x institutional upper limit of normal\nCreatinine clearance glomerular filtration rate (GFR) greater than 30 ml/min per modified Cockcroft-Gault formula\nInterval of greater than 4 weeks since allogeneic blood or marrow transplantation (BMT) if performed; and absence of active graft versus host disease (GVHD)\nThe effects of veliparib on the developing human fetus are unknown; for this reason and because PARP inhibiting agents as well as topoisomerase inhibitors and platinating agents are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months following the last dose of study drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of veliparib administration\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study with the exception of hydroxyurea for cytoreduction; therapy with tyrosine kinase inhibitors (TKIs) directed against JAK2, BCR-ABL or FLT3 will be allowed to be continued until 24 hours prior to start of therapy on trial\nPatients with active uncontrolled infection; antibiotic therapy for fevers, and continuation of treatment of prior infection are allowed\nPatients who have active central nervous system (CNS) disease are excluded; patients with known active CNS leukemia should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events\nPatients who are receiving any other investigational agents; patients who have completed therapy with an investigational agent should be off this therapy for at least 5 half-lives or two weeks, whichever is shorter\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib, topotecan or carboplatin\nUncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPregnant women are excluded from this study because veliparib is PARP inhibiting agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with veliparib, breastfeeding should be discontinued if the mother is treated with veliparib; these potential risks may also apply to topotecan and carboplatin used in this study\nHuman immunodeficiency virus (HIV)-patients positive patients are not excluded if they have CD4+ cells >= 250/mm^3 and negligible viral load and are on a stable combination antiretroviral therapy\nHistory of uncontrolled seizure disorder, including focal or generalized seizure within the past year"
            },
            {
                  "document": "Inclusion Criteria:\n\nAcute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS) in confirmed relapse\nConfirmation of 'measurable disease'\nPatient may not have received definitive salvage chemotherapy for their post-transplant relapse within the past 21 days.\nBe willing and able to provide written informed consent/assent for the trial\nBe \u2265 18 years of age on day of signing informed consent\nBe willing to provide tissue from bone marrow biopsies\nHave a performance status of 0, to 1 on the ECOG Performance Scale. Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death.\nDemonstrate adequate organ function\nFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication.\nFemale subjects of childbearing potential must be willing to use an adequate method of contraception\nMale subjects of childbearing potential must agree to use an adequate method of contraception\n\nExclusion Criteria:\n\nHas had relapse prior to primary neutrophil engraftment or \u226421 days post HCT.\nHas received >1 line of chemotherapy or other treatment directed towards post-transplant relapse prior to study entry\nRapidly progressive relapse requiring urgent chemotherapy as determined by treating physician\nIs currently participating and receiving study therapy of an investigational agent and received study therapy within 2 weeks of the first dose of treatment.\nHas a diagnosis of active GvHD (\u2265 Grade I)\nReceiving systemic steroid therapy of > 10mg prednisone daily or equivalent*\nHas received GM-CSF within 14 days of first dose of pembrolizumab\nHas a known history of active TB (Bacillus Tuberculosis)Hypersensitivity to pembrolizumab or any of its excipients\nHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered from adverse events\nHas had prior chemotherapy within 21 days or radiation therapy within 14 days prior to study Day 1 or who has not recovered from adverse events\nHas a known additional (secondary) malignancy that is progressing or requires active treatment\nHas known or suspected active central nervous system (CNS) metastases and/or carcinomatous meningitis\nHas a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis\nHas a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\nIs pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial\nHas received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent\nHas a known history of Human Immunodeficiency Virus (HIV)\nHas known active Hepatitis B or Hepatitis C\nHas received a live vaccine within 30 days of planned start of study therapy"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatient with disease (stage) eligible per cohort\n\nCOHORT 1: patients undergoing high dose chemotherapy with autologous stem cell rescue and ?high-risk? disease as defined below:\n\nDiffuse large cell lymphoma or peripheral T cell lymphoma (including specified World Health Organization [WHO] subtypes) not in computed tomography (CT)-positron emission tomography (PET) complete remission at time of high dose therapy\nDiffuse large cell lymphoma with ?double hit? or ?double expressor? features\nDiffuse large cell lymphoma or peripheral T cell lymphoma (including WHO specified subtypes) refractory to standard induction therapy OR relapsing within 1 year of treatment OR in greater that second complete remission (CR)\nMantle cell lymphoma not in CR1\n\nMultiple myeloma with ONE (or more) of the following high risk features:\n\nLess than very good partial remission at time of high dose therapy\nHigh Revised-International Staging System (R-ISS) (stage III ? 2 microglobulin >= 5.5 plus lactate dehydrogenase [LDH] > upper limit of normal [ULN] and/or del17p, t(4;14), t(14;16)) at time of diagnosis\nCytogenetics or fluorescent in situ hybridization (FISH) del17p\n\nCOHORT 2: patients with high risk disease having undergone an allogeneic hematopoietic stem cell transplant from a 10/10 human leukocyte antigen (HLA) matched donor with one of the following disease subtypes:\n\nAcute myeloid leukemia (AML) in CR1 with high risk features (European Leukemia Network [ELN]) at presentation\n\nDiagnostic sample with either t(6;9), t(9;22), 11q23, inv 3, -5, -7, del17p, complex cytogenetics, NPMwt-flt3ITD+, OR p53 mutation (mut); patients whose samples have mutations in RUNX1 or ASXL1 are also eligible (unless the patient has favorable cytogenetics)\nAML in CR1 with measurable minimal residual disease (MRD) by molecular (e.g., myeloid mutation profile, polymerase chain reaction [PCR] for NPM1, core-binding factor [CBF], mixed lineage leukemia [MLL]) or flow cytometry\nAML not in CR1 (including patients with morphologic CR but with incomplete recovery, CRi)\nMyelodysplastic syndrome (MDS) with complex cytogenetics, 17p deletion or p53 mutation, or JAK2 or RAS mutation\nTreatment-related MDS or AML\nAcute lymphoblastic leukemia (ALL) not in CR1\nALL with MRD\nAny hematologic malignancy relapsed or with persistent disease after allogeneic hematopoietic stem cell transplant\nMultiple myeloma\nNon-Hodgkin lymphoma (NHL) with chemoresistant disease at time of transplant\nAny patient undergoing allogeneic hematopoietic stem cell transplant and an anticipated rate of relapse > 80% based upon published data and for which there is consensus amongst the Hematologic Malignancies Tumor Study Group that enrollment is appropriate\nAvailability of a genetic child, genetic parent or sibling as a potential HLA haploidentical donor\nMeets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT 1) or allogeneic hematopoietic stem cell transplant (COHORT 2) and has signed consent for those procedures\nDONOR: Donor must be related to patient and be partially (>= 3/6 antigen) HLA-matched\n\nDONOR: Donor must meet all Robert Wood Johnson (RWJ) Blood Services requirements for hematopoietic stem cell donation including:\n\nAge >= 18 years old;\nNormal hemogram (white blood cells [WBC] 4.0-10.0 x 10^3/mm^3; platelet count 150,000 to 440,000/mm^3 ; hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%\nNot pregnant or lactating;\nNot human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-cell lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by RWJ Blood Services;\nNo uncontrolled infections, other medical or psychological/social conditions, or medications that might increase the likelihood of patient or donor adverse effects or poor outcomes;\nMeet other blood bank criteria for blood product donation (as determined by RWJ Blood Center screening history and laboratory studies)\n\nExclusion Criteria:\n\nNon-English speaking person\nPatients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing < 10/10 HLA allele matched allogeneic transplant are not eligible\nPregnant women\nDONOR: Non-English speaking person\nDONOR: Pregnant women"
            },
            {
                  "document": "Inclusion Criteria:\n\nINCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT)\nDiagnosis of acute myeloid leukemia (AML), acute biphenotypic leukemia, or acute lymphoblastic leukemia (ALL); CML transformed to blast crisis is eligible\nPlanned allogeneic HCT using fludarabine phosphate (FLU)/melphalan hydrochloride (MEL) or FLU/busulfan (BU) conditioning\nPlanned graft versus host disease (GVHD) prophylaxis consisting of tacrolimus (TAC)/methotrexate (MTX) or TAC/sirolimus (SRL)\nHuman leukocyte antigen (HLA) identical sibling donor, HLA matched unrelated donor, or donor mismatched at 1 HLA allele or antigen\nLess than or equal to 5% blasts on bone marrow examination within 60 days of starting conditioning\nAge >= 18 years and =< 70 years\nAble to give informed consent\n\nSubjects will be eligible if their planned conditioning regimen for allogeneic HCT consists of one of the two following standard reduced intensity conditioning regimens:\n\nFLU/MEL: fludarabine phosphate (fludarabine) 120 to 180 mg/m^2; melphalan hydrochloride (melphalan) =< 150 mg/m^2\nFLU/BU: fludarabine 120 to 180 mg/m^2; busulfan =< 8 mg/kg orally or =< 6.4 mg/kg intravenously\n\nSubjects will be eligible if their planned post grafting immunosuppression consists of one of the two following regimens:\n\nTAC/MTX: tacrolimus (oral or intravenous) and intravenous methotrexate administered according to institutional standard practice.\nTAC/SRL: tacrolimus (oral or intravenous) and oral sirolimus, administered according to institutional standards of care\nINCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION)\nAge >= 18 years\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2\nAbsolute neutrophil count (ANC) > 0.75 x 10^9/L\nPlatelet count > 50 x 10^9/L\nHemoglobin > 8.0 g/dL without transfusion or growth factor support for at least 7 days prior to screening (with the exception of pegylated granulocyte-colony stimulating factor [G-CSF] and darbopoietin, which require at least 14 days of abstinence prior to screening)\nSerum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal\nEstimated creatinine clearance >= 30 mL/min via Cockroft-Gault formula\nBilirubin =< 1.5 x upper limit of normal (unless elevated bilirubin is due to Gilbert's syndrome or of non-hepatic origin)\nProthrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) =< 1.5 x upper limit of normal\nFemale subjects who are of non-reproductive potential (ie, post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy); female subjects of childbearing potential must have a negative serum pregnancy test upon screening\nMale and female subjects who agree to use both a highly effective method of birth control (eg, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], sexual abstinence, or sterilized partner) and a barrier method (eg, condoms, vaginal ring, sponge, etc) during the period of therapy and for 30 days after the last dose of study drug for females and 90 days after the last dose of the study drug for males\nBetween day +60 and day +90 after allogeneic HCT\n\nExclusion Criteria:\n\nEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active involvement of the central nervous system with malignancy (previous central nervous system [CNS] involvement is allowed if clearance of CNS disease has been documented prior to enrollment)\nEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Pregnant or breastfeeding\nEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Karnofsky performance status < 60%\nEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active leukemia (> 5% leukemic blasts in peripheral blood or bone marrow)\nEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Non-hematologic malignancy with a life expectancy of < 5 years\nEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection; subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment; those who are PCR positive will be excluded\nEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Known bleeding disorders (eg, von Willebrand's disease) or hemophilia\n\nEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): History of other malignancies, except:\n\nMalignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\nAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated carcinoma in situ without evidence of disease\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Active and uncontrolled acute GVHD grades III or IV\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Use of secondary therapy for acute GVHD at any time (defined as any systemic therapy intended to treat acute GVHD besides corticosteroids)\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Requirement for anticoagulation with warfarin or other vitamin K antagonists (concomitant use of other anticoagulants is permitted)\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Relapsed leukemia (> 5% leukemic blasts in peripheral blood or bone marrow after allogeneic HCT)\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Karnofsky performance status < 60%\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): History of stroke or intracranial hemorrhage within 6 months prior to screening\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Any life threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Major surgery within 4 weeks of first dose of study drug\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Any uncontrolled active systemic infection\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unresolved toxicities from prior anti cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unwilling or unable to participate in all required study evaluations and procedures\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations)\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Currently active, clinically significant hepatic impairment (Child-Pugh class B or C)\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Lactating or pregnant\nEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Uncontrolled cardiac arrhythmias"
            },
            {
                  "document": "Inclusion Criteria:\n\nConfirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification\nPresence of FLT3-ITD and/or D835 mutation(s) in bone marrow or peripheral blood\nAge \u2265 18 years and \u2264 60 years\nAdequate hepatic function within 48 hours prior to induction chemotherapy\nAdequate renal functions within 48 hours prior to induction chemotherapy\nECOG performance status within 48 hours prior to induction chemotherapy \u2264 3\nEligible for intensive cytarabine/daunorubicin (7+3) chemotherapy specified\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia (APL)\nKnown clinically active central nervous system (CNS) leukemia\nSevere liver disease\nActive infections\nKnown, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)\nKnown infection with human immunodeficiency virus (HIV)\nPrior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of acute myeloid leukemia (\u226520% of blasts in the bone marrow)\n\nPreviously untreated AML\n\nAML de novo\nAML secondary to the myelodysplastic syndromes (MDS)\nAML secondary towards used therapies or agents, which can induce leukemia (e.g., irradiation, alkylating drugs, topoisomerase II inhibitors) with a primary tumor in remission for at least 2 years.\nAge \u2265 18 years and \u226460 years while signing a written consent form\n\nA clinical condition allowing induction treatment to be performed\n\nGeneral state according to the ECOG \u2264 2 scale (Annex 1)\nIndex of comorbidities, HCT-CI \u2264 3, according to Sorror et al. (43) (Annex 2)\n\nNormal function of the liver and kidneys defined as:\n\nBilirubin of \u22641.5 of the upper limit of the normal range\nALT \u22642.5 x of the upper limit of the normal range\nAST \u22642.5 x of the upper limit of the normal range\nCreatinine \u22641.5 of the upper limit of the normal range\nA negative pregnancy test result in women of reproductive age, or women after menopause\nThe patient has understood and signed an informed consent form (Annex 3)\nThe patient has given consent to adhere to scheduled appointments in the study and the remaining protocol requirements.\n\nExclusion Criteria:\n\nDiagnosis or suspicion of acute promyelocytic leukemia (APL)\nLack of consent for participation in the study\nActive cancerous disease other than AML (with the exception of carcinoma basocellulare cutis)\nDiagnosis of unstable angina pectoris, significant cardiac arrhythmia or class III or IV congestive heart failure according to the New York Heart Association (NYHA) functional classification\nPregnancy\nUncontrolled mycotic, bacterial or viral systemic infection\nActive HIV, or hepatitis B or C virus infection\nThe use of another form of experimental therapy within 28 days of the commencement of treatment\nThe presence of another comorbidity or improper study results which could expose the patient to excessive hazard (HCT-CI>3)\nAny other serious health disorders, abnormal results of laboratory tests or mental disorders which would interfere with participation in the study\nThe presence of other comorbidities which would disturb the interpretation of the data obtained in the study."
            },
            {
                  "document": "Inclusion Criteria:\n\nConfirmed diagnosis of AML according to World Health Organization (WHO) 2016 classification\nPresence of FLT3-ITD and/or D835 mutation(s)\nSubjects must be primary refractory or relapsed to 1st line intensive treatment for AML or refractory or relapsed after second line of treatment for AML\nAge \u2265 18 years and \u2264 75 years\nAdequate hepatic function\nAdequate renal functions\nECOG performance status \u2264 3\n\nExclusion Criteria:\n\nKnown clinically active central nervous system(CNS) leukemia\nSevere liver disease\nKnown, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)\nPrior anti-leukemia therapy within the 14 days prior to randomization. Prior use of quizartinib or gilteritinib must be discontinued 21 days prior to randomization. Prior use of hydroxyurea or other palliative treatment for leukocytosis is allowed.\nPrevious treatment with crenolanib or prior participation in clinical trial involving crenolanib."
            },
            {
                  "document": "Inclusion Criteria:\n\nAge >= 18 and =< 70 years\nPatients with acute myeloid leukemia both flt3 positive and negative\nHuman leukocyte antigen (HLA)-identical sibling or 8/8 matched unrelated donor available\nLife expectancy of at least 12 weeks (3 months)\nDirect bilirubin =< 1 mg/dL\nAlanine transaminase (ALT) =< 3 x upper limit of normal\nSerum creatinine =< 1.5 x the upper limit of normal\nCreatinine clearance >= 50\nDiffusing capacity for carbon monoxide (DLCO) > 50% of predicted corrected for hemoglobin\nLeft ventricular ejection fraction (LVEF) >= 50%\nSubjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure\nWomen of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test\nSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 30 days after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate\nSubject must be able to swallow and retain oral medication\n\nExclusion Criteria:\n\nAcute myeloid leukemia in first complete molecular remission and favorable risk disease as defined by presence of t(8:21) or inv (16)\nPatients with a comorbidity score > 3. The principal investigator is the final arbiter of eligibility for comorbidity score > 3\nUncontrolled hypertension (systolic pressure > 140 mm Hg or diastolic pressure > 90 mm Hg [NCI-Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0] on repeated measurement) despite optimal medical management\n\nActive or clinically significant cardiac disease including:\n\nCongestive heart failure - New York Heart Association (NYHA) > class II\nActive coronary artery disease\nCardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin\nUnstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization\nEvidence or history of bleeding diathesis or coagulopathy. Patients with bleeding due to prior thrombocytopenia are permitted\nSubject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v. 4.0 grade 2 or higher within 4 weeks before randomization; any other hemorrhage/bleeding event of NCI-CTCAE v. 4.0 grade 3 or higher within 4 weeks before randomization\nSubjects with thrombotic, embolic, venous, or arterial cerebrovascular event (including transient ischemic attacks) within 6 months of informed consent\nSubjects who have used strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, phenobarbital, St. John's wort [Hypericum perforatum], dexamethasone at a dose of greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days before randomization\nSubjects with any previously untreated or concurrent cancer except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor. Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before randomization are allowed. All cancer treatments must be completed at least 3 years prior to study entry (i.e., signature date of the informed consent form)\nPresence of a non-healing wound, non-healing ulcer, or bone fracture\nHistory of organ allograft (including corneal transplant)\nKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial\nAny malabsorption condition\nWomen who are pregnant or breast-feeding\nInability to comply with the protocol and/or not willing or not available for follow-up assessments\nAny medical, psychological, or psychosocial condition which, in the investigator's opinion, makes the subject unsuitable for trial participation\nMajor surgery within 30 days prior to start of study drug\nPatients who received inotuzumab and/or gemtuzumab in the past\n\nTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids\n\nHowever, prophylactic anticoagulation as described below is allowed:\n\nLow dose warfarin (1 mg orally, once daily) with prothrombin time international normalized ratio (PT-INR). =< 1.5 x upper limit of normal (ULN) is permitted. Infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on sorafenib or capecitabine therapy. Therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes\nLow dose aspirin (=< 100 mg daily)\nProphylactic doses of heparin or low molecular weight heparin"
            },
            {
                  "document": "Inclusion Criteria:\n\nAges > 50 years with hematologic malignancies treatable by unrelated hematopoietic cell transplant (HCT)\nAges 18-50 years with hematologic diseases treatable by allogeneic HCT who through pre-existing medical conditions or prior therapy are considered to be at high risk for regimen related toxicity associated with a high dose transplant (> 40% risk of transplant related mortality [TRM]); this criterion can include patients with a hematopoietic cell transplant-comorbidity index (HCT-CI) score of > 3; transplants should be approved for these inclusion criteria by the principal investigators at the collaborating centers and at Fred Hutchinson Cancer Research Center (FHCRC)\nAges 18-50 years with chronic lymphocytic leukemia (CLL)\nAges 18-50 years with hematologic diseases treatable by allogeneic HCT who refuse a high-dose HCT; transplants must be approved for these inclusion criteria by the principal investigators at the collaborating centers and at FHCRC\nAggressive nonHodgkin lymphomas (NHL) and other histologies such as diffuse large B cell NHL- not eligible for autologous HCT, not eligible for high-dose allogeneic HCT, or after failed autologous HCT\nMantle cell NHL-may be treated in first complete remission (CR); (diagnostic lumbar puncture [LP] required pre-transplant)\nLow grade NHL - with < 6 month duration of CR between courses of conventional therapy\nCLL - must have either 1) failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing fludarabine (FLU) (or another nucleoside analog, e.g. cladribine [2-CDA], pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog); 2) failed FLU-cyclophosphamide (CY)-rituximab (FCR) combination chemotherapy at any time point; or 3) have \"17p deletion\" cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in 1st CR; or 4) patients with a diagnosis of CLL (or small lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL; 5) patients failing to achieve a response to ibrutinib as first-line therapy; 6) patients not responding to ibrutinib, idelalisib, or venetoclax as salvage therapy or intolerant of these agents as salvage therapy due to side effects; all CLL patients must have received prior myelosuppressive chemotherapy\nHodgkin lymphoma - must have received and failed frontline therapy\nMultiple myeloma - must have received prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted\nAcute myeloid leukemia (AML) - must have < 5% marrow blasts at the time of transplant\nAcute lymphocytic leukemia (ALL) - must have < 5% marrow blasts at the time of transplant\nChronic myeloid leukemia (CML) - patients in CP1 must have failed or be intolerant of tyrosine kinase inhibitors (TKIs); patients beyond CP1 will be accepted if they have < 5% marrow blasts at time of transplant\nMyelodysplasia (MDS)/myeloproliferative syndrome (MPS)/chronic myelomonocytic leukemia (CMML) - patients must have < 5% marrow blasts at time of transplant\nWaldenstrom's macroglobulinemia - must have failed 2 courses of therapy\nMixed Phenotype Acute Leukemia (MPAL) - must have < 5% marrow blasts at the time of transplant.\nBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - must be in complete remission at the time of transplant\n\nHLA-MATCHED UNRELATED DONOR: FHCRC matching allowed will be grades 1.0 to 2.1; unrelated donors who are prospectively:\n\nMatched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing;\nOnly a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing\nHLA-MATCHED UNRELATED DONOR: Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment; this determination is based on the standard practice of the individual institution; the recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT; if the PRA shows > 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained; the donor should be excluded if any of the cytotoxic cross match assays are positive; for those patients with an HLA Class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is an absolute donor exclusion\nHLA-MATCHED UNRELATED DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0102, and this type of mismatch is not allowed\nHLA-MATCHED UNRELATED DONOR: Only granulocyte colony-stimulating factor (G-CSF) mobilized PBSC will be permitted as a HSC source on this protocol\n\nHLA-MISMATCHED UNRELATED DONOR: Unrelated volunteer donors who are mismatched with the recipient within one of the following limitations:\n\nMismatch for one HLA class I antigen with or without an additional mismatch for one HLA-class I allele, but matched for HLA-DRB1 and HLA-DQ, OR\nMismatched for two HLA class I alleles, but matched for HLA-DRB1 and HLA-DQ\nHLA class I HLA-A, -B, -C allele matched donors allowing for any one or two DRB1 and/or DQB1 antigen/allele mismatch\nHLA-MISMATCHED UNRELATED DONOR: HLA-matching must be based on results of high resolution typing at HLA-A, -B, -C, - DRB1, and -DQ\nHLA-MISMATCHED UNRELATED DONOR: If the patient is homozygous at the mismatch HLA class I locus or II locus, the donor must be heterozygous at that locus and one allele must match the patient (i.e., patient is homozygous A*01:01 and donor is heterozygous A*01:01, A*02:01); this mismatch will be considered a one-antigen mismatch for rejection only\n\nExclusion Criteria:\n\nPatients with rapidly progressive intermediate or high grade NHL\nPatients with a diagnosis of chronic myelomonocytic leukemia (CMML) who have not received induction chemotherapy\nPatients with refractory anemia with excess blasts (RAEB) who have not received myelosuppressive chemotherapy i.e. induction chemotherapy and will receive conditioning Regimen B (fludarabine and total body irradiation [TBI]) will be excluded; patients with RAEB who have not received myelosuppressive chemotherapy but who will receive conditioning Regimen A are eligible for this study as long as other inclusion and exclusion criteria are met\nCNS involvement with disease refractory to intrathecal chemotherapy\nPresence of circulating blasts (in the blood) detected by standard pathology for patients with AML, ALL or CML\nPresence of >= 5% circulating leukemic blasts (in the blood) detected by standard pathology for patients with MDS/MPS/CMML\nFertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment\nFemales who are pregnant or breast-feeding\nPatients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than 20% chance of having disease recurrence within 5 years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy\nFungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month\n\nOrgan dysfunction\n\nCardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist\n\nPulmonary:\n\n** Diffusing capacity of the lungs for carbon monoxide (DLCO) < 40%, forced expiratory volume in the first second of breath (FEV1) < 40% and/or receiving supplementary continuous oxygen; when pulmonary function tests (PFTs) cannot be obtained, the 6-minute walk test (6MWT, also known as exercise oximetry) will be used: Any patient with oxygen saturation on room air of < 89% during a 6MWT will be excluded\n\nThe FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules\nLiver function abnormalities: Patients with clinical or laboratory evidence of liver disease would be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension; patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bridging fibrosis, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, or symptomatic biliary disease\nKarnofsky scores < 60\nPatient has poorly controlled hypertension and on multiple antihypertensives\nHuman immunodeficiency virus (HIV) positive patients\nActive bacterial or fungal infections unresponsive to medical therapy\nThe addition of cytotoxic agents for \"cytoreduction\" with the exception of tyrosine kinase inhibitors (such as imatinib), cytokine therapy, hydroxyurea, low dose cytarabine, chlorambucil, or Rituxan will not be allowed within three weeks of the initiation of conditioning\nPatients on hemodialysis\nDONOR: Donor (or centers) who will exclusively donate marrow\nDONOR: Donors who are HIV-positive and/or, medical conditions that would result in increased risk for G-CSF mobilization and harvest of peripheral blood stem cell (PBSC)\nDONOR: Patients who are homozygous at the mismatched HLA class I or II locus, the donor is excluded if homozygous at the mismatched locus (i.e., patient is homozygous A *01:01 and donor is homozygous A *02:01); this type of mismatch is considered a two-antigen mismatch and is not allowed"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must have relapsed or refractory cancer.\nParticipants must have adequate hepatic and kidney function.\nParticipants less than or equal to 16 years of age must have performance status of Lansky greater than or equal to 50% and participants greater than 16 years of age must have performance status of Karnofsky greater than or equal to 50%.\nParticipants with solid tumors (with the exception of neuroblastoma) must have adequate bone marrow function in Part 1.\nFor the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors must have evidence of BCL-2 expression (except participants with TCF3-HLF ALL).\n\nExclusion Criteria:\n\nParticipants with primary brain tumors or disease metastatic to the brain.\nParticipants who have central nervous system (CNS) disease with cranial involvement that requires radiation.\n\nParticipants who have received any of the following within the listed time frame, prior to the first dose of study drug\n\nInotuzumab ozogamicin or gemtuzumab ozogamicin within 30 days\nBiologic agent (i.e., antibodies) for anti-neoplastic intent within 30 days or 5 half-lives whichever is shorter.\nCAR-T infusion or other cellular therapy within 30 days\nAnticancer therapy including chemotherapy, radiation therapy, targeted small molecule agents, investigational agents within 14 days or 5 half-lives, whichever is shorter (Exceptions: Ph+ALL participants on Tyrosine Kinase Inhibitor (TKI) at Screening may enroll and remain on TKI therapy to control disease and TCF3-HLF ALL participants are allowed to have received chemotherapy within 14 days or 5 half-lives, whichever is shorter).\nSteroid therapy for anti-neoplastic intent within 5 days (with the exception of TCF3-HLF ALL participants).\nRequires ongoing hydroxyurea (hydroxyurea permitted up to first dose)\nParticipants who are less than 100 days post-transplant, or greater than or equal to 100 days post-transplant with active graft versus host disease (GVHD), or are receiving immunosuppressant therapy within 7 days prior to first dose of study drug.\nParticipants who are less than 6 weeks post-131 I-metaiodobenzylguanidine (mIBG) therapy.\n\nParticipants who have received the following within 7 days prior to the first dose of study drug:\n\nStrong and moderate Cytochrome P450 3A (CYP3A) inhibitors (Part 1 Dose Determination);\nStrong and moderate CYP3A inducers (Part 1 Dose Determination and Part 2 Cohort Expansion).\nParticipants who have not recovered from clinically significant adverse effect(s)/toxicity(s) of the previous therapy (Exception: Chemotherapy induced side effects that are expected to return to baseline in TCF3-HLF ALL participants).\nParticipants who have active, uncontrolled infections.\n\nParticipants with malabsorption syndrome or any other condition that precludes enteral administration.\n\nParticipants with recent positive test for SARS-CoV-2 (COVID-19) and no follow up test with negative result cannot be enrolled. Participants with contact to persons with COVID-19 and participants with signs and symptoms for COVID-19 infection must be tested before enrolling."
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of AML by World Health Organization (WHO) criteria. Patients with high risk myelodysplastic syndrome (MDS) as defined by the presence of >= 10% blasts are also eligible at the discretion of the principal investigator\nPatients older than 65 who are deemed fit to receive intensive chemotherapy by the treating physician will be eligible after discussion with the principal investigator (PI).\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2\nCreatinine clearance >= 30 mL/min based on the Cockcroft-Gault equation\nTotal bilirubin < 1.5 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement\nAbility to understand and provide signed informed consent\nMale subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug\nOnly patients who are relapsed, refractory, or intolerant of standard AML therapy will be eligible for Part 1 (minimum of 1 prior line of AML-directed therapy)\n\nExclusion Criteria:\n\nPatients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)\nPatients having received any prior BCL2 inhibitor therapy\nSubject has known active central nervous system (CNS) involvement with AML\nPatients with New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 40% by echocardiogram or multi-gated acquisition (MUGA) scan\nPatients with a history of myocardial infarction within the last 6 months or unstable / uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias\nPatients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C\nPatients with known dysphagia, short-gut syndrome, or other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orally\nSubject has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study\nSubject has a white blood cell count > 25 x 10{9}/L. (Note: hydroxyurea is permitted to meet this criterion)\nNursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception (a) appropriate method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)"
            },
            {
                  "document": "Inclusion Criteria:\n\nEligible diseases include:\n\nA. Acute Lymphoblastic Leukemia (B- or T-ALL)\n\nComplete Response (CR)1-ultra high risk features\n\nUnfavorable cytogenetics\nHypodiploidy\nInduction failure\nMinimal Residual Disease (MRD) positive after consolidation\n\nCR-2:\n\nAny of the high risk features listed in CR1\nB-ALL: any relapse considered eligible for transplant\nT- ALL\nCR-3-any\n\nB. Acute Myeloid Leukemia\n\nMRD >5% at day 22 induction 1\nMRD >0.1% after induction 2\nFLT/ITD with allelic ratio > 0.4 and MRD >0.1% at day 22 or 29 induction 1\nTranslocation (6:9), (8:6), (16:21), monosomy 7, monosomy 5, 5q\nM7 with KMT2A rearrangements, inv(16)(p13.3q24.3) [CBFA2T3-GLIS2] or t(11;12)(p15;p13) [NUP98-KDM5A]\nAML in 2nd or subsequent CR\nTherapy related or Secondary AML\nRefractory anemia with excess blasts (RAEB)2\n\nC. Myelodysplastic syndrome D. Mixed Phenotype Acute Leukemia MRD>1% after consolidation E. Non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL) beyond first remission\n\nAge \u22653 to \u226445 years old. Subjects 1 and 2 (in Cohort 1) will be \u2265 12 years old\nAvailable mismatched related donor (mMRD) or mismatched unrelated donor (mMUD), Human leukocyte antigen (HLA) matched 8/10 or 9/10\nLansky (age <16) or Karnofsky (age \u226516) performance status \u226580%\nAble and willing to provide written, signed informed consent (assent as appropriate)\n\nHave adequate organ function defined as the following:\n\nSerum Creatinine <1.5 X upper limit of normal (ULN) or 24-hour creatinine clearance >50 ml/min\nSerum bilirubin \u2264 2 x ULN\n\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST)\n\n\u226410 x ULN\n\nDiffusion Capacity of the Lungs (DLCO) >60% predicted (in children, O2 saturation >92% on room air)\nLeft ventricular ejection fraction >45% (in children, shortening fraction >26%)\nMale and female subjects of child bearing potential must agree to use an effective method of birth control to avoid pregnancy throughout the transplant procedure, while on immunosuppression, and if the subject experiences any chronic GvHD.\n\nExclusion Criteria:\n\nPrior bone marrow or peripheral blood HSCT within the last 6 (six) months\nHLA-matched related or unrelated donor available\nAny active, uncontrolled infection at the time of enrollment\nPregnant or lactating females\nAny severe concurrent disease which, in the judgement of the investigator, would place the patient at increased risk during participation in the study\nAny subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction or on treatment to support cardiac dysfunction\nHIV positive\nNon-cooperative behavior or non-compliance of the patient and/or of his/her family\nReceived another investigational agent within 30 days of enrollment\nPatients with Down's syndrome"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must have a diagnosis of AML or acute leukemia of ambiguous lineage (acute undifferentiated leukemia or mixed phenotype acute leukemia) and have refractory leukemia, defined as persistent leukemia after at least two courses of induction chemotherapy; or relapsed leukemia, defined as the re-appearance of leukemia after the achievement of remission.\n\nPatients in all categories above must have \u2265 5% blasts in the bone marrow as assessed by morphology or \u2265 1 blasts in the bone marrow as assessed by flow cytometry. However, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with \u2265 5% blasts in the peripheral blood. In addition, patients in all categories must not be eligible to undergo curative therapy, such as immediate SCT, because of disease burden, time needed to identify a stem cell donor, or other reasons.\n\n* Adequate organ function defined as the following:\n\nDirect bilirubin \u2264 1.5 x institutional upper limit of normal (ULN)\nAST (SGOT) and ALT (SGPT) \u2264 4 x ULN\nNormal creatinine for age or a calculated creatinine clearance \u2265 60 mL/min/1.73 m2\n\nLeft ventricular ejection fraction \u2265 40% or shortening fraction \u2265 25%\n\nSt. Jude patients must be between 2 years and \u2264 21 years of age, on therapy (active patient), or within 3 years of completion of therapy. Patients treated at collaborating sites must be \u2264 24 years old.\nPerformance status: Lansky \u2265 50 for patients who are \u2264 16 years old and Karnofsky \u2265 50% for patients who are > 16 years old.\nPatients must have fully recovered from the acute effects of all prior therapy and cannot have evidence of graft-versus-host disease (GVHD)\n\nExclusion Criteria:\n\nMust not be pregnant or breastfeeding. Male or female of reproductive potential must agree to use effective contraception for the duration of study participation.\nPatients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocytic leukemia, or bone marrow failure syndromes are not eligible.\nUncontrolled infection. Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable.\nImpairment of GI function or GI disease that may significantly alter the absorption of venetoclax."
            },
            {
                  "document": "Subjects who are able and willing to give written informed consent\n\nDocumented primary or secondary AML, as defined by the WHO criteria (2008), by histopathology refractory to previous induction chemotherapy and/or relapsed after achieving remission with a prior chemotherapy and who are not candidates for other available therapy likely to confer clinical benefit.\nFor Phase 2a only: in addition to inclusion criteria 2 above, patients must have a FLT3 mutation of any type\nEastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\nIn the absence of rapidly progressing disease, the interval from prior treatment to time of FF-10101-01 administration should be at least 14 days for cytotoxic agents other than hydroxyurea, at least 5 half-lives for non-cytotoxic agents, and 14 days for monoclonal antibody therapies. Hydroxyurea may be continued for a maximum of 14 days from the start of FF-10101-01 dosing, through Cycle 1 Day 14, with a maximal dose of 5 grams/day\nPersistent chronic clinically significant toxicities from prior chemotherapy or surgery must be \u2264Grade 2\nIf subject has had a hematopoietic stem cell transplant, subject must be \u226560 days post-transplant with no clinically significant GVHD requiring systemic therapy\nAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \u22643 times the upper limit of normal and total bilirubin of \u22641.5x the upper limit of normal. If total bilirubin is equal to or exceeds 1.5x the upper limit of normal, the subject can still be included if direct bilirubin is \u22641.5x the upper limit of normal\nCalculated creatinine clearance of \u226560 mL/min\nFemale subjects of childbearing potential and sexually mature male subjects must agree to use a medically accepted method of contraception other than an oral contraceptive for the duration of the study.\n\nExclusion Criteria:\n\nSubjects diagnosed with acute promyelocytic leukemia\nSubjects with Bcr-Abl positive leukemia (chronic myelogenous leukemia in blast crisis)\nSubjects with clinically active CNS leukemia\nSubjects with major surgery within 28 days prior to the first administration of FF-10101-01\nSubjects with radiation therapy within 28 days prior to the first administration of FF-10101-01\nSubjects with active malignant disease requiring therapy other than AML or myelodysplastic syndrome with transformation into AML\nSubjects with an active uncontrolled infection\nSubjects with a medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the subject's safety as a study subject, or that could interfere with the study objectives\nSubjects known to have human immunodeficiency virus infection, or who have active hepatitis B or C infection as determined by serological testing\nSubjects with congestive heart failure, New York Heart Association (NYHA) Class 3 or 4, or subjects with a past history of congestive heart failure NYHA Class 3 or 4 and in whom echocardiogram or multiple gate acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a LVEF <40%\nFemale subjects who are pregnant or breast feeding\nSubjects on 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or other drugs known to have muscle toxicity\nSubjects taking strong inhibitors of CYP3A4 will be excluded from the study unless therapeutic substitution is possible\nSubjects taking strong inducers of CYP3A4 will be excluded from the study unless therapeutic substitution is possible\nUse of systemic immunosuppressive agents within 14 days prior to first dose of FF-10101\nSubjects taking drugs known to cause Torsades de Pointes will be excluded from the study unless therapeutic substitution is possible\nSubjects known to have long QT syndrome\nSubjects with mean QTcF values following 3 ECGs conducted 5 minutes apart of >470 msec"
            },
            {
                  "document": "Inclusion Criteria:\n\nThe patient must have a diagnosis of one of the following (one must be yes):\n\nAcute myeloid leukemia (AML)\nAcute lymphoblastic leukemia (ALL)\nChronic lymphoblastic leukemia (CLL)\nChronic myelogenous leukemia (CML) (chronic phase intolerant or unresponsive to tyrosine kinase inhibitors, accelerated phase, history of blast crisis)\nMyelodysplastic syndrome (MDS)\nNon-Hodgkin lymphoma (NHL)\nHodgkin lymphoma (HL) (received and failed frontline therapy or failed autologous transplantation or inability to collect enough peripheral blood stem cells [PBSC] for autologous hematopoietic cell transplant [auto-HCT])\nMultiple myeloma (MM)\nSevere aplastic anemia\n\nHistocompatible donor identified:\n\nRelated donor matched 5/6 or better (A, B, DRB1)\nUnrelated donor matched 7/8 or better (A, B, C and DRB1)\nPatients with severe aplastic anemia do not have disease requirements; however, if the patient has a mismatched donor, the patient must have had prior therapy with ATG.\n\nThe following are eligible for study inclusion:\n\nPatients with MDS/MPN only require <5% myeloblast on bone marrow evaluation.\nPatients with AML, ALL or CLL may be in CRi, patients with MM may be in VGPR\n\nPatients with NHL/HL must be in CR\n\nHave a Karnofsky performance status score of > 50%\nDiffusing capacity of the lung for carbon monoxide (DLCO) > 40% predicted, corrected for hemoglobin and/or alveolar ventilation\nLeft ventricular ejection fraction > 40%\nBilirubin =< 3 x upper limit of normal\nLiver alkaline phosphatase =< 3 x upper limit of normal\nSerum glutamic-oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 3 x upper limit of normal\nCalculated creatinine clearance > 40 cc/min by the modified Cockroft-Gault formula\nPatient must be cleared pre-transplant by Radiation Oncology to be able to receive 400 cGy\nParticipants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\nPatients who have failed a prior autologous or allogeneic transplant are eligible; however, at least 6 months must have elapsed between the start of this reduced intensity conditioning regimen and the last transplant if patient had a prior autologous or myeloablative allogeneic bone marrow transplant (BMT)\nAt least 2 weeks since prior radiation treatment and/or surgery. Appropriate washout of prior chemotherapy per BMT standard of care. If medication is not on the list, go by physician discretion\nParticipant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\nModerate to severe myelofibrosis within 60 days prior to transplant\nPresence of human leukocyte antigen (HLA) antibodies to the donor within 60 days prior to transplant\nPatients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening. (i.e., serious, uncontrolled psychiatric illness/social situations that would limit compliance with study requirements)\nUncontrolled diabetes mellitus, cardiovascular disease, active serious infection or other condition which, in the opinion of treating physician, would make this protocol unreasonably hazardous for the patient\nKnown human immunodeficiency virus (HIV) positive\nPregnant or nursing female participants\nUnwilling or unable to follow protocol requirements\nAny condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study intervention"
            },
            {
                  "document": "Main Inclusion Criteria:\n\nPatients with relapsed or primary refractory AML (as defined in WHO criteria) with >5% bone marrow blasts\nPatients with CD123+ blast cells (verified by flow cytometry)\nEastern Cooperative Oncology Group Performance Status (ECOG-PS) of \u22641\nAdequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period\n(Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)\nOther criteria may apply\n\nMain Exclusion Criteria:\n\nPatients with APL or CNS Leukemia\nPrevious investigation gene or cell therapy (including CAR)\n\u2265 2 prior allogeneic SCTs\nPrior treatment with rituximab or other anti-CD20 therapy within 3 months\nAny known active or uncontrolled infection\nOther criteria may apply"
            },
            {
                  "document": "Inclusion Criteria:\n\nPARENT/CAREGIVER: Adult primary caregiver of children treated for leukemia or lymphoblastic lymphoma (LL) and daily contact with the child\nPARENT/CAREGIVER: One or both parents self-identify as Hispanic/Latino and the primary participating parent/caregiver is monolingual or bilingual Spanish speaking\nCHILD: Children treated for acute leukemia (e.g. acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML]), LL, or other types of leukemia (if treated intensively) aged 5-12 years and their parents/caregivers\nCHILD: Child has completed cancer treatment and is up to 10 years post-treatment\nCHILD: Child understands English and is enrolled in school (but can be bilingual)\n\nExclusion Criteria:\n\nHistory of major psychiatric condition (e.g. psychosis) in parent or child; severe neurodevelopmental disorder in child (e.g. Down's syndrome)\nRecent or current participation in educational/behavioral intervention study with similar focus"
            },
            {
                  "document": "INCLUSION CRITERIA:\n\nDiagnostic criteria: Patients must have one of the following diagnoses:\n\nAcute myeloid leukemia fulfilling the criteria of the WHO Classification (see Appendix I), or\n>5% but < 20% marrow myeloblasts and evidence of a clonal de novo AML genetic abnormality [e.g., t(8;21), inv(16), t(9;11)], or\nMyeloid sarcoma (also referred to as extramedullary myeloid tumor, granulocytic sarcoma, or chloroma), with or without evidence of a leukemia process in the bone marrow or peripheral blood, with confirmation of myeloid differentiation, or\nHigh grade myelodysplastic syndrome (MDS) with greater than 5% blasts, or\nPatients with treatment related myeloid neoplasms including AML and MDS, provided their cumulative anthracycline dose has not exceeded 230 mg/m2 doxorubicin equivalents.\n\nOther criteria - Patients must meet all the following criteria:\n\nAge > 28 days and < 22 years at time of study entry inclusive, and\nNo prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or less for hyperleukocytosis), and\nWritten informed consent according to institutional guidelines, and\nFemale patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollment, and\nMale and female participants of reproductive potential must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.\n\nEXCLUSION CRITERIA:\n\nDown syndrome\nAcute promyelocytic leukemia (APL)\nBCR-ABL1 chronic myeloid leukemia in blast crisis (CML-BC)\nJuvenile myelomonocytic leukemia (JMML)\nFanconi anemia (FA)\nKostmann syndrome\nShwachman syndrome\nOther bone marrow failure syndromes or low grade (<5% bone marrow blasts) MDS.\nUse of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.\nUse of investigational agents within 30 days or any anticancer therapy for this malignancy within 2 weeks before study entry with the exception of IT therapy, hydroxyurea, or low-dose cytarabine as specified in the protocol document. The patient must have recovered from all acute toxicities from any previous therapy.\nSystemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).\nPregnant or lactating.\nAny significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.\nPrior chemotherapy, with the exception of hydroxyurea or low-dose cytarabine as specified in the protocol document. The patient must have recovered from all acute toxicities from any previous therapy.\nPatients with treatment related myeloid neoplasms with cumulative anthracyclines greater than 230 mg/m2 doxorubicin equivalents."
            },
            {
                  "document": "Inclusion Criteria:\n\nNewly diagnosed patients for the following conditions\n\nColon cancer stage III and IV\nRectal cancer stage II, III, IV\nGlioblastoma multiforme (brain) -- no stage\nNon-small cell lung cancer stage IIIA, IIIB, IV\nSmall cell lung cancer, limited stage and extensive stage\nCastration-resistant prostate cancer\nHead and neck cancer stage III and IV\nGastric cancer stage III and IV\nEsophageal cancer stage III and IV\nPancreatic cancer stage II, III, IV\nRenal cell carcinoma, stage IV\nBreast cancer, stage IV, if triple negative ER/PR/H2N negative or on systemic chemotherapy\nSarcoma, stage IV\nBladder carcinoma, stage IV\nAcute myeloid leukemia\nMelanoma, stage III and IV\nOvarian cancer, stage III and IV\nHigh grade myelodysplastic syndrome (MDS)\nAny patient with recurrent or progressive cancer\nPatients must have the ability to understand and willingness to sign a written informed consent document\nPatient must have ongoing oncologic needs and plan to receive all care at the study institution and not already be in hospice or home-care\n\nExclusion Criteria:\n\nPatients must have capacity to consent\nPregnant patients are excluded"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge \u226518 years at the time of informed consent.\nMorphologically documented primary Acute Myeloid Leukemia (AML) or AML secondary to Myelodysplastic Syndrome (MDS) or therapy related AML (t-AML), as defined by World Health Organization (WHO) criteria.\n\nPatients must meet one of the following criteria:\n\nIn first or subsequent relapse or refractory status, with or without prior hematopoietic stem cell transplant (HSCT) OR\nPatients with MDS transformed to AML will be eligible even if they had not received prior therapy for AML.\nEastern Cooperative Oncology Group (ECOG) performance score 0-2.\nPatients must meet the following clinical laboratory criteria: Direct bilirubin \u2264 1.5 X the upper limit of the normal range (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3 X ULN unless related to AML or Gilbert syndrome or hemolysis. Calculated creatinine clearance \u226530 mL/min\nLeft ventricular ejection fraction (LVEF) \u2265 45%\n\nExclusion Criteria:\n\nAcute Promyelocytic Leukemia.\nPregnant or breast feeding women.\nParticipation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients >= 18 years of age with previously untreated Ph-positive ALL (either t(9;22) and/or BCR-ABL positive) (includes patients initiated on first cycle of hyper-CVAD before cytogenetics known. These patients could have received one or two cycles of chemotherapy with or without other TKIs and still eligible.\n\nIf they achieved CR, they are assessable only for event-free and overall survival, or\nIf they failed to achieve CR, they are assessable for CR, event-free, and overall survival.\n\nPatients >= 18 years of age with relapsed/refractory Ph-positive ALL or lymphoid accelerated or blast phase chronic myelogenous leukemia (CML)\n\nPerformance status =< 2 (Eastern Cooperative Oncology Group [ECOG] scale)\nTotal serum bilirubin =< 2 x upper limit of normal (ULN), unless due to Gilbert's syndrome\nAlanine aminotransferase (ALT) =< 3 x ULN\nAspartate aminotransferase (AST) =< 3 x ULN\nSerum lipase and amylase =< 1.5 x ULN\nCreatinine =< 2.0 mg/dl\nFemale patients who: are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR if they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse\nMale patients, even if surgically sterilized (i.e., status post-vasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse\nAdequate cardiac function as assessed clinically by history and physical examination\nSigned informed consent\n\nExclusion Criteria:\n\nActive serious infection not controlled by oral or intravenous antibiotics\nKnown active hepatitis B. Patients with chronic hepatitis B who are on appropriate viral suppressive therapy may be allowed after discussion with the principal investigator (PI)\nHistory of acute pancreatitis within 1 year of study or history of chronic pancreatitis\nHistory of alcohol abuse\nUncontrolled hypertriglyceridemia\nActive secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year\nActive grade III-V cardiac failure as defined by the New York Heart Association criteria\nUncontrolled, or active cardiovascular disease, specifically including, but not restricted to: myocardial infarction (MI), stroke, or revascularization within 3 months; unstable angina or transient ischemic attack; congestive heart failure prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards prior to enrollment; diagnosed or suspected congenital long QT syndrome; clinically significant atrial or ventricular arrhythmias as determined by the treating physician; prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 470 msec) unless corrected after electrolyte replacement. or approved by cardiologist; Significant venous or arterial thromboembolism including deep venous thrombosis or pulmonary embolism. Patients with a history of treated prior superficial or catheter associated phlebitis will not be considered as significant embolism and after discussion with principal investigator (PI) will not be excluded from eligibility. Uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 140mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control\nTaking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days or 5 half-lives before the first dose of ponatinib in patients with newly diagnosed only\nHistory or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. Patients with active CNS leukemia will NOT be excluded\nCurrent autoimmune disease or history of autoimmune disease with potential CNS involvement\nTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator\nPregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control\nHistory of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand's disease); and diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\nPatients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of histologically confirmed relapsed or refractory (R/R) acute myeloid leukemia or R/R acute lymphoblastic leukemia for which no available standard therapies are indicated or anticipated to result in a durable response\nOnly patients with R/R ALL will be eligible for cohort C\nPatients must not have had leukemia therapy for 14 days prior to starting palbociclib. However, patients with rapidly proliferative disease may receive hydroxyurea as needed until 24 hours prior to starting therapy on this protocol and during the first cycle of study\nBilirubin =< 2 mg/dL\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or =< 5 x ULN if related to leukemic involvement\nCreatinine =< 1.5 x ULN\nKnown cardiac ejection fraction of > or = 45% within the past 3 months\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2\nA negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial\nPatient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol\n\nExclusion Criteria:\n\nPregnant women are excluded from this study because the agent used in this study has the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided\nUncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPatient with documented hypersensitivity to any of the components of the therapy program\nPatients with active, uncontrolled central nervous system (CNS) leukemia will not be eligible\nMen and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation\nPatients with known history of serous retinopathy will not be eligible\nPrior treatment with palbociclib"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with acute leukemia or chronic myelogenous leukemia with no circulating blasts and with less than 10% blasts in the bone marrow\nPatients with myelodysplastic syndrome (MDS) with intermediate-2 or high risk per International Prognostic Scoring System (IPSS) (or intermediate, high, very high risk by Revised International Prognostic Scoring System [IPSS-R]) or myeloproliferative neoplasm; primary or secondary if high-risk features or refractory disease\nPatients with chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular, marginal zone, diffuse large B-cell, Hodgkin lymphoma, or mantle cell lymphoma with chemosensitive disease at time of transplantation; all types of lymphoma are eligible\nHigh risk, or refractory and relapsed multiple myeloma\nNo available human leukocyte antigen (HLA)-matched related donor\nAvailable matched unrelated donor\nEjection fraction at rest >= 50%\nKarnofsky performance status (KPS) >= 70\nMeasured creatinine clearance more than 60 mL/min. The updated Schwartz formula should be used for pediatric patients (>=5 to 12 years old)\nCarbon monoxide diffusing capability test (DLCO) >= 50% (adjusted for hemoglobin) and forced expiratory volume in 1 second (FEV1) >= 50%\nTotal bilirubin < 1.5 x the upper limit of normal; patients who have been diagnosed with Gilbert's disease are allowed to exceed the defined bilirubin value of 1.5 x the upper limit of normal\nAlanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x the upper limit of normal\nAlkaline phosphatase < 2.5 x the upper limit of normal\nFemale subjects (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing of the informed consent through 12 months post-transplant\nMale subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception, or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant\nAll subjects must have the ability to understand and the willingness to sign a written informed consent document\n\nDONOR INCLUSION CRITERIA\n\n7 out of 8 at high resolution using deoxyribonucleic acid (DNA)-based typing with either antigen or allele mismatched HLA (-A, -B, -C, and -DR) or 8/8 HLA-mismatched with either double DQ mismatch (10/12) or combined DQ and DP mismatch\nDonor must be willing to donate peripheral blood stem cells\nSuitable donor\nMedically cleared to donate per National Marrow Donor Program (NMDP)\nAbsence of donor-specific antibodies (DSA) to the mismatched HLA-locus\nDonor choices per matched unrelated donor (MUD) committee according to center standard operating procedure (SOP)\n\nExclusion Criteria:\n\nPrior allogeneic transplant\nActive central nervous system (CNS) involvement by malignant cells\nPatients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment\nPatients with transformed lymphoma (e.g., Richter's transformation arising in follicular lymphoma or chronic lymphocytic leukemia)\nPatients seropositive for the human immunodeficiency virus (HIV)\nPatients with active hepatitis B or C determined by polymerase chain reaction (PCR)\nMyocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiography (ECG) abnormality at screening must be documented by the investigator as not medically relevant\nFemale patients who are lactating or pregnant\nPatients with a serious medical or psychiatric illness likely to interfere with participation in this clinical study\nHistory of another primary malignancy that has not been in remission for at least 3 years (the following are exempt from the 3-year limit: non-melanoma skin cancer, fully excised melanoma in situ [Stage 0], curatively treated localized prostate cancer, and cervical or breast carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear)\nPsychosocial issues: no appropriate caregivers identified, or non-compliant to medications\nSubjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have advanced AML, ALL, high-risk MDS, or MPAL (also known as biphenotypic) meeting one of the following descriptions:\n\nAML, ALL, or MPAL in first remission with evidence of measurable residual disease (MRD) by flow cytometry\nAML, ALL, or MPAL beyond first remission (i.e., having relapsed at least one time after achieving remission in response to a treatment regimen)\nAML, ALL, or MPAL representing primary refractory disease (i.e., having failed to achieve remission at any time following one or more prior treatment regimens)\nAML evolved from myelodysplastic or myeloproliferative syndromes\nMDS expressed as refractory anemia with excess blasts (RAEB)\nChronic myelomonocytic leukemia (CMML) by French-American-British (FAB) criteria\nPatients not in remission must have CD45-expressing leukemic blasts; patients in remission do not require phenotyping and may have leukemia previously documented to be CD45 negative (because in remission patients, virtually all antibody binding is to non-malignant cells which make up >= 95% of nucleated cells in the marrow)\nPatients should have a circulating blast count of less than 10,000/mm^3 (control with hydroxyurea or similar agent is allowed)\nPatients must have an estimated creatinine clearance greater than 50/ml per minute by the following formula (Cockcroft-Gault); serum creatinine value must be within 28 days prior to registration\nPatients must have normal hepatic function (bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT] < 2 times the upper limit of normal)\nEastern Cooperative Oncology Group (ECOG) < 2 or Karnofsky >= 70\nPatients must be free of uncontrolled infection\nPatients with prior non-myeloablative or reduced-intensity conditioning allogeneic-hematopoietic cell transplant (HCT) must have no evidence of ongoing GVHD and be off all immunosuppression for at least 6 weeks at time of enrollment\n\nPatients must have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA) and/or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) or bone marrow donation, as follows:\n\nRelated donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1; phenotypic identity must be confirmed by high-resolution typing\n\nUnrelated donor:\n\nMatched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR\nMismatched for a single allele without antigen mismatching at HLA-A, B, or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing\nDonors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment; the recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT; if the PRA shows > 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained; the donor should be excluded if any of the cytotoxic cross match assays are positive; for those patients with an HLA Class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is an absolute donor exclusion\nPatient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0102, and this type of mismatch is not allowed\n\nExclusion Criteria:\n\nPatients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects\nLeft ventricular ejection fraction < 35%\nCorrected diffusing capacity of the lungs for carbon monoxide (DLCO) < 35% or receiving supplemental continuous oxygen; when pulmonary function test (PFT)s cannot be obtained, the 6-minute walk test (6MWT, also known as exercise oximetry) will be used: Any patient with oxygen saturation on room air of < 89% during a 6MWT will be excluded\nLiver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease\nPatients who are known to be seropositive for human immunodeficiency virus (HIV)\nPerceived inability to tolerate diagnostic or therapeutic procedures\nActive central nervous system (CNS) leukemia at time of treatment\nPatients with prior myeloablative allogeneic-HCT\nWomen of childbearing potential who are pregnant (beta-human chorionic gonadotropin positive [beta-HCG+] or breast feeding\nFertile men and women unwilling to use contraceptives during and for 12 months post-transplant\nInability to understand or give an informed consent\nAllergy to murine-based monoclonal antibodies\nKnown contraindications to radiotherapy"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge 18-65 years\n\nPatients with AML or MDS who meet the following criteria:\n\na. Relapsed or refractory AML (including AML in CR2)\n\nb. Poor-risk AML in first remission, with remission defined as <5% bone marrow blasts morphologically:\n\nAML arising from MDS or a myeloproliferative disorder, or secondary AML\nPoor risk molecular features including presence of FLT3 internal tandem duplication mutation.\n\nPoor-risk cytogenetics: Monosomal karyotype, complex karyotype (> 3 abnormalities), inv(3), t(3;3), t(6;9), MLL rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7\n\nc. Primary refractory disease\n\nd. MDS with at least one of the following poor-risk features:\n\nPoor-risk cytogenetics including 3q abnormalities, 7/7q minus or complex cytogenetics (>3 abnormalities)\nCurrent or previous INT-2 or high IPSS score\nTreatment-related MDS\nMDS diagnosed before age 21 years\nProgression on or lack of response to standard DNA-methyltransferase inhibitor therapy\nLife-threatening cytopenias, including those requiring regular PRBC or platelet transfusions e. CML with a history of accelerated or blast phase\n\nPatients must have a related or unrelated peripheral blood stem cell donor as follows:\n\nSibling donor must be a 6/6 match for HLA-A, -B at intermediate (or higher) resolution and -DRB1 at high resolution using DNA based typing\nUnrelated donors must be at least 7/8 match at HLA-A, -B, -C and DRB1 at high resolution using DNA-based typing\n\nExclusion criteria:\n\nPresence of significant co morbidity as shown by:\n\nLeft ventricular ejection fraction < 50%\nCreatinine clearance <30ml/min\nBilirubin > 2.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST > 5 x ULN\nFEV1 and FVC < 50% of predicted or DLCO <50% of predicted once corrected for anemia\n\nf. Karnofsky score <70 (appendix C)\n\ng. Hematopoietic cell transplantation comorbidity index >3\n\nh. Active viral hepatitis or HIV infection\n\nj. Cirrhosis\n\nPregnancy\nPatients unable to sign informed consent\nPatient who have previously received radiation to >20% of bone marrow containing areas.\n\n4. DONOR ELIGIBILITY AND SELECTION\n\n4.1. Donor Selection\n\nDonor evaluation and selection is by standard for normal clinical practice. No study procedures are to be performed on donors. All donors must be willing to donate peripheral blood stem cells and meet institutional or NMDP criteria for donation.\n\nThe following prioritization will be used when selecting donors:\n\nWhen possible, an HLA compatible sibling will be used as a donor.\nFor patients who do not have an HLA compatible sibling, an unrelated donor will be used\n8/8 matched unrelated donors are preferred over single antigen mismatched donors.\n\nIf more than one potential volunteer unrelated donor is considered suitable further selection of the most suitable donor is at the discretion of the treating physician. The following serves only as a guide for prioritization:\n\nAge of donor (18-24 > 25-34 > 35-44 > 45+)\nSex and parity of donor (male > female, nulliparous female > parous, multiparous female)\nCytomegalovirus (CMV) status, if recipient is CMV seronegative (CMV- > CMV+)"
            },
            {
                  "document": "Inclusion Criteria:\n\nAcute myelogenous leukemia diagnosed by WHO criteria with one of the following (patients with biphenotypic leukemia are eligible, provided that the treating physician determines an AML treatment regimen is appropriate)\n\nPrimary refractory disease following > 1cycle of chemotherapy, (such as hypomethylating agent or induction chemotherapy)\nFirst relapse or higher. Patients with primary or secondary acute myelogenous leukemia are eligible.\nAge 18-70 years old\nLVEF > 50 %\nECOG Performance status 0-2\nAble to adhere to study schedule and other protocol requirements.\n\nParticipants must have normal organ function as defined below, unless felt due to underlying disease and approved by the overall PI. Patients with Gilbert's disease may have total bilirubin up to < 3 x ULN.\n\nCreatinine < 2.0mg/dl\nTotal bilirubin < 1.5 x ULN\nAST (SGOT) and ALT (SGPT) < 3 x ULN.\nPatients may receive hydroxyurea, steroids, or leukapheresis as necessary until Day 5 of treatment.\nPatients must give voluntary written informed consent and HIPAA authorization before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.\nPatients may have had prior treatment for MDS or AML, including prior lenalidomide for MDS or AML or another condition.\nPatient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least 90 days between transplant and study entry.\nPatients may also have had donor lymphocyte infusion if there is at least 60 days between donor lymphocyte infusion and study entry.\nPatients on immunosuppression are also eligible.\nFemales of childbearing potential (FCBP)\u2020 must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to receiving treatment with lenalidomide, and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.\nAbility to understand and the willingness to sign a written informed consent document.\nAll study participants must be registered into the mandatory Revlimid REMS \u00ae program, and be willing and able to comply with the requirements of the REMs \u00ae program. Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS\u00ae program\n\nExclusion Criteria:\n\nKnown hypersensitivity to thalidomide or lenalidomide (if applicable).\nThe development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.\nKnown seropositive for human immunodeficiency virus (HIV). HIV testing is not required. Hepatitis testing is not required.\nPatients who have had a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.\nAny serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the consent form.\nAny condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\nPatients with major surgery within 28 days prior to treatment.\nPatients with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\nPatient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within 7 days of study entry.\nPatients with acute promyelocytic leukemia.\nFemales who are pregnant"
            },
            {
                  "document": "Inclusion Criteria:\n\nHistologically confirmed diagnosis of acute myeloid leukemia (AML) [Cohort B] or myelodysplastic syndrome (MDS) [Cohort A] or BPDCN [Cohort C] per 2016 WHO criteria\n\nCD123 / IL3RA expression on the subject's AML or MDS blasts or BPDCN cells determined locally within 3 months of first protocol treatment\n\nAge >= 18 years with relapsed or refractory AML (hydroxyurea is not considered a prior treatment regimen) [Cohort B]\n\nOR\n\nAge >= 18 years with treatment-na\u00efve AML who decline intensive induction chemotherapy or who are unfit due to co-morbidity or other factors (see APPENDIX A for unfitness definitions) (hydroxyurea is not considered a prior treatment regimen) [Cohort B]\n\nOR\n\nAge >= 18 years with MDS and > 10% myeloblasts in the bone marrow [Cohort A]\n\nOR\n\nAge >= 18 years with relapsed or refractory BPDCN (hydroxyurea is not considered a prior treatment regimen) [Cohort C]\n\nAdequate organ function as defined by:\n\nAlbumin > 3.2 g/dL (in the absence of receipt of intravenous albumin in the previous 72 hours) Serum creatinine < 1.5x ULN Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5x ULN Total bilirubin < 1.5x ULN (if thought to be > 1.5x ULN due to Gilbert's disease or the patient's AML, must discuss with the PI) Creatine phosphokinase (CPK) < 2.5x ULN Left ventricular ejection fraction > institutional lower limit of normal by MUGA scan or echocardiogram within 30 days of first protocol treatment\n\n[Cohorts B and C] WBC < 20,000 / uL on day of first therapy, cytoreduction may be achieved using hydroxyurea\n\nAbility to understand and the willingness to sign a written informed consent document.\n\nAble to adhere to study visit schedule and other protocol requirements including follow-up for survival assessment\n\nWomen of child-bearing potential must agree to use adequate contraception for the duration of study participation and for 2 months after completion of protocol treatment.\n\nMen treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation and 2 months after completion of protocol treatment.\n\nExclusion Criteria:\n\nPrior treatment with venetoclax [Cohorts B or C], unless it was last taken >2 months before protocol therapy\n\nDiagnosis of acute promyelocytic leukemia\n\nReceived treatment with chemotherapy, radiation, or biologic cancer therapy within 14 days of first protocol treatment, except for intrathecal chemotherapy. Prior and concurrent hydroxyurea is permitted.\n\nHematopoietic stem cell transplantation (HSCT) within 60 days of screening or active graft versus-host-disease\n\nActive CNS involvement by AML or BPDCN. Screening lumbar puncture (LP) required for patients with BPDCN. If history of treated CNS involvement, must have had two consecutive negative LPs since last CNS involvement, which may include the screening LP\n\nKnown positive status for HIV infection; known active hepatitis B or hepatitis C infection\n\nClinically significant cardiopulmonary disease including uncontrolled or NYHA class 3 or 4 congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled arrhythmia, myocardial infarction or stroke within 6 months of first protocol treatment, or QTc > 480 ms\n\nPatients with known active advanced malignant solid tumors are excluded (except for basal or squamous skin cancers, or carcinomas in situ). Patients with additional hematologic malignancies that require treatment are excluded.\n\nPregnant women are excluded from this study because there is an unknown but potential risk for adverse events in the developing fetus with SL-401, azacitidine, and venetoclax (negative urine or serum pregnancy test required within 14 days of Cycle 1, Day 1). Because nursing infants have unknown potential for adverse events secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated with SL-401, azacitidine, and venetoclax.\n\nPatients with uncontrolled infection shall not be enrolled until infection is treated and brought under control. Patients with active infection are permitted to enroll provided that the infection is controlled\n\n[Cohorts B and C] Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)\n\n[Cohorts B and C] Patients on strong CYP3A inducers within 7 days of first dose of study treatment."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have one of the following hematologic malignancies: a. Acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics, flt3 mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndrome (MDS), Langerhan's cell histiocytosis, any disease beyond first remission. b. Myelodysplastic syndrome (MDS): MDS International Prognostic Scoring System (IPSS) INT-1 will be enrolled only if the subjects have failed previous leukemia treatments and are transfusion-dependent. MDS may be primary or therapy related, including patients that will be considered for transplant. Including the following categories: 1) Revised IPSS intermediate and high risk groups, 2) MDS with transfusion dependency, 3) Failure to respond or progression of disease on hypomethylating agents, 4) Refractory anemia with excess of blasts, 5) Transformation to acute leukemia, 6) Chronic myelomonocytic leukemia, 7) Atypical MDS/myeloproliferative syndromes, 8) Complex karyotype, abn(3g), -5/5g-, -7/7g-, abn(12p), abn(17p). c. Acute lymphoblastic leukemia (ALL) patients with the following will be considered: induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease. Patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or evidence of minimal residual disease, or acute biphenotypic leukemia which excludes > 7 chromosomal abnormalities, or double hit non-Hodgkin's lymphoma. Non-Hodgkin's lymphoma (NHL) in second or third complete remission or relapse (including relapse post autologous hematopoietic stem cell transplant), or relapsed double hit lymphoma. Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease with progression after standard of care therapy or have failed/been intolerant to ibrutinib. Chronic myelogenous leukemia (CML) second chronic phase or accelerated phase. Hodgkin's disease (HD): Induction failure after the first complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant), or those with active disease.\nThe first 6 patients must be >= 18 and =< 65 years old. The subsequent patients may include pediatric patients >= 12 and =< 65 years old. Eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician.\nPerformance score of at least 80% by Karnofsky or performance score (PS) < 3 (Eastern Cooperative Oncology Group [ECOG]) (age >= 12 years)\nLeft ventricular ejection fraction of > 40%.\nPulmonary function test (PFT) demonstrating a diffusion capacity of least 50% predicted.\nCreatinine =< 1.5 mg/dL for patients 12 years old and older and =< 1 for patients younger than 12 years old.\nSerum glutamate pyruvate transaminase (SGPT) =< to 2.0 x normal.\nBilirubin =< to 2.0 x normal.\nNegative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization and willing to use an effective contraceptive measure while on study.\nPatients must have two cord blood (CB) units available which are matched with the patient at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens. Each cord must contain at least 1.5 x 10^7 total nucleated cells/Kg recipient body weight (pre-thaw).\nHave identified a backup cells source in case of engraftment failure. The source can be autologous, related or unrelated.\nPatient must not have a 10/10 HLA matched family member or unrelated donor.\nPatients will have a back-up graft from any of the following: an available fraction of autologous marrow; or peripheral blood progenitor cells (PBPCs) harvested and cryopreserved; or family member donor; or a third cord blood unit.\nPrior to initiating chemotherapy in this study, twenty-one or more days must have elapsed since the patient's last radiation or chemotherapy administration (Hydrea, Gleevec and other tyrosine kinase inhibitors [TKI] as well as intrathecal therapy are accepted exceptions).\n\nExclusion Criteria:\n\nPatients with known history of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS).\nPatients with positive hepatitis serology that is definitive of active disease.\nActive central nervous system (CNS) disease in patient with history of CNS malignancy.\nPatients with chronic active hepatitis or cirrhosis. If positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsy.\nPatients with uncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy, decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation (excluding primary disease for which CB transplantation is proposed), or psychiatric condition that would limit informed consent.\nPositive beta HCG in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or breast-feeding.\nPediatric patients with acute lymphoblastic leukemia (ALL) that is t (9,22) positive in first remission are not eligible unless there is evidence of minimal residual disease after initial induction and/or consolidation treatment or the pediatric Philadelphia chromosome positive (Ph+) ALL is clinically refractory to available therapies with evidence of persistence in the bone marrow or peripheral blood.\nPatients with options for treatment that are known to be curative are not eligible."
            },
            {
                  "document": "Inclusion Criteria:\n\nAges 16 years old and up\nPerformance Status 70 percent or above\nPatients should have the following diseases:\nAcute myelogenous leukemia (AML)\nAcute lymphocytic leukemia or lymphoblastic lymphoma (ALL)\nTransfusion dependent myelodysplastic syndrome (MDS)\nNon-Hodgkin's Lymphoma (NHL)\nChronic lymphocytic leukemia (CLL)\nPulmonary function as measured by forced expiratory volume at one second (FEV1) and/or corrected diffusing capacity of lung for carbon monoxide (DLCO) at 60 percent of predicted or above\nLeft ventricular ejection fraction at 45 percent or above\nIf the donor-specific HLA antibodies (DSA) are positive, the patient must undergo a desensitization protocol resulting in undetectable DSA prior to day of transplant\n\nExclusion Criteria:\n\nLess than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except for hydroxyurea)\nUncontrolled bacterial, fungal or viral infections at time of study enrollment\nPositive for HIV, human T-cell leukemia virus (HTLV-1) and/or Hepatitis C\nSubjects with signs/symptoms of active central nervous system (CNS) disease"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipant must have histological confirmation of acute myeloid leukemia (AML) by World Health Organization criteria, be ineligible for intensive induction chemotherapy and either be:\n\n\u2265 75 years of age OR\n\n\u2265 18 to 74 years of age and fulfill at least one criteria associated with lack of fitness for intensive induction chemotherapy:\n\nEastern Cooperative Oncology Group (ECOG) performance status of 2 - 3\nCardiac history of congestive heart failure (CHF) requiring treatment or ejection fraction \u2264 50% or chronic stable angina\nDiffusing capacity of the lung for carbon monoxide (DLCO) \u2264 65% or forced expiratory volume in 1 second (FEV1) \u2264 65%\nCreatinine clearance \u2265 30 mL/min to < 45 ml/min\nModerate hepatic impairment with total bilirubin > 1.5 to \u2264 3.0 \u00d7 upper limit of normal (ULN)\nOther comorbidity that the physician judges to be incompatible with conventional intensive chemotherapy which must be reviewed and approved by the study medical monitor before study enrollment\n\nParticipant must have an ECOG performance status:\n\nof 0 to 2 for subjects \u2265 75 years of age OR\nof 0 to 3 for subjects between 18 to 74 years of age\nParticipant must have a projected life expectancy of at least 12 weeks.\nParticipant must have adequate renal function as demonstrated by a creatinine clearance \u2265 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24-hour urine collection.\n\nParticipant must have adequate liver function as demonstrated by:\n\naspartate aminotransferase (AST) \u2264 3.0 \u00d7 ULN*\nalanine aminotransferase (ALT) \u2264 3.0 \u00d7 ULN*\n\nbilirubin \u2264 1.5 \u00d7 ULN*\n\nSubjects who are < 75 years of age may have bilirubin of \u2264 3.0 \u00d7 ULN\n\n(*Unless considered to be due to leukemic organ involvement.)\n\nFemale participants must be either postmenopausal defined as:\n\nAge > 55 years with no menses for 12 or more months without an alternative medical cause.\nAge \u2264 55 years with no menses for 12 or more months without an alternative medical cause AND a follicle-stimulating hormone (FSH) level > 40 IU/L.\n\nOR\n\nPermanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n\nOR\n\nA woman of childbearing potential (WOCBP) practicing at least one protocol specified method of birth control starting at Study Day 1 through at least 180 days after the last dose of study drug.\nMale participants who are sexually active, must agree, from Study Day 1 through at least 180 days after the last dose of study drug, to practice protocol specified methods of contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 180 days after the last dose of study drug.\n\nFemales of childbearing potential must have negative results for pregnancy test performed:\n\nAt Screening with a serum sample obtained within 14 days prior to the first study drug administration, and\nPrior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.\nSubjects with borderline pregnancy tests at Screening must have a serum pregnancy test \u2265 3 days later to document continued lack of a positive result.\nParticipant must voluntarily sign and date an informed consent form, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.\n\nExclusion Criteria:\n\nParticipant has received any prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Note: Prior treatment for myelodysplastic syndrome is allowed except for use of cytarabine.\nParticipant had an antecedent myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia (CML) with or without BCR-ABL 1 translocation and AML with BCR-ABL 1 translocation.\nParticipants that have acute promyelocytic leukemia (APL).\nParticipant has known central nervous system (CNS) involvement with AML.\nParticipant has known human immunodeficiency virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Screening, if required per local guidelines or institutional standards.\nParticipant is known to be positive for hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals (non-exclusionary medications) are not excluded.\n\nParticipant has received strong or moderate cytochrome P450 3A4 (CYP3A) inducers 7 days prior to the initiation of study treatment.\n\nChinese subjects are excluded from receiving strong and/or moderate CYP3A inhibitors 7 days prior to the initiation of study treatment through the end of intensive pharmacokinetic (PK) collection (24 hours post dose on Cycle 1 Day 10).\nParticipant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit within 3 days prior to the initiation of study treatment.\nParticipant has cardiovascular disability status of New York Heart Association Class > 2. Class 2 is defined as cardiac disease which subjects are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or angina pain. Class 3 is defined as cardiac disease which subjects are comfortable at rest but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4 is defined as cardiac disease which subjects have an inability to carry on any physical activity without discomfort, symptoms of heart failure at rest, and if any physical activity is undertaken then discomfort increases.\nParticipant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients of LDAC that in the opinion of the investigator would adversely affect his/her participating in this study.\nParticipant has a malabsorption syndrome or other condition that precludes enteral route of administration.\nParticipant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).\n\nParticipant has a history of other malignancies prior to study entry, with the exception of:\n\nAdequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent.\nParticipant has a white blood cell count > 25 \u00d7 10^9/L. (Note: hydroxyurea administration or leukapheresis is permitted to meet this criterion).\nPrevious treatment with venetoclax and/or current participation in any other research study with investigational products."
            },
            {
                  "document": "Recipient Inclusion Criteria:\n\nRelapsed AML after HLA-matched related or unrelated allogeneic hematopoietic cell transplant (per IWG definition of relapse)\nFor pilot pediatric/young adult patient cohort \u22651 and <18 years of age\nFor phase 2 adult patient cohort \u226518 years of age\nAvailable original donor (same donor as used for the initial stem cell transplant) that is willing and eligible for non-mobilized collection\nPatients with known central nervous system (CNS) involvement with AML are eligible provided that they have been treated and cerebrospinal fluid (CSF) is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment.\nKarnofsky performance status > 60 %\n\nAdequate organ function as defined below:\n\nTotal bilirubin < 2 mg/dL\nAST(SGOT)/ALT(SGPT) < 3.0 x IULN\nCreatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73 m2 by Cockcroft-Gault Formula\nOxygen saturation \u226590% on room air\nNot currently requiring systemic corticosteroid therapy (10 mg or less of prednisone or equivalent doses of other systemic steroids are allowed) or any other immune suppressive medications\nWomen of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study including throughout the initial evaluation period (100 days after CIML NK cell infusion).\nAbility to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nRecipient Exclusion Criteria:\n\nAcute or chronic GvHD with ongoing active systemic treatment.\nCirculating blast count >30,000/uL by morphology or flow cytometry (cyto-reductive therapies including leukapheresis or hydroxyurea are allowed).\nUncontrolled bacterial or viral infections, or known HIV, Hepatitis B, or Hepatitis C infection.\nUncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities.\nNew or progressive pulmonary infiltrates concerning for new or uncontrolled infectious process.\nKnown hypersensitivity to one or more of the study agents\nReceived any investigational drugs within the 14 days prior to CIML NK cell infusion date\nPregnant and/or breastfeeding\n\nDonor Inclusion Criteria:\n\nAt least 18 years of age\nSame donor as used for the allo-HCT\nIn general good health, and medically able to tolerate leukapheresis\nAbility to understand and willingness to sign an IRB approved written informed consent document\n\nDonor Exclusion Criteria:\n\nActive hepatitis, positive for HTLV, or HIV on donor viral screen\nPregnant"
            },
            {
                  "document": "Inclusion Criteria:\n\nUnderstand and voluntarily sign an informed consent form\nDiagnosis of acute myeloid leukemia (AML) (other than acute promyelocytic leukemia [APL]) with refractory/relapsed disease; patients with relapsed/refractory high-risk ([intermediate-2 or higher by International Prognostic Scoring System [IPSS] and/or >= 10% blasts]). Myelodysplastic syndrome (MDS) will also be eligible. (Treatment approach for relapsed/refractory AML is very similar to that of high risk MDS)\nAll non-hematological toxicity of previous cancer therapy should have resolved to =< grade 1 (except alopecia or other toxicities not involving major organs)\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2 at study entry\nSerum creatinine =< 2 mg/dL and estimated glomerular filtration rate or creatinine clearance >= 20 ml/min\nTotal bilirubin =< 2 mg/dL\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)\nWomen of childbearing potential must be practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: eg, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization (the vasectomized partner should be the sole partner for that subject); true abstinence (when this is in line with the preferred and usual lifestyle of the subject) during and after the study (3 months after the last dose of daratumumab for women)\nA man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug\nAML relapse > 6 months since autologous or allogeneic stem cell transplantation, provided there is no active graft-versus-host disease (GVHD) > grade 1; no treatment with high dose steroids for GVHD (up to 20 mg prednisolone or equivalent); no treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus (blood levels of 0.5-0.6 ug/mL)\n\nExclusion Criteria:\n\nPregnant or breast feeding females\nCancer chemotherapy within 2 weeks prior to start of daratumumab treatment (exception hydroxyurea). Use of hydroxyurea to control proliferative disease will be allowed prior to starting therapy on study and for 7 days during cycle 1-3 (maximum daily dose of 7 gm)\nSubject has received daratumumab or other anti-CD38 therapies previously\nSubject has received a cumulative dose of corticosteroids more than the equivalent of >= 140 mg of prednisone within the 2 week period before cycle 1, day 1\nSubject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. NOTE: FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normal\nSubject has a history of another malignancy within 5 years before cycle 1, day 1 (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the IND office and supporter's medical monitor, is considered cured with minimal risk of recurrence)\nSubject is known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [anti-HBs and anti-HBc, respectively]) or hepatitis C (anti-hepatitis C virus [HCV] antibody positive or HCV-ribonucleic acid [RNA] quantitation positive)\nSubject has clinically significant cardiac disease, including: myocardial infarction within 1 year before cycle 1, day 1, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association class III-IV); cardiac arrhythmia (Common Terminology Criteria for Adverse Events [CTCAE] version 4.03 grade 2 or higher) or clinically significant electrocardiogram (ECG) abnormalities; screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) > 470 msec\nSubject has known severe allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to the latest version of the Investigator Brochure), or known sensitivity to mammalian-derived products\nSubject has any concurrent medical condition or disease (eg, active systemic infection, laboratory abnormalities) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study\nExclude patients with known Kell antibodies"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have histologic evidence of high risk acute myeloid leukemia defined as one of the following:\n\nNon-M3 AML refractory to standard primary induction therapy\nNon-M3 AML relapsed after (i) any standard induction therapy (ii) any number of standard or experimental salvage therapies\nNewly diagnosed non-M3 AML not eligible for intensive induction chemotherapy\nSubjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less\nSubjects must have a life expectancy of at least 4 weeks\nSubjects must be able to consume oral medication\nSubjects must have recovered from the toxic effects of any prior chemotherapy to= < grade 1 (except alopecia)\nCreatinine clearance (CrCL) >= 45\nTotal bilirubin =< 2 x upper limit of normal (ULN)\nSerum glutamate pyruvate transaminase (SGPT) alanine aminotransferase (ALT) =< 2 x ULN\nNegative pregnancy test for women with child-bearing potential\nPatients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing\n\nExclusion Criteria:\n\nSubjects with FAB M3 (t(15;17)(q22;q21)[PML-RARalpha]) are not eligible\nSubjects must not be receiving any chemotherapy agents (except hydroxyurea); intrathecal methotrexate and cytarabine are permissible\nSubjects must not be receiving growth factors, except for erythropoietin\nSubjects with a \"currently active\" second malignancy, other than non-melanoma skin cancer, carcinoma in situ of the cervix, resected incidental prostate cancer (staged pT2 with Gleason score =< 6 and postoperative prostate-specific antigen [PSA] < 0.5 ng/mL), or other adequately treated carcinoma-in-situ are ineligible; patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for >= 1 year\nSubjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure (New York Heart Association [NYHA] class 3), myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible\nSubjects with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible\nSubjects must not have evidence of active leukemia in the central nervous system (CNS)\nSubjects must not have received any investigational agents within 14 days or 5 half-lives (whichever is longer) of study entry\nSubjects must not be pregnant or breastfeeding; pregnancy tests must be obtained for all females of child-bearing potential; pregnant or lactating patients are ineligible for this study; males or women of childbearing potential may not participate unless they have agreed to use an effective contraceptive method (defined as hormonal contraceptives, intrauterine devices, surgical contraceptives, or condoms)\nSubjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least 2 weeks before study entry\nSubjects with bacteremia must have documented negative blood cultures prior to study entry\nSubjects who are suitable for and willing to receive standard intensive induction therapy\nSubjects who are candidates for allogeneic transplantation, have a suitable donor, and are willing to undergo transplantation"
            },
            {
                  "document": "Inclusion Criteria:\n\nTP53 mutant AML. The presence of a TP53 mutation should be determined by Genoptix (or institutional preferred equivalent assay). Detection of a TP53 mutation at the time of initial diagnosis is sufficient for enrollment at the time of relapsed/refractory disease. Detection of a TP53 mutation in either the peripheral blood or bone marrow is adequate for enrollment. Alternatively, patients who have not had TP53 mutation analysis performed, but who have > 20% TP53 positive cells by immunohistochemistry detected on a bone marrow aspirate may also be enrolled,29 provided that mutation analysis is requested at the time of enrollment.\n\nRelapsed/refractory AML following 7+3 (or similar cytarabine containing induction chemotherapy for AML) disease detected by one of the following methods:\n\nbone marrow blasts > 5%, or\nHematologics flow cytometry assay (threshold > 0.5%) (alternative equivalent assay may be substituted), or\nPersistent cytogenetic abnormality (e.g. del5, del17p, etc), by FISH or conventional karotyping, or\nPersistent TP53 mutation (at least 5 variant reads with at least 50x coverage) determined by Genoptix (or institutional preferred equivalent assay).\nPatients with > 10% blasts on a day +14 bone marrow biopsy following 7+3 may either be enrolled or may be treated with a course of standard re-induction (e.g. 5+2 or similar) and then re-evaluated for response. Eligible patients will meet any of the above criteria on a subsequent biopsy.\n\nBone marrow and organ function as defined below:\n\nPeripheral white blood cell count < 50,000/mcl (patients may receive hydroxyurea as necessary for cytoreduction),\nTotal bilirubin < 1.5 x upper limit of normal,\nAST and ALT < 2.5 x upper limit of normal,\nSerum creatinine < 2.0 x upper limit of normal, and,\nAt least 18 years of age.\nWomen of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately\nAbility to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable\nPerformance status \u2264 3\n\nExclusion Criteria:\n\nPrior treatment with either decitabine or azacitidine or an investigational agent\nAcute promyelocytic leukemia with PML-RARA or t(15;17).\nHistory of HIV, Hepatitis B, or Hepatitis C infection.\nConcurrent illness including, but not limited to, ongoing uncontrolled infection, symptomatic NYHA class 3 or 4 congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.\nRadiation therapy within 14 days of enrollment.\nChemotherapy administration in the 7 days preceding enrollment with the exception of hydroxyurea, which can be continued until Cycle 2. A washout period for oral tyrosine kinase inhibitors (e.g. Jakafi, etc) is not required, although tyrosine kinase inhibitors therapy must be discontinued prior to enrollment.\nMalignancies (other than AML) requiring active therapy or diagnosed within the last year, with the exception of non-melanoma skin cancer which can be treated or in situ malignancies (such as cervical, breast, prostate, etc.)\nCurrently receiving any other investigational agents.\nKnown central nervous system (CNS) leukemia or testicular involvement of leukemia\nA history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the study.\nPregnant and/or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test within 7 days of study entry."
            },
            {
                  "document": "Inclusion Criteria:\n\nUnderstands and is willing to sign an informed consent form (ICF) prior to initiation of any study-specific procedure.\n18 years of age at the time of consenting.\nA pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification that is progressing.\nHas failed (refractory) or relapsed after no more than 2 prior regimens, and for whom for whom no other standard therapy options are available.\nSubjects with prior autologous and allogeneic hematopoietic stem cell transplantation (allo HSCT) are eligible.\n\nAdequate laboratory results including the following:\n\nSerum creatinine \u2264 2.0 mg/dL\nTotal bilirubin \u2264 1.5 x upper limit of institutional normal (ULN), unless due to Gilbert's syndrome\nAspartate transaminase (AST) or alanine transaminase (ALT) \u2264 3 x ULN, unless due to organ leukemic involvement\nEastern Cooperative Oncology Group (ECOG) performance score 0-2.\nThe subject should be off any anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic or any investigational agents for at least 14 days or 5 half lives, whichever is greater, prior to enrollment with the exception of hydroxyurea. All prior treatment-related non-hematologic toxicities must have resolved to \u2264 grade 2 prior to screening.\nFemale subject of childbearing potential (ie, premenopausal or not surgically sterile) must agree to use effective contraception from Day 1 until 28 days after the last dose of study drug, and have a negative serum or urine pregnancy test within 2 weeks prior to Day 1. Sexually active male subjects must also use effective contraception from Day 1 until 90 days after the last dose of any study drug.\nFemale subject must agree not to breastfeed at screening and throughout the study period and for 45 days after the final study drug administration. Female subject must not donate ova starting at screening and throughout the study period and for 45 days after the final study drug administration.\nMale subject must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.\nAgree to adhere to all study protocol requirements.\n\nExclusion Criteria:\n\nSubject has BCR-ABL-positive leukemia (Chronic myeloid leukemia [CML] in blast crisis).\nSubject is diagnosed as acute promyelocytic leukemia (APL).\nSubject has AML secondary to prior chemotherapy.\nSubject has active clinically significant graft versus host disease (GVHD) or is on treatment with systemic corticosteroids for GVHD (except grade 1 skin GVHD). At least 3 months must have elapsed since completion of allogeneic stem cell transplantation.\nSubject had a myocardial infarction within 6 months of enrollment, heart failure (New York Heart Association (NYHA) Class III or IV), uncontrolled angina, severe uncontrolled ventricular arrhythmias, left ventricular ejection fraction (LVEF) \u2264 40% or evidence of acute ischemia or active conduction system abnormalities.\nPresence of a systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).\nKnown in tolerance and allergy to cytarabine.\nActive central nervous system (CNS) disease.\nKnown positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.\nPrior exposure to CWP232291.\nPregnant or breastfeeding women.\nSuitable for imminent bone marrow transplant, or within 4 weeks of one.\nMajor surgery within 4 weeks prior to the first study dose.\nConcurrent other malignancy, unless the patient has been disease-free for at least five years following curative intent therapy, with the following exceptions: (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent."
            },
            {
                  "document": "Inclusion Criteria:\n\nSigned, informed consent must be obtained prior to any study specific procedures\nSubjects with a histologically confirmed diagnosis of MDS, including both MDS and refractory anemia with excess blasts (RAEB)-T (acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria) by World Health Organization (WHO) and chronic myelomonocytic leukemia (CMML) are eligible\nSubjects with high-risk MDS (i.e. International Prognostic Scoring System [IPSS] Intermediate-2 or high-risk; or R-IPSS high or very-high risk). Patients with Intermediate-1 risk by IPSS or Intermediate risk by R-IPSS and with IDH1 or IDH2, or high-risk molecular features including TP53, ASXL1, EZH2, and/or RUNX1 mutations are also eligible\nSubjects with prior hypomethylating agent therapy exposure may be eligible based on discussion with the principal investigator (PI)\nEastern Cooperative Oncology Group (ECOG) performance status of 0-2\nSerum bilirubin =< 2 x the upper limit of normal (ULN) (except for patients with Gilbert's disease)\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the laboratory ULN\nCreatinine clearance > 30 mL/min based on the Cockcroft-Gault equation\nAble to understand and voluntarily sign a written informed consent, and willing and able to comply with protocol requirements\nResolution of all treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to < grade 1 prior to the first dose of study treatment\nFemale patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days of the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug. Post-menopausal females (>= 45 years old and without menses for >= 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potential\n\nExclusion Criteria:\n\nAny prior or coexisting medical condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in the study\nPsychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures\nActive uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection\nClinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy\nPatients with known active central nervous system (CNS) disease, including leptomeningeal involvement\nImpaired cardiac function, uncontrolled cardiac arrhythmia, or clinically significant cardiac disease including the following: a) New York Heart Association grade III or IV congestive heart failure, b) myocardial infarction within the last 6 months\nSubjects with a corrected QT (QTc) > 480 ms (QTc > 510 msec for subjects with a bundle branch block at baseline)\nNursing or pregnant women\nSubjects with known hypersensitivity to study drugs or their excipients"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of relapsed/refractory advanced malignancies. Specifically: relapsed refractory refractory acute myeloid leukemia that have failed one line of prior therapy, myelodysplastic syndrome that have failed hypomethylating agents, myelofibrosis that have failed ruxolitinib or are ineligible for this therapy.\n18 years of age or greater.\nECOG performance status of 0-1.\nAble to provide informed consent.\nSubjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 2 months after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate.\nAble to swallow and retain oral medication.\n\nNormal organ and marrow function defined as:\n\nTotal bilirubin \u2264 1.5 x the upper limits of normal (ULN) except for patients with Gilbert's disease.\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 x ULN (\u2264 5 x ULN for subjects with liver involvement of their cancer).\nAlkaline phosphatase limit \u2264 2.5 x ULN (\u2264 5 x ULN for subjects with liver or bone involvement of their cancer).\nSerum creatinine \u2264 1.5 x the ULN.\nInternational normalized ratio (INR)/ Partial thromboplastin time (PTT) \u2264 1.5 x ULN. (Subjects who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists.)\n\nExclusion Criteria:\n\nPrevious assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter the study.\nSystemic antineoplastic therapy in the past 14 days (excluding hydroxyurea).\nUncontrolled hypertension (systolic pressure >140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management.\n\nActive or clinically significant cardiac disease including:\n\nCongestive heart failure - New York Heart Association (NYHA) > Class II.\nActive coronary artery disease.\nCardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.\nUnstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization.\nEvidence or history of bleeding diathesis or coagulopathy.\nEligible for, have a suitable donor and are willing to undergo Hematopoietic Stem Cell Transplantation (HSCT)\nAny hemorrhage or bleeding event \u2265 NCI CTCAE Grade 3 within 4 weeks prior to start of study medication.\nThrombotic, embolic, venous or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent.\nPreviously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated non-melanoma skin carcinoma, noninvasive aerodigestive neoplasms or superficial bladder tumor. Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed. All cancer treatments must be completed at least 3 years prior to registration.\nKnown history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.\nPresence of a non-healing wound, non-healing ulcer or bone fracture.\nMajor surgical procedure or significant traumatic injury within 28 days before start of study medication.\nRenal failure requiring hemo-or peritoneal dialysis.\nSeizure disorder requiring medication.\nPersistent proteinuria \u2265 Grade 3 NCI-CTCAE v4.0 (> 3.5 g/24 hrs, measured by urine protein: creatinine ratio on a random urine sample).\nInterstitial lung disease with ongoing signs and symptoms at the time of informed consent.\nPleural effusion or ascites that causes respiratory compromise (\u2265 NCI-CTCAE version 4.0 Grade 2 dyspnea).\nHistory of organ allograft (including corneal transplant). Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.\nAny malabsorption condition.\nWomen who are pregnant or breast-feeding, or intend to become pregnant during the study. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.\nSubstance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results.\nPresence of unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 grade 0 or 1 with the exception of alopecia. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by regorafenib (e.g. hearing loss, neuropathy) may be included after consultation with the principal investigator.\nUncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements"
            },
            {
                  "document": "Inclusion Criteria:\n\nMale or female age \u226518 years old;\nSigned informed consent form\n\nOne of the two following:\n\ni) AML either de novo or secondary [any subtype except acute promyelocytic leukemia (APL)] who either:\n\nare in relapse to standard therapy following an initial response\nfailed primary induction therapy with no CR (failed \u22652 courses of intensive induction therapy. Intensive chemotherapy defined as an intensity of \u2265 5+2)\nnewly diagnosed untreated AML in patients \u2265 65 years of age with high risk cytogenetics, if they are not candidates for standard available induction chemotherapy\nAML secondary to MDS, either relapsed or refractory, previously treated with hypomethylating agents for at least 4 cycles;\nRelapsed or refractory AML unfit for intensive chemotherapy previously treated with a low intensity regimen (e.g. low dose Ara-c, hypomethylating agent, etc.) including Venetoclax for at least 2 cycles;\n\nOR ii) MDS patients who meet the following criteria: very high-risk disease (IPSS-R score > 6, Greenberg et al., 2012), either relapsed or refractory, previously treated with hypomethylating agents for at least 4 cycles;\n\nMust have baseline BM sample taken by BMA/BMB within 28 days prior to first dose of MCLA-117 for CLEC12A detection;\nEstimated life expectancy of at least 8 weeks;\nEastern Cooperative Oncology Group (ECOG) performance status \u2264 2;\nSignificant toxicities incurred as a result of previous anti-cancer therapy resolved to \u2264 Grade 1 (NCI-CTCAE version 4.03);\nAcceptable laboratory values at screening;\nMale patients must agree to use an adequate and medically accepted method of contraception throughout the study and for at least 6 months after if their sexual partners are women of child bearing potential (WOCBP).\nWOCBP must be using highly effective and medically accepted method of contraception to avoid pregnancy throughout the study and for at least 6 months after the study ;\nWOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug.\nPeripheral blast count </= 30,000/mm3 at the time of initiation of infusion on Cycle 1 Day 1.\nAble and willing to comply with all study procedures.\n\nExclusion Criteria:\n\nDiagnosis of chronic myelogenous leukemia in blast crisis;\nPrior hematopoietic stem cell transplantation (this exclusion applies for dose escalation Part 1 and Cohort A of Part 2);\nFor patients in Cohort B of Part 2, prior hematopoietic stem cell transplantation is allowed under certain circumstances.\nTreatment with anticancer medications, investigational drugs or radiotherapy is allowed within 2 weeks or 5 half-lives prior to start of MCLA-117;\nPrevious receipt of live vaccines in the 4 weeks prior to study drug administration;\nChronic concurrent need of use of corticosteroids > 10 mg/day of oral prednisone or the equivalent, except topical preparations (e.g., topical creams, steroid inhaler, nasal spray or ophthalmic solution);\nUse of immunosuppressant medications within 4 weeks of MCLA-117 administration;\nClinically active central nervous system (CNS) leukemia;\nPatients who are pregnant or lactating;\nPatients with an active infection or with an unexplained fever during screening or on the first scheduled day of dosing;\nPatients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;\nPatients with known HIV, hepatitis B or C;\nPatients with New York Heart Association Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 50%, or significant uncontrolled cardiac disease, current diagnosis of unstable angina, uncontrolled congestive heart failure, new myocardial infarction, or ventricular arrhythmia requiring medication;\nPrior malignancy (other than basal cell carcinoma and cervical in situ carcinoma) unless treated with a curative intend and without evidence of malignant disease for 1 year before screening. Patients with prior hematologic malignancies that have progressed to AML (such as Myelodysplastic syndrome, myeloproliferative neoplasms, bi-phenotypic leukemias, AcuteLymphocyticLeukemia) or AML that has relapsed are eligible;\nUrinary protein >2+ possibly indicative of renal disease. If the 24 hours urine protein shows a result of < 100 mg protein, subject can be eligible;\nPatients with any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results;\nWOCBP or males with a WOCB partners not willing to use highly effective and medically accepted methods of contraception for 6 months after last study drug administration.\nNeed for concurrent other cytoreductive chemotherapy."
            },
            {
                  "document": "Inclusion Criteria:\n\nRelapsed or refractory:\n\nGroups A, B, or C: Multiple myeloma (MM) previously treated with an immunomodulatory drug (IMID), a proteosome inhibitor and an alkylating agent; OR\nGroups A or B: Acute myeloid leukemia (AML), excluding acute promyelocytic leukemia (PML-RARA rearranged- AML-M3); either primary refractory or relapsed/refractory disease after at least two front line chemotherapy regimens (note: induction and consolidation chemotherapy is considered one line of therapy); diagnosis based on 2008 World Health Organization (WHO) criteria; OR\nGroups A, B, or C: Relapsed T-cell lymphoma (TCL) or the following types: peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS); angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell (ALCL), and cutaneous TCL (CTCL) of mycosis fungoides (MF); patients should have failed standard therapy and in the case of PTCL-NOS, AITL, and ALCL either have failed or be ineligible for high-dose therapy with autologous stem cell transplant\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 times upper limit of normal (ULN) (obtained =< 14 days prior to registration)\nCreatinine =< 2.0 mg/dL (obtained =< 14 days prior to registration)\nDirect bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)\nInternational normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (obtained =< 14 days prior to registration)\nIf baseline liver disease, Child Pugh score not exceeding class A (obtained =< 14 days prior to registration)\nNegative pregnancy test for persons of child-bearing potential (obtained =< 14 days prior to registration)\n\nFOR MULTIPLE MYELOMA ONLY: Measurable disease of multiple myeloma as defined by at least ONE of the following:\n\nSerum monoclonal protein >= 1.0 g/dL by protein electrophoresis\n>= 200 mg of monoclonal protein in the urine on 24-hour electrophoresis\nSerum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio\nFOR MULTIPLE MYELOMA ONLY: Absolute neutrophil count (ANC) >= 1000/uL (obtained =< 14 days prior to registration)\nFOR MULTIPLE MYELOMA ONLY: Platelet (PLT) >= 100,000/uL (obtained =< 14 days prior to registration)\nFOR MULTIPLE MYELOMA ONLY: Hemoglobin >= 8.5 g/dl (obtained =< 14 days prior to registration)\nFOR AML ONLY: No ANC restriction (obtained =< 14 days prior to registration)\nFOR AML ONLY: PLT >= 10,000/uL (transfusion to get platelets >= 10,000 is allowed) (obtained =< 14 days prior to registration)\nFOR AML ONLY: Hemoglobin >= 7.5 g/dl (obtained =< 14 days prior to registration)\nFOR AML ONLY: Absence of uncompensated disseminated intravascular coagulation (DIC- as diagnosed by standard International Society on Thrombosis and Hemostasis [ISTH] criteria)\nFOR TCL ONLY: ANC >= 1,000/uL (obtained =< 14 days prior to registration)\nFOR TCL ONLY: PLT >= 100,000/uL (obtained =< 14 days prior to registration)\nFOR TCL ONLY: Hemoglobin >= 8.5 g/dl (obtained =< 14 days prior to registration)\nFOR TCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): must have at least one lesion that has a single diameter of > 2 cm or tumor cells in the blood > 5 x 10^9/L; NOTE: skin lesions can be used if the area is > 2 cm in at least one diameter and photographed with a ruler and the images are available in the medical record\nAbsence of active central nervous system (CNS) involvement; NOTE: pre-enrollment lumbar puncture not mandatory\nAbility to provide written informed consent\nWillingness to return to Mayo Clinic for follow-up\nLife expectancy >= 12 weeks\nEastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\nWilling to provide mandatory biological specimens for research purposes\n\nExclusion Criteria:\n\nAvailability of and patient acceptance of curative therapy\nUncontrolled infection\nActive tuberculosis or hepatitis, or history of hepatitis B or C, or chronic hepatitis\n\nAny of the following prior therapies:\n\nChemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =< 2 weeks prior to registration\nImmunotherapy (monoclonal antibodies) =< 4 weeks prior to registration\nExperimental agent in case of AML or TCL within 4 half-lives of the last dose of the agent\nNew York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia [SVT])\nActive CNS disorder or seizure disorder or known CNS disease or neurologic symptomatology; in case of AML active CNS involvement as detected by lumbar puncture or neuro-imaging (only to be done if clinically indicated)\nHuman immunodeficiency virus (HIV) positive test result or other immunodeficiency or immunosuppression\n\nOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation);\n\nNOTE: in AML, the concurrent use of hydroxyurea to help control proliferative counts is allowed throughout the treatment protocol;\nNOTE: in TCL, patients may use topical emollients or corticosteroids, acetic acid soaks, etc. to control pruritis and prevent infection; no topical chemotherapy is allowed (no topical nitrogen mustard)\n\nAny of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\nPregnant women or women of reproductive ability who are unwilling to use effective contraception\nNursing women\nMen who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment\nPrior allogeneic bone marrow transplant\nAML ONLY: Current disseminated intravascular coagulopathy (DIC)\nADDITION EXCLUSION CRITERIA FOR GROUP A (LOW TUMOR BURDEN) ONLY\nAML ONLY: Acute promyelocytic leukemia (PML-RARA rearranged- AML-M3)\nAML ONLY: AML with > 30% circulating blasts and > 50% bone marrow blasts\nMULTIPLE MYELOMA ONLY: Multiple : >= 15% plasmas cells or plasmacytoma > 5 cm in largest diameter\nTCL ONLY: Any mass >= 5 cm\nADDITIONAL EXCLUSION CRITERIA FOR GROUP C (COMBINATION WITH CYCLOPHOSPHAMIDE) ONLY:\nDiagnosis of AML"
            },
            {
                  "document": "Inclusion Criteria:\n\nAdults, age 60 years or older at the time of diagnosis unless in a specific known cytogenetic and genomic group for which treatment in Group A or B is allowed by the sub-study where age 18 and older is allowed.\nSubjects or their legal representative must be able to understand and provide written informed consent\nCohort Inclusion Criteria - Group A: Subjects must have previously untreated acute myeloid leukemia (AML) according to the WHO classification with no prior treatment other than hydroxyurea. Prior therapy for myelodysplastic syndrome (MDS), myeloproliferative syndromes (MPD), or aplastic anemia is permitted but not with hypomethylating agents.\nCohort Inclusion Criteria - Group B: Subjects must have relapsed or refractory AML according to the WHO classification. For study purposes, refractory AML is defined as failure to ever achieve CR or recurrence of AML within 6 months of achieving CR; relapsed AML is defined as all others with disease after prior remission.\n\nExclusion Criteria:\n\nIsolated myeloid sarcoma (meaning, patients must have blood or marrow involvement with AML to enter the study)\nAcute promyelocytic leukemia\nSymptomatic central nervous system (CNS) involvement by AML\nSigns of leukostasis requiring urgent therapy\nDisseminated intravascular coagulopathy with active bleeding or signs of thrombosis\nPatients with psychological, familial, social, or geographic factors that otherwise preclude them from giving informed consent, following the protocol, or potentially hamper compliance with study treatment and follow-up\nAny other significant medical condition, including psychiatric illness or laboratory abnormality, that would preclude the patient participating in the trial or would confound the interpretation of the results of the trial"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients diagnosed with acute myeloid leukemia (AML) by World Health Organization (WHO) classification, meeting one of following criteria:\n\nAge 60 or older, newly diagnosed, untreated, who are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines\nAge 60 or older with relapsed or refractory disease\nYounger adult patients with previously untreated high-risk disease (complex karyotype, inv[3] or t[3;3], t[6;9], monosomal karyotype, therapy-related and secondary disease) that are unwilling to undergo or not candidates for conventional induction chemotherapy with cytarabine/anthracyclines and/or allogeneic stem cell transplantation\nYounger patients with refractory/relapsed AML who are otherwise not candidates for allogeneic stem cell transplantation\nPatients with extramedullary disease who meet one of the above criteria may be included\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nPatients with co-morbid medical illness, life expectancy attributed to this must be greater than 6 months\nThe effects of pevonedistat and decitabine on the developing fetus is unknown; for this reason, women of child bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for 4 months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n\nFemale patients must be:\n\nPostmenopausal for at least 1 year before the screening visit, OR\nSurgically sterile, OR\n\nIf they are of childbearing potential\n\nAgree to practice 1 highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), OR\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception)\n\nMale patients, even if surgically sterilized (i.e., status post-vasectomy) must:\n\nAgree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug (female and male condoms should not be used together), or\nAgree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception)\nCreatinine < 1.5 X institutional upper limit of normal\nOR creatinine clearance >= 60 mL/min for patients with creatinine levels above 1.5 X institutional upper limit of normal\nCardiac ejection fraction >= 50%\nAlbumin > 2.7 g/dL\nTotal bilirubin =< institutional upper limit of normal (ULN) (except in patients with Gilbert's syndrome; patients with Gilbert's syndrome may enroll if direct bilirubin is =< 1.5 x ULN\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ULN unless higher levels are related to leukemic infiltration\nHemoglobin > 8 g/dL; patients may be transfused to receive this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed\nAll subjects must have the ability to understand and the willingness to sign a written informed consent\n\nThe following patients are allowed:\n\nPatients may have been treated for AML or antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, 5-azacitidine or decitabine\nAny prior chemo therapy must have been completed >= 2 weeks prior to day 1 of study treatment and the participant must have recovered to eligibility levels from prior toxicity\nThere is no limit for prior chemo regimens\nPatients may have received hematopoietic stem cell transplantation for AML or other diseases\nHydroxyurea is allowed prior to day 1 of study treatment for count control and during cycle 1; the use of hydroxyurea is not allowed beyond completion of cycle 1\n\nExclusion Criteria:\n\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat or decitabine\nPatients have received prior chemotherapy or radiation for AML < two weeks before study enrollment, or those who have not recovered from the adverse events due to agents administered\nFemales who are both lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drug\nPatients with additional (other than AML) active malignancies, other than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin; patients are not considered to have a \"currently active\" malignancy if they have completed therapy for a prior malignancy and disease free from prior malignancies for > 2 years\nLife-threatening illness unrelated to cancer\n\nKnown cardiopulmonary disease defined as one of the following:\n\nUnstable angina\nUncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg)\nCardiomyopathy or history of ischemic heart disease\nArrhythmia (eg, history of polymorphic ventricular fibrillation or torsade de pointes); permanent atrial fibrillation (a fib) defined as a fib >= 6 months; persistent a fib defined as sustained a fib lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening; however, patients with < grade 3 atrial fibrillation (a fib) for a period of at least 6 months may enroll; grade 3 a fib is symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation; patients with paroxysmal a fib are permitted to enroll\nImplantable cardioverter defibrillator\nCongestive heart failure (New York Heart Association [NYHA] class III or IV; or class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within 4 weeks before screening),\nMyocardial infarction and/or revascularization (eg, coronary artery bypass graft, stent) within 6 months of first dose of study drug\nPatients who had ischemic heart disease who have had ACS, MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll\nModerate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing)\nPulmonary hypertension\nPatients with uncontrolled coagulopathy or bleeding disorder\nProlonged rate corrected QT (QTc) interval of > 500 msec, calculated according to institutional guidelines\nLeft ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography\nKnown moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis\nAny serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures\nTreatment with any investigational products within 14 days before the first dose of any study drug\nActive uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, septicemia, or methicillin resistant Staphylococcus aureus infection\nMajor surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period\nKnown central nervous system (CNS) involvement\nKnown human immunodeficiency virus (HIV) seropositive\nKnown hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection; Note: Patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load; patients who have positive hepatitic C antibody may be included if they have an undetectable hepatitis C viral load\nKnown hepatic cirrhosis or severe pre-existing hepatic impairment\nSystemic antineoplastic therapy or radiotherapy for other malignant conditions within 14 days before the first dose of any study drug, except for hydroxyurea\nWhite blood cell (WBC) > 50,000/mcL\nTreatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of the study drug; clinically significant metabolic enzyme inducers are not permitted during this study (CYP3A4/5 inducers)\nFemale patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)\nMale patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)\nSubjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\npatients with diagnosis of Acute Myeloid Leukemia, all comers (completed) and bearing IDH1 or IDH2 mutation (open for recruitment)\nPatient has no standard therapeutic options available and has either Relapsed AML unsuitable for intensive chemotherapy and not eligible for any approved targeted therapy or Primary refractory AML unsuitable for intensive chemotherapy and not eligible for any approved targeted therapy\n\nExclusion Criteria:\n\nanti-cancer treatments (including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy or investigational drugs) received within 14 days or 5 half-lives for targeted therapies (whichever is shorter) before first dose of study drug (to be supplemented)"
            },
            {
                  "document": "Inclusion Criteria:\n\nAny of the following hematologic malignancies:\n\nAcute myeloid leukemia (AML) in first cytomorphological remission (with < 5% blasts in the bone marrow) with Disease Risk Index (DRI) intermediate or above, or in second or higher cytomorphological remission (with < 5% blasts in the bone marrow)\nAcute lymphoblastic leukemia (ALL) in first or higher remission (with < 5% blasts in the bone marrow)\nMyelodysplastic syndrome (MDS): transfusion-dependent (requiring at least one transfusion per month), or intermediate or higher Revised International Prognostic Scoring System (IPSS-R) risk group\nClinical justification of allogeneic stem cell transplantation where a suitable HLA matched sibling or unrelated donor is unavailable in a timely manner\nAvailability of a related haploidentical donor with one fully shared haplotype and 2 to 4 mismatches at the HLA-A, -B, -C, and -DRB1 loci of the unshared haplotype, as determined by high resolution human leukocyte antigen (HLA)-typing\nKarnofsky Performance Status (KPS) \u2265 70%\nMale or female, age \u2265 18 years and \u2264 70 years. Patients aged \u2265 65 years must have a Sorror score \u2264 3\nPatient weight \u2265 25 kg and \u2264 130 kg\nAvailability of a donor aged \u2265 16 years and \u2264 75 years who is eligible according to local requirements and regulations. Donors aged < 16 years are allowed if they are the only option for an HSCT, if they are permitted by local regulations, and if the IRB/IEC approves participation in the study.\nFor females of childbearing potential who are sexually active and males who have sexual contact with a female of childbearing potential: willingness to use of reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) during study participation\nGiven written informed consent (patient and donor)\n\nExclusion Criteria:\n\nDiagnosis of chronic myelomonocytic leukemia (CMML)\nAvailability of a suitable HLA-matched sibling or unrelated donor in a donor search\nPrior allogeneic hematopoietic stem cell transplantation\nDiffusing capacity for carbon monoxide (hemoglobin corrected DLCO) < 50% predicted\nLeft ventricular ejection fraction < 45% (evaluated by echocardiogram or MUGA scan)\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 \u00d7 upper limit of normal (CTCAE grade 2)\nCreatinine clearance < 50 ml/min (calculated or measured)\nPositive pregnancy test or breastfeeding of patient or donor (women of childbearing age only)\nEstimated probability of surviving less than 3 months\nKnown allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)\nKnown hypersensitivity to cyclophosphamide or any of its metabolites\nAny contraindication for GVHD prophylaxis with mycophenolate mofetil, cyclosporine A, or tacrolimus\nKnown presence of HLA antibodies against the non-shared donor haplotype\nPositive viral test of the patient or donor for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum, human T-lymphotropic virus (HTLV)-1 (if tested), HTLV-2 (if tested), West Nile virus (WNV; if tested), or Zika virus (if tested)\nAny other condition that, in the opinion of the investigator, makes the patient or donor ineligible for the study"
            },
            {
                  "document": "Registration Inclusion Criteria\n\nParticipant is considered a suitable candidate for HCT and has an acceptable source of allogeneic donor stem cells, as defined per institutional practice (allogeneic HCT for any donor source [matched sibling, unrelated donor (URD), mismatched URD, related haploidentical, or umbilical cord blood] and any graft source [umbilical cord, BM, peripheral blood (PB)], and any conditioning [myeloablative conditioning (MAC), reduced intensity conditioning (RIC), or non-myeloablative conditioning (NMA)] will be permitted).\nParticipant is considered a legal adult by local regulation at the time of signing informed consent form (ICF).\nParticipant consents to allow access to diagnostic BM aspirate or PB sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic that is being developed in parallel with gilteritinib.\n\nParticipant has confirmed, morphologically documented AML in CR1. For the purposes of registration, CR1 will be defined as < 5% blasts in the BM with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.\n\nParticipant has not received more than 2 cycles of induction chemotherapy to achieve CR1. The induction cycles can be the same regimen or different regimens. The regimen(s) may contain conventional agents, investigational agents, or a combination of both.\nParticipants with CR with incomplete count recovery (CRp or CRi) are allowed. Incomplete platelet recovery (CRp) is defined as CR with platelet count < 100 x 109/L. Incomplete blood count recovery (CRi) is defined as CR with residual neutropenia < 1 x 109/L with or without complete platelet recovery. Red blood cell count (RBC) and platelet transfusion independence is not required.\nThe maximum time allowed from establishment of CR1 to registration is 12 months.\nParticipant has presence of the FLT3/ITD activating mutation in the BM or PB as determined by the local institution at diagnosis.\n\nParticipant must meet the following criteria as indicated on the clinical laboratory tests:\n\nSerum creatinine within normal range, or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 40 mL/min/1.73m2 as calculated with the Cockcroft-Gault equation with adjustment if total body weight is \u2265 125% of ideal body weight.\nTotal bilirubin (TBL) \u2264 2.5 mg/dL, except for participants with Gilbert's syndrome.\nSerum AST and/or alanine aminotransferase (ALT) < 3 x institutional upper limit of normal (ULN).\nParticipant has left ventricular ejection fraction at rest \u2265 40%.\nParticipant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) \u2265 50% predicted and/or forced expiratory volume in 1 second (FEV1) \u2265 50% predicted.\n\nFemale participants must either:\n\nBe of non-childbearing potential:\npostmenopausal (defined as at least 1 year without menses) prior to screening or\ndocumented as surgically sterilized (at least 1 month prior to the screening visit)\n\nOr, if of childbearing potential,\n\nAgree not to try to become pregnant during the study for 6 months after the final study drug administration\nAnd have a negative serum pregnancy test at screening\nAnd, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and throughout the study period and for 6 months after the final study drug administration.\nFor United Kingdom sites:\nHighly effective forms of birth control include:\nConsistent and correct usage of established hormonal contraceptives that inhibit ovulation\nEstablished intrauterine device (IUD) or intrauterine system (IUS)\nFemale participants must agree not to breastfeed or donate ova throughout the study drug treatment period and for 6 months after the final study drug administration.\n\nMale participants (even if surgically sterilized), and partners who are women of childbearing potential must be using highly effective contraception in addition to a barrier method throughout the study drug treatment period and for 127 days after the final study drug administration.\n\nFor United Kingdom sites:\nHighly effective forms of birth control include:\nConsistent and correct usage of established hormonal contraceptives that inhibit ovulation\nEstablished IUD or IUS\nVasectomy (A vasectomy is a highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.)\nMale is sterile due to a bilateral orchiectomy\nMale participants must not donate sperm throughout the study drug treatment period and for 127 days after the final study drug administration.\nParticipant is able to take an oral medication.\nParticipant agrees not to participate in another interventional study while on treatment.\n\nRandomization Inclusion Criteria\n\nParticipant is \u2265 30 days and \u2264 90 days from hematopoietic cell infusion.\nParticipant has achieved engraftment. Engraftment is defined as ANC \u2265 500 cells/\u03bcL and platelets \u2265 20000/\u03bcL on 3 consecutive measurements (each occurring at least 1 day apart). The participant must not have had a platelet transfusion within 7 days prior to the first measurement.\nParticipant has confirmed ongoing morphologically documented AML in CR1. For the purposes of randomization, CR1 will be defined as < 5% blasts with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.\n\nParticipant meets the following criteria as indicated on the clinical laboratory tests:\n\nSerum creatinine within normal range, or if serum creatinine outside normal range, then GFR > 40 mL/min/1.73m2 as calculated with the Cockcroft-Gault equation with adjustment if total body weight is \u2265 125% of ideal body weight.\nTBL < 2.5 mg/dL, except for participants with Gilbert's syndrome.\nSerum AST and/or ALT < 3 x institutional ULN.\nSerum potassium and magnesium \u2265 the institutional lower limit of normal (LLN).\n\nIf the participant has developed overall grades II-IV acute GVHD, the following criteria must be met to be randomized:\n\nNo requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1 week of randomization\nNo escalation of systemic immunosuppression in terms of increase of corticosteroids or addition of new agent / modality within 2 weeks of randomization. (Note that increasing calcineurin inhibitors or sirolimus to achieve therapeutic trough levels is allowed.) Topical skin and topical gastrointestinal steroids are allowed.\nParticipant is able to take oral medication.\n\nRegistration Exclusion Criteria\n\nParticipant has had a prior allogeneic transplant.\nParticipant has Karnofsky performance status score < 70% .\nParticipant requires treatment with concomitant drugs that are strong inducers of CYP3A within 14 days of start of study drug.\nParticipant requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the participant.\nParticipant has a Fridericia-corrected QT interval (QTcF) > 450 msec (average of triplicate determinations) per central read.\nParticipant has long QT Syndrome at screening.\nParticipant has a known infection with human immunodeficiency virus (HIV).\nParticipant has active hepatitis B infection as determined by NAAT or surface antigen assay. Participants who have acquired immunity from past exposure (HBcAb positive / HBsAb positive / HBsAg negative) are eligible.\nParticipant has active hepatitis C infection as determined by NAAT. NAAT must be performed if the participant has positive serology for hepatitis C. Participants who have had past exposure and have no detectable virus either through spontaneous clearance or treatment are eligible.\n\nParticipant has an uncontrolled infection. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to registration. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to registration.\n\nProgressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.\nPersisting fever without other signs or symptoms will not be interpreted as progressing infection.\nParticipant has had a myocardial infarction within 6 months prior to registration or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.\nParticipant has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.\nParticipant is breast feeding or pregnant.\nParticipant has prior malignancies, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ.\n\nCancer treated with curative intent \u2265 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.\n\nRandomization Exclusion Criteria\n\nParticipant requires treatment with concomitant drugs that are strong inducers of CYP3A within 14 days of starting study drug.\nParticipant requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR or sigma nonspecific receptor with the exception of drugs that are considered by the investigator to be absolutely essential for the care of the participant and for which no acceptable alternative exists.\nParticipant has a QTcF interval > 450 msec (average of triplicate determinations) by central read.\nParticipant has a need for supplemental oxygen with the exception of using previously existing non-invasive continuous positive airway pressure (CPAP) at night.\nParticipant has used investigational agents within 4 weeks of randomization.\nParticipant has used experimental therapy for acute GVHD within 4 weeks of randomization. If unsure of the definition of \"experimental\", discussion with one of the protocol chairs is recommended.\n\nParticipant has an uncontrolled infection. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.\n\nProgressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.\nPersisting fever without other signs or symptoms will not be interpreted as progressing infection."
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipant must have confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, previously untreated and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due age or comorbidities.\nParticipant must be >= 18 years of age.\nParticipant must have a projected life expectancy of at least 12 weeks.\n\nParticipant must be considered ineligible for induction therapy defined by the following:\n\na. >= 75 years of age; or b. >= 18 to 74 years of age with at least one of the following comorbidities: i. Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or 3; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction <= 50% or chronic stable angina; iii. Diffusing capacity of the Lung for Carbon Monoxide (DLCO) <= 65% or Forced Expiratory Volume in 1 second (FEV1) <= 65%; iv. Creatinine clearance >= 30 mL/min to < 45 ml/min; v. Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 \u00d7 Upper Limit of Normal (ULN); vi. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Medical Director during screening and before study enrollment.\n\nParticipant must have an ECOG Performance status:\n\n0 to 2 for Participants >= 75 years of age or\n0 to 3 for Participants >= 18 to 74 years of age.\nParticipant must have adequate renal function as demonstrated by a creatinine >= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.\n\nParticipant must have adequate liver function as demonstrated by:\n\naspartate aminotransferase (AST) <= 3.0 x ULN*\nalanine aminotransferase (ALT) <= 3.0 x ULN*\nbilirubin <= 1.5 x ULN* * Unless considered to be due to leukemic organ involvement\n\ni. Subjects who are < 75 years of age may have a bilirubin of <= 3.0 x ULN\n\nFemale participants must be either postmenopausal defined as:\n\nAge > 55 years with no menses for 12 or more months without an alternative medical cause.\nAge \u2264 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level > 40 IU/L; or\nPermanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); or\nWomen of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control, starting at Study Day 1 through at least 90 days after the last dose of study drug.\nMale Participants who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.\n\nFemale participants of childbearing potential must have negative results for pregnancy test performed:\n\nAt Screening with a serum sample obtained within 14 days prior to the first study drug administration, and\nPrior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.\nParticipant must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.\n\nExclusion Criteria:\n\nParticipant has received treatment with the following:\n\nA hypomethylating agent, venetoclax and/or chemo therapeutic agent for Myelodysplastic syndrome (MDS).\nChimeric Antigen Receptor (CAR)-T cell therapy.\nExperimental therapies for MDS or Acute Myeloid Leukemia (AML).\nCurrent participation in another research or observational study.\nParticipant has history of myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.\n\nParticipant has the following:\n\na. Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute Myeloid Leukemia.\n\nParticipant has acute promyelocytic leukemia\nParticipant has known active central nervous system (CNS) involvement with AML.\nParticipant has known HIV infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax) HIV testing will be performed at Screening, only if required per local guidelines or institutional standards.\nParticipant is known to be positive for hepatitis B or C infection [HCV Ab indicative of a previous or current infection; and/or positive HBs Ag or detected sensitivity on HBV DNA PCR test for HBc Ab and/or HBs Ab positivity] with the exception of those with an undetectable viral load within 3 months screening. Hepatitis B or C testing is not required.\nParticipant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment; additional details as described in the protocol.\nParticipant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.\nParticipant has a cardiovascular disability status of New York Heart Association Class > 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.\nParticipant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients of azacitidine that in the opinion of the investigator would adversely affect his/her participating in this study.\nParticipant has a malabsorption syndrome or other condition that precludes enteral route of administration.\nParticipant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).\n\nParticipant has a history of other malignancies within 2 years prior to study entry, with the exception of:\n\nAdequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;\nBasal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\nPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent; requires discussion with TA MD.\nParticipant has a white blood cell count > 25 \u00d7 10^9/L. (Hydroxyurea or leukapheresis are permitted to meet this criterion.)"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant using a reduced intensity conditioning is planned or has been performed and patient is prior to day 60 post-transplant.\n\nAble to begin study treatment between day +42 and day +60 after the transplant and meets the following transplant related requirements:\n\nSustained neutrophil (ANC > 1000/mcL) and platelet (> 30,000/mcL) engraftment\n>50% donor myeloid and lymphoid chimerism blood or bone marrow on most recent bone marrow (BM) evaluation\nNo evidence of recurrent disease on most recent bone marrow evaluation (day 21 or 28 post-transplant is acceptable)\nNo morphologic evidence of relapse (< 5% bone marrow blasts) on most recent BM evaluation (Day 21 or 28 post-transplant is acceptable)\nBeing followed in the outpatient setting (not an inpatient)\nNo plan of giving other anti-cancer treatment directed at diseases under study (i.e. maintenance therapy [e.g. sorafenib for FLT3m+ AML or hypomethylating therapy], additional therapy for MRD)\nIf acute GVHD is present it must be clinically improving on topical steroids and/or on low dose systemic steroids (\u2264 0.3 mg/kg/day prednisone) and with clinical stability for at least 1 week prior to determination of eligibility. GVHD prophylaxis will be continued per individual institutional standard practice\n\nOne of the following donor graft sources used for the transplant:\n\nGroup 1: sibling donor\nGroup 2: haploidentical donor [with post-transplant cyclophosphamide]\nGroup 3: unrelated donor\nGroup 4: unrelated umbilical cord blood\nKarnofsky performance status \u2265 70%\n\nAdequate organ function within 14 days of study enrollment defined as:\n\nRenal: serum creatinine: \u2264 2.0 mg/dL\nHepatic: SGOT \u2264 3 x upper limit of institutional normal (ULN)\nSexually active females of child-bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy.\nVoluntary written consent prior to the performance of any research related procedures\n\nExclusion Criteria:\n\nPrior N-803 (previously known as ALT-803)\nPregnant or breastfeeding - N-803 is an investigational agent. Women of child bearing potential must have a negative pregnancy test at screening.\nClass II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)\nMarked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval > 500 milliseconds)\nActive uncontrolled bacterial, fungal, or viral infections - all prior infections must have resolved following optimal therapy and must be afebrile for at least 24 hours at time of enrollment.\nActive autoimmune disease requiring immunosuppressive therapy (GVHD prophylaxis is permitted per institutional practice)\nHistory of severe asthma and currently on chronic medications (mild asthma requiring inhaled steroids only is eligible)\nReceived any investigational agent within the 14 days before the start of study treatment (1st dose of N-803)"
            },
            {
                  "document": "Inclusion Criteria:\n\nMale or female subjects with AML, MDS or mature B cell lymphomas that have relapsed following matched-related donor (MRD) or matched unrelated donor (MUD) (HLA-A -B -C -DR -DQ) alloSCT are eligible for enrollment\n\nSigned written informed consent\n\nSubjects must have signed and dated an IRB-approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.\nSubjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.\n\nTarget population\n\nSubjects must be \u2265 18 years of age.\nSubjects must have an ECOG performance status of 0-1 (Appendix).\nSubjects have undergone alloSCT > 90 days prior to enrollment from a matched-related donor (MRD), matched-unrelated donor (MUD), cord blood donor, or haplo-identical and cord blood donor.\nThere must be histological confirmation of relapse after alloSCT of any of the following diseases: any mature B cell lymphoma (cHL or NHL), AML or MDS.\nSubjects must be off of all immunosuppressive medications for a minimum of 2 weeks with the exception of physiologic doses of corticosteroids.\nSubjects with B cell lymphoma must have measurable disease, defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with CT scan. Minimum measurement must be > 15 mm in the longest diameter and > 10 mm in the short axis.\nSubjects must not have had any prior investigational agents or devices within 4 weeks of beginning study drug\nSubjects must have no prior history of VOD\n\nSubjects must demonstrate adequate organ function as defined below. All screening labs should be performed within 10 days of treatment initiation.\n\nHematological Absolute neutrophil count (ANC) \u2265 500 /mcL Platelets \u2265 20,000 /mcL Hemoglobin \u2265 8 g/dL (RBC transfusions are OK)\n\nRenal Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) \u2264 1.5 X upper limit of normal (ULN) or\n\n60 mL/min for subject with creatinine levels > 1.5 X institutional ULN\n\nHepatic Serum total bilirubin \u2264 1.5 X ULN or direct bilirubin \u2264 ULN for subjects with total bilirubin levels > 1.5X ULN AST (SGOT) and ALT (SGPT) \u2264 2.5 X ULN Albumin \u2265 2.0 mg/dL\n\nCoagulation International Normalized Ratio (INR) or Prothrombin Time (PT) \u2264 1.5 X ULN unless subject is receiving anticoagulant therapy, in which case, the PT/INR should be within therapeutic range for intended use. Activated Partial Thromboplastin Time (aPTT) \u2264 1.5 X ULN unless subject is receiving anticoagulant therapy, in which case, the PTT should be within therapeutic range for intended use.\n\n*Creatinine clearance should be calculated per institutional standard.\n\nFemale subjects of childbearing potential should have a negative urine or serum pregnancy test (\u03b2-hCG) within 72 hours prior to receiving the first dose of study medication.\nFemale subjects with childbearing potential should be willing to use 2 methods of contraception, be surgically sterile, or abstain from heterosexual activity throughout the course of the study, until 120 days after the final dose of study medication. Subjects with childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. Abstinence is acceptable if this is the established and preferred contraceptive method for the subject.\nMale subjects should agree to use an adequate method of contraception starting with the first dose of study medication until 120 days after the final dose of study medicine. Abstinence is acceptable if this is the established and preferred contraceptive method for the subject.\n\nExclusion Criteria:\n\n1. Target disease exclusions\n\nSubjects must not have known central nervous system involvement by disease (parenchymal, meningeal or cerebrospinal fluid) 2. Medical history, concurrent diseases, and prior treatments\nSubjects must not have a history of any positive test for hepatitis B or hepatitis C indicating active disease or previous exposure.\nSubjects must not have a history of human immunodeficiency virus (HIV) infection.\nSubjects must not be receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to the first dose of study medication. The use of physiologic doses of corticosteroids is acceptable.\nSubjects must not be concurrently receiving disease-modifying therapy in another therapeutic investigational study.\nSubjects must not have received a prior monoclonal antibody within 4 weeks prior to the first dose of study medication, and must have recovered (\u2264 grade 1) from adverse events related to any anti-cancer agent administered > 4 weeks previous to the first dose of study medication.\nSubjects must not have received chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of study medication, and must have recovered (\u2264 grade 1) from adverse events related to a previously administered agent.\nSubjects must not have received a donor lymphocyte infusion (DLI) within 8 weeks prior to the first dose of study medication.\nSubjects must not have a history of severe (grade 3-4) acute GVHD, and/or current > grade 1 acute GHVD. Subjects must not have a history of chronic GVHD (whether limited or extensive stage).\nSubjects must not have autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\nSubjects must not have a known history of congestive heart failure, unstable angina pectoris, or cardiac arrhythmia (with the exception of chronic and rate-controlled atrial fibrillation).\nSubjects must not have a history of other serious underlying medical or psychiatric condition that, in the opinion of the investigator, would impair the ability to receive, tolerate and or comply with the planned treatment and follow-up.\nSubjects must not have a history of a known secondary primary malignancy that is not in remission and/or that requires active therapy. Exceptions include non-melanoma skin cancers and in situ cervical cancer that has undergone curative-intent local therapy.\nSubjects must not have a known active infection requiring intravenous antibiotic therapy.\nSubjects must not have a history of (non-infectious) pneumonitis that required steroid treatment, evidence of interstitial lung disease, or active, non-infectious pneumonitis. Subjects must not have active, non-infectious colitis.\nSubjects must not be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the final dose of study medication.\nSubjects must not have received a live vaccine within 30 days prior to the first dose of study medication.\nSubjects must not be or have an immediate family member (spouse, parent, legal guardian, sibling or child) who is an investigational site sponsor or staff directly involved with the trial, unless IRB approval is granted previously."
            },
            {
                  "document": "Inclusion Criteria:\n\nLack of a human leukocyte antigen (HLA) matched related donor, lack of an immediately available 8/8 HLA matched unrelated donor\nPatients must be diagnosed with a high-risk and/or advanced hematologic malignancy defined as one of the following\nAcute lymphocytic leukemia (ALL) in complete remission (CR)1 with high-risk features including adverse cytogenetic such as t(9;22), t(1;19), t(4;11), or MLL gene rearrangements; in second or greater morphologic remission; persistent minimal residual disease\nAcute myeloid leukemia (AML) in CR1 with intermediate-risk disease and persistent detectable minimal residual disease (MRD), or with high-risk features defined as: greater than 1 cycle of induction therapy required to achieve remission; preceding myelodysplastic syndrome (MDS) or myeloproliferative disease; presence of FLT3 mutations or internal tandem duplications, DNMT3a, TET2, MLL-partial tandem duplication (PTD), ASXL1, PHF6; FAB M6 or M7 classification; adverse cytogenetics including: -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8, complex (> 3 abnormalities)\nPatients with AML must have less than 10% bone marrow blasts and < 100/mcL absolute peripheral blood blast count\nPatients with AML in CR2, subsequent CR or with active disease at transplant (< 10% bone marrow blasts)\nMDS with International Prognostic Scoring System (IPSS) intermediate-2 or higher, therapy-related MDS or chronic myelomonocytic leukemia (CMML)\nAplastic anemia with absolute neutrophil count (ANC) < 1,000 and transfusion dependent after failed immunosuppression therapy\nChronic myeloid leukemia (CML) >= 1st chronic phase, after failed >=2 lines of tyrosine kinase inhibitors; patients who progressed to blast phase must be in morphologic remission at transplant\nRelapsed Hodgkin's disease or non-Hodgkin's lymphoma (NHL)\nPatients with chemo-sensitive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with persistent or recurrent disease after fludarabine-based regimens with < 25% involvement by CLL/SLL cells\nPatients with lymphoblastic lymphoma in remission or after partial response to chemotherapy\nPatients with poor prognosis multiple myeloma by cytogenetics del13, del 17p, t(4;14) or t(14;16) or hypodiploidy, with advanced disease (stage >= 2) and /or relapsed after autologous stem cell transplant\nZubrod performance status 0-1 or Karnofsky performance status > 70%; patients > 50 years will have to have a Sorror Comorbidity Index =< 3\nAvailable haploidentical donor willing and eligible to undergo a peripheral blood collection\nLeft ventricular ejection fraction (LVEF) > 40%\nBilirubin =< 1.5 mg/dl (unless Gilbert's syndrome), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 200 IU/ml for adults; conjugated (direct) bilirubin < 2 x upper limit of normal\nSerum creatinine clearance >= 50 ml/min (calculated with Cockcroft-Gault formula)\nDiffusing capacity for carbon monoxide (DLCO) >= 45% predicted corrected for hemoglobin\nPatient or patient's legal representative must provide written informed consent\n\nExclusion Criteria:\n\nHuman immunodeficiency virus (HIV) positive; active hepatitis B or C\nPatients with active infections; the principal investigator (PI) is the final arbiter of the eligibility\nLiver cirrhosis with greater than grade 1 stage 1 inflammation/fibrosis\nUncontrolled central nervous system (CNS) involvement by tumor cells within the past 2 months\nHistory of another primary malignancy that has not been in remission for at least 3 years; (the following are exempt from the 3-year limit: nonmelanoma skin cancer, fully excised melanoma in situ [stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear)\nPositive beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization\nInability to comply with medical therapy or follow-up"
            },
            {
                  "document": "Inclusion Criteria:\n\nPhase I: Adult subjects with advanced MDS requiring therapy who were previously treated with either azacitidine or decitabine for at least 4 cycles and deemed to have failed therapy due to progression of disease using International Working Group (IWG) criteria (\"refractory\") or losing their previously documented response to the therapy (\"relapsed\")\nPhase II: Adult subjects with advanced MDS requiring therapy who were previously treated with either azacitidine or decitabine for at least 4 cycles and deemed to have failed therapy due to progression of disease using IWG criteria (\"refractory\") or losing their previously documented response to the therapy (\"relapsed\")\n\nMDS should be classified as:\n\nIntermediate 1-risk or higher risk according to the international prognostic scoring system (IPSS) or revised IPSS\nChronic myelomonocytic leukemia (CMML)\n\nDuring the 8 weeks prior to inclusion in study, subjects must have a baseline bone marrow examination including all of the following:\n\nCytomorphology to confirm bone marrow blasts;\nCytogenetics; AND\nEastern Cooperative Oncology Group (ECOG) status 0-2\nSubject is able to understand and willing to comply with protocol requirements and instructions\nSubject has signed and dated informed consent\nTotal bilirubin (except for Gilbert's syndrome) =< 2.5 x upper limit of normal (ULN)\nAspartate aminotransferase (ALT) and alanine aminotransferase (AST) =< 3 x ULN\nCreatinine =< 2.5 x ULN\n\nFor women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of atezolizumab\n\nA woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus)\nExamples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices\nThe reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\n\nFor men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:\n\nWith female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 120 days after the last dose of guadecitabine; men must refrain from donating sperm during this same period\nWith pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 30 days after the last dose of guadecitabine to avoid exposing the embryo\nThe reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception\nWomen of childbearing potential (WOCBP) must have a negative serum test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 72 hours prior to the start of investigational product\n\nExclusion Criteria:\n\nAny active history of a known autoimmune disease; subjects with vitiligo, type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger are permitted to enroll\nSubjects with a history of interstitial lung disease; patients requiring continuous supplemental oxygen are excluded to avoid possible complications from pneumonitis\nHistory of idiopathic pulmonary fibrosis, organizing pneumonitis (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis\nPatients who are actively receiving any other anticancer therapy\nPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to HMAs\nPatients with a diagnosis of acute myeloid leukemia (AML) not transformed from MDS or transformed from MDS with > 30% blasts in bone marrow or white blood cells (WBC) > 25 x 10^3/L\nPatients with short life expectancy (less than 3 months) due to comorbidity other than MDS\nFemale subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotropin [B-hCG] pregnancy test)\nPatients with current alcohol or drug abuse\nPatients who have received treatment with an investigational drug within 30 days preceding the first dose of study medication\n\nPatients with uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n\nPatients with prior infections must be afebrile for >= 72 hours and completed any antibiotics prior to receiving study drug\nIn patients who received IV antibiotics for active infection, a washout period of 14 days is required prior to initiating study therapy (exception: patients with febrile neutropenia in whom no infectious etiology has been determined/documented)\nPatients receiving chronic antimicrobial prophylaxis therapy (e.g. antifungal prophylaxis) may be included in the study provided there is no active infection\n\nPatients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatment\n\nSerious infection requiring oral or IV antibiotics/antifungals/antivirals and/or hospitalization within 28 days prior to screening\nPatients on prophylactic oral antibiotics, antifungals and antivirals due to prolonged neutropenia in the absence of documented infection are eligible\nPatients who are treated with IV antibiotics for neutropenic fever, are eligible if no infectious etiology was determined and the last dose of antibiotics was >= 7 days from cycle 1, day 1\nPatients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of uncontrolled autoimmune disease\nMedication-related exclusion criteria\nPrior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\nPrior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapeutic agents (e.g. ipilimumab)\nTreatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1\nTreatment with any investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)\nTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1\nPatients who have received acute, low-dose, systemic immunosuppressant medications may be enrolled\nThe use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed\nHistory of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\nPatients with prior allogeneic bone marrow transplantation or prior solid organ transplantation"
            },
            {
                  "document": "Inclusion Criteria:\n\nSubject is considered an adult according to local regulation at the time of obtaining consent form (ICF).\nSubject consents to allow access to subject's diagnostic bone marrow aspirate or peripheral blood sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic test for gilteritinib.\nSubject has confirmed morphologically documented AML, excluding acute promyelocytic leukemia (APL), in CR1 (including CRp and CRi). For the purposes of enrollment, CR will be defined as < 5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer rods) in the bone marrow with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.\nSubject will not proceed with transplantation as either a decision not to proceed with transplantation has been made either on the recommendation of the treating physician or by the patient or a suitable donor could not be identified.\nSubject is < 2 months from the start of the last cycle of consolidation and should have completed the recommended number of consolidations per local practice.\nSubject has had no use of investigational agents, with the exception of FLT3 inhibiting agents during induction and/or consolidation therapy, within the prior 4 weeks.\nSubject has had presence of the FLT3/ITD activating mutation in the bone marrow or peripheral blood as determined by the local institution at diagnosis.\nSubject has an ECOG performance status 0 to 2.\n\nSubject must meet the following criteria as indicated on the clinical laboratory tests:\n\nSerum creatinine \u2264 1.5 x institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 40 mL/min/1.73m^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.\nSerum total bilirubin \u2264 2.5 mg/dL (43 \u03bcmol/L), except for subjects with Gilbert's syndrome.\nSerum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN.\nSerum potassium and serum magnesium \u2265 institutional lower limit of normal (LLN).\nAbsolute neutrophil count (ANC) \u2265 500/\u03bcl and platelets \u2265 20000/\u03bcl (unsupported by transfusions).\nSubject is suitable for oral administration of study drug.\n\nFemale subject must either:\n\nBe of nonchildbearing potential:\nPostmenopausal (defined as at least 1 year without any menses) prior to screening, or\nDocumented surgically sterile or status posthysterectomy (at least 1 month prior to screening)\nOr, if of childbearing potential,\nAgree not to try to become pregnant during the study and for 6 months after the final study drug administration\nAnd have a negative urine or serum pregnancy test at screening\nAnd, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards (in addition to a barrier method) starting at screening and throughout the study period and for 6 months after the final study drug administration.\nFemale subject must agree not to breastfeed starting at screening and throughout the study period, and for 2 months and 1 week after the final study drug administration.\nFemale subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.\nMale subject and subject's female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards (in addition to a barrier method) starting at screening and continue throughout the study period and for 4 months and 1 week after the final study drug administration.\nMale subject must not donate sperm starting at screening and throughout the study period and for 4 months and 1 week after the final study drug administration.\nSubject agrees not to participate in another interventional study while on treatment.\n\nExclusion Criteria:\n\nSubject has had prior allogeneic transplant.\nSubject has QTcF interval > 450 msec (average of triplicate determinations based on central reading).\nSubject with Long QT Syndrome.\nSubject with hypokalemia and hypomagnesemia at screening (defined as values below LLN).\nSubject has clinically active central nervous system leukemia.\nSubject is known to have human immunodeficiency virus infection.\nSubject has active hepatitis B or C.\nSubject has an uncontrolled infection. If a bacterial or viral infection is present, the subject must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the subject must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.\nSubject has progressing infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\nSubject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 1 month prior to study entry results in a left ventricular ejection fraction that is \u2265 45%.\nSubject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.\nSubject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.\nSubject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.\nSubject has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.\nSubject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent \u2265 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.\nSubject has any condition which makes the subject unsuitable for study participation."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have histologic confirmation of relapsed and or refractory hematologic malignancy, locally advanced or metastatic colon/rectal carcinoma, or refractory and/or relapsed soft tissue sarcomas and have failed at least one standard line of therapy.\nPatients will be eligible if they have either declined standard treatment regimens or if there is no standard approach to curative salvage therapy per National Comprehensive Cancer Network (NCCN) guidelines in the setting of relapsed/refractory disease.\nIn addition, patients for whom a potential 29-day delay in treatment will not interfere with the subject's potential therapeutic options can be eligible per the treating physician's discretion.\n\nMalignancies can include:\n\nAcute myeloid leukemia\nMyelodysplastic syndrome\nAcute lymphoblastic leukemia\nChronic myeloid leukemia\nChronic lymphocytic leukemia\nNon Hodgkin Lymphoma\nHodgkin Lymphoma\nMyeloproliferative syndromes\nPlasma cell myeloma\nColon/rectal carcinoma\n\nSoft tissue sarcomas including but not limited to Ewing's sarcoma and Rhabdomyosarcoma\n\nPatients must have recovered from acute toxicities of prior chemotherapy or stem cell transplant. Any prior non-hematologic vital organ toxicity (cardiac, pulmonary, hepatic, renal) of previous therapy must have resolved to grade 1 or less.\nAll previous chemotherapy or radiation must be completed at least 3 weeks prior to study entry. Immunologic therapy must be completed at least 3 weeks prior to study entry. Patients with prior stem cell transplant must be greater than 365 days post-transplant.\nEastern Cooperative Oncology Group (ECOG) performance status \u22642\n\nOrgan function criteria (There is no exclusion for the presence of cytopenias),\n\nSerum total bilirubin <2 mg/dl (except if known Gilbert syndrome and normal transaminases)\nAspartate aminotransferase (AST) (SGOT) < 2.5 X institutional upper limit of normal\nAlanine aminotransferase (ALT) (SGPT) < 2.5 X institutional upper limit of normal\nPulmonary function (DLCO) >40% of the expected value corrected for alveolar volume and hemoglobin\nSerum Creatinine \u2264 1.5 X institutional upper limit of normal\nSubjects must have the ability to understand and the willingness to sign a written informed consent document.\nWomen of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry and for the duration of study participation. Women of child-bearing age must have documented negative pregnancy test prior to start of lympho-depleting regimen.\n\nExclusion Criteria:\n\nSubjects receiving any other investigational agents.\nSubjects for whom a potential 29-day delay in treatment will interfere with the subject's potential therapeutic options.\nPatients with untreated malignant involvement of the central nervous system (CNS) should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Head imaging will be necessary to document absence of CNS involvement in patients with colon/rectal cancer and soft tissue sarcomas. Patients with hematologic malignancies who have undergone treatment for malignant involvement of the CNS must have no evidence of residual disease by imaging or CSF sampling prior to study enrollment.\nHistory of allergic reactions to chemotherapy agents used in this protocol as part of lymphodepletion regimen (Fludarabine and Cyclophosphamide)\nPatients with uncontrolled intercurrent illness including, but not limited to ongoing active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nPregnant or breastfeeding women are excluded from this study.\nHIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with chemotherapeutic agents. In addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.\nChronic active untreated hepatitis B or C infection.\nRecipients of previous allogeneic transplants who have rash involving more than 10% body surface area attributed to graft versus host disease (GVHD) (> Grade 1 GVHD of skin). Stem cell transplant recipients will be excluded if they are still receiving immunosuppression including steroids for GVHD or have active GVHD in any organ (except for Grade 1 only of skin, not requiring treatment)."
            },
            {
                  "document": "Inclusion Criteria:\n\nSubjects with evidence of AML or myelodysplastic syndrome (MDS) that meet at least one of the following criteria:\n\nRelapsed AML: evidence of >= 5% blasts in the bone marrow; or reappearance of blasts in the peripheral blood; or development of extramedullary disease (according to 2003 IWG criteria) who relapse after:\n\nAllogeneic hematopoietic stem cell transplant, or\nAfter one cycle of standard cytotoxic chemotherapy or two cycles of any hypomethylating agent-based therapy\nRefractory AML: =< 2 prior induction regimens (example: patients who receive 7+3 followed by 5+2 would count as one induction regimen) or a minimum of two cycles of any hypomethylating agent-based therapy\nTreatment-naive AML: must be 75 years and older with de novo or secondary AML to be considered eligible\n\nRelapsed MDS: disease recurrence after CR, partial remission (PR) or hematologic improvement with bone marrow blasts >= 5% who relapse after:\n\nAllogeneic hematopoietic stem cell transplant, or\nAfter four cycles of any hypomethylating agent-based therapy\nRefractory MDS: disease progression at any time after initiation of hypomethylating agent treatment or persistent bone marrow blasts >= 5% despite a minimum of four cycles of hypomethylating agent therapy\nUntreated or previously treated therapy- related or secondary MDS\nAllowed prior allogeneic hematopoietic stem cell transplantation (allo-HCT) regardless of stem cell source; patients must be at least 3 months post allo-HCT (at time of treatment start); mismatched transplantations would be allowed\nPatients must be off systemic immunosuppressive medications > 2 weeks prior to treatment start; if patients are in systemic corticosteroids and must be on a dose of prednisone 5 mg/day or less (or equivalent), then patients must be on this reduced dose for > 1 week prior to treatment start; topical steroids are allowed\nIf post allo-HCT, then patient must have baseline donor T cell chimerism of >= 20% (from peripheral blood); evaluation can be made within 4 weeks of treatment start\nNo limitations on prior therapies\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\n\nTotal bilirubin =< 1.5 x local institutional upper limit of normal (ULN)\n\nIf elevated total bilirubin is due Gilbert's disease or disease-related hemolysis then total bilirubin =< 3.0 x local institutional ULN\nAspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT) =< 3.0 x local institutional ULN\nAlanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT) =< 3.0 x local institutional ULN\nSerum creatinine =< 2.0 x local institutional ULN\nNegative serum pregnancy test for women who are of child bearing potential (test must be repeated if performed > 72 hours from treatment start); the effects of ipilimumab on the developing human fetus are unknown; for this reason and because immunotherapy agents as well as decitabine are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after study drug administration\nPatients with known active human immunodeficiency virus (HIV) infection; patients with chronic HIV with a CD4 > 250, undetectable viral load by polymerase chain reaction (PCR), without opportunistic infection, and on a stable regimen of highly active anti-retroviral therapy (HAART) therapy would be eligible\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nParticipants who have had chemotherapy or radiotherapy within 2 weeks prior to treatment start or those who have not recovered from adverse events due to agents administered more than 2 weeks prior to treatment start\n\nHydroxyurea is allowed for symptomatic leukocytosis if clinically necessary; a total white blood cell (WBC) count < 25 x 10^9/L prior to first dose of decitabine on trial is required; prior leukapheresis and/or prior or concurrent treatment with hydroxyurea to achieve this level are allowed\nOngoing concurrent hormonal therapy is allowed\n\nParticipants with known central nervous system (CNS) involvement with leukemia or who are receiving intrathecal chemotherapy for active CNS leukemia\n\nThose with a history of CNS involvement that has been completely treated and those who require intrathecal chemotherapy prophylaxis are eligible in the expansion cohorts\n\nPrior hypomethylating agent (HMA) therapy is allowed, however this study excludes patients with progression or relapse that occur while receiving HMA-based therapy within 12 weeks prior to treatment start on study; disease progression is defined as either: (1) patients with prior MDS who progress to AML (defined by the presence of >= 20% blasts in peripheral blood or bone marrow) on HMA-based therapy; OR (2) patients with AML with evidence of progressive disease according to European Leukemia Net [ELN] 2017 criteria) (e.g. > 50% increase in marrow blasts over baseline or > 50% increase in peripheral blasts to > 25 x 10^9/L (> 25,000/uL) (in absence of differentiation syndrome)\n\n(Note: Patients who relapse post-transplant who received HMA treatment prior to transplant are eligible for study)\nDonor lymphocyte infusion within 8 weeks prior to treatment start if post-transplant\nFor patients that are post-transplant, ineligible patients include those with a history of overall grade III or IV (severe) acute GVHD at any time even if resolved\nPatients with a history of prior treatment with anti-CTLA-4, anti-PD 1 antibody, or anti-PDL1 antibody\nParticipants who are receiving any other investigational agents\nParticipants with known CNS involvement with leukemia or who are receiving intrathecal chemotherapy that is either prophylactic or therapeutic; history of CNS involvement that has been completely treated (no longer receiving intrathecal chemotherapy) will be allowed\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; any other prior or ongoing condition, in the opinion of the investigator, that could adversely affect the safety of the patient or impair the assessment of study results; as patients with AML and MDS are prone to infections, if patients are actively being treated with appropriate antibiotics or antifungal therapy with clinical evidence of infection control, then they will be considered eligible for study\nAutoimmune disease: Patients who are not eligible include those with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's granulomatosis]); CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis, multiple sclerosis); patients with a history of autoimmune disease (specifically including: diabetes mellitus, vitiligo, Hashimoto's thyroiditis) who are asymptomatic, do not require immune suppression or steroids, and do not have threatened vital organ function from these conditions may be considered after discussion with the principal investigator (PI)\nNo concurrent active malignancies are allowed on study for >= 2 years prior to treatment start with the exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast\nPatients with known active hepatitis B virus (HBV) infection should be excluded because of potential effects on immune function and/or drug interactions; however, if a patient has HBV history with an undetectable HBV load by polymerase chain reaction (PCR), no liver-related complications, and is on definitive HBV therapy, then he/she would be eligible for study\nPatients with known active hepatitis C virus (HCV) infection; patients with a history of HCV infection who received definitive therapy and has an undetectable viral load by PCR would be eligible\nPregnant women are excluded from this study because ipilimumab has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ipilimumab, breastfeeding should be discontinued if the mother is treated with ipilimumab; these potential risks may also apply to decitabine"
            },
            {
                  "document": "Inclusion:\n\nSubjects with AML should have failed any prior induction therapy regimen or have relapsed after prior therapy (defined as patients in first relapse and less than 12 months from diagnosis [short first remission] or in second or later relapse: Dose-escalation phase: Subjects with confirmed relapsed or refractory AML and no available treatment options with known benefit. Expansion phase: Subjects with relapsed/refractory AML who have failed therapy with up to one prior salvage regimen and no available treatment options with known benefit Exception: SCT or stem cell therapy for subjects who previously underwent SCT/stem cell therapy, and are currently in remission will not be considered a salvage regimen.\nEastern Cooperative Oncology Group (ECOG) </= 2\nPatients who have had prior SCT are eligible if they have a relapse > 3 months since autologous or allogeneic stem cell transplantation provided, 1) No clinically significant active graft-versus-host disease (GVHD > grade 1); 2) No treatment with high dose steroids for GVHD (i.e. >20 mg Prednisolone or equivalent per day); 3) No treatment with immunosuppressive drugs with the exception of cyclosporine and tacrolimus.\nSubjects with history of central nervous system (CNS) disease are allowed if at the time of day 1 of the study there is no evidence of active CNS disease as documented by negative imaging or spinal fluid analysis carried out at least 2 weeks prior to the first study drug administration in a subject with no clinical signs of CNS disease.\nAdequate renal and hepatic function: 1) Serum creatinine </= 2.0 X ULN; 2) Total bilirubin </= 2 times the upper limit of normal (ULN) (or </= 3.0 x ULN if deemed to be elevated due to Gilbert's disease or leukemia); 3) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) </= 2.5 times ULN (</= 5.0 x ULN if due to leukemic involvement).\nNegative urine pregnancy test within 72 hours prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post- menopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months).\nHave been informed of other treatment options and is not a candidate for standard treatment options or stem cell transplant at the time of enrollment.\nAge >/= 18 years.\nIn the absence of rapidly progressing disease, the interval from prior treatment to time of initiation of IACS-010759 administration will be at least 2 weeks or 5 half-lives (whichever is shorter) for cytotoxic/noncytotoxic agents and biological/immune therapies, including investigational agents. The half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochures, or drug-administration manuals) and will be documented in the protocol eligibility document. The use of chemotherapeutic or anti-leukemic agents is not permitted during the study with the following exceptions: (1) intrathecal therapy for subjects with controlled CNS leukemia at the discretion of the PI and with the agreement of the Sponsor. (2) Use of hydroxyurea for subjects with rapidly proliferative disease is allowed before the start of study therapy and for the first 2 cycles on therapy. These medications will be recorded in the case-report form.\nWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment. Adequate methods of contraception include: 1) Total abstinence when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; 2) Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment;\n#10 continued: 3) Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject;4) Combination of any of the two following (a+b or a+c or b+c): a. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception;b. Placement of an intrauterine device (IUD) or intrauterine system (IUS); c. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository. In case of use of oral contraception, women should have been stable on the same pill before taking study treatment.\n#11 continued: Note: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.\nAble and willing to give valid written informed consent.\n\nExclusion:\n\nPrior exposure to IACS-010759 or other oxidative phosphorylation Inhibitors.\nUnstable cardiovascular function: 1) Symptomatic ischemia, or 2) Uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic agents are excluded; 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or 3) Congestive heart failure (CHF) NYHA Class >/= 3, or 4) Myocardial infarction (MI) within 6 months; 5) Left ventricular ejection fraction < 40 %; 6) hypertension > 160 mm Hg systolic or > 100 mm Hg diastolic with or without antihypertensive therapy.\nMajor surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery from the surgical procedure\nPresence of >/= CTCAE grade 2 toxicity (except alopecia or peripheral neuropathy) due to prior cancer therapy.\nKnown positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV).\nActive uncontrolled infection. Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines is acceptable.\nParticipation in any other clinical trial involving another investigational agent for the treatment of AML within 2 weeks prior to day 1 of the study or at least 5 half-lives of the investigational agent, whichever is shorter.\nLactate levels > 2 mmol/L and or and serum pH <7.35 at screening.\nSubject currently being treated with biguanides or other agents known to increase risk of lactic acidosis.\nSubject has significant gastrointestinal abnormalities, including ulcerative colitis, chronic diarrhea associated with intestinal malabsorption, Crohn's disease, and/or prior surgical procedures affecting absorption or requirement for intravenous (IV) alimentation.\nSubjects with uncontrolled Type I or II diabetes mellitus\nMental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.\nWomen who are breast-feeding or pregnant as evidenced by positive urine pregnancy test done within 72 hours of first dosing.\nSubject has a concurrent active malignancy under treatment, with the exception of: -Adequately treated carcinoma in situ of the breast or cervix uteri; -Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; -Low-grade, early-stage prostate cancer with no requirement for therapy; -Previous malignancy confined\nAcute promyelocytic leukemia.\nAny concomitant disease or condition that, in the clinical judgment of the treating physician, is likely to prevent the subject from complying with any aspect of the protocol or that may put the subject at unacceptable risk.\nSubjects with >/= grade 1 peripheral neuropathy at screening."
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of AML based on 2008 WHO criteria. AML may be de novo, following a prior hematologic disorder, including MDS or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-related.\nPHASES 1 AND 2: Patients with AML that has relapsed after, or is refractory to, first-line therapy, with or without subsequent additional therapy, and are currently considered unfit for, or unlikely to respond to, cytotoxic chemotherapy.\nPHASE 2 ONLY: Patients previously untreated for AML who are considered unfit for cytotoxic chemotherapy by virtue of performance status, comorbidities, advanced age and/or low likelihood of response based on disease characteristics, or who decline cytotoxic induction chemotherapy.\nPatients who have undergone autologous stem cell transplantation (autoSCT) are eligible provided that they are \u2265 4 weeks from stem cell infusion.\nPatients who have undergone allogeneic SCT (alloSCT) are eligible if they are \u2265 60 days from stem cell infusion, have no evidence of graft versus host disease (GVHD) > Grade 1, and are \u2265 2 weeks off all immunosuppressive therapy.\nPrevious cytotoxic chemotherapy must have been completed at least 3 weeks and radiotherapy at least 2 weeks prior to Day 1 of treatment on the study, and all adverse events (excluding alopecia) due to agents administered more than 4 weeks earlier should have recovered to < Grade 1. Patients with hematologic malignancies are expected to have hematologic abnormalities at study entry. Hematologic abnormalities that are thought to be primarily related to leukemia are not considered to be toxicities (AE) and do not need to resolve to < Grade 1.\nPrior DNA methyl transferase inhibitor administration (azacitidine, decitabine, or guadecitabine) for AML or for antecedent MDS is allowed if this clinical trial is considered the best treatment option, but azacitidine, decitabine, or guadecitabine must have been stopped at least 3 weeks prior to Day 1 of treatment on the study.\nAll biologic agents including hematopoietic growth factors must have been stopped at least 1 week prior to Day 1 of treatment on the study.\nAge \u226518 years. Because no dosing or adverse event data are currently available on the use of decitabine or talazoparib in patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.\nECOG performance status \u22642 (Karnofsky \u226560%).\nLife expectancy of greater than 2 months.\n\nPatients must have normal organ and marrow function as defined below:\n\nTotal bilirubin within normal institutional limits unless thought due to hemolysis or to Gilbert's syndrome;\nAST(SGOT)/ALT(SGPT) \u22642.5 \u00d7 institutional upper limit of normal;\nCreatinine within normal institutional limits;\n\nOR\n\n\u2022 Creatinine clearance \u226560 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.\n\nFemale patients of childbearing potential must have a negative pregnancy test, and female patients of childbearing potential and male patients must agree to use adequate contraception.\n\nDecitabine has been assigned to pregnancy category D by the FDA. Pregnant women must not take decitabine and female subjects must immediately stop taking decitabine and inform their doctor if they become pregnant during treatment. Decitabine is expected to result in adverse reproductive effects and can cause fetal harm when administered to a pregnant woman. In preclinical studies in mice and rats, decitabine was teratogenic, fetotoxic, and embryotoxic.\n\nStudies in pregnant animals to evaluate the effect of talazoparib on pregnancy have not been performed.\n\nBecause decitabine is known to be teratogenic and the effects of talazoparib on the developing human fetus are unknown, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of decitabine and talazoparib administration.\n\nIt is not known whether decitabine is excreted in human milk. Similarly, studies in lactating animals to evaluate the effect of talazoparib have not been performed, and thus, it is not known whether talazoparib is excreted in human milk. Therefore, breast-feeding should be stopped during decitabine and talazoparib treatment.\n\nAbility to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nPatients with acute promyelocytic leukemia.\nPatients with active central nervous system leukemia or requiring maintenance intrathecal chemotherapy.\nPatients receiving concurrent chemotherapy, radiation therapy, or immunotherapy for AML.\nPatients receiving any other investigational agents.\nHyperleukocytosis with >50,000 blasts/\u03bcl. Hydroxyurea for blast count control is permitted before starting treatment, but must be stopped prior to starting treatment on the study. Patients will be withdrawn from the study if > 50,000 blasts/\u03bcl occur or recur > 14 days after starting treatment on the study.\nActive, uncontrolled infection. Patients with infection controlled with antibiotics are eligible.\nUncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that per investigator's judgment would limit compliance with study requirements.\nPatients who are pregnant or nursing.\nPatients who have had chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy within 2 weeks for antecedent malignancies prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or talazoparib.\n\nKnown HIV infection.\n\nHIV-positive patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.\n\nPrevious treatment with talazoparib."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with high-risk hematologic malignancies with anticipated poor prognosis with non transplant therapy, including those in remission or with induction failure and after treated or untreated relapse; Diagnoses to be included a) Acute myeloid leukemia; b) Acute lymphocytic leukemia; c) Chronic myeloid leukemia; d) Chronic lymphoproliferative disorder; e) Myelodysplastic syndrome; f) Myeloproliferative syndromes; g) Non-Hodgkin's lymphoma; h) Hodgkin's Lymphoma; i) Multiple myeloma\nPatients must have a haploidentical related donor or a fully matched related or unrelated donor\nPerformance score of >= 70 by Karnofsky/Lansky or performance score (PS) 0 to 1 (Eastern Cooperative Oncology Group [ECOG] =< 1)\nLeft ventricular ejection fraction >= 50%\nAdequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume; children unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of >= 92% on room air\nCreatinine clearance (calculated creatinine clearance by Cockcroft-Gault using adjusted body weight if actual body weight is 20% greater than ideal is permitted) should be > 50 ml/min\nBilirubin =< 2 x the upper limit of normal (except with patients high indirect bilirubin due to Gilbert's syndrome, hypersplenism, or hemolysis)\nSerum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 200\nNegative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization; women of child bearing potential must be willing to use an effective contraceptive measure while on study\nPatient or patient's legal representative able to sign informed consent\n\nExclusion Criteria:\n\nHuman immunodeficiency virus (HIV) seropositivity\nUncontrolled infections\nPatients with comorbidity score > 3; the principal investigator is the final arbiter of eligibility for comorbidity score > 3\nPrior allogeneic transplant\nPatients with active hepatitis B and C\nPatients with prior coronary artery disease\nPatients who received inotuzumab and/or gemtuzumab in the past"
            },
            {
                  "document": "Inclusion Criteria:\n\nVoluntary signed and dated IRB/IEC approved written informed consent form in accordance with regulatory and local guidelines.\nBe 18 years or older and 70 years or younger on the day of signing consent\nHave a confirmed diagnosis of non-M3 acute myeloid leukemia (AML) (Intermediate-II is high risk. Our population will consist of Intermediate-II and high risk patients or any FLT3+ AML) or IPSS intermediate -2 or high risk myelodysplastic syndrome (MDS) (Appendices A and B).\nHave an available 6/6 related donor or an unrelated donor with a 10/10 match for HLA-A, B, C, DRB1 and DQ antigen who consents to provide a marrow or peripheral blood stem cell allograft. Typing is by DNA techniques: intermediate resolution for A, B and C, and high resolution for DRB1/DQ\nBe receiving one of the following conditioning regimen: fludarabine at a dose of 30 mg/m2 IV daily for 5 days, busulfan at a dose of 130 mg/m2 IV daily for 2 days, and rabbit antithymocyte globulin (ATG) at a dose of 2 mg/kg IV daily for 2 days OR fludarabine at a dose of 30 mg/m2 IV daily for 4 days, melphalan at a dose of 140 mg/m2 for one day with or without ATG at a dose of 2 mg/kg IV daily for 2 days\nBe deemed eligible for an allogenic stem cell transplantation as per institutional guidelines of the Blood and Marrow Transplantation Program at John Theurer Cancer Center at Hackensack University Medical Center\n\nPatients with adequate organ function as measured by:\n\nCardiac: left ventricular ejection fraction at rest > 50%\nHepatic: serum total bilirubin < 1.5x upper limit of normal for age as per local laboratory (with the exception of isolated hyperbilirubinemia due to Gilbert's syndrome); ALT and AST < 4x upper limit of normal for age as per local laboratory\nRenal: serum creatinine < 2x upper limit of normal for age (as per local laboratory). For patients with serum creatinine above the normal range, a glomerular filtration rate (measured as per institutional practice, typically creatinine clearance) equal to or greater than 60 mL/min (corrected to 1.73m2 body surface area) is required.\nPulmonary: FEVl, FVC and DLCO (corrected for Hb) >50% predicted.\nHave a performance status of 2 or lower on ECOG performance scale.\n\nWomen of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.\n\nVersion 1.0 23Mar2017 Page 4 of 73\n\nWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Female subjects of childbearing potential should agree to ongoing pregnancy testing, to be performed prior to each dosing of ipilimumab and nivolumab. See Note below for definition of WOCBP.\nWomen must not be breastfeeding.\nMen who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab, and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product, even if they have had a vasectomy. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception). See Note below for definition of WOCBP.\nFemales of childbearing potential must be willing to use two methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 2 years. See Note below for definition of WOCBP.\n\nExclusion Criteria:\n\nHas known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 20 mg/day prednisone equivalents) for at least 4 weeks prior to study drug administration. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability. Note: Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 20 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.\nIs unable or unwilling to sign informed consent.\nHas an active, known, or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger\nPatients should be excluded if they have a condition such as GVHD requiring systemic treatment with either corticosteroids (> 20 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 20 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Note: Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalation corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 20 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.\nAs there is potential for hepatictoxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen.\nHas received a prior allogeneic stem cell transplant.\nHas a history of hypersensitivity to nivolumab, ipilimumab, or any of its excipients, or severe hypersensitivity reaction to any previous monoclonal antibody.\nHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to Day 1 of checkpoint inhibitor treatment administration or who has not recovered (i.e., t administration mAb) within 4 weeks prior to t dose of trial treatment. Rituximab within that time frame is allowed.\nHas active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Note: Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 20 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.\nHas known history of, or any evidence of active, non-infectious pneumonitis.\nHas an active infection requiring intravenous systemic therapy.\nHas a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\nIs pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\nHas received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.\nHas a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) or known acquired immunodeficiency syndrome (AIDS).\nHas known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).\nHas the presence of a large accumulation of ascites or pleural effusions, which would be a contraindication to the administration of methotrexate for GVHD prophylaxis.\nHas known history of grade 3 or 4 GVHD."
            },
            {
                  "document": "Inclusion Criteria:\n\nCohort #1\n\nHave histologically or cytologically confirmed relapsed or refractory AML (i.e. \u22655% blasts by manual differential on bone marrow aspirate/biopsy/flow cytometry), excluding acute promyelocytic leukemia (APL; FAB M3; t(15;17))\nBe willing and able to provide written informed consent/assent for the trial.\nBe > 18 years of age on day of signing informed consent.\n\nNot be appropriate candidate for intensive salvage chemotherapy due to co-morbidities or other disease- or treatment-related factors.\n\nNOTE: Subjects who received prior treatment with hypomethylating agents either for Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MPN), or AML will be eligible if they achieved response to hypomethylating agents in the past (PR or CR) and did not progress while receiving therapy with hypomethylating agents.\n\nNOTE: Subjects who had prior allogeneic stem cell transplant (alloHSCT) will be eligible as long as they have been at least 3 months after allogeneic HSCT and are off of all immune suppression for at least 3 weeks (>21 days) and have no evidence of active graft versus host disease (GVHD). Subjects with prior alloHSCT will NOT be eligible for enrollment during the safety run in phase.\n\nDemonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 14 days of treatment initiation.\nECOG performance status \u2264 2.\nA projected life expectancy of at least 12 weeks.\nFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\nFemale subjects of childbearing potential (Section 5.8.2) must be willing to use an adequate method of contraception as outlined in Section 5.8.2 - Contraception, for the course of the study through 120 days after the last dose of study medication.\n\nNote: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nMale subjects of childbearing potential (Section 5.8.2) must agree to use an adequate method of contraception as outlined in Section 5.8.2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n\nNote: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nAs determined by the enrolling physician or protocol designee, ability of the patient to understand and comply with study procedures for the entire length of the study.\n\nCohort #2\n\nHave histologically and cytologically confirmed newly diagnosed AML (i.e. \u2265 20% blasts by manual differential on bone marrow aspirate/biopsy and/or in peripheral blood), excluding acute promyelocytic leukemia (APL; FAB M3, t (15;17))\nBe willing and able to provide written informed consent/assent for the trial.\nBe \u226565 years of age on day of signing informed consent.\n\nHave received NO prior treatment for AML with the exception of hydroxyurea/leukapheresis.\n\nNOTE: Subjects may have been treated for pre-existent myeloid disorder such as Myelodysplastic Syndrome or Myeloproliferative Neoplasm excluding hypomethylating agents.\n\nDemonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 14 days of treatment initiation.\nECOG performance status \u2264 2.\nA projected life expectancy of at least 12 weeks.\nFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\nFemale subjects of childbearing potential (Section 5.8.2) must be willing to use an adequate method of contraception as outlined in Section 5.8.2 - Contraception, for the course of the study through 120 days after the last dose of study medication.\n\nNote: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nMale subjects of childbearing potential (Section 5.8.2) must agree to use an adequate method of contraception as outlined in Section 5.8.2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n\nNote: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nAs determined by the enrolling physician or protocol designee, ability of the patient to understand and comply with study procedures for the entire length of the study.\n\nAdequate Organ Function Laboratory Values\n\nWhite blood cell (WBC) count <30,000 /mcL\n\nSerum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) \u22641.5 X upper limit of normal (ULN) OR \u226560 mL/min for subject with creatinine levels > 1.5 X institutional ULN Serum total bilirubin \u2264 1.5 X ULN* AST (SGOT) and ALT (SGPT) \u2264 3 X ULN Albumin >2.5 mg/dL International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) \u22641.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n\n\u22641.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n\nExclusion Criteria:\n\nCohort #1\n\nIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n\nNOTE: Subjects who were treated on a clinical study of allogeneic stem cell transplant (alloHSCT) will be eligible if they are at least 3 months after allogeneic HCT and are at least 3 weeks (>21 days) off of all immune suppression and have no evidence of active GVHD (physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed). Subjects with prior alloHSCT will not be eligible for enrollment during the safety run in phase.\n\nHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\nHas a known history of active TB (Bacillus Tuberculosis)\nHypersensitivity to pembrolizumab or any of its excipients.\nHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n\nHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks or growth factors within 1 week prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent.\n\nNote: Subjects with \u2264 Grade 2 neuropathy are an exception to this criterion and may qualify for the study.\nNote: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.\nHas a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\nHas known active central nervous system (CNS) leukemia. Subjects with previously treated CNS leukemia may participate provided that they have documented clearance of CNS leukemia and are not actively treated with intrathecal chemotherapy.\nHas active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Subjects that require intermittent use of bronchodilators or local steroid injections will not be excluded from the study.\nHas known history of, or any evidence of active, non-infectious pneumonitis.\nHas an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal). Patients with infection under active treatment and controlled with antibiotics are eligible.\nHas a white blood cell count > 30 x 109/L. NOTE: Leukapheresis and Hydroxyurea is permitted to meet this criterion and should be stopped \u226512 hours before starting treatment on the study.\nHas a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\nIs pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\nHas received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\nHas a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\nHas known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).\nHas received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist\u00ae) are live attenuated vaccines, and are not allowed.\n\nCohort #2\n\nHas received treatment with hypomethylating agent for pre-existent myeloid disorder such Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasm (MPN).\nIs currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment for pre-existent myeloid disorder such as MDS or MPN.\nNot be eligible for treatment with a standard cytarabine and anthracycline or similar intensive induction chemotherapy due to co-morbidities or other factors, or is unwilling to receive intensive induction therapy.\nHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\nHas a known history of active TB (Bacillus Tuberculosis)\nHypersensitivity to pembrolizumab or any of its excipients.\nHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n\nHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks or growth factors within 1 week prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent.\n\nNote: Subjects with \u2264 Grade 2 neuropathy are an exception to this criterion and may qualify for the study.\nNote: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.\nHas a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\nHas known active central nervous system (CNS) leukemia. Subjects with previously treated CNS leukemia may participate provided that they have documented clearance of CNS leukemia and are not actively treated with intrathecal chemotherapy.\nHas active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Subjects that require intermittent use of bronchodilators or local steroid injections will not be excluded from the study.\nHas known history of, or any evidence of active, non-infectious pneumonitis.\nHas an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal). Patients with infection under active treatment and controlled with antibiotics are eligible.\nHas a white blood cell count > 30 x 109/L. NOTE: Leukapheresis and hydroxyurea is permitted to meet this criterion and should be stopped \u226512 hours before starting treatment on the study.\nHas a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\nIs pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\nHas received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\nHas a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\nHas known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).\nHas received a live vaccine within 30 days of planned start of study therapy."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have histologically or cytologically documented newly diagnosed de novo Acute Myeloid Leukemia (non-APL) that has not yet been treated. Hydrea and ATRA previous treatments are acceptable.\nPatients must not have a secondary AML (defined as a history of prior radiation therapy or systemic chemotherapy, CMML or MDS not treated with a hypomethylating agent) however history of previous MDS treated with a hypomethylating agent IS allowed.\nHydroxyurea may be used to control leukocytosis, provided that it is without Grade >2 toxicity, and can be taken until start of therapy.\nAge >18 years.\nECOG performance status of \u2264 2 and fit for induction therapy in the opinion of the treating physician.\nLaboratory values \u22642 weeks must be:\nAST(SGOT)/ALT(SGPT)\u2264 2.5 X institutional upper limit of normal\nBilirubin \u2264 2 X ULN (3X if known history of Gilbert'syndrome)\nCreatinine clearance (CrCl) must be > 20 mL/min\nBaseline left ventricular ejection fraction of at least 40% by MUGA or ECHO.\nFemale patients of childbearing potential must agree to use 2 methods of contraception (including 1 highly effective and 1 effective method of contraception) and have a negative serum pregnancy test at Screening. Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatment.\nAbility to understand and the willingness to sign an IRB-approved informed consent document.\n\nExclusion Criteria:\n\nPatients who have received any therapy other than hydroxyurea or ATRA with the purpose of treating their AML or patients with core binding factor AML or Acute Promyelocytic Leukemia are not eligible.\nPatients with a secondary AML (defined as a history of prior radiation therapy or systemic chemotherapy, CMML or MDS not treated with a hypomethylating agent) however history of previous MDS treated with a hypomethylating agent IS allowed.\nPatients having received prior radiotherapy, treatment with cytotoxic agents, treatment with biologic agents or any anti-cancer therapy for a non-AML malignancy within the 4 weeks prior to treatment with selinexor, or those who have not fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment).\nPatients with another active malignancy that requires treatment excluding non-melanoma skin cancers.\nPatients that have received a chemotherapy regimen with stem cell support in the previous 6 months.\nPatients with known central nervous system involvement should be excluded from this clinical trial because the penetration of selinexor into the CNS is not currently known.\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor.\nUncontrolled concurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia\nPsychiatric illness/social situations that would limit compliance with study requirements.\nPatients with known HIV infection or hepatitis (Note: Patients with known HIV infection are excluded because patients with an immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy.\nPregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued.\nPatients unable to swallow tablets, patients with malabsorption syndrome, or any other GI disease or GI dysfunction that could interfere with absorption of study treatment\nPrior exposure to a SINE compound"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must be at least 18 years of age.\n\nPatients must have:\n\na. Relapsed and/or refractory non-APL AML that has failed to achieve a complete remission (CR) or partial remission (PR) following standard induction therapy, or has relapsed after any duration of CR or PR i. Patients must have measurable disease with bone marrow blasts \u22655%at screening\n\nb. Relapsed and/or refractory higher-risk MDS (High / Very High Risk, as defined by the Revised International Prognostic Scoring System (IPSS-R)) that has failed to achieve a CR or PR, or any hematologic improvement (HI, per IWG 2006 criteria) after standard therapy with hypomethylating agents (e.g., azacitidine, decitabine), or has relapsed after any duration of CR or PR or HI i. Patients must have measurable disease with bone marrow blasts >5% at screening\n\nc. Newly diagnosed, treatment-na\u00efve non-APL AML in patients who, at the time of study entry are unlikely to tolerate standard intensive chemotherapy due to age, performance status, or comorbidities based on at least one of the following criteria (Ferrara et al, 2013):\n\ni. Age \u2265 75 years old ii. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 iii. Cardiac history of congestive heart failure (CHF) or documented ejection fraction (EF) \u2264 50% iv. Pulmonary disease with DLCO \u2264 65% or FEVI \u2264 65% v. Creatinine clearance \u2265 30 mL/min to < 45 mL/min vi. Hepatic impairment with total bilirubin > 1.5 to \u2264 3.0 x upper limit of normal (ULN) vii. Any other comorbidity that the Investigator judges to be incompatible with intensive chemotherapy, and reviewed and approved by the Sponsor prior to enrollment\n\nd. Transfusion dependent lower-risk MDS without the del 5q abnormality, in patients refractory to erythropoietin treatment or unlikely to respond to erythropoietin treatment (EPO >500).\n\ni. Lower-risk MDS: Very Low /Low / Intermediate Risk, as defined by IPSS-R. ii.Red blood cell (RBC) transfusion dependent anemia defined as no eight consecutive weeks without RBC transfusions within the 16 weeks prior to study entry, or \u22654 RBC transfusions within the 8 weeks prior to study entry.\n\niii.Refractory to or ineligible for ESAs is defined as RBC-Transfusion Dependence despite ESA treatment of \u226540,000 units/week recombinant human erythropoietin for 8 weeks or an equivalent dose of darbepoetin (150 \u00b5g/week) or serum EPO level >500 mU/mL in patients not previously treated with ESAs.\n\nPatients must be evaluated for the RARA super-enhancer associated biomarker or RARA pathway associated biomarker at the time of study screening.\n\na. Patients in arms 1, 2A, 3, and 4 must be positive as defined by a pre-determined cut-off\n\nMust be amenable to serial bone marrow aspirates and peripheral blood sampling during the study.\nECOG Performance Status (PS) of 0, 1 or 2. For newly diagnosed AML patients < 75 years of age, ECOG 0-3; for \u2265 75 years of age, ECOG 0-2.\n\nAdequate organ function as defined by:\n\nTotal bilirubin \u2264 1.5 x the upper limit of normal (ULN), unless suspected to have Gilbert's disease. For newly diagnosed AML patients < 75 years of age, total bilirubin \u2264 3 x ULN; for \u2265 75 years of age, total bilirubin \u2264 1.5 x ULN.\nALT and AST \u2264 3 x ULN or \u2264 5 x ULN if documented liver infiltration with leukemia cells\nSerum creatinine \u2264 2.0 x ULN or calculated creatinine clearance \u2265 45 mL/min based on the Cockroft-Gault GFR estimation. For newly diagnosed AML patients < 75 years of age, creatinine clearance \u2265 30 mL/min; for \u2265 75 years of age, creatinine clearance \u2265 45 mL/min.\nDiscontinued use of chemotherapy, radiation therapy, or growth factors for at least 2 weeks prior to first study treatment, with the exception of hydroxyurea.\nNo investigational agents within 2 weeks prior to first study treatment.\nNo strong inducers of CYP3A4 (see Appendix 13.5) within 2 weeks prior to first study treatment.\nResolved acute effects of any prior AML/MDS therapy to baseline or \u2264 Grade 1 CTCAE severity.\nSerum/urine pregnancy test (for females of childbearing potential) that is negative at screening and immediately prior to initiation of treatment (first dose).\n\nExclusion Criteria:\n\nAcute promyelocytic leukemia (APL, M3 subtype of AML) or patients with a t(9:22) cytogenetic translocation.\nHyperleukocytosis (leukocytes \u226525 x 109/L) at study entry. These patients may be treated with hydroxyurea according to routine practice, and enroll in the study when the leukocyte count falls below 25 x 109/L.\nPatients known to be refractory to platelet or packed red cell transfusions per Institutional Guidelines, or a patient who refuses blood product support.\nPrior treatment with all-trans retinoic acid (ATRA) or systemic retinoid for the treatment of hematologic malignancy.\nSY-1425 and daratumumab combination only - Prior or concurrent exposure to daratumumab or other CD38 therapies5.\n\nSY-1425 and daratumumab combination only - Subject has either of the following:\n\nKnown chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is <50% of predicted normal.\nKnown moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification. Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study.\nPatients with active malignancy (not including basal cell carcinoma, non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer treated with hormone therapy). Patients with history of other cancers should be free of disease for at least 2 years.\nPatients with hypertriglyceridemia defined as >1000 mg/dL (CTCAE Grade 4).\nPatients with clinically significant cardiac disease including one of the following currently or in the previous 6 months: myocardial infarction, unstable cardiac function due to unstable angina or congestive heart failure, congenital long QT syndrome, torsades de pointes or significant ventricular arrhythmias .\nPatients with known active uncontrolled central nervous system (CNS) leukemia.\nPatients taking Vitamin A supplements (>10,000 IU/d) unless discontinued prior to first dose of study drug, or having hypervitaminosis A.\nPregnant females; breastfeeding females; and males and females of childbearing potential not willing to use two highly effective methods of birth control, one being barrier method. Intrauterine Devices (IUD) and birth control pills are not barrier methods, but are highly effective especially when combined with a barrier method (e.g. latex condom or a diaphragm or cervical cap) while taking investigational product (SY-1425) and continuing contraception use for at least 90 days after the last dose of study drug. Men/women should not donate sperm or ova during this time frame."
            },
            {
                  "document": "Inclusion Criteria for Transplant Recipient:\n\nAge less than or equal to 21 years.\n\nAny of the following hematologic malignancies that has relapsed or remains refractory after prior allogeneic HCT (this includes any stage of disease - such as refractory due to induction failure, refractory in relapse, or in any CR - as long as the hematologic malignancy remained persistent or returned after a previous allogeneic HCT):\n\nALL, AML, Myeloid Sarcoma, CML, Juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL)\nHas a suitable single haplotype matched (\u2265 3 of 6) family member donor.\nDoes not have any other active malignancy other than the one for which this transplant is indicated.\nIf prior CNS leukemia, it must be treated and in CNS CR\nDoes not have current uncontrolled bacterial, fungal, or viral infection.\n\nThere is no minimum time from the previous transplant, but patients must meet the following criteria:\n\nLeft ventricular ejection fraction > 40%, or shortening fraction \u2265 25%.\nCreatinine clearance (CrCl) or glomerular filtration rate (GFR) \u2265 50 ml/min/1.73m2.\nForced vital capacity (FVC) \u2265 40% of predicted value; or pulse oximetry \u2265 92% on room air if patient is unable to perform pulmonary function testing.\nKarnofsky or Lansky (age-dependent) performance score \u2265 50 (See Appendix A).\nBilirubin \u2264 3 times the upper limit of normal for age.\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) \u2264 5 times the upper limit of normal for age.\nNot pregnant. If female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment.\nNot breast feeding\n\nInclusion Criteria for Haploidentical Donor:\n\nAt least single haplotype matched (\u2265 3 of 6) family member\nAt least 18 years of age.\nHIV negative.\nNot pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).\nNot breast feeding.\n\nRegarding donation eligibility, is identified as either:\n\nCompleted the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR\nDoes not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271."
            },
            {
                  "document": "Recipient Inclusion Criteria:\n\nRefractory AML without complete remission (CR) after 2 or more cycles of induction therapy (primary induction failure), or AML relapsed after obtaining a CR and failed one or more cycles of re-induction therapy. Standard dose 10-day decitabine (20 mg/m2 daily IV x 10 days) or 7-day azacitidine (75-100 mg/m2 daily SC/IV x 7 days) will be considered as one cycle of induction therapy.\nAt least 18 years of age\nAvailable HLA-haploidentical donor that meets the criteria in the protocol\nPatients with known CNS involvement with AML are eligible provided that they have been treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment.\nKarnofsky performance status > 60 %\n\nAdequate organ function as defined below:\n\nTotal bilirubin < 2 mg/dl\nAST(SGOT)/ALT(SGPT) < 3.0 x IULN\nCreatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73 m2 by Cockcroft-Gault Formula\nOxygen saturation \u226590% on room air and adjusted DLCO of at least 40%\nEjection fraction \u226540%\nAble to be off of corticosteroids (10 mg or less of prednisone or equivalent doses of other systemic steroids are allowed) and any other immune suppressive medications beginning on Day -3\nWomen of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study and throughout the DLT evaluation period.\nAbility to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nRecipient Exclusion Criteria:\n\nRelapsed after allogeneic transplantation.\nCirculating blast count >30,000/uL by morphology or flow cytometry (cyto-reductive therapies including leukapheresis or hydroxyurea are allowed).\nUncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection.\nPresence of donor specific antibodies (DSA) with Mean Fluorescence Intensity (MFI) of >5000 as assessed by the single antigen bead assay, < 6 weeks prior to starting transplant conditioning\nUncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities.\nNew progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that have not been evaluated with bronchoscopy. Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections)\nKnown hypersensitivity to one or more of the study agents\nReceived any investigational drugs within the 14 days prior to the first day of transplant conditioning\nPregnant and/or breastfeeding\n\nDonor Inclusion Criteria:\n\nRelated donor (sibling, offspring, or offspring of sibling)\nAt least 18 years of age\nHLA-haploidentical donor/recipient match by at least Class I serologic typing at the A&B locus.\nIn general good health, and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.\nAbility to understand and willingness to sign an IRB approved written informed consent document\n\nDonor Exclusion Criteria:\n\nPositive for hepatitis, HTLV, or HIV infection\nPregnant and/or breastfeeding"
            },
            {
                  "document": "Inclusion Criteria\n\nAt the time of Screening, participants must meet all of the following criteria to be considered eligible to participate in the study:\n\nAdults \u226518 years of age\nFemales must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study and for 30 days after the last dose of study drug or decitabine\nMales must agree to use an adequate method of contraception during the study and for at least 30 days after the last dose of study drug or decitabine\n\nHistologically documented diagnosis (based on the 2008 World Health Organization [WHO] Classification) (Vardiman et al. 2009) of one of the following:\n\nNewly diagnosed untreated AML; or\nUntreated secondary AML, including AML that has progressed from MDS\nIn some cases of AML associated with specific genetic abnormalities, however, the diagnosis of AML may be made if the blast count is less than 20% (Dohner et al. 2017) - specifically AML with t(15;17), t(8;21), inv(16), or t(16;16))\nRelapsed or Refractory AML\nInvestigator considers previously untreated participant ineligible for (or unwilling to receive) intensive induction therapy based on medical reasons, disease characteristics such as genetics, type of AML (untreated or secondary), or participant characteristics such as age, performance status, co-morbidities, organ dysfunctions, or patient election of low-intensity treatment\nEligible for venetoclax and decitabine therapy, based on Investigator assessment\nParticipant's WBC count is 25 x 10^9/L or less at study initiation. The use of leukapheresis or hydroxyurea before treatment initiation to achieve this is permitted.\n\nAdequate hepatic and renal functions as defined by:\n\nAspartate transaminase (AST) and alanine transaminase (ALT) \u22642.5 times the upper limit of normal (ULN); and\nUsually total bilirubin \u2264 1.5 ULN. In specific cases the PI may request a waiver of this requirement with medical justification and agreement with the medical monitor and Bio-Path holdings. And;\nEstimated glomerular filtration rate (eGFR) of at least 40 ml/min. These estimations can be calculated using any of the following methods (Appendix E: Formulas):\n\ni. Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation\n\nGFR = 141 \u00d7 min (Scr /\u03ba, 1)^\u03b1 \u00d7 max(Scr /\u03ba, 1)^-1.209 \u00d7 0.993^Age \u00d7 1.018 [if female] \u00d7 1.159 [if black] ii. Cockcroft gault equation\nCockcroft Gault equation utilizing the TBW (Total body weight) to calculate an estimated creatinine clearance\nCrCl = [(140 - age) x TBW] / (Scr x 72) x 0.85 [if female] iii. Modification of Diet in Renal Disease (MDRD) Study equation\nGFR (mL/min/1.73 m^2) = 175 \u00d7 (Scr)^-1.154 \u00d7 (Age)^-0.203 \u00d7 0.74 [if female] x 1.212 [if African American (AA)] iv. Creatinine clearance estimated by 24-hr urine collection for creatinine clearance\nDocumented Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\nRecovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment\nWilling and able to provide written informed consent 7.2. Exclusion Criteria\n\nAt the time of Screening, participants who meet any of the following criteria will be excluded from participating in the study:\n\nActive non-hematologic or lymphoid malignancy other than AML treated with immuno- or chemotherapy within the previous 12 months except active non- melanoma, non-invasive skin cancer will be allowed.\nKnown, active leptomeningeal leukemia requiring intrathecal therapy. NOTE: Patients with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening\nIsolated extramedullary leukemia without also meeting bone marrow criteria for acute leukemia (for AML usually = 20% blasts in BMA or BMB). Patients may have leukemia with lower blast counts (Dohner et al. 2010). Bio-Path Holdings and Investigator concurrence required.\nAcute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARA\nChronic myeloid leukemia (CML) in any phase\nReceipt of any anti-cancer therapy within 14 days prior to C1D1, with the exception of hydroxyurea or anagrelide (within 24 hours), TKI (within 1day), a single dose of cytarabine (for proliferative disease)\nUncontrolled active, untreated, or progressive infection\nReceipt of any investigational agent or study treatment within 30 days prior to C1D1\nFemales who are capable of becoming pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug\nSerious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study\nKnown active or clinically significant hepatitis B infection (based on positive surface antigen [HBsAg]), hepatitis C infection (based on positive antibody [HCV Ab]), or human immunodeficiency virus (HIV-1 or HIV-2, based on positive antibody)\nHistory of any hypersensitivity to venetoclax or decitabine, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor\nPresence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant baseline ECG abnormality (e.g., QTcF >470 msec)\nWithin the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack\nUncontrolled seizure disorder (i.e., seizures within the past 2 months)\nCannot receive live attenuated vaccine immunization prior to, during, or after treatment with venetoclax until B-cell recovery occurs\nUnable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason"
            },
            {
                  "document": "Inclusion Criteria:\n\nNon-favorable risk AML\nIn CR-1 or subsequent CR\nCompleted at least one cycle of consolidation chemotherapy\nCollection of at least 2x106/kg CD34+ cells\nKPS of 70% or greater\n\nExclusion Criteria:\n\nReceived investigational agent within 4 weeks of first dose\nPrior chemotherapy, radiation therapy within 2 weeks of first dose\nHypersensitivity to pembrolizumab or any of its excipients\nReceived prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent"
            },
            {
                  "document": "Inclusion Criteria:\n\nWilling and able to provide written informed consent for the trial\n> 18 years and < 70 years of age on day of signing informed consent\nEastern Cooperative Oncology Group (ECOG) Performance Status 0-1\nHave histologically or cytologically confirmed recurrent AML as defined by \u22655 % myeloblasts in the bone marrow aspirate and or biopsy.\nMust have received at least 1 cycle of induction therapy for front-line AML including cytarabine continuous infusion + anthracycline +/- cladribine or etoposide for 1 or 2 cycles, or liposomal cytarabine and daunorubicin (CPX-351), or high dose cytarabine with or without fludarabine, cladribine or clofarabine, > 4 cycles of azacitidine/decitabine or the equivalent experimental therapy (the latter as confirmed by the PI)\nCytoreduction allowed with hydroxyurea and/or leukapheresis for up to 14 days prior to D1 of treatment under LCCC1522. Patients must be off hydroxyurea for > 12 hours prior to D1 of treatment under LCCC1522\n\nDemonstrate adequate organ function as defined below. All screening labs should be performed within 14 days of D1 of treatment under LCCC1522.\n\nSerum creatinine \u22641.5 X upper limit of normal (ULN) OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl)-- \u226560 mL/min for subject with creatinine levels > 1.5 X institutional ULN Serum total bilirubin \u2264 1.5 X ULN unless due to Gilbert's Disease, hemolysis or leukemic infiltration OR Direct bilirubin \u2264 ULN for subjects with total bilirubin levels > 1.5 ULN Aspartate Aminotransferase (AST)(SGOT) and Alanine Aminotransferase (ALT) (SGPT) \u2264 5 X ULN International Normalized Ratio (INR) or Prothrombin Time (PT)- \u22641.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants or patient has disseminated intravascular coagulation deemed by investigator to be due to leukemia Activated Partial Thromboplastin Time (aPTT) \u22641.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants or patient has disseminated intravascular coagulation deemed by investigator to be due to leukemia\n\nFemale subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of HiDAC treatment and again prior to D1 of pembrolizumab treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\nFemale subjects of childbearing potential should be willing to use adequate method of contraception for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. The two birth control methods can be two barrier methods or a barrier method plus a hormonal method to prevent pregnancy. Subjects should start using birth control from the screening visit throughout the study period up to 120 days after the last dose of study therapy.\n\nNote: Abstinence is acceptable if this is the usual lifestyle preferred contraception for the subject.\n\nMale subjects must agree to use an adequate method of contraception starting with D1 of HiDAC through 120 days after the last dose of study therapy.\n\nNote: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nAs determined by the enrolling physician or protocol designee, ability of the patient to understand and comply with study procedures\n\nExclusion Criteria:\n\nIs currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.\nHas a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of HiDAC treatment. Note: use of steroid eye drops starting at the time of HiDAC administration is allowed.\nHas a known history of active Bacillus Tuberculosis (TB)\nHypersensitivity to pembrolizumab or any of its excipients\nHas had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n\nHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with \u2264 Grade 2 neuropathy are an exception to this criterion and may qualify for the study.\n\nNote: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.\n\nHas a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer that has undergone potentially curative therapy.\nHas known active central nervous system (CNS) leukemia; subjects with previously treated CNS disease may participate provided they are stable (without evidence of active disease by imaging for at least 4 weeks prior to the first dose of treatment, and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to D1 of treatment.\nHas active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\nHas evidence of interstitial lung disease or a history of ( non-infectious) pneumonitis that required steroids or current pneumonitis.\nHas a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\nIs pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\nHas received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)\nHas a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\nHas known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., hepatitis C virus (HCV) RNA qualitative is detected).\nHas received a live vaccine within 30 days prior to the first dose of trial treatment Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist\u00ae) are live attenuated vaccines, and are not allowed\nHas uncontrolled intercurrent illness including, but not limited to, active and uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, and uncontrolled symptomatic cardiac arrhythmia. Patients with infection under active treatment and controlled with antibiotics are eligible.\nDiagnosed with acute promyelocytic leukemia (APL, M3)\n\nReceipt of previous allogeneic stem cell transplant; receipt of previous autologous transplant for AML or non-AML condition is allowed\n\n-"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge 18-60 years.\nConsidered to be suitable intensive (cytotoxic) induction candidates.\nHas previously untreated, de novo, non-M3 AML with intermediate-risk disease (Intermediate-I or Intermediate-II) as defined by ELN criteria OR normal cytogenetics with mutated NPM1 without FLT3-ITD. Monoallelic CEBPA mutations are not considered favorable risk and are therefore eligible.\nHas undergone cytotoxic induction therapy\nIn a morphologic complete remission with incomplete blood count recovery, or morphologic complete remission post-induction after no more than 2 induction cycles as defined by revised IWG criteria\nPatients at Washington University must be enrolled in HRPO# 201011766 (\"Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases\").This is not a requirement for secondary sites. However, secondary sites must provide informed consent forms that document that permission for whole genome, whole exome, and/or genome wide sequencing, and data sharing among institutions, was obtained. Because we will be also be sequencing non-diseased (normal) tissue, the informed consent forms must explicitly ask if patients wish to be informed, (or in the case of their death, their next-of-kin) if a deleterious mutation is identified in their non-diseased tissue, as this may be heritable.\nWomen of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\nAble to understand and willing to sign an IRB approved written informed consent document.\n\nWilling to comply with the treatment assignment:\n\nIntent to proceed with HiDAC consolidation for LAM VAF <2.5%\nIntent to proceed with either HiDAC consolidation or allogeneic stem cell transplantation, at the discretion of the treating physician, for LAM \u22652.5%\n\nExclusion Criteria:\n\nDiagnosis acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA.\nTherapy-related AML (defined as occurrence of AML due to prior exposure to chemotherapy or radiation for malignancy).\nSecondary AML (defined as development of AML in patients with an antecedent hematological malignancy).\nHas a medical or psychosocial conditions that would prevent study compliance.\nKnown seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B vaccine are eligible.\nHistory of allergic reaction to compounds of similar chemical or biologic composition to cytarabine.\nPregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 3 days of signing consent."
            },
            {
                  "document": "Inclusion Criteria:\n\nSubject is considered an adult according to local regulation at the time of obtaining informed consent.\nSubject has a diagnosis of previously-untreated AML according to World Health Organization (WHO) classification [Swerdlow et al, 2008] as determined by pathology review at the treating institution.\nSubject is positive for FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD] [D835/I836] mutation) (or for Korea only: ITD alone or ITD with concurrent TKD activating mutation) in bone marrow or whole blood as determined by central laboratory. Note: Only requirement of FLT3 mutation assessment by central laboratory is only applicable to the randomization portion of the study.\n\nSubject is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:\n\nSubject is \u2265 65 years of age and ineligible for intensive induction chemotherapy.\nSubject is \u2265 18 to 64 years of age and has any of the following comorbidities: [Ex-US Only]: Congestive heart failure (New York Heart Association {NYHA} class \u2264 3) or ejection fraction (Ef) \u2264 50%; [US Only]: Severe cardiac disorder e.g. congestive heart failure (New York Heart Association [NYHA] class \u2264 3) requiring treatment, ejection fraction \u2264 50%, or chronic stable angina; [Ex-US Only]: Creatinine > 2 mg/dL (177 \u00b5mol/L), dialysis or prior renal transplant; [US Only]: Creatinine clearance < 45 mL/min; ECOG performance status \u2265 2;\n[Ex-US Only]: Known pulmonary disease with decreased diffusion capacity of lung for carbon monoxide (DLCO) and/or requiring oxygen \u2264 2 liters per minute; [US Only] Severe pulmonary disorder (e.g., diffusion capacity of lung for carbon monoxide [DLCO] \u2264 65% or forced expiratory volume in the first second [FEV1] \u2264 65%); Prior or current malignancy that does not require concurrent treatment; Subject has received a cumulative anthracycline dose above 400 mg/m2 of doxorubicin (or cumulative maximum dose of another anthracycline). Any other comorbidity incompatible with intensive chemotherapy must be reviewed and approved by the Medical Monitor during screening and before randomization.\n\nSubject must meet the following criteria as indicated on the clinical laboratory tests:\n\nSerum AST and ALT \u2264 3.0 x Institutional upper limit of normal (ULN)\nSerum total bilirubin \u2264 1.5 x Institutional ULN\nSerum potassium \u2265 Institutional lower limit of normal (LLN)\nSerum magnesium \u2265 Institutional LLN Repletion of potassium and magnesium levels during the screening period is allowed.\nSubject is suitable for oral administration of study drug.\n\nFemale subject is eligible to participate if female subject is not pregnant and at least one of the following conditions applies:\n\nNot a woman of childbearing potential (WOCBP); OR\nWOCBP agrees to follow the contraceptive guidance starting at screening and continue throughout the study period, and for at least 180 days after the final study drug administration.\nFemale subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration.\nFemale subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.\nMale subject with female partners of childbearing potential must agree to use contraception as detailed in Contraception Requirements, starting at screening and continue throughout the study period, and for 120 days after the final study drug administration.\nMale subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.\nSubject agrees not to participate in another interventional study while on treatment.\n\nExclusion Criteria:\n\nSubject was diagnosed as acute promyelocytic leukemia (APL).\nSubject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).\n\nSubject has received previous therapy for AML, with the exception of the following:\n\nEmergency leukapheresis\nHydroxyurea\nPreemptive treatment with retinoic acid prior to exclusion of APL \u2264 7 days\nGrowth factor or cytokine support\nSteroids\nSubject has clinically active central nervous system leukemia.\nSubject has been diagnosed with another malignancy that requires concurrent treatment (with the exception of hormone therapy limited to those therapies that prevent recurrence and/or spread of cancer) or hepatic malignancy regardless of need for treatment.\nSubject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 CYP3A/P-glycoprotein (P-gp).\nSubject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-gp with the exception of drugs that are considered absolutely essential for the care of the subject.\nSubject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.\nSubject has congestive heart failure classified as New York Heart Association Class IV.\nSubject with mean Fridericia-corrected QT interval (QTcF) > 480 ms at screening based on central reading.\nSubject with a history of Long QT Syndrome at screening.\n[Ex-US Only]: Subject has known pulmonary function tests with diffusion capacity of lung for carbon monoxide (DLCO) \u2264 50%, forced expiratory volume in the first second (FEV1) \u2264 60%, dyspnea at rest or requiring oxygen or any pleural neoplasm (Transient use of supplemental oxygen is allowed.)\n\nSubject has active hepatitis B or C or other active hepatic disorder.\n\nSubjects with positive hepatitis B surface antigen (HBsAg) or detectable hepatitis B DNA are not eligible.\nSubjects with negative HBsAg, positive hepatitis B core antibody and negative hepatitis B surface antibody will be eligible if hepatitis B DNA is undetectable.\nSubjects with antibodies to hepatitis C virus will be eligible if hepatitis C RNA is undetectable\nSubject has any condition which makes the subject unsuitable for study participation, including any contraindications of azacitidine.\nSubject has a known or suspected hypersensitivity to ASP2215, azacitidine or any components of the formulations used.\n[US Only]: Subject is \u2265 65 to 74 years of age, suitable for and willing to receive intensive induction chemotherapy."
            },
            {
                  "document": "Key Inclusion Criteria:\n\nMale and female patients aged 18 years and older, inclusive;\n\nPatients must have a hematologic malignancy for which allogeneic hematopoietic peripheral blood cell transplantation is deemed clinically appropriate.\n\nEligible diseases and stages include the following:\n\nAcute myeloid leukemia\nAcute lymphoblastic leukemia, including T lymphoblastic lymphoma with a history of marrow involvement\nMyelodysplatic Syndrome\nChronic Myelogenous leukemia\nAvailability of a suitable 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated mPB donor;\nmBP donor collection that meets protocol specifications;\nAdequate performance status, defined as Karnofsky score greater than 70%;\n\nFor female patients of childbearing potential, all of the following criteria must be met:\n\nThey are not pregnant (i.e., female patients must have a negative serum pregnancy test at screening);\nThey are not breastfeeding;\nThey do not plan to become pregnant during the study; and\nThey are using an effective method of contraception from screening to the end of the study, unless their sexual partner is surgically sterile\nFor male patients, agreement to use condoms with spermicide during sexual intercourse from screening to the end of study; and\nWillingness and ability to sign an IRB/IEC approved ICF before performance of any study specific procedures or tests and to comply with protocol visits, and study procedures.\n\nKey Exclusion Criteria:\n\nPhase 1 only: known bone marrow fibrosis; Phase 2 only: Bone marrow fibrosis grade 3 (severe) or greater;\nPositive serology for human immunodeficiency virus (HIV) or human T-cell lymphotropic virus (HTLV) at any time prior to enrollment;\nCurrently uncontrolled bacterial, viral, or fungal infection (progression of clinical symptoms despite therapy);\nPrior autologous or allogeneic HCT;\nActive malignancy, other than the one for which the allogeneic mPB transplant is being performed, within 12 months of enrollment, excluding superficial basal cell and carcinoma in situ cervical cancer;\nPulmonary disease, renal dysfunction, hepatic disease, cardiac disease, neurologic disease;\nParticipation in another clinical trial involving an investigational product within 30 days prior to screening; or\nAny condition or therapy, which, in the opinion of the Investigator, might pose a risk to the patient or make participation in the study not in the best interest of the patient."
            },
            {
                  "document": "Inclusion Criteria:\n\nApplicable disease criteria\nPatients must have one or two partially HLA-matched CBUs\nBack-up stem cell source\nAdequate Karnofsky/Lansky Performance score\nSufficient physiological reserves\nSigned written informed consent\n\nExclusion Criteria:\n\nHLA-matched donor able to donate\nPrior allogeneic HSCT\nOther active malignancy\nActive or uncontrolled infection\nActive/symptoms of central nervous system (CNS) disease\nPregnancy or lactation"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge 18-60 years, inclusive\nNewly diagnosed disease with either a diagnosis of \"high-risk\" MDS (>= 10% blasts in marrow or blood), high-risk myeloproliferative neoplasm (MPN; >= 10% blasts in blood or bone marrow), or AML other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO) classification. Patients with biphenotypic AML are eligible; such \"high-risk\" MDS or MPN have natural history much closer to AML than to lower risk MDS or MPN and have responded similarly to \"AML-type\" therapy.\nOutside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution by appropriate clinical staff. Flow cytometric analysis of peripheral blood and/or bone marrow should be performed according to institutional practice guidelines.\nTreatment-related mortality (TRM) score =< 13.1 as calculated with simplified model\nThe use of hydroxyurea prior to study registration is allowed. Patients with symptoms/signs of hyperleukocytosis, white blood cell (WBC) > 100,000/uL, or acute symptoms can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to study day 0 enrollment\nBilirubin =< 2 times institutional upper limit of normal unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (assessed within 10 days prior to study day 0)\nSerum creatinine =< 2.0 mg/dL (assessed within 10 days prior to study day 0)\nLeft ventricular ejection fraction >= 45%, assessed within 3 months prior to study day 0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure\nWomen of childbearing potential and men must agree to use adequate contraception beginning at the signing of the consent until at least 3 months after the last dose of study drug\nProvide written informed consent (or legal representative)\n\nExclusion Criteria:\n\nMyeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for CML-directed tyrosine kinase inhibitor treatment (excluding sorafenib)\nConcomitant illness associated with a likely survival of < 1 year\nActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]). Patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24-48 hours prior to study day 0, unless fever is thought to be secondary to the underlying hematologic disease.\nActive or clinically significant (or symptomatic) cardiac disease, including active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin within the last 3 months, unstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before study day 0\nPrevious receipt of azacitidine, decitabine, anthracyclines, cytarabine, or other nucleoside analogues for treatment of AML or MPN/MDS other than as noted for cytarabine\nPregnancy or lactation\nConcurrent treatment with any other investigational agent that has anti-leukemia activity or another drug with anti-AML-activity"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have one of the following hematologic malignancies: acute myelogenous leukemia (AML), induction failure, high-risk for relapse first remission (with intermediate-risk or high-risk cytogenetics including complex karyotype, abnormal [abn][3q], -5/5q-, -7/7q-, abn[12p], abn[17p], myeloid/lymphoid or mixed-lineage leukemia [MLL] gene re-arrangement and t [6;9]47, fms related tyrosine kinase 3 [flt3] mutation positive and/or evidence of minimal residual disease by flow cytometry), secondary leukemia from prior chemotherapy and/or arising from myelodysplastic syndromes (MDS), any disease beyond first remission\nMyelodysplastic syndrome (MDS): Primary or therapy related, including patients that will be considered for transplant; these include any of the following categories: 1) revised International Prognostic Scoring System (IPSS) intermediate and high risk groups, 2) malondialdehyde (MDA) with transfusion dependency, 3) failure to respond or progression of disease on hypomethylating agents, 4) refractory anemia with excess of blasts, 5) transformation to acute leukemia, 6) chronic myelomonocytic leukemia, 7) atypical MDS/myeloproliferative syndromes, 8) complex karyotype, abn(3g), -5/5g-, -7/7g-, abn(12p), abn(17p)\nAcute lymphoblastic leukemia (ALL): Induction failure, primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease; patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time: with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure, and/or evidence of minimal residual disease or acute biphenotypic leukemia, or double hit non-Hodgkin's lymphoma\nNon-Hodgkin's lymphoma (NHL) in second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant); relapsed double hit lymphomas; patients with options for treatment that are known to be curative are not eligible\nSmall lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following a minimum of two lines of standard therapy\nChronic myeloid leukemia (CML) second chronic phase or accelerated phase\nHodgkin's disease (HD): Induction failures, after first complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant), or those with active disease\nMultiple myeloma: stage II or III, symptomatic, secretory multiple myeloma requiring treatment\nA person (such as a haploidentical family member) or unit of cord blood must be identified as a source of back-up cells source in case of engraftment failure\nPatient age criteria: age >= 15 and =< 45 years (myeloablative regimen 1; age >= 15 and =< 80 years (nonmyeloablative regimen 2) at the discretion of the investigator(s); age >= 15 and =< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy may receive reduced intensity regimen 3\nPerformance score of at least 60% by Karnofsky\nLeft ventricular ejection fraction of at least 40% (myeloablative regimen 1, reduced intensity regimen 3)\nLeft ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2)\nPulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least 50% predicted value for hemoglobin concentration (myeloablative regimen 1, reduced intensity regimen 3)\nSerum creatinine within normal range, or if serum creatinine outside normal range, then renal function (measured or estimated creatinine clearance or glomerular filtration rate [GFR]) > 40mL/min/1.73 m^2\nSerum glutamate pyruvate transaminase (SGPT)/bilirubin < to 2.0 x normal (myeloablative regimen 1), reduced intensity regimen 3; SGPT/bilirubin < to 4.0 x normal (nonmyeloablative regimen 2)\nNegative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months\nPatients with options for treatment that are known to be curative are not eligible\nPatients enrolled in this study may be enrolled on other supportive care investigational new drug (IND) studies at the discretion of the principal investigator (PI)\n\nExclusion Criteria:\n\nHuman immunodeficiency virus (HIV) positive; HIV results will be determined by nucleic acid testing\nUncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy, decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation (excluding primary disease for which cord blood [CB] transplantation is proposed), or psychiatric condition that would limit informed consent\nActive central nervous system (CNS) disease in patient with history of CNS malignancy\nAvailability of appropriate, willing, human leukocyte antigen (HLA)-matched related stem cell donor"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge, Performance Status, and Graft Criteria\n\n<70 years of age with no matched 5/6 or 6/6 sibling donor - patients \u2265 70 and \u2264 75 years of age may be eligible if they have a Co-Morbidity score \u2264 2 (http://www.qxmd.com/calculate-online/hematology/hct-ci)\nKarnofsky score \u2265 70% (\u2265 16 years) or Lansky score \u2265 50 (< 16 years)\nUCB graft selected according to current University of Minnesota umbilical cord blood graft selection algorithm\n\nEligible Diseases All diseases listed below are advanced hematologic malignancies not curable by conventional chemotherapy. Responses to conventional treatment range from zero to 30% but are typically short lived.\n\nAcute Leukemias: Must be in remission by morphology (<5% blasts). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse.\n\nAcute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in \u2264 60 years old that is NOT considered as favorable-risk. Favorable risk AML is defined as having one of the following:\n\nt(8,21) without cKIT mutation\ninv(16) or t(16;16) without cKIT mutation\nNormal karyotype with mutated NPM1 and wild type FLT-ITD\nNormal karyotype with double mutated CEBPA\nAcute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation\n\nAcute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL. High risk ALL is defined as having one of the following:\n\nEvidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1\n30 years of age or older at diagnosis\nWhite blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis\nCNS leukemia involvement during the course of disease\nSlow cytologic response (>10% lymphoblasts in bone marrow on Day 14 of induction therapy)\nEvidence of persistent immonophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapy\nBiphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR\nChronic myelogenous leukemia in chronic or accelerated phase, or CML blast crisis in morphological remission (<5% blasts): Chronic phase patients must have failed at least two tyrosine kinase inhibitors, been intolerant to all available TKIs, or have T315I mutation.\nMyelodysplastic syndrome: IPSS INT-2 or High Risk; R-IPSS High or Very High; WHO classification: RAEB-1, RAEB-2; Severe Cytopenias: ANC < 0.8, Anemia or thrombocytopenia requiring transfusion; Poor or very poor risk cytogenetics based on IPSS or R-IPSS definitions; therapy-related MDS. Blasts must be < 5% by bone marrow aspirate morphology. If \u22655% blasts, patient requires chemotherapy for cytoreduction to <5% blasts prior to transplantation.\nMRD positive leukemia (AML, ALL or accelerated/blast phase CML). Selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative status.\nLeukemia or MDS in aplasia. These patients may be taken to transplant if after induction therapy they remain with aplastic bone marrow and no morphological or flow-cytometry evidence of disease \u2265 28 days post-therapy. These high risk patients will be analyzed separately.\nBurkitt's lymphoma in CR2 or subsequent CR\nRelapsed T-Cell Lymphoma that is chemotherapy sensitive in CR/PR that has failed or ineligible for an autologous transplant.\nNatural killer cell malignancies\nLarge-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease who are ineligible for an autologous transplant.\nRelapsed Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma which have progressed within 12 months of achieving a partial or complete remission. Patients who had remissions lasting > 12 months, are eligible after at least two prior therapies. Patients with bulky disease should be considered for debulking chemotherapy before transplant. Patients with refractory disease are eligible, unless bulky disease and an estimated tumor doubling time of less than one month.\nLymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive.\nRelapsed Multiple Myeloma that is chemotherapy sensitive and has failed or ineligible for an autologous transplant.\nPlasma Cell Leukemia after initial therapy if achieved at least in partial remission; or relapsed and achieved subsequent remission (CR/PR)\nAcquired Bone marrow failure syndromes, except for Fanconi anemia\nMyeloproliferative Neoplasms/Myelofibrosis\nOther Leukemia Subtypes: A major effort in the field of hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee.\n\nAdditional Criteria for Bulky Disease (lymphomas)\n\nIf stable disease is best response, the largest residual nodal mass must < 5 cm (approximately)\nIf response to previous therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm (approximately)\nOrgan Function Criteria\n\nAdequate organ function is defined as:\n\nCardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40%. For children that are not able to cooperate with MUGA and echocardiography, such should be clearly stated in the physician's note.\nPulmonary: DLCO, FEV1, FVC \u2265 40% predicted, and absence of O2 requirements. For children that are not able to cooperate with PFTs, a pulse oximetry with exercise should be attempted. If neither test can be obtained it should be clearly stated in the physician's note.\nLiver: Transaminases \u2264 5 x upper limit of normal (ULN) and total bilirubin \u2264 2.5 mg/dL except for patients with Gilbert's syndrome or hemolysis\n\nRenal: Creatinine \u2264 2.0 mg/dl (adults) and creatinine clearance \u2265 40 mL/min (pediatrics). Adults with a creatinine > 1.2 mg/dl or a history of renal dysfunction must have estimated creatinine clearance \u2265 40 ml/min/1.73m^2. Adequate performance status is defined as Karnofsky score \u2265 70% (\u2265 16 years of age) or Lansky score \u2265 50 (pediatrics)\n\nSexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment.\nVoluntary written consent (adult or parent/guardian with presentation of the minor information sheet, if appropriate)\n\nExclusion Criteria:\n\nPregnant or breast feeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.\nUntreated active infection\nActive HIV infection or known HIV positive serology\nLess than 3 months since prior myeloablative transplant\nEvidence of progressive disease by imaging modalities or biopsy - persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression.\nCML in blast crisis\nLarge cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on salvage therapy.\nActive central nervous system malignancy"
            },
            {
                  "document": "Inclusion Criteria:\n\nPathologically proven acute myeloid leukemia (AML) (except acute promyelocytic leukemia [APL] with the t(15;17) translocation) or intermediate, high-risk, or very high risk Myelodysplastic Syndrome (MDS) as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R) which is relapsed or refractory (R/R) to standard therapy and/or for which standard therapy is contraindicated or which has not adequately responded to standard therapy.\nPatients must have documented IDH1-R132 gene-mutated disease as evaluated by the site\nGood performance status\nGood kidney and liver function\n\nExclusion Criteria:\n\nPatients with symptomatic central nervous system (CNS) metastases or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy\nCongestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias\nActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy"
            },
            {
                  "document": "INCLUSION CRITERIA:\n\nFor participants in Japan only: if a participant is younger than 20 years at the time of signing the informed consent form, informed consent must be obtained from both the participant and his/her legal representative\n(Multiple myeloma [MM] participants) Pathologically documented, multiple myeloma relapsed or refractory disease after at least 2 lines of therapy\n(MM participants only) Measurable disease per the International Myeloma Working Group response criteria\n(Acute myeloid leukemia [AML] participants) AML as defined by the World Health Organization Classification persisting or recurring following one or more treatment courses, and for participants in Japan, determined by the investigator to be not eligible for approved anticancer drug therapy in Japan; EXCEPT acute promyelocytic leukemia.\n(AML participants only) More than 5% blasts in bone marrow and Circulating white blood cells < 25,000/ul.\nMust be willing and able to undergo a core bone marrow biopsy (MM participants only) and bone marrow aspirate (MM and AML participants) at screening.\nEastern Cooperative Oncology Group (ECOG) performance status of \u2264 2,\n(MM partiicpants only) Satisfactory hematological function without transfusion or growth factor support\nLife expectancy of > 3 months, in the opinion of the investigator\nAdequate hepatic function\nAdequate cardiac function\nAdequate renal function\nFemale participants of childbearing potential must have a negative serum or urine pregnancy test\nOther inclusion criteria may apply\n\nEXCLUSION CRITERIA:\n\nPreviously received an allogeneic stem cell transplant within 6 months OR having received immunosuppressive therapy within the last three months OR having signs or symptoms of acute or chronic graft-versus-host disease\nAutologous stem cell transplant less than 90 days prior to study day 1\n(MM participants only) MM with Immunoglobulin M subtype\n(MM participants only) Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome\n(MM participants only) Existing plasma cell leukemia\n(MM participants only) Waldenstrom's macroglobulinemia\n(MM participants only) Amyloidosis\nInfection requiring intravenous anti-infective treatments within 1 week of study enrollment (day 1)\nMyocardial infarction within 6 months of enrollment, symptomatic congestive heart failure (New York Heart Association > class II)\nHistory of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 6 months prior to enrollment\nCurrently receiving treatment in another investigational device or drug study. Other investigational procedures while participating in this study will be allowed if approved by Amgen medical monitor\nParticipants with elevated cardiac troponin above the manufacturer's 99th percentile upper reference limit for ADVIA Centaur XP assay at screening performed by the central laboratory\nParticipants with evidence of recent cardiac injury at screening based on creatine kinase-muscle/brain, N-terminal prohormone of brain natriuretic peptide, and electrocardiogram\nOther exclusion criteria may apply\n(AML Part 3d only) History of QT prolongation, torsades de pointes, ventricular tachycardia and cardiac arrest\nHistory or evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection unless agreed upon with medical monitor."
            },
            {
                  "document": "Inclusion Criteria:\n\nMust be competent and able to comprehend, sign, and date an Ethics Committee (EC) or Institutional Review Board approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests;\nIs \u226518 years or the minimum legal adult age (whichever is greater) and \u226475 years (at Screening);\nNewly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening);\nEastern Cooperative Oncology Group (ECOG) performance status 0-2 (at the time the participant signs their first ICF);\nPresence of FLT3-ITD activating mutation in bone marrow (allelic ratio of \u22653% FLT3-ITD/total FLT3);\nParticipant is receiving standard \"7+3\" induction chemotherapy regimen as specified in the protocol;\n\nAdequate renal function defined as:\n\na. Creatinine clearance >50 mL/min, as calculated with the modified Cockcroft Gault equation\n\nAdequate hepatic function defined as:\n\nTotal serum bilirubin (TBL) \u22641.5 \u00d7 upper limit of normal (ULN) unless the participant has documented Gilbert's syndrome or the increase is related to increased unconjugated (indirect) bilirubin due to hemolysis;\nSerum alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) \u22642.5 \u00d7 ULN;\nSerum electrolytes within normal limits: potassium, calcium (total, or corrected for serum albumin in case of hypoalbuminemia or ionized calcium) and magnesium. If outside of normal limits, participant will be eligible when electrolytes are corrected;\nIf a woman of childbearing potential, must have a negative serum pregnancy test upon entry into this study and must be willing to use highly effective birth control upon enrollment, during the treatment period and for 6 months following the last dose of investigational drug or cytarabine, whichever is later. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months);\nIf male, must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for 6 months following the last dose of investigational drug or cytarabine, whichever is later.\n\nExclusion Criteria:\n\nDiagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).\nDiagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms;\n\nPrior treatment for AML, except for the following allowances:\n\nLeukapheresis;\nTreatment for hyperleukocytosis with hydroxyurea;\nCranial radiotherapy for central nervous system (CNS) leukostasis;\nProphylactic intrathecal chemotherapy;\nGrowth factor/cytokine support;\nPrior treatment with quizartinib or other FLT3-ITD inhibitors;\nPrior treatment with any investigational drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;\nHistory of known CNS leukemia, including cerebrospinal fluid positive for AML blasts; lumbar puncture is recommended for participants with symptoms of CNS leukemia to rule out extramedullary CNS involvement;\nHistory of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for at least 2 years;\n\nUncontrolled or significant cardiovascular disease, including any of the following:\n\nBradycardia of less than 50 beats per minute, unless the participant has a pacemaker;\nFridericia's Heart Rate Correction Formula (QTcF) interval >450 msec;\nDiagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);\nSystolic blood pressure \u2265180 mmHg or diastolic blood pressure \u2265110 mmHg;\nHistory of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);\nHistory of second (Mobitz II) or third degree heart block (participants with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);\nHistory of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;\nHistory of New York Heart Association Class 3 or 4 heart failure;\nKnown history of left ventricular ejection fraction (LVEF) \u226445% or less than the institutional lower limit of normal;\nComplete left bundle branch block;\nActive acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;\nKnown active clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C);\nKnown history of human immunodeficiency virus (HIV). Participants should be tested for HIV prior to Randomization if required by local regulations or EC;\nHistory of hypersensitivity to any excipients in the quizartinib/placebo tablets;\nFemales who are pregnant or breastfeeding;\nOtherwise considered inappropriate for the study by the Investigator."
            },
            {
                  "document": "Inclusion Criteria:\n\nAbility to provide informed consent\nAbility to tolerate intensive therapy with vosaroxin 90 mg/m^2 and cytarabine\nEastern Cooperative Oncology Group (ECOG) performance status 0-2 at time of study entry\nMorphologically confirmed new diagnosis of AML in accordance with World Health Organization (WHO) diagnostic criteria\nPatients who have received hydroxyurea alone or have previously received \"non-cytotoxic\" therapies for myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) (e.g., thalidomide or lenalidomide, 5-azacytidine or decitabine, histone deacetylase inhibitors, low-dose Cytoxan, tyrosine kinase or dual tyrosine kinase [TK]/SRC proto-oncogene, non-receptor tyrosine kinase [src] inhibitors) will be allowed\nSerum creatinine =< 2.0 mg/dL\nHepatic enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) =< 2.5 x upper limit of normal\nTotal bilirubin =< 1.5 x upper limit of normal unless clearly related to Gilbert's disease, hemolysis or leukemic infiltrate\nFOR PATIENTS IN STAGE 1 (PATIENTS #1-#17)\n\n>= 55 years of age with AML of any risk classification, or 18-54 years of age with high-risk AML disease based on one of the following:\n\nAntecedent hematologic disorder including myelodysplasia (MDS)-related AML (MDS/AML) and prior myeloproliferative disorder (MPD)\nTreatment-related myeloid neoplasms (t-AML/t-MDS)\nAML with FLT3-ITD\nMyeloid sarcoma\nAML with multilineage dysplasia (AML-MLD)\nAdverse cytogenetics (defined as -5/-5q; -7/-7q; abnormal 3q, 9q, 11q, 20q, 21q or 17p; t(6;9); t(9;22); trisomy 8; trisomy 13; trisomy 21; complex karyotypes (>= 3 clonal abnormalities); monosomal karyotypes\nFOR PATIENTS IN STAGE 2 (ENROLLED PATIENT #18 AND BEYOND)\n>= 55 years of age with AML of any risk classification, or 18-54 years of age with intermediate or high risk AML as defined by National Comprehensive Cancer Network (NCCN) risk assignment\n\nExclusion Criteria:\n\nSTAGES 1 AND 2\nPatients with acute promyelocytic leukemia (APL) as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or fluorescence in situ hybridization (FISH) or molecular testing\nAny previous treatment with vosaroxin\n\nConcomitant chemotherapy, radiation therapy\n\nFor patients with hyperleukocytosis with > 50,000 blasts/\u03bcL; leukapheresis or hydroxyurea may be used prior to study drug administration for cytoreduction at the discretion of the treating physician\n\nActive, uncontrolled infection\n\nPatients with infection under active treatment and controlled with antibiotics, antivirals, or antifungals are eligible\nChronic hepatitis is acceptable\nActive, uncontrolled graft vs. host disease (GVHD) following allogeneic transplant for non-AML condition (e.g. MDS, lymphoid malignancy, aplastic anemia); patients with GVHD controlled on stable doses of immunosuppressants are eligible\nPresence of other life-threatening illness\nLeft ventricular ejection fraction (LVEF) < 40% as measured by echocardiogram or multi gated acquisition scan (MUGA)\nKnown or suspected central nervous system (CNS) involvement of active AML\nOther active malignancies including other hematologic malignancies or other malignancies within 12 months before randomization, except nonmelanoma skin cancer or cervical intraepithelial neoplasia\nHistory of myocardial infarction (MI), unstable angina, cerebrovascular accident, or transient ischemic attack (CVA/TIA) within 3 months before randomization\n\nPrior or current therapy:\n\nHydroxyurea or medications to reduce blast count within 24 hours before randomization\nTreatment with an investigational product within 14 days before randomization, or not recovered from all acute effects of previously administered investigational products\nRenal insufficiency requiring hemodialysis or peritoneal dialysis\nPregnant or breastfeeding\nKnown human immunodeficiency virus (HIV) seropositivity\nAny other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator or medical monitor\nADDITIONAL EXCLUSION CRITERIA APPLIED TO STAGE 1\nPatients 18-54 years of age with \"good risk\" AML defined as the presence of t(8;21), inv(16), or t(16;16) as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or FISH\nPatients with t(8;21), inv(16), t(16;16) who are unable to receive anthracycline based induction will be allowed to enroll provided the medical reason they are unable to receive anthracyclines is clearly documented and provided they fulfill all other eligibility and criteria"
            },
            {
                  "document": "INCLUSION CRITERIA\n\nWritten informed consent signed prior to any screening procedures and in accordance with federal, local, and institutional guidelines.\nAge \u226518 years.\n\nAdequate hepatic function:\n\ntotal bilirubin \u22642 times the upper limit of normal (ULN) (except participants with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of \u22644 times ULN),\naspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22642.5 times ULN (except participants with known liver involvement of their tumor who must have their AST and ALT \u22645.0 times ULN).\nAdequate renal function: estimated creatinine clearance of \u226530 mL/min, calculated using the formula of Cockcroft and Gault (140-Age) \u00d7 Mass (kg)/(72 \u00d7 creatinine mg/dL); multiply by 0.85 if female.\n\nContraception:\n\nParticipants with RRMM, CRC, RR high-risk MDS (Part F Phase 2), and AML (Part H): Female participants of child-bearing potential must agree to use dual methods of contraception (including 1 highly effective and 1 effective method of contraception) and have a negative serum test at Screening, and male participants must use an effective barrier method of contraception if sexually active. For both male and female participants, effective methods of contraception must be used throughout the study and for 3 months following the last dose.\nParticipants with RR mCRPC: Participants must use an effective barrier method of contraception if sexually active. Effective methods of contraception must be used throughout the study and for 3 months following the last dose.\nParticipants with newly diagnosed intermediate/high-risk MDS (Part G): Female participants of child-bearing potential must agree to use dual methods of contraception (including 1 highly effective and 1 effective method of contraception) and have a negative serum pregnancy test at Screening, and male participants must use an effective barrier method of contraception if sexually active. For both male and female participants, effective methods of contraception must be used throughout the study and for 6 months following the last dose.\n\nINDICATION-SPECIFIC INCLUSION CRITERIA\n\nRelapsed/Refractory Multiple Myeloma (Parts A1, A2, and B - Completed):\n\nSymptomatic, histologically confirmed MM and evidence of disease progression, based on IMWG guidelines.\n\nParticipants must have measurable disease as defined by at least 1 of the following:\n\nSerum M-protein \u22650.5 g/dL by serum protein electrophoresis (SPEP) or for immunoglobulin (Ig) A myeloma, by quantitative IgA. If SPEP is felt to be unreliable for routine M-protein measurement (e.g., for participants with IgA MM), then quantitative Ig levels by nephelometry; or\nUrinary M-protein excretion at least 200 mg/24 hours; or\nSerum free light chain (FLC) whereby the involved light chain measures \u226510 mg/dL and with an abnormal ratio.\nPreviously treated with \u22653 prior regimens (lines of therapy) that included at least 1 of each of the following: an immunomodulatory drug, a proteasome inhibitor, and a steroid.\nMM refractory to the participants most recent anti-MM regimen.\nParticipants receiving hematopoietic growth factor support including erythropoietin, darbepoetin, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, and platelet stimulators can continue to do so, but must be transfusion independent for at least 1 week prior to Cycle 1 Day 1 (C1D1) in the study.\nAdequate hematopoietic function: total white blood cell (WBC) count \u22651500/mm^3, absolute neutrophil count (ANC) \u2265800/mm^3, hemoglobin (Hb) \u22658.0 g/dL, and platelet count \u226575,000/mm^3.\nEastern Cooperative Oncology Group (ECOG) performance status of \u22641.\n\nLife expectancy of \u22654 months.\n\nRelapsed/Refractory Colorectal Cancer (Part C - Completed):\n\nHistological or cytological documentation of adenocarcinoma of the colon or rectum.\nMeasurable disease by RECIST v1.1.\nMetastatic disease not suitable for upfront curative-intent surgery.\nParticipants with site-defined KRAS status (wild-type or mutant) from a fresh or archival tumor biopsy prior to enrollment. All participants must be willing to have fresh biopsies to obtain tumor tissue for biomarker analysis.\nDocumented evidence of progressive disease according to RECIST v1.1.\n\nPrior treatment (with completion of a course of therapy, or to disease progression or intolerability) with each of the following:\n\nFluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapies (e.g., FOLFOX and/or FOLFIRI)\nif KRAS wild-type, an anti-EGFR therapy,\nPrior third line treatment with regorafenib or TAS-102, will be assessed on an individual basis,\nNote: The requirement for prior third line regorafenib will be assessed on an individual basis by the investigator in consultation with the Karyopharm Medical Monitor\nRadiation and surgery are not considered as prior anticancer regimens\nParticipants should not be transfusion dependent.\nAdequate hematopoietic function: ANC \u22651000/mm^3, hemoglobin (Hb) \u22659.0 g/dL, and platelet count \u2265100,000/mm^3.\nECOG performance status of \u22641.\n\nLife expectancy of \u22654 months.\n\nRelapsed/Refractory Metastatic Castration-resistant Prostate Cancer (Parts D and E - Completed):\n\nHistologically confirmed adenocarcinoma of the prostate with archival tumor tissue available for molecular analyses. If the participants does not have a prior histological diagnosis, then a fresh biopsy at Screening may be used for this purpose.\n\na. Optional: All participants will be asked to have fresh biopsies to obtain tumor tissue for biomarker analysis.\n\nSurgically or medically castrated, with testosterone levels of <50 ng/dL (<2.0 nM). If the participant is being treated with luteinizing hormone-releasing hormone (LHRH) agonists (participants who have not undergone orchiectomy), and participants must have shown to progress on this.\n\nDocumented mCRPC progression as assessed by the Investigator with 1 of the following:\n\nProstate-specific antigen (PSA) progression defined by a minimum of 3 rising PSA levels (at approximately Day -30 and approximately Day -45) with an interval of >1 week between each determination. The PSA values at the Screening visit should be >2 \u03bcg/L (>2 ng/mL); participants on systemic glucocorticoids for control of symptoms must have documented PSA progression by Prostate Cancer Working Group 3 (PCWG3) while on systemic glucocorticoids prior to commencing C1D1 of treatment.\nRadiographic progression of soft tissue disease by modified RECIST criteria 1.1 or of bone metastasis with 2 or more documented new bone lesions on a bone scan with or without PSA progression.\nInitial response (per modified PCWG3 Guidelines) to second generation anti-hormonal therapy (examples: abiraterone, enzalutamide, TAK 700), but later relapsed. Disease relapse would be defined as progressive disease at the time of entry per inclusion criterion 24.\nZero to 2 previous taxane-based chemotherapy regimens. If docetaxel chemotherapy is used more than once, this will be considered as 1 regimen. Participants may have had prior exposure to cabazitaxel treatment. Participants may be taxane na\u00efve.\nAt least 2 weeks from completion of any radiotherapy including a single fraction of radiotherapy for the purposes of palliation (confined to 1 field) is permitted.\nParticipants should not be transfusion dependent.\nAlbumin >2.5 g/dL.\nAdequate hematopoietic function: ANC \u22651000/mm^3, hemoglobin (Hb) \u22659.0 g/dL, and platelet count \u2265100,000/mm^3.\nPart E only: Participants currently receiving treatment with abiraterone and appropriate to continue in the opinion of the Investigator. Participants must also have been on and continue on a stable dose of corticosteroids (prednisone or dexamethasone) for 30 days prior to C1D1.\nECOG performance status of \u22641.\n\nLife expectancy of \u22654 months.\n\nRR High-risk Myelodysplastic Syndrome (Part F Phase 2):\n\nDocumented diagnosis of MDS with 5% to 19% myeloblasts in the bone marrow (2016 WHO classification)\nThe marrow histopathology must be documented by recent bone marrow biopsy\nParticipants should be intermediate, high- or very-high-risk MDS by IPSS-R\n\nParticipants with HMA (primary)-refractory MDS, including:\n\n\u22652 cycles of hypomethylating agents (azacitidine and/or decitabine, ASTX727, or experimental agents) with clear progressive disease (PD) (pancytopenia, with \u226550% increase in bone marrow blasts) or participants progressed to a higher-risk category of MDS OR\n\u22654 cycles of azacitidine and/or decitabine (or other hypomethylating therapy) with SD/lack of improvement (no CR/mCR/PR/HI) per IWG criteria\nECOG performance status of <2\n\nPrior to enrolling a participant with imminent risk of AML transformation (per opinion of the Investigator) or for participants with RAEB-2 MDS, the Medical Monitor must be contacted\n\nNewly Diagnosed Intermediate/High-risk Myelodysplastic Syndrome (Part G):\n\nDocumented diagnosis of MDS with 5% to 19% myeloblasts in the bone marrow (2016 WHO classification)\n\nThe marrow histopathology must be documented in bone marrow biopsy\nParticipants should be intermediate, high- or very high-risk MDS by IPSS-R\nNo prior therapy for MDS. (One prior cycle of a hypomethylating agent is allowed, but no other cytotoxic chemotherapy is permitted within 2 weeks of starting study treatment.)\n\nECOG performance status of <2\n\nAML Maintenance (Post-alloSCT) Therapy (Part H):\n\nParticipants with de novo AML or AML secondary to prior myelodysplastic disease\nReceived an allogeneic SCT\nAt the time of allogeneic SCT, no prior allogeneic HSCT\nParticipants must be able to start study treatment between 40 and 100 days following alloSCT\n\nParticipants with CR/CRi status confirmed prior to alloSCT according to the following criteria, must also be MRD-positive by multi-parameter flow cytometry (MFC) at either pre-allo or at time of enrollment:\n\nComplete remission:\n\n<5% blasts in bone marrow\nAbsence of blasts with Auer rods\nAbsence of extramedullary disease\nIndependent of blood transfusions\nPeripheral neutrophil count \u22651.0 x 10^9/L\nPlatelet count \u2265100 x 10^9/L\n\nComplete remission with incomplete blood count recovery:\n\n<5% blasts in bone marrow\nAbsence of blasts with Auer rods\nAbsence of extramedullary disease\nIndependent of blood transfusions\nPeripheral neutrophil count <1.0 x 10^9/L, or\nPlatelet count <100 x 10^9/L\n\nIf not in CR/CRi with MRD positivity prior to alloSCT, may have any of the following high-risk features:\n\nRelapsed AML, not in CR\nIf CR2 or greater, may enroll regardless of disease characteristics at initial diagnosis\nHigh-risk cytogenetics at time of diagnosis\nAdequate engraftment within 14 days prior to starting study therapy: ANC \u22651.0 x 10^9/L without daily use of myeloid growth factor, and platelet count 75 x 10^9/L without platelet transfusion within 1 week\nECOG performance status of \u22642\n\nEXCLUSION CRITERIA\n\nParticipants in All Parts of the Study:\n\nFemale participants who are pregnant or lactating\nMajor surgery within 4 weeks before C1D1\n\nImpaired cardiac function or clinically significant cardiac diseases, including any of the following:\n\nUnstable angina or acute myocardial infarction \u22643 months prior to C1D1\nClinically significant heart disease (e.g., symptomatic congestive heart failure [e.g., >NYHA Class 2]; uncontrolled arrhythmia, or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen)\nUncontrolled active severe systemic infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1\nParticipants with known symptomatic brain metastasis are not suitable for enrollment. Participants with asymptomatic, stable, treated brain metastases are eligible for study entry\nParticipants with a known history of human immunodeficiency virus (HIV); HIV testing is not required as part of this study\nKnown, active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen)\n\nPrior malignancies:\n\nParticipants with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (i.e., cervix) may enroll irrespective of the time of diagnosis\nParticipants with relapsed/refractory MM, CRC, and mCRPC only: Prior malignancies which may interfere with the interpretation of the study. Cancer treated with curative intent <5 years previously will not be allowed unless approved by the Sponsor. Cancer treated with curative intent >5 years previously and without evidence of recurrence will be allowed.\nFor participants in Arms F Phase 2, G, and H: Prior malignancy is not an exclusion\nParticipants with gastrointestinal tract disease (or uncontrolled vomiting or diarrhea) that could interfere with the absorption of eltanexor (or ASTX727 in Part G)\nSerious psychiatric or medical conditions that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give consent\n\nParticipants unwilling to comply with the protocol including required biopsies and sample collections required to measure disease\n\nINDICATION-SPECIFIC EXCLUSION CRITERIA\n\nRelapsed/Refractory Multiple Myeloma (RRMM) (Parts A1, A2 and B - Completed):\n\nTime since the last prior therapy for treatment of RRMM:\n\nRadiation, chemotherapy, immunotherapy or any other anticancer therapy, including investigational anticancer therapy \u22642 weeks prior to C1D1\nPalliative steroids for disease related symptoms are allowed up to 3 days prior to C1D1.\nParticipants must have recovered or stabilized (\u2264Grade 1 or to their baseline) from toxicities related to their previous treatment except for alopecia\nParticipants with active graft versus host disease after allogeneic stem cell transplantation. At least 3 months must have elapsed since completion of allogeneic stem cell transplantation\n\nGrade >2 peripheral neuropathy or Grade 2 peripheral neuropathy with pain within 2 weeks prior to C1D1\n\nRelapsed/Refractory Colorectal Cancer (Part C - Completed):\n\nRadiotherapy, chemotherapy, or any other anticancer therapy, including investigational anticancer therapy within 2 weeks prior to Screening. Participants must have recovered from clinically significant toxicities. The site of irradiation should have evidence of progressive disease (new lesions or increase in lesion size) if this is the only site of disease\n\nParticipants who have been treated with their most recent chemotherapy or investigational drugs \u226421 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment, and/or have any acute toxicities due to prior chemotherapy and/ or radiotherapy that have not resolved to a NCI CTCAE v4.03 Grade 0 or Grade 1 with the exception of chemotherapy induced alopecia and Grade 2 peripheral neuropathy\n\nRelapsed/Refractory Metastatic Castration-Resistant Prostate Cancer (Parts D and E - Completed):\n\nParticipants who have been treated with their most recent chemotherapy or investigational drugs \u226421 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment, and/or have any acute toxicities due to prior chemotherapy and/ or radiotherapy that have not resolved to a NCI CTCAE v4.03 Grade 0 or Grade 1 with the exception of chemotherapy-induced alopecia and Grade 2 peripheral neuropathy\n\nInitiating bisphosphonate therapy or adjusting bisphosphonate dose/regimen within 30 days prior to C1D1. Participants on a stable bisphosphonate or denosumab regimen are eligible and may continue\n\nRR High-risk Myelodysplastic Syndrome (Part F Phase 2):\n\nIPSS-R very low or low-risk MDS\nEvidence of transformation to AML by the World Health Organization (WHO) (\u226520% blasts in bone marrow or peripheral blood)\n\nParticipants who demonstrate doubling of their bone marrow blast percentage within 4 weeks prior to Screening and have absolute blast percentage of > 15% at the time of Screening\n\nNewly Diagnosed Intermediate/High-risk Myelodysplastic Syndrome (Part G):\n\nIPSS-R very low or low-risk MDS\n\nEvidence of transformation to AML by the WHO (\u226520% blasts in bone marrow or peripheral blood)\n\nAML Maintenance (Post-alloSCT) Therapy (Part H):\n\nUse of any of the following after transplantation and prior to starting study treatment: chemotherapeutic agents for chemotherapy; investigational agents/therapies; azacitidine, decitabine or other demethylating agents; or lenalidomide, thalidomide, or pomalidomide\nActive GVHD Grade 2 or higher\nConcurrent use of corticosteroids equivalent of prednisone at a dose >0.5 mg/kg"
            },
            {
                  "document": "Inclusion Criteria:\n\nAll patients with histologically or cytologically confirmed relapsed or refractory acute myeloid leukemia (AML) (except acute promyelocytic leukemia) or relapsed or refractory high-risk myelodysplastic syndrome (HRMDS) (intermediate 2 [Int-2] or higher risk by International Prognostic Scoring System [IPSS]); patients with chronic myelomonocytic leukemia (CMML) can be enrolled if they can be classified as HRMDS using MDS criteria; patients should not have received more than one salvage therapy; second induction regimen or stem cell transplant in remission will be considered salvage therapy; refractory subjects, up to second consecutive salvage\nPatients must have a performance status of 0-2 (Eastern Cooperative Oncology Group [ECOG] scale)\nSerum creatinine less than or equal to 1.3 mg/dL and/or creatinine clearance > 40 mL/min\nBilirubin less than or equal to 1.5 mg/dl (unless due to Gilbert's syndrome)\nSerum glutamic-oxaloacetic transaminase (SGOT)/aspartate transaminase (AST) or serum glutamate pyruvate transaminase (SGPT)/alanine transferase (ALT) less than or equal to 2.5 X the upper limit of normal (ULN) for the reference lab\nPatients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] >/= 45%)\nCorrected QT (QTc) interval =/< 470 msecs, no familial history of QTc prolongation or ventricular arrhythmias\nFemale patients must not be pregnant or lactating; female patients of childbearing potential (including those < 1 year post-menopausal) and male patients must agree to use contraception\nPatients who have received prior stem cell transplantation will be allowed to enroll as long as prior transplantation has been at least 3 months before enrollment in the trial and any transplant related toxicities have subsided to grade 1 or less\n\nExclusion Criteria:\n\nPatients must not have untreated or uncontrolled life-threatening infection\nPatients must not have been treated with CHK1/2 inhibitors\nPatients must not have received chemotherapy and/or radiation therapy within 2 weeks of start of protocol treatment; hydroxyurea is allowed up to 48 hours prior to starting therapy in the setting of rapidly proliferating disease\nPatients must not have received an investigational anti-cancer drug within two weeks of start of protocol treatment\nPatients must not have active central nervous system leukemia; patients with history of central nervous system (CNS) leukemia with no evidence of active CNS disease may be enrolled; maintenance intrathecal chemotherapy for adequately treated CNS involvement with leukemia is allowed with approval from the study supporter\nPatients must not have significant cardiac co-morbidity including: history of acute coronary syndromes (including myocardial infarction and unstable angina) within 12 months; coronary angioplasty or stenting within 6 months; history or evidence of current >/= class III congestive heart failure as defined by the New York Heart Association (NYHA); patients with intra-cardiac defibrillators or permanent pacemakers"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have had histologic verification of AML at original diagnosis\n\nPatient must have one of the following:\n\nRecurrent disease with >= 5% blasts in the bone marrow (M2/M3 bone marrow), with or without extramedullary disease.\nRecurrent disease with an absolute blast count greater than 1,000 per microliter in the peripheral blood with or without extramedullary disease\n\nTo be eligible for the dose-finding phase: (the dose-finding phase completed in 12/2016)\n\nRelapsed patients\n\nPatients must be in first relapse, and\nPatients must not have received prior re-induction therapy\n\nRefractory patients\n\nPatients must not have received more than one attempt at remission induction, which may consist of up to two different therapy courses; Children Oncology Group (COG) AAML1031 de novo therapy including induction I and induction II is an example\n\nTreatment-related AML (t-AML)\n\nPatients must be previously untreated for secondary AML\n\nTo be eligible for the phase 2 efficacy phase:\n\nRelapse patients:\n\nPatients must be in first marrow relapse, and\nPatients must not have received prior re-induction therapy; donor lymphocyte infusion (DLI) is considered a re-induction attempt\nPatients must have the status of CNS1 or CNS2 only, and no clinical signs or neurologic symptoms suggestive of CNS leukemia, such as cranial palsy\nPatients must have a performance status corresponding to an Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age; Note: patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score\nPatients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, stem cell transplant or radiotherapy prior to entering this study; all prior treatment-related toxicities must have resolved to =< grade 2 prior to enrollment\n\nMyelosuppressive chemotherapy: must not have received myelosuppressive chemotherapy within 3 weeks of entry onto this study (excluding hydroxyurea)\n\nCytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of CPX-351\nBiologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent such as steroids, retinoids; Note: for agents that have known adverse events occurring beyond 7 days after administration (i.e. monoclonal antibodies), this period must be extended beyond the time during which acute adverse events are known to occur\nRadiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation; Note: patients must have received =< than 13.6 Gray (Gy) prior radiation to the mediastinum\n\nStem cell transplant (SCT): no evidence of active graft vs. host disease for at least 4 weeks; for allogeneic SCT patients, >= 3 months must have elapsed since transplant\n\nMust have received no more than 1 prior autologous or allogeneic stem cell transplant.\nPatients must be off all systemic immunosuppressive therapy for at least 2 weeks, excluding hydrocortisone for physiologic cortisol replacement\n\nIntrathecal cytotoxic therapy:\n\nNo waiting period is required for patients having received intrathecal cytarabine, methotrexate, and/or hydrocortisone\nAt least 14 days must have elapsed since receiving liposomal cytarabine (DepoCyte) by intrathecal injection\n\nGrowth factors:\n\nPatients must not have received growth factors for 7 days prior to CPX-351\nPatients must not have received pegfilgrastim for 14 days prior to CPX-351\n\nCreatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\n\nAge 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (males and females)\nAge 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (males and females)\nAge 6 to < 10 years: maximum serum creatinine 1.0 mg/dL (males and females)\nAge 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (males and females)\nAge 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (males) and 1.4 mg/dL (females)\nAge >= 16 years: maximum serum creatinine 1.7 mg/dL (males) and 1.4 mg/dL (females)\nDirect bilirubin < 1.5 x upper limit of normal (ULN) for age and institution\nSerum glutamate pyruvate (SGPT) (alanine aminotransferase [ALT]) =< 3.0 x upper limit of normal (ULN) for age and institution (unless it is related to leukemic involvement)\nShortening fraction of >= 27% by echocardiogram, or\nEjection fraction of >= 50% by radionuclide angiogram or echocardiogram\nCorrected QT (using Bazett's formula [QTcB]) interval < 500 msecs\nPatients with seizure disorder may be enrolled if on anticonvulsants and if seizures are well controlled\nCentral nervous system (CNS) toxicity =< grade 2\n\nPatients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:\n\nNo history of HIV complications with the exception of cluster of differentiation (CD)4 count < 200 cells/mm^3\nNo antiretroviral therapy with overlapping toxicity such as myelosuppression\nHIV viral loads below the limit of detection\nNo history of highly active antiretroviral therapy (HAART)-resistant HIV\nAll patients and/or their parents or legal guardians must sign a written informed consent\nAll institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\n\nExclusion Criteria:\n\nPatients who have received > 450 mg/m^2 daunorubicin equivalents; patients who relapse after receiving AAML0531/AAML1031 therapy will be eligible for this study, provided they have not received any additional anthracyclines; NOTE: for the purposes of determining eligibility for this protocol, the following cardiotoxicity multipliers will be used to determine daunorubicin equivalents:\n\nDoxorubicin (doxorubicin hydrochloride): 1\nMitoxantrone: 3\nIdarubicin: 3\nEpirubicin: 0.5\nPatients who are currently receiving another investigational drug\nPatients receiving medications for treatment of left ventricular systolic dysfunction\n\nPatients with any of the following diagnoses:\n\nAcute promyelocytic leukemia (APL)\nDown syndrome\nFanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome\nWilson's disease and any other disorder of copper metabolism\nJuvenile myelomonocytic leukemia (JMML)\nPatients with documented active, uncontrolled infection at the time of study entry\nPatients with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infections\nPatients with prior allergy to daunorubicin and/or cytarabine\nFemale patients who are pregnant are ineligible\nLactating females are not eligible\nFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\nSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 6 months after the last dose of chemotherapy"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must \u226518 years of age\nPreviously untreated AML (de novo or secondary) defined according to World Health Organization (WHO) criteria, excluding acute promyelocytic leukemia (APL) [AML with t(15;17)], with locally documented IDH1 and/or IDH2 gene mutation scheduled for induction therapy followed by consolidation therapy. Participants with secondary AML is defined as AML arising after myelodysplastic syndromes (MDSs) or other antecedent hematologic disorders (AHDs) or AML arising after exposure to genotoxic injury including radiation and/or chemotherapy are also eligible. Participants may have had previous treatment for MDS or other AHD, including hypomethylating agents (HMAs), provided it was \u2265 14 days prior to study drug initiation\nEastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 2\nAdequate hepatic function as evidenced by: serum total bilirubin \u22641.5 \u00d7 upper limit of normal (ULN) unless considered due to Gilbert's disease, a gene mutation in UGT1A1 (only for patients who will be receiving AG-221), or leukemic involvement following approval by the study Sponsor; aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) \u22643.0 \u00d7 ULN, unless considered due to leukemic involvement following approval by the study Sponsor\nAdequate renal function as evidenced by serum creatinine \u22642.0 \u00d7 ULN or creatinine clearance 40 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR)\nAgree to serial blood and bone marrow sampling\nMeet any criteria necessary for the safe and proper use of the induction and consolidation agents involved in this trial\nAble to understand and willing to sign an informed consent form. A legally authorized representative may consent on behalf of a participant who is otherwise unable to provide informed consent, if acceptable to, and approved by, the site's Institutional Review Board (IRB)/Independent Ethics Committee (IEC).\nFemale participants with reproductive potential must agree to undergo a medically supervised pregnancy test prior to starting study drug. The first pregnancy test will be performed at screening (within 7 days prior to first study drug administration). A pregnancy test should also be performed on the day of the first study drug administration and confirmed negative prior to dosing as well as before dosing on Day 1 of all subsequent cycles\nFemale participants with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of the therapy. Participants with reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy or tubal occlusion or who have not been naturally postmenopausal for at least 24 consecutive months. Females of reproductive potential as well as fertile men and their partners who are female of reproductive potential must agree to abstain from sexual intercourse or to use one highly effective form (for participants receiving AG-221) or two highly effective forms (for participants receiving AG-120) of contraception from the time of giving informed consent, during the study, and for 2 months (for participants receiving AG-221) and for 4 months (for participants receiving AG-120) following the last dose of AG-120 or AG-221 (females and males). A highly effective form of contraception is defined as hormonal oral contraceptives, injectables, patches, intrauterine devices, double-barrier method (e.g., synthetic condoms, diaphragm or cervical cap with spermicidal foam, cream, or gel) or male partner sterilization\n\nExclusion Criteria:\n\nPrior chemotherapy for AML. Hydroxyurea is allowed prior to enrollment for the control of peripheral leukemic blasts in participants with leukocytosis; hydroxyurea may be allowed on study with study Sponsor approval\nTaking medications with narrow therapeutic windows, unless they can be transferred to other medications prior to enrolling or unless the medications can be properly monitored during the study\nTaking known strong cytochrome P450 (CYP) 3A4 inducers, unless they can be transferred to other medications prior to enrolling. For participants taking AG-120, systemic administration of a moderate or strong CYP3A4 inhibitor requires careful monitoring of the heart rate-corrected QT interval (QTc) using Fridericia's formula (QTcF)\nTaking P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) or OATP1B1/1B3 transporter-sensitive substrate medications unless they can be transferred to alternative medications within \u22655 half-lives prior to administration of AG-221, or unless the medications can be adequately monitored during the study. There are no restrictions regarding the co-administration of such medications with AG-120.\nPregnant or breastfeeding\nUncontrolled active infection or uncontrolled invasive fungal infection (positive blood or tissue culture). An infection controlled with an approved or closely monitored antibiotic/antifungal treatment is allowed\nPrior history of malignancy, other than MDS or AML, unless the participant has been free of the disease for \u22651 year prior to the start of study treatment However, participants with the following history/concurrent conditions are allowed: basal or squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; incidental histologic finding of prostate cancer\nSignificant active cardiac disease within 6 months prior to the start of study treatment, including New York Heart Association (NYHA) Class III or IV congestive heart failure; myocardial infarction, unstable angina and/or stroke; or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO), or by other methods according to institutional practice, obtained within 28 days prior to the start of study treatment\nQTc interval using Fridericia's formula (QTcF) \u2265450 milliseconds (msec) or other factors that increase the risk of QT interval prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome). Bundle branch block and prolonged QTc are permitted with approval of the study Sponsor\nTaking medications that are known to prolong the QT interval unless they can be transferred to other medications within \u22655 half-lives prior to dosing (If equivalent medication is not available QTc will be closely monitored)\nKnown infection caused by human immunodeficiency virus (HIV) or active hepatitis B or C\nDysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs\nClinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is required only if there is a clinical suspicion of CNS involvement by leukemia during screening.\nImmediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation\nAny other medical or psychological condition deemed by the Investigator to be likely to interfere with a participant's ability to give informed consent or participate in the study"
            },
            {
                  "document": "INCLUSION CRITERIA:\n\nIndividuals must meet all the following criteria to be eligible for this study.\n\nSubject, parent, or legal guardian, if applicable, must have given written informed consent. For patients \u2264 17 years of age who are developmentally able, assent or affirmation will be obtained.\nAge 0-26, inclusive, at time of consent.\nDiagnosis of myelodysplastic syndrome or acute myeloid leukemia, either high-risk (defined below), relapsed or primary refractory, MRD-positive without circulating myeloblasts or active extramedullary disease at the time of transplant. Active marrow disease is permitted. High-risk AML features are defined by the following: RAM phenotype; adverse cytogenetic abnormalities of monosomy 5, monosomy 7, 5q deletion, or other unfavorable prognostic markers according to cytogenetics, FISH, or next generation sequencing (NGS); presence of FLT3 positive internal tandem duplication (FLT3/ITD+), particularly high allelic ratio; treatment-related AML; or positive minimal residual disease (MRD) at end of Induction I.\nStem cell sources include bone marrow, peripheral blood stem cells, or umbilical cord blood. Related bone marrow, peripheral blood stem cell, or cord blood unit: sibling should be HLA-matched at A, B, and DR-B1 loci. Unrelated cord blood unit should be at a minimum of 4/6 matched at antigen level on HLA A and B, and allele level at HLA DR-B1 loci. Unrelated bone marrow or peripheral blood stem cell donor should be HLA allele level matched at DR-B1.\nMinimum pre-freezing cell dose for cord blood units: 3 x 10^7 total nucleated cells/kg and 1.5 x 10^5 CD34+ cells/kg. If this is not attainable, then double cord blood transplant should be considered.\nSubject must have adequate performance status: Lansky score \u226560% for patients <16 years, Karnofsky score \u226560% for patients \u226516 years.\nSubject must have adequate pre-transplant organ function to undergo one of the two conditioning regimens, either the myeloablative conditioning (MAC) OR reduced-intensity conditioning (RIC) regimen. If a subject does not meet the following organ function criteria for the MAC regimen, the RIC regimen will be considered if eligibility criteria is met. The RIC regimen may also be considered, regardless of MAC eligibility, if deemed appropriate by the Principal Investigator and/or treating physician.\n\nPre-transplant organ function criteria for Myeloablative Conditioning regimen:\n\nRenal: creatinine clearance or radioisotope GFR \u226570 mL/min/1.73 m2.\nHepatic: total bilirubin \u22642.0 mg/dL unless the increase in bilirubin is attributable to Gilbert's syndrome; and SGOT (AST), SGPT (ALT), and Alkaline Phosphatase <4 x upper limit of normal (ULN) for age.\nCardiac: normal cardiac function by echocardiogram or radionuclide scan, as defined by left ventricular ejection fraction at rest >45% or shortening fraction >26%.\nPulmonary: FEV1, FVC, and DLCO (corrected for hemoglobin) \u226550% of predicted; if unable to perform pulmonary function tests, then oxygen saturation \u226592% on room air.\n\nOR\n\nPre-transplant organ function criteria for Reduced-Intensity Conditioning regimen:\n\nRenal: creatinine clearance or radioisotope GFR \u226570 mL/min/1.73 m2.\nHepatic: total bilirubin \u22642.5 mg/dL unless the increase in bilirubin is attributable to Gilbert's syndrome; and SGOT (AST), SGPT (ALT), and Alkaline Phosphatase <5 x upper limit of normal (ULN) for age.\nCardiac: normal cardiac function by echocardiogram or radionuclide scan, as defined by left ventricular ejection fraction at rest >40% or shortening fraction >26%.\n\nPulmonary: FEV1, FVC, and DLCO (corrected for hemoglobin) \u226540% of predicted; if unable to perform pulmonary function tests, then oxygen saturation \u226592% on room air.\n\nHIV and HTLV negative, by either PCR or serology.\nNegative pregnancy test for females \u226510 years old or who have reached menarche.\nAll females of childbearing potential and sexually active males must agree to use an FDA approved method of birth control for up to 12 months after HSCT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause a birth defect.\n\nEXCLUSION CRITERIA:\n\nIndividuals who meet any of the following criteria are not eligible for this protocol.\n\nUncontrolled bacterial, viral, fungal, or other infection at the time of cytoreduction, defined by positive blood cultures and/or fevers >38.0 within 24 hours of start of conditioning therapy.\nFemales who are pregnant or who are lactating.\nPast or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n\nAdditional Exclusion Criteria for Myeloablative Conditioning (MAC) Only Individuals who meet any of the following criteria are not eligible for the MAC regimen.\n\nRecipient of either an autologous or allogeneic stem cell transplant within 3 months of the start of conditioning.\nPatients with any inherited bone marrow failure syndrome including, but not limited to, Fanconi anemia, Shwachman-Diamond syndrome, dyskeratosis congenita or Down syndrome (defined as either constitutional trisomy 21 or constitutional mosaicism of trisomy 21)."
            },
            {
                  "document": "Inclusion Criteria\n\nAny of the following high risk or recurrent hematological malignancies:\nHodgkin lymphoma (HL)\nNon-Hodgkin lymphoma (NHL)\nChronic lymphocytic leukemia (CLL)\nMultiple myeloma (MM)\nAcute myelogenous leukemia (AML)\nAcute lymphocytic leukemia (ALL)\nChronic myelogenous leukemia (CML)\n\nMyelodysplastic syndrome (MDS)\n\n*Note: Determination that the malignancy is high risk will be made by the investigator.\n\nInvestigator determination that the patient is an appropriate candidate for reduced intensity allogeneic SCT with the standard Massey Cancer Center-Virginia Commonwealth Health System Bone Marrow Transplant MCC-VCUHS BMT Program regimen employed in this trial\nPatients with or without previous myeloablative autologous transplant\n\nHLA-matched stem cell donor, either related (6/6 or 5/6 loci matched) or unrelated (8/8 or 7/8 loci matched)\n\n*Note: Unrelated donors must be matched at HLA-A, -B, -C, and -DRB1 loci. However, a single locus mismatch will be acceptable in the event a more closely matched donor is not available.\n\nAge \u2265 40 to < 75 years; patients 18 to 39 years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioning\nKarnofsky Performance Status of 70-100%\nNegative serology for HIV\nWomen who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines\nAbility to understand and the willingness to sign a written informed consent document *Note: The consent form must be signed and dated prior to initiation of SCT preparative treatments.\n\nExclusion Criteria\n\nPrevious therapeutic radiation therapy (RT) that exceeds critical structure tolerance doses as determined by a radiation oncologist\nUncontrolled viral, fungal, or bacterial infection\nActive meningeal or central nervous system disease\n\nPrevious therapy with rabbit anti-thymocyte globulin (ATG); previous treatment with equine ATG is allowed if more than 3 months ago\n\n*Note: Previous myeloablative autologous transplant is permitted but not required.\n\nPregnancy or breastfeeding\nMedical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have histologic evidence of high risk acute myeloid leukemia defined as one of the following:\n\nPrimary refractory non-M3 AML\n\nResidual leukemia after a minimum of 2 prior courses of chemotherapy (Same or different)\nEvidence of leukemia recurrence after a nadir bone marrow biopsy demonstrates no evidence of residual leukemia.\nEvidence of leukemia after induction therapy which, in the opinion of the investigator, would be appropriate for reinduction with sirolimus/MEC therapy.\nRelapsed non-M3 AML\nPreviously untreated non-M3 AML age >60 with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inv16(p13;q22), or t(16;16)(p13;q22) [CBF\u03b2;MYH11] by cytogenetics, FISH, or RT-PCR\nPreviously untreated secondary AML (from antecedent hematologic malignancy or following therapy with radiation or chemotherapy for another disease) with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inv16(p13;q22), or t(16;16)(p13;q22) [CBF\u03b2;MYH11] by cytogenetics, FISH, or RT-PCR\nSubjects must be \u2265 18 years of age.\nSubjects must have an ECOG performance status of 2 or less (see Appendix1).\nSubjects must have a life expectancy of at least 4 weeks.\nSubjects must be able to consume oral medication.\nSubjects must have recovered from the toxic effects of any prior chemotherapy to =< Grade 1 (except alopecia).\n\nRequired initial laboratory values:\n\nCreatinine \u2264 2.0mg/dL\ntotal or direct bilirubin \u2264 1.5mg/dL; SGPT (ALT) \u2264 3xULN\nnegative pregnancy test for women with child-bearing potential.\nPatients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.\nSubjects must have a left ventricular ejection fraction (LVEF) of \u2265 45%.\n\nExclusion Criteria:\n\nSubjects with FAB M3 (t (15; 17) (q22; q21) [PML-RAR\u03b1]) are not eligible.\n\nSubjects must not be receiving any chemotherapy agents (except Hydroxyurea).\n\na) Intrathecal methotrexate and cytarabine are permissible.\n\nSubjects must not be receiving growth factors, except for erythropoietin.\nSubjects with a \"currently active\" second malignancy, other than non-melanoma skin cancers are not eligible.\nSubjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.\n\nSubjects taking the following are not eligible:\n\nCarbamazepine (e.g., Tegretol)\nRifabutin (e.g., Mycobutin) or\nRifampin (e.g., Rifadin)\nRifapentine (e.g., Priftin)\nSt. John's wort\nClarithromycin (e.g., Biaxin)\nCyclosporine (e.g. Neoral or Sandimmune)\nDiltiazem (e.g., Cardizem)\nErythromycin (e.g., Akne-Mycin, Ery-Tab)\nItraconazole (e.g., Sporanox)\nKetoconazole (e.g., Nizoral)\nTelithromycin (e.g., Ketek)\nVerapamil (e.g., Calan SR, Isoptin, Verelan)\nVoriconazole (e.g., VFEND)\nTacrolimus (e.g. Prograf) Subjects taking fluconozole, voriconizole, itraconazole, posaconazole, and ketokonazole within 72 hours of study drug starting are not eligible. Reinstitution of fluconozole, voriconizole, itraconazole, posaconazole, ketokonazole and diltiazem is permissible 72 hours after the last dose of sirolimus."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients treated on this study will have:\n\nAcute myeloid leukemia in morphologic CR not requiring treatment for their disease for 6 weeks\nA history of AML with < 20% residual blasts after induction therapy and persisting with <20% blasts for at least 8 weeks without reinduction.\nRA or RARS or isolated 5q- can proceed to transplant without any treatment\nRAEB-1, RCMD+/-RS, or MDS NOS with stable disease for 6 months (as documented by serial bone marrow examinations) in the absence of any therapy but growth factors or transfusion support. Patients who require treatment to \"control their disease\" must show chemo-responsiveness\nCMML or RAEB-2 must demonstrate chemo-responsiveness. Chemo-responsiveness is defined as a blast percentage decrease by at least 5 percentage points and there must be less than 20% blasts after treatment and at the time of transplant\nHodgkin or Indolent Non-Hodgkin's lymphoma\nMyeloma with < 5% plasma cells in the marrow\nMyeloproliferative disorders\nAplastic Anemia\nA hematological or oncological disease (not listed) in which allogeneic HSCT is thought to be beneficial, and the disease is chemoresponsive.\nPatients without clear manifestation of their disease status in terms of stage and/or responsiveness should be discussed with the PI and enrollment analysis should be documented in the study records.\nPatients must have a related donor who is HLA mismatched at 2, 3, or 4 antigens at the HLA-A; B; C; DR loci in the GVHD direction. (Patients with related donors who are HLA identical or are a 1-antigen mismatch may be treated on this therapeutic approach, but will have their outcomes will not be part of the statistical aims of the study (see Statistical Section). The HLA matched related category includes patients with a syngeneic donor.\nPatients must have had front line therapy for their disease.\n\nPatients must adequate organ function:\n\nLVEF (Left ventricular end diastolic function) of >/=45%.\nDLCO (Diffusing Capacity of the Lung for Carbon Monoxide ) \u226545% of predicted corrected for hemoglobin, FEV-1 (forced expiratory volume at 1 second \u226550% of predicted\nAdequate liver function as defined by a serum bilirubin <1.8, AST or ALT < 2.5X upper limit of normal\nCreatinine Clearance of \u2265 60 mL/min\nHCT-CI/Age Score \u2264 5 points (Patients with greater than 5 points will be allowed for trial with approval of the PI and the Co-PI or his designee. This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than HCT-CI 5 points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities.\nKPS\u2265 90% patients older than 70 years, KPS\u2265 80% patients younger than 70 years\nPatients must be willing to use contraception if they have childbearing potential\n\nExclusion Criteria:\n\nPerformance status < 90% in patients 70 years old or greater, <80% in patients less than age 70 years\nHCT-CI/age Score >5 points (Patients with greater than 5 points will be allowed for trial with approval of the Principal Investigator and the Co-Principal Investigator or his designee. This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than HCT-CI 5 points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities.\nA diagnosis of CMML, unless in morphologic CR\nHIV positive\nActive involvement of the central nervous system with malignancy\nInability to obtain informed consent from patient or surrogate\nPregnancy\nPatients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder\nPatients who have received alemtuzumab or antithymocyte globulin within 8 weeks of the transplant admission. The absence of these therapies in the medical record will serve as documentation that they were not given.\nPatients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with AML in remission (defined as CR, CR with incomplete platelet recovery -CRp-, CR with incomplete hematologic recovery -CRi-, or partial remission defined as a bone marrow with < 10% blasts after therapy with or without hematologic recovery)\nHigh risk for relapse defined as: 1st CR with high risk features for relapse (including history of prior malignancy treated with chemotherapy or radiotherapy, or history of myelodysplastic syndrome, myeloproliferative disorder, chronic myelomonocytic leukemia, myelodysplastic syndrome [MDS]/myeloproliferative neoplasm [MPN] or other hematologic malignancy thought to have evolved to AML [i.e., secondary AML, (sAML)]; high risk cytogenetics at diagnosis; fms-related tyrosine kinase 3 [FLT3] mutated at diagnosis; or presence or minimal residual disease assessed by polymerase chain reaction [PCR], cytogenetics, and/or flow cytometry at time of enrollment) 2nd CR regardless of disease characteristics at the time of diagnosis\nHave received induction chemotherapy and at least one cycle of consolidation chemotherapy; patients should have achieved a CR within 12 months of enrollment onto protocol\nNo further chemotherapy or stem cell transplant (SCT) planned at the time of enrollment\nCreatinine =< 1.5 x upper limit of normal (ULN)\nSerum bilirubin =< 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nFemales of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (b-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must agree to use an effective contraception method during the study and for 23 weeks after the last dose of the study drug; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy\nMales who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 31 weeks following the last dose of study drug\nPatients or their legally authorized representative must provide written informed consent\n\nExclusion Criteria:\n\nHistory of another primary invasive malignancy that has not been definitively treated or in remission for at least 2 years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)\nAny major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 2 weeks prior to the first dose of the study drugs\nPatients with any other known concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes; cardiovascular disease including congestive heart failure New York Heart Association [NYHA] class III or IV, myocardial infarction within 6 months, and poorly controlled hypertension; chronic renal failure; or active uncontrolled infection) which, in the opinion of the investigator could compromise participation in the study\nPatients unwilling or unable to comply with the protocol\nPatients who are on steroids (> 10 mg/day or equivalent) or immune suppression medications\nPatients with autoimmune diseases (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's granulomatosis])\nPatients with a history of inflammatory bowel disease such as Crohn's disease and ulcerative colitis\nPatients known to be positive for hepatitis B surface antigen expression or with active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months), or with known human immunodeficiency virus (HIV) infection\nCurrent therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents\nFemales who are pregnant or lactating\nPatients with history of previous immunomodulatory therapy (not including lenalidomide or thalidomide)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with any of the following diagnoses are eligible: 1) high-risk MDS (i.e. refractory anemia with excess blasts [RAEB-1 or RAEB-2] by World Health Organization [WHO] classification, or any WHO subset with International Prognostic Scoring System [IPSS] intermediate-2 or high, or any patients that have failed prior therapy with hypomethylating agents); 2) chronic myelomonocytic leukemia (CMML); 3) acute myeloid leukemia (AML) by WHO classification; 4) chronic myeloid leukemia in blast phase (CML-BP); 5) myelofibrosis with high-risk features (e.g., accelerated phase disease -10-19% blasts in peripheral blood or bone marrow-, or with Dynamic International Prognostic Scoring System [DIPSS]-plus high risk score)\nPatients must have relapsed/refractory disease and have failed, or are not candidates for, or have declined all available therapies of proven efficacy; they should also not be eligible for at the time of enrollment or have declined hematopoietic stem cell transplantation\nEastern Cooperative Oncology Group (ECOG) performance status of 0-2\nThe effects of Hu8F4 on a fetus or nursing child are unknown; women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative urine pregnancy test within 2 weeks prior to beginning treatment on this trial; nursing patients are excluded; sexually active men must also use acceptable contraceptive methods for the duration of time on study\nPatients must have human leukocyte antigen (HLA)-A2 phenotype\nMust be able and willing to give written informed consent\nPatients must be at least 2 weeks from prior chemotherapy, radiation therapy, or major surgery, and at least 4 weeks or 5 half lives from other investigational anticancer therapy, and have recovered from prior toxicities at least to grade 1; the exception is hydroxyurea that requires no washout prior to the start of study drug\nClinically significant toxicities from prior chemotherapy must not be greater than grade 1\nClearance creatinine or glomerular filtration rate (GFR) >= 40 mL/min\nTotal bilirubin =< 1.5 x the upper limit of normal unless considered due to Gilbert's syndrome or leukemic involvement\nAlanine aminotransferase (ALT) =< 3 x the upper limit of normal unless considered due to leukemic involvement\n\nExclusion Criteria:\n\nUncontrolled intercurrent illness including, but not limited to uncontrolled infection (patients must have no temperature >= 38.3 degrees Celsius [C] due to infection for at least 48 hrs to consider an infection controlled), psychiatric illness that would limit compliance with study requirements, or active heart disease including confirmed myocardial infarction within previous 3 months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication, or uncontrolled congestive heart failure New York (NY) Heart Association class III or IV\nPatients with current active malignancies or any remission for < 18 months, except patients with carcinoma in situ or with non-melanoma skin cancer who may have active disease or be in remission for less than 6 months\nPatients receiving any other standard or investigational treatment for their hematologic malignancy other than supportive care\nPatients who have had any major surgical procedure within 14 days of day 1\nPatients with known central nervous system infiltration with leukemia\nPatients who received an allogeneic stem cell transplant =< 90 days from the start of therapy\nPatients with active >= grade 3 graft versus host disease (GVHD), or receiving systemic steroids (> 10 mg/day of prednisone or equivalent) for GVHD\nPatients with known active central nervous system (CNS) disease; patients with history of active CNS disease should have at least two negative spinal fluid evaluations before being considered eligible"
            },
            {
                  "document": "Inclusion criteria:\n\nInformed consent provided\n18 years or older\nRelapsed/refractory AML: AML as defined by the WHO Classification persisting or recurring following one or more treatment courses except promyelocytic leukemia (APML)\n\nExclusion criteria:\n\nActive extramedullary AML in testes or central nervous system (CNS)\nKnown hypersensitivity to immunoglobulins or to any other component of the IP formulation (eg, sucrose, captisol, potassium, polysorbate 80, citrate, lysine)\nPrior malignancy (other than in situ cancer) unless treated with curative intent and without evidence of disease for > 1 years before screening"
            },
            {
                  "document": "Inclusion Criteria:\n\nAll subjects must have the ability to understand and the willingness to sign a written informed consent\nPatients must have a life expectancy of > 3 months\nPatients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\nPatients must have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic Neoplasms\n\nPatients must meet one of the three treatment history criteria:\n\nRelapsed AML who have failed at least 1 line of salvage therapy\nDe novo AML who have not achieved CR after 2 lines of therapy\nAML evolving from myelodysplastic syndrome (MDS) or myeloproliferative disorder who have failed hypomethylating agent or induction chemotherapy\nPatients who have relapsed after allogeneic hematopoietic cell transplant (HCT) are eligible if they are at least 3 months after HCT, do not have active graft vs. host disease (GVHD) and are off immunosuppression except for maintenance dose of steroids (prednisone 10 mg/day or less)\nAt least 2 weeks from prior chemotherapy or radiation therapy to time of start of treatment, except for hydroxyurea or corticosteroid therapy which may be continued through cycle 1\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)\nTotal bilirubin =< 1.5 X ULN\nCorrected QT (QTc) =< 480 ms\nCalculated creatinine clearance (CrCl) >= 50 mL/min per 24 hour urine collection or the Cockcroft-Gault formula\nNegative serum or urine beta-human chorionic gonadotropin (beta-HCG) test (female of childbearing potential only), to be performed locally within the screening period\nAgreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for three months following duration of study participation; the effects of study treatment on a developing fetus have the potential for teratogenic or abortifacient effects; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n\nExclusion Criteria:\n\nCurrent or planned use of other investigational agents, or concurrent biological chemotherapy, or radiation therapy during the study treatment period\nExpected to undergo HCT within 120 days of enrollment\nCurrent or planned use of agents that prolong or suspected to prolong QTc\nDiagnosis of acute promyelocytic leukemia\nActive central nervous system leukemia\nActive fungal infection or bacterial sepsis\nActive peptic ulcer disease\nHistory of heart failure or cardiac arrhythmia\nOther active malignancy except for localized skin cancer, bladder, prostate, breast or cervical carcinoma in situ\nPregnant women and women who are lactating; 8-chloro-adenosine is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 8-chloro-adenosine, breastfeeding should be discontinued if the mother is treated with 8-chloro-adenosine\nAny other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures\nProspective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must be 18 years of age or older\n\nPatients with a confirmed diagnosis of AML or MDS, according to World Health Organization (WHO) classification (excluding acute promyelocytic leukaemia) with recurrent or refractory disease as defined below.\n\nFor AML:\n\nPrimary induction failure (PIF) after \u2265 2 cycles of chemotherapy.\nFirst relapse.\nRelapse refractory to salvage chemotherapy\nSecond or subsequent relapse.\nFor MDS, either refractory anemia with excess blasts (RAEB) I or RAEB II who failed at least one chemotherapy regimen including either cytarabine or a hypomethylating agent.\nPatients must have Karnofsky Performance score of \u226570\nWomen of child-bearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to treatment start\nPatients must be capable of understanding and complying with protocol requirements, and must be able and willing to sign a written informed consent form\n\nExclusion Criteria:\n\nPersistent clinically significant toxicities from previous chemotherapy\nKnown positive status for human immunodeficiency virus (HIV)\nPregnant and nursing patients\nUncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements\nImpairment of hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into this clinical study\nActive heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure. Any New York Heart Association (NYHA) grade 3 or 4.\nAny medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities"
            },
            {
                  "document": "Inclusion Criteria:\n\nAvailability of an eligible haploidentical donor\nHematologic malignancy or solid tumor\nPatients with more than one malignancy (hematologic or solid tumor) are eligible\n\nPatients with hematologic malignancy must have no HLA identical sibling or suitable unrelated donor OR time needed to find an acceptable unrelated donor match would likely result in disease progression such that the patient may become ineligible for any type of potentially curative transplant\n\nRelapsed or primary therapy-refractory AML with bone marrow blast < 20%\nHigh-risk refractory or relapsed ALL in patients for whom transplantation is deemed indicated (relapse occurring < 30 months from diagnosis, patients relapsing after previous allogeneic transplant, relapse after 2nd remission, primary induction failure or hypodiploidy)\nRelapsed Hodgkin lymphoma unable to achieve 2nd remission or Very Good Partial Response (VGPR) and therefore ineligible to receive autologous hematopoietic stem cell transplant (auto-HSCT)\nHodgkin lymphoma relapsing after auto-HSCT\nPrimary refractory or relapsed non-Hodgkin lymphoma unable to achieve 2nd remission or VGPR and therefore ineligible to receive auto-HSCT\nNon-Hodgkin lymphoma relapsing after auto-HSCT\nMyelodysplastic Syndrome/Myeloproliferative Syndrome\n\nSolid Tumor\n\nPatients with solid tumor must have failed or have been ineligible to receive auto-HSCT or if auto-HSCT would not offer > 20% chance of cure\n\nNeuroblastoma\n\nhigh risk with relapsed or refractory disease\n\nSoft tissue sarcomas (Rhabdomyosarcoma, Ewing sarcoma, Primitive Neuroectodermal Tumor or other high-risk extracranial solid tumors)\n\nRelapsed or primary refractory metastatic\n1st complete remission, but very high-risk features (i.e., < 20% survival with conventional therapy)\n\nOsteosarcoma\n\nFailure to achieve Complete Response (CR) following initial therapy\nRelapsed with pulmonary or bone metastases and did not achieve a CR with surgery and/or chemotherapy\nKarnofsky (patients > 16 years) or Lansky (patients 16 years or older) performance score of \u2265 60\nLife expectancy of \u2265 3 months\nPatient must have fully recovered from acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\nStudy enrollment no earlier than 3 months after preceding HSCT\nGlomerular Filtration Rate (GFR) \u2265 60 ml/min/1.73m2\nTotal bilirubin < 3 mg/dL\nALT (alanine aminotransferase, SCPT) \u2264 5 x Upper LImit of Normal (ULN) for age\nEjection fraction of > 40% by Multigated Acquisition Scan (MUGA) or echocardiogram\nNo evidence of dyspnea at rest\nNo supplemental oxygen requirement\nIf measured, carbon monoxide diffusion capacity (DLCO) >50%\nNo severe peripheral neuropathy, signs of leukoencephalopathy or active Central Nervous System (CNS) infection\nPatients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsant therapy\nIf of reproductive potential, negative pregnancy test and willing to use effective birth control method\nInformed consent from patient or legal guardian (if patient is minor)\n\nInclusion Criteria for Donors:\n\nDonor must be 18 years of age minimum, 65 years of age maximum\nDonor must be in good general health as determined by evaluating medical provider\n\nMust meet donor criteria for human cells, tissues, and cellular and tissue-based products per Code of Federal Regulations 21 CFR 1271, subpart C. Specifically:\n\nDonor screening in accordance with 1271.75 indicates that the donor:\n\nIs free from risk factors for, and clinical evidence of, infection due to relevant communicable disease agents and diseases; and\nIs free from communicable disease risks associated with xenotransplantation; and\nThe results of donor testing for relevant communicable disease agents in accordance with 1271.80 and 1271.85 are negative or nonreactive, except as provided in 1271.80(d)(1).\nHaploidentical by HLA-typing\nPreference will be given to donors who demonstrate KIR incompatibility with recipient HLA class I ligands defined as the donor expressing a KIR gene for which the corresponding HLA class I ligand is not expressed by the recipient.\n\nNegative testing for relevant communicable diseases:\n\nHepatitis B surface antigen (HBsAg)\nHepatitis B core antibody (Anti-HBc)\nHepatitis C antibody (Anti-HCV)\nHIV 1 & 2 antibody (Anti-HIV-1, 2 plus O)\nHTLV I/II antibody (Anti-HTLV I/II)\nRPR (Syphilis TP)\nCMV (Capture CMV)\nMPX for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR)\nNAT for West Nile Virus (WNV-PCR)\nT. Cruzi - EIA (Chagas)\n\nExclusion Criteria:\n\nPregnant or breast-feeding\nHIV infection\nHeart failure or uncontrolled cardiac rhythm disturbance\nUncontrolled, Serious Active Infection\nPrior organ allograft\nSignificant serious intercurrent illness unrelated to cancer or its treatment not covered by other exclusion criteria expected to significantly increase the risk of HSCT\nAny mental or physical condition, in the opinion of the PI (or PI designee), which could interfere with the ability of the subject (or the only parent or legal guardian available to care for the subject) to understand or adhere to the requirements of the study\nEnrollment in any other clinical study from screening up to Day 100 (unless PI judges such enrollment would not interfere with endpoints of this study)\n\nExclusion Criteria for Donors:\n\nLactating females\nPregnant females"
            },
            {
                  "document": "Inclusion Criteria:\n\nAll subjects must have the ability to understand and the willingness to sign a written informed consent\nParticipant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT\n\nPlanned HCT for the treatment of the following hematologic malignancies:\n\nLymphoma (Hodgkin and Non-Hodgkin)\nMyelodysplastic syndrome\nAcute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood; persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography (PET) scan without progression is allowed)\nAcute myeloid leukemia in first or second remission\nChronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase\nOther hematologic malignancies including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis; patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\nPatients undergoing a second allogeneic (allo) HCT are not eligible (patients who have undergone a previous autologous HCT are eligible)\nCMV seropositive (recipient)\nPlanned related or unrelated HCT, with 8/8 (A,B,C,DRB1) high/intermediate resolution HLA donor allele matching\nPlanned HCT with minimal to no-T cell depletion of graft\nConditioning and immunosuppressive regimens according to institutional guidelines are permitted\nNegative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration\nSeronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration\nAgreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n\nExclusion Criteria:\n\nAny prior investigational CMV vaccine\nExperimental anti-CMV chemotherapy in the last 6 months\nLive attenuated vaccines\nMedically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus [HPV]) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections)\nAllergy treatment with antigens injections\nAlemtuzumab or any equivalent in vivo T-cell depleting agent\nAntiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valganciclovir (VAL), foscarnet (FOS), Cidofovir, CMX-001, maribavir; acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)\nProphylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment\nOther investigational product - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited\nOther medications that might interfere with the evaluation of the investigational product\nPatients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible\nPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study\nAny other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/ psychological issues, etc\nProspective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients will be eligible to receive donor-derived multiTAA-specific T cells following any type of allogeneic HSCT as;\n\n(i) Adjuvant therapy for AML/MDS (Group A) or\n\n(ii) Treatment for refractory/relapsed or minimal residual AML/MDS disease (Group B)\n\nResidual disease at the time of transplant or post transplant relapse is defined as PCR positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy, in the peripheral blood or any other extramedullary sites.\n\nMinimal residual disease (MRD) will be defined as detection in blood, bone marrow, or other tissues of any of the following:\n\n(i) Any leukemia specific marker such as t(8;21); inv 16; t (15;17), t(9;22) or t(4;11) documented in the patient's leukemia cells pre-transplant on a post-transplant evaluation.\n\n(ii) Expression of a leukemia associated antigen known to be a marker for residual disease like WT1.\n\n(iii) A leukemia-specific phenotype (e.g. expression of markers including CD13 and/or CD33 and/or CD117 and/or HLA-DR+) post-transplant at a level of \u2265 0.01%.\n\n(ix) Mixed donor chimerism (> 20%).\n\nLife expectancy \u2265 6 weeks.\nKarnofsky/Lansky score of \u2265 50.\nPatient or parent/guardian capable of providing informed consent.\nBilirubin \u2264 2X upper limit of normal.\nAST \u2264 3X upper limit of normal.\nUndergoing stem cell transplant at CAGT.\nSerum creatinine \u2264 2X upper limit of normal.\nHgb \u2265 7.0 g/dL (can be transfused).\nPulse oximetry of > 90% on room air.\nSexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusion. Male partner should use a condom.\nAvailable donor-derived multiTAA-specific T cell line.\nNo other investigational anti-neoplastic therapy for one month prior to entry in this study.\n\nExclusion Criteria:\n\nPatients receiving ATG or Campath within 28 days of infusion.\nPatients receiving a Donor Lymphocyte Infusion within 4 weeks of planned T cell infusion.\nLess than 30 days post-allogeneic stem cell transplant.\nSevere intercurrent infection.\nEvidence of GVHD > Grade II.\nPregnant or lactating.\nCurrently taking corticosteroids (> 0.5 mg/kg/day prednisone or equivalent)."
            },
            {
                  "document": "Inclusion Criteria:\n\nProvision of signed written informed consent.\n\nHistological, molecular or cytological confirmation of:\n\nPart A: Participants must have received previous treatment with cytotoxic chemotherapy (with or without hematopoietic stem cell transplantation) or a gene expression modulator, such as a demethylating agent. Participants suitable for intensive chemotherapy should be in second or subsequent relapse or be refractory to at least two induction regimens. If eligible they should have undergone hematopoietic stem cell transplantation. Participants receiving an allograft in first remission would be eligible at the time of relapse. Participants who are unsuitable for intensive chemotherapy as a result of advanced age or co-morbidities should have relapsed following at least one line of therapy or be refractory.\nPart B1: Participants with AML who are unsuitable for intensive chemotherapy as a result of advanced age or co-morbidities. Participants should have relapsed following at least one line of therapy or be refractory to such prior therapy. Participants should not have received standard dose intensive chemotherapy.\nPart B2: Participants with AML who are unsuitable for intensive chemotherapy as a result of advancing age or co-morbidities and who are suitable to receive treatment with cytarabine.\nPart B3: Participants with AML who are unsuitable for intensive chemotherapy as a result if advancing age or co-morbidities and who are suitable to receive treatment with decitabine.\nPart B4: Participants with MDS (with the exception of deletion 5q MDS) including intermediate and high-risk participants who must have received prior treatment for their disease. Prior treatment may include those participants who have received hypomethylating agents, decitabine or other approved treatments for MDS.\n\nPart B5: Participants with relapsed or refractory AML who are unsuitable for intensive chemotherapy as a result of advanced age or co-morbidities meeting the following criteria:\n\nMust have received at least one prior treatment for AML Are suitable to receive treatment with \"low-dose\" cytarabine (LDAC). LDAC is defined as 20 mg cytarabine administered subcutaneously twice daily for 10 days every 28 days. The number of participants with refractory AML, defined as no hematological response to last AML treatment and/or participants who have received 2 or more prior treatments for AML, will be restricted to 1/3 of the sample size (i.e. no more than 6 evaluable participants).\nEastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.\nAge 18 years or older.\nFemale participants of childbearing potential must have a negative serum pregnancy test within 3 days prior to taking their first dose of bemcentinib. Male participants and female participants of reproductive potential must practice highly effective methods of contraception (such as hormonal implants, combined oral contraceptives, injectable contraceptives, intrauterine device with hormone spirals, total sexual abstinence, vasectomy) throughout the study and for >=3 months after the last dose of bemcentinib.\n\nFemale participants are considered NOT of childbearing potential if they have a history of surgical sterility or evidence of post-menopausal status defined as any of the following:\n\nNatural menopause with last menses >1 year ago.\nRadiation induced oophorectomy with last menses >1 year ago.\nChemotherapy induced menopause with last menses >1 year ago.\n\nExclusion Criteria:\n\nParticipants who have a matched donor and are candidates for allogeneic bone marrow transplantation.\nPregnant or lactating\n\nHistory of the following cardiac conditions:\n\nCongestive cardiac failure of >Class II severity according to the New York Heart Association (defined as symptomatic at less than ordinary levels of activity)\nIschemic cardiac event including myocardial infarction within 3 months prior to first dose. Participants with prior history or ECG evidence of old myocardial infarction should be discussed with the Sponsor to confirm eligibility.\nUncontrolled cardiac disease, including unstable angina, uncontrolled hypertension (i.e. sustained systolic BP >160 mmHg or diastolic BP >90 mmHg), or need to change medication within 6 weeks of provision of consent due to lack of BP control\nHistory or presence of sustained bradycardia (<=55 beats per minute), left bundle branch block, cardiac pacemaker or ventricular arrhythmia.\n\nNote: Participants with supraventricular arrhythmia should be discussed with the Sponsor to confirm eligibility.\n\nFamily history of long QTc syndrome; personal history of long QTc syndrome or previous drug-induced QTc prolongation of at least Grade 3 (QTc >500 ms).\nPresence of any factors that increase the risk for QTc prolongation, e.g. resistant or inadequately treated heart failure, presence of hypokalemia or hypomagnesemia not corrected by, or not responding to, replacement therapy or inadequately treated hypothyroidism as defined by the thyroid-stimulating hormone not within the expected range of the institution.\nAbnormal left ventricular ejection fraction (less than the lower limit of normal for a participants of that age at the treating institution or <45%, whichever is lower).\nCurrent treatment with any agent known to cause QT prolongation and have a risk for Torsades de Pointes which cannot be discontinued at least 5 half-lives or 2 weeks prior to the first dose of study treatment. Please see Appendix 3 for list of relevant medications.\nScreening 12-lead ECG with a measurable QTcF >450 ms.\nOngoing infection requiring systemic treatment. participants who are on prophylactic antimicrobials or who have been afebrile for 48 hours following the initiation of antimicrobials are eligible.\nInadequate liver function as demonstrated by serum bilirubin >=1.5 times the upper limits of normal range (ULN) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >=2.5 times the ULN (or >=5 times the ULN for AST or ALT in the presence of liver involvement by leukemia).\nInability to tolerate oral medication.\nExisting gastrointestinal disease affecting drug absorption such as celiac disease or Crohn's disease.\nKnown lactose intolerance.\nRequires vitamin K antagonists. Note: participants receiving low doses prescribed to maintain the patency of venous access devices may be included.\nTreatment with any of the following H2 receptor antagonists, proton pump inhibitors or antacids within 3 days of administration of bemcentinib.\nTreatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index.\nPrevious bowel resection that would interfere with drug absorption.\nEvidence of ongoing gastrointestinal graft versus host disease.\nHematopoietic stem cell transplantation within 6 months.\nImpaired renal function as demonstrated by a creatinine clearance of <30 mL/min determined by Cockcroft-Gault formula.\nRadiotherapy or chemotherapy within the 14 days prior to the first dose of bemcentinib being administered (other than hydroxyurea).\nReceiving an investigational anti-cancer treatment concurrently or within 14 days or five half-lives (whichever is shorter) of either the parent drug or any known active metabolite prior to the start of bemcentinib.\nUnresolved CTCAE >=Grade 2 toxicity (other than stable toxicity) from previous anti-cancer therapy excluding alopecia.\nAny evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the participants to participate in the study or which could jeopardize compliance with the protocol.\nActive, uncontrolled central nervous system (CNS) disease including CNS leukemia.\nActive infection with human immunodeficiency virus (HIV), hepatitis B or C viruses - screening for viral infections is not required for entry to this study.\nMajor surgery within 28 days prior to the start of bemcentinib - excluding skin biopsies and procedures for insertion of central venous access devices.\nHypersensitivity to cytarabine, decitabine or any of its excipients.\nPrior exposure to Astellas ASP2215 (FLT3/AXL Inhibitor - Gilteritinib)."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have histologically or cytologically documented relapsed and/or refractory acute myeloid leukemia or granulocytic sarcoma\nEastern Cooperative Oncology Group (ECOG) performance status of =< 3\nExpected survival > 3 months\nWomen of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation\nFertile men must practice effective contraceptive methods during the study period, unless documentation of infertility exists\nMentally competent, ability to understand and willingness to sign the informed consent form\nNo radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 2 weeks prior to treatment with CPI-613; hydroxyurea and oral tyrosine kinase inhibitors being used without grade =< 2 toxicity can be taken until day 1 of therapy; patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment); patients with persisting, non-hematologic, non-infectious toxicities from prior treatment =< grade 2 are eligible, but must be documented as such\nAspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 3 x upper normal limit (UNL), alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 3 x UNL (=< 5 x upper limit of normal [ULN] if liver metastases present)\nBilirubin =< 1.5 x UNL\nSerum creatinine =< 1.5 mg/dL or 133 umol/L\nInternational normalized ratio or INR must be < 1.5\nLeft ventricular ejection fraction (by transthoracic echocardiography [TTE], multigated acquisition scan [MUGA] or cardiac magnetic resonance imaging [MRI]) sufficient to safely administer mitoxantrone as determined by the treating physician\n\nExclusion Criteria:\n\nSerious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, pericardial disease or New York Heart Association class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity\nPatients with active central nervous system (CNS) or epidural tumor\nAny active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease)\nPregnant women, or women of child-bearing potential not using reliable means of contraception\nLactating females\nFertile men unwilling to practice contraceptive methods during the study period\nLife expectancy less than 3 months\nAny condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients\nUnwilling or unable to follow protocol requirements\nPatients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusion\nActive heart disease including myocardial infarction within previous 6 months, symptomatic coronary artery disease, uncontrolled arrhythmias, or symptomatic congestive heart failure\nEvidence of ongoing, uncontrolled infection\nPatients with known human immunodeficiency virus (HIV) infection\nPatients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatment (the use of Hydrea is allowed)\nPatients who have received immunotherapy of any type within the past 4 weeks prior to initiation of CPI-613 treatment\nRequirement for immediate palliative treatment of any kind including surgery\nPatients that have received a chemotherapy regimen with stem cell support in the previous 6 months\nA history of additional risk factors for torsade de pointes (e.g., clinically significant heart failure, hypokalemia, family history of long QT syndrome)"
            },
            {
                  "document": "Inclusion Criteria:\n\nEligible patients will have a histopathologically confirmed diagnosis of hematologic malignancy in one of the following categories:\n\nAcute myelogenous leukemia\n\nIn first complete remission (CR1) with poor risk cytogenetics according to National Comprehensive Cancer Network (NCCN) guidelines for acute myeloid leukemia (AML): monosomal karyotype, -5, 5q-,-7,7q-, inv (3), t(3;3), t(6;9), t(9;22) and complex karyotypes (>= 3 unrelated abnormalities [abn]) and normal cytogenetics with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplications (ITD) mutation\nIn pediatrics, all of the above and 11q23-non t(9;11)\nIn second complete remission (CR2) or third complete remission (CR3)\nWith chemosensitive primary refractory disease\n\nAcute lymphocytic leukemia\n\nIn CR1 with poor risk cytogenetics:\n\nFor adults according to NCCN guidelines for acute lymphoblastic leukemia (ALL): hypoploidy (< 44 chromosomes); t(v;11q23): mixed lineage leukemia (MLL) rearranged; t(9;22) (q34;q11.2); complex cytogenetics (5 or more chromosomal abnormalities); high white blood cell (WBC) at diagnosis (>= 30,000 for B lineage or >= 50,000 for T lineage)\nFor pediatrics t(9;22), intrachromosomal amplification of chromosome 21 (iAMP21)loss of 13q, and abnormal 17p\nIn CR2 or CR3\nWith chemosensitive primary refractory disease\nMyelodysplastic syndrome in high-intermediate (int-2) and high risk categories\nKarnofsky or Lansky performance status >= 80\nA pretreatment measured creatinine clearance (absolute value) of >= 50 ml/minute\nSerum bilirubin =< 2.0 mg/dl\nSerum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 2.5 times the institutional upper limits of normal\nEjection fraction measured by echocardiogram or multigated acquisition scan (MUGA) >= 50%\nDiffusing capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in one second (FEV1) > 60% predicted\nWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\nThe recipient must have a related donor genotypically human leukocyte antigen (HLA)-A, B,C and DRB1 loci haploidentical to the recipient\nNo HLA matched sibling or matched unrelated donor is available\n\nPatients should be off all previous intensive therapy, chemotherapy or radiotherapy for 3 weeks prior to commencing therapy on this study\n\n* (NOTE: Low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted; these include: hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors [TKIs]; FLT-3 inhibitors such as sorafenib, crenolanib, quizartinib, midostaurin can also be given up to 3 days before conditioning regimen)\n\nAdequate organ function\nAll subjects must have the ability to understand and the willingness to sign a written informed consent\nPrior radiation therapy that would exclude the use of TMLI\n\nDONOR ELIGIBILITY CRITERIA:\n\nDONOR: Age =< 60 years of age\nDONOR: For younger donors, no more than 20 mL bone marrow may be harvested per kg of donor body weight\nDONOR: Medical history and physical examination confirm good health status as defined by institutional standards\nDONOR: Seronegative for human immunodeficiency virus (HIV) antigen (Ag), HIV 1+2 antibody (Ab), human T-lymphotropic virus (HTLV) I/II Ab, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) (immunoglobulin [Ig]M and IgG), hepatitis C virus (HCV) Ab, rapid plasma reagin (RPR) for syphilis within 30 days of apheresis collection\nDONOR: Genotypically haploidentical as determined by HLA typing, preferably a non-maternal HLA haploidentical relative; eligible donors include biological parents, siblings or half siblings, or children\nDONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of mobilization\nDONOR: The donor must have been informed of the investigational nature of this study and have signed a consent form in accordance with federal guidelines and the guidelines of the participating institution\nDONOR: Selection of a haploidentical donor will require absence of pre-existing donor-directed anti-HLA antibodies in the recipient\n\nExclusion Criteria:\n\nPatients should not have any uncontrolled illness including ongoing or active bacterial, viral or fungal infection\n\nPatients may not be receiving any other investigational agents, or concurrent biological, intensive chemotherapy, or radiation therapy for the previous three weeks from conditioning\n\n* (NOTE: Low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted; these include: hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors [TKIs]; FLT-3 inhibitors such as sorafenib, crenolanib, quizartinib, midostaurin can also be given up to 3 days before conditioning regimen)\n\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the pre- or post-transplant regimen\nPregnant women are excluded from this study\nPatients with other active malignancies are ineligible for this study, other than non-melanoma skin cancers\nThe recipient has a medical problem or neurologic/psychiatric dysfunction which would impair his/her ability to be compliant with the medical regimen and to tolerate transplantation or would prolong hematologic recovery which in the opinion of the principal investigator would place the recipient at unacceptable risk\nPatients may not have had a prior autologous or allogeneic transplant\nHLA-matched or partially matched (7/8 or 8/8) related or unrelated donor is available to donate\nPatients may not have received more than 3 prior regimens, where the regimen intent was to induce remission\nPatients treatment history may not include anti-CD33 monoclonal antibody therapy (e.g., SGN-CD33 or Mylotarg)\nSubjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study\n\nDONOR EXCLUSION CRITERIA:\n\nDONOR: Evidence of active infection\nDONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis\nDONOR: Factors which place the donor at increased risk for complications from leukapheresis or granulocyte-colony stimulating factor (G-CSF) therapy\nDONOR: HIV positive"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipant has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS) according to WHO classification (2008) as determined by pathology review at the treating institute.\n\nParticipant is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant (HSCT)).\n\nRefractory to first-line AML therapy is defined as:\n\n1. Participant did not achieve complete remission/complete remission with incomplete hematologic recovery/complete remission with incomplete platelet recovery (CR/CRi/CRp) under initial therapy. A Participant eligible for standard therapy must receive at least one cycle of an anthracycline containing induction block in standard dose for the selected induction regimen. A Participant not eligible for standard therapy must have received at least one complete block of induction therapy seen as the optimum choice of therapy to induce remission for this subject.\n\nUntreated first hematologic relapse is defined as:\n\nParticipant must have achieved a CR/CRi/CRp (criteria as defined by [Cheson et al, 2003], see Section 5.3) with first line treatment and has hematologic relapse.\nParticipant is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab. A Participant with rapidly proliferative disease and unable to wait for the central lab results can be enrolled based on a local test performed after completion of the last interventional treatment. Participants can be enrolled from a local test result if they have any of the following FLT3 mutations: FLT3 internal tandem duplication (ITD), FLT3 tyrosine kinase domain (TKD)/D835 or FLT3- TKD/I836.\nParticipant has an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2.\nParticipant is eligible for pre-selected salvage chemotherapy.\n\nParticipant must meet the following criteria as indicated on the clinical laboratory tests:\n\nSerum aspartate aminotransferase and alanine aminotransferase \u2264 2.5 x upper limit of normal (ULN)\nSerum total bilirubin \u2264 1.5 x ULN\nSerum creatinine \u2264 1.5 x ULN or an estimated glomerular filtration rate of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.\nParticipant is suitable for oral administration of study drug.\n\nFemale Participant must either:\n\nBe of non-child bearing potential:\n\npost-menopausal (defined as at least 1 year without any menses) prior to Screening, or\ndocumented as surgically sterile (at least 1 month prior to Screening)\n\nOr, if of childbearing potential,\n\nAgree not to try to become pregnant during the study and for 180 days after the final study administration\nAnd have a negative urine pregnancy test at Screening\nAnd, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards in addition to a barrier method starting at Screening and throughout the study period and for 180 days after the final study drug administration.\nFemale Participant must agree not to breastfeed at Screening and throughout the study period and for 60 days after the final study drug administration.\nFemale Participant must not donate ova starting at Screening and throughout the study period and for 180 days after the final study drug administration.\nMale Participant and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at Screening and continue throughout the study period and for 120 days after the final study drug administration.\nMale Participant must not donate sperm starting at Screening and throughout the study period and 120 days after the final study drug administration.\nParticipant agrees not to participate in another interventional study while on treatment.\n\nExclusion Criteria:\n\nParticipant was diagnosed as acute promyelocytic leukemia (APL).\nParticipant has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).\nParticipant has AML secondary to prior chemotherapy for other neoplasms (except for MDS).\nParticipant is in second or later hematologic relapse or has received salvage therapy for refractory disease\nParticipant has clinically active central nervous system leukemia.\nParticipant has been diagnosed with another malignancy, unless disease-free for at least 5 years. Participants with treated nonmelanoma skin cancer, in situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. Participants with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed or treated with definitive radiotherapy.\nParticipant has received prior treatment with ASP2215 or other FLT3 inhibitors (with the exception of sorafenib and midostaurin used in first-line therapy regimen as part of induction, consolidation, and/or maintenance).\nParticipant has clinically significant abnormality of coagulation profile, such as disseminated intravascular coagulation (DIC).\nParticipant has had major surgery within 4 weeks prior to the first study dose.\nParticipant has radiation therapy within 4 weeks prior to the first study dose.\nParticipant has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or Participant with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram performed within 3 months prior to study entry results in a left ventricular ejection fraction that is \u2265 45%.\nParticipant requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.\nParticipants with mean of triplicate Fridericia-corrected QT interval (QTcF) > 450 ms at Screening based on central reading.\nParticipants with Long QT Syndrome at Screening.\nParticipants with hypokalemia and hypomagnesemia at Screening (defined as values below lower limit of normal [LLN]).\nParticipant requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.\nParticipant requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.\nParticipant has an active uncontrolled infection.\nParticipant is known to have human immunodeficiency virus infection.\nParticipant has active hepatitis B or C, or other active hepatic disorder.\nParticipant has any condition which makes the Participant unsuitable for study participation.\nParticipant has active clinically significant GVHD or is on treatment with systemic corticosteroids for GVHD.\nParticipant has an FLT3 mutation other than the following: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836."
            },
            {
                  "document": "Inclusion Criteria:\n\nPotential participants must have newly diagnosed, previously untreated acute myeloid leukemia (AML) (excluding M3); Must have adverse-risk AML defined as poor-risk karyotype (complex, monosomal or other known poor risk cytogenetic abnormality), poor-risk mutations/fusion genes or known history of antecedent hematologic disorder, or treatment related AML, or be \u226560 years of age; Cytogenetics, FISH or mutational analysis confirming adverse risk features must have been done within 90 days prior to enrollment.\nMay not have undergone any prior therapy for their AML other than hydroxyurea. However, if patients had an antecedent myelodysplastic syndrome (MDS), prior treatment with a hypomethylating agent or any other therapy (with the exception of allogeneic stem cell transplant) used to treat their MDS is allowed.\nAge \u226518 years\nEastern Cooperative Oncology Group (ECOG) performance status \u2264 2\nLife expectancy of greater than 2 months\nMust have normal organ function\nAble and willing to adhere to the study visit schedule and other protocol requirements\nBaseline left ventricular ejection fraction (LVEF) \u2265 50%\nWomen of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli-international units per milliliter (mIU)mL) within 10 days and again within 24 hours prior to beginning study treatment. Participants of childbearing potential must practice recommended contraception. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Breastfeeding mothers must agree to discontinue nursing if the mother is treated with selinexor.\nAbility to understand and the willingness to sign a written informed consent document\nAble to swallow capsules and have no evidence of GI tract abnormality that would alter the absorption of oral medications\nProthrombin time (PT) and partial thromboplastin time (PTT) \u2264 1.5 x upper limit of normal (ULN)\n\nExclusion Criteria:\n\nMay not be receiving any other investigational agents\nDocumented central nervous system (CNS) involvement of AML\nAML with favorable risk cytogenetic abnormalities including t(15;17), t(8;21) or inv(16)\nPotential participants who are in the blast phase of chronic myeloid leukemia\nMajor surgery within 2 weeks of first dose of study drug; must have recovered from the effects of any surgery performed greater than 2 weeks prior\nWhite blood cell (WBC) count \u226550,000 on hydroxyurea\nPredicted inability to tolerate standard induction chemotherapy with daunorubicin and cytarabine\nUncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nHIV-positive, receiving combination anti-retroviral therapy\nNo other malignancies in addition to AML that are currently requiring treatment with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast\nHistory of allogeneic stem cell transplant for MDS or any other antecedent hematologic disorder."
            },
            {
                  "document": "Inclusion Criteria:\n\nHistory of AML according to World Health Organization (WHO) classification\nFirst allogeneic hematopoietic stem cell transplantation (HSCT) using myeloablative conditioning (MAC), non-myeloablative (NMA), or reduced-intensity conditioning (RIC) preparative regimens.\nFLT3-ITD or FLT3-D835 positive disease at any time during disease course.\nHematopoietic stem cell source is either with peripheral blood, bone marrow or cord blood.\nDonor source is matched related, unrelated, haploidentical donor or cord blood.\n\nAt the time of allogeneic HSCT:\n\nNo more than 1 antigen mismatch at HLA-A, -B, -C, -DRB1 or -DQB1 locus for unrelated donor with peripheral blood and bone marrow as the hematopoietic stem cell source; and\nBone marrow blast \u2264 10%\nNo sooner than 45 days but no later than 90 days after allogeneic HSCT.\nPost-transplant bone marrow blast count \u2264 5% confirmed by standard of care bone marrow biopsy performed post-transplant (at least 30 days post-transplant).\nEvidence of donor engraftment as defined by institutional standard T cell chimerism > 50%.\nAdequate engraftment within 7 days prior to starting study therapy: ANC \u2265 1.0 x 109/L without daily use of myeloid growth factor; and platelet \u2265 25 x 109/L without platelet transfusion within 1 week\nNon-hematological toxicities \u2264 Grade 2\nSerum creatinine \u2264 1.5 \u00d7 ULN OR creatinine clearance \u2265 50mL/min/1.73 m2 for subjects with creatinine levels above institutional normal\nAdequate liver function with serum AST, ALT and bilirubin within the normal range at the time of crenolanib commencement\nAcute graft-versus-host disease (GVHD) \u2264 Grade 1, either no signs of chronic GVHD or mild chronic GVHD graded as limited disease\nEastern Cooperative Oncology Group (ECOG) performance status of 0-2\nAge \u2265 18 years with the capacity to give written informed consent\nNon-pregnant and non-nursing women of childbearing potential must have a negative serum or urine pregnancy test (\"Women of childbearing potential\" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months)\nWomen of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for 90 days following completion of therapy\n\nExclusion Criteria:\n\nActive GVHD grade \u2265 2\nConcurrent use of corticosteroids equivalent of prednisone at a dose > 0.5 mg/kg\nActive and/or untreated central nervous system (CNS) leukemia\nConcomitant therapies for treatment or control of leukemia.\n\nUse of any of the following after transplantation and prior to starting study therapy:\n\nChemotherapeutic agents for therapy of AML (note that prophylactic use of these agents is allowed in this study, e.g., methotrexate for GVHD)\nInvestigational agents/therapies\nAzacitidine, decitabine or other demethylating agents\nLenalidomide, thalidomide and pomalidomide\nUncontrolled infection\nKnown positive for human immunodeficiency virus (HIV); active hepatitis B (HBV) or hepatitis C (HCV) infection\nSignificant cardiac disease (New York Heart Association classes III or IV) or unstable angina despite medication\nPregnant or breast-feeding\nReceipt of investigational agents within 5 half-lives of last dose of investigational agent\nPrior treatment with crenolanib with progression on treatment"
            },
            {
                  "document": "Inclusion Criteria:\n\nARM 1 SALVAGE COHORT: Patients with AML or biphenotypic or bilineage leukemia who have failed prior therapy; patients with AML should have failed prior therapy or have relapsed after prior therapy will be eligible for Arm 1;\nARM 2 SALVAGE COHORT: Patients with AML who have failed up to one prior salvage therapy (i.e. salvage 1 or 2 status) will be eligible for Arm 2 relapse cohort; allogeneic stem cell transplant for patients in remission at the time of stem cell transplant will not be considered a salvage regimen; similarly, hydroxyurea if used alone will not be considered a salvage regimen\nARM 1 AND 2 FRONT LINE OLDER COHORT: Patients age 65 years and above with previously untreated AML who are unfit for or decline standard induction therapy; prior therapy with hydroxyurea, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowed, however prior therapy with chemotherapy agents for the disease under study is not allowed; patients may have received one dose of cytarabine (up to 2 g/m2 administered at presentation for control) of hyperleucocytosis\nPatients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who received therapy for the MDS or CMML and progress to AML are eligible at the time of diagnosis of AML regardless any prior therapy for MDS or CMML; the World Health Organization (WHO) classification will be used for AML; prior therapy for MDS or CMML will not be considered as a prior therapy for AML, hence such patients will be considered as frontline AML and eligible for the frontline elderly cohort\nPrior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowed\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nTotal bilirubin =< 2 times upper limit of normal (x ULN) (=< 3 x ULN if considered to be due to leukemic involvement or Gilbert's syndrome)\nAspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)\nSerum creatinine =< 2 x ULN or glomerular filtration rate (GFR) >= 50\nPatients must provide written informed consent\nIn the absence of rapidly progressing disease, the interval from prior treatment to time of initiation of 5-azacytidine and nivolumab will be at least 2 weeks OR at least 5 half-lives for cytotoxic/noncytotoxic agents; the half-life for the therapy in question will be based on published pharmacokinetic literature (abstracts, manuscripts, investigator brochure's, or drug-administration manuals) and will be documented in the protocol eligibility document; since the effect of both nivolumab and 5-azacytidine may be delayed; use of one dose of cytarabine (up to 2 g/m2) or hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and during the study treatment; concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\nFemales must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment\nWomen of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment; adequate methods of contraception include: total abstinence when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment; in case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment; male sterilization (at least 6 months prior to screening); for female patients on the study, the vasectomized male partner should be the sole partner for that patient\n\nCombination of any of the two following\n\nUse of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception\nPlacement of an intrauterine device (IUD) or intrauterine system (IUS)\nBarrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository; in case of use of oral contraception, women should have been stable on the same pill before taking study treatment; note: oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception\nWomen are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential\nPatients with graft versus host disease (GVHD) active < grade 2 who are on a stable dose of immunosuppressive therapy (tacrolimus, cyclosporine, or other) for > 2 weeks will be included; Note: subjects may be using systemic corticosteroids or topical or inhaled corticosteroids\n\nExclusion Criteria:\n\nPatients with known allergy or hypersensitivity to nivolumab, ipilimumab, 5-azacytidine, or any of their components\nPatients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis that is uncontrolled in the opinion of the treating physician\nPatients who have previously been treated with nivolumab and/or ipilimumab in combination with 5-azacytidine will be excluded\n\nPatients with a known history of any of the following autoimmune diseases are excluded:\n\nPatients with a history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis)\nPatients with a history of rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's granulomatosis)\nPatients with organ allografts (such as renal transplant) are excluded\nPatients with active GVHD > grade 2 will be excluded; patients with recent increase in the immunosuppressive medication dose within last 2 weeks to control GVHD will not be included; patients with grade 1 or lower GVHD on =< 10 mg prednisone without any additional immunosuppressive therapies (tacrolimus, prograf, etc) will be eligible\nPatients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia\nActive and uncontrolled disease/(active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association [NYHA] class III/IV, clinically significant and uncontrolled arrhythmia) as judged by the treating physician\nPatients with known human immunodeficiency virus seropositivity will be excluded\nKnown to be positive for hepatitis B by surface antigen expression; known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)\nAny other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\nPatients unwilling or unable to comply with the protocol\nPregnant or breastfeeding\nAcute promyelocytic leukemia (APL)"
            },
            {
                  "document": "Inclusion Criteria:\n\nAll subjects must have the ability to understand and the willingness to sign a written informed consent\nParticipant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT\n\nPlanned HCT for the treatment of the following hematologic malignancies:\n\nLymphoma (Hodgkin and non-Hodgkin)\nMyelodysplastic syndrome\nAcute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status needs to be in hematologic remission by bone marrow and peripheral blood; persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography [PET] scan without progression is allowed)\nAcute myeloid leukemia in first or second remission\nChronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase\nOther hematologic malignancies including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis; patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\nHLA A*0201 High resolution, 4-digit typing is required at HLA-A2 to ensure A*0201 status.\nCMV seropositive (recipient)\nPlanned related or unrelated HCT, with HLA donor allele matching; related donor must be an 8/8 match for HLA-A, -B, and -C at intermediate (or higher) resolution, and -DRB1 at high resolution using deoxyribonucleic acid (DNA)-based typing; unrelated donor must be an 8/8 match at HLA-A, -B, -C, and -DRB1 at high resolution using DNA-based typing; patients undergoing a second allo HCT are not eligible (patients who have undergone a previous autologous HCT are eligible)\nPlanned HCT with no ex-vivo T cell depletion of graft; conditioning and immunosuppressive regimens according to institutional guidelines are permitted\nNegative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration\nSeronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration\nAgreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n\nExclusion Criteria:\n\nAny prior investigational CMV vaccine\nExperimental anti-CMV chemotherapy in the last 6 months\n\nPlanned medications from the time of HCT to day 70 post-HCT:\n\nLive attenuated vaccines\nMedically indicated subunit (Engerix-B for HBV; Gardasil for human papilloma virus [HPV]) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections)\nAllergy treatment with antigens injections\nAlemtuzumab or any equivalent in vivo T-cell depleting agent; this includes anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide\nAntiviral medications with known therapeutic effects against CMV such as ganciclovir (GCV)/valine (VAL), foscarnet (FOS), cidofovir, hexadecyloxypropyl-cidofovir (CMX-001) and maribavir; acyclovir has no therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)\nOther investigational product - concurrent enrollment in other clinical trials using an investigational product is prohibited\nOther medications that might interfere with the evaluation of the investigational product\nPatients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible\nPregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study\nAny other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/psychological issues, etc\nProspective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have previously untreated AML and be candidates for intensive induction chemotherapy; patients are allowed to have had prior hydroxyurea\nPatients must not have acute promyelocytic leukemia (APL) and must not have evidence of t(15;17)(q22;q21)\nPatients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (restricted to ECOG performance status [PS] 0-2 if age > 70 years)\nPatients must have left ventricular ejection fraction (LVEF) > 45% or within institutional normal limits\nPatients must be able to lie still for a 1.5 hour PET scan\nPatient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidine\nPatient must NOT weigh more than the maximum weight limit for the PET/CT table for the scanner(s) to be used at each center\nThe patient is participating in the trial at an institution which has agreed to perform the imaging research studies, completed the ECOG-American College of Radiology Imaging Network (ACRIN) defined scanner qualification procedures and received ECOG-ACRIN approval as outlined\nWomen must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)"
            },
            {
                  "document": "Inclusion criteria:\n\nPatients must have previously untreated MDS, AML, or CMML according to the WHO 2016 classification.\nMDS patients must have Intermediate (>3 to 4.5 points), High Risk (>4.5 - 6) or Very High Risk (>6 points) disease according to the Revised International Prognostic Scoring System 2012 (IPSS-R).\nClinical indication for treatment with azacitidine for MDS or AML.\n\nExclusion criteria:\n\nPatients with AML who are candidates for standard induction chemotherapy as first line treatment.\nPatients with known active CNS leukemia.\nPrior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with the following diseases: acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) undergoing second allogeneic (allo)-stem cell transplant (SCT) using the same donor or different donor for disease relapse; patients with other hematologic malignancies, including acute lymphoblastic leukemia (ALL), will be at the discretion of the investigators\nKarnofsky performance status of 70 or above\nLife expectancy is not severely limited by concomitant illness\nAdequate cardiac and pulmonary function; patients with decreased left ventricular ejection fraction (LVEF) =< 40% or diffusion capacity of carbon monoxide (DLCO) =< 50% of predicted will be evaluated by cardiology or pulmonary prior to enrollment on this protocol\nSerum creatinine =<1.5 mg/dL or creatinine clearance > 50 ml/min; some patients with minor deviations may be accepted on protocol after discussion with the principal investigator (PI)\nSerum bilirubin =< 2.0 mg/dl; some patients with minor deviations may be accepted on protocol after discussion with the PI\nSerum glutamic oxaloacetic transaminase (SGPT) < 5 x upper limit of normal; some patients with minor deviations may be accepted on protocol after discussion with the PI\nNo evidence of chronic active hepatitis or cirrhosis\nHuman immunodeficiency virus (HIV)-negative\nPatient is not pregnant\nPatient or guardian able to sign informed consent\nDONOR: Since these patients already had first allo-SCT; in the majority time, the same matched donor has been used for second allo-SCT; if the patients have multiple donors, alternative matched (8/8 or 10/10) donor could be used for the second allo-SCT; the donor could be matched related donors or matched unrelated donors from registry\n\nDONOR: If more than one potential volunteer unrelated donor is considered suitable, further selection of the most suitable donor will be prioritized as follows or will follow our institutional guideline from our stem cell transplant standard operating procedure (SOP):\n\nAge of donor (18-24 > 25-34 > 35-44 > 45+)\nSex of donor (male > female, nulliparous female > parous, multiparous female)\nCytomegalovirus (CMV) status, if recipient is CMV seronegative (CMV- > CMV+"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipants must meet the following criteria on screening examination to be eligible to participate in the study:\nA diagnosis of recurrent, persistent, or progressive acute myelogenous leukemia (AML), defined as >= 5% blasts in a patient with known prior history of AML, or recurrent, persistent, or progressive myelodysplastic syndrome (MDS) according to WHO criteria.\nMust have undergone an allogeneic SCT (regardless of stem cell source)\nPatients must be 18 years or older\nAble to adhere to study schedule and other protocol requirements\nMust be off all immunosuppressive medications (except prednisone) for at least 2 weeks prior to study entry.\nMust be on less than 21 mg of oral prednisone daily for GVHD\nECOG performance status 0-2 (see Appendix 2)\n\nParticipants must have the following organ function all within 21 days prior to enrollment\n\nTotal bilirubin \u2264 2.0 mg/dl unless due to underlying conjugation disease such as Gilbert's\nALT and AST \u2264 3X the upper limit of normal\nCreatinine < 2.0 mg/dl\nPatients may receive hydroxyurea or leukopheresis as necessary\nPatients must give voluntary written informed consent and HIPA authorization before performance of any study-related procedure not part of normal medical care with the understanding that consent maybe withdrawn by the subject at any time without prejudice to future medical care.\nAll previous cancer therapy including donor lymphocyte infusions must have been discontinued at least 2 weeks prior to treatment in this study.\nAll study participants must be registered in the RevREMS\u00ae program and be willing and able to comply with the requirements of REMS\u00ae program.\nFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS\u00ae program.\n\nExclusion Criteria:\n\nParticipants who exhibit any of the following conditions at screening will not be eligible for admission into the study.\nEjection fraction < 40% obtained by either MUGA or echocardiogram\nPatients who had had a myocardial infarction within 6 months of enrollment or have New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.\nAny serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the consent form.\nAny condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at an unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\nPatients with major surgery within 28 days prior to trial enrollment\nPatients with greater than or equal to grade 2 peripheral neuropathy or active herpes infection\nPatients with \u2265 grade 3 acute graft-versus-host disease are excluded from the study\nPatients with moderate or severe chronic graft-versus host requiring more than 20 mg of oral prednisone therapy are excluded from the study.\nPatients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cirrhosis, chronic obstructive or restrictive pulmonary disease, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia\nPatients with any serious or medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol\nFemale subject is pregnant or breast-feeding. Lactating females must agree not to breastfeed while taking lenalidomide.\nPatient has received an investigational drug within 14 days of enrollment\nKnown hypersensitivity to thalidomide or lenalidomide\nKnown hypersensitivity to Velcade, boron, or mannitol\nThe development of erythema nodosum as characterized by desquamating rash while taking thalidomide or similar drugs\nConcurrent use of other anti-cancer agents or treatment\nKnown positive for HIV\nDiagnosed or treated for a non-hematologic malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.\nRadiation therapy within 3 weeks before randomization. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy."
            },
            {
                  "document": "Inclusion Criteria:\n\nAML patients in first complete remission (CR) (CR1) or first complete remission with incomplete blood count recovery (CRi) after induction and consolidation chemotherapy; except young (< 60 years) AML patients in European LeukemiaNet favorable group; (Since young AML patients in the European LeukemiaNet favorable group have excellent 2 year progression free survival [PFS] at around 64%, further maintenance therapy might ot provide additional benefit; thus the current trial will exclude young favorable group AML patients), patients could receive any cycle consolidation or no consolidation per the discretion by the treating physician\nWithin 60 days after bone marrow biopsy confirmed remission after the patients recover from their last course of chemotherapy, the goal will be to consent the eligible patient prior to the remission confirmation bone marrow biopsy at the end of the planned chemotherapy); ideally, the research samples will be collected during the bone marrow biopsy, and the patient will be enrolled to the study within 2 weeks of the bone marrow biopsy; if there is delay to enroll the patient after the bone marrow biopsy and research sample collection, it is ok not to repeat bone marrow biopsy within 4 weeks, after the last bone marrow biopsy, if there is no sign of disease relapse; a repeat bone marrow biopsy should be done if the delay of enrollment is more than 4 weeks after the last bone marrow biopsy; patients with confirmed remission within 60 days after the last bone marrow biopsy, without research samples collection, should have a repeat bone marrow biopsy conducted within two weeks prior to enrolling on the study\nPatient is not a candidate for stem cell transplant due to advanced age or co-morbidities; or the enrollee does not have donor available; or the enrollee declines stem cell transplant due to personal belief; or stem cell transplant is not standard of care based on the risk category of disease\nEastern Cooperative Oncology Group (ECOG)/Karnofsky performance status of 0 or 1 (Karnofsky >= 70%)\nLife expectancy of greater than 6 months\nLeukocytes >= 1,500/mcL\nAbsolute neutrophil count >= 1,000/mcL\nPlatelets >= 50,000/mcL or recovery to the baseline count\nTotal bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN\nAmylase and lipase =< 1.5 x ULN without any symptoms of pancreatitis\nSerum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula)\nThe effects of nivolumab on the developing human fetus are unknown; for this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug nivolumab; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception\nWomen of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL\nWOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; these durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days\nShould a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier\nPatients who are receiving any other investigational agents\nPatients should be excluded if they have had prior treatment with an anti-programmed cell death protein 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\nPatients with known central nervous system (CNS) involvement may be excluded because of poor prognosis and concerns regarding progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; however, if CNS disease is cleared before the treatment with nivolumab, patients could be allowed if no permanent CNS damage\nHistory of severe hypersensitivity reaction to any monoclonal antibody\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPregnant women are excluded from this study because nivolumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with nivolumab, breastfeeding should be discontinued if the mother is treated with nivolumab\nPatients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load by PCR is undetectable with/without active treatment and absolute lymphocyte count >= 350/ul\nPatients with a positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (hepatitis C virus [HCV] antibody) indicating acute or chronic infection might be enrolled if the viral load by PCR is undetectable with/without active treatment\nPatients with active autoimmune disease or history of autoimmune disease that might recur should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease; patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sj\u00f6gren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible\nPatients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)\nPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted\nPatients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis should be evaluated for the potential need for additional treatment before coming on study"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with biopsy-proven acute myeloid leukemia or myelodysplastic syndrome with persistent disease or in remission\nHuman leukocyte antigen (HLA)-identical sibling or 8/8 matched unrelated donor transplant\nPatients age 18 to 70 years old; eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients age 2-17 years may be enrolled after at least 10 adults (ages 18-70 years old) have been assessed for safety at day 30\nDirect bilirubin < 1 mg/dl\nAlanine aminotransferase (ALT) < 3 times upper limit of normal\nCreatinine clearance > 50 ml/min (calculated creatinine clearance is permitted)\nForced expiratory volume in 1 second (FEV1) >= 50% of expected corrected for hemoglobin and/or volume\nForced vital capacity (FVC) >= 50% of expected corrected for hemoglobin and/or volume\nDiffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume\nChildren unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of >= 92% on room air\nLeft ventricular ejection fraction (LVEF) >= 40%\nPatient, legally authorized representative (LAR), or parent able to sign informed consent; able to give assent for patients age 7-17\nNegative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization; women of child bearing potential must be willing to use an effective contraceptive measure while on study\nPerformance score of >= 70 by Karnofsky/Lansky or performance status (PS) 0 or 1 (Eastern Cooperative Oncology Group [ECOG] =< 1)\n\nExclusion Criteria:\n\nPrior allogeneic or autologous transplantation\nUncontrolled infections\nHuman immunodeficiency virus (HIV) seropositivity\nHematopoietic cell transplantation (HCT) co-morbidity index score > 3; the principal investigator is the final arbiter of eligibility for comorbidity score > 3\nPatients with prior coronary artery disease"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses:\n\nAcute lymphocytic leukemia in first or subsequent remission\nAcute myeloid leukemia in first or subsequent remission\nAcute lymphocytic leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 (Arms A or C only)\nAcute myeloid leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 (Arms A or C only)\nRefractory anemia with excess blasts (RAEB-1 and RAEB-2) (if the patient has received previous induction chemotherapy within 60 days)\nChronic myelogenous leukemia with a history of accelerated phase or blast crisis (if the patient has received at least one course of induction chemotherapy)\nOther acute leukemia or related neoplasm (including but not limited to 'biphenotypic', 'undifferentiated' or 'ambiguous lineage' acute leukemia, blastic plasmacytoid dendritic cell neoplasm or lymphoblastic lymphoma)\nPatients 0-49 years old will be enrolled in Arm A or C (high-intensity)\nPatients 50-60 years old will be enrolled in Arm B or D (lower intensity); patients eligible for Arms B or D also include those who have received previous allogeneic HCT, or who have co-morbid conditions rendering them unsuitable for high-dose conditioning, determined in consultation with the principal investigator\nPatient with a HLA-matched (HLA-A, B, C, and DR beta 1 [DRB1] molecularly matched) unrelated donor or related donor capable of donating PBSC\nDONOR INCLUSION:\nHLA-matched related donors >= 18 years and capable and willing to donate PBSC (Arms A and B)\nHLA-matched unrelated donors (HLA-A, B, C, and DRB1 matched based on high-resolution typing) capable and willing to donate PBSC (Arms C and D)\n\nExclusion Criteria:\n\nPatients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation\nPatients on other experimental protocols for prevention of acute GVHD\nPatient weight >= 100 kg; patients >= 70 kg with MUDs must be discussed with the principal investigator\nPatients who are human immunodeficiency virus positive (HIV+)\nPatients with uncontrolled infections for whom myeloablative HCT is considered contraindicated by the consulting infectious disease physician (upper respiratory tract viral infection does not constitute an uncontrolled infection in this context)\nPatients with organ dysfunction\nARM A OR C EXCLUSION:\nCreatinine > 1.5 mg/dl at the present time; patients with a known history of creatinine > 1.5 mg/dl must have a current estimated creatinine clearance of > 40 ml/min\nCardiac ejection fraction < 45%\nDiffusing capacity of the lung for carbon monoxide (DLCO) corrected < 60%; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the oxygen (O2) saturation is < 92% on room air\nLiver function abnormality; patients who have liver function tests (LFTs) (including total bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) >= twice the upper limit of normal should be evaluated by a gastrointestinal (GI) physician; unless there is a clear precipitating factor (such as an azole, methotrexate, Bactrim or another drug); if the GI physician considers that HCT on the high-intensity arms of protocol is contraindicated for that patient the patient may be considered for treatment on the lower intensity arm of the protocol or excluded from the protocol; patients with Gilbert's syndrome and no other known liver function abnormality and patients with reversible drug-related transaminitis do not necessarily require GI consultation and may be included on the high-intensity arms of the protocol\nARM B OR D EXCLUSION:\nCreatinine > 2.0 mg/dl at the present time; patients with a known history of creatinine > 1.5 mg/dl must have a current estimated creatinine clearance > 40 ml/min\nCardiac ejection fraction < 35%\nDLCO corrected < 50%; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the O2 saturation is < 92% on room air; patients with a DLCO 50-60% must also have a partial pressure of oxygen (pO2) of > 80 mmHg\nLiver function abnormality; patients who have LFTs >= twice the upper limit of normal should be evaluated by a GI physician unless there is a clear precipitating factor (such as an azole, methotrexate, Bactrim or another drug); patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded\nPatients will be excluded from Arms A and C if they have received a previous myeloablative transplant; patients who have received a prior HCT at least 6 months prior may be considered for inclusion on Arms B or D after discussion with the principal investigator (PI)\nPatients with a life expectancy < 3 months from co-existing disease other than the leukemia or RAEB\nPatients who are pregnant or breast-feeding\nFertile patients of child bearing age unwilling to use contraception during and for 12 months post-transplant\nPatients with a significant other medical conditions that would make them unsuitable for transplant\nPatients with a known hypersensitivity to tacrolimus, methotrexate (Arm A or C) or MMF (Arm B or D)\nDONOR EXCLUSION:\nDonors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection\nDonors who fail eligibility requirements for donation of cells or tissue for donation of a Human Cell and Tissue Products (HCT/P) will be excluded unless use of the cells complies urgent medical need or allogeneic use in a first-degree or second-degree relative\nUnrelated donors donating outside of the United States of America (USA)"
            },
            {
                  "document": "Inclusion Criteria:\n\nTo be considered eligible for enrollment into this study, all of the following inclusion criteria must be met during the screening period:\nDocumented AML by peripheral blood and bone marrow analyses meeting WHO criteria, excluding patients with acute promyelocytic leukemia (APL)\nPatients with AML refractory to primary induction chemotherapy, relapsed disease, or age \u2265 60 and not appropriate for standard cytotoxic therapy due to age, performance status, and/or adverse risk factors according to the treating physician\nAge \u2265 18 years\nKarnofsky performance status \u2265 50% or ECOG performance status 0-2\nLife expectancy \u2265 6 weeks\nAble to understand the investigational nature of this study and to provide written consent to participate in it\nSigned written IRB-approved Informed Consent document\n\nAdequate hepatic and renal function:\n\nserum bilirubin \u2264 1.5 X institutional ULN OR serum direct bilirubin \u2264 2 X institutional ULN\nserum ALT and AST \u2264 2.5 X institutional ULN\nserum alkaline phosphatase < 5 X institutional ULN\nserum creatinine \u2264 2.0 mg/dL\ncorrected calcium level \u2265 institutional LLN\nNegative pregnancy test in women of child-bearing potential\nWomen and men of child-producing potential must agree to use effective contraceptive methods during the study period (including post-treatment observation period)\n\nExclusion Criteria:\n\nA patient will be considered not eligible for enrollment into this study if any of the following criteria are met during the screening period:\nEvidence of leukemic meningitis or other CNS involvement by leukemia\nUncontrolled or poorly controlled hypertension (systolic BP \u2265 160 mmHg or diastolic BP \u2265 100 mmHg) Note: an isolated reading that is not sustained will be permitted.\nEvidence of NYHA Class III or IV cardiac disease, or presence of unstable life-threatening arrhythmia, or history of myocardial infarction during the past 6 months\nActive bacterial, fungal, or viral infection requiring systemic treatment\nKnown infection with HIV\nHistory or major surgery within 4 weeks before the first dose of study treatment, or not recovered from prior surgery\nExposure to any other investigational agent at any time within 4 weeks before the first dose of study treatment\nExposure to any other anti-leukemic therapy (except hydroxyurea, see Section 5.5.1) within 2 weeks before the first dose of study treatment\nPregnant or lactating female\nUnwilling or unable to comply with the requirements of the study protocol"
            },
            {
                  "document": "Recipient procurement Inclusion criteria:\n\nAged 6 months to 80 years\nReceived prior or anticipated myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant\n\nPatients (Arm A) who have undergone allo-HSCT with high risk or relapse or residual/recurrent disease (see below) OR patients (Arm B) with high risk or relapsed/refractory disease (> 2 regimens with greater than M1 marrow or persistent HD) with anticipated allo-HSCT:\n\nAcute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Ambiguous lineage leukemia or lymphoma, Chronic Myelogenous leukemia (CML), CMML, MDS:\nEvidence of active leukemia or lymphoma disease by flow cytometry, morphology, or cytogenetic evaluation within the marrow or extramedullary sites.\nHodgkin's Lymphoma that has failed or are intolerant of Brentuximab, Non-Hodgkin Lymphoma (NHL) including Grey Zone Lymphoma, Anaplastic large cell lymphoma (ALCL), and mantle cell lymphoma:\nEvidence of lymphoma by morphology, Positron Emission Tomography (PET)/ Computed tomography (CT) uptake in a site of previous disease in the absence of other etiologies.\nARM C only includes patients with high risk AML and MDS who have received an allo-HSCT and have not had hematologic relapse of disease.\nKarnofsky/Lansky score of \u2265 50\nAgree to use contraceptive measures during study protocol participation (when age appropriate)\nPatient or parent/guardian capable of providing informed consent.\nT cell chimerism > 94% if collected from recipient of allo-HSCT (performed within the last 6 months)\nIf the product is procured from the recipient in the autologous (Arm B) setting, the absolute lymphocyte count should be greater than or equal to 600 for procurement. Please note: If a patient has already undergone an allogeneic HSCT, it is NOT allowed to generate TAA-T from patient blood collected post-HSCT under Arm A or C\n\nRecipient Procurement Exclusion Criteria:\n\nPatients with uncontrolled infections\nCurrent evidence of GVHD > grade 2 or bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis Pregnancy or lactating (female of childbearing potential) Recipient Inclusion criteria for initial TAA-T administration and for subsequent infusions\n\nPatients (Arm A) who have undergone allo-HSCT with high risk or relapse or residual/recurrent disease (see below) OR patients (Arm B) with high risk or relapsed/refractory disease (> 2 regimens with greater than M1 marrow or persistent HD) with anticipated allo-HSCT:\n\no Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Ambiguous lineage leukemia or lymphoma, Chronic Myelogenous leukemia (CML), CMML, MDS: Evidence of active leukemia or lymphoma disease by flow cytometry, morphology, or cytogenetic evaluation within the marrow or extramedullary sites.\n\no Hodgkin's Lymphoma that has failed or are intolerant of Brentuximab, NHL including Grey Zone Lymphoma, ALCL, and mantle cell lymphoma: Evidence of lymphoma by morphology, PET/CT uptake in a site of previous disease in the absence of other etiologies.\n\no ARM C only includes patients with high risk AML and MDS who have received an allo-HSCT and have not had hematologic relapse of disease.\n\nSteroids less than 0.5 mg/kg/day prednisone or equivalent.\nKarnofsky/Lansky score of \u2265 50.\nBilirubin < 2.5 mg/dL, AST/ALT <5x upper limit of normal, Serum creatinine < 1.0 or 2x the upper limit of normal (whichever is higher).\nPulse oximetry of > 90% on room air.\nAbsolute neutrophil count > 250/ \u00b5L (may be supported with Granulocyte colony-stimulating factor (GCSF)).\nAgree to use contraceptive measures during study protocol participation (when age appropriate).\nPatient or parent/guardian capable of providing informed consent.\nLVEF > 50% or LVSF > 27% (performed within the last 6 months) if history of TBI >500 cGy for arm A and B.\nTotal chimerism > 50%; or if cancer cells preclude this, donor T cell chimerism > 50% (performed within the last 6 months).\n\nRecipient Exclusion criteria for initial and subsequent TAA-T infusions\n\nPatients who received ATG, Campath, or other T cell immunosuppressive monoclonal antibodies within 28 days prior to TAA-T infusion.\nNo investigational therapies (under IND, not extensively studied in the current clinical context) within 28 days prior to TAA-T infusion.\n\nFor allogeneic HSCT recipients PD-1 inhibitors or other T cell activating agents will be excluded. For Arm B, if the patient has tolerated these agents without autoimmunity, these may be continued with the TAA-T infusion.\n\nUncontrolled infections\nActive Bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis\nCurrent evidence of GVHD > grade 2 for Arm A and B; Active GVHD of any grade is exclusion for arm C patients.\nPregnancy or lactating (female of childbearing potential)"
            },
            {
                  "document": "Inclusion Criteria:\n\nARM 1 - AML: Research patients enrolled are those patients with relapsed or refractory CD123+ AML de novo, or secondary OR participants who are at high risk for disease recurrence NOTE: CD123+ biphenotypic acute leukemia or CD123+ acute lymphoblastic leukemia (ALL) may also be considered but only after discussion with the study principal investigator (PI)\n\nRelapsed AML is defined as patients that had a first complete remission (CR) before developing recurrent disease (increased bone marrow blasts)\nRefractory AML is defined as patients that have not achieved a first CR after 2 cycles of induction chemotherapy; for patients with AML evolving from myelodysplastic syndrome, they should have completed at least one cycle of induction chemotherapy\nARM 2 - BPDCN: Research participants with a diagnosis of BPDCN, according to World Health Organization (WHO) classification by hematopathology, who underwent at least 1 line of systemic therapy for BPDCN and who have persistent or recurrent disease in at least one of the following are eligible: peripheral blood, bone marrow, lymph nodes, spleen, cutaneous lesions or other sites OR participant who are at high risk for disease recurrence\nFOR BOTH STUDY ARMS: Research participants must have bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML or BPDCN; CD123 positivity must be confirmed by either flow cytometry or immunohistochemistry within 90 days of study entry; cytogenetics, flow cytometry, and molecular studies (such as FMS-like tyrosine kinase-3 [FLT-3] status) will be obtained as per standard practice; however, for research participants who are at a high risk of recurrence, they must have historical bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML or BPDCN; CD123 positivity must be confirmed by either flow cytometry or immunohistochemistry prior to start of lymphodepletion\nKarnofsky performance status score >= 70\nA life expectancy >= 16 weeks at time of enrollment\nPediatric research participants must weigh > 50 kg\nWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\nCalculated creatinine clearance (absolute value) of >= 50 mL/minute or creatinine < 2.0 mg/dl or < 2 times upper limit of normal for the research participant's age group\nSerum bilirubin =< 3.0 mg/dL\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times the institutional upper limits of normal\nEjection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) >= 50%\nONLY research participants experiencing hypoxia with oxygen saturation less than 92% are required to have diffusion capacity of carbon monoxide (DLCO) or forced expiratory volume in one second (FEV1) > 45% predicted\n\nResearch participants' last dose of prior chemotherapy or radiation must be >= 2 weeks before leukapheresis\n\n* Note: the above criterion is not applicable if the research participant's donor is undergoing leukapheresis\n\nIf a research participant has undergone prior allogeneic stem cell transplant, he/she must be off all immunosuppressants for graft versus host disease (GVHD) for at least 2 weeks before undergoing leukapheresis\n\n* Note: the above criterion is not applicable if the research participant's donor is undergoing leukapheresis\n\nNegative serum or urine pregnancy test\n\nAll research participants must have the ability to understand and willingness to sign a written informed consent or age appropriate assent for pediatric patients\n\n* Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed; however, the research participant is allowed to proceed with lymphodepletion and T cell infusion only after the translated full consent form is signed\n\nELIGIBILITY TO PROCEED WITH PERIPHERAL BLOOD MONONUCLEAR CELL (PMBC) COLLECTION:\n\n* If research participant is undergoing leukapheresis:\n\nHe/she has acceptable venous access as assessed by Donor Apheresis Center or if venous access was not acceptable, a Hickman Catheter or temporary line was placed prior to scheduled leukapheresis\nHe/she has undergone prior alloSCT, they must be at least 2 weeks from having received the last dose of immunosuppressant medications to undergo PBMC collection for T cell manufacturing\nHis/her last dose of prior chemotherapy, immunotherapy or radiation is at least 2 weeks out from PBMC collection\n\nELIGIBILITY TO UNDERGO LYMPHODEPLETION Note: evaluations should be performed no more than 7 days prior to lymphodepletion\n\nResearch participant with central nervous system (CNS) leukemic involvement that is refractory to intrathecal chemotherapy and/or cranio-spinal radiation but effectively treated to completion remission (< 5 white blood cell[WBC]/mm^3 and no blast in cerebrospinal fluid [CSF]) is eligible to proceed with lymphodepletion\nResearch participants must have a donor or stem cells source identified for allogeneic transplantation, either related (7/8 or 8/8 allele matched or haploidentical), unrelated 7/8 or 8/8 allele match) donor, or cord blood stem cell source (at lease 4/6 matched)\nResearch participants with a response less than a CR or complete response with incomplete hematopoietic recovery (CRi) or detectable minimal residual disease (MRD) positive disease\nResearch participant has a released cryopreserved T cell product for CAR T cell infusion on approximately day 0\nResearch participant must be at least 2 weeks out from having received the last dose of investigational agent\nKarnofsky performance status (KPS) >= 70\nDocumented measurable or evaluable disease\nNon hematological toxicity related to prior therapy must either have returned to =< grade 2, baseline, or deemed irreversible\nResearch participants of reproductive potential must agree to use and utilize and adequate method of contraception throughout treatment and for at least 8 weeks after T cell infusion\nIf a research participant has undergone prior allogeneic stem cell transplant, he/she must be off all immunosuppressants for GVHD for at least 7 days before beginning lymphodepletion\nPulmonary: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air\nCardiovascular: not requiring pressor support, no symptomatic cardiac arrhythmias, no acute coronary syndrome, or uncontrolled hypertension\nRenal Function: calculated creatinine clearance (absolute value) of >= 50 mL/minute or creatinine < 2.0 mg/dl or < 2 times upper limit of normal for the research participant's age group\nLiver Function: adequate liver function defined as total bilirubin =< 3.0 mg/dl\nALT and AST =< 5 times the institutional upper limits of normal\nNeurological: research participant without clinically significant encephalopathy/new focal deficits\nInfectious diseases: no clinical evidence of uncontrolled active infectious process\n\nELIGIBILITY CRITERIA AT TIME OF INFUSION OF GENETICALLY MODIFIED T CELLS\n\nResearch participants has undergone lymphodepletion\nPulmonary: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air\nCardiovascular: not requiring pressor support, no symptomatic cardiac arrhythmias, no acute coronary syndrome, or uncontrolled hypertension\nRenal Function: calculated creatinine clearance (absolute value) of >= 50 mL/minute or creatinine < 2.0 mg/dl or < 2 times upper limit of normal for the research participant's age group\nLiver Function: adequate liver function defined as total bilirubin =< 3.0 mg/dl\nALT and AST =< 5 times the institutional upper limits of normal\nNeurological: research participant without clinically significant encephalopathy/new focal deficits\nInfectious diseases: no clinical evidence of uncontrolled active infectious process\nResearch participant must be off all anti-leukemic drugs, with the exception of the lymphodepleting regimens, at least 7 days prior to CAR T cell infusion\n\nELIGIBILITY CRITERIA TO UNDERGO OPTIONAL T CELL ABLATION\n\nResearch participant has >= 1% CAR T cells in the peripheral blood\nPulmonary: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air\nCardiovascular: not requiring pressor support, no symptomatic cardiac arrhythmias, no acute coronary syndrome, or uncontrolled hypertension\nRenal Function: serum creatinine did NOT increase by more than 2.5 fold from baseline (at time of screening)\nLiver Function: adequate liver function defined as total bilirubin =< 3.0 mg/dl\nAST =< 5 x ULN, ALT =< 5 x ULN\nNeurological: research participant without clinically significant encephalopathy/new focal deficits\nInfectious diseases: no clinical evidence of uncontrolled active infectious process\n\nALLOGENEIC DONOR CRITERIA FOR APHERESIS DONATION:\n\nRelated donor selection will be conducted in accordance with City of Hope's Department of Hematology & Hematopoietic Cell Transplantation criteria and, in the case of unrelated donor from a transplant center, will comply with the National Marrow Donor Program's (NMDP) donor selection standards; when a potentially eligible recipient of an unrelated donor product from an NMDP Center is identified, the recipient will complete an NMDP search transfer request to allow City of Hope (COH) NMDP staff to contact the NMDP Coordinating Center, who in turn, will contact the donor's prior Donor Center; the search will follow the NMDP Policy for subsequent donation requests; any form deemed appropriate and necessary by the NMDP, including the Subsequent Donation Request Form, Therapeutic T Cell Collection Prescription and Therapeutic Stem Cell Collection Prescription, will be submitted as required\nIn the case of a related donor: The identified donor must be the original donor whose stem cells were used for the research participant's allogeneic stem cell transplantation (alloSCT)\nFor both related and unrelated donors: The donor's hepatitis B surface antigen must be negative and the hepatitis C antibody must be nonreactive; in the case of a positive hepatitis C antibody result, the hepatitis C virus (HCV) viral polymerase chain reaction (PCR) will have to be performed and the results should be negative\n\nExclusion Criteria:\n\nResearch participants with uncontrolled intercurrent illness including, but not limited to ongoing or active or poorly controlled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements; such social situations include but are not limited to lack of reliable means of transportation for follow up, inability to make time for required clinic visits due to work or family needs, or lack of reliable ways of communication with the study team in the event that the participant is seriously ill\nResearch participants who have tested human immunodeficiency virus (HIV) positive, or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollment\nResearch participants with presence of other active malignancy. However, research participants with history of prior malignancy treated with curative intent and in complete remission are eligible\nPregnant and lactating women are excluded from this study\n\nStudy-Specific Exclusion\n\nFailure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study\nHistory of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab\n\nDependence on corticosteroids:\n\nIf the participant is undergoing leukapheresis: physiological replacement doses of steroids are allowed - prednisone no more than 7.5 mg, hydrocortisone less than 12 mg/m^2/day\n\nHowever, all participants must be able to reduce steroid requirement to no more than physiological replacement doses prior to start of lymphodepletion\nActive autoimmune disease requiring systemic immunosuppressive therapy\nResearch participants will be excluded, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nConfirmed diagnosis of primary or secondary AML [any subtype except acute promyelocytic leukemia (APL)] according to World Health Organization (WHO) classification\n\nPatients with AML must meet one of the following criteria, a or b:\n\na. Primary Induction Failure (PIF) AML, defined as disease refractory to one of the following, i or ii: i. An intensive induction attempt, per institution. Induction attempts include high-dose and/or standard-dose cytarabine\n\n\u00b1 an anthracyclines/anthracenedione \u00b1 an anti-metabolite, with or without growth factor or targeted therapy containing regimens.\n\nExamples include but are not limited to:\n\nOne cycle of high dose cytarabine (HiDAC) containing regimen\nOne cycle of liposomal cytarabine and daunorubicin\nTwo cycles of standard dose cytarabine containing regimen ii. For adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; PIF is defined as AML refractory to one of the following less intensive regimens, 1 or 2:\n\n1. \u2265 2 but \u2264 4 cycles of Bcl-2 inhibitors in combination with azacitidine, decitabine, or low dose cytarabine 2. \u2265 2 but \u2264 4 cycles of gemtuzumab ozogamicin monotherapy b. Early relapse (ER) AML, defined as AML in first relapse with initial CR1 duration < 6 months 3. Limit of 3 prior lines of therapy: up to 2 induction (induction, re-induction) or 1 induction plus/minus 1 consolidation attempt, followed by a maximum of 1 salvage/re-induction attempt.\n\nEastern Cooperative Oncology Group (ECOG) performance status \u22642\nLife expectancy of at least 4 weeks\nPeripheral blast count </= 20,000/mm3 at the time of first dose\nAcceptable laboratory parameters and adequate organ reserve\n\nExclusion Criteria:\n\nHistory of allogeneic stem cell transplantation\nPrior treatment with an anti-CD123-directed agent\nNeed for concurrent other cytoreductive chemotherapy\nAny active untreated autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid clinically and with stable supplementation)\nSecond primary malignancy that requires active therapy. Adjuvant hormonal therapy is allowed.\nAntitumor therapy or investigational agent within 14 days or 5 half-lives of Cycle 1 Day 1.\nRequirement, at the time of study entry, for concurrent steroids > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, otic preparations, nasal spray or ophthalmic solution\nUse of immunosuppressant medications in the 2 weeks of Cycle 1 Day 1\nUse of granulocyte colony stimulating or granulocyte-macrophage colony stimulating factor in the 2 weeks of Cycle 1 Day 1\nKnown central nervous system (CNS) leukemia\nActive uncontrolled infection (including, but not limited to viral, bacterial, fungal, or mycobacterial infection),\n\nKnown human immunodeficiency virus infection, unless all of the following criteria are met:\n\ni. CD4+ count \u2265 350 cells/\u03bcL, ii. undetectable viral load, and iii. receiving highly active antiretroviral therapy.\n\nKnown, active, history of or current acute or chronic hepatitis B or C virus (HBV) infection (as evidenced by detectable HBV surface antigen and HBV DNA \u2265 500 IU/mL),\nHistory of hepatitis C virus (HCV) infection, unless the infection has been treated and cured,\nActive SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study entry, testing for ongoing infection should follow local clinical practice guidelines/standards. Participants with a positive test result for ongoing SARS-CoV-2 infection, known asymptomatic infection, or suspected infection are excluded unless or until asymptomatic and with subsequent negative SARS-CoV-2 laboratory test."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have a diagnosis of Fanconi anemia\n\nPatients must have one of the following hematologic diagnoses:\n\nSevere Aplastic Anemia (SAA), with bone marrow cellularity of <25% OR Severe Isolated Single Lineage Cytopenia and at least one of the following features:\n\nPlatelet count <20 x 109/L or platelet transfusion dependence*\nANC <1000 x 109/L\nHgb <8 gm/dl or red cell transfusion dependence*\nMyelodysplastic Syndrome (MDS) (based on WHO or IPSS Classification\nAcute Myelogenous Leukemia (untreated, in remission or with refractory or relapsed disease)\nDonors will be either human leukocyte antigen (HLA) compatible unrelated or HLA-genotypically matched related donors (no fully matched sibling donor).\nPatients and donors may be of either gender or any ethnic background.\nPatients must have a Karnofsky adult, or Lansky pediatric performance scale status > 70%.\n\nPatients must have adequate physical function measured by:\n\nCardiac: asymptomatic or if symptomatic then 1) left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise or 2) Shortening Fraction > 29%\nHepatic: < 5 x upper limit of normal (ULN) alanine transaminase (ALT) and < 2.0 mg/dl total serum bilirubin.\nRenal: serum creatinine <1.5 mg/dl or if serum creatinine is outside the normal range, then CrCl > 50 ml/min/1.73 m2\nPulmonary: asymptomatic or if symptomatic, DLCO > 50% of predicted\nEach patient must be willing to participate as a research subject and must sign an informed consent form.\nFemale patients and donors must not be pregnant or breastfeeding at the time of signing consent. Women must be willing to undergo a pregnancy test prior to transplant and avoid becoming pregnant while on study.\n\nExclusion Criteria:\n\nActive CNS leukemia\nFemale patients who are pregnant (positive serum or urine HCG) or breast-feeding.\nActive uncontrolled viral, bacterial or fungal infection\nPatient seropositive for HIV-I/II; HTLV -I/II"
            },
            {
                  "document": "Inclusion Criteria:\n\nChild diagnosed with any AML, relapsed ALL, stage 3 or 4 Burkitt's or diffuse B large cell lymphoma/leukemia OR about to receive autologous or allogeneic HSCT for any indication\nChild expected to be an inpatient for at least 3 weeks after initiation of chemotherapy or conditioning\nChild aged 8 to 18 years at enrollment. Conditioning regimen may be myeloablative or reduced intensity\n\nExclusion Criteria:\n\nFollowing features present to an extent that would preclude compliance with yoga, as assessed by the attending physician: a) motor disability, b) cognitive disability, c) cardiopulmonary symptoms, or d) known compression fracture resulting in disability\nParent or patient cannot understand verbal English\nFor HSCT patients, planned non-myeloablative conditioning regimen."
            },
            {
                  "document": "Inclusion Criteria:\n\nAll allograft patients > 2 years of age.\n\nPatients will have one of the following malignancies:\n\na. Patients with refractory or relapsed: acute myelogenous leukemia (AML) (including inv16, t(8;21) or t(15;17)) or high risk myelodysplastic syndrome (MDS) (defined as bone marrow blasts > or = 5%) are eligible. Patients may be in remission at the time of entry.\n\nPatients with adequate organ function and performance status criteria measured by:\n\nKarnofsky score greater than or equal to 70% or Performance status of < or = 2 by the Eastern Cooperative Oncology Group (ECOG) scale\nAdequate liver function (bilirubin of < 2mg/dL, serum glutamate pyruvate transaminase < 3 * ULN) and renal function (creatinine < 2mg/dL)\nSigned informed consent indicating that patients are aware of the investigational nature of this study in accordance with the regulations of Loyola University Medical Center\nPatients must have undergone allogeneic stem cell transplant within 40-60 days before starting treatment and be self-sufficient in caloric intake along with no active graft vs. host disease\n\nExclusion Criteria:\n\nNursing and pregnant females are excluded.\nActive and uncontrolled infections will cause patients to be excluded.\nPatients already receiving valproic acid or receiving other anticonvulsants will be excluded.\nLow risk AML in complete remission 1, will not be candidates for this study.\nPatients with an absolute neutrophil count less than 1500 will be excluded\nPatients with platelets less than 50,000 will be excluded\nChildren less than 2 years of age will be excluded due to increased hepatotoxicity from valproic acid in this age group"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndromes (MDS) with fewer than 10% myeloblasts or lymphoblasts in the bone marrow and no blasts in the peripheral blood on morphologic analysis performed within 30 days of start of the conditioning regimen; if remission bone marrow is available beyond 30 days a new bone marrow evaluation is required to assess remission status\n\nThe diagnosis of AML, ALL, or MDS will be based on World Health Organization (WHO) criteria\nPre-transplant bone marrow sample must be evaluable for assessment of remission status (i.e. aspirate smear containing particles and/or evaluable bone marrow core biopsy)\nPatients with leukemia infiltration in the central nervous system (CNS) are eligible if cerebrospinal fluid (CSF) cytospin is negative for myeloblasts or lymphoblasts at time of enrollment\nIf the patient has an intra-abdominal chloroma on presentation, and has a partial response or complete response to treatment (size reduction of chloroma and marrow blast < 10%), the patient is eligible; however the chloroma must be included as part of the treatment target\n\nFor patients receiving treatment of their AML, MDS or ALL prior to transplantation:\n\nInterval between the start of a cycle of conventional cytotoxic chemotherapy and the start of conditioning regimen must be at least 30 days\nInterval between completing treatment with a hypomethylating agent or other non-cytotoxic chemotherapy and the start of conditioning regimen must be at least 10 days\nHematopoietic Cell Transplantation-Specific Comorbidity Index score (HCT-CI) =< 4 for patients in Cohort 1 and > 4 for Cohort 2\nPatient must be able to lie still in full body cast for 45 minutes\nMust have a suitable donor defined as a sibling matched at 5/6 or 6/6 antigens (human leukocyte antigen [HLA]-A, B, and DRB1) or an unrelated volunteer matched at 7/8 or 8/8 HLA alleles (HLA-A, B, C, and DRB1)\nSigned informed consent\n\nDONOR: \"High resolution\" typing at HLA-A, B, C and DRB1 alleles\n\nSingle antigen mismatch for siblings and single allele mismatch for volunteer unrelated donors is acceptable\nDonors must be >= 17 years of age\n\nExclusion Criteria:\n\nCirculating peripheral blood myeloblasts or lymphoblasts on morphologic analysis from time of last treatment to time of enrollment\nPrior allograft or prior autograft\nActive CNS disease as identified by positive CSF cytospin at time of enrollment\nKarnofsky performance score < 70\nSymptomatic uncontrolled coronary artery disease or ejection fraction < 40%\nTotal bilirubin >= 2 x the upper limit of normal\nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x the upper limit of normal\nDiffusion capacity of the lung for carbon monoxide (DLCO) < 40%\nForced expiratory volume in one second (FEV1) < 50% (corrected for hemoglobin)\nReceiving supplementary continuous oxygen\nCreatinine clearance < 50 mL/min/1.73m^2\nPatients with active uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms)\nPatients seropositive for the human immunodeficiency virus (HIV)\nFemales who are pregnant or breastfeeding\nFertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment\nPatients who had prior radiation to more than 20% bone marrow containing areas or to any areas exceeding 2000 cGy\n\nDONOR:\n\nDonors will be excluded if they are an identical twin of the recipient\nFemales who are pregnant (positive serum beta human chorionic gonadotropin beta [\u03b2 HCG]) or uninterruptible breastfeeding\nHIV seropositive\nDonors receiving experimental therapy or investigational agents unless approved by the protocol chair"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a diagnosis of AML, acute biphenotypic leukemia, or high risk MDS (>= 10% blasts or International Prognostic Scoring System [IPSS] >= intermediate-2) will be eligible; patients with CML in myeloid blast phase are also eligible\nFor frontline cohorts (1 or 4): no prior potentially curative therapy for leukemia; prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, decitabine, tretinoin (ATRA), or a total dose of cytarabine up to 2 g (for emergency use for stabilization) is allowed; patients deemed able to receive venetoclax (ie. insurance clearance) will be assigned to frontline cohort 4; patients with secondary AML who have been treated for their antecedent myeloid neoplasm will be enrolled into the separate secondary AML cohort\nFor salvage cohort: patients with previously treated, relapsed or refractory AML, acute biphenotypic leukemia, or CML in myeloid blast phase are eligible\nBilirubin =< 2 mg/dL\nAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or < 5 x ULN if related to leukemic involvement\nCreatinine =<1.5 x ULN\nKnown cardiac ejection fraction of >= 45% within the past 6 months\nEastern Cooperative Oncology Group (ECOG) performance status of =< 2\nA negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial\nPatient must have the ability to understand the requirements of the study and signed informed consent a signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol\n\nExclusion Criteria:\n\nPregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects; because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided\nUncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPatient with documented hypersensitivity to any of the components of the chemotherapy program\nMen and women of childbearing potential who do not practice contraception; women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation"
            },
            {
                  "document": "Inclusion Criteria:\n\nParticipant has the ability and the willingness to sign the informed consent document (for adults only, for participants with mild cognitive abilities may use a legally authorized representative)\nDocumented (signed) informed consent; the patient, family member and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting all pertinent information with respect to risks and benefits to donor and recipient will be presented; alternative treatment modalities will be discussed; the risks are explained in detail in the enclosed consent forms\nKarnofsky performance status >= 70% =< 2\nAcute lymphocytic leukemia or acute myelogenous leukemia who are not in first remission or second remission i.e. after failing induction therapy, or in relapse or beyond second remission; (prior therapy with VP-16 and Cytoxan is allowed)\nAll candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical siblings who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR or DQ and a killer immunoglobulin-like receptor (KIR) mismatch at C will be allowed; all ABO blood group combinations of the donor/recipient are acceptable\nThe time from the end last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days from planned start of study treatment; Note: Chemotherapy given within 14 days of planned study enrollment for the purpose of controlling counts is permitted\nTotal bilirubin =< 1.5 x upper limit of normal (ULN) OR 3 x ULN for Gilbert's disease\nSerum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 5 x ULN\nMeasured creatinine clearance >= 80 ml/min per 24 hour urine collection OR serum creatinine =< 1.3 mg/dL\nWomen of child bearing potential only: Negative urine or serum pregnancy test\nPulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted normal value\nEchocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall motion is \"abnormal\" or \"altered\")\nElectrocardiogram (EKG) showing no ischemic changes and no abnormal rhythm\nAgreement of men AND women-of-child-bearing-potential to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\nDONOR ELIGIBILITY: Donor evaluation and eligibility will be assessed as per current City of Hope standard operating procedure (SOP)\n\nExclusion Criteria:\n\nPrior autologous or allogeneic hematopoietic stem cell\nPrior radiation therapy that would exclude the use of TMLI\nPlans during the trial to receive any other (non-trial) investigational agents, or concurrent biological, chemotherapy, or radiation therapy; (chemotherapy for white blood count control is permitted)\nUncontrolled illness including ongoing or active infection\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to etoposide\nPatients with other active malignancies are ineligible for this study, other than localized malignancies\nPatients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation\nWomen who are planning to become pregnant or breast feed during the trial\nSubjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nAge: Patient must be \u2265 12 months (365 days) and \u2264 21 years.\n\nHistologically confirmed diagnosis of relapsed or refractory ALL (including Burkitt leukemia), AML, mixed lineage leukemia, biphenotypic leukemia, or chronic myelogenous leukemia (CML) in blast crisis.\n\nRefractory disease defined as: Persistent disease after at least two induction cycles.\nRelapsed disease: Second or subsequent relapse, any relapse refractory to salvage chemotherapy\nSubjects must have bone marrow with \u2265 5% blasts (M2 or M3 marrow) definitively identified either on a bone marrow aspirate or biopsy sample, as assessed by morphology, immunohistochemical studies, flow cytometry, karyotype, cytogenetic testing such as fluorescent in situ hybridization (FISH) or other molecular studies.\nSubject would not benefit from additional cytotoxic chemotherapy as determined by the treating physician.\nPatients with CNS 1 or CNS 2 disease are eligible. Patients with isolated CNS relapse or CNS 3 disease are not eligible. Please refer to Section 11.1.3 for definitions of CNS disease status and interpretation of traumatic lumbar punctures.\n\nPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet all of the following criteria:\n\nMyelosuppressive chemotherapy: 14 days must have elapsed since the completion of myelosuppressive therapy. Individuals may have received any of the following medications within 14 days without a \"wash-out\" period:\n\nStandard maintenance therapy (vincristine, 6MP, corticosteroids, low dose methotrexate)\nHydroxyurea\nIntrathecal chemotherapy with methotrexate, hydrocortisone and/or cytarabine.\n\nRadiation therapy (XRT):\n\nTotal Body Irradiation (TBI) or craniospinal radiation therapy: Must have been completed more than 90 days from study entry\nPalliative XRT: XRT for chloromas does not require a washout period.\nBiologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.\nImmunotherapy: At least 6 weeks after the completion of any type of immunotherapy, e.g. tumor vaccines and chimeric antigen receptor T-cells.\nMonoclonal antibodies: At least 3 half-lives of the antibody after the last dose of a monoclonal antibody. (See table on DVL homepage listing monoclonal antibody half-lives: https://members.childrensoncologygroup.\n\nPerformance status:\n\n-- Lansky \u2265 50 for individuals 18 months- \u2264 16 years old; Karnofsky > 50% for individuals 17-21 years old (See Appendix I).\n\nAdequate organ function defined as the following:\n\nDirect bilirubin \u22641.5 X institutional upper limit of normal (ULN)\nAST (SGOT)/ALT (SGPT) \u2264 3X institutional ULN\nCreatinine below institutional ULN or creatinine clearance \u2265 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal\nEchocardiogram must have a shortening fraction or an ejection fraction greater than institutional lower limit of normal for age and gender. Echocardiogram must be obtained while patient is not receiving cardiotropic medications (eg., pressors or afterload reducers).\nOxygen saturation over 90% by pulse oximetry without administration of supplemental oxygen.\nFemale patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.\nFemale patients with infants must agree not to breastfeed their infants while on this study.\nThe effects of KPT-330 on the developing human fetus are unknown. For this reason and because many chemotherapeutic agents are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\nAbility of participant (or parent/guardian for participants who are minors) to understand and the willingness to sign the written informed consent document.\n\nExclusion Criteria:Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.\n\nInability to take or tolerate enteral medications\nIndividuals with CNS 3 leukemia\nIndividuals with Down syndrome\n\nPatients with prior hematopoietic stem cell transplant (HSCT) are eligible, with the exception of the following:\n\nAutologous HSCT within 60 days of study entry\nAllogeneic HSCT within 90 days of study entry\nEvidence of graft-versus-host-disease (GVHD)\nTreatment with immunosuppressive medications within 14 days; however, weaning or stable doses of steroids (must be \u2264 20 mg/m2/day of prednisone equivalents) and/or calcineurin inhibitors are permitted.\n\nTreatment with hematopoietic growth factors (G-CSF):\n\nLong-acting (e.g., Neulasta) within 14 days prior to study entry\nShort-acting (e.g., Neupogen) within 7 days prior to study entry\nTreatment with an investigational agent within 28 days of study entry, or 3 half-lives, whichever is longer.\nPatients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.\nAny ECG abnormality that in the opinion of the principal investigator would preclude safe participation in the study\nPatients refractory to red blood cell or platelet transfusions.\nPatients receiving anti-coagulation therapy are eligible as long as anti-coagulation regimen has been stable for > 1 month.\nPatients with systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment.\nFor dose-escalation cohort only, known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required. HIV positive patients will be eligible for the dose-expansion cohort.\nKnown active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen); baseline testing for viral hepatitis is not required.\nImpairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of KPT-330 (e.g. ulcerative colitis, uncontrolled nausea, vomiting, diarrhea, malabsorption or history of small bowel resection)\nIndividuals with significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.\nIndividuals with a history of a different malignancy (other than acute leukemia) are ineligible except for the following circumstances: Individuals are eligible if the different malignancy is in complete remission at the time of study entry.\nPregnant women are excluded from this study because KPT-330 is a chemotherapeutic agent with unknown teratogenic or abortifacient effects.\nIndividuals who are eligible for allogeneic hematopoietic stem cell transplantation (HSCT) as determined by the treating physician, and have a suitable donor or appropriate stem cell source available\nIndividuals who would benefit from additional cytotoxic chemotherapy as determined by the treating physician"
            },
            {
                  "document": "Key Inclusion Criteria:\n\nSubject must be \u226518 years of age.\nSubjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy based on local or central evaluation.\nSubjects must be amenable to serial bone marrow biopsies, peripheral blood sampling, and urine sampling during the study.\nSubjects must have ECOG PS of 0 to 2.\nPlatelet count \u226520,000/\u00b5L (Transfusions to achieve this level are allowed).\nSubjects must have adequate hepatic function as evidenced by: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) \u22643.0 \u00d7 ULN, unless considered due to leukemic disease and serum total bilirubin \u22641.5 x upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic disease\nSubjects must have adequate renal function as evidenced by a serum creatinine \u22642.0 \u00d7 ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration rate (GFR)\nSubjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer.\nFemale subjects with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy and on the first day of study drug administration.\n\nKey Exclusion Criteria:\n\nSubjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin GVHD is permitted.)\nSubjects who received systemic anticancer therapy or radiotherapy <14 days prior to their first day of study drug administration. (Hydroxyurea is allowed prior to enrollment and after the start of AG-120).\nSubjects who received an investigational agent <14 days prior to their first day of study drug administration.\nSubjects who are pregnant or breastfeeding.\nSubjects with an active severe infection or with an unexplained fever >38.5\u00b0C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, subjects with tumor fever may be enrolled).\nSubjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.\nSubjects with a history of myocardial infarction within the last 6 months of screening.\nSubjects with a known unstable or uncontrolled angina pectoris.\nSubjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\nSubjects with known unstable or uncontrolled angina pectoris.\nSubjects with heart-rate corrected QT (QTc) interval \u2265450 ms or other factors that increase the risk of QT prolongation or arrhythmic events.\nPatients taking medications that are known to prolong the QT interval\nSubjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.\nSubjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during screening.\nSubjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation."
            },
            {
                  "document": "Inclusion Criteria: General Eligibility (All Patients)\n\nMust be < 22 years of age\nDiagnosed with a malignant disease\nMust be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and must sign an informed consent\nFor unrelated donor: A human leukocyte antigen (HLA) 8/10, 9/10 or 10/10 matched unrelated adult donor (MUD) will be required for study entry\nFor related donor: A 5/10, 6/10, 7/10, 8/10, 9/10 or 10/10 matched (or partially matched) family donor will be required for study entry\nAdequate renal function\nAdequate liver function\nAdequate cardiac function\nAdequate pulmonary function\n\nExclusion Criteria:\n\nPatients with documented uncontrolled infection at the time of study entry are not eligible\nFemales who are pregnant or breast feeding at the time of study entry are not eligible"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients who have undergone T cell depleted allogeneic hematopoietic stem cell transplantation at MSKCC for:\n\nDe novo myelodysplastic syndromes (MDS): IPSS-1 with poor risk cytogenetics or higher IPSS.\nAcute myelogenous leukemia (AML) in first remission that required more than 1 cycle of treatment to achieve remission or with the following cytogenetic abnormalities: FLT3 mutation, deletion/monosomy of chromosome 5 or 7, MLL gene rearrangement, or more than or equal to 3 cytogenetics abnormalities. Also patients in second or greater remission.\nPatients with Secondary MDS/AML.\nPatients will be considered eligible for the study if after transplant they achieved hematologic (<5% blasts) and cytogenetic remission.\nPatients will be eligible to enter the study between 60-120 days post transplant.\nAge: pediatrics and adults patients - 1 year old-75 years old.\nKarnofsky performance status >=60% for patients >16yo and Lansky performance status >=60% for patients \u226416yo\nStable blood counts (ANC>1000/uL, Hb>8gr/dL, Plt>50,000/ uL) not supported by transfusions.\nRenal: Serum creatinine <1.5 ULN\nHepatic: <3xULN ALT and <1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia.\nCardiac: Adequate cardiac function measured by LVEF>50%. If asymptomatic, pretransplant echocardiogram is adequate. If symptomatic, echocardiogram needs to be repeated.\nEach patient must be willing to participate as a research subject and must sign an informed consent form.\n\nExclusion Criteria:\n\nPatients will be excluded from the trial if at time of enrollment:\n\nActive uncontrolled bacterial, fungal or viral infection.\nEvidence of uncontrolled graft-versus-host disease.\nPulmonary: new onset hypoxia\n\nKnown or suspected hypersensitivity to 5'-azacitadine or mannitol.\n\nEvidence of residual disease either by increased blasts count (>5%) or persistence of previous known cytogenetics abnormalities.\nPeripheral blood neutrophil chimerism: less than 95% donor."
            },
            {
                  "document": "Inclusion Criteria:\n\nEligible Disease Status\n\nAcute Myeloid Leukemia (AML): high risk CR1 (as evidenced by preceding MDS, high risk cytogenetics, \u2265 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia; CR2+. All patients must be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a cellularity of \u226515%.\nVery high risk pediatric patients with AML: Patients <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy.\nAcute Lymphocytic Leukemia (ALL): high risk CR1 as defined by cytogenetics (such as t(9;22), t (1:19), t(4;11), other MLL rearrangements, hypodiploidy, or IKZF1 abnormalities), DNA index < 0.81, > 1 cycle to obtain CR or presence minimal residual disease (MRD). Patients in CR2+ are eligible. All patients must be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a cellularity of \u226515%.\nVery high risk pediatric patients with ALL: patients <21 years are also considered high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction or M3 marrow at the end of induction. They are eligible once they achieved a complete remission.\nChronic Myelogenous Leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate.\nPlasma Cell Leukemia after initial therapy, who achieved at least a partial remission\nAdvanced Myelofibrosis\nMyelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia or high risk cytogenetics: Blasts must be < 10% by a representative bone marrow aspirate morphology.\nChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone B-Cell Lymphoma or Follicular Lymphoma are eligible if there was disease progression/relapse within 12 of achieving a partial or complete remission. Patients who had remissions lasting > 12 months, are eligible after at least two prior therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be considered for de-bulking chemotherapy before transplant.\nLymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy in CR1+ or PR1+.\nLarge Cell NHL > CR2/> PR2: Patients in CR2/PR2 with initial short remission (<6 months) are eligible.\nLymphoblastic Lymphoma, Burkitt's Lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year.\nMultiple Myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or \u03b2-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapy.\nMyeloproliferative Syndromes\nAvailability of suitable UCB unit(s)\n0 to 55 years\nVoluntary written consent (adult or parental/guardian)\n\nExclusion Criteria:\n\nprevious irradiation that precludes the safe administration of TBI - Radiation Oncology will evaluate all patients who have had previous radiation therapy\nchemotherapy refractory large cell and high grade NHL (ie progressive disease after > 2 salvage regimens)\nif \u2264 18 years old, prior myeloablative transplant within the last 6 months. If >18 years old prior myeloablative allotransplant or autologous transplant\nextensive prior therapy including > 12 months alkylator therapy or > 6 months alkylator therapy with extensive radiation\npregnant or breastfeeding\nHIV positive"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have one of the following documented diseases:\n\nChronic myelogenous leukemia\nChronic lymphocytic leukemia\nMultiple myeloma\nMyelodysplasia\nMyeloproliferative disorder\nNon-Hodgkin's lymphoma\nHodgkin's disease\nAcute myelogenous leukemia\nAcute lymphoblastic leukemia\nAcute biphenotypic leukemia\n\nPatients must be undergoing a myeloablative allogeneic hematopoietic cell transplant with one of the following conditioning regimens:\n\nBusulfan (\u2265 12.8 mg/kg IV or PO) and cyclophosphamide (\u2265 120 mg/kg)\n\n--- Busulfan dose may be adjusted according to pharmacokinetics targeting a daily AUC of 5000 \u03bcmol-min/L, per institution standard of practice.\n\nTotal body irradiation (TBI) (\u2265 1200 cGy) and etoposide (60 mg/kg)\nTBI (\u2265 1200 cGy) and cyclophosphamide (120 mg/kg)\nPatient must have achieved and be in complete morphologic remission prior to starting conditioning regimen\nPatient's donor must be a related or unrelated human leukocyte antigen (HLA) 8/8 allele-level match (HLA-A, B, C and DRB1)\nAdult patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; pediatric patients must have Lansky score \u2265 60%\nPatients must have a life expectancy of 100 days\nPatients must sign written informed consent\n\nExclusion Criteria:\n\nPatients who have undergone any prior transplant\nPatients who are seropositive for human immunodeficiency virus (HIV)\nPatients with any medical illness or concurrent psychiatric illness which, in the investigators' opinion, cannot be adequately controlled with appropriate therapy\nPatients who are pregnant or lactating"
            },
            {
                  "document": "Inclusion Criteria:\n\nMDS, myelodysplastic syndrome/myeloproliferative neoplasia overlap disorders (including chronic myelomonocytic leukemia [CMML], and MDS/myeloproliferative neoplasm [MPN] unclassifiable syndromes)\nAML, other than acute promyelocytic leukemia (APL), in first or second remission or with minimal residual disease\nWith Karnofsky index or Lansky Play-Performance scale > 70% on pre-transplant evaluation\nAble to give informed consent (if > 18 years), or with a legal guardian capable of giving informed consent (if < 18 years)\nPatients with previous autologous or allogeneic HCT are allowed to enroll\nDONOR: Human leukocyte antigen (HLA)-identical related donors or\nDONOR: Unrelated donors matched for HLA-A, B, C, DRB1, and DQB1 as defined by high resolution deoxyribonucleic acid (DNA) typing; mismatch for one HLA allele is allowed\nDONOR: Donors able to undergo peripheral blood stem cell collection or bone marrow harvest\nDONOR: Donors in good general health, with a Karnofsky or Lansky play performance score > 90%\nDONOR: Donors able to give informed consent (if > 18 years), or with a legal guardian capable of giving informed consent (if < 18 years)\n\nExclusion Criteria:\n\nReceiving umbilical cord blood\nWith impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist\nWith impaired pulmonary function as evidenced by partial pressure of oxygen (pO2) < 70 mm Hg and carbon monoxide diffusing capability test (DLCO) < 70% of predicted or pO2 < 80 mm Hg and DLCO < 60% of predicted; (or, for pediatric patients unable to perform pulmonary function tests, then oxygen (O2) saturation < 92% on room air), or receiving supplementary continuous oxygen\nWith impaired renal function as evidenced by creatinine-clearance < 50% for age, weight, height or serum creatinine > 2 x upper limit of normal or dialysis-dependent\nWith hepatic dysfunction as evidenced by total bilirubin > 2.0 x upper limit of normal or evidence of synthetic dysfunction or severe cirrhosis\nWith hepatic dysfunction as evidenced by aspartate aminotransferase (AST) > 2.0 x upper limit of normal or evidence of synthetic dysfunction or severe cirrhosis\nWith active infectious disease requiring deferral of conditioning, as recommended by an infectious disease specialist\nWith human immunodeficiency virus (HIV)-positivity or active infectious hepatitis\nWith central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy, cranial irradiation or both prior to initiating conditioning (day -6)\nPatients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies who have been rendered with no evidence of disease, but have a greater than 20% chance of having disease recurrence within 5 years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy\nWith life expectancy severely limited by diseases other than malignancy\nWomen who are pregnant or lactating\nWith known hypersensitivity to treosulfan or fludarabine (fludarabine phosphate)\nReceiving another experimental drug within 4 weeks before initiation of conditioning (day -6)\nUnable to give informed consent (if > 18 years) or with a legal guardian (if < 18 years) unable to give informed consent\nDONOR: Individuals deemed unable to undergo marrow harvesting or PBSC mobilization and leukapheresis\nDONOR: Individuals who are HIV-positive\nDONOR: Individuals with active infectious hepatitis\nDONOR: Females with a positive pregnancy test\nDONOR: Persons unable to give informed consent (if > 18 years) or with a legal guardian (if < 18 years) unable to give informed consent"
            },
            {
                  "document": "Inclusion Criteria:\n\nPHASE I\nRefractory or relapsed disease defined as follows: patients with MDS or chronic myelomonocytic leukemia (CMML) should have failed prior therapy (e.g., with a hypomethylating agent, clofarabine, and/or with lenalidomide); patients with AML should have failed any prior induction therapy or have relapsed after prior therapy; patients (any age) with MDS or CMML who received therapy with a hypomethylating agent and progress to AML are eligible at the time of diagnosis of AML regardless any prior therapy for AML. The World Health Organization (WHO) classification will be used for AML; patients with any of the eligible diagnoses who have received no prior therapy are eligible if not candidates to receive standard intensive therapy (i.e., high-dose cytarabine-based chemotherapy).\nPatients are eligible regardless of their FLT3 mutation status.\nPHASE II\nCOHORT 2A: Patients with MDS, CMML or AML who are either: age 60 years or older and newly diagnosed, previously untreated. Prior therapy with hydroxyurea or single agent ara-C for the purpose of control of white blood cells (WBC) is acceptable.; age 18 years or older and with refractory or relapse disease who have received no more than one prior treatment regimen and will be receiving first salvage. For this purpose, a second induction cycle with the same drugs used during the first cycle, consolidation chemotherapy or stem cell transplant in complete remission (CR) (or complete response with incomplete platelet recovery [CRp] or complete response with incomplete bone marrow recovery [CRi]) will be considered part of the prior regimen. Prior therapy for MDS (or other malignancies) is not considered a prior regimen for AML in patients who progress from MDS (or other malignancies).\nCOHORT 2A: Patients (any age) with MDS or CMML who received therapy with a hypomethylating agent and progress to AML are eligible at the time of diagnosis of AML regardless any prior therapy for AML. The WHO classification will be used for AML.\nCOHORT 2A: Patients must have evidence of FLT3 ITD in their most recent assessment.\nCOHORT 2B: Patients with MDS, CMML or AML who are either: Age 60 years or older and newly diagnosed, previously untreated. Prior therapy with hydroxyurea or single agent ara-C for the purpose of control of WBC is acceptable or age 18 years or older and with refractory or relapse disease who have received no more than two prior treatment regimens and will be receiving second salvage, or who have received a prior SCT and will be receiving their first salvage. For this purposes, a second induction cycle with the same drugs used during the first cycle, consolidation chemotherapy or stem cell transplant in CR (or CRp or CRi) will be considered part of the prior regimen. Prior therapy for MDS (or other malignancies) is not considered a prior regimen for AML in patients who progress from MDS (or other malignancies)\nCOHORT 2B: Patients (any age) with MDS or CMML who received therapy with a hypomethylating agent and progress to AML are eligible at the time of diagnosis of AML regardless any prior therapy for AML. The WHO classification will be used for AML\nCOHORT 2B: Patients must have no evidence of FLT3 mutations in their most recent assessment\nPHASE I AND II\nEastern Cooperative Oncology Group (ECOG) performance status =< 2.\nBilirubin =< 2 x upper limit of normal (ULN).\n\nAlanine aminotransferase (ALT) =< 2.5 x ULN.\n\nFor patients with suspected liver infiltration from leukemia ALT should be =< 5 ULN.\nCreatinine =< 2 x ULN.\nSerum potassium, magnesium, and calcium (normalized for albumin) levels should be at least within institutional normal limits.\nPatients must provide written informed consent.\nPatients must have been off chemotherapy for 2 weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy. The additional days of hydrea after 28 is permitted as clinically indicated, on case by case basis after discussion with the principal investigator (PI). Other agents given transiently with the intention to control rapid proliferation such as 1-2 doses of single agent ara-C or few doses of sorafenib are also allowed.\nWomen of childbearing potential must practice contraception. Women considered not of childbearing potential include any of the following: no menses for at least 2 years or menses within 2 years but amenorrheic for at least 2 months and luteinizing hormone (LH) and follicular stimulating hormone (FSH) values within normal range (according to definition of postmenopausal for laboratory used) or bilateral oophorectomy or radiation castration and amenorrheic for at least 3 months. Females of childbearing potential should practice effective methods of contraception. Effective methods of contraception include barrier methods (e.g., condoms, diaphragm), spermicidal jelly or foam, oral, depo provera, or injectable contraceptives, intrauterine devices, tubal ligation, and abstinence. Male patients with female partners who are of childbearing potential should also practice contraception.\nNegative urine or serum pregnancy test.\n\nExclusion Criteria:\n\nPatients with known allergy or hypersensitivity to quizartinib, mannitol, AZA, cytarabine or any of their components.\nSerum potassium < 3.5 mEq/L despite supplementation, or > 5.5 mEq/L.\nSerum magnesium above or below the institutional normal limit despite adequate management.\nSerum calcium (corrected for albumin levels) above or below institutional normal limit despite adequate management.\nPatients with known significant impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of quizartinib.\nPatients with any other known disease concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, cardiovascular disease including congestive heart failure, myocardial infarction within 6 months and poorly controlled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study. Patients with current active malignancies or any remission for < 6 months, except patients with carcinoma in situ or with non-melanoma skin cancer who may have active disease or be in remission for less than 6 months.\nPatients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis.\nPatients who have had any major surgical procedure within 14 days of day 1.\nPatients with known malignant disease of the central nervous system.\nImpaired cardiac function including any of the following: screening electrocardiography (ECG) with a corrected QT (QTc) > 450 msec. The QTc interval will be calculated by Fridericia's correction factor (QTcF) at screening and on day 5 prior to the first dose of AC220. The QTcF will be derived from the average QTcF in triplicate; if QTcF > 450 msec on day 5, AC220 will not be given; patients with congenital long QT syndrome; history or presence of sustained ventricular tachycardia requiring medical intervention; any history of clinically significant ventricular fibrillation or torsades de pointes; Known history of second or third degree heart block (may be eligible if the patient currently has a pacemaker); sustained heart rate of < 50/minute on pre-entry ECG; right bundle branch block + left anterior hemiblock (bifascicular block); patients with myocardial infarction or unstable angina within 6 months prior to starting study drug; congestive heart failure (CHF) New York (NY) Heart Association class III or IV. Atrial fibrillation documented within 2 weeks prior to first dose of study drug; patients who require treatment with concomitant drugs that prolong QT/QTc interval or strong CYP3A4 inhibitors or inducers with the exception of antibiotics, antifungals, and antivirals that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject.\nKnown family history of congenital long QT syndrome."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients in 1st or 2nd remission with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), who are eligible for stem cell transplant. Remission defined as no circulating blasts, < 5% blasts in the bone marrow, normalization of previously detected cytogenetic abnormalities, no extramedullary disease\n\nHigh risk myelodysplastic syndrome (MDS)\n\nIntermediate II and high risk by International Prognostic Scoring System (IPSS)\nIntermediate, high, or very high by World Health Organization (WHO) classification-based Prognostic Scoring System (WPSS)\nTransfusion dependent\nTherapy-related MDS or MDS evolved from previous hematological disorder (excepting myelofibrosis)\nPatients with chronic myelomonocytic leukemia (CMML) are allowed to be enrolled\nPatients with MDS that has evolved to AML must be in remission\nPatients must not be eligible for full ablative regimens by the attending physician\nPatients with AML or MDS arising from myeloproliferative neoplasm can be enrolled after principal investigator (PI) approval on case to case basis, depends on the spleen size and degree of bone marrow fibrosis\nPerformance status of >= 70% on the Karnofsky scale\nWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect she is pregnant while participating on the trial, she should inform her treating physician immediately\nBone marrow and peripheral blood studies must be available for confirmation of diagnosis; cytogenetics, flow cytometry, and molecular studies (such as Flt-3 status) will be obtained as per standard practice\nBone marrow aspirates/biopsies should be performed within 28 (+ 4 day window) days from registration to confirm disease remission status\nA pretreatment measured creatinine clearance (absolute value) of >= 60 mL/minute\nPatients must have a serum bilirubin =< 2.0 mg/dl\nPatients must have serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 2.5 times the institutional upper limit of normal\nEjection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%\nDiffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in 1 second (FEV1) > 45% predicted\nAvailability of a human leukocyte antigen (HLA) matched (6/6) sibling donor or 8/8 matched unrelated donor; Donors with mismatch at HLA-A, HLA-B, HLA-C, and HLA-DR will be reviewed by matched unrelated donor (MUD) committee and allowed if their mismatch with the recipient does not require additional GVHD prophylaxis (other than tacrolimus and sirolimus), donors with mismatch at HLA-DQ or HLA-DPB are eligible; donor evaluation according to City of Hope (COH) standard operating procedure (SOP)\nDonor stem cell source can be either peripheral blood or bone marrow\nAll patients must have a psychosocial evaluation prior to transplant as per COH SOP\nAll subjects must have the ability to understand and the willingness to sign a written informed consent\nALL or AML patients who received chemotherapy (induction or consolidation) can proceed to transplant once bone marrow cellularity is > 10 % with no evidence of leukemia\n\nExclusion Criteria:\n\nPatients who have received a prior autologous or allogeneic transplant are excluded\nPatients with significant hepatic dysfunction (not meeting liver function tests [LFT] eligibility criteria)\nPatients with MDS evolved into AML that is not in remission\nPatients with acute promyelocytic leukemia\nPatients with myeloproliferative neoplasms\nPatients with suspected or proven central nervous system (CNS) leukemia; (diagnostic lumbar puncture not required before enrollment)\nUncontrolled intercurrent illness including, but not limited to ongoing or active or poorly controlled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements\nPregnant and lactating women are excluded from this study\nPatients who do not agree to practice effective forms of contraception\nHuman immunodeficiency virus (HIV)-positive patients are excluded from this study\nPatients are excluded if they are hepatitis B surface antigen (sAg), hepatitis B (Hep B) core antibody (cAb), or hepatitis C (Hep C) positive. Patients with Hepatitis B cAB positive and Hepatitis B PCR negative are eligible if they started prophylactic treatment prior to registration to trial\nPatients who have received radiation therapy as part of their leukemia treatment may be ineligible and individual cases must be presented to the study principal investigator (PI) for determination of eligibility\nAny psychiatric, social or compliance issues that, in the treating physician's opinion, will interfere with completion of the transplant treatment and follow up\nMedical or psychiatric reasons which make the donor unlikely to tolerate or cooperate with filgrastim (G-CSF) therapy or leukapheresis or bone marrow harvest\nKnown allergies to clofarabine, melphalan, sirolimus or tacrolimus\nPatients with other active malignancies (besides AML, ALL, MDS) requiring treatment or where there is concern of progression are ineligible for this study; however, patients with previously treated skin cancer, early stage cervical or prostate cancer may be eligible if there is no evidence of residual disease\nCord blood as a donor source is not acceptable\nSubjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have a diagnosis of one of the following:\n\nMDS (Arm A): High-risk MDS defined as: >5% blasts in bone marrow and/or the following cytogenetic categories: presence of inv(3)/t(3q)/del(3q), -7/del(7q), complex cytogenetics (3 or more abnormalities)\nAML (Arm B): Relapsed/refractory/unable to tolerate conventional chemotherapy\nMDS or AML as above BUT with prior therapy with Azacitibine (Arm C): Patients who meet criteria for either Arm A or Arm B but have been treated or are currently treated with Azacitibine *Note: As of July 2018, only high risk MDS patients will be eligible as Arm B is closed. As of October 2017, those patients with MDS who have received prior treatment will now be enrolled in Arm A as Arm C is closed.\nPatients must be \u2265 18 years old\nPatients must have an ECOG performance status of <= 2 (see Attachment 1).\nPatients must have a life expectancy of at least 4 weeks.\nPatients must be able to consume oral medication.\nPatients must have completed any radiotherapy four weeks prior to study entry, 0-2 weeks for local palliative XRT (small port).\nPatients must have recovered from the toxic effects of any prior chemotherapy to < Grade 2 (except for alopecia).\nRequired initial laboratory values: Creatinine\u2264 2.0mg/dL; total or direct bilirubin \u2264 1.5mg/dL (if not due to the leukemia itself or known Gilbert's Syndrome);(as documented by treating physician) SGPT(ALT) \u2264 3xULN; glucose <200 mg/dL, negative pregnancy test for women of child-bearing potential.\nPatients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.\nPatients may have had a prior stem cell transplant (autologous or allogeneic), however they may not have active GvHD, nor be on any immunosuppression\n\nExclusion Criteria:\n\nPatients must not be receiving any chemotherapy agents (except Hydroxyurea)\n\nIntrathecal ARA-C and intrathecal methotrexate are permissible (as they are not systemic and only isolated to the central nervous system).\nPatients can not have received more than 3 prior lines of therapy for their hematologic malignancy. Patient may have previously had azacitidine or decitabine will be eligible to enroll on Arm A (MDS)\nPatients must not be receiving growth factors.\nPatients with a current second malignancy requiring systemic therapy, other than non-melanoma skin cancers, are not eligible. If a patient has had a prior second malignancy that is not currently requiring active treatment, the patient will be considered eligible.\nPatients with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.\n\nPatients may not take any of the following medications while on study, but will be considered eligible if medication is discontinued 72 hrs prior to first dose of Sirolimus:\n\nCarbamazepine (e.g. Tegretol)\nRifabutin (e.g. Mycobutin)\nRifampin (e.g. Rifadin)\nRifapentine (e.g. Priftin)\nSt. John's Wort- may decrease effects of sirolimus by decreasing the amount of sirolimus in the body\nClarithromycin (e.g. Biaxin)\nCyclosporin e.g. (Neoral or Sandimmune)\nDiltiazem (e.g. Cardizem)\nErythromycin (e.g. Akne-Mycin, Ery-Tab)\nItraconazole (e.g. Sporanox)\nFluconazole (e.g. Diflucan)\nKetoconazole (e.g. Nizoral)\nTelithromycin (e.g. Ketek)\nVerapamil (e.g. Calan SR, Isoptin, Verelan)\nVoriconazole (e.g. VFEND) - May increase the effects of sirolimus by increasing the amount of this medicine in the body. Can take 72 hours after last dose of Sirolimus\nTacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side effects in patients on sirolimus.\nPatients with known HIV positivity or AIDS-related illness are not eligible.\nPatients with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible.\nPatients must not have received any investigational agents within 21days of study entry.\nPatients must not be pregnant or breastfeeding. Pregnancy tests must be obtained for all females of child-bearing potential. Pregnant or lactating patients are ineligible for this study due to the unknown human fetal or teratogenic toxicities of rapamycin. Males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method.\nPatients who have uncontrolled infection are not eligible. Patients must have any active infections under control. Fungal disease must be stable for at least 2 weeks before study entry. Patients with bacteremia must have documented negative blood cultures prior to study entry."
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have histologically or cytologically confirmed acute myeloid leukemia (AML) by World Health Organization (WHO) criteria in the blood and/or marrow AND age >= 60 and not candidates/refuse standard induction treatment OR who have one of the following: poor risk cytogenetics, AML following antecedent hematologic disorder, or therapy-related AML\nPatients with relapsed or refractory AML age >= 18 years are also eligible for treatment; patients may have been treated for antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, 5-azacitidine or the 5 day schedule of decitabine; patients who have received the 10 day schedule of decitabine for treatment an antecedent hematologic disorder or AML are not eligible\nIf the patient has co-morbid medical illness, life expectancy attributed to this must be greater than 6 months\nEastern Cooperative Oncology Group (ECOG) performance status =< 2\nTotal bilirubin < 2.0 mg/dL\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transferase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transferase [SGPT]) < 2.5 X institutional upper limit of normal\nCreatinine < 2.0 mg/dL or creatinine clearance (CrCl) >= 60 mL/min\nProthrombin time (PT)/international normalized ratio (INR) monitoring, < 1.5 x institutional upper limits of normal\nBoth women and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; if the patient does not agree, the patient is not eligible\nAbility to understand and willingness to sign the written informed consent document\n\nExclusion Criteria:\n\nPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; hydroxyurea may be administered for count control both pre-treatment and during cycle 1 only\nPatients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment\nPatients with active central nervous system disease or with granulocytic sarcoma as sole site of disease\nPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib, bortezomib or decitabine that are not easily managed\nUncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; as infection is a common feature of AML, patients with active infection are permitted to enroll provided that the infection is under control; myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, uncontrolled hypertension, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities\nPatients with serious medical or psychiatric illness likely to interfere with participation in this clinical study\nPatients with pre-existing grade 2 or higher neuropathy or other serious neurologic toxicity that would significantly increase risk of complications from bortezomib therapy are excluded\nPatients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligible\nPatients with advanced malignant solid tumors are excluded\nPatients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib\nPatients who are taking concomitant medications that in the investigator's opinion are strong inducers of the cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) enzymes and therefore likely to interact with the study agents, will not be eligible"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses:\n\nAcute lymphocytic leukemia in first or subsequent remission\nAcute myeloid leukemia in first or subsequent remission\nAcute lymphocytic leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3\nAcute myeloid leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3\nRefractory anemia with excess blasts (RAEB-1 and RAEB-2)\nChronic myelogenous leukemia with a history of accelerated phase or blast crisis\nOther acute leukemia (including but not limited to 'biphenotypic', 'undifferentiated' or 'ambiguous lineage' acute leukemia)\nPatient with a human leukocyte antigen (HLA)-identical (HLA-A, B, C, and ribonucleic acid [RNA] binding motif protein 45 [DRB1] molecularly matched) unrelated donor or related donor capable of donating PBSC\nDONOR: HLA-matched unrelated donors (HLA-A, B, C, and DRB1 matched based on high-resolution typing) capable and willing to donate PBSC\nDONOR: HLA-matched related donors >= 18 years and capable and willing to donate PBSC\n\nExclusion Criteria:\n\nPatients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation\nPatients on other experimental protocols for prevention of acute GVHD\nPatients who weigh >= 70 kg must be discussed with the principal investigator prior to enrolling on the protocol\nPatients who are human immunodeficiency virus positive (HIV+)\nPatients with uncontrolled infections for whom myeloablative hematopoietic stem cell transplant (HCT) is considered contraindicated by the consulting infectious disease physician (upper respiratory tract viral infection does not constitute an uncontrolled infection in this context)\nCreatinine > 1.5 mg/dl\nCardiac ejection fraction < 45%\nPatients who can perform pulmonary function tests will be excluded if they have a diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) of < 60% predicted; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the oxygen (O2) saturation is < 92% on room air\nPatients who have liver function test (LFTs) (including total bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) >= twice the upper limit of normal should be evaluated by a gastrointestinal (GI) physician unless there is a clear precipitating factor (such as an azole, methotrexate, Bactrim or another drug); if the GI physician considers that HCT on protocol 2660 is contraindicated for that patient the patient will be excluded from the protocol; patients with Gilbert's syndrome and no other known liver function abnormality and patients with reversible drug-related transaminitis do not necessarily require GI consultation and may be included on the protocol\nPatients with a life expectancy < 3 months from co-existing disease other than the leukemia or RAEB\nPatients who are pregnant or breast-feeding\nFertile patients of child bearing age unwilling to use contraception during and for 12 months post-transplant\nPatients with a significant other medical conditions that would make them unsuitable for transplant\nPatients with a known hypersensitivity to tacrolimus\nDONOR: Donors who are HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection\nDONOR: Donors who fail eligibility requirements for donation of cells or tissue per section 21 Code of Federal Regulations (CFR) 1271 for donation of a HCT/product (P) will be excluded unless use of the cells complies with 21 CFR 1271.65(b)(iii) (urgent medical need) or with 21 CFR 1271.65(b)(i) (allogeneic use in a first-degree or second-degree relative)\nDONOR: Unrelated donors donating outside of the United States of America (USA) or Germany"
            },
            {
                  "document": "Inclusion Criteria:\n\nAcute myeloid leukemia who fail to achieve complete remission with one course of induction chemotherapy or after relapse; patients must have less than 20% bone marrow or peripheral blood blasts\n\nAcute myeloid leukemia in first remission with any of the following high risk features defined as:\n\nAdverse cytogenetics: -5, deletion (del) 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype (> 3 abnormalities)\nPreceding myelodysplastic or myeloproliferative syndrome\nPresence of high risk molecular abnormalities including FLT3 mutations, DNMT3A, TET2; ras; kit\nFrench-American-British (FAB) monosomy (M)6 or M7 classification\nTreatment related acute myeloid leukemia (AML)\nResidual cytogenetic or molecular abnormalities\nMyelodysplastic syndromes with intermediate, high or very high risk Revised International Prognostic Scoring System (R-IPSS) score, chronic myelomonocytic leukemia (CMML) or therapy related myelodysplastic syndromes (MDS)\n\nChronic myeloid leukemia (CML) which:\n\nFailed to achieve a cytogenetic remission to tyrosine kinase inhibitor treatment or has a cytogenetic relapse\nHas ever been in accelerated phase or blast crisis\nPatient must have an identified HLA (A,B,C,DR) compatible related or unrelated donor who is age 16 years of age or older and weighs at least 110 pounds for the stem cell donation\nZubrod performance status 0 to 2 or Karnofsky of at least 60\nLeft ventricular ejection fraction >= 45%; no uncontrolled arrhythmias or uncontrolled symptomatic cardiac disease\nForced expiratory volume in one second (FEV1) >= 50% of expected, corrected for hemoglobin\nForced vital capacity (FVC) >= 50% of expected, corrected for hemoglobin\nDiffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of expected, corrected for hemoglobin\nBilirubin =< 1.5 mg/dl (unless Gilbert's syndrome)\nSerum glutamate pyruvate transaminase (SGPT) =< 200 IU/ml unless related to patient malignancy\nHepatitis B surface antigen negative and hepatitis C antibody negative\nNo evidence of chronic active hepatitis or cirrhosis\nPatients with a history of hepatitis C, but have a negative viral load, are eligible\nThe protocol chairman will determine the eligibility of patients related to hepatic abnormalities\nSerum creatinine < 1.5 mg%\nPatient or patient's legal representative, parent(s) or guardian able to sign informed consent; patients aged 7 to < 18 to provide assent\nPediatric patients (age 7-18 years) will be entered only after 3 adult patients have been entered without dose limiting toxicity\n\nExclusion Criteria:\n\nUncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy; the protocol principal investigator (PI) is the final arbiter of eligibility\nPleural/pericardial effusion or ascites > 1 L\nPatients who are known to be human immunodeficiency virus (HIV)-seropositive\nPregnancy: positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization\nWomen of child bearing potential not willing to use an effective contraceptive measure while on study\nPatients who are known to have allergy to mouse proteins"
            },
            {
                  "document": "Inclusion Criteria:\n\nAML, CMML-with excess blasts, MDS-RAEB not in remission prior to leukemia cell harvest\nHLA 8/8 or 7/8 matched related or unrelated donor available\nECOG performance status of 0-2\nSuitable candidate for myeloablative or reduced intensity conditioning allogeneic HSCT using PBSC or marrow as stem cell resource\nNormal organ function\n\nExclusion Criteria:\n\nPregnant or breastfeeding\nLeukemia with active CNS involvement\nPositive HIV or HTLV-1 serology\nHistory of allergic reactions to compounds of similar chemical or biologic composition to GM-CSF\nUncontrolled intercurrent illness\nHistory of different malignancy except if disease free for at least two years or cervical cancer in situ, basal or squamous cell carcinoma of the skin diagnosed and treated within the past two years\nPrior allogeneic transplant"
            },
            {
                  "document": "Inclusion Criteria:\n\nAny patient with a high-risk hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. High risk is defined as:\n\nAcute myeloid leukemia with high risk features as defined by:\n\nAge greater than or equal to 60\nSecondary AML (prior therapy or hematologic malignancy)\nNormal cytogenetics but FLT3/ITD positive\nAny relapse or primary refractory disease\nGreater than 3 cytogenetic abnormalities or any one of the following cytogenetic abnormalities: -5/del(5q), -7/del(7q), Abn(9q),(11q),(3q),(21q),(17p),t(6;9), t(6;11), t(11;19), +8,del(12p),inv(3),t(10;11),-17, 11q 23\nAny single autosomal monosomy\nAcute lymphoid leukemia in 1st or 2nd morphological remission. ALL with any morphological evidence of disease will not be eligible.\nMyelodysplasia (MDS) other than refractory anemia (RA), refractory anemia with rare sideroblasts (RARS), or isolated 5q- syndrome subtypes.\nHodgkin's or Non-Hodgkin's lymphoma in 2nd or greater remission or with persistent disease.\nMyeloma with evidence of persistent disease after front-line therapy.\nChronic myeloid leukemia (CML) resistant to signal transducer inhibitor (STI) therapy\nMyelofibrosis and CMML\nEssential Thrombocytopenia or Polycythemia Vera with current or past evidence of evolution to acute leukemia\nAny hematological malignancy not cited above which is thought to be high-risk with increased chance of post HSCT relapse. Patients in this category require specific approval of the PI and the TJU BMT attending physician group for entrance.\nAny hematological malignancy or dyscrasia not cited above which is thought to be high-risk with increased chance of post HSCT relapse.\nAny patient who has an aggressive disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history. Examples are patients with previous treatment with radiation therapy precluding TBI, or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen.\nPatients with aplastic anemia may be treated on this protocol, with outcomes reported descriptively.\nPatients must have a related donor who is at least a 4 antigen match at the Human Leukocyte Antigen (HLA)-A; B; C; DR loci. Patients with only a 1 out of 8 mismatch in the GVH direction will be classified in the matched related category\n\nPatients must adequate organ function:\n\nLeft ventricular end diastolic function (LVEF) of >50%\nDiffusion Lung Capacity of Oxygen (DLCO) >50% of predicted corrected for hemoglobin\nAdequate liver function as defined by a serum bilirubin <1.8, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5X upper limit of normal\nCreatinine Clearance of \u2265 60 mL/min 4) Patients must have adequate KPS and HCT-CI scores:\nPatients < age 60 years must have a KPS of \u226580% and an HCT-CI score of 5 or less\nPatients aged 60 to 65 years must have a KPS of \u226580% and an HCT-CI score of 4 or less\nPatients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less\nPatients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less (Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the PI and at least 1 Co-I not on the primary care team of the patient). This is an adjustment to account for healthy patients who meet the spirit of the protocol but have histories that result in higher than guideline HCT-CI points. An examples is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities 5) Patients must be willing to use contraception if they have childbearing potential 6) Patient or patient's guardian is able to give informed consent\n\nExclusion Criteria:\n\nHIV positive\nActive involvement of the central nervous system with malignancy\nPregnancy\nPatients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder\nPatients who have received alemtuzumab or ATG within 8 weeks of the transplant admission.\nPatients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol"
            },
            {
                  "document": "Recipient Inclusion Criteria\n\nPatients with the following diseases that are histopathologically confirmed are eligible\n\nAcute leukemia, primary refractory or beyond CR1, or minimal residual disease (MRD) positivity.\nHigh risk acute myeloid leukemia in CR1 with any of the following features:\nComplex karyotype(\u22653 clonal chromosomal abnormalities)\n\nAny of the following high risk chromosomal abnormalities:\n\nMonosomal karyotype (-5, 5q-, -7, 7q-)\nt(11q23), t(9;11), inv(3), t(3;3) t(6;9) t(9;22)\nNormal karyotype with fms-like tyrosine kinase 3 (FLT3)-ITD mutation\nOther high risk features as determined by molecular studies, or clinical presentation as assessed by the treating physician\nChronic myelogenous leukemia (accelerated, blast or second chronic phase)\nMyelodysplastic syndromes\nMyeloproliferative syndromes\nNon-Hodgkin lymphoma with poor risk features not suitable for autologous HCT\nAge \u226518 yo and \u2264 60 yo for patients in Cohort 1 only. At the start of Cohort 2A and beyond, eligibility will be expanded to allow pediatric patients age \u2265 13 yo.\nCardiac ejection fraction \u2265 45%\nLung diffusion capacity \u2265 50%\nCalculated creatinine clearance \u2265 50 cc/min\nSerum glutamic-pyruvic transaminase( SGPT) and serum glutamic-oxaloacetic transaminase (SGOT) \u2264 3.0 x ULN (Upper limit of normal), unless elevated secondary to disease.\nTotal bilirubin \u2264 2 x ULN (patients with Gilbert's syndrome may be included at the discretion of the PI or where hemolysis has been excluded\nAvailability of a HLA matched donor (related or unrelated) defined by Class I (HLA-A and B) serologic typing (or higher resolution) and Class II (HLA DRB1) molecular typing. An HLA matched donor is defined for this study to be a sibling that is HLA matched 6/6; or an unrelated donor that is HLA matched 6/6 or 5/6. A sibling may be a \"half sibling.\"\nKarnofsky performance status \u226570%\n\nRecipient Exclusion Criteria\n\nSeropositive for any of the following:\n\nHIV ab; hepatitis B sAg; hepatitis C ab\n\nPrior myeloablative therapy or hematopoietic cell transplant\nCandidate for autologous transplant\nHIV positive\nActive uncontrolled bacterial, viral or fungal infection, defined as currently taking antimicrobial therapy and progression of clinical symptoms.\nUncontrolled central nervous system (CNS) disease involvement\nPregnant or a lactating female\nPositive serum or urine beta human chorionic gonadotropin (HCG) test in females of childbearing potential within 3 weeks of registration\nPsychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow up care\n\nDonor Inclusion Criteria\n\nAge \u226513 yo and \u2264 75 years\nKarnofsky performance status of \u2265 70% defined by institutional standards\n\nSeronegative for HIV 1 RNA (polymerase chair reaction (PCR); HIV 1 and HIV 2 ab (antibody); HTLV 1 and HTLV 2 ab; PCR+ or sAg (surface antigen) hepatitis B ; or PCR+ or sAg for hepatitis C; negative for the Treponema pallidum antibody Syphilis screen; and negative for HIV 1 and hepatitis C by nucleic acid testing (NAT) within 30 days of apheresis collection. In the case that T pallidum antibody tests are positive, donors must:\n\nBe evaluated and show no evidence of syphilis infection of any stage by physical exam and history\nHave completed effective antibiotic therapy to treat syphilis\nHave a documented negative non treponemal test (such as RPR) or in the case of a positive non treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease\nMust be 6/6 matched sibling donor as determined by HLA typing\nFemale donors of child-bearing potential must have a negative serum or urine beta-HCG test within three weeks of mobilization\nCapable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate\nAgreeable to 2nd donation of Peripheral blood stem cell (PBPC) (or bone marrow harvest) in the event of graft failure\nThe donor or legal guardian greater than 18 years of age, capable of signing an institutional review board (IRB-approved consent form.\n\nDonor Exclusion Criteria\n\nEvidence of active infection or viral hepatitis\nHIV positive\nMedical, physical, or psychological reason that would place the donor at increased risk for complications from growth factor or leukapheresis\nLactating female"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must express HLA-A*0201\n\nPatients who are currently undergoing or who previously underwent matched allogeneic HCT for:\n\nAML: Prospective enrollment will now be limited to patients with relapsed disease (overt relapse or minimal residual disease) at any time post allogeneic HCT\nMDS will no longer be a criterion for eligibility\nCML will no longer be a criterion for eligibility\nPatients must have an HLA-matched donor of hematopoietic stem cells (related or unrelated)\nPatients must be able to provide blood and bone marrow samples and undergo the procedures required for this protocol\nPatients must be >= 15 kg, as patients with lower weight would be incapable of providing high volume and frequent blood samples for monitoring and analysis\nPatients must be able to give informed consent; parent or legal representative will be asked to consent for patients younger than 18 year old\nDONOR: Patient and donor (related or unrelated) must be HLA-matched and express HLA-A*0201\nDONOR: Donor must be Epstein-Barr virus (EBV) or cytomegalovirus (CMV) seropositive\nDONOR: Donor must be age 18 or older\nDONOR: In good general health\nDONOR: Able to give informed consent\n\nExclusion Criteria:\n\nCentral nervous system (CNS) tumor refractory to intrathecal chemotherapy and/or cranio-spinal radiation\nIn patients whose leukemic cells are available for evaluation, the expression of WT1 in the patient's bone marrow will be determined; if WT1 expression in the patient's bone marrow is not highly expressed by polymerase chain reaction (PCR), the patient will be excluded from the study; patients with no evaluable leukemia will be eligible for enrollment based on the high frequency of positive leukemias (> 90%), and leukemia will be evaluated for WT1 expression if recurrence is detected\nHuman immunodeficiency virus (HIV) seropositive; testing for HIV should be within 6 months of enrollment\nMedical or psychological conditions that would make the patient unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)\nPregnancy or breast-feeding; women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test result within 14 days before the first dose of WT1-specific T cell infusion; woman of non-childbearing potential will be defined as being postmenopausal greater than one year or who have had a bilateral tubal ligation or hysterectomy; all recipients of WT1-specific T cells will be counseled to use effective birth control during participation in this study and for 12 months after the last T cell infusion\nDONOR: Less than 18 years old\nDONOR: Active infectious hepatitis\nDONOR: HIV or human T-lymphotropic virus (HTLV) seropositive\nDONOR: Pregnancy or nursing\nDONOR: Significant medical conditions (e.g. immunosuppressive therapy) that would make the donor an unsuitable T cell donor\nDONOR: Unable to give informed consent"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of acute myeloid leukemia (AML) as defined by the World Health Organization\n\nMolecular AML-risk group is less-than-favorable as defined by any of the following criteria:\n\nThe absence of good-risk karyotype t(8;21), inv(16), t(16;16), or t(15;17)identified by metaphase karyotype\nThe absence of t(8;21), inv(16), t(16;16), or t(15;17) identified by fluorescent in situ hybridization(FISH)\nThe absence of the corresponding fusion transcripts, AML1-eight-twenty-one corepressor (ETO), core-binding factor, beta subunit (CBF\u03b2)-smooth muscle myosin heavy chain (SMMHC), or progressive multifocal leukoencephalopathy (PML)-retinoic acid receptor alpha (RARa), identified by reverse transcriptase-polymerase chain reaction (RT-PCR)\nPatient does not have acute promyelocytic leukemia (APL, French-American-British [FAB] M3)\nEastern Cooperative Oncology Group (ECOG) performance status \u2264 2 (Karnofsky \u2265 60%)\n\nAdequate cardiac function as defined by either of the following:\n\nAn echocardiogram demonstrating an ejection fraction within normal limits\nA multi gated acquisition (MUGA) scan demonstrating an ejection fraction within normal limits\nAspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) \u2264 2.5 times institutional upper limit of normal (ULN)\nCreatinine \u2264 2 mg/dL OR creatinine clearance \u2265 50 mL/min\n\nTotal bilirubin \u2264 2 times ULN\n\nPatients with documented diagnosis of Gilbert syndrome resulting in elevated total bilirubin levels will be eligible, provided all other eligibility criteria are met\nPatients with a total bilirubin of 2-3 mg/dL and direct (conjugated) bilirubin in the normal range will be eligible, provided all other eligibility criteria are met\n\nPregnant and nursing subjects may not be enrolled and pregnancy must be avoided; women of child-bearing potential-defined as a sexually active woman who has not undergone hysterectomy and who has had menses any time within the preceding 24 months-must have a negative serum or urine pregnancy test within 7 days prior to registration; women and men of childbearing potential must either commit to continued abstinence from heterosexual intercourse or commit to two acceptable methods of birth control-one highly effective method (e.g., IUD, oral or non-oral hormonal contraceptive, tubal ligation or partner's vasectomy) and one additional effective method (e.g., latex condom, diaphragm or cervical cap) at the same time from the time of screening through final Treatment Response Assessment\n\nNOTE: should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the subject should inform their treating phy-sician immediately\nNOTE: the effects of decitabine on the developing human fetus are unknown but it is a know teratogen in mammals (mice)\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nChemotherapy (other than hydroxyurea) or radiation within the 2 weeks prior to planned therapy on this study or ongoing adverse events due to agents administered more than 2 weeks earlier\nConcurrent treatment with other investigational agents is not permitted\nCumulative lifetime dose of anthracycline chemotherapeutic > 80 mg/m^2\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition of decitabine, cytarabine or daunorubicin\n\nUncontrolled intercurrent illness considered by the investigator to constitute an unwarranted high risk for investigational drug treatment; examples include, but not limited to the following:\n\nUncontrolled serious infection; or\nUnstable angina pectoris; or\nUncontrolled cardiac arrhythmia; or\nActive second malignancy requiring treatment; or\nSymptomatic congestive heart failure\n\nHIV-positive subjects with a CD4 count < 200 cells/\u03bcL are excluded due to the increased risk of lethal infections when treated with marrow-suppressive chemotherapy(87)\n\nNOTE: subjects with HIV infection and a CD4 count >= 200 cells/\u03bcL are eligible but combination antiretroviral therapy should be held during administration of chemotherapy due to the potential for pharmacokinetic interactions with decita-bine, cytarabine or daunorubicin. Antiretroviral therapy may be resumed 24 hours after completion of the last dose of induction chemotherapy\nSubject has a psychiatric disorder, altered mental status or social situation that would preclude understanding of the informed consent process and/or limit compliance with study requirements\nSubject has an inability or unwillingness, in the opinion of the investigator, to comply with the protocol requirements\nSubjects with central nervous system (CNS) (or leptomeningeal) infiltration by AML may be considered for treatment at the Investigator's discretion and following discussion with the Principle Investigator; all neurologic deficits must be noted prior to enrollment on study\nSubject has circulating blast count > 50,000/\u03bcL (subjects may be enrolled if circulating blast count is controlled by hydroxyurea and/or, if clinically indicated, by leukophoresis)"
            },
            {
                  "document": "Inclusion Criteria:\n\nHLA A*0201 subtype\nCMV seropositive\nAble and willing to sign the informed consent form (ICF)\nWillingness to be followed for the planned duration of the trial (6 months post-HCT)\nSeronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative)\nPlanned related or unrelated HCT, with 8/8 or 7/8 (A, B, C, DRB1) high resolution HLA donor allele matching\n\nHCT for the treatment of hematologic cancers including, but not limited to:\n\nAcute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status needs to be in hematologic remission by bone marrow/peripheral blood; persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography [PET] scan without progression is allowed)\nChronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase\nHodgkin and non-Hodgkin lymphoma\nMyelodysplastic syndrome\nPlanned HCT with minimal to no-T cell depletion of graft\nUse of contraception up to 90 days post-HCT\nNegative pregnancy test for female recipient\nDISEASE STATUS: Recipients to be enrolled are patients eligible for allogeneic HCT, who were diagnosed with hematologic cancers including:\nAcute lymphoblastic leukemia (ALL); B-precursor ALL; T cell ALL\nAcute myeloid leukemia (AML), acute promyelocytic leukemia; treatment related AML\nChronic lymphoid leukemia; adult T cell leukemia/lymphoma, chronic lymphocytic leukemia not otherwise specified (NOS), hairy cell leukemia; prolymphocytic leukemia (B or T); T cell large granular (gran.) lymphocytic (lymph.) leukemia (leuk)\nChronic myeloproliferative disease (CML); chronic eosinophilic leukemia (CEL)/hypereosinophilic syndrome; chronic idiopathic myelofibrosis; CML - Philadelphia chromosome; essential thrombocythemia; polycythemia vera\nLeukemia, not otherwise specified (NOS)\nMyelodysplastic syndrome, NOS; chronic myelomonocytic leukemia\nHodgkin lymphoma, NOS; Hodgkin lymphoma nodular lymphocyte predominant (LP), NOS; Hodgkin lymphoma - like post-transplant lymphoproliferative disorder (PTLD)\nLymphoma, NOS\nNon-Hodgkin lymphoma (NHL); anaplastic large-cell lymphoma (ALCL), cutaneous, ALCL, systemic; Burkitt lymphoma/leukemia; cutaneous T-cell lymphoma (CTCL)/mycosis fungoides; CTCL/Sezary syndrome; diffuse large B-cell lymphoma; mucosa associated lymphoid tissue (MALT)-lymphoma; extranodal natural killer (NK)/T cell lymphoma, extranodal NK/T lymphoma nasal; follicular lymphoma; lymphoplasmacytic lymphoma mantle cell lymphoma; mediastinal large B-cell lymphoma; nodal marginal zone B-cell lymphoma (lymph.); NHL aggressive, NOS; NHL indolent, NOS; NHL, NOS; peripheral T cell lymphoma, NOS; PTLD (monoclonal); PTLD (polyclonal); precursor (precur.) B-lymphoblastic lymphoma; precur T-lymphoblastic lymphoma; primary central nervous system (CNS) lymphoma; primary effusion lymphoma; small lymphocytic lymphoma, NOS\nMyeloma, NOS; monoclonal gammopathy of undetermined significance (MGUS); solitary plasmacytoma\nWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\nAll medications, supportive care, blood products or radiation therapy taken or administered during the trial will be documented in the subject's clinical/hospital and case report form (CRF), using City of Hope (COH) guidelines; the subject's clinical information will be recorded on the appropriate CRF\nConcurrent enrollment in other clinical trials using an investigational product is prohibited\nThe use of alemtuzumab for immunosuppression is not permitted in this study\nProphylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment is not allowed\n\nMedications that might interfere with the evaluation of the investigational product should not be administered, from 30 days prior to participation on the trial and up to 14 days after the second vaccination (day 70 post-HCT); medications in this category include, but are not limited to:\n\nLive attenuated vaccines\nMedically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections)\nAntiviral treatment for herpes simplex virus (HSV), human herpes virus 6 (HHV6), Epstein-Barr virus (EBV) and adenovirus including the use of GVC/VAL, FOS, Cidofovir, CMX-001 may also suppress reactivation of CMV, thus it will not be allowed in this study; patients requiring such treatment before randomization (day 28) will be removed from the study and replaced; reasons for removal will be reported in the patient's CRF\nAll enrolled recipients who will require anti-CMV therapy before day 28 will be replaced, treated and monitored as required by COH standard of care; GVC/VAL, FOS, Cidofovir, CMX-001 may be used according to COH standard of care (SOC) for preemptive management of CMV viremia; should antiviral treatment be required after day 28, the planned 2nd vaccine injection at day 56 will not be administered (vaccine arm only)\nAll subjects must have the ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\nA poor-risk patient, as defined by any of the following:\n\nChronic myelogenous leukemia in blast crisis\nAcute myeloid leukemia beyond second remission\nMultiple myeloma\nAplastic anemia\nPlanned immunosuppression with alemtuzumab or any equivalent in vivo T-cell depleting agent\nIn vitro T cell depleted graft\nPlanned prophylactic therapy with CMV immunoglobulin\nPlanned CMV prophylactic therapy\nExperimental anti-CMV chemotherapy in the last 6 months\nDiagnosed with autoimmune disease\n\nReceipt of the following substances:\n\nAny prior investigational CMV vaccine\nLive attenuated vaccines, medically indicated subunit or killed vaccines from 30 days prior to participation in the trial and up to 14 days after the second vaccination (day 70 post-HCT)\nInvestigational research products or allergy treatment with antigens injections from 30 days prior to participation in the trial and up to 14 days after the second vaccination (day 70 post-HCT)\nPregnant and/or breast feeding if a female recipient\nRefusing to use contraception up to 90 days post-HCT\nPOST-HCT STUDY-SPECIFIC EXCLUSIONS:\n\nOn days 28 and 56 post-HCT (immunization day for the vaccine arm) all study recipients (vaccine and observation arms) will be reviewed for eligibility and ruled ineligible to initiate or continue in the study and receive vaccination (for the vaccine arm) if:\n\nDiagnosed with > grade 2 graft-versus-host disease (GVHD) before day 28 post-HCT, and diagnosed with > grade 2 GVHD between day 28 post-HCT and administration of the 2nd vaccine at day 56\nReceived steroid therapy with prednisone > 1 mg/kg/day, less than 7 days prior to injection\nHad relapse\nExperience graft failure (absolute neutrophil count < 500/mm^3)\nReceived antiviral treatment with GVC/VAL, FOS, Cidofovir, CMX-001 at any point during the 28 day period\nThere are ongoing non-hematological post-HCT toxicities >= grade 3 non-hematological (hem) adverse events (AE's), with exception of grade 3 glucose intolerance and grade 3 non-hem labs; cholesterol, triglyceride, and hyperglycemia"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with high-risk hematologic malignancies with anticipated poor prognosis with non transplant therapy, including those in remission or with induction failure and after treated or untreated relapse. Diagnoses to be included a) Acute myeloid leukemia; b) Acute lymphocytic leukemia; c) Chronic myeloid leukemia; d) Chronic lymphocytic leukemia; e) Myelodysplastic syndrome; f) Myeloproliferative syndromes; g) Non-Hodgkins lymphoma; h) Hodgkins Lymphoma; i) Multiple myeloma.\nPatients must have a histocompatible stem cell donor. An HLA-identical related donor or a 8/8 matched unrelated donor.\nAge 5 to 75 years old.\nPerformance score of >/= 70 by Karnofsky/Lansky or PS 0 to 1 (ECOG </=1).\nLeft ventricular ejection fraction at least 40%.\nAdequate pulmonary function with FEV1, FVC and DLCO >/=50% of expected corrected for hemoglobin and/or volume. Children unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of >/= 92% on room air\nCreatinine clearance (calculated creatinine clearance is permitted) should be >40 ml/min.\nBilirubin </= 2 x the upper limit of normal (except Gilbert's Syndrome). SGPT (ALT) < 200.\nNegative Beta HCG test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.\nPatient or patient's legal representative, parent(s) or guardian able to sign informed consent.\n\nExclusion Criteria:\n\nHIV seropositivity.\nUncontrolled infections."
            },
            {
                  "document": "Inclusion Criteria:\n\nInclusion Criteria at Time of Procurement:\n\nLack of a suitable conventional donor (i.e. 5/6 or 6/6 related, or 5/6 or 6/6 unrelated donor), or presence of a rapidly progressive disease not permitting time to identify an unrelated donor.\n\nHigh risk disease in one of the following:\n\nMyelodysplastic syndrome (MDS) in one of the following categories: RCMD with an IPSS-R of intermediate, poor, or very poor, RAEB-1, or RAEB-2\nAcute myeloid leukemia (AML) after first relapse or primary refractory disease\nChronic myelogenous leukemia (CML) in Chronic Phase 2 or greater, Accelerated Phase or Blast Crisis\nAcute lymphoblastic leukemia (ALL) after first relapse or primary refractory disease, or High-Grade Non Hodgkin lymphoma (NHL) Stage III or IV after first relapse or primary refractory disease\nHemophagocytic lymphohistiocytosis (HLH)\nFamilial hemophagocytic lymphohistiocytosis (FLH)\nViral-associated hemophagocytic syndrome (VAHS)\nT or NK cell lymphoproliferative syndrome\nX-linked lymphoproliferative disease (XLP)\n\nInclusion Criteria at Time of T Cell Infusion:\n\nEngrafted with an absolute neutrophil count (ANC) > 500 cells/\u00b5L\nGreater than or equal to 50% donor chimerism in either peripheral blood or bone marrow, or relapse of their original disease\nLife expectancy > 30 days\nLansky/Karnofsky score greater than or equal to 60\nAbsence of severe renal disease (creatinine > 2X upper limit of normal for age)\nAbsence of severe hepatic disease (direct bilirubin > 3X upper limit of normal or SGOT > 3X upper limit of normal)\nOxygen saturation > 94% on room air\nPatient/Guardian able to give informed consent\nAP1903 available in sufficient quantities to allow for treatment of the patient\n\nExclusion Criteria:\n\nExclusion Criteria at Time of T Cell Infusion:\n\nGvHD\nSevere intercurrent infection\nPregnancy*\n\nOther investigational drugs in the prior 30 days\n\nPregnancy test only required for at-risk individuals, defined as female patients of childbearing potential who have received a reduced-intensity conditioning regimen."
            },
            {
                  "document": "Inclusion Criteria:\n\nAny patient with hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. Patients treated on this protocol will be without morphological evidence of disease (complete remission or \"CR\"), or if the patient has evidence of disease, the patient must have had at least a good partial response (PR) to the most recent therapy and the disease must be chemoresponsive.\n\nPatients treated on this study will have:\n\nAcute leukemia in 1st or 2nd CR\nMDS (myelodysplastic syndrome), specific subtypes of RA (refractory anemia) or RARS (refractory anemia with ringed sideroblasts) subtypes.\nHodgkin or Indolent Non-Hodgkin's lymphoma with chemosensitive disease\nMyeloma without morphological evidence of disease, or a deep PR to the most recent therapy\nMyeloproliferative disorders with at least a PR to current therapy\nAplastic Anemia\nA hematological or oncological disease (not listed) that meets the criteria reviewed above (in CR or with a good PR).\nPatients must have a related donor who is HLA mismatched at 2, 3, or 4 antigens at the HLA-A; B; C; DR loci in the GVHD direction. (Patients with related donors who are HLA identical or are a 1-antigen mismatch may be treated on this therapeutic approach, but will have their outcomes will not be part of the statistical aims of the study (see Summary section).\n\nPatients must adequate organ function:\n\nLVEF (Left ventricular end diastolic function) of >50%\nDLCO (Diffusing Capacity of the Lung for Carbon Monoxide ) \u226550% of predicted corrected for hemoglobin\nAdequate liver function as defined by a serum bilirubin <1.8, AST or ALT < 2.5X upper limit of normal\nCreatinine Clearance of \u2265 60 mL/min\nPerformance status \u2265 80% (TJU Karnofsky) for patients \u2265 60 years old or \u226570% for patients < 60 years old.\nHCT-CI Score \u2264 4 points for patients \u2265 60 years old or \u2264 5 points for patients < 60 years old.\nPatients must be willing to use contraception if they have childbearing potential\nAble to give informed consent\n\nExclusion Criteria:\n\nPerformance status < 80% (TJU Karnofsky) for patients \u2265 60 years old or <70% for patients < 60.\nHematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score > 4 points for patients \u2265 60 years old or > 5 points for patients < 60.\nHIV positive\nActive involvement of the central nervous system with malignancy\nInability to obtain informed consent\nPregnancy\nPatients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder\nPatients who have received alemtuzumab within 8 weeks of the transplant admission, or who have recently received horse or rabbit anti-thymocyte globulin and have an anti-thymocyte globulin level of > 2 ugm/ml\nPatients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must be newly diagnosed with de novo acute myelogenous leukemia\n\nPatients with previously untreated primary AML who meet the customary criteria for AML with >= 20% bone marrow blasts as set out in the 2008 World Health Organization (WHO) Myeloid Neoplasm Classification are eligible\n\nAttempts to obtain bone marrow either by aspirate or biopsy must be made unless clinically prohibitive; in cases where it is clinically prohibitive, peripheral blood with an excess of 20% blasts and in which adequate flow cytometric and cytogenetics/fluorescent in situ hybridization (FISH) testing is feasible can be substituted for the marrow exam at diagnosis\n\nPatients with < 20% bone marrow blasts are eligible if they have:\n\nA karyotypic abnormality characteristic of de novo AML (t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22) or 11q23 abnormalities\nThe unequivocal presence of megakaryoblasts, or\nBiopsy proven isolated myeloid sarcoma (myeloblastoma; chloroma, including leukemia cutis)\nPatients with any performance status are eligible for enrollment\nPrior therapy with hydroxyurea, all-trans retinoic acid (ATRA), corticosteroids (any route), and IT cytarabine given at diagnosis is allowed; hydroxyurea and ATRA must be discontinued prior to initiation of protocol therapy; patients who have previously received any other chemotherapy, radiation therapy or any other antileukemic therapy are not eligible for this protocol\n\nExclusion Criteria:\n\nPatients with any of the following constitutional conditions are not eligible:\n\nFanconi anemia\nShwachman syndrome\nAny other known bone marrow failure syndrome\nPatients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 Note: enrollment may occur pending results of clinically indicated studies to exclude these conditions\n\nPatients with any of the following oncologic diagnoses are not eligible:\n\nAny concurrent malignancy\nJuvenile myelomonocytic leukemia (JMML)\nPhiladelphia chromosome positive AML\nBiphenotypic or bilineal acute leukemia\nAcute promyelocytic leukemia\nAcute myeloid leukemia arising from myelodysplasia\nTherapy-related myeloid neoplasms Note: enrollment may occur pending results of clinically indicated studies to exclude these conditions\nPregnancy and breast feeding\nFemale patients who are pregnant are ineligible\nLactating females are not eligible unless they have agreed not to breastfeed their infants\nFemale patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\nSexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation"
            },
            {
                  "document": "Inclusion Criteria:\n\nDocumentation of disease as assessed by the Alliance reference laboratory at the Ohio State University per Cancer and Leukemia Group B (CALGB) 20202, molecular diagnosis of core-binding factor (CBF) acute myeloid leukemia (AML) by reverse transcriptase polymerase chain reaction (RT-PCR) positive for RUNX1-RUNX1T1 fusion transcript resulting from t(8;21)(q22;q22) (or a variant form) or CBFB-MYH11 fusion transcript resulting from inv(16)(p13.1q22) or t(16;16)(p13.1;q22) (any % bone marrow or blood blasts render the diagnosis of CBF AML based on the World Health Organization [WHO] classification)\n\nNo prior chemotherapy for leukemia or myelodysplasia with the following exceptions:\n\nEmergency leukapheresis\nEmergency treatment for hyperleukocytosis with hydroxyurea,\nCranial radiotherapy (RT) for central nervous system (CNS) leukostasis (one dose only),\nGrowth factor/cytokine support/non-cytotoxic molecular-targeted agents\nAML patients with a history of antecedent myelodysplasia (MDS) remain eligible for treatment on this trial\nPatients who have developed therapy related myeloid neoplasm (t-MN) after prior radiation therapy or chemotherapy for another cancer or disorder are eligible\nLeft ventricular ejection fraction >= lower limit of institutional normal by multigated acquisition (MUGA) or echocardiogram (ECHO) scan\nPatients must not have had myocardial infarction within 6 months of registration\nPatients must not have had ventricular tachyarrhythmia within 6 months of registration\nPatients must have no major conduction abnormality (unless a cardiac pacemaker is present)\nBilirubin must not be < 2.5 times upper limit of normal\nPatients must be non-pregnant and non-nursing; pregnant or nursing patients may not be enrolled; women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration; women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control - one highly effective method (e.g., intrauterine device [IUD], hormonal, tubal ligation, or partner's vasectomy), and one additional effective method (e.g., latex condom, diaphragm, or cervical cap) - AT THE SAME TIME, before she begins dasatinib therapy, during treatment and at least 12 weeks after treatment is complete; \"Women of childbearing potential\" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months\nPatients with congenital long QT syndrome or non-congenital corrected QT (QTc) prolongation (defined as a QTc interval consistently equal to or greater than 480 msecs) that cannot be corrected by infusion of electrolytes and/or discontinuation of other medications prior to start of treatment are excluded"
            },
            {
                  "document": "Inclusion Criteria:\n\nMeets one of the following sets of criteria:\n\nMyelodysplastic syndromes (MDS):\n\nDisease with high-risk features (found either at diagnosis or before initiation of cytotoxic therapy), defined as one of the following:\n\nInternational prognostic scoring system (IPSS) risk >= intermediate-2\nRefractory anemia with excess blasts by French-American-British (FAB) classification\nHigh-risk cytogenetics (either complex or -7)\nLess than 10% bone marrow blasts as determined by bone marrow biopsy within the past 4 weeks (reduction in marrow blast percentage may be achieved with chemotherapy or other therapy)\nLess than 75 years old\n\nAcute myeloid leukemia (AML):\n\nNo FAB M3\nNo acute leukemia following blast transformation of prior chronic myelogenous leukemia or other myeloproliferative disease\nPatients with preceding MDS or treatment-related AML are eligible\nPrior central nervous system (CNS) involvement is allowed provided the disease is in remission at transplantation\n\nMorphologic complete remission (leukemia-free state) is defined as meeting all of the following criteria:\n\nBone marrow blasts < 5% (as determined by bone marrow within the past 4 weeks), but without requirement for normal peripheral blood counts\nNo extramedullary leukemia\nNo blasts in peripheral blood\n\nAchieved complete remission (CR) after no more than 2 courses of induction chemotherapy\n\nPatients treated with azacitidine or decitabine who achieve a leukemia-free state are eligible (may have required up to 4 courses of therapy to reach this status)\nAge 60 to 74 years\n\nDonors must meet the following criteria:\n\nOne of the following:\n\nHLA-identical sibling (6/6) by serologic typing for class (A, B) and low-resolution molecular typing for class II (DRB1)\nMatched unrelated donor (8/8) by high-resolution molecular typing at HLA-A, -B, -C, and DRB1\nNo syngeneic donors\nEastern Cooperative Oncology Group (ECOG) performance status 0-2\nCalculated creatinine clearance \u2265 40 mL/min\nBilirubin < 2 mg/dL OR bilirubin 2-3 mg/dL provided direct bilirubin is normal\nAspartate aminotransferase (AST) < 3 times upper limit of normal\nDiffusing capacity of the lung for carbon monoxide (DLCO) > 40% with no symptomatic pulmonary disease\nLeft ventricle ejection fraction (LVEF) >= 30% by echocardiogram (ECHO) or multigated acquisition (MUGA)\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nNo uncontrolled diabetes mellitus or active serious infections\nNo known hypersensitivity to E. coli-derived products, azacitidine, or mannitol\nNo human immunodeficiency virus (HIV) infection or active hepatitis B or C\n\nPrior azacitidine or decitabine allowed\n\nNo patients who progressed from MDS to AML during treatment with azacitidine or decitabine\nAt least 4 weeks since prior deoxyribonucleic acid (DNA)-hypomethylating chemotherapy, radiotherapy, and/or surgery\n\nNo more than 2 courses of consolidation therapy before transplantation (for patients with AML)\n\nAny consolidation regimen that does not require transplantation can be used\nNo more than 6 months from documentation of morphologic CR to transplantation"
            },
            {
                  "document": "Inclusion Criteria:\n\nHistologically or cytologically confirmed diagnosis of one of the following:\n\nRelapsed or refractory acute myeloid leukemia (AML); patients with acute promyelocytic leukemia t(15;17) must have failed tretinoin (ATRA), arsenic, and gemtuzumab ozogamycin to be eligible (patients should be refractory to all three agents-absence of durable hematologic response or relapse with complete remission [CR] duration of less than 6 months)\nRelapsed or refractory pre-B- or T-cell acute lymphoblastic leukemia (ALL); patients with Philadelphia chromosome-positive (Ph+) ALL [t(9;22)] will be eligible provided that they have failed (intolerance/resistance) at least 2 different tyrosine kinase inhibitors (TKIs) or have a mutation associated with resistance to TKIs (T315I)\nChronic myelogenous leukemia (CML) in accelerated or blastic phase; patients failed (resistance/intolerance) at least 2 different TKIs or have a mutation associated with resistance to TKIs (T315I)\nChronic myelomonocytic leukemia-2 (CMML-2) defined as having > 10% blasts (including promonocytes) in the bone marrow or > 5-19% blasts (including promonocytes) in the peripheral blood\nAML arising in the setting of antecedent myelodysplasia (MDS) or myeloproliferative disorder (MPD)\nTherapy-related AML\nUntreated AML in adults 60 years of age and older who are not candidates for induction chemotherapy due to poor-risk features including adverse cytogenetics or molecular markers (fms-related tyrosine kinase 3 [FLT3] internal tandem duplication [ ITD]+), or are unwilling to receive intensive induction chemotherapy; adverse cytogenetics: complex karyotype (>= 3 chromosomal abnormalities), 5q-, 7q-, 9q-, 20q-, abn12p, +21, +8, t(6;9), t(6;11), t(11;19), -7, -5, inv3/t(3;3), abn11q23, abn17p, abn21q\nUntreated ALL in adults 60 years of age and older who are not candidates for induction chemotherapy due to poor-risk features including adverse cytogenetics [t(4;11); t(1;19), hypodyploidy] or are unwilling to receive intensive induction chemotherapy; patients with Ph+ ALL [t(9;22)] will be eligible provided that they have failed (intolerance/resistance) at least 2 different TKIs or have a mutation associated with resistance to TKIs (T315I)\n\nPrevious therapy\n\nOnly patients who have received or are ineligible for established curative regimens, including stem cell transplantation when applicable, can be enrolled on this study\nPatients may have received any number of prior chemotherapy regimens, which may include allogeneic or autologous transplantation, provided that performance status and organ function are maintained\nPrevious cytotoxic chemotherapy should have been completed at least 3 weeks and radiotherapy at least 2 weeks prior to treatment on the study (6 weeks if the last regimen included carmustine [BCNU] or mitomycin C) and all adverse events (excluding alopecia, acne, rash) due to agents administered more than 3 weeks earlier should recover to =< grade 1; patients with hematologic malignancies are expected to have hematologic abnormalities at study entry; these abnormalities which are thought to be primarily related to the underlying leukemia, are not considered to be toxicities (AE) and do not need to resolve to =< grade 1\nPatients should stop taking all biologic agents including hematopoietic growth factors, imatinib or similar TKIs, at least 1 week prior to treatment on the study and all adverse events (excluding alopecia, acne, rash) due to agents administered more than 1 week earlier should recover to =< grade 1; since only patients with advanced Ph+ ALL and CML in accelerated/blast phase are eligible for this study, this short period off TKIs was selected to avoid rapid leukemia progression; if using hydroxyurea, corticosteroids, or leukopheresis for blast count control, patients must be off >= 24 hrs before starting treatment on the study\nPatients who have undergone autologous stem cell transplantation (ASCT) are eligible provided that they are >= 4 weeks from stem cell infusion and meet other eligibility criteria\nPatients who have undergone allogeneic SCT (alloSCT) are eligible if they are >= 60 days post stem cell infusion, have no evidence of graft vs. host disease, and are >= 2 weeks off all immunosuppressive therapy\nEastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\nPatients have to be able to swallow pills\nTotal or direct bilirubin < 2 mg/dl\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 5 X institutional upper limit of normal\nCreatinine < 2 mg/dl\nFemale patients of childbearing potential must have a negative pregnancy test\nFemale patients of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days afterward; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nPatients may not be receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy\nAny previous treatment with temozolomide\nPatients with active central nervous system leukemia are excluded from this clinical trial because they may develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; patients with a history of central nervous system (CNS) leukemia but no active disease at the time of enrollment are eligible\nHyperleukocytosis with > 30,000 blasts/ul; (if using hydroxyurea, corticosteroids, or leukopheresis for blast count control, patients must be off >= 24 hrs before starting treatment on the study); once patient starts treatment on the study the hydroxyurea use should be avoided, however, for patients with rapidly proliferating disease use of hydroxyurea is allowed on treatment days 1 through 12 if it becomes necessary to control a rising white blood cell (WBC) or leukostasis; the WBC need not reach 30,000/ul to start hydroxyurea during protocol days 1-12; the decision to start hydroxyurea during this time is at the discretion of the treating physician\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or temozolomide used in this study\nActive, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible\nUncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888\nKnown human immunodeficiency virus (HIV) infected patients (HIV testing will not be performed as a part of screening) on combination antiretroviral therapy, exclusive of zidovudine or starvudine, or HIV infected patients not on or willing to suspend antiretroviral therapy will be eligible provided that their cluster of differentiation (CD)4 cell count is greater than 250/mm3; HIV infected patients with CD4 count equal or less than 250/mm3 will be excluded"
            },
            {
                  "document": "Inclusion Criteria:\n\nScreening:\n\nPatients with AML at initial diagnosis or at first relapse\n18 years of age or older\nECOG Performance Status 0-2\nLife expectancy of greater than 9 weeks\nLaboratory values within limits outlined in the protocol\nWomen of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation\n\nPrior to Cell Collections for Dendritic Cell Generation:\n\nPatients must have obtained complete remission with chemotherapy defined by the absence of circulating blasts, and less then 5% blasts on bone marrow examination following hematopoietic recovery\nResolution of all chemotherapy related Grade III-IV toxicity as per CTC criteria 4.0\nLaboratory values as outlined in the protocol\nFor patients with evidence of minimal residual disease prior to vaccination, assessment of minimal residual disease status by cytogenetics or FISH will be followed post vaccination\n\nPrior to Post-Chemotherapy Immunotherapy:\n\nResolution of all chemotherapy related grade III-IV toxicity\nLaboratory values as outlined in the protocol\nAt least 2 doses of fusion vaccine produced\n\nExclusion Criteria:\n\nScreening:\n\nActive or history of autoimmune disorders/conditions including Type 1 diabetes. Type II diabetes, vitiligo or stable hyperthyroidism will not be considered exclusion criteria\nHIV positive\nSignificant cardiac disease characterized by symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia\nPregnant women\nIndividuals with a history of a different malignancy are ineligible except for circumstances outlined in the protocol document\n\nPrior to Cell Collection for Dendritic Cell Generation:\n\nSerious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure\nPatients who choose to proceed with allogeneic or autologous transplant at the time of remission will not be vaccinated and will come off study"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must be newly diagnosed with a clinical diagnosis of acute promyelocytic leukemia initially by morphology (bone marrow or peripheral blood); bone marrow is highly preferred but in cases where marrow cannot be obtained at diagnosis, peripheral blood will be accepted; APL is considered a hematological emergency and treatment should be initiated as quickly as possible without waiting for molecular or cytogenetic/fluorescence in situ hybridization (FISH) confirmation; for patients who are unable to begin receiving ATRA in a timely manner following a presumed diagnosis of APL, consideration should be given to initiating ATRA and proceeding with treatment outside of the AAML0631 protocol; if the RQ-PCR results are known at the time of study enrollment, the patient must demonstrate PML-RARA and/or RARA-PML transcripts by RQ-PCR to be eligible; patients without evidence of APL by bone marrow or peripheral blood morphology but with isolated myeloid sarcoma (myeloblastoma; chloroma, including leukemia cutis) are eligible provided that the t(15;17) translocation is documented on either marrow or tumor tissue by cytogenetics, FISH, or PCR prior to study enrollment; in this situation, touch preps from the tumor site can be evaluated by FISH with PML-RARA probes; NOTE: A lumbar puncture is not required to be enrolled on study; if the diagnosis of APL is known or suspected, extreme caution must be exercised in performing a lumbar puncture during active coagulopathy; in addition a computed tomography (CT) or magnetic resonance imaging (MRI) should be considered to rule out the possibility of an associated chloroma if central nervous system (CNS) disease is suspected or proven; if CNS disease is documented, patients are still eligible\nNo minimal performance status criteria\nThe patient must not have received systemic definitive treatment for APL or other suspected leukemia, including cytotoxic chemotherapy, retinoids, or arsenic; prior therapy with corticosteroids, hydroxyurea, or leukopheresis will not exclude the patient; if a patient received intrathecal cytarabine prior to the diagnosis of APL being known, the patient will still be eligible as long as they meet all other eligibility requirements\n\nExclusion Criteria:\n\nPregnant women or nursing mothers are excluded; treatment under this protocol would expose an unborn child to significant risks; patients should not be pregnant or plan to become pregnant while on treatment; women and men of reproductive potential should agree to use an effective means of birth control; there is an extremely high risk of fetal malformation if pregnancy occurs while on ATRA in any amount even for short periods\nPatients with a pre-existing prolonged QT Syndrome will not be eligible for this protocol due to the use of arsenic trioxide which can prolong the QT interval"
            },
            {
                  "document": "Inclusion Criteria:\n\nCytopathologically or histopathologically confirmed diagnosis of AML, MDS (RAEB-1, -2) or CMML, who are either relapsed or refractory to standard therapy, or are considered inappropriate candidates for standard therapy.\nInappropriateness for standard therapy requires a) MDS patients: not be a candidate for immediate allogeneic stem cell transplantation, not have a -5q-cytogenetic abnormality (unless previously received lenalidomide), and not be an appropriate candidate for a DNA hypomethylating agent b) AML patients must be 60 years of age or greater and have one of more of the following documented poor risk factors: ECOG Performance Status = 2, 70 years of age or older, unfavorable cytogenetics.\nLife expectancy of at least 12 weeks\nNot likely to require cytoreductive therapy within one month (other than hydroxyurea)\nECOG Performance Status of 2 or less\nSerum transaminase activity (AST/SGOT & ALT/SGPT) < 2.5 x ULN\nSerum total bilirubin < 1.5 x ULN ( with the exception of individuals with Gilbert's disease)\nINR < 1.3 (or < 3 on anticoagulants)\nFasting serum cholesterol 300mg/dl or 7.75 mmol/L or less AND fasting triglycerides 2.5 ULN or less\n\nExclusion Criteria:\n\nPrior allogeneic, syngeneic, or autologous bone marrow transplant or stem cell transplant less than 2 months previously\nFemale patients who are pregnant or breast feeding or adults of child bearing not employing double barrier contraception\nConcurrent severe and/or uncontrolled medical or psychiatric condition which may interfere with the completion of the study\nImpairment of gastrointestinal function or GI disease that may significantly alter absorption of PKC412 or RAD001\nUncontrolled active infection\nAny pulmonary infiltrate on teh baseline chest x-ray known to be new in the previous 4 weeks\nPatients with a Grade 2 or higher hypercholesterolemia or hypertriglyceridemia despite lipid-lowering therapy\nPatients with history of another malignancy within the past 5 years, with the exception of adequately treated basal or squamous cell skin carcinoma or cervical carcinoma in situ\nHistory of non-compliance to medical regimens and patients who are unwilling or unable to comply with this protocol\nPrior treatment with any investigational drug within preceding 4 weeks\nChronic treatment with systemic steroids or another immunosuppressive agent\nPatients should not receive immunization with attenuated live vaccines within one week of study entry or during study period\nAny severe or uncontrolled medical conditions or other conditions that could affect their participation\nKnown history of HIV seropositivity\nKnown hypersensitivity to RAD001 or other rapamycins or to its excipients\nKnown hypersensitivity to PKC412 or to its excipients\nDiagnosis of acute promyelocytic leukemia"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients must have untreated AML, or high-risk myelodysplastic syndromes (MDS) (refractory anemia with excess blasts, [RAEB], or RAEB \"in transformation\" [RAEB-t]) characterized by t(8;21), inv(16), or t(16;16); the presence of additional abnormalities is irrelevant\nPatients must provide written consent\nParticipants will not be excluded based on performance status; for patients with Eastern Cooperative Oncology Group (ECOG) performance status >= to 3 the dosing schedule will be discussed with study chairman\nPatients with organ dysfunction will not be excluded from the study; for patients with evidence of organ dysfunction (creatinine >= 1.5, cardiac ejection fraction =< 50%, total bilirubin >=2 and aspartate aminotransferase [AST]/alanine aminotransferase [ALT] >= 3 times upper limit of normal [ULN]), dose adjustments/omissions will be made\nUp to one cycle of prior induction therapy will be permitted to include patients in whom presence of \"good-risk\" cytogenetics was initially missed; if the patient is in remission from induction therapy, he/she will receive post-remission therapy; if the patient is not in remission then he/she will receive induction therapy\nPatients of child bearing potential should practice effective methods of contraception\n\nExclusion Criteria:\n\nPregnant and lactating females will be excluded"
            },
            {
                  "document": "Inclusion Criteria:\n\nGRAFT CRITERIA:\n\nUCB units will be selected according to current umbilical cord blood graft selection algorithm; one or 2 UCB units may be used to achieve the required cell dose\nThe UCB graft is matched at 4-6 human leukocyte antigen (HLA)-A, B, DRB1 antigens with the recipient; this may include 0-2 antigen mismatches at the A or B or DRB1 loci; unit selection based on cryopreserved nucleated cell dose and HLA-A,B, DRB1 using intermediate resolution A, B antigen and DRB1 allele typing\nIf 2 UCB units are required to reach the target cell dose, each unit must be a 4-6 antigen match to the recipient\n\nAge and Disease Criteria:\n\nHigh-dose TBI regimen: 6 months to =< 45 years\nMiddle-intensity TBI regimen: 6 months to =< 65 years\nConditioning regimen selection should be based on the underlying disease, presence of minimum residual disease (MRD), age, co-morbidities, and attending physician\n\nAcute myeloid leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia:\n\nAll patients must be in complete remission (CR) as defined by hematologic recovery and < 5% blasts by morphology/flow cytometry in a representative bone marrow sample with cellularity >= 15% for age; patients who do not have high-risk features (for example preceding myelodysplastic syndrome [MDS], high-risk cytogenetics, >= 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia or >= CR2) must be discussed with the principal investigator (PI) prior to enrollment and at the Patient Care Conference or equivalent group such as the pediatric leukemia board as an alternative\nPatients in whom adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the PI prior to enrollment; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval\nVery high risk pediatric/young adult patients with acute myeloid leukemia (AML): Patients =< 25 years, however, are eligible with (M2 marrow) with =< 25% blasts in marrow after having failed one or more cycles of chemotherapy; this group of patients will be analyzed separately\n\nAcute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia:\n\nAll patients must be in CR as defined by < 5% blasts by morphology; flow cytometry in a representative bone marrow sample with cellularity >= 15% for age; patients who do not have high-risk disease (high risk CR1, greater than one cycle to obtain CR or >= CR2) must be discussed with the PI prior to enrollment and at the Patient Care Conference or equivalent group such as the pediatric leukemia board as an alternative\nPatients in whom adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the principal investigator Ann Dahlberg prior to enrollment; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with PI approval\nChronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate\nAdvanced myelofibrosis\nMyelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (i.e., refractory anemia with excess blasts [RAEB], RAEB in transformation [RAEBt]) or refractory anemia with severe pancytopenia or high risk cytogenetics; blasts must be < 10% by a representative bone marrow aspirate morphology\nLymphoblastic lymphoma, Burkitt's lymphoma, and other high-grade non-Hodgkin lymphoma (NHL) after initial therapy if stage III/IV in first partial response (PR1) or after progression if stage I/II < 1 year; stage III/IV patients are eligible after progression in CR/PR\nChronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma or follicular lymphoma that have progressed after at least two different prior therapies; patients with bulky disease (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before transplant; these patients must be presented at primary care center (PCC) prior to enrollment, given potential competing eligibility on autotransplant protocols\nMantle-cell lymphoma, prolymphocytic leukemia: Eligible after initial therapy in >= CR1 or >= PR1\n\nLarge cell NHL > CR2/> second partial response (PR2):\n\nPatients in CR2/PR2 with initial short remission (< 6 months) are eligible\nThese patients must be presented at PCC prior to enrollment, given potential competing eligibility on autotransplant protocols\nMultiple myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or beta-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapy\nPerformance status score: Karnofsky (for adults) >= 70% or Eastern Cooperative Oncology Group (ECOG) 0-1 or Lansky (for children) >= 50%\nCreatinine < 2.0 mg/dL (for adults) or creatinine clearance > 60 ml/min (for children)\nPatients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, histology, and the degree of portal hypertension; patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded\nDiffusion capacity for carbon monoxide corrected (DLCOcorr) > 50% normal or a pediatric patient who is unable to perform pulmonary function tests (PFTs) but has adequate pulmonary function\nLeft ventricular ejection fraction > 45% or shortening fraction > 26%\n\nExclusion Criteria:\n\nUncontrolled viral or bacterial infection at the time of study enrollment\nActive or recent (prior 6 month) invasive fungal infection without interdisciplinary (ID) consult and approval\nHistory of human immunodeficiency virus (HIV) infection\nPregnant or breastfeeding\nChemotherapy refractory large cell and high grade NHL (i.e., progressive disease after > 2 salvage regimens)\nPatients with history of prior myeloablative transplant containing full dose TBI (greater than 8 gray [Gy]) will not be eligible for Regimen A; however, they may still enroll on Regimen B if they otherwise meet inclusion and exclusion criteria\nAny prior myeloablative transplant within the last 6 months\nPatients >= 45 years: comorbidity score of 5 or higher\nPatients who have received Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar), as part of their salvage therapy are not eligible for Regimen A"
            },
            {
                  "document": "Inclusion Criteria:\n\nPatients with a)acute myeloid leukemia exclusive of patients in first complete remission with good risk cytogenetics (translocation 8,21,translocation 15, 17 or inversion 16); B)myelodysplastic syndrome; c)acute lymphocytic leukemia exclusive of patients in first remission without negative prognostic markers; d) relapsed or refractory nonHodgkin's lymphoma or Hodgkin's disease; e)relapsed or refractory multiple myeloma or f)relapsed or refractory chronic lymphocytic leukemia.\nPatients who are considered appropriate for reduced intensity transplantation must present with at least one of the following: A. Age over 50 B. History of a prior hematopoietic stem cell transplant C. Patient with compromised organ function or comorbid conditioning such that a standard ablative transplant would be considered high risk. D. Patient with low grade Lymphoma or CLL for which reduced intensity transplant would be the optimal therapy compared to an ablative regimen\nPatients will have a related or unrelated donor matched at 5/6 or 6/6 HLA loci.\nPatients must be greater than or equal to 18 years old, and younger than or equal to 75 years old to participate in the study.\nPatients must have ECOG performance status of 0-2\nPulmonary function tests demonstrate DLCO (adjusted for Hgb)>50% predicted\nCardiac ejection fraction >40%\n\nLaboratories:\n\nBilirubin less than or equal to 1.5mg/dL x ULN\nAST/ALT/Alkaline Phosphatase less than or equal to 2.5x ULN\nSerum creatinine less than or equal to 1.0mg/dL; if serum creatinine > 1.0MG/dL, then the estimated glomerular filtration rate (GFR) must be >60mL/min/1.73m^2 as calculated by the Modification of Diet in Renal Disease equation where Predicted GRF (ml/min/1.73m^2)=186x (serum creatinine)^1.154x(age in years)^-0.203x(0.742 if patient is female) x (1.212 if patient is black)\nPatients with serologic evidence of hepatitis B or C exposure will undergo liver biopsy to assess for presence of active hepatitis or fibrosis and quantification of risk of proceeding with transplant.\n\n10. All patients must be capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent. All patients must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines.\n\n11. Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.\n\n12. Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment\n\nExclusion Criteria:\n\nPatients who are HIV+ will be excluded.\nPatients must not have serious intercurrent illness such as uncontrolled systemic infection or significant organ compromise which significantly increases the risk of undergoing allogeneic transplantation.\nPregnant and lactating women will be excluded."
            },
            {
                  "document": "Inclusion Criteria:\n\nPathologically confirmed diagnosis of 1 of aggressive MPD or AML out of MPD\n\nAggressive phase high-risk myeloproliferative disorders (i.e., polycythemia vera, essential thrombocythemia, or Ph-negative chronic myelogenous leukemia) meeting \u2265 1 of the following criteria:\n\nMarrow blasts > 5%\nPeripheral blood blasts plus progranulocytes > 10%\nNew onset or increasing myelofibrosis OR;\nNew onset or > 25% increase in hepatomegaly or splenomegaly\nNew onset constitutional symptoms (i.e., fever, weight loss, splenic pain, or bone pain)\nPatients who failed primary induction therapy or relapsed after achieving complete remission are eligible\nNo active CNS leukemia; patients with a history of CNS disease must be stable for > 3 months after treatment and off steroid treatment prior to study enrollment\n\nChronic myelomonocytic leukemia meeting either of the following criteria:\n\n5-19% bone marrow blasts (aggressive)\nAt least 20% marrow blasts (transformation)\nECOG performance status 0-2\nNo hyperleukocytosis with >= 50,000 blasts/uL\nAST, ALT, and alkaline phosphatase =< 5 times upper limit of normal\nBilirubin =< 2.0 mg/dL\nCreatinine normal OR creatinine clearance >= 60 mL/min\nLVEF >= 45% by MUGA or ECHO\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception during and for 30 days after completion of study therapy\nNo active disseminated intravascular coagulation\nNo active uncontrolled infection\nPatients with infection that is under active treatment and controlled with antibiotics are eligible\nNo other life-threatening illness\nNo mental deficits and/or psychiatric history that would preclude giving informed consent or following protocol\nNo prior or current seizure disorder or a history of seizure\nNo more than 3 prior cytotoxic regimens\nAt least 3 weeks since prior cytotoxic chemotherapy\nAt least 2 weeks since prior radiotherapy\nAt least 4 weeks since prior autologous or allogeneic stem cell transplantation\nNo active graft-versus-host disease\nAt least 1 week since prior biologic therapies, including hematopoietic growth factors\nAt least 24 hours since prior hydroxyurea, steroids, imatinib mesylate, arsenic trioxide, interferon, or other noncytotoxic agents for blast count control\nNo prior ABT-888\nNo other concurrent chemotherapy, radiotherapy, or immunotherapy\nNo concurrent antiretroviral therapy for HIV-positive patients\nNo other concurrent investigational or commercial agents or therapies for this cancer"
            },
            {
                  "document": "Inclusion Criteria:\n\nDiagnosis of hematologic cancer or other disease, including any of the following:\n\nChronic myelogenous leukemia in first or second chronic phase\n\nAcute lymphoblastic leukemia (ALL), meeting any of the following criteria:\n\nRelapsed ALL enrolled on a Children's Oncology Group (COG) relapse clinical trial OR received \u2265 1 round of reinduction therapy (4-6 weeks) and 1 round of intensive consolidation chemotherapy (3-6 weeks)\nALL in second complete remission (CR)* after a bone marrow, extramedullary, or combined bone marrow and extramedullary relapse\n\nVery high-risk ALL in first CR, defined as any of the following:\n\nPhiladelphia chromosome-positive ALL\nHypodiploidy (< 44 chromosomes)\nMixed lineage leukemia rearrangement\nInduction failure\n\nAcute myeloid leukemia in first or second CR\n\nInduction therapy must be completed\nJuvenile myelomonocytic leukemia\nMyelodysplastic syndromes\nNo clinically evident CNS or extramedullary disease\nNo blasts seen on cerebrospinal fluid cytospin\nPost-relapse reinduction therapy must be completed\nNot planning to receive reduced-intensity conditioning regimen\nNot planning to receive a graft that has undergone T-cell depletion\nNo Down syndrome\nMatched sibling donor must be available and must be enrolled on ASCT0631D companion study\nKarnofsky performance status (PS) 60-100% (patients > 16 years of age) OR Lansky PS 60-100% (patients \u2264 16 years of age)\nAST or ALT < 5 times upper limit of normal for age\nBilirubin < 2.5 mg/dL (unless due to Gilbert's syndrome)\n\nCreatinine clearance or radioisotope glomerular filtration rate \u2265 70 mL/min OR serum creatinine base on age and/or gender as follows:\n\n0.4 mg/dL (1 month to < 6 months of age)\n0.5 mg/dL (6 months to < 1 year of age)\n0.6 mg/dL (1 to 2 years of age)\n0.8 mg/dL (2 to < 6 years of age)\n1.0 mg/dL (6 to < 10 years of age)\n1.2 mg/dL (10 to < 13 years of age)\n1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age)\n1.7 mg/dL (male) or 1.4 mg/dL (female) (\u2265 16 years of age)\nShortening fraction \u2265 27% by echocardiogram OR LVEF \u2265 50% by radionuclide angiogram\n\nFEV_1, FVC, and DLCO \u2265 60% OR meets the following criteria (for patients unable to cooperate for pulmonary function tests):\n\nNo evidence of dyspnea at rest\nNo exercise intolerance\nNo requirement for supplemental oxygen therapy\nNot pregnant or nursing\nNo known HIV\n\nNo known uncontrolled fungal, bacterial, or viral infections\n\nPatients acquiring fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT scan\nNo prior allogeneic or autologous stem cell transplantation"
            },
            {
                  "document": "Inclusion Criteria:\n\nEligibility Criteria for the phase I portion (step 1); patients must have a diagnosis of either MDS according to French-American-British (FAB) and International Prognostic Scoring System (IPSS) criteria, or a diagnosis of AML according to FAB or World Health Organization (WHO) criteria\n\nMDS: All patients must have an established diagnosis of myelodysplastic syndrome confirmed by peripheral blood and bone marrow maturational abnormalities in the erythroid, megakaryocytic and granulocytic series, defined according to the French -American-British (F.A.B.) classification\n\nRefractory anemia (RA), defined as having anemia with =< 1% blasts in the peripheral blood and dyserythropoiesis; neutropenia and thrombocytopenia may also be present but are less common; the bone marrow is usually normocellular or hypercellular with < 5% blast cells\nRefractory anemia with ring sideroblasts (RARS), defined as refractory anemia above, but also including the presence of ringed sideroblasts comprising >= 15% of all nucleated cells in the bone marrow\nRefractory anemia with excess blasts (RAEB), defined as having 5-20% myeloblasts in the bone marrow and less than 5% blasts in the peripheral blood, together with abnormalities in erythroid megakaryocytic and granulocytic maturation consistent with myelodysplasia\nRefractory anemia with excess blasts in transformation (RAEB-T), defined as 21-29% myeloblasts in the marrow, or more than 5% blasts in the peripheral blood, or Auer rods in granulocytic precursors in the marrow or blood (with < 30% myeloblasts in the marrow)\nChronic myelomonocytic leukemia (CMMoL) defined as an absolute monocytosis (> 1 x 10^9/liter) with < 5% blasts in the peripheral blood and < 20% blasts in the bone marrow; additional criteria include a white blood cell (WBC) =< 13 x 10^9/L\n\nFor patients with refractory anemia or refractory anemia with ring sideroblasts and IPSS =< 0.5, must also meet at least one of the following criteria to be eligible:\n\nSymptomatic anemia requiring packed red blood cell (PRBC) transfusions for at least 3 months prior to study entry (document), or\nThrombocytopenia with platelet counts =< 50,000/ml or significant clinical hemorrhage (e.g., gastrointestinal [GI], gastric ulcer [GU] or gynecologic [GYN] hemorrhage requiring platelet transfusion; petechiae alone do not constitute sufficient hemorrhage)\nNeutropenia with absolute neutrophil count < 1000/ul with an infection requiring treatment with antibiotics\nPatients with MDS classified according to IPSS criteria with intermediate -1, intermediate -2 or high risk disease are eligible\nPatients with low risk MDS (IPSS Score < 0.5) must additionally meet criteria as outlined for patients with refractory anemia or refractory anemia with ring sideroblasts above\n\nAML - phase 1 only; patients with AML are not eligible for phase II; patients with AML defined according to FAB or WHO criteria will be eligible for the phase I portion of this study (phase 1 only); additional selection criteria:\n\nDe novo AML or AML evolving from MDS associated with intermediate or poor risk cytogenetics in patients who decline standard chemotherapy or who have failed or relapsed following one prior regimen\nAdditionally, patient's disease must be stable i.e. WBC =< 25 x 10^9/L who have exhibited stable WBC not requiring intervention for WBC control with hydroxyurea, chemotherapy or leukophoresis for > 4 weeks\nNo corticosteroids, interferon or retinoids within one month prior to study\nNo treatment with granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or other hematopoietic growth factors, e.g. erythropoietin within one month prior to study\nNo prior treatment with azacitidine, decitabine or vorinostat\nPatients should not have taken valproic acid, or any other histone deacetylase inhibitor, for at least 2 weeks prior to enrollment\nPatients may not have been treated with an investigational agent in the 28 days prior to study entry and must have recovered from all side effects\nPatients previously treated for cancer other than leukemia with chemotherapy or radiation therapy may be eligible; they may not have received radiation or chemotherapy within the past 12 months and must have been free of any evidence of the malignancy during the past 3 years; patients with a prior history of leukemia who relapse with MDS are ineligible\nEastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\nLife expectancy of greater than 2 months\nTotal bilirubin =< 1.5 x upper limit of normal (ULN); unless the patient has active hemolysis, or the elevation is secondary to ineffective erythropoiesis\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional ULN\nCreatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\nTreatment must begin within 2 to 4 weeks of completing prestudy tests\nWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\nAbility to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nPatients who have had chemotherapy or radiotherapy within 12 months prior to entering the study or those with another malignancy who have had evidence of the malignancy during the 3 years prior to study entry\nPatients may not be receiving any other investigational agents\nPatients may not have central nervous system (CNS) involvement with MDS or AML\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or other agents used in study\nPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat\nAny other serious medical or psychiatric illness which would limit survival to < 3 months or prevent the granting of informed consent\nUncontrolled or severe congestive heart failure; (does not include patients with high output congestive heart failure [CHF] states secondary to anemia which can be controlled)\n>= 30% myeloblasts in the bone marrow or M6 leukemia as defined by FAB criteria (phase II component of the study)\nPrior treatment with G-CSF, GM-CSF, or other hematopoietic growth factors, erythropoietin within one month prior to study; no interferon or retinoids within one month prior to study\nKnown positive serology for human immunodeficiency virus (HIV); appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated\nActive systemic bacterial, fungal of viral infection; infection should be fully treated and the patient afebrile for 7 days before study entry\nPrior history of leukemia (step 2 phase II component of the study only)\nUncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPatients with advanced hepatic tumors are excluded"
            },
            {
                  "document": "Inclusion Criteria:\n\nMatched sibling donor (HLA 8/8), if available, or a unrelated partially HLA matched single unit based on the following priority:\n\n1st priority: 4/6 matched unit, cell dose >5 x 10-7 nucleated cells/kg\n2nd priority: 5/6 matched unit, cell dose > 4 x 10-7 nucleated cells/kg\n3rd priority: 6/6 matched unit, cell dose > 3 x 10-7 nucleated cells/kg\n\nPatients aged \u2264 3 years at diagnosis (not age of transplant) with hematological malignancy as detailed below:\n\nAcute myeloid leukemia: high risk CR1 as evidenced by:\n\nHigh risk cytogenetics t(4;11) or other MLL rearrangements; chromosome 5, 7, or 19 abnormalities; complex karyotype (>5 distinct changes); \u2265 2 cycles to obtain complete response (CR); CR2 or higher; Preceding myelodysplastic syndrome (MDS); All patients must be in CR or early relapse (i.e., <15% blasts in BM).\nAcute lymphocytic leukemia: high risk CR1 as evidenced by: High-risk cytogenetic: t(4;11) or other MLL rearrangements; hypodiploid; t(9;22); >1 cycle to obtain CR; CR2 or higher; All patients must be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a cellularity of \u226515%.\nMyelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt) or refractory anemia with severe pancytopenia or high risk cytogenetics. Blasts must be < 10% by a representative bone marrow aspirate morphology.\nPersistent or rising minimal residual disease (MRD) after standard chemotherapy regimens: Patients with evidence of minimal residual disease at the completion of therapy or evidence of rising MRD while on therapy. MRD will be defined by either flow cytometry (>0.1% residual cells in the blast gate with immune phenotype of original leukemic clone), by molecular techniques (PCR or FISH) or conventional cytogenetics (g-banding).\nNew Leukemia Subtypes: A major effort in the field of pediatric hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new high risk features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee.\n\nRecipients must have a Lansky score \u2265 50% and have acceptable organ function defined as:\n\nRenal: glomerial filtration rate > 60ml/min/1.73m^2\nHepatic: bilirubin, AST/ALT, ALP < 5 x upper limit of normal,\nPulmonary function: oxygen saturation >92%\nCardiac: left ventricular ejection fraction > 45%.\nVoluntary written informed consent before performance of any study-related procedure not part of normal medical care.\n\nExclusion Criteria:\n\nActive infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days).\nHistory of HIV infection or known positive serology\nMyeloablative transplant within the last 6 months.\nEvidence of active extramedullary disease (including central nervous system leukemia)."
            }
      ]
}